PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Altznauer, F; Conus, S; Cavalli, A; Folkers, G; Simon, HU				Altznauer, F; Conus, S; Cavalli, A; Folkers, G; Simon, HU			Calpain-1 regulates Bax and subsequent Smac-dependent caspase-3 activation in neutrophil apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; CYTOCHROME-C RELEASE; CELL-DEATH; FAS LIGAND; DIFFERENTIAL EXPRESSION; HUMAN EOSINOPHILS; CALPASTATIN; PROTEASE; MITOCHONDRIA; INHIBITOR	In the absence and in the resolution of inflammatory responses, neutrophils rapidly undergo spontaneous apoptosis. Here we report about a new apoptosis pathway in these cells that requires calpain-1 activation and is essential for the enzymatic activation of the critical effector caspase-3. Decreased levels of calpastatin, a highly specific intrinsic inhibitor of calpain, resulted in activation of calpain-1, but not calpain-2, in neutrophils undergoing apoptosis, a process that was blocked by a specific calpain-1 inhibitor or by intracellular delivery of a calpastatin peptide. Further support for the importance of the calpastatin-calpain system was obtained by analyzing neutrophils from patients with cystic fibrosis that exhibited delayed apoptosis, associated with markedly increased calpastatin and decreased calpain-1 protein levels compared with neutrophils from control individuals. Additional studies were designed to place calpain-1 into the hierarchy of biochemical events leading to neutrophil apoptosis. Pharmacological calpain inhibition during spontaneous and Fas receptor-induced neutrophil apoptosis prevented cleavage of Bax into an 18-kDa fragment unable to interact with Bcl-x(L). Moreover, calpain blocking prevented the mitochondrial release of cytochrome c and Smac, which was indispensable for caspase-3 processing and enzymatic activation, both in the presence and absence of agonistic anti-Fas receptor antibodies. Taken together, calpastatin and calpain-1 represent critical proximal elements in a cascade of pro-apoptotic events leading to Bax, mitochondria, and caspase-3 activation, and their altered expression appears to influence the life span of neutrophils under pathologic conditions.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland; Univ Bologna, Dept Pharmaceut Sci, I-40126 Bologna, Italy; Univ Zurich, Dept Pharmaceut Sci, CH-8057 Zurich, Switzerland	University of Bern; University of Bologna; University of Zurich	Simon, HU (corresponding author), Univ Bern, Dept Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.	hus@pki.unibe.ch	Simon, Hans-Uwe/AAU-7410-2020	Simon, Hans-Uwe/0000-0002-9404-7736; Folkers, Gerd/0000-0002-3620-705X; CAVALLI, ANDREA/0000-0002-6370-1176				Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Case DAPD, 1999, AMBER 6; CLARK JM, 1980, J CELL BIOL, V84, P102, DOI 10.1083/jcb.84.1.102; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Coxon A, 1999, J EXP MED, V190, P923, DOI 10.1084/jem.190.7.923; Daigle I, 2002, NAT MED, V8, P61, DOI 10.1038/nm0102-61; Daigle I, 2001, INT ARCH ALLERGY IMM, V126, P147, DOI 10.1159/000049506; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dibbert B, 1999, P NATL ACAD SCI USA, V96, P13330, DOI 10.1073/pnas.96.23.13330; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fecho K, 1998, J LEUKOCYTE BIOL, V64, P373, DOI 10.1002/jlb.64.3.373; Gao G, 2000, J CELL BIOCHEM, V80, P53; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hebestreit H, 1998, J EXP MED, V187, P415, DOI 10.1084/jem.187.3.415; Heinisch IVWM, 2000, EUR J IMMUNOL, V30, P3441, DOI 10.1002/1521-4141(2000012)30:12<3441::AID-IMMU3441>3.0.CO;2-L; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; IWAI K, 1994, BLOOD, V84, P1201; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kato M, 2000, J BIOCHEM, V127, P297, DOI 10.1093/oxfordjournals.jbchem.a022607; KAWASAKI H, 1989, J BIOCHEM, V106, P274, DOI 10.1093/oxfordjournals.jbchem.a122844; Knepper-Nicolai B, 1998, J BIOL CHEM, V273, P30530, DOI 10.1074/jbc.273.46.30530; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li M, 2000, J BIOL CHEM, V275, P39702, DOI 10.1074/jbc.M007369200; Li ZZ, 1996, J MED CHEM, V39, P4089, DOI 10.1021/jm950541c; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Maianski NA, 2002, BLOOD, V99, P672, DOI 10.1182/blood.V99.2.672; MAKI M, 1989, J BIOL CHEM, V264, P18866; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; Murphy BM, 2003, J EXP MED, V197, P625, DOI 10.1084/jem.20021862; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; Ruiz-Vela A, 2001, J EXP MED, V194, P247, DOI 10.1084/jem.194.3.247; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCHMANDT R, 1994, J IMMUNOL, V152, P96; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; SIMON HU, 1994, J IMMUNOL, V153, P364; Simon HU, 2003, IMMUNOL REV, V193, P101, DOI 10.1034/j.1600-065X.2003.00038.x; Squier MKT, 1999, J CELL PHYSIOL, V178, P311, DOI 10.1002/(SICI)1097-4652(199903)178:3<311::AID-JCP5>3.3.CO;2-K; Squier MKT, 1997, J IMMUNOL, V158, P3690; Squier MKT, 1996, CELL DEATH DIFFER, V3, P275; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Watson RWG, 1999, FEBS LETT, V453, P67, DOI 10.1016/S0014-5793(99)00688-2; Weinmann P, 1999, BLOOD, V93, P3106; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Yang YL, 1997, BLOOD, V89, P550, DOI 10.1182/blood.V89.2.550; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868; ZHOU H, 1998, J BIOL CHEM, V274, P11549	68	135	143	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5947	5957		10.1074/jbc.M308576200	http://dx.doi.org/10.1074/jbc.M308576200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14612448	hybrid			2022-12-25	WOS:000188776500110
J	Bakker, RA; Casarosa, P; Timmerman, H; Smit, MJ; Leurs, R				Bakker, RA; Casarosa, P; Timmerman, H; Smit, MJ; Leurs, R			Constitutively active G(q/11)-coupled receptors enable signaling by co-expressed G(i/o)-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-COUPLED-RECEPTOR; G-BETA-GAMMA; HISTAMINE H-1 RECEPTOR; HUMAN CYTOMEGALOVIRUS-INFECTION; SARCOMA-ASSOCIATED HERPESVIRUS; HETEROTRIMERIC G-PROTEINS; SMOOTH-MUSCLE-CELLS; INVERSE AGONISM; CHEMOKINE RECEPTOR	Co-expression of guanine nucleotide-binding regulatory (G) protein-coupled receptors (GPCRs), such as the G(i/o)-coupled human 5-hydroxytryptamine receptor 1B (5-HT1BR), with the G(q/11)-coupled human histamine 1 receptor (H1R) results in an overall increase in agonist-independent signaling, which can be augmented by 5-HT1BR agonists and inhibited by a selective inverse 5-HT1BR agonist. Interestingly, inverse H1R agonists inhibit constitutively H1R-mediated as well as 5-HT1BR agonist-induced signaling in cells co-expressing both receptors. This phenomenon is not solely characteristic of 5-HT1BR; it is also evident with muscarinic M-2 and adenosine A(1) receptors and is mimicked by mastoparan-7, an activator of G(i/o) proteins, or by over-expression of Gbetagamma subunits. Likewise, expression of the G(q/11)-coupled human cytomegalovirus (HCMV)-encoded chemokine receptor US28 unmasks a functional coupling of G(i/o)-coupled CCR1 receptors that is mediated via the constitutive activity of receptor US28. Consequently, constitutively active G(q/11)-coupled receptors, such as the H1R and HCMV-encoded chemokine receptor US28, constitute a regulatory switch for signal transduction by G(i/o)-coupled receptors, which may have profound implications in understanding the role of both constitutive GPCR activity and GPCR cross-talk in physiology as well as in the observed pathophysiology upon HCMV infection.	Vrije Univ Amsterdam, Div Med Chem, Leiden Amsterdam Ctr Drug Res, NL-1081 HV Amsterdam, Netherlands	Leiden University; Leiden University - Excl LUMC; Vrije Universiteit Amsterdam	Leurs, R (corresponding author), Vrije Univ Amsterdam, Div Med Chem, Leiden Amsterdam Ctr Drug Res, Boelelaan 1083, NL-1081 HV Amsterdam, Netherlands.	leurs@few.vu.nl	Leurs, Rob/ABB-4299-2021; Leurs, Rob/AAC-8508-2022	Leurs, Rob/0000-0003-1354-2848				Adan RAH, 2003, TRENDS PHARMACOL SCI, V24, P315, DOI 10.1016/S0165-6147(03)00130-5; Amerongen GPV, 1998, CIRC RES, V83, P1115, DOI 10.1161/01.RES.83.11.1115; Aoki Y, 1998, AM J PHYSIOL-LUNG C, V274, pL1030, DOI 10.1152/ajplung.1998.274.6.L1030; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Bakker RA, 2000, EUR J PHARMACOL, V387, pR5, DOI 10.1016/S0014-2999(99)00803-1; Bakker RA, 2001, MOL PHARMACOL, V60, P1133, DOI 10.1124/mol.60.5.1133; Billstrom MA, 1998, J VIROL, V72, P5535, DOI 10.1128/JVI.72.7.5535-5544.1998; Blaukat A, 2000, MOL CELL BIOL, V20, P6837, DOI 10.1128/MCB.20.18.6837-6848.2000; Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; Brady AE, 2002, CELL SIGNAL, V14, P297, DOI 10.1016/S0898-6568(01)00239-X; Casarosa P, 2003, J BIOL CHEM, V278, P5172, DOI 10.1074/jbc.M210033200; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; Chan JSC, 2000, MOL PHARMACOL, V57, P700, DOI 10.1124/mol.57.4.700; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; Dickenson JM, 1998, EUR J PHARMACOL, V348, P279, DOI 10.1016/S0014-2999(98)00148-4; Drews J, 2000, SCIENCE, V287, P1960, DOI 10.1126/science.287.5460.1960; GAO JL, 1994, J BIOL CHEM, V269, P28539; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Hanke S, 2001, MOL CELL BIOL, V21, P8452, DOI 10.1128/MCB.21.24.8452-8460.2001; Hashimoto T, 2002, JPN J PHARMACOL, V88, P256, DOI 10.1254/jjp.88.256; Hilairet S, 2003, J BIOL CHEM, V278, P23731, DOI 10.1074/jbc.M212369200; Horuk R, 2001, CYTOKINE GROWTH F R, V12, P313, DOI 10.1016/S1359-6101(01)00014-4; Hu QH, 1999, J BIOL CHEM, V274, P33995, DOI 10.1074/jbc.274.48.33995; Huang S, 2001, J BIOL CHEM, V276, P40977, DOI 10.1074/jbc.M105242200; Kenakin T, 2002, ANNU REV PHARMACOL, V42, P349, DOI 10.1146/annurev.pharmtox.42.091401.113012; KOWALIK TF, 1993, P NATL ACAD SCI USA, V90, P1107, DOI 10.1073/pnas.90.3.1107; LEURS R, 1994, J NEUROCHEM, V62, P519; Leurs R, 1998, TRENDS BIOCHEM SCI, V23, P418, DOI 10.1016/S0968-0004(98)01287-0; Meij JTA, 1996, MOL CELL BIOCHEM, V157, P31; Milligan G, 1997, TRENDS PHARMACOL SCI, V18, P468, DOI 10.1016/S0165-6147(97)90685-4; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Morisset S, 2000, NATURE, V408, P860, DOI 10.1038/35048583; NEALE RF, 1987, EUR J PHARMACOL, V136, P1, DOI 10.1016/0014-2999(87)90772-2; Pan ZXK, 1998, J IMMUNOL, V160, P3038; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Quitterer U, 1999, P NATL ACAD SCI USA, V96, P10626, DOI 10.1073/pnas.96.19.10626; Rahman A, 2002, CIRC RES, V91, P398, DOI 10.1161/01.RES.0000033520.95242.A2; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Robinson AJ, 2001, BRIT J PHARMACOL, V133, P1378, DOI 10.1038/sj.bjp.0704200; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Schmidt P, 2001, MOL ENDOCRINOL, V15, P553, DOI 10.1210/me.15.4.553; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; Selbie LA, 1997, BIOCHEM J, V328, P153; Selbie LA, 1998, TRENDS PHARMACOL SCI, V19, P87, DOI 10.1016/S0165-6147(97)01166-8; Selkirk JV, 1998, BRIT J PHARMACOL, V125, P202, DOI 10.1038/sj.bjp.0702059; Shahrestanifar M, 1999, J BIOL CHEM, V274, P3828, DOI 10.1074/jbc.274.6.3828; Shepard LW, 2001, J BIOL CHEM, V276, P45979, DOI 10.1074/jbc.M104783200; Shibutani T, 1997, J CLIN INVEST, V100, P2054, DOI 10.1172/JCI119738; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; Tate CG, 1996, TRENDS BIOTECHNOL, V14, P426, DOI 10.1016/0167-7799(96)10059-7; Ushio-Fukai M, 1999, MOL PHARMACOL, V55, P142, DOI 10.1124/mol.55.1.142; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Waldhoer M, 2003, J BIOL CHEM, V278, P19473, DOI 10.1074/jbc.M213179200; Wise A, 1997, BIOCHEM J, V321, P721, DOI 10.1042/bj3210721; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Xie Z, 2002, J BIOL CHEM, V277, P11979, DOI 10.1074/jbc.M109751200; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; Yang M, 2003, MOL PHARMACOL, V64, P447, DOI 10.1124/mol.64.2.447; Yang M, 2001, J IMMUNOL, V166, P6885, DOI 10.4049/jimmunol.166.11.6885; Yao LN, 2002, CELL, V109, P733, DOI 10.1016/S0092-8674(02)00763-8; Yildiz O, 1998, LIFE SCI, V62, P1723, DOI 10.1016/S0024-3205(97)01166-1; Zhao DZ, 2003, AM J PHYSIOL-CELL PH, V284, pC1397, DOI 10.1152/ajpcell.00328.2002; Zhen XC, 2001, MOL PHARMACOL, V60, P857	67	45	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5152	5161		10.1074/jbc.M309200200	http://dx.doi.org/10.1074/jbc.M309200200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14610092	hybrid			2022-12-25	WOS:000188776500015
J	Kang, XD; Falick, AM; Nelson, RE; Gao, GH; Rogers, K; Aphasizhev, R; Simpson, L				Kang, XD; Falick, AM; Nelson, RE; Gao, GH; Rogers, K; Aphasizhev, R; Simpson, L			Disruption of the zinc finger motifs in the Leishmania tarentolae LC-4 (=TbMP63) L-complex editing protein affects the stability of the L-complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI; U-DELETION; MITOCHONDRIA; INSERTION; IDENTIFICATION; ASSOCIATION; COMPONENTS	The uridine insertion/deletion editing complex, which we have termed the L-complex, is composed of at least 16 polypeptides stabilized entirely by protein-protein interactions. Three L-complex proteins contain zinc finger motifs that could be involved in these interactions. In Leishmania these proteins are labeled LC-1, LC-4, and LC-7b, and the orthologs in Trypanosoma brucei are labeled MP81, MP63, and MP42. Overexpression of TAP-tagged LC-4 in Leishmania tarentolae led to a partial localization of the protein in the L-complex together with the endogenous LC-4 protein, suggesting at least a dimeric organization. Disruption of zinc fingers 1 or 2 (ZnF-1 and ZnF-2) in the tagged LC-4 protein was performed by mutation of the two zinc-binding cysteines to glycines. Disruption of ZnF-1 led to a partial growth defect and a substantive breakdown of the L-complex, whereas disruption of ZnF-2 had no effect on cell growth and caused a partial breakdown of the L-complex. A close interaction of LC-4 with 2-4 proteins, including REL1 (RNA ligase) and LC-3, was suggested by chemical crosslinking and co-immunoprecipitation experiments. Our results suggest that both ZnF-1 and ZnF-2 in LC-4 play a role in protein-protein interactions and indicate that the LC-4 subcomplex may be required for formation or stability of the entire L-complex.	Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Mass Spectrometry Lab, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Simpson, L (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, 6780 MRL, Los Angeles, CA 90095 USA.	simpson@kdna.ucla.edu		Rogers, Kestrel/0000-0002-0233-3613; Afasizhev, Ruslan/0000-0002-4595-6618	NIAID NIH HHS [AI09102] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009102, R37AI009102] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen TE, 1998, MOL CELL BIOL, V18, P6014, DOI 10.1128/MCB.18.10.6014; Aphasizhev R, 2003, RNA, V9, P62, DOI 10.1261/rna.2134303; Aphasizhev R, 2003, EMBO J, V22, P913, DOI 10.1093/emboj/cdg083; Bienvenut WV, 2002, PROTEOMICS, V2, P868, DOI 10.1002/1615-9861(200207)2:7<868::AID-PROT868>3.0.CO;2-D; COBURN CM, 1991, MOL BIOCHEM PARASIT, V46, P169, DOI 10.1016/0166-6851(91)90210-W; Cruz-Reyes J, 1998, MOL CELL, V1, P401, DOI 10.1016/S1097-2765(00)80040-4; Domingo GJ, 2003, EUKARYOT CELL, V2, P569, DOI 10.1128/EC.2.3.569-577.2003; Ernst NL, 2003, MOL CELL, V11, P1525, DOI 10.1016/S1097-2765(03)00185-0; Estevez AM, 1999, GENE, V240, P247, DOI 10.1016/S0378-1119(99)00437-0; Gao GH, 2003, J BIOL CHEM, V278, P27570, DOI 10.1074/jbc.M303317200; Huang CE, 2002, MOL CELL BIOL, V22, P3194, DOI 10.1128/MCB.22.9.3194-3203.2002; Iuchi S, 2001, CELL MOL LIFE SCI, V58, P625, DOI 10.1007/PL00000885; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; Panigrahi AK, 2003, RNA, V9, P484, DOI 10.1261/rna.2194603; Panigrahi AK, 2001, MOL CELL BIOL, V21, P6833, DOI 10.1128/MCB.21.20.6833-6840.2001; Panigrahi AK, 2001, MOL CELL BIOL, V21, P380, DOI 10.1128/MCB.21.2.380-389.2001; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Schnaufer A, 2003, MOL CELL, V12, P307, DOI 10.1016/S1097-2765(03)00286-7; Schnaufer A, 2001, SCIENCE, V291, P2159, DOI 10.1126/science.1058655; SIMPSON L, 2004, IN PRESS RNA	21	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					3893	3899		10.1074/jbc.M310185200	http://dx.doi.org/10.1074/jbc.M310185200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14604987	hybrid			2022-12-25	WOS:000188554300001
J	Sachdev, D; Hartell, JS; Lee, AV; Zhang, XH; Yee, D				Sachdev, D; Hartell, JS; Lee, AV; Zhang, XH; Yee, D			A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; SMOOTH-MUSCLE-CELLS; IGF-I; ATHYMIC MICE; LIGAND OCCUPANCY; EWINGS-SARCOMA; MELANOMA-CELLS; COLON-CANCER; TUMOR-CELLS; EXPRESSION	We have previously shown that LCC6 wild-type (WT) cells, a metastatic variant of MDA-MB-435 cancer cells originally derived from a breast cancer patient, exhibit enhanced motility in response to IGF-I compared with the parent MDA-MB-435 cells. To further understand the role of the type I insulin-like growth factor (IGF) receptor (IGF1R) in cancer metastasis we inhibited signaling via IGF1R using a C-terminal-truncated IGF1R. The truncated receptor retains the ligand binding domain but lacks the autophosphorylated tyrosine residues in the carboxyl terminus. Cells stably transfected with this truncated receptor (LCC6-DN cells) overexpressed the truncated IGF1R messenger RNA nearly 50-fold over endogenous receptor. The truncated receptor in the LCC6-DN cells behaved in a dominant negative manner to inhibit endogenous IGF1R activation by IGF-I. Compared with the LCC6-WT cells, LCC6-DN cells failed to phosphorylate the adaptor proteins insulin receptor substrate-1 and -2 in response to IGF-I and did not activate Akt after exposure to IGF-I. Unlike LCC6-WT cells, LCC6-DN cells did not show enhanced motility in response to IGF-I. To assay for metastasis, LCC6-WT and LCC6-DN cells were injected into the mammary fat pads of mice, and the primary xenograft tumors were removed after 21 days. Mice sacrificed 5 weeks later showed multiple lung metastases derived from LCC-WT xenografts, whereas mice harboring LCC6-DN xenografts showed no lung metastases. Our data show that IGF1R can regulate several aspects of the malignant phenotype. In these cells, metastasis but not proliferation requires IGF1R function.	Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Baylor College of Medicine	Yee, D (corresponding author), Univ Minnesota, Ctr Canc, MMC 806,420 Delaware St SE, Minneapolis, MN 55455 USA.	yeexx006@umn.edu		Yee, Douglas/0000-0002-3387-4009; Lee, Adrian/0000-0001-9917-514X	NCI NIH HHS [R01 CA74285, P30 CA77398] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077398, R01CA074285] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		All-Ericsson C, 2002, INVEST OPHTH VIS SCI, V43, P1; Andre F, 1999, INT J CANCER, V83, P497, DOI 10.1002/(SICI)1097-0215(19991112)83:4<497::AID-IJC11>3.3.CO;2-4; ARTEAGA CL, 1989, J CLIN INVEST, V84, P1418, DOI 10.1172/JCI114315; Bartucci M, 2001, CANCER RES, V61, P6747; BASERGA R, 1994, CELL PROLIFERAT, V27, P63, DOI 10.1111/j.1365-2184.1994.tb01406.x; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAmbrosio C, 1996, CANCER RES, V56, P4013; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Dunn SE, 1998, CANCER RES, V58, P3353; Dunn SE, 1997, CANCER RES, V57, P2687; Ellison G, 2002, J CLIN PATHOL-MOL PA, V55, P294, DOI 10.1136/mp.55.5.294; Fidler IJ, 1999, CANCER CHEMOTH PHARM, V43, pS3, DOI 10.1007/s002800051091; FIDLER IJ, 1999, CANC J SCI AM S1, V4, P58; FIGUEROA JA, 1993, J CELL PHYSIOL, V157, P229, DOI 10.1002/jcp.1041570204; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Hadsell DL, 1996, ENDOCRINOLOGY, V137, P321, DOI 10.1210/en.137.1.321; Hailey J, 2002, MOL CANCER THER, V1, P1349; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Jackson JG, 2001, ONCOGENE, V20, P7318, DOI 10.1038/sj.onc.1204920; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; Jones John I., 1995, Progress in Growth Factor Research, V6, P319, DOI 10.1016/0955-2235(95)00015-1; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leonessa F, 1996, BRIT J CANCER, V73, P154, DOI 10.1038/bjc.1996.29; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; Li SL, 2000, CANCER IMMUNOL IMMUN, V49, P243, DOI 10.1007/s002620000115; Long L, 1998, EXP CELL RES, V238, P116, DOI 10.1006/excr.1997.3814; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Mauro L, 2003, J CELL PHYSIOL, V194, P108, DOI 10.1002/jcp.10207; Mauro L, 2001, J BIOL CHEM, V276, P39892, DOI 10.1074/jbc.M106673200; NICOLSON GL, 1992, ONCOL RES, V4, P389; Nishizuka Itaru, 2002, Breast Cancer, V9, P26, DOI 10.1007/BF02967543; Plymate SR, 1997, ENDOCRINOLOGY, V138, P1728, DOI 10.1210/en.138.4.1728; Pollak M, 2000, EUR J CANCER, V36, P1224, DOI 10.1016/S0959-8049(00)00102-7; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; PRICE JE, 1990, CANCER RES, V50, P717; Price JE, 1996, BREAST CANCER RES TR, V39, P93, DOI 10.1007/BF01806081; Reinmuth N, 2002, LAB INVEST, V82, P1377, DOI 10.1097/01.LAB.0000032411.41603.C2; Resnik JL, 1998, CANCER RES, V58, P1159; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Sachdev D, 2003, CANCER RES, V63, P627; Satyamoorthy K, 2002, CELL GROWTH DIFFER, V13, P87; Scotlandi K, 1998, CANCER RES, V58, P4127; Scotlandi K, 2002, CANCER GENE THER, V9, P296, DOI 10.1038/sj.cgt.7700442; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; TOLLEFSEN SE, 1991, BIOCHEMISTRY-US, V30, P48, DOI 10.1021/bi00215a008; Turner BC, 1997, CANCER RES, V57, P3079; TWENTYMAN PR, 1987, BRIT J CANCER, V56, P279, DOI 10.1038/bjc.1987.190; VandenBerg CL, 1997, EUR J CANCER, V33, P1108, DOI 10.1016/S0959-8049(97)00071-3; Wu YP, 2002, CANCER RES, V62, P1030; YEE D, 1989, J BIOL CHEM, V264, P21439; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zhang XH, 2002, CANCER RES, V62, P4369; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217	63	127	140	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					5017	5024		10.1074/jbc.M305403200	http://dx.doi.org/10.1074/jbc.M305403200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14615489	hybrid			2022-12-25	WOS:000188554300128
J	Sironi, JJ; Ouchi, T				Sironi, JJ; Ouchi, T			STAT1-induced apoptosis is mediated by caspases 2, 3, and 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; DNA-BINDING DOMAIN; IFN-GAMMA; SIGNAL-TRANSDUCTION; CELL-DEATH; TRANSCRIPTIONAL ACTIVATION; ALPHA-INTERFERON; GENE-EXPRESSION; EXPORT SIGNAL; STAT1	STAT1 (signal transducer and activator of transcription 1) has been implicated as a mediator of a variety of biological responses in response to stimulation by specific growth factors and cytokines. To understand better the role of STAT1 in the interferon-gamma (IFN-gamma)-induced phenotype, we generated an active form of STAT1 (STAT1C) by substituting Cys residues for both Arg-656 and Asn-658 within the C-terminal loop of the STAT1 SH2 domain. The IFN-gamma activation site element was stimulated and bound efficiently by STAT1C without IFN-gamma treatment. STAT1C was found to be tyrosine-phosphorylated in the nucleus for more than 30 h after IFN-gamma stimulation. STAT1-negative U3A cells reexpressing STAT1C showed retarded cell growth and underwent apoptosis when treated with IFN-gamma. Further analysis demonstrated that apoptosis was preceded by proteolytic cleavage of caspases 2, 3, and 7, and wild type STAT1 also induced cleavage of caspase 7 when expressed in STAT1-negative U3A cells, indicating that STAT1C augments potential activity of wild type STAT1. Studies with cycloheximide treatment showed that protein synthesis induced in the first 24 h after IFN-gamma treatment was required for apoptosis under these conditions. Finally, we found that STATIC-induced apoptosis was, in part, mediated by caspase 2, 3, and 7 because benzyloxycarbonyl-valyl-aspartyl-valyl-alanyl-aspartic acid fluoromethyl ketone (Z-VDVAD-FMK) treatment partially blocked apoptosis. These results suggest that prolonged nuclear localization of activated STAT1 results in apoptosis involving specific regulation of caspase pathway.	NYU, Derald H Ruttenberg Canc Ctr, Mt Sinai Sch Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; New York University	Ouchi, T (corresponding author), NYU, Derald H Ruttenberg Canc Ctr, Mt Sinai Sch Med, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.	Toru.Ouchi@mssm.edu	SIRONI, JUAN/A-6798-2009		NATIONAL CANCER INSTITUTE [R01CA079892, R01CA090631] Funding Source: NIH RePORTER; NCI NIH HHS [CA79892, CA90631] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; Begitt A, 2000, P NATL ACAD SCI USA, V97, P10418, DOI 10.1073/pnas.190318397; Besser D, 1999, MOL CELL BIOL, V19, P1401; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; BUSCHLE M, 1993, J EXP MED, V177, P213, DOI 10.1084/jem.177.1.213; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DeBerry C, 1997, BIOCHEM J, V327, P73, DOI 10.1042/bj3270073; Dupuis S, 2001, SCIENCE, V293, P300, DOI 10.1126/science.1061154; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gooch JL, 2000, CELL GROWTH DIFFER, V11, P335; GRAWUNDER U, 1993, EUR J IMMUNOL, V23, P544, DOI 10.1002/eji.1830230237; HAQUE SJ, 1995, J BIOL CHEM, V270, P25709, DOI 10.1074/jbc.270.43.25709; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Ke SA, 1999, PROG BIOPHYS MOL BIO, V71, P405, DOI 10.1016/S0079-6107(98)00051-0; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lee CK, 2000, J IMMUNOL, V165, P3571, DOI 10.4049/jimmunol.165.7.3571; Lee CK, 2000, J IMMUNOL, V164, P1286, DOI 10.4049/jimmunol.164.3.1286; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Ramana CV, 2000, ONCOGENE, V19, P2619, DOI 10.1038/sj.onc.1203525; Ranger AM, 2001, NAT GENET, V28, P113, DOI 10.1038/88815; Rojas R, 1996, LEUKEMIA, V10, P1782; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Shuai K, 1996, MOL CELL BIOL, V16, P4932; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tan JA, 2002, J BIOL CHEM, V277, P16993, DOI 10.1074/jbc.M109217200; ten Hoeve J, 2002, MOL CELL BIOL, V22, P5662, DOI 10.1128/MCB.22.16.5662-5668.2002; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; Wu TR, 2002, J BIOL CHEM, V277, P47572, DOI 10.1074/jbc.M207536200; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zong C, 1996, EMBO J, V15, P4515, DOI 10.1002/j.1460-2075.1996.tb00829.x	55	91	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4066	4074		10.1074/jbc.M307774200	http://dx.doi.org/10.1074/jbc.M307774200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14623896	hybrid			2022-12-25	WOS:000188554300020
J	Zhang, JW; Klemm, DJ; Vinson, C; Lane, MD				Zhang, JW; Klemm, DJ; Vinson, C; Lane, MD			Role of CREB in transcriptional regulation of CCAAT/enhancer-binding protein beta gene during adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC CLONAL EXPANSION; GROWTH FACTOR-I; ADIPOCYTE DIFFERENTIATION; 3T3-L1 CELLS; CYCLIC-AMP; ADIPOSE CONVERSION; PREADIPOCYTE DIFFERENTIATION; INHIBITS ADIPOGENESIS; TRANSGENIC MICE; KINASE AKT/PKB	The proximal promoter of the C/EBPbeta gene possesses dual cis regulatory elements (TGA1 and TGA2), both of which contain core CREB binding sites. Comparison of the activities of C/EBPbeta promoter-reporter genes with 5'-truncations or site-directed mutations in the TGA elements showed that both are required for maximal promoter function. Electrophoretic mobility shift and chromatin immunoprecipitation (ChIP) analyses with antibodies specific to CREB and ATF1 showed that these CREB family members associate with the proximal promoter both in vitro and ex vivo. Immunoblotting and ChIP analysis revealed that other CREB family members, CREM and ATF1, are up-regulated and associate with the proximal C/EBPbeta promoter in mouse embryonic fibroblasts (MEFs) from CREB(-/-) mice. ChIP analysis of wild-type MEFs and 3T3-L1 preadipocytes revealed that interaction of phospho-CREB, the active form of CREB, with the C/EBPbeta gene promoter occurs only after induction of differentiation of 3T3-L1 preadipocytes and MEFs. Consistent with the interaction of CREB and ATF1 at the TGA regulatory elements, expression of constitutively active CREB strongly activated C/EBPbeta promoter-reporter genes, induced expression of endogenous C/EBPbeta, and caused adipogenesis in the absence of the hormonal inducers normally required. Conversely, expression of a dominant-negative CREB blocked promoter-reporter activity, expression of C/EBPbeta, and adipogenesis. When subjected to the standard adipocyte differentiation protocol, wild-type MEFs differentiate into adipocytes at high frequency, whereas CREB(-/-) MEFs exhibit greatly reduced expression of C/EBPbeta and differentiation. The low level of expression of C/EBPbeta and differentiation in CREB(-/-) MEFs appears to be due to up-regulation of other CREB protein family members, i.e. ATF1 and CREM.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Biochem Cellular & Mol Biol Program, Baltimore, MD 21205 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Cardiovasc Pulm Res Lab, Denver, CO 80262 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lane, MD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Rm 512 WBSB, Baltimore, MD 21205 USA.	dlane@jhmi.edu	Zhang, Jiangwen/A-7654-2013	Zhang, Jiangwen/0000-0002-2911-8446	NHLBI NIH HHS [HLHL14985] Funding Source: Medline; NIDDK NIH HHS [DK38418, DK53969] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC005271, Z01BC005271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053969, R01DK038418] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbott DW, 1997, J BIOL CHEM, V272, P32454, DOI 10.1074/jbc.272.51.32454; Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; BRANDES R, 1990, BIOCHIM BIOPHYS ACTA, V1054, P219, DOI 10.1016/0167-4889(90)90244-8; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Casimir DA, 1996, DIFFERENTIATION, V60, P203, DOI 10.1046/j.1432-0436.1996.6040203.x; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6506; Gnudi L, 1996, P NUTR SOC, V55, P191, DOI 10.1079/PNS19960020; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; Hwang CS, 1996, P NATL ACAD SCI USA, V93, P873, DOI 10.1073/pnas.93.2.873; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Klemm DJ, 1998, J BIOL CHEM, V273, P917, DOI 10.1074/jbc.273.2.917; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LEE H, 1991, FEBS LETT, V280, P134, DOI 10.1016/0014-5793(91)80221-N; Lee KAW, 1991, CURR OPIN CELL BIOL, V3, P953, DOI 10.1016/0955-0674(91)90113-D; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; Patel YM, 1999, P NATL ACAD SCI USA, V96, P1279, DOI 10.1073/pnas.96.4.1279; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; Rosen ED, 2000, GENE DEV, V14, P1293; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHMIDT W, 1990, J BIOL CHEM, V265, P15489; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; STRAUS DS, 1984, ENDOCR REV, V5, P356, DOI 10.1210/edrv-5-2-356; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tang QQ, 1997, P NATL ACAD SCI USA, V94, P13571, DOI 10.1073/pnas.94.25.13571; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P44, DOI 10.1073/pnas.0137044100; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; VAN RLR, 1976, J CLIN INVEST, V58, P699, DOI 10.1172/JCI108516; WILLIAMS PM, 1991, MOL CELL BIOL, V11, P4959, DOI 10.1128/MCB.11.10.4959; YANG VW, 1989, P NATL ACAD SCI USA, V86, P3629, DOI 10.1073/pnas.86.10.3629; Yarwood SJ, 1998, MOL CELL ENDOCRINOL, V138, P41; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	51	194	205	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4471	4478		10.1074/jbc.M311327200	http://dx.doi.org/10.1074/jbc.M311327200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14593102	hybrid			2022-12-25	WOS:000188554300067
J	Gewinner, C; Hart, G; Zachara, N; Cole, R; Beisenherz-Huss, C; Groner, B				Gewinner, C; Hart, G; Zachara, N; Cole, R; Beisenherz-Huss, C; Groner, B			The coactivator of transcription CREB-binding protein interacts preferentially with the glycosylated form of Stat5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; O-GLCNAC TRANSFERASE; MAMMARY EPITHELIAL-CELLS; BETA-CASEIN GENE; DNA-BINDING; CYTOSOLIC PROTEINS; TETRATRICOPEPTIDE REPEATS; GLUCOCORTICOID RECEPTOR; SERINE PHOSPHORYLATION; TRANSACTIVATION DOMAIN	The signal transducer and activator of transcription (Stat) gene family comprises seven members with similarities in their domain structure and a common mode of activation. Members of this gene family mediate interferon induction of gene transcription and the response to a large number of growth factors and hormones. Extracellular ligand binding to transmembrane receptors causes the intracellular activation of associated tyrosine kinases, phosphorylation of Stat molecules, dimerization, and translocation to the nucleus. Prolactin-induced phosphorylation of Stat5 is a key event in the development and differentiation of mammary epithelial cells. In addition to the crucial phosphorylation at tyrosine 694, we have identified an O-linked N-acetylglucosamine (O-GlcNAc) as another secondary modification essential for the transcriptional induction by Stat5. This modification was only found on nuclear Stat5 after cytokine activation. Similar observations were made with Stat1, Stat3, and Stat6. Glycosylation of Stat5, however, does not seem to be a prerequisite for nuclear translocation. Mass spectrometric analysis revealed a glycosylated peptide in the N-terminal region of Stat5. Replacement of threonine 92 by an alanine residue (Stat5a-T92A) strongly reduced the prolactin induction of Stat5a glycosylation and abolished transactivation of a target gene promoter. Only the glycosylated form of Stat5 was able to bind the coactivator of transcription CBP, an essential interaction for Stat5-mediated gene transcription.	Inst Biomed Res, D-60596 Frankfurt, Germany; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD USA; Univ Freiburg, Inst Anat 1, D-79104 Freiburg, Germany	Johns Hopkins University; University of Freiburg	Gewinner, C (corresponding author), Beth Israel Deaconess Med Ctr, Div Signal Transduct, 330 Brookline Ave,HIM 1018, Boston, MA 02215 USA.	cgewinne@caregroup.harvard.edu		Hart, Gerald/0000-0001-7812-4351				Akimoto Y, 1999, DIABETES, V48, P2407, DOI 10.2337/diabetes.48.12.2407; Akimoto Y, 2001, ARCH BIOCHEM BIOPHYS, V389, P166, DOI 10.1006/abbi.2001.2331; Ali S, 1998, J BIOL CHEM, V273, P7709, DOI 10.1074/jbc.273.13.7709; Aoki N, 2000, J BIOL CHEM, V275, P39718, DOI 10.1074/jbc.M005615200; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Beisenherz-Huss C, 2001, MOL CELL ENDOCRINOL, V183, P101, DOI 10.1016/S0303-7207(01)00588-3; Beuvink I, 2000, J BIOL CHEM, V275, P10247, DOI 10.1074/jbc.275.14.10247; Boehmelt G, 2000, EMBO J, V19, P5092, DOI 10.1093/emboj/19.19.5092; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; Cheng XG, 2001, J BIOL CHEM, V276, P10570, DOI 10.1074/jbc.M010411200; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; Cole RN, 1999, J NEUROCHEM, V73, P418, DOI 10.1046/j.1471-4159.1999.0730418.x; Comer FI, 1999, BBA-GEN SUBJECTS, V1473, P161, DOI 10.1016/S0304-4165(99)00176-2; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; Comer FI, 2001, BIOCHEMISTRY-US, V40, P7845, DOI 10.1021/bi0027480; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; DONG DLY, 1993, J BIOL CHEM, V268, P16679; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Duverger E, 1996, GLYCOBIOLOGY, V6, P381, DOI 10.1093/glycob/6.4.381; Fagerlund R, 2002, J BIOL CHEM, V277, P30072, DOI 10.1074/jbc.M202943200; Fang B, 2001, EXP CELL RES, V263, P243, DOI 10.1006/excr.2000.5110; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; GOOLEY AA, 1991, BIOCHEM BIOPH RES CO, V178, P1194, DOI 10.1016/0006-291X(91)91019-9; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Greis KD, 1996, ANAL BIOCHEM, V234, P38, DOI 10.1006/abio.1996.0047; GREIS KD, 1994, J VIROL, V68, P8339, DOI 10.1128/JVI.68.12.8339-8349.1994; GRONER B, 1995, CURR OPIN GENET DEV, V5, P587, DOI 10.1016/0959-437X(95)80027-1; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hanover JA, 2001, FASEB J, V15, P1865, DOI 10.1096/fj.01-0094rev; Hart GW, 1996, GLYCOBIOLOGY, V6, P711, DOI 10.1093/glycob/6.7.711; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; John S, 1999, MOL CELL BIOL, V19, P1910; Konrad RJ, 2001, BIOCHEM J, V356, P31, DOI 10.1042/0264-6021:3560031; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kreppel LK, 1999, J BIOL CHEM, V274, P32015, DOI 10.1074/jbc.274.45.32015; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Liu K, 2000, P NATL ACAD SCI USA, V97, P2820, DOI 10.1073/pnas.97.6.2820; Lubas WA, 2000, J BIOL CHEM, V275, P10983, DOI 10.1074/jbc.275.15.10983; Maurer AB, 2002, BLOOD, V99, P2647, DOI 10.1182/blood.V99.8.2647; Mauvais-Jarvis F, 2002, J CLIN INVEST, V109, P141, DOI 10.1172/JCI200213305; McBride KM, 2002, EMBO J, V21, P1754, DOI 10.1093/emboj/21.7.1754; Medina L, 1998, GLYCOBIOLOGY, V8, P383, DOI 10.1093/glycob/8.4.383; Miller MW, 1999, ARCH BIOCHEM BIOPHYS, V367, P51, DOI 10.1006/abbi.1999.1237; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Parekh RB, 1997, CURR OPIN BIOTECH, V8, P718, DOI 10.1016/S0958-1669(97)80126-7; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; Sayeski PP, 1996, J BIOL CHEM, V271, P15237, DOI 10.1074/jbc.271.25.15237; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; Shaw P, 1996, ONCOGENE, V12, P921; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Stoecklin E, 1997, MOL CELL BIOL, V17, P6708, DOI 10.1128/MCB.17.11.6708; Vosseller K, 2001, BIOCHIMIE, V83, P575, DOI 10.1016/S0300-9084(01)01295-0; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wartmann M, 1996, J BIOL CHEM, V271, P31863, DOI 10.1074/jbc.271.50.31863; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; YAMAMOTO K, 1981, BIOCHEMISTRY-US, V20, P5894, DOI 10.1021/bi00523a037; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Yki-Jarvinen H, 1998, METABOLISM, V47, P449, DOI 10.1016/S0026-0495(98)90058-0; Zachara NE, 2002, CHEM REV, V102, P431, DOI 10.1021/cr000406u; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	80	132	138	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3563	3572		10.1074/jbc.M306449200	http://dx.doi.org/10.1074/jbc.M306449200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14597631	hybrid			2022-12-25	WOS:000188379600053
J	Lemercier, G; Espiau, B; Ruiz, FA; Vieira, M; Luo, SH; Baltz, T; Docampo, R; Bakalara, N				Lemercier, G; Espiau, B; Ruiz, FA; Vieira, M; Luo, SH; Baltz, T; Docampo, R; Bakalara, N			A pyrophosphatase regulating polyphosphate metabolism in acidocalcisomes is essential for Trypanosoma brucei virulence in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-31 NMR-SPECTROSCOPY; INORGANIC PYROPHOSPHATASE; LEISHMANIA-MAJOR; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL ACIDOCALCISOMES; ESCHERICHIA-COLI; INFECTIVE FORMS; EF-HAND; CRUZI; BINDING	We report the functional characterization of a soluble pyrophosphatase (TbVSP1), which localizes to acidocalcisomes, a vesicular acidic compartment of Trypanosoma brucei. Depending on the pH and the cofactors Mg2+ or Zn2+, both present in the compartment, the enzyme hydrolyzes either inorganic pyrophosphate (PPi) (k(cat)=385 s(-1)) or tripolyP (polyP(3)) and polyphosphate (polyP) of 28 residues (polyP(28)) with k(cat) values of 52 and 3.5 s(-1), respectively. An unusual N-terminal domain of 160 amino acids, containing a putative calcium EF-hand-binding domain, is involved in protein oligomerization. Using double-stranded RNA interference methodology, we produced an inducible bloodstream form (BF) deficient in the TbVSP1 protein (BFiVSP1). The long-chain polyP levels of these mutants were reduced by 60%. Their phenotypes revealed a deficient polyP metabolism, as indicated by their defective response to phosphate starvation and hyposmotic stress. BFiVSP1 did not cause acute virulent infection in mice, demonstrating that TbVSP1 is essential for growth of bloodstream forms in the mammalian host.	CNRS, UMR 5162, Lab Genom Fonct Trypanosomatides, F-33076 Bordeaux, France; Univ Illinois, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA; Univ Illinois, Ctr Zoonoses Res, Urbana, IL 61802 USA	Centre National de la Recherche Scientifique (CNRS); University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Bakalara, N (corresponding author), CNRS, UMR 5162, Lab Genom Fonct Trypanosomatides, Bat 3A,146 Rue Leo Saignat, F-33076 Bordeaux, France.	bakalara@u-bordeaux2.fr	Ruiz, Felix A./B-1032-2008	Ruiz, Felix A./0000-0003-0748-5015				Bakalara N, 2000, J BIOL CHEM, V275, P8863, DOI 10.1074/jbc.275.12.8863; BALTZ T, 1985, EMBO J, V4, P1273, DOI 10.1002/j.1460-2075.1985.tb03772.x; BATES PF, 1983, GENE, V26, P137, DOI 10.1016/0378-1119(83)90183-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUN R, 1979, ACTA TROP, V36, P387; CAMPBELL DA, 1989, NUCLEIC ACIDS RES, V17, P458, DOI 10.1093/nar/17.1.458; Davis JP, 2002, J BIOL CHEM, V277, P49716, DOI 10.1074/jbc.M208488200; Docampo R, 1999, PARASITOL TODAY, V15, P443, DOI 10.1016/S0169-4758(99)01531-8; Docampo R, 2001, MOL BIOCHEM PARASIT, V114, P151, DOI 10.1016/S0166-6851(01)00246-8; Dutoya S, 2001, J BIOL CHEM, V276, P49117, DOI 10.1074/jbc.M105962200; Godsel LM, 1999, EMBO J, V18, P2057, DOI 10.1093/emboj/18.8.2057; Hyytia T, 2001, BIOCHEMISTRY-US, V40, P4645, DOI 10.1021/bi010049x; Jiang SS, 1997, ARCH BIOCHEM BIOPHYS, V346, P105, DOI 10.1006/abbi.1997.0279; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; Kornberg A, 1999, ANNU REV BIOCHEM, V68, P89, DOI 10.1146/annurev.biochem.68.1.89; Kulaev IS, 2000, BIOCHEMISTRY-MOSCOW+, V65, P271; KUMBLE KD, 1995, J BIOL CHEM, V270, P5818, DOI 10.1074/jbc.270.11.5818; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; LEFURGEY A, 1990, MOL BIOCHEM PARASIT, V40, P77, DOI 10.1016/0166-6851(90)90081-V; LeFurgey A, 2001, COMP BIOCHEM PHYS A, V128, P385, DOI 10.1016/S1095-6433(00)00319-6; Lemercier G, 2003, J CHROMATOGR B, V786, P305, DOI 10.1016/S1570-0232(02)00745-6; Lemercier G, 2002, J BIOL CHEM, V277, P37369, DOI 10.1074/jbc.M204744200; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; LUNDIN M, 1991, J BIOL CHEM, V266, P12168; Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578; Montalvetti A, 2001, J BIOL CHEM, V276, P33930, DOI 10.1074/jbc.M103950200; Moreno B, 2002, FEBS LETT, V523, P207, DOI 10.1016/S0014-5793(02)02977-0; Moreno B, 2000, J BIOL CHEM, V275, P28356, DOI 10.1074/jbc.M003893200; Rodrigues CO, 1999, MOL CELL BIOL, V19, P7712; Rodrigues CO, 2002, J BIOL CHEM, V277, P50899, DOI 10.1074/jbc.M208940200; Rohloff P, 2003, MOL BIOCHEM PARASIT, V126, P219, DOI 10.1016/S0166-6851(02)00277-3; Ruiz VL, 2001, FRONTIERS, V22, P22, DOI 10.1353/fro.2001.0045; SAMBOROK J, 1989, MOL CLONING LAB MANU; Schroder HC, 2000, BIOCHEMISTRY-MOSCOW+, V65, P296; Sethuraman A, 2001, P NATL ACAD SCI USA, V98, P8542, DOI 10.1073/pnas.151269398; SHATTON JB, 1983, ANAL BIOCHEM, V130, P114, DOI 10.1016/0003-2697(83)90657-7; Sivula T, 1999, FEBS LETT, V454, P75, DOI 10.1016/S0014-5793(99)00779-6; Urbina JA, 1999, J BIOL CHEM, V274, P33609, DOI 10.1074/jbc.274.47.33609; Vagabov VM, 2000, BIOCHEMISTRY-MOSCOW+, V65, P349; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; VERCESI AE, 1994, BIOCHEM J, V304, P227, DOI 10.1042/bj3040227; Wirtz E, 1998, NUCLEIC ACIDS RES, V26, P4626, DOI 10.1093/nar/26.20.4626; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WURST H, 1995, J BACTERIOL, V177, P898, DOI 10.1128/jb.177.4.898-906.1995; Zyryanov AB, 2002, BIOCHEM J, V367, P901, DOI 10.1042/BJ20020880	45	65	66	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3420	3425		10.1074/jbc.M309974200	http://dx.doi.org/10.1074/jbc.M309974200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14615483	hybrid			2022-12-25	WOS:000188379600036
J	Markova, SV; Golz, S; Frank, LA; Kalthof, B; Vysotski, ES				Markova, SV; Golz, S; Frank, LA; Kalthof, B; Vysotski, ES			Cloning and expression of cDNA for a luciferase from the marine copepod Metridia longa - A novel secreted bioluminescent reporter enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARGULA-HILGENDORFII LUCIFERASE; GREEN FLUORESCENT PROTEIN; GENE-EXPRESSION; FIREFLY LUCIFERASE; PROMOTER ACTIVITY; MAMMALIAN-CELLS; RECEPTOR; CANCER; PHOTOPROTEINS; LUMINESCENCE	Metridia longa is a marine copepod from which a blue bioluminescence originates as a secretion from epidermal glands in response to various stimuli. We demonstrate that Metridia luciferase is specific for coelenterazine to produce blue light (lambda(max)=480 nm). Using an expression cDNA library and functional screening, we cloned and sequenced the cDNA encoding the Metridia luciferase. The cDNA is an 897-bp fragment with a 656-bp open reading frame, which encodes a 219-amino acid polypeptide with a molecular weight of 23,885. The polypeptide contains an N-terminal signal peptide of 17 amino acid residues for secretion. On expression of the Metridia luciferase gene in mammalian Chinese hamster ovary cells the luciferase is detected in the culture medium confirming the existence of a naturally occurring signal peptide for secretion in the cloned luciferase. The novel secreted luciferase was tested in a practical assay application in which the activity of A2a and NPY2 G-protein-coupled receptors was detected. These results clearly suggest that the secreted Metridia luciferase is well suited as a reporter for monitoring gene expression and, in particular, for the development of novel ultra-high throughput screening technologies.	Russian Acad Sci, Siberian Branch, Inst Biophys, Photobiol Lab, Krasnoyarsk 660036, Russia; Bayer AG, Pharma Res Mol Screening Technol, D-42096 Wuppertal, Germany	Russian Academy of Sciences; Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences; Biophysics Institute, Siberian Branch, Russian Academy of Sciences; Bayer AG	Vysotski, ES (corresponding author), Russian Acad Sci, Siberian Branch, Inst Biophys, Photobiol Lab, Krasnoyarsk 660036, Russia.	vys@bmb.uga.edu	Markova, Svetlana V./AAT-7574-2020; Frank, Ludmila A/P-8560-2015; Vysotski, Eugene/I-1761-2013	Markova, Svetlana V./0000-0001-5702-1193; Vysotski, Eugene/0000-0002-5884-3081				Ando S, 2002, MOL CELL ENDOCRINOL, V193, P121, DOI 10.1016/S0303-7207(02)00105-3; Bevis BJ, 2002, NAT BIOTECHNOL, V20, P83, DOI 10.1038/nbt0102-83; Bhaumik S, 2002, P NATL ACAD SCI USA, V99, P377, DOI 10.1073/pnas.012611099; Bi XJ, 2002, J BIOTECHNOL, V93, P231, DOI 10.1016/S0168-1656(01)00400-X; Broussard DR, 2002, J VIROL, V76, P2087, DOI 10.1128/jvi.76.5.2087-2099.2002; CAMPBELL AK, 1990, MAR BIOL, V104, P219, DOI 10.1007/BF01313261; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE GL, 1962, J MAR BIOL ASSOC UK, V42, P541, DOI 10.1017/S0025315400054254; Duisit G, 2002, MOL THER, V6, P446, DOI 10.1006/mthe.2002.0690; Evstigneev PV., 1990, BIOLUMINESCENCE MARI; GANDELMAN O, 1994, J BIOLUM CHEMILUM, V9, P363, DOI 10.1002/bio.1170090603; Hough RB, 2002, P NATL ACAD SCI USA, V99, P8145, DOI 10.1073/pnas.122231099; ILLARIONOV BA, 1992, DOKL AKAD NAUK+, V326, P911; INOUYE S, 1992, P NATL ACAD SCI USA, V89, P9584, DOI 10.1073/pnas.89.20.9584; Inouye S, 2000, FEBS LETT, V481, P19, DOI 10.1016/S0014-5793(00)01963-3; JOHNSON CH, 1995, SCIENCE, V269, P1863, DOI 10.1126/science.7569925; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; KONDO T, 1993, P NATL ACAD SCI USA, V90, P5672, DOI 10.1073/pnas.90.12.5672; Kostrouchova M, 2002, P NATL ACAD SCI USA, V99, P9254, DOI 10.1073/pnas.112213799; Langer I, 2001, CELL CALCIUM, V30, P229, DOI 10.1054/ceca.2001.0230; LEMBERT N, 1995, BIOCHEM J, V305, P929, DOI 10.1042/bj3050929; Liu JX, 2000, LUMINESCENCE, V15, P45, DOI 10.1002/(SICI)1522-7243(200001/02)15:1<45::AID-BIO553>3.0.CO;2-E; Liu S, 2001, J BIOTECHNOL, V87, P1, DOI 10.1016/S0168-1656(00)00421-1; Liu Y, 2000, PLASMID, V44, P250, DOI 10.1006/plas.2000.1486; LORENZ WW, 1991, P NATL ACAD SCI USA, V88, P4438, DOI 10.1073/pnas.88.10.4438; Markova SV, 2002, BIOCHEMISTRY-US, V41, P2227, DOI 10.1021/bi0117910; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; Radford JC, 2002, J BIOL CHEM, V277, P38810, DOI 10.1074/jbc.M203694200; Ronen M, 2002, P NATL ACAD SCI USA, V99, P10555, DOI 10.1073/pnas.152046799; Tanahashi Y, 2001, ANAL BIOCHEM, V289, P260, DOI 10.1006/abio.2000.4932; THOMPSON EM, 1990, GENE, V96, P257, DOI 10.1016/0378-1119(90)90261-O; THOMPSON EM, 1995, P NATL ACAD SCI USA, V92, P1317, DOI 10.1073/pnas.92.5.1317; THOMPSON EM, 1989, P NATL ACAD SCI USA, V86, P6567, DOI 10.1073/pnas.86.17.6567; TSUJI FI, 1995, PHOTOCHEM PHOTOBIOL, V62, P657, DOI 10.1111/j.1751-1097.1995.tb08713.x; Yoon K, 2000, MOL CELL ENDOCRINOL, V162, P211, DOI 10.1016/S0303-7207(99)00261-0; Yoshida R, 1998, BIOCHEM BIOPH RES CO, V242, P659, DOI 10.1006/bbrc.1997.8045	37	110	129	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3212	3217		10.1074/jbc.M309639200	http://dx.doi.org/10.1074/jbc.M309639200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14583604	hybrid			2022-12-25	WOS:000188379600011
J	Pandey, KC; Sijwali, PS; Singh, A; Na, BK; Rosenthal, PJ				Pandey, KC; Sijwali, PS; Singh, A; Na, BK; Rosenthal, PJ			Independent intramolecular mediators of folding, activity, and inhibition for the Plasmodium falciparum cysteine protease falcipain-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT FALCIPAIN-2; CRYSTAL-STRUCTURE; PROTEINASE; SELECTIVITY; EXPRESSION; CHAPERONE; REVEALS; POTENCY; PEPTIDE; TARGETS	The Plasmodium falciparum cysteine protease falcipain-2 is a trophozoite hemoglobinase and potential antimalarial drug target. Unlike other studied papain family proteases, falcipain-2 does not require its prodomain for folding to active enzyme. Rather, folding is mediated by an amino-terminal extension of the mature protease. As in related enzymes, the prodomain is a potent inhibitor of falcipain-2. We now report further functional evaluation of the domains of falcipain-2 and related plasmodial proteases. The minimum requirement for folding of falcipain-2 and four related plasmodial cysteine proteases was inclusion of a 14-15-residue amino-terminal folding domain, beginning with a conserved Tyr. Chimeras of the falcipain-2 catalytic domain with extensions from six other plasmodial proteases folded normally and had kinetic parameters (k(cat)/K-m 124,000-195,000 M-1 s(-1)) similar to those of recombinant falcipain-2 (k(cat)/K-m 120,000 M-1 s(-1)), indicating that the folding domain is functionally conserved across the falcipain-2 subfamily. Correct folding also occurred when the catalytic domain was refolded with a separate prodomain-folding domain construct but not with an isolated folding domain peptide. Thus, the prodomain mediated interaction between the other two domains when they were not covalently bound. The prodomain-catalytic domain interaction was independent of the active site, because it was blocked by free inactive catalytic domain but not by the active site-binding peptide leupeptin. The folded catalytic domain retained activity after purification from the prodomain-folding domain construct (k(cat)/K-m 168,000 M-1 s(-1)), indicating that the folding domain is not required for activity once folding has been achieved. Activity was lost after nonreducing gelatin SDS-PAGE but not native gelatin PAGE, indicating that correct disulfide bonds are insufficient to direct appropriate folding. Our results identify unique features of the falcipain-2 subfamily with independent mediation of activity, folding, and inhibition.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94143 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Rosenthal, PJ (corresponding author), Univ Calif San Francisco, Box 0811, San Francisco, CA 94143 USA.	rosnthl@itsa.ucsf.edu			NCRR NIH HHS [RR01081] Funding Source: Medline; NIAID NIH HHS [AI35800] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI035800, R29AI035800, R01AI035800] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAILLY E, 1992, J PROTOZOOL, V39, P593, DOI 10.1111/j.1550-7408.1992.tb04856.x; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breman JG, 2001, AM J TROP MED HYG, V64, P1; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; DLUZEWSKI AR, 1986, EXP PARASITOL, V62, P416, DOI 10.1016/0014-4894(86)90050-0; Dua M, 2001, MOL BIOCHEM PARASIT, V116, P95, DOI 10.1016/S0166-6851(01)00306-1; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Guay J, 2000, EUR J BIOCHEM, V267, P6311, DOI 10.1046/j.1432-1327.2000.01730.x; Jaswal SS, 2002, NATURE, V415, P343, DOI 10.1038/415343a; KARRER KM, 1993, P NATL ACAD SCI USA, V90, P3063, DOI 10.1073/pnas.90.7.3063; LaLonde JM, 1999, BIOCHEMISTRY-US, V38, P862, DOI 10.1021/bi9822271; Lew VL, 2003, BLOOD, V101, P4189, DOI 10.1182/blood-2002-08-2654; Olliaro PL, 1999, PHARMACOL THERAPEUT, V81, P91, DOI 10.1016/S0163-7258(98)00036-9; Podobnik M, 1997, J MOL BIOL, V271, P774, DOI 10.1006/jmbi.1997.1218; Ridley RG, 2002, NATURE, V415, P686, DOI 10.1038/415686a; ROSENTHAL PJ, 1991, J CLIN INVEST, V88, P1467, DOI 10.1172/JCI115456; ROSENTHAL PJ, 1988, J CLIN INVEST, V82, P1560, DOI 10.1172/JCI113766; Rosenthal PJ, 2002, CURR PHARM DESIGN, V8, P1659, DOI 10.2174/1381612023394197; ROSENTHAL PJ, 1993, J CLIN INVEST, V91, P1052, DOI 10.1172/JCI116262; Shenai BR, 2000, J BIOL CHEM, V275, P29000, DOI 10.1074/jbc.M004459200; Shinde U, 2000, SEMIN CELL DEV BIOL, V11, P35, DOI 10.1006/scdb.1999.0349; Sijwali PS, 2002, J BIOL CHEM, V277, P14910, DOI 10.1074/jbc.M109680200; Sijwali PS, 2001, BIOCHEM J, V360, P481, DOI 10.1042/0264-6021:3600481; Sijwali PS, 2001, PROTEIN EXPRES PURIF, V22, P128, DOI 10.1006/prep.2001.1416; SMITH SM, 1989, J BIOL CHEM, V264, P20487; TAYLOR MAJ, 1995, PROTEIN ENG, V8, P59, DOI 10.1093/protein/8.1.59; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Wongsrichanalai C, 2002, LANCET INFECT DIS, V2, P209, DOI 10.1016/S1473-3099(02)00239-6; Yamamoto Y, 1999, ARCH INSECT BIOCHEM, V42, P167, DOI 10.1002/(SICI)1520-6327(199911)42:3&lt;167::AID-ARCH1&gt;3.0.CO;2-Z	31	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3484	3491		10.1074/jbc.M310536200	http://dx.doi.org/10.1074/jbc.M310536200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14625277	hybrid			2022-12-25	WOS:000188379600044
J	Ryazanova, LV; Dorovkov, MV; Ansari, A; Ryazanov, AG				Ryazanova, LV; Dorovkov, MV; Ansari, A; Ryazanov, AG			Characterization of the protein kinase activity of TRPM7/ChaK1, a protein kinase fused to the transient receptor potential ion channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN KINASE; ELONGATION FACTOR-2 KINASE; DIVALENT METAL CATION; TYROSINE KINASE; CATALYTIC DOMAIN; SECONDARY HYPOCALCEMIA; MIC CHANNELS; DICTYOSTELIUM; FAMILY; MECHANISM	Channel-kinase TRPM7/ChaK1 is a member of a recently discovered family of protein kinases called alpha-kinases that display no sequence homology to conventional protein kinases. It is an unusual bifunctional protein that contains an alpha-kinase domain fused to an ion channel. The TRPM7/ChaK1 channel has been characterized using electrophysiological techniques, and recent evidence suggests that it may play a key role in the regulation of magnesium homeostasis. However, little is known about its protein kinase activity. To characterize the kinase activity of TRPM7/ChaK1, we expressed the kinase catalytic domain in bacteria. ChaK1-cat is able to undergo autophosphorylation and to phosphorylate myelin basic protein and histone H3 on serine and threonine residues. The kinase is specific for ATP and cannot use GTP as a substrate. ChaK1-cat is insensitive to staurosporine (up to 0.1 mM) but can be inhibited by rottlerin. Because the kinase domain is physically linked to an ion channel, we investigated the effect of ions on ChaK1-cat activity. The kinase requires Mg2+ (optimum at 4-10 mM) or Mn2+ (optimum at 3-5 mM), with activity in the presence of Mn2+ being 2 orders of magnitude higher than in the presence of Mg2+. Zn2+ and Co2+ inhibited ChaK1-cat kinase activity. Ca2+ at concentrations up to 1 mM did not affect kinase activity. Considering intracellular ion concentrations, our results suggest that, among divalent metal ions, only Mg2+ can directly modulate TRPM7/ChaK1 kinase activity in vivo.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Ryazanov, AG (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Lane, Piscataway, NJ 08854 USA.	ryazanag@umdnj.edu	ryazanov, alexey/J-8081-2017					Adams JA, 2001, CHEM REV, V101, P2271, DOI 10.1021/cr000230w; Clancy CE, 1997, J BIOL CHEM, V272, P11812, DOI 10.1074/jbc.272.18.11812; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Cote GP, 1997, J BIOL CHEM, V272, P6846, DOI 10.1074/jbc.272.11.6846; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DRENNAN D, 2004, IN PRESS PROG BIOPHY; FUTEY LM, 1995, J BIOL CHEM, V270, P523, DOI 10.1074/jbc.270.2.523; Grace MR, 1997, BIOCHEMISTRY-US, V36, P1874, DOI 10.1021/bi962138t; GSCHWENDT M, 1994, FEBS LETT, V338, P85, DOI 10.1016/0014-5793(94)80121-5; Hermosura MC, 2002, J PHYSIOL-LONDON, V539, P445, DOI 10.1113/jphysiol.2001.013361; KOLAND JG, 1990, BIOCHIM BIOPHYS ACTA, V1052, P489, DOI 10.1016/0167-4889(90)90160-F; Kozak JA, 2002, J GEN PHYSIOL, V120, P221, DOI 10.1085/jgp.20028601; Liang WC, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-19; Luo X, 2001, J BIOL CHEM, V276, P17836, DOI 10.1074/jbc.M009366200; Monteilh-Zoller MK, 2003, J GEN PHYSIOL, V121, P49, DOI 10.1085/jgp.20028740; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Pavur KS, 2000, BIOCHEMISTRY-US, V39, P12216, DOI 10.1021/bi0007270; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Ryazanov AG, 2002, FEBS LETT, V514, P26, DOI 10.1016/S0014-5793(02)02299-8; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; Ryazanov AG, 1999, CURR BIOL, V9, pR43, DOI 10.1016/S0960-9822(99)80006-2; Ryazanova LV, 2001, MOL BIOL+, V35, P271, DOI 10.1023/A:1010499720185; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; Schlingmann KP, 2002, NAT GENET, V31, P166, DOI 10.1038/ng889; Schmitz C, 2003, CELL, V114, P191, DOI 10.1016/S0092-8674(03)00556-7; Shugar D, 1996, ACTA BIOCHIM POL, V43, P9; Sun GQ, 1997, BIOCHEMISTRY-US, V36, P2139, DOI 10.1021/bi962291n; Sun GQ, 1999, BIOCHEMISTRY-US, V38, P5659, DOI 10.1021/bi982793w; Tian GC, 2002, BIOPHYS CHEM, V95, P79, DOI 10.1016/S0301-4622(01)00251-4; Walder RY, 2002, NAT GENET, V31, P171, DOI 10.1038/ng901; WEDEGAERTNER PB, 1989, J BIOL CHEM, V264, P11346; WENTE SR, 1990, P NATL ACAD SCI USA, V87, P2805, DOI 10.1073/pnas.87.7.2805; WOLFF DJ, 1981, J BIOL CHEM, V256, P1846; Yamaguchi H, 2001, MOL CELL, V7, P1047, DOI 10.1016/S1097-2765(01)00256-8; YUAN CJ, 1993, J BIOL CHEM, V268, P17683	40	141	152	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3708	3716		10.1074/jbc.M308820200	http://dx.doi.org/10.1074/jbc.M308820200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14594813	hybrid			2022-12-25	WOS:000188379600071
J	Baumgrass, R; Zhang, YX; Erdmann, F; Thiel, A; Weiwad, M; Radbruch, A; Fischer, G				Baumgrass, R; Zhang, YX; Erdmann, F; Thiel, A; Weiwad, M; Radbruch, A; Fischer, G			Substitution in position 3 of cyclosporin A abolishes the cyclophilin-mediated gain-of-function mechanism but not immunosuppression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCINEURIN PHOSPHATASE-ACTIVITY; PROLYL CIS/TRANS ISOMERASES; TRANSCRIPTION FACTOR NFAT1; X-RAY-STRUCTURE; CELLULAR-REGULATION; ENZYME-INHIBITION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; IMMUNOPHILIN; COMPLEXES	Binary complex formation between the immunosuppressive drug cyclosporin A (CsA) and cyclophilin 18 is the prerequisite for the ability of CsA to inhibit the protein phosphatase activity of calcineurin, a central mediator of antigen-receptor signaling. We show here that several CsA derivatives substituted in position 3 can inhibit calcineurin without prior formation of a complex with cyclophilin 18. [Methylsarcosine(3)] CsA was shown to inhibit calcineurin, either in its free form with an IC50 value of 10 muM, or in its complex form with cyclophilin 18 with an IC50 of 500 nM. [Dimethylaminoethylthiosarcosine(3)] CsA ([Dat-Sar(3)] CsA) was found to inhibit calcineurin on its own, with an IC50 value of 1.0 muM, but was not able to inhibit calcineurin after forming the [Dat-Sar(3)] CsA-cyclophilin 18 binary complex. Despite their different inhibitory properties, both CsA and [Dat-Sar(3)] CsA suppressed T cell proliferation and cytokine production mainly through blocking NFAT activation and interleukin-2 gene expression. Furthermore, to demonstrate that [Dat-Sar(3)] CsA can inhibit calcineurin in a cyclophilin-independent manner in vivo, we tested its effect in a Saccharomyces cerevisiae strain (Delta12), in which all the 12 cyclophilins and FKBPs were deleted. [Dat-Sar(3)] CsA, but not CsA, bypassed the requirement for cellular cyclophilins and caused growth inhibition in the salt-stressed Delta12 strain.	Max Planck Res Unit Enzymol Prot Folding, D-06120 Halle An Der Saale, Germany; Deutsch Rheuma Forschungszentrum Berlin, D-10117 Berlin, Germany	Max Planck Society; Deutsches Rheuma-Forschungszentrum (DRFZ)	Fischer, G (corresponding author), Max Planck Res Unit Enzymol Prot Folding, Weinbergweg 22, D-06120 Halle An Der Saale, Germany.	fischer@enzyme-halle.mpg.de	Thiel, Andreas/F-1539-2013; Erdmann, Frank/AAF-1091-2021	Erdmann, Frank/0000-0001-5261-0984; Baumgrass, Ria/0000-0002-3289-1608; Thiel, Andreas/0000-0002-5515-4002; Radbruch, Andreas/0000-0001-5753-0000				Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Barford D, 1996, TRENDS BIOCHEM SCI, V21, P407, DOI 10.1016/S0968-0004(96)10060-8; Batiuk TD, 1997, J CLIN INVEST, V100, P1894, DOI 10.1172/JCI119719; Baumgrass R, 2001, J BIOL CHEM, V276, P47914, DOI 10.1074/jbc.M103273200; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BREUDER T, 1994, P NATL ACAD SCI USA, V91, P5372, DOI 10.1073/pnas.91.12.5372; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P9398, DOI 10.1073/pnas.152665399; Cardenas Maria E., 1994, Perspectives in Drug Discovery and Design, V2, P103, DOI 10.1007/BF02171739; Creighton T. E., 1993, PROTEINS STRUCTURES; CUMME GA, 1986, BIOMED BIOCHIM ACTA, V45, P961; Dolinski K, 1997, P NATL ACAD SCI USA, V94, P13093, DOI 10.1073/pnas.94.24.13093; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; Fox DS, 2002, BIOESSAYS, V24, P894, DOI 10.1002/bies.10157; Gautschi M, 2002, P NATL ACAD SCI USA, V99, P4209, DOI 10.1073/pnas.062048599; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Hemenway Charles S., 1999, Cell Biochemistry and Biophysics, V30, P115, DOI 10.1007/BF02737887; HU MK, 1995, J MED CHEM, V38, P4164, DOI 10.1021/jm00021a005; Huai Q, 2002, P NATL ACAD SCI USA, V99, P12037, DOI 10.1073/pnas.192206699; Jin L, 2002, P NATL ACAD SCI USA, V99, P13522, DOI 10.1073/pnas.212504399; Keleti T., 1986, BASIC ENZYME KINETIC; KESSLER H, 1990, HELV CHIM ACTA, V73, P1818, DOI 10.1002/hlca.19900730703; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; MIKOL V, 1993, J MOL BIOL, V234, P1119, DOI 10.1006/jmbi.1993.1664; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; MILTENYI S, 1990, CYTOMETRY, V11, P231, DOI 10.1002/cyto.990110203; Mondragon A, 1997, BIOCHEMISTRY-US, V36, P4934, DOI 10.1021/bi9631935; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NELSON PA, 1993, J IMMUNOL, V150, P2139; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; PELECH S, 1985, EUR J BIOCHEM, V148, P245, DOI 10.1111/j.1432-1033.1985.tb08832.x; Puech J, 1998, J ENZYM INHIB, V14, P27, DOI 10.3109/14756369809036544; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Richter A, 1999, J EXP MED, V190, P1439, DOI 10.1084/jem.190.10.1439; Schreiber SL, 1998, BIOORGAN MED CHEM, V6, P1127, DOI 10.1016/S0968-0896(98)00126-6; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SEEBACH D, 1993, HELV CHIM ACTA, V76, P1564, DOI 10.1002/hlca.19930760415; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; Thiel A, 1999, ARTHRITIS RES, V1, P25, DOI 10.1186/ar7; Tradler T, 1997, FEBS LETT, V407, P184, DOI 10.1016/S0014-5793(97)00345-1; TUNG HYL, 1985, EUR J BIOCHEM, V148, P253, DOI 10.1111/j.1432-1033.1985.tb08833.x; WAELKENS E, 1984, BIOCHEM BIOPH RES CO, V120, P397, DOI 10.1016/0006-291X(84)91267-1; WENGER RM, 1994, FEBS LETT, V340, P255, DOI 10.1016/0014-5793(94)80149-5; Zenke G, 2001, J IMMUNOL, V166, P7165, DOI 10.4049/jimmunol.166.12.7165; Zhang W, 1996, J EXP MED, V183, P413, DOI 10.1084/jem.183.2.413; Zhu J, 2000, CELL MOL LIFE SCI, V57, P411, DOI 10.1007/PL00000703	50	32	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2470	2479		10.1074/jbc.M304754200	http://dx.doi.org/10.1074/jbc.M304754200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14583619	hybrid			2022-12-25	WOS:000188211300018
J	Li, FQ; Person, RE; Takemaru, KI; Williams, K; Meade-White, K; Ozsahin, AH; Gungor, T; Moon, RT; Horwitz, M				Li, FQ; Person, RE; Takemaru, KI; Williams, K; Meade-White, K; Ozsahin, AH; Gungor, T; Moon, RT; Horwitz, M			Lymphoid enhancer factor-1 links two hereditary leukemia syndromes through core-binding factor alpha regulation of ELA2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE CONGENITAL NEUTROPENIA; ACUTE MYELOID-LEUKEMIA; STIMULATING FACTOR-RECEPTOR; RUNT HOMOLOGY DOMAIN; BETA-CATENIN; DNA-BINDING; TRANSCRIPTION FACTOR; C-MYB; AML1/PEBP2-ALPHA-B GENE; KOSTMANN-SYNDROME	Two hereditary human leukemia syndromes are severe congenital neutropenia (SCN), caused by mutations in the gene ELA2, encoding the protease neutrophil elastase, and familial platelet disorder with acute myelogenous leukemia (AML), caused by mutations in the gene AML1, encoding the transcription factor core-binding factor alpha (CBFalpha). In mice, CBFalpha regulates the expression of ELA2, suggesting a common link for both diseases. However, gene- targeted mouse models have failed to reproduce either human disease, thus prohibiting further in vivo studies in mice. Here we investigate CBFalpha regulation of the human ELA2 promoter, taking advantage of bone marrow obtained from patients with either illness. In particular, we have identified novel ELA2 promoter substitutions ( - 199 C to A) within a potential motif for lymphoid enhancer factor-1 (LEF-1), a transcriptional mediator of Wnt/beta-catenin signaling, in SCN patients. The LEF-1 motif lies adjacent to a potential CBFalpha binding site that is in a different position in human compared with mouse ELA2. We find that LEF-1 and CBFalpha co-activate ELA2 expression. In vitro, the high mobility group domain of LEF-1 interacts with the runt DNA binding and proline-, serine-, threonine-rich activation domains of CBFalpha. ELA2 transcript levels are up-regulated in bone marrow of an SCN patient with the -199 C to A substitution. Conversely, a mutation of the CBFalpha activation domain, found in a patient with familial platelet disorder with AML, fails to stimulate the ELA2 promoter in vitro, and bone marrow correspondingly demonstrates reduced ELA2 transcript. Observations in these complementary patients indicate that LEF-1 cooperates with CBFalpha to activate ELA2 in vivo and also suggest the possibility that up-regulating promoter mutations can contribute to SCN. Two hereditary AML predisposition syndromes may therefore intersect via LEF-1, potentially linking them to more generalized cancer mechanisms.	Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pharmacol, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Sch Med, Ctr Dev Biol, Seattle, WA 98195 USA; Univ Hosp Geneva, CH-1211 Geneva 14, Switzerland; Univ Childrens Hosp, CH-8032 Zurich, Switzerland	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Geneva; University Children's Hospital Zurich	Horwitz, M (corresponding author), Univ Washington, Sch Med, Dept Med, Div Med Genet, 1705 NE Pacific St,HSB-K236B, Seattle, WA 98195 USA.	horwitz@u.washington.edu	Güngör, Tayfun/ABF-4256-2020; Moon, Randall/M-5605-2019; Moon, Randall T/B-1743-2014	Güngör, Tayfun/0000-0002-3261-1186; Moon, Randall/0000-0002-9352-1408; Moon, Randall T/0000-0002-9352-1408; Horwitz, Marshall/0000-0002-1683-1680	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK055820, R01DK058161] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55820, DK58161] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banerjee A, 2001, J PEDIAT HEMATOL ONC, V23, P487, DOI 10.1097/00043426-200111000-00005; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Benson KF, 2003, NAT GENET, V35, P90, DOI 10.1038/ng1224; Bernard T, 1998, BRIT J HAEMATOL, V101, P141, DOI 10.1046/j.1365-2141.1998.00652.x; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; BIETH JG, 1998, HDB PROTEOLYTIC ENZY, P54; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; Chung EJ, 2002, BLOOD, V100, P982, DOI 10.1182/blood.V100.3.982; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; Dale DC, 2000, BLOOD, V96, P2317, DOI 10.1182/blood.V96.7.2317.h8002317_2317_2322; Dintilhac A, 2002, J BIOL CHEM, V277, P7021, DOI 10.1074/jbc.M108417200; Downing JR, 2000, SEMIN CELL DEV BIOL, V11, P347, DOI 10.1006/scdb.2000.0183; DOWTON SB, 1985, BLOOD, V65, P557; Duan ZJ, 2003, P NATL ACAD SCI USA, V100, P5932, DOI 10.1073/pnas.1031694100; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Freedman MH, 2002, SEMIN HEMATOL, V39, P128, DOI 10.1053/shem.2002.31912; Friedman AD, 2002, INT J HEMATOL, V75, P466, DOI 10.1007/BF02982108; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Grenda DS, 2002, BLOOD, V100, P3221, DOI 10.1182/blood-2002-05-1372; Horwitz M, 1999, NAT GENET, V23, P433, DOI 10.1038/70544; Horwitz M, 2003, CANCER INVEST, V21, P579, DOI 10.1081/CNV-120022378; HORWITZ M, 2002, GENETIC BASIS COMMON, P749; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Imai Y, 2002, LEUKEMIA LYMPHOMA, V43, P617, DOI 10.1080/10428190290012155; Kahler RA, 2003, J BIOL CHEM, V278, P11937, DOI 10.1074/jbc.M211443200; Kelly LM, 2002, ANNU REV GENOM HUM G, V3, P179, DOI 10.1146/annurev.genom.3.032802.115046; KOEFFLER HP, 1980, BLOOD, V56, P344; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Kundu M, 2002, BLOOD, V100, P2449, DOI 10.1182/blood-2002-04-1064; Kurokawa M, 1996, J BIOL CHEM, V271, P16870, DOI 10.1074/jbc.271.28.16870; LEITCH HA, 1994, LEUKEMIA, V8, P605; Li FQ, 2001, J BIOL CHEM, V276, P14230, DOI 10.1074/jbc.M010279200; LIGHTSEY AL, 1985, AM J HEMATOL, V18, P59, DOI 10.1002/ajh.2830180109; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; Mao SF, 1999, MOL CELL BIOL, V19, P3635; Mayall TP, 1997, GENE DEV, V11, P887, DOI 10.1101/gad.11.7.887; McWhirter JR, 1999, P NATL ACAD SCI USA, V96, P11464, DOI 10.1073/pnas.96.20.11464; Melnick A, 2000, BLOOD, V96, P3939, DOI 10.1182/blood.V96.12.3939.h8003939_3939_3947; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; NILSSON K, 1974, INT J CANCER, V13, P808, DOI 10.1002/ijc.2910130609; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Penther D, 2002, LEUKEMIA, V16, P1131, DOI 10.1038/sj.leu.2402479; Person RE, 2003, NAT GENET, V34, P308, DOI 10.1038/ng1170; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Roland B, 2001, CANCER GENET CYTOGEN, V126, P78, DOI 10.1016/S0165-4608(00)00393-9; Rubnitz JE, 1999, LEUKEMIA, V13, P6, DOI 10.1038/sj.leu.2401258; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Sazani P, 2001, NUCLEIC ACIDS RES, V29, P3965, DOI 10.1093/nar/29.19.3965; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Speck NA, 1999, CANCER RES, V59, p1789S; Srikanth S, 1998, BBA-GENE STRUCT EXPR, V1398, P215, DOI 10.1016/S0167-4781(98)00039-6; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Thiele A, 2001, J IMMUNOL, V167, P6786, DOI 10.4049/jimmunol.167.12.6786; Thomas JO, 2001, BIOCHEM SOC T, V29, P395, DOI 10.1042/BST0290395; van de Wetering M, 2002, CELL, V109, pS13, DOI 10.1016/S0092-8674(02)00709-2; Verbeek W, 1999, BLOOD, V93, P3327, DOI 10.1182/blood.V93.10.3327; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeidler C, 2002, SEMIN HEMATOL, V39, P82, DOI 10.1053/shem.2002.31913; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	68	32	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2873	2884		10.1074/jbc.M310759200	http://dx.doi.org/10.1074/jbc.M310759200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14594802	Green Accepted, hybrid			2022-12-25	WOS:000188211300067
J	Remmert, K; Olszewski, TE; Bowers, MB; Dimitrova, M; Ginsburg, A; Hammer, JA				Remmert, K; Olszewski, TE; Bowers, MB; Dimitrova, M; Ginsburg, A; Hammer, JA			CARMIL is a Bona fide capping protein interactant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN POLYMERIZATION; ACANTHAMOEBA-CASTELLANII; ESCHERICHIA-COLI; SH3 DOMAIN; MYOSIN-I; BINDING; IDENTIFICATION; ACAN125; LOCALIZATION; PEPTIDE	CARMIL, also known as Acan 125, is a multidomain protein that was originally identified on the basis of its interaction with the Src homology 3 (SH3) domain of type I myosins from Acanthamoeba. In a subsequent study of CARMIL from Dictyostelium, pull-down assays indicated that the protein also bound capping protein and the Arp2/3 complex. Here we present biochemical evidence that Acanthamoeba CARMIL interacts tightly with capping protein. In biochemical preparations, CARMIL copurified extensively with two polypeptides that were shown by microsequencing to be the alpha- and beta-subunits of Acanthamoeba capping protein. The complex between CARMIL and capping protein, which is readily demonstratable by chemical cross-linking, can be completely dissociated by size exclusion chromatography at pH 5.4. Analytical ultracentrifugation, surface plasmon resonance and SH3 domain pull-down assays indicate that the dissociation constant of capping protein for CARMIL is similar to0.4 muM or lower. Using CARMIL fusion proteins, the binding site for capping protein was shown to reside within the carboxyl-terminal, similar to200 residue, proline-rich domain of CARMIL. Finally, chemical cross-linking, analytical ultracentrifugation, and rotary shadowed electron microscopy revealed that CARMIL is asymmetric and that it exists in a monomer 7 dimer equilibrium with an association constant of 1.0 x 10(6) M-1. Together, these results indicate that CARMIL self-associates and interacts with capping protein with affinities that, given the cellular concentrations of the proteins (similar to1 and 2 muM for capping protein and CARMIL, respectively), indicate that both activities should be physiologically relevant.	NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hammer, JA (corresponding author), NHLBI, Cell Biol Lab, NIH, Bldg 50,Rm 2523,9000 Rockville Pike, Bethesda, MD 20892 USA.	hammerj@nhlbi.nih.gov		Hammer, John/0000-0002-2496-5179	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000514, Z01HL000310, ZIAHL000514] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; COOPER JA, 1984, J CELL BIOL, V99, P217, DOI 10.1083/jcb.99.1.217; COOPER JA, 1985, BIOCHEMISTRY-US, V24, P793, DOI 10.1021/bi00324a039; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; GORDON DJ, 1976, J BIOL CHEM, V251, P4778; IVANENKOV VV, 1995, J BIOL CHEM, V270, P14651, DOI 10.1074/jbc.270.24.14651; Jung G, 2001, J CELL BIOL, V153, P1479, DOI 10.1083/jcb.153.7.1479; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Kortt AA, 1997, ANAL BIOCHEM, V253, P103, DOI 10.1006/abio.1997.2333; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Lee WL, 1999, J BIOL CHEM, V274, P35159, DOI 10.1074/jbc.274.49.35159; Nosworthy NJ, 1998, BIOCHEMISTRY-US, V37, P6718, DOI 10.1021/bi980126x; Palmgren S, 2001, J CELL BIOL, V155, P251, DOI 10.1083/jcb.200106157; SCHACHMAN HK, 1959, ULTRACENTRIFUGATION, P239; SHAPIRO BM, 1968, BIOCHEMISTRY-US, V7, P2153, DOI 10.1021/bi00846a018; Stafford WF, 1997, CURR OPIN BIOTECH, V8, P14, DOI 10.1016/S0958-1669(97)80152-8; Taoka M, 2003, J BIOL CHEM, V278, P5864, DOI 10.1074/jbc.M211509200; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; XU P, 1995, J BIOL CHEM, V270, P25316, DOI 10.1074/jbc.270.43.25316; Xu P, 1997, P NATL ACAD SCI USA, V94, P3685, DOI 10.1073/pnas.94.8.3685; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045; Zolkiewski M, 1997, BIOCHEMISTRY-US, V36, P7876, DOI 10.1021/bi962947c; Zot HG, 2000, ARCH BIOCHEM BIOPHYS, V375, P161, DOI 10.1006/abbi.1999.1648	24	28	29	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					3068	3077		10.1074/jbc.M308829200	http://dx.doi.org/10.1074/jbc.M308829200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14594951	hybrid			2022-12-25	WOS:000188211300088
J	Runyan, CE; Schnaper, HW; Poncelet, AC				Runyan, CE; Schnaper, HW; Poncelet, AC			The phosphatidylinositol 3-kinase/Akt pathway enhances Smad3-stimulated mesangial cell collagen I expression in response to transforming growth factor-beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; AIRWAY SMOOTH-MUSCLE; PHOSPHOINOSITIDE 3-KINASE; TGF-BETA; SIGNALING PATHWAYS; TYROSINE KINASES; SMAD PROTEINS; TRANSCRIPTION; GENE; PHOSPHORYLATION	Transforming growth factor (TGF)-beta has been associated with renal glomerular matrix accumulation. We previously showed that Smad3 promotes COL1A2 gene activation by TGF-beta1 in human glomerular mesangial cells. Here, we report that the PI3K/Akt pathway also plays a role in TGF-beta1-increased collagen I expression. TGF-beta1 stimulates the activity of phosphoinositide-dependent kinase (PDK)-1, a downstream target of PI3K, starting at 1 min. Akt, a kinase downstream of PDK-1, is phosphorylated and concentrates in the membrane fraction within 5 min of TGF-beta1 treatment. The PI3K inhibitor LY294002 decreases TGF-beta1-stimulated alpha1(I) and alpha2(I) collagen mRNA expression. Similarly, LY294002 or an Akt dominant negative construct blocks TGF-beta1 induction of COL1A2 promoter activity. However, PI3K stimulation alone is not sufficient to increase collagen I expression, since neither a constitutively active p110 PI3K construct nor PDGF, which induces Akt phosphorylation, is able to stimulate COL1A2 promoter activity or mRNA expression, respectively. LY294002 inhibits stimulation of COL1A2 promoter activity by Smad3. In a Gal4-LUC assay system, blockade of the PI3K pathway significantly decreases TGF-beta1-induced transcriptional activity of Gal4-Smad3. Activity of SBE-LUC, a Smad3/4-responsive construct, is stimulated by over-expression of Smad3 or Smad3D, in which the three C-terminal serine phospho-acceptor residues are mutated. This induction is blocked by LY294002, suggesting that inhibition of the PI3K pathway decreases Smad3 transcriptional activity independently of C-terminal serine phosphorylation. However, TGF-beta1-induced total serine phosphorylation of Smad3 is decreased by LY294002, suggesting that Smad3 is phosphorylated by the PI3K pathway at serine residues other than the direct TGF-beta receptor I target site. Thus, although the PI3K-PDK1-Akt pathway alone is insufficient to stimulate COL1A2 gene transcription, its activation by TGF-beta1 enhances Smad3 transcriptional activity leading to increased collagen I expression in human mesangial cells. This crosstalk between the Smad and PI3K pathways likely contributes to TGF-beta1 induction of glomerular scarring.	Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Poncelet, AC (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pediat, W-140,303 E Chicago Ave, Chicago, IL 60611 USA.	anne-c@northwestern.edu			NIDDK NIH HHS [R01 DK049362, DK49362] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049362, R56DK049362] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P1139, DOI 10.1021/bi00274a023; Border WA, 1997, KIDNEY INT, V51, P1388, DOI 10.1038/ki.1997.190; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Choudhury GG, 1997, AM J PHYSIOL-RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Dupont J, 2003, BIOL REPROD, V68, P1877, DOI 10.1095/biolreprod.102.012005; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Ettinger SL, 1996, J BIOL CHEM, V271, P14514, DOI 10.1074/jbc.271.24.14514; Ghosh-Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200; Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503; Hayashida T, 1999, KIDNEY INT, V56, P1710, DOI 10.1046/j.1523-1755.1999.00733.x; Hayashida T, 2003, FASEB J, V17, P1576, DOI 10.1096/fj.03-0037fje; Higaki M, 1999, ARTERIOSCL THROM VAS, V19, P2127, DOI 10.1161/01.ATV.19.9.2127; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Krymskaya VP, 1997, AM J PHYSIOL-LUNG C, V273, pL1220, DOI 10.1152/ajplung.1997.273.6.L1220; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lanvin O, 2003, EUR J IMMUNOL, V33, P1372, DOI 10.1002/eji.200323761; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Poncelet AC, 1999, KIDNEY INT, V56, P1354, DOI 10.1046/j.1523-1755.1999.00680.x; Poncelet AC, 1998, AM J PHYSIOL-RENAL, V275, pF458; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; Reif S, 2003, J BIOL CHEM, V278, P8083, DOI 10.1074/jbc.M212927200; Ricupero DA, 2001, AM J PHYSIOL-CELL PH, V281, pC99, DOI 10.1152/ajpcell.2001.281.1.C99; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Runyan CE, 2003, AM J PHYSIOL-RENAL, V285, pF413, DOI 10.1152/ajprenal.00082.2003; SHARMA K, 1995, DIABETES, V44, P1139, DOI 10.2337/diabetes.44.10.1139; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Valderrama-Carvajal H, 2002, NAT CELL BIOL, V4, P963, DOI 10.1038/ncb885; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wicks SJ, 2000, MOL CELL BIOL, V20, P8103, DOI 10.1128/MCB.20.21.8103-8111.2000; Yakmovych I, 2001, FASEB J, V15, P553; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	45	186	210	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2632	2639		10.1074/jbc.M310412200	http://dx.doi.org/10.1074/jbc.M310412200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14610066	hybrid			2022-12-25	WOS:000188211300038
J	Yang, EJ; Yoon, JH; Chung, KC				Yang, EJ; Yoon, JH; Chung, KC			Bruton's tyrosine kinase phosphorylates cAMP-responsive element-binding protein at serine 133 during neuronal differentiation in immortalized hippocampal progenitor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; RECEPTOR-MEDIATED ACTIVATION; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; NEURITE OUTGROWTH; GENE-EXPRESSION; NERVOUS-SYSTEM; CYCLIC-AMP; CREB; SRC	Bruton's tyrosine kinase (BTK) is a member of the Tec family of kinases, which is a subgroup of the nonreceptor cytoplasmic protein tyrosine kinases. BTK has been shown to be important in the proliferation, differentiation, and signal transduction of B cells. Mutations in BTK result in B cell immune deficiency disorders, such as X-linked agammaglobulinemia in humans and X-linked immunodeficiency in mice. Although BTK plays multiple roles in the life of a B cell, its functional role in neuronal cells has not been elucidated. In the present study, we demonstrate that BTK activates transcription factor, cAMP response element (CRE)-binding protein (CREB), and subsequent CRE-mediated gene transcription during basic fibroblast growth factor (bFGF)-induced neuronal differentiation in immortalized hippocampal progenitor cells (H19-7). The kinase activity of BTK is also induced by bFGF, and BTK directly phosphorylates CREB at Ser-133 residue, indicating that BTK has a dual protein kinase activity. In addition, blockading BTK activation significantly inhibits CREB phosphorylation as well as the neurite outgrowth induced by bFGF in H19-7 cells. These results suggest that the activation of BTK and the subsequent phosphorylation of CREB at Ser-133 are important in the neuronal differentiation of hippocampal progenitor cells.	Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Dept Med Sci, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Dept Otorhinolaryngol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea	Yonsei University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Chung, KC (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, Shinchon Dong 134, Seoul 120749, South Korea.	kchung@yonsei.ac.kr	Yoon, Joo-Heon/E-5781-2016	Yoon, Joo-Heon/0000-0003-2404-7156				Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; Chung KC, 1998, MOL CELL BIOL, V18, P2272, DOI 10.1128/MCB.18.4.2272; Craxton A, 1999, J BIOL CHEM, V274, P30644, DOI 10.1074/jbc.274.43.30644; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; Ghil SH, 2000, J NEUROCHEM, V74, P151, DOI 10.1046/j.1471-4159.2000.0740151.x; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Heinonen JE, 2002, FEBS LETT, V527, P274, DOI 10.1016/S0014-5793(02)03206-4; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Hsueh RC, 2000, ADV IMMUNOL, V75, P283, DOI 10.1016/S0065-2776(00)75007-3; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Jiang A, 1998, J EXP MED, V188, P1297, DOI 10.1084/jem.188.7.1297; Jurado LAP, 1998, HUM MOL GENET, V7, P325, DOI 10.1093/hmg/7.3.325; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; Kawakami Y, 1998, J IMMUNOL, V161, P1795; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; Kuo WL, 1997, MOL CELL BIOL, V17, P4633, DOI 10.1128/MCB.17.8.4633; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Mohamed AJ, 2000, J BIOL CHEM, V275, P40614, DOI 10.1074/jbc.M006952200; Nore BF, 2000, EUR J IMMUNOL, V30, P145, DOI 10.1002/1521-4141(200001)30:1<145::AID-IMMU145>3.0.CO;2-0; Novina CD, 1999, MOL CELL BIOL, V19, P5014; Parker D, 1996, MOL CELL BIOL, V16, P694; Prigent SA, 2000, METH MOL B, V124, P251; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Radhakrishnan I, 1998, FEBS LETT, V430, P317, DOI 10.1016/S0014-5793(98)00680-2; RAWLINGS DJ, 1994, IMMUNOL REV, V138, P105, DOI 10.1111/j.1600-065X.1994.tb00849.x; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Satterthwaite AB, 2000, IMMUNOL REV, V175, P120, DOI 10.1034/j.1600-065X.2000.017504.x; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Shimomura A, 1998, J NEUROCHEM, V70, P1029; Sung JY, 2001, J BIOL CHEM, V276, P13858, DOI 10.1074/jbc.M010610200; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Uckun FM, 1998, BIOCHEM PHARMACOL, V56, P683, DOI 10.1016/S0006-2952(98)00122-1; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; XIE HJ, 1995, J IMMUNOL, V154, P1717; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yang EJ, 2001, J BIOL CHEM, V276, P39819, DOI 10.1074/jbc.M104091200; YANG WY, 1995, J BIOL CHEM, V270, P20832, DOI 10.1074/jbc.270.35.20832	50	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1827	1837		10.1074/jbc.M308722200	http://dx.doi.org/10.1074/jbc.M308722200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14597636	hybrid, Green Published			2022-12-25	WOS:000188005700033
J	Davies, CC; Mason, J; Wakelam, MJO; Young, LS; Eliopoulos, AG				Davies, CC; Mason, J; Wakelam, MJO; Young, LS; Eliopoulos, AG			Inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S6 KINASE; TRANSLATION INITIATION; EPITHELIAL-CELLS; FAS LIGAND; HYPER-IGM; B-CELLS; ACTIVATION; DEATH; PHOSPHORYLATION; INDUCTION	CD40, a member of the tumor necrosis factor receptor superfamily, is frequently expressed in carcinomas where its stimulation results in induction of apoptosis when de novo protein synthesis is inhibited. The requirement of protein synthesis inhibition for efficient killing suggests that CD40 transduces potent survival signals capable of suppressing its pro-apoptotic effects. We have found that inhibition of CD40 signaling on the phosphatidylinositol 3-kinase (PI3K) and ERK MAPK but not on the p38 MAPK axis disrupts this balance and sensitizes carcinoma cells to CD40-mediated cell death. The CD40-mediated PI3K and ERK activities were found to converge on the regulation of protein synthesis in carcinoma cells via a pathway involving the activation of p90 ribosomal S6 kinase (p90Rsk) and p70S6 kinases, upstream of the translation elongation factor eEF2. In addition, CD40 ligation was found to mediate a PI3K- and mammalian target of rapamycin (mTOR)-dependent phosphorylation of 4E-BP1 and its subsequent dissociation from the mRNA cap-binding protein eIF4E as well as an ERK-dependent phosphorylation of eIF4E, thus promoting translation initiation. Concomitantly, the antiapoptotic protein cFLIP was found to be induced in CD40 ligand-stimulated carcinoma cells in a PI3K-, ERK-, and mammalian target of rapamycin (mTOR)-dependent manner and down-regulation of cFLIPS expression sensitized to CD40-mediated carcinoma cell death. These data underline the significance of the PI3K and ERK pathways in controlling the balance between CD40-mediated survival and death signals through the regulation of the protein synthesis machinery. Pharmacological agents that target this machinery or its upstream kinases could, therefore, be exploited for CD40-based tumor therapy.	Univ Birmingham, Sch Med, Canc Res United Kingdom Inst Canc Studies, Birmingham B15 2TA, W Midlands, England; Univ Birmingham, Sch Med, MRC, Ctr Immune Regulat, Birmingham B15 2TA, W Midlands, England	University of Birmingham; University of Birmingham	Eliopoulos, AG (corresponding author), Univ Birmingham, Sch Med, Canc Res United Kingdom Inst Canc Studies, Birmingham B15 2TA, W Midlands, England.		Young, Lawrence S/B-7213-2009; ELIOPOULOS, ARISTIDES/ABI-6632-2020; ELIOPOULOS, ARISTIDES/R-9449-2018	Young, Lawrence S/0000-0003-3919-4298; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Davies, Clare/0000-0003-3097-1791; Wakelam, Michael/0000-0003-4059-9276				Afford SC, 1999, J EXP MED, V189, P441, DOI 10.1084/jem.189.2.441; Baker MP, 1998, BLOOD, V92, P2830, DOI 10.1182/blood.V92.8.2830.420k10_2830_2843; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; CALLARD RE, 1993, IMMUNOL TODAY, V14, P559, DOI 10.1016/0167-5699(93)90188-Q; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deregibus MC, 2003, J BIOL CHEM, V278, P18008, DOI 10.1074/jbc.M300711200; Djerbi M, 2001, SCAND J IMMUNOL, V54, P180, DOI 10.1046/j.1365-3083.2001.00941.x; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Eliopoulos AG, 2003, EMBO J, V22, P3855, DOI 10.1093/emboj/cdg386; Eliopoulos AG, 2000, MOL CELL BIOL, V20, P5503, DOI 10.1128/MCB.20.15.5503-5515.2000; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; Fulda S, 2000, CANCER RES, V60, P3947; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; Ghamande S, 2001, CANCER RES, V61, P7556; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; GORDON J, 1995, BLOOD REV, V9, P53, DOI 10.1016/0268-960X(95)90040-3; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; Gulbins E, 1996, J IMMUNOL, V157, P2844; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hayward AR, 1997, J IMMUNOL, V158, P977; Hennino A, 2001, J EXP MED, V193, P447, DOI 10.1084/jem.193.4.447; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; Hess S, 1996, J EXP MED, V183, P159, DOI 10.1084/jem.183.1.159; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Hirano A, 1999, BLOOD, V93, P2999; Kashiwada M, 1998, J EXP MED, V187, P237, DOI 10.1084/jem.187.2.237; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; Knox PG, 2003, J IMMUNOL, V170, P677, DOI 10.4049/jimmunol.170.2.677; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Papadaki HA, 2003, BLOOD, V101, P2591, DOI 10.1182/blood-2002-09-2898; Patel NA, 2001, J BIOL CHEM, V276, P22648, DOI 10.1074/jbc.M101260200; Perez D, 2003, J VIROL, V77, P2651, DOI 10.1128/JVI.77.4.2651-2662.2003; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; Vonderheide RH, 2001, J CLIN ONCOL, V19, P3280, DOI 10.1200/JCO.2001.19.13.3280; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Wilson KF, 2000, J BIOL CHEM, V275, P37307, DOI 10.1074/jbc.C000482200; Young LS, 1998, IMMUNOL TODAY, V19, P502, DOI 10.1016/S0167-5699(98)01340-1	50	65	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1010	1019		10.1074/jbc.M303820200	http://dx.doi.org/10.1074/jbc.M303820200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14581487	hybrid			2022-12-25	WOS:000187722800024
J	Gonzales, C; Voirol, MJ; Giacomini, M; Gaillard, RC; Pedrazzini, T; Pralong, FP				Gonzales, C; Voirol, MJ; Giacomini, M; Gaillard, RC; Pedrazzini, T; Pralong, FP			The neuropeptide Y Y1 receptor mediates NPY-induced inhibition of the gonadotrope axis under poor metabolic conditions	FASEB JOURNAL			English	Article						feeding; puberty; reproduction; hypothalamus; leptin	AMPHETAMINE-REGULATED TRANSCRIPT; LUTEINIZING-HORMONE SECRETION; CONGENITAL LEPTIN DEFICIENCY; OBESE GENE-PRODUCT; NORMAL FEMALE MICE; LATERAL VENTRICLE; PARAVENTRICULAR NUCLEUS; SEXUAL-MATURATION; OB/OB MICE; PUBERTAL DEVELOPMENT	Hypothalamic neuropeptide Y (NPY) plays a central role in the control of food intake, energy balance, and modulation of neuroendocrine functions. In particular, an increase in NPY expression participates in the inhibition of the reproductive activity under poor nutritional conditions. The present study was designed to evaluate further the involvement of the Y1 subtype of NPY receptors in these effects. Food intake, body weight gain, and the onset of puberty were studied in groups of wild-type and Y1 deficient mice that were either fed ad libitum or subjected to a 30% restriction in food intake. This moderate feeding restriction induced a similar deficit in body weight gain in wild-type and in Y1 knockout mice. However, although wild-type mice experienced the expected delay of puberty, all mice in the food restriction group and lacking Y1 could go through puberty over the time of the experiment despite decreases in circulating leptin levels and increases in hypothalamic NPY expression. This observation demonstrates that the absence of Y1 impairs the perception of decreasing energy stores by the gonadotrope axis, demonstrating a physiological role for Y1 in the sensing of endogenous metabolic parameters by the hypothalamus.	Univ Hosp, Div Endocrinol Diabetol & Metab, CH-1011 Lausanne, Switzerland; Univ Hosp, Div Hypertens, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Pralong, FP (corresponding author), Univ Hosp, Div Endocrinol, CH-1011 Lausanne, Switzerland.	Francois.Pralong@chuv.hospvd.ch	Giacomini, Mauro/D-3194-2013	Giacomini, Mauro/0000-0001-5646-2034	Swiss national science foundation [32-00B0-100858/1]; Novartis Foundation	Swiss national science foundation(Swiss National Science Foundation (SNSF)European Commission); Novartis Foundation(Novartis)	This work was supported by grants from the Swiss national science foundation (#32-00B0-100858/1) and the Novartis Foundation. The authors wish to thank Michel L. Aubert for his precious comments and suggestions during the revision of the manuscript.	Adam CL, 2002, NEUROENDOCRINOLOGY, V75, P250, DOI 10.1159/000054716; Ahima RS, 1997, J CLIN INVEST, V99, P391, DOI 10.1172/JCI119172; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; ALLEN YS, 1983, SCIENCE, V221, P877, DOI 10.1126/science.6136091; BAUERDANTOIN AC, 1993, ENDOCRINOLOGY, V133, P2413, DOI 10.1210/en.133.6.2413; Bergonzelli GE, 2001, DIABETES, V50, P2666, DOI 10.2337/diabetes.50.12.2666; Blomqvist AG, 1997, TRENDS NEUROSCI, V20, P294, DOI 10.1016/S0166-2236(96)01057-0; BRADY LS, 1990, NEUROENDOCRINOLOGY, V52, P441, DOI 10.1159/000125626; BRONSON FH, 1986, ENDOCRINOLOGY, V118, P2483, DOI 10.1210/endo-118-6-2483; Cabrele C, 2000, J PEPT SCI, V6, P97, DOI 10.1002/(SICI)1099-1387(200003)6:3<97::AID-PSC236>3.0.CO;2-E; Campbell RE, 2001, NEUROENDOCRINOLOGY, V74, P106, DOI 10.1159/000054676; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CATZEFLIS C, 1993, ENDOCRINOLOGY, V132, P224, DOI 10.1210/en.132.1.224; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Cheung CC, 1997, ENDOCRINOLOGY, V138, P855, DOI 10.1210/en.138.2.855; Edwards CMB, 1999, J ENDOCRINOL, V160, pR7, DOI 10.1677/joe.0.160R007; El Majdoubi M, 2000, P NATL ACAD SCI USA, V97, P6179; Farooqi IS, 2002, J CLIN INVEST, V110, P1093, DOI 10.1172/JCI200215693; Fekete C, 2002, ENDOCRINOLOGY, V143, P4513, DOI 10.1210/en.2002-220574; GARTHWAITE TL, 1980, ENDOCRINOLOGY, V107, P671, DOI 10.1210/endo-107-3-671; Gehlert DR, 1998, P SOC EXP BIOL MED, V218, P7; GRUAZ NM, 1993, ENDOCRINOLOGY, V133, P1891, DOI 10.1210/en.133.4.1891; Gruaz NM, 1998, J NEUROENDOCRINOL, V10, P627, DOI 10.1046/j.1365-2826.1998.00247.x; HAAS DA, 1987, LIFE SCI, V41, P2725, DOI 10.1016/0024-3205(87)90465-6; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMILTON GD, 1986, AM J PHYSIOL, V250, pR370, DOI 10.1152/ajpregu.1986.250.3.R370; Jain MR, 1999, ENDOCRINOLOGY, V140, P5171, DOI 10.1210/en.140.11.5171; KALRA SP, 1984, LIFE SCI, V35, P1173, DOI 10.1016/0024-3205(84)90187-5; KALRA SP, 1992, ENDOCRINOLOGY, V130, P3323, DOI 10.1210/en.130.6.3323; KALRA SP, 1991, P NATL ACAD SCI USA, V88, P10931, DOI 10.1073/pnas.88.23.10931; Lebrethon MC, 2000, ENDOCRINOLOGY, V141, P1464, DOI 10.1210/en.141.4.1464; Li C, 1999, ENDOCRINOLOGY, V140, P5382, DOI 10.1210/en.140.11.5382; MCDONALD JK, 1989, ENDOCRINOLOGY, V125, P186, DOI 10.1210/endo-125-1-186; MINAMI S, 1990, NEUROENDOCRINOLOGY, V52, P112, DOI 10.1159/000125548; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Parent AS, 2000, REGUL PEPTIDES, V92, P17, DOI 10.1016/S0167-0115(00)00144-0; Pedrazzini T, 1998, NAT MED, V4, P722, DOI 10.1038/nm0698-722; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PIERROZ DD, 1995, NEUROENDOCRINOLOGY, V61, P293, DOI 10.1159/000126851; Plant TM, 2001, FRONT NEUROENDOCRIN, V22, P107, DOI 10.1006/frne.2001.0211; Pralong FP, 2000, REGUL PEPTIDES, V95, P47, DOI 10.1016/S0167-0115(00)00130-0; Pralong FP, 2002, FASEB J, V16, P712, DOI 10.1096/fj.01-0754fje; Raposinho PD, 2000, NEUROENDOCRINOLOGY, V71, P2, DOI 10.1159/000054514; Raposinho PD, 2001, MOL CELL ENDOCRINOL, V185, P195, DOI 10.1016/S0303-7207(01)00620-7; Raposinho PD, 1999, ENDOCRINOLOGY, V140, P4046, DOI 10.1210/en.140.9.4046; SAHU A, 1987, PEPTIDES, V8, P921, DOI 10.1016/0196-9781(87)90081-7; SAHU A, 1988, PEPTIDES, V9, P83, DOI 10.1016/0196-9781(88)90013-7; Sainsbury A, 2001, PEPTIDES, V22, P467, DOI 10.1016/S0196-9781(01)00342-4; Sainsbury A, 2002, GENE DEV, V16, P1077, DOI 10.1101/gad.979102; SCHWARTZ MW, 1993, BRAIN RES BULL, V31, P361, DOI 10.1016/0361-9230(93)90228-4; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; SUTTON SW, 1988, ENDOCRINOLOGY, V123, P2152, DOI 10.1210/endo-123-4-2152; Toufexis DJ, 2002, J NEUROENDOCRINOL, V14, P492, DOI 10.1046/j.1365-2826.2002.00805.x; WADE GN, 1992, NEUROSCI BIOBEHAV R, V16, P235, DOI 10.1016/S0149-7634(05)80183-6; WAHLESTEDT C, 1987, BRAIN RES, V417, P33, DOI 10.1016/0006-8993(87)90176-4; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	58	36	39	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					137	139		10.1096/fj.03-0189fje	http://dx.doi.org/10.1096/fj.03-0189fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597564				2022-12-25	WOS:000188829300052
J	Jhabvala-Romero, F; Evans, A; Guo, SH; Denton, M; Clinton, GM				Jhabvala-Romero, F; Evans, A; Guo, SH; Denton, M; Clinton, GM			Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2	ONCOGENE			English	Article						herstatin; heregulin; HER-2; HER-3; tamoxifen; breast cancer	NEU DIFFERENTIATION FACTOR; TYROSINE KINASE; ESTROGEN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; HORMONAL-THERAPY; HER2/NEU ERBB-2; EXPRESSION; PROTEIN; PATHWAY	Ligands of the ErbB family of receptors and estrogens control the proliferation of breast cancer cells. Overexpression of human EGF receptor HER-2 (erbB2) leads to amplified heregulin (HRG) signaling, promoting more aggressive breast cancer that is nonresponsive to estrogen and the antiestrogenic drug tamoxifen. Herstatin (Hst), a secreted HER-2 gene product, binds to the HER-2 receptor ectodomain blocking receptor activation. The aim of this study was to investigate the impact of this HER-2 inhibitor on HRG-induced signaling, proliferation, and sensitivity to tamoxifen in breast cancer cells with and without HER-2 overexpression. The expression of Hst in MCF7 cells eliminated HRG signaling through both mitogen-activated protein kinase and Akt pathways and prevented HRG-mediated proliferation. The loss in signaling corresponded to downregulation of the HRG receptors, HER-3 and HER-4, whereas HER-2 overexpression strongly stimulated the levels of both HRG receptors. Although Hst blocked HRG signaling in both parental and HER-2 transfected cells, it enhanced sensitivity to tamoxifen only in the MCF7 cells that overexpressed HER-2. To evaluate further the efficacy of Hst as an anticancer agent, His-tagged Hst was expressed in transfected insect cells, purified, and added to the breast cancer cells. As in the transfected cells, purified Hst inhibited HER-3 levels and suppressed HRG-induced proliferation of MCF7 and BT474 breast cancer cells. In contrast, the HER-2 monoclonal antibody, herceptin, downregulated HER-2, but not HER-3. These results suggest the potential use of Hst against HRG-mediated growth of breast cancers with high and low levels of HER-2 and against tamoxifen resistance in HER-2 overexpressing breast cancer.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Clinton, GM (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	clinton@ohsu.edu		Evans, Adam/0000-0002-4250-2127				Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Arteaga CL, 2001, SEMIN ONCOL, V28, P30, DOI 10.1053/sonc.2001.29722; Azios NG, 2001, ONCOGENE, V20, P5199, DOI 10.1038/sj.onc.1204555; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Christianson TA, 1998, CANCER RES, V58, P5123; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; Dowsett M, 2001, ENDOCR-RELAT CANCER, V8, P191, DOI 10.1677/erc.0.0080191; Dowsett M, 2001, CANCER RES, V61, P8452; Gilbertson RJ, 1998, CANCER RES, V58, P3932; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Heldin Carl-Henrik, 1996, Cytokine and Growth Factor Reviews, V7, P3, DOI 10.1016/1359-6101(96)00002-0; Hijazi MM, 2000, INT J ONCOL, V17, P629; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JESCHKE M, 1995, INT J CANCER, V60, P730, DOI 10.1002/ijc.2910600527; Justman QA, 2002, J BIOL CHEM, V277, P20618, DOI 10.1074/jbc.M111359200; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Klapper LN, 2000, ADV CANCER RES, V77, P25; Kurokawa H, 2000, CANCER RES, V60, P5887; Lewis GD, 1996, CANCER RES, V56, P1457; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; Mazumdar A, 2001, CANCER RES, V61, P400; Nicholson BP, 2000, SEMIN ONCOL, V27, P33, DOI 10.1053/sonc.2000.19897; Pegram M, 2000, SEMIN ONCOL, V27, P13; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Ram TG, 2000, J CELL PHYSIOL, V183, P301, DOI 10.1002/(SICI)1097-4652(200006)183:3<301::AID-JCP2>3.0.CO;2-W; READ LD, 1990, CANCER RES, V50, P3947; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Sartor CI, 2001, MOL CELL BIOL, V21, P4265, DOI 10.1128/MCB.21.13.4265-4275.2001; SCHLESSINGER J, 1988, COLD SPRING HARB SYM, V53, P515, DOI 10.1101/SQB.1988.053.01.059; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Sweeney C, 2001, J BIOL CHEM, V276, P22685, DOI 10.1074/jbc.M100602200; Tan M, 1999, CANCER RES, V59, P1620; Tang CK, 1996, CANCER RES, V56, P3350; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Xiong SB, 2001, CANCER RES, V61, P1727	48	26	33	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2003	22	50					8178	8186		10.1038/sj.onc.1206912	http://dx.doi.org/10.1038/sj.onc.1206912			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603258				2022-12-25	WOS:000186403400012
J	Wan, XL; Helman, LJ				Wan, XL; Helman, LJ			Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II-overexpressing rhabdomyosarcomas cells	ONCOGENE			English	Article						Akt; phosphorylation; PTEN	TUMOR-SUPPRESSOR PTEN; GROWTH-FACTOR-II; INTEGRIN-LINKED KINASE; SIGNAL-TRANSDUCTION; PROSTATE-CANCER; GLIOMA-CELLS; ACTIVATION; INSULIN; INHIBITION; EXPRESSION	Constitutive activation of Akt has been found in many types of human cancer, and is believed to promote proliferation and increased cell survival thereby contributing to cancer progression. In this study, we examined Akt phosphorylation on Ser473 and Thr308 in seven IGF-II-overexpressing rhabdomyosarcomas (RMS) cells. All the RMS cell lines tested had high levels of Akt phosphorylation on Thr308, whereas three cell lines (Rh5, Rh18, and CTR) had a much lower level of Akt phosphorylation on Ser473. To determine whether the difference in Akt phosphorylation on Ser473, but not on Thr308, observed among cell lines is a cell-specific phenomenon or due to other factors, which possibly downregulate Akt phosphorylation, we examined expression of PTEN protein, which acts as a negative regulator of the PI3K/Akt signaling pathway through its ability to dephosphorylate phosphatidylinositol 3,4,5-triphosphate (PIP3). The levels of PTEN expression inversely correlate with Akt phosphorylation on Ser473, but not on Thr308. Consistent with this finding, transfection of wild-type PTEN into RMS and mouse myoblast C2C12 cells resulted in reduced Akt phosphorylation on Ser473, but not on Thr308. Our data suggest that Ser473 may be a key target residue for PTEN to modulate the effects of IGF-II on activating the PI3K/Akt pathway in RMS cells. A better understanding of the pathway in RMS will likely contribute to insights into the biology of the RMS tumorigenesis and hopefully lead to novel therapeutic options.	NCI, Mol Oncol Sect, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Helman, LJ (corresponding author), NCI, Mol Oncol Sect, Pediat Oncol Branch, NIH, Bldg 10,Rm 13N240, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [ZIASC006892, Z01SC006892] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brodbeck D, 2001, J BIOL CHEM, V276, P29550, DOI 10.1074/jbc.M104633200; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Davies MA, 1998, CANCER RES, V58, P5285; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; ELBADRY OM, 1991, J CLIN INVEST, V87, P648, DOI 10.1172/JCI115042; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Ghosh AK, 1999, GENE, V235, P85, DOI 10.1016/S0378-1119(99)00206-1; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Kroner C, 2000, J BIOL CHEM, V275, P27790, DOI 10.1074/jbc.M000540200; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; Tsatsanis C, 2000, INT J MOL MED, V5, P583; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Wan XL, 2002, NEOPLASIA, V4, P400, DOI 10.1038/sj.neo.7900242; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598	53	96	96	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8205	8211		10.1038/sj.onc.1206878	http://dx.doi.org/10.1038/sj.onc.1206878			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603261				2022-12-25	WOS:000186403400015
J	Srivastava, OP; Kirk, MC; Srivastava, K				Srivastava, OP; Kirk, MC; Srivastava, K			Characterization of covalent multimers of crystallins in aging human lenses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-A-CRYSTALLIN; INTERMEDIATE-FILAMENT PROTEIN; CATARACTOUS HUMAN LENSES; HUMAN SENILE CATARACTOGENESIS; BEADED-FILAMENT; B-CRYSTALLIN; STRUCTURAL PROTEINS; ASSEMBLY PROPERTIES; OXIDATIVE STRESS; GENE STRUCTURE	The purpose of this study was to characterize covalent multimers with molecular mass of >90 kDa in the water-insoluble (WI) proteins of aging human lenses. The experimental approach was to first separate the multimers (molecular mass >90 kDa) as individual spots by two-dimensional gel electrophoresis and next analyze compositions of each multimers by matrix-assisted laser desorption ionization-time of flight and electrospray ionization-tandem mass spectrometric (ES-MS/MS) methods. The WI proteins from lenses of 25- and 41-year-old subjects showed distinct 5- and 16-multimer spots on two-dimensional gels, respectively, but the spots from 52- and 72-year-old lenses were non-descript and diffused. ES-MS/MS analyses showed two types of covalent multimers in 25- and 41-year-old lenses, i.e. the first type composed of fragments of eight different crystallins (i.e. alphaA, alphaB, betaA3, betaA4, betaB1, betaB2, gammaS, and gammaD), and the second type of alpha-, beta-, and gamma-crystallins (possibly fragments) and two beaded filament proteins (phakinin and filensin). The most commonly identified species in the complexes of 41-year-old lenses were: alphaA-fragment (C-terminally truncated, residues 1-157), alphaB-fragment (residues 83 90), betaB1-crystallin (residues 60-71), betaA3 (residues 33 44), betaA4 (residues 106-117), filensin (residues 78-90), and phakinin (residues 77-89). Three post-translational modifications (i.e. oxidation of Met and Trp, conversion of Ser to dehydroalanine, and formylation of His) were observed in alphaA-crystallin fragment, and the first two modifications could cross-link proteins. Together, the results suggested that covalent multimers appeared early in life (i.e. 25 years of age) and increased in number with aging, and the two beaded filament proteins form covalent complexes with crystallin fragments in vivo.	Univ Alabama Birmingham, Dept Physiol Opt, Mass SpectrometryShared Facil, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pharmacol, Mass SpectrometryShared Facil, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Comprehens Canc, Mass SpectrometryShared Facil, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Srivastava, OP (corresponding author), Univ Alabama Birmingham, Dept Physiol Opt, Mass SpectrometryShared Facil, 924 S-18th St,Worrell Bldg, Birmingham, AL 35294 USA.	Srivasta@uab.edu			NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR011329, S10RR013795] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA13148] Funding Source: Medline; NCRR NIH HHS [S10RR-13795, S10RR-11329] Funding Source: Medline; NEI NIH HHS [EY-06400] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDLEY UP, 1989, INVEST OPHTH VIS SCI, V30, P706; BENEDEK GB, 1987, CURR EYE RES, V6, P1421, DOI 10.3109/02713688709044506; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BESSEMS GJH, 1987, EXP EYE RES, V44, P691, DOI 10.1016/S0014-4835(87)80139-2; CARTER JM, 1995, EXP EYE RES, V60, P181, DOI 10.1016/S0014-4835(95)80009-3; CENEDELLA RJ, 1992, CURR EYE RES, V11, P801, DOI 10.3109/02713689209000753; Chiu ML, 1996, BIOCHEMISTRY-US, V35, P2332, DOI 10.1021/bi952073e; CLARK R, 1969, EXP EYE RES, V8, P172, DOI 10.1016/S0014-4835(69)80029-1; Cobb BA, 2000, J BIOL CHEM, V275, P6664, DOI 10.1074/jbc.275.9.6664; Conley YP, 2000, AM J HUM GENET, V66, P1426, DOI 10.1086/302871; Finley EL, 1998, PROTEIN SCI, V7, P2391, DOI 10.1002/pro.5560071116; FITZGERALD PG, 1989, CURR EYE RES, V8, P801, DOI 10.3109/02713688909000870; Friedman M, 1999, J AGR FOOD CHEM, V47, P1295, DOI 10.1021/jf981000+; Fujii N, 2001, BBA-PROTEIN STRUCT M, V1549, P179, DOI 10.1016/S0167-4838(01)00258-8; FUJII N, 1994, BBA-PROTEIN STRUCT M, V1204, P157, DOI 10.1016/0167-4838(94)90003-5; Goulielmos G, 1996, J CELL BIOL, V132, P643, DOI 10.1083/jcb.132.4.643; Hanson SRA, 2000, EXP EYE RES, V71, P195, DOI 10.1006/exer.2000.0868; Herbert B, 1999, ELECTROPHORESIS, V20, P660, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<660::AID-ELPS660>3.0.CO;2-Q; Hess JF, 1998, EXP EYE RES, V66, P625, DOI 10.1006/exer.1998.0478; Hess JF, 1996, J BIOL CHEM, V271, P6729, DOI 10.1074/jbc.271.12.6729; Jakobs PM, 2000, AM J HUM GENET, V66, P1432, DOI 10.1086/302872; JEDZINIAK JA, 1978, INVEST OPHTH VIS SCI, V171, P51; JEDZINIAK JA, 1975, EXP EYE RES, V20, P367, DOI 10.1016/0014-4835(75)90118-9; Jimenez-Asensio J, 1999, J BIOL CHEM, V274, P32287, DOI 10.1074/jbc.274.45.32287; KANAYAMA T, 1987, EXP EYE RES, V44, P165, DOI 10.1016/S0014-4835(87)80001-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORAND L, 1988, ADV POSTTRANSLATIONA, P79; Lund AL, 1996, EXP EYE RES, V63, P661, DOI 10.1006/exer.1996.0160; MASAKI S, 1992, BIOCHEM BIOPH RES CO, V186, P190, DOI 10.1016/S0006-291X(05)80792-2; MCDERMOTT M, 1991, BIOCHEMISTRY-US, V30, P8653, DOI 10.1021/bi00099a023; MORGAN CF, 1989, BIOCHEMISTRY-US, V28, P5065, DOI 10.1021/bi00438a025; NAGARAJ RH, 1991, P NATL ACAD SCI USA, V88, P10257, DOI 10.1073/pnas.88.22.10257; Quinlan RA, 1996, TRENDS CELL BIOL, V6, P123, DOI 10.1016/0962-8924(96)20001-7; Reszka KJ, 1996, FREE RADICAL BIO MED, V20, P23, DOI 10.1016/0891-5849(95)02018-7; Sandilands A, 2003, EXP EYE RES, V76, P385, DOI 10.1016/S0014-4835(02)00330-5; Shridas P, 2001, FEBS LETT, V499, P245, DOI 10.1016/S0014-5793(01)02565-0; Smith JB, 1997, FREE RADICAL RES, V26, P103, DOI 10.3109/10715769709097789; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; Srivastava OP, 2003, MOL VIS, V9, P110; SRIVASTAVA OP, 1988, EXP EYE RES, V47, P525, DOI 10.1016/0014-4835(88)90092-9; Srivastava OP, 1996, CURR EYE RES, V15, P511, DOI 10.3109/02713689609000762; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; Takemoto L, 2000, MOL VIS, V6, P164; Takemoto L, 1998, INT J BIOL MACROMOL, V22, P331, DOI 10.1016/S0141-8130(98)00031-2; Takemoto L, 1996, EXP EYE RES, V63, P585, DOI 10.1006/exer.1996.0149; Takemoto LJ, 1996, EXP EYE RES, V62, P499, DOI 10.1006/exer.1996.0060; Tang DX, 1999, OPHTHALMIC RES, V31, P452, DOI 10.1159/000055571; Thampi P, 2002, INVEST OPHTH VIS SCI, V43, P3265	48	56	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10901	10909		10.1074/jbc.M308884200	http://dx.doi.org/10.1074/jbc.M308884200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14623886	hybrid			2022-12-25	WOS:000220157600011
J	Liu, XY; Du, N				Liu, XY; Du, N			Zero-sized effect of nano-particles and inverse homogeneous nucleation - Principles of freezing and antifreeze	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ICE-NUCLEATION; PROTEINS; WATER; BINDING	It was found that freezing of water in terms of homogeneous nucleation of ice never occurs even in ultra-clean micro-sized water droplets under normal conditions. More surprisingly, at sufficiently low supercoolings, foreign nano-particles exert no effect on the nucleation barrier of ice; it is as if they physically "vanished." This effect, called hereafter the "zero-sized" effect of foreign particles (or nucleators), leads to the entry of a so-called inverse homogeneous-like nucleation domain, in which nucleation is effectively suppressed. The freezing temperature of water corresponds to the transition temperature from the inverse homogeneous-like nucleation regime to foreign particle-mediated heterogeneous nucleation. The freezing temperature of water is mainly determined by (i) the surface roughness of nucleators at large supercoolings, (ii) the interaction and structural match between nucleating ice and the substrate, and (iii) the size of the effective surface of nucleators at low supercoolings. Our experiments showed that the temperature of -40 degreesC, commonly regarded as the temperature of homogeneous nucleation-mediated freezing, is actually the transition temperature from the inverse homogeneous-like nucleation regime to foreign particle-mediated heterogeneous nucleation in ultra-clean water. Taking advantage of inverse homogeneous-like nucleation, the interfacial tensions between water and ice in very pure water and antifreeze aqueous solutions were measured at a very high precision for the first time. The principles of freezing promotion and antifreeze and the selection for the biological ice nucleation and antifreeze proteins are obtained. The results provide completely new insights into freezing and antifreeze phenomena and bear generic implications for all crystallization systems.	Natl Univ Singapore, Fac Sci, Dept Phys, Singapore 117542, Singapore	National University of Singapore	Liu, XY (corresponding author), Natl Univ Singapore, Fac Sci, Dept Phys, Singapore 117542, Singapore.	phyliuxy@nus.edu.sg	Liu, XY/E-5090-2010; Li, Jingliang/A-6039-2011; Zhou, Weiqian/B-8991-2011	Liu, XY/0000-0002-4747-1251; Li, Jingliang/0000-0003-0709-2246; Liu, Xiang-Yang/0000-0002-5592-6885				ADAMSON AW, 1990, PHYSICAL CHEM SURFAC, P78; Davies PL, 1997, CURR OPIN STRUC BIOL, V7, P828, DOI 10.1016/S0959-440X(97)80154-6; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; Du N, 2003, J BIOL CHEM, V278, P36000, DOI 10.1074/jbc.M305222200; Duman JG, 2001, ANNU REV PHYSIOL, V63, P327, DOI 10.1146/annurev.physiol.63.1.327; Fall Ray, 1995, P63; GARSIDE J, 2000, BIOL MINERALIZATION, P23; Graether SP, 2001, BIOPHYS J, V80, P1169, DOI 10.1016/S0006-3495(01)76093-6; HARE DE, 1987, J CHEM PHYS, V87, P4840, DOI 10.1063/1.453710; Houston ME, 1998, J BIOL CHEM, V273, P11714, DOI 10.1074/jbc.273.19.11714; Jia ZC, 1996, NATURE, V384, P285, DOI 10.1038/384285a0; Jia ZC, 2002, TRENDS BIOCHEM SCI, V27, P101, DOI 10.1016/S0968-0004(01)02028-X; KANNO H, 1977, J PHYS CHEM-US, V81, P2639, DOI 10.1021/j100541a013; Knight CA, 2000, NATURE, V406, P249, DOI 10.1038/35018671; KNIGHT CA, 1967, FREEZING SUPERCOOLED, P8; Koop T, 2000, NATURE, V406, P611, DOI 10.1038/35020537; Koop T, 1998, J PHYS CHEM A, V102, P8924, DOI 10.1021/jp9828078; LEE RE, 1995, BIOL ICE NUCL ITS AP, pR5; Liou YC, 2000, NATURE, V406, P322, DOI 10.1038/35018604; Liu JQ, 2001, BOT BULL ACAD SINICA, V42, P61; Liu XY, 1999, J CHEM PHYS, V111, P1628, DOI 10.1063/1.479391; Liu XY, 2003, J AM CHEM SOC, V125, P888, DOI 10.1021/ja020355d; Liu XY, 2001, APPL PHYS LETT, V79, P39, DOI 10.1063/1.1384007; MULLIN JW, 1997, CRYSTALLIZATION, P182; MUTAFTSCHIEV B, 1993, HDB CRYSTAL GROWTH; NIELSEN AE, 1971, J CRYST GROWTH, V11, P233, DOI 10.1016/0022-0248(71)90090-X; Ning D, 2002, APPL PHYS LETT, V81, P445, DOI 10.1063/1.1492849; Petrov V., 1999, Proceedings Thirty-First Annual North American Power Symposium, P23; RASMUSSEN DH, 1982, J CRYST GROWTH, V56, P56, DOI 10.1016/0022-0248(82)90012-4; Sohnel O, 1992, PRECIPITATION BASIC, P41; TURNBULL D, 1950, J APPL PHYS, V21, P1022, DOI 10.1063/1.1699435; Vali Gabor, 1995, P1	32	42	45	2	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6124	6131		10.1074/jbc.M310487200	http://dx.doi.org/10.1074/jbc.M310487200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14602714	hybrid			2022-12-25	WOS:000188776500128
J	Kim, BE; Wang, FD; Dufner-Beattie, J; Andrews, GK; Eide, DJ; Petris, MJ				Kim, BE; Wang, FD; Dufner-Beattie, J; Andrews, GK; Eide, DJ; Petris, MJ			Zn2+-stimulated endocytosis of the mZIP4 zinc transporter regulates its location at the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACRODERMATITIS-ENTEROPATHICA; FUNCTIONAL EXPRESSION; METAL TRANSPORTER; YEAST; PROTEIN; DEGRADATION; FIBROBLASTS; ABSORPTION; THERAPY; ENCODES	Zinc is an essential nutrient for all organisms. Its requirement in humans is illustrated dramatically by the genetic disorder acrodermatitis enteropathica (AE). AE is caused by the reduced uptake of dietary zinc by enterocytes, and the ensuing systemic zinc deficiency leads to dermatological lesions and immune and reproductive dysfunction. The gene responsible for AE, SLC39A4, encodes a member of the ZIP family of metal transporters, hZIP4. The mouse ZIP4 protein, mZIP4, stimulates zinc uptake in cultured cells, and studies in mice have demonstrated that zinc treatment decreases mZIP4 mRNA levels in the gut. In this study, we demonstrated using transfected cultured cells that the mZIP4 protein is also regulated at a post-translational level in response to zinc availability. Zinc deficiency increased mZIP4 protein levels at the plasma membrane, and this was associated with increased zinc uptake. Significantly, treating cells with low micromolar zinc concentrations stimulated the rapid endocytosis of the transporter. Zinc-regulated localization of the human ZIP4 protein was also demonstrated in cultured cells. These findings suggest that zinc-regulated trafficking of human and mouse ZIP4 is a key mechanism controlling dietary zinc absorption and cellular zinc homeostasis.	Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA; Univ Missouri, Dept Biochem, Columbia, MO 65211 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Kansas; University of Kansas Medical Center	Petris, MJ (corresponding author), Univ Missouri, Dept Nutr Sci, 217 Gwynn Hall, Columbia, MO 65211 USA.	petrism@missouri.edu	Wang, Fudi/L-7888-2018	Wang, Fudi/0000-0001-8730-0003	NIDDK NIH HHS [DK59893, DK063975] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063975, R01DK059893] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATHERTON DJ, 1979, CLIN SCI, V56, P505, DOI 10.1042/cs0560505; BAUDON JJ, 1978, ARCH FR PEDIATR, V35, P63; BOHANE TD, 1977, GASTROENTEROLOGY, V73, P587; BRAUN OH, 1976, EUR J PEDIATR, V121, P247, DOI 10.1007/BF00443018; CHESTERS JK, 1983, J INHERIT METAB DIS, V6, P34, DOI 10.1007/BF01811321; Cousins R J, 1989, Adv Exp Med Biol, V249, P3; Cousins RJ, 2000, J NUTR, V130, p1384S, DOI 10.1093/jn/130.5.1384S; Cragg RA, 2002, J BIOL CHEM, V277, P22789, DOI 10.1074/jbc.M200577200; Dufner-Beattie J, 2003, J BIOL CHEM, V278, P33474, DOI 10.1074/jbc.M305000200; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; EIDE DJ, 2004, IN PRESS PFLUEGERS A; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Gaither LA, 2000, J BIOL CHEM, V275, P5560, DOI 10.1074/jbc.275.8.5560; Gaither LA, 2001, J BIOL CHEM, V276, P22258, DOI 10.1074/jbc.M101772200; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Grider A, 1998, BIOL TRACE ELEM RES, V61, P1, DOI 10.1007/BF02784035; HEMPE JM, 1991, J NUTR, V121, P1389, DOI 10.1093/jn/121.9.1389; Huang LP, 2002, J BIOL CHEM, V277, P26389, DOI 10.1074/jbc.M200462200; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Korshunova YO, 1999, PLANT MOL BIOL, V40, P37, DOI 10.1023/A:1026438615520; Krebs NF, 2000, J NUTR, V130, p358S, DOI 10.1093/jn/130.2.358S; KRIEGER I, 1982, PEDIATRICS, V69, P773; Kury S, 2002, NAT GENET, V31, P239, DOI 10.1038/ng913; LOMBECK I, 1975, LANCET, V1, P855; LORINCZ AL, 1967, ARCH DERMATOL, V96, P736, DOI 10.1001/archderm.96.6.736; MESSER HH, 1982, J NUTR, V112, P652, DOI 10.1093/jn/112.4.652; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; OHLSSON A, 1981, ACTA PAEDIATR SCAND, V70, P269, DOI 10.1111/j.1651-2227.1981.tb05556.x; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 2003, J BIOL CHEM, V278, P9639, DOI 10.1074/jbc.M209455200; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; VAZQUEZ F, 1995, BIOL TRACE ELEM RES, V50, P109, DOI 10.1007/BF02789413; Wang K, 2002, AM J HUM GENET, V71, P66, DOI 10.1086/341125; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	34	103	111	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4523	4530		10.1074/jbc.M310799200	http://dx.doi.org/10.1074/jbc.M310799200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14612438	hybrid			2022-12-25	WOS:000188554300073
J	Rao, R; Hao, CM; Breyer, MD				Rao, R; Hao, CM; Breyer, MD			Hypertonic stress activates glycogen synthase kinase 3 beta-mediated apoptosis of renal medullary interstitial cells, suppressing an NF kappa B-driven cyclooxygenase-2-dependent survival pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-MOLECULE INHIBITORS; HYPEROSMOTIC STRESS; GENE-EXPRESSION; LITHIUM; KINASE-3-BETA; PHOSPHORYLATION; GLUTATHIONE; PROTECTION; TRANSPORT; MECHANISM	The survival of renal medullary interstitial cells (RMICs) requires their adaptation to rapid shifts in ambient tonicity normally occurring in the renal medulla. Previous studies determined that cyclooxygenase-2 (COX 2) activation is critical for this adaptation. The present studies find that these adaptive mechanisms are dampened by the simultaneous activation of an apoptotic pathway linked to a glycogen synthase kinase 3beta (GSK 3beta). Inhibition of GSK 3 by LiCl or specific small molecule GSK inhibitors increased RMIC survival following hypertonic stress, and transduction of RMICs with a constitutively active GSK 3beta (AdGSK 3betaA9) significantly increased apoptosis, consistent with a proapoptotic role of GSK 3beta. Following GSK 3beta inhibition, increased survival was accompanied by increased COX 2 expression and COX 2 reporter activity. In contrast, GSK 3beta overexpression reduced COX 2 reporter activity. Importantly, enhanced RMIC survival produced by GSK 3beta inhibition was completely dependent on COX 2 because it was abolished by a COX 2-specific inhibitor, SC58236. The signaling pathway by which GSK 3beta suppresses COX 2 expression was then explored. GSK 3beta inhibition increased both NFkappaB and beta-catenin activity associated with decreased IkappaB and increased beta-catenin levels. The increase in COX 2 following GSK 3beta inhibition was entirely blocked by NFkappaB inhibition using mutant IkappaB adenovirus. However, adenoviral overexpression of beta-catenin did not increase COX 2 levels. These findings suggest that GSK 3beta negatively regulates COX 2 expression and that GSK 3beta inhibitors protect RMICs from hypertonic stress via induction of NFkappaB-COX 2-dependent pathway.	Vanderbilt Univ, Med Ctr, Div Nephrol, Nashville, TN 37232 USA	Vanderbilt University	Breyer, MD (corresponding author), Vanderbilt Univ, Med Ctr, Div Nephrol, S3223,Med Ctr N, Nashville, TN 37232 USA.	Matthew.Breyer@vanderbilt.edu		Breyer, Matthew/0000-0003-1880-371X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039261, R21DK065024] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 065024, 2P50-DK39261] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Araki Y, 2003, CANCER RES, V63, P728; Bach PH, 1998, TOXICOL PATHOL, V26, P73, DOI 10.1177/019262339802600110; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baskiewicz-Masiuk M, 2003, CELL PROLIFERAT, V36, P265, DOI 10.1046/j.1365-2184.2003.00283.x; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Blackwell TS, 1999, CHEST, V116, p73S, DOI 10.1378/chest.116.suppl_1.73S; Bournat JC, 2000, J NEUROSCI RES, V61, P21, DOI 10.1002/1097-4547(20000701)61:1<21::AID-JNR3>3.0.CO;2-7; Burg MB, 1997, CURR OPIN NEPHROL HY, V6, P430, DOI 10.1097/00041552-199709000-00004; Centeno F, 1998, NEUROREPORT, V9, P4199, DOI 10.1097/00001756-199812210-00036; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.00251.x; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; GUAN Y, 1997, AM J PHYSIOL, V273, pF185; HAERTELWIESMANN M, 2000, J BIOL CHEM; Hao CM, 1999, AM J PHYSIOL-RENAL, V277, pF352, DOI 10.1152/ajprenal.1999.277.3.F352; Hao CM, 2000, J CLIN INVEST, V106, P973, DOI 10.1172/JCI9956; Hao CM, 2002, J BIOL CHEM, V277, P21341, DOI 10.1074/jbc.M200695200; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Harris RC, 2001, AM J PHYSIOL-RENAL, V281, pF1, DOI 10.1152/ajprenal.2001.281.1.F1; Harwood AJ, 2003, BIOCHEM PHARMACOL, V66, P179, DOI 10.1016/S0006-2952(03)00187-4; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Howe LR, 2001, J BIOL CHEM, V276, P20108, DOI 10.1074/jbc.M010692200; Inoue H, 2000, J BIOL CHEM, V275, P28028; INOUYE M, 1995, J RADIAT RES, V36, P203, DOI 10.1269/jrr.36.203; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Li Junsheng, 2003, Mol Cancer, V2, P32, DOI 10.1186/1476-4598-2-32; Loberg RD, 2002, J BIOL CHEM, V277, P41667, DOI 10.1074/jbc.M206405200; Markowitz GS, 2000, J AM SOC NEPHROL, V11, P1439, DOI 10.1681/ASN.V1181439; Martinez A, 2002, MED RES REV, V22, P373, DOI 10.1002/med.10011; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Mora A, 2001, J NEUROCHEM, V78, P199, DOI 10.1046/j.1471-4159.2001.00410.x; Neuhofer W, 1998, KIDNEY INT, V54, pS165, DOI 10.1046/j.1523-1755.1998.06735.x; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; Nonaka S, 1998, NEUROREPORT, V9, P2081, DOI 10.1097/00001756-199806220-00031; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Oyama T, 1998, J IMMUNOL, V160, P1224; Sanchez JF, 2003, MOL CELL BIOL, V23, P4649, DOI 10.1128/MCB.23.13.4649-4662.2003; Schwabe RF, 2002, AM J PHYSIOL-GASTR L, V283, pG204, DOI 10.1152/ajpgi.00016.2002; Sekhar KR, 1997, BIOCHEM BIOPH RES CO, V234, P588, DOI 10.1006/bbrc.1997.6697; Stoothoff WH, 2001, J NEUROSCI RES, V65, P573, DOI 10.1002/jnr.1187; SUGAWARA M, 1988, AM J PHYSIOL, V254, pR863, DOI 10.1152/ajpregu.1988.254.6.R863; Taglialatela G, 1997, J NEUROSCI RES, V47, P155; van Es JH, 2001, EXP CELL RES, V264, P126, DOI 10.1006/excr.2000.5142; Wang H, 1996, PLANT CELL, V8, P375, DOI 10.1105/tpc.8.3.375; WOODGETT JR, 2001, SCI STKE; Yang AH, 1997, KIDNEY INT, V51, P1280, DOI 10.1038/ki.1997.175	54	77	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					3949	3955		10.1074/jbc.M309325200	http://dx.doi.org/10.1074/jbc.M309325200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14607840	hybrid			2022-12-25	WOS:000188554300008
J	Steinman, HA; Burstein, E; Lengner, C; Gosselin, J; Pihan, G; Duckett, CS; Jones, SN				Steinman, HA; Burstein, E; Lengner, C; Gosselin, J; Pihan, G; Duckett, CS; Jones, SN			An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTIONAL ACTIVITY; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; MESSENGER-RNA; P53; EXPRESSION; PROTEIN; GENE; ONCOGENE	The Mdm2 gene is amplified in approximately one-third of human sarcomas and overexpressed in a variety of other human cancers. Mdm2 functions as an oncoprotein, in part, by acting as a negative regulator of the p53 tumor suppressor protein. Multiple spliced forms of Mdm2 transcripts have been observed in human tumors; however, the contribution of these variant transcripts to tumorigenesis is unknown. In this report, we isolate alternative splice forms of Mdm2 transcripts from sarcomas that spontaneously arise in Mdm2-overexpressing mice, including Mdm2-b, the splice form most commonly observed in human cancers. Transduction of Mdm2-b into a variety of cell types reveals that Mdm2-b promotes p53-independent cell growth, inhibits apoptosis, and up-regulates the RelA subunit of NFkappaB. Furthermore, expression of Mdm2-b induces tumor formation in transgenic mice. These results identify a p53-independent role for Mdm2 and determine that an alternate spliced form of Mdm2 can contribute to formation of cancer via a p53-independent mechanism. These findings also provide a rationale for the poorer prognosis of those patients presenting with tumors harboring multiple Mdm2 transcripts.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Michigan System; University of Michigan; University of Massachusetts System; University of Massachusetts Worcester	Jones, SN (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, S3-123,55 Lake Ave N, Worcester, MA 01655 USA.	stephen.jones@umassmed.edu	Burstein, Ezra/B-7247-2016	Burstein, Ezra/0000-0003-4341-6367; Duckett, Colin/0000-0001-9413-2263; Lengner, Christopher/0000-0002-0574-5189	NATIONAL CANCER INSTITUTE [R01CA077735, R56CA077735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; NCI NIH HHS [CA77735] Funding Source: Medline; NIDDK NIH HHS [5P30DK32520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Bartel F, 2001, INT J CANCER, V95, P168, DOI 10.1002/1097-0215(20010520)95:3<168::AID-IJC1029>3.0.CO;2-A; Boyd MT, 2000, J BIOL CHEM, V275, P31883, DOI 10.1074/jbc.M004252200; Brenner Michael, 1996, Methods (Orlando), V10, P351, DOI 10.1006/meth.1996.0113; BUESORAMOS CE, 1993, BLOOD, V82, P2617; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CORDONCARDO C, 1994, CANCER RES, V54, P794; Dang JJ, 2002, CANCER RES, V62, P1222; de Toledo SM, 2000, ONCOGENE, V19, P6185, DOI 10.1038/sj.onc.1204020; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Evans SC, 2001, ONCOGENE, V20, P4041, DOI 10.1038/sj.onc.1204533; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Glasgow JN, 2000, J NEUROCHEM, V75, P1377, DOI 10.1046/j.1471-4159.2000.0751377.x; GRAND RJA, 1995, VIROLOGY, V210, P323, DOI 10.1006/viro.1995.1349; Gu LB, 2002, BLOOD, V99, P3367, DOI 10.1182/blood.V99.9.3367; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Jones SN, 1996, GENE, V175, P209, DOI 10.1016/0378-1119(96)00151-5; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Juven-Gershon T, 1998, MOL CELL BIOL, V18, P3974, DOI 10.1128/MCB.18.7.3974; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Matsumoto R, 1998, CANCER RES, V58, P609; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weissenberger J, 1997, ONCOGENE, V14, P2005, DOI 10.1038/sj.onc.1201168; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yam CH, 1999, CANCER RES, V59, P5075	51	87	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4877	4886		10.1074/jbc.M305966200	http://dx.doi.org/10.1074/jbc.M305966200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14612455	hybrid			2022-12-25	WOS:000188554300113
J	Swanson, PC; Volkmer, D; Wang, L				Swanson, PC; Volkmer, D; Wang, L			Full-length RAG-2, and not full-length RAG-1, specifically suppresses RAG-mediated transposition but not hybrid joint formation or disintegration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROKEN DNA-MOLECULES; V(D)J RECOMBINATION; PROTEIN; CELL; CLEAVAGE; COMPLEXES; SEQUENCE; INITIATION; DELETION; REGION	RAG-1 and RAG-2 initiate V(D)J recombination by introducing DNA breaks at recombination signal sequences flanking a pair of antigen receptor gene segments. Occasionally, the RAG proteins mediate two other alternative DNA rearrangements in vivo: the rejoining of signal and coding ends and the transposition of signal ends into unrelated DNA. In contrast, truncated, catalytically active "core" RAG proteins readily catalyze these reactions in vitro, suggesting that full-length RAG proteins directly or indirectly suppress these undesired reactions in vivo. To discriminate between direct and indirect suppression models, full-length RAG proteins were purified and characterized in vitro. From mammalian cells, full-length RAG-1 is readily purified with core RAG-2 but not full-length RAG-2 and vice versa. Despite differences in DNA binding activity, recombinase containing either core or full-length RAG-1 or RAG-2 possess comparable cleavage, rejoining, and end-processing activity, as well as similar usage preferences for canonical versus cryptic recombination signals. However, recombinase containing full-length RAG-2, but not full-length RAG-1, exhibits dramatically reduced transposition activity in vitro. These data suggest RAG-mediated transposition and rejoining are differentially regulated by the full-length RAG proteins in vivo (the former directly by RAG-2 and the latter indirectly through other factors) and argue that noncore portions of the RAG proteins have little or no direct influence over V(D)J recombinase site specificity.	Creighton Univ, Med Ctr, Dept Med Microbiol & Immunol, Omaha, NE 68178 USA	Creighton University	Swanson, PC (corresponding author), Creighton Univ, Med Ctr, Dept Med Microbiol & Immunol, 2500 Calif Plaza, Omaha, NE 68178 USA.	pswanson@creighton.edu			NIAID NIH HHS [1 R01 AI055599-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055599] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agard EA, 2000, MOL CELL BIOL, V20, P5032, DOI 10.1128/MCB.20.14.5032-5040.2000; Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Akamatsu Y, 2003, P NATL ACAD SCI USA, V100, P1209, DOI 10.1073/pnas.0237043100; Bailin T, 1999, MOL CELL BIOL, V19, P4664; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Besmer E, 1998, MOL CELL, V2, P817, DOI 10.1016/S1097-2765(00)80296-8; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; Dai Y, 2003, P NATL ACAD SCI USA, V100, P2462, DOI 10.1073/pnas.0437964100; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Elkin SK, 2003, EMBO J, V22, P1931, DOI 10.1093/emboj/cdg184; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Gauss GH, 1996, MOL CELL BIOL, V16, P258; GE H, 1994, J BIOL CHEM, V269, P17136; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Han JO, 1997, MOL CELL BIOL, V17, P2226, DOI 10.1128/MCB.17.4.2226; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; Kirch SA, 1998, EMBO J, V17, P4881, DOI 10.1093/emboj/17.16.4881; Kirch SA, 1996, EUR J IMMUNOL, V26, P886, DOI 10.1002/eji.1830260425; Lewis SM, 1997, MOL CELL BIOL, V17, P3125, DOI 10.1128/MCB.17.6.3125; LEWIS SM, 1988, CELL, V55, P1099, DOI 10.1016/0092-8674(88)90254-1; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; Li WH, 1997, MOL CELL BIOL, V17, P6932, DOI 10.1128/MCB.17.12.6932; Li Z, 1996, IMMUNITY, V5, P575, DOI 10.1016/S1074-7613(00)80272-1; Liang HE, 2002, IMMUNITY, V17, P639, DOI 10.1016/S1074-7613(02)00448-X; LIN WC, 1994, P NATL ACAD SCI USA, V91, P2733, DOI 10.1073/pnas.91.7.2733; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; McMahan CJ, 1997, J IMMUNOL, V158, P2202; Melek M, 2000, CELL, V101, P625, DOI 10.1016/S0092-8674(00)80874-0; Melek M, 1998, SCIENCE, V280, P301, DOI 10.1126/science.280.5361.301; Messier TL, 2003, EMBO J, V22, P1381, DOI 10.1093/emboj/cdg137; Mo XM, 2000, NUCLEIC ACIDS RES, V28, P1228, DOI 10.1093/nar/28.5.1228; MORZYCKAWROBLEWSKA E, 1988, SCIENCE, V242, P261, DOI 10.1126/science.3140378; NADEL B, 1995, J IMMUNOL, V155, P4322; Nadel B, 1997, MOL CELL BIOL, V17, P3768, DOI 10.1128/MCB.17.7.3768; Noordzij JG, 2000, BLOOD, V96, P203, DOI 10.1182/blood.V96.1.203.013k33_203_209; Ross AE, 2003, MOL CELL BIOL, V23, P5308, DOI 10.1128/MCB.23.15.5308-5319.2003; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; ROTH DB, 1993, P NATL ACAD SCI USA, V90, P10788, DOI 10.1073/pnas.90.22.10788; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V21, P5644, DOI 10.1093/nar/21.24.5644; Santagata S, 1998, J BIOL CHEM, V273, P16325, DOI 10.1074/jbc.273.26.16325; Santagata S, 1999, MOL CELL, V4, P935, DOI 10.1016/S1097-2765(00)80223-3; Sawchuk DJ, 1997, J EXP MED, V185, P2025, DOI 10.1084/jem.185.11.2025; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; Sekiguchi J, 2001, MOL CELL, V8, P1383, DOI 10.1016/S1097-2765(01)00423-3; Shockett PE, 1999, MOL CELL BIOL, V19, P4159; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; Steen SB, 1999, MOL CELL BIOL, V19, P3010; Swanson PC, 2002, MOL CELL BIOL, V22, P7790, DOI 10.1128/MCB.22.22.7790-7801.2002; Swanson PC, 2002, MOL CELL BIOL, V22, P1340, DOI 10.1128/MCB.22.5.1340-1351.2002; Swanson PC, 1999, MOL CELL BIOL, V19, P3674; Swanson PC, 1998, IMMUNITY, V9, P115, DOI 10.1016/S1074-7613(00)80593-2; Swanson PC, 2001, MOL CELL BIOL, V21, P449, DOI 10.1128/MCB.21.2.449-458.2001; Tsai CL, 2003, EMBO J, V22, P1922, DOI 10.1093/emboj/cdg185; vanGent DC, 1997, EMBO J, V16, P2665, DOI 10.1093/emboj/16.10.2665; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; Yurchenko V, 2003, GENE DEV, V17, P581, DOI 10.1101/gad.1058103	61	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4034	4044		10.1074/jbc.M311100200	http://dx.doi.org/10.1074/jbc.M311100200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14612436	hybrid			2022-12-25	WOS:000188554300016
J	Costamagna, E; Garcia, B; Santisteban, P				Costamagna, E; Garcia, B; Santisteban, P			The functional interaction between the paired domain transcription factor Pax8 and Smad3 is involved in transforming growth factor-beta repression of the sodium/iodide symporter gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID NA+/I-SYMPORTER; FRTL-5 CELLS; DNA-BINDING; IODIDE TRANSPORTER; UPSTREAM ENHANCER; PRIMARY CULTURE; ACTIVIN-A; DIFFERENTIATION; EXPRESSION; GROWTH-FACTOR-BETA-1	Transforming growth factor-beta (TGF-beta) is a secreted protein that regulates proliferation, differentiation, and death in various cell types, including thyroid cells, although few details are known about its mechanisms of action in this cell type. Here, we studied the role of TGF-beta on the regulation of sodium/iodide symporter (NIS) gene expression in PC Cl3 thyroid cells. TGF-beta inhibits thyroid-stimulated hormone (TSH)-induced NIS mRNA and protein levels in a dose-dependent manner. This effect takes place at the transcriptional level, as TGF-beta inhibits TSH-induced transcription of a luciferase reporter construct containing a 2.8-kb DNA fragment of the rat NIS promoter. The inhibitory effect of TGF-beta was partially overcome by inhibitory Smad7 and mimicked by overexpression of either Smad3 or a constitutively activated mutant of TGF-beta receptor I (acALK-5). Using internal deletions of the promoter, we defined a region between -2,841 to -1,941, which includes the NIS upstream enhancer (NUE), as responsible for the TGF-beta/Smad inhibitory effect. NUE contains two binding sites for the paired domain transcription factor Pax8, the main factor controlling NIS transcription. The physical interaction observed between Pax8 and Smad3 appears to be responsible for the decrease in Pax8 binding to DNA. Expression of Pax8 mRNA and protein was also decreased by TGF-beta treatment. The results suggest that, through activation of Smad3, TGF-beta decreases Pax8 DNA binding activity as well as Pax8 mRNA and protein levels, which are at least partially involved in TGF-beta-induced down-regulation of NIS gene expression in thyroid follicular cells. Our results thus demonstrate a novel mechanism of Smad3 function in regulating thyroid cell differentiation by functionally antagonizing the action of the paired domain transcription factor Pax8.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Santisteban, P (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.	psantisteban@iib.uam.es	Santisteban, Pilar/E-7829-2016	Santisteban, Pilar/0000-0002-2758-796X				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bidey SP, 1999, J ENDOCRINOL, V160, P321, DOI 10.1677/joe.0.1600321; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carneiro C, 1998, ONCOGENE, V16, P1455, DOI 10.1038/sj.onc.1201662; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Claisse D, 1999, J CELL SCI, V112, P1405; COHEN MM, 2003, AM J MED GENET, V116, pA1; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; DAMANTE G, 1994, BBA-GENE STRUCT EXPR, V1218, P255, DOI 10.1016/0167-4781(94)90176-7; Damante G, 2001, PROG NUCLEIC ACID RE, V66, P307; DE la Vieja A, 2000, PHYSIOL REV, V80, P1083, DOI 10.1152/physrev.2000.80.3.1083; De Leo R, 2000, J BIOL CHEM, V275, P34100, DOI 10.1074/jbc.M003043200; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; di Magliano MP, 2000, P NATL ACAD SCI USA, V97, P13144; Di Palma T, 2003, J BIOL CHEM, V278, P3395, DOI 10.1074/jbc.M205977200; Dohan O, 2003, ENDOCR REV, V24, P48, DOI 10.1210/er.2001-0029; Endo T, 1997, MOL ENDOCRINOL, V11, P1747, DOI 10.1210/me.11.11.1747; Filetti S, 1999, EUR J ENDOCRINOL, V141, P443, DOI 10.1530/eje.0.1410443; Franzen A, 1999, ENDOCRINOLOGY, V140, P4300, DOI 10.1210/en.140.9.4300; Garcia B, 2002, MOL ENDOCRINOL, V16, P342, DOI 10.1210/me.16.2.342; GRUBECKLOEBENSTEIN B, 1989, J AUTOIMMUN, V2, P171, DOI 10.1016/0896-8411(89)90128-5; Hill CS, 1999, INT J BIOCHEM CELL B, V31, P1249, DOI 10.1016/S1357-2725(99)00093-X; Jhiang S M, 2000, Rev Endocr Metab Disord, V1, P205, DOI 10.1023/A:1010083132071; Kang HC, 2001, ENDOCRINOLOGY, V142, P267, DOI 10.1210/en.142.1.267; Kawaguchi A, 1997, THYROID, V7, P789, DOI 10.1089/thy.1997.7.789; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Levy O, 1997, P NATL ACAD SCI USA, V94, P5568, DOI 10.1073/pnas.94.11.5568; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Mansouri A, 1996, CURR OPIN CELL BIOL, V8, P851, DOI 10.1016/S0955-0674(96)80087-1; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MORRIS JC, 1988, ENDOCRINOLOGY, V123, P1385, DOI 10.1210/endo-123-3-1385; Moustakas A, 2001, J CELL SCI, V114, P4359; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; Moustakas Aristidis, 2002, Journal of Cell Science, V115, P3355; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ohmori M, 1998, MOL ENDOCRINOL, V12, P727, DOI 10.1210/me.12.5.727; Ohno M, 1999, MOL CELL BIOL, V19, P2051; PANG XP, 1992, ENDOCRINOLOGY, V131, P45, DOI 10.1210/en.131.1.45; Pekary AE, 1998, ENDOCRINOLOGY, V139, P703, DOI 10.1210/en.139.2.703; Pekary AE, 1997, THYROID, V7, P647, DOI 10.1089/thy.1997.7.647; Poleev A, 1997, EUR J BIOCHEM, V247, P860, DOI 10.1111/j.1432-1033.1997.00860.x; Postiglione MP, 2002, P NATL ACAD SCI USA, V99, P15462, DOI 10.1073/pnas.242328999; Riedel C, 2001, TRENDS BIOCHEM SCI, V26, P490, DOI 10.1016/S0968-0004(01)01904-1; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Schulte KM, 2001, THYROID, V11, P3, DOI 10.1089/10507250150500603; Shen DHY, 2001, THYROID, V11, P415, DOI 10.1089/105072501300176372; STUART ET, 1994, ANNU REV GENET, V28, P219, DOI 10.1146/annurev.ge.28.120194.001251; Taki K, 2002, MOL ENDOCRINOL, V16, P2266, DOI 10.1210/me.2002-0109; TATON M, 1993, MOL CELL ENDOCRINOL, V95, P13, DOI 10.1016/0303-7207(93)90024-E; Tong Q, 1997, BIOCHEM BIOPH RES CO, V239, P34, DOI 10.1006/bbrc.1997.7432; Yuan WH, 2001, J BIOL CHEM, V276, P38502, DOI 10.1074/jbc.M107081200	53	85	90	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3439	3446		10.1074/jbc.M307138200	http://dx.doi.org/10.1074/jbc.M307138200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14623893	Green Published, hybrid			2022-12-25	WOS:000188379600039
J	Courville, P; Chaloupka, R; Veyrier, F; Cellier, MFM				Courville, P; Chaloupka, R; Veyrier, F; Cellier, MFM			Determination of transmembrane topology of the Escherichia coli natural resistance-associated macrophage protein (Nramp) ortholog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; METAL-ION TRANSPORTER; MEMBRANE-PROTEIN; INTRACELLULAR INFECTIONS; CYTOPLASMIC MEMBRANE; IRON TRANSPORT; GENE FUSION; PREDICTION; FAMILY; EXPRESSION	The natural resistance-associated macrophage protein (Nramp) defines a conserved family of secondary metal transporters. Molecular evolutionary analysis of the Nramp family revealed the early duplication of an ancestral eukaryotic Nramp gene, which was likely derived from a bacterial ortholog and characterized as a proton-dependent manganese transporter MntH (Makui, H., Roig, E., Cole, S. T., Helmann, J.D., Gros, P., and Cellier, M. F. (2000) Mol. Microbiol. 35, 1065-1078). Escherichia coli MntH represents a model of choice to study structure function relationship in the Nramp protein family. Here, we report E. coli MntH transmembrane topology using a combination of in silico predictions, genetic fusion with cytoplasmic and periplasmic reporters, and MntH functional assays. Constructs of the secreted form of beta-lactamase (Blam) revealed extra loops between transmembrane domains 1/2, 5/6, 7/8, and 9/10, and placed the C terminus periplasmically; chloramphenicol acetyltransferase constructs indicated cytoplasmic loops 2/3, 6/7, 8/9, and 10/11. Two intra loops for which no data were produced (N terminus, intra loop 4/5) both display composition bias supporting their deduced localization. The extra loops 5/6 and 6/ 7 and periplasmic exposure of the C terminus were confirmed by targeted reporter insertion. Three of them preserved MntH function as measured by a disk assay of divalent metal uptake and a fluorescence assay of divalent metal-dependent proton transport, whereas a truncated form lacking transmembrane domain 11 was inactive. These results demonstrate that EcoliA is a type III integral membrane protein with 11 transmembrane domains transporting both divalent metal ions and protons.	INRS, Inst Armand Frappier, Laval, PQ H7V 1B7, Canada; Charles Univ, Inst Phys, CR-12116 Prague 2, Czech Republic	University of Quebec; Institut national de la recherche scientifique (INRS); Charles University Prague	Cellier, MFM (corresponding author), INRS, Inst Armand Frappier, 531 Bd Prairies, Laval, PQ H7V 1B7, Canada.	mathieu.cellier@inrs-iaf.uquebec.ca	veyrier, Frederic/AAF-9229-2020; courville, pascal/A-5170-2009					Adler J, 2002, J BACTERIOL, V184, P3313, DOI 10.1128/JB.184.12.3313-3320.2002; Agranoff D, 1999, J EXP MED, V190, P717, DOI 10.1084/jem.190.5.717; Andersen JB, 1998, APPL ENVIRON MICROB, V64, P2240; Belouchi A, 1995, PLANT MOL BIOL, V29, P1181, DOI 10.1007/BF00020461; Benoit S, 1998, J BACTERIOL, V180, P6625, DOI 10.1128/JB.180.24.6625-6634.1998; Boyer E, 2002, INFECT IMMUN, V70, P6032, DOI 10.1128/IAI.70.11.6032-6042.2002; BROOMESMITH JK, 1986, GENE, V49, P341, DOI 10.1016/0378-1119(86)90370-7; Cellier M, 1996, TRENDS GENET, V12, P201, DOI 10.1016/0168-9525(96)30042-5; CELLIER M, 1995, P NATL ACAD SCI USA, V92, P10089, DOI 10.1073/pnas.92.22.10089; Cellier MFM, 2001, TRENDS GENET, V17, P365, DOI 10.1016/S0168-9525(01)02364-2; COLIGAN JE, 2002, CURRENT PROTOCOLS PR, V1; Drew D, 2002, P NATL ACAD SCI USA, V99, P2690, DOI 10.1073/pnas.052018199; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Forbes JR, 2001, TRENDS MICROBIOL, V9, P397, DOI 10.1016/S0966-842X(01)02098-4; GRUENHEID S, 1995, GENOMICS, V25, P514, DOI 10.1016/0888-7543(95)80053-O; GUNN FJ, 1995, MOL MICROBIOL, V15, P771, DOI 10.1111/j.1365-2958.1995.tb02384.x; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HERMAN C, 1995, MOL MICROBIOL, V18, P247, DOI 10.1111/j.1365-2958.1995.mmi_18020247.x; Hirata T, 1998, J BIOCHEM-TOKYO, V124, P1206, DOI 10.1093/oxfordjournals.jbchem.a022239; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Horsburgh MJ, 2002, MOL MICROBIOL, V44, P1269, DOI 10.1046/j.1365-2958.2002.02944.x; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Juretic D, 2002, J CHEM INF COMP SCI, V42, P620, DOI 10.1021/ci010263s; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kuhn DE, 2001, J LEUKOCYTE BIOL, V69, P43; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lao Demelo Madrazo, 2002, In Silico Biology, V2, P485; Makui H, 2000, MOL MICROBIOL, V35, P1065, DOI 10.1046/j.1365-2958.2000.01774.x; Melen K, 2003, J MOL BIOL, V327, P735, DOI 10.1016/S0022-2836(03)00182-7; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; Muckenthaler M, 2003, NAT GENET, V34, P102, DOI 10.1038/ng1152; Nilsson J, 2000, FEBS LETT, V486, P267, DOI 10.1016/S0014-5793(00)02321-8; Olsen KN, 2002, APPL ENVIRON MICROB, V68, P4145, DOI 10.1128/AEM.68.8.4145-4147.2002; Ott CM, 2002, J CELL SCI, V115, P2003; Picard V, 2000, J BIOL CHEM, V275, P35738, DOI 10.1074/jbc.M005387200; Portnoy ME, 2000, MOL CELL BIOL, V20, P7893, DOI 10.1128/MCB.20.21.7893-7902.2000; Que Q, 2000, MOL MICROBIOL, V35, P1454, DOI 10.1046/j.1365-2958.2000.01811.x; Reeve I, 2002, P NATL ACAD SCI USA, V99, P8608, DOI 10.1073/pnas.142287699; Richer E, 2003, J MOL EVOL, V57, P363, DOI 10.1007/s00239-003-2472-z; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; SAIER MH, 2001, MICROBIAL TRANSPORT, P1; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; TATE CG, 1993, J BIOL CHEM, V268, P26850; TRAXLER B, 1993, J MEMBRANE BIOL, V132, P1; Ulmschneider MB, 2001, BBA-BIOMEMBRANES, V1512, P1, DOI 10.1016/S0005-2736(01)00299-1; van Geest M, 2000, MICROBIOL MOL BIOL R, V64, P13, DOI 10.1128/MMBR.64.1.13-33.2000; Vidal SM, 1996, J IMMUNOL, V157, P3559; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; WEST AH, 1992, J BIOL CHEM, V267, P24625; Zelazny A, 1996, BIOCHEMISTRY-US, V35, P10872, DOI 10.1021/bi960815d; ZHANG YB, 1990, GENE, V96, P51, DOI 10.1016/0378-1119(90)90340-W	52	28	32	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3318	3326		10.1074/jbc.M309913200	http://dx.doi.org/10.1074/jbc.M309913200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14607838	hybrid			2022-12-25	WOS:000188379600023
J	Shibazaki, M; Takeuchi, T; Ahmed, S; Kikuchi, H				Shibazaki, M; Takeuchi, T; Ahmed, S; Kikuchi, H			Suppression by p38 MAP kinase inhibitors (pyridinyl imidazole compounds) of Ah receptor target gene activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin and the possible mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; SIGNAL-TRANSDUCTION PATHWAY; CYTOCHROME-P-450 1A1; ALPHA-NAPHTHOFLAVONE; DIOXIN RECEPTOR; HEPG2 CELLS; KAPPA-B; PROTEIN; EXPRESSION; INDUCTION	Cytochrome P-450 1A1 (CYP1A1) is known to be induced by aromatic hydrocarbons, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), through activation of the aryl hydrocarbon receptor (AhR). We found that p38 MAP kinase inhibitors (SB203580 and SB202190; 40 muM each; pyridinyl imidazole compounds) suppressed CYP1A1-mRNA induction by TCDD (2 nM) in mouse hepatoma Hepa-1 cells and in human hepatoma HepG2 cells, and also suppressed CYP1B1-mRNA induction by TCDD (2 nM) in human breast adenocarcinoma MCF7 cells. An analogue compound, SB202474, which does not inhibit p38 MAP kinase, also suppressed CYP1A1-mRNA induction by TCDD. Moreover, overexpression of a dominant-negative gene for p38 MAP kinase in Hepa-1 cells did not suppress Cyp1a1 reporter gene induction by TCDD. Therefore, the suppression of Cyp1a1 transcription by pyridinyl imidazole compounds is not because of their inhibition of p38 MAP kinase activity. Because SB203580 did not inhibit in vitro AhR transformation by TCDD, this compound was not acting as a simple AhR antagonist. SB203580 decreased TCDD-induced histone acetylation levels in the region of the Cyp1a1 gene promoter, especially around the TATA box sequence. This result suggests the possibility that pyridinyl imidazole compounds suppress the recruitment of some co-activator that has the histone acetyltransferase activity necessary for CYP1A1-mRNA transcription.	Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Aoba Ku, Sendai, Miyagi 9808575, Japan	Tohoku University	Kikuchi, H (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Aoba Ku, 4-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	hkikuchi@idac.tohoku.ac.jp						Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Ciolino HP, 1999, MOL PHARMACOL, V56, P760; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; GONZALEZ FJ, 1985, NUCLEIC ACIDS RES, V13, P7269, DOI 10.1093/nar/13.20.7269; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HARPER PA, 1992, MOL PHARMACOL, V42, P603; Hossain A, 1998, J BIOL CHEM, V273, P19853, DOI 10.1074/jbc.273.31.19853; Huang M, 2002, J BIOL CHEM, V277, P28364, DOI 10.1074/jbc.C200321200; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Ke S, 2001, J BIOL CHEM, V276, P39638, DOI 10.1074/jbc.M106286200; Kikuchi H, 1998, ARCH BIOCHEM BIOPHYS, V358, P351, DOI 10.1006/abbi.1998.0869; Kikuchi H, 2002, CYTOGENET GENOME RES, V97, P51, DOI 10.1159/000064040; Kikuchi H, 2001, CHEMOSPHERE, V43, P815, DOI 10.1016/S0045-6535(00)00438-0; Kobayashi A, 1997, J BIOCHEM, V122, P703; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LESCA P, 1995, BIOCHEM BIOPH RES CO, V209, P474, DOI 10.1006/bbrc.1995.1526; MERCHANT M, 1992, ARCH BIOCHEM BIOPHYS, V298, P389, DOI 10.1016/0003-9861(92)90426-W; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OKEY AB, 1994, TRENDS PHARMACOL SCI, V15, P226, DOI 10.1016/0165-6147(94)90316-6; Petrulis JR, 2003, J BIOL CHEM, V278, P2677, DOI 10.1074/jbc.M209331200; Puga A, 2000, BIOCHEM PHARMACOL, V60, P1129, DOI 10.1016/S0006-2952(00)00403-2; Puga A, 2000, BIOCHEM PHARMACOL, V59, P997, DOI 10.1016/S0006-2952(99)00406-2; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Reiners JJ, 1997, MOL CARCINOGEN, V19, P91, DOI 10.1002/(SICI)1098-2744(199707)19:2<91::AID-MC4>3.0.CO;2-O; Reiners JJ, 1998, MOL PHARMACOL, V53, P438, DOI 10.1124/mol.53.3.438; Shimizu Y, 2000, P NATL ACAD SCI USA, V97, P779, DOI 10.1073/pnas.97.2.779; Sulentic CEW, 1998, MOL PHARMACOL, V53, P623, DOI 10.1124/mol.53.4.623; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; Tan ZQ, 2002, BIOCHEM PHARMACOL, V64, P771, DOI 10.1016/S0006-2952(02)01138-3; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; Wang S, 2002, J BIOL CHEM, V277, P11821, DOI 10.1074/jbc.M110122200; WILHELMSSON A, 1994, J BIOL CHEM, V269, P19028; Xin L, 2003, BIOESSAYS, V25, P507, DOI 10.1002/bies.10267; Xu L, 1997, BIOCHEM PHARMACOL, V53, P951, DOI 10.1016/S0006-2952(97)00113-5; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	40	40	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3869	3876		10.1074/jbc.M305880200	http://dx.doi.org/10.1074/jbc.M305880200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14594946	hybrid			2022-12-25	WOS:000188379600089
J	Interthal, H; Quigley, PM; Hol, WGJ; Champoux, JJ				Interthal, H; Quigley, PM; Hol, WGJ; Champoux, JJ			The role of lysine 532 in the catalytic mechanism of human topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINASES; DNA TOPOISOMERASE; INTEGRASE FAMILY; NUCLEOTIDE-SEQUENCE; DRUG CAMPTOTHECIN; CRYSTAL-STRUCTURE; FLP RECOMBINASE; ACTIVE-SITE; YEAST; BINDING	Based on co-crystal structures of human topoisomerase I with bound DNA, Lys(532) makes a minor groove contact with the strongly preferred thymidine residue at the site of covalent attachment (-1 position). Replacement of Lys532 with either arginine or alanine has essentially no effect on the sequence preference of the enzyme, indicating that this interaction is not required for the preference for a T at the -1 position. Although both the cleavage and religation activities of the K532R mutant enzyme are reduced, cleavage is reduced to a greater extent than religation. The reverse is true for the K532A mutant enzyme with religation so impaired that the nicked intermediate accumulates during plasmid relaxation assays. Consistent with the shift in the cleavage religation equilibrium toward cleavage for the K532A mutant enzyme, expression of the mutant enzyme in Saccharomyces cerevisiae is cytotoxic, and thus this mutant enzyme mimics the effects of the anticancer drug camptothecin. Cleavage assays with the mutant enzymes using an oligonucleotide containing a 5'-bridging phosphorothiolate indicate that Lys(532) functions as a general acid during cleavage to protonate the leaving 5'-oxygen. It is possible that the contact with the -1 base is important during catalysis to provide positional rigidity to the active site. The corresponding residues in the vaccinia virus topoisomerase and the tyrosine recombinases may have similar critical roles in catalysis.	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Champoux, JJ (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.	champoux@u.washington.edu			NIGMS NIH HHS [GM49156] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049156] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aihara H, 2003, MOL CELL, V12, P187, DOI 10.1016/S1097-2765(03)00268-5; ALSNER J, 1992, J BIOL CHEM, V267, P12408; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; BURGIN AB, 1995, NUCLEIC ACIDS RES, V23, P2973, DOI 10.1093/nar/23.15.2973; Cao YH, 1999, J MOL BIOL, V289, P517, DOI 10.1006/jmbi.1999.2793; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chen Y, 2000, MOL CELL, V6, P885, DOI 10.1016/S1097-2765(05)00088-2; Chen Y, 2003, J BIOL CHEM, V278, P24800, DOI 10.1074/jbc.M300853200; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; CRAIG NL, 1983, CELL, V35, P795, DOI 10.1016/0092-8674(83)90112-5; DARPA P, 1990, CANCER RES, V50, P6919; ENG WK, 1988, MOL PHARMACOL, V34, P755; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; Fiorani P, 1999, MOL PHARMACOL, V56, P1105, DOI 10.1124/mol.56.6.1105; Grainge I, 1999, MOL MICROBIOL, V33, P449, DOI 10.1046/j.1365-2958.1999.01493.x; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; HOESS RH, 1982, P NATL ACAD SCI-BIOL, V79, P3398, DOI 10.1073/pnas.79.11.3398; HOLM C, 1989, CANCER RES, V49, P6365; Holstege FCP, 1997, METHODS, V12, P203, DOI 10.1006/meth.1997.0472; HSIANG YH, 1988, CANCER RES, V48, P1722; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 2002, P NATL ACAD SCI USA, V99, P1853, DOI 10.1073/pnas.032613199; Krogh BO, 2002, J BIOL CHEM, V277, P5711, DOI 10.1074/jbc.C100681200; MADDEN KR, 1995, EMBO J, V14, P5399, DOI 10.1002/j.1460-2075.1995.tb00224.x; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARKER LH, 1993, J MOL BIOL, V231, P6, DOI 10.1006/jmbi.1993.1252; Petersen BO, 1996, J MOL BIOL, V263, P181, DOI 10.1006/jmbi.1996.0568; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Redinbo MR, 2000, BIOCHEMISTRY-US, V39, P6832, DOI 10.1021/bi992690t; Reid RJD, 1998, BBA-GENE STRUCT EXPR, V1400, P289, DOI 10.1016/S0167-4781(98)00142-0; ROSS W, 1983, CELL, V33, P261, DOI 10.1016/0092-8674(83)90355-0; RYAN AJ, 1994, CARCINOGENESIS, V15, P823, DOI 10.1093/carcin/15.5.823; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SENECOFF JF, 1988, J MOL BIOL, V201, P405, DOI 10.1016/0022-2836(88)90147-7; Sherman F, 1986, LAB COURSE MANUAL ME; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Stewart L, 1997, J MOL BIOL, V269, P355, DOI 10.1006/jmbi.1997.1056; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Yang Z, 2001, J BIOL CHEM, V276, P677, DOI 10.1074/jbc.M007593200	53	38	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2984	2992		10.1074/jbc.M309959200	http://dx.doi.org/10.1074/jbc.M309959200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14594810	hybrid			2022-12-25	WOS:000188211300079
J	Kumar, N; Zhao, PL; Tomar, A; Galea, CA; Khurana, S				Kumar, N; Zhao, PL; Tomar, A; Galea, CA; Khurana, S			Association of villin with phosphatidylinositol 4,5-bisphosphate regulates the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; PHOSPHOINOSITIDE-BINDING; F-ACTIN; TYROSINE PHOSPHORYLATION; LIMITED PROTEOLYSIS; CALCIUM-DEPENDENCE; CAPPING PROTEIN; HIGH-AFFINITY; PH DOMAIN; IN-VIVO	Villin, an epithelial cell actin-binding protein, severs actin in vitro and in vivo. Previous studies report that phosphatidylinositol 4,5-bisphosphate (PIP2) regulates actin severing by villin, presumably by interaction with villin. However, direct association of villin with PIP2 has never been characterized. In this report, we presented mutational analysis to identify the PIP2-binding sites in villin. Villin (human) binds PIP2 with a K-d of 39.5 muM, a stoichiometry of 3.3, and a Hill coefficient of 1. We generated deletion mutants of villin lacking putative PIP2-binding sites and examined the impact of these mutations on PIP2 binding and actin dynamics. Our analysis revealed the presence of three PIP2-binding sites, two in the amino-terminal core and one in the carboxyl-terminal headpiece of human villin. Synthetic peptides analogous with these sites confirmed the binding domains. Circular dichroism and quenching of intrinsic tryptophan fluorescence revealed a significant conformational change in these peptides ensuing in their association with PIP2. By using site-directed mutagenesis (arginine 138 to alanine), we demonstrated the presence of an identical F-actin and PIP2-binding site in the capping and severing domain of villin. In contrast, the mutants lysine 822 and 824 to alanine demonstrated the presence of an overlapping F-actin and PIP2-binding site in the actin cross-linking domain of villin. Consistent with this observation, association of villin with PIP2 inhibited the actin capping and severing functions of villin and enhanced the actin bundling function of villin. Our studies revealed that structural changes induced by association with PIP2 could regulate the actin-modifying functions of villin. This study provided biochemical proof of the functional significance of villin association with PIP2 and identified the molecular mechanisms involved in the regulation of actin dynamics by villin and PIP2.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA	University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital	Khurana, S (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave,Nash 402, Memphis, TN 38163 USA.	skhurana@utmem.edu	Galea, Charles/O-8800-2014; Galea, Charles/C-5074-2013	Galea, Charles/0000-0003-2730-1105; Galea, Charles/0000-0003-0485-7709; Khurana, Seema/0000-0002-6884-810X; Kumar, Narendra/0000-0002-1193-0954	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054755] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-54755] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albers TM, 1996, CELL BIOL INT, V20, P821, DOI 10.1006/cbir.1996.0105; ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; BEMENT WM, 1993, J CELL BIOL, V121, P565, DOI 10.1083/jcb.121.3.565; Benesch S, 2002, J BIOL CHEM, V277, P37771, DOI 10.1074/jbc.M204145200; BRETSCHER A, 1980, CELL, V20, P839, DOI 10.1016/0092-8674(80)90330-X; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Chockalingam PS, 1999, BIOCHEMISTRY-US, V38, P5596, DOI 10.1021/bi982564+; Chou J, 2002, INT J BIOCHEM CELL B, V34, P776, DOI 10.1016/S1357-2725(01)00177-7; Cunningham CC, 2001, J BIOL CHEM, V276, P43390, DOI 10.1074/jbc.M105289200; DEARRUDA MV, 1992, J BIOL CHEM, V267, P13079; DiNubile MJ, 1997, BBA-MOL CELL RES, V1358, P261, DOI 10.1016/S0167-4889(97)00076-1; EZZELL RM, 1989, DEVELOPMENT, V106, P407; Ferrary E, 1999, J CELL BIOL, V146, P819, DOI 10.1083/jcb.146.4.819; Flanagan LA, 1997, BIOPHYS J, V73, P1440, DOI 10.1016/S0006-3495(97)78176-1; Fraley TS, 2003, J BIOL CHEM, V278, P24039, DOI 10.1074/jbc.M213288200; Friederich E, 1999, J BIOL CHEM, V274, P26751, DOI 10.1074/jbc.274.38.26751; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; Fukami K, 1996, J BIOL CHEM, V271, P2646, DOI 10.1074/jbc.271.5.2646; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; FURUHASHI K, 1992, BIOCHEM BIOPH RES CO, V184, P1261, DOI 10.1016/S0006-291X(05)80018-X; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GLENNEY JR, 1981, P NATL ACAD SCI-BIOL, V78, P2810, DOI 10.1073/pnas.78.5.2810; GRONE HJ, 1986, AM J PATHOL, V124, P294; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Haugh JM, 1999, J BIOL CHEM, V274, P8958, DOI 10.1074/jbc.274.13.8958; HESTERBERG LK, 1983, J BIOL CHEM, V258, P365; HESTERBERG LK, 1983, J BIOL CHEM, V258, P359; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; HOFMANN A, 1992, CELL MOTIL CYTOSKEL, V23, P133, DOI 10.1002/cm.970230206; HORVAT B, 1990, HISTOCHEMISTRY, V93, P661, DOI 10.1007/BF00272210; Itoh T, 2002, CELL SIGNAL, V14, P733, DOI 10.1016/S0898-6568(02)00028-1; Janmey PA, 1999, CHEM PHYS LIPIDS, V101, P93, DOI 10.1016/S0009-3084(99)00058-4; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; Jones GA, 2000, ARCH BIOCHEM BIOPHYS, V375, P229, DOI 10.1006/abbi.1999.1670; Khurana S, 1997, J BIOL CHEM, V272, P30115, DOI 10.1074/jbc.272.48.30115; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; Lambrechts A, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-12; Lanier LM, 2000, CURR BIOL, V10, pR655, DOI 10.1016/S0960-9822(00)00685-0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; Lin KM, 1997, J BIOL CHEM, V272, P20443, DOI 10.1074/jbc.272.33.20443; Lu PJ, 1996, BIOCHEMISTRY-US, V35, P14027, DOI 10.1021/bi961878z; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; Mochizuki Y, 1999, J BIOL CHEM, V274, P36790, DOI 10.1074/jbc.274.51.36790; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; NORTHROP J, 1986, J BIOL CHEM, V261, P9274; NUSRAT A, 1992, J CLIN INVEST, V89, P1501, DOI 10.1172/JCI115741; Palmgren S, 2001, J CELL BIOL, V155, P251, DOI 10.1083/jcb.200106157; Panebra A, 2001, AM J PHYSIOL-CELL PH, V281, pC1046, DOI 10.1152/ajpcell.2001.281.3.C1046; Pfannstiel J, 2001, J BIOL CHEM, V276, P49476, DOI 10.1074/jbc.M104760200; PREVELIGE PE, 1993, BIOPHYS J, V64, P824, DOI 10.1016/S0006-3495(93)81443-7; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; SIMENEL C, 1995, INT J PEPT PROT RES, V45, P574; STINSON RA, 1997, BIOCHEM J, V131, P719; Stock A, 1999, EMBO J, V18, P5274, DOI 10.1093/emboj/18.19.5274; Suetsugu S, 2001, J BIOL CHEM, V276, P33175, DOI 10.1074/jbc.M102866200; Van Troys M, 2000, BIOCHEMISTRY-US, V39, P12181, DOI 10.1021/bi000816c; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; WALSH TP, 1984, BIOCHEMISTRY-US, V23, P6099, DOI 10.1021/bi00320a030; WARD LD, 1985, METHOD ENZYMOL, V117, P400; Xian WJ, 2002, J MOL BIOL, V322, P755, DOI 10.1016/S0022-2836(02)00841-0; Xian WJ, 1995, BIOPHYS J, V69, P2695, DOI 10.1016/S0006-3495(95)80140-2; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; YIN HL, 1988, J CELL BIOL, V106, P805, DOI 10.1083/jcb.106.3.805; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; YU FX, 1992, J BIOL CHEM, V267, P14616; Zhai LW, 2002, BIOCHEMISTRY-US, V41, P11750, DOI 10.1021/bi0263762; Zhai LW, 2001, J BIOL CHEM, V276, P36163, DOI 10.1074/jbc.C100418200; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	84	62	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					3096	3110		10.1074/jbc.M308878200	http://dx.doi.org/10.1074/jbc.M308878200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14594952	hybrid			2022-12-25	WOS:000188211300091
J	Renshaw, SA; Dempsey, CE; Barnes, FA; Bagstaff, SM; Dower, SK; Bingle, CD; Whyte, MKB				Renshaw, SA; Dempsey, CE; Barnes, FA; Bagstaff, SM; Dower, SK; Bingle, CD; Whyte, MKB			Three novel bid proteins generated by alternative splicing of the human bid gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; BCL-2 FAMILY; CYTOCHROME-C; BONE-MARROW; BH3 DOMAIN; APOPTOSIS; CLEAVAGE; MITOCHONDRIA; MEMBER; LINE	Bid, a BH3-only Bcl-2 protein, is activated by proteolytic cleavage exposing the BH3 domain, which then induces apoptosis by interacting with pro-apoptotic Bcl-2 family proteins (e.g. Bax and Bak) at the mitochondrial surface. The arrangement of domains within Bid suggested that Bid function might be regulated in part by alternative splicing. We have determined the gene structure of human Bid and identified a number of novel exons. We have also demonstrated endogenous mRNA and protein expression for three novel isoforms of Bid, generated using these exons. Bid(S) contains the N-terminal regulatory domains of Bid without the BH3 domain; Bid(EL) corresponds to full-length Bid with additional N-terminal sequence; and Bid(ES) contains only the Bid sequence downstream of the BH3 domain. Expression of these isoforms is regulated during granulocyte maturation. In functional studies Bid(EL) induces apoptosis, whereas BidS abrogates the pro-apoptotic effects of truncated Bid and inhibits Fas-mediated apoptosis. Bid(ES) induces apoptosis but is also able to partially inhibit the pro-apoptotic effects of truncated Bid. These three novel endogenously expressed isoforms of Bid are distinct in their expression, their cellular localization, and their effects upon cellular apoptosis. Differential expression of these novel Bid isoforms may regulate the function of Bid following cleavage and thus influence the fate of cells exposed to a range of pro-apoptotic stimuli.	Univ Sheffield, Royal Hallamshire Hosp, Div Gen Med, Acad Unit Resp Med,Sect Funct Gen, Sheffield S10 2JF, S Yorkshire, England; Univ Sheffield, Royal Hallamshire Hosp, Div Gen Med, Acad Unit Cell Biol,Sect Funct Gen, Sheffield S10 2JF, S Yorkshire, England	University of Sheffield; University of Sheffield	Whyte, MKB (corresponding author), Univ Sheffield, Royal Hallamshire Hosp, Div Gen Med, Acad Unit Resp Med,Sect Funct Gen, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.	m.k.whyte@sheffield.ac.uk	Renshaw, Steve/E-6192-2010; Whyte, Moira/E-6210-2010	Renshaw, Steve/0000-0003-1790-1641; dower, steve/0000-0002-4675-4225; Bingle, Colin/0000-0002-5405-6988				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199; Bingle CD, 2000, J BIOL CHEM, V275, P22136, DOI 10.1074/jbc.M909572199; Bjerregaard MD, 2003, BLOOD, V101, P4322, DOI 10.1182/blood-2002-03-0835; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Cazzola M, 2000, BLOOD, V95, P3280, DOI 10.1182/blood.V95.11.3280.011k41_3280_3288; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cowland JB, 1999, J IMMUNOL METHODS, V232, P191, DOI 10.1016/S0022-1759(99)00176-3; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Esposti MD, 2003, CELL DEATH DIFFER, V10, P1300, DOI 10.1038/sj.cdd.4401306; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Itoh M, 2000, ORAL ONCOL, V36, P277, DOI 10.1016/S1368-8375(00)00010-5; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; LANOTTE M, 1991, BLOOD, V77, P1080; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Lutter M, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-22; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Renshaw SA, 2000, J LEUKOCYTE BIOL, V67, P662, DOI 10.1002/jlb.67.5.662; Renshaw SA, 2003, J IMMUNOL, V170, P1027, DOI 10.4049/jimmunol.170.2.1027; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; STRAUSBERG R, 2002, MAMMALIAN GENE COLLE; Tan KO, 1999, J BIOL CHEM, V274, P23687, DOI 10.1074/jbc.274.34.23687; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Xie ZH, 1998, BIOCHEMISTRY-US, V37, P6410, DOI 10.1021/bi973052i; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zinkel SS, 2003, GENE DEV, V17, P229, DOI 10.1101/gad.1045603	52	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2846	2855		10.1074/jbc.M309769200	http://dx.doi.org/10.1074/jbc.M309769200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14583606	hybrid			2022-12-25	WOS:000188211300064
J	Zagar, Y; Chaumaz, G; Lieberherr, M				Zagar, Y; Chaumaz, G; Lieberherr, M			Signaling cross-talk from G beta(4) subunit to Elk-1 in the rapid action of androgens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; PHOSPHOLIPASE-C; MAP KINASE; TYROSINE KINASE; ACTIVATION; TESTOSTERONE; MEMBRANE; HORMONE; BETA; PATHWAY	Androgens act on transcription via intracellular androgen receptors (ARs), but they also have rapid AR-independent effects. We have identified the multistep processes involved in the rapid actions of androgens in male osteoblasts, which also possess the classical AR. Incubating cells with 5alpha-dihydroxytestosterone ( 100 pM, DHT) rapidly increased ( 1 min) the phosphorylation of the transcription factor Elk-1, and this was inhibited by pertussis toxin (PTX). DHT activated ERK1/2, a substrate of Elk-1, within 15 s but had no effect on p38 MAPK or JNK/SAPK. The inhibitors PD98059 (MEK1/2); Go6976, Go6983, and chelerythrine ( protein kinase C); wortmannin and LY294002 ( phosphatidylinositol 3-kinase); PP1 (Src); and PTX all blunted the DHT-stimulated phosphorylation of ERK1/2. DHT increased the phosphorylation of c-Raf-1 within 5 s; this was blocked by conventional protein kinase C and phosphatidylinositol 3-kinase inhibitors. The first activated membrane protein was the PTX-sensitive Gbeta(4) subunit coupled to phospholipase C-beta2, which triggered a rapid ( 5 s) increase in intracellular calcium and diacylglycerol formation. The androgen antagonist cyproterone acetate did not modify the responses to DHT. Lastly an anti-AR antibody directed against the ligand binding domain recognized a protein at the plasma membrane. The cascade of rapid effects triggered by androgens may involve the classical AR at the plasma membrane or an uncharacterized form of AR that is insensitive to nuclear antagonists.	INRA, Lab Nutr 7 Secur Alimentaire, F-78350 Jouy En Josas, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay	Lieberherr, M (corresponding author), INRA, Lab Nutr 7 Secur Alimentaire, Domaine de Vilvert,Batiment 230, F-78350 Jouy En Josas, France.	lieberhe@diamant.jouy.inra.fr						Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Armen TA, 2000, J CELL BIOCHEM, V79, P620, DOI 10.1002/1097-4644(20001215)79:4<620::AID-JCB110>3.3.CO;2-8; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Benten WPM, 1999, FASEB J, V13, P123, DOI 10.1096/fasebj.13.1.123; Benten WPM, 1999, MOL BIOL CELL, V10, P3113, DOI 10.1091/mbc.10.10.3113; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; BOYER JL, 1994, J BIOL CHEM, V269, P2814; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunet A, 1997, ESSAYS BIOCHEM, V32, P1; Cato A., 2002, SCI STKE; Cheng JJ, 2001, J BIOL CHEM, V276, P31368, DOI 10.1074/jbc.M011317200; Christian HC, 2000, ENDOCRINOLOGY, V141, P3111, DOI 10.1210/en.141.9.3111; Estrada M, 2003, ENDOCRINOLOGY, V144, P3586, DOI 10.1210/en.2002-0164; Estrada M, 2000, AM J PHYSIOL-ENDOC M, V279, pE132, DOI 10.1152/ajpendo.2000.279.1.E132; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GONG YW, 1995, ENDOCRINOLOGY, V136, P2172, DOI 10.1210/en.136.5.2172; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Gutkind J.S, 2000, SCI STKE; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Heinlein CA, 2002, MOL ENDOCRINOL, V16, P2181, DOI 10.1210/me.2002-0070; HOFMANN SL, 1982, J BIOL CHEM, V257, P4359; HRYB DJ, 1990, J BIOL CHEM, V265, P6048; IKONEN T, 1994, ENDOCRINOLOGY, V135, P1359, DOI 10.1210/en.135.4.1359; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Le Mellay V, 1999, J CELL BIOCHEM, V75, P138, DOI 10.1002/(SICI)1097-4644(19991001)75:1<138::AID-JCB14>3.0.CO;2-I; Le Mellay V, 2000, J CELL BIOCHEM, V79, P173, DOI 10.1002/1097-4644(20001101)79:2<173::AID-JCB10>3.0.CO;2-3; LeMellay V, 1997, J BIOL CHEM, V272, P11902, DOI 10.1074/jbc.272.18.11902; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; LUI WS, 1998, CELL SIGNAL, V10, P529; LUST WD, 1976, ANAL BIOCHEM, V72, P8, DOI 10.1016/0003-2697(76)90500-5; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Papakonstanti EA, 2003, MOL ENDOCRINOL, V17, P870, DOI 10.1210/me.2002-0253; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; RHEE SG, 1991, BIOCHEM SOC T, V19, P337, DOI 10.1042/bst0190337; Rosner W, 1999, STEROIDS, V64, P100, DOI 10.1016/S0039-128X(98)00108-1; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Vanderschueren D, 1998, BONE, V23, P391, DOI 10.1016/S8756-3282(98)00131-8; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; WONG G, 1974, NATURE, V252, P713, DOI 10.1038/252713a0; WU DQ, 1992, J BIOL CHEM, V267, P1811; YANG LJ, 1993, J BIOL CHEM, V268, P3739; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Zhu X, 1997, MOL CELL ENDOCRINOL, V134, P9, DOI 10.1016/S0303-7207(97)00168-8	61	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2403	2413		10.1074/jbc.M309132200	http://dx.doi.org/10.1074/jbc.M309132200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14602719	hybrid			2022-12-25	WOS:000188211300011
J	Raucci, A; Laplantine, E; Mansukhani, A; Basilico, C				Raucci, A; Laplantine, E; Mansukhani, A; Basilico, C			Activation of the ERK1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; NEURONAL DIFFERENTIATION; SIGNALING PATHWAYS; PHEOCHROMOCYTOMA CELLS; FACTOR RECEPTOR-3; OXIDATIVE STRESS; BONE-DEVELOPMENT; PC12 CELLS; FGF; PHOSPHORYLATION	Fibroblast growth factors (FGFs) regulate long bone development by affecting the proliferation and differentiation of chondrocytes. FGF treatment inhibits the proliferation of chondrocytes both in vitro and in vivo, but the signaling pathways involved have not been clearly identified. In this report we show that both the MEK-ERK1/2 and p38 MAPK pathways, but not phospholipase Cgamma or phosphatidylinositol 3-kinase, play a role in FGF-mediated growth arrest of chondrocytes. Chemical inhibitors of the MEK1/2 or the p38 MAPK pathways applied to rat chondrosarcoma (RCS) chondrocytes significantly prevented FGF-induced growth arrest. The retinoblastoma family members p107 and p130 were previously shown to be essential effectors of FGF-induced growth arrest in chondrocytes. The dephosphorylation of p107, one of the earliest events in RCS growth arrest, was significantly blocked by MEK1/2 inhibitors but not by the p38 MAPK inhibitors, whereas that of p130, which occurs later, was partially prevented both by the MEK and p38 inhibitors. Furthermore, by expressing the nerve growth factor (NGF) receptor, TrkA, and the epidermal growth factor (EGF) receptor, ErbB1, in RCS cells we show that NGF treatment of the transfected cells caused growth inhibition, whereas EGF did not. FGF- and NGF-induced growth inhibition is accompanied by a strong and sustained activation of ERK1/2 and p38 MAPK and a decrease of AKT phosphorylation, whereas EGF induces a much more transient activation of p38 and ERK1/2 and increases AKT phosphorylation. These results indicate that inhibition of chondrocyte proliferation by FGF requires both ERK1/2 and p38 MAPK signaling and also suggest that sustained activation of these pathways is required to achieve growth inhibition.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA	New York University	Basilico, C (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.	basilc01@med.nyu.edu	Raucci, Angela/K-3722-2018	Raucci, Angela/0000-0003-1333-9671; Mansukhani, Alka/0000-0003-1020-3242	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013745] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 013745] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aikawa T, 2001, J BIOL CHEM, V276, P29347, DOI 10.1074/jbc.M101859200; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Bang OS, 2001, J CELL SCI, V114, P81; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bogdan S, 2001, CURR BIOL, V11, pR292, DOI 10.1016/S0960-9822(01)00167-1; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Cook SJ, 1999, MOL CELL BIOL, V19, P330; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dailey L, 2003, J CELL BIOL, V161, P1053, DOI 10.1083/jcb.200302075; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Guay J, 1997, J CELL SCI, V110, P357; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Harper SJ, 2001, CELL SIGNAL, V13, P299, DOI 10.1016/S0898-6568(01)00148-6; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Jullien J, 2002, J BIOL CHEM, V277, P38700, DOI 10.1074/jbc.M202348200; JUN T, 1999, SCI STKE; Kim JY, 2002, J CELL PHYSIOL, V190, P29, DOI 10.1002/jcp.10049; KLINT P, 1999, FRONT BIOSCI, V4, P165; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Laplantine E, 2002, J CELL BIOL, V158, P741, DOI 10.1083/jcb.200205025; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Matsumoto T, 2002, J CELL BIOL, V156, P149, DOI 10.1083/jcb.200103096; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; Murakami M, 1999, CELL GROWTH DIFFER, V10, P333; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Sahni M, 2001, DEVELOPMENT, V128, P2119; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Voorhoeve PM, 1999, ONCOGENE, V18, P679, DOI 10.1038/sj.onc.1202289; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zapf-Colby A, 1999, ONCOGENE, V18, P4908, DOI 10.1038/sj.onc.1202861; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	67	97	111	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1747	1756		10.1074/jbc.M310384200	http://dx.doi.org/10.1074/jbc.M310384200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14593093	hybrid			2022-12-25	WOS:000188005700024
J	Hirose, T; Sowa, Y; Takahashi, S; Saito, S; Yasuda, C; Shindo, N; Furuichi, K; Sakai, T				Hirose, T; Sowa, Y; Takahashi, S; Saito, S; Yasuda, C; Shindo, N; Furuichi, K; Sakai, T			p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y	ONCOGENE			English	Article						HDAC inhibitor; Gadd45; Oct-1; CCAAT; promoter	WAF1/CIP1 GENE PROMOTER; SP1 SITES; IN-VIVO; P53; BUTYRATE; ACETYLATION; ACTIVATION; EXPRESSION; BINDING; ARREST	Histone deacetylase ( HDAC) inhibitors cause growth arrest at the G1 and/ or G2/M phases, and induce differentiation and/ or apoptosis in a wide variety of tumour cells. The growth arrest at G1 phase by HDAC inhibitors is thought to be highly dependent on the upregulation of p21/WAF1, but the precise mechanism by which HDAC inhibitors cause G2/M arrest or apoptosis in tumour cells is unknown. Gadd45 causes cell cycle arrest at the G2/M phase transition and participates in genotoxic stress-induced apoptosis. We show here that it is also induced by a typical HDAC inhibitor, trichostatin A (TSA), through its promoter, in a p53-independent manner. To identify the mechanism of activation of the gadd45 promoter, we performed luciferase reporter analyses and electrophoretic mobility shift assays. These revealed that both the Oct-1 and CCAAT sites are needed for the full activation by TSA. We also found that the transcription factors Oct-1 and NF-Y specifically bind to each site. Thus, HDAC inhibitors can induce Gadd45 through its promoter without the need for functional p53, and both the Oct-1 and NF-Y concertedly participate in TSA-induced activation of the gadd45 promoter.	Kyoto Prefectural Univ Med, Dept Prevent Med, Kamigyo Ku, Kyoto 6028566, Japan; Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Labs, Tsukuba, Ibaraki 3058585, Japan	Kyoto Prefectural University of Medicine; Astellas Pharmaceuticals	Sowa, Y (corresponding author), Kyoto Prefectural Univ Med, Dept Prevent Med, Kamigyo Ku, Kyoto 6028566, Japan.	ysowa@basic.kpu-m.ac.jp						Adachi N, 2000, GENE, V245, P49, DOI 10.1016/S0378-1119(00)00040-8; Archer SY, 1999, CURR OPIN GENET DEV, V9, P171, DOI 10.1016/S0959-437X(99)80026-4; Blagosklonny MV, 2001, CANCER RES, V61, P4301; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; Chen ZX, 2002, CANCER LETT, V188, P127, DOI 10.1016/S0304-3835(02)00322-1; Della Ragione F, 2001, FEBS LETT, V499, P199, DOI 10.1016/S0014-5793(01)02539-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Espinos E, 1999, MOL CELL BIOL, V19, P3474; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Kakizawa T, 2001, J BIOL CHEM, V276, P9720, DOI 10.1074/jbc.M008531200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kojima H, 1999, J IMMUNOL, V162, P5063; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Li CJ, 1999, P NATL ACAD SCI USA, V96, P13369, DOI 10.1073/pnas.96.23.13369; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; SAKAI T, 1996, JPN J HYG, V50, P1036; SAMBROOK J, 2001, MOL CLONING, pCH17; Schwachtgen JL, 1998, BLOOD, V92, P1247, DOI 10.1182/blood.V92.4.1247.416k08_1247_1258; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Sowa Y, 2000, BIOFACTORS, V12, P283, DOI 10.1002/biof.5520120142; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Takahashi S, 2001, CANCER RES, V61, P1187; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Xu Y, 2001, GENE, V269, P141, DOI 10.1016/S0378-1119(01)00445-0; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhang W, 2001, INT J ONCOL, V18, P749	48	100	106	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2003	22	49					7762	7773		10.1038/sj.onc.1207091	http://dx.doi.org/10.1038/sj.onc.1207091			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586402				2022-12-25	WOS:000186240200006
J	Lenting, PJ; Westein, E; Terraube, V; Ribba, AS; Huizinga, EG; Meyer, D; de Groot, PG; Denis, CV				Lenting, PJ; Westein, E; Terraube, V; Ribba, AS; Huizinga, EG; Meyer, D; de Groot, PG; Denis, CV			An experimental model to study the in vivo survival of von Willebrand factor - Basic aspects and application to the R1205H mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IB-ALPHA; FACTOR-VIII; VONWILLEBRAND-FACTOR; PLATELET-ADHESION; DOMINANT MODIFIER; BINDING-SITE; BLOOD-GROUP; MATURE VWF; A3 DOMAIN; DISEASE	To explore the molecular basis of von Willebrand factor (VWF) clearance, an experimental model employing VWF-deficient mice was developed. Biodistribution was examined by the injection of radiolabeled VWF, which was primarily directed to the liver with minor amounts in other organs. Disappearance of VWF from plasma was characterized by a rapid initial phase ( t(1/2) alpha = 13 min) and a slow secondary phase (t(1/2) alpha = 3 h), with a mean residence time (MRT) of 2.8 h. A similar clearance was observed for VWF consisting of only high or low molecular weight multimers, indicating that, in our experimental model, clearance is independent of multimeric distribution. This allowed us to compare the survival of full-length VWF to truncated variants. Deletion of both the amino-terminal D'-D3 and carboxyl-terminal D4-CK domains resulted in a fragment with a similar clearance to wild-type VWF. Deletion of only the D'-D3 region was associated with an almost 2-fold lower recovery and increased clearance (MRT = 1.6 h), whereas deletion of only the D4-CK region resulted in a significantly reduced clearance ( MRT = 4.5 h, p < 0.02). These results point to a role of the D'-D3 region in preventing clearance of VWF. Furthermore, replacement of D3 domain residue Arg-1205 by His resulted in a markedly increased clearance ( MRT = 0.3 h; p = 0.004). Therefore, this mutation seems to abrogate the protective effect of the D'-D3 region. In vitro analysis of this mutant also revealed a 2-fold reduced affinity for VWF propeptide at low pH, showing that mutation of Arg-1205 results not only in an increased clearance rate but is also associated with an impaired pH-dependent interaction with VWF propeptide.	Univ Med Ctr Utrecht, Dept Haematol, Lab Thrombosis & Haemostasis, NL-3485 CX Utrecht, Netherlands; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Crystal & Struct Chem, NL-3485 CX Utrecht, Netherlands; INSERM, U143, F-94276 Le Kremlin Bicetre, France	Utrecht University; Utrecht University Medical Center; Utrecht University; Institut National de la Sante et de la Recherche Medicale (Inserm)	Lenting, PJ (corresponding author), Univ Med Ctr Utrecht, Dept Haematol G 03 647, Lab Thrombosis & Haemostasis, Heidelberglaan 100, NL-3485 CX Utrecht, Netherlands.	p.j.lenting@lab.azu.nl	Lenting, Peter/AAH-5663-2019; Lenting, Peter/F-8269-2013; Denis, Cecile/A-7649-2011; ribba, anne-sophie/N-3109-2013	Lenting, Peter/0000-0002-7937-3429; Lenting, Peter/0000-0002-7937-3429; Denis, Cecile/0000-0001-5152-9156; Ribba, Anne-Sophie/0000-0001-5342-8455				Arany E, 1996, GROWTH REGULAT, V6, P32; Brown SA, 2003, J THROMB HAEMOST, V1, P1714, DOI 10.1046/j.1538-7836.2003.00359.x; Budde U, 2001, Rev Clin Exp Hematol, V5, P335, DOI 10.1046/j.1468-0734.2001.00048.x; CARLOS SJ, 2003, THROMB HAEMOSTASIS, V89, P468; CASANA P, 2003, J THROMB HAEMOST S, V1; Casonato A, 2002, BLOOD, V99, P180, DOI 10.1182/blood.V99.1.180; de Wit TR, 2001, BEST PRACT RES CL HA, V14, P241; Denis C, 1998, P NATL ACAD SCI USA, V95, P9524, DOI 10.1073/pnas.95.16.9524; Denis CV, 2002, INT J HEMATOL, V75, P3, DOI 10.1007/BF02981972; Denis CV, 2001, BLOOD, V97, P465, DOI 10.1182/blood.V97.2.465; Dobrkovska A, 1998, HAEMOPHILIA, V4, P33; Ellies LG, 2002, P NATL ACAD SCI USA, V99, P10042, DOI 10.1073/pnas.142005099; FUCHS HE, 1984, J CLIN INVEST, V73, P1696, DOI 10.1172/JCI111377; Gavazova S, 2002, BLOOD, V100, p128A; GILL JC, 1987, BLOOD, V69, P1691; Goodeve A, 2001, BEST PRACT RES CL HA, V14, P235, DOI 10.1053/beha.2001.0131; Haberichter SL, 2000, BLOOD, V96, P1808, DOI 10.1182/blood.V96.5.1808.h8001808_1808_1815; Haberichter SL, 2003, BLOOD, V101, P1384, DOI 10.1182/blood-2002-07-2281; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; Lahorte CMM, 2003, NUCL MED COMMUN, V24, P871, DOI 10.1097/01.mnm.0000084585.29433.58; LANKHOF H, 1995, BLOOD, V86, P1035, DOI 10.1182/blood.V86.3.1035.bloodjournal8631035; Lankhof H, 1996, THROMB HAEMOSTASIS, V75, P950; Lankhof H, 1999, THROMB HAEMOSTASIS, V81, P976; Lenting PJ, 1999, J BIOL CHEM, V274, P23734, DOI 10.1074/jbc.274.34.23734; LESTER WA, 2003, J THROMB HAEMOST S, V1; MANNUCCI PM, 1988, BLOOD, V71, P65; MERIANE F, 1993, BLOOD COAGUL FIBRIN, V4, P1023, DOI 10.1097/00001721-199304060-00018; Mohlke KL, 1999, CELL, V96, P111, DOI 10.1016/S0092-8674(00)80964-2; O'Donnell J, 2001, TRANSFUSION MED, V11, P343, DOI 10.1046/j.1365-3148.2001.00315.x; Obert B, 1999, BLOOD, V93, P1959, DOI 10.1182/blood.V93.6.1959.406k01_1959_1968; Orstavik K H, 1990, Folia Haematol Int Mag Klin Morphol Blutforsch, V117, P527; Romijn RA, 2003, J BIOL CHEM, V278, P15035, DOI 10.1074/jbc.M208977200; Ruggeri ZM, 2003, J THROMB HAEMOST, V1, P1335, DOI 10.1046/j.1538-7836.2003.00260.x; Sadler JE, 2003, BLOOD, V101, P2089, DOI 10.1182/blood-2002-09-2892; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Schneppenheim R, 2000, THROMB HAEMOSTASIS, V83, P136; Schwarz HP, 2000, BLOOD, V95, P1703, DOI 10.1182/blood.V95.5.1703.005k20_1703_1708; SIXMA JJ, 1991, EUR J BIOCHEM, V196, P369, DOI 10.1111/j.1432-1033.1991.tb15826.x; Stoddart JH, 1996, BLOOD, V88, P1692; Turecek PL, 1997, BLOOD, V90, P3555, DOI 10.1182/blood.V90.9.3555; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; VISCHER UM, 1994, BLOOD, V83, P3536; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; Wannamethee SG, 2002, CIRCULATION, V105, P1785, DOI 10.1161/01.CIR.0000016346.14762.71; WARE J, 1993, J BIOL CHEM, V268, P8376; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788; White G, 1998, SEMIN HEMATOL, V35, P33; Yarnell JWG, 2001, BLOOD COAGUL FIBRIN, V12, P721, DOI 10.1097/00001721-200112000-00015	48	121	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12102	12109		10.1074/jbc.M310436200	http://dx.doi.org/10.1074/jbc.M310436200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14613933	hybrid			2022-12-25	WOS:000220334900015
J	Snyder, AM; Clark, BM; Robert, B; Ruban, AV; Bungard, RA				Snyder, AM; Clark, BM; Robert, B; Ruban, AV; Bungard, RA			Carotenoid specificity of light-harvesting complex II binding sites - Occurrence of 9-cis-violaxanthin in the neoxanthin-binding site in the parasitic angiosperm Cuscuta reflexa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYSTEM-II; CHLOROPHYLL FLUORESCENCE; SPECTROSCOPIC ANALYSIS; ARABIDOPSIS-THALIANA; XANTHOPHYLL CYCLE; HIGHER-PLANTS; ENERGY; IDENTIFICATION; RECONSTITUTION; CONFIGURATION	The parasitic angiosperm Cuscuta reflexa has a highly unusual carotenoid composition in that it does not contain neoxanthin, an otherwise ubiquitous component of the major light-harvesting complex protein (LHCIIb) in all other higher plant species studied to date (1). Combined HPLC and mass spectrometric analysis has enabled us to detect in tissues of C. reflexa two new types of xanthophylls: lutein-5,6-epoxide and 9-cis-violaxanthin. We have isolated the LHCIIb complex from thylakoids and analyzed chlorophyll and carotenoid composition. The data show that the 9-cis-violaxanthin is present in amounts similar to that of neoxanthin in most plants. On the other hand, lutein-5,6-epoxide was found to be in substoichiometric quantities, suggesting a peripheral location similar to the loosely-associated all-trans-violaxanthin and also enabling suitable accessibility for the de-epoxidase (VDE). Absorption spectroscopy revealed close similarities of the excited state energies of neoxanthin and 9-cis-violaxanthin in vitro and in intact LHCIIb complex. Resonance Raman analysis clearly indicates a cis conformation of violaxanthin in the complex, confirming the pigment analysis data and proving that not only does violaxanthin replace neoxanthin as an intrinsic component of LHCIIb in C. reflexa but it also adopts the same 9-cis conformation of neoxanthin. These results suggest that the N1 binding site of LHCIIb preferentially binds 9-cis-5,6-epoxy carotenoids, which has implications for the features of this binding site and its role in the photosystem II antenna assembly and stability.	Univ Sheffield, Dept Mol Biol & Biotechnol, Robert Hill Inst, Sheffield S10 2TN, S Yorkshire, England; Univ Canterbury, Sch Biol Sci, Christchurch 8020, New Zealand; Univ Canterbury, Dept Chem, Christchurch 8020, New Zealand; Ctr Etud Saclay, Dept Biol Joliot Curie, Serv Biophys Fonct Membranaires, CNRS,URA 2096, F-91191 Gif Sur Yvette, France; Ecole Normale Super, Dept Biol, UMR 8543, F-75230 Paris 05, France	University of Sheffield; University of Canterbury; University of Canterbury; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Ruban, AV (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Robert Hill Inst, Sheffield S10 2TN, S Yorkshire, England.	ruban@wotan.ens.fr; ralph.bungard@canterbury.ac.nz	Robert, Bruno/D-1264-2012	Robert, Bruno/0000-0001-5999-4538				Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; Bassi R, 2000, PHOTOSYNTH RES, V64, P243, DOI 10.1023/A:1006409506272; Bungard RA, 1999, P NATL ACAD SCI USA, V96, P1135, DOI 10.1073/pnas.96.3.1135; Bungard RA, 1997, AUST J PLANT PHYSIOL, V24, P205, DOI 10.1071/PP96085; Croce R, 1999, FEBS LETT, V456, P1, DOI 10.1016/S0014-5793(99)00907-2; Croce R, 1999, J BIOL CHEM, V274, P29613, DOI 10.1074/jbc.274.42.29613; Garcia-Plazaola JI, 2003, FUNCT PLANT BIOL, V30, P319, DOI 10.1071/FP02224; Hibberd JM, 1998, PLANTA, V205, P506, DOI 10.1007/s004250050349; Hobe S, 2000, EUR J BIOCHEM, V267, P616, DOI 10.1046/j.1432-1327.2000.01060.x; Hurry V, 1997, PLANT PHYSIOL, V113, P639, DOI 10.1104/pp.113.2.639; Jahns P, 2001, J BIOL CHEM, V276, P22154, DOI 10.1074/jbc.M102147200; KUBLBRANDT W, 1991, NATURE, V350, P130; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Lokstein H, 2002, BBA-BIOENERGETICS, V1553, P309, DOI 10.1016/S0005-2728(02)00184-6; MOLNAR P, 1980, PHYTOCHEMISTRY, V19, P623, DOI 10.1016/0031-9422(80)87027-0; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; PAULSON H, 1990, PLANTA, V181, P146; PETER GF, 1991, J BIOL CHEM, V266, P16745; Phillip D, 2002, J BIOL CHEM, V277, P25160, DOI 10.1074/jbc.M202002200; Phillip D, 1999, J PHOTOCH PHOTOBIO B, V49, P89, DOI 10.1016/S1011-1344(99)00019-6; PLUMLEY FG, 1995, PLANT CELL, V7, P689, DOI 10.2307/3870172; PLUMLEY FG, 1987, P NATL ACAD SCI USA, V84, P146, DOI 10.1073/pnas.84.1.146; ROCK CD, 1991, P NATL ACAD SCI USA, V88, P7496, DOI 10.1073/pnas.88.17.7496; Ruban AV, 2000, FEBS LETT, V477, P181, DOI 10.1016/S0014-5793(00)01799-3; Ruban AV, 1999, J BIOL CHEM, V274, P10458, DOI 10.1074/jbc.274.15.10458; RUBAN AV, 1994, PLANT PHYSIOL, V104, P227, DOI 10.1104/pp.104.1.227; Ruban AV, 2002, J BIOL CHEM, V277, P42937, DOI 10.1074/jbc.M207823200; RUBAN AV, 1992, BIOCHIM BIOPHYS ACTA, V1102, P30, DOI 10.1016/0005-2728(92)90061-6; Ruban AV, 1997, BIOCHEMISTRY-US, V36, P7855, DOI 10.1021/bi9630725; Ruban AV, 2001, J BIOL CHEM, V276, P24862, DOI 10.1074/jbc.M103263200; RUBAN AV, 1995, BIOCHEMISTRY-US, V34, P2333, DOI 10.1021/bi00007a029; Tardy F, 1996, J PHOTOCH PHOTOBIO B, V34, P87, DOI 10.1016/1011-1344(95)07272-1; Verhoeven AS, 1999, PLANT PHYSIOL, V120, P727, DOI 10.1104/pp.120.3.727; Wentworth M, 2003, J BIOL CHEM, V278, P21845, DOI 10.1074/jbc.M302586200	35	35	35	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5162	5168		10.1074/jbc.M309676200	http://dx.doi.org/10.1074/jbc.M309676200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14610095	hybrid			2022-12-25	WOS:000188776500016
J	Snyder, AK; Williams, CR; Johnson, A; O'Donnell, M; Bloom, LB				Snyder, AK; Williams, CR; Johnson, A; O'Donnell, M; Bloom, LB			Mechanism of loading the Escherichia coli DNA polymerase III sliding clamp - II. Uncoupling the beta and DNA binding activities of the gamma complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION MACHINE; ONE HOLOENZYME PARTICLE; CRYSTAL-STRUCTURE; DELTA-SUBUNIT; PROCESSIVITY FACTOR; ATP HYDROLYSIS; LOADER; WRENCH; SWITCH; PCNA	Sliding clamps tether DNA polymerases to DNA to increase the processivity of synthesis. The Escherichia coli gamma complex loads the beta sliding clamp onto DNA in an ATP-dependent reaction in which ATP binding and hydrolysis modulate the affinity of the gamma complex for beta and DNA. This is the second of two reports (Williams, C. R., Snyder, A. K., Kuzmic, P., O'Donnell, M., and Bloom, L. B. (2004) J. Biol. Chem. 279, 4376-4385) addressing the question of how ATP binding and hydrolysis regulate specific interactions with DNA and beta. Mutations were made to an Arg residue in a conserved SRC motif in the delta' and gamma subunits that interacts with the ATP site of the neighboring gamma subunit. Mutation of the delta' subunit reduced the ATP-dependent beta binding activity, whereas mutation of the gamma subunits reduced the DNA binding activity of the gamma complex. The gamma complex containing the delta' mutation gave a pre-steady-state burst of ATP hydrolysis, but at a reduced rate and amplitude relative to the wild-type gamma complex. A pre-steady-state burst of ATP hydrolysis was not observed for the complex containing they mutations, consistent with the reduced DNA binding activity of this complex. The differential effects of these mutations suggest that ATP binding at the gamma(1) site may be coupled to conformational changes that largely modulate interactions with beta, whereas ATP binding at the gamma(2) and/or gamma(3) site may be coupled to conformational changes that have a major role in interactions with DNA. Additionally, these results show that the "arginine fingers" play a structural role in facilitating the formation of a conformation that has high affinity for beta and DNA.	Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA	State University System of Florida; University of Florida; Rockefeller University; Howard Hughes Medical Institute	Bloom, LB (corresponding author), Univ Florida, Dept Biochem & Mol Biol, POB 100245, Gainesville, FL 32610 USA.	lbloom@ufl.edu	Bloom, Linda B/F-3684-2014		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38839, GM55596, R01 GM055596] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ason B, 2000, J BIOL CHEM, V275, P3006, DOI 10.1074/jbc.275.4.3006; Ason B, 2003, J BIOL CHEM, V278, P10033, DOI 10.1074/jbc.M211741200; Bertram JG, 2000, J BIOL CHEM, V275, P28413, DOI 10.1074/jbc.M910441199; Bertram JG, 1998, J BIOL CHEM, V273, P24564, DOI 10.1074/jbc.273.38.24564; Davey MJ, 2002, NAT REV MOL CELL BIO, V3, P826, DOI 10.1038/nrm949; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; GRIEP MA, 1988, BIOCHEMISTRY-US, V27, P5210, DOI 10.1021/bi00414a040; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; Indiani C, 2003, J BIOL CHEM, V278, P40272, DOI 10.1074/jbc.M305828200; Jeruzalmi D, 2002, CURR OPIN STRUC BIOL, V12, P217, DOI 10.1016/S0959-440X(02)00313-5; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; Johnson A, 2003, J BIOL CHEM, V278, P14406, DOI 10.1074/jbc.M212708200; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P291, DOI 10.1007/978-1-4757-3061-6; Leu FP, 2000, J BIOL CHEM, V275, P34609, DOI 10.1074/jbc.M005495200; Leu FP, 2003, MOL CELL, V11, P315, DOI 10.1016/S1097-2765(03)00042-X; MAKI S, 1988, J BIOL CHEM, V263, P6555; Moarefi I, 2000, J MOL BIOL, V296, P1215, DOI 10.1006/jmbi.1999.3511; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; O'Donnell M, 2001, CURR BIOL, V11, pR935, DOI 10.1016/S0960-9822(01)00559-0; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; Podobnik M, 2003, STRUCTURE, V11, P253, DOI 10.1016/S0969-2126(03)00027-3; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; Stewart J, 2001, J BIOL CHEM, V276, P19182, DOI 10.1074/jbc.M100592200; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Williams CR, 2004, J BIOL CHEM, V279, P4376, DOI 10.1074/jbc.M310429200; Yao N, 2000, J BIOL CHEM, V275, P11440, DOI 10.1074/jbc.275.15.11440	36	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4386	4393		10.1074/jbc.M310430200	http://dx.doi.org/10.1074/jbc.M310430200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14610068	hybrid			2022-12-25	WOS:000188554300057
J	Jeong, W; Yoon, HW; Lee, SR; Rhee, SG				Jeong, W; Yoon, HW; Lee, SR; Rhee, SG			Identification and characterization of TRP14, a thioredoxin-related protein of 14 kDa - New insights into the specificity of thioredoxin function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI THIOREDOXIN; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; MAMMALIAN PEROXIREDOXIN; MOLECULAR-CLONING; HYDROGEN-PEROXIDE; REDOX REGULATION; REDUCED FORM; REDUCTASE	We have identified and characterized a 14-kDa human thioredoxin (Trx)-related protein designated TRP14. This cytosolic protein was expressed in all tissues and cell types examined, generally in smaller amounts than Trx1. Although TRP14 contains five cysteines, only the two Cys residues in its WCPDC motif were exposed and redox sensitive. Unlike Trx1, which was an equally good substrate for both Trx reductase 1 (TrxR1) and TrxR2, oxidized TRP14 was reduced by TrxR1 but not by TrxR2. Biochemical characterization of TRP14 suggested that, like Trx1, TRP14 is a disulfide reductase; its active site cysteine is sufficiently nucleophilic with the pK(a) value of 6.1; and its redox potential (-257 mV) is similar to those of other cellular thiol reductants. However, although TRP14 reduced small disulfide-containing peptides, it did not reduce the disulfides of known Trx1 substrates, ribonucleotide reductase, peroxiredoxin, and methionine sulfoxide reductase. These results suggest that TRP14 and Trx1 might act on distinct substrate proteins.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Ewha Womans University	Rhee, SG (corresponding author), Bldg 50,Room 3523,South Dr,MSC 8015, Bethesda, MD 20892 USA.	sgrhee@nih.gov						Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; Collin V, 2003, J BIOL CHEM, V278, P23747, DOI 10.1074/jbc.M302077200; GLEASON FK, 1990, BIOCHEMISTRY-US, V29, P3701, DOI 10.1021/bi00467a016; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Hirota K, 2002, ANN NY ACAD SCI, V957, P189, DOI 10.1111/j.1749-6632.2002.tb02916.x; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1972, J BIOL CHEM, V247, P1992; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; Hutter DE, 1997, EXP CELL RES, V232, P435, DOI 10.1006/excr.1997.3527; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; Jeong W, 2004, J BIOL CHEM, V279, P3151, DOI 10.1074/jbc.M307959200; JOELSON T, 1990, J BIOL CHEM, V265, P3183; KALLIS GB, 1980, J BIOL CHEM, V255, P261; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kim JR, 2000, ANAL BIOCHEM, V283, P214, DOI 10.1006/abio.2000.4623; Kirlin WG, 1999, FREE RADICAL BIO MED, V27, P1208, DOI 10.1016/S0891-5849(99)00145-8; KRAUSE G, 1991, J BIOL CHEM, V266, P4056; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Li N, 1998, J CELL PHYSIOL, V177, P148, DOI 10.1002/(SICI)1097-4652(199810)177:1<148::AID-JCP16>3.0.CO;2-9; Lin TY, 1999, BIOCHEMISTRY-US, V38, P15508, DOI 10.1021/bi9907678; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; LUNDSTROM J, 1993, BIOCHEMISTRY-US, V32, P6649, DOI 10.1021/bi00077a018; Matsuo Y, 2001, J BIOL CHEM, V276, P10032, DOI 10.1074/jbc.M011037200; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Miranda-Vizuete A, 2001, J BIOL CHEM, V276, P31567, DOI 10.1074/jbc.M101760200; Mossner E, 1999, J BIOL CHEM, V274, P25254, DOI 10.1074/jbc.274.36.25254; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; Qin J, 2000, ANTIOXID REDOX SIGN, V2, P827, DOI 10.1089/ars.2000.2.4-827; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; RUTHIER N, 2002, ANN NY ACAD SCI, V973, P520; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Slaby I, 1996, J BIOL CHEM, V271, P3091, DOI 10.1074/jbc.271.6.3091; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Stadtman ER, 2002, MOL CELL BIOCHEM, V234, P3, DOI 10.1023/A:1015916831583; Stubbe J, 1998, TRENDS BIOCHEM SCI, V23, P438, DOI 10.1016/S0968-0004(98)01296-1; Takeuchi J, 2000, ANTIOXID REDOX SIGN, V2, P83, DOI 10.1089/ars.2000.2.1-83; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2	52	87	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3142	3150		10.1074/jbc.M307932200	http://dx.doi.org/10.1074/jbc.M307932200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14607844	hybrid			2022-12-25	WOS:000188379600003
J	Sakamoto, S; Qin, JZ; Navarro, A; Gamero, A; Potla, R; Yi, TL; Zhu, W; Baker, DP; Feldman, G; Larner, AC				Sakamoto, S; Qin, JZ; Navarro, A; Gamero, A; Potla, R; Yi, TL; Zhu, W; Baker, DP; Feldman, G; Larner, AC			Cells previously desensitized to type 1 interferons display different mechanisms of activation of stat-dependent gene expression from naive cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; STIMULATED JAK/STAT PATHWAY; GAMMA-INTERFERON; TRANSCRIPTIONAL INDUCTION; BETA-INTERFERON; PHOSPHORYLATED STAT1; BINDING PROTEIN; DNA; INHIBITION; ALPHA	Over the past decade, a wealth of knowledge has been obtained concerning the mechanisms by which interferons (IFNs) and other cytokines activate or down-regulate immediate early genes via the Jak/Stat pathway. In contrast, little information is available on interferon-activated gene expression in naive cells compared with cells that have been desensitized and subsequently resensitized to the actions of these cytokines. In naive cells, the ISG54 gene is activated via IFN beta-stimulated formation of ISGF3, a heterotrimeric DNA binding complex consisting of p48 (IRF9) and tyrosine-phosphorylated Stat1 and Stat2. In contrast, in previously desensitized cells IFNbeta weakly stimulates the assembly of an ISGF3-like complex that lacks Stat1, even though ISG54 mRNA induction is the same as in naive cells. The lack of Stat1 tyrosine phosphorylation and DNA binding is due to increased activity of a protein-tyrosine phosphatase. In cells that do not express the tyrosine phosphatase Tc-PTP, the rate of Stat1 dephosphorylation is the same in naive and previously desensitized cells. These results implicate Tc-PTP in a novel role in the regulation of type 1 interferon-stimulated gene expression.	Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA; Biogen Inc, Cambridge, MA 02142 USA; US FDA, Div Monoclonal Antibodies, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Biogen; US Food & Drug Administration (FDA)	Larner, AC (corresponding author), Lerner Res Inst, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	larnera@ccf.iorg			NATIONAL CANCER INSTITUTE [R01CA077366] Funding Source: NIH RePORTER; NCI NIH HHS [CA77366] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoki N, 2000, J BIOL CHEM, V275, P39718, DOI 10.1074/jbc.M005615200; AWATA T, 1994, DIABETOLOGIA, V37, P1159, DOI 10.1007/BF00418381; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; DAVID M, 1995, MOL CELL BIOL, V15, P7050; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; Dupont SA, 2002, J INTERF CYTOK RES, V22, P491, DOI 10.1089/10799900252952280; FINBLOOM DS, 1991, J BIOL CHEM, V266, P22545; Gao JJ, 2000, EUR J IMMUNOL, V30, P1551, DOI 10.1002/1521-4141(200006)30:6<1551::AID-IMMU1551>3.0.CO;2-Y; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Heise MT, 1998, VIROLOGY, V241, P331, DOI 10.1006/viro.1997.8969; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; INABA K, 1986, J EXP MED, V163, P1030, DOI 10.1084/jem.163.4.1030; IRIESASAKI MJ, 2000, SEMINAR IMMUNOL, V12, P379; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Kraus TA, 2003, J BIOL CHEM, V278, P13033, DOI 10.1074/jbc.M212972200; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LARNER AC, 1986, J BIOL CHEM, V261, P453; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Navarro L, 1999, J BIOL CHEM, V274, P35535, DOI 10.1074/jbc.274.50.35535; Paulson M, 2002, NAT CELL BIOL, V4, P140, DOI 10.1038/ncb747; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PETRICOIN EF, 1992, MOL CELL BIOL, V12, P4486, DOI 10.1128/MCB.12.10.4486; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Poast J, 2002, J INTERF CYTOK RES, V22, P1035, DOI 10.1089/107999002760624260; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; SEDMAK DD, 1995, ARCH VIROL, V140, P111, DOI 10.1007/BF01309727; Shuai K, 1996, MOL CELL BIOL, V16, P4932; ten Hoeve J, 2002, MOL CELL BIOL, V22, P5662, DOI 10.1128/MCB.22.16.5662-5668.2002; VILLARETE L, 1995, INFECT IMMUN, V63, P1468, DOI 10.1128/IAI.63.4.1468-1472.1995; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; Wu TR, 2002, J BIOL CHEM, V277, P47572, DOI 10.1074/jbc.M207536200; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Zhu W, 2002, J BIOL CHEM, V277, P35787, DOI 10.1074/jbc.C200346200	44	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3245	3253		10.1074/jbc.M309631200	http://dx.doi.org/10.1074/jbc.M309631200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14600148	hybrid			2022-12-25	WOS:000188379600015
J	Yin, HY; Morrow, JD; Porter, NA				Yin, HY; Morrow, JD; Porter, NA			Identification of a novel class of endoperoxides from arachidonate autoxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; PERFORMANCE LIQUID-CHROMATOGRAPHY; LOW-DENSITY-LIPOPROTEIN; FORMED IN-VIVO; CHOLESTERYL ARACHIDONATE; PEROXIDATION PRODUCTS; LIPID-PEROXIDATION; DIACYL PEROXIDES; ACID; EPOXYISOPROSTANE	Free radical-initiated lipid autoxidation in low density lipoprotein (LDL) has been implicated in the pathogenesis of atherosclerosis. Oxidation of the lipid components of LDL leads to a complex mixture of hydroperoxides, bicyclic endoperoxides, monocyclic peroxides, and serial cyclic peroxides. The oxidation compounds and/or their decomposition products can modify protein components, which may lead to various diseases. A novel class of peroxides (termed dioxolane-isoprostanes) having a bicyclic endoperoxide moiety characteristic of the isoprostanes and a dioxolane peroxide functionality in the same molecule was identified in the product mixture formed from in vitro autoxidation of cholesteryl arachidonate. The same products are also detected in in vitro oxidized LDL. Various mass spectrometric techniques have been applied to characterize these new peroxides. The structure of these compounds has also been confirmed by independent synthesis. We reason, based on the free radical mechanism of the transformation, that only the 12- and 8-peroxyl radicals (those leading to 12-HPETE and 8-HPETE) of arachidonate can form these new peroxides. We also suggest that the formation of these peroxides provides a rationale to explain the fact that 5- and 15-series isoprostanes are formed in preference to 8- and 12- series. Furthermore, series of other isoprostanes, such as dioxolane A(2), D-2, E-2, etc., can be derived from the dioxolane-isoprostane peroxides. These findings offer further insights into the oxidation products of arachidonate and the opportunity to study their potential biological relevance.	Vanderbilt Univ, Ctr Mol Toxicol, Dept Chem, Nashville, TN 37235 USA; Vanderbilt Univ, Ctr Mol Toxicol, Dept Pharmacol, Nashville, TN 37235 USA; Vanderbilt Univ, Vanderbilt Inst Chem Biol, Nashville, TN 37235 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Porter, NA (corresponding author), Vanderbilt Univ, Ctr Mol Toxicol, Dept Chem, Box 1822,Stn B, Nashville, TN 37235 USA.	n.porter@vanderbilt.edu		yin, hui yong/0000-0001-7049-1560	NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL017921, R01HL017921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER; NCI NIH HHS [CA 77839] Funding Source: Medline; NHLBI NIH HHS [HL17921] Funding Source: Medline; NIDDK NIH HHS [DK 48831] Funding Source: Medline; NIEHS NIH HHS [P30 ES00267] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline; PHS HHS [CHE 9996188] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Boutaud O, 2001, BIOCHEMISTRY-US, V40, P6948, DOI 10.1021/bi002629k; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Dickinson JS, 2002, J AM SOC MASS SPECTR, V13, P1227, DOI 10.1016/S1044-0305(02)00456-7; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Esterbauer H., 1991, MEMBRANE LIPID OXIDA; Fessel JP, 2002, P NATL ACAD SCI USA, V99, P16713, DOI 10.1073/pnas.252649099; FitzGerald GA, 2001, J CLIN INVEST, V107, P1335, DOI 10.1172/JCI13037; FOLCH J, 1957, J BIOL CHEM, V226, P497; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; HARVRILLA CM, 2000, THESIS DUKE U DURHAM; Havrilla CM, 2000, J AM CHEM SOC, V122, P8042, DOI 10.1021/ja001180f; Hock H., 1936, ANGEW CHEM, V49, P595; Homan R, 1998, J CHROMATOGR B, V708, P21, DOI 10.1016/S0378-4347(97)00651-8; Kenar JA, 1996, CHEM RES TOXICOL, V9, P737, DOI 10.1021/tx9600098; KIEFER H, 1966, TETRAHEDRON LETT, V7, P6163; Liang YL, 2003, FREE RADICAL BIO MED, V34, P409, DOI 10.1016/S0891-5849(02)01018-3; MENDENHALL GD, 1983, TETRAHEDRON LETT, V24, P451; MILNE GL, 2002, THESIS VANDERBILT U; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; NAGATA R, 1989, TETRAHEDRON LETT, V30, P2817, DOI 10.1016/S0040-4039(00)99133-0; Patel RP, 2000, FREE RADICAL BIO MED, V28, P1780, DOI 10.1016/S0891-5849(00)00235-5; PORTER NA, 1980, FREE RADICALS BIOL, V4, P261; Pratico D, 2001, TRENDS ENDOCRIN MET, V12, P243, DOI 10.1016/S1043-2760(01)00411-8; Roberts LJ, 2002, CELL MOL LIFE SCI, V59, P808, DOI 10.1007/s00018-002-8469-8; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; Rocca B, 2002, INT IMMUNOPHARMACOL, V2, P603, DOI 10.1016/S1567-5769(01)00204-1; Rondeau D, 2003, J MASS SPECTROM, V38, P931, DOI 10.1002/jms.501; SATTLER W, 1994, METHOD ENZYMOL, V233, P269; SCHMAKER VN, 1986, METHOD ENZYMOL, V128, P155; Singh G, 2000, ANAL CHEM, V72, P3007, DOI 10.1021/ac000374a; Suarna C, 1997, AUST J CHEM, V50, P1129, DOI 10.1071/C97044; Subbanagounder G, 2002, J BIOL CHEM, V277, P7271, DOI 10.1074/jbc.M107602200; Watson AD, 1999, J BIOL CHEM, V274, P24787, DOI 10.1074/jbc.274.35.24787; Waugh RJ, 1997, FREE RADICAL BIO MED, V23, P943, DOI 10.1016/S0891-5849(97)00133-0; Waugh RJ, 1996, J AM SOC MASS SPECTR, V7, P490, DOI 10.1016/1044-0305(95)00709-1; YIN H, 2002, THESIS VANDERBILT U; Yin HY, 2000, RAPID COMMUN MASS SP, V14, P1248, DOI 10.1002/1097-0231(20000730)14:14<1248::AID-RCM18>3.0.CO;2-B; Yin HY, 2003, J BIOL CHEM, V278, P16720, DOI 10.1074/jbc.M300604200; Yin HY, 2003, ANAL BIOCHEM, V313, P319, DOI 10.1016/S0003-2697(02)00621-8; Yin HY, 2002, J AM CHEM SOC, V124, P7745, DOI 10.1021/ja0201092; Yin HY, 2001, J AM SOC MASS SPECTR, V12, P449, DOI 10.1016/S1044-0305(01)00205-7	41	50	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3766	3776		10.1074/jbc.M307137200	http://dx.doi.org/10.1074/jbc.M307137200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14594817	hybrid			2022-12-25	WOS:000188379600078
J	Ono, Y; Kakinuma, K; Torii, F; Irie, A; Nakagawa, K; Labeit, S; Abe, K; Suzuki, K; Sorimachi, H				Ono, Y; Kakinuma, K; Torii, F; Irie, A; Nakagawa, K; Labeit, S; Abe, K; Suzuki, K; Sorimachi, H			Possible regulation of the conventional calpain system by skeletal muscle-specific calpain, p94/calpain 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHY TYPE 2A; BACULOVIRUS EXPRESSION SYSTEM; MUSCULAR-DYSTROPHY; FUNCTIONAL-PROPERTIES; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; MESSENGER-RNA; P94; PROTEASE; PURIFICATION	p94 (also called calpain 3) is the skeletal muscle-specific calpain and is considered to be a "modulator protease" in various cellular processes. Analysis of p94 at the protein level is an urgent issue because the loss of p94 protease activity causes limb-girdle muscular dystrophy type 2A. In this study, we enzymatically characterized one alternatively spliced variant of p94, p94: exons 6-15-16-(p94Delta), which lacks two of the p94-specific insertion sequences. In contrast to p94, which has hardly been studied enzymatically due to its rapid, thorough, and apparently Ca2+-independent autolytic activity, p94Delta was stably expressed in COS and insect cells. p94Delta showed Ca2+-dependent caseinolytic and autolytic activities and an inhibitor spectrum similar to those of the conventional calpains. However, calpastatin did not inhibit p94Delta and is a substrate for p94Delta, which is consistent with the properties of p94, presenting p94 as a possible regulator of the conventional calpain system. We also established a semi-quantitative fluorescence resonance energy transfer assay using the calpastatin sequence specifically to measure p94 activity. This method detects the activity of COS-expressed p94 and p94Delta, suggesting that it has potential to evaluate p94 activity in vivo and in the diagnosis of limb-girdle muscular dystrophy type 2A.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Lab Biol Funct,Bunkyo Ku, Tokyo 1138657, Japan; Japan Sci & Technol, CREST, Kawaguchi 3320012, Japan; Univ Klinikum Mannheim, Inst Anasthesiol & Operat Intens Med, D-68167 Mannheim, Germany; Tokyo Metropolitan Inst Gerontol, Tokyo 1730015, Japan	University of Tokyo; Japan Science & Technology Agency (JST); Ruprecht Karls University Heidelberg; Tokyo Metropolitan Institute of Gerontology	Sorimachi, H (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Lab Biol Funct,Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	ahsori@mail.ecc.u-tokyo.ac.jp	Sorimachi, Hiroyuki/C-6448-2009	Sorimachi, Hiroyuki/0000-0001-9509-6727				Branca D, 1999, EUR J BIOCHEM, V265, P839, DOI 10.1046/j.1432-1327.1999.00817.x; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Fukiage C, 2002, J BIOL CHEM, V277, P20678, DOI 10.1074/jbc.M200697200; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Gregorio CC, 1999, CURR OPIN CELL BIOL, V11, P18, DOI 10.1016/S0955-0674(99)80003-9; Herasse M, 1999, MOL CELL BIOL, V19, P4047; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Ilian MA, 2001, J AGR FOOD CHEM, V49, P1990, DOI 10.1021/jf0010026; ISHIURA S, 1978, J BIOCHEM, V84, P225, DOI 10.1093/oxfordjournals.jbchem.a132111; Jia Zongchao, 2002, Methods Mol Biol, V172, P51; Kinbara K, 1997, ARCH BIOCHEM BIOPHYS, V342, P99, DOI 10.1006/abbi.1997.0108; Kinbara K, 1998, BIOCHEM J, V335, P589, DOI 10.1042/bj3350589; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; Lee HJ, 1999, ARCH BIOCHEM BIOPHYS, V362, P22, DOI 10.1006/abbi.1998.1021; Ma H, 1998, INVEST OPHTH VIS SCI, V39, P454; Ma H, 2000, INVEST OPHTH VIS SCI, V41, P4232; Maruyama K, 2002, TRENDS BIOCHEM SCI, V27, P264, DOI 10.1016/S0968-0004(02)02068-6; Masumoto H, 1998, J BIOCHEM, V124, P957, DOI 10.1093/oxfordjournals.jbchem.a022213; Meyer SL, 1996, BIOCHEM J, V314, P511, DOI 10.1042/bj3140511; Nakagawa K, 2001, J BIOCHEM-TOKYO, V130, P605, DOI 10.1093/oxfordjournals.jbchem.a003025; Ono Y, 1998, BIOCHEM BIOPH RES CO, V245, P289, DOI 10.1006/bbrc.1998.8085; Ono Y, 2000, CALCIUM: THE MOLECULAR BASIS OF CALCIUM ACTION IN BIOLOGY AND MEDICINE, P443; Ono Y, 1998, J BIOL CHEM, V273, P17073, DOI 10.1074/jbc.273.27.17073; Perrin BJ, 2002, INT J BIOCHEM CELL B, V34, P722, DOI 10.1016/S1357-2725(02)00009-2; Porn-Ares MI, 1998, CELL DEATH DIFFER, V5, P1028, DOI 10.1038/sj.cdd.4400424; Rey MA, 2002, FEBS LETT, V532, P401, DOI 10.1016/S0014-5793(02)03722-5; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Richard I, 2000, J CELL BIOL, V151, P1583, DOI 10.1083/jcb.151.7.1583; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; Sorimachi H, 1997, J MOL BIOL, V270, P688, DOI 10.1006/jmbi.1997.1145; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; Sorimachi H, 1995, J BIOL CHEM, V270, P31158, DOI 10.1074/jbc.270.52.31158; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Spencer MJ, 2002, P NATL ACAD SCI USA, V99, P8874, DOI 10.1073/pnas.132269299; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Tagawa K, 2000, HUM MOL GENET, V9, P1393, DOI 10.1093/hmg/9.9.1393; Tidball JG, 2000, INT J BIOCHEM CELL B, V32, P1, DOI 10.1016/S1357-2725(99)00095-3; Todd B, 2003, J MOL BIOL, V328, P131, DOI 10.1016/S0022-2836(03)00274-2; Trinick J, 1999, TRENDS CELL BIOL, V9, P377, DOI 10.1016/S0962-8924(99)01641-4; Vilei EM, 1997, J BIOL CHEM, V272, P25802, DOI 10.1074/jbc.272.41.25802	43	89	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2761	2771		10.1074/jbc.M308789200	http://dx.doi.org/10.1074/jbc.M308789200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14594950	hybrid			2022-12-25	WOS:000188211300054
J	Breitinger, U; Breitinger, HG; Bauer, F; Fahmy, K; Glockenhammer, D; Becker, CM				Breitinger, U; Breitinger, HG; Bauer, F; Fahmy, K; Glockenhammer, D; Becker, CM			Conserved high affinity ligand binding and membrane association in the native and refolded extracellular domain of the human glycine receptor alpha 1-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; GATED ION CHANNELS; CIRCULAR-DICHROISM; ALPHA-SUBUNIT; PROTEIN CONFORMATION; SECONDARY STRUCTURE; ESCHERICHIA-COLI; EXPRESSION; SPECTROSCOPY; WATER	The strychnine-sensitive glycine receptor ( GlyR) is a ligand-gated chloride channel composed of ligand binding alpha- and gephyrin anchoring beta-subunits. To identify the secondary and quaternary structures of extramembraneous receptor domains, the N-terminal extracellular domain (alpha1-(1-219)) and the large intracellular TM3-4 loop (alpha1-(309 - 392)) of the human GlyR alpha1-subunit were individually expressed in HEK293 cells and in Escherichia coli. The extracellular domain obtained from E. coli expression was purified in its denatured form and refolding conditions were established. Circular dichroism and Fourier-transform-infrared spectroscopy suggested similar to 25% alpha-helix and similar to48% beta-sheet for the extracellular domain, while no alpha-helices were detectable for the TM3 - 4 loop. Size exclusion chromatography and sucrose density centrifugation indicated that isolated glycine receptor domains assembled into multimers of distinct molecular weight. For the extracellular domain from E. coli, we found an apparent molecular weight compatible with a 15 mer by gel filtration. The N-terminal domain from HEK293 cells, analyzed by sucrose gradient centrifugation, showed a bimodal distribution, suggesting oligomerization of similar to5 and 15 subunits. Likewise, for the intracellular domain from E. coli, a single molecular mass peak of similar to49 kDa indicated oligomerization in a defined native structure. As shown by [H-3] strychnine binding, expression in HEK293 cells and refolding of the isolated extracellular domain reconstituted high affinity antagonist binding. Cell fractionation, alkaline extraction experiments, and immunocytochemistry showed a tight plasma membrane association of the isolated GlyR N-terminal protein. These findings indicate that distinct functional characteristics of the full-length GlyR are retained in the isolated N-terminal domain.	Univ Erlangen Nurnberg, Emil Fischer Zentrum, Inst Biochem, D-91054 Erlangen, Germany; Univ Bayreuth, Lehrstuhl Biopolymere, D-95440 Bayreuth, Germany; Rossendorf Inc, Forschungszentrum Rossendorf EV, Inst Kern & Hadronenphys, D-01314 Dresden, Germany	University of Erlangen Nuremberg; University of Bayreuth; Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR)	Becker, CM (corresponding author), Univ Erlangen Nurnberg, Emil Fischer Zentrum, Inst Biochem, Fahrstr 17, D-91054 Erlangen, Germany.	cmb@biochem.uni-erlangen.de	Breitinger, Hans-Georg/ABD-3247-2021; Fahmy, Karim/B-2708-2017	Breitinger, Hans-Georg/0000-0003-0111-3528; Fahmy, Karim/0000-0002-8752-5824				Alexeev T, 1999, EUR J BIOCHEM, V259, P310, DOI 10.1046/j.1432-1327.1999.00041.x; BANDEKAR J, 1992, BIOCHIM BIOPHYS ACTA, V1120, P123, DOI 10.1016/0167-4838(92)90261-B; Becker K, 2000, CHANNELOPATHIES - COMMON MECHANISMS IN AURA, ARRHYTHMIA AND ALKALOSIS, P199, DOI 10.1016/B978-044450489-0/50010-0; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; Breitinger HG, 1998, CURR PHARM DESIGN, V4, P315; Breitinger HG, 2002, CHEMBIOCHEM, V3, P1043, DOI 10.1002/1439-7633(20021104)3:11<1042::AID-CBIC1042>3.0.CO;2-7; Breitinger HG, 2001, J BIOL CHEM, V276, P29657, DOI 10.1074/jbc.M100446200; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Cascio M, 2002, BIOPOLYMERS, V66, P359, DOI 10.1002/bip.10314; Cascio M, 2001, J BIOL CHEM, V276, P20981, DOI 10.1074/jbc.M010968200; Chen GQ, 1997, P NATL ACAD SCI USA, V94, P13431, DOI 10.1073/pnas.94.25.13431; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; Fischer M, 2001, P NATL ACAD SCI USA, V98, P3567, DOI 10.1073/pnas.041594798; Fletcher CM, 1999, EMBO J, V18, P2631, DOI 10.1093/emboj/18.9.2631; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; Heiring C, 2001, PROTEIN ENG, V14, P183, DOI 10.1093/protein/14.3.183; Hucho F, 2001, ANGEW CHEM INT EDIT, V40, P3101, DOI 10.1002/1521-3773(20010903)40:17<3100::AID-ANIE3100>3.0.CO;2-A; Kling C, 1997, NEUROSCIENCE, V78, P411, DOI 10.1016/S0306-4522(96)00567-2; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; Laube B, 2002, TRENDS PHARMACOL SCI, V23, P519, DOI 10.1016/S0165-6147(02)02138-7; METHOT N, 1994, BIOCHEMISTRY-US, V33, P7709, DOI 10.1021/bi00190a026; MIELKE DL, 1988, J BIOL CHEM, V263, P3177; MOORE WM, 1974, FEBS LETT, V45, P145, DOI 10.1016/0014-5793(74)80832-X; Opella SJ, 1999, NAT STRUCT BIOL, V6, P374, DOI 10.1038/7610; PFEIFFER F, 1982, J BIOL CHEM, V257, P9389; Psaridi-Linardaki L, 2002, J BIOL CHEM, V277, P26980, DOI 10.1074/jbc.M110731200; Rudolph R, 1996, FASEB J, V10, P49, DOI 10.1096/fasebj.10.1.8566547; SCHMITT B, 1987, BIOCHEMISTRY-US, V26, P805, DOI 10.1021/bi00377a022; Schofield PR, 1996, COLD SPRING HARB SYM, V61, P333; SCHOLTZ JM, 1991, BIOPOLYMERS, V31, P1463, DOI 10.1002/bip.360311304; Schweimer K, 2002, BIOCHEMISTRY-US, V41, P5120, DOI 10.1021/bi015986j; SONTHEIMER H, 1989, NEURON, V2, P1491, DOI 10.1016/0896-6273(89)90195-5; Tang P, 2002, BIOPHYS J, V83, P252, DOI 10.1016/S0006-3495(02)75166-7; Tsetlin VI, 2002, EUR J BIOCHEM, V269, P2801, DOI 10.1046/j.1432-1033.2002.02961.x; Unwin N, 1996, J MOL BIOL, V257, P586, DOI 10.1006/jmbi.1996.0187; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Wells GB, 1998, J BIOL CHEM, V273, P964, DOI 10.1074/jbc.273.2.964; West AP, 1997, J BIOL CHEM, V272, P25468, DOI 10.1074/jbc.272.41.25468; WU CSC, 1990, J PROTEIN CHEM, V9, P119, DOI 10.1007/BF01024993; Xue H, 2001, J MOL BIOL, V312, P915, DOI 10.1006/jmbi.2001.5022; YAGER P, 1984, BIOPHYS J, V45, P26, DOI 10.1016/S0006-3495(84)84095-3; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Yao Y, 2002, J BIOL CHEM, V277, P12613, DOI 10.1074/jbc.M108845200	49	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1627	1636		10.1074/jbc.M303811200	http://dx.doi.org/10.1074/jbc.M303811200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14593111	hybrid			2022-12-25	WOS:000188005700010
J	Dye, JF; Vause, S; Johnston, T; Clark, P; Firth, JA; D'Souza, SW; Sibley, CP; Glazier, JD				Dye, JF; Vause, S; Johnston, T; Clark, P; Firth, JA; D'Souza, SW; Sibley, CP; Glazier, JD			Characterization of cationic amino acid transporters and expression of endothelial nitric oxide synthase in human placental microvascular endothelial cells	FASEB JOURNAL			English	Article						placenta; arginine; transport; endothelium; eNOS	MEMBRANE-PROTEIN; SYSTEM Y(+); LOCALIZATION; SPECIFICITY; ACTIVATION; DEPENDENCE; RELEASE; CLONING	We investigated the expression and activity of arginine transporters and endothelial nitric oxide synthase (eNOS) in human placental microvascular endothelial cells (HPMEC). Using RT-PCR amplification products for eNOS, CAT1, CAT2A, CAT2B, CAT4, 4F2hc (CD98), rBAT and the light chains y(+)LAT1, y(+)LAT2, and b(0+)AT1 were detected in HPMEC, but not B0+. Immunohistochemistry and Western blotting confirmed the presence of 4F2hc and CAT1 protein in HPMEC. 4F2hc-light chain dimers were indicated by a shift in molecular mass detected under nonreducing conditions. L-Arginine transport into HPMEC was independent of Na+ or Cl- and was inhibited by the neutral amino acid glutamine, but not by cystine. The K-i for glutamine inhibition was greater in the absence of Na+. Kinetic analysis supported a two-transporter model attributed to system y(+)L and system y(+). Expression of eNOS in HPMEC was detectable by immunohistochemistry and ELISA but not by Western blotting. Activity of eNOS in HPMEC, measured over 48 h, either as the basal production of nitric oxide (NO) or as the accumulation of intracellular cGMP was not detectable. We conclude that HPMEC transport cationic amino acids by systems y(+) and y(+)L and that basal eNOS expression and activity in these cells is low.	Imperial Coll Sch Med, Div Biomed Sci, London SW7 2AZ, England; Univ Manchester, St Marys Hosp, Acad Unit Child Hlth, Manchester M13 0JH, Lancs, England	Imperial College London; University of Manchester	Glazier, JD (corresponding author), Univ Manchester, St Marys Hosp, Acad Unit Child Hlth, Hathersage Rd, Manchester M13 0JH, Lancs, England.	jglazier@fs3.scg.man.ac.uk	Dye, Julian/U-3396-2019		British Heart Foundation	British Heart Foundation(British Heart Foundation)	We gratefully acknowledge the generous donation of human CAT1 antibody from Dr. Sergey Zharikov (University of Florida, Gainesville) and Dr. Edward Block (Veterans Affairs Medical Center, Gainesville, FL). We would like to thank Dr. S. Greenwood for her helpful technical advice and discussions, Ms. L. Laurence and Ms. M. Cretney for their excellent laboratory assistance, Dr. W. G. Bardsley for his advice and training in regard to the use of the SIMFIT computer program, and the staff at the Central Delivery Units of St. Mary's Hospitals in Manchester and London for their assistance in obtaining placentas. This work was supported by the British Heart Foundation.	ANGELO S, 1994, J MEMBRANE BIOL, V141, P183; Ayuk PTY, 2000, AM J PHYSIOL-CELL PH, V278, pC1162, DOI 10.1152/ajpcell.2000.278.6.C1162; BERTRAN J, 1993, J BIOL CHEM, V268, P14842; BUSSOLATI O, 1993, AM J PHYSIOL, V265, pC1006, DOI 10.1152/ajpcell.1993.265.4.C1006; BUTTERY LDK, 1994, PLACENTA, V15, P257, DOI 10.1016/0143-4004(94)90017-5; CETIN I, 1990, AM J OBSTET GYNECOL, V162, P253, DOI 10.1016/0002-9378(90)90860-A; Chillaron J, 2001, AM J PHYSIOL-RENAL, V281, pF995, DOI 10.1152/ajprenal.2001.281.6.F995; CLOSS EI, 1999, MEMBRANE TRANSPORTER, P229; Deves R, 2000, J MEMBRANE BIOL, V173, P165, DOI 10.1007/s002320001017; Deves R, 1998, PHYSIOL REV, V78, P487, DOI 10.1152/physrev.1998.78.2.487; Dye JF, 2001, MICROVASC RES, V62, P94, DOI 10.1006/mvre.2001.2333; Dye JF, 2001, PLACENTA, V22, P32, DOI 10.1053/plac.2000.0579; Feron O, 1999, CURR OPIN NEPHROL HY, V8, P55, DOI 10.1097/00041552-199901000-00010; Firth JA, 1996, PLACENTA, V17, P89, DOI 10.1016/S0143-4004(96)80001-4; Goligorsky MS, 2002, AM J PHYSIOL-RENAL, V283, pF1, DOI 10.1152/ajprenal.00377.2001; Govers R, 2001, AM J PHYSIOL-RENAL, V280, pF193, DOI 10.1152/ajprenal.2001.280.2.F193; Graf P, 2001, BRIT J PHARMACOL, V132, P1193, DOI 10.1038/sj.bjp.0703921; JAFFE EA, 1973, J CLIN INVEST, V71, P974; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KRISHNAKUMAR K, 2003, AM J PHYSIOL-CELL PH, V284, pC1784; McDonald KK, 1997, J BIOL CHEM, V272, P31213, DOI 10.1074/jbc.272.50.31213; MITCHELL JA, 1990, EUR J PHARMACOL, V182, P573, DOI 10.1016/0014-2999(90)90058-E; MYATT L, 1993, PLACENTA, V14, P487, DOI 10.1016/S0143-4004(05)80202-4; Orpana AK, 1996, AM J OBSTET GYNECOL, V174, P1056, DOI 10.1016/S0002-9378(96)70350-2; Ou W, 2003, VIROLOGY, V308, P101, DOI 10.1016/S0042-6822(02)00086-7; Ranta VH, 1998, HYPERTENS PREGNANCY, V17, P307, DOI 10.3109/10641959809009604; Rojas AM, 1999, J MEMBRANE BIOL, V168, P199, DOI 10.1007/s002329900509; Sala R, 2002, AM J PHYSIOL-CELL PH, V282, pC134, DOI 10.1152/ajpcell.2002.282.1.C134; Sladek SM, 1997, AM J PHYSIOL-REG I, V272, pR441, DOI 10.1152/ajpregu.1997.272.2.R441; Sloan JL, 1999, J BIOL CHEM, V274, P23740, DOI 10.1074/jbc.274.34.23740; SOBREVIA L, 1995, J PHYSIOL-LONDON, V489, P183, DOI 10.1113/jphysiol.1995.sp021040; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; TSUKAHARA H, 1993, BIOCHEM BIOPH RES CO, V193, P722, DOI 10.1006/bbrc.1993.1685; Verrey F, 1999, J MEMBRANE BIOL, V172, P181, DOI 10.1007/s002329900595; Wagner CA, 2001, AM J PHYSIOL-CELL PH, V281, pC1077, DOI 10.1152/ajpcell.2001.281.4.C1077; Wolf S, 2002, BIOCHEM J, V364, P767, DOI 10.1042/BJ20020084; Zarlingo TJ, 1997, PLACENTA, V18, P511, DOI 10.1016/0143-4004(77)90004-2; Zharikov SI, 2001, AM J PHYSIOL-LUNG C, V280, pL465, DOI 10.1152/ajplung.2001.280.3.L465	38	41	43	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					125	127		10.1096/fj.02-0916fje	http://dx.doi.org/10.1096/fj.02-0916fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597568				2022-12-25	WOS:000188829300048
J	Huang, SS; Ling, TY; Tseng, WF; Huang, YH; Tang, FM; Leal, SM; Huang, JS				Huang, SS; Ling, TY; Tseng, WF; Huang, YH; Tang, FM; Leal, SM; Huang, JS			Cellular growth inhibition by IGFBP-3 and TGF-beta(1) requires LRP-1	FASEB JOURNAL			English	Article						type V TGF-beta receptor; IGFBP-3 receptor; growth inhibition; epithelial cells; carcinogenesis	LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; FACTOR-BETA RECEPTOR; TGF-BETA; ALPHA-2-MACROGLOBULIN RECEPTOR; V RECEPTOR; FUNCTIONAL MODULATION; HIGH-AFFINITY; TUMOR-CELLS; EXPRESSION	The type V TGF-beta receptor (TbetaR-V)/ IGFBP-3 receptor mediates the IGF-independent growth inhibition induced by IGFBP-3. It also mediates the growth inhibitory response to TGF-beta(1), in concert with other TGF-beta receptor types, and its loss may contribute to the malignant phenotype of human carcinoma cells. Here we demonstrate that TbetaR-V is identical to LRP-1/alpha(2)M receptor as shown by MALDI-TOF analysis of tryptic peptides of TbetaR-V purified from bovine liver. In addition, I-125-IGFBP-3 affinity-labeled TbetaR-V in MvlLu cells is immunoprecipitated by antibodies to LRP-l and TbetaR-V. RAP, an LRP-l antagonist, inhibits binding of I-125-TGF-beta(1) and I-125-IGFBP-3 to TbetaR-V and diminishes IGFBP-3-induced growth inhibition in MvlLu cells. Absent or low levels of LRP-1, as with TbetaR-V, have been linked to the malignant phenotype of carcinoma cells. Mutagenized Mv1Lu cells selected for reduced expression of LRP-l have an attenuated growth inhibitory response to TGF-beta(1), and IGFBP-3. LRP-l -deficient mouse embryonic fibroblasts lack a growth inhibitory response to TGF-beta(1), and IGFBP-3. On the other hand, stable transfection of H1299 human lung carcinoma cells with LRP-l cDNA restores the growth inhibitory response. These results suggest that the LRP-1/TbetaR-V/IGFBP-3 receptor is required for the growth inhibitory response to IGFBP-3 and TGF-beta(1).	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; Taipei Med Univ, Dept Biochem, Taipei, Taiwan	Saint Louis University; Academia Sinica - Taiwan; Taipei Medical University	Huang, SS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	huangss@slu.edu; huangjs@slu.edu		Ling, Thai-Yen/0000-0002-3992-883X	NCI NIH HHS [CA 38808] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; Boensch C, 1999, J BIOL CHEM, V274, P10582, DOI 10.1074/jbc.274.15.10582; Bu GJ, 1998, CURR OPIN LIPIDOL, V9, P149, DOI 10.1097/00041433-199804000-00012; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Eickelberg O, 2002, J BIOL CHEM, V277, P823, DOI 10.1074/jbc.M105110200; Fink SP, 2001, CANCER RES, V61, P256; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; GONIAS SL, 1994, ANN NY ACAD SCI, V737, P273, DOI 10.1111/j.1749-6632.1994.tb44318.x; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Heldin NE, 1999, MOL CELL ENDOCRINOL, V153, P79, DOI 10.1016/S0303-7207(99)00086-6; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hocevar BA, 1998, MINER ELECTROL METAB, V24, P131, DOI 10.1159/000057360; Howell BW, 2001, CURR OPIN NEUROBIOL, V11, P74, DOI 10.1016/S0959-4388(00)00176-8; Huang SS, 1997, J BIOL CHEM, V272, P27155, DOI 10.1074/jbc.272.43.27155; HUANG SS, 1988, J BIOL CHEM, V263, P1535; Koong AC, 2000, CANCER RES, V60, P883; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Leal SM, 1999, J BIOL CHEM, V274, P6711, DOI 10.1074/jbc.274.10.6711; Li YH, 1997, CANCER LETT, V111, P199, DOI 10.1016/S0304-3835(96)04520-X; Liu CX, 2000, CANCER RES, V60, P1961; Liu QJ, 1997, J BIOL CHEM, V272, P18891, DOI 10.1074/jbc.272.30.18891; Lutz C, 2002, J BIOL CHEM, V277, P43143, DOI 10.1074/jbc.M204426200; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOUSTAKAS A, 1995, J BIOL CHEM, V270, P765, DOI 10.1074/jbc.270.2.765; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; OGRADY P, 1992, J BIOL CHEM, V267, P21033; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OGRADY P, 1991, BIOCHEM BIOPH RES CO, V179, P378, DOI 10.1016/0006-291X(91)91381-L; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Ravitz MJ, 1997, ADV CANCER RES, V71, P165, DOI 10.1016/S0065-230X(08)60099-8; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Strickland DK, 2002, TRENDS ENDOCRIN MET, V13, P66, DOI 10.1016/S1043-2760(01)00526-4; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; Taipale J, 1996, J BIOL CHEM, V271, P4342; VANLEUVEN F, 1979, J BIOL CHEM, V254, P5155; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WILLNOW TE, 1994, J CELL SCI, V107, P719; Wu HB, 2000, J CELL BIOCHEM, V77, P288, DOI 10.1002/(SICI)1097-4644(20000501)77:2<288::AID-JCB11>3.0.CO;2-J; Yamamoto M, 1997, CANCER RES, V57, P2799; YAMASHITA H, 1995, J BIOL CHEM, V270, P770, DOI 10.1074/jbc.270.2.770; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2; Ziere GJ, 1996, EUR J BIOCHEM, V242, P703, DOI 10.1111/j.1432-1033.1996.0703r.x	52	126	129	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2003	17	14					2068	2081		10.1096/fj.03-0256com	http://dx.doi.org/10.1096/fj.03-0256com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	750AA	14597676				2022-12-25	WOS:000186961200043
J	Moore, L; Venkatachalam, S; Vogel, H; Watt, JC; Wu, CL; Steinman, H; Jones, SN; Donehower, LA				Moore, L; Venkatachalam, S; Vogel, H; Watt, JC; Wu, CL; Steinman, H; Jones, SN; Donehower, LA			Cooperativity of p19(ARF), Mdm2, and p53 in murine tumorigenesis	ONCOGENE			English	Article						19(ARF); Mdm2; p53; mouse cancer model; tumor suppressor	CARCINOGEN-INDUCED TUMORIGENESIS; SOFT-TISSUE SARCOMAS; ARF TUMOR-SUPPRESSOR; MDM2-DEFICIENT MICE; EMBRYONIC LETHALITY; STABILIZES P53; INK4A LOCUS; CANCER; APOPTOSIS; OVEREXPRESSION	The p19(ARF) gene product responds to oncogenic stresses by interfering with the inhibitory effects of Mdm2 on p53, thus enhancing p53 activity and its antiproliferative functions. The absence of p19(ARF) in the mouse leads to early tumor susceptibility, presumably in part due to decreased p53 activity. To examine the tumorigenic cooperativity of p19(ARF), Mdm2, and p53 in vivo, p19(ARF)-deficient mice were crossed first to p53-deficient mice and then to Mdm2 transgenic mice. The progeny were monitored for tumors. Cooperativity between p19(ARF) and p53 deficiencies in accelerating tumor formation was observed for most genotypes except p53 -/- p19(ARF) -/- mice. p53 -/- p19(ARF) -/- mice had a tumor incidence similar to p53 -/- mice. In this context, tumor suppression by ARF appears to be primarily p53 dependent. The majority of the p19(ARF) +/- tumors deleted the wildtype p19(ARF) allele, in agreement with the previous studies, suggesting that p19(ARF) is a classic 'two hit' tumor suppressor. In a p53+/- background, however, all p19(ARF) +/ - tumors retained a wildtype ARF allele and most also retained wildtype p53. In the second cross between p19(ARF)-deficient and Mdm2 transgenic mice, cooperativity in tumor incidence between Mdm2 overexpression and ARF deficiency was observed, consistent with the role of p19(ARF) in negatively regulating Mdm2 activity. These experiments further demonstrate in vivo the inter-relationships of the p19(ARF)-Mdm2-p53 signaling axis in tumor suppression.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Tennessee, Dept Biochem & Cell & Mol Biol, Knoxville, TN 37996 USA; Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA; Univ Massachusetts, Med Ctr, Dept Cell Biol, Worcester, MA 01655 USA	Baylor College of Medicine; Baylor College of Medicine; University of Tennessee System; University of Tennessee Knoxville; Stanford University; University of Massachusetts System; University of Massachusetts Worcester	Donehower, LA (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Plaza, Houston, TX 77030 USA.			Vogel, Otto Hannes/0000-0002-0960-3508				Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bai F, 2003, MOL CELL BIOL, V23, P1269, DOI 10.1128/MCB.23.4.1269-1277.2003; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Foster CJ, 2002, ONCOGENE, V21, P3525, DOI 10.1038/sj.onc.1205441; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; KAMB A, 1994, SCIENCE, V264, P440; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KNUDSON AG, 1984, CANCER DETECT PREV, V7, P1; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kuo ML, 2003, CANCER RES, V63, P1046; LEACH FS, 1993, CANCER RES, V53, P2231; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038/35003670; LUNA RMD, 1995, NATURE, V378, P203; McDonnell TJ, 1999, J PATHOL, V188, P322, DOI 10.1002/(SICI)1096-9896(199907)188:3<322::AID-PATH372>3.0.CO;2-F; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Reinke V, 1999, CELL GROWTH DIFFER, V10, P147; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2001, MOL CELL, V8, P1187, DOI 10.1016/S1097-2765(01)00425-7; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tsai KY, 2002, P NATL ACAD SCI USA, V99, P16865, DOI 10.1073/pnas.262499599; Tsuji K, 2002, BIOCHEM BIOPH RES CO, V295, P621, DOI 10.1016/S0006-291X(02)00723-4; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Venkatachalam S, 2001, TOXICOL PATHOL, V29, P147, DOI 10.1080/019262301753178555; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weber HO, 2002, ONCOGENE, V21, P3207, DOI 10.1038/sj.onc.1205429; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	44	44	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7831	7837		10.1038/sj.onc.1206985	http://dx.doi.org/10.1038/sj.onc.1206985			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586409	Bronze			2022-12-25	WOS:000186240200013
J	Yoshida, Y; Hasunuma, K				Yoshida, Y; Hasunuma, K			Reactive oxygen species affect photomorphogenesis in Neurospora crassa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE-LIGHT PHOTORECEPTOR; CAROTENOID BIOSYNTHETIC GENE; SUPEROXIDE-DISMUTASE SOD-1; CONIDIATION-SPECIFIC GENES; WHITE-COLLAR MUTANTS; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; CIRCADIAN CLOCK; PROTEIN; PHOTOREGULATION	In Neurospora crassa, several biological phenomena such as the synthesis of carotenoids in the mycelia and polarity of perithecia are regulated by light. We found that a sod-1 mutant, with a defective Cu,Zn-type superoxide dismutase (SOD), showed accelerated light-dependent induction of carotenoid accumulation in the mycelia compared with the wild type. The initial rate of light-induced carotenoid accumulation in the sod-1 mutant was faster than that in the vvd mutant known to accumulate high concentrations. This acceleration was suppressed by treatment with antioxidant reagents. Light-induced transcription of genes involved in carotenoid synthesis, al-1, -2, and -3, was sustained in the sod-1 mutant, whereas it was transient in the wild type. Moreover sod-1 was defective in terms of light-induced polarity of perithecia. By genetic analysis, the enhancement in light-inducible carotenoid synthesis in sod-1 was dependent on the wild type alleles of wc-1 and wc-2. However, the sod-l;vvd double mutant showed additive effects on the carotenoid accumulation in the mycelia. These results suggested that intracellular reactive oxygen species regulated by SOD-1 could affect the light-signal transduction pathway via WC proteins.	Yokohama City Univ, Grad Sch Integrated Sci, Kihara Inst Biol Res, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan	Yokohama City University	Hasunuma, K (corresponding author), Yokohama City Univ, Grad Sch Integrated Sci, Kihara Inst Biol Res, Totsuka Ku, 641-12 Maioka Cho, Yokohama, Kanagawa 2440813, Japan.	kohji@yokohama-cu.ac.jp						Ahmad M, 1998, MOL CELL, V1, P939, DOI 10.1016/S1097-2765(00)80094-5; Alfonso M, 2000, PLANT PHYSIOL, V122, P505, DOI 10.1104/pp.122.2.505; Alscher RG, 2002, J EXP BOT, V53, P1331, DOI 10.1093/jexbot/53.372.1331; BAIMA S, 1991, J PHOTOCH PHOTOBIO B, V11, P107, DOI 10.1016/1011-1344(91)80253-E; Ballario P, 1998, MOL MICROBIOL, V29, P719, DOI 10.1046/j.1365-2958.1998.00955.x; Ballario P, 1996, EMBO J, V15, P1650, DOI 10.1002/j.1460-2075.1996.tb00510.x; Briggs WR, 1999, ANNU REV CELL DEV BI, V15, P33, DOI 10.1146/annurev.cellbio.15.1.33; Bruchez JJP, 1996, MOL GEN GENET, V252, P223; CHARY P, 1990, J BIOL CHEM, V265, P18961; CHARY P, 1989, J BACTERIOL, V171, P2646, DOI 10.1128/jb.171.5.2646-2652.1989; CHARY P, 1994, GENETICS, V137, P723; Cheng P, 2003, P NATL ACAD SCI USA, V100, P5938, DOI 10.1073/pnas.1031791100; Cheng P, 2002, MOL CELL BIOL, V22, P517, DOI 10.1128/MCB.22.2.517-524.2002; Christie JM, 2001, J BIOL CHEM, V276, P11457, DOI 10.1074/jbc.R100004200; CHURCH GM, 1988, SCIENCE, V240, P185, DOI 10.1126/science.3353714; Crosson S, 2001, P NATL ACAD SCI USA, V98, P2995, DOI 10.1073/pnas.051520298; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; DEGLIINNOCENTI F, 1984, J BACTERIOL, V159, P757, DOI 10.1128/JB.159.2.757-761.1984; Dodson RE, 2002, PROG NUCLEIC ACID RE, V72, P129, DOI 10.1016/S0079-6603(02)72069-2; Dragovic Z, 2002, EMBO J, V21, P3643, DOI 10.1093/emboj/cdf377; FELDMAN JF, 1982, ANNU REV PLANT PHYS, V33, P583, DOI 10.1146/annurev.pp.33.060182.003055; FISCHER LJ, 1980, LIFE SCI, V26, P1405, DOI 10.1016/0024-3205(80)90043-0; Froehlich AC, 2002, SCIENCE, V297, P815, DOI 10.1126/science.1073681; HARDING RW, 1983, PLANT PHYSIOL, V72, P996, DOI 10.1104/pp.72.4.996; HARDING RW, 1981, PLANT PHYSIOL, V68, P745, DOI 10.1104/pp.68.3.745; He QY, 2002, SCIENCE, V297, P840, DOI 10.1126/science.1072795; Heintzen C, 2001, CELL, V104, P453, DOI 10.1016/S0092-8674(01)00232-X; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; KENDRICH RE, 1994, PHOTOMORPHOGENESIS P; Laloraya MM, 1999, BIOCHEM BIOPH RES CO, V256, P293, DOI 10.1006/bbrc.1999.0327; LANGFEULNER J, 1975, PHOTOCHEM PHOTOBIOL, V21, P179, DOI 10.1111/j.1751-1097.1975.tb06649.x; Lauter FR, 1996, J GENET, V75, P375, DOI 10.1007/BF02966316; LAUTER FR, 1991, NUCLEIC ACIDS RES, V19, P6883, DOI 10.1093/nar/19.24.6883; Lewis ZA, 2002, MOL MICROBIOL, V45, P917, DOI 10.1046/j.1365-2958.2002.03074.x; LI CG, 1995, DEV BIOL, V169, P90, DOI 10.1006/dbio.1995.1129; Linden H, 1997, EMBO J, V16, P98, DOI 10.1093/emboj/16.1.98; Linden H, 2002, SCIENCE, V297, P777, DOI 10.1126/science.1075485; Linden H, 1997, MOL GEN GENET, V254, P111, DOI 10.1007/s004380050398; Liu Y, 1998, SCIENCE, V281, P825, DOI 10.1126/science.281.5378.825; MEYEROWITZ EM, 1994, ARABIDOPSIS; Michan S, 2003, EUKARYOT CELL, V2, P798, DOI 10.1128/EC.2.4.798-808.2003; MOHAMED A, 1991, PLANT MOL BIOL, V16, P891, DOI 10.1007/BF00015080; Neill SJ, 2002, J EXP BOT, V53, P1237, DOI 10.1093/jexbot/53.372.1237; NELSON MA, 1989, MOL CELL BIOL, V9, P1271, DOI 10.1128/MCB.9.3.1271; Nowrousian M, 2003, GENETICS, V164, P923; Oda K, 1997, MOL GEN GENET, V256, P593, DOI 10.1007/s004380050607; ODA K, 1994, FEBS LETT, V345, P162, DOI 10.1016/0014-5793(94)00436-6; Ogura Y, 2001, J BIOL CHEM, V276, P21228, DOI 10.1074/jbc.M011381200; Quail PH, 1997, BIOESSAYS, V19, P571, DOI 10.1002/bies.950190708; RONDON IJ, 1995, FEBS LETT, V359, P267, DOI 10.1016/0014-5793(95)00066-I; SARGENT ML, 1967, PLANT PHYSIOL, V42, P1504, DOI 10.1104/pp.42.11.1504; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; SCHMIDHAUSER TJ, 1994, J BIOL CHEM, V269, P12060; SCHMIDHAUSER TJ, 1990, MOL CELL BIOL, V10, P5064, DOI 10.1128/MCB.10.10.5064; SCHROEDER WA, 1995, J BIOL CHEM, V270, P18374, DOI 10.1074/jbc.270.31.18374; Schwerdtfeger C, 2003, EMBO J, V22, P4846, DOI 10.1093/emboj/cdg451; Schwerdtfeger C, 2001, MOL MICROBIOL, V39, P1080, DOI 10.1046/j.1365-2958.2001.02306.x; Shrode LB, 2001, FUNGAL GENET BIOL, V32, P169, DOI 10.1006/fgbi.2001.1264; Sokolovsky V., 1990, FUNGAL GENET NEWSLET, V37, P41; TATUM EL, 1950, AM J BOT, V37, P38, DOI 10.2307/2438138; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; WEINANDER R, 1994, J BIOL CHEM, V269, P71; WU TW, 1994, BIOCHEM PHARMACOL, V48, P419, DOI 10.1016/0006-2952(94)90115-5	63	61	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6986	6993		10.1074/jbc.M310060200	http://dx.doi.org/10.1074/jbc.M310060200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14625272	hybrid			2022-12-25	WOS:000188969200094
J	Hahn, JS; Thiele, DJ				Hahn, JS; Thiele, DJ			Activation of the Saccharomyces cerevisiae heat shock transcription factor under glucose starvation conditions by Snf1 protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBCELLULAR-LOCALIZATION; YEAST SNF1; IN-VIVO; GENE; BINDING; STRESS; PHOSPHATASE; EXPRESSION; PHOSPHORYLATION; PATHWAYS	Heat shock transcription factor (HSF) is an evolutionarily conserved protein that mediates eukaryotic transcriptional responses to stress. Although the mammalian stress-responsive HSF1 isoform is activated in response to a wide array of seemingly unrelated stresses, including heat shock, pharmacological agents, infection and inflammation, little is known about the precise mechanisms or pathways by which this factor is activated by many stressors. The baker's yeast Saccharomyces cerevisiae encodes a single HSF protein that responds to heat stress and glucose starvation and provides a simple model system to investigate how a single HSF is activated by multiple stresses. Although induction of the HSF target gene CUP1 by glucose starvation is dependent on the Snf1 kinase, HSF-dependent heat shock induction of CUP1 is Snf1-independent. Approximately 165 in vivo targets for HSF have been identified in S. cerevisiae using chromatin immunoprecipitation combined with DNA microarrays. Interestingly, similar to30% of the HSF direct target genes are also induced by the diauxic shift, in which glucose levels begin to be depleted. We demonstrate that HSF and Snf1 kinase interact in vivo and that HSF is a direct substrate for phosphorylation by Snf1 kinase in vitro. Furthermore, glucose starvation-dependent, but not heat shock-dependent HSF phosphorylation, and enhanced chromosomal HSF DNA binding to low affinity target promoters such as SSA3 and HSP30, occurred in a Snf1-dependent manner. Consistent with a more global role for HSF and Snf1 in activating gene expression in response to changes in glucose availability, expression of a subset of HSF targets by glucose starvation was dependent on Snf1 and the HSF carboxyl-terminal activation domain.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Thiele, DJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	dennis.thiele@duke.edu	Rho, Hyunji/R-6242-2016	Rho, Hyunji/0000-0001-7650-8933	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059911] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59911] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn SG, 2003, GENE DEV, V17, P516, DOI 10.1101/gad.1044503; Amoros M, 2001, MOL MICROBIOL, V39, P1523, DOI 10.1046/j.1365-2958.2001.02339.x; Bertram PG, 2002, MOL CELL BIOL, V22, P1246, DOI 10.1128/MCB.22.4.1246-1252.2002; Brachmann CB, 1998, YEAST, V14, P115; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; CELENZA JL, 1989, MOL CELL BIOL, V9, P5045, DOI 10.1128/MCB.9.11.5045; Christians E, 2000, NATURE, V407, P693, DOI 10.1038/35037669; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Erkine AM, 1996, MOL CELL BIOL, V16, P7004; Erkine AM, 1999, MOL CELL BIOL, V19, P1627; ESTRUCH F, 1993, MOL CELL BIOL, V13, P3872, DOI 10.1128/MCB.13.7.3872; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; Grably MR, 2002, MOL MICROBIOL, V44, P21, DOI 10.1046/j.1365-2958.2002.02860.x; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; HOJ A, 1994, EMBO J, V13, P2617; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; Jedlicka P, 1997, EMBO J, V16, P2452, DOI 10.1093/emboj/16.9.2452; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; Jiang R, 1997, MOL CELL BIOL, V17, P2099, DOI 10.1128/MCB.17.4.2099; Kurihara T, 2000, MOL BIOL CELL, V11, P983, DOI 10.1091/mbc.11.3.983; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lin JT, 1999, MOL CELL BIOL, V19, P3237; Littlefield O, 1999, NAT STRUCT BIOL, V6, P464; Liu HD, 1996, GENE DEV, V10, P592; Liu XD, 1997, EMBO J, V16, P6466, DOI 10.1093/emboj/16.21.6466; Ludin K, 1998, P NATL ACAD SCI USA, V95, P6245, DOI 10.1073/pnas.95.11.6245; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; Mayordomo I, 2002, J BIOL CHEM, V277, P35650, DOI 10.1074/jbc.M204198200; Morano KA, 1999, GENE EXPRESSION, V7, P271; Morimoto R. I., 1994, COLD SPRING HARBOR M, V26; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Nath N, 2003, MOL CELL BIOL, V23, P3909, DOI 10.1128/MCB.23.11.3909-3917.2003; Nover L, 2001, CELL STRESS CHAPERON, V6, P177, DOI 10.1379/1466-1268(2001)006<0177:AATHST>2.0.CO;2; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Sanz P, 2000, MOL CELL BIOL, V20, P1321, DOI 10.1128/MCB.20.4.1321-1328.2000; Schuller HJ, 2003, CURR GENET, V43, P139, DOI 10.1007/s00294-003-0381-8; Sekinger EA, 2001, CELL, V105, P403, DOI 10.1016/S0092-8674(01)00329-4; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; Storici F, 2001, NAT BIOTECHNOL, V19, P773, DOI 10.1038/90837; Sutherland CM, 2003, CURR BIOL, V13, P1299, DOI 10.1016/S0960-9822(03)00459-7; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Vincent O, 1998, EMBO J, V17, P7002, DOI 10.1093/emboj/17.23.7002; Vincent O, 2001, GENE DEV, V15, P1104, DOI 10.1101/gad.879301; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Young ET, 2003, J BIOL CHEM, V278, P26146, DOI 10.1074/jbc.M301981200; Zhong M, 1999, J BIOL CHEM, V274, P3135, DOI 10.1074/jbc.274.5.3135	60	114	119	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5169	5176		10.1074/jbc.M311005200	http://dx.doi.org/10.1074/jbc.M311005200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14612437	hybrid			2022-12-25	WOS:000188776500017
J	Topolska, AE; Lidgett, A; Truman, D; Fujioka, H; Coppel, RL				Topolska, AE; Lidgett, A; Truman, D; Fujioka, H; Coppel, RL			Characterization of a membrane-associated rhoptry protein of Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-CELL SELECTION; TOXOPLASMA-GONDII; PARASITOPHOROUS VACUOLE; ERYTHROCYTE-MEMBRANE; ANCHORED PROTEINS; APICAL ORGANELLES; MALARIA PARASITES; INVASION; IDENTIFICATION; ANTIGEN	Invasive forms of apicomplexan parasites contain secretory organelles called rhoptries that are essential for entry into host cells. We present a detailed characterization of an unusual rhoptry protein of the human malaria parasite Plasmodium falciparum, the rhoptry-associated membrane antigen (RAMA) that appears to have roles in both rhoptry biogenesis and host cell invasion. RAMA is synthesized as a 170-kDa protein in early trophozoites, several hours before rhoptry formation and is transiently localized within the endoplasmic reticulum and Golgi within lipid-rich microdomains. Regions of the Golgi membrane containing RAMA bud to form vesicles that later mature into rhoptries in a process that is inhibitable by brefeldin A. Other rhoptry proteins such as RhopH3 and RAP1 are found in close apposition with RAMA suggesting direct protein-protein interactions. We suggest that RAMA is involved in trafficking of these proteins into rhoptries. In rhoptries, RAMA is proteolytically processed to give a 60-kDa form that is anchored in the inner face of the rhoptry membrane by means of the glycosylphosphatidylinositol anchor. The p60 RAMA form is discharged from the rhoptries of free merozoites and binds to the red blood cell membrane by its most C-terminal region. In early ring stages RAMA is found in association with the parasitophorous vacuole.	Monash Univ, Dept Microbiol, Clayton, Vic 3800, Australia; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	Monash University; Case Western Reserve University	Coppel, RL (corresponding author), Monash Univ, Dept Microbiol, POB 53,Wellington Rd, Clayton, Vic 3800, Australia.	ross.coppel@med.monash.edu.au	Coppel, Ross L/A-6626-2008	Coppel, Ross L/0000-0002-4476-9124	NIDDK NIH HHS [DK-32094] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIKAWA M, 1981, J CELL BIOL, V91, P55, DOI 10.1083/jcb.91.1.55; Allen M J, 1994, PCR Methods Appl, V4, P71; ANDERS RF, 1988, PROG ALLERGY, V41, P148; Baldi DL, 2000, EMBO J, V19, P2435, DOI 10.1093/emboj/19.11.2435; Bannister LH, 2000, PARASITOLOGY, V121, P273, DOI 10.1017/S0031182099006320; BANNISTER LH, 1986, PARASITOLOGY, V92, P291, DOI 10.1017/S0031182000064064; Black CG, 2001, MOL BIOCHEM PARASIT, V114, P217, DOI 10.1016/S0166-6851(01)00265-1; Blackman MJ, 2001, MOL BIOCHEM PARASIT, V117, P11, DOI 10.1016/S0166-6851(01)00328-0; Blair PL, 2002, MOL BIOCHEM PARASIT, V122, P35, DOI 10.1016/S0166-6851(02)00067-1; Bradley PJ, 2001, INT J PARASITOL, V31, P1177, DOI 10.1016/S0020-7519(01)00242-9; Bradley PJ, 1999, MOL BIOCHEM PARASIT, V100, P103, DOI 10.1016/S0166-6851(99)00035-3; BRAUNBRETON C, 1988, NATURE, V332, P457, DOI 10.1038/332457a0; BRAUNBRETON C, 1988, BIOL CELL, V64, P223, DOI 10.1016/0248-4900(88)90081-0; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BROWN HJ, 1991, MOL BIOCHEM PARASIT, V49, P99, DOI 10.1016/0166-6851(91)90133-Q; COPPEL RL, 1987, MOL BIOCHEM PARASIT, V25, P73, DOI 10.1016/0166-6851(87)90020-X; DLUZEWSKI AR, 1989, J CELL SCI, V92, P691; ELMENDORF HG, 1993, PARASITOL TODAY, V9, P98, DOI 10.1016/0169-4758(93)90216-3; ETZION Z, 1991, MOL BIOCHEM PARASIT, V47, P51, DOI 10.1016/0166-6851(91)90147-X; HAYNES JD, 1988, J EXP MED, V167, P1873, DOI 10.1084/jem.167.6.1873; Hiller NL, 2003, J BIOL CHEM, V278, P48413, DOI 10.1074/jbc.M307266200; Howard RF, 1998, INFECT IMMUN, V66, P380, DOI 10.1128/IAI.66.1.380-386.1998; HOWARD RF, 1984, AM J TROP MED HYG, V33, P1055, DOI 10.4269/ajtmh.1984.33.1055; JAIKARIA NS, 1993, MOL BIOCHEM PARASIT, V57, P269, DOI 10.1016/0166-6851(93)90203-A; Kaasch AJ, 2000, CURR OPIN MICROBIOL, V3, P422, DOI 10.1016/S1369-5274(00)00115-6; Kaneko O, 2002, MOL BIOCHEM PARASIT, V121, P275, DOI 10.1016/S0166-6851(02)00042-7; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Lobo CA, 2003, MOL BIOCHEM PARASIT, V128, P59, DOI 10.1016/S0166-6851(03)00050-1; Mayer DCG, 2001, P NATL ACAD SCI USA, V98, P5222, DOI 10.1073/pnas.081075398; MILLER LH, 1979, J EXP MED, V149, P172, DOI 10.1084/jem.149.1.172; NDENGELE MM, 1995, EXP PARASITOL, V81, P191, DOI 10.1006/expr.1995.1108; Preiser P, 2000, MICROBES INFECT, V2, P1461, DOI 10.1016/S1286-4579(00)01301-0; Rayner JC, 2000, P NATL ACAD SCI USA, V97, P9648, DOI 10.1073/pnas.160469097; RIDLEY RG, 1991, MOL BIOCHEM PARASIT, V47, P245, DOI 10.1016/0166-6851(91)90184-8; RIDLEY RG, 1990, PARASITOLOGY, V101, P187, DOI 10.1017/S0031182000063228; Roggwiller E, 1996, MOL BIOCHEM PARASIT, V82, P13, DOI 10.1016/0166-6851(96)02714-4; SADAK A, 1988, MOL BIOCHEM PARASIT, V29, P203, DOI 10.1016/0166-6851(88)90075-8; SAMYELLOWE TY, 1995, J EUKARYOT MICROBIOL, V42, P224, DOI 10.1111/j.1550-7408.1995.tb01570.x; SAMYELLOWE TY, 1988, J CELL BIOL, V106, P1507, DOI 10.1083/jcb.106.5.1507; SAUL A, 1990, MOL BIOCHEM PARASIT, V42, P55, DOI 10.1016/0166-6851(90)90112-Y; SCHOFIELD L, 1986, MOL BIOCHEM PARASIT, V18, P183, DOI 10.1016/0166-6851(86)90037-X; Sinai AP, 2001, J CELL BIOL, V154, P95, DOI 10.1083/jcb.200101073; SMYTHE J A, 1990, Technique (Philadelphia), V2, P133; SMYTHE JA, 1988, P NATL ACAD SCI USA, V85, P5195, DOI 10.1073/pnas.85.14.5195; Soldati D, 1998, MOL BIOCHEM PARASIT, V96, P37, DOI 10.1016/S0166-6851(98)00090-5; STEWART MJ, 1986, AM J TROP MED HYG, V35, P37, DOI 10.4269/ajtmh.1986.35.37; Stowers AW, 1996, MOL BIOCHEM PARASIT, V82, P167, DOI 10.1016/0166-6851(96)02730-2; Striepen B, 2001, MOL BIOCHEM PARASIT, V113, P45, DOI 10.1016/S0166-6851(00)00379-0; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TRIGLIA T, 1992, PARASITOL TODAY, V8, P225, DOI 10.1016/0169-4758(92)90118-L; VanWye J, 1996, MOL BIOCHEM PARASIT, V83, P107, DOI 10.1016/S0166-6851(96)02759-4; Waller KL, 1999, J BIOL CHEM, V274, P23808, DOI 10.1074/jbc.274.34.23808; Wang L, 2003, MOL BIOCHEM PARASIT, V130, P149, DOI 10.1016/S0166-6851(03)00165-8; Wang L, 1999, INFECT IMMUN, V67, P2193, DOI 10.1128/IAI.67.5.2193-2200.1999; Zhang XQ, 1997, BIOCHEM J, V323, P197, DOI 10.1042/bj3230197	58	101	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4648	4656		10.1074/jbc.M307859200	http://dx.doi.org/10.1074/jbc.M307859200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14613941	hybrid			2022-12-25	WOS:000188554300087
J	Zhao, J; Wang, XM				Zhao, J; Wang, XM			Arabidopsis phospholipase D alpha 1 interacts with the heterotrimeric G-protein alpha-subunit through a motif analogous to the DRY motif in G-protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSCISIC-ACID; PHOSPHATIDIC-ACID; CLONING; GAMMA; GENE; BETA; POLYPHOSPHOINOSITIDES; ACCUMULATION; INVOLVEMENT; EXPRESSION	Phospholipase D (PLD) and heterotrimeric G-protein both play important, diverse roles in cellular regulation and signal transduction. Here we have determined the physical interaction between plant PLD and the only canonical alpha-subunit (Galpha) of the G-protein in Arabidopsis thaliana and the molecular basis for the interaction. PLDalpha1 expressed in either Escherichia coli or Arabidopsis was co-precipitated with Galpha. PLDalpha1 contains a sequence motif analogous to the Galpha-interacting DRY motif normally conserved in G-protein-coupled receptors. Mutation of the central Lys residue PLDK564A of this motif abolished the PLDalpha1-Galpha binding, whereas mutation of the two flanking residues PLDE563A and PLDF565A decreased the binding. Addition of Galpha to PLDalpha1 inhibited PLDalpha1 activity, whereas the PLDK564A mutation that disrupted the Galpha-PLDalpha1 binding abolished the inhibition. GTP relieved the Galpha inhibition of PLDalpha1 activity and also inhibited the binding between PLDalpha1 and Galpha. Meanwhile, the PLDalpha1-Galpha interaction stimulated the intrinsic GTPase activity of Galpha. Therefore, these results have demonstrated the direct binding between Galpha and PLDalpha1, identified the DRY motif on PLDalpha1 as the site for the interaction, and indicated that the interaction modulates reciprocally the activities of PLDalpha1 and Galpha.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Wang, XM (corresponding author), Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA.	wangs@ksu.edu	Zhao, Jian/Q-8591-2019; Zhao, Jian/A-2336-2008; Wang, Xuemin/M-2853-2013	Zhao, Jian/0000-0002-4416-7334; wang, xuemin/0000-0002-6251-6745				Alewijnse AE, 2000, MOL PHARMACOL, V57, P890; Assmann SM, 2002, PLANT CELL, V14, pS355, DOI 10.1105/tpc.001792; Blumer JB, 2003, J BIOL CHEM, V278, P23217, DOI 10.1074/jbc.C200686200; Chen JG, 2003, SCIENCE, V301, P1728, DOI 10.1126/science.1087790; Cismowski MJ, 2001, LIFE SCI, V68, P2301, DOI 10.1016/S0024-3205(01)01019-0; Colucci G, 2002, P NATL ACAD SCI USA, V99, P4736, DOI 10.1073/pnas.072087699; Dyer JH, 1995, PLANT PHYSIOL, V109, P1497; Fan L, 1999, PLANT PHYSIOL, V119, P1371, DOI 10.1104/pp.119.4.1371; Fan L, 1997, PLANT CELL, V9, P2183, DOI 10.1105/tpc.9.12.2183; Jones AM, 2002, CURR OPIN PLANT BIOL, V5, P402, DOI 10.1016/S1369-5266(02)00288-1; Katagiri T, 2001, PLANT J, V26, P595, DOI 10.1046/j.1365-313x.2001.01060.x; Lapik YR, 2003, PLANT CELL, V15, P1578, DOI 10.1105/tpc.011890; Lein W, 2001, BBA-MOL CELL BIOL L, V1530, P172, DOI 10.1016/S1388-1981(00)00182-7; MA H, 1990, P NATL ACAD SCI USA, V87, P3821, DOI 10.1073/pnas.87.10.3821; Mason MG, 2001, BBA-GENE STRUCT EXPR, V1520, P147, DOI 10.1016/S0167-4781(01)00262-7; McGee JD, 2003, PLANT CELL PHYSIOL, V44, P1013, DOI 10.1093/pcp/pcg125; Munnik T, 1995, PLANT CELL, V7, P2197, DOI 10.1105/tpc.7.12.2197; Offermanns S, 2003, PROG BIOPHYS MOL BIO, V83, P101, DOI 10.1016/S0079-6107(03)00052-X; Pappan K, 1999, ARCH BIOCHEM BIOPHYS, V368, P347, DOI 10.1006/abbi.1999.1325; Pappan K, 1997, J BIOL CHEM, V272, P7048, DOI 10.1074/jbc.272.11.7048; Qin CB, 2002, PLANT PHYSIOL, V128, P1057, DOI 10.1104/pp.010928; Qin WS, 1997, J BIOL CHEM, V272, P28267, DOI 10.1074/jbc.272.45.28267; Ritchie S, 2000, PLANT PHYSIOL, V124, P693, DOI 10.1104/pp.124.2.693; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Sang YM, 2001, PLANT J, V28, P135, DOI 10.1046/j.1365-313X.2001.01138.x; Sang YM, 2001, PLANT PHYSIOL, V126, P1449, DOI 10.1104/pp.126.4.1449; Scheer A, 2000, MOL PHARMACOL, V57, P219; Ullah H, 2002, PLANT PHYSIOL, V129, P897, DOI 10.1104/pp.005017; Ullah H, 2001, SCIENCE, V292, P2066, DOI 10.1126/science.1059040; Wang CX, 2001, PLANT PHYSIOL, V127, P1102, DOI 10.1104/pp.010444; Wang CX, 2000, PLANT CELL, V12, P2237, DOI 10.1105/tpc.12.11.2237; Wang XM, 2002, CURR OPIN PLANT BIOL, V5, P408, DOI 10.1016/S1369-5266(02)00283-2; Wang XQ, 2001, SCIENCE, V292, P2070, DOI 10.1126/science.1059046; WEISS CA, 1994, P NATL ACAD SCI USA, V91, P9554, DOI 10.1073/pnas.91.20.9554; Welti R, 2002, J BIOL CHEM, V277, P31994, DOI 10.1074/jbc.M205375200; Zhang WH, 2003, PLANT CELL, V15, P2285, DOI 10.1105/tpc.013961; Zheng L, 2000, J BIOL CHEM, V275, P19700, DOI 10.1074/jbc.M001945200	37	145	162	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1794	1800		10.1074/jbc.M309529200	http://dx.doi.org/10.1074/jbc.M309529200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14594812	hybrid			2022-12-25	WOS:000188005700029
J	Kanazawa, T; Taneike, I; Akaishi, R; Yoshizawa, F; Furuya, N; Fujimura, S; Kadowaki, M				Kanazawa, T; Taneike, I; Akaishi, R; Yoshizawa, F; Furuya, N; Fujimura, S; Kadowaki, M			Amino acids and insulin control autophagic proteolysis through different signaling pathways in relation to mTOR in isolated rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; MAMMALIAN TARGET; HEPATIC PROTEOLYSIS; PROTEIN-SYNTHESIS; MESSENGER-RNAS; RAPAMYCIN TOR; LEUCINE; PHOSPHORYLATION; TRANSLATION; AVAILABILITY	Autophagy, a major bulk proteolytic pathway, contributes to intracellular protein turnover, together with protein synthesis. Both are subject to dynamic control by amino acids and insulin. The mechanisms of signaling and cross-talk of their physiological anabolic effects remain elusive. Recent studies established that amino acids and insulin induce p70 S6 kinase (p70(S6k)) phosphorylation by mTOR, involved in translational control of protein synthesis. Here, the signaling mechanisms of amino acids and insulin in macroautophagy in relation to mTOR were investigated. In isolated rat hepatocytes, both regulatory amino acids (RegAA) and insulin coordinately activated p70(S6k) phosphorylation, which was completely blocked by rapamycin, an mTOR inhibitor. However, rapamycin blocked proteolytic suppression by insulin, but did not block inhibition by RegAA. These contrasting results suggest that insulin controls autophagy through the mTOR pathway, but amino acids do not. Furthermore, micropermeabilization with Saccharomyces aureus alpha-toxin completely deprived hepatocytes of proteolytic responsiveness to RegAA and insulin, but still maintained p70(S6k) phosphorylation by RegAA. In contrast, Leu(8)-MAP, a non-transportable leucine analogue, did not mimic the effect of leucine on p70(S6k) phosphorylation, but maintained the activity on proteolysis. Finally, BCH, a System L-specific amino acid, did not affect proteolytic suppression or mTOR activation by leucine. All the results indicate that mTOR is not common to the signaling mechanisms of amino acids and insulin in autophagy, and that the amino acid signaling starts extracellularly with their "receptor(s)," probably other than transporters, and is mediated through a novel route distinct from the mTOR pathway employed by insulin.	Niigata Univ, Fac Agr, Dept Appl Biol Chem, Niigata 9502181, Japan; Utsunomiya Univ, Fac Agr, Dept Anim Sci, Utsunomiya, Tochigi 3218505, Japan	Niigata University; Utsunomiya University	Kadowaki, M (corresponding author), Niigata Univ, Fac Agr, Dept Appl Biol Chem, 2-8050 Ikarashi, Niigata 9502181, Japan.	kadowaki@agr.niigata-u.ac.jp	Furuya, Norihiko/K-7299-2015	Furuya, Norihiko/0000-0001-7695-4271				Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; Anthony JC, 2002, DIABETES, V51, P928, DOI 10.2337/diabetes.51.4.928; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cheley S, 1997, PROTEIN ENG, V10, P1433, DOI 10.1093/protein/10.12.1433; Christie GR, 2002, J BIOL CHEM, V277, P9952, DOI 10.1074/jbc.M107694200; CORNELL NW, 1980, ANAL BIOCHEM, V102, P326, DOI 10.1016/0003-2697(80)90162-1; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Dice J. F., 2000, LYSOSOMAL PATHWAYS P; Dumont JE, 2002, AM J PHYSIOL-CELL PH, V283, pC2, DOI 10.1152/ajpcell.00581.2001; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; Fox Heather L., 1998, American Journal of Physiology, V275, pC1232; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Haussinger D, 1999, GASTROENTEROLOGY, V116, P921, DOI 10.1016/S0016-5085(99)70076-4; Iraqui I, 1999, MOL CELL BIOL, V19, P3360; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; KADOWAKI M, 1994, J BIOL CHEM, V269, P3703; KADOWAKI M, 1992, J BIOL CHEM, V267, P22060; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; KHAIRALLAH EA, 1976, J BIOL CHEM, V251, P1375; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lynch CJ, 2000, J CELL BIOCHEM, V77, P234, DOI 10.1002/(SICI)1097-4644(20000501)77:2<234::AID-JCB7>3.0.CO;2-I; Lynch CJ, 2001, J NUTR, V131, p861S, DOI 10.1093/jn/131.3.861S; MIOTTO G, 1994, J BIOL CHEM, V269, P25348; MIOTTO G, 1992, J BIOL CHEM, V267, P22066; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889; Mordier S, 2000, J BIOL CHEM, V275, P29900, DOI 10.1074/jbc.M003633200; MORDIER S, 2002, SENSING SIGNALING CE, P189; MORTIMORE GE, 1994, BIOCHEM BIOPH RES CO, V203, P200, DOI 10.1006/bbrc.1994.2168; MORTIMORE GE, 2001, HDB PHYSL, V2, P553; NIELSEN PJ, 1982, J BIOL CHEM, V257, P2316; Niioka S, 1998, J BIOCHEM, V124, P1086, DOI 10.1093/oxfordjournals.jbchem.a022225; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; PACITTI AJ, 1993, AM J PHYSIOL, V265, pG90, DOI 10.1152/ajpgi.1993.265.1.G90; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE74, DOI 10.1152/ajpendo.2000.279.1.E74; Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; Ueno T, 1999, J BIOL CHEM, V274, P15222, DOI 10.1074/jbc.274.21.15222; van Sluijters DA, 2000, BIOCHEM J, V351, P545, DOI 10.1042/0264-6021:3510545; VENERANDO R, 1994, AM J PHYSIOL, V266, pC455, DOI 10.1152/ajpcell.1994.266.2.C455; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178	56	161	173	0	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8452	8459		10.1074/jbc.M306337200	http://dx.doi.org/10.1074/jbc.M306337200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14610086	hybrid			2022-12-25	WOS:000189103300128
J	Buccellato, LJ; Tso, M; Akinci, OI; Chandel, NS; Budinger, GRS				Buccellato, LJ; Tso, M; Akinci, OI; Chandel, NS; Budinger, GRS			Reactive oxygen species are required for hyperoxia-induced Bax activation and cell death in alveolar epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; SUPEROXIDE-DISMUTASE; ELECTRON-TRANSPORT; INDUCED APOPTOSIS; TRANSGENIC MICE; MITOCHONDRIAL-MEMBRANE; OXIDANT INJURY; RAT LUNGS; BCL-2; GENERATION	Exposure of animals to hyperoxia results in respiratory failure and death within 72 h. Histologic evaluation of the lungs of these animals demonstrates epithelial apoptosis and necrosis. Although the generation of reactive oxygen species (ROS) is widely thought to be responsible for the cell death observed following exposure to hyperoxia, it is not clear whether they act upstream of activation of the cell death pathway or whether they are generated as a result of mitochondrial membrane permeabilization and caspase activation. We hypothesized that the generation of ROS was required for hyperoxia-induced cell death upstream of Bax activation. In primary rat alveolar epithelial cells, we found that exposure to hyperoxia resulted in the generation of ROS that was completely prevented by the administration of the combined superoxide dismutase/catalase mimetic EUK-134 (Eukarion, Inc., Bedford, MA). Exposure to hyperoxia resulted in the activation of Bax at the mitochondrial membrane, cytochrome c release, and cell death. The administration of EUK-134 prevented Bax activation, cytochrome c release, and cell death. In a mouse lung epithelial cell line (MLE-12), the overexpression of Bcl-X-L protected cells against hyperoxia by preventing the activation of Bax at the mitochondrial membrane. We conclude that exposure to hyperoxia results in Bax activation at the mitochondrial membrane and subsequent cytochrome c release. Bax activation at the mitochondrial membrane requires the generation of ROS and can be prevented by the overexpression of Bcl-X-L.	Northwestern Univ, Div Pulm & Crit Care Med, Chicago, IL 60611 USA	Northwestern University	Budinger, GRS (corresponding author), Northwestern Univ, Div Pulm & Crit Care Med, 303 E Chicago Ave,Tarry 14-707, Chicago, IL 60611 USA.	s-buding@northwestern.edu		Akinci, Ibrahim Ozkan/0000-0003-1657-3869	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL071463, K08HL067835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060472] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67835-01, P01HL071463-01A4] Funding Source: Medline; NIGMS NIH HHS [GM60472-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBAUGH DG, 1967, LANCET, V2, P319; Barazzone C, 2000, AM J RESP CELL MOL, V22, P517, DOI 10.1165/ajrcmb.22.5.f180; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budinger GRS, 2002, J BIOL CHEM, V277, P15654, DOI 10.1074/jbc.M109317200; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Chandel NS, 2000, J APPL PHYSIOL, V88, P1880, DOI 10.1152/jappl.2000.88.5.1880; Chen Q, 2003, CELL DEATH DIFFER, V10, P323, DOI 10.1038/sj.cdd.4401148; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123; Folz RJ, 1999, J CLIN INVEST, V103, P1055, DOI 10.1172/JCI3816; FREEMAN BA, 1981, J BIOL CHEM, V256, P986; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; GUIDOT DM, 1993, J BIOL CHEM, V268, P26699; Ilizarov AM, 2001, AM J RESP CELL MOL, V24, P436, DOI 10.1165/ajrcmb.24.4.4240; Kalivendi SV, 2001, J BIOL CHEM, V276, P47266, DOI 10.1074/jbc.M106829200; Kamencic H, 2000, ANAL BIOCHEM, V286, P35, DOI 10.1006/abio.2000.4765; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Kazzaz JA, 1999, ANN NY ACAD SCI, V887, P164, DOI 10.1111/j.1749-6632.1999.tb07930.x; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kirkland RA, 2002, J NEUROSCI, V22, P6480; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lee PJ, 2003, FREE RADICAL BIO MED, V35, P341, DOI 10.1016/S0891-5849(03)00279-X; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li Y, 2003, AM J RESP CELL MOL, V29, P779, DOI 10.1165/rcmb.2003-0087RC; Mantell LL, 1999, ANN NY ACAD SCI, V887, P171, DOI 10.1111/j.1749-6632.1999.tb07931.x; McClintock DS, 2002, MOL CELL BIOL, V22, P94, DOI 10.1128/MCB.22.1.94-104.2002; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; OLIVERA WG, 1995, AM J RESP CRIT CARE, V152, P1229, DOI 10.1164/ajrccm.152.4.7551375; Parinandi NL, 2003, AM J PHYSIOL-LUNG C, V284, pL26, DOI 10.1152/ajplung.00123.2002; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Ridge KM, 1997, AM J PHYSIOL-LUNG C, V273, pL246, DOI 10.1152/ajplung.1997.273.1.L246; Romashko J, 2003, FREE RADICAL BIO MED, V35, P978, DOI 10.1016/S0891-5849(03)00494-5; SANDERS SP, 1993, J CLIN INVEST, V91, P46, DOI 10.1172/JCI116198; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; VanKlaveren RJ, 1997, AM J PHYSIOL-LUNG C, V273, pL548, DOI 10.1152/ajplung.1997.273.3.L548; Ward NS, 2000, AM J RESP CELL MOL, V22, P535, DOI 10.1165/ajrcmb.22.5.3808; WHITE CW, 1991, J CLIN INVEST, V87, P2162, DOI 10.1172/JCI115249; WISPE JR, 1992, J BIOL CHEM, V267, P23937	42	144	155	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6753	6760		10.1074/jbc.M310145200	http://dx.doi.org/10.1074/jbc.M310145200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14625274	hybrid			2022-12-25	WOS:000188969200068
J	Ouchane, S; Steunou, AS; Picaud, M; Astier, C				Ouchane, S; Steunou, AS; Picaud, M; Astier, C			Aerobic and anaerobic Mg-protoporphyrin monomethyl ester cyclases in purple bacteria - A strategy adopted to bypass the repressive oxygen control system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CENTER; ISOCYCLIC RING FORMATION; RIBONUCLEOTIDE REDUCTASE; RHODOBACTER-SPHAEROIDES; RUBRIVIVAX-GELATINOSUS; ESCHERICHIA-COLI; CHLAMYDOMONAS-REINHARDTII; CHLOROPHYLL BIOSYNTHESIS; GENE-EXPRESSION; BACTERIOCHLOROPHYLL	Two different mechanisms for Mg-protoporphyrin monomethyl ester (MgPMe) cyclization are shown to coexist in Rubrivivax gelatinosus and are proposed to be conserved in all facultative aerobic phototrophs: an anaerobic mechanism active under photosynthesis or low oxygenation, and an aerobic mechanism active only under high oxygenation conditions. This was confirmed by analyzing the bacteriochlorophyll accumulation in the wild type and in three mutant strains grown under low or high aeration. A mutant lacking the acsF gene is photosynthetic, exhibits normal bacteriochlorophyll accumulation under low oxygenation and anaerobiosis, and accumulates MgPMe under high oxygenation. The photosynthesis-deficient bchE mutant produces bacteriochlorophyll only under high oxygenation and accumulates MgPMe under low oxygenation and anaerobiosis. The double knockout mutant is devoid of photosystem and accumulates MgPMe under both conditions indicating the involvement of the two enzymes at the same step of the biosynthesis pathway. Oxygen-mediated expression of bchE was studied in the wild type and in a regulatory mutant. The reverse transcriptase-PCR and the bchE promoter activity results demonstrate that the expression of the bchE gene is oxygen-independent and suggest that it is rather the enzyme activity that should be oxygen-sensitive. No obvious sequence similarities were found between oxygen-dependent AcsF and the oxygen-independent anaerobic Mg-protoporphyrin monomethylester cyclase (BchE) enzymes. However, common to all BchE proteins is the conserved CXXK-CXXC sequence. This motif is essential for 4Fe-4S cluster formation in many anaerobic enzymes. Expression and purification of BchE were achieved, and the UV-visible spectral analyses confirmed the presence of an active 4Fe-4S cluster in this protein. The use of different classes of enzymes catalyzing the same reaction under different oxygen growth conditions appears to be a common feature of different biosynthetic pathways, and the benefit of possessing both aerobic and anaerobic systems is discussed.	CNRS, Ctr Genet Mol, UPR 2167, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Ouchane, S (corresponding author), CNRS, Ctr Genet Mol, UPR 2167, Batiment 26,Ave Terrasse, F-91198 Gif Sur Yvette, France.	souchane@cgm.cnrs-gif.fr	Ouchane, Soufian/ABE-2609-2020	Ouchane, Soufian/0000-0002-8161-3866; Steunou, Anne Soisig/0000-0002-0731-0226				AGALIDIS I, 1990, PHOTOSYNTH RES, V23, P249, DOI 10.1007/BF00034855; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bauer CE, 1996, CELL, V85, P5, DOI 10.1016/S0092-8674(00)81074-0; Beale SI, 1999, PHOTOSYNTH RES, V60, P43, DOI 10.1023/A:1006297731456; CASADO C, 1991, FEMS MICROBIOL LETT, V83, P153; Fischer HM, 2001, J BACTERIOL, V183, P1300, DOI 10.1128/JB.183.4.1300-1311.2001; Gough SP, 2000, P NATL ACAD SCI USA, V97, P6908, DOI 10.1073/pnas.97.12.6908; Heck C, 1996, MOL MICROBIOL, V20, P1165, DOI 10.1111/j.1365-2958.1996.tb02637.x; Igarashi N, 2001, J MOL EVOL, V52, P333, DOI 10.1007/s002390010163; JORDAN A, 1994, P NATL ACAD SCI USA, V91, P12892, DOI 10.1073/pnas.91.26.12892; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; KOVACH ME, 1994, BIOTECHNIQUES, V16, P800; Layer G, 2002, J BIOL CHEM, V277, P34136, DOI 10.1074/jbc.M205247200; Moseley J, 2000, EMBO J, V19, P2139, DOI 10.1093/emboj/19.10.2139; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; Ollagnier-de Choudens S, 2000, BIOCHEMISTRY-US, V39, P4165, DOI 10.1021/bi992090u; ORMEJOHNSON WH, 1982, IRON SULFUR PROTEINS, P67; Ouchane S, 1996, MOL GEN GENET, V252, P379, DOI 10.1007/BF02173002; Ouchane S, 1997, EMBO J, V16, P4777, DOI 10.1093/emboj/16.15.4777; Pinta V, 2002, J BACTERIOL, V184, P746, DOI 10.1128/JB.184.3.746-753.2002; Poole AM, 2002, J MOL EVOL, V55, P180, DOI 10.1007/s00239-002-2315-3; Porra RJ, 1998, EUR J BIOCHEM, V257, P185, DOI 10.1046/j.1432-1327.1998.2570185.x; PORRA RJ, 1995, FEBS LETT, V371, P21, DOI 10.1016/0014-5793(95)00854-3; Porra RJ, 1996, EUR J BIOCHEM, V239, P85, DOI 10.1111/j.1432-1033.1996.0085u.x; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Quinn JM, 2002, PLANT PHYSIOL, V128, P463, DOI 10.1104/pp.010694; Rompf A, 1998, MOL MICROBIOL, V29, P985, DOI 10.1046/j.1365-2958.1998.00980.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Suzuki JY, 1997, ANNU REV GENET, V31, P61, DOI 10.1146/annurev.genet.31.1.61; Tamarit J, 2000, J BIOL CHEM, V275, P15669, DOI 10.1074/jbc.275.21.15669; UFFEN RL, 1976, P NATL ACAD SCI USA, V73, P3298, DOI 10.1073/pnas.73.9.3298; YANG ZM, 1990, J BACTERIOL, V172, P5001, DOI 10.1128/jb.172.9.5001-5010.1990; Zeilstra-Ryalls JH, 1998, METHOD ENZYMOL, V297, P151	33	93	100	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6385	6394		10.1074/jbc.M309851200	http://dx.doi.org/10.1074/jbc.M309851200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14617630	hybrid			2022-12-25	WOS:000188969200024
J	Cruz, AC; Frank, BT; Edwards, ST; Dazin, PF; Peschon, JJ; Fang, KC				Cruz, AC; Frank, BT; Edwards, ST; Dazin, PF; Peschon, JJ; Fang, KC			Tumor necrosis factor-alpha-converting enzyme controls surface expression of c-kit and survival of embryonic stem cell-derived mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; SOLUBLE KIT; IN-VITRO; DISEASE SEVERITY; DOWN-REGULATION; CLEAVAGE; LIGAND; APOPTOSIS; CHYMASE; STIMULATION	Transmembrane metalloproteinases of the disintegrin and metalloproteinase ( ADAM) family control cell signaling interactions via hydrolysis of protein extracellular domains. Prior work has shown that the receptor tyrosine kinase, c- Kit ( CD117), is essential for mast cell survival and that serum levels of c- Kit increase in proliferative mast cell disorders, suggesting the existence of c- Kit shedding pathways in mast cells. In the present work, we report that tumor necrosis factor alpha- converting enzyme ( TACE; ADAM- 17) mediates shedding of c- Kit. Stimulation of transfected cells with phorbol 12- myristate 13- acetate ( PMA) induced metalloproteinase- mediated release of c- Kit ectodomain, which increased further upon TACE overexpression. By contrast, TACE-deficient fibroblasts did not demonstrate inducible release, thus identifying TACE as the metalloproteinase primarily responsible for PMA- induced c- Kit shedding. Surface expression of c- Kit by the human mast cell- 1 line decreased upon phorbol- induced shedding, which involved metalloproteinase activity susceptible to inhibition by tissue inhibitor of metalloproteinase ( TIMP)- 3. To further explore the role of TACE in shedding of c- Kit from mast cells, we compared the behavior of mast cells derived from murine embryonic stem cells. In these studies, PMA decreased surface c- Kit levels on mast cells expressing wild- type ( +/ +) TACE but not on those expressing an inactive mutant ( Delta Zn/ Delta Zn), confirming the role of TACE in PMA- induced c- Kit shedding. Compared with TACE (+)/ (+) cells, TACE(DeltaZn/DeltaZn) mast cells also demonstrated decreased constitutive shedding and increased basal surface expression of c- Kit, with diminished apoptosis in response to c- Kit ligand deprivation. These data suggest that TACE controls mast cell survival by regulating shedding and surface expression of c- Kit.	Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Amgen Inc, Seattle, WA 98101 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Amgen	Fang, KC (corresponding author), Univ Calif San Francisco, Inst Cardiovasc Res, Box 0911, San Francisco, CA 94143 USA.	kfang@itsa.ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064897] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-64897] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akin C, 2000, BLOOD, V96, P1267, DOI 10.1182/blood.V96.4.1267.h8001267a_1267_1273; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; Bauvois B, 2001, J LEUKOCYTE BIOL, V70, P11; BELLOC F, 1994, CYTOMETRY, V17, P59, DOI 10.1002/cyto.990170108; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 2003, BIOCHEM SOC SYMP, V70, P39, DOI 10.1042/bss0700039; Broudy VC, 1999, BLOOD, V94, P1979; Broudy VC, 2001, CYTOKINE, V15, P188, DOI 10.1006/cyto.2001.0907; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Costa JJ, 1996, J EXP MED, V183, P2681, DOI 10.1084/jem.183.6.2681; Dahlen DD, 2001, LEUKEMIA RES, V25, P413, DOI 10.1016/S0145-2126(00)00122-3; Doedens JR, 2003, BIOCHEM BIOPH RES CO, V308, P331, DOI 10.1016/S0006-291X(03)01381-0; Frank BT, 2001, J IMMUNOL, V166, P2783, DOI 10.4049/jimmunol.166.4.2783; Garrington TP, 2000, EMBO J, V19, P5387, DOI 10.1093/emboj/19.20.5387; Garton KJ, 2001, J BIOL CHEM, V276, P37993; Guo L, 2002, MOL CELL PROTEOMICS, V1, P30, DOI 10.1074/mcp.M100020-MCP200; GURISH MF, 2001, J EXP MED, V194, P1; Hamel W, 1996, CYTOMETRY, V25, P173, DOI 10.1002/(SICI)1097-0320(19961001)25:2<173::AID-CYTO6>3.0.CO;2-I; IEMURA A, 1994, AM J PATHOL, V144, P321; Kanbe T, 2001, BRIT J DERMATOL, V144, P1148, DOI 10.1046/j.1365-2133.2001.04224.x; MATIN R, 1992, J HISTOCHEM CYTOCHEM, V40, P781, DOI 10.1177/40.6.1588024; Mellon MB, 2002, J IMMUNOL, V168, P290, DOI 10.4049/jimmunol.168.1.290; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schwager SLU, 1999, BIOCHEMISTRY-US, V38, P10388, DOI 10.1021/bi990357j; Schwager SLU, 2001, BIOCHEMISTRY-US, V40, P15624, DOI 10.1021/bi011063c; THARP MD, 1985, J HISTOCHEM CYTOCHEM, V33, P27, DOI 10.1177/33.1.2578142; Tsai M, 2000, P NATL ACAD SCI USA, V97, P9186, DOI 10.1073/pnas.160254997; TSAI M, 1991, J EXP MED, V174, P125, DOI 10.1084/jem.174.1.125; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WEIDNER N, 1992, AM J PATHOL, V140, P847; WYPYCH J, 1995, BLOOD, V85, P66, DOI 10.1182/blood.V85.1.66.bloodjournal85166; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; Yeatman CF, 2000, J EXP MED, V192, P1093, DOI 10.1084/jem.192.8.1093; YEE NS, 1993, J BIOL CHEM, V268, P14189; YEE NS, 1994, J BIOL CHEM, V269, P31991	43	50	52	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5612	5620		10.1074/jbc.M312323200	http://dx.doi.org/10.1074/jbc.M312323200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14625290	hybrid			2022-12-25	WOS:000188776500071
J	Hong-Geller, E; Mollhoff, M; Shiflett, PR; Gupta, G				Hong-Geller, E; Mollhoff, M; Shiflett, PR; Gupta, G			Design of chimeric receptor mimics with different TcRV beta isoforms - Type-specific inhibition of superantigen pathogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; STAPHYLOCOCCAL-ENTEROTOXIN-B; SHOCK-SYNDROME TOXIN-1; 3-DIMENSIONAL STRUCTURE; CLASS-II; CRYSTAL-STRUCTURE; BACTERIAL SUPERANTIGENS; PROTEIN; AUREUS; CHAIN	Staphylococcus aureus enterotoxins (S.E.) A-I, and toxic-shock syndrome toxin TSST-1 act as superantigens to cause overstimulation of the host immune system, leading to the onset of various diseases including food poisoning and toxic shock syndrome. SAgs bind as intact proteins to the DRalpha1 domain of the MHC class II receptor and the TcRVbeta domain from the T cell receptor and cause excessive release of cytokines such as IL-2, TNF-alpha, and IFN-gamma, and hyperproliferation of T cells. In addition, different SAgs bind and activate different TcRVbeta isoforms during pathogenesis of human immune cells. These two properties of SAgs prompted us to design several chimeric DRalpha1-linker-TcRVbeta proteins using different TcRVbeta isoforms to create chimeras that would specifically inhibit the pathogenesis of SAgs against which they were designed. In this study, we compare the design, interaction, and inhibitory properties of three different DRalpha1-linker-TcRVbeta chimeras targeted against three different SAgs, SEB, SEC3, and TSST-1. The inhibitory properties of the chimeras were tested by monitoring IL-2 release and T cell proliferation using a primary human cell model. We demonstrate that the three chimeras specifically inhibit the pathogenesis of their target superantigen. We performed molecular modeling to analyze the structural basis of the type specificity exhibited by different chimeras designed against their target SAgs, examine the role of the linker in determining binding and specificity, and suggest site-specific mutations in the chimera to enhance binding affinity. The fact that our strategy works equally well for SEB and TSST-1, two widely different phylogenic variants, suggests that the DRalpha1-linkerTcRVbeta chimeras may be developed as a general therapy against a broad spectrum of superantigens released during Staphylococcal infection.	Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87544 USA	United States Department of Energy (DOE); Los Alamos National Laboratory	Gupta, G (corresponding author), Los Alamos Natl Lab, Biosci Div, HRL-1,MS-M888, Los Alamos, NM 87544 USA.	gxg@lanl.gov						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arad G, 2000, NAT MED, V6, P414, DOI 10.1038/74672; Arcus VL, 2000, J MOL BIOL, V299, P157, DOI 10.1006/jmbi.2000.3725; Arcus VL, 2002, J BIOL CHEM, V277, P32274, DOI 10.1074/jbc.M203914200; Balaban N, 1998, SCIENCE, V280, P438, DOI 10.1126/science.280.5362.438; Chi YI, 2002, J BIOL CHEM, V277, P22839, DOI 10.1074/jbc.M201932200; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; Fields BA, 1996, NATURE, V384, P188, DOI 10.1038/384188a0; FONTENOT JD, 1995, P NATL ACAD SCI USA, V92, P315, DOI 10.1073/pnas.92.1.315; Fraser J, 2000, MOL MED TODAY, V6, P125, DOI 10.1016/S1357-4310(99)01657-3; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haddad JJ, 2002, BIOCHEM BIOPH RES CO, V297, P700, DOI 10.1016/S0006-291X(02)02287-8; Hong-Geller E, 2003, J MOL RECOGNIT, V16, P91, DOI 10.1002/jmr.612; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; KAPPLER J, 1994, P NATL ACAD SCI USA, V91, P8462, DOI 10.1073/pnas.91.18.8462; Kieke MC, 2001, J MOL BIOL, V307, P1305, DOI 10.1006/jmbi.2001.4560; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KREISWIRTH B, 1993, SCIENCE, V259, P227, DOI 10.1126/science.8093647; LAURENCE J, 1992, NATURE, V358, P255, DOI 10.1038/358255a0; Leder L, 1998, J EXP MED, V187, P823, DOI 10.1084/jem.187.6.823; Lehnert NM, 2001, BIOCHEMISTRY-US, V40, P4222, DOI 10.1021/bi002172e; Li HM, 1998, IMMUNITY, V9, P807, DOI 10.1016/S1074-7613(00)80646-9; MALCHIODI EL, 1995, J EXP MED, V182, P1833, DOI 10.1084/jem.182.6.1833; MARRACK P, 1990, SCIENCE, V248, P1066; Orengo CA, 1996, METHOD ENZYMOL, V266, P617; Papageorgiou AC, 2000, TRENDS MICROBIOL, V8, P369, DOI 10.1016/S0966-842X(00)01793-5; Papageorgiou AC, 1998, J MOL BIOL, V277, P61, DOI 10.1006/jmbi.1997.1577; Papageorgiou AC, 1996, PROTEIN SCI, V5, P1737, DOI 10.1002/pro.5560050826; PEARLMAN DA, 1995, AMBER 4 1; Pearson H, 2002, NATURE, V418, P469, DOI 10.1038/418469b; Prasad GS, 1997, PROTEIN SCI, V6, P1220; Reiser H, 1996, NEW ENGL J MED, V335, P1369, DOI 10.1056/NEJM199610313351807; Sanchez R, 1999, J COMPUT PHYS, V151, P388, DOI 10.1006/jcph.1999.6200; SCHIFFENBAUER J, 1993, P NATL ACAD SCI USA, V90, P8543, DOI 10.1073/pnas.90.18.8543; Shinefield H, 2002, NEW ENGL J MED, V346, P491, DOI 10.1056/NEJMoa011297; Sundberg EJ, 2002, CURR OPIN IMMUNOL, V14, P36, DOI 10.1016/S0952-7915(01)00296-5; Ulrich RG, 1995, TRENDS MICROBIOL, V3, P463, DOI 10.1016/S0966-842X(00)89011-3; Yarwood JM, 2000, FEMS MICROBIOL LETT, V192, P1, DOI 10.1016/S0378-1097(00)00400-6	39	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5676	5684		10.1074/jbc.M309388200	http://dx.doi.org/10.1074/jbc.M309388200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14604991	hybrid			2022-12-25	WOS:000188776500079
J	Maxfield, AB; Heaton, DN; Winge, DR				Maxfield, AB; Heaton, DN; Winge, DR			Cox17 is functional when tethered to the mitochondrial inner membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; COPPER/ZINC SUPEROXIDE-DISMUTASE; SACCHAROMYCES-CEREVISIAE; INTERMEMBRANE SPACE; METALLOCHAPERONE COX17; CU(I)-BINDING PROTEIN; MUTATIONAL ANALYSIS; YEAST SCO1; GENE; TRAFFICKING	Cox17 is an essential protein in the assembly of cytochrome c oxidase within the mitochondrion. Cox17 is implicated in providing copper ions for formation of Cu-A and Cu-B sites in the oxidase complex. To address whether Cox17 is functional in shuttling copper ions to the mitochondrion, Cox17 was tethered to the mitochondrial inner membrane by a fusion to the transmembrane domain of the inner membrane protein, Sco2. The copper-binding domain of Sco2 that projects into the inter-mitochondrial membrane space was replaced with Cox17. The Sco2/Cox17 fusion protein containing the mitochondrial import sequence and transmembrane segment of Sco2 is exclusively localized within the mitochondrion. The Sco2/Cox17 protein restores respiratory growth and normal cytochrome oxidase activity in cox17Delta cells. These studies suggest that the function of Cox17 is confined to the mitochondrial intermembrane space. Domain mapping of yeast Cox17 reveals that the carboxyl-terminal segment of the protein has a function within the intermembrane space that is independent of copper ion binding. The essential C-terminal function of Cox17 maps to a candidate amphipathic helix that is important for mitochondrial uptake and retention of the Cox17 protein. This motif can be spatially separated from the N-terminal copper-binding functional motif. Possible roles of the C-terminal motif are discussed.	Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA; Brigham Young Univ, Laie, HI 96762 USA	Utah System of Higher Education; University of Utah; Brigham Young University; Brigham Young University - Hawaii	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA.	dennis.winge@hsc.utah.edu	Winge, Dennis/G-3611-2010		NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES003817, R01ES003817] Funding Source: NIH RePORTER; NCI NIH HHS [5P30-CA 42014] Funding Source: Medline; NIDDK NIH HHS [T32 DK07115] Funding Source: Medline; NIEHS NIH HHS [ES 03817] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Amaravadi R, 1997, HUM GENET, V99, P329, DOI 10.1007/s004390050367; BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHWALD P, 1991, MOL GEN GENET, V229, P413, DOI 10.1007/BF00267464; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Diekert K, 1999, P NATL ACAD SCI USA, V96, P11752, DOI 10.1073/pnas.96.21.11752; Field LS, 2003, J BIOL CHEM, V278, P28052, DOI 10.1074/jbc.M304296200; Frey TG, 2000, TRENDS BIOCHEM SCI, V25, P319, DOI 10.1016/S0968-0004(00)01609-1; Gamonet F, 1998, EUR J BIOCHEM, V251, P716, DOI 10.1046/j.1432-1327.1998.2510716.x; Gaume B, 1998, EMBO J, V17, P6497, DOI 10.1093/emboj/17.22.6497; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Heaton D, 2000, J BIOL CHEM, V275, P37582, DOI 10.1074/jbc.M006639200; Heaton DN, 2001, BIOCHEMISTRY-US, V40, P743, DOI 10.1021/bi002315x; Henle ES, 1997, J BIOL CHEM, V272, P19095, DOI 10.1074/jbc.272.31.19095; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Lin SJ, 1997, J BIOL CHEM, V272, P9215; LINDER MC, 1996, AM J CLIN NUTR, V63, P7975; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; PEROTTI ME, 1983, J HISTOCHEM CYTOCHEM, V31, P351, DOI 10.1177/31.3.6186730; Pfanner N, 2002, CURR OPIN CELL BIOL, V14, P400, DOI 10.1016/S0955-0674(02)00355-1; Punter FA, 2003, J BIOL CHEM, V278, P30875, DOI 10.1074/jbc.M302358200; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rentzsch A, 1999, CURR GENET, V35, P103, DOI 10.1007/s002940050438; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; Sass E, 2003, J BIOL CHEM, V278, P45109, DOI 10.1074/jbc.M302344200; SCHULZE M, 1988, MOL GEN GENET, V211, P492, DOI 10.1007/BF00425706; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; Valentine JS, 1998, CURR OPIN CHEM BIOL, V2, P253, DOI 10.1016/S1367-5931(98)80067-7; [No title captured]	40	79	81	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5072	5080		10.1074/jbc.M311772200	http://dx.doi.org/10.1074/jbc.M311772200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14615477	hybrid			2022-12-25	WOS:000188776500006
J	Trinczek, B; Brajenovic, M; Ebneth, A; Drewes, G				Trinczek, B; Brajenovic, M; Ebneth, A; Drewes, G			MARK4 is a novel microtubule-associated proteins/microtubule affinity-regulating kinase that binds to the cellular microtubule network and to centrosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED CEREBELLAR MACRONEURONS; C-ELEGANS EMBRYOS; PROTEIN-KINASE; TAU-PROTEIN; ALZHEIMERS-DISEASE; NEURONAL POLARITY; NEURITE OUTGROWTH; GROWING AXONS; LIVING CELLS; IN-SITU	The MARK protein kinases were originally identified by their ability to phosphorylate a serine motif in the microtubule-binding domain of tau that is critical for microtubule binding. Here, we report the cloning and expression of a novel human paralog, MARK4, which shares 75% overall homology with MARK1-3 and is predominantly expressed in brain. Homology is most pronounced in the catalytic domain (90%), and MARK4 readily phosphorylates tau and the related microtubule-associated protein 2 ( MAP2) and MAP4. In contrast to the three paralogs that all exhibit uniform cytoplasmic localization, MARK4 colocalizes with the centrosome and with microtubules in cultured cells. Overexpression of MARK4 causes thinning out of the microtubule network, concomitant with a reorganization of microtubules into bundles. In line with these findings, we show that a tandem affinity-purified MARK4 protein complex contains alpha-, beta-, and gamma-tubulin. In differentiated neuroblastoma cells, MARK4 is localized prominently at the tips of neurite-like processes. We suggest that although the four MARK/PAR-1 kinases might play multiple cellular roles in concert with different targets, MARK4 is likely to be directly involved in microtubule organization in neuronal cells and may contribute to the pathological phosphorylation of tau in Alzheimer's disease.	Cellzome AG, D-69117 Heidelberg, Germany; Univ Kansas, Dept Med Chem, Lawrence, KS 66045 USA; EVOTEC Neurosci GmbH, D-22525 Hamburg, Germany	GlaxoSmithKline; Cellzome GmbH; University of Kansas; Evotec	Drewes, G (corresponding author), Cellzome AG, Meyerhofstr 1, D-69117 Heidelberg, Germany.	Gerard.Drewes@Cellzome.com		Drewes, Gerard/0000-0003-0575-6766				Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Bessone S, 1999, DEV BIOL, V214, P87, DOI 10.1006/dbio.1999.9379; Biernat J, 2002, MOL BIOL CELL, V13, P4013, DOI 10.1091/mbc.02-03-0046; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; Black MM, 1996, J NEUROSCI, V16, P3601; Bohm H, 1997, CURR BIOL, V7, P603, DOI 10.1016/S0960-9822(06)00260-0; Brown AJH, 1999, MOL CELL NEUROSCI, V13, P119, DOI 10.1006/mcne.1999.0736; BRUGG B, 1993, NEUROSCIENCE, V52, P489, DOI 10.1016/0306-4522(93)90401-Z; CACERES A, 1992, NEURON, V9, P607, DOI 10.1016/0896-6273(92)90025-9; CACERES A, 1991, J NEUROSCI, V11, P1515; Cassimeris L, 2001, INT REV CYTOL, V210, P163; Chang LF, 2003, DEV CELL, V4, P521, DOI 10.1016/S1534-5807(03)00094-7; Chin JY, 2000, J NEUROPATH EXP NEUR, V59, P966, DOI 10.1093/jnen/59.11.966; Cox DN, 2001, CURR BIOL, V11, P75, DOI 10.1016/S0960-9822(01)00027-6; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; Drewes G, 2003, FEBS LETT, V554, P45, DOI 10.1016/S0014-5793(03)01080-9; Drewes G, 1998, TRENDS BIOCHEM SCI, V23, P307, DOI 10.1016/S0968-0004(98)01245-6; Drewes G, 2003, CURR OPIN CELL BIOL, V15, P199, DOI 10.1016/S0955-0674(03)00005-X; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; Ebneth A, 1999, CELL MOTIL CYTOSKEL, V44, P209, DOI 10.1002/(SICI)1097-0169(199911)44:3<209::AID-CM6>3.0.CO;2-4; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GOTZ J, 1995, EMBO J, V14, P1304, DOI 10.1002/j.1460-2075.1995.tb07116.x; Gundersen GG, 2002, NAT REV MOL CELL BIO, V3, P296, DOI 10.1038/nrm777; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Guo S, 1996, NATURE, V382, P455, DOI 10.1038/382455a0; Haass Christian, 1999, Trends in Cell Biology, V9, P241, DOI 10.1016/S0962-8924(99)01576-7; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HILL DP, 1990, DEVELOPMENT, V108, P159; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hurov JB, 2001, MOL CELL BIOL, V21, P3206, DOI 10.1128/MCB.21.9.3206-3219.2001; Huynh JR, 2001, DEVELOPMENT, V128, P1201; Iida J, 2002, J MOL BIOL, V320, P97, DOI 10.1016/S0022-2836(02)00402-3; Illenberger S, 1998, MOL BIOL CELL, V9, P1495, DOI 10.1091/mbc.9.6.1495; Illenberger S, 1996, J BIOL CHEM, V271, P10834, DOI 10.1074/jbc.271.18.10834; Jenkins SM, 2000, J NEUROCHEM, V74, P1463, DOI 10.1046/j.1471-4159.2000.0741463.x; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LEVIN DE, 1990, P NATL ACAD SCI USA, V87, P8272, DOI 10.1073/pnas.87.21.8272; Li Y, 1996, J NEUROSCI, V16, P531; Mandell JW, 1996, PERSPECT DEV NEUROBI, V4, P125; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Moritz M, 2001, CURR OPIN STRUC BIOL, V11, P174, DOI 10.1016/S0959-440X(00)00187-1; Ono T, 1997, CYTOGENET CELL GENET, V79, P101, DOI 10.1159/000134692; Ossipova Olga, 2002, Gene Expression Patterns, V2, P145, DOI 10.1016/S0925-4773(02)00306-4; Probst A, 1996, ACTA NEUROPATHOL, V92, P588, DOI 10.1007/s004010050565; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; Shulman JM, 2000, CELL, V101, P377, DOI 10.1016/S0092-8674(00)80848-X; Stearns T, 1997, CELL, V91, P303, DOI 10.1016/S0092-8674(00)80414-6; Sun TQ, 2001, NAT CELL BIOL, V3, P628, DOI 10.1038/35083016; Tomancak P, 2000, NAT CELL BIOL, V2, P458, DOI 10.1038/35017101; Vaccari T, 2002, CURR BIOL, V12, P1524, DOI 10.1016/S0960-9822(02)01079-5; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	57	119	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5915	5923		10.1074/jbc.M304528200	http://dx.doi.org/10.1074/jbc.M304528200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14594945	hybrid			2022-12-25	WOS:000188776500107
J	Wei, G; Bai, XM; Esko, JD				Wei, G; Bai, XM; Esko, JD			Temperature-sensitive glycosaminoglycan biosynthesis in a Chinese hamster ovary cell mutant containing a point mutation in glucuronyltransferase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE BIOSYNTHESIS; HNK-1 CARBOHYDRATE EPITOPE; PROTEIN LINKAGE REGION; MOLECULAR-CLONING; UDP-GLCUA; PROTEOGLYCANS; CHONDROITIN; EXPRESSION; TETRASACCHARIDE; GLYCOPROTEINS	In previous studies, we reported the isolation and characterization of a Chinese hamster ovary cell mutant (pgsG) defective in glucuronyltransferase I (GlcATI). This enzyme adds the terminal GlcA residue in the core protein-linkage tetrasaccharide (GlcAbeta1,3Galbeta1,3Galbeta1, 4Xylbeta-O-) on which glycosaminoglycan assembly occurs (Bai, X. M., Wei, G., Sinha, A., and Esko, J. D. (1999) J. Biol. Chem. 274, 13017-13024; Wei, G., Bai, X. M., Sarkar, A. K., and Esko, J. D. (1999) J. Biol. Chem. 274, 7857-7864). Here we show that incorporation of (SO4)-S-35 into glycosaminoglycans in the mutant is temperature-sensitive, with greater synthesis occurring at 33degreesC compared with 37degreesC. Wild-type cells show the opposite thermal dependence. Rabbit antiserum to hamster GlcATI failed to detect cross-reactive material in pgsG cells by immunofluorescence and Western blotting. Furthermore, expression of chimeric proteins composed of mutant GlcATI fused to IgG binding domain of protein A or to green fluorescent protein did not yield the proteins at the expected mass. The green fluorescent protein-tagged version appeared as a truncated protein, and immunofluorescence showed large perinuclear bodies at 30degreesC. At 37degreesC, the fusion protein was not readily detectable. Sequencing cDNAs from mutant and wildtype cells revealed a single base transition (G331A) in the open reading frame in pgsG cells, which resulted in a Val-111 --> Met substitution. These data suggest that pgsG cells contain a labile form of GlcATI that causes conditional expression of glycosaminoglycans dependent on temperature.	Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Esko, JD (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, 9500 Gilman Dr,CMM-E 1055, La Jolla, CA 92093 USA.	jesko@ucsd.edu			NIGMS NIH HHS [R37GM33063, R24 GM61894] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033063, R24GM061894] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai XM, 1997, J BIOL CHEM, V272, P23172, DOI 10.1074/jbc.272.37.23172; Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BAME KJ, 1994, BIOCHEM J, V303, P81, DOI 10.1042/bj3030081; BAME KJ, 1989, J BIOL CHEM, V264, P8059; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1986, J BIOL CHEM, V261, P5725; Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; HAM RG, 1965, P NATL ACAD SCI USA, V53, P288, DOI 10.1073/pnas.53.2.288; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P905, DOI 10.1093/glycob/7.7.905; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Kitagawa H, 2001, BIOCHEM J, V358, P539, DOI 10.1042/0264-6021:3580539; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; OKA S, 1992, J BIOL CHEM, V267, P22711; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Pedersen LC, 2002, J BIOL CHEM, V277, P21869, DOI 10.1074/jbc.M112343200; Pinhal MAS, 2001, P NATL ACAD SCI USA, V98, P12984, DOI 10.1073/pnas.241175798; Sarkar AK, 1995, CARBOHYD RES, V279, P161, DOI 10.1016/0008-6215(95)00304-5; Seiki T, 1999, BIOCHEM BIOPH RES CO, V255, P182, DOI 10.1006/bbrc.1999.0151; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; Terayama K, 1998, J BIOL CHEM, V273, P30295, DOI 10.1074/jbc.273.46.30295; Tone Y, 1999, FEBS LETT, V459, P415, DOI 10.1016/S0014-5793(99)01287-9; Tsuchida K, 1999, EUR J BIOCHEM, V264, P461, DOI 10.1046/j.1432-1327.1999.00635.x; Wei G, 1999, J BIOL CHEM, V274, P7857, DOI 10.1074/jbc.274.12.7857; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885	33	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5693	5698		10.1074/jbc.M311621200	http://dx.doi.org/10.1074/jbc.M311621200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14623881	hybrid			2022-12-25	WOS:000188776500081
J	Bambai, B; Rogge, CE; Stec, B; Kulmacz, RJ				Bambai, B; Rogge, CE; Stec, B; Kulmacz, RJ			Role of Asn-382 and Thr-383 in activation and inactivation of human prostaglandin H synthase cyclooxygenase catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE SYNTHASE; ARACHIDONIC-ACID; GLUTATHIONE-PEROXIDASE; SELECTIVE-INHIBITION; REACTION-KINETICS; TYROSYL RADICALS; HYDROPEROXIDE; AND-2; PURIFICATION; BIOSYNTHESIS	Cyclooxygenase catalysis by prostaglandin H synthase-1 and -2 (PGHS-1 and -2) requires activation of the normally latent enzyme by peroxide-dependent generation of a free radical at Tyr-385 (PGHS-1 numbering) in the cyclooxygenase active site; the Tyr-385 radical has also been linked to self-inactivation processes that impose an ultimate limit on cyclooxygenase catalysis. Cyclooxygenase activation is more resistant to suppression by cytosolic glutathione peroxidase in PGHS-2 than in PGHS-1. This differential response to peroxide scavenging enzymes provides a basis for the differential catalytic regulation of the two PGHS isoforms observed in vivo. We sought to identify structural differences between the isoforms, which could account for the differential cyclooxygenase activation, and used site-directed mutagenesis of recombinant human PGHS-2 to focus on one heme-vicinity residue that diverges between the two isoforms, Thr-383, and an adjacent residue that is conserved between the isoforms, Asn-382. Substitutions of Thr-383 (histidine in most PGHS-1) with histidine or aspartate decreased cyclooxygenase activation efficiency by about 40%, with little effect on cyclooxygenase specific activity or self-inactivation. Substitutions of Asn-382 with alanine, aspartate, or leucine had little effect on the cyclooxygenase specific activity or activation efficiency but almost doubled the cyclooxygenase catalytic output before self-inactivation. Asn-382 and Thr-383 mutations did not appreciably alter the K-m, value for arachidonate, the cyclooxygenase product profile, or the Tyr-385 radical spectroscopic characteristics, confirming the structural integrity of the cyclooxygenase site. The side chain structures of Asn-382 and Thr-383 in PGHS-2 thus selectively influence two important aspects of cyclooxygenase catalytic regulation: activation by peroxide and self-inactivation.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Houston, TX 77030 USA; Univ Texas, Dept Chem, El Paso, TX 79968 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas El Paso	Kulmacz, RJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, 6431 Fannin St,MSB 5-284, Houston, TX 77030 USA.	richard.j.kulmacz@uth.tmc.edu		Bambai, Bijan/0000-0002-9947-1691; Stec, Boguslaw/0000-0002-8696-0349	NIGMS NIH HHS [GM 52170] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052170] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bambai B, 2000, J BIOL CHEM, V275, P27608; BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; EGAN RW, 1976, J BIOL CHEM, V251, P7329; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; George HJ, 1996, PROTEIN EXPRES PURIF, V7, P19, DOI 10.1006/prep.1996.0003; Goodwin DC, 2000, BIOCHEMISTRY-US, V39, P5422, DOI 10.1021/bi992752f; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; Kiefer JR, 2000, NATURE, V405, P97, DOI 10.1038/35011103; Koshkin V, 1999, BBA-PROTEIN STRUCT M, V1430, P341, DOI 10.1016/S0167-4838(99)00016-3; KULMACZ RJ, 1987, BIOCHEM BIOPH RES CO, V148, P539, DOI 10.1016/0006-291X(87)90910-7; KULMACZ RJ, 1985, BIOCHEM BIOPH RES CO, V130, P918, DOI 10.1016/0006-291X(85)90504-2; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; KULMACZ RJ, 1987, PROSTAGLANDINS, V34, P225, DOI 10.1016/0090-6980(87)90246-2; KULMACZ RJ, 1986, ARCH BIOCHEM BIOPHYS, V249, P273, DOI 10.1016/0003-9861(86)90003-2; KULMACZ RJ, 1994, J BIOL CHEM, V269, P5527; Kulmacz RJ, 1998, FEBS LETT, V430, P154, DOI 10.1016/S0014-5793(98)00657-7; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; KULMACZ RJ, 1987, PROSTAGLANDINS RELAT; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landino LM, 1997, J BIOL CHEM, V272, P21565, DOI 10.1074/jbc.272.34.21565; LAWRENCE RA, 1974, EXP EYE RES, V18, P563, DOI 10.1016/0014-4835(74)90062-1; Lu GQ, 1999, J BIOL CHEM, V274, P16162, DOI 10.1074/jbc.274.23.16162; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; Morita I, 2002, PROSTAG OTH LIPID M, V68-9, P165, DOI 10.1016/S0090-6980(02)00029-1; Ornberg RL, 1999, ADV EXP MED BIOL, V469, P131; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; RAZ A, 1990, BIOCHEM J, V269, P603, DOI 10.1042/bj2690603; Sakamoto H, 2000, J BIOL CHEM, V275, P40028, DOI 10.1074/jbc.M003191200; Shitashige M, 1998, BBA-LIPID LIPID MET, V1389, P57, DOI 10.1016/S0005-2760(97)00129-X; Smith T, 2000, ARCH BIOCHEM BIOPHYS, V375, P195, DOI 10.1006/abbi.1999.1659; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Song I, 2001, BIOCHEM BIOPH RES CO, V289, P869, DOI 10.1006/bbrc.2001.6071; Thuresson ED, 2001, J BIOL CHEM, V276, P10347, DOI 10.1074/jbc.M009377200; Tsai AL, 2000, PROSTAG OTH LIPID M, V62, P231, DOI 10.1016/S0090-6980(00)00083-6; Tsai AL, 2002, J BIOL CHEM, V277, P38311, DOI 10.1074/jbc.M206961200; Tsai AL, 1999, J BIOL CHEM, V274, P21695, DOI 10.1074/jbc.274.31.21695; Tsai TC, 1998, J AM CHEM SOC, V120, P227, DOI 10.1021/ja9728482; WEI CH, 1995, BIOCHEMISTRY-US, V34, P8499, DOI 10.1021/bi00026a034; Wu G, 1999, J BIOL CHEM, V274, P9231, DOI 10.1074/jbc.274.14.9231; Wu G, 2003, BIOCHEMISTRY-US, V42, P13772, DOI 10.1021/bi035415m	48	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4084	4092		10.1074/jbc.M304762200	http://dx.doi.org/10.1074/jbc.M304762200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14625295	hybrid			2022-12-25	WOS:000188554300022
J	Bobick, BE; Kulyk, WM				Bobick, BE; Kulyk, WM			The MEK-ERK signaling pathway is a negative regulator of cartilage-specific gene expression in embryonic limb mesenchyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOGLYCAN CORE PROTEIN; KINASE-C-ALPHA; CHICK LIMB; ARTICULAR CHONDROCYTES; GROWTH-FACTORS; IN-VITRO; MICROMASS CULTURES; CHONDROGENESIS; DIFFERENTIATION; CELLS	The extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase pathway, also known as the MEK-ERK kinase cascade, has recently been implicated in the regulation of embryonic cartilage differentiation. However, its precise role in this complex process remains controversial. To more thoroughly examine the role of the MEK-ERK kinase cascade in chondrogenesis, we analyzed the effects of two structurally different pharmacological inhibitors of MEK, the upstream kinase activator of ERK, on chondrocyte differentiation in micromass cultures of embryonic chick limb mesenchyme cells. We found that the MEK inhibitors, U0126 and PD98059, promote increased accumulation of cartilage-characteristic mRNA transcripts for type II collagen, aggrecan, and the transcription factor, Sox9. PD98059 treatment stimulated increased deposition of sulfated glycosaminoglycan into both Alcian blue-stainable cartilage matrix and the surrounding culture medium, whereas U0126 elevated glycosaminoglycan secretion into the medium fraction alone. Both MEK inhibitors increased total type II collagen protein accumulation in micromass culture and elevated the activity of a transfected type II collagen enhancer-luciferase reporter gene. Thus, pharmacological MEK inhibition induced increased expression of multiple chondrocyte differentiation markers. Conversely, transfection of limb mesenchyme cells with a constitutively active MEK1 plasmid resulted in a prominent decrease in the activity of a co-transfected type II collagen enhancer-luciferase reporter gene. Collectively, these findings support the hypothesis that signaling through the MEK-ERK kinase cascade may function as an important inhibitory regulator of embryonic cartilage differentiation.	Univ Saskatchewan, Coll Med, Dept Anat & Cell Biol, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan	Kulyk, WM (corresponding author), Univ Saskatchewan, Coll Med, Dept Anat & Cell Biol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	kulykw@duke.usask.ca						Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Akiba E, 2001, DEV GROWTH DIFFER, V43, P165; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; Bushweller JH, 2000, SEMIN CELL DEV BIOL, V11, P377, DOI 10.1006/scdb.2000.0182; Carlson MRJ, 1998, J EXP ZOOL, V282, P715, DOI 10.1002/(SICI)1097-010X(19981215)282:6<715::AID-JEZ7>3.0.CO;2-F; CARRINGTON JL, 1991, DEV BIOL, V146, P406, DOI 10.1016/0012-1606(91)90242-U; Chang FM, 2003, INT J ONCOL, V22, P469; Chang SH, 1998, J BIOL CHEM, V273, P19213, DOI 10.1074/jbc.273.30.19213; CHOI B, 1995, BIOCHEM BIOPH RES CO, V216, P1034, DOI 10.1006/bbrc.1995.2724; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Farquharson C, 1996, J ENDOCRINOL, V148, P465, DOI 10.1677/joe.0.1480465; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; GAY SW, 1984, J EXP ZOOL, V232, P317, DOI 10.1002/jez.1402320219; GEDUSPAN JS, 1993, DEV BIOL, V156, P500, DOI 10.1006/dbio.1993.1096; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; Gould MC, 2000, EXP CELL RES, V260, P175, DOI 10.1006/excr.2000.5014; Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521-1878(200002)22:2<138::AID-BIES5>3.3.CO;2-W; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HASSELL JR, 1982, TERATOGEN CARCIN MUT, V2, P325, DOI 10.1002/1520-6866(1990)2:3/4<325::AID-TCM1770020314>3.0.CO;2-1; Hilger RA, 2002, ONKOLOGIE, V25, P511, DOI 10.1159/000068621; Hirota Y, 2000, OSTEOARTHR CARTILAGE, V8, P241, DOI 10.1053/joca.1999.0297; Hoffman LM, 1999, INT J DEV BIOL, V43, P167; Hoffman UM, 2003, J BONE JOINT SURG AM, V85A, P124, DOI 10.2106/00004623-200300002-00017; Ito Y, 2002, DEV DYNAM, V224, P69, DOI 10.1002/dvdy.10088; JIANG H, 1995, INT J DEV BIOL, V39, P617; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; KAWAMURA M, 1988, DEV BIOL, V130, P435, DOI 10.1016/0012-1606(88)90339-9; Kim DW, 2003, J BIOL CHEM, V278, P27532, DOI 10.1074/jbc.M301461200; Konat GW, 1996, SCANNING MICROSCOPY SUPPLEMENT 10, 1996, P57; KOSHER RA, 1986, DEV BIOL, V118, P112, DOI 10.1016/0012-1606(86)90078-3; KOSHER RA, 1986, J CELL BIOL, V102, P1151, DOI 10.1083/jcb.102.4.1151; KOSHER RA, 1976, DEV BIOL, V53, P265, DOI 10.1016/0012-1606(76)90228-1; Kulyk WM, 2000, EXP CELL RES, V255, P327, DOI 10.1006/excr.1999.4784; KULYK WM, 1991, DEV BIOL, V146, P38, DOI 10.1016/0012-1606(91)90444-8; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Laufer E, 1997, SCIENCE, V278, P305, DOI 10.1126/science.278.5336.305; Lefebvre V, 2001, OSTEOARTHR CARTILAGE, V9, pS69, DOI 10.1053/joca.2001.0447; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; Macias D, 1997, DEVELOPMENT, V124, P1109; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; Mansour SJ, 1996, CELL GROWTH DIFFER, V7, P243; Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113; Oh CD, 2000, J BIOL CHEM, V275, P5613, DOI 10.1074/jbc.275.8.5613; Pizette S, 2000, DEV BIOL, V219, P237, DOI 10.1006/dbio.2000.9610; POOLE AR, 2000, ARTHRITIS ALLIED CON, V1, P226; SAI S, 1986, P NATL ACAD SCI USA, V83, P5081, DOI 10.1073/pnas.83.14.5081; Seghatoleslami MR, 2003, J CELL BIOCHEM, V88, P1129, DOI 10.1002/jcb.10458; SOLURSH M, 1982, DEV BIOL, V94, P311, DOI 10.1016/0012-1606(82)90350-5; Takahashi K, 2001, DEV DYNAM, V222, P252, DOI 10.1002/dvdy.1185; Tuan RS, 2003, J BONE JOINT SURG AM, V85A, P137, DOI 10.2106/00004623-200300002-00019; van Osch GJVM, 1998, OSTEOARTHR CARTILAGE, V6, P187, DOI 10.1053/joca.1998.0111; van Osch GJVM, 2002, BIORHEOLOGY, V39, P215; VUORIO E, 1982, NUCLEIC ACIDS RES, V10, P1175, DOI 10.1093/nar/10.4.1175; Weinstein-Oppenheimer CR, 2000, PHARMACOL THERAPEUT, V88, P229, DOI 10.1016/S0163-7258(00)00085-1; Weston AD, 2002, J CELL BIOL, V158, P39, DOI 10.1083/jcb.200112029; Yoon YM, 2000, J BONE MINER RES, V15, P2197, DOI 10.1359/jbmr.2000.15.11.2197; Yoon YM, 2000, J BIOL CHEM, V275, P12353, DOI 10.1074/jbc.275.16.12353	58	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4588	4595		10.1074/jbc.M309805200	http://dx.doi.org/10.1074/jbc.M309805200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14617631	hybrid			2022-12-25	WOS:000188554300080
J	Kim, S; Domon-Dell, C; Kang, JH; Chung, DH; Freund, JN; Evers, BM				Kim, S; Domon-Dell, C; Kang, JH; Chung, DH; Freund, JN; Evers, BM			Down-regulation of the tumor suppressor PTEN by the tumor necrosis factor-alpha/nuclear factor-kappa B (NF-kappa B)-inducing kinase/NF-kappa B pathway is linked to a default I kappa B-alpha autoregulatory loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-GROWTH; GERMLINE MUTATIONS; INDUCED APOPTOSIS; GENE-EXPRESSION; TNF-ALPHA; ACTIVATION; INHIBITION; PROTEIN; CANCER; TRANSCRIPTION	The PTEN ((p) under bar hosphatase and (t) under bar ensin homolog deleted on chromosome t (en) under bar) tumor suppressor gene affects multiple cellular processes including cell growth, proliferation, and cell migration by antagonizing phosphatidylinositol 3-kinase (PI3K). However, mechanisms by which PTEN expression is regulated have not been studied extensively. Similar to PTEN, tumor necrosis factor-alpha (TNF-alpha) affects a wide spectrum of diseases including inflammatory processes and cancer by acting as a mediator of apoptosis, inflammation, and immunity. In this study, we show that treatment of cancer cell lines with TNF-alpha decreases PTEN expression. In addition, overexpression of TNF-alpha downstream signaling targets, nuclear factor-kappaB (NF-kappaB)-inducing kinase (NIK) and p65 nuclear factor NF-kappaB, lowers PTEN expression, suggesting that TNF-alpha-induced down-regulation of PTEN is mediated through a TNF-alpha/NIK/NF-kappaB pathway. Down-regulation of PTEN by NIK/NF-kappaB results in activation of the PI3K/Akt pathway and augmentation of TNF-alpha-induced PI3K/Akt stimulation. Importantly, we demonstrate that this effect is associated with a lack of an inhibitor of kappaB (IkappaB)-alpha autoregulatory loop. Moreover, these findings suggest the interaction between PI3K/Akt and NF-kappaB via transcriptional regulation of PTEN and offer one possible explanation for increased tumorigenesis in systems in which NF-kappaB is chronically activated. In such a tumor system, these findings suggest a positive feedback loop whereby Akt activation of NF-kappaB further stimulates Akt via down-regulation of the PI3K inhibitor PTEN.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA; INSERM, U381, F-67200 Strasbourg, France	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Evers, BM (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	mevers@utmb.edu	Domon-Dell, Claire/P-2368-2017; Freund, Jean-Noel/R-4383-2016	Freund, Jean-Noel/0000-0002-0971-3774; DOMON-DELL, Claire/0000-0002-8445-9593	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056338, R01DK048498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG010885] Funding Source: NIH RePORTER; NIA NIH HHS [R37-AG10885] Funding Source: Medline; NIDDK NIH HHS [R01-DK35608, R01-DK48498, P30-DK56338] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Farrow B, 2003, BIOCHEM BIOPH RES CO, V301, P50, DOI 10.1016/S0006-291X(02)02983-2; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Guo DQ, 1996, J BIOL CHEM, V271, P615, DOI 10.1074/jbc.271.2.615; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu YH, 2000, J MED CHEM, V43, P3045, DOI 10.1021/jm000117y; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Jobin C, 1998, J IMMUNOL, V160, P410; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; Kim S, 2002, GASTROENTEROLOGY, V123, P1163, DOI 10.1053/gast.2002.36043; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Ozes ON, 1999, NATURE, V401, P82; Paramio JM, 1999, ONCOGENE, V18, P7462, DOI 10.1038/sj.onc.1203151; Patel L, 2001, CURR BIOL, V11, P764, DOI 10.1016/S0960-9822(01)00225-1; Place RF, 2003, J CELL PHYSIOL, V195, P470, DOI 10.1002/jcp.10262; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Sakurada A, 1999, INT J ONCOL, V15, P1069; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Shen Z, 2002, BIOTECHNIQUES, V32, P1168, DOI 10.2144/02325dd07; Sheng XY, 2002, BIOCHEM BIOPH RES CO, V292, P422, DOI 10.1006/bbrc.2002.6662; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, CANCER RES, V59, P442; VAN AD, 1996, SCIENCE, V274, P787; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wilson CA, 2002, CELL DEATH DIFFER, V9, P1321, DOI 10.1038/sj.cdd.4401107; WU HY, 1994, J BIOL CHEM, V269, P20067; Yang XZ, 2003, CANCER RES, V63, P1122	54	89	91	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4285	4291		10.1074/jbc.M308383200	http://dx.doi.org/10.1074/jbc.M308383200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14623898	Green Published, hybrid			2022-12-25	WOS:000188554300046
J	Ohlmeier, S; Kastaniotis, AJ; Hiltunen, JK; Bergmann, U				Ohlmeier, S; Kastaniotis, AJ; Hiltunen, JK; Bergmann, U			The yeast mitochondrial proteome, a study of fermentative and respiratory growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; 2-DIMENSIONAL ELECTROPHORESIS; GEL-ELECTROPHORESIS; CARBON METABOLISM; MESSENGER-RNA; CYTOCHROME-C; PROTEINS; IDENTIFICATION; DISEASE	Saccharomyces cerevisiae is able to switch from fermentation to respiration (diauxic shift) with major changes in metabolic activity. This phenomenon has been previously studied on the transcriptional level. Here we present a parallel analysis of the yeast mitochondrial proteome and the corresponding transcriptional activity in cells grown on glucose (fermentation) and glycerol (respiration). A two-dimensional reference gel for this organelle proteome was established (available at www.biochem.oulu.fi/proteomics/), which contains about 800 intense spots. From 459 spots 253 individual proteins were identified, among them low abundant and hydrophobic proteins, and 37 proteins previously deemed hypothetical, with partially unknown cellular localization. After the diauxic shift, mitochondrial levels of only 18 proteins were changed (17 increased, with 1 decreased), among them proteins involved in the tricarboxylic acid cycle (Sdh1p, Sdh2p, and Sdh4p) and the respiratory chain (Cox4p, Cyb2p, and Qcr7p), proteins contributing to other respiratory pathways (Ach1p, Adh2p, Ald4p, Cat2p, Icl2p, and Pdh1p), and two proteins with unknown function (Om45p and Ybr230p). Apart from an overall increase in mitochondrial protein mass, the mitochondrial proteome remains remarkably constant, even in a major metabolic adaptation. This seemingly disagrees with results of the DNA microarray analyses, where a rather heterogenous up- or down-regulation of genes encoding mitochondrial proteins implies large changes in the proteome. We propose that the discrepancy between proteome and transcriptional regulation, apart from different translation efficiency, indicates a changed turnover rate of proteins in different physiological conditions.	Univ Oulu, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland	University of Oulu; Finland National Institute for Health & Welfare; University of Oulu	Ohlmeier, S (corresponding author), Univ Oulu, Bioctr Oulu, POB 3000, FIN-90014 Oulu, Finland.	Steffen.Ohlmeier@oulu.fi		Kastaniotis, Alexander/0000-0003-3624-9214; Hiltunen, Kalervo/0000-0002-3073-9602				Abadjieva A, 2001, J BIOL CHEM, V276, P42869, DOI 10.1074/jbc.M103732200; Achleitner G, 1999, EUR J BIOCHEM, V264, P545, DOI 10.1046/j.1432-1327.1999.00658.x; Anderson L, 1997, ELECTROPHORESIS, V18, P533, DOI 10.1002/elps.1150180333; Athenstaedt K, 1999, J BACTERIOL, V181, P6441, DOI 10.1128/JB.181.20.6441-6448.1999; Attardi G, 2002, MITOCHONDRION, V2, P27, DOI 10.1016/S1567-7249(02)00032-6; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Bardel J, 2002, PROTEOMICS, V2, P880, DOI 10.1002/1615-9861(200207)2:7<880::AID-PROT880>3.0.CO;2-0; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; Blank L, 2002, MICROBIOL-SGM, V148, P133, DOI 10.1099/00221287-148-1-133; Blom J, 2000, APPL ENVIRON MICROB, V66, P1970, DOI 10.1128/AEM.66.5.1970-1973.2000; BLOOM H, 1987, ELECTROPHORESIS, V8, P93; BOONCHIRD C, 1991, EUR J BIOCHEM, V199, P325, DOI 10.1111/j.1432-1033.1991.tb16128.x; Bota DA, 2001, MITOCHONDRION, V1, P33, DOI 10.1016/S1567-7249(01)00005-8; Boucherie H, 1996, ELECTROPHORESIS, V17, P1683, DOI 10.1002/elps.1150171106; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brookes PS, 2002, PROTEOMICS, V2, P969, DOI 10.1002/1615-9861(200208)2:8<969::AID-PROT969>3.0.CO;2-3; Buttner K, 2001, ELECTROPHORESIS, V22, P2908, DOI 10.1002/1522-2683(200108)22:14<2908::AID-ELPS2908>3.0.CO;2-M; CAPEILLEREBLANDIN C, 1982, EUR J BIOCHEM, V128, P533; Chinnery PF, 2002, MITOCHONDRION, V2, P149, DOI 10.1016/S1567-7249(02)00046-6; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DEWINDE JH, 1997, YEAST STRESS RESPONS, P7; Egner A, 2002, P NATL ACAD SCI USA, V99, P3370, DOI 10.1073/pnas.052545099; Elgersma Y, 1996, BBA-REV BIOMEMBRANES, V1286, P269, DOI 10.1016/S0304-4157(96)00012-3; ENTIAN KD, 1992, TRENDS BIOCHEM SCI, V17, P506, DOI 10.1016/0968-0004(92)90341-6; Epstein CB, 2001, MOL BIOL CELL, V12, P297, DOI 10.1091/mbc.12.2.297; Farcasanu IC, 1999, BIOSCI BIOTECH BIOCH, V63, P1871, DOI 10.1271/bbb.63.1871; Fossati G, 2003, J IMMUNOL, V170, P1964, DOI 10.4049/jimmunol.170.4.1964; Fountoulakis M, 2002, ELECTROPHORESIS, V23, P311, DOI 10.1002/1522-2683(200202)23:2<311::AID-ELPS311>3.0.CO;2-0; Futcher B, 1999, MOL CELL BIOL, V19, P7357; Gancedo C., 1989, YEASTS, V3, P205; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; GORG A, 1995, ELECTROPHORESIS, V16, P1079, DOI 10.1002/elps.11501601183; Grandier-Vazeille X, 2001, BIOCHEMISTRY-US, V40, P9758, DOI 10.1021/bi010277r; Griffin TJ, 2002, MOL CELL PROTEOMICS, V1, P323, DOI 10.1074/mcp.M200001-MCP200; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Haurie V, 2001, J BIOL CHEM, V276, P76, DOI 10.1074/jbc.M008752200; Herbert B, 1999, ELECTROPHORESIS, V20, P660, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<660::AID-ELPS660>3.0.CO;2-Q; Hermann GJ, 1997, J CELL BIOL, V137, P141, DOI 10.1083/jcb.137.1.141; Igual JC, 1996, MOL GEN GENET, V252, P446, DOI 10.1007/s004380050249; Inadome H, 2001, BIOSCI BIOTECH BIOCH, V65, P2577, DOI 10.1271/bbb.65.2577; Jambrina E, 2003, J BIOL CHEM, V278, P14134, DOI 10.1074/jbc.M211388200; JONES EW, 1977, GENETICS, V85, P23; Joseph-Horne T, 2001, BBA-BIOENERGETICS, V1504, P179, DOI 10.1016/S0005-2728(00)00251-6; Kal AJ, 1999, MOL BIOL CELL, V10, P1859, DOI 10.1091/mbc.10.6.1859; Karlberg O, 2000, YEAST, V17, P170, DOI 10.1002/1097-0061(20000930)17:3<170::AID-YEA25>3.0.CO;2-V; Karpichev IV, 1998, MOL CELL BIOL, V18, P6560, DOI 10.1128/MCB.18.11.6560; Kernec F, 2001, PHYSIOL GENOMICS, V6, P117, DOI 10.1152/physiolgenomics.2001.6.2.117; Kruft V, 2001, PLANT PHYSIOL, V127, P1694, DOI 10.1104/pp.010474; Kumar A, 2002, GENE DEV, V16, P707, DOI 10.1101/gad.970902; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; La Piana G, 2003, ARCH BIOCHEM BIOPHYS, V410, P201, DOI 10.1016/S0003-9861(02)00687-2; Lascaris R, 2003, GENOME BIOL, V4; Lithgow T, 2000, FEBS LETT, V476, P22, DOI 10.1016/S0014-5793(00)01663-X; LIU YS, 1995, EUR J BIOCHEM, V228, P291, DOI 10.1111/j.1432-1033.1995.tb20262.x; Lopez MF, 2000, ELECTROPHORESIS, V21, P3427, DOI 10.1002/1522-2683(20001001)21:16<3427::AID-ELPS3427>3.0.CO;2-L; Lousa CD, 2002, BIOCHEMISTRY-US, V41, P14412, DOI 10.1021/bi02641490; Luttik MAH, 1998, J BIOL CHEM, V273, P24529, DOI 10.1074/jbc.273.38.24529; Maaheimo H, 2001, EUR J BIOCHEM, V268, P2464, DOI 10.1046/j.1432-1327.2001.02126.x; Maassen JA, 2002, AM J MED GENET, V115, P66, DOI 10.1002/ajmg.10346; Madeo F, 1998, MOL BIOL CELL, V9, P131, DOI 10.1091/mbc.9.1.131; Marc P, 2002, EMBO REP, V3, P159, DOI 10.1093/embo-reports/kvf025; McAlisterHenn L, 1997, PROG NUCLEIC ACID RE, V57, P317, DOI 10.1016/S0079-6603(08)60285-8; McCammon MT, 2003, MOL BIOL CELL, V14, P958, DOI 10.1091/mbc.E02-07-0422; Meisinger C, 2000, ANAL BIOCHEM, V287, P339, DOI 10.1006/abio.2000.4868; METZLER DE, 1977, BIOCH CHEM REACTIONS, P100; Miinalainen IJ, 2003, J BIOL CHEM, V278, P20154, DOI 10.1074/jbc.M302851200; Millar AH, 2001, PLANT PHYSIOL, V127, P1711, DOI 10.1104/pp.010387; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; Pandolfo M, 2002, BLOOD CELL MOL DIS, V29, P536, DOI 10.1006/bcmd.2002.0591; PERLMAN PS, 1974, ARCH BIOCHEM BIOPHYS, V162, P248, DOI 10.1016/0003-9861(74)90125-8; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; PRONK JT, 1994, MICROBIOL-UK, V140, P717, DOI 10.1099/00221287-140-4-717; Przybyla-Zawislak B, 1999, GENETICS, V152, P153; Rabilloud T, 2002, BIOCHEMISTRY-US, V41, P144, DOI 10.1021/bi0114776; Rabilloud T, 1998, ELECTROPHORESIS, V19, P1006, DOI 10.1002/elps.1150190616; RONNE H, 1995, TRENDS GENET, V11, P12, DOI 10.1016/S0168-9525(00)88980-5; Scheffler IE, 2001, MITOCHONDRION, V1, P3, DOI 10.1016/S1567-7249(00)00002-7; Sherer TB, 2002, NEUROSCIENTIST, V8, P192, DOI 10.1177/1073858402008003004; Steinmetz LM, 2002, NAT GENET, V31, P400, DOI 10.1038/ng929; Sun JT, 2002, GENETICS, V161, P661; Swerdlow RH, 2002, INT REV NEUROBIOL, V53, P341; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; van Roermund CWT, 1999, EMBO J, V18, P5843, DOI 10.1093/emboj/18.21.5843; Werhahn W, 2002, ELECTROPHORESIS, V23, P640, DOI 10.1002/1522-2683(200202)23:4&lt;640::AID-ELPS640&gt;3.0.CO;2-F; YAFFE MP, 1989, J BIOL CHEM, V264, P21091	87	130	134	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					3956	3979		10.1074/jbc.M310160200	http://dx.doi.org/10.1074/jbc.M310160200			24	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14597615	hybrid			2022-12-25	WOS:000188554300009
J	Wei, YD; Tepperman, K; Huang, MY; Sartor, MA; Puga, A				Wei, YD; Tepperman, K; Huang, MY; Sartor, MA; Puga, A			Chromium inhibits transcription from polycyclic aromatic hydrocarbon-inducible promoters by blocking the release of histone deacetylase and preventing the binding of p300 to chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CROSS-LINKS; FACTOR-KAPPA-B; GENOTOXIC CARCINOGEN CHROMIUM(VI); DIFFERENTIALLY EXPRESSED GENES; FALSE DISCOVERY RATE; CDNA MICROARRAY; CYTOCHROME P4501A1; RECEPTOR COMPLEX; INTACT-CELLS; AH RECEPTOR	Co-contamination with complex mixtures of carcinogenic metals, such as chromium, and polycyclic aromatic hydrocarbons is a common environmental problem with multiple biological consequences. Chromium exposure alters inducible gene expression, forms chromium-DNA adducts and chromium-DNA cross-links, and disrupts transcriptional activator-co-activator complexes. We have shown previously that exposure of mouse hepatoma Hepa-1 cells to chromate inhibits the induction of the Cyp1a1 and Nqo1 genes by dioxin. Here we have tested the hypothesis that chromium blocks gene expression by interfering with the assembly of productive transcriptional complexes at the promoter of inducible genes. To this end, we have studied the effects of chromium on the expression of genes induced by benzo[a]pyrene (B[a]P), another aryl hydrocarbon receptor agonist, and characterized the disruption of Cyp1a1 transcriptional induction by chromium. Gene expression profiling by using high density microarray analysis revealed that the inhibitory effect of chromium on B[a]P-dependent gene induction was generalized, affecting the induction of over 50 different genes involved in a variety of signaling transduction pathways. The inhibitory effect of chromium on Cyp1a1 transcription was found to depend on the presence of promoter-proximal sequences and not on the cis-acting enhancer sequences that bind the aryl hydrocarbon receptor-aryl hydrocarbon receptor nuclear translocator complex. By using transient reporter assays and chromatin immunoprecipitation analyses, we found that chromium prevented the B[a]P-dependent release of HDAC-1 from Cyp1a1 chromatin and blocked p300 recruitment. These results provide a mechanistic explanation for the observation that chromium inhibits inducible but not constitutive gene expression.	Univ Cincinnati, Coll Med, Ctr Environm Genet, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Arts & Sci, Dept Biol Sci, Cincinnati, OH 45220 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Puga, A (corresponding author), Univ Cincinnati, Med Ctr, Dept Environm Hlth, Coll Med, POB 670056, Cincinnati, OH 45267 USA.	Alvaro.Puga@UC.EDU	Puga, Alvaro/B-7676-2008; Sartor, Maureen/L-2902-2019		NIEHS NIH HHS [P42 ES04908, R01 ES10708, R01 ES010807, P30 ES06096] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096, R01ES010807, P42ES004908] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		*AG TOX SUBST DIS, 2002, CERCLA PRIOR LIST HA; ALCEDO JA, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.5.1089; Bagchi D, 2002, TOXICOLOGY, V180, P5, DOI 10.1016/S0300-483X(02)00378-5; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BERNHARD HP, 1973, DEV BIOL, V35, P83, DOI 10.1016/0012-1606(73)90008-0; BYRDY FA, 1995, J CHROMATOGR A, V712, P311, DOI 10.1016/0021-9673(95)00528-U; Chang CY, 1998, MOL CELL BIOL, V18, P525, DOI 10.1128/MCB.18.1.525; Chen F, 1997, ARCH BIOCHEM BIOPHYS, V338, P165, DOI 10.1006/abbi.1996.9849; Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S; DeRisi J, 1996, NAT GENET, V14, P457; Dudoit S, 2002, STAT SINICA, V12, P111; HAMILTON JW, 1989, MOL CARCINOGEN, V2, P274, DOI 10.1002/mc.2940020508; Ihnat MA, 1997, CLIN CANCER RES, V3, P1339; *INT AG RES CANC, 1990, EV CARC RISK HUM, V49, P120; Kaltreider RC, 1999, MOL CARCINOGEN, V25, P219; Ke S, 2001, J BIOL CHEM, V276, P39638, DOI 10.1074/jbc.M106286200; KLEIN CB, 1996, TOXICOLOGY METALS, P205; Kobayashi A, 1996, J BIOL CHEM, V271, P12310, DOI 10.1074/jbc.271.21.12310; Kobayashi A, 1997, J BIOCHEM, V122, P703; Kumar MB, 1999, GENE EXPRESSION, V8, P273; Kumar MB, 1999, J BIOL CHEM, V274, P22155, DOI 10.1074/jbc.274.32.22155; Kurdistani SK, 2002, NAT GENET, V31, P248, DOI 10.1038/ng907; Maier A, 2000, MOL CARCINOGEN, V28, P225, DOI 10.1002/1098-2744(200008)28:4<225::AID-MC5>3.0.CO;2-O; Majumder S, 2003, J BIOL CHEM, V278, P26216, DOI 10.1074/jbc.M302887200; MANNING FCR, 1992, MOL CARCINOGEN, V6, P270, DOI 10.1002/mc.2940060409; Mattagajasingh SN, 1999, MOL CELL BIOCHEM, V199, P149, DOI 10.1023/A:1006910732307; MCCAFFREY J, 1994, MOL CARCINOGEN, V10, P189, DOI 10.1002/mc.2940100403; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; Nguyen TA, 1999, ARCH BIOCHEM BIOPHYS, V367, P250, DOI 10.1006/abbi.1999.1282; O'Brien T, 2001, MOL CELL BIOCHEM, V222, P173, DOI 10.1023/A:1017918330073; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Rushing SR, 2002, ARCH BIOCHEM BIOPHYS, V403, P189, DOI 10.1016/S0003-9861(02)00233-3; Shumilla JA, 1999, J BIOL CHEM, V274, P36207, DOI 10.1074/jbc.274.51.36207; Tian YN, 2003, J BIOL CHEM, V278, P44041, DOI 10.1074/jbc.M306443200; Tong JK, 2002, CHEM BIOL, V9, P668, DOI 10.1016/S1074-5521(02)00158-8; *US EPA, 2003, NAT PRIOR LIST; Wang S, 2002, J BIOL CHEM, V277, P11821, DOI 10.1074/jbc.M110122200; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; WETTERHAHN KE, 1989, BIOL TRACE ELEM RES, V21, P405, DOI 10.1007/BF02917282; WETTERHAHN KE, 1989, SCI TOTAL ENVIRON, V86, P113, DOI 10.1016/0048-9697(89)90199-X; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Wolfinger RD, 2001, J COMPUT BIOL, V8, P625, DOI 10.1089/106652701753307520; XU J, 1994, CARCINOGENESIS, V15, P1443, DOI 10.1093/carcin/15.7.1443; YE JP, 1995, CARCINOGENESIS, V16, P2401, DOI 10.1093/carcin/16.10.2401; ZHITKOVICH A, 1992, CARCINOGENESIS, V13, P1485, DOI 10.1093/carcin/13.8.1485	47	84	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4110	4119		10.1074/jbc.M310800200	http://dx.doi.org/10.1074/jbc.M310800200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14625279	hybrid			2022-12-25	WOS:000188554300025
J	Wu, SF; De Luca, F				Wu, SF; De Luca, F			Role of cholesterol in the regulation of growth plate chondrogenesis and longitudinal bone growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELATED-PROTEIN; INDIAN-HEDGEHOG; SONIC-HEDGEHOG; DIFFERENTIATION; CHONDROCYTES; EXPRESSION; GENES; RAT; BIOSYNTHESIS; MICE	Inborn errors of cholesterol synthesis are associated with multiple systemic abnormalities, including skeletal malformations. The regulatory role of cholesterol during embryogenesis appears to be mediated by Shh, a signaling molecule in which activity depends on molecular events involving cholesterol. Based on this evidence, we hypothesized that cholesterol, by modifying the activity of Ihh (another of the Hedgehog family proteins) in the growth plate, regulates longitudinal bone growth. To test this hypothesis, we treated rats with AY 9944, an inhibitor of the final reaction of cholesterol synthesis. After 3 weeks, AY 9944 reduced the cumulative growth, tibial growth, and the tibial growth plate height of the rats. To determine whether cholesterol deficiency affects bone growth directly at the growth plate, we then cultured fetal rat metatarsal bones in the presence of AY 9944. After 4 days, AY 9944 suppressed metatarsal growth and growth plate chondrocyte proliferation and hypertrophy. The inhibitory effect on chondrocyte hypertrophy was confirmed by the AY 9944-mediated decreased expression of collagen X. Lastly, AY 9944 decreased the expression of Ihh in the metatarsal growth plate. We conclude that reduced cholesterol synthesis in the growth plate, possibly by altering the normal activity of Ihh, results in suppressed longitudinal bone growth and growth plate chondrogenesis.	Drexel Univ, Coll Med, St Christophers Hosp Children, Dept Pediat,Sect Endocrinol & Diabet, Philadelphia, PA 19134 USA	Drexel University	De Luca, F (corresponding author), Drexel Univ, Coll Med, St Christophers Hosp Children, Dept Pediat,Sect Endocrinol & Diabet, Erie Ave & Front St, Philadelphia, PA 19134 USA.	francesco.deluca@drexel.edu						AHARINEJAD S, 1995, ANAT REC, V242, P111, DOI 10.1002/ar.1092420115; APTE SS, 1992, EUR J BIOCHEM, V206, P217, DOI 10.1111/j.1432-1033.1992.tb16919.x; BAGI C, 1989, CALCIFIED TISSUE INT, V45, P342, DOI 10.1007/BF02556004; BAGI CM, 1992, J BONE MINER RES, V7, P29; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; De Luca F, 2001, ENDOCRINOLOGY, V142, P430, DOI 10.1210/en.142.1.430; *DEP HLTH ED WELF, 1988, DEP HLTH ED WELF PUB, V8523; FARNUM CE, 1987, ANAT REC, V219, P221, DOI 10.1002/ar.1092190303; Gofflot F, 2001, DEV DYNAM, V220, P99, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1092>3.0.CO;2-G; HUNZIKER EB, 1994, MICROSC RES TECHNIQ, V28, P505, DOI 10.1002/jemt.1070280606; IANNOTTI JP, 1990, ORTHOP CLIN N AM, V21, P1; Jeong J, 2002, J CLIN INVEST, V110, P591, DOI 10.1172/JCI200216506; Karp SJ, 2000, DEVELOPMENT, V127, P543; Kelley R I, 2000, Adv Pediatr, V47, P1; Kobayashi T, 2002, DEVELOPMENT, V129, P2977; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Lunstrum GP, 1999, J HISTOCHEM CYTOCHEM, V47, P1, DOI 10.1177/002215549904700101; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Nwokoro NA, 2001, MOL GENET METAB, V74, P105, DOI 10.1006/mgme.2001.3226; Opitz JM, 2002, PEDIATR PATHOL MOL M, V21, P153, DOI 10.1080/15227950252852078; PELTON RW, 1990, DEVELOPMENT, V110, P609; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; Roux C, 2000, AM J CLIN NUTR, V71, p1270S, DOI 10.1093/ajcn/71.5.1270s; SMITH DW, 1964, J PEDIATR-US, V64, P210, DOI 10.1016/S0022-3476(64)80264-X; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Van Der Eerden BCJ, 2000, J BONE MINER RES, V15, P1045, DOI 10.1359/jbmr.2000.15.6.1045	28	47	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4642	4647		10.1074/jbc.M305518200	http://dx.doi.org/10.1074/jbc.M305518200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14612457	hybrid			2022-12-25	WOS:000188554300086
J	Chow, KH; Courcelle, J				Chow, KH; Courcelle, J			RecO acts with RecF and RecR to protect and maintain replication forks blocked by UV-induced DNA damage in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-RECOMBINATION; BINDING-PROTEIN; ILLEGITIMATE RECOMBINATION; ULTRAVIOLET-IRRADIATION; STRAND EXCHANGE; THYMINE DIMERS; SOS RESPONSE; MUTANT; REPAIR; MUTATIONS	In Escherichia coli, recF and recR are required to stabilize and maintain replication forks arrested by UV-induced DNA damage. In the absence of RecF, replication fails to recover, and the nascent lagging strand of the arrested replication fork is extensively degraded by the RecQ helicase and RecJ nuclease. recO mutants are epistatic with recF and recR with respect to recombination and survival assays after DNA damage. In this study, we show that RecO functions with RecF and RecR to protect the nascent lagging strand of arrested replication forks after UV-irradiation. In the absence of RecO, the nascent DNA at arrested replication forks is extensively degraded and replication fails to recover. The extent of nascent DNA degradation is equivalent in single, double, or triple mutants of recF, recO, or recR, and the degradation is dependent upon RecJ and RecQ functions. Because RecF has been shown to protect the nascent lagging strand from degradation, these observations indicate that RecR and RecO function with RecF to protect the same nascent strand of the arrested replication fork and are likely to act at a common point during the recovery process. We discuss these results in relation to the biochemical and cellular properties of RecF, RecO, and RecR and their potential role in loading RecA filaments to maintain the replication fork structure after the arrest of replication by UV-induced DNA damage.	Mississippi State Univ, Dept Biol Sci, Mississippi State, MS 39762 USA	Mississippi State University	Chow, KH (corresponding author), Mississippi State Univ, Dept Biol Sci, POB GY, Mississippi State, MS 39762 USA.	kc10@msstate.edu						Courcelle J, 2003, SCIENCE, V299, P1064, DOI 10.1126/science.1081328; Courcelle J, 1999, MOL GEN GENET, V262, P543, DOI 10.1007/s004380051116; Courcelle J, 1997, P NATL ACAD SCI USA, V94, P3714, DOI 10.1073/pnas.94.8.3714; Courcelle J, 1999, J BACTERIOL, V181, P916, DOI 10.1128/JB.181.3.916-922.1999; Courcelle J, 2001, P NATL ACAD SCI USA, V98, P8196, DOI 10.1073/pnas.121008898; COX MM, 1982, J BIOL CHEM, V257, P8523; DELUCIA P, 1969, NATURE, V224, P1164, DOI 10.1038/2241164a0; Friedman KL, 1995, METHOD ENZYMOL, V262, P613; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Hanawalt P. C., 1967, P 7 INT C BIOCH JAP, P650; HEDGE SP, 1996, P NATL ACAD SCI USA, V93, P14468; HEGDE S, 1995, MOL GEN GENET, V246, P254, DOI 10.1007/BF00294689; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; HORII ZI, 1968, PHOTOCHEM PHOTOBIOL, V8, P93, DOI 10.1111/j.1751-1097.1968.tb05850.x; KOLODNER R, 1985, J BACTERIOL, V163, P1060, DOI 10.1128/JB.163.3.1060-1066.1985; KONFORTI BB, 1987, P NATL ACAD SCI USA, V84, P690, DOI 10.1073/pnas.84.3.690; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; LOVETT ST, 1984, J BACTERIOL, V157, P190, DOI 10.1128/JB.157.1.190-196.1984; LUISIDELUCA C, 1994, J MOL BIOL, V236, P124, DOI 10.1006/jmbi.1994.1123; MADIRAJU MVVS, 1988, P NATL ACAD SCI USA, V85, P6592, DOI 10.1073/pnas.85.18.6592; MADIRAJU MVVS, 1992, BIOCHEMISTRY-US, V31, P10529, DOI 10.1021/bi00158a016; MAHDI AA, 1989, MOL GEN GENET, V216, P503, DOI 10.1007/BF00334397; Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6; Murphy KC, 2000, GENE, V246, P321, DOI 10.1016/S0378-1119(00)00071-8; NAKAYAMA H, 1984, MOL GEN GENET, V195, P474, DOI 10.1007/BF00341449; Rangarajan S, 2002, MOL MICROBIOL, V43, P617, DOI 10.1046/j.1365-2958.2002.02747.x; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; SANDLER SJ, 1994, J BACTERIOL, V176, P3661, DOI 10.1128/JB.176.12.3661-3672.1994; SANDLER SJ, 1994, MOL GEN GENET, V245, P741, DOI 10.1007/BF00297281; SETLOW RB, 1963, SCIENCE, V142, P1464, DOI 10.1126/science.142.3598.1464; SETLOW RB, 1964, P NATL ACAD SCI USA, V51, P226, DOI 10.1073/pnas.51.2.226; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; SMITH KC, 1969, MUTAT RES, V8, P481, DOI 10.1016/0027-5107(69)90065-7; THOMS B, 1987, J BACTERIOL, V169, P1731, DOI 10.1128/jb.169.4.1731-1736.1987; Ukita T, 1996, J BACTERIOL, V178, P2362, DOI 10.1128/jb.178.8.2362-2367.1996; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; UMEZU K, 1994, J BIOL CHEM, V269, P30005; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; WANG TCV, 1993, MUTAT RES, V294, P157, DOI 10.1016/0921-8777(93)90024-B; Webb BL, 1997, CELL, V91, P347, DOI 10.1016/S0092-8674(00)80418-3; WHITBY MC, 1995, MOL GEN GENET, V246, P174, DOI 10.1007/BF00294680	42	69	71	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3492	3496		10.1074/jbc.M311012200	http://dx.doi.org/10.1074/jbc.M311012200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14625283	hybrid			2022-12-25	WOS:000188379600045
J	Debreceni, B; Gao, Y; Guo, FK; Zhu, KJ; Jia, BQ; Zheng, Y				Debreceni, B; Gao, Y; Guo, FK; Zhu, KJ; Jia, BQ; Zheng, Y			Mechanisms of guanine nucleotide exchange and Rac-mediated signaling revealed by a dominant negative trio mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DBL HOMOLOGY DOMAIN; ACTIN STRESS FIBERS; BINDING PROTEIN RHO; FAMILY GTPASES; CDC42 GTPASES; CELL; GROWTH; MUTAGENESIS; MG2+	Rho family GTPases play important roles in a variety of cellular processes, including actin cytoskeleton reorganization, transcription activation, and DNA synthesis. Dominant negative mutants of Rho GTPases, such as T17NRac1, that block the endogenous Rho protein activation by sequestering upstream guanine nucleotide exchange factors (GEFs) have been widely used to implicate specific members of the Rho family in various signaling pathways. We show here that such an approach could produce potentially misleading results since many Rho GEFs can interact with multiple Rho proteins promiscuously, and overexpression of one dominant negative Rho protein mutant may affect the activity of other members of the Rho family. Based on the available structural information, we have identified the highly conserved amino acid pairing of Asn(1406)Trio-Asp(65)Rac1 of the GEF-Rho GTPase interaction as the critical catalytic machinery required for the Rac1 GDP/GTP exchange reaction. The N1406A/D1407A mutant of Trio acted dominant negatively in vitro by retaining Rac1 binding activity but losing GEF catalytic activity and competitively inhibited Rac1 activation by wild type Trio. It readily blocked the platelet-derived growth factor (PDGF)-induced lamellipodia formation and inhibited the wild type Trio-induced serum response factor activation. Moreover the mutant was able to selectively inhibit Dbl-induced Rac1 activation without affecting RhoA activity in cells. In contrast to the non-discriminative inhibitory effect displayed by T17NRac1, the Trio mutant was ineffective in inhibiting PDGF-stimulated DNA synthesis and Dbl-induced transformation, revealing the Rac-independent functions of PDGF and Dbl. These studies identify a conserved pair of amino acid residues of the Trio-Rac interaction that is likely to be essential to the GEF catalysis of Rho family GTPases and demonstrate that a dominant negative mutant derived from a Rho GTPase regulator constitutes a new generation of specific inhibitors of Rho GTPase signaling pathways.	Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA; Univ Pecs, Fac Med, Dept Med Chem & Biochem, H-7624 Pecs, Hungary	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; University of Pecs	Zheng, Y (corresponding author), Childrens Hosp Res Fdn, Div Expt Hematol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	yi.zheng@chmcc.org	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060523] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 53943, GM 60523] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Bellanger JM, 1998, ONCOGENE, V16, P147, DOI 10.1038/sj.onc.1201532; Beraud-Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Cheng L, 2002, MOL CELL BIOL, V22, P6895, DOI 10.1128/MCB.22.19.6895-6905.2002; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HART MJ, 1994, J BIOL CHEM, V269, P62; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Li R, 1999, J BIOL CHEM, V274, P29648, DOI 10.1074/jbc.274.42.29648; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; VAN AL, 1997, GENE DEV, V11, P2295; Vanni C, 2002, J BIOL CHEM, V277, P19745, DOI 10.1074/jbc.M111025200; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zhang BL, 2000, J BIOL CHEM, V275, P25299, DOI 10.1074/jbc.M001027200; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zhu KJ, 2000, J BIOL CHEM, V275, P25993, DOI 10.1074/jbc.M003780200	44	42	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3777	3786		10.1074/jbc.M308282200	http://dx.doi.org/10.1074/jbc.M308282200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14597635	hybrid			2022-12-25	WOS:000188379600079
J	Goulding, CW; Apostol, MI; Gleiter, S; Parseghian, A; Bardwell, J; Gennaro, M; Eisenberg, D				Goulding, CW; Apostol, MI; Gleiter, S; Parseghian, A; Bardwell, J; Gennaro, M; Eisenberg, D			Gram-positive DsbE proteins function differently from gram-negative DsbE homologs - A structure to function analysis of DsbE from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOREDOXIN-LIKE PROTEIN; CYTOCHROME-C BIOGENESIS; THIOL-DISULFIDE OXIDOREDUCTASES; REDOX PROPERTIES; BRADYRHIZOBIUM-JAPONICUM; IN-VIVO; FOLDING CATALYST; ISOMERASE DSBA; BOND FORMATION; REVEALS	Mycobacterium tuberculosis, a Gram-positive bacterium, encodes a secreted Dsb-like protein annotated as Mtb DsbE (Rv2878c, also known as MPT53). Because Dsb proteins in Escherichia coli and other bacteria seem to catalyze proper folding during protein secretion and because folding of secreted proteins is thought to be coupled to disulfide oxidoreduction, the function of Mtb DsbE may be to ensure that secreted proteins are in their correctly folded states. We have determined the crystal structure of Mtb DsbE to 1.1 Angstrom resolution, which reveals a thioredoxin-like domain with a typical CXXC active site. These cysteines are in their reduced state. Biochemical characterization of Mtb DsbE reveals that this disulfide oxidoreductase is an oxidant, unlike Gram-negative bacteria DsbE proteins, which have been shown to be weak reductants. In addition, the pK(a) value of the active site, solvent-exposed cysteine is similar to2 pH units lower than that of Gram-negative DsbE homologs. Finally, the reduced form of Mtb DsbE is more stable than the oxidized form, and Mtb DsbE is able to oxidatively fold hirudin. Structural and biochemical analysis implies that Mtb DsbE functions differently from Gram-negative DsbE homologs, and we discuss its possible functional role in the bacterium.	Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Energy, Inst Genom & Proteom, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Publ Hlth Res Inst, Newark, NJ 07103 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Michigan System; University of Michigan	Eisenberg, D (corresponding author), Howard Hughes Med Inst, POB 951570, Los Angeles, CA 90095 USA.	david@mbi.ucla.edu		Gennaro, Maria Laura/0000-0003-4801-3567	NIGMS NIH HHS [GM646222] Funding Source: Medline; PHS HHS [20298-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; Capitani G, 2001, J MOL BIOL, V311, P1037, DOI 10.1006/jmbi.2001.4913; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P14985, DOI 10.1021/bi970071j; Collet JF, 2002, J BIOL CHEM, V277, P26886, DOI 10.1074/jbc.M203028200; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Edeling MA, 2002, STRUCTURE, V10, P973, DOI 10.1016/S0969-2126(02)00794-3; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Fabianek RA, 1999, ARCH MICROBIOL, V171, P92, DOI 10.1007/s002030050683; Fabianek RA, 1997, J BIOL CHEM, V272, P4467, DOI 10.1074/jbc.272.7.4467; Fabianek RA, 2000, FEMS MICROBIOL REV, V24, P303, DOI 10.1111/j.1574-6976.2000.tb00544.x; Goulding Celia W., 2002, Current Drug Targets - Infectious Disorders, V2, P121, DOI 10.2174/1568005023342551; Goulding CW, 2003, BIOPHYS CHEM, V105, P361, DOI 10.1016/S0301-4622(03)00101-7; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; Grove J, 1996, MOL GEN GENET, V252, P332; Guddat LW, 1998, STRUCT FOLD DES, V6, P757, DOI 10.1016/S0969-2126(98)00077-X; Hennecke J, 1999, J MOL BIOL, V286, P1197, DOI 10.1006/jmbi.1998.2531; Hennecke J, 1997, J BIOL CHEM, V272, P189; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hu SH, 1997, J MOL BIOL, V268, P137, DOI 10.1006/jmbi.1997.0940; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; Kranz RG, 2002, RES MICROBIOL, V153, P1, DOI 10.1016/S0923-2508(01)01278-5; Li Q, 2001, BIOCHEM BIOPH RES CO, V283, P849, DOI 10.1006/bbrc.2001.4876; LOFERER H, 1995, J BIOL CHEM, V270, P26178, DOI 10.1074/jbc.270.44.26178; Manca C, 1997, INFECT IMMUN, V65, P16, DOI 10.1128/IAI.65.1.16-23.1997; Manning PA, 1997, GENE, V192, P63, DOI 10.1016/S0378-1119(97)00036-X; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MISSIAKAS D, 1993, P NATL ACAD SCI USA, V90, P7084, DOI 10.1073/pnas.90.15.7084; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; Mossner E, 1998, PROTEIN SCI, V7, P1233; Nooren IMA, 2003, J MOL BIOL, V325, P991, DOI 10.1016/S0022-2836(02)01281-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; Reid E, 2001, BIOCHEM J, V355, P51, DOI 10.1042/0264-6021:3550051; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; Rossmann R, 1997, FEBS LETT, V406, P249, DOI 10.1016/S0014-5793(97)00270-6; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Schroder E, 1998, PROTEIN SCI, V7, P2465, DOI 10.1002/pro.5560071125; Setterdahl AT, 2000, BIOCHEMISTRY-US, V39, P10172, DOI 10.1021/bi000663t; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; Stewart EJ, 1999, EMBO J, V18, P5963, DOI 10.1093/emboj/18.21.5963; Thony-Meyer L, 2002, BIOCHEM SOC T, V30, P633; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Wiker HG, 1999, MICROB PATHOGENESIS, V26, P207, DOI 10.1006/mpat.1998.0267; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, 1993, J MOL BIOL, V233, P559, DOI 10.1006/jmbi.1993.1535; Yu J, 1999, MICROBES INFECT, V1, P1221, DOI 10.1016/S1286-4579(99)00239-7; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; ZavYalov VP, 1997, BIOCHEM J, V324, P571, DOI 10.1042/bj3240571; Zhang HZ, 1996, MOL MICROBIOL, V21, P787, DOI 10.1046/j.1365-2958.1996.431403.x	57	59	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3516	3524		10.1074/jbc.M311833200	http://dx.doi.org/10.1074/jbc.M311833200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14597624	hybrid			2022-12-25	WOS:000188379600048
J	Jiang, Y; Li, H; Zhu, L; Zhou, JM; Perrett, S				Jiang, Y; Li, H; Zhu, L; Zhou, JM; Perrett, S			Amyloid nucleation and hierarchical assembly of Ure2p fibrils - Role of asparagine/glutamine repeat and nonrepeat regions of the prion domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; NEURODEGENERATIVE DISEASES; PROTEIN DETERMINANT; ALZHEIMERS-DISEASE; YEAST; AGGREGATION; MECHANISM; GLUTAMINE; FIBERS; MODEL	The yeast prion protein Ure2 forms amyloid-like filaments in vivo and in vitro. This ability depends on the N-terminal prion domain, which contains Asn/Gln repeats, a motif thought to cause human disease by forming stable protein aggregates. The Asn/Gln region of the Ure2p prion domain extends to residue 89, but residues 15-42 represent an island of "normal" random sequence, which is highly conserved in related species and is relatively hydrophobic. We compare the time course of structural changes monitored by thioflavin T (ThT) binding fluorescence and atomic force microscopy for Ure2 and a series of prion domain mutants under a range of conditions. Atomic force microscopy height images at successive time points during a single growth experiment showed the sequential appearance of at least four fibril types that could be readily differentiated by height (5, 8, 12, or 9 nm), morphology (twisted or smooth), and/or time of appearance (early or late in the plateau phase of ThT binding). The Ure2 dimer (h=2.6+/-0.5 nm) and granular particles corresponding to higher order oligomers (h=4-12 nm) could also be detected. The mutants 15Ure2 and Delta15-42Ure2 showed the same time-dependent variation in fibril types but with an increased lag time detected by ThT binding compared with wild-type Ure2. In addition, Delta15-42Ure2 showed reduced binding to ThT. The results imply a role of the conserved region in both amyloid nucleation and formation of the binding surface recognized by ThT. Further, Ure2 amyloid formation is a multistep process via a series of fibrillar intermediates.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Chinese Acad Sci, Inst Phys, Ctr Condensed Matter, State Key Lab Magnetism, Beijing 100080, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Institute of Physics, CAS	Zhou, JM (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd,Chaoyang Dist, Beijing 100101, Peoples R China.	zhoujm@sun5.ibp.ac.cn; sarah.perrett@iname.com	Perrett, Sarah/AAS-9483-2020	Perrett, Sarah/0000-0003-0137-0997				Balbirnie M, 2001, P NATL ACAD SCI USA, V98, P2375, DOI 10.1073/pnas.041617698; Baxa U, 2003, J BIOL CHEM, V278, P43717, DOI 10.1074/jbc.M306004200; Baxa U, 2002, P NATL ACAD SCI USA, V99, P5253, DOI 10.1073/pnas.082097899; Bousset L, 2003, J STRUCT BIOL, V141, P132, DOI 10.1016/S1047-8477(02)00606-8; Bousset L, 2002, EMBO J, V21, P2903, DOI 10.1093/emboj/cdf303; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chamberlain AK, 2000, BIOPHYS J, V79, P3282, DOI 10.1016/S0006-3495(00)76560-X; Chen S, 2001, J MOL BIOL, V311, P173, DOI 10.1006/jmbi.2001.4850; Chen SM, 2002, BIOCHEMISTRY-US, V41, P7391, DOI 10.1021/bi011772q; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; Edskes HK, 2002, P NATL ACAD SCI USA, V99, P16384, DOI 10.1073/pnas.162349599; Edskes HK, 1999, P NATL ACAD SCI USA, V96, P1498, DOI 10.1073/pnas.96.4.1498; Galani D, 2002, J MOL BIOL, V315, P213, DOI 10.1006/jmbi.2001.5234; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Goldsbury C, 1999, J MOL BIOL, V285, P33, DOI 10.1006/jmbi.1998.2299; Haass C, 2001, NAT NEUROSCI, V4, P859, DOI 10.1038/nn0901-859; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Ionescu-Zanetti C, 1999, P NATL ACAD SCI USA, V96, P13175, DOI 10.1073/pnas.96.23.13175; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kad NM, 2003, J MOL BIOL, V330, P785, DOI 10.1016/S0022-2836(03)00583-7; Kelly JW, 2000, NAT STRUCT BIOL, V7, P824, DOI 10.1038/82815; Khurana R, 2003, BIOPHYS J, V85, P1135, DOI 10.1016/S0006-3495(03)74550-0; Khurana R, 2001, J BIOL CHEM, V276, P22715, DOI 10.1074/jbc.M011499200; LESSER GJ, 1990, PROTEINS, V8, P6, DOI 10.1002/prot.340080104; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Li X, 2001, PROTEINS, V42, P1, DOI 10.1002/1097-0134(20010101)42:1<1::AID-PROT10>3.0.CO;2-N; MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93; Masison DC, 1997, P NATL ACAD SCI USA, V94, P12503, DOI 10.1073/pnas.94.23.12503; Muller DJ, 1997, J STRUCT BIOL, V119, P172, DOI 10.1006/jsbi.1997.3875; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Perrett S, 1999, J MOL BIOL, V290, P331, DOI 10.1006/jmbi.1999.2872; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; Perutz MF, 2001, NATURE, V412, P143, DOI 10.1038/35084141; Perutz MF, 2002, P NATL ACAD SCI USA, V99, P5596, DOI 10.1073/pnas.042681599; Perutz MF, 2002, P NATL ACAD SCI USA, V99, P5591, DOI 10.1073/pnas.042681399; PERUTZ MF, 1994, P NATL ACAD SCI USA, V92, P6509; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Schlumpberger M, 2000, PROTEIN SCI, V9, P440; Serio TR, 2002, ADV PROTEIN CHEM, V59, P391; Speransky VV, 2001, J CELL BIOL, V153, P1327, DOI 10.1083/jcb.153.6.1327; Stine WB, 1996, J PROTEIN CHEM, V15, P193, DOI 10.1007/BF01887400; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; Thakur AK, 2002, P NATL ACAD SCI USA, V99, P17014, DOI 10.1073/pnas.252523899; Thual C, 1999, J BIOL CHEM, V274, P13666, DOI 10.1074/jbc.274.19.13666; Thual C, 2001, BIOCHEMISTRY-US, V40, P1764, DOI 10.1021/bi001916l; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Zhou JM, 2001, BIOCHEM BIOPH RES CO, V287, P147, DOI 10.1006/bbrc.2001.5556; Zhu L, 2003, BIOCHEM BIOPH RES CO, V311, P525, DOI 10.1016/j.bbrc.2003.10.027; Zhu L, 2003, J MOL BIOL, V328, P235, DOI 10.1016/S0022-2836(03)00249-3	53	53	56	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3361	3369		10.1074/jbc.M310494200	http://dx.doi.org/10.1074/jbc.M310494200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14610069	hybrid			2022-12-25	WOS:000188379600028
J	Kamaraju, AK; Adjalley, S; Zhang, PL; Chebath, J; Revel, M				Kamaraju, AK; Adjalley, S; Zhang, PL; Chebath, J; Revel, M			C/EBP-delta induction by gp130 signaling - Role in transition to myelin gene expressing phenotype in a melanoma cell line model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN BETA; TRANSCRIPTION FACTOR; NEURAL CREST; MICE LACKING; INTERLEUKIN-6; FAMILY; PAX3; ACTIVATION; REGULATOR; MITF	Expression of genes encoding structural myelin proteins marks the inception of the myelinating Schwann cell (SC) phenotype. Earlier embryonic SC as well as adult non-myelinating SC produce the intermediate filament glial fibrillary acid protein (GFAP), which disappears from the myelinating SC. We previously observed that triggering of the gp130 receptor system by the IL6RIL6 ligand, comprising interleukin-6 (IL-6) fused to the soluble IL-6 receptor, induces myelin gene expression in rat embryonic dorsal root ganglia (DRG) cultures as well as in the murine melanoma cell line B16/F10.9. Study of target genes regulated by IL6RIL6 indicates a strong and selective induction of the transcriptional regulator C/EBP-delta in DRG cultures and in the F10.9 cell line. As shown here, silencing of C/EBP-delta mRNA and protein expression by introduction of small interference RNA-producing plasmids in the F10.9 cells prevented the induction of myelin protein zero (P0) and myelin basic protein (MBP) mRNAs by IL6RIL6. Doxycycline-regulated overexpression of C/EBP-delta was sufficient to induce accumulation of P0 and MBP mRNAs, the effect being selective, because C/EBP-delta did not affect several other genes strongly regulated by IL6RIL6. Interestingly, GFAP was inhibited by C/EBP-delta overexpression, leading to a modulation of the ratio between myelin gene products versus GFAP and suggesting that C/EBP-delta plays a role in the switch to a myelinating phenotype. The down-regulation of Pax3, also typical of the transition to myelinating cells, was observed after C/EBP-delta expression in correlation to P0 induction and to decrease of melanogenesis and cell growth. In cultures of dissociated cells of embryonic rat DRG, where we knocked-down the C/EBP-delta mRNA, we found an inhibition of P0 mRNA induction by IL6RIL6, showing that the role of C/EBP-delta on this myelin gene is not unique to the melanoma system.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Revel, M (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	michel.revel@weizmann.ac.il		Chebath, Judith/0000-0002-8151-7428				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; Alonzi T, 1997, IMMUNOBIOLOGY, V198, P144, DOI 10.1016/S0171-2985(97)80035-6; BERRY SA, 1999, AM J PHYSIOL, V276, pE1374; Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Charles A, 2001, J CELL BIOCHEM, V83, P414, DOI 10.1002/jcb.1239; Chebath J, 1997, EUR CYTOKINE NETW, V8, P359; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Dearth LR, 2003, J BIOL CHEM, V278, P11246, DOI 10.1074/jbc.M207930200; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Durda PJ, 2003, MOL CANCER RES, V1, P411; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; Gigliotti AP, 2003, EXP BIOL MED, V228, P278, DOI 10.1177/153537020322800306; Goding CR, 2000, GENE DEV, V14, P1712; Haggiag S, 2001, J NEUROSCI RES, V64, P564, DOI 10.1002/jnr.1108; Haggiag S, 1999, FEBS LETT, V457, P200, DOI 10.1016/S0014-5793(99)01040-6; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; JESSEN KR, 1990, DEVELOPMENT, V109, P91; Jessen KR, 1998, MICROSC RES TECHNIQ, V41, P393, DOI 10.1002/(SICI)1097-0029(19980601)41:5<393::AID-JEMT6>3.0.CO;2-R; Jung N, 2000, EUR J BIOCHEM, V267, P6180, DOI 10.1046/j.1432-1327.2000.01692.x; Kamaraju AK, 2002, J BIOL CHEM, V277, P15132, DOI 10.1074/jbc.M200004200; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KIOUSSI C, 1995, NEURON, V15, P553, DOI 10.1016/0896-6273(95)90144-2; Kioussi C, 1996, TRENDS GENET, V12, P84, DOI 10.1016/0168-9525(96)81411-9; Martinez-Esparza M, 2001, INT J BIOCHEM CELL B, V33, P971, DOI 10.1016/S1357-2725(01)00068-1; Martinez-Esparza M, 1999, CELL MOL BIOL, V45, P991; McKnight SL, 2001, CELL, V107, P259, DOI 10.1016/S0092-8674(01)00543-8; Menard C, 2002, NEURON, V36, P597, DOI 10.1016/S0896-6273(02)01026-7; MONUKI ES, 1993, MECH DEVELOP, V42, P15, DOI 10.1016/0925-4773(93)90095-F; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Nakashima K, 1999, J NEUROSCI, V19, P5429; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PORGADOR A, 1989, J IMMUNOGENET, V16, P291; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; RAMJI DP, 1994, BIOCHEM SOC T, V22, pS358, DOI 10.1042/bst022358s; Saito H, 2003, PIGM CELL RES, V16, P261, DOI 10.1034/j.1600-0749.2003.00039.x; Scholl FA, 2001, CANCER RES, V61, P823; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Slutsky SG, 2003, J BIOL CHEM, V278, P8960, DOI 10.1074/jbc.M210569200; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; Sterneck E, 1998, P NATL ACAD SCI USA, V95, P10908, DOI 10.1073/pnas.95.18.10908; Sterneck E, 1998, J NEUROCHEM, V70, P2424; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Zorick TS, 1996, CURR OPIN CELL BIOL, V8, P870, DOI 10.1016/S0955-0674(96)80090-1	57	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3852	3861		10.1074/jbc.M310443200	http://dx.doi.org/10.1074/jbc.M310443200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14600146	hybrid			2022-12-25	WOS:000188379600087
J	Kikkert, M; Doolman, R; Dai, M; Avner, R; Hassink, G; van Voorden, S; Thanedar, S; Roitelman, J; Chau, V; Wiertz, E				Kikkert, M; Doolman, R; Dai, M; Avner, R; Hassink, G; van Voorden, S; Thanedar, S; Roitelman, J; Chau, V; Wiertz, E			Human HRD1 is an E3 ubiquitin ligase involved in degradation of proteins from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-COA REDUCTASE; MOTILITY FACTOR-RECEPTOR; T-CELL-RECEPTOR; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; REGULATED DEGRADATION; MULTIUBIQUITIN CHAIN; APOLIPOPROTEIN B100; PROTEASOME PATHWAY; QUALITY-CONTROL; ER	The ubiquitin system plays an important role in endoplasmic reticulum (ER)-associated degradation of proteins that are misfolded, that fail to associate with their oligomerization partners, or whose levels are metabolically regulated. E3 ubiquitin ligases are key enzymes in the ubiquitination process as they recognize the substrate and facilitate coupling of multiple ubiquitin units to the protein that is to be degraded. The Saccharomyces cerevisiae ER-resident E3 ligase Hrd1p/Der3p functions in the metabolically regulated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and additionally facilitates the degradation of a number of misfolded proteins from the ER. In this study we characterized the structure and function of the putative human orthologue of yeast Hrd1p/Der3p, designated human HRD1. We show that human HRD1 is a nonglycosylated, stable ER protein with a cytosolic RING-H2 finger domain. In the presence of the ubiquitin-conjugating enzyme UBC7, the RING-H2 finger has in vitro ubiquitination activity for Lys(48)-specific polyubiquitin linkage, suggesting that human HRD1 is an E3 ubiquitin ligase involved in protein degradation. Human HRD1 appears to be involved in the basal degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase but not in the degradation that is regulated by sterols. Additionally we show that human HRD1 is involved in the elimination of two model ER-associated degradation substrates, TCR-alpha and CD3-delta.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Leiden Univ, Med Ctr, Dept Med Microbiol, NL-2300 RC Leiden, Netherlands; Chaim Sheba Med Ctr, Inst Lipid & Atherosclerosis Res, IL-52621 Tel Hashomer, Israel	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Chaim Sheba Medical Center	Chau, V (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA.	vchau@psu.edu	Kikkert, Marjolein/AAK-5514-2020	Kikkert, Marjolein/0000-0002-5779-7386	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062194] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62194] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cook WJ, 1997, BIOCHEMISTRY-US, V36, P1621, DOI 10.1021/bi962639e; Coscoy L, 2003, TRENDS CELL BIOL, V13, P7, DOI 10.1016/S0962-8924(02)00005-3; de Virgilio M, 1999, MOL BIOL CELL, V10, P4059, DOI 10.1091/mbc.10.12.4059; Deak PM, 2001, J BIOL CHEM, V276, P10663, DOI 10.1074/jbc.M008608200; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Gardner RG, 2001, MOL CELL BIOL, V21, P4276, DOI 10.1128/MCB.21.13.4276-4291.2001; Gardner RG, 2000, J CELL BIOL, V151, P69, DOI 10.1083/jcb.151.1.69; Gardner RG, 1999, J BIOL CHEM, V274, P31671, DOI 10.1074/jbc.274.44.31671; Gardner RG, 2001, J BIOL CHEM, V276, P8681, DOI 10.1074/jbc.M007888200; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HAAS AL, 1991, J BIOL CHEM, V266, P5104; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Haynes CM, 2002, J CELL BIOL, V158, P91, DOI 10.1083/jcb.200201053; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kaneko M, 2002, FEBS LETT, V532, P147, DOI 10.1016/S0014-5793(02)03660-8; Kikkert M, 2001, BIOCHEM J, V358, P369, DOI 10.1042/0264-6021:3580369; Kikuno R, 2002, NUCLEIC ACIDS RES, V30, P166, DOI 10.1093/nar/30.1.166; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEW AM, 1987, J IMMUNOL, V138, P807; Liang JS, 2003, J BIOL CHEM, V278, P23984, DOI 10.1074/jbc.M302683200; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Nadav E, 2003, BIOCHEM BIOPH RES CO, V303, P91, DOI 10.1016/S0006-291X(03)00279-1; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Ponting CP, 2000, BIOCHEM J, V351, P527, DOI 10.1042/0264-6021:3510527; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Ravid T, 2000, J BIOL CHEM, V275, P35840, DOI 10.1074/jbc.M004793200; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; Shamu CE, 2001, MOL BIOL CELL, V12, P2546, DOI 10.1091/mbc.12.8.2546; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; Swanson R, 2001, GENE DEV, V15, P2660, DOI 10.1101/gad.933301; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Xu LW, 2003, ARCH BIOCHEM BIOPHYS, V414, P232, DOI 10.1016/S0003-9861(03)00168-1; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890; Zhou MY, 1999, MOL CELL, V4, P925, DOI 10.1016/S1097-2765(00)80222-1	55	279	290	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3525	3534		10.1074/jbc.M307453200	http://dx.doi.org/10.1074/jbc.M307453200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14593114	hybrid			2022-12-25	WOS:000188379600049
J	Loland, CJ; Granas, C; Javitch, JA; Gether, U				Loland, CJ; Granas, C; Javitch, JA; Gether, U			Identification of intracellular residues in the dopamine transporter critical for regulation of transporter conformation and cocaine binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTONIN TRANSPORTER; BETA(2)-ADRENERGIC RECEPTOR; SUBSTANCE-P; ACCESSIBILITY; EXPRESSION; SITE; OLIGOMERIZATION; DOMAINS; ACID; INTERNALIZATION	Recently we showed evidence that mutation of Tyr-335 to Ala (Y335A) in the human dopamine transporter (hDAT) alters the conformational equilibrium of the transport cycle. Here, by substituting, one at a time, 16 different bulky or charged intracellular residues, we identify three residues, Lys-264, Asp-345, and Asp-436, the mutation of which to alanine produces a phenotype similar to that of Y335A. Like Y335A, the mutants (K264A, D345A, and D436A) were characterized by low uptake capacity that was potentiated by Zn2+. Moreover, the mutants displayed lower affinity for cocaine and other inhibitors, suggesting a role for these residues in maintaining the structural integrity of the inhibitor binding crevice. The conformational state of K264A, Y335A, and D345A was investigated by assessing the accessibility to MTSET ([2-(trimethylammonium)ethyl]methanethiosulfonate) of a cysteine engineered into position 159 (I159C) in transmembrane segment 3 of the MTSET-insensitive "E2C" background (C90A/C306A). Unlike its effect at the corresponding position in the homologous norepinephrine transporter (NET I155C), MTSET did not inhibit uptake mediated by E2C I159C. Furthermore, no inhibition was observed upon treatment with MTSET in the presence of dopamine, cocaine, or Zn2+. Without Zn2+, E2C I159C/K264A, E2C I159C/Y335A, and E2C I159C/D345A were also not inactivated by MTSET. In the presence of Zn2+ (10 muM), however, MTSET (0.5 mM) caused up to similar to60% inactivation. As in NET I155C, this inactivation was protected by dopamine and enhanced by cocaine. These data are consistent with a Zn2+-dependent partial reversal of a constitutively altered conformational equilibrium in the mutant transporters. They also suggest that the conformational equilibrium produced by the mutations resembles that of the NET more than that of the DAT. Moreover, the data provide evidence that the cocaine-bound state of both DAT mutants and of the NET is structurally distinct from the cocaine-bound state of the DAT.	Univ Copenhagen, Panum Inst, Mol Neuropharmacol Grp, Dept Pharmacol, DK-2200 Copenhagen N, Denmark; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	University of Copenhagen; Columbia University; Columbia University	Gether, U (corresponding author), Univ Copenhagen, Panum Inst, Mol Neuropharmacol Grp, Dept Pharmacol, DK-2200 Copenhagen N, Denmark.	gether@neuropharm.ku.dk	Loland, Claus/E-5975-2014	Loland, Claus/0000-0002-1773-1446; Gether, Ulrik/0000-0002-0020-3807; Javitch, Jonathan/0000-0001-7395-2967	NIDA NIH HHS [DA 11495, P01 DA 12408] Funding Source: Medline; NIMH NIH HHS [MH 57324] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011495, P01DA012408] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Androutsellis-Theotokis A, 2002, J NEUROSCI, V22, P8370; Androutsellis-Theotokis A, 2001, J BIOL CHEM, V276, P45933, DOI 10.1074/jbc.M107462200; ARNIS S, 1994, J BIOL CHEM, V269, P23879; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Blakely RD, 2000, CURR OPIN NEUROBIOL, V10, P328, DOI 10.1016/S0959-4388(00)00088-X; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen NH, 2000, EUR J PHARMACOL, V405, P329, DOI 10.1016/S0014-2999(00)00563-X; Chen NH, 2000, J BIOL CHEM, V275, P1608, DOI 10.1074/jbc.275.3.1608; Chen NH, 2001, J NEUROCHEM, V77, P1116, DOI 10.1046/j.1471-4159.2001.00312.x; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; Gainetdinov RR, 2003, ANNU REV PHARMACOL, V43, P261, DOI 10.1146/annurev.pharmtox.43.050802.112309; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; GETHER U, 1992, FEBS LETT, V296, P241, DOI 10.1016/0014-5793(92)80295-R; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GIROS B, 1992, MOL PHARMACOL, V42, P383; GOLDBERG NR, 2003, STRATEGIES MOL NEURO, P213; Granas C, 2003, J BIOL CHEM, V278, P4990, DOI 10.1074/jbc.M205058200; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Itokawa M, 2000, MOL PHARMACOL, V57, P1093; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Lin ZC, 2000, FASEB J, V14, P715, DOI 10.1096/fasebj.14.5.715; Lin ZC, 2002, MOL PHARMACOL, V61, P885, DOI 10.1124/mol.61.4.885; Loland CJ, 2002, P NATL ACAD SCI USA, V99, P1683, DOI 10.1073/pnas.032386299; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; MacAulay N, 2003, J BIOL CHEM, V278, P28771, DOI 10.1074/jbc.M213023200; Norgaard-Nielsen K, 2002, FEBS LETT, V524, P87, DOI 10.1016/S0014-5793(02)03008-9; Norregaard L, 2001, Curr Opin Drug Discov Devel, V4, P591; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Norregaard L, 2000, BIOCHEMISTRY-US, V39, P15836, DOI 10.1021/bi0018335; Reith MEA, 2001, J BIOL CHEM, V276, P29012, DOI 10.1074/jbc.M011785200; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Vaughan RA, 2001, MOL PHARMACOL, V59, P1157, DOI 10.1124/mol.59.5.1157; Wu XH, 2003, MOL PHARMACOL, V63, P653, DOI 10.1124/mol.63.3.653; Zou MF, 2001, J MED CHEM, V44, P4453, DOI 10.1021/jm0101904	42	77	77	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3228	3238		10.1074/jbc.M304755200	http://dx.doi.org/10.1074/jbc.M304755200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14597628	hybrid			2022-12-25	WOS:000188379600013
J	Bruce, LJ; Pan, RJ; Cope, DL; Uchikawa, M; Gunn, RB; Cherry, RJ; Tanner, MJA				Bruce, LJ; Pan, RJ; Cope, DL; Uchikawa, M; Gunn, RB; Cherry, RJ; Tanner, MJA			Altered structure and anion transport properties of band 3 (AE1, SLC4A1) in human red cells lacking glycophorin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANES; RENAL TUBULAR-ACIDOSIS; BLOOD-CELLS; ACTIVE SIALOGLYCOPROTEINS; XENOPUS-OOCYTES; PROTEIN; ANTIBODIES; SITE; EXPRESSION; DIFFUSION	We have studied the properties of band 3 in different glycophorin A (GPA)-deficient red cells. These red cells lack either both GPA and glycophorin B (GPB) ((MMk)-M-k cells) or GPA ( En(a-) cells) or contain a hybrid of GPA and GPB (MiV cells). Sulfate transport was reduced in all three red cell types to similar to 60% of that in normal control red cells as a result of an increased apparent K-m for sulfate. Transport of the monovalent anions iodide and chloride was also reduced. The reduced iodide transport resulted from a reduction in the V-max for iodide transport. The anion transport site was investigated by measuring iodide fluorescence quenching of eosin-5-maleimide (EMA)-labeled band 3. The GPA-deficient cells had a normal K-d for iodide binding, in agreement with the unchanged K-m found in transport studies. However, the apparent diffusion quenching constant (K-q) was increased, and the fluorescence polarization of band 3-bound EMA decreased in the variant cells, suggesting increased flexibility of the protein in the region of the EMA-binding site. This increased flexibility is probably associated with the decrease in V-max observed for iodide transport. Our results suggest that band 3 in the red cell can take up two different structures: one with high anion transport activity when GPA is present and one with lower anion transport activity when GPA is absent.	Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England; Univ Essex, Dept Biol Sci, Colchester CO4 3SQ, Essex, England; Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QQ, England; Japanese Red Cross, Tokyo Blood Ctr, Tokyo 1500012, Japan; Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA	University of Bristol; University of Essex; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Japanese Red Cross Medical Center; Emory University	Bruce, LJ (corresponding author), Bristol Inst Transfus Sci, Southmead Rd, Bristol BS10 5NB, Avon, England.	lesley.bruce@nbs.nhs.uk		Bruce, Lesley/0000-0001-5922-7072	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066173] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-66173] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANSTEE DJ, 1981, SEMIN HEMATOL, V18, P13; Auffray I, 2001, BLOOD, V97, P2872, DOI 10.1182/blood.V97.9.2872; BRUCE LJ, 1994, BLOOD, V84, P916; BRUCE LJ, 1995, BLOOD, V85, P541; Bruce LJ, 2003, BLOOD, V101, P4180, DOI 10.1182/blood-2002-09-2824; CARTRON J-P, 1992, Transfusion Medicine Reviews, V6, P63, DOI 10.1016/S0887-7963(92)70158-8; CASEY JR, 1992, J BIOL CHEM, V267, P11940; CHE A, 1995, BIOPHYS J, V68, P1881, DOI 10.1016/S0006-3495(95)80365-6; COBB CE, 1990, BIOCHEMISTRY-US, V29, P8283, DOI 10.1021/bi00488a012; GAHMBERG CG, 1976, J BIOL CHEM, V251, P6108; GARDNER B, 1989, IMMUNOLOGY, V68, P283; GROVES JD, 1994, J MEMBRANE BIOL, V140, P81; GROVES JD, 1992, J BIOL CHEM, V267, P22163; GUNN RB, 1989, METHOD ENZYMOL, V173, P54; Hassoun H, 1998, BLOOD, V91, P2146, DOI 10.1182/blood.V91.6.2146.2146_2146_2151; KNOWLES DW, 1994, BIOPHYS J, V66, P1726, DOI 10.1016/S0006-3495(94)80965-8; MACARA IG, 1983, J BIOL CHEM, V258, P1785; MILANICK MA, 1982, J GEN PHYSIOL, V79, P87, DOI 10.1085/jgp.79.1.87; NIGG EA, 1979, BIOCHEMISTRY-US, V18, P3457, DOI 10.1021/bi00583a004; NIGG EA, 1980, BIOCHEMISTRY-US, V19, P1887, DOI 10.1021/bi00550a024; OIKAWA K, 1985, BIOCHEMISTRY-US, V24, P2843, DOI 10.1021/bi00333a005; OKUBO Y, 1988, VOX SANG, V54, P107, DOI 10.1111/j.1423-0410.1988.tb01626.x; PAN RJ, 1995, BIOCHEMISTRY-US, V34, P4880, DOI 10.1021/bi00014a045; PASSOW H, 1986, REV PHYSIOL BIOCH P, V103, P61; PAULITSCHKE M, 1995, BLOOD, V86, P342, DOI 10.1182/blood.V86.1.342.bloodjournal861342; Ribeiro ML, 2000, BLOOD, V96, P1602; RING SM, 1994, VOX SANG, V67, P226, DOI 10.1111/j.1423-0410.1994.tb01665.x; SCHOFIELD AE, 1992, NATURE, V355, P836, DOI 10.1038/355836a0; TANNER MJA, 1976, BIOCHEM J, V155, P701, DOI 10.1042/bj1550701; Tanphaichitr VS, 1998, J CLIN INVEST, V102, P2173, DOI 10.1172/JCI4836; TELEN MJ, 1990, BLOOD, V76, P842; TOKUNAGA E, 1979, J IMMUNOGENET, V6, P383; VENGELENTYLER V, 1981, TRANSFUSION, V21, P1; WAINWRIGHT SD, 1989, BIOCHEM J, V258, P211, DOI 10.1042/bj2580211; Wang L, 1997, J BIOL CHEM, V272, P10631; Young MT, 2003, J BIOL CHEM, V278, P32954, DOI 10.1074/jbc.M302527200; Young MT, 2000, BIOCHEM J, V350, P53, DOI 10.1042/0264-6021:3500053	37	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2414	2420		10.1074/jbc.M309826200	http://dx.doi.org/10.1074/jbc.M309826200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14604989	hybrid			2022-12-25	WOS:000188211300012
J	Dong, MQ; Li, ZJ; Pinon, DI; Lybrand, TP; Miller, LJ				Dong, MQ; Li, ZJ; Pinon, DI; Lybrand, TP; Miller, LJ			Spatial approximation between the amino terminus of a peptide agonist and the top of the sixth transmembrane segment of the secretin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARATHYROID-HORMONE-RECEPTOR; DIRECT IDENTIFICATION; EXTRACELLULAR DOMAIN; BINDING DOMAIN; DISTINCT SITE; RESIDUE; CHOLECYSTOKININ; DETERMINANTS; ACTIVATION; LIGAND	Distinct spatial approximations between residues within the secretin pharmacophore and its receptor can provide important constraints for modeling this agonist-receptor complex. We previously used a series of probes incorporating photolabile residues into positions 6, 12, 13, 14, 18, 22, and 26 of the 27-residue peptide and demonstrated that each covalently labeled a site within the receptor amino terminus. Although supporting a critical role of this domain for ligand binding, it does not explain the molecular mechanism of receptor activation. Here, we developed probes having photolabile residues at the amino terminus of secretin to explore possible approximations with a different receptor domain. The first probe incorporated a photolabile p-benzoyl-L-phenylalanine into the position of His(1) of rat secretin ([Bpa(1), Tyr(10)] secretin-27). Because His(1) is critical for function, we also positioned a photolabile Bpa as an amino-terminal extension, in positions -1 ( rat [Bpa(-1), Tyr(10)] secretin-27) and -2 ( rat [Bpa(-2), Gly(-1),Tyr(10)] secretin-27). Each analog was shown to be a full agonist, stimulating cAMP accumulation in receptor-bearing Chinese hamster ovary-SecR cells in a concentration-dependent manner, with the position -2 probe being most potent. They bound specifically and saturably, although the position 1 analog had lowest affinity, and all were able to label the receptor efficiently. Sequential specific cleavage, purification, and sequencing demonstrated that the sites of covalent attachment for each probe were high within the sixth transmembrane segment. This suggests that secretin binding may exert tension between the receptor amino terminus and the transmembrane domain to elicit a conformational change effecting receptor activation.	Mayo Clin Scottsdale, Ctr Canc, Scottsdale, AZ 85259 USA; Mayo Clin Scottsdale, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA; Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Struct Biol, Nashville, TN 37232 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix; Vanderbilt University; Vanderbilt University	Miller, LJ (corresponding author), Mayo Clin Scottsdale, Ctr Canc, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	miller@mayo.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033290] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46577] Funding Source: Medline; NINDS NIH HHS [NS-33290] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Asmann YW, 2000, MOL PHARMACOL, V58, P911, DOI 10.1124/mol.58.5.911; Bazarsuren A, 2002, BIOPHYS CHEM, V96, P305, DOI 10.1016/S0301-4622(02)00023-6; Behar V, 2000, J BIOL CHEM, V275, P9, DOI 10.1074/jbc.275.1.9; Behar V, 1999, ENDOCRINOLOGY, V140, P4251, DOI 10.1210/en.140.9.4251; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; Case D. A., 2002, AMBER 7; *CHEM COMP GROUP I, 1997, MOE 2001 01; CLORE GM, 1988, EUR J BIOCHEM, V171, P479, DOI 10.1111/j.1432-1033.1988.tb13814.x; Dong MQ, 2000, J BIOL CHEM, V275, P26032, DOI 10.1074/jbc.M000612200; Dong MQ, 2003, J BIOL CHEM, V278, P48300, DOI 10.1074/jbc.M309166200; Dong MQ, 1999, J BIOL CHEM, V274, P19161, DOI 10.1074/jbc.274.27.19161; Dong MQ, 2002, MOL ENDOCRINOL, V16, P2490, DOI 10.1210/me.2002-0111; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; Donnelly D, 1997, FEBS LETT, V409, P431, DOI 10.1016/S0014-5793(97)00546-2; Frimurer TM, 1999, PROTEINS, V35, P375, DOI 10.1002/(SICI)1097-0134(19990601)35:4<375::AID-PROT1>3.0.CO;2-2; Ganguli SC, 1998, J PHARMACOL EXP THER, V286, P593; GARDELLA TJ, 1994, ENDOCRINOLOGY, V135, P1186, DOI 10.1210/en.135.3.1186; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; GREGORET LM, 1990, J MOL BIOL, V211, P959, DOI 10.1016/0022-2836(90)90086-2; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; HEFFORD MA, 1989, BIOCHIM BIOPHYS ACTA, V998, P267, DOI 10.1016/0167-4838(89)90283-5; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; Horn F, 1998, RECEPTOR CHANNEL, V5, P305; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; Konopka JB, 1996, P NATL ACAD SCI USA, V93, P6764, DOI 10.1073/pnas.93.13.6764; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; Mannstadt M, 1999, AM J PHYSIOL-RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pellegrini M, 1998, BIOCHEMISTRY-US, V37, P12737, DOI 10.1021/bi981265h; Perrin MH, 2001, J BIOL CHEM, V276, P31528, DOI 10.1074/jbc.M101838200; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; Qi LJ, 1997, BIOCHEMISTRY-US, V36, P12442, DOI 10.1021/bi970997r; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Spalding TA, 1997, BIOCHEMISTRY-US, V36, P10109, DOI 10.1021/bi970565g; SWANSON E, 1995, PSSHOW 4D VERSION; *TRIP INC, 2003, SYBYL 6 9; ULRICH CD, 1993, GASTROENTEROLOGY, V105, P1534, DOI 10.1016/0016-5085(93)90162-6; Vilardaga JP, 1996, BIOCHEM BIOPH RES CO, V218, P842, DOI 10.1006/bbrc.1996.0150; Zang MW, 2003, MOL PHARMACOL, V63, P993, DOI 10.1124/mol.63.5.993	48	69	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2894	2903		10.1074/jbc.M310407200	http://dx.doi.org/10.1074/jbc.M310407200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14593094	hybrid			2022-12-25	WOS:000188211300069
J	Kaduce, TL; Fang, X; Harmon, SD; Oltman, CL; Dellsperger, KC; Teesch, LM; Gopal, VR; Falck, JR; Campbell, WB; Weintraub, NL; Spector, AA				Kaduce, TL; Fang, X; Harmon, SD; Oltman, CL; Dellsperger, KC; Teesch, LM; Gopal, VR; Falck, JR; Campbell, WB; Weintraub, NL; Spector, AA			20-Hydroxyeicosatetraenoic acid (20-HETE) metabolism in coronary endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; HUMAN SKIN FIBROBLASTS; ARACHIDONIC-ACID; EPOXYEICOSATRIENOIC ACIDS; 12-HYDROXYEICOSATETRAENOIC ACID; CYTOCHROME-P450 METABOLITES; PROSTAGLANDIN PRODUCTION; PROTEIN-KINASE; BLOOD-PRESSURE; MONOOXYGENASES	We have investigated the role of endothelial cells in the metabolism of 20-hydroxyeicosatetraenoic acid (20-HETE), a vasoactive mediator synthesized from arachidonic acid by cytochrome P450 omega-oxidases. Porcine coronary artery endothelial cells (PCEC) incorporated 20-[H-3]HETE primarily into the sn-2 position of phospholipids through a coenzyme A-dependent process. The incorporation was reduced by equimolar amounts of arachidonic, eicosapentaenoic or 8,9-epoxyeicosatrienoic acids, but some uptake persisted even when a 10-fold excess of arachidonic acid was available. The retention of 20-[H-3]HETE increased substantially when methyl arachidonoyl fluorophosphonate, but not bromoenol lactone, was added, suggesting that a Ca2+-dependent cytosolic phospholipase A(2) released the 20-HETE contained in PCEC phospholipids. Addition of calcium ionophore A23187 produced a rapid release of 20-[H-3]HETE from the PCEC, a finding that also is consistent with a Ca2+-dependent mobilization process. PCEC also converted 20-[H-3]HETE to 20-carboxy-arachidonic acid (20-COOH-AA) and 18-, 16-, and 14-carbon beta-oxidation products. 20-COOH-AA produced vasodilation in porcine coronary arterioles, but 20-HETE was inactive. These results suggest that the incorporation of 20-HETE and its subsequent conversion to 20-COOH-AA in the endothelium may be important in modulating coronary vascular function.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, High Resolut Mass Spect Facil, Iowa City, IA 52242 USA; Univ Missouri, Dept Internal Med, Columbia, MO 65212 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA	University of Iowa; University of Iowa; University of Iowa; University of Missouri System; University of Missouri Columbia; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Medical College of Wisconsin	Spector, AA (corresponding author), Univ Iowa, Dept Biochem, 4-403 BSB,51 Newton Rd, Iowa City, IA 52242 USA.	arthur-spector@uiowa.edu	Spector, Arthur/AAG-9860-2020	Falck, John/0000-0002-9219-7845; Weintraub, Neal/0000-0002-5138-3705	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013799] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL062984, R01HL072845, R01HL051055, R01HL070860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER; NCRR NIH HHS [RR13799] Funding Source: Medline; NHLBI NIH HHS [HL72845, HL62984, HL51055, HL070860] Funding Source: Medline; NIGMS NIH HHS [GM31278] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alonso-Galicia M, 1999, AM J PHYSIOL-RENAL, V277, pF790, DOI 10.1152/ajprenal.1999.277.5.F790; Balsinde J, 2000, J BIOL CHEM, V275, P22544, DOI 10.1074/jbc.M910163199; Birks EK, 1997, AM J PHYSIOL-LUNG C, V272, pL823, DOI 10.1152/ajplung.1997.272.5.L823; Capdevila JH, 2001, BIOCHEM BIOPH RES CO, V285, P571, DOI 10.1006/bbrc.2001.5167; Capdevila JH, 2000, J LIPID RES, V41, P163; Carroll M A, 2001, Med Sci Monit, V7, P567; Carroll MA, 1997, KIDNEY INT, V51, P1696, DOI 10.1038/ki.1997.234; Croft KD, 2000, AM J PHYSIOL-RENAL, V279, pF544, DOI 10.1152/ajprenal.2000.279.3.F544; DENNING GM, 1983, J LIPID RES, V24, P993; ESCALANTE B, 1991, SCIENCE, V251, P799, DOI 10.1126/science.1846705; Escalante BA, 2002, AM J PHYSIOL-RENAL, V282, pF144, DOI 10.1152/ajprenal.0064.2001; Fang X, 2003, PROSTAG OTH LIPID M, V71, P33, DOI 10.1016/S0090-6980(03)00002-9; Fang X, 1999, J LIPID RES, V40, P699; Fang X, 2000, J LIPID RES, V41, P66; Fang X, 2002, AM J PHYSIOL-HEART C, V283, pH2306, DOI 10.1152/ajpheart.00448.2002; Fang X, 2001, J BIOL CHEM, V276, P14867, DOI 10.1074/jbc.M011761200; Fang X, 1996, CIRC RES, V79, P784, DOI 10.1161/01.RES.79.4.784; Gebremedhin D, 1998, J PHYSIOL-LONDON, V507, P771, DOI 10.1111/j.1469-7793.1998.771bs.x; GORDON JA, 1990, J CLIN INVEST, V85, P1173, DOI 10.1172/JCI114550; HARDER DR, 1995, J VASC RES, V32, P79, DOI 10.1159/000159080; HARDER DR, 1994, AM J PHYSIOL, V266, pH2098, DOI 10.1152/ajpheart.1994.266.5.H2098; Holla VR, 2001, P NATL ACAD SCI USA, V98, P5211, DOI 10.1073/pnas.081627898; Imig JD, 1996, AM J PHYSIOL-REG I, V270, pR217, DOI 10.1152/ajpregu.1996.270.1.R217; Jacobs ER, 1999, AM J PHYSIOL-LUNG C, V276, pL280, DOI 10.1152/ajplung.1999.276.2.L280; Johnson CA, 1999, J BIOL CHEM, V274, P27689, DOI 10.1074/jbc.274.39.27689; Kroetz DL, 2002, CURR OPIN LIPIDOL, V13, P273, DOI 10.1097/00041433-200206000-00007; Lange A, 1997, J BIOL CHEM, V272, P27345, DOI 10.1074/jbc.272.43.27345; Maier KG, 2001, CURR OPIN NEPHROL HY, V10, P81, DOI 10.1097/00041552-200101000-00013; MANNA S, 1983, TETRAHEDRON LETT, V24, P33, DOI 10.1016/S0040-4039(00)81319-2; McGiff JC, 1999, AM J PHYSIOL-REG I, V277, pR607, DOI 10.1152/ajpregu.1999.277.3.R607; MOORE SA, 1988, J CELL PHYSIOL, V137, P75, DOI 10.1002/jcp.1041370109; Muthalif MM, 2000, HYPERTENSION, V36, P604, DOI 10.1161/01.HYP.36.4.604; Oltman CL, 2000, AM J PHYSIOL-ENDOC M, V279, pE176, DOI 10.1152/ajpendo.2000.279.1.E176; Pratt PF, 1998, HYPERTENSION, V31, P237, DOI 10.1161/01.HYP.31.1.237; Roman RJ, 2000, CLIN EXP PHARMACOL P, V27, P855, DOI 10.1046/j.1440-1681.2000.03349.x; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; SCHWARTZMAN ML, 1989, J BIOL CHEM, V264, P11658; Schwartzman ML, 1996, NEPHRON, V73, P652; SHEN XY, 1988, BIOCHEMISTRY-US, V27, P996, DOI 10.1021/bi00403a024; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Snyder GD, 2002, AM J PHYSIOL-HEART C, V283, pH1936, DOI 10.1152/ajpheart.00321.2002; SPECTOR AA, 1981, J CLIN INVEST, V68, P1003, DOI 10.1172/JCI110322; SPECTOR AA, 1983, J LIPID RES, V24, P1595; Sun CW, 1999, HYPERTENSION, V33, P414, DOI 10.1161/01.HYP.33.1.414; TOMODA H, 1987, BIOCHIM BIOPHYS ACTA, V921, P595; VanRollins M, 1996, J BIOL CHEM, V271, P14001, DOI 10.1074/jbc.271.24.14001; VANROLLINS M, 1993, J LIPID RES, V34, P1931; WANG LX, 1990, J LIPID RES, V31, P2265; Wang MH, 2001, AM J PHYSIOL-REG I, V280, pR255, DOI 10.1152/ajpregu.2001.280.1.R255; Weintraub NL, 1999, AM J PHYSIOL-HEART C, V277, pH2098, DOI 10.1152/ajpheart.1999.277.5.H2098; Weintraub NL, 1997, CIRC RES, V81, P258, DOI 10.1161/01.RES.81.2.258; Widstrom RL, 2001, BIOCHEMISTRY-US, V40, P1070, DOI 10.1021/bi001602y; Zink MH, 2001, AM J PHYSIOL-HEART C, V280, pH693, DOI 10.1152/ajpheart.2001.280.2.H693; Zou AP, 1996, AM J PHYSIOL-REG I, V270, pR228, DOI 10.1152/ajpregu.1996.270.1.R228	54	46	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2648	2656		10.1074/jbc.M306849200	http://dx.doi.org/10.1074/jbc.M306849200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14612451	hybrid			2022-12-25	WOS:000188211300040
J	Krall, R; Zhang, Y; Barbieri, JT				Krall, R; Zhang, Y; Barbieri, JT			Intracellular membrane localization of Pseudomonas ExoS and Yersinia YopE in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; EUKARYOTIC CELLS; AERUGINOSA EXOS; III SECRETION; EXOENZYME-S; PLASMA-MEMBRANE; TERMINAL DOMAIN; MESSENGER-RNA; RHO GTPASES; HELA-CELLS	ExoS (453 amino acids) is a bi-functional type-III cytotoxin of Pseudomonas aeruginosa. Residues 96-233 comprise the Rho GTPase-activating protein ( Rho GAP) domain, while residues 234-453 comprise the 14-3-3-dependent ADP-ribosyltransferase domain. Residues 51-72 represent a membrane localization domain (MLD), which targets ExoS to perinuclear vesicles within mammalian cells. YopE (219 amino acids) is a type-III cytotoxin of Yersinia that is also a Rho GAP. Residues 96-219 comprise the YopE Rho GAP domain. While the Rho GAP domains of ExoS and YopE share structural homology, unlike ExoS, the intracellular localization of YopE within mammalian cells has not been resolved and is the subject of this investigation. Deletion mapping showed that the N terminus of YopE was required for intracellular membrane localization of YopE in CHO cells. A fusion protein containing the N-terminal 84 amino acids of YopE localized to a punctate-perinuclear region in mammalian cells and co-localized with a fusion protein containing the MLD of ExoS. Residues 54-75 of YopE (termed YopE-MLD) were necessary and sufficient for intracellular localization in mammalian cells. The YopE-MLD localized ExoS to intracellular membranes and targeted ExoS to ADP-ribosylate small molecular weight membrane proteins as observed for native type-III delivered ExoS. These data indicate that the YopE MLD functionally complements the ExoS MLD for intracellular targeting in mammalian cells.	Med Coll Wisconsin, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Barbieri, JT (corresponding author), Med Coll Wisconsin, Milwaukee, WI 53226 USA.	jtb01@mcw.edu						AHNERTHILGER G, 1992, BIOCHEM J, V284, P321, DOI 10.1042/bj2840321; Anderson DM, 1997, SCIENCE, V278, P1140, DOI 10.1126/science.278.5340.1140; Andor A, 2001, CELL MICROBIOL, V3, P301, DOI 10.1046/j.1462-5822.2001.00114.x; Birtalan SC, 2002, MOL CELL, V9, P971, DOI 10.1016/S1097-2765(02)00529-4; Black DS, 2000, MOL MICROBIOL, V37, P515, DOI 10.1046/j.1365-2958.2000.02021.x; Boyd AP, 2000, J BACTERIOL, V182, P4811, DOI 10.1128/JB.182.17.4811-4821.2000; Evdokimov AG, 2002, PROTEIN SCI, V11, P401, DOI 10.1110/ps.34102; Fields KA, 1999, INFECT IMMUN, V67, P5395, DOI 10.1128/IAI.67.10.5395-5408.1999; Frank DW, 1997, MOL MICROBIOL, V26, P621, DOI 10.1046/j.1365-2958.1997.6251991.x; Giamarellou H, 2000, INT J ANTIMICROB AG, V16, P103, DOI 10.1016/S0924-8579(00)00212-0; Goehring UM, 1999, J BIOL CHEM, V274, P36369, DOI 10.1074/jbc.274.51.36369; Hakansson S, 1996, MOL MICROBIOL, V20, P593, DOI 10.1046/j.1365-2958.1996.5251051.x; Hakansson S, 1996, EMBO J, V15, P5812, DOI 10.1002/j.1460-2075.1996.tb00968.x; Haraga A, 2003, INFECT IMMUN, V71, P4052, DOI 10.1128/IAI.71.7.4052-4058.2003; Krall R, 2002, INFECT IMMUN, V70, P360, DOI 10.1128/IAI.70.1.360-367.2002; Lesser CF, 2001, EMBO J, V20, P1840, DOI 10.1093/emboj/20.8.1840; Lloyd SA, 2002, MOL MICROBIOL, V43, P51, DOI 10.1046/j.1365-2958.2002.02738.x; Lloyd SA, 2001, MOL MICROBIOL, V39, P520, DOI 10.1046/j.1365-2958.2001.02271.x; MICHIELS T, 1990, INFECT IMMUN, V58, P2840, DOI 10.1128/IAI.58.9.2840-2849.1990; Pederson KJ, 1998, MOL MICROBIOL, V30, P751, DOI 10.1046/j.1365-2958.1998.01106.x; Pederson KJ, 1999, MOL MICROBIOL, V32, P393, DOI 10.1046/j.1365-2958.1999.01359.x; Pederson KJ, 2000, MOL MICROBIOL, V37, P287, DOI 10.1046/j.1365-2958.2000.01990.x; ROSQVIST R, 1991, INFECT IMMUN, V59, P4562, DOI 10.1128/IAI.59.12.4562-4569.1991; ROSQVIST R, 1990, MOL MICROBIOL, V4, P657, DOI 10.1111/j.1365-2958.1990.tb00635.x; Schesser K, 1996, J BACTERIOL, V178, P7227, DOI 10.1128/jb.178.24.7227-7233.1996; Skrzypek E, 1998, MOL MICROBIOL, V30, P1051, DOI 10.1046/j.1365-2958.1998.01135.x; SORY MP, 1994, MOL MICROBIOL, V14, P583, DOI 10.1111/j.1365-2958.1994.tb02191.x; STRALEY SC, 1989, INFECT IMMUN, V57, P1200, DOI 10.1128/IAI.57.4.1200-1210.1989; von Pawel-Rammingen U, 2000, MOL MICROBIOL, V36, P737, DOI 10.1046/j.1365-2958.2000.01898.x; Wurtele M, 2001, NAT STRUCT BIOL, V8, P23	30	57	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2747	2753		10.1074/jbc.M301963200	http://dx.doi.org/10.1074/jbc.M301963200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14597627	hybrid			2022-12-25	WOS:000188211300052
J	Maillard, P; Lavergne, JP; Siberil, S; Faure, G; Roohvand, F; Petres, S; Teillaud, JL; Budkowska, A				Maillard, P; Lavergne, JP; Siberil, S; Faure, G; Roohvand, F; Petres, S; Teillaud, JL; Budkowska, A			Fc gamma receptor-like activity of hepatitis C virus core protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TO-CELL SPREAD; CRYSTAL-STRUCTURE; IMMUNOGLOBULIN-G; CYTOPLASMIC TAIL; IMMUNE EVASION; COMPLEX; IGG; BINDING; INTERNALIZATION; PHOSPHORYLATION	We have previously demonstrated that viral particles with the properties of nonenveloped hepatitis C virus (HCV) nucleocapsids occur in the serum of HCV-infected individuals ( 1). We show here that nucleocapsids purified directly from serum or isolated from HCV virions have FcgammaR-like activity and bind "nonimmune" IgG via its Fcgamma domain. HCV core proteins produced in Escherichia coli and in the baculovirus expression system also bound "nonimmune" IgG and their Fcgamma fragments. Folded conformation was required for IgG binding because the FcgammaR-like site of the core protein was inactive in denaturing conditions. Studies with synthetic core peptides showed that the region spanning amino acids 3 - 75 was essential for formation of the IgG-binding site. The interaction between the HCV core and human IgG is more efficient in acidic ( pH 6.0) than in neutral conditions. The core protein-binding site on the IgG molecule differs from those for C1q, FcgammaRII (CD32), and FcgammaRIII (CD16) but overlaps with that for soluble protein A from Staphylococcus aureus (SpA), which is located in the CH2-CH3 interface of IgG. These characteristics of the core-IgG interaction are very similar to those of the neonatal FcRn. Surface plasmon resonance studies suggested that the binding of an anti-core antibody to HCV core protein might be "bipolar" through its paratope to the corresponding epitope and by its Fcgamma region to the FcgammaR-like motif on this protein. These features of HCV nucleocapsids and HCV core protein may confer an advantage for HCV in terms of survival by interfering with host defense mechanisms mediated by the Fcgamma part of IgG.	Inst Pasteur, Unite Venins, F-75724 Paris 15, France; CNRS, UMR 5086, Inst Biol & Chim Prot, F-69367 Lyon 07, France; INSERM, U255, Ctr Rech Biomed Cordeliers, F-75270 Paris 06, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Budkowska, A (corresponding author), Inst Pasteur, Unite Venins, 25 Rue Docteur Roux, F-75724 Paris 15, France.	abudkow@pasteur.fr	Roohvand, Farzin/K-8931-2018	Roohvand, Farzin/0000-0002-9597-3555; Siberil, Sophie/0000-0003-0184-2886; Teillaud, Jean-Luc/0000-0003-4442-9565; petres, stephane/0000-0002-4716-565X				Alcami A, 2000, TRENDS MICROBIOL, V8, P410, DOI 10.1016/S0966-842X(00)01830-8; Antonsson A, 2001, J GEN VIROL, V82, P1137, DOI 10.1099/0022-1317-82-5-1137; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Baumert TF, 1998, J VIROL, V72, P3827, DOI 10.1128/JVI.72.5.3827-3836.1998; BLUMBERG RS, 1995, J CLIN INVEST, V95, P2397, DOI 10.1172/JCI117934; CHANG SC, 1994, BIOCHEM BIOPH RES CO, V205, P1284, DOI 10.1006/bbrc.1994.2804; Chapman TL, 1999, J BIOL CHEM, V274, P6911, DOI 10.1074/jbc.274.11.6911; Collins WJ, 2003, J VIROL, V77, P2686, DOI 10.1128/JVI.77.4.2686-2695.2003; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Dickinson BL, 1999, J CLIN INVEST, V104, P903, DOI 10.1172/JCI6968; Dingwell KS, 1998, J VIROL, V72, P8933, DOI 10.1128/JVI.72.11.8933-8942.1998; FRANK I, 1989, J VIROL, V63, P4479, DOI 10.1128/JVI.63.11.4479-4488.1989; Ghetie V, 2000, ANNU REV IMMUNOL, V18, P739, DOI 10.1146/annurev.immunol.18.1.739; GOODING LR, 1992, CELL, V71, P5; HAN JQ, 1997, VIRAL HEPATITIS LIVE, P228; Haymann JP, 2000, J AM SOC NEPHROL, V11, P632, DOI 10.1681/ASN.V114632; Heyman B, 2000, ANNU REV IMMUNOL, V18, P709, DOI 10.1146/annurev.immunol.18.1.709; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; JONES DB, 1986, HEMATOL ONCOL, V4, P315, DOI 10.1002/hon.2900040408; Kittlesen DJ, 2000, J CLIN INVEST, V106, P1239, DOI 10.1172/JCI10323; Large MK, 1999, J IMMUNOL, V162, P931; Lu W, 2002, VIROLOGY, V300, P20, DOI 10.1006/viro.2002.1524; Maillard P, 2001, J VIROL, V75, P8240, DOI 10.1128/JVI.75.17.8240-8250.2001; MARRACK P, 1994, CELL, V76, P323, DOI 10.1016/0092-8674(94)90339-5; Martin WL, 2001, MOL CELL, V7, P867, DOI 10.1016/S1097-2765(01)00230-1; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; Maxwell KF, 1999, NAT STRUCT BIOL, V6, P437; McLauchlan J, 2000, J VIRAL HEPATITIS, V7, P2; McLauchlan J, 2002, EMBO J, V21, P3980, DOI 10.1093/emboj/cdf414; Nagashunmugam T, 1998, J VIROL, V72, P5351, DOI 10.1128/JVI.72.7.5351-5359.1998; Okada K, 1996, CLIN NEPHROL, V45, P71; Olson JK, 1997, J VIROL, V71, P4042, DOI 10.1128/JVI.71.5.4042-4054.1997; Olson JK, 1997, J VIROL, V71, P110, DOI 10.1128/JVI.71.1.110-119.1997; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; Rouard H, 1997, Int Rev Immunol, V16, P147, DOI 10.3109/08830189709045707; Sansonno D, 2003, CLIN EXP IMMUNOL, V133, P275, DOI 10.1046/j.1365-2249.2003.02204.x; Schilling R, 2003, J VIROL, V77, P8882, DOI 10.1128/JVI.77.16.8882-8892.2003; SHIH CM, 1995, J VIROL, V69, P1160, DOI 10.1128/JVI.69.2.1160-1171.1995; Shrivastava A, 1998, J VIROL, V72, P9722, DOI 10.1128/JVI.72.12.9722-9728.1998; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; Sondermann P, 2001, J MOL BIOL, V309, P737, DOI 10.1006/jmbi.2001.4670; Sondermann P, 1999, EMBO J, V18, P1095, DOI 10.1093/emboj/18.5.1095; THALE R, 1994, J VIROL, V68, P7757; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Van de Walle GR, 2003, J GEN VIROL, V84, P939, DOI 10.1099/vir.0.18663-0; VIVIER E, 1992, INT IMMUNOL, V4, P1313, DOI 10.1093/intimm/4.11.1313; West AP, 2000, BIOCHEMISTRY-US, V39, P9698, DOI 10.1021/bi000749m; Wines BD, 2000, J IMMUNOL, V164, P5313, DOI 10.4049/jimmunol.164.10.5313; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998; Zhu XP, 2001, J IMMUNOL, V166, P3266, DOI 10.4049/jimmunol.166.5.3266	52	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2430	2437		10.1074/jbc.M311470200	http://dx.doi.org/10.1074/jbc.M311470200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14610077	hybrid			2022-12-25	WOS:000188211300014
J	Matsuzawa, T; Fukui, A; Kashimoto, T; Nagao, K; Oka, K; Miyake, M; Horiguchi, Y				Matsuzawa, T; Fukui, A; Kashimoto, T; Nagao, K; Oka, K; Miyake, M; Horiguchi, Y			Bordetella dermonecrotic toxin undergoes proteolytic processing to be translocated from a dynamin-related endosome into the cytoplasm in an acidification-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; DIPHTHERIA-TOXIN; CHOLERA-TOXIN; ACTIVATION; PROTEIN; ENTRY; CELLS; IDENTIFICATION; FURIN; PURIFICATION	Bordetella pertussis dermonecrotic toxin (DNT), which activates intracellular Rho GTPases, is a single chain polypeptide composed of an N-terminal receptor-binding domain and a C-terminal enzymatic domain. We found that DNT was cleaved by furin, a mammalian endoprotease, on the C-terminal side of Arg(44), which generates an N-terminal fragment almost corresponding to the receptor-binding domain and a C-terminal remainder (DeltaB) containing the enzymatic domain. These two fragments remained associated even after the cleavage and made a nicked form. DNT mutants insensitive to furin had no cellular effect, whereas the nicked toxin was much more potent than the intact form, indicating that the nicking by furin was a prerequisite for action. DeltaB, but not the nicked toxin, associated with artificial liposomes and activated Rho in cells resistant to DNT because of a lack of surface receptor. These results imply that DeltaB, dissociated from the binding domain, fully possesses the ability to enter the cytoplasm across the lipid bilayer membrane. The translocation ability of DeltaB was found to be attributable to the N-terminal region encompassing amino acids 45 - 166, including a putative transmembrane domain. Pharmacological analyses with various reagents disturbing vesicular trafficking revealed that the translocation requires neither the acidification of the endosomes nor retrograde vesicular transport to deeper organelles, although DNT appeared to be internalized via a dynamin-dependent endocytosis. We conclude that DNT binds to its receptor and is internalized into endosomes where the proteolytic processing occurs. DeltaB, liberated from the binding domain after the processing, begins to translocate the enzymatic domain into the cytoplasm.	Osaka Univ, Microbial Dis Res Inst, Dept Bacterial Toxinol, Osaka 5650871, Japan	Osaka University	Horiguchi, Y (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Bacterial Toxinol, Yamada Oka 3-1, Osaka 5650871, Japan.	horiguti@biken.osaka-u.ac.jp						Barth H, 2000, J BIOL CHEM, V275, P18704, DOI 10.1074/jbc.M000596200; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Contamin S, 2000, MOL BIOL CELL, V11, P1775, DOI 10.1091/mbc.11.5.1775; Falnes PO, 2000, CURR OPIN CELL BIOL, V12, P407, DOI 10.1016/S0955-0674(00)00109-5; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; GETHING MJ, 1978, P NATL ACAD SCI USA, V75, P2737, DOI 10.1073/pnas.75.6.2737; GORDON VM, 1994, INFECT IMMUN, V62, P333, DOI 10.1128/IAI.62.2.333-340.1994; GORDON VM, 1989, J BIOL CHEM, V264, P14792; HORIGUCHI Y, 1991, INFECT IMMUN, V59, P1112, DOI 10.1128/IAI.59.3.1112-1116.1991; HORIGUCHI Y, 1990, FEMS MICROBIOL LETT, V66, P39, DOI 10.1111/j.1574-6968.1990.tb03969.x; Horiguchi Y, 1997, P NATL ACAD SCI USA, V94, P11623, DOI 10.1073/pnas.94.21.11623; HORIGUCHI Y, 1995, J CELL SCI, V108, P3243; Jeng RL, 2001, CURR BIOL, V11, pR691, DOI 10.1016/S0960-9822(01)00410-9; Kashimoto T, 1999, INFECT IMMUN, V67, P3727, DOI 10.1128/IAI.67.8.3727-3732.1999; Klenk H D, 1988, Adv Virus Res, V34, P247, DOI 10.1016/S0065-3527(08)60520-5; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; LENCER WI, 1993, J CLIN INVEST, V92, P2941, DOI 10.1172/JCI116917; Lord JM, 1998, J CELL BIOL, V140, P733; Masuda M, 2000, EMBO J, V19, P521, DOI 10.1093/emboj/19.4.521; Masuda M, 2002, INFECT IMMUN, V70, P998; Matsuzawa T, 2002, INFECT IMMUN, V70, P3427, DOI 10.1128/IAI.70.7.3427-3432.2002; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; OGATA M, 1990, J BIOL CHEM, V265, P20678; OHISHI I, 1987, INFECT IMMUN, V55, P1461, DOI 10.1128/IAI.55.6.1461-1465.1987; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Ren JH, 1999, SCIENCE, V284, P955, DOI 10.1126/science.284.5416.955; Rossetto O, 2001, TOXICON, V39, P27, DOI 10.1016/S0041-0101(00)00163-X; Sandvig K, 2000, EMBO J, V19, P5943, DOI 10.1093/emboj/19.22.5943; SANDVIG K, 2003, BACTERIAL PROTEIN TO, P157; Schmitz A, 2000, J CELL BIOL, V148, P1203, DOI 10.1083/jcb.148.6.1203; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; TSUNEOKA M, 1993, J BIOL CHEM, V268, P26461; Umata T, 1998, J BIOL CHEM, V273, P8351, DOI 10.1074/jbc.273.14.8351; UMATA T, 1990, J BIOL CHEM, V265, P21940; XU YR, 1995, INFECT IMMUN, V63, P825, DOI 10.1128/IAI.63.3.825-832.1995; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z	38	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2866	2872		10.1074/jbc.M310340200	http://dx.doi.org/10.1074/jbc.M310340200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14597616	hybrid			2022-12-25	WOS:000188211300066
J	Olszewska-Pazdrak, B; Ives, KL; Park, J; Townsend, CM; Hellmich, MR				Olszewska-Pazdrak, B; Ives, KL; Park, J; Townsend, CM; Hellmich, MR			Epidermal growth factor potentiates cholecystokinin/gastrin receptor-mediated Ca2+ release by activation of mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; EGF RECEPTOR; CCKB/GASTRIN RECEPTOR; COUPLED RECEPTORS; PEPTIDE RECEPTOR; GENE-EXPRESSION; GASTRIN; TRANSACTIVATION; CANCER; PATHWAYS	Small differences in amplitude, duration, and temporal patterns of change in the concentration of free intracellular Ca2+ ([Ca2+](i)) can profoundly affect cell physiology, altering programs of gene expression, cell proliferation, secretory activity, and cell survival. We report a novel mechanism for amplitude modulation of [Ca2+](i) that involves mitogen-activated protein kinase (MAPK). We show that epidermal growth factor (EGF) potentiates gastrin-(1 - 17) (G17)-stimulated Ca2+ release from intracellular Ca2+ stores through a MAPK-dependent pathway. G17 activation of the cholecystokinin/gastrin receptor (CCK2R), a G protein-coupled receptor, stimulates release of Ca2+ from inositol 1,4,5-triphosphate-sensitive Ca2+ stores. Pretreating rat intestinal epithelial cells expressing CCK2R with EGF increased the level of G17-stimulated Ca2+ release from intracellular stores. The stimulatory effect of EGF on CCK2R-mediated Ca2+ release requires activation of the MAPK kinase (MEK) 1,2/extracellular signal-regulated kinase (ERK) 1,2 pathway. Inhibition of the MEK1,2/ERK1,2 pathway by either serum starvation or treatment with selective MEK1,2 inhibitors PD98059 and U0126 or expression of a dominant-negative mutant form of MEK1 decreased the amplitude of the G17-stimulated Ca2+ release response. Activation of the MEK1,2/ERK1,2 pathway either by pretreating cells with EGF or by expression of constitutively active K-ras (K-rasV12G) or MEK1 (MEK1*) increased the amplitude of G17-stimulated Ca2+ release. Although EGF, MEK1*, and K-rasV12G activated the MEK1,2/ERK1,2 pathway, they did not increase [Ca2+](i) in the absence of G17. These data demonstrate that the activation state of the MEK1,2/ERK1,2 pathway can modulate the amplitude of the CCK2R-mediated Ca2+ release response and identify a novel mechanism for cross-talk between EGF receptor-and CCK2R-regulated signaling pathways.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Hellmich, MR (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	mhellmic@utmb.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048345, R01DK058119] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 58119, R01 DK 48345] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Akagi K, 1999, BBA-MOL CELL RES, V1452, P243, DOI 10.1016/S0167-4889(99)00137-8; Akagi M, 2003, BRIT J CANCER, V88, P796, DOI 10.1038/sj.bjc.6600811; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bierkamp C, 2002, ONCOGENE, V21, P7656, DOI 10.1038/sj.onc.1205999; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Bruns CJ, 2000, CANCER RES, V60, P2926; CARRAWAY RE, 1994, REGUL PEPTIDES, V53, P17, DOI 10.1016/0167-0115(94)90155-4; Castagliuolo I, 2000, J BIOL CHEM, V275, P26545, DOI 10.1074/jbc.M003990200; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daulhac L, 1997, BIOCHEM J, V325, P383, DOI 10.1042/bj3250383; Dockray GJ, 1999, J PHYSIOL-LONDON, V518, P315, DOI 10.1111/j.1469-7793.1999.0315p.x; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; GALLO V, 1987, J NEUROSCI, V7, P2203; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Guo YS, 2002, J BIOL CHEM, V277, P48755, DOI 10.1074/jbc.M209016200; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; Hellmich MR, 2000, J BIOL CHEM, V275, P32122, DOI 10.1074/jbc.M005754200; Hellmich MR, 1999, J BIOL CHEM, V274, P23901, DOI 10.1074/jbc.274.34.23901; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; Hutter D, 2000, J GERONTOL A-BIOL, V55, pB125, DOI 10.1093/gerona/55.3.B125; Ikeyama S, 2002, FASEB J, V16, pA1163, DOI 10.1096/fj.01-0409fje; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Miyazaki Y, 1996, BIOCHEM BIOPH RES CO, V223, P36, DOI 10.1006/bbrc.1996.0842; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; RUTTEN MJ, 1993, AM J PHYSIOL, V265, pG361, DOI 10.1152/ajpgi.1993.265.2.G361; SIRINEK KR, 1985, AM J SURG, V149, P35, DOI 10.1016/S0002-9610(85)80006-4; SMITH JP, 1988, GASTROENTEROLOGY, V95, P1541; SMITH JP, 1995, AM J PHYSIOL-REG I, V268, pR135, DOI 10.1152/ajpregu.1995.268.1.R135; Smith JP, 1998, INT J ONCOL, V12, P411; SONG I, 1993, P NATL ACAD SCI USA, V90, P9085, DOI 10.1073/pnas.90.19.9085; Wang RN, 1997, DIABETOLOGIA, V40, P887, DOI 10.1007/s001250050764; WANK SA, 1995, AM J PHYSIOL-GASTR L, V269, pG628, DOI 10.1152/ajpgi.1995.269.5.G628; WATSON S, 1989, BRIT J CANCER, V59, P554, DOI 10.1038/bjc.1989.112; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WU T, 1995, BRAIN RES, V683, P242, DOI 10.1016/0006-8993(95)00379-5; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zhukova E, 2001, J CELL PHYSIOL, V189, P291, DOI 10.1002/jcp.10018	48	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1853	1860		10.1074/jbc.M309481200	http://dx.doi.org/10.1074/jbc.M309481200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14602717	hybrid			2022-12-25	WOS:000188005700036
J	Sashchenko, LP; Dukhanina, EA; Yashin, DV; Shatalov, YV; Romanova, EA; Korobko, EV; Demin, AV; Lukyanova, TI; Kabanova, OD; Khaidukov, SV; Kiselev, SL; Gabibov, AG; Gnuchev, NV; Georgiev, GP				Sashchenko, LP; Dukhanina, EA; Yashin, DV; Shatalov, YV; Romanova, EA; Korobko, EV; Demin, AV; Lukyanova, TI; Kabanova, OD; Khaidukov, SV; Kiselev, SL; Gabibov, AG; Gnuchev, NV; Georgiev, GP			Peptidoglycan recognition protein Tag7 forms a cytotoxic complex with heat shock protein 70 in solution and in lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MOLECULAR CHAPERONE HSC70; PEPTIDE BINDING; RESISTANT CELLS; TARGET-CELLS; DROSOPHILA; HSP70; CLONING; RELEASE; ATPASE	The peptidoglycan recognition protein Tag7 is shown to form a stable 1: 1 complex with the major stress protein Hsp70. Neither protein is cytotoxic by itself, but their complex induces apoptotic death in several tumor-derived cell lines even at subnanomolar concentrations. The minimal part of Hsp70 needed to evoke cytotoxicity is residues 450 - 463 of its peptide-binding domain, but full cytotoxicity requires its ATPase activity; remarkably, Tag7 liberated from the complex at high ATP is not cytotoxic. The Tag7-Hsp70 complex is produced by tag7-transfected cells and by lymphokine-activated killers, being assembled within the cell and released into the medium through the Golgi apparatus by a mechanism different from the commonly known granule exocytosis. Thus, we demonstrate how a heat shock protein may perform functions clearly distinct from chaperoning or cell rescue and how peptidoglycan recognition proteins may be involved in innate immunity and anti-cancer defense.	Russian Acad Sci, Inst Gene Biol, Univ Oslo, Biomed Unit, Moscow 117334, Russia; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow 117334, Russia; Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Moscow 117334, Russia; Moscow MV Lomonosov State Univ, Moscow 119899, Russia	Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Lomonosov Moscow State University	Georgiev, GP (corresponding author), Russian Acad Sci, Inst Gene Biol, Univ Oslo, Biomed Unit, Moscow 117334, Russia.	georg@biogen.msk.su	Khaidukov, Sergey/AAH-4269-2021; Kiselev, Sergey/AAO-1247-2020; Korobko, Elena/AAP-1193-2021; Dukhanina, Elena/S-2326-2016	Korobko, Elena/0000-0002-9752-9714; Lukyanova, Tamara/0000-0003-4193-2843; kiselev, sergey/0000-0001-7921-6987; Dukhanina, Elena/0000-0002-2828-9112				Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; BARANKIEWICZ J, 1988, J BIOL CHEM, V263, P7094; Benaroudj N, 1997, J BIOL CHEM, V272, P8744, DOI 10.1074/jbc.272.13.8744; BRONTE V, 1993, CELL IMMUNOL, V152, P110, DOI 10.1006/cimm.1993.1271; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; DEAN C, 1992, IMMUNOCHEMICAL PROTO, P43; Dressel R, 2000, J IMMUNOL, V164, P2362, DOI 10.4049/jimmunol.164.5.2362; Dukhanina E A, 2000, Dokl Biol Sci, V371, P224; Dukhanina EA, 1999, DOKL AKAD NAUK+, V365, P826; GEORGIEV GP, 1998, GENE THER MOL BIOL, V1, P381; Geromanos S, 2000, ANAL CHEM, V72, P777, DOI 10.1021/ac991071n; Gnuchev NV, 1997, BIOCHEM BIOPH RES CO, V234, P655, DOI 10.1006/bbrc.1997.6617; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; GRAVES SS, 1986, J IMMUNOL, V137, P1977; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; Hantschel M, 2000, CELL STRESS CHAPERON, V5, P438, DOI 10.1379/1466-1268(2000)005<0438:HPMEOP>2.0.CO;2; Hayakawa M, 1996, BIOCHEM BIOPH RES CO, V220, P681, DOI 10.1006/bbrc.1996.0464; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kibardin A V, 2000, Dokl Biochem, V372, P103; KIM BB, 1990, J IMMUNOL METHODS, V131, P213, DOI 10.1016/0022-1759(90)90192-X; Kim KW, 2002, J CELL BIOCHEM, V85, P334, DOI 10.1002/jcb.10139; Kiselev SL, 1998, J BIOL CHEM, V273, P18633, DOI 10.1074/jbc.273.29.18633; KUPFER A, 1985, J MOL CELL IMMUNOL, V2, P37; Kustikova OS, 1996, GENETIKA+, V32, P621; LIN TI, 1977, ANAL BIOCHEM, V77, P10, DOI 10.1016/0003-2697(77)90284-6; Liu C, 2000, J BIOL CHEM, V275, P24490, DOI 10.1074/jbc.M001239200; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; LIU CC, 1989, P NATL ACAD SCI USA, V86, P3286, DOI 10.1073/pnas.86.9.3286; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Mirkina I. I., 2000, Genetika, V36, P1492; Multhoff G, 2001, CELL STRESS CHAPERON, V6, P337, DOI 10.1379/1466-1268(2001)006<0337:AMHPSN>2.0.CO;2; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; PIZZO P, 1992, J IMMUNOL, V149, P3372; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Russell R, 1998, BIOCHEMISTRY-US, V37, P596, DOI 10.1021/bi972025p; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; Sashchenko L. P., 2000, Molekulyarnaya Biologiya (Moscow), V34, P816; Sashchenko LP, 1996, IMMUNOL LETT, V53, P25, DOI 10.1016/0165-2478(96)02609-0; SASHCHENKO LP, 1993, IMMUNOL LETT, V37, P153, DOI 10.1016/0165-2478(93)90025-W; SASHCHENKO LP, 1994, IMMUNOL LETT, V39, P243; STROUS GJ, 1993, J BIOL CHEM, V268, P2341; Stuart JK, 1998, J BIOL CHEM, V273, P22506, DOI 10.1074/jbc.273.35.22506; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Szyllo K, 2003, MEDIAT INFLAMM, V12, P131, DOI 10.1080/0962935031000134842; Takeda S, 1996, BIOCHEMISTRY-US, V35, P4636, DOI 10.1021/bi952903o; Tydell CC, 2002, J BIOL CHEM, V277, P19658, DOI 10.1074/jbc.M200659200; VANHAESEBROECK B, 1991, CANCER RES, V51, P2469; YOUNG JDE, 1986, J CELL BIOCHEM, V32, P151, DOI 10.1002/jcb.240320207	50	57	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2117	2124		10.1074/jbc.M307513200	http://dx.doi.org/10.1074/jbc.M307513200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14585845	hybrid			2022-12-25	WOS:000188005700068
J	Trioulier, Y; Torch, S; Blot, B; Cristina, N; Chatellard-Causse, C; Verna, JM; Sadoul, R				Trioulier, Y; Torch, S; Blot, B; Cristina, N; Chatellard-Causse, C; Verna, JM; Sadoul, R			Alix, a protein regulating endosomal trafficking, is involved in neuronal death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE NEURONS; N-TERMINAL KINASE; CELL-DEATH; C-JUN; DOWN-REGULATION; ALZHEIMERS-DISEASE; GRANULOVACUOLAR DEGENERATION; CA2+-DEPENDENT MANNER; ACTIVATED CASPASE-3; ALG-2 INTERACTS	Alix/AIP1 is a cytoplasmic protein, which was first characterized as an interactor of ALG-2, a calcium-binding protein necessary for cell death. Alix has also recently been defined as a regulator of the endo-lysosomal system. Here we have used post-mitotic cerebellar neurons to test Alix function in caspase-dependent and - independent cell death. Indeed, these neurons survived when cultured in 25 mM potassium-containing medium but underwent apoptosis soon after the extracellular potassium was lowered to 5 mM. In agreement with other studies, we show that caspases are activated after K+ deprivation, but that inhibition of these proteases, using the pancaspase inhibitor boc-aspartyl(OMe)-fluoromethylketone, has no effect on cell survival. Transfection experiments demonstrated that Alix overexpression is sufficient to induce caspase activation, whereas overexpression of its C-terminal half, Alix-CT, blocks caspase activation and cell death after K+ deprivation. We also define a 12-amino acid PXY repeat of the C-terminal proline-rich domain necessary for binding ALG-2. Deletion of this domain in Alix or in Alix-CT abolished the effects of the overexpressed proteins on neuronal survival, demonstrating that the ALG-2-binding region is crucial for the death-modulating function of Alix. Overall, these findings define the Alix/ALG-2 complex as a regulator of cell death controlling both caspase-dependent and - independent pathways. They also suggest a molecular link between the endo-lysosomal system and the effectors of the cell death machinery.	Hop A Michallon, UJF, INSERM, Lab Neurodegenerescence & Plast, F-38043 Grenoble 9, France	CHU Grenoble Alpes; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Sadoul, R (corresponding author), CHU Grenoble, Lab Neurodegenerescence & Plast, FMI 0108,Pavillon Neurol,BP 217, F-38043 Grenoble 9, France.	remy.sadoul@ujf-grenoble.fr	TORCH, sakina/N-7717-2013; TORCH, SAKINA/AAC-2994-2019	SADOUL, Remy/0000-0002-4763-0320; TORCH, Sakina/0000-0003-3691-4376				Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; Chatellard-Causse C, 2002, J BIOL CHEM, V277, P29108, DOI 10.1074/jbc.M204019200; Chen B, 2000, J BIOL CHEM, V275, P19275, DOI 10.1074/jbc.M908994199; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Coffey ET, 2002, J NEUROSCI, V22, P4335, DOI 10.1523/JNEUROSCI.22-11-04335.2002; Coffey ET, 2000, J NEUROSCI, V20, P7602; Finkbeiner S, 1997, BIOESSAYS, V19, P657, DOI 10.1002/bies.950190803; Fraboulet S, 2003, GENE EXPR PATTERNS, V3, P139, DOI 10.1016/S1567-133X(03)00025-5; GALLO V, 1987, J NEUROSCI, V7, P2203; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Gout I, 2000, EMBO J, V19, P4015, DOI 10.1093/emboj/19.15.4015; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; Harada J, 1999, JPN J PHARMACOL, V79, P369, DOI 10.1254/jjp.79.369; HEMMING FJ, 2004, IN PRESS NEUROSCIENC; HORNUNG JP, 1989, J COMP NEUROL, V283, P425, DOI 10.1002/cne.902830310; Ikeuchi T, 1998, Hum Cell, V11, P125; Jang IK, 2002, MOL CELL BIOL, V22, P4094, DOI 10.1128/MCB.22.12.4094-4100.2002; Jiang LW, 2002, TRENDS CELL BIOL, V12, P362, DOI 10.1016/S0962-8924(02)02322-X; Katoh K, 2003, J BIOL CHEM, V278, P39104, DOI 10.1074/jbc.M301604200; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kowanetz K, 2003, J BIOL CHEM, V278, P39735, DOI 10.1074/jbc.M304541200; Lacana E, 1997, J IMMUNOL, V158, P5129; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Martin-Serrano J, 2003, P NATL ACAD SCI USA, V100, P12414, DOI 10.1073/pnas.2133846100; Miller TM, 1996, J NEUROSCI, V16, P7487; Miller TM, 1997, J BIOL CHEM, V272, P9847; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Pillay CS, 2002, BIOCHEM J, V363, P417, DOI 10.1042/0264-6021:3630417; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Satoh H, 2002, BBA-PROTEINS PROTEOM, V1600, P61, DOI 10.1016/S1570-9639(02)00445-4; Satoh H, 2002, BIOCHEM BIOPH RES CO, V291, P1166, DOI 10.1006/bbrc.2002.6600; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Su JH, 2002, ACTA NEUROPATHOL, V104, P1, DOI 10.1007/s00401-002-0548-2; Su JH, 2001, BRAIN RES, V898, P350, DOI 10.1016/S0006-8993(01)02018-2; Tanabe H, 1998, EUR J NEUROSCI, V10, P1403, DOI 10.1046/j.1460-9568.1998.00148.x; Taylor J, 1997, J NEUROCHEM, V68, P1598; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; Watson A, 1998, J NEUROSCI, V18, P751; Wu Y, 2001, DIFFERENTIATION, V67, P139, DOI 10.1046/j.1432-0436.2001.670406.x; Wu Y, 2002, ONCOGENE, V21, P6801, DOI 10.1038/sj.onc.1205849; Xia ZG, 1996, J NEUROSCI, V16, P5425; Yamagishi S, 2001, J BIOL CHEM, V276, P5129, DOI 10.1074/jbc.M007258200	53	80	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2046	2052		10.1074/jbc.M309243200	http://dx.doi.org/10.1074/jbc.M309243200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14585841	hybrid			2022-12-25	WOS:000188005700059
J	Wu, ZLL; Lech, M; Beeler, DL; Rosenberg, RD				Wu, ZLL; Lech, M; Beeler, DL; Rosenberg, RD			Determining heparan sulfate structure in the vicinity of specific sulfotransferase recognition sites by mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOGLYCANS; EXPRESSION	Sulfated motifs on heparan sulfate (HS) are involved in various extracellular processes from cell signaling to enzymatic regulation, but the structures of these motifs are obscure. We have developed a strategy to determine the structure of sulfotransferase recognition sites which constitute these motifs. Stable isotope is first introduced into specific sites on HS with HS sulfotransferases and the modified HS is then digested into oligosaccharides of differing sizes. The overlapping oligosaccharides containing the introduced stable isotope are identified by changes in the m/z profiles by mass spectrometry, and their relationships are elucidated. In this way, the HS structures in the vicinity of the sulfotransferase recognition site are quickly determined and groups on precursor structures of HS that direct the action of HS sulfotransferases are pinpointed.	MIT, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Rosenberg, RD (corresponding author), MIT, Dept Biol, 31 Ames St,MIT Bldg 68-488, Cambridge, MA 02142 USA.	rdrrosen@mit.edu		Wu, Zhengliang/0000-0002-0700-0906	NHLBI NIH HHS [1P01 HL 66105, 5R01 HL 59479] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066105, R01HL059479] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bobardt MD, 2003, IMMUNITY, V18, P27, DOI 10.1016/S1074-7613(02)00504-6; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Conrad H. E., 1988, HEPARIN BINDING PROT; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Kuberan B, 2003, J BIOL CHEM, V278, P52613, DOI 10.1074/jbc.M305029200; Kuberan B, 2003, NAT BIOTECHNOL, V21, P1343, DOI 10.1038/nbt885; Kuberan B, 2002, J AM CHEM SOC, V124, P8707, DOI 10.1021/ja0178867; Lander AD, 1998, MATRIX BIOL, V17, P465, DOI 10.1016/S0945-053X(98)90093-2; Li JP, 2003, J BIOL CHEM, V278, P28363, DOI 10.1074/jbc.C300219200; LINKER A, 1984, CARBOHYD RES, V127, P75, DOI 10.1016/0008-6215(84)85107-1; Liu J, 2002, MED RES REV, V22, P1, DOI 10.1002/med.1026; Mochizuki H, 2003, J BIOL CHEM, V278, P26780, DOI 10.1074/jbc.M301861200; Murthy KHM, 2001, CELL, V104, P301, DOI 10.1016/S0092-8674(01)00214-8; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; ROSENBERG RD, 1997, J CLIN INVEST, V100, P67; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SILVERBERG I, 1985, CARBOHYD RES, V137, P227, DOI 10.1016/0008-6215(85)85163-6; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Turnbull J, 2001, TRENDS CELL BIOL, V11, P75, DOI 10.1016/S0962-8924(00)01897-3; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Wu ZLL, 2003, J BIOL CHEM, V278, P17121, DOI 10.1074/jbc.M212590200; Wu ZLL, 2002, FASEB J, V16, P539, DOI 10.1096/fj.01-0807com; Zhang LJ, 1999, J BIOL CHEM, V274, P5681, DOI 10.1074/jbc.274.9.5681	24	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1861	1866		10.1074/jbc.M311398200	http://dx.doi.org/10.1074/jbc.M311398200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14602711	hybrid			2022-12-25	WOS:000188005700037
J	Yoshida, Y; Kumar, A; Koyama, Y; Peng, HB; Arman, A; Boch, JA; Auron, PE				Yoshida, Y; Kumar, A; Koyama, Y; Peng, HB; Arman, A; Boch, JA; Auron, PE			Interleukin 1 activates STAT3/nuclear factor-kappa B cross-talk via a unique TRAF6-and p65-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDE SYNTHASE GENE; IL-6 SIGNALING PATHWAYS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; C-SRC; PHOSPHATIDYLINOSITOL 3-KINASE; DEPENDENT MECHANISM; MESSENGER-RNA; IL1B GENE; STAT3	Interleukins (IL) 1 and 6 are important cytokines that function via the activation, respectively, of the transcription factors NF-kappaB and STAT3. We have observed that a specific type of kappaB DNA sequence motif supports both NF-kappaB p65 homodimer binding and cooperativity with non-tyrosine-phosphorylated STAT3. This activity, in contrast to that mediated by kappaB DNA motifs that do not efficiently bind p65 homodimers, is shown to be uniquely dependent upon signal transduction through the carboxyl terminus of TRAF6. Furthermore, STAT3 and p65 are shown to physically interact, in vivo, and this interaction appears to inhibit the function of "classical" STAT3 GAS-like binding sites. The distinct p50 form of NF-kappaB is also shown to interact with STAT3. However, in contrast to p65, p50 cooperates with STAT3 bound to GAS sites. These data argue for a novel transcription factor cross-talk mechanism that may help resolve inconsistencies previously reported regarding the mechanism of IL-1 inhibition of IL-6 activity during the acute-phase response.	Beth Israel Deaconess Med Ctr, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA	Harvard University; Beth Israel Deaconess Medical Center; New England Baptist Hospital; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Auron, PE (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, W1142 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15261 USA.	auron@pitt.edu		/0000-0003-1658-3119	NCI NIH HHS [CA 68544] Funding Source: Medline; NIAID NIH HHS [AI 44122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahmed ST, 2000, J IMMUNOL, V165, P5227, DOI 10.4049/jimmunol.165.9.5227; Arman A, 2003, ADV EXP MED BIOL, V534, P297; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Bhattacharya S, 2003, J CLIN INVEST, V111, P553, DOI 10.1172/JCI200315372; Bode JG, 2001, J IMMUNOL, V167, P1469, DOI 10.4049/jimmunol.167.3.1469; Bode JG, 1999, FEBS LETT, V463, P365, DOI 10.1016/S0014-5793(99)01662-2; Born TL, 1998, J BIOL CHEM, V273, P29445, DOI 10.1074/jbc.273.45.29445; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHANGDENG H, 2002, MOL CELL, V9, P789; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; CONTI P, 1995, MOL CELL BIOCHEM, V142, P171, DOI 10.1007/BF00928938; Dadgostar H, 1998, J BIOL CHEM, V273, P24775, DOI 10.1074/jbc.273.38.24775; Dadgostar H, 2000, J BIOL CHEM, V275, P2539, DOI 10.1074/jbc.275.4.2539; Deon D, 2001, J IMMUNOL, V167, P5395, DOI 10.4049/jimmunol.167.9.5395; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Ganster RW, 2001, P NATL ACAD SCI USA, V98, P8638, DOI 10.1073/pnas.151239498; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; Grey A, 2000, ENDOCRINOLOGY, V141, P2129, DOI 10.1210/en.141.6.2129; Han ZS, 1999, J BIOL CHEM, V274, P21355, DOI 10.1074/jbc.274.30.21355; KAPSTEIN A, 1996, J BIOL CHEM, V271, P5961; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Koyama Y, 1996, J IMMUNOL, V157, P5097; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P137; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Liu HZ, 1999, CURR BIOL, V9, P101, DOI 10.1016/S0960-9822(99)80023-2; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Lund TC, 1999, CELL SIGNAL, V11, P789, DOI 10.1016/S0898-6568(99)00045-5; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Marmiroli S, 1998, FEBS LETT, V438, P49, DOI 10.1016/S0014-5793(98)01270-8; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Messner B, 1997, J IMMUNOL, V159, P3330; Ng DCH, 2001, J BIOL CHEM, V276, P29490, DOI 10.1074/jbc.M100699200; Niehof M, 2001, J BIOL CHEM, V276, P9016, DOI 10.1074/jbc.M009284200; Ramana CV, 2000, ONCOGENE, V19, P2619, DOI 10.1038/sj.onc.1203525; REDDY S, 1997, J BIOL CHEM, V272, P167; Schaefer LK, 1999, BIOCHEM BIOPH RES CO, V266, P481, DOI 10.1006/bbrc.1999.1853; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; Schulte R, 2000, FASEB J, V14, P1471, DOI 10.1096/fj.14.11.1471; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Shen XI, 2000, BIOCHEM J, V352, P913, DOI 10.1042/0264-6021:3520913; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Stoiber D, 1999, J IMMUNOL, V163, P2640; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tinnell SB, 1998, INT IMMUNOL, V10, P1529, DOI 10.1093/intimm/10.10.1529; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Tsukada J, 1996, MOL CELL BIOL, V16, P2183; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Vidalain PO, 2000, EMBO J, V19, P3304, DOI 10.1093/emboj/19.13.3304; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wara-Aswapati N, 1999, MOL CELL BIOL, V19, P6803; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Yamazaki S, 2001, J BIOL CHEM, V276, P27657, DOI 10.1074/jbc.M103426200; Yang ZY, 2000, J BIOL CHEM, V275, P21272, DOI 10.1074/jbc.M000145200; Yoo JY, 2001, J BIOL CHEM, V276, P26421, DOI 10.1074/jbc.M009935200; Yu ZY, 2002, BIOCHEM J, V367, P97, DOI 10.1042/BJ20020588; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zhang XK, 2001, J BIOL CHEM, V276, P33576, DOI 10.1074/jbc.M104978200; Zhang ZX, 2000, BLOOD, V96, P3466, DOI 10.1182/blood.V96.10.3466.h8003466_3466_3472; Zhao DZ, 2001, J BIOL CHEM, V276, P44464, DOI 10.1074/jbc.M104942200; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	72	106	112	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1768	1776		10.1074/jbc.M311498200	http://dx.doi.org/10.1074/jbc.M311498200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14593105	hybrid			2022-12-25	WOS:000188005700026
J	Larsson, SL; Skogsberg, J; Bjorkegren, J				Larsson, SL; Skogsberg, J; Bjorkegren, J			The low density lipoprotein receptor prevents secretion of dense ApoB100-containing lipoproteins from the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; APOLIPOPROTEIN-B SECRETION; APO-B; ABETALIPOPROTEINEMIA GENE; EMBRYONIC LETHALITY; RICH LIPOPROTEINS; MCA-RH7777 CELLS; KNOCKOUT MICE; LDL RECEPTOR; CORE LIPIDS	The assembly and secretion of very low density lipoproteins (VLDL) require microsomal triglyceride transfer protein (MTP). Recent evidence also suggests a role for the low density lipoprotein (LDL) receptor in this process. However, the relative importance of MTP in the two steps of VLDL assembly and the specific role of the LDL receptor still remain unclear. To further investigate the role of MTP and the LDL receptor in VLDL assembly, we bred mice harboring "floxed" Mttp alleles (Mttp(flox/flox)) and a Cre transgene on a low-density lipoprotein receptor-deficient background to generate mice with double deficiency in the liver (Ldlr(-/-) Mttp(Delta/Delta)). In contrast to the plasma of Ldlr(+/+) Mttp(Delta/Delta) mice, the plasma of Ldlr(-/-) Mttp(Delta/Delta) mice contained apoB100. Accordingly, Ldlr(-/-) Mttp(Delta/Delta) but not Ldlr(+/+) Mttp(Delta/Delta) hepatocytes secreted apoB100-containing lipoprotein particles. The secreted lipoproteins were of LDL and HDL sizes but no VLDL-sized lipoproteins could be detected. These findings indicate that hepatic LDL receptors function as "gatekeepers" targeting dense apoB100-containing lipoproteins for degradation. In addition, these results suggest that very low levels of MTP are insufficient to mediate the second step but sufficient for the first step of VLDL assembly.	Karolinska Hosp, Karolinska Inst, King Gustaf V Res Inst, Atherosclerosis Res Unit, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Bjorkegren, J (corresponding author), Karolinska Hosp, Karolinska Inst, King Gustaf V Res Inst, Atherosclerosis Res Unit, S-17176 Stockholm, Sweden.							Bakillah A, 2000, BIOCHEMISTRY-US, V39, P4892, DOI 10.1021/bi9924009; Bjorkegren J, 2001, J BIOL CHEM, V276, P38511, DOI 10.1074/jbc.M106839200; Bradbury P, 1999, J BIOL CHEM, V274, P3159, DOI 10.1074/jbc.274.5.3159; Carlson K, 1973, J Clin Pathol Suppl (Assoc Clin Pathol), V5, P32; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; ENDO A, 1992, J LIPID RES, V33, P1569; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; Gillian-Daniel DL, 2002, P NATL ACAD SCI USA, V99, P4337, DOI 10.1073/pnas.072557199; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1997, CURR OPIN LIPIDOL, V8, P131, DOI 10.1097/00041433-199706000-00002; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Gregg Richard E., 1994, Current Opinion in Lipidology, V5, P81, DOI 10.1097/00041433-199404000-00003; HOEG JM, 1990, J LIPID RES, V31, P1761; Hussain MM, 1997, BIOCHEMISTRY-US, V36, P13060, DOI 10.1021/bi971395a; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KARPE F, 1994, J LIPID RES, V35, P1311; Kim E, 1998, J CLIN INVEST, V101, P1468; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; Leung GK, 2000, J BIOL CHEM, V275, P7515, DOI 10.1074/jbc.275.11.7515; Levy E, 2002, J BIOL CHEM, V277, P16470, DOI 10.1074/jbc.M102385200; Levy E, 1996, HEPATOLOGY, V23, P848, DOI 10.1002/hep.510230428; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA PTS, 1986, P NATL ACAD SCI USA, V83, P8370, DOI 10.1073/pnas.83.21.8370; Marks DL, 1999, J BIOL CHEM, V274, P451, DOI 10.1074/jbc.274.1.451; Millar JS, 2002, ARTERIOSCL THROM VAS, V22, P989, DOI 10.1161/01.ATV.0000018304.30943.06; Pan MH, 2002, J BIOL CHEM, V277, P4413, DOI 10.1074/jbc.M107460200; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; Rajewsky K, 1996, J CLIN INVEST, V98, P600, DOI 10.1172/JCI118828; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; Schuster H, 2002, ATHEROSCLEROSIS SUPP, V2, P27, DOI 10.1016/S1567-5688(01)00019-8; Segrest JP, 1999, J LIPID RES, V40, P1401; Sellers JA, 2001, J LIPID RES, V42, P1897; Shelness GS, 2001, CURR OPIN LIPIDOL, V12, P151, DOI 10.1097/00041433-200104000-00008; Twisk J, 2000, J CLIN INVEST, V105, P521, DOI 10.1172/JCI8623; Veniant MM, 2000, J CLIN INVEST, V106, P1501, DOI 10.1172/JCI10695; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P16741	40	48	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					831	836		10.1074/jbc.M303057200	http://dx.doi.org/10.1074/jbc.M303057200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14583618	hybrid			2022-12-25	WOS:000187722800004
J	Monaghan, E; Gueorguiev, V; Wilkins-Port, C; McKeown-Longo, PJ				Monaghan, E; Gueorguiev, V; Wilkins-Port, C; McKeown-Longo, PJ			The receptor for urokinase-type plasminogen activator regulates fibronectin matrix assembly in human skin fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN ACTIVATION; CELL-ADHESION; MONOCLONAL-ANTIBODIES; SIGNALING PATHWAYS; PLASMA FIBRONECTIN; BINDING DOMAIN; SITE; MIGRATION; KINASE; LOCALIZATION	Previous studies have indicated that the receptor for urokinase-type plasminogen activator, uPAR, can form functional complexes with integrin receptors thereby modulating integrin activity. In the present study, the role of uPAR in the regulation of alpha(5)beta(1)-dependent polymerization of the fibronectin matrix was investigated. Incubation of fibroblast monolayers with the P-25 peptide, a uPAR ligand, resulted in a 12-15-fold increase in the accumulation of exogenous fibronectin in the cell layer. The exogenous fibronectin co-localized in the extracellular matrix with endogenous cell-derived fibronectin, and its deposition into the matrix was inhibited by blocking antibodies against the beta(1) integrin receptor. The P-25-dependent increase in fibronectin assembly was associated with a 7-8-fold increase in the expression of matrix assembly sites as well as a 37-fold increase in the rate of transfer of cell surface-bound fibronectin into a detergent-insoluble matrix. The effects of P-25 on the matrix assembly were attenuated by incubating cells with either phospholipase C or with antibodies against uPAR, confirming a role for uPAR in the P-25-dependent increase in matrix assembly. P-25-treated cells exhibited a 10-fold increase in the binding of the 120-kDa cell-binding fragment of fibronectin suggesting an increase in alpha(5)beta(1) affinity for fibronectin. Consistent with this, treatment of cells with P-25 also resulted in a 6-10-fold increase in the binding of two different monoclonal antibodies that recognize the active conformation of the beta(1) integrin. These results indicate that P-25 increases matrix assembly by altering the activation state of the alpha(5)beta(1) integrin receptor and suggest that changes in integrin activation affect both the number of matrix assembly sites as well as the rate of transfer of cell-bound fibronectin into a detergent-insoluble matrix. These data provide direct evidence that uPAR and integrin receptors synergistically regulate the levels of fibronectin in the extracellular matrix.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College	McKeown-Longo, PJ (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, 47 New Scotland Ave, Albany, NY 12208 USA.	mckeowp@mail.amc.edu			NATIONAL CANCER INSTITUTE [R56CA058626, R01CA058626, R01CA069612] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007194] Funding Source: NIH RePORTER; NCI NIH HHS [CA-58626, CA-69612] Funding Source: Medline; NHLBI NIH HHS [T32-HL-07194] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Baneyx G, 2002, P NATL ACAD SCI USA, V99, P5139, DOI 10.1073/pnas.072650799; Baneyx G, 2001, P NATL ACAD SCI USA, V98, P14464, DOI 10.1073/pnas.251422998; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; Brenner KA, 2000, ONCOGENE, V19, P3156, DOI 10.1038/sj.onc.1203626; Bultmann H, 1998, J BIOL CHEM, V273, P2601, DOI 10.1074/jbc.273.5.2601; CARNEMOLLA B, 1987, FEBS LETT, V215, P269, DOI 10.1016/0014-5793(87)80160-6; Chen F, 1996, J BIOL CHEM, V271, P9084, DOI 10.1074/jbc.271.15.9084; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; Christopher RA, 1997, J CELL SCI, V110, P569; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; Erickson HP, 2002, J MUSCLE RES CELL M, V23, P575, DOI 10.1023/A:1023427026818; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; Garcia AJ, 2002, BIOCHEMISTRY-US, V41, P9063, DOI 10.1021/bi025752f; Garcia AJ, 1998, J BIOL CHEM, V273, P10988, DOI 10.1074/jbc.273.18.10988; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Hocking DC, 1999, J BIOL CHEM, V274, P27257, DOI 10.1074/jbc.274.38.27257; Hocking DC, 1996, J CELL BIOL, V133, P431, DOI 10.1083/jcb.133.2.431; Hocking DC, 1998, J CELL BIOL, V141, P241, DOI 10.1083/jcb.141.1.241; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Hynes RO, 1990, FIBRONECTINS; Jo M, 2003, J BIOL CHEM, V278, P1642, DOI 10.1074/jbc.M210877200; Kjoller L, 2001, J CELL BIOL, V152, P1145, DOI 10.1083/jcb.152.6.1145; KOWALCZYK AP, 1992, J CELL PHYSIOL, V152, P126, DOI 10.1002/jcp.1041520117; Langenbach KJ, 1999, J BIOL CHEM, V274, P7032, DOI 10.1074/jbc.274.11.7032; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1984, J BIOL CHEM, V259, P2210; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MCKEOWNLONGO PJ, 1987, J CELL BIOL, V104, P601, DOI 10.1083/jcb.104.3.601; MCKEOWNLONGO PJ, 1989, FIBRONECTIN, P163; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Ohashi T, 1999, P NATL ACAD SCI USA, V96, P2153, DOI 10.1073/pnas.96.5.2153; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; Petty HR, 1996, IMMUNOL TODAY, V17, P209, DOI 10.1016/0167-5699(96)30013-3; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; PLOUG M, 1991, J BIOL CHEM, V266, P1926; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; Sechler JL, 2001, J CELL BIOL, V154, P1081, DOI 10.1083/jcb.200102034; Sechler JL, 1997, MOL BIOL CELL, V8, P2563, DOI 10.1091/mbc.8.12.2563; Simon DI, 2000, J BIOL CHEM, V275, P10228, DOI 10.1074/jbc.275.14.10228; Simon DI, 1996, BLOOD, V88, P3185, DOI 10.1182/blood.V88.8.3185.bloodjournal8883185; Tarui T, 2001, J BIOL CHEM, V276, P3983, DOI 10.1074/jbc.M008220200; van der Pluijm G, 2001, AM J PATHOL, V159, P971, DOI 10.1016/S0002-9440(10)61773-7; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Wierzbicka-Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670; Wierzbicka-Patynowski I, 2002, J BIOL CHEM, V277, P19703, DOI 10.1074/jbc.M200270200; Wilcox-Adelman SA, 2000, CELL ADHES COMMUN, V7, P477, DOI 10.3109/15419060009040305; WU CY, 1995, J CELL SCI, V108, P2511; XUE W, 1994, J IMMUNOL, V152, P4630; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415; Zhang QH, 1999, J BIOL CHEM, V274, P368, DOI 10.1074/jbc.274.1.368; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	70	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1400	1407		10.1074/jbc.M310374200	http://dx.doi.org/10.1074/jbc.M310374200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14602715	hybrid			2022-12-25	WOS:000187722800069
J	Wu, SF; Palese, T; Mishra, OM; Delivoria-Papadopoulos, M; De Luca, F				Wu, SF; Palese, T; Mishra, OM; Delivoria-Papadopoulos, M; De Luca, F			Effects of Ca2+ sensing receptor activation in the growth plate	FASEB JOURNAL			English	Article						bone growth; endochondral ossification; chondrocytes	LONGITUDINAL BONE-GROWTH; SKELETAL PHENOTYPE; CALCIUM; CHONDROCYTES; HOMEOSTASIS; PHOSPHATE; RICKETS; MICE; CELL	The Ca2+-sensing receptor (CaR) is a G protein-coupled receptor expressed in many mammalian tissues, including the long bone.s growth plate. CaR knockout mice exhibit growth retardation, suggesting that CaR may promote skeletal growth. However, the complex phenotype of these knockout mice, which includes hyperparathyroidism, hypercalcemia, and hypophosphatemia, may confound the effects of CaR activation. To determine whether CaR regulates growth plate chondrogenesis and longitudinal bone growth, we chose an organ culture model. Fetal rat metatarsal bones (dpc 20) were cultured in serum-free medium for 7 days in the presence or absence of NPS-R-568, a CaR agonist. The addition of 10 nM NPS-R-568 increased the cumulative longitudinal growth of the metatarsal explants. To explore the underlying mechanisms, we then assessed the effects of NPS-R-568 on growth plate chondrocyte hypertrophy/differentiation and chondrocyte proliferation. After 7 days in culture, NPS-R-568 increased the height of the growth plate hypertrophic zone and the expression of collagen X, a marker of growth plate chondrocyte differentiation (assessed by immunohistochemistry). NPSR-568 also induced a significant increase of the height of the growth plate proliferative zone and of the total thymidine incorporation in the metatarsal bone. In conclusion, our findings suggest that the activation of CaR in the growth plate accelerates longitudinal bone growth by stimulating growth plate chondrogenesis.	St Christophers Hosp Children, Philadelphia, PA 19134 USA; Drexel Univ, St Christophers Hosp Children, Coll Med, Dept Pediat,Sect Endocrinol & Diabet, Philadelphia, PA USA; Drexel Univ, St Christophers Hosp Children, Coll Med, Dept Pediat,Sect Neonatal Med, Philadelphia, PA USA; Univ Maryland, Sch Med, Dept Pediat, Div Pediat Endocrinol, Baltimore, MD USA	Drexel University; Drexel University; University System of Maryland; University of Maryland Baltimore	De Luca, F (corresponding author), St Christophers Hosp Children, Erie Ave & Front St, Philadelphia, PA 19134 USA.	francesco.deluca@drexel.edu						AHARINEJAD S, 1995, ANAT REC, V242, P111, DOI 10.1002/ar.1092420115; Amling M, 1999, ENDOCRINOLOGY, V140, P4982, DOI 10.1210/en.140.11.4982; BAGI C, 1989, CALCIFIED TISSUE INT, V45, P342, DOI 10.1007/BF02556004; BAGI CM, 1992, J BONE MINER RES, V7, P29; BONEN DK, 1991, J CELL BIOL, V115, P1171, DOI 10.1083/jcb.115.4.1171; BREUR GJ, 1991, J ORTHOPAED RES, V9, P348, DOI 10.1002/jor.1100090306; Brown EM, 2000, ANNU REV NUTR, V20, P507, DOI 10.1146/annurev.nutr.20.1.507; BRUCKNER P, 1989, J CELL BIOL, V109, P2537, DOI 10.1083/jcb.109.5.2537; Chang WH, 1999, ENDOCRINOLOGY, V140, P1911, DOI 10.1210/en.140.4.1911; Chang YH, 1999, ENDOCRINOLOGY, V140, P5883, DOI 10.1210/en.140.12.5883; De Luca F, 2001, ENDOCRINOLOGY, V142, P430, DOI 10.1210/en.142.1.430; FARNUM CE, 1987, MICROSCOP RES TECH, V28, P505; Garner SC, 2001, ENDOCRINOLOGY, V142, P3996, DOI 10.1210/en.142.9.3996; HUNZIKER EB, 1994, MICROSC RES TECHNIQ, V28, P505, DOI 10.1002/jemt.1070280606; IANNOTTI JP, 1990, ORTHOP CLIN N AM, V21, P1; KLEIN GL, 1993, ANN MED, V25, P379, DOI 10.3109/07853899309147300; Lunstrum GP, 1999, J HISTOCHEM CYTOCHEM, V47, P1, DOI 10.1177/002215549904700101; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; Noonan KJ, 1998, J ORTHOPAED RES, V16, P500, DOI 10.1002/jor.1100160416; Wang DS, 2001, J BIOL CHEM, V276, P33995, DOI 10.1074/jbc.M007757200; WUTHIER RE, 1993, J NUTR, V123, P301, DOI 10.1093/jn/123.suppl_2.301; Zuscik MJ, 2002, EXP CELL RES, V276, P310, DOI 10.1006/excr.2002.5527	22	42	45	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					143	145		10.1096/fj.03-0294fje	http://dx.doi.org/10.1096/fj.03-0294fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597561				2022-12-25	WOS:000188829300054
J	Conte, N; Delaval, B; Ginestier, C; Ferrand, A; Isnardon, D; Larroque, C; Prigent, C; Seraphin, B; Jacquemier, J; Birnbaum, D				Conte, N; Delaval, B; Ginestier, C; Ferrand, A; Isnardon, D; Larroque, C; Prigent, C; Seraphin, B; Jacquemier, J; Birnbaum, D			TACC1-chTOG-Aurora A protein complex in breast cancer	ONCOGENE			English	Article						Aurora kinase; breast cancer; cell division; chTOG protein; microtubule; SM proteins; TACC protein; tissue microarray; RNAi	DROSOPHILA AURORA-A; SM-LIKE PROTEIN; MESSENGER-RNA; COILED-COIL; TRANSLATIONAL CONTROL; D-TACC; SERINE/THREONINE KINASE; EXPRESSION ANALYSIS; TUMOR SUPPRESSOR; GENE FAMILY	The three human TACC (transforming acidic coiled-coil) genes encode a family of proteins with poorly defined functions that are suspected to play a role in oncogenesis. A Xenopus TACC homolog called Maskin is involved in translational control, while Drosophila D-TACC interacts with the microtubule-associated protein MSPS (Mini SPindleS) to ensure proper dynamics of spindle pole microtubules during cell division. We have delineated here the interactions of TACC1 with four proteins, namely the microtubule-associated chTOG (colonic and hepatic tumor-overexpressed gene) protein (ortholog of Drosophila MSPS), the adaptor protein TRAP (tudor repeat associator with PCTAIRE2), the mitotic serine/threonine kinase Aurora A and the mRNA regulator LSM7 (Like-Sm protein 7). To measure the relevance of the TACC1-associated complex in human cancer we have examined the expression of the three TACC, chTOG and Aurora A in breast cancer using immunohistochemistry on tissue microarrays. We show that expressions of TACC1, TACC2, TACC3 and Aurora A are significantly correlated and downregulated in a subset of breast tumors. Using siRNAs, we further show that depletion of chTOG and, to a lesser extent of TACC1, perturbates cell division. We propose that TACC proteins, which we also named 'Taxins', control mRNA translation and cell division in conjunction with microtubule organization and in association with chTOG and Aurora A, and that these complexes and cell processes may be affected during mammary gland oncogenesis.	Inst J Paoli I Calmettes, INSERM, U119, IFR57,Dept Mol Oncol, F-13009 Marseille, France; Inst J Paoli I Calmettes, Imaging Core Facil, F-13009 Marseille, France; CRLC Val Aurelle Paul Lamarque, INSERM, E229, Montpellier, France; Fac Med, CNRS, UMR 6061, IFR 97,Lab Cycle Cellulaire, Rennes, France; Ctr Genet Mol, Gif Sur Yvette, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Centre National de la Recherche Scientifique (CNRS)	Birnbaum, D (corresponding author), Inst J Paoli I Calmettes, INSERM, U119, IFR57,Dept Mol Oncol, 27 Bd Lei Roure, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr	Ginestier, Christophe/M-8828-2017	Ginestier, Christophe/0000-0002-7477-3837; Birnbaum, Daniel/0000-0001-7920-9883; Conte, Nathalie/0000-0002-1010-3121; Seraphin, Bertrand/0000-0002-5168-1921				Aitola M, 2003, J HISTOCHEM CYTOCHEM, V51, P455, DOI 10.1177/002215540305100407; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Barbarese E, 2002, J NEUROCHEM, V81, P93; Barbee SA, 2002, CURR BIOL, V12, P1502, DOI 10.1016/S0960-9822(02)01111-9; Berdnik D, 2002, CURR BIOL, V12, P640, DOI 10.1016/S0960-9822(02)00766-2; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Blagden SP, 2003, NAT CELL BIOL, V5, P505, DOI 10.1038/ncb0603-505; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Bouveret E, 2000, EMBO J, V19, P1661, DOI 10.1093/emboj/19.7.1661; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Charrasse S, 1998, J CELL SCI, V111, P1371; CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x; Charrasse S, 2000, EXP CELL RES, V254, P249, DOI 10.1006/excr.1999.4740; Chen HM, 2000, MOL BIOL CELL, V11, P1357, DOI 10.1091/mbc.11.4.1357; Chen SS, 2002, EMBO J, V21, P4491, DOI 10.1093/emboj/cdf409; Conte N, 2002, ONCOGENE, V21, P5619, DOI 10.1038/sj.onc.1205658; Cremet JY, 2003, MOL CELL BIOCHEM, V243, P123, DOI 10.1023/A:1021608012253; Cullen CF, 2001, NAT CELL BIOL, V3, P637, DOI 10.1038/35083025; Dutertre S, 2002, ONCOGENE, V21, P6175, DOI 10.1038/sj.onc.1205775; Gergely F, 2002, BIOESSAYS, V24, P915, DOI 10.1002/bies.10162; Gergely F, 2000, EMBO J, V19, P241, DOI 10.1093/emboj/19.2.241; Gergely F, 2000, P NATL ACAD SCI USA, V97, P14352, DOI 10.1073/pnas.97.26.14352; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 1999, J CELL SCI, V112, P3591; Ginestier C, 2002, AM J PATHOL, V161, P1223, DOI 10.1016/S0002-9440(10)64399-4; GREGELY F, 2003, GENE DEV, V17, P336; Groisman I, 2000, CELL, V103, P435, DOI 10.1016/S0092-8674(00)00135-5; Groisman I, 2002, CELL, V109, P473, DOI 10.1016/S0092-8674(02)00733-X; Hao ZL, 2002, MOL REPROD DEV, V63, P291, DOI 10.1002/mrd.90012; Hirose T, 1997, EUR J BIOCHEM, V249, P481, DOI 10.1111/j.1432-1033.1997.t01-1-00481.x; Hirose T, 2000, EUR J BIOCHEM, V267, P2113, DOI 10.1046/j.1432-1327.2000.01218.x; Huang XQ, 1999, GENOME RES, V9, P868, DOI 10.1101/gr.9.9.868; Huang YS, 2002, EMBO J, V21, P2139, DOI 10.1093/emboj/21.9.2139; Kramer A, 2002, LEUKEMIA, V16, P767, DOI 10.1038/sj.leu.2402454; Lappin TR, 2002, LEUKEMIA LYMPHOMA, V43, P1455, DOI 10.1080/1042819022386644; Lauffart B, 2003, GENOMICS, V81, P192, DOI 10.1016/S0888-7543(02)00039-3; Lauffart B, 2002, BIOCHEM J, V363, P195, DOI 10.1042/0264-6021:3630195; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; Line A, 2002, CANCER GENET CYTOGEN, V139, P78, DOI 10.1016/S0165-4608(02)00607-6; Line A, 2002, BRIT J CANCER, V86, P1824, DOI 10.1038/sj.bjc.6600321; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Mack GJ, 2000, MICROSC RES TECHNIQ, V49, P409, DOI 10.1002/(SICI)1097-0029(20000601)49:5<409::AID-JEMT2>3.0.CO;2-V; McKeveney PJ, 2001, BRIT J HAEMATOL, V112, P1016, DOI 10.1046/j.1365-2141.2001.02644.x; Mendez R, 2002, EMBO J, V21, P1833, DOI 10.1093/emboj/21.7.1833; Mendez R, 2001, NAT REV MOL CELL BIO, V2, P521, DOI 10.1038/35080081; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Nonet GH, 2001, CANCER RES, V61, P1250; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Popovici C, 2001, BIOCHEM BIOPH RES CO, V288, P362, DOI 10.1006/bbrc.2001.5794; Pu JJ, 2001, CYTOKINE, V13, P129, DOI 10.1006/cyto.2000.0812; Raff JW, 2002, TRENDS CELL BIOL, V12, P222, DOI 10.1016/S0962-8924(02)02268-7; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Richter JD, 2001, P NATL ACAD SCI USA, V98, P7069, DOI 10.1073/pnas.111146498; Roghi C, 1998, J CELL SCI, V111, P557; Sadek CM, 2000, MECH DEVELOP, V97, P13, DOI 10.1016/S0925-4773(00)00415-9; Sadek CM, 2003, GENE EXPR PATTERNS, V3, P203, DOI 10.1016/S1567-133X(02)00066-2; Salgado-Garrido J, 1999, EMBO J, V18, P3451, DOI 10.1093/emboj/18.12.3451; Schweinfest CW, 1997, CANCER RES, V57, P2961; Selenko P, 2001, NAT STRUCT BIOL, V8, P27; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Spittle C, 2000, J BIOL CHEM, V275, P20748, DOI 10.1074/jbc.M002597200; STEADMAN BT, 2002, J BIOL CHEM, V363, P195; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; Tharun S, 2000, NATURE, V404, P515, DOI 10.1038/35006676; Theurkauf WE, 2001, NAT CELL BIOL, V3, pE159, DOI 10.1038/35083110; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	71	78	87	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2003	22	50					8102	8116		10.1038/sj.onc.1206972	http://dx.doi.org/10.1038/sj.onc.1206972			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603251				2022-12-25	WOS:000186403400005
J	Discenza, MT; He, SJ; Lee, TH; Chu, LL; Bolon, B; Goodyer, P; Eccles, M; Pelletier, J				Discenza, MT; He, SJ; Lee, TH; Chu, LL; Bolon, B; Goodyer, P; Eccles, M; Pelletier, J			WT1 is a modifier of the Pax2 mutant phenotype: cooperation and interaction between WT1 and Pax2	ONCOGENE			English	Article						WT1; Pax2; kidney development; protein-protein interactions	TUMOR SUPPRESSOR GENE; WILMS-TUMOR; KIDNEY DEVELOPMENT; UROGENITAL DEVELOPMENT; EXPRESSION; RECEPTOR; REPRESSION; INHIBITION; MUTATIONS; FAMILY	Metanephric kidney development requires an inductive interaction between the ureteric bud and progenitor mesenchyme, where the early expression of two genes, Wilms' tumour 1 (WT1) and paired box 2 (Pax2), establishes critical but unknown developmental pathways. Indeed, transgenic mice with deregulated overexpression of Pax2 exhibit structural kidney defects and impaired renal function, as do mice harboring targeted disruptions and/or spontaneous mutations of either the Pax2 or WT1 genes. WT1 and Pax2 are thought to regulate each other's expression during renal development. To better de. ne the relationship between WT1 and Pax2, we generated mouse embryos containing heterozygous mutations in both genes. WT1(+/-)/Pax2(1Neu/+) kidneys were 50% smaller than wildtype kidneys. They were characterized by severe attenuation of the renal medulla, and reduced development of calyces and the renal pelvis. Renal cortex development in compound heterozygotes culminated in fewer nephrons than in WT1(+/-), Pax2(1Neu/+) or wild-type mice. Only minor variations in the mesenchymal expression pattern of Pax2 protein, and the mRNA expression levels of Pax2 and WT1, were noted in mutant kidneys. We show that WT1 and Pax2 proteins interact in vitro and in vivo, demonstrating that WT1 and Pax2 can form a molecular complex. Our data suggest that WT1 is a modifier of the Pax2 mutant phenotype.	Univ Otago, Dept Pathol, Dunedin 9015, New Zealand; McGill Univ, Dept Biochem, Montreal, PQ, Canada; Amgen Inc, Dept Pathol, Thousand Oaks, CA 91320 USA; McGill Univ, Montreal Childrens Hosp, Dept Pediat, Montreal, PQ H3H 1P3, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ, Canada	University of Otago; McGill University; Amgen; McGill University; McGill University	Eccles, M (corresponding author), Univ Otago, Dept Pathol, Hercus Bldg,Hanover St,POB 913, Dunedin 9015, New Zealand.		Lee, Tae Ho/AAT-1721-2020					Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; Dehbi M, 1996, ONCOGENE, V13, P447; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; Eccles MR, 1998, PEDIATR NEPHROL, V12, P712, DOI 10.1007/s004670050533; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; EVERS P, 1994, J HISTOCHEM CYTOCHEM, V42, P1555, DOI 10.1177/42.12.7983356; Favor J, 1996, P NATL ACAD SCI USA, V93, P13870, DOI 10.1073/pnas.93.24.13870; GNARRA JR, 1995, CANCER RES, V55, P4092; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; Kim J, 2000, FEBS LETT, V474, P121, DOI 10.1016/S0014-5793(00)01590-8; Kreidberg JA, 1999, MOL REPROD DEV, V52, P366, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;366::AID-MRD5&gt;3.0.CO;2-Y; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Lechner MS, 2000, NUCLEIC ACIDS RES, V28, P2741, DOI 10.1093/nar/28.14.2741; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lee TH, 2002, J BIOL CHEM, V277, P44826, DOI 10.1074/jbc.M205667200; Lee TH, 2001, PHYSIOL GENOMICS, V7, P187, DOI 10.1152/physiolgenomics.00046.2001; Little M, 1999, BIOESSAYS, V21, P191, DOI 10.1002/(SICI)1521-1878(199903)21:3<191::AID-BIES3>3.3.CO;2-#; McConnell MJ, 1997, ONCOGENE, V14, P2689, DOI 10.1038/sj.onc.1201114; Moore AW, 1999, DEVELOPMENT, V126, P1845; MURATOVSKA A, 2003, IN PRESS ONCOGENE; Palmer RE, 2001, CURR BIOL, V11, P1805, DOI 10.1016/S0960-9822(01)00560-7; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; Porteous S, 2000, HUM MOL GENET, V9, P1, DOI 10.1093/hmg/9.1.1; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; Schedl A, 2000, CURR OPIN GENET DEV, V10, P543, DOI 10.1016/S0959-437X(00)00125-8; Sim EUH, 2002, ONCOGENE, V21, P2948, DOI 10.1038/sj.onc.1205373; Torres M, 1995, DEVELOPMENT, V121, P4057; WERNER H, 1995, MOL CELL BIOL, V15, P3516; WERNER H, 1995, INT J BIOCHEM CELL B, V27, P987, DOI 10.1016/1357-2725(95)00074-Y; Wheat W, 1999, MOL CELL BIOL, V19, P2231	39	27	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8145	8155		10.1038/sj.onc.1206997	http://dx.doi.org/10.1038/sj.onc.1206997			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603255				2022-12-25	WOS:000186403400009
J	Benelli, R; Peissel, B; Manenti, G; Gariboldi, M; Vanzetto, C; Albini, A; Dragani, TA				Benelli, R; Peissel, B; Manenti, G; Gariboldi, M; Vanzetto, C; Albini, A; Dragani, TA			Allele-specific patterns of the mouse parathyroid hormone-related protein: influences on cell adhesion and migration	ONCOGENE			English	Article						cancer modifier genes; genetic susceptibility; polymorphism skin cancer	EXTRACELLULAR-MATRIX; TUMOR INVASION; PTHRP; PEPTIDE; BREAST; EXPRESSION; MOTILITY; RECEPTOR; LINE	The mouse parathyroid hormone-like hormone Pthlh(Pro) and Pthlh(Thr) variants are linked with susceptibility and resistance to skin carcinogenesis of Car-S and Car-R mice, respectively, and with in vitro effects ( Oncogene, 19: 5324 - 5328, 2000). We have identified an additional Pthlh variant, consisting of Thr and three amino-acid changes in the C-terminus (Pthlh(SerAspTyr)), carried by an evolutionarily distant Mus spretus (SPRET/Ei) inbred strain. When transfected into NCI-H520 tumor cells, this Pthlh(SerAspTyr) variant did not stimulate tumor growth in nude mice. Analysis of cell adhesion, migration, and invasion patterns of Pthlh(Pro)-, Pthlh(Thr)-, and Pthlh(SerAspTyr)- transfected NCI-H520 cells revealed a 1.5-fold decrease in adhesion efficiency on both collagen type I and Matrigel, and a 5-6-fold increase in migration capability in Pthlh(Pro) transfectants as compared to nontransfected, vector-transfected, Pthlh(Thr)-, or Pthlh(SerAspTyr)- transfected cells. These findings suggest that the cancer modifier effects of the mouse Pthlh gene are mediated by differential cell adhesion and migration effects of PTHrP variants.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Ist Nazl Ric Canc, Mol Biol Lab, I-16132 Genoa, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Genoa; IRCCS AOU San Martino IST	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.		Manenti, Giacomo/J-3339-2017; Benelli, Roberto/AAF-3143-2019; Peissel, Bernard/E-8187-2017; Dragani, Tommaso A./K-4493-2016; Gariboldi, Manuela/K-4744-2016	Manenti, Giacomo/0000-0002-4887-4482; Benelli, Roberto/0000-0002-9769-0954; Peissel, Bernard/0000-0001-9233-3571; Dragani, Tommaso A./0000-0001-5915-4598; Albini, Adriana/0000-0002-9624-5103; Gariboldi, Manuela/0000-0001-8406-165X				Akino K, 2000, ENDOCRINOLOGY, V141, P4313, DOI 10.1210/en.141.11.4313; ALBINI A, 1987, CANCER RES, V47, P3239; Albini A, 1998, Pathol Oncol Res, V4, P230; Bakre MM, 2002, NAT MED, V8, P995, DOI 10.1038/nm753; Boccellino M, 2000, J CELL PHYSIOL, V183, P254, DOI 10.1002/(SICI)1097-4652(200005)183:2<254::AID-JCP12>3.0.CO;2-U; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Conlan LA, 2002, FEBS LETT, V527, P71, DOI 10.1016/S0014-5793(02)03164-2; De Miguel F, 2001, ENDOCRINOLOGY, V142, P4096, DOI 10.1210/en.142.9.4096; Fassina G, 1996, INT J ONCOL, V8, P253; Goomer RS, 2000, ENDOCRINOLOGY, V141, P4613, DOI 10.1210/en.141.12.4613; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; Luparello C, 1999, FEBS LETT, V463, P265, DOI 10.1016/S0014-5793(99)01635-X; Manenti G, 2000, ONCOGENE, V19, P5324, DOI 10.1038/sj.onc.1203916; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; Muller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630; Nagase H, 1999, P NATL ACAD SCI USA, V96, P15032, DOI 10.1073/pnas.96.26.15032; POSTLETHWAITE AE, 1976, J EXP MED, V144, P1188, DOI 10.1084/jem.144.5.1188; Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142; Rabbani SA, 2000, INT J ONCOL, V16, P197; Sepulveda VAT, 2002, ENDOCRINOLOGY, V143, P596, DOI 10.1210/en.143.2.596; Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306; Ye YM, 2001, REGUL PEPTIDES, V101, P19, DOI 10.1016/S0167-0115(01)00259-2	22	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7711	7715		10.1038/sj.onc.1207088	http://dx.doi.org/10.1038/sj.onc.1207088			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586397				2022-12-25	WOS:000186240200001
J	Bravo, SB; Pampin, S; Cameselle-Teijeiro, J; Carneiro, C; Dominguez, F; Barreiro, F; Alvarez, CV				Bravo, SB; Pampin, S; Cameselle-Teijeiro, J; Carneiro, C; Dominguez, F; Barreiro, F; Alvarez, CV			TGF-beta-induced apoptosis in human thyrocytes is mediated by p27(kip1) reduction and is overridden in neoplastic thyrocytes by NF-kappa B activation	ONCOGENE			English	Article						TGF-beta; thyroid cancer; p27; apoptosis; NF-kappa B	THYROID-TUMORS; PROLIFERATIVE ACTIVITY; MESSENGER-RNA; GROWTH; CELLS; EXPRESSION; QUIESCENCE; RESISTANCE; RECEPTOR; MODEL	Millions of people worldwide suffer goiter, a proliferative disease of the follicular cells of the thyroid that may become neoplastic. Thyroid neoplasms have low proliferative index, low apoptotic index and a high incidence of metastasis. TGF-beta is overexpressed in thyroid follicular tumor cells. To investigate the role of TGF-beta in thyroid tumor progression, we established cultures of human thyrocytes from different proliferative pathologies ( Grave's disease, multinodular goiter, follicular adenoma, papillary carcinoma), lymph node metastasis, and a normal thyroid sample. All cultures maintained the thyrocyte phenotype. TGF-beta induced cell-cycle arrest in all cultures, in contrast with results reported for other epithelial tumors. In deprived medium, TGF-beta induced apoptosis in normal thyrocyte cultures and all neoplastic cultures except the metastatic cultures. This apoptosis was mediated by a reduction in p27(kip1) levels, inducing cell-cycle initiation. Antisense p27 expression induced apoptosis in the absence of TGF-beta. By contrast, in cells in which p27 was overexpressed, TGF-beta had a survival effect. In growth medium, a net survival effect occurs in neoplastic thyrocytes only, not normal thyrocytes, due to activation of the NF-kappaB survival program. Together, these findings suggest that (a) thyroid neoplasms are due to reduced apoptosis, not increased division, in line with the low proliferative index of these pathologies, and (b) TGF-beta induces apoptosis in normal thyrocytes via p27 reduction, but that in neoplastic thyrocytes this effect is overridden by activation of the NF-kappaB program.	Univ Santiago de Compostela, Sch Med, Dept Physiol, Santiago De Compostela 15782, Spain; Hosp Clin Univ, Dept Pathol, Santiago De Compostela 15706, Spain; Hosp Clin Univ, Dept Surg, Santiago De Compostela 15706, Spain	Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela	Alvarez, CV (corresponding author), Univ Santiago de Compostela, Sch Med, Dept Physiol, San Francisco S-N, Santiago De Compostela 15782, Spain.	fscralvi@usc.es	Lopez, Susana Belén Bravo/F-8487-2016; Alvarez, Clara V/AAN-4173-2020	Lopez, Susana Belén Bravo/0000-0001-7615-3079; Alvarez, Clara V/0000-0003-1500-4058				Achenbach TV, 2000, CLIN CANCER RES, V6, P3006; ASA SL, 2001, CANC HDB, pCH9; Asmis LM, 1996, J ENDOCRINOL, V149, P485, DOI 10.1677/joe.0.1490485; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Blaydes JP, 1996, INT J CANCER, V65, P525, DOI 10.1002/(SICI)1097-0215(19960208)65:4<525::AID-IJC22>3.3.CO;2-G; Carneiro C, 1998, ONCOGENE, V16, P1455, DOI 10.1038/sj.onc.1201662; Chan JKC, 2000, DIAGNOSTIC HISTOPATH, P959; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; D'Agnano I, 2001, ONCOGENE, V20, P2814, DOI 10.1038/sj.onc.1204392; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; Derwahl M, 2002, TRENDS ENDOCRIN MET, V13, P23, DOI 10.1016/S1043-2760(01)00519-7; Derwahl M, 2000, BEST PRACT RES CL EN, V14, P577, DOI 10.1053/beem.2000.0104; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Eymin B, 1999, ONCOGENE, V18, P1411, DOI 10.1038/sj.onc.1202437; Freitas JE, 2000, SEMIN NUCL MED, V30, P88, DOI 10.1053/nm.2000.4597; Goretzki PE, 2000, WORLD J SURG, V24, P913, DOI 10.1007/s002680010174; GRUBECKLOEBENSTEIN B, 1989, J CLIN INVEST, V83, P764, DOI 10.1172/JCI113955; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Kammori M, 2002, EXP GERONTOL, V37, P513, DOI 10.1016/S0531-5565(01)00178-4; KATOH R, 1995, HUM PATHOL, V26, P139, DOI 10.1016/0046-8177(95)90029-2; Khoo MLC, 2002, J CLIN ENDOCR METAB, V87, P1814, DOI 10.1210/jcem.87.4.8353; Kimura ET, 1999, THYROID, V9, P119, DOI 10.1089/thy.1999.9.119; Ladha MH, 1998, MOL CELL BIOL, V18, P6605, DOI 10.1128/MCB.18.11.6605; Lazzereschi D, 1997, CANCER RES, V57, P2071; LEE TK, 1985, HUM PATHOL, V16, P1042, DOI 10.1016/S0046-8177(85)80282-3; Levy O, 1998, J BIOL CHEM, V273, P22657, DOI 10.1074/jbc.273.35.22657; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Matthews P, 2001, J PATHOL, V194, P183, DOI 10.1002/path.848; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Moore D, 1998, HISTOPATHOLOGY, V32, P35; MORTENSEN JD, 1955, J CLIN ENDOCR METAB, V15, P1270, DOI 10.1210/jcem-15-10-1270; Mothersill C, 1995, Methods Mol Biol, V43, P25; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; SOARES P, 1994, CANCER, V73, P2879, DOI 10.1002/1097-0142(19940601)73:11<2879::AID-CNCR2820731135>3.0.CO;2-E; Sreelekha TT, 2000, THYROID, V10, P117, DOI 10.1089/thy.2000.10.117; Urbano AG, 2000, ENDOCRINOLOGY, V141, P1893, DOI 10.1210/en.141.5.1893; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333; Yoshida A, 1999, SURG TODAY, V29, P204	45	44	44	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2003	22	49					7819	7830		10.1038/sj.onc.1207029	http://dx.doi.org/10.1038/sj.onc.1207029			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586408				2022-12-25	WOS:000186240200012
J	Orlandi, I; Bettiga, M; Alberghina, L; Vai, M				Orlandi, I; Bettiga, M; Alberghina, L; Vai, M			Transcriptional profiling of ubp10 null mutant reveals altered subtelomeric gene expression and insurgence of oxidative stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOA4 DEUBIQUITINATING ENZYME; SACCHAROMYCES-CEREVISIAE; CELL-DEATH; YEAST; APOPTOSIS; PATHWAY; GENOME; SIR4; UBIQUITINATION; PROTEASOME	UBP10 codes for a deubiquitinating enzyme of Saccharomyces cerevisiae whose loss of function determines slow growth rate and partial impairment of silencing at telomeres and HM loci. A genome-wide analysis performed on a ubp10 disruptant revealed alterations in expression of subtelomeric genes together with a broad change in the whole transcriptional profile, closely parallel to that induced by oxidative stress. This response was accompanied by intracellular accumulation of reactive oxygen species as well as by DNA fragmentation and phosphatidylserine externalization, two markers of apoptosis. SIR4 inactivation mitigated the wide transcriptome remodeling of the ubp10 null mutant affecting particularly the stress transcriptional profile. Moreover, the ubp10sir4 disruptant did not display apoptotic markers. These results argue in favor of an involvement of deubiquitination in transcriptional control and suggest a linkage between oxidative stress and apoptotic pathway in budding yeast.	Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, I-20126 Milan, Italy	University of Milano-Bicocca	Vai, M (corresponding author), Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, Piazza Sci 2, I-20126 Milan, Italy.	marina.vai@unimib.it	Bettiga, Maurizio/A-4690-2013	Bettiga, Maurizio/0000-0001-5934-8720; Alberghina, Lilia/0000-0003-1694-931X				Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; Amerik AY, 1997, EMBO J, V16, P4826; Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Bernstein BE, 2002, CHEM BIOL, V9, P1167, DOI 10.1016/S1074-5521(02)00265-X; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Chang JF, 2003, STRUCTURE, V11, P637, DOI 10.1016/S0969-2126(03)00093-5; Checler F, 2000, BBA-MOL BASIS DIS, V1502, P133, DOI 10.1016/S0925-4439(00)00039-9; CHENG L, 1994, MOL GEN GENET, V243, P358, DOI 10.1007/BF00301072; Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880; Collinson EJ, 2002, J BIOL CHEM, V277, P16712, DOI 10.1074/jbc.M111686200; Denu JM, 2003, TRENDS BIOCHEM SCI, V28, P41, DOI 10.1016/S0968-0004(02)00005-1; Estruch F, 2000, FEMS MICROBIOL REV, V24, P469, DOI 10.1016/S0168-6445(00)00035-8; Fan HY, 1996, GENETICS, V142, P749; FEDEROFF HJ, 1982, J BACTERIOL, V149, P1064, DOI 10.1128/JB.149.3.1064-1070.1982; Frohlich KU, 2000, FEBS LETT, V473, P6, DOI 10.1016/S0014-5793(00)01474-5; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Gelli A, 2002, MOL MICROBIOL, V46, P845, DOI 10.1046/j.1365-2958.2002.03213.x; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; Granucci F, 2001, NAT IMMUNOL, V2, P882, DOI 10.1038/ni0901-882; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Higgins VJ, 2002, YEAST, V19, P203, DOI 10.1002/yea.811; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Huang Y, 2002, NUCLEIC ACIDS RES, V30, P1465, DOI 10.1093/nar/30.7.1465; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Jamieson DJ, 1998, YEAST, V14, P1511, DOI 10.1002/(SICI)1097-0061(199812)14:16<1511::AID-YEA356>3.3.CO;2-J; JOHNSON AD, 1995, CURR OPIN GENET DEV, V5, P552, DOI 10.1016/0959-437X(95)80022-0; Kahana A, 1999, MOL CELL BIOL, V19, P6608; Kahana A, 2001, BIOCHEM BIOPH RES CO, V282, P916, DOI 10.1006/bbrc.2001.4669; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; Koerkamp MG, 2002, MOL BIOL CELL, V13, P2783, DOI 10.1091/mbc.E02-02-0075; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Laun P, 2001, MOL MICROBIOL, V39, P1166, DOI 10.1046/j.1365-2958.2001.02317.x; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Ligr M, 2001, MOL BIOL CELL, V12, P2422, DOI 10.1091/mbc.12.8.2422; Ludovico P, 2001, MICROBIOL-SGM, V147, P3335, DOI 10.1099/00221287-147-12-3335; Luo KH, 2002, GENE DEV, V16, P1528, DOI 10.1101/gad.988802; Madeo F, 2002, CURR GENET, V41, P208, DOI 10.1007/s00294-002-0310-2; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Mimnaugh EG, 2001, CELL DEATH DIFFER, V8, P1182, DOI 10.1038/sj.cdd.4400924; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; Papa FR, 1999, MOL BIOL CELL, V10, P741, DOI 10.1091/mbc.10.3.741; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; POPOLO L, 1993, CURR GENET, V24, P382, DOI 10.1007/BF00351845; Posas F, 2000, J BIOL CHEM, V275, P17249, DOI 10.1074/jbc.M910016199; Qi HY, 2003, J BIOL CHEM, V278, P15136, DOI 10.1074/jbc.M212808200; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schwartz AL, 1999, ANNU REV MED, V50, P57; Singer MS, 1998, GENETICS, V150, P613; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Smith JS, 1998, GENETICS, V149, P1205; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; ter Linde JJM, 1999, J BACTERIOL, V181, P7409, DOI 10.1128/JB.181.24.7409-7413.1999; VANONI M, 1983, J BACTERIOL, V156, P1282, DOI 10.1128/JB.156.3.1282-1291.1983; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567; Yale J, 2001, J BIOL CHEM, V276, P15996, DOI 10.1074/jbc.M008209200	73	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6414	6425		10.1074/jbc.M306464200	http://dx.doi.org/10.1074/jbc.M306464200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14623890	hybrid			2022-12-25	WOS:000188969200027
J	Evans, JH; Leslie, CC				Evans, JH; Leslie, CC			The cytosolic phospholipase A(2) catalytic domain modulates association and residence time at Golgi membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LIPID-BINDING DOMAIN; INTERFACIAL BINDING; CRYSTAL-STRUCTURE; TRYPTOPHAN RESIDUES; SIGNALING PATHWAYS; ARACHIDONIC-ACID; CALCIUM; TRANSLOCATION; PHOSPHORYLATION	Cytosolic phospholipase A(2) (cPLA(2)) catalyzes release of arachidonic acid from membranes following translocation to Golgi and endoplasmic reticulum. In response to an intracellular calcium concentration ([Ca2+](i)) increase, the C2 domain binds Ca2+ and brings the catalytic domain into proximity with its phospholipid substrate. Because membrane residence is important in the regulation of cPLA(2) activity, we explored the contributions of the C2 and catalytic domains in mediating membrane residence using an imaging approach in live cells with fluorescent protein chimeras of cPLA(2). The isolated cPLA(2) C2 domain associated with Golgi membranes rapidly in proportion to the [Ca2+](i), allowing for its use as a [Ca2+](i) indicator. cPLA(2) association with Golgi was slower than the isolated C2 domain in response to a [Ca2+](i) increase. After [Ca2+](i) decrease, cPLA(2) remained associated with membrane in a Ca2+-independent fashion whereas C2 domain rapidly dissociated. Ca2+-independent membrane association was greatly reduced by mutation of Trp(464), located at the membrane-exposed face of the catalytic domain, to Gly or Ala. Mutation of Trp(464) to Phe supported Ca2+-independent association similar to wild type. These results demonstrate a role for the cPLA(2) catalytic domain in regulating membrane association and membrane residence time.	Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Leslie, CC (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, 1400 Jackson St, Denver, CO 80206 USA.	lesliec@njc.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303, F32HL010507, R01HL061378] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61378, HL34303, HL10507] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baker SF, 1998, BIOCHEMISTRY-US, V37, P13203, DOI 10.1021/bi981223t; Ball A, 1999, P NATL ACAD SCI USA, V96, P6637, DOI 10.1073/pnas.96.12.6637; Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; Das S, 2002, J BIOL CHEM, V277, P23838, DOI 10.1074/jbc.M202322200; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Evans JH, 1999, AM J PHYSIOL-LUNG C, V277, pL30, DOI 10.1152/ajplung.1999.277.1.L30; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Evans JH, 1999, CELL CALCIUM, V26, P103, DOI 10.1054/ceca.1999.0060; Evans JH, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-30; Feng JW, 2002, J BIOL CHEM, V277, P19867, DOI 10.1074/jbc.M200938200; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gelb MH, 1999, CURR OPIN STRUC BIOL, V9, P428, DOI 10.1016/S0959-440X(99)80059-1; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; Ghomashchi F, 2001, BBA-BIOMEMBRANES, V1513, P160, DOI 10.1016/S0005-2736(01)00349-2; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Hirabayashi T, 2000, BBA-MOL CELL BIOL L, V1488, P124, DOI 10.1016/S1388-1981(00)00115-3; Hirabayashi T, 1999, J BIOL CHEM, V274, P5163, DOI 10.1074/jbc.274.8.5163; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Nalefski EA, 1998, BIOCHEMISTRY-US, V37, P17642, DOI 10.1021/bi982372e; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P3089, DOI 10.1021/bi001968a; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P13216, DOI 10.1021/bi010761u; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Putney JW, 1998, SCIENCE, V279, P191, DOI 10.1126/science.279.5348.191; Ridder ANJA, 2000, BIOCHEMISTRY-US, V39, P6521, DOI 10.1021/bi000073v; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; Sugita S, 2002, EMBO J, V21, P270, DOI 10.1093/emboj/21.3.270; Sumandea M, 1999, BIOCHEMISTRY-US, V38, P16290, DOI 10.1021/bi9921384; Teruel MN, 2002, SCIENCE, V295, P1910, DOI 10.1126/science.1065028; Xu GY, 1998, J MOL BIOL, V280, P485, DOI 10.1006/jmbi.1998.1874	50	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6005	6016		10.1074/jbc.M311246200	http://dx.doi.org/10.1074/jbc.M311246200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14623879	hybrid			2022-12-25	WOS:000188776500116
J	Townsley, FM; Thompson, B; Bienz, M				Townsley, FM; Thompson, B; Bienz, M			Pygopus residues required for its binding to legless are critical for transcription and development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATENIN-TCF COMPLEX; BETA-CATENIN; COLORECTAL-CANCER; GENE-EXPRESSION; PHD-FINGER; ACTIVATION; ENDOCYTOSIS; DROSOPHILA; INTERACTS; DOMAIN	Pygopus and Legless/Bcl-9 are recently discovered core components of the Wnt signaling pathway that are required for the transcriptional activity of Armadillo/beta-catenin and T cell factors. It has been proposed that they are part of a tri-partite adaptor chain (Armadillo > Legless> Pygopus) that recruits transcriptional co-activator complexes to DNA-bound T cell factor. Here, we identify four conserved residues at the putative PHD domain surface of Drosophila and mouse Pygopus that are required for their binding to Legless in vitro and in vivo. The same residues are also critical for the transactivation potential of DNA-tethered Pygopus in transfected mammalian cells and for rescue activity of pygopus mutant embryos. These residues at the Legless > Pygopus interface thus define a specific molecular target for blocking Wnt signaling during development and cancer.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Bienz, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	mb2@mrc-lmb.cam.ac.uk		Thompson, Barry/0000-0002-0103-040X				Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Belenkaya TY, 2002, DEVELOPMENT, V129, P4089; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Daniels DL, 2001, TRENDS BIOCHEM SCI, V26, P672, DOI 10.1016/S0968-0004(01)01952-1; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Howard JP, 2002, J CELL BIOL, V157, P315, DOI 10.1083/jcb.200110027; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Parker DS, 2002, DEVELOPMENT, V129, P2565; Pascual J, 2000, J MOL BIOL, V304, P723, DOI 10.1006/jmbi.2000.4308; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tan PK, 1996, J CELL BIOL, V135, P1789, DOI 10.1083/jcb.135.6.1789; Thompson B, 2002, NAT CELL BIOL, V4, P367, DOI 10.1038/ncb786; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	25	65	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5177	5183		10.1074/jbc.M309722200	http://dx.doi.org/10.1074/jbc.M309722200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14612447	hybrid			2022-12-25	WOS:000188776500018
J	Dumenil, G; Montminy, TP; Tang, M; Isberg, RR				Dumenil, G; Montminy, TP; Tang, M; Isberg, RR			IcmR-regulated membrane insertion and efflux by the Legionella pneumophila IcmQ protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEGIONNAIRES-DISEASE; PLASMA-MEMBRANE; PORE FORMATION; SHIGELLA-FLEXNERI; EPITHELIAL-CELLS; PHAGOSOME; SECRETION; IDENTIFICATION; TRANSLOCATION; REGION	Legionella pneumophila proliferates within alveolar macrophages as a central property of Legionnaires' disease. Intracellular growth involves formation of a replicative phagosome, which requires the bacterial Dot/Icm system, a multiprotein secretion apparatus that translocates proteins from the bacterium across the macrophage plasma membrane. Two components of this system, IcmR and IcmQ, are proposed to exhibit a chaperone/substrate relationship similar to that observed in other protein translocation systems. We report here that IcmQ inserts into lipid membranes and forms pores that allow the efflux of the dye calcein but not Dextran 3000. Both membrane insertion and pore formation were inhibited by IcmR. Trypsin digestion mapping demonstrated that IcmQ is subdivided into two functional domains. The N-terminal region of IcmQ was necessary and sufficient for insertion into lipid membranes and calcein efflux. The C-terminal domain was necessary for efficient association of the protein with lipid bilayers. IcmR was found to bind to the N-terminal portion of the protein thus providing a mechanism for its ability to inhibit IcmQ pore-forming activity. Localization of IcmQ on the surface of the L. pneumophila shortly after infection as well as its pore-forming capacities suggest a role for IcmQ in forming a channel that leads translocated effectors out of the bacterium.	Tufts Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	Howard Hughes Medical Institute; Tufts University; Tufts University	Isberg, RR (corresponding author), Tufts Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02111 USA.	ralph.isberg@tufts.edu	Dumenil, Guillaume/N-3377-2019; Dumenil, Guillaume/F-7567-2015	Dumenil, Guillaume/0000-0001-9174-9110; Dumenil, Guillaume/0000-0001-9174-9110				BERGER KH, 1994, MOL MICROBIOL, V14, P809, DOI 10.1111/j.1365-2958.1994.tb01317.x; BERGER KH, 1993, MOL MICROBIOL, V7, P7, DOI 10.1111/j.1365-2958.1993.tb01092.x; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BRAND BC, 1994, MOL MICROBIOL, V14, P797, DOI 10.1111/j.1365-2958.1994.tb01316.x; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CELADA A, 1984, J EXP MED, V160, P55, DOI 10.1084/jem.160.1.55; Christie PJ, 2000, TRENDS MICROBIOL, V8, P354, DOI 10.1016/S0966-842X(00)01792-3; Clemens DL, 2000, INFECT IMMUN, V68, P2671, DOI 10.1128/IAI.68.5.2671-2684.2000; Coers J, 2000, MOL MICROBIOL, V38, P719, DOI 10.1046/j.1365-2958.2000.02176.x; Conover GM, 2003, MOL MICROBIOL, V48, P305, DOI 10.1046/j.1365-2958.2003.03400.x; Cornelis GR, 2000, ANNU REV MICROBIOL, V54, P735, DOI 10.1146/annurev.micro.54.1.735; De Geyter C, 2000, EUR J BIOCHEM, V267, P5769, DOI 10.1046/j.1432-1327.2000.01649.x; Deng WY, 1999, MOL MICROBIOL, V31, P1795, DOI 10.1046/j.1365-2958.1999.01316.x; Dumas F, 2001, P NATL ACAD SCI USA, V98, P485, DOI 10.1073/pnas.011477898; Dumenil G, 2001, MOL MICROBIOL, V40, P1113, DOI 10.1046/j.1365-2958.2001.02454.x; Fields BS, 1996, TRENDS MICROBIOL, V4, P286, DOI 10.1016/0966-842X(96)10041-X; FRASER DW, 1977, NEW ENGL J MED, V297, P1189, DOI 10.1056/NEJM197712012972201; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; GLAVIN FL, 1979, ANN INTERN MED, V90, P555, DOI 10.7326/0003-4819-90-4-555; Hakansson S, 1996, EMBO J, V15, P5812, DOI 10.1002/j.1460-2075.1996.tb00968.x; Hayward RD, 2000, MOL MICROBIOL, V37, P727, DOI 10.1046/j.1365-2958.2000.02027.x; Heuck AP, 2000, MOL CELL, V6, P1233, DOI 10.1016/S1097-2765(00)00119-2; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HORWITZ MA, 1983, J EXP MED, V158, P1319, DOI 10.1084/jem.158.4.1319; HORWITZ MA, 1983, J EXP MED, V158, P2108, DOI 10.1084/jem.158.6.2108; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Kagan JC, 2002, NAT CELL BIOL, V4, P945, DOI 10.1038/ncb883; KATZ SM, 1982, LAB INVEST, V46, P24; KAYALAR C, 1986, BIOCHIM BIOPHYS ACTA, V860, P51, DOI 10.1016/0005-2736(86)90497-9; Kirby JE, 1998, MOL MICROBIOL, V27, P323, DOI 10.1046/j.1365-2958.1998.00680.x; Komano T, 2000, MOL MICROBIOL, V35, P1348, DOI 10.1046/j.1365-2958.2000.01769.x; Matsuzaki K, 1997, BIOPHYS J, V73, P831, DOI 10.1016/S0006-3495(97)78115-3; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MENARD R, 1994, EMBO J, V13, P5293, DOI 10.1002/j.1460-2075.1994.tb06863.x; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; Molmeret M, 2002, MOL MICROBIOL, V43, P1139, DOI 10.1046/j.1365-2958.2002.02842.x; Molmeret M, 2002, INFECT IMMUN, V70, P69, DOI 10.1128/IAI.70.1.69-78.2002; MORALES VM, 1991, GENE, V97, P39, DOI 10.1016/0378-1119(91)90007-X; Nagai H, 2002, SCIENCE, V295, P679, DOI 10.1126/science.1067025; Neyt C, 1999, MOL MICROBIOL, V33, P971, DOI 10.1046/j.1365-2958.1999.01537.x; NICHOLSON C, 1993, BIOPHYS J, V65, P2277, DOI 10.1016/S0006-3495(93)81324-9; Roy CR, 1998, MOL MICROBIOL, V28, P663, DOI 10.1046/j.1365-2958.1998.00841.x; Roy CR, 1997, INFECT IMMUN, V65, P571, DOI 10.1128/IAI.65.2.571-578.1997; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Segal G, 1998, P NATL ACAD SCI USA, V95, P1669, DOI 10.1073/pnas.95.4.1669; Segal G, 1997, INFECT IMMUN, V65, P5057, DOI 10.1128/IAI.65.12.5057-5066.1997; SLATIN SL, 1994, NATURE, V371, P158, DOI 10.1038/371158a0; Swanson MS, 1996, INFECT IMMUN, V64, P2585, DOI 10.1128/IAI.64.7.2585-2594.1996; SWANSON MS, 1995, INFECT IMMUN, V63, P3609, DOI 10.1128/IAI.63.9.3609-3620.1995; Swanson MS, 2000, ANNU REV MICROBIOL, V54, P567, DOI 10.1146/annurev.micro.54.1.567; Tilney LG, 2001, J CELL SCI, V114, P4637; Vogel JP, 1999, CURR OPIN MICROBIOL, V2, P30, DOI 10.1016/S1369-5274(99)80005-8; Vogel JP, 1998, SCIENCE, V279, P873, DOI 10.1126/science.279.5352.873; Wattiau P, 1996, MOL MICROBIOL, V20, P255, DOI 10.1111/j.1365-2958.1996.tb02614.x; Wiater LA, 1998, INFECT IMMUN, V66, P4450	55	33	37	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4686	4695		10.1074/jbc.M309908200	http://dx.doi.org/10.1074/jbc.M309908200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14625271	hybrid			2022-12-25	WOS:000188554300092
J	Kim, J; Parker, JSL; Murray, KE; Nibert, ML				Kim, J; Parker, JSL; Murray, KE; Nibert, ML			Nucleoside and RNA triphosphatase activities of orthoreovirus transcriptase cofactor mu 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REOVIRUS LAMBDA-1 PROTEIN; ACTIVE-SITE; ELECTRON-MICROSCOPY; NUCLEIC-ACIDS; M1 GENE; CORE; PHOSPHOHYDROLASE; IDENTIFICATION; ATPASE; REGION	The mammalian Orthoreovirus (mORV) core particle is an icosahedral multienzyme complex for viral mRNA synthesis and provides a delimited system for mechanistic studies of that process. Previous genetic results have identified the mORV p,2 protein as a determinant of viral strain differences in the transcriptase and nucleoside triphosphatase activities of cores. New results in this report provided biochemical and genetic evidence that purified mu2 is itself a divalent cation-dependent nucleoside triphosphatase that can remove the 5' gamma-phosphate from RNA as well. Alanine substitutions in a putative nucleotide binding region of mu2 abrogated both functions but did not affect the purification profile of the protein or its known associations with microtubules and mORV muNS protein in vivo. In vitro microtubule binding by purified mu2 was also demonstrated and not affected by the mutations. Purified mu2 was further demonstrated to interact in vitro with the mORV RNA-dependent RNA polymerase, lambda3, and the presence of lambda3 mildly stimulated the triphosphatase activities of mu2. These findings confirm that mu2 is an enzymatic component of the mORV core and may contribute several possible functions to viral mRNA synthesis.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	Harvard University; Harvard Medical School; University of Wisconsin System; University of Wisconsin Madison	Nibert, ML (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.	mnibert@hms.harvard.edu		Parker, John/0000-0003-4487-4175	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047904, K08AI052209] Funding Source: NIH RePORTER; NIAID NIH HHS [K08 AI52209, R01 AI47904] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Attoui H, 2002, J GEN VIROL, V83, P1941, DOI 10.1099/0022-1317-83-8-1941; BANERJEE AK, 1971, NATURE-NEW BIOL, V230, P169, DOI 10.1038/newbio230169a0; BARTLETT NM, 1974, J VIROL, V14, P315, DOI 10.1128/JVI.14.2.315-326.1974; Becker MM, 2001, J VIROL, V75, P1459, DOI 10.1128/JVI.75.3.1459-1475.2001; Bentley D, 2002, CURR OPIN CELL BIOL, V14, P336, DOI 10.1016/S0955-0674(02)00333-2; Bisaillon M, 1997, J BIOL CHEM, V272, P18298, DOI 10.1074/jbc.272.29.18298; Bisaillon M, 1997, J BIOL CHEM, V272, P29954, DOI 10.1074/jbc.272.47.29954; Bisaillon M, 1997, VIRUS RES, V51, P231, DOI 10.1016/S0168-1702(97)00092-0; BORSA J, 1970, J VIROL, V6, P295, DOI 10.1128/JVI.6.3.295-302.1970; Brentano L, 1998, J VIROL, V72, P8354, DOI 10.1128/JVI.72.10.8354-8357.1998; Broering TJ, 2002, J VIROL, V76, P8285, DOI 10.1128/JVI.76.16.8285-8297.2002; Bujnicki JM, 2001, GENOME BIOL, V2; CLEVELAND DR, 1986, J VIROL, V60, P307, DOI 10.1128/JVI.60.1.307-311.1986; Coombs KM, 1996, J VIROL, V70, P4237, DOI 10.1128/JVI.70.7.4237-4245.1996; DRAYNA D, 1982, J VIROL, V41, P110, DOI 10.1128/JVI.41.1.110-118.1982; Dryden KA, 1998, VIROLOGY, V245, P33, DOI 10.1006/viro.1998.9146; FARSETTA DL, 2000, THESIS U WISCONSIN M; FAUSNAUGH J, 1990, J BIOL CHEM, V265, P7669; Furuichi Y, 1976, Prog Nucleic Acid Res Mol Biol, V19, P3; GILLIES S, 1971, SCIENCE, V174, P694, DOI 10.1126/science.174.4010.694; Gross CH, 1996, J VIROL, V70, P1706, DOI 10.1128/JVI.70.3.1706-1713.1996; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; HALLER BL, 1995, J VIROL, V69, P357, DOI 10.1128/JVI.69.1.357-364.1995; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; KAPULER AM, 1970, NATURE, V225, P1209, DOI 10.1038/2251209a0; Kim J, 2002, J VIROL, V76, P12211, DOI 10.1128/JVI.76.23.12211-12222.2002; LEMAY G, 1994, J GEN VIROL, V75, P3261, DOI 10.1099/0022-1317-75-11-3261; Luongo CL, 1998, J BIOL CHEM, V273, P23773, DOI 10.1074/jbc.273.37.23773; Luongo CL, 2000, J BIOL CHEM, V275, P2804, DOI 10.1074/jbc.275.4.2804; MAO ZX, 1991, VIROLOGY, V185, P377, DOI 10.1016/0042-6822(91)90785-A; Martins A, 2003, NUCLEIC ACIDS RES, V31, P1455, DOI 10.1093/nar/gkg244; Mbisa JL, 2000, VIROLOGY, V272, P16, DOI 10.1006/viro.2000.0362; MOROZOV SY, 1989, NUCLEIC ACIDS RES, V17, P5394, DOI 10.1093/nar/17.13.5394; Myette JR, 1996, J BIOL CHEM, V271, P11945, DOI 10.1074/jbc.271.20.11945; NIBERT ML, 1991, J CLIN INVEST, V88, P727, DOI 10.1172/JCI115369; Nibert ML, 1998, CURR TOP MICROBIOL, V233, P1; Nibert ML., 2001, FIELDS VIROLOGY, P1679; Noble S, 1997, J VIROL, V71, P2182, DOI 10.1128/JVI.71.3.2182-2191.1997; Noble S, 1997, J VIROL, V71, P7728, DOI 10.1128/JVI.71.10.7728-7735.1997; Parker JSL, 2002, J VIROL, V76, P4483, DOI 10.1128/JVI.76.9.4483-4496.2002; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Reinisch KM, 2000, NATURE, V404, P960, DOI 10.1038/35010041; RIKKONEN M, 1994, J VIROL, V68, P5804, DOI 10.1128/JVI.68.9.5804-5810.1994; Sablin EP, 2001, CURR OPIN STRUC BIOL, V11, P716, DOI 10.1016/S0959-440X(01)00265-2; SHERRY B, 1994, J VIROL, V68, P8461, DOI 10.1128/JVI.68.12.8461-8465.1994; STARNES MC, 1993, VIROLOGY, V193, P356, DOI 10.1006/viro.1993.1132; Tao YZ, 2002, CELL, V111, P733, DOI 10.1016/S0092-8674(02)01110-8; Vasiljeva L, 2000, J BIOL CHEM, V275, P17281, DOI 10.1074/jbc.M910340199; Walenta JH, 2001, J CELL BIOL, V152, P923, DOI 10.1083/jcb.152.5.923; WIENER JR, 1989, VIROLOGY, V169, P293, DOI 10.1016/0042-6822(89)90154-2; Yin P, 1996, J VIROL, V70, P1223, DOI 10.1128/JVI.70.2.1223-1227.1996; Yue Z, 1998, CURR TOP MICROBIOL, V233, P31; Zhang X, 2003, NAT STRUCT BIOL, V10, P1011, DOI 10.1038/nsb1009; ZOU S, 1992, VIRUS RES, V22, P159, DOI 10.1016/0168-1702(92)90042-8	55	47	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4394	4403		10.1074/jbc.M308637200	http://dx.doi.org/10.1074/jbc.M308637200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14613938	hybrid, Green Published			2022-12-25	WOS:000188554300058
J	Fernandez, C; Ramos, AM; Sancho, P; Amran, D; de Blas, E; Aller, P				Fernandez, C; Ramos, AM; Sancho, P; Amran, D; de Blas, E; Aller, P			12-O-tetradecanoylphorbol-13-acetate may both potentiate and decrease the generation of apoptosis by the antileukemic agent arsenic trioxide in human promonocytic cells - Regulation by extracellular signal-regulated protein kinases and glutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID-LEUKEMIA CELLS; HL-60 CELLS; INDUCED DIFFERENTIATION; SYNERGISTIC INDUCTION; T-CELLS; ACTIVATION; P38; EXPRESSION; INHIBITOR; MODULATION	Arsenic trioxide (As2O3) caused apoptosis in U-937 human promonocytic cells. This effect was potentiated by the simultaneous addition of the glutathione (GSH) synthesis inhibitor DL-buthionine-(R,S)-sulfoximine or the protein kinase C activators 12-O-tetradecanoylphorbol-13-acetate (TPA) and bryostatin 1. In addition TPA decreased the intracellular GSH content, caused ERK activation, and potentiated the As2O3-provoked activation of p38 and JNK. The addition of N-acetyl-L-cysteine, the PKC inhibitor GF109203X, and the MEK/ERK inhibitors PD98059 and U0126 attenuated both apoptosis induction and GSH decrease, whereas the p38 inhibitor SB203580 and the JNK inhibitor SP600125 were ineffective. TPA also potentiated ERK activation and GSH depletion when added simultaneously to cadmium chloride (CdCl2) and doxorubicin. However, TPA only enhanced apoptosis in the case of CdCl2, which is a GSH-sensitive agent, whereas it reduced the toxicity of doxorubicin and other DNA-specific drugs. Finally, preincubation for 14-24 h with TPA did not potentiate but, instead, attenuated the As2O3- and CdCl2-provoked apoptosis. The same result was obtained by preincubation with bryostatin 1 and other differentiation inducers. It is concluded that TPA increases the apoptotic action of As2O3, an effect mediated by ERK activation and GSH depletion. However, the increase in apoptosis is only effective in non-differentiated cells.	CSIC, Ctr Invest Biol, Madrid 28040, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Aller, P (corresponding author), CSIC, Ctr Invest Biol, Ramiro de Maeztu 9, Madrid 28040, Spain.	aller@cib.csic.es	Sancho, Patricia/ABH-5258-2020	Sancho, Patricia/0000-0002-1092-5395				Behrens MM, 1999, NEUROSCIENCE, V94, P917, DOI 10.1016/S0306-4522(99)00212-2; Belyaeva EA, 2002, ARCH BIOCHEM BIOPHYS, V405, P252, DOI 10.1016/S0003-9861(02)00400-9; Bhat NR, 1999, J NEUROCHEM, V72, P112, DOI 10.1046/j.1471-4159.1999.0720112.x; Cai X, 2000, LEUKEMIA, V14, P262, DOI 10.1038/sj.leu.2401650; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; Cartee L, 2002, MOL PHARMACOL, V61, P1313, DOI 10.1124/mol.61.6.1313; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; Dickinson DA, 2002, BIOCHEM PHARMACOL, V64, P1019, DOI 10.1016/S0006-2952(02)01172-3; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FERNANDES RS, 1994, BIOCHEM PHARMACOL, V48, P675, DOI 10.1016/0006-2952(94)90044-2; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Frantz B, 1998, BIOCHEMISTRY-US, V37, P13846, DOI 10.1021/bi980832y; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; GALAN A, 2001, BIOCHIM BIOPHYS ACTA, V1538, P34; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; HASS R, 1994, CRIT REV ONCOGENESIS, V5, P359, DOI 10.1615/CritRevOncog.v5.i4.20; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Hu XM, 2003, CANCER CHEMOTH PHARM, V52, P47, DOI 10.1007/s00280-003-0629-5; Huang XJ, 1999, MED ONCOL, V16, P58, DOI 10.1007/BF02787360; Iwama K, 2001, INT J CANCER, V92, P518, DOI 10.1002/ijc.1220; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Jun CD, 1999, CELL IMMUNOL, V194, P36, DOI 10.1006/cimm.1999.1480; KRAFT AS, 1986, P NATL ACAD SCI USA, V83, P1334, DOI 10.1073/pnas.83.5.1334; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; LEONARD A, 1991, METALS THEIR COMPOUN, P751; MARQUARDT B, 1994, ONCOGENE, V9, P3213; Messmer UK, 1997, BRIT J PHARMACOL, V121, P625, DOI 10.1038/sj.bjp.0701156; Miller WH, 2002, CANCER RES, V62, P3893; Murgo AJ, 2001, ONCOLOGIST, V6, P22, DOI 10.1634/theoncologist.6-suppl_2-22; OCHI T, 1988, CHEM-BIOL INTERACT, V65, P1, DOI 10.1016/0009-2797(88)90026-9; RIUS C, 1989, CELL DIFFER DEV, V28, P39, DOI 10.1016/0922-3371(89)90021-X; RIUS C, 1990, EXP CELL RES, V188, P129, DOI 10.1016/0014-4827(90)90287-K; RIUS C, 1992, J CELL SCI, V101, P395; Sarker M, 2001, CELL DEATH DIFFER, V8, P172, DOI 10.1038/sj.cdd.4400791; SCOTT N, 1993, CHEM RES TOXICOL, V6, P102, DOI 10.1021/tx00031a016; Shiiki K, 2000, CELL DEATH DIFFER, V7, P939, DOI 10.1038/sj.cdd.4400727; Shonai T, 2002, CELL DEATH DIFFER, V9, P963, DOI 10.1038/sj.cdd.4401050; Soderstrom TS, 2002, J IMMUNOL, V169, P2851, DOI 10.4049/jimmunol.169.6.2851; SOLARY E, 1993, BLOOD, V81, P1359; Sordet O, 1999, CELL DEATH DIFFER, V6, P351, DOI 10.1038/sj.cdd.4400499; Sordet O, 2001, BLOOD, V97, P3931, DOI 10.1182/blood.V97.12.3931; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Troyano A, 2001, J BIOL CHEM, V276, P47107, DOI 10.1074/jbc.M104516200; Vrana JA, 2001, BLOOD, V97, P2105, DOI 10.1182/blood.V97.7.2105; Vrana JA, 1998, DIFFERENTIATION, V63, P33, DOI 10.1046/j.1432-0436.1998.6310033.x; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wang ZY, 2001, CANCER CHEMOTH PHARM, V48, pS72, DOI 10.1007/s002800100309; XU HM, 1993, EXP CELL RES, V209, P367, DOI 10.1006/excr.1993.1322; Zhuang SG, 2001, ONCOGENE, V20, P6764, DOI 10.1038/sj.onc.1204867	55	45	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3877	3884		10.1074/jbc.M310665200	http://dx.doi.org/10.1074/jbc.M310665200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14610070	hybrid, Green Published			2022-12-25	WOS:000188379600090
J	Hosaka, M; Suda, M; Sakai, Y; Izumi, T; Watanabe, T; Takeuchi, T				Hosaka, M; Suda, M; Sakai, Y; Izumi, T; Watanabe, T; Takeuchi, T			Secretogranin III binds to cholesterol in the secretory granule membrane as an adapter for chromogranin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHWAY SORTING RECEPTOR; DISULFIDE-BONDED LOOP; CARBOXYPEPTIDASE-E; REGULATED PATHWAY; ON/OFF SWITCH; PROTEIN; BIOGENESIS; STORAGE; PROINSULIN; DOMAIN	Granin-family proteins, including chromogranin A (CgA) and secretogranin III (SgIII), are transported to secretory granules (SGs) in neuroendocrine cells. We previously showed that SgIII binds strongly to CgA in an intragranular milieu and targets CgA to SGs in pituitary and pancreatic endocrine cells. In this study, we demonstrated that with a sucrose density gradient of rat insulinoma-derived INS-1 cell homogenates, SgIII was localized to the SG fraction and was fractionated to the SG membrane (SGM) despite lacking the transmembrane region. With depletion of cholesterol from the SGM using methyl-beta-cyclodextrin, SgIII was impaired to bind to the SGM. Both SgIII and CgA were solubilized from the SGM by Triton X-100 in contrast to the Triton X-100 insolubility of carboxypeptidase E. SgIII and carboxypeptidase E strongly bound to the SGM-type liposome in intragranular conditions, but CgA did not. Instead, CgA bound to the SGM-type liposome only in the presence of SgIII. Immunocytochemical and pulse-chase experiments revealed that SgIII deleting the N-terminal lipid-binding region missorted to the constitutive pathway in mouse corticotroph-derived AtT-20 cells. Thus, we suggest that SgIII directly binds to cholesterol components of the SGM and targets CgA to SGs in pituitary and pancreatic endocrine cells.	Gunma Univ, Inst Mol & Cellular Regulat, Dept Mol Med, Maebashi, Gumma 3718512, Japan; Asahikawa Med Coll, Dept Anat 2, Asahikawa, Hokkaido 0788510, Japan	Gunma University; Asahikawa Medical College	Takeuchi, T (corresponding author), Gunma Univ, Inst Mol & Cellular Regulat, Dept Mol Med, 3-39-15 Showa Machi, Maebashi, Gumma 3718512, Japan.	tstake@showa.gunma-u.ac.jp		Hosaka, Masahiro/0000-0002-1422-1774; Watanabe, Tsuyoshi/0000-0002-6094-7728				Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Blazquez M, 2000, BIOCHEM J, V349, P843, DOI 10.1042/bj3490843; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; Cowley DJ, 2000, J BIOL CHEM, V275, P7743, DOI 10.1074/jbc.275.11.7743; Crawford JL, 2002, REPRODUCTION, V124, P267, DOI 10.1530/reprod/124.2.267; Dannies PS, 1999, ENDOCR REV, V20, P3, DOI 10.1210/er.20.1.3; Day R, 2003, TRENDS ENDOCRIN MET, V14, P10, DOI 10.1016/S1043-2760(02)00011-5; Dhanvantari S, 2000, J BIOL CHEM, V275, P29887, DOI 10.1074/jbc.M005364200; Glombik MM, 1999, EMBO J, V18, P1059, DOI 10.1093/emboj/18.4.1059; Glombik MM, 2000, BIOCHIMIE, V82, P315, DOI 10.1016/S0300-9084(00)00195-4; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Holthuis JCM, 1996, J NEUROCHEM, V66, P2248; Hosaka M, 1999, NEURON, V24, P377, DOI 10.1016/S0896-6273(00)80851-X; Hosaka M, 2002, MOL BIOL CELL, V13, P3388, DOI 10.1091/mbc.02-03-0040; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; HUTTON JC, 1988, ENDOCRINOLOGY, V122, P1014, DOI 10.1210/endo-122-3-1014; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Irminger JC, 1997, J BIOL CHEM, V272, P27532, DOI 10.1074/jbc.272.44.27532; Kim T, 2003, TRENDS ENDOCRIN MET, V14, P56, DOI 10.1016/S1043-2760(02)00041-3; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; KINGSLEY DM, 1990, EMBO J, V9, P395, DOI 10.1002/j.1460-2075.1990.tb08123.x; Kromer A, 1998, J CELL BIOL, V140, P1331, DOI 10.1083/jcb.140.6.1331; Natori S, 1996, P NATL ACAD SCI USA, V93, P4431, DOI 10.1073/pnas.93.9.4431; Normant E, 1998, ENDOCRINOLOGY, V139, P2137, DOI 10.1210/en.139.4.2137; OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x; OTTIGER HP, 1990, J NEUROSCI, V10, P3135; Rindler MJ, 1998, J BIOL CHEM, V273, P31180, DOI 10.1074/jbc.273.47.31180; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Sakai Y, 2003, J HISTOCHEM CYTOCHEM, V51, P227, DOI 10.1177/002215540305100211; STINCHCOMBE JC, 1994, CELL BIOL LAB HDB, P557; Takei K, 2001, TRENDS CELL BIOL, V11, P385, DOI 10.1016/S0962-8924(01)02082-7; TAM WWH, 1993, EUR J CELL BIOL, V62, P294; Taupenot L, 2003, NEW ENGL J MED, V348, P1134, DOI 10.1056/NEJMra021405; Taupenot L, 2002, J CELL SCI, V115, P4827, DOI 10.1242/jcs.00140; Tooze SA, 2001, TRENDS CELL BIOL, V11, P116, DOI 10.1016/S0962-8924(00)01907-3; Varlamov O, 1997, ENDOCRINOLOGY, V138, P4883, DOI 10.1210/en.138.11.4883; Wang YZ, 2000, TRAFFIC, V1, P952, DOI 10.1034/j.1600-0854.2000.011205.x; Wasmeier C, 2002, TRAFFIC, V3, P654, DOI 10.1034/j.1600-0854.2002.30907.x; Watanabe T, 1998, ENDOCRINOLOGY, V139, P2765, DOI 10.1210/en.139.6.2765; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; Yi Z, 2002, MOL CELL BIOL, V22, P1858, DOI 10.1128/MCB.22.6.1858-1867.2002; Yoo SH, 2000, TRENDS NEUROSCI, V23, P424, DOI 10.1016/S0166-2236(00)01621-0; Zhang CF, 2003, BIOCHEM J, V369, P453, DOI 10.1042/BJ20020827	47	76	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3627	3634		10.1074/jbc.M310104200	http://dx.doi.org/10.1074/jbc.M310104200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14597614	hybrid			2022-12-25	WOS:000188379600061
J	Palii, SS; Chen, H; Kilberg, MS				Palii, SS; Chen, H; Kilberg, MS			Transcriptional control of the human sodium-coupled neutral amino acid transporter system a gene by amino acid availability is mediated by an intronic element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE SYNTHETASE GENE; TISSUE EXPRESSION PATTERN; UNFOLDED PROTEIN RESPONSE; FUNCTIONAL-CHARACTERISTICS; ADAPTIVE REGULATION; STRESS-RESPONSE; ANIMAL-CELLS; HUMAN ATA2; ACTIVATION; DEPRIVATION	System A amino acid transporter (SNAT2) gene expression is up-regulated at the transcriptional level in response to amino acid deprivation. Functional analysis of genomic fragments 5' upstream of the transcription start site, for both human and mouse SNAT2 genes showed that these regions exhibit promoter activity, but were amino acid unresponsive. However, when the human and mouse constructs were extended to include intron 1, it was observed that the rate of transcription was increased following amino acid deprivation. Deletion analysis of the human gene identified an intron 1 sequence spanning 54 nucleotides that was sufficient for conferring amino acid-dependent regulation to a minimal SNAT2 promoter. Alignment of the corresponding region from the human, mouse, and rat genomes revealed three highly conserved sequences. From site-directed mutagenesis, it was concluded that one of these sites functions as an amino acid response element (AARE) to regulate transcription. The core sequence of this site is identical to the AARE in the human CHOP gene. The SNAT2 AARE, along with a nearby conserved CAAT box, has enhancer activity in that it functions in an orientation and position independent manner, and it confers regulated transcription to a heterologous promoter.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Kilberg, MS (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, Box 100245,JHMHC, Gainesville, FL 32610 USA.	mkilberg@ufl.edu			NIDDK NIH HHS [DK-59315] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059315] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bain PJ, 2002, J NUTR, V132, P3023, DOI 10.1093/jn/131.10.3023; Barbosa-Tessmann IP, 1999, BIOCHEM J, V339, P151, DOI 10.1042/0264-6021:3390151; Barbosa-Tessmann IP, 1999, J BIOL CHEM, V274, P31139, DOI 10.1074/jbc.274.44.31139; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; Bode BP, 2001, J NUTR, V131, p2475S, DOI 10.1093/jn/131.9.2475S; Broer S, 2002, PFLUG ARCH EUR J PHY, V444, P457, DOI 10.1007/s00424-002-0840-y; Brosnan JT, 2003, J NUTR, V133, p2068S, DOI 10.1093/jn/133.6.2068S; Bruhat A, 2000, MOL CELL BIOL, V20, P7192, DOI 10.1128/MCB.20.19.7192-7204.2000; Bruhat A, 2002, J BIOL CHEM, V277, P48107, DOI 10.1074/jbc.M206149200; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; GAZZOLA GC, 1972, BIOCHIM BIOPHYS ACTA, V266, P407, DOI 10.1016/0005-2736(72)90097-1; Gazzola RF, 2001, FEBS LETT, V490, P11; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; Hatanaka T, 2000, BBA-BIOMEMBRANES, V1467, P1, DOI 10.1016/S0005-2736(00)00252-2; Hyde R, 2003, BIOCHEM J, V373, P1, DOI 10.1042/BJ20030405; Jefferson LS, 2001, J NUTR, V131, p2460S, DOI 10.1093/jn/131.9.2460S; Kilberg M, 2002, J NUTR, V132, P1801, DOI 10.1093/jn/132.7.1801; KILBERG MS, 1989, METHOD ENZYMOL, V173, P564; Leung-Pineda V, 2002, J BIOL CHEM, V277, P16585, DOI 10.1074/jbc.M110972200; Ling R, 2001, BBA-BIOMEMBRANES, V1512, P15, DOI 10.1016/S0005-2736(01)00310-8; MACKENZIE B, 2004, IN PRESS PFLUGERS AR; RIGGS TR, 1972, BIOCHEM J, V128, P19, DOI 10.1042/bj1280019; SAIER MH, 1988, J MEMBRANE BIOL, V104, P1, DOI 10.1007/BF01871898; Siu F, 2001, J BIOL CHEM, V276, P48100, DOI 10.1074/jbc.M109533200; Sugawara M, 2000, BBA-BIOMEMBRANES, V1509, P7, DOI 10.1016/S0005-2736(00)00349-7; Sugawara M, 2000, J BIOL CHEM, V275, P16473, DOI 10.1074/jbc.C000205200; TARNUZZER RW, 1990, J BIOL CHEM, V265, P13914; Varoqui H, 2000, J BIOL CHEM, V275, P4049, DOI 10.1074/jbc.275.6.4049; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; Yao DD, 2000, J BIOL CHEM, V275, P22790, DOI 10.1074/jbc.M002965200; Zhong C, 2003, BIOCHEM J, V372, P603, DOI 10.1042/BJ20030076	32	73	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3463	3471		10.1074/jbc.M310483200	http://dx.doi.org/10.1074/jbc.M310483200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14623874	hybrid			2022-12-25	WOS:000188379600042
J	Sukumar, N; Dewanti, AR; Mitra, B; Mathews, FS				Sukumar, N; Dewanti, AR; Mitra, B; Mathews, FS			High resolution structures of an oxidized and reduced flavoprotein - The water switch in a soluble form of (S)-mandelate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINACH GLYCOLATE OXIDASE; PSEUDOMONAS-PUTIDA; ACID OXIDASE; FLAVOCYTOCHROME B(2); ACTIVE-SITE; RAT-KIDNEY; PROTEIN; SEQUENCE; BINDING; MUTANT	The crystal structures of a soluble mutant of the flavoenzyme mandelate dehydrogenase (MDH) from Pseudomonas putida and of the substrate-reduced enzyme have been analyzed at 1.35-Angstrom resolution. The mutant (MDH-GOX2) is a fully active chimeric enzyme in which residues 177-215 of the membrane-bound MDH are replaced by residues 176-195 of glycolate oxidase from spinach. Both structures permit full tracing of the polypeptide backbone chain from residues 4-356, including a 4-residue segment that was disordered in an earlier study of the oxidized protein at 2.15 Angstrom resolution. The structures of MDH-GOX2 in the oxidized and reduced states are virtually identical with only a slight increase in the bending angle of the flavin ring upon reduction. The only other structural changes within the protein interior are a 10degrees rotation of an active site tyrosine side chain, the loss of an active site water, and a significant movement of six other water molecules in the active site by 0.45 to 0.78 Angstrom. Consistent with solution studies, there is no apparent binding of either the substrate, mandelate, or the oxidation product, benzoylformate, to the reduced enzyme. The observed structural changes upon enzyme reduction have been interpreted as a rearrangement of the hydrogen bonding pattern within the active site that results from binding of a proton to the N-5 position of the anionic hydroquinone form of the reduced flavin prosthetic group. Implications for the low oxidase activity of the reduced enzyme are also discussed.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Washington University (WUSTL); Wayne State University	Mathews, FS (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.	mathews@biochem.wustl.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054102] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54102, GM20530] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON N, 1985, BIOCHEM J, V231, P407, DOI 10.1042/bj2310407; BELMOUDEN A, 1993, EUR J BIOCHEM, V214, P17, DOI 10.1111/j.1432-1033.1993.tb17891.x; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cunane LM, 2002, BIOCHEMISTRY-US, V41, P4264, DOI 10.1021/bi0119870; Dewanti AR, 2003, BIOCHEMISTRY-US, V42, P12893, DOI 10.1021/bi035349o; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; Ghisla S., 1991, CHEM BIOCH FLAVOENZY, P243; KATAOKA M, 1992, EUR J BIOCHEM, V204, P799, DOI 10.1111/j.1432-1033.1992.tb16698.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LE KHD, 1991, J BIOL CHEM, V266, P20877; LEDERER F, 1991, CHEM BIOCH FLAVOENZY, V2, P153; Lehoux IE, 1999, BIOCHEMISTRY-US, V38, P5836, DOI 10.1021/bi990024m; LINDQVIST Y, 1989, J MOL BIOL, V209, P151, DOI 10.1016/0022-2836(89)90178-2; LINDQVIST Y, 1991, J BIOL CHEM, V266, P3198; LINDQVIST Y, 1989, J BIOL CHEM, V264, P3624; MASSEY V, 1994, J BIOL CHEM, V269, P22459; Mattevi A, 1996, P NATL ACAD SCI USA, V93, P7496, DOI 10.1073/pnas.93.15.7496; MITRA B, 1993, BIOCHEMISTRY-US, V32, P12959, DOI 10.1021/bi00211a003; Mullis K B, 1991, PCR Methods Appl, V1, P1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; ROUSSEL A, 1989, TURBO FRODO SILICON, P77; Sawyer D. T., 1981, OXYGEN OXYRADICALS C, P15; Sukumar N, 2001, BIOCHEMISTRY-US, V40, P9870, DOI 10.1021/bi010938k; Sun WM, 1996, J BIOL CHEM, V271, P17226, DOI 10.1074/jbc.271.29.17226; TSOU AY, 1990, BIOCHEMISTRY-US, V29, P9856, DOI 10.1021/bi00494a015; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M; Xu Y, 1999, BIOCHEMISTRY-US, V38, P12367, DOI 10.1021/bi990996u; Xu Y, 2002, BIOCHEMISTRY-US, V41, P12313, DOI 10.1021/bi026258e; XU Y, 1999, FLAVINS FLAVOPROTEIN, P487	33	27	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3749	3757		10.1074/jbc.M310049200	http://dx.doi.org/10.1074/jbc.M310049200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14604988	hybrid			2022-12-25	WOS:000188379600076
J	Tzubery, T; Rimon, A; Padan, E				Tzubery, T; Rimon, A; Padan, E			Mutation E252C increases drastically the K-m value for Na+ and causes an alkaline shift of the pH dependence of NhaA Na+/H+ antiporter of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; FLUORESCENCE SPECTROSCOPY; CONFORMATIONAL-CHANGE; HELICOBACTER-PYLORI; LACTOSE PERMEASE; ION-TRANSPORT; MEMBRANE; PROTEIN; IDENTIFICATION; CHANNEL	A single Cys replacement of Glu at position 252 (E252C) in loop VIII-IX of NhaA increases drastically the K-m for Na+ (50-fold) of the Na+/H+ antiporter activity of NhaA and shifts the pH dependence of NhaA activity, by one pH unit, to the alkaline range. In parallel, E252C causes a similar alkaline pH shift to the pH-induced conformational change of loop VIII-IX. Thus, although both the Na+/H+ antiporter activity of wild type NhaA and its accessibility to trypsin at position Lys(249) in loop VIII-IX increase with pH between pH 6.5 and 7.5, the response of E252C occurs above pH 8. Furthermore, probing accessibility of pure E252C protein in dodecyl maltoside solution to 2-(4'-maleimidylanilino)-naphthalene-6-sulfonic acid revealed that E252C itself undergoes a pH-dependent conformational change, similar to position Lys(249), and the rate of the pH-induced conformational change is increased specifically by the presence of Na+ or Li+, the specific ligands of the antiporter. Chemical modification of E252C by N-ethylmaleimide, 2-(4'-maleimidylanilino)-naphthalene-6-sulfonic acid; [2-(trimethylammonium) ethyl] methane thiosulfonate, or (2-sulfonatoethyl) methanethiosulfonate reversed, to a great extent, the pH shift conferred by E252C but had no effect on the K-m of the mutant antiporter.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Padan, E (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.	etana@vms.huji.ac.il						AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BIGELOW DJ, 1991, BIOCHEMISTRY-US, V30, P2113, DOI 10.1021/bi00222a016; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; Dayem MA, 2003, J BIOL CHEM, V278, P1518, DOI 10.1074/jbc.M210053200; Galili L, 2002, BIOCHEMISTRY-US, V41, P609, DOI 10.1021/bi011655v; Gerchman Y, 1999, J BIOL CHEM, V274, P24617, DOI 10.1074/jbc.274.35.24617; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; Gerchman Y, 2001, BIOCHEMISTRY-US, V40, P3403, DOI 10.1021/bi002669o; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; GORIN G, 1966, ARCH BIOCHEM BIOPHYS, V115, P593, DOI 10.1016/0003-9861(66)90079-8; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; Grunewald M, 2002, J BIOL CHEM, V277, P26074, DOI 10.1074/jbc.M202248200; GUPTE SS, 1983, J BIOL CHEM, V258, P5005; GUPTE SS, 1979, J BIOL CHEM, V254, P362; Haugland R. P., 1983, EXCITED STATES BIOPO, P29; Haugland R P., 1989, HDB FLUORESCENT PROB; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Inoue S, 2001, J BIOCHEM, V129, P569, DOI 10.1093/oxfordjournals.jbchem.a002892; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li J, 2002, P NATL ACAD SCI USA, V99, P11605, DOI 10.1073/pnas.192439299; MAY JM, 1993, BIOCHEMISTRY-US, V32, P2907, DOI 10.1021/bi00062a022; Noumi T, 1997, J BIOCHEM-TOKYO, V121, P661; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; Padan E, 2003, SODIUM-HYDROGEN EXCHANGER: FROM MOLECULE TO ITS ROLE IN DISEASE, P91; Padan E, 2000, BACTERIAL STRESS RESPONSES, P117; PADAN E, 1989, J BIOL CHEM, V264, P20297; Padan E, 2001, BBA-BIOENERGETICS, V1505, P144, DOI 10.1016/S0005-2728(00)00284-X; Padan E, 1998, FEBS LETT, V441, P53, DOI 10.1016/S0014-5793(98)01524-5; Padan E., 1996, HDB BIOL PHYS, V2, P501; PHILLIPS WJ, 1991, J BIOL CHEM, V266, P11017; PINNER E, 1993, J BIOL CHEM, V268, P1729; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; Rimon A, 2002, BIOCHEMISTRY-US, V41, P14897, DOI 10.1021/bi0261342; Rimon A, 1998, J BIOL CHEM, V273, P26470, DOI 10.1074/jbc.273.41.26470; RIMON A, 1995, J BIOL CHEM, V270, P26813, DOI 10.1074/jbc.270.45.26813; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; Rothman A, 1996, J BIOL CHEM, V271, P32288, DOI 10.1074/jbc.271.50.32288; Rothman A, 1997, BIOCHEMISTRY-US, V36, P14572, DOI 10.1021/bi971800y; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TAGLICHT D, 1993, J BIOL CHEM, V268, P5382; Tamura N, 2001, J BIOL CHEM, V276, P20330, DOI 10.1074/jbc.M007993200; Tsuboi Y, 2003, J BIOL CHEM, V278, P21467, DOI 10.1074/jbc.M301932200; Venturi M, 2000, J BIOL CHEM, V275, P4734, DOI 10.1074/jbc.275.7.4734; Venturi M., 2002, PRACTICAL GUIDE MEMB, P179; Wakabayashi S, 2003, SODIUM-HYDROGEN EXCHANGER: FROM MOLECULE TO ITS ROLE IN DISEASE, P35; Williams KA, 1999, EMBO J, V18, P3558, DOI 10.1093/emboj/18.13.3558; Williams KA, 2000, NATURE, V403, P112, DOI 10.1038/47534; WU JH, 1995, BIOCHEMISTRY-US, V34, P8257, DOI 10.1021/bi00026a007; WU JH, 1994, PROTEIN SCI, V3, P2294, DOI 10.1002/pro.5560031214	53	51	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3265	3272		10.1074/jbc.M309021200	http://dx.doi.org/10.1074/jbc.M309021200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14604993	hybrid			2022-12-25	WOS:000188379600017
J	Bonello, MR; Khachigian, LM				Bonello, MR; Khachigian, LM			Fibroblast growth factor-2 represses platelet-derived growth factor receptor-alpha (PDGFR-alpha) transcription via ERK1/2-dependent Sp1 phosphorylation and an atypical cis-acting element in the proximal PDGFR-alpha promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; SIGNAL-TRANSDUCTION PATHWAYS; VASCULAR ENDOTHELIAL-CELLS; BINDING PROTEIN-DELTA; GENE-EXPRESSION; ATHEROSCLEROSIS; PROLIFERATION; ACTIVATION; APOPTOSIS; INDUCTION	Platelet-derived growth factor ( PDGF) is a potent mitogen and chemoattractant for vascular smooth muscle cells (SMCs) whose biological activity is mediated via its high affinity interaction with specific cell surface receptors. The molecular mechanisms governing the expression of PDGF receptor-alpha (PDGFR-alpha) are poorly understood. Here we demonstrate that PDGFR-alpha protein and transcriptional regulation in SMCs is under the positive regulatory influence of the zinc finger nuclear protein, Sp1. Electrophoretic mobility shift, competition, and supershift analysis revealed the existence of an atypical G-rich Sp1-binding element located in the PDGFR-alpha promoter - 61 to - 52 bp upstream of the transcriptional start site. Mutation of this sequence ablated endogenous Sp1 binding and activation of the PDGFR-alpha promoter. PDGFR-alpha transcription, mRNA, and protein expression were repressed in SMCs exposed to fibroblast growth factor-2 (FGF-2). This inhibition was rescued by the blockade of extracellular signal-regulated kinase-1/2 (ERK1/2). FGF-2 repression of PDGFR-alpha transcription was abrogated upon mutation of this Sp1-response element. FGF-2 stimulated Sp1 phosphorylation in an ERK1/2-but not p38-dependent manner, the growth factor enhancing Sp1 interaction with the PDGFR-alpha promoter. Mutation of residues Thr(453) and Thr(739) in Sp1 ( amino acids phosphorylated by ERK) blocked FGF-2 repression of PDGFR-alpha transcription. These findings, taken together, demonstrate that FGF-2 stimulates ERK1/2-dependent Sp1 phosphorylation, thereby repressing PDGFR-alpha transcription via the - 61/ - 52 element in the PDGFR-alpha promoter. Phosphorylation triggered by FGF-2 switches Sp1 from an activator to a repressor of PDGFR-alpha transcription, a finding previously unreported in any Sp1-dependent gene.	Univ New S Wales, Dept Pathol, Ctr Vasc Res, Sydney, NSW 2052, Australia; Prince Wales Hosp, Dept Haematol, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Khachigian, LM (corresponding author), Univ New S Wales, Dept Pathol, Ctr Vasc Res, Sydney, NSW 2052, Australia.	L.Khachigian@unsw.edu.Au	Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323				Bennett MR, 1998, ATHEROSCLEROSIS, V138, P3, DOI 10.1016/S0021-9150(98)00013-6; Betsholtz C, 2001, BIOESSAYS, V23, P494, DOI 10.1002/bies.1069; DZAU VJ, 1994, HYPERTENSION, V23, P1132, DOI 10.1161/01.HYP.23.6.1132; Enarsson M, 2002, MOL CANCER RES, V1, P147; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; Fukuoka T, 1999, J BIOL CHEM, V274, P25576, DOI 10.1074/jbc.274.36.25576; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; HernandezSanchez C, 1997, J BIOL CHEM, V272, P4663, DOI 10.1074/jbc.272.8.4663; HUGHES SE, 1993, CARDIOVASC RES, V27, P1214, DOI 10.1093/cvr/27.7.1214; Irvine CD, 2000, CARDIOVASC SURG, V8, P121, DOI 10.1016/S0967-2109(99)00090-3; Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200; KAWAGISHI J, 1995, GENOMICS, V30, P224, DOI 10.1006/geno.1995.9883; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; Kitami Y, 1999, CIRC RES, V84, P64; KITAMI Y, 1995, J CLIN INVEST, V96, P558, DOI 10.1172/JCI118068; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Lindroos PM, 1998, J IMMUNOL, V161, P3464; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Pintucci G, 2002, FASEB J, V16, P598, DOI 10.1096/fj.01-0815fje; Rafty LA, 2001, NUCLEIC ACIDS RES, V29, P1027, DOI 10.1093/nar/29.5.1027; Rossig L, 2001, BASIC RES CARDIOL, V96, P11, DOI 10.1007/s003950170073; RUBINI M, 1994, EXP CELL RES, V211, P374, DOI 10.1006/excr.1994.1101; Samson SLA, 2002, J MOL ENDOCRINOL, V29, P265, DOI 10.1677/jme.0.0290265; Santiago FS, 1999, AM J PATHOL, V154, P937, DOI 10.1016/S0002-9440(10)65341-2; Tortorella LL, 2001, J BIOL CHEM, V276, P13709, DOI 10.1074/jbc.M100091200; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VASSBOTN FS, 1994, J BIOL CHEM, V269, P13874; WANG CY, 1994, P NATL ACAD SCI USA, V91, P7061, DOI 10.1073/pnas.91.15.7061	34	74	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2377	2382		10.1074/jbc.M308254200	http://dx.doi.org/10.1074/jbc.M308254200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14593115	hybrid			2022-12-25	WOS:000188211300008
J	Ricard-Blum, S; Feraud, O; Lortat-Jacob, H; Rencurosi, A; Fukai, N; Dkhissi, F; Vittet, D; Imberty, A; Olsen, BR; van der Rest, M				Ricard-Blum, S; Feraud, O; Lortat-Jacob, H; Rencurosi, A; Fukai, N; Dkhissi, F; Vittet, D; Imberty, A; Olsen, BR; van der Rest, M			Characterization of endostatin binding to heparin and heparan sulfate by surface plasmon resonance and molecular modeling - Role of divalent cations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOGENESIS INHIBITOR ENDOSTATIN; ANTIANGIOGENIC ACTIVITY; ENDOTHELIAL-CELLS; EMBRYOID BODIES; ZINC-BINDING; TUMOR-GROWTH; DOMAIN; ORGANIZATION	Endostatin (20 kDa) is a C-terminal proteolytic fragment of collagen XVIII that is localized in vascular basement membrane zones in various organs. It binds zinc, heparin/heparan sulfate, laminin, and sulfatides and inhibits angiogenesis and tumor growth. Here we determined the kinetics and affinity of the interaction of endostatin with heparin/heparan sulfate and investigated the effects of divalent cations on these interactions and on the biological activities of endostatin. The binding of human recombinant endostatin to heparin and heparan sulfate was studied by surface plasmon resonance using BIAcore technology and further characterized by docking and molecular dynamics simulations. Kinetic data, evaluated using a 1: 1 interaction model, showed that heparan sulfate bound to and dissociated from endostatin faster than heparin and that endostatin bound to heparin and heparan sulfate with a moderate affinity (K-D similar to 2 muM). Molecular modeling of the complex between endostatin and heparin oligosaccharides predicted that, compared with mutagenesis studies, two further arginine residues, Arg(47) and Arg(66), participated in the binding. The binding of endostatin to heparin and heparan sulfate required the presence of divalent cations. The addition of ZnCl2 to endostatin enhanced its binding to heparan sulfate by similar to 40% as well as its antiproliferative effect on endothelial cells stimulated by fibroblast growth factor-2, suggesting that this activity is mediated by the binding of endostatin to heparan sulfate. In contrast, no increase in the antiangiogenic and anti-proliferative activities of endostatin promoted by vascular endothelial growth factor was observed upon the addition of zinc.	UJF, CNRS, CEA, Inst Biol Struct,UMR 5075, F-38027 Grenoble 01, France; CEA, Dept Reponse & Dynam Cellulaires, F-38054 Grenoble, France; Ctr Rech Macromol Vegetales, F-38041 Grenoble 9, France; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Hop St Louis, INSERM, U553, F-75475 Paris 10, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Harvard University; Harvard Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Ricard-Blum, S (corresponding author), UJF, CNRS, CEA, Inst Biol Struct,UMR 5075, 41 Rue Jules Horowitz, F-38027 Grenoble 01, France.	ricard@ibs.fr	Vittet, Daniel/M-3611-2018; Imberty, Anne/P-6451-2018	FERAUD, Olivier/0000-0002-5332-600X; Imberty, Anne/0000-0001-6825-9527; RICARD-BLUM, Sylvie/0000-0001-9263-1851	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036820, R37AR036820] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR36820] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Blackhall FH, 2003, BIOCHEM J, V375, P131, DOI 10.1042/BJ20030730; Boehm T, 1998, BIOCHEM BIOPH RES CO, V252, P190, DOI 10.1006/bbrc.1998.9617; CLARK M, 1998, J COMPUT CHEM, V8, P982; Ding YH, 1998, P NATL ACAD SCI USA, V95, P10443, DOI 10.1073/pnas.95.18.10443; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Dkhissi F, 2003, HUM GENE THER, V14, P997, DOI 10.1089/104303403766682250; Feraud O, 2001, LAB INVEST, V81, P1669, DOI 10.1038/labinvest.3780380; Hohenester E, 2000, J MOL BIOL, V297, P1, DOI 10.1006/jmbi.2000.3553; Hohenester E, 1998, EMBO J, V17, P1656, DOI 10.1093/emboj/17.6.1656; IMBERTY A, 1999, PERSPECTIVES STRUCTU, P392; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Kreuger J, 2002, EMBO J, V21, P6303, DOI 10.1093/emboj/cdf638; Kruger EA, 2000, BIOCHEM BIOPH RES CO, V268, P183, DOI 10.1006/bbrc.1999.2018; Lyon M, 2000, J BIOL CHEM, V275, P4599, DOI 10.1074/jbc.275.7.4599; Marneros AG, 2001, MATRIX BIOL, V20, P337, DOI 10.1016/S0945-053X(01)00151-2; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PARRISH RF, 1981, BIOCHEM J, V193, P407, DOI 10.1042/bj1930407; Ramchandran R, 2002, CRIT REV EUKAR GENE, V12, P175, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i3.20; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Ren B, 2003, METHOD FIND EXP CLIN, V25, P215, DOI 10.1358/mf.2003.25.3.769643; Ricard-Blum S, 2002, J BIOL CHEM, V277, P33864, DOI 10.1074/jbc.M205018200; Sadir R, 2001, J BIOL CHEM, V276, P8288, DOI 10.1074/jbc.M008110200; Sasaki T, 2002, IUBMB LIFE, V53, P77, DOI 10.1080/15216540211466; Sasaki T, 1998, EMBO J, V17, P4249, DOI 10.1093/emboj/17.15.4249; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; Sim B K, 1999, Angiogenesis, V3, P41, DOI 10.1023/A:1009058931769; Vittet D, 1997, P NATL ACAD SCI USA, V94, P6273, DOI 10.1073/pnas.94.12.6273; Vittet D, 1996, BLOOD, V88, P3424, DOI 10.1182/blood.V88.9.3424.bloodjournal8893424; Waldherr-Teschner M., 1992, Advances in Scientific Visualization, P58; Wickstrom SA, 2002, CANCER RES, V62, P5580; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414	35	112	114	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2927	2936		10.1074/jbc.M309868200	http://dx.doi.org/10.1074/jbc.M309868200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14585835	Green Published, hybrid			2022-12-25	WOS:000188211300073
J	Liu, YL; Burch-Smith, T; Schiff, M; Feng, SH; Dinesh-Kumar, SP				Liu, YL; Burch-Smith, T; Schiff, M; Feng, SH; Dinesh-Kumar, SP			Molecular chaperone Hsp90 associates with resistance protein n and its signaling proteins SGT1 and Rar1 to modulate an innate immune response in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCF UBIQUITIN-LIGASE; DISEASE RESISTANCE; MEDIATED RESISTANCE; ESSENTIAL COMPONENT; COP9 SIGNALOSOME; GENE-N; TOLL; ARABIDOPSIS; MAINTENANCE; CAPACITOR	SGT1 and Rar1 are important signaling components of resistance (R) gene-mediated plant innate immune responses. Here we report that SGT1 and Rar1 associate with the molecular chaperone Hsp90. In addition, we show that Hsp90 associates with the resistance protein N that confers resistance to tobacco mosaic virus. This suggests that Hsp90-SGT1-Rar1 and R proteins might exist in one complex. Suppression of Hsp90 in Nicotiana benthamiana plants shows that it plays an important role in plant growth and development. In addition, Hsp90 suppression in NN plants compromises N-mediated resistance to tobacco mosaic virus. Our results reveal a new role for SGT1- and Rar1-associated chaperone machinery in R gene-mediated defense signaling.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University	Dinesh-Kumar, SP (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.	savithramma.dinesh-kumar@yale.edu	Schiff, Manuel/G-3596-2017; Liu, Yule/E-5700-2010	Schiff, Manuel/0000-0001-8272-232X; Liu, Yule/0000-0002-4423-6045	NIGMS NIH HHS [R01 GM 62625] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062625] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Austin MJ, 2002, SCIENCE, V295, P2077, DOI 10.1126/science.1067747; Azevedo C, 2002, SCIENCE, V295, P2073, DOI 10.1126/science.1067554; Bandholtz L, 2003, CELL MOL LIFE SCI, V60, P422, DOI 10.1007/s000180300035; Caplan Avrom J., 2003, EMBO Reports, V4, P126, DOI 10.1038/sj.embor.embor742; Chinkers M, 2001, TRENDS ENDOCRIN MET, V12, P28, DOI 10.1016/S1043-2760(00)00335-0; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; FINLEY RL, 1996, GENE PROBES PRACTICA, P169; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; Garcia-Ranea JA, 2002, FEBS LETT, V529, P162, DOI 10.1016/S0014-5793(02)03321-5; Hammond-Kosack KE, 2003, CURR OPIN BIOTECH, V14, P177, DOI 10.1016/S0958-1669(03)00035-1; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Imai J, 2003, EMBO J, V22, P3557, DOI 10.1093/emboj/cdg349; Kanzaki H, 2003, MOL PLANT PATHOL, V4, P383, DOI [10.1046/j.1364-3703.2003.00186.x, 10.1046/J.1364-3703.2003.00186.X]; Kitagawa K, 1999, MOL CELL, V4, P21, DOI 10.1016/S1097-2765(00)80184-7; Krishna P, 1997, PLANT MOL BIOL, V33, P457, DOI 10.1023/A:1005709308096; Krishna P, 2001, CELL STRESS CHAPERON, V6, P238, DOI 10.1379/1466-1268(2001)006<0238:THFOPI>2.0.CO;2; Liu Y, 2002, PLANT CELL, V14, P1483, DOI 10.1105/tpc.002493; Liu YL, 2002, PLANT J, V30, P415, DOI 10.1046/j.1365-313X.2002.01297.x; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Pearl LH, 2002, ADV PROTEIN CHEM, V59, P157; Peart JR, 2002, P NATL ACAD SCI USA, V99, P10865, DOI 10.1073/pnas.152330599; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pratt WB, 1999, CELL SIGNAL, V11, P839, DOI 10.1016/S0898-6568(99)00064-9; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; Randow F, 2001, NAT CELL BIOL, V3, P891, DOI 10.1038/ncb1001-891; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Ruiz MT, 1998, PLANT CELL, V10, P937, DOI 10.1105/tpc.10.6.937; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Shirasu K, 1999, CELL, V99, P355, DOI 10.1016/S0092-8674(00)81522-6; Stemmann O, 2002, P NATL ACAD SCI USA, V99, P8585, DOI 10.1073/pnas.082223899; Takahashi A, 2003, P NATL ACAD SCI USA, V100, P11777, DOI 10.1073/pnas.2033934100; Vabulas RM, 2002, CURR TOP MICROBIOL, V270, P169; Vabulas RM, 2002, J BIOL CHEM, V277, P20847, DOI 10.1074/jbc.M200425200; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Zhang SQ, 1998, P NATL ACAD SCI USA, V95, P7433, DOI 10.1073/pnas.95.13.7433; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	40	259	278	3	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2101	2108		10.1074/jbc.M310029200	http://dx.doi.org/10.1074/jbc.M310029200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14583611	hybrid			2022-12-25	WOS:000188005700066
J	Tseng, Y; An, KM; Esue, O; Wirtz, D				Tseng, Y; An, KM; Esue, O; Wirtz, D			The bimodal role of filamin in controlling the architecture and mechanics of F-actin networks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING PROTEIN; ALPHA-ACTININ; BINDING PROTEIN; PERIVENTRICULAR HETEROTOPIA; FILAMENTS; GELS; DETERMINES; CELLS; MICROHETEROGENEITY; VISCOELASTICITY	Reconstituted actin filament networks have been used extensively to understand the mechanics of the actin cortex and decipher the role of actin cross-linking proteins in the maintenance and deformation of cell shape. However, studies of the mechanical role of the F-actin cross-linking protein filamin have led to seemingly contradictory conclusions, in part due to the use of ill-defined mechanical assays. Using quantitative rheological methods that avoid the pitfalls of previous studies, we systematically tested the complex mechanical response of reconstituted actin filament networks containing a wide range of filamin concentrations and compared the mechanical function of filamin with that of the cross-linking/bundling proteins alpha-actinin and fascin. At steady state and within a well defined linear regime of small non-destructive deformations, F-actin solutions behave as highly dynamic networks ( actin polymers are still sufficiently mobile to relax the stress) below the cross-linking-to-bundling threshold filamin concentration, and they behave as covalently cross-linked gels above that threshold. Under large deformations, F-actin networks soften at low filamin concentrations and strain-harden at high filamin concentrations. Filamin cross-links F-actin into networks that are more resilient, stiffer, more solid-like, and less dynamic than alpha-actinin and fascin. These results resolve the controversy by showing that F-actin/filamin networks can adopt diametrically opposed rheological behaviors depending on the concentration in cross-linking proteins.	Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Grad Program Mol Biophys, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Wirtz, D (corresponding author), Johns Hopkins Univ, Dept Chem & Biomol Engn, 3400 N Charles St, Baltimore, MD 21218 USA.	wirtz@jhu.edu	Wirtz, Denis/A-3257-2010					[Anonymous], 1980, VISCOELASTIC PROPERT; Coulombe PA, 2000, TRENDS CELL BIOL, V10, P420, DOI 10.1016/S0962-8924(00)01828-6; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; Doi M., 1989, THEORY POLYM DYNAMIC; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; Flanagan LA, 2001, J CELL BIOL, V155, P511, DOI 10.1083/jcb.200105148; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Furuike S, 2001, FEBS LETT, V498, P72, DOI 10.1016/S0014-5793(01)02497-8; Glogauer M, 1998, J BIOL CHEM, V273, P1689, DOI 10.1074/jbc.273.3.1689; HARTWIG JH, 1981, J MOL BIOL, V145, P563, DOI 10.1016/0022-2836(81)90545-3; JANMEY PA, 1994, J BIOL CHEM, V269, P32503; JANMEY PA, 1990, NATURE, V345, P89, DOI 10.1038/345089a0; Kreis T., 1999, GUIDEBOOK CYTOSKELET, V2nd; LANGANGER G, 1984, J CELL BIOL, V99, P1324, DOI 10.1083/jcb.99.4.1324; Matsudaira Paul, 1994, Seminars in Cell Biology, V5, P165, DOI 10.1006/scel.1994.1021; Morse DC, 1998, MACROMOLECULES, V31, P7044, DOI 10.1021/ma980304u; NUNNALLY MH, 1980, J CELL BIOL, V87, P219, DOI 10.1083/jcb.87.1.219; Palmer A, 1998, RHEOL ACTA, V37, P97, DOI 10.1007/s003970050095; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Rief M, 1999, J MOL BIOL, V286, P553, DOI 10.1006/jmbi.1998.2466; Santi MR, 2001, J NEUROPATH EXP NEUR, V60, P856, DOI 10.1093/jnen/60.9.856; SATO M, 1987, NATURE, V325, P828, DOI 10.1038/325828a0; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Tang JX, 1999, BIOPHYS J, V76, P2208, DOI 10.1016/S0006-3495(99)77376-5; Tseng Y, 2002, BIOPHYS J, V83, P3162, DOI 10.1016/S0006-3495(02)75319-8; Tseng Y, 2002, J BIOL CHEM, V277, P18143, DOI 10.1074/jbc.M110868200; Tseng Y, 2001, BIOPHYS J, V81, P1643, DOI 10.1016/S0006-3495(01)75818-3; Tseng Y, 2001, J MOL BIOL, V310, P351, DOI 10.1006/jmbi.2001.4716; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; WACHSSTOCK DH, 1993, BIOPHYS J, V65, P205, DOI 10.1016/S0006-3495(93)81059-2; Xu JY, 1999, CELL MOTIL CYTOSKEL, V42, P73, DOI 10.1002/(SICI)1097-0169(1999)42:1<73::AID-CM7>3.0.CO;2-Z; Xu JY, 1998, J BIOL CHEM, V273, P9570, DOI 10.1074/jbc.273.16.9570; Xu JY, 2000, J BIOL CHEM, V275, P35886, DOI 10.1074/jbc.M002377200; Yamada S, 2003, J STRUCT BIOL, V143, P45, DOI 10.1016/S1047-8477(03)00101-1; Yamada S, 2002, MOL BIOL CELL, V13, P382, DOI 10.1091/mbc.01-10-0522; YASUTAKA O, 1995, BIOCHEMISTRY-US, V34, P6745, DOI 10.1021/bi00020a020; ZANER KS, 1986, J BIOL CHEM, V261, P7615	38	102	104	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1819	1826		10.1074/jbc.M306090200	http://dx.doi.org/10.1074/jbc.M306090200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14594947	hybrid			2022-12-25	WOS:000188005700032
J	Denison, SR; Wang, F; Becker, NA; Schule, B; Kock, N; Phillips, LA; Klein, C; Smith, DI				Denison, SR; Wang, F; Becker, NA; Schule, B; Kock, N; Phillips, LA; Klein, C; Smith, DI			Alterations in the common fragile site gene Parkin in ovarian and other cancers	ONCOGENE			English	Article						common fragile sites; Parkinson's disease; ovarian cancer	RECESSIVE JUVENILE PARKINSONISM; UBIQUITIN-PROTEIN LIGASE; FHIT GENE; MUTATIONS; DISEASE; FRA16D; INSTABILITY; SUPPRESSOR; REGION; WWOX	The cloning and characterization of the common fragile site (CFS) FRA6E (6q26) identified Parkin, the gene involved in the pathogenesis of many cases of juvenile, early-onset and, rarely, late-onset Parkinson's disease, as the third large gene to be localized within a large CFS. Initial analyses of Parkin indicated that in addition to playing a role in Parkinson's disease, it might also be involved in the development and/or progression of ovarian cancer. These analyses also indicated striking similarities among the large CFS-locus genes: fragile histidine triad gene (FHIT; 3p14.2), WW domain-containing oxidoreductase gene (WWOX; 16q23), and Parkin (6q26). Analyses of FHIT and WWOX in a variety of different cancer types have identified the presence of alternative transcripts with whole exon deletions. Interestingly, various whole exon duplications and deletions have been identified for Parkin in juvenile and early-onset Parkinson's patients. Therefore, we performed mutational/exon rearrangement analysis of Parkin in ovarian cancer cell lines and primary tumors. Four (66.7%) cell lines and four (18.2%) primary tumors were identified as being heterozygous for the duplication or deletion of a Parkin exon. Additionally, three of 23 (13.0%) nonovarian tumor-derived cell lines were also identified as having a duplication or deletion of one or more Parkin exons. Analysis of Parkin protein expression with antibodies revealed that most of the ovarian cancer cell lines and primary tumors had diminished or absent Parkin expression. While functional analyses have not yet been performed for Parkin, these data suggest that like FHIT and WWOX, Parkin may represent a tumor suppressor gene.	Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Div Expt Pathol, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Med Univ Lubeck, Dept Neurol, D-23538 Lubeck, Germany; Med Univ Lubeck, Dept Human Genet, D-23538 Lubeck, Germany	Mayo Clinic; University of Lubeck; University of Lubeck	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Div Expt Pathol, Dept Lab Med & Pathol, 200 1st St SW, Rochester, MN 55905 USA.	smith.david@mayo.edu		Schuele, Birgitt/0000-0002-9952-5776; Klein, Christine/0000-0003-2102-3431	NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arlt MF, 2002, GENE CHROMOSOME CANC, V33, P82, DOI 10.1002/gcc.10000; Becker NA, 2002, ONCOGENE, V21, P8713, DOI 10.1038/sj.onc.1205950; Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Corbin S, 2002, CANCER RES, V62, P3477; Darios F, 2003, HUM MOL GENET, V12, P517, DOI 10.1093/hmg/ddg044; Denison SR, 2003, GENE CHROMOSOME CANC, V38, P40, DOI 10.1002/gcc.10236; Druck T, 1997, CANCER RES, V57, P504; Druck T, 1998, ONCOL RES, V10, P341; Feany MB, 2003, NEURON, V38, P13, DOI 10.1016/S0896-6273(03)00201-0; GAMMA A, 1997, CANCER RES, V57, P1435; Hattori N, 1998, ANN NEUROL, V44, P935, DOI 10.1002/ana.410440612; Hedrich K, 2002, NEUROLOGY, V58, P1239, DOI 10.1212/WNL.58.8.1239; Hedrich K, 2001, HUM MOL GENET, V10, P1649, DOI 10.1093/hmg/10.16.1649; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Hoenicka J, 2002, ARCH NEUROL-CHICAGO, V59, P966, DOI 10.1001/archneur.59.6.966; Horowitz JM, 2001, J CHEM NEUROANAT, V21, P75, DOI 10.1016/S0891-0618(00)00111-3; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Huynh DP, 2000, ANN NEUROL, V48, P737, DOI 10.1002/1531-8249(200011)48:5<737::AID-ANA7>3.3.CO;2-4; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Ishii H, 2001, JAMA-J AM MED ASSOC, V286, P2441, DOI 10.1001/jama.286.19.2441; Kahns S, 2002, J BIOL CHEM, V277, P15303, DOI 10.1074/jbc.M111534200; Kann M, 2002, ANN NEUROL, V51, P621, DOI 10.1002/ana.10179; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; Krummel KA, 2002, GENE CHROMOSOME CANC, V34, P154, DOI 10.1002/gcc.10047; Le Beau MM, 1998, GENE CHROMOSOME CANC, V21, P281, DOI 10.1002/(SICI)1098-2264(199804)21:4<281::AID-GCC1>3.0.CO;2-V; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Mangelsdorf M, 2000, CANCER RES, V60, P1683; Nichols WC, 2002, J MED GENET, V39, P489, DOI 10.1136/jmg.39.7.489; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Paige AJW, 2000, CANCER RES, V60, P1690; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; Shiraishi T, 2001, P NATL ACAD SCI USA, V98, P5722, DOI 10.1073/pnas.091095898; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Smith DI, 1998, INT J ONCOL, V12, P187; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; Tanaka K, 2001, J MOL MED, V79, P482, DOI 10.1007/s001090100242; Verma RS., 1995, HUMAN CHROMOSOMES PR, V2; West A, 2002, AM J MED GENET, V114, P584, DOI 10.1002/ajmg.10525; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	45	171	174	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2003	22	51					8370	8378		10.1038/sj.onc.1207072	http://dx.doi.org/10.1038/sj.onc.1207072			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614460				2022-12-25	WOS:000186541500015
J	Zhao, LY; Liu, Y; Bertos, NR; Yang, XJ; Liao, DQ				Zhao, LY; Liu, Y; Bertos, NR; Yang, XJ; Liao, DQ			PCAF is a coactivator for p73-mediated transactivation	ONCOGENE			English	Article						transcription coactivator; PCAF; p73; tumor suppressor; acetyltransferase; protein-protein interaction	P53 HOMOLOG P73; KINASE C-ABL; DNA-DAMAGE; INDUCE APOPTOSIS; TRANSCRIPTIONAL ACTIVITIES; P53-RELATED PROTEIN; TUMOR-SUPPRESSOR; BINDING-PROTEIN; TERMINAL DOMAIN; TARGET GENES	The tumor suppressor p53-related p73 shares significant amino-acid sequence identity with p53. Like p53, p73 recognizes canonical p53 DNA-binding sites and activates p53-responsive target genes and induces apoptosis. Moreover, transcription coactivator p300/CBP binds to and coactivates with both p53 and p73 in stimulating the expression of their target genes. Here, we report that coactivator PCAF binds to p73. The N-terminal transactivation domain (TAD) and the conserved oligomerization domain (OD) of p73 are both required for its interaction with PCAF. Conversely, PCAF's HAT-domain is required for and both the N-terminal region and Bromo domain enhance binding of PCAF to p73. Significantly, PCAF stimulates p73-mediated transactivation, and binding of PCAF to p73 is necessary for p73's transactivation activity. PCAF-specific siRNA dramatically reduces p73-mediated transactivation. Stimulation of p73-mediated transactivation by PCAF requires the HAT domain of PCAF and the p53-binding site within the p21 promoter. In vivo, coexpression of wild-type, but not HAT-deficient PCAF with p73beta markedly increases p21 expression. Furthermore, cotransfection of PCAF and p73 leads to increased apoptosis and reduced colony formation. Collectively, these data suggest that p73 recruit PCAF to specific promoters to activate the transcription of p73 target genes.	Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ Sherbrooke, Fac Med, Dept Microbiol & Infect Dis, Sherbrooke, PQ, Canada; McGill Univ, Ctr Hlth, Dept Med, Mol Oncol Grp, Montreal, PQ, Canada; Univ Florida, UF Shands Canc Ctr, Gainesville, FL USA	State University System of Florida; University of Florida; University of Sherbrooke; McGill University; State University System of Florida; University of Florida	Liao, DQ (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, 1600 SW Arch Rd, Gainesville, FL 32610 USA.		Liao, Daiqing/A-8941-2008		NATIONAL CANCER INSTITUTE [R01CA092236] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA92236] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Bres V, 2002, EMBO J, V21, P6811, DOI 10.1093/emboj/cdf669; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Gong JG, 1999, NATURE, V399, P806; Gu JJ, 2001, ONCOGENE, V20, P3519, DOI 10.1038/sj.onc.1204454; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Harton JA, 2001, J BIOL CHEM, V276, P38715, DOI 10.1074/jbc.M106652200; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Huang SM, 2000, EMBO J, V19, P6792, DOI 10.1093/emboj/19.24.6792; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; James P, 1996, GENETICS, V144, P1425; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 2000, J CELL SCI, V113, P1661; Liu Y, 2000, MOL CELL BIOL, V20, P5540, DOI 10.1128/MCB.20.15.5540-5553.2000; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Marin MC, 2000, BBA-REV CANCER, V1470, pM93, DOI 10.1016/S0304-419X(00)00010-X; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Muth V, 2001, EMBO J, V20, P1353, DOI 10.1093/emboj/20.6.1353; Ozaki T, 1999, CANCER RES, V59, P5902; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; Prabhu NS, 1998, INT J ONCOL, V13, P5; Prives C, 1999, J PATHOL, V187, P112; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; SCHILTZ RL, 2000, BIOCHIM BIOPHYS ACTA, V1470, P37; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Takada N, 1999, CANCER RES, V59, P2810; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Ueda Y, 2001, BIOCHEM J, V356, P859, DOI 10.1042/0264-6021:3560859; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 2001, J BIOL CHEM, V276, P48, DOI 10.1074/jbc.C000722200; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598; Zhao RB, 2000, GENE DEV, V14, P981; Zhu JH, 2001, ONCOGENE, V20, P4050, DOI 10.1038/sj.onc.1204516; Zhu JH, 1998, CANCER RES, V58, P5061	63	27	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8316	8329		10.1038/sj.onc.1206916	http://dx.doi.org/10.1038/sj.onc.1206916			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614455				2022-12-25	WOS:000186541500010
J	Burger, M; Glodek, A; Hartmann, T; Schmitt-Graff, A; Silberstein, LE; Fujii, N; Kipps, TJ; Burger, JA				Burger, M; Glodek, A; Hartmann, T; Schmitt-Graff, A; Silberstein, LE; Fujii, N; Kipps, TJ; Burger, JA			Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells	ONCOGENE			English	Article						chemokine receptor; lung cancer; signal transduction; integrin activation; adhesion; migration	CHEMOKINE RECEPTOR CXCR4; LEUKEMIA B-CELLS; BONE-MARROW; TRANSENDOTHELIAL MIGRATION; HEMATOPOIETIC PROGENITORS; SIGNAL-TRANSDUCTION; CD34(+) CELLS; STEM-CELLS; VLA-4; FIBRONECTIN	Small-cell lung cancer (SCLC) is an aggressive, rapidly metastasizing neoplasm. The chemokine stromal cell-derived factor-1 (SDF-1/CXCL12) is constitutively secreted by marrow stromal cells and plays a key role for homing of hematopoietic cells to the marrow. Here, we report that tumor cells from patients with SCLC express high levels of functional CXCR4 receptors for the chemokine CXCL12. Reverse transcriptase-polymerase chain reaction and flow cytometry demonstrated CXCR4 mRNA and CXCR4 surface expression in SCLC cell lines. Immunohistochemistry of primary tumor samples from SCLC patients revealed high expression of CXCR4. CXCL12 elicited CXCR4 receptor endocytosis, actin polymerization, and a robust activation of phospho-p44/42 mitogen-activated protein kinase in SCLC cells. Furthermore, CXCL12 induced SCLC cell invasion into extracellular matrix and firm adhesion to marrow stromal cells. Stromal cell adhesion of SCLC cells was significantly inhibited by the specific CXCR4 antagonist T140, pertussis toxin, antivascular cell adhesion molecule-1(VCAM-1) antibodies, and CS-1 peptide, demonstrating the importance of CXCR4 chemokine receptor activation and alpha4beta1 integrin binding, respectively. In addition, CXCL12 enhanced the adhesion of SCLC cells to immobilized VCAM-1, demonstrating that CXCR4 chemokine receptors can induce integrin activation on SCLC cells. As SCLC has a high propensity for bone marrow involvement, our findings suggest that CXCR4 chemokine receptors and alpha4beta1 integrins play a critical role in the interaction of SCLC cells with stromal cells in the tumor microenvironment.	Freiburg Univ Hosp, Dept Internal Med, Freiburg, Germany; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Freiburg Univ Hosp, Dept Pathol, Freiburg, Germany; Kyoto Univ, Grad Sch Pharmaceut Sci, Kyoto, Japan; Univ Calif San Diego, Dept Med, Div Hematol Oncol, La Jolla, CA 92093 USA	University of Freiburg; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Freiburg; Kyoto University; University of California System; University of California San Diego	Burger, JA (corresponding author), Freiburg Univ Hosp, Dept Med, Div Hematol Oncol, Hugstetterstr 55, D-79106 Freiburg, Germany.	burger@mm11.ukl.uni-freiburg.de	Hartmann, Tanja Nicole/AAA-6735-2020; Hartmann, Tanja Nicole/C-9345-2017; Hartmann, Tanja Nicole/C-9345-2017	Hartmann, Tanja Nicole/0000-0002-0377-7179; Hartmann, Tanja Nicole/0000-0002-0377-7179; Hartmann, Tanja Nicole/0000-0002-2633-7301				Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BARAK LS, 1980, P NATL ACAD SCI-BIOL, V77, P980, DOI 10.1073/pnas.77.2.980; Boyle DL, 2000, CELL IMMUNOL, V200, P1, DOI 10.1006/cimm.2000.1610; Burger JA, 2000, BLOOD, V96, P2655; Burger JA, 1999, BLOOD, V94, P3658, DOI 10.1182/blood.V94.11.3658.423k11_3658_3667; Burger JA, 2001, J CLIN INVEST, V107, P305, DOI 10.1172/JCI11092; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747; Hidalgo A, 2001, EXP HEMATOL, V29, P345, DOI 10.1016/S0301-472X(00)00668-8; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; IHDE D, 1993, CANC PRINCIPLES PRAC, P591; IHDE DC, 1992, NEW ENGL J MED, V327, P1434; Imai K, 1999, BLOOD, V93, P149, DOI 10.1182/blood.V93.1.149.401a02_149_156; Kijima T, 2002, CANCER RES, V62, P6304; Kristensen CA, 1996, CRIT REV ONCOL HEMAT, V22, P27, DOI 10.1016/1040-8428(94)00170-7; LASSEN U, 1995, J CLIN ONCOL, V13, P1215, DOI 10.1200/JCO.1995.13.5.1215; Ma Q, 1999, IMMUNITY, V10, P463, DOI 10.1016/S1074-7613(00)80046-1; MASN DY, 2001, TISSUE ANTIGENS, V58, P425; Mohle R, 1998, BLOOD, V91, P4523, DOI 10.1182/blood.V91.12.4523.412k04_4523_4530; Moore MAS, 2001, BIOESSAYS, V23, P674, DOI 10.1002/bies.1095; Moser B, 1998, Int Rev Immunol, V16, P323, DOI 10.3109/08830189809043000; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murphy PM, 2001, NEW ENGL J MED, V345, P833, DOI 10.1056/NEJM200109133451113; Nagasawa T, 1998, SEMIN IMMUNOL, V10, P179, DOI 10.1006/smim.1998.0128; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nebreda AR, 1999, SCIENCE, V286, P1309, DOI 10.1126/science.286.5443.1309; PAPAYANNOPOULOU T, 1995, P NATL ACAD SCI USA, V92, P9647, DOI 10.1073/pnas.92.21.9647; Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296; Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200; Sanz-Rodriguez F, 2001, BLOOD, V97, P346, DOI 10.1182/blood.V97.2.346; Schraufstatter IU, 2001, AM J PHYSIOL-LUNG C, V280, pL1094, DOI 10.1152/ajplung.2001.280.6.L1094; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; SIMMONS PJ, 1992, BLOOD, V80, P388; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Taichman RS, 2002, CANCER RES, V62, P1832; Tamamura H, 1998, BIOCHEM BIOPH RES CO, V253, P877, DOI 10.1006/bbrc.1998.9871; TEIXIDO J, 1992, J CLIN INVEST, V90, P358, DOI 10.1172/JCI115870; Verfaillie CM, 1998, BLOOD, V92, P2609, DOI 10.1182/blood.V92.8.2609; Wright DE, 2002, J EXP MED, V195, P1145, DOI 10.1084/jem.20011284; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	44	219	230	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2003	22	50					8093	8101		10.1038/sj.onc.1207097	http://dx.doi.org/10.1038/sj.onc.1207097			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603250				2022-12-25	WOS:000186403400004
J	Kuga, H; Morisaki, T; Nakamura, K; Onishi, H; Noshiro, H; Uchiyama, A; Tanaka, M; Katano, M				Kuga, H; Morisaki, T; Nakamura, K; Onishi, H; Noshiro, H; Uchiyama, A; Tanaka, M; Katano, M			Interferon-gamma suppresses transforming growth factor-beta-induced invasion of gastric carcinoma cells through cross-talk of Smad pathway in a three-dimensional culture model	ONCOGENE			English	Article						TGF-beta; IFN-gamma; gastric carcinoma; three-dimensional culture; Smad	UROKINASE PLASMINOGEN-ACTIVATOR; BREAST-CANCER CELLS; TGF-BETA; IN-VITRO; GENE-EXPRESSION; NUCLEAR-LOCALIZATION; HUMAN-FIBROBLASTS; SKIN FIBROBLASTS; GLIOMA INVASION; COLLAGEN GELS	We reconstituted a three-dimensional gastric carcinoma model similar to invasive gastric carcinoma tissue. This model consists of a human gastric carcinoma cell line, GCTM-1, a human fibroblast cell line, TIG-1-20, and transforming growth factor-beta (TGF-beta)-containing type I collagen gel. Using this model, we were able to observe the growth of the two cell types, especially carcinoma cell invasive growth, in real time for more than 30 days. TGF-beta and TIG-1-20 were essential for GCTM-1 invasive growth and proliferation, respectively. TGF-beta induced the enhanced expression of matrix metalloproteinase 9 (MMP9) and urokinase-type plasminogen activator (uPA) in GCTM-1 at both the protein and enzymatic activity levels. The TGF-beta-induced invasion of GCTM-1 was inhibited by MMP9- or uPA-antisense (AS) oligonucleotide transfection to GCTM-1. When exogenous interferon-gamma (IFN-gamma) was added to this model, TGF-beta-dependent GCTM-1 invasion was significantly inhibited, concomitant with the decreased expression of MMP9 and uPA. The intracellular signal transduction of Smad was examined to analyse the mechanism of the inhibitory effect of IFN-gamma. TGF-beta accelerated the phosphorylation of Smad2/3 and nuclear translocation of the Smad2/3 Smad4 complex in GCTM-1, but these TGF-beta-induced effects were significantly inhibited by IFN-gamma-induced Smad7 expression. When GCTM-1 was cotransfected with AS oligonucleotide of Smad2 and Smad3, the TGF-beta-induced invasion of GCTM-1 disappeared. In addition, the inhibitory effect of IFN-gamma on TGF-beta-dependent GCTM-1 invasion vanished by the AS oligonucleotide of Smad7 transfection. These results indicate that IFN-gamma inhibits TGF-beta-dependent GCTM-1 invasion through cross-talk in the Smad pathway. IFN-gamma may be a new therapeutic tool for TGF-beta-expressed invasive carcinomas.	Kyushu Univ, Grad Sch Med Sci, Dept Canc Therapy & Res, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Clin Oncol & Surg, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Katano, M (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Canc Therapy & Res, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							ALBINI A, 1987, CANCER RES, V47, P3239; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ANKRAPP DP, 1993, CANCER RES, V53, P3399; [Anonymous], GENOME BIOL; ARNOLETTI JP, 1995, CANCER, V76, P998, DOI 10.1002/1097-0142(19950915)76:6<998::AID-CNCR2820760613>3.0.CO;2-0; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bauman GS, 1999, INT J DEV NEUROSCI, V17, P643, DOI 10.1016/S0736-5748(99)00023-4; Bell HS, 1999, J NEUROSURG, V91, P989, DOI 10.3171/jns.1999.91.6.0989; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; COFFEY RJ, 1988, CANCER RES, V48, P1596; DAVID M, 1995, PHARMACOL THERAPEUT, V65, P149, DOI 10.1016/0163-7258(94)00050-D; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Ellenrieder V, 2001, INT J CANCER, V93, P204, DOI 10.1002/ijc.1330; ELLIS MJC, 1994, BREAST CANCER RES TR, V31, P249, DOI 10.1007/BF00666158; Festuccia C, 2000, INT J CANCER, V85, P407, DOI 10.1002/(SICI)1097-0215(20000201)85:3<407::AID-IJC18>3.0.CO;2-8; Fink SP, 2001, CANCER RES, V61, P256; Funaba M, 2002, J BIOL CHEM, V277, P41361, DOI 10.1074/jbc.M204597200; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806; GURUJEYALAKSHMI G, 1995, EXP LUNG RES, V21, P791, DOI 10.3109/01902149509050842; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HLATKY L, 1994, CANCER RES, V54, P6083; HOFLAND LJ, 1995, INT J CANCER, V60, P93, DOI 10.1002/ijc.2910600114; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Inagaki Y, 2001, J CELL PHYSIOL, V187, P117, DOI 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1059>3.0.CO;2-S; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; KESKIOJA J, 1988, J CELL BIOL, V106, P451, DOI 10.1083/jcb.106.2.451; Kikuchi S, 2000, HEPATO-GASTROENTEROL, V47, P1256; Kunz-Schughart LA, 2001, EXP CELL RES, V266, P74, DOI 10.1006/excr.2001.5210; Leivonen SK, 2002, J BIOL CHEM, V277, P46338, DOI 10.1074/jbc.M206535200; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; MAHARA K, 1994, BRIT J CANCER, V69, P777, DOI 10.1038/bjc.1994.147; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Matrisian LM, 2001, CANCER RES, V61, P3844; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Montgomery E, 2001, AM J PATHOL, V158, P537, DOI 10.1016/S0002-9440(10)63995-8; Mori Y, 2000, EXP CELL RES, V258, P374, DOI 10.1006/excr.2000.4930; Morisaki T, 2000, ANTICANCER RES, V20, P3363; Morrissey D, 1999, CLIN EXP METASTAS, V17, P77; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Nakamura M, 1998, BRIT J CANCER, V78, P1373, DOI 10.1038/bjc.1998.687; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; Pasche B, 2001, J CELL PHYSIOL, V186, P153, DOI 10.1002/1097-4652(200002)186:2<153::AID-JCP1016>3.0.CO;2-J; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; Rossi L, 2000, INT J CANCER, V85, P667, DOI 10.1002/(SICI)1097-0215(20000301)85:5<667::AID-IJC12>3.0.CO;2-1; Saito H, 1999, CANCER, V86, P1455, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1455::AID-CNCR11>3.0.CO;2-L; Sandusky G, 2002, J BIOL CHEM, V277, P49815, DOI 10.1074/jbc.C200543200; Sehgal I, 1996, CANCER RES, V56, P3359; SHIPLEY GD, 1986, CANCER RES, V46, P2068; Shyu RY, 2000, J SURG ONCOL, V75, P122, DOI 10.1002/1096-9098(200010)75:2<122::AID-JSO9>3.0.CO;2-4; Sowa H, 2002, J BIOL CHEM, V277, P36024, DOI 10.1074/jbc.M206030200; Teti A, 1997, INT J CANCER, V72, P1013; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; Tredget EE, 2000, J INTERF CYTOK RES, V20, P143, DOI 10.1089/107999000312540; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; URA H, 1991, CANCER RES, V51, P3550; Verrecchia F, 2003, J BIOL CHEM, V278, P1585, DOI 10.1074/jbc.M206927200; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; Yashiro M, 1996, BRIT J CANCER, V74, P1096, DOI 10.1038/bjc.1996.496; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366	66	25	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7838	7847		10.1038/sj.onc.1207046	http://dx.doi.org/10.1038/sj.onc.1207046			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586410				2022-12-25	WOS:000186240200014
J	Garcia, A; Subramanian, V; Sekowski, A; Bhattacharyya, S; Love, MW; Brasaemle, DL				Garcia, A; Subramanian, V; Sekowski, A; Bhattacharyya, S; Love, MW; Brasaemle, DL			The amino and carboxyl termini of perilipin A facilitate the storage of triacylglycerols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; LIPID DROPLETS; LIPOLYTIC STIMULATION; ADIPOCYTE LIPOLYSIS; MEDIATED LIPOLYSIS; 3T3-L1 ADIPOCYTES; PROTEIN; TRANSLOCATION; EXPRESSION; OBESITY	Perilipin A is the most abundant lipid droplet-associated protein in adipocytes and serves important functions in regulating triacylglycerol levels by reducing rates of basal lipolysis and facilitating hormonally stimulated lipolysis. We have previously shown that the central region of perilipin A targets and anchors it to lipid droplets, at least in part via three moderately hydrophobic sequences that embed the protein into the hydrophobic core of the droplet. The current study examines the roles of the amino and carboxyl termini of perilipin A in facilitating triacylglycerol storage. Amino- and carboxyl-terminal truncation mutations of mouse perilipin A were stably expressed in 3T3-L1 preadipocytes, which lack perilipins. Triacylglycerol content of the cells was quantified as a measure of perilipin function and was compared with that of cells expressing full-length perilipin A or control cells lacking perilipins. The amino-terminal sequence between amino acids 122 and 222, including four 10-11-amino acid sequences predicted to form amphipathic beta-strands and a consensus site for cAMP-dependent protein kinase, and the carboxyl terminus of 112 amino acids that is unique to perilipin A were critical to facilitate triacylglycerol storage. The precocious expression of full-length perilipin A in 3T3-L1 preadipocytes aided more rapid storage of triacylglycerol during adipose differentiation. By contrast, the expression of highly truncated amino- or carboxyl-terminal mutations of perilipin failed to serve a dominant negative function in lowering triacylglycerol storage during adipose differentiation. We conclude that the amino and carboxyl termini are critical to the function of perilipin A in facilitating triacylglycerol storage.	Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Brasaemle, DL (corresponding author), Rutgers State Univ, Dept Nutr Sci, 96 Lipman Dr, New Brunswick, NJ 08901 USA.	Brasaemle@AESOP.Rutgers.edu		Brasaemle, Dawn/0000-0002-8553-8285	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054797] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54797] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brasaemle DL, 2000, BBA-MOL CELL BIOL L, V1483, P251, DOI 10.1016/S1388-1981(99)00179-1; Brasaemle DL, 1997, J BIOL CHEM, V272, P9378; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; Garcia A, 2003, J BIOL CHEM, V278, P625, DOI 10.1074/jbc.M206602200; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Lu XY, 2001, MAMM GENOME, V12, P741, DOI 10.1007/s00335-01-2055-5; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; Mottagui-Tabar S, 2003, DIABETOLOGIA, V46, P789, DOI 10.1007/s00125-003-1112-x; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tansey JT, 2003, J BIOL CHEM, V278, P8401, DOI 10.1074/jbc.M211005200; Wang YX, 2003, OBES RES, V11, P930, DOI 10.1038/oby.2003.128; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200; Zhang HH, 2003, J BIOL CHEM, V278, P51535, DOI 10.1074/jbc.M309591200	27	38	43	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8409	8416		10.1074/jbc.M311198200	http://dx.doi.org/10.1074/jbc.M311198200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14610073	hybrid			2022-12-25	WOS:000189103300124
J	Zawadzki, KM; Taylor, SS				Zawadzki, KM; Taylor, SS			cAMP-dependent protein kinase regulatory subunit type II beta - Active site mutations define an isoform-specific network for allosteric signaling by cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY DXMS; MOUSE LYMPHOMA-CELLS; A-MUTANT MICE; CYCLIC-AMP; CATALYTIC SUBUNIT; BINDING-SITES; ALPHA SUBUNIT; SKELETAL-MUSCLE; ACTIVATION; COMMUNICATION	cAMP-dependent protein kinase (cAPK) contains a regulatory (R) subunit dimer bound to two catalytic (C) subunits. Each R monomer contains two cAMP-binding domains, designated A and B. The sequential binding of two cAMPs releases active C. We describe here the properties of RIIbeta and two mutant RIIbeta subunits, engineered by converting a conserved Arg to Lys in each cAMP-binding domain thereby yielding a protein that contains one intact, high affinity cAMP-binding site and one defective site. Structure and function were characterized by circular dichroism, steady-state fluorescence, surface plasmon resonance and holoenzyme activation assays. The K-a for RIIbeta is 610 nm, which is 10-fold greater than its K-d(cAMP) and significantly higher than for RIalpha and RIIalpha. The Arg mutant proteins demonstrate that the conserved Arg is important for both cAMP binding and organization of each domain and that binding to domain A is required for activation. The K-a of the A domain mutant protein is 21-fold greater than that of wild-type and the K-d(cAMP) is increased 7-fold, confirming that cAMP must bind to the mutated site to initiate activation. The domain B mutant K-a is 2-fold less than its K-d(cAMP), demonstrating that, unlike RIalpha, cAMP can access the A site even when the B site is empty. Removal of the B domain yields a K. identical to the Kd(cAMP) of full-length RIIbeta, indicating that the B domain inhibits holoenzyme activation for RIIbeta. In RIalpha, removal of the B domain generates a protein that is more difficult to activate than the wild-type protein.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Taylor, SS (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.	staylor@ucsd.edu			NIGMS NIH HHS [GM34921, GM08326-10] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034921] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; Anand GS, 2002, J MOL BIOL, V323, P377, DOI 10.1016/S0022-2836(02)00919-1; Brandon EP, 1997, CURR OPIN NEUROBIOL, V7, P397, DOI 10.1016/S0959-4388(97)80069-4; BUBIS J, 1988, J BIOL CHEM, V263, P9668; BUILDER SE, 1980, J BIOL CHEM, V255, P2350; Canaves JM, 2000, BIOCHEMISTRY-US, V39, P15022, DOI 10.1021/bi001563q; Canaves JM, 2002, J MOL EVOL, V54, P17, DOI 10.1007/s00239-001-0013-1; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; Coffino P, 1976, Recent Prog Horm Res, V32, P669; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; CORBIN JD, 1975, J BIOL CHEM, V250, P218; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; DANIEL V, 1973, P NATL ACAD SCI USA, V70, P76, DOI 10.1073/pnas.70.1.76; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; Diller TC, 2001, STRUCTURE, V9, P73, DOI 10.1016/S0969-2126(00)00556-6; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FRIEDRICH U, 1977, P NATL ACAD SCI USA, V74, P679, DOI 10.1073/pnas.74.2.679; Gangal M, 1998, BIOCHEMISTRY-US, V37, P13728, DOI 10.1021/bi980560z; GORMAN KB, 1994, SOMAT CELL MOLEC GEN, V20, P301, DOI 10.1007/BF02254719; Hamuro Y, 2003, J MOL BIOL, V327, P1065, DOI 10.1016/S0022-2836(03)00234-1; Hemmer W, 1997, ANAL BIOCHEM, V245, P115, DOI 10.1006/abio.1996.9952; Herberg FW, 1996, BIOCHEMISTRY-US, V35, P2934, DOI 10.1021/bi951647c; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; Huang LJS, 1998, J BIOL CHEM, V273, P26739, DOI 10.1074/jbc.273.41.26739; NEITZEL JJ, 1991, BIOCHEMISTRY-US, V30, P733, DOI 10.1021/bi00217a023; OGREID D, 1981, FEBS LETT, V129, P287, DOI 10.1016/0014-5793(81)80185-8; OGREID D, 1982, FEBS LETT, V150, P161, DOI 10.1016/0014-5793(82)81326-4; Pace C N, 1986, Methods Enzymol, V131, P266; Rehmann H, 2003, NAT STRUCT BIOL, V10, P26, DOI 10.1038/nsb878; RUBIN CS, 1979, J BIOL CHEM, V254, P3797; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; STEINBERG RA, 1977, CELL, V10, P381, DOI 10.1016/0092-8674(77)90025-3; STEINBERG RA, 1984, MOL CELL BIOL, V4, P1086, DOI 10.1128/MCB.4.6.1086; Steinberg RA, 1996, J BIOL CHEM, V271, P27630, DOI 10.1074/jbc.271.44.27630; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; SYMCOX MM, 1994, J BIOL CHEM, V269, P23025; Thiele TE, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-10-j0003.2000; Zawadzki KM, 2003, PROTEIN SCI, V12, P1980, DOI 10.1110/ps.03166903; Zawadzki KM, 2003, PROTEINS, V51, P552, DOI 10.1002/prot.10326; Zhang LZ, 2001, AM J PHYSIOL-CELL PH, V281, pC1642, DOI 10.1152/ajpcell.2001.281.5.C1642	40	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7029	7036		10.1074/jbc.M310804200	http://dx.doi.org/10.1074/jbc.M310804200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14625280	hybrid			2022-12-25	WOS:000188969200100
J	Ahn, EY; Lim, ST; Cook, WJ; McDonald, JM				Ahn, EY; Lim, ST; Cook, WJ; McDonald, JM			Calmodulin binding to the Fas death domain - Regulation by Fas activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED APOPTOSIS; T-CELLS; CHOLANGIOCARCINOMA CELLS; CALCIUM-CHANNELS; FAS/APO-1 CD95; PROTEIN; RECOGNITION; CA2+/CALMODULIN; REQUIREMENT; MODULATION	Fas (APO-1/CD95) is a cell surface receptor that initiates apoptotic pathways, and its cytoplasmic domain interacts with various molecules suggesting that Fas signaling is complex and regulated by multiple proteins. Calmodulin (CaM) is an intracellular Ca2+-binding protein, and it mediates many of the effects of Ca2+. Here, we demonstrate that CaM binds to Fas directly and identify the CaM-binding site on the cytoplasmic death domain (DD) of Fas. Fas binds to CaM-Sepharose and is co-immunoprecipitated with CaM. Other death receptors, such as tumor necrosis factor receptor, DR4, and DR5 do not bind to CaM. The interaction between Fas and CaM is Ca2+-dependent. Deletion mapping analysis with various GST-fused Fas cytoplasmic domain fragments revealed that the fragment containing helices 1, 2, and 3 of the Fas DD has the CaM-binding ability. Sequence analysis of this fragment predicted a potential CaM-binding site in helix 2 and connected loops. A valine 254 to asparagine mutation in this region, which is analogous to the identified mutant allele of Fas in lpr mice that have a deficiency in Fas-mediated apoptosis, showed reduced CaM binding. Computer modeling of the interaction between CaM and helix 2 of the Fas DD predicted that amino acids, which are important for Fas-CaM binding, and point mutations of these amino acids caused reduced Fas-CaM binding. The interaction between Fas and CaM is increased similar to2-fold early upon Fas activation (at 30 min) and is decreased to similar to50% of control at 2 h. These findings suggest a novel function of CaM in Fas-mediated apoptosis.	Univ Alabama, UAB Ctr Metab Bone Dis, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Vet Affairs Med Ctr, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	McDonald, JM (corresponding author), Univ Alabama, UAB Ctr Metab Bone Dis, Dept Pathol, 509 LHRB,1530 3rd Ave S, Birmingham, AL 35294 USA.	mcdonald@path.uab.edu		Lim, Steve/0000-0003-0323-8607				Ahn EY, 2003, AM J PATHOL, V163, P2053, DOI 10.1016/S0002-9440(10)63563-8; ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; Drum CL, 2002, NATURE, V415, P396, DOI 10.1038/415396a; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Liao BR, 1999, P NATL ACAD SCI USA, V96, P6217, DOI 10.1073/pnas.96.11.6217; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; Micoli KJ, 2000, J BIOL CHEM, V275, P1233, DOI 10.1074/jbc.275.2.1233; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; OWENSCHAUB LB, 1993, J IMMUNOTHER, V14, P234, DOI 10.1097/00002371-199310000-00011; Pan G, 1999, AM J PATHOL, V155, P193, DOI 10.1016/S0002-9440(10)65113-9; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; Scoltock AB, 2000, J BIOL CHEM, V275, P30586, DOI 10.1074/jbc.M004058200; Sen CK, 1999, CELL DEATH DIFFER, V6, P481, DOI 10.1038/sj.cdd.4400514; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; WATANABEFUKUNAG.R, 1992, NATURE, V356, P317; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yap Kyoko L., 2000, Journal of Structural and Functional Genomics, V1, P8, DOI 10.1023/A:1011320027914; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	37	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5661	5666		10.1074/jbc.M311040200	http://dx.doi.org/10.1074/jbc.M311040200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14594800	hybrid			2022-12-25	WOS:000188776500077
J	Gottifredi, V; McKinney, K; Poyurovsky, MV; Prives, C				Gottifredi, V; McKinney, K; Poyurovsky, MV; Prives, C			Decreased p21 levels are required for efficient restart of DNA synthesis after S phase block	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; NUCLEOTIDE EXCISION-REPAIR; CELL NUCLEAR ANTIGEN; TERMINAL DOMAIN; MAMMALIAN-CELLS; RE-REPLICATION; INHIBITOR P21; IN-VITRO; P53; DEGRADATION	The cyclin-dependent kinase inhibitor p21, a major transcriptional target of the tumor suppressor p53, plays a critical role in cell cycle arrest in G(1) and G(2) after DNA damage. It was previously shown that in some human cell lines when S phase is arrested, p53 is transcriptionally impaired such that some p53 targets including p21 are only weakly induced. We show here that during S phase arrest proteasome-mediated turnover of p21 is significantly increased in a manner that is independent of p53. It is well established that p21 can interact both with cyclin-dependent kinase complexes and with proliferating cell nuclear antigen ( PCNA). Interestingly, the scant amount of p21 detected during S phase block cannot fully saturate cyclin A-cyclin-dependent kinase 2 complexes and does not interact detectably with PCNA. Importantly, DNA elongation assays in isolated nuclei show that the C terminus of p21 containing the PCNA-binding domain effectively blocks this process. This implies that p21 down-regulation could be an essential requirement for efficient restart of DNA synthesis. In line with this, only cells expressing low levels of p21 immediately progress through the cell cycle upon release from S phase arrest, whereas the remaining few high p21 producing cells move much more slowly through S. Thus, p21 down-regulation is multiply determined and is required for the reversibility of the arrest in S phase.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	clp3@columbia.edu	Gottifredi, Vanesa/AAI-1788-2019	Gottifredi, Vanesa/0000-0001-9656-5951	NATIONAL CANCER INSTITUTE [R37CA058316, R01CA058316] Funding Source: NIH RePORTER; NCI NIH HHS [CA58316] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, MOL CELL BIOL, V16, P6623; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Borel F, 2002, J CELL SCI, V115, P2829; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Cai K, 1998, P NATL ACAD SCI USA, V95, P12254, DOI 10.1073/pnas.95.21.12254; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189; Cooper MP, 1999, MOL BIOL CELL, V10, P2119, DOI 10.1091/mbc.10.7.2119; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Diffley JFX, 2001, CURR BIOL, V11, pR367, DOI 10.1016/S0960-9822(01)00196-8; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottifredi V, 2001, MOL CELL BIOL, V21, P1066, DOI 10.1128/MCB.21.4.1066-1076.2001; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Hammond EM, 2003, J BIOL CHEM, V278, P12207, DOI 10.1074/jbc.M212360200; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; Komarova EA, 1997, CANCER RES, V57, P5217; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Krude T, 2000, J BIOL CHEM, V275, P13699, DOI 10.1074/jbc.275.18.13699; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Krude T, 1999, EXP CELL RES, V247, P148, DOI 10.1006/excr.1998.4342; Li A, 2001, NAT CELL BIOL, V3, pE182, DOI 10.1038/35087119; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Liu QH, 2000, GENE DEV, V14, P1448; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; McKinney K, 2002, MOL CELL BIOL, V22, P6797, DOI 10.1128/MCB.22.19.6797-6808.2002; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; Oku T, 1998, GENES CELLS, V3, P357, DOI 10.1046/j.1365-2443.1998.00199.x; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Prives C, 1999, J PATHOL, V187, P112; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Skildum AJ, 2002, J BIOL CHEM, V277, P5145, DOI 10.1074/jbc.M109179200; Spruck CH, 2002, CELL CYCLE, V1, P248, DOI 10.4161/cc.1.4.132; Sugimoto M, 2002, ONCOGENE, V21, P8067, DOI 10.1038/sj.onc.1206019; TIMSON J, 1975, MUTAT RES, V32, P115, DOI 10.1016/0165-1110(75)90002-0; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Waga S, 1998, MOL CELL BIOL, V18, P4177, DOI 10.1128/MCB.18.7.4177; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324	54	63	63	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5802	5810		10.1074/jbc.M310373200	http://dx.doi.org/10.1074/jbc.M310373200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14597617	hybrid			2022-12-25	WOS:000188776500094
J	Jeong, W; Chang, TS; Boja, ES; Fales, HM; Rhee, SG				Jeong, W; Chang, TS; Boja, ES; Fales, HM; Rhee, SG			Roles of TRP14, a thioredoxin-related protein in tumor necrosis factor-alpha signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; STRESS-INDUCED APOPTOSIS; TNF RECEPTOR 1; OXIDATIVE STRESS; TRANSCRIPTION FACTOR; HYDROGEN-PEROXIDE; REDOX REGULATION; PROTECTIVE ACTIVITY; ACTIVATION; ASK1	The possible roles of a 14-kDa human thioredoxin (Trx)-related protein (TRP14) in TNF-alpha signaling were studied in comparison with those of Trx1 by RNA interference in HeLa cells. Depletion of TRP14 augmented the TNF-alpha-induced phosphorylation and degradation of IkappaBalpha as well as the consequent activation of NF-kappaB to a greater extent than did Trx1 depletion. Deficiency of TRP14 or Trx1 enhanced TNF-alpha-induced activation of caspases and subsequent apoptosis by a similar extent. The TNF-alpha-induced activation of c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinases (MAPKs), however, was promoted by depletion of TRP14 but not by that of Trx1. Unlike Trx1, TRP14 neither associated with nor inhibited the kinase activity of apoptosis signal-regulating kinase-1 (ASK1), an upstream activator of JNK and p38. In combination with the results in the accompanying paper that TRP14 did not reduce the known substrates of Trx1, these results suggest that TRP14 modulates TNF-alpha signaling pathways, provably by interacting with proteins distinct from the targets of Trx1. In an effort to identify target proteins of TRP14, a mutant of TRP14, in which the active site cysteine (Cys46) was substituted with serine, was shown to form a disulfide-linked complex with LC8 cytoplasmic dynein light chain. The complex was detected in HeLa cells treated with H2O2 or TNF-alpha but not in untreated cells, suggesting that LC8 cytoplasmic dynein light chain is a possible substrate of TRP14.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; NHLBI, Biophys Chem Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Ewha Womans University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Rhee, SG (corresponding author), Bldg 50,Room 3523,South Dr,MSC 8015, Bethesda, MD 20892 USA.	sgrhee@nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005506, Z01HL001003, ZIAHL001003] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andoh T, 2002, J BIOL CHEM, V277, P9655, DOI 10.1074/jbc.M110701200; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baker A, 2000, BIOCHEM BIOPH RES CO, V268, P78, DOI 10.1006/bbrc.1999.1908; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bonizzi G, 2000, BIOCHEM PHARMACOL, V59, P7, DOI 10.1016/S0006-2952(99)00290-7; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Chang TS, 2002, J BIOL CHEM, V277, P25370, DOI 10.1074/jbc.M110432200; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Crepieux P, 1997, MOL CELL BIOL, V17, P7375, DOI 10.1128/MCB.17.12.7375; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Garg AK, 2002, MOL IMMUNOL, V39, P509, DOI 10.1016/S0161-5890(02)00207-9; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Hampton MB, 1998, ANN NY ACAD SCI, V854, P328, DOI 10.1111/j.1749-6632.1998.tb09913.x; Hashimoto S, 1999, BIOCHEM BIOPH RES CO, V258, P443, DOI 10.1006/bbrc.1999.0658; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ihling C, 2003, RAPID COMMUN MASS SP, V17, P1240, DOI 10.1002/rcm.1049; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Jaspers I, 2001, AM J RESP CELL MOL, V24, P769, DOI 10.1165/ajrcmb.24.6.4344; Jeong W, 2004, J BIOL CHEM, V279, P3142, DOI 10.1074/jbc.M307932200; KING SM, 2000, BIOCHIM BIOPHYS, V17, P60; Korn SH, 2001, J BIOL CHEM, V276, P35693, DOI 10.1074/jbc.M104321200; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Ma XR, 2001, ONCOGENE, V20, P3703, DOI 10.1038/sj.onc.1204477; MATSUDA M, 1991, J IMMUNOL, V147, P3837; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Matsuzawa A, 2002, ANTIOXID REDOX SIGN, V4, P415, DOI 10.1089/15230860260196218; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; Motohashi K, 2001, P NATL ACAD SCI USA, V98, P11224, DOI 10.1073/pnas.191282098; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Qin J, 2000, ANTIOXID REDOX SIGN, V2, P827, DOI 10.1089/ars.2000.2.4-827; Rhee S G, 2000, Sci STKE, V2000, ppe1; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sartorius U, 2001, CHEMBIOCHEM, V2, P20, DOI 10.1002/1439-7633(20010105)2:1<20::AID-CBIC20>3.3.CO;2-O; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SHOJI Y, 1995, IMMUNOLOGY, V84, P543; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Takeuchi J, 2000, ANTIOXID REDOX SIGN, V2, P83, DOI 10.1089/ars.2000.2.1-83; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; Verdoucq L, 1999, J BIOL CHEM, V274, P19714, DOI 10.1074/jbc.274.28.19714; WAN XS, 1994, DNA CELL BIOL, V13, P1127, DOI 10.1089/dna.1994.13.1127; Wang XD, 2001, GENE DEV, V15, P2922; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; WONG GHW, 1995, BBA-MOL BASIS DIS, V1271, P205, DOI 10.1016/0925-4439(95)00029-4; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999	66	62	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3151	3159		10.1074/jbc.M307959200	http://dx.doi.org/10.1074/jbc.M307959200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14607843	hybrid			2022-12-25	WOS:000188379600004
J	Ruan, WM; Becker, V; Klingmuller, U; Langosch, D				Ruan, WM; Becker, V; Klingmuller, U; Langosch, D			The interface between self-assembling erythropoietin receptor transmembrane segments corresponds to a membrane-spanning leucine zipper	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPHORIN-A; CONSTITUTIVE ACTIVATION; POINT MUTATION; AMINO-ACID; DOMAIN; DIMERIZATION; PROTEIN; RESIDUES; MOTIF; IDENTIFICATION	Structural and functional studies recently indicated that the erythropoietin receptor exists as a preassembled homodimer whose activation by ligand binding requires self-interaction of its transmembrane segment. Here, we probed the interface formed by the transmembrane segments by asparagine-scanning mutagenesis in a natural membrane. We show that this interface is based on a leucine zipper-like heptad repeat pattern of amino acids. The strongest impact of asparagine was observed at position 241, suggesting the highest packing density around this position, which is in agreement with results obtained upon mutation to alanine. Interestingly, the same face of the transmembrane helix had previously been shown to enter a heterophilic interaction with the transmembrane segment of gp55-P, a viral membrane protein that leads to ligand-independent receptor activation in infected cells. Further, functional characterization of an erythropoietin receptor mutant with asparagine at position 241 in a hematopoietic cell line showed that this protein could still be activated by erythropoietin yet was not constitutively active. This suggests that forced self-interaction of the transmembrane segments does not suffice to induce signaling of the erythropoietin receptor.	Tech Univ Munich, Lehrstuhl Chem Biopolymere, D-85354 Freising Weihenstephan, Germany; Max Planck Inst Immunobiol, D-79108 Freiburg, Germany	Technical University of Munich; Max Planck Society	Langosch, D (corresponding author), Tech Univ Munich, Lehrstuhl Chem Biopolymere, Weihenstephaner Berg 3, D-85354 Freising Weihenstephan, Germany.	langosch@lrz.tum.de	Klingmüller, Ursula/G-8477-2013	Klingmüller, Ursula/0000-0001-9845-3099				Brosig B, 1998, PROTEIN SCI, V7, P1052; Choma C, 2000, NAT STRUCT BIOL, V7, P161; CHUNG SW, 1989, P NATL ACAD SCI USA, V86, P7957, DOI 10.1073/pnas.86.20.7957; Constantinescu SN, 1999, EMBO J, V18, P3334, DOI 10.1093/emboj/18.12.3334; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; DEBER CM, 1993, P NATL ACAD SCI USA, V90, P11648, DOI 10.1073/pnas.90.24.11648; Fleming KG, 2001, PROTEINS, V45, P313, DOI 10.1002/prot.1151; Forbes LV, 2002, ONCOGENE, V21, P5981, DOI 10.1038/sj.onc.1205767; Gurezka R, 2001, J BIOL CHEM, V276, P45580, DOI 10.1074/jbc.M105362200; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KOLMAR H, 1994, BIOL CHEM H-S, V375, P61; Kubatzky KF, 2001, CURR BIOL, V11, P110, DOI 10.1016/S0960-9822(01)00018-5; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Laage R, 1997, EUR J BIOCHEM, V249, P540, DOI 10.1111/j.1432-1033.1997.00540.x; Laage R, 2000, J BIOL CHEM, V275, P17481, DOI 10.1074/jbc.M910092199; Langosch D, 1998, PROTEINS, V31, P150, DOI 10.1002/(SICI)1097-0134(19980501)31:2<150::AID-PROT5>3.0.CO;2-Q; Langosch D, 2002, IUBMB LIFE, V54, P109, DOI 10.1080/15216540214538; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; Lear JD, 2003, BIOCHEMISTRY-US, V42, P6400, DOI 10.1021/bi020573j; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Neidhardt F.C., 1996, ESCHERICHIA COLI SAL, V1; NEUMANN D, 1993, J BIOL CHEM, V268, P13639; Onishi M, 1996, BLOOD, V88, P1399, DOI 10.1182/blood.V88.4.1399.bloodjournal8841399; Pinto LH, 1997, P NATL ACAD SCI USA, V94, P11301, DOI 10.1073/pnas.94.21.11301; Popot JL, 2000, ANNU REV BIOCHEM, V69, P881, DOI 10.1146/annurev.biochem.69.1.881; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; RUAN W, 2003, IN PRESS PROTEIN SCI; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Smith SO, 1996, NAT STRUCT BIOL, V3, P252, DOI 10.1038/nsb0396-252; Smith SO, 2001, BIOCHEMISTRY-US, V40, P6553, DOI 10.1021/bi010357v; SUBCZYNSKI WK, 1994, BIOCHEMISTRY-US, V33, P7670, DOI 10.1021/bi00190a022; Swameye I, 2003, P NATL ACAD SCI USA, V100, P1028, DOI 10.1073/pnas.0237333100; Tarr K, 1997, J BIOL CHEM, V272, P9099; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WHITE SH, 1981, NATURE, V290, P161, DOI 10.1038/290161a0; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; Wilson IA, 1999, CURR OPIN STRUC BIOL, V9, P696, DOI 10.1016/S0959-440X(99)00032-9; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154; ZON LI, 1992, MOL CELL BIOL, V12, P2949, DOI 10.1128/MCB.12.7.2949	47	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3273	3279		10.1074/jbc.M309311200	http://dx.doi.org/10.1074/jbc.M309311200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14602718	hybrid			2022-12-25	WOS:000188379600018
J	Stotz, SC; Barr, W; McRory, JE; Chen, L; Jarvis, SE; Zamponi, GW				Stotz, SC; Barr, W; McRory, JE; Chen, L; Jarvis, SE; Zamponi, GW			Several structural domains contribute to the regulation of N-type calcium channel inactivation by the beta(3) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLTAGE-DEPENDENT INACTIVATION; AMINO-TERMINUS; CA2+ CHANNELS; IDENTIFICATION; DETERMINANTS; REGION	Calcium channel beta subunits are essential regulatory elements of the gating properties of high voltage-activated calcium channels. Co-expression with beta(3) subunits typically accelerates inactivation, whereas co-expression with beta(4) subunits results in a slowly inactivating phenotype. Here, we have examined the molecular basis of the differential effect of these two subunits on the inactivation characteristics of Ca(v)2.2 + alpha(2)-delta(1) N-type calcium channels by creating a series of 22 chimeric beta subunits that are based on various combinations of variable and conserved regions of the parent beta subunit isoforms. Our data show that replacement of the N terminus region of beta(4) with a corresponding 14-amino acid stretch of beta(3) sequence accelerates the inactivation kinetics to levels seen with wild type beta(3). A similar kinetic speeding is observed by a concomitant substitution of the second conserved and variable regions, but not when these regions are substituted individually, suggesting that 1) the second variable and conserved regions cooperatively regulate N-type calcium channel inactivation and 2) that there are two redundant mechanisms that allow the beta(3) subunit to accelerate N-type channel inactivation. In contrast with previous reports in Ca(v)2.1 calcium channels, deletion of the C-terminal region of Ca(v)2.2 did not alter the regulation of the channel by wild type and chimeric beta subunits. Hence, the molecular underpinnings of beta subunit regulation of voltage-gated calcium channels appear to vary with calcium channel subtype.	Univ Calgary, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary	Zamponi, GW (corresponding author), Univ Calgary, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	Zamponi@ucalgary.ca		Zamponi, Gerald W./0000-0002-0644-9066				Borodinsky LN, 2003, J NEUROCHEM, V84, P1411, DOI 10.1046/j.1471-4159.2003.01638.x; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Geib S, 2002, J BIOL CHEM, V277, P10003, DOI 10.1074/jbc.M106231200; Hamid J, 1999, J BIOL CHEM, V274, P6195, DOI 10.1074/jbc.274.10.6195; Hurley JF, 2000, P NATL ACAD SCI USA, V97, P9293, DOI 10.1073/pnas.160589697; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Liang HY, 2003, NEURON, V39, P951, DOI 10.1016/S0896-6273(03)00560-9; Lilienbaum A, 2003, MOL CELL BIOL, V23, P2680, DOI 10.1128/MCB.23.8.2680-2698.2003; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Qin N, 1996, AM J PHYSIOL-CELL PH, V271, pC1539, DOI 10.1152/ajpcell.1996.271.5.C1539; Qin N, 1998, P NATL ACAD SCI USA, V95, P4690, DOI 10.1073/pnas.95.8.4690; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; Restituito S, 2000, J NEUROSCI, V20, P9046; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; Stephens GJ, 2000, J PHYSIOL-LONDON, V525, P377, DOI 10.1111/j.1469-7793.2000.t01-1-00377.x; Stotz SC, 2001, J BIOL CHEM, V276, P33001, DOI 10.1074/jbc.M104387200; Stotz SC, 2001, TRENDS NEUROSCI, V24, P176, DOI 10.1016/S0166-2236(00)01738-0; Stotz SC, 2000, J BIOL CHEM, V275, P24575, DOI 10.1074/jbc.M000399200; STOTZ SC, 2004, IN PRESS J PHYSL; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Walker D, 1998, J BIOL CHEM, V273, P2361, DOI 10.1074/jbc.273.4.2361; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825	26	21	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3793	3800		10.1074/jbc.M308991200	http://dx.doi.org/10.1074/jbc.M308991200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14602720	hybrid			2022-12-25	WOS:000188379600081
J	Eyre, DR; Pietka, T; Weis, MA; Wu, JJ				Eyre, DR; Pietka, T; Weis, MA; Wu, JJ			Covalent cross-linking of the NC1 domain of collagen type IX to collagen type II in cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY CORNEAL STROMA; INTERVERTEBRAL DISC; FIBRILS; SITES; CLEAVAGE; PEPTIDES; MOLECULE; PROTEIN; FACIT; CHAIN	From a study to understand the mechanism of covalent interaction between collagen types II and IX, we present experimental evidence for a previously unrecognized molecular site of cross-linking. The location relative to previously defined cross-linking sites predicts a specific manner of interaction and folding of collagen IX on the surface of nascent collagen II fibrils. The initial evidence came from Western blot analysis of type IX collagen extracted by pepsin from fetal human cartilage, which showed a molecular species that had properties indicating an adduct between the alpha1(II) chain and the C-terminal domain (COL1) of type IX collagen. A similar component was isolated from bovine cartilage in sufficient quantity to confirm this identity by N-terminal sequence analysis. Using an antibody that recognized the putative cross-linking sequence at the C terminus of the alpha1(IX) chain, cross-linked peptides were isolated by immunoaffinity chromatography from proteolytic digests of human cartilage collagen. They were characterized by immunochemistry, N-terminal sequence analysis, and mass spectrometry. The results establish a link between a lysine near the C terminus (in the NC1 domain) of alpha1(IX) and the known cross-linking lysine at residue 930 of the alpha1(II) triple helix. This cross-link is speculated to form early in the process of interaction between collagen IX molecules and collagen II polymers. A model of molecular folding and further cross-linking is predicted that can spatially accommodate the formation of all six known cross-linking interactions to the collagen IX molecule on a fibril surface. Of particular biological significance, this model can accommodate potential interfibrillar as well as intrafibrillar links between the collagen IX molecules themselves, so providing a mechanism whereby collagen IX could stabilize a collagen fibril network.	Univ Washington, Dept Orthopaed & Sports Med, Orthopaed Res Labs, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Eyre, DR (corresponding author), Univ Washington, Dept Orthopaed & Sports Med, Orthopaed Res Labs, Box 356500, Seattle, WA 98195 USA.	deyre@u.washington.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR036794, R01AR037318, R01AR036794, R37AR037318] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR36794, AR37318, R01 AR036794, R37 AR037318] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ATLEY LM, 1998, T ORTHOP RES SOC, V23, P850; BISHOP PN, 1994, BIOCHEM J, V299, P497, DOI 10.1042/bj2990497; Chapman KL, 2003, PEDIATR PATHOL MOL M, V22, P53, DOI 10.1080/15227950307699; Diab M, 1996, BIOCHEM J, V314, P327, DOI 10.1042/bj3140327; Ellsworth JL, 2002, OSTEOARTHR CARTILAGE, V10, P308, DOI 10.1053/joca.2002.0514; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; EYRE D R, 1990, P188; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; Fitch J, 1998, DEV DYNAM, V212, P27, DOI 10.1002/(SICI)1097-0177(199805)212:1<27::AID-AJA3>3.3.CO;2-5; FITCH JM, 1988, DEV BIOL, V128, P396, DOI 10.1016/0012-1606(88)90301-6; Fitzgerald J, 2001, FEBS LETT, V505, P275, DOI 10.1016/S0014-5793(01)02754-5; GORDON MK, 1989, J BIOL CHEM, V264, P19772; Hagg R, 1997, J BIOL CHEM, V272, P20650, DOI 10.1074/jbc.272.33.20650; Hagg R, 1998, J CELL BIOL, V142, P285, DOI 10.1083/jcb.142.1.285; Ichimura S, 2000, ARCH BIOCHEM BIOPHYS, V378, P33, DOI 10.1006/abbi.2000.1805; KINTER M, 2000, PROTEIN SEQUENCING I, P153; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mechling DE, 1996, J BIOL CHEM, V271, P13781, DOI 10.1074/jbc.271.23.13781; Miles CA, 1998, J MOL BIOL, V277, P135, DOI 10.1006/jmbi.1997.1603; MULLERGLAUSER W, 1986, J CELL BIOL, V102, P1931, DOI 10.1083/jcb.102.5.1931; Newall JF, 1995, BIOCHEM SOC T, V23, pS517, DOI 10.1042/bst023517s; Olsen BR, 1997, INT J BIOCHEM CELL B, V29, P555, DOI 10.1016/S1357-2725(96)00100-8; Pihlajamaa T, 1998, MATRIX BIOL, V17, P237, DOI 10.1016/S0945-053X(98)90063-4; Poole CA, 1997, OSTEOARTHR CARTILAGE, V5, P191, DOI 10.1016/S1063-4584(97)80014-3; RICHARDSON GP, 1987, HEARING RES, V25, P45, DOI 10.1016/0378-5955(87)90078-5; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; Vizzini A, 2002, BBA-GENE STRUCT EXPR, V1577, P38, DOI 10.1016/S0167-4781(02)00403-7; WU JJ, 1992, J BIOL CHEM, V267, P23007; Wu JJ, 2003, J BIOL CHEM, V278, P24521, DOI 10.1074/jbc.M302431200; WU JJ, 1991, J BIOL CHEM, V266, P5625; WU JJ, 1984, BIOCHEM BIOPH RES CO, V123, P1033, DOI 10.1016/S0006-291X(84)80237-5	33	81	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2568	2574		10.1074/jbc.M311653200	http://dx.doi.org/10.1074/jbc.M311653200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14602708	hybrid			2022-12-25	WOS:000188211300030
J	Ro, DK; Douglas, CJ				Ro, DK; Douglas, CJ			Reconstitution of the entry point of plant phenylpropanoid metabolism in yeast (Saccharomyces cerevisiae) - Implications for control of metabolic flux into the phenylpropanoid pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE AMMONIA-LYASE; TRANS-CINNAMIC ACID; CELL-SUSPENSION CULTURES; MESSENGER-RNA LEVELS; PINUS-TAEDA; FERULATE 5-HYDROXYLASE; ENDOPLASMIC-RETICULUM; LIGNIN BIOSYNTHESIS; ENZYME COMPLEXES; HYBRID POPLAR	Phenylalanine ammonia lyase (PAL), cinnamate 4-hydroxylase (C4H), and the C4H redox partner cytochrome P450 reductase (CPR) are important in allocating significant amounts of carbon from phenylalanine into phenylpropanoid biosynthesis in plants. It has been proposed that multienzyme complexes (MECs) containing PAL and C4H are functionally important at this entry point into phenylpropanoid metabolism. To evaluate the MEC model, two poplar PAL isoforms presumed to be involved in either flavonoid (PAL2) or in lignin biosynthesis (PAL4) were independently expressed together with C4H and CPR in Saccharomyces cerevisiae, creating two yeast strains expressing either PAL2, C4H and CPR or PAL4, C4H and CPR. When [H-3]Phe was fed, the majority of metabolized [H-3]Phe was incorporated into p-[H-3]coumarate, and Phe metabolism was highly reduced by inhibiting C4H activity. PAL alone expressers metabolized very little phenylalanine into cinnamic acid. To test for intermediate channeling between PAL and C4H, we fed [H-3]Phe and [C-14]cinnamate simultaneously to the triple expressers, but found no evidence for channeling of the endogenously synthesized [H-3]cinnamate into p-coumarate. Therefore, efficient carbon flux from Phe to p-coumarate via reactions catalyzed by PAL and C4H does not appear to require channeling through a MEC in yeast, and instead biochemical coupling of PAL and C4H is sufficient to drive carbon flux into the phenylpropanoid pathway. This may be the primary mechanism by which carbon allocation into phenylpropanoid metabolism is controlled in plants.	Univ British Columbia, Dept Bot, Vancouver, BC V6T 1Z4, Canada	University of British Columbia	Douglas, CJ (corresponding author), Univ British Columbia, Dept Bot, Vancouver, BC V6T 1Z4, Canada.	cdouglas@interchange.ubc.ca	Ro, Dae-Kyun/G-9289-2012; Douglas, Carl J/B-1384-2013	Ro, Dae-Kyun/0000-0003-1288-5347; 				Allina SM, 1998, PLANT PHYSIOL, V116, P743, DOI 10.1104/pp.116.2.743; Anterola AM, 2002, J BIOL CHEM, V277, P18272, DOI 10.1074/jbc.M112051200; Anterola AM, 1999, BIOCHEM BIOPH RES CO, V261, P652, DOI 10.1006/bbrc.1999.1097; APPERT C, 1994, EUR J BIOCHEM, V225, P491, DOI 10.1111/j.1432-1033.1994.00491.x; Blount JW, 2000, PLANT PHYSIOL, V122, P107, DOI 10.1104/pp.122.1.107; BOLWELL GP, 1988, PHYTOCHEMISTRY, V27, P2109, DOI 10.1016/0031-9422(88)80106-7; Burbulis IE, 1999, P NATL ACAD SCI USA, V96, P12929, DOI 10.1073/pnas.96.22.12929; Chong J, 2001, PLANT PHYSIOL, V125, P318, DOI 10.1104/pp.125.1.318; CLAUSEN M, 1994, GENE, V142, P107, DOI 10.1016/0378-1119(94)90363-8; COOPER TG, 1981, MOL BIOL YEAST SACCH, P39; Cukovic D, 2001, BIOL CHEM, V382, P645, DOI 10.1515/BC.2001.076; CZICHI U, 1975, PLANTA, V125, P115, DOI 10.1007/BF00388698; CZICHI U, 1977, PLANTA, V134, P133, DOI 10.1007/BF00384962; Franke R, 2000, PLANT J, V22, P223, DOI 10.1046/j.1365-313x.2000.00727.x; Frey M, 1997, SCIENCE, V277, P696, DOI 10.1126/science.277.5326.696; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GOODEY AR, 1982, J GEN MICROBIOL, V128, P2615; Gray-Mitsumune M, 1999, PLANT MOL BIOL, V39, P657, DOI 10.1023/A:1006148715050; Grayson DA, 1996, ARCH BIOCHEM BIOPHYS, V332, P239, DOI 10.1006/abbi.1996.0338; HAHLBROCK K, 1976, EUR J BIOCHEM, V61, P199, DOI 10.1111/j.1432-1033.1976.tb10012.x; HAVIR EA, 1968, BIOCHEMISTRY-US, V7, P1904, DOI 10.1021/bi00845a039; HRAZDINA G, 1985, ARCH BIOCHEM BIOPHYS, V237, P88, DOI 10.1016/0003-9861(85)90257-7; HRAZDINA G, 1987, P NATL ACAD SCI USA, V84, P8966, DOI 10.1073/pnas.84.24.8966; Humphreys JM, 1999, P NATL ACAD SCI USA, V96, P10045, DOI 10.1073/pnas.96.18.10045; Jin HL, 2000, EMBO J, V19, P6150, DOI 10.1093/emboj/19.22.6150; JORRIN J, 1990, PLANT PHYSIOL, V92, P447, DOI 10.1104/pp.92.2.447; Kao YY, 2002, PLANT PHYSIOL, V130, P796, DOI 10.1104/pp.006262; Kiefer E, 2000, PLANT MOL BIOL REP, V18, P33, DOI 10.1007/BF02825291; LANDRY LG, 1995, PLANT PHYSIOL, V109, P1159, DOI 10.1104/pp.109.4.1159; Liu CJ, 2001, PLANT CELL, V13, P2643, DOI 10.1105/tpc.13.12.2643; Lorenzen M, 1996, PLANT PHYSIOL, V112, P1625, DOI 10.1104/pp.112.4.1625; MAVANDAD M, 1990, PLANT PHYSIOL, V94, P671, DOI 10.1104/pp.94.2.671; Mayer MJ, 2001, PLANT CELL, V13, P1669, DOI 10.1105/tpc.13.7.1669; McKegney GR, 1996, PHYTOCHEMISTRY, V41, P1259, DOI 10.1016/0031-9422(95)00677-X; Osakabe K, 1999, P NATL ACAD SCI USA, V96, P8955, DOI 10.1073/pnas.96.16.8955; OSAKABE Y, 1995, PLANT MOL BIOL, V28, P1133, DOI 10.1007/BF00032674; Rasmussen S, 1999, PLANT CELL, V11, P1537, DOI 10.1105/tpc.11.8.1537; Ro DK, 2001, PLANT PHYSIOL, V126, P317, DOI 10.1104/pp.126.1.317; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sarkanen K. V., 1971, LIGNINS OCCURRENCE F, P43; Schalk M, 1998, PLANT PHYSIOL, V118, P209, DOI 10.1104/pp.118.1.209; SUBRAMANIAM R, 1993, PLANT PHYSIOL, V102, P71, DOI 10.1104/pp.102.1.71; TEWARI YB, 1987, J PHYS CHEM-US, V91, P904, DOI 10.1021/j100288a028; URBAN P, 1994, EUR J BIOCHEM, V222, P843, DOI 10.1111/j.1432-1033.1994.tb18931.x; Urrestarazu A, 1998, MOL GEN GENET, V257, P230, DOI 10.1007/s004380050643; vanHeerden PS, 1996, J BIOL CHEM, V271, P12350, DOI 10.1074/jbc.271.21.12350; WAGNER GJ, 1984, PLANT PHYSIOL, V74, P901, DOI 10.1104/pp.74.4.901; WEBB A. DINSMOOR, 1963, ADVAN APPL MICROBIOL, V5, P317, DOI 10.1016/S0065-2164(08)70014-5; YALPANI N, 1993, PLANT PHYSIOL, V103, P315, DOI 10.1104/pp.103.2.315; YAMADA S, 1981, APPL ENVIRON MICROB, V42, P773, DOI 10.1128/AEM.42.5.773-778.1981	50	90	104	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2600	2607		10.1074/jbc.M309951200	http://dx.doi.org/10.1074/jbc.M309951200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14607837	hybrid			2022-12-25	WOS:000188211300034
J	Shteper, PJ; Zcharia, E; Ashhab, Y; Peretz, T; Vlodavsky, I; Ben-Yehuda, D				Shteper, PJ; Zcharia, E; Ashhab, Y; Peretz, T; Vlodavsky, I; Ben-Yehuda, D			Role of promoter methylation in regulation of the mammalian heparanase gene	ONCOGENE			English	Article						promoter methylation; epigenetic regulation; 5-azacytidine; 5-aza-2 ' deoxycytidine; mammalian heparanase; tumour metastasis	DNA METHYLATION; TUMOR-METASTASIS; EXTRACELLULAR-MATRIX; ABL1 METHYLATION; CPG METHYLATION; EXPRESSION; CANCER; CLONING; HYPERMETHYLATION; INHIBITION	Mammalian heparanase (endo-beta-glucuronidase) degrades heparan sulfate proteoglycans and is an important modulator of the extracellular matrix and associated factors. The enzyme is preferentially expressed in neoplastic tissues and contributes to tumour metastasis and angiogenesis. To investigate the epigenetic regulation of the heparanase locus, methylation-specific and bisulfite PCR were performed on a panel of 22 human cancer cell lines. Cytosine methylation of the heparanase promoter was associated with inactivation of the affected allele. Despite lack of sequence homology, extensively methylated CpG islands were found both in human choriocarcinoma (JAR) and rat glioma (C-6) cells which lack heparanase activity. Treatment of these cells with demethylating agents (5-azacytidine, 5-aza-2'-deoxycytidine) resulted in stable dose- and time-dependant promoter hypomethylation accompanied by reappearance of heparanase mRNA, protein and enzymatic activity. An inhibitor of histone deacetylase, Trichostatin A, failed to induce either of these effects. Upregulation of heparanase expression and activity by demethylating drugs was associated with a marked increase in lung colonization by pretreated C-6 rat glioma cells. The increased metastatic potential in vivo was inhibited in mice treated with laminaran sulfate, a potent inhibitor of heparanase activity. We propose a model wherein expression of mammalian heparanase gene is modulated by the interplay between trans-activating genetic and cis-inhibitory epigenetic elements in its promoter.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel; Hadassah Hebrew Univ Med Ctr, Dept Hematol, IL-91120 Jerusalem, Israel; Hadassah Hebrew Univ Med Ctr, Dept Oncol, IL-91120 Jerusalem, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Vlodavsky, I (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel.	vlodavsk@cc.huji.ac.il	Ashhab, Yaqoub/AAC-8789-2019		NATIONAL CANCER INSTITUTE [R21CA087085] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA87085] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andela VB, 2000, CANCER RES, V60, P6557; Asimakopoulos FA, 1999, BLOOD, V94, P2452, DOI 10.1182/blood.V94.7.2452.419k23_2452_2460; Ben-Porath I, 2000, CURR OPIN GENET DEV, V10, P550, DOI 10.1016/S0959-437X(00)00126-X; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bitan M, 2002, EXP HEMATOL, V30, P34, DOI 10.1016/S0301-472X(01)00766-4; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Esteller M, 2001, CANCER RES, V61, P3225; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; Friedmann Y, 2000, AM J PATHOL, V157, P1167, DOI 10.1016/S0002-9440(10)64632-9; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A; Goldshmidt O, 2002, P NATL ACAD SCI USA, V99, P10031, DOI 10.1073/pnas.152070599; Goldshmidt O, 2001, J BIOL CHEM, V276, P29178, DOI 10.1074/jbc.M102462200; Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jiang P, 2002, J BIOL CHEM, V277, P8989, DOI 10.1074/jbc.M105682200; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134; Koliopanos A, 2001, CANCER RES, V61, P4655; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lu WC, 2003, ONCOGENE, V22, P919, DOI 10.1038/sj.onc.1206201; Lynch Catherine A, 2002, Mol Cancer, V1, P2, DOI 10.1186/1476-4598-1-2; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Melki JR, 1999, CANCER RES, V59, P3730; Miao HQ, 1999, INT J CANCER, V83, P424, DOI 10.1002/(SICI)1097-0215(19991029)83:3<424::AID-IJC20>3.3.CO;2-C; Miyakura Y, 2003, GENE CHROMOSOME CANC, V36, P17, DOI 10.1002/gcc.10134; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Parish CR, 2001, BBA-REV CANCER, V1471, pM99, DOI 10.1016/S0304-419X(01)00017-8; RACHMILEWITZ J, 1995, ONCOGENE, V11, P863; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327; Shteper PJ, 2001, LEUKEMIA, V15, P575, DOI 10.1038/sj.leu.2402026; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135; Umezawa A, 1997, MOL CELL BIOL, V17, P4885, DOI 10.1128/MCB.17.9.4885; VanLint C, 1996, GENE EXPRESSION, V5, P245; Velinov M, 2000, MOL GENET METAB, V69, P81, DOI 10.1006/mgme.1999.2941; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1994, INVAS METAST, V14, P290; VLODAVSKY I, 1983, CANCER RES, V43, P2704; VLODAVSKY I, 1992, INVAS METAST, V12, P112; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; Yokomori N, 1998, MOL ENDOCRINOL, V12, P1241, DOI 10.1210/me.12.8.1241; YOKOMORI N, 1995, MOL CELL BIOL, V15, P5355	72	92	97	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2003	22	49					7737	7749		10.1038/sj.onc.1207056	http://dx.doi.org/10.1038/sj.onc.1207056			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586400				2022-12-25	WOS:000186240200004
J	Tao, YX; Johnson, NB; Segaloff, DL				Tao, YX; Johnson, NB; Segaloff, DL			Constitutive and agonist-dependent self-association of the cell surface human lutropin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE RECEPTORS; PROTEIN-COUPLED RECEPTORS; LUTROPIN/CHORIOGONADOTROPIN RECEPTOR; GONADOTROPIN RECEPTOR; CHORIOGONADOTROPIN RECEPTOR; INACTIVATING MUTATIONS; SIGNAL-TRANSDUCTION; OVERLAP EXTENSION; TRANSFECTED CELLS; DIMERIZATION	The human lutropin receptor (hLHR) is a G protein-coupled receptor (GPCR) that plays an essential role in reproductive physiology. The present studies were undertaken to determine whether the hLHR self-associates. We show that high molecular weight complexes of the hLHR can be co-immunoprecipitated from 293 cells transfected with differentially tagged hLHRs. These complexes are detected only in extracts from cells that have been co-transfected and not in extracts combined from cells expressing only one form of tagged hLHR, confirming the in vivo self-association of the receptor. In transiently transfected cells, in which a small percentage of cells overexpress hLHR and most of the hLHR is located intracellularly in the ER, the self-associated hLHR is composed predominantly of immature hLHR. When cells were transiently co-transfected with wildtype hLHR and a misfolded mutant of the hLHR, a physical association of the ER-localized misfolded mutant with the immature hLHR was observed, resulting in a decreased cell surface expression of the wild-type receptor. In contrast, in stably transfected cells, where the majority of cells express receptor and there is much less intracellular accumulation of hLHR, the self-associated forms of the hLHR are composed predominantly of cell surface receptor. The abundance of cell surface hLHR dimers and oligomers, as detected on SDS gels, is increased further upon human choriogonadotropin treatment of the stably transfected cells. In addition to documenting the self-association of cell surface hLHR, our results underscore the importance of the cellular distribution of recombinant GPCR as it relates to the nature of the GPCR dimerization and oligomerization.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Segaloff, DL (corresponding author), Univ Iowa, Dept Physiol & Biophys, 5-470 Bowen Sci Bldg, Iowa City, IA 52242 USA.	deborah-segaloff@uiowa.edu	Tao, Ya-Xiong/K-4939-2019	Tao, Ya-Xiong/0000-0003-4737-749X	NICHD NIH HHS [HD22196] Funding Source: Medline; NIDDK NIH HHS [DK25295, DK07759] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD022196] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abell A, 1996, J BIOL CHEM, V271, P4518; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; ASCOLI M, 1978, P NATL ACAD SCI USA, V75, P99, DOI 10.1073/pnas.75.1.99; Ascoli M, 2002, ENDOCR REV, V23, P141, DOI 10.1210/er.23.2.141; Bai M, 1997, J CLIN INVEST, V99, P88, DOI 10.1172/JCI119137; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Bradbury FA, 1997, J BIOL CHEM, V272, P5921, DOI 10.1074/jbc.272.9.5921; Bradford M. M., 1976, ANAL BIOCHEM, V53, P304; Catt K J, 1980, Recent Prog Horm Res, V36, P557; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CRINE P, 1984, ANN NY ACAD SCI, V438, P224, DOI 10.1111/j.1749-6632.1984.tb38289.x; Davis DP, 1997, MOL ENDOCRINOL, V11, P550, DOI 10.1210/me.11.5.550; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; Fabritz J, 1998, BIOCHEMISTRY-US, V37, P664, DOI 10.1021/bi972355+; Fukushima Y, 1997, FEBS LETT, V409, P283, DOI 10.1016/S0014-5793(97)00531-0; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; HARWOOD JP, 1978, MOL CELL ENDOCRINOL, V11, P121, DOI 10.1016/0303-7207(78)90001-1; He L, 2002, CELL, V108, P271, DOI 10.1016/S0092-8674(02)00613-X; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HIPKIN RW, 1992, MOL ENDOCRINOL, V6, P2210, DOI 10.1210/me.6.12.2210; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hunzicker-Dunn M, 2003, J BIOL CHEM, V278, P42744, DOI 10.1074/jbc.M306133200; Jaquette J, 1997, ENDOCRINOLOGY, V138, P85, DOI 10.1210/en.138.1.85; Ji IH, 2002, MOL ENDOCRINOL, V16, P1299, DOI 10.1210/me.16.6.1299; Karpa KD, 2000, MOL PHARMACOL, V58, P677, DOI 10.1124/mol.58.4.677; KREMER H, 1995, NAT GENET, V9, P160, DOI 10.1038/ng0295-160; KURADA P, 1995, NEURON, V14, P571, DOI 10.1016/0896-6273(95)90313-5; KUSUDA S, 1988, J BIOL CHEM, V263, P3046; Latronico AC, 1999, AM J HUM GENET, V65, P949, DOI 10.1086/302602; Latronico AC, 1996, NEW ENGL J MED, V334, P507, DOI 10.1056/NEJM199602223340805; Le Gouill C, 1999, J BIOL CHEM, V274, P12548, DOI 10.1074/jbc.274.18.12548; Lee CW, 2002, J BIOL CHEM, V277, P15795, DOI 10.1074/jbc.M111818200; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; Martens JWM, 2002, J CLIN ENDOCR METAB, V87, P2506, DOI 10.1210/jc.87.6.2506; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Min L, 2000, MOL ENDOCRINOL, V14, P1797, DOI 10.1210/me.14.11.1797; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; Pfeiffer M, 2002, J BIOL CHEM, V277, P19762, DOI 10.1074/jbc.M110373200; Roess DA, 2000, ENDOCRINOLOGY, V141, P4518, DOI 10.1210/en.141.12.4518; ROZELL TG, 1995, MOL ENDOCRINOL, V9, P1727; Salim K, 2002, J BIOL CHEM, V277, P15482, DOI 10.1074/jbc.M201539200; SOJAR HT, 1989, J BIOL CHEM, V264, P2552; Toledo SPA, 1996, J CLIN ENDOCR METAB, V81, P3850, DOI 10.1210/jc.81.11.3850; VUHAILUUTHI MT, 1992, BIOCHEMISTRY-US, V31, P8377, DOI 10.1021/bi00150a035; Zhu CC, 2002, J BIOL CHEM, V277, P28228, DOI 10.1074/jbc.M204221200	48	72	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5904	5914		10.1074/jbc.M311162200	http://dx.doi.org/10.1074/jbc.M311162200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14594799	hybrid			2022-12-25	WOS:000188776500106
J	Way, TD; Kao, MC; Lin, JK				Way, TD; Kao, MC; Lin, JK			Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; NF-KAPPA-B; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; NEU ONCOGENE; IN-VIVO; MONOCLONAL-ANTIBODIES; SIGNAL-TRANSDUCTION; OVARIAN-CANCER; EGF RECEPTOR	Apigenin is a low toxicity and non-mutagenic phytopolyphenol and protein kinase inhibitor. It exhibits anti-proliferating effects on human breast cancer cells. Here we examined several human breast cancer cell lines having different levels of HER2/neu expression and found that apigenin exhibited potent growth-inhibitory activity in HER2/neu-overexpressing breast cancer cells but was much less effective for those cells expressing basal levels of HER2/neu. Induction of apoptosis was also observed in HER2/neu-overexpressing breast cancer cells in a dose- and time-dependent manner. However, the one or more molecular mechanisms of apigenin-induced apoptosis in HER2/neu-overexpressing breast cancer cells remained to be elucidated. A cell survival pathway involving phosphatidylinositol 3-kinase (PI3K), and Akt is known to play an important role in inhibiting apoptosis in response to HER2/neu-overexpressing breast cancer cells, which prompted us to investigate whether this pathway plays a role in apigenin-induced apoptosis in HER2/neu-overexpressing breast cancer cells. Our results showed that apigenin inhibits Akt function in tumor cells in a complex manner. First, apigenin directly inhibited the PI3K activity while indirectly inhibiting the Akt kinase activity. Second, inhibition of HER2/neu autophosphorylation and transphosphorylation resulting from depleting HER2/neu protein in vivo was also observed. In addition, apigenin inhibited Akt kinase activity by preventing the docking of PI3K to HER2/HER3 heterodimers. Therefore, we proposed that apigenin-induced cellular effects result from loss of HER2/neu and HERS expression with subsequent inactivation of PI3K and AKT in cells that are dependent on this pathway for cell proliferation and inhibition of apoptosis. This implies that the inhibition of the HER2/ HERS heterodimer function provided an especially effective strategy for blocking the HER2/neu-mediated transformation of breast cancer cells. Our results also demonstrated that apigenin dissociated the complex of HER2/neu and GRP94 that preceded the depletion of HER2/neu. Apigenin-induced degradation of mature HER2/neu involves polyubiquitination of HER2/neu and subsequent hydrolysis by the proteasome.	Natl Taiwan Univ 1, Coll Med, Inst Biochem & Mol Biol, Taipei 10018, Taiwan; Natl Def Univ, Natl Def Med Ctr, Dept Biochem, Taipei 114, Taiwan	National Taiwan University; National Defense Medical Center; National Defense University - Taiwan	Lin, JK (corresponding author), Natl Taiwan Univ 1, Coll Med, Inst Biochem & Mol Biol, Sect 1,Jen Ai Rd, Taipei 10018, Taiwan.	jklin@ha.mc.ntu.edu.tw						Agullo G, 1997, BIOCHEM PHARMACOL, V53, P1649, DOI 10.1016/S0006-2952(97)82453-7; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ALIMANDI M, 1995, ONCOGENE, V10, P1813; BIRT DF, 1998, CHEMOPREVENTION CANC, P1263; Bodey B, 1997, ANTICANCER RES, V17, P1319; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Caltagirone S, 2000, INT J CANCER, V87, P595, DOI 10.1002/1097-0215(20000815)87:4&lt;595::AID-IJC21&gt;3.0.CO;2-5; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHAUMONTET C, 1994, CARCINOGENESIS, V15, P2325, DOI 10.1093/carcin/15.10.2325; Chavany C, 1996, J BIOL CHEM, V271, P4974; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1988, ONCOGENE, V2, P273; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Duthie G, 2000, CURR OPIN LIPIDOL, V11, P43, DOI 10.1097/00041433-200002000-00007; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GEAHLEN RL, 1989, J NAT PROD, V52, P982, DOI 10.1021/np50065a011; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hellyer NJ, 2001, J BIOL CHEM, V276, P42153, DOI 10.1074/jbc.M102079200; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Hong RL, 1999, CLIN CANCER RES, V5, P1884; Huang YT, 1996, EUR J CANCER, V32A, P146, DOI 10.1016/0959-8049(95)00540-4; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KASPRZYK PG, 1992, CANCER RES, V52, P2771; KATSUMATA M, 1995, NAT MED, V1, P644, DOI 10.1038/nm0795-644; KUO ML, 1995, BIOCHEM BIOPH RES CO, V212, P767, DOI 10.1006/bbrc.1995.2035; KUO ML, 1992, MUTAT RES, V270, P87, DOI 10.1016/0027-5107(92)90119-M; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; Lin JK, 1997, J CELL BIOCHEM, P39; Lindenmeyer F, 2001, NUTR CANCER, V39, P139, DOI 10.1207/S15327914nc391_19; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Nakashio A, 2000, CANCER RES, V60, P5303; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Ozes ON, 1999, NATURE, V401, P82; Page C, 2000, ANTICANCER RES, V20, P407; PARK JW, 1995, P NATL ACAD SCI USA, V92, P1327, DOI 10.1073/pnas.92.5.1327; Pegram M, 2000, SEMIN ONCOL, V27, P13; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Rajkumar T, 1996, J PATHOL, V179, P381, DOI 10.1002/(SICI)1096-9896(199608)179:4<381::AID-PATH603>3.0.CO;2-X; ROSE DP, 1986, CANCER-AM CANCER SOC, V58, P2363, DOI 10.1002/1097-0142(19861201)58:11<2363::AID-CNCR2820581102>3.0.CO;2-#; SANJAY G, 2002, ONCOGENE, V21, P3727; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Wang CF, 1997, NUTR CANCER, V28, P236, DOI 10.1080/01635589709514582; Wang IK, 1999, EUR J CANCER, V35, P1517, DOI 10.1016/S0959-8049(99)00168-9; Wang WQ, 2000, MOL CARCINOGEN, V28, P102; Xing XM, 1996, CANCER GENE THER, V3, P168; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Yin F, 2001, ANTICANCER RES, V21, P413; Yin F, 1999, THYROID, V9, P369, DOI 10.1089/thy.1999.9.369; YOKOTA J, 1986, LANCET, V1, P765; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1995, ONCOGENE, V11, P1383; YU DH, 1994, CANCER RES, V54, P3150; YUSA K, 1990, J NATL CANCER I, V82, P1633, DOI 10.1093/jnci/82.20.1633; ZHANG LS, 1995, CANCER RES, V55, P3890; ZHANG YJ, 1995, ONCOGENE, V10, P1947	71	191	204	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4479	4489		10.1074/jbc.M305529200	http://dx.doi.org/10.1074/jbc.M305529200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14602723	hybrid			2022-12-25	WOS:000188554300068
J	Ferreira, IA; Eybrechts, KL; Mocking, AIM; Kroner, C; Akkerman, JWN				Ferreira, IA; Eybrechts, KL; Mocking, AIM; Kroner, C; Akkerman, JWN			IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein G(i)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLATELETS; CYCLIC-NUCLEOTIDES; DIABETES-MELLITUS; SECRETED ADP; ACTIVATION; RECEPTOR; PHOSPHORYLATION; COLLAGEN; CAMP; IDENTIFICATION	Platelet agonists initiate aggregation and secretion by activating receptors coupled to the G-protein G(q), thereby raising cytosolic Ca2+, [Ca2+](i). The rise in [Ca2+](i) is facilitated via inhibition of cAMP formation by the inhibitory G-protein of adenylyl cyclase, G(i). Since insulin attenuates platelet activation, we investigated whether insulin interferes with cAMP regulation. Here we report that insulin (0.5-200 nmol/liter) interferes with agonist-induced increases in [Ca2+](i) (ADP, thrombin), cAMP suppression (thrombin), and aggregation (ADP). The effects of insulin are as follows: ( i) independent of the P2Y(12) receptor, which mediates ADP-induced cAMP lowering; (ii) not observed during G(s)-mediated cAMP formation; (iii) unaffected by treatments that affect phosphodiesterases (3-isobutyl-1-methylxanthine); and (iv) not changed by interfering with NO-mediated regulation of cAMP degradation (N-G-monomethyl-L-arginine). Hence, insulin might interfere with G(i). Indeed, insulin induces the following: (i) tyrosine phosphorylation of the insulin receptor, the insulin receptor substrate-1 (IRS-1) and G(i)alpha(2); (ii) co-precipitation of IRS-1 with G(i)alpha(2) but not with other Galpha subunits. Despite persistent receptor activation, the association of IRS-1 with G(i)alpha(2) is transient, being optimal at 5 min and 1 nmol/liter insulin, which is sufficient to suppress Ca2+ signaling by ADP, and at 10 min and 100 nmol/liter insulin, which is required to suppress Ca2+ signaling by thrombin. Epinephrine, a known platelet sensitizer and antagonist of insulin, abolishes the effect of insulin on [Ca2+](i), tyrosine phosphorylation of G(i)alpha(2), and aggregation by interfering with the phosphorylation of the insulin receptor beta subunit. We conclude that insulin attenuates platelet functions by interfering with cAMP suppression through IRS-1 and G(i).	Univ Med Ctr Utrecht, Dept Hematol, Thrombosis & Haemostasis Lab, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands; Unilever Res Labs, Unilever Hlth Inst, NL-3133 AT Vlaardingen, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Unilever	Ferreira, IA (corresponding author), Univ Med Ctr Utrecht, Dept Hematol, Thrombosis & Haemostasis Lab, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	i.a.ferreira@lab.azu.nl						AKKERMAN JW, 2002, PLATELETS THROMBOTIC, P204; Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570; Carr ME, 2001, J DIABETES COMPLICAT, V15, P44, DOI 10.1016/S1056-8727(00)00132-X; EIGENTHALER M, 1992, EUR J BIOCHEM, V205, P471, DOI 10.1111/j.1432-1033.1992.tb16803.x; FALCON C, 1988, BIOCHEM BIOPH RES CO, V157, P1190, DOI 10.1016/S0006-291X(88)81000-3; Gachet C, 2001, THROMB HAEMOSTASIS, V86, P222; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAJEK AS, 1979, J CLIN INVEST, V63, P1060, DOI 10.1172/JCI109375; Hunt DG, 2002, J APPL PHYSIOL, V92, P1285, DOI 10.1152/japplphysiol.01009.2001; Jantzen HM, 2001, J CLIN INVEST, V108, P477; Juska A, 1999, BIOCHEM J, V340, P245, DOI 10.1042/0264-6021:3400245; Keummerle JF, 2001, J BIOL CHEM, V276, P7187, DOI 10.1074/jbc.M011145200; Kim S, 2002, BLOOD, V99, P3629, DOI 10.1182/blood.V99.10.3629; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; KRUPINSKI J, 1988, J BIOL CHEM, V263, P12333; LAUGWITZ KL, 1994, METHOD ENZYMOL, V237, P283; LOPEZAPARICIO P, 1992, BIOCHEM BIOPH RES CO, V186, P517, DOI 10.1016/S0006-291X(05)80838-1; LUTTRELL LM, 1995, J BIOL CHEM, V270, P12984, DOI 10.1074/jbc.270.22.12984; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; OKAMOTO T, 1993, FEBS LETT, V334, P143, DOI 10.1016/0014-5793(93)81700-A; Remijn JA, 2002, ARTERIOSCL THROM VAS, V22, P686, DOI 10.1161/01.ATV.0000012805.49079.23; Riondino S, 2001, THROMB HAEMOSTASIS, V85, P320, DOI 10.1055/s-0037-1615687; Sage SO, 2000, CELL CALCIUM, V28, P119, DOI 10.1054/ceca.2000.0139; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Schwarz UR, 2001, BIOCHEM PHARMACOL, V62, P1153, DOI 10.1016/S0006-2952(01)00760-2; Selheim F, 1999, BIOCHEM BIOPH RES CO, V263, P780, DOI 10.1006/bbrc.1999.1450; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; Trovati M, 1997, DIABETES, V46, P742, DOI 10.2337/diabetes.46.5.742; Trovati M, 1998, DIABETOLOGIA, V41, P609, DOI 10.1007/s001250050958; Turk Z, 1996, HORM METAB RES, V28, P95, DOI 10.1055/s-2007-979136; van Gorp RMA, 2002, EUR J BIOCHEM, V269, P1543, DOI 10.1046/j.1432-1033.2002.02806.x; Westerbacka J, 2002, ARTERIOSCL THROM VAS, V22, P167, DOI 10.1161/hq0102.101546; WINOCOUR PD, 1992, DIABETES, V41, P26, DOI 10.2337/diab.41.2.S26; Yang J, 2000, P NATL ACAD SCI USA, V97, P9984, DOI 10.1073/pnas.180194597	34	88	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3254	3264		10.1074/jbc.M305474200	http://dx.doi.org/10.1074/jbc.M305474200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14602724	hybrid			2022-12-25	WOS:000188379600016
J	Szczesna-Cordary, D; Guzman, G; Ng, SS; Zhao, JJ				Szczesna-Cordary, D; Guzman, G; Ng, SS; Zhao, JJ			Familial hypertrophic cardiomyopathy-linked alterations in Ca2+ binding of human cardiac myosin regulatory light chain affect cardiac muscle contraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TROPOMYOSIN; TROPONIN-T; MUTATIONS; GENE; PROTEINS; DISEASE; IDENTIFICATION; CONFORMATION	The ventricular isoform of human cardiac regulatory light chain (HCRLC) has been shown to be one of the sarcomeric proteins associated with familial hypertrophic cardiomyopathy (FHC), an autosomal dominant disease characterized by left ventricular and/or septal hypertrophy, myofibrillar disarray, and sudden cardiac death. Our recent studies have demonstrated that the properties of isolated HCRLC could be significantly altered by the FHC mutations and that their detrimental effects depend upon the specific position of the missense mutation. This report reveals that the Ca2+ sensitivity of myofibrillar ATPase activity and steady-state force development are also likely to change with the location of the specific FHC HCRLC mutation. The largest effect was seen for the two FHC mutations, N47K and R58Q, located directly in or near the single Ca2+-Mg2+ binding site of HCRLC, which demonstrated no Ca2+ binding compared with wild-type and other FHC mutants (A13T, F18L, E22K, P95A). These two mutants when reconstituted in porcine cardiac muscle preparations increased Ca2(+) sensitivity of myofibrillar ATPase activity and force development. These results suggest the importance of the intact Ca2+ binding site of HCRLC in the regulation of cardiac muscle contraction and imply its possible role in the regulatory light chain-linked pathogenesis of FHC.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA	University of Miami	Szczesna-Cordary, D (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Rm 6113,Rosenstiel Med Sci Bldg R-189,1600 NW 10t, Miami, FL 33136 USA.	dszczesna@med.miami.edu			NHLBI NIH HHS [R01 HL071778, HL071778, R01 HL071778-01A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071778] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGSHAW CR, 1977, FEBS LETT, V81, P386, DOI 10.1016/0014-5793(77)80560-7; CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; Epstein ND, 1998, ADV EXP MED BIOL, V453, P105; Fiske CH, 1925, J BIOL CHEM, V66, P375; Flavigny J, 1998, J MOL MED-JMM, V76, P208, DOI 10.1007/s001090050210; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Gulick J, 1997, CIRC RES, V80, P655, DOI 10.1161/01.RES.80.5.655; Hoffmann B, 2001, Hum Mutat, V17, P524, DOI 10.1002/humu.1143; HOLROYDE MJ, 1979, J BIOL CHEM, V254, P6478; HOLT JC, 1975, BIOCHEMISTRY-US, V14, P4600, DOI 10.1021/bi00692a007; Huang W, 1998, EUR J BIOCHEM, V257, P457, DOI 10.1046/j.1432-1327.1998.2570457.x; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levine RJC, 1999, MOL CELL BIOCHEM, V195, P1, DOI 10.1023/A:1006940513097; MARON BJ, 1995, CIRCULATION, V92, P785, DOI 10.1161/01.CIR.92.4.785; Mogensen J, 1999, J CLIN INVEST, V103, pR39, DOI 10.1172/JCI6460; Mogensen J, 2001, J MED GENET, V38, P193, DOI 10.1136/jmg.38.3.193; Moore DD, 1995, GLOB MOB SURV; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Richard P, 2003, CIRCULATION, V107, P2227, DOI 10.1161/01.CIR.0000066323.15244.54; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; Roopnarine O, 2003, BIOPHYS J, V84, P2440, DOI 10.1016/S0006-3495(03)75048-6; Sanbe A, 2000, CIRC RES, V87, P296, DOI 10.1161/01.RES.87.4.296; Sanbe A, 2000, AM J PHYSIOL-HEART C, V279, pH1355, DOI 10.1152/ajpheart.2000.279.3.H1355; Satoh M, 1999, BIOCHEM BIOPH RES CO, V262, P411, DOI 10.1006/bbrc.1999.1221; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SOLARO RJ, 1971, BIOCHIM BIOPHYS ACTA, V245, P259, DOI 10.1016/0005-2728(71)90033-8; Szczesna D, 2002, J APPL PHYSIOL, V92, P1661, DOI 10.1152/japplphysiol.00858.2001; Szczesna D, 2001, J BIOL CHEM, V276, P7086, DOI 10.1074/jbc.M009823200; Szczesna Danuta, 2003, Current Drug Targets - Cardiovascular & Haematological Disorders, V3, P187, DOI 10.2174/1568006033481474; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; WU CSC, 1976, BIOCHEMISTRY-US, V15, P3007, DOI 10.1021/bi00659a011; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	38	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3535	3542		10.1074/jbc.M307092200	http://dx.doi.org/10.1074/jbc.M307092200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14594949	hybrid			2022-12-25	WOS:000188379600050
J	Vaaje-Kolstad, G; Vasella, A; Peter, MG; Netter, C; Houston, DR; Westereng, B; Synstad, B; Eijsink, VGH; van Aalten, DMF				Vaaje-Kolstad, G; Vasella, A; Peter, MG; Netter, C; Houston, DR; Westereng, B; Synstad, B; Eijsink, VGH; van Aalten, DMF			Interactions of a family 18 chitinase with the designed inhibitor HM508 and its degradation product, chitobiono-delta-lactone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-ASSISTED CATALYSIS; ACID-SEQUENCE SIMILARITIES; HIGH-RESOLUTION STRUCTURES; GLYCOSYL HYDROLASES; SERRATIA-MARCESCENS; CRYSTAL-STRUCTURES; PARASITE INVASION; MOSQUITO MIDGUT; ALLOSAMIDIN; COMPLEX	We describe enzymological and structural analyses of the interaction between the family 18 chitinase ChiB from Serratia marcescens and the designed inhibitor N,N'-diacetylchitobionoxime-N-phenylcarbamate (HM508). HM508 acts as a competitive inhibitor of this enzyme with a K-i in the 50 muM range. Active site mutants of ChiB show K-i values ranging from 1 to 200 muM, providing insight into some of the interactions that determine inhibitor affinity. Interestingly, the wild type enzyme slowly degrades HM508, but the inhibitor is essentially stable in the presence of the moderately active D142N mutant of ChiB. The crystal structure of the D142N-HM508 complex revealed that the two sugar moieties bind to the -2 and -1 subsites, whereas the phenyl group interacts with aromatic side chains that line the +1 and +2 subsites. Enzymatic degradation of HM508, as well as a Trp-->Ala mutation in the +2 subsite of ChiB, led to reduced affinity for the inhibitor, showing that interactions between the phenyl group and the enzyme contribute to binding. Interestingly, a complex of enzymatically degraded HM508 with the wild type enzyme showed a chitobiono-delta-lactone bound in the -2 and -1 subsites, despite the fact that the equilibrium between the lactone and the hydroxy acid forms in solution lies far toward the latter. This shows that the active site preferentially binds the E-4 conformation of the -1 sugar, which resembles the proposed transition state of the reaction.	Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland; Agr Univ Norway, Dept Chem & Biotechnol, N-1432 As, Norway; ETH Honggerberg, CH-8093 Zurich, Switzerland; Univ Potsdam, Inst Chem, D-14469 Potsdam, Germany	University of Dundee; Norwegian University of Life Sciences; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Potsdam	van Aalten, DMF (corresponding author), Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland.	dava@davapc1.bioch.dundee.ac.uk	Westereng, Bjørge/A-1688-2013	Westereng, Bjørge/0000-0002-5141-7231; Houston, Douglas/0000-0002-3469-1546; van Aalten, Daan/0000-0002-1499-6908				Arai N, 2000, CHEM PHARM BULL, V48, P1442, DOI 10.1248/cpb.48.1442; BEER D, 1990, HELV CHIM ACTA, V73, P1918, DOI 10.1002/hlca.19900730714; Berecibar A, 1999, CHEM REV, V99, P779, DOI 10.1021/cr980033l; Bokma E, 2002, EUR J BIOCHEM, V269, P893, DOI 10.1046/j.0014-2956.2001.02721.x; Bortone K, 2002, J MOL BIOL, V320, P293, DOI 10.1016/S0022-2836(02)00444-8; Brameld KA, 1998, J AM CHEM SOC, V120, P3571, DOI 10.1021/ja972282h; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brurberg MB, 1996, MICROBIOL-SGM, V142, P1581, DOI 10.1099/13500872-142-7-1581; COHEN E, 1993, ARCH INSECT BIOCHEM, V22, P245, DOI 10.1002/arch.940220118; Davies GJ, 2003, BIOCHEM SOC T, V31, P523, DOI 10.1042/BST0310523; FORD LO, 1974, J MOL BIOL, V88, P349, DOI 10.1016/0022-2836(74)90487-2; Heightman TD, 1999, ANGEW CHEM INT EDIT, V38, P750, DOI 10.1002/(SICI)1521-3773(19990315)38:6<750::AID-ANIE750>3.0.CO;2-6; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Hooft RWW, 1996, PROTEINS, V26, P363; Houston DR, 2002, BIOCHEM J, V368, P23, DOI 10.1042/BJ20021034; Houston DR, 2002, P NATL ACAD SCI USA, V99, P9127, DOI 10.1073/pnas.132060599; Izumida H, 1996, J ANTIBIOT, V49, P829, DOI 10.7164/antibiotics.49.829; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KETZ EU, 1976, ARCH PHARM, V309, P741, DOI 10.1002/ardp.19763090911; KOLSTAD G, 2003, IN PRESS BIOCH BIOPH; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Papanikolau Y, 2003, ACTA CRYSTALLOGR D, V59, P400, DOI 10.1107/S0907444902021923; Rao FV, 2003, J BIOL CHEM, V278, P20110, DOI 10.1074/jbc.M300362200; ROUGNY A, 1976, B SOC CHIM FR II-CH, P833; SAKUDA S, 1987, J ANTIBIOT, V40, P296, DOI 10.7164/antibiotics.40.296; SAKUDA S, 1986, TETRAHEDRON LETT, V27, P2475, DOI 10.1016/S0040-4039(00)84560-8; SAKUDA S, 1996, CHITIN ENZYMOLOGY, V2, P203; SECEMSKI II, 1972, J BIOL CHEM, V247, P4740; Shiomi K, 2000, TETRAHEDRON LETT, V41, P2141, DOI 10.1016/S0040-4039(00)00099-X; SYNSTAD B, 2000, ADV CHITIN SCI, V4, P524; Tabudravu JN, 2002, BIOORGAN MED CHEM, V10, P1123, DOI 10.1016/S0968-0896(01)00372-8; Tews I, 1997, J AM CHEM SOC, V119, P7954, DOI 10.1021/ja970674i; Tsai YL, 2001, INFECT IMMUN, V69, P4048, DOI 10.1128/IAI.69.6.4048-4054.2001; van Aalten DMF, 2001, P NATL ACAD SCI USA, V98, P8979, DOI 10.1073/pnas.151103798; van Aalten DMF, 2000, P NATL ACAD SCI USA, V97, P5842, DOI 10.1073/pnas.97.11.5842; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; VANSCHELTINGA ACT, 1994, STRUCTURE, V2, P1181, DOI 10.1016/S0969-2126(94)00120-0; VANSCHELTINGA ACT, 1995, BIOCHEMISTRY-US, V34, P15619, DOI 10.1021/bi00048a003; Vinetz JM, 1999, P NATL ACAD SCI USA, V96, P14061, DOI 10.1073/pnas.96.24.14061; Vinetz JM, 2000, J BIOL CHEM, V275, P10331, DOI 10.1074/jbc.275.14.10331; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WATANABE T, 1993, J BIOL CHEM, V268, P18567	44	35	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3612	3619		10.1074/jbc.M310057200	http://dx.doi.org/10.1074/jbc.M310057200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14597613	hybrid			2022-12-25	WOS:000188379600059
J	De Guzman, RN; Martinez-Yamout, MA; Dyson, HJ; Wright, PE				De Guzman, RN; Martinez-Yamout, MA; Dyson, HJ; Wright, PE			Interaction of the TAZ1 domain of the CREB-binding protein with the activation domain of CITED2 - Regulation by competition between intrinsically unstructured ligands for non-identical binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; STRUCTURAL BASIS; HIF-ALPHA; HYDROXYLATION; RECRUITMENT; HIF-1-ALPHA; CBP/P300; NMR; VHL; TRANSACTIVATION	The TAZ1 domain of the homologous transcriptional coactivators CREB-binding protein (CBP) and p300 forms a complex with CITED2 (CBP/p300-interacting transactivator with ED-rich tail), inhibiting the activity of the hypoxia inducible factor (HIF-1alpha) and thereby attenuating the cellular response to low tissue oxygen concentration. We report the NMR structure of the CBP TAZ1 domain bound to the activation domain of CITED2. The structure of TAZ1, consisting of four alpha-helices (alpha(1)-alpha(4)) stabilized by three zinc atoms, is very similar in the CITED2 and HIF-1alpha complexes. The activation domain of CITED2 is unstructured when free and folds upon binding, forming a helix (termed alpha(A)) and an extended structure that wraps around TAZ1. The CITED2 alpha(A) helix packs in the TAZ1 alpha(1)/alpha(4) interface, a site that forms weak interactions with the poorly defined amino-terminal alpha-helix of HIF-1alpha. CITED2 and HIF-1alpha both contain a four residue motif,LP(E/Q)L, which binds in the TAZ1 alpha(1)/alpha(2)/alpha(3) junction in each complex. The carboxyl-terminal region of CITED2 forms an extended structure with hydrophobic contacts in the TAZ1 alpha(1)/alpha(3) interface in the site occupied by the HIF-1alpha alpha(B) helix. CITED2 does not bind at all to the TAZ1 site occupied by the HIF-1alpha carboxyl-terminal helix. The HIF-1alpha and CITED2 domains utilize partly overlapping surfaces of TAZ1 to achieve high affinity binding and to compete effectively with each other for interaction with CBP/p300; CITED2 and HIF-1alpha use these binding sites differently to maintain similar binding affinities in order to displace each other in a feedback loop during the hypoxic response.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Wright, PE (corresponding author), Scripps Res Inst, Dept Mol Biol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	wright@scripps.edu	Dyson, Jane/D-4160-2011	Dyson, Jane/0000-0001-6855-3398; Wright, Peter/0000-0002-1368-0223	NCI NIH HHS [CA96865] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096865] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bamforth SD, 2001, NAT GENET, V29, P469, DOI 10.1038/ng768; BAX A, 1994, METHOD ENZYMOL, V239, P79; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Braganca J, 2003, J BIOL CHEM, V278, P16021, DOI 10.1074/jbc.M208144200; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Case D.A., 2002, AMBER, V7; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; De Guzman RN, 2000, J MOL BIOL, V303, P243, DOI 10.1006/jmbi.2000.4141; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Demarest SJ, 2002, NATURE, V415, P549, DOI 10.1038/415549a; Duggan BM, 2001, J BIOMOL NMR, V19, P321, DOI 10.1023/A:1011227824104; Freedman SJ, 2003, NAT STRUCT BIOL, V10, P504, DOI 10.1038/nsb936; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Tsui V, 2000, J AM CHEM SOC, V122, P2489, DOI 10.1021/ja9939385; Wishart DS, 1998, BIOCHEM CELL BIOL, V76, P153, DOI 10.1139/bcb-76-2-3-153; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yin Z, 2002, P NATL ACAD SCI USA, V99, P10488, DOI 10.1073/pnas.162371799; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; [No title captured]	32	79	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					3042	3049		10.1074/jbc.M310348200	http://dx.doi.org/10.1074/jbc.M310348200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14594809	hybrid			2022-12-25	WOS:000188211300085
J	Ahmad, T; Farnie, G; Bundred, NJ; Anderson, NG				Ahmad, T; Farnie, G; Bundred, NJ; Anderson, NG			The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; SIGNALING PATHWAYS; CARCINOMA-CELLS; ACTIVATION; INHIBITION; EGF; TRANSACTIVATION; PROLIFERATION; BINDING; LINES	The signals used by insulin-like growth factor I (IGF-I) to stimulate proliferation in human mammary epithelial cells have been investigated. IGF-I caused the activation of both ERKs and Akt. Activation of ERKs was slower and more transient than that of Akt. ZD1839, a specific epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitor, prevented activation of ERKs but not Akt by IGF-I. Inhibition of the EGFR with function-blocking monoclonal antibodies also specifically blocked IGF-I-induced ERK activation. These effects occurred in primary mammary epithelial cells and in two cell lines derived from normal mammary epithelium but not in mammary fibroblasts or IGF-I-responsive breast carcinoma cell lines. Although IGF-I stimulated the proliferation of both normal and carcinoma cell lines, ZD1839 blocked this only in the normal line. ZD1839 had no effect on IGF-I receptor (IGF-IR) autophosphorylation in intact cells. IGF-I-induced ERK activation was insensitive to a broad spectrum matrix-metalloproteinase inhibitor and to CRM-197, an inhibitor of the EGFR ligand heparin-bound epidermal growth factor. EGFR was detectable within IGF-IR immunoprecipitates from normal mammary epithelial cells. Treatment of cells with IGF-I led to an increase in the amount of tyrosine-phosphorylated EGFR within these complexes. ZD1839 had no effect on complex formation but completely abolished their associated EGFR tyrosine phosphorylation. These findings indicate that IGF-I utilizes a novel EGFR-dependent signaling pathway involving the formation of a complex between the IGF-IR and the EGFR to activate the ERK pathway and to stimulate proliferation in normal human mammary epithelial cells. This form of regulation may be lost during malignant progression.	Univ Manchester, Sch Med, Acad Dept Surg, Div Canc Studies, Manchester M13 9PT, Lancs, England	University of Manchester	Anderson, NG (corresponding author), Univ Manchester, Sch Med, Acad Dept Surg, Div Canc Studies, G186 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	neil.anderson@man.ac.uk	farnie, gillian/GLT-8777-2022	Farnie, Gillian/0000-0002-1407-2529	Breast Cancer Now [2001:210] Funding Source: Medline	Breast Cancer Now		Anderson NG, 2002, FRONT BIOSCI-LANDMRK, V7, pD1926, DOI 10.2741/anderson; Balana ME, 2001, ONCOGENE, V20, P34, DOI 10.1038/sj.onc.1204050; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Burgaud JL, 1996, EXP CELL RES, V223, P412, DOI 10.1006/excr.1996.0096; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; De Leon DD, 1992, GROWTH FACTORS, V6, P327, DOI 10.3109/08977199209021544; FAN Z, 1994, J BIOL CHEM, V269, P27595; FENTON SE, 1994, EXP CELL RES, V210, P102, DOI 10.1006/excr.1994.1015; Gilmore AP, 2002, J BIOL CHEM, V277, P27643, DOI 10.1074/jbc.M108863200; Hermanto U, 2001, ONCOGENE, V20, P7551, DOI 10.1038/sj.onc.1204964; Hermanto U, 2000, CELL GROWTH DIFFER, V11, P655; IMAGAWA W, 1985, ENDOCRINOLOGY, V116, P1514, DOI 10.1210/endo-116-4-1514; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; MYAL Y, 1984, CANCER RES, V44, P5486; Nicholson KM, 2003, BREAST CANCER RES TR, V81, P117, DOI 10.1023/A:1025765215765; Nolan MK, 1997, INT J CANCER, V72, P828, DOI 10.1002/(SICI)1097-0215(19970904)72:5<828::AID-IJC20>3.0.CO;2-3; Pennisi PA, 2002, CANCER RES, V62, P6529; Petley T, 1999, HORM METAB RES, V31, P70, DOI 10.1055/s-2007-978701; PEYRAT JP, 1992, BREAST CANCER RES TR, V22, P59, DOI 10.1007/BF01833334; Prenzel N, 2000, BREAST CANCER RES, V2, P184, DOI 10.1186/bcr52; Putz T, 1999, CANCER RES, V59, P227; RAM TG, 1995, J CELL PHYSIOL, V163, P589, DOI 10.1002/jcp.1041630320; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; STAMPS AC, 1994, INT J CANCER, V57, P865, DOI 10.1002/ijc.2910570616; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; Strange KS, 2002, BREAST CANCER RES TR, V75, P203, DOI 10.1023/A:1019915101457; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; SUTHERLAND RL, 1992, J STEROID BIOCHEM, V41, P315, DOI 10.1016/0960-0760(92)90357-O; Swantek JL, 1999, ENDOCRINOLOGY, V140, P3163, DOI 10.1210/en.140.7.3163; Thomas Melodie, 2002, Semin Oncol Nurs, V18, P20, DOI 10.1053/sonu.2002.37408; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Wakeling AE, 2002, CANCER RES, V62, P5749; White MF, 1998, RECENT PROG HORM RES, V53, P119; Yamamoto M, 1998, J MED CHEM, V41, P1209, DOI 10.1021/jm970404a	36	94	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1713	1719		10.1074/jbc.M306156200	http://dx.doi.org/10.1074/jbc.M306156200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14593113	hybrid			2022-12-25	WOS:000188005700020
J	Kolossov, VL; Rebeiz, CA				Kolossov, VL; Rebeiz, CA			Chloroplast biogenesis 88 - Protochlorophyllide b occurs in green but not in etiolated plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUANTITATIVE-DETERMINATION; COMPLEX; MONOVINYL; SPECTROFLUOROMETRY; CONVERSION; ETIOPLASTS; DIVINYL; BINDING; BARLEY; POR	It has recently been reported that protochlorophyllide ( Pchlide) b is an abundant pigment in barley etioplasts but is rather unstable, as it is rapidly converted to Pchlide a by 7-formyl reductase during pigment extraction with conventional 80% acetone (Reinbothe, S., Pollmann, S., and Reinbothe, C. ( 2003) J. Biol. Chem. 278, 800 - 806). It has also been claimed that extraction of barley etioplasts with 100% acetone containing 0.1% diethyl pyrocarbonate prevents the conversion of Pchlide b to Pchlide a and leads to the detection of large amounts of Pchlide b in the isolated etioplasts. In this work the extraction protocol of Reinbothe et al. is compared with the more conventional 80% aqueous acetone extraction method. No Pchlide b was detected either in etiolated barley leaves or isolated barley etioplasts irrespective of the extraction protocol. On the other hands, small amounts of Pchlide b were detected in green barley leaves and isolated chloroplasts, extracted either with 80% acetone or 100% acetone containing 0.1% diethyl pyrocarbonate. It is concluded that the proposed occurrence of a light-harvesting POR-Pchlide-a, b complex in etiolated plant tissues is untenable, and its ensuing consequences and implications, for the greening process, are irrelevant.	Univ Illinois, Lab Plant Biochem & Photobiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Rebeiz, CA (corresponding author), Univ Illinois, Lab Plant Biochem & Photobiol, Urbana, IL 61801 USA.							Armstrong GA, 2000, TRENDS PLANT SCI, V5, P40, DOI 10.1016/S1360-1385(99)01513-7; BELANGER FC, 1980, PLANT SCI LETT, V18, P343, DOI 10.1016/0304-4211(80)90097-8; BELANGER FC, 1984, SPECTROCHIM ACTA A, V40, P807, DOI 10.1016/0584-8539(84)80171-3; Ioannides IM, 1997, ANAL BIOCHEM, V249, P241, DOI 10.1006/abio.1997.2179; Ito H, 1996, J BIOL CHEM, V271, P1475, DOI 10.1074/jbc.271.3.1475; Rebeiz CA, 2002, HEME CHLOROPHYLL BIL, P111; Rebeiz CA, 2003, HDB PHOTOCHEMISTRY P, V4, P183; Reinbothe C, 2003, J BIOL CHEM, V278, P816, DOI 10.1074/jbc.M209739200; Reinbothe C, 2003, J BIOL CHEM, V278, P807, DOI 10.1074/jbc.M209738200; Reinbothe C, 1999, NATURE, V397, P80, DOI 10.1038/16283; Reinbothe S, 2003, J BIOL CHEM, V278, P800, DOI 10.1074/jbc.M209737200; REINBOTHE S, 1990, PLANTA, V181, P176, DOI 10.1007/BF02411535; REINBOTHE S, 1993, EMBO J, V12, P365; Scheumann V, 1999, FEBS LETT, V445, P445, DOI 10.1016/S0014-5793(99)00169-6; SHEDBALKAR VP, 1991, J BIOL CHEM, V266, P17151; TRIPATHY BC, 1985, ANAL BIOCHEM, V149, P43, DOI 10.1016/0003-2697(85)90475-0	16	16	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49675	49678		10.1074/jbc.C300449200	http://dx.doi.org/10.1074/jbc.C300449200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14594820	hybrid			2022-12-25	WOS:000187068200005
J	Fassl, S; Leisser, C; Huettenbrenner, S; Maier, S; Rosenberger, G; Strasser, S; Grusch, M; Fuhrmann, G; Leuhuber, K; Polgar, D; Stani, J; Tichy, B; Nowotny, C; Krupitza, G				Fassl, S; Leisser, C; Huettenbrenner, S; Maier, S; Rosenberger, G; Strasser, S; Grusch, M; Fuhrmann, G; Leuhuber, K; Polgar, D; Stani, J; Tichy, B; Nowotny, C; Krupitza, G			Transferrin ensures survival of ovarian carcinoma cells when apoptosis is induced by TNF alpha, FasL, TRAIL, or Myc	ONCOGENE			English	Article						transferrin; apoptosis; TNF alpha; myc; survival; ovarian cancer	TUMOR-NECROSIS-FACTOR; PYRIDOXAL ISONICOTINOYL HYDRAZONE; FERRITIN HEAVY-CHAIN; C-MYC; HEMATOPOIETIC-CELLS; H-FERRITIN; RIBONUCLEOTIDE REDUCTASE; BENZAMIDE RIBOSIDE; GENE-EXPRESSION; GROWTH-FACTOR	The activation of Myc induces apoptosis of human ovarian adenocarcinoma N.1 cells when serum factors are limited. However, the downstream mechanism that is triggered by Myc is unknown. Myc-activation and treatment with the proapoptotic ligands TNFalpha, FasL, and TRAIL induced H-ferritin expression under serum-deprived conditions. H-ferritin chelates intracellular iron and also intracellular iron sequestration by deferoxamine-induced apoptosis of N.1 cells. Supplementation of serum-free medium with holo-transferrin blocked apoptosis of N.1 cells that was induced by Myc-activation or by treatment with TNFalpha, FasL, and TRAIL, whereas apotransferrin did not prevent apoptosis. This suggests that intracellular iron depletion was a trigger for apoptosis and that transferrin-bound iron rescued N.1 cells. Furthermore, apoptosis of primary human ovarian carcinoma cells, which was induced by TNFalpha, FasL, and TRAIL, was also inhibited by holotransferrin. The data suggest that Myc-activation, FasL, TNFalpha, and TRAIL disturbed cellular iron homeostasis, which triggered apoptosis of ovarian carcinoma cells and that transferrin iron ensured survival by re-establishing this homeostasis.	Univ Vienna, Inst Clin Pathol, A-1090 Vienna, Austria; Univ Vienna, Inst Zool, A-1090 Vienna, Austria; Univ Vienna, Dept Obstet & Gynaecol, A-1090 Vienna, Austria	University of Vienna; University of Vienna; University of Vienna	Krupitza, G (corresponding author), Univ Vienna, Inst Clin Pathol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Grusch, Michael/C-1183-2008	Grusch, Michael/0000-0001-5486-9340; Krupitza, Georg/0000-0003-2949-7906				Alcantara O, 2001, EXP HEMATOL, V29, P1060, DOI 10.1016/S0301-472X(01)00683-X; ASKEW DS, 1991, ONCOGENE, V6, P1915; Baik MG, 1998, INT J MOL MED, V2, P39; BARNES D, 1979, NATURE, V281, P388, DOI 10.1038/281388a0; Buss JL, 2003, BIOCHEM PHARMACOL, V65, P161, DOI 10.1016/S0006-2952(02)01512-5; Davidson MG, 1998, EXP EYE RES, V66, P207, DOI 10.1006/exer.1997.0413; Desole MS, 1998, NEUROSCI LETT, V247, P1, DOI 10.1016/S0304-3940(98)00260-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Ferreira C, 2001, BLOOD, V98, P525, DOI 10.1182/blood.V98.3.525; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Fuhrmann G, 1999, MUTAT RES-REV MUTAT, V437, P205, DOI 10.1016/S1383-5742(99)00084-8; Grusch M, 1999, CELL DEATH DIFFER, V6, P736, DOI 10.1038/sj.cdd.4400546; Grusch M, 2002, CELL DEATH DIFFER, V9, P169, DOI 10.1038/sj.cdd.4400937; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Honda KI, 2001, INT J MOL MED, V8, P135; Hua WH, 1995, J STEROID BIOCHEM, V55, P279, DOI 10.1016/0960-0760(95)00187-5; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kawabata H, 2001, BLOOD, V98, P1949, DOI 10.1182/blood.V98.6.1949; Kawabata H, 2001, BLOOD, V98, P2714, DOI 10.1182/blood.V98.9.2714; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Kovar J, 1997, PATHOBIOLOGY, V65, P61, DOI 10.1159/000164105; Kovar J, 2001, IN VITRO CELL DEV-AN, V37, P450; Krupitza G, 1998, CELL DEATH DIFFER, V5, P758, DOI 10.1038/sj.cdd.4400417; KRUPITZA G, 1995, INT J CANCER, V61, P649, DOI 10.1002/ijc.2910610511; Kyriakou D, 1998, EUR J HAEMATOL, V60, P21; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; Leardi A, 1998, BRIT J HAEMATOL, V102, P746, DOI 10.1046/j.1365-2141.1998.00834.x; Lesnikov V, 2001, EXP HEMATOL, V29, P477, DOI 10.1016/S0301-472X(00)00687-1; Leung Y. M., 1993, Biological Signals, V2, P117; Lin FB, 1998, ARCH BIOCHEM BIOPHYS, V352, P51, DOI 10.1006/abbi.1998.0588; Lok CN, 1998, BIOL SIGNAL RECEPT, V7, P157; Maclean K, 2001, J CELL BIOCHEM, V82, P171, DOI 10.1002/jcb.1111; MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; NAYLOR MS, 1993, J CLIN INVEST, V91, P2194, DOI 10.1172/JCI116446; Pang JHS, 1996, J CLIN INVEST, V97, P2204, DOI 10.1172/JCI118661; Quirk SM, 2000, BIOL REPROD, V63, P49, DOI 10.1095/biolreprod63.1.49; Richardson DR, 1997, BLOOD, V89, P3025, DOI 10.1182/blood.V89.8.3025; Rollet-Labelle E, 1998, FREE RADICAL BIO MED, V24, P563, DOI 10.1016/S0891-5849(97)00292-X; Rosenberger G, 2000, LIFE SCI, V67, P3131, DOI 10.1016/S0024-3205(00)00901-2; ROUAULT TA, 1987, P NATL ACAD SCI USA, V84, P6335, DOI 10.1073/pnas.84.18.6335; SALMERON A, 1995, J IMMUNOL, V154, P1675; Shi YF, 1997, J IMMUNOL, V159, P5318; Simonitsch I, 1998, BRIT J CANCER, V78, P862, DOI 10.1038/bjc.1998.594; SLOTMAN BJ, 1988, ANTICANCER RES, V8, P417; Sunstrom NAS, 2000, BIOTECHNOL PROGR, V16, P698, DOI 10.1021/bp000102t; Szekeres T, 1997, CRIT REV CL LAB SCI, V34, P503, DOI 10.3109/10408369709006424; Tanaka T, 1997, BBA-MOL CELL RES, V1357, P91, DOI 10.1016/S0167-4889(97)00016-5; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; TSUJI Y, 1991, J BIOL CHEM, V266, P7257; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x; WEI Y, 1990, BIOCHEM BIOPH RES CO, V169, P289, DOI 10.1016/0006-291X(90)91466-6; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; WU S, 1992, AM J OBSTET GYNECOL, V166, P997, DOI 10.1016/0002-9378(92)91379-O; WU S, 1993, CANCER RES, V53, P1939; Yuan XM, 1999, FREE RADICAL RES, V30, P221, DOI 10.1080/10715769900300241	56	28	31	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8343	8355		10.1038/sj.onc.1207047	http://dx.doi.org/10.1038/sj.onc.1207047			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614458				2022-12-25	WOS:000186541500013
J	Zhou, MX; Gu, LB; Zhu, NX; Woods, WG; Findley, HW				Zhou, MX; Gu, LB; Zhu, NX; Woods, WG; Findley, HW			Transfection of a dominant-negative mutant NF-kappa B inhibitor (IkBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IkBm and p53	ONCOGENE			English	Article						IkB; p53; apoptosis; leukemia	CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTORS; CANCER-CELLS; ALPHA; DEGRADATION; EXPRESSION; RESISTANCE; LYMPHOMA; GROWTH; PROLIFERATION	To investigate the possible role of inhibiting NF-kB activation in sensitizing tumor cells to chemotherapy-induced apoptosis, we transfected the dominant-negative mutant inhibitor of NF-kB (IkBm) into the EU-1 cell line, an acute lymphoblastic leukemia (ALL) line with constitutive NF-kB activation. Overexpression of IkBm significantly reduced constitutive NF-kB activity in EU-1 cells, resulting in decreased cell growth. In response to apoptosis induced by chemotherapeutic drugs, IkBm-transfected cells (EU-1/IkBm) exhibited increased sensitivity to vincristine (VCR), whereas sensitivity to doxorubicin (Dox) was not changed as compared to neo-transfected control (EU-1/neo) cells. To further evaluate the link between IkBm and sensitivity to Dox and VCR, we demonstrated that both endogenous IkBalpha and ectopic IkBm bind to p53. In response to Dox, the cytosolic p53. IkBalpha complex rapidly dissociated due to downregulation of IkBalpha. However, the p53. IkBm complex did not dissociate under these conditions. Although treatment of EU-1/IkBm cells with Dox increased the expression of p53, the nondissociating p53. IkBm complex resulted in decreased p53 function, as demonstrated by absence of cell-cycle arrest and induction of p53 target genes. Contrastingly, VCR-induced cell death neither down-regulated IkBalpha nor induced p53, as shown by the lack of NF-kB activation and p53-mediated gene expression in VCR-treated cells. Our data suggest that IkBm simultaneously downregulates NF-kB activation and sequesters p53 in the cytoplasm, thus enhancing NF-kB-regulated apoptosis but blocking p53-dependent apoptosis.	Emory Univ, Sch Med, Div Pediat Hematol Oncol BMT, Dept Pediat, Atlanta, GA 30322 USA	Emory University	Zhou, MX (corresponding author), Emory Univ, Sch Med, Div Pediat Hematol Oncol BMT, Dept Pediat, 2040 Ridgewood Dr NE, Atlanta, GA 30322 USA.	mzhou@emory.edu			NATIONAL CANCER INSTITUTE [R01CA082323] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA82323] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; Bentires-Alj M, 1999, CANCER RES, V59, P811; Chandra J, 1998, BLOOD, V92, P4220, DOI 10.1182/blood.V92.11.4220.423k49_4220_4229; Chang NS, 2002, J BIOL CHEM, V277, P10323, DOI 10.1074/jbc.M106607200; Conway RM, 1998, EUR J CANCER, V34, P1741, DOI 10.1016/S0959-8049(98)00234-2; Doerre S, 1999, J IMMUNOL, V163, P269; Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848; Findley HW, 1997, BLOOD, V89, P2986, DOI 10.1182/blood.V89.8.2986; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Groninger E, 2000, BRIT J HAEMATOL, V111, P875, DOI 10.1046/j.1365-2141.2000.02420.x; Gugasyan R, 2000, IMMUNOL REV, V176, P134; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; HWANG S, 1995, CANCER BIOCHEM BIOPH, V14, P265; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; JORDAN MA, 1991, CANCER RES, V51, P2212; Kawai H, 1999, CANCER RES, V59, P6038; Kordes U, 2000, LEUKEMIA, V14, P399, DOI 10.1038/sj.leu.2401705; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Lorenzo E, 2002, J BIOL CHEM, V277, P10883, DOI 10.1074/jbc.M107442200; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Orlowski RZ, 1998, CANCER RES, V58, P4342; Post A, 1998, J NEUROSCI, V18, P8236; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schauer SL, 1998, J IMMUNOL, V160, P4398; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; VAN AD, 1996, SCIENCE, V274, P787; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WU HY, 1994, J BIOL CHEM, V269, P20067; ZHOU MX, 1994, LEUKEMIA, V8, P659	45	49	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2003	22	50					8137	8144		10.1038/sj.onc.1206911	http://dx.doi.org/10.1038/sj.onc.1206911			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603254				2022-12-25	WOS:000186403400008
J	DeArmond, D; Brattain, MG; Jessup, JM; Kreisberg, J; Malik, S; Zhao, SJ; Freeman, JW				DeArmond, D; Brattain, MG; Jessup, JM; Kreisberg, J; Malik, S; Zhao, SJ; Freeman, JW			Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines	ONCOGENE			English	Article						growth factors; ErbB-2; cell signaling; pancreatic cancer	CYCLIN D1; FACTOR-ALPHA; CONSTITUTIVE ACTIVATION; BREAST-CANCER; SIGNAL TRANSDUCERS; TYROSINE KINASES; CDK INHIBITORS; ABERRANT REGULATION; DEPENDENT KINASE; FACTOR RECEPTORS	Pancreatic ductal adenocarcinoma (PDAC) cell lines, MIA PaCa-2, and UK Pan-1, were used to investigate the role of ErbB2 in PDAC oncogenesis. Both these cell lines exhibit exogenous growth factor-independent proliferation that was attributed to the production of autocrine growth factors and/or overexpression of growth factor receptors. The exogenous growth factor-independent phenotype displayed by these PDAC cell lines was dependent on ErbB2 kinase activity since treatment of cells with tyrphostin AG879 prevented serum-free media (SFM) induction of cell proliferation. We determined that ErbB2 kinase contributed to aberrant cell cycle regulation in PDAC through the induction of cyclin D1 levels and the suppression of p21(Cip1) and p27(Kip1). Inhibition of ErbB2 kinase led to cell cycle arrest marked by an increased association of p27(Kip1) with cdk2 and reduced levels of phosphorylated pRb. We further observed constitutive STAT3 activation in the PDAC cell lines and an increase in STAT3 activation upon stimulating quiescent cells with SFM. Inhibitors of ErbB2 kinase blocked STAT3 activation, whereas inhibition of EGFR kinase led to a slight reduction of STAT3 activation. STAT3 was coimmunoprecipitated with ErbB2. SFM stimulation caused an increase in the association of ErbB2 and STAT3, which was blocked by inhibition of ErbB2 kinase. Expression of a STAT3 dominant negative prevented SFM-stimulated cell proliferation of MIA PaCa-2 cells, suggesting that activation of STAT3 by ErbB2 is required for a growth factor-independent phenotype of these cells. Consistent with this observation in PDAC cell lines, we found that most PDAC tumor specimens ( 10 of 11) showed constitutive activation of STAT3 and that ErbB2 was readily detected in most of these tumors ( nine of 11). We believe that these findings indicate a novel mechanism of oncogenesis in PDAC and may suggest future therapeutic strategies in the treatment of PDAC.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA; Audie L Murphy Mem Vet Adm Med Ctr, Res & Dev, San Antonio, TX 78229 USA; Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Georgetown Univ, Med Ctr, Dept Surg, Washington, DC 20007 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Roswell Park Cancer Institute; Georgetown University	Freeman, JW (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.				NCI NIH HHS [R01 CA69122, P30 CA 54174] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069122, P30CA054174] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALLRED DC, 1992, HUM PATHOL, V23, P974, DOI 10.1016/0046-8177(92)90257-4; Aziz N, 1999, MOL CELL BIOL, V19, P1101; Bartkova J, 1997, Prog Cell Cycle Res, V3, P211; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brennan PJ, 2000, ONCOGENE, V19, P6093, DOI 10.1038/sj.onc.1203967; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Busse D, 2000, SEMIN ONCOL, V27, P3, DOI 10.1053/sonc.2000.19891; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; Dugan MC, 1997, PANCREAS, V14, P229, DOI 10.1097/00006676-199704000-00003; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Fralix KD, 2000, CANCER, V88, P2010, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2010::AID-CNCR5>3.0.CO;2-5; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; Friess H, 1999, ANN SURG, V230, P767, DOI 10.1097/00000658-199912000-00005; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gartel AL, 2000, ONCOGENE, V19, P961, DOI 10.1038/sj.onc.1203411; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; HALL PA, 1990, J PATHOL, V161, P195, DOI 10.1002/path.1711610305; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Howell GM, 1998, MOL CELL BIOL, V18, P303, DOI 10.1128/MCB.18.1.303; Howell GM, 1998, J BIOL CHEM, V273, P9214, DOI 10.1074/jbc.273.15.9214; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JASKIEWICZ K, 1994, ANTICANCER RES, V14, P1919; Jiang DH, 1998, J BIOL CHEM, V273, P31471, DOI 10.1074/jbc.273.47.31471; Jiang DH, 1998, J CELL PHYSIOL, V175, P174, DOI 10.1002/(SICI)1097-4652(199805)175:2<174::AID-JCP7>3.3.CO;2-E; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Klapper LN, 2000, ADV CANCER RES, V77, P25; KLOPPEL G, 1985, HISTOPATHOLOGY, V9, P841, DOI 10.1111/j.1365-2559.1985.tb02870.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Mack L, 1997, HUM PATHOL, V28, P974, DOI 10.1016/S0046-8177(97)90014-9; Masuda M, 2002, CANCER RES, V62, P3351; OHMICHI M, 1993, BIOCHEMISTRY-US, V32, P4650, DOI 10.1021/bi00068a024; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; OSHEROV N, 1993, J BIOL CHEM, V268, P11134; SATOH K, 1993, CANCER, V72, P51, DOI 10.1002/1097-0142(19930701)72:1<51::AID-CNCR2820720112>3.0.CO;2-O; Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; SOMERVILLE JE, 1992, J CLIN PATHOL, V45, P16, DOI 10.1136/jcp.45.1.16; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; Worsley SD, 1997, GYNECOL ONCOL, V64, P189, DOI 10.1006/gyno.1996.4569; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMANAKA Y, 1993, HUM PATHOL, V24, P1127, DOI 10.1016/0046-8177(93)90194-L; Yeh TC, 1999, CELL MOL LIFE SCI, V55, P1523, DOI 10.1007/s000180050392; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZIOBER BL, 1993, J BIOL CHEM, V268, P691	70	50	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7781	7795		10.1038/sj.onc.1206966	http://dx.doi.org/10.1038/sj.onc.1206966			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586404				2022-12-25	WOS:000186240200008
J	Fixemer, T; Wissenbach, U; Flockerzi, V; Bonkhoff, H				Fixemer, T; Wissenbach, U; Flockerzi, V; Bonkhoff, H			Expression of the Ca2+-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression	ONCOGENE			English	Article						prostate cancer; TRPV6; in situ hybridization; prognostic marker; TRP cation channel	CALCIUM-CHANNEL; GLEASON SCORE; PREDICT; BIOPSY; ANTIGEN; STAGE	Members of the TRP superfamily of cation channels have homeostatic and regulatory functions in cells and changes in their expression may contribute to malignant growth. Previously, we have demonstrated that the gene of the Ca2+-selective cation channel CaT-L or TRPV6 is not expressed in benign prostate tissues including benign prostate hyperplasia, but is upregulated in prostate cancer. Here, we report on the differential expression of TRPV6 mRNA in prostate tissue obtained from 140 patients with prostate cancer. Using in situ hybridization, TRPV6 transcripts were undetectable in benign prostate tissue, high-grade prostatic intraepithelial neoplasia (n = 57), incidental adenocarcinoma and all tumors less than 2.3 cubic centimeter (cc). In prostatectomy specimens from 97 clinically organ-confined tumors, TRPV6 expression correlated significantly with the Gleason score (P = 0.032), pathological stage (P<0.001) and extraprostatic extension (P = 0.025). Lymph node metastasis (n = 17) and androgen-insensitive tumors (n = 27) revealed TRPV6 expression in 63 and 67% of cases, respectively. The latter, however, revealed markedly and significantly decreased levels when compared with untreated tumors (P = 0.044). In summary, the data demonstrate that TRPV6 expression is associated with prostate cancer progression. Accordingly, TRPV6 represents a prognostic marker and, as a plasma membrane Ca2+ channel, a promising target for new therapeutic strategies to treat advanced prostate cancer.	Univ Saarland, Inst Expt & Klin Pharmakol & Toxikol, D-66421 Homburg, Germany; Univ Saarland, Inst Allgemeine & Spezielle Pathol, D-66421 Homburg, Germany	Saarland University; Saarland University	Flockerzi, V (corresponding author), Univ Saarland, Inst Expt & Klin Pharmakol & Toxikol, D-66421 Homburg, Germany.							Bonkhoff H, 1999, AM J PATHOL, V155, P641, DOI 10.1016/S0002-9440(10)65160-7; CUPP MR, 1995, J UROLOGY, V153, P1543, DOI 10.1016/S0022-5347(01)67458-5; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Mariot P, 2002, J BIOL CHEM, V277, P10824, DOI 10.1074/jbc.M108754200; NARAYAN P, 1995, UROLOGY, V46, P205, DOI 10.1016/S0090-4295(99)80195-2; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Partin AW, 1997, JAMA-J AM MED ASSOC, V277, P1445, DOI 10.1001/jama.277.18.1445; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Steinberg DM, 1997, AM J SURG PATHOL, V21, P566, DOI 10.1097/00000478-199705000-00010; Toyota M, 1999, CANCER RES, V59, P4535; Wills ML, 1998, UROLOGY, V51, P759, DOI 10.1016/S0090-4295(98)00011-9; Wissenbach U, 2001, J BIOL CHEM, V276, P19461, DOI 10.1074/jbc.M009895200	12	177	192	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7858	7861		10.1038/sj.onc.1206895	http://dx.doi.org/10.1038/sj.onc.1206895			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586412				2022-12-25	WOS:000186240200016
J	Williams, SL; Valnot, I; Rustin, P; Taanman, JW				Williams, SL; Valnot, I; Rustin, P; Taanman, JW			Cytochrome c oxidase subassemblies in fibroblast cultures from patients carrying mutations in COX10, SCO1, or SURF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL-DNA DEPLETION; BLUE-NATIVE-ELECTROPHORESIS; LEIGH-SYNDROME; OXIDATIVE-PHOSPHORYLATION; YEAST SCO1; HYPERTROPHIC CARDIOMYOPATHY; CU(I)-BINDING PROTEIN; BOVINE HEART; HUMAN-CELLS; HEME-O	Cytochrome c oxidase contains two redox-active copper centers (Cu(A) and Cu(B)) and two redox-active heme A moieties. Assembly of the enzyme relies on several assembly factors in addition to the constituent subunits and prosthetic groups. We studied fibroblast cultures from patients carrying mutations in the assembly factors COX10, SCO1, or SURF1. COX10 is involved in heme A biosynthesis. SCO1 is required for formation of the Cu(A) center. The function of SURF1 is unknown. Immunoblot analysis of native gels demonstrated severely decreased levels of holoenzyme in the patient cultures compared with controls. In addition, the blots revealed the presence of five subassemblies: three subassemblies involving the core subunit MTCO1 but apparently no other subunits; a subassembly containing subunits MTCO1, COX4, and COX5A; and a subassembly containing at least subunits MTCO1, MTCO2, MTCO3, COX4, and COX5A. As some of the subassemblies correspond to known assembly intermediates of human cytochrome c oxidase, we think that these subassemblies are probably assembly intermediates that accumulate in patient cells. The MTCO1.COX4.COX5A subassembly was not detected in COX10-deficient cells, which suggests that heme A incorporation into MTCO1 occurs prior to association of MTCO1 with COX4 and COX5A. SCO1-deficient cells contained accumulated levels of the MTCO1.COX4.COX5A subassembly, suggesting that MTCO2 associates with the MTCO1.COX4.COX5A subassembly after the CuA center of MTCO2 is formed. Assembly in SURF1-deficient cells appears to stall at the same stage as in SCO1-deficient cells, pointing to a role for SURF1 in promoting the association of MTCO2 with the MTCO1.COX4.COX5A subassembly.	UCL, Royal Free & Univ Coll Med Sch, Univ Dept Clin Neurosci, London NW3 2PF, England; Hop Necker Enfants Malad, INSERM, U393, Unite Rech Handicaps Genet Enfant, F-75015 Paris, France	University of London; University College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Taanman, JW (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Univ Dept Clin Neurosci, London NW3 2PF, England.	j.taanman@rfc.ucl.ac.uk	Taanman, Jan W/A-5379-2011	Taanman, Jan W/0000-0002-5476-9785				Agostino A, 2003, HUM MOL GENET, V12, P399, DOI 10.1093/hmg/ddg038; Antonicka H, 2003, HUM MOL GENET, V12, P2693, DOI 10.1093/hmg/ddg284; Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489; Arnold I, 2002, BBA-MOL CELL RES, V1592, P89, DOI 10.1016/S0167-4889(02)00267-7; Barrientos A, 2002, GENE, V286, P53, DOI 10.1016/S0378-1119(01)00803-4; Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43; Barros MH, 2001, FEBS LETT, V492, P133, DOI 10.1016/S0014-5793(01)02249-9; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; BOURGERON T, 1992, BIOCHEM BIOPH RES CO, V186, P16, DOI 10.1016/S0006-291X(05)80769-7; BUCHWALD P, 1991, MOL GEN GENET, V229, P413, DOI 10.1007/BF00267464; CALHOUN MW, 1994, TRENDS BIOCHEM SCI, V19, P325, DOI 10.1016/0968-0004(94)90071-X; Capaldi RA, 1995, METHOD ENZYMOL, V260, P117, DOI 10.1016/0076-6879(95)60134-1; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; Dickinson EK, 2000, J BIOL CHEM, V275, P26780; Glerum DM, 1997, J BIOL CHEM, V272, P19088, DOI 10.1074/jbc.272.30.19088; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Hanson BJ, 2001, J BIOL CHEM, V276, P16296, DOI 10.1074/jbc.M011162200; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Huttemann M, 2003, MOL REPROD DEV, V66, P8, DOI 10.1002/mrd.10327; Huttemann M, 2003, GENE, V312, P95, DOI 10.1016/S0378-1119(03)00604-8; Huttemann M, 2001, GENE, V267, P111, DOI 10.1016/S0378-1119(01)00385-7; Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795; Jaksch M, 2001, NEUROLOGY, V57, P1440, DOI 10.1212/WNL.57.8.1440; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KLEMENT P, 1995, ANAL BIOCHEM, V231, P218, DOI 10.1006/abio.1995.1523; KRUMMECK G, 1990, CURR GENET, V18, P13, DOI 10.1007/BF00321109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lode A, 2000, FEBS LETT, V485, P19, DOI 10.1016/S0014-5793(00)02176-1; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; Marusich MF, 1997, BBA-MOL BASIS DIS, V1362, P145, DOI 10.1016/S0925-4439(97)00061-6; Mattatall NR, 2000, J BIOL CHEM, V275, P28802, DOI 10.1074/jbc.M002741200; McEwan AG, 2002, FEBS LETT, V518, P10, DOI 10.1016/S0014-5793(02)02532-2; Michel H, 1998, ANNU REV BIOPH BIOM, V27, P329, DOI 10.1146/annurev.biophys.27.1.329; Musatov A, 2000, BIOCHEMISTRY-US, V39, P12996, DOI 10.1021/bi000884z; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; Nijtmans LGJ, 2001, FEBS LETT, V498, P46, DOI 10.1016/S0014-5793(01)02447-4; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; Papadopoulou LC, 1999, NAT GENET, V23, P333; Paret C, 1999, FEBS LETT, V447, P65, DOI 10.1016/S0014-5793(99)00266-5; Pequignot MO, 2001, HUM MUTAT, V17, P374, DOI 10.1002/humu.1112.abs; Poyau A, 1999, FEBS LETT, V462, P416, DOI 10.1016/S0014-5793(99)01571-9; SAIKI K, 1993, J BIOL CHEM, V268, P26041; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SCHAGGER H, 1995, ELECTROPHORESIS, V16, P763, DOI 10.1002/elps.11501601125; Schagger H, 1996, ELECTROPHORESIS, V17, P709, DOI 10.1002/elps.1150170415; STEFFENS G, 1976, H-S Z PHYSIOL CHEM, V357, P1125, DOI 10.1515/bchm2.1976.357.2.1125; Taanman JW, 1997, HUM MOL GENET, V6, P935, DOI 10.1093/hmg/6.6.935; Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192; TAANMAN JW, 1993, BIOCHIM BIOPHYS ACTA, V1225, P95, DOI 10.1016/0925-4439(93)90128-N; Taanman JW, 1997, J BIOENERG BIOMEMBR, V29, P151, DOI 10.1023/A:1022638013825; Taanman JW, 2001, BIOCHEM SOC T, V29, P446, DOI 10.1042/BST0290446; Taanman JW, 1996, BBA-MOL BASIS DIS, V1315, P199, DOI 10.1016/0925-4439(95)00127-1; TAANMAN JW, 1993, J BIOL CHEM, V268, P18754; Tiranti V, 1999, HUM MOL GENET, V8, P2533, DOI 10.1093/hmg/8.13.2533; Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; Valnot I, 2000, AM J HUM GENET, V67, P1104; Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245; Wharton DC., 1967, METHOD ENZYMOL, P245; WIELBURSKI A, 1983, BIOCHEM J, V212, P829, DOI 10.1042/bj2120829; Williams SL, 2001, MOL GENET METAB, V73, P340, DOI 10.1006/mgme.2001.3206; Williams SL, 2001, LAB INVEST, V81, P1069, DOI 10.1038/labinvest.3780319; Yao JB, 1999, HUM MOL GENET, V8, P2541, DOI 10.1093/hmg/8.13.2541; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804	68	115	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7462	7469		10.1074/jbc.M309232200	http://dx.doi.org/10.1074/jbc.M309232200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14607829	hybrid			2022-12-25	WOS:000189103300013
J	Gorner, K; Holtorf, E; Odoy, S; Nuscher, B; Yamamoto, A; Regula, JT; Beyer, K; Haass, C; Kahle, PJ				Gorner, K; Holtorf, E; Odoy, S; Nuscher, B; Yamamoto, A; Regula, JT; Beyer, K; Haass, C; Kahle, PJ			Differential effects of Parkinson's disease-associated mutations on stability and folding of DJ-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY-ONSET PARKINSONISM; CRYSTAL-STRUCTURE; ANDROGEN RECEPTOR; ALPHA-SYNUCLEIN; PROTEIN; FERTILIZATION; PATHWAY; TARGET; FORMS	Mutations in the PARK7/DJ-1 gene cause autosomal-recessive Parkinson's disease. In some patients the gene is deleted. The molecular basis of disease in patients with point mutations is less obvious. We have investigated the molecular properties of [L166P]DJ-1 and the novel variant [E64D]DJ-1. When transfected into nonneuronal and neuronal cell lines, steady-state expression levels of [L166P]DJ-1 were dramatically lower than wild-type [WT]DJ-1 and [E64D]DJ-1. Cycloheximide and pulse-chase experiments revealed that the decreased expression levels of [L166P]DJ-1 were because of accelerated protein turnover. Proteasomal degradation was not the major pathway of DJ-1 breakdown because treatment with the proteasome inhibitor MG-132 caused only minimal accumulation of DJ-1, even of the very unstable [L166P]DJ-1 mutant. Because of the structural resemblance of DJ-1 with bacterial cysteine proteases, we considered an autoproteolytic mechanism. However, neither pharmacological inhibition nor site-directed mutagenesis of the putative active site residue Cys-106 stabilized DJ-1. To gain further insight into the structural defects of DJ-1 mutants, human [WT]DJ-1 and both mutants were expressed in Escherichia coli. As in eukaryotic cells, expression levels of [L166P]DJ-1 were dramatically reduced compared with [WT]DJ-1 and [E64D]DJ-1. Circular dichroism spectrometry revealed that the solution structures of [WT]DJ-1 and [E64D]DJ-1 are rich in beta-strand and alpha-helix conformation. alpha-Helices were more susceptible to thermal denaturation than the beta-sheet, and [WT]DJ-1 was more flexible in this regard than [E64D]DJ-1. Thus, structural defects of [E64D]DJ-1 only become apparent upon denaturing conditions, whereas the L166P mutation causes a drastic defect that leads to excessive degradation.	Univ Munich, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany; Univ Munich, Adolf Butenandt Inst, Prot Anal Unit, D-80336 Munich, Germany	University of Munich; University of Munich	Haass, C (corresponding author), Univ Munich, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, Schillerstr 44, D-80336 Munich, Germany.	chaass@pbm.med.uni-muenchen.de; pkahle@pbm.med.uni-muenchen.de		Regula, Joerg Thomas/0000-0002-7343-1077				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bonifati V, 2002, ANN NEUROL, V51, P253, DOI 10.1002/ana.10106; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Dawson TM, 2003, J CLIN INVEST, V111, P145, DOI 10.1172/JCI200317575; Dev KK, 2003, NEUROPHARMACOLOGY, V45, P14, DOI 10.1016/S0028-3908(03)00140-0; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Hague S, 2003, ANN NEUROL, V54, P271, DOI 10.1002/ana.10663; Hod Y, 1999, J CELL BIOCHEM, V72, P435, DOI 10.1002/(SICI)1097-4644(19990301)72:3<435::AID-JCB12>3.3.CO;2-8; Honbou K, 2003, J BIOL CHEM, V278, P31380, DOI 10.1074/jbc.M305878200; Huai Q, 2003, FEBS LETT, V549, P171, DOI 10.1016/S0014-5793(03)00764-6; Kahle PJ, 2002, J NEUROCHEM, V82, P449, DOI 10.1046/j.1471-4159.2002.01020.x; Macedo MG, 2003, HUM MOL GENET, V12, P2807, DOI 10.1093/hmg/ddg304; McNaught KS, 2003, ANN NEUROL, V53, pS73, DOI 10.1002/ana.10512; Miller DW, 2003, J BIOL CHEM, V278, P36588, DOI 10.1074/jbc.M304272200; Mitsumoto A, 2001, FREE RADICAL RES, V35, P301, DOI 10.1080/10715760100300831; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Niki T, 2003, MOL CANCER RES, V1, P247; Okada M, 2002, BIOL PHARM BULL, V25, P853, DOI 10.1248/bpb.25.853; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Tao X, 2003, J BIOL CHEM, V278, P31372, DOI 10.1074/jbc.M304221200; Van Duijn CM, 2001, AM J HUM GENET, V69, P505; Wagenfeld A, 1998, BIOCHEM BIOPH RES CO, V251, P545, DOI 10.1006/bbrc.1998.9512; Wilson MA, 2003, P NATL ACAD SCI USA, V100, P9256, DOI 10.1073/pnas.1133288100	24	74	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6943	6951		10.1074/jbc.M309204200	http://dx.doi.org/10.1074/jbc.M309204200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14607841	hybrid			2022-12-25	WOS:000188969200089
J	Buryskova, M; Pospisek, M; Grothey, A; Simmet, T; Burysek, L				Buryskova, M; Pospisek, M; Grothey, A; Simmet, T; Burysek, L			Intracellular interleukin-1 alpha functionally interacts with histone acetyltransferase complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; GENE-EXPRESSION; TRANSCRIPTION INITIATION; NUCLEAR-LOCALIZATION; ACTIVATION FUNCTIONS; CHROMATIN-STRUCTURE; ADA-COMPLEX	Interleukin-1alpha (IL-1alpha) is an inflammatory cytokine acting extracellularly via membrane receptors. Interestingly, a significant portion of synthesized IL-1alpha is not secreted; instead, it is actively translocated into the cell nucleus. IL-1alpha was indeed shown to be involved in certain intracellular processes, such as control of proliferation, apoptosis, or migration, however, the mechanisms of such actions are not known. Here we show that intracellular IL-1alpha fused to the Ga14p DNA-binding domain (Gal4BD) possesses strong transactivation potential that can be boosted by overexpression of the transcriptional coactivator p300. We demonstrate that the IL-1alpha precursor interacts via its N-terminal peptide (IL-1NTP) with histone acetyltransferases p300, PCAF, Gcn5 and with the adaptor component Ada3, and that it integrates into the PCAF-p300 complex in a non-destructive manner. In analogy with known acidic coactivators, yeast strains expressing Gal4BD/IL-1NTP display a toxic phenotype that can be relieved by depletion of various components of the SAGA complex. Our data provide the first solid evidence for the nuclear target of the IL-1alpha precursor and suggest its novel function in transcriptional control.	Univ Ulm, Dept Pharmacol Nat Prod & Clin Pharmacol, D-89081 Ulm, Germany; Charles Univ Prague, Dept Genet & Microbiol, CR-12844 Prague, Czech Republic	Ulm University; Charles University Prague	Burysek, L (corresponding author), Univ Ulm, Dept Pharmacol Nat Prod & Clin Pharmacol, Helmholtzstr 20, D-89081 Ulm, Germany.	ladislav.burysek@medizin.uni-ulm.de	Burýšek, Ladislav/M-7369-2019; Pospisek, Martin/A-9100-2008	Pospisek, Martin/0000-0002-9490-8911; Syrovets, Tatiana/0000-0002-6751-2233				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARU M, 1991, J VIROL, V65, P3496, DOI 10.1128/JVI.65.7.3496-3503.1991; Beasley D, 1999, AM J PHYSIOL-HEART C, V276, pH901, DOI 10.1152/ajpheart.1999.276.3.H901; Bhaumik SR, 2001, GENE DEV, V15, P1935, DOI 10.1101/gad.911401; Burysek L, 1999, J VIROL, V73, P7334; Burysek L, 1996, CYTOKINE, V8, P460, DOI 10.1006/cyto.1996.0062; Caillaud A, 2002, J BIOL CHEM, V277, P49417, DOI 10.1074/jbc.M207484200; Chen BS, 2001, J BIOL CHEM, V276, P23881, DOI 10.1074/jbc.M102893200; Debets R, 2001, J IMMUNOL, V167, P1440, DOI 10.4049/jimmunol.167.3.1440; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; Dorr A, 2002, EMBO J, V21, P2715, DOI 10.1093/emboj/21.11.2715; DOUVDEVANI A, 1992, INT J CANCER, V51, P822, DOI 10.1002/ijc.2910510526; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Kimbrell DA, 2001, NAT REV GENET, V2, P256, DOI 10.1038/35066006; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KORNUC M, 1988, MOL CELL BIOL, V8, P3717, DOI 10.1128/MCB.8.9.3717; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Kulesza CA, 2002, ONCOGENE, V21, P1411, DOI 10.1038/sj.onc.1205201; Kurooka K, 2000, J BIOL CHEM, V275, P17211, DOI 10.1074/jbc.M000909200; Li M, 2000, MOL CELL BIOL, V20, P8254, DOI 10.1128/MCB.20.21.8254-8263.2000; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; MAIER JAM, 1994, MOL CELL BIOL, V14, P1845, DOI 10.1128/MCB.14.3.1845; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; Marmorstein R, 2001, CURR OPIN GENET DEV, V11, P155, DOI 10.1016/S0959-437X(00)00173-8; MARTELPELLETIER J, 1992, ARTHRITIS RHEUM, V35, P530, DOI 10.1002/art.1780350507; McMahon GA, 1997, J BIOL CHEM, V272, P28202, DOI 10.1074/jbc.272.45.28202; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; Nakatani Y, 2001, GENES CELLS, V6, P79, DOI 10.1046/j.1365-2443.2001.00411.x; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; Pollock AS, 2003, FASEB J, V17, P203, DOI 10.1096/fj.02-0602com; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Seki T, 1996, J CELL PHYSIOL, V168, P648; Smith DE, 2000, J BIOL CHEM, V275, P1169, DOI 10.1074/jbc.275.2.1169; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Stevenson FT, 1997, P NATL ACAD SCI USA, V94, P508, DOI 10.1073/pnas.94.2.508; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; Suhara W, 2002, J BIOL CHEM, V277, P22304, DOI 10.1074/jbc.M200192200; Takeda K, 2001, GENES CELLS, V6, P733, DOI 10.1046/j.1365-2443.2001.00458.x; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; TURNER BM, 1991, J CELL SCI, V99, P13; Vignali M, 2000, EMBO J, V19, P2629, DOI 10.1093/emboj/19.11.2629; Wang T, 2001, EMBO J, V20, P6404, DOI 10.1093/emboj/20.22.6404; WESSENDORF JHM, 1993, J BIOL CHEM, V268, P22100; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Yin HL, 2001, CYTOKINE, V15, P122, DOI 10.1006/cyto.2001.0891; Young BA, 2002, CELL, V109, P417, DOI 10.1016/S0092-8674(02)00752-3	51	77	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4017	4026		10.1074/jbc.M306342200	http://dx.doi.org/10.1074/jbc.M306342200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14612453	hybrid			2022-12-25	WOS:000188554300014
J	Monteleone, G; Mann, J; Monteleone, I; Vavassori, P; Bremner, R; Fantini, M; Blanco, GD; Tersigni, R; Alessandroni, L; Mann, D; Pallone, F; MacDonald, TT				Monteleone, G; Mann, J; Monteleone, I; Vavassori, P; Bremner, R; Fantini, M; Blanco, GD; Tersigni, R; Alessandroni, L; Mann, D; Pallone, F; MacDonald, TT			A failure of transforming growth factor-beta 1 negative regulation maintains sustained NF-kappa B activation in gut inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING-GROWTH-FACTOR; TGF-BETA; BOWEL-DISEASE; TARGETED DISRUPTION; TISSUE-INJURY; RESPONSES; CELLS; IMMUNE; SMAD7; INTERLEUKIN-12	Immunologically mediated tissue damage in the gut is associated with increased production of proinflammatory cytokines, which activate the transcription factor NF-kappaB in a variety of different cell types. The mechanisms/factors that negatively regulate NF-kappaB in the human gut and the pathways leading to the sustained NF-kappaB activation in gut inflammation remain to be identified. Pretreatment of normal human intestinal lamina propria mononuclear cells (LPMC) with transforming growth factor-beta1 (TGF-beta1) resulted in a marked suppression of TNF-alpha-induced NF-kappaB p65 accumulation in the nucleus, NF-kappaB binding DNA activity, and NF-kappaB-dependent gene activation. TGF-beta1 also increased IkappaBalpha transcripts and protein in normal LPMC. In marked contrast, treatment of LPMC from patients with inflammatory bowel disease with TGF-beta1 did not reduce TNF-induced NF-kappaB activation due to the overexpression of Smad7. Indeed inhibiting Smad7 by specific antisense oligonucleotides increased IkappaBalpha expression and reduced NF-kappaB p65 accumulation in the nucleus. This effect was due to endogenous TGF-beta1. TGF-beta1 directly stimulated IkappaBalpha promoter transcriptional activity in gut fibroblasts in vitro, and overexpression of Smad7 blocked this effect. These data show that TGF-beta1 is a negative regulator of NF-kappaB activation in the gut and that Smad7 maintains high NF-kappaB activity in gut inflammation by blocking TGF-beta1 signaling.	Univ Roma Tor Vergata, Dipartimento Med Interna, I-00133 Rome, Italy; Univ Roma Tor Vergata, Ctr Eccellenza Studio Malattie Complesse & Multia, I-00133 Rome, Italy; Univ Southampton, Sch Med, Southampton Gen Hosp, Div Infect Inflammat & Repair, Southampton SO16 6YD, Hants, England; Osped S Camillo Forlanini, Unita Operat Chirurg Flajani, I-00133 Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; University of Southampton; Azienda Ospedaliera San Camillo-Forlanini	Monteleone, G (corresponding author), Univ Roma Tor Vergata, Dipartimento Med Interna, Via Montpellier 1, I-00133 Rome, Italy.	Gi.Monteleone@Med.uniroma2.it	Monteleone, Ivan/AEW-2892-2022; Monteleone, Giovanni/AAE-1418-2021	Monteleone, Ivan/0000-0002-3212-832X; Mann, Derek/0000-0003-0950-243X				Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Bajaj-Elliott M, 1998, J CLIN INVEST, V102, P1473, DOI 10.1172/JCI2792; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bitzer M, 2000, GENE DEV, V14, P187; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Fiocchi C, 1998, GASTROENTEROLOGY, V115, P182, DOI 10.1016/S0016-5085(98)70381-6; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Hahm KB, 2001, GUT, V49, P190, DOI 10.1136/gut.49.2.190; Han SH, 1998, J PHARMACOL EXP THER, V287, P1105; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Lopez-Rovira T, 2000, J BIOL CHEM, V275, P28937, DOI 10.1074/jbc.M909923199; Maeda H, 1996, J IMMUNOL, V156, P73; Monteleone G, 2001, J CLIN INVEST, V108, P601, DOI 10.1172/JCI200112821; Monteleone G, 1999, GASTROENTEROLOGY, V117, P1069, DOI 10.1016/S0016-5085(99)70391-4; Monteleone G, 1997, GASTROENTEROLOGY, V112, P1169, DOI 10.1016/S0016-5085(97)70128-8; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Neurath MF, 1998, GUT, V43, P856, DOI 10.1136/gut.43.6.856; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Rogler G, 2001, SCAND J GASTROENTERO, V36, P389, DOI 10.1080/003655201300051216; Schottelius AJG, 1999, J BIOL CHEM, V274, P31868, DOI 10.1074/jbc.274.45.31868; Schreiber S, 1998, GUT, V42, P477, DOI 10.1136/gut.42.4.477; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sovak MA, 1999, CELL GROWTH DIFFER, V10, P537; Strober W, 2002, ANNU REV IMMUNOL, V20, P495, DOI 10.1146/annurev.immunol.20.100301.064816; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280	28	118	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					3925	3932		10.1074/jbc.M303654200	http://dx.doi.org/10.1074/jbc.M303654200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14600158	hybrid			2022-12-25	WOS:000188554300005
J	Seet, LF; Liu, NS; Hanson, BJ; Hong, WJ				Seet, LF; Liu, NS; Hanson, BJ; Hong, WJ			Endofin recruits TOM1 to endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIFICITY PROTEIN PHOSPHATASE; EAR HOMOLOGY DOMAIN; RAB5 EFFECTOR EEA1; GAMMA-ADAPTIN; GGA PROTEINS; HRS INTERACTS; VHS DOMAIN; BINDING; FAMILY; ENDOCYTOSIS	Endofin is an endosomal protein implicated in regulating membrane trafficking. It is characterized by the presence of a phosphatidylinositol 3-phosphate-binding FYVE domain positioned in the middle of the molecule. To determine its potential effectors or binding partners, we used the carboxyl-terminal half of endofin as bait to screen a human brain cDNA library in a yeast two-hybrid system. Three clones that encode TOM1 were recovered. TOM1 is a protein closely related to the VHS (VPS-27, Hrs, and STAM) domain-containing GGA family. Although the function of the GGAs in mediating Golgi to lysosomal trafficking is well established, the subcellular localization and function of TOM1 remain unknown. Glutathione S-transferase pull-down assays as well as co-immunoprecipitation experiments confirmed that the carboxyl-terminal half of endofin binds specifically to the carboxyl-terminal region of TOM1. Neither SARA nor Hrs, two other FYVE domain proteins, interact with this region of TOM1. Moreover, endofin does not interact with the analogous region of two other members of the TOM1 protein family, namely, TOM1-like 1 (TOM1-L1) or TOM1-like 2 (TOM1-L2). The carboxyl-terminal region of TOM1 was used as immunogen to generate TOM1-specific antibody. This antibody can distinguish TOM1 from the other family members as well as co-immunoprecipitate endogenous endofin. It also revealed the primarily cytosolic distribution of TOM1 in a variety of cell types by immunofluorescence analyses. In addition, sucrose density gradient analysis showed that both TOM1 and endofin can be detected in cellular compartments marked by the early endosomal marker EEA1. A marked recruitment of TOM1 to endosomes was observed in cells overexpressing endofin or its carboxyl-terminal fragment, indicating TOM1 to be an effector for endofin and suggesting a possible role for TOM1 in endosomal trafficking.	Inst Mol & Cell Biol, Membrane Biol Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Seet, LF (corresponding author), Inst Mol & Cell Biol, Membrane Biol Lab, 30 Med Dr, Singapore 117609, Singapore.	mcbslf@imcb.a-star.edu.sg	HONG, Wanjin/E-9927-2010					Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bean AJ, 2000, J BIOL CHEM, V275, P15271, DOI 10.1074/jbc.275.20.15271; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; Boman AL, 2001, J CELL SCI, V114, P3413; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Cormont M, 2001, P NATL ACAD SCI USA, V98, P1637, DOI 10.1073/pnas.031586998; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Estrada L, 2001, HUM MOL GENET, V10, P485, DOI 10.1093/hmg/10.5.485; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Kauppi M, 2002, J CELL SCI, V115, P899; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Kwong J, 2000, J CELL SCI, V113, P2273; Lohi O, 1998, FEBS LETT, V440, P255, DOI 10.1016/S0014-5793(98)01401-X; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; Mattera R, 2003, EMBO J, V22, P78, DOI 10.1093/emboj/cdg015; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Mills IG, 2001, J CELL SCI, V114, P1959; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Nielsen E, 2000, J CELL BIOL, V151, P601, DOI 10.1083/jcb.151.3.601; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Obaishi H, 1998, J BIOL CHEM, V273, P18697, DOI 10.1074/jbc.273.30.18697; Panopoulou E, 2002, J BIOL CHEM, V277, P18046, DOI 10.1074/jbc.M107983200; Pornillos O, 2003, J CELL BIOL, V162, P425, DOI 10.1083/jcb.200302138; Poussu A, 2000, J BIOL CHEM, V275, P7176, DOI 10.1074/jbc.275.10.7176; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Raiborg C, 2002, CELL STRUCT FUNCT, V27, P403, DOI 10.1247/csf.27.403; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Ridley SH, 2001, J CELL SCI, V114, P3991; Seet LF, 2001, J BIOL CHEM, V276, P42445, DOI 10.1074/jbc.M105917200; Seroussi E, 1999, GENOMICS, V57, P380, DOI 10.1006/geno.1998.5739; Seykora JT, 2002, J BIOL CHEM, V277, P2812, DOI 10.1074/jbc.M106813200; Shisheva A, 1999, MOL CELL BIOL, V19, P623; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Stockinger W, 2002, EMBO J, V21, P4259, DOI 10.1093/emboj/cdf435; Takatsu H, 2000, BIOCHEM BIOPH RES CO, V271, P719, DOI 10.1006/bbrc.2000.2700; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Yang HB, 2002, J BIOL CHEM, V277, P30219, DOI 10.1074/jbc.M111933200; Zhao RX, 2000, BIOCHEM BIOPH RES CO, V270, P222, DOI 10.1006/bbrc.2000.2417; Zhao RX, 2001, EXP CELL RES, V265, P329, DOI 10.1006/excr.2001.5185; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	51	30	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4670	4679		10.1074/jbc.M311228200	http://dx.doi.org/10.1074/jbc.M311228200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14613930	hybrid			2022-12-25	WOS:000188554300090
J	Wang, QD; Miyakoda, M; Yang, WD; Khillan, J; Stachura, DL; Weiss, MJ; Nishikura, K				Wang, QD; Miyakoda, M; Yang, WD; Khillan, J; Stachura, DL; Weiss, MJ; Nishikura, K			Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-DEAMINASE; MESSENGER-RNA; CANDIDATE ENZYME; STEM-CELLS; GLUR-B; DROSOPHILA; MICRORNA; MOUSE; REQUIREMENT; DISRUPTION	One type of RNA editing involves the conversion of adenosine residues into inosine in double-stranded RNA through the action of adenosine deaminases acting on RNA (ADAR). A-to-I RNA editing of the coding sequence could result in synthesis of proteins not directly encoded in the genome. ADAR edits also non-coding sequences of target RNAs, such as introns and 3'-untranslated regions, which may affect splicing, translation, and mRNA stability. Three mammalian ADAR gene family members (ADAR1-3) have been identified. Here we investigated phenotypes of mice homozygous for ADAR1 null mutation. Although live ADAR1(-/-) embryos with normal gross appearance could be recovered up to E11.5, widespread apoptosis was detected in many tissues. Fibroblasts derived from ADAR1(-/-) embryos were also prone to apoptosis induced by serum deprivation. Our results demonstrate an essential requirement for ADAR1 in embryogenesis and suggest that it functions to promote survival of numerous tissues by editing one or more double-stranded RNAs required for protection against stress-induced apoptosis.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Nishikura, K (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	kazuko@wistar.upenn.edu	Weiss, Mitchell J/A-1245-2013; Weiss, Mitchell J/W-9814-2018	Weiss, Mitchell J/0000-0003-2460-3036	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061692] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Carmichael GG, 2003, NAT BIOTECHNOL, V21, P371, DOI 10.1038/nbt0403-371; Chen CX, 2000, RNA, V6, P755, DOI 10.1017/S1355838200000170; Cho DSC, 2003, J BIOL CHEM, V278, P17093, DOI 10.1074/jbc.M213127200; Dabiri GA, 1996, EMBO J, V15, P34, DOI 10.1002/j.1460-2075.1996.tb00331.x; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Gerber A, 1997, RNA, V3, P453; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; Hogan BLM, 1994, MANIPULATING MOUSE E, P253, DOI [10. 1007/ 978- 1- 60327- 019- 9_ 13 PMID: 19504073, DOI 10.1007/978-1-60327-019-9_]; Hough RF, 1999, NUCLEIC ACIDS RES, V27, P3424, DOI 10.1093/nar/27.17.3424; Ihle JN, 2000, CELL, V102, P131, DOI 10.1016/S0092-8674(00)00017-9; Kawakubo K, 2000, GENE, V258, P165, DOI 10.1016/S0378-1119(00)00368-1; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Knight SW, 2002, MOL CELL, V10, P809, DOI 10.1016/S1097-2765(02)00649-4; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lai F, 1997, MOL CELL BIOL, V17, P2413, DOI 10.1128/MCB.17.5.2413; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Maas S, 2003, J BIOL CHEM, V278, P1391, DOI 10.1074/jbc.R200025200; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Melcher T, 1996, J BIOL CHEM, V271, P31795, DOI 10.1074/jbc.271.50.31795; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; Miyamura Y, 2003, AM J HUM GENET, V73, P693, DOI 10.1086/378209; Morse DP, 2002, P NATL ACAD SCI USA, V99, P7906, DOI 10.1073/pnas.112704299; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Niswender CM, 1999, J BIOL CHEM, V274, P9472, DOI 10.1074/jbc.274.14.9472; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; Orkin SH, 2000, NAT REV GENET, V1, P57, DOI 10.1038/35049577; Palis J, 1999, DEVELOPMENT, V126, P5073; Palladino MJ, 2000, CELL, V102, P437, DOI 10.1016/S0092-8674(00)00049-0; Palladino MJ, 2000, RNA, V6, P1004, DOI 10.1017/S1355838200000248; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; Patton DE, 1997, NEURON, V19, P711, DOI 10.1016/S0896-6273(00)80383-9; Postic C, 2000, GENESIS, V26, P149, DOI 10.1002/(SICI)1526-968X(200002)26:2<149::AID-GENE16>3.0.CO;2-V; Raitskin O, 2001, P NATL ACAD SCI USA, V98, P6571, DOI 10.1073/pnas.111153798; Reenan RA, 2000, NEURON, V25, P139, DOI 10.1016/S0896-6273(00)80878-8; Rosenthal JJC, 2002, NEURON, V34, P743, DOI 10.1016/S0896-6273(02)00701-8; Rueter SM, 1999, NATURE, V399, P75, DOI 10.1038/19992; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Seeburg PH, 2003, CURR OPIN NEUROBIOL, V13, P279, DOI 10.1016/S0959-4388(03)00062-X; Slavov D, 2000, GENE, V250, P53, DOI 10.1016/S0378-1119(00)00175-X; Slavov D, 2000, GENE, V250, P41, DOI 10.1016/S0378-1119(00)00174-8; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Tonkin LA, 2002, EMBO J, V21, P6025, DOI 10.1093/emboj/cdf607; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Wang Q, 2000, SCIENCE, V290, P1765, DOI 10.1126/science.290.5497.1765; Wang QD, 2000, J NEUROCHEM, V74, P1290; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1; Yelin R, 2003, NAT BIOTECHNOL, V21, P379, DOI 10.1038/nbt808; YILI Y, 1995, EMBO J, V14, P6095	56	349	356	0	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4952	4961		10.1074/jbc.M310162200	http://dx.doi.org/10.1074/jbc.M310162200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14613934	hybrid			2022-12-25	WOS:000188554300121
J	Meehan, S; Berry, Y; Luisi, B; Dobson, CM; Carver, JA; MacPhee, CE				Meehan, S; Berry, Y; Luisi, B; Dobson, CM; Carver, JA; MacPhee, CE			Amyloid fibril formation by lens crystallin proteins and its implications for cataract formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ALPHA-CRYSTALLIN; CHAPERONE-LIKE ACTIVITY; HEAT-SHOCK PROTEINS; X-RAY-DIFFRACTION; MOLECULAR CHAPERONE; IN-VITRO; GUANIDINE-HYDROCHLORIDE; GAMMA-CRYSTALLINS; HUMAN-DISEASE; B-CRYSTALLIN	The alpha-, beta-, and gamma-crystallins are the major structural proteins within the eye lens and are responsible for its exceptional stability and transparency. Under mildly denaturing conditions, all three types of bovine crystallin assemble into fibrillar structures in vitro. Characterization by transmission electron microscopy, dye binding assays, and x-ray fiber diffraction shows that these species have all of the characteristics of fibrils associated with the family of amyloid diseases. Moreover, the full-length proteins are incorporated into the fibrils, (i.e. no protein cleavage is required for these species to form), although for the gamma-crystallins some fragmentation occurs under the conditions employed in this study. Our findings indicate that the inherent stability of the beta-sheet supramolecular structure adopted by the crystallins in the eye lens and the chaperone ability of alpha-crystallin must be crucial for preventing fibril formation in vivo. The crystallins are very stable proteins but undergo extensive post-translational modification with age that leads to their destabilization. The ability of the crystallins to convert into fibrils under destabilizing conditions suggests that this process could contribute to the development of cataract with aging.	Univ Cambridge, Cavendish Lab, Biol Phys Grp, Cambridge CB3 0HE, England; Univ Wollongong, Dept Chem, Wollongong, NSW 2522, Australia; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England	University of Cambridge; University of Wollongong; University of Cambridge; University of Cambridge	MacPhee, CE (corresponding author), Univ Cambridge, Cavendish Lab, Biol Phys Grp, Madingley Rd, Cambridge CB3 0HE, England.	cem48@cam.ac.uk	Carver, John Adrian/J-3825-2014; MacPhee, Cait/F-6679-2013	Carver, John Adrian/0000-0002-2441-8108; MacPhee, Cait/0000-0001-8313-8387				AUGUSTEYN RC, 1989, BIOCHIM BIOPHYS ACTA, V999, P293, DOI 10.1016/0167-4838(89)90012-5; AUGUSTEYN RC, 1988, BIOCHIM BIOPHYS ACTA, V957, P192, DOI 10.1016/0167-4838(88)90272-5; Bousset L, 2003, J STRUCT BIOL, V141, P132, DOI 10.1016/S1047-8477(02)00606-8; Bousset L, 2002, EMBO J, V21, P2903, DOI 10.1093/emboj/cdf303; Burgio MR, 2000, BIOCHEM BIOPH RES CO, V268, P426, DOI 10.1006/bbrc.1999.2036; Burgio MR, 2001, MOL VIS, V7, P228; Carver JA, 1996, EXP EYE RES, V63, P639, DOI 10.1006/exer.1996.0158; Clark JI, 2000, CURR OPIN STRUC BIOL, V10, P52, DOI 10.1016/S0959-440X(99)00048-2; Das BK, 1997, BIOCHEM BIOPH RES CO, V236, P370, DOI 10.1006/bbrc.1997.6950; David LL, 1996, J BIOL CHEM, V271, P4273; Derham BK, 1999, PROG RETIN EYE RES, V18, P463, DOI 10.1016/S1350-9462(98)00030-5; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Doss-Pepe EW, 1998, EXP EYE RES, V67, P657, DOI 10.1006/exer.1998.0561; Eckert R, 2002, PFLUG ARCH EUR J PHY, V443, P843, DOI 10.1007/s00424-001-0760-2; Fezoui Y, 2002, J BIOL CHEM, V277, P36948, DOI 10.1074/jbc.M204168200; Frederikse PH, 2000, CURR EYE RES, V20, P462, DOI 10.1076/0271-3683(200006)20:6;1-Y;FT462; Fu L, 2002, FEBS LETT, V513, P213, DOI 10.1016/S0014-5793(02)02313-X; GLENNER GG, 1972, J HISTOCHEM CYTOCHEM, V20, P821, DOI 10.1177/20.10.821; Goldstein LE, 2003, LANCET, V361, P1258, DOI 10.1016/S0140-6736(03)12981-9; Harding J., 1991, CATARACT BIOCH EPIDE; Harding J J, 1998, Curr Opin Ophthalmol, V9, P10, DOI 10.1097/00055735-199802000-00003; Hatters DM, 2001, J BIOL CHEM, V276, P33755, DOI 10.1074/jbc.M105285200; Heon E, 1999, AM J HUM GENET, V65, P1261, DOI 10.1086/302619; Hiratsuka Yoshimune, 2001, Nippon Ganka Gakkai Zasshi, V105, P369; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; Kelly JW, 1998, P NATL ACAD SCI USA, V95, P930, DOI 10.1073/pnas.95.3.930; Koretz JF, 1998, INT J BIOL MACROMOL, V22, P283, DOI 10.1016/S0141-8130(98)00026-9; Kudva YC, 1997, FEBS LETT, V416, P117, DOI 10.1016/S0014-5793(97)01180-0; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Lund AL, 1996, EXP EYE RES, V63, P661, DOI 10.1006/exer.1996.0160; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; Pande A, 2000, P NATL ACAD SCI USA, V97, P1993, DOI 10.1073/pnas.040554397; Pande A, 2001, P NATL ACAD SCI USA, V98, P6116, DOI 10.1073/pnas.101124798; Pepys MB, 2001, PHILOS T R SOC B, V356, P203, DOI 10.1098/rstb.2000.0766; Poon S, 2002, J BIOL CHEM, V277, P39532, DOI 10.1074/jbc.M204855200; Sandilands A, 2002, EMBO J, V21, P6005, DOI 10.1093/emboj/cdf609; SCHURTENBERGER P, 1991, BIOPOLYMERS, V31, P1229, DOI 10.1002/bip.360311011; SIEZEN RJ, 1982, EXP EYE RES, V34, P969, DOI 10.1016/0014-4835(82)90077-X; SIEZEN RJ, 1979, EXP EYE RES, V28, P551, DOI 10.1016/0014-4835(79)90043-5; Slingsby C, 1999, EYE, V13, P395, DOI 10.1038/eye.1999.113; SNELLINGEN T, 2002, COCHRANE LIB; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; Srinivas V, 2002, J PROTEIN CHEM, V21, P87, DOI 10.1023/A:1014572110926; SRIVASTAVA OP, 1992, EXP EYE RES, V54, P893, DOI 10.1016/0014-4835(92)90153-J; Stege GJJ, 1999, BIOCHEM BIOPH RES CO, V262, P152, DOI 10.1006/bbrc.1999.1167; STEVENS A, 1987, CURR EYE RES, V6, P739, DOI 10.3109/02713688709034839; Sun TX, 1998, J BIOL CHEM, V273, P286, DOI 10.1074/jbc.273.1.286; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Treweek TM, 2003, AUST J CHEM, V56, P357, DOI 10.1071/CH03031; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; Zurdo J, 2001, J AM CHEM SOC, V123, P8141, DOI 10.1021/ja016229b	54	149	155	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3413	3419		10.1074/jbc.M308203200	http://dx.doi.org/10.1074/jbc.M308203200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14615485	hybrid			2022-12-25	WOS:000188379600035
J	Dame, C; Sola, MC; Lim, KC; Leach, KM; Fandrey, J; Ma, Y; Knopfle, G; Engel, JD; Bungert, J				Dame, C; Sola, MC; Lim, KC; Leach, KM; Fandrey, J; Ma, Y; Knopfle, G; Engel, JD; Bungert, J			Hepatic erythropoietin gene regulation by GATA-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; MESSENGER-RNA EXPRESSION; CENTRAL-NERVOUS-SYSTEM; TRANSGENIC MICE; ERYTHROID-DIFFERENTIATION; CELL-LINES; HEMATOPOIETIC DEFECT; NEGATIVE REGULATION; BINDING-PROTEIN; FETAL LIVER	Erythropoietin production switches from fetal liver to adult kidney during development. GATA transcription factors 2 and 3 could be involved in modulating this switch, because they were shown to negatively regulate erythropoietin gene transcription through a promoter proximal GATA site. Herein, we analyzed the role of several GATA factors in the regulation of the erythropoietin gene in human liver and in hepatoma cells. Although GATA-3 expression in hepatocytes increases during human development, erythropoietin mRNA accumulation is unaltered in mutant mice lacking GATA-3. We found that GATA-2, -3, -4, and -6 are all expressed in human hepatocytes and that GATA-4 exhibits the most prominent Epo promoter binding activity in vitro and in vivo. Inhibition of GATA-4 expression by RNA interference leads to a dramatic reduction in Epo gene transcription in Hep3B cells. Moreover, GATA-4 expression is high and limited to hepatocytes in the fetal liver, whereas GATA-4 expression in the adult liver is low and restricted to epithelial cells surrounding the biliary ducts. Thus, GATA-4 is critical for transcription of the Epo gene in hepatocytes and may contribute to the switch in the site of Epo gene expression from the fetal liver to the adult kidney.	Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ Florida, Div Neonatol, Gainesville, FL 32610 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Essen Gesamthsch, Inst Physiol, D-45147 Essen, Germany; Univ Bonn, Dept Pathol, D-53127 Bonn, Germany	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Michigan System; University of Michigan; University of Duisburg Essen; University of Bonn	Bungert, J (corresponding author), Univ Florida, Dept Biochem & Mol Biol, POB 100245, Gainesville, FL 32610 USA.	jbungert@college.med.ufl.edu	Fandrey, Joachim/AAA-3524-2021	Fandrey, Joachim/0000-0001-9585-0531	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052356] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52356] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIRD WC, 1994, J BIOL CHEM, V269, P883; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Bai YQ, 2000, MOL CARCINOGEN, V28, P184, DOI 10.1002/1098-2744(200007)28:3<184::AID-MC7>3.0.CO;2-6; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; BONDURANT MC, 1991, SEMIN HEMATOL, V28, P20; Bossard P, 1998, DEVELOPMENT, V125, P4909; Charron F, 1999, MOL CELL BIOL, V19, P4355; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Dame C, 1998, BLOOD, V92, P3218, DOI 10.1182/blood.V92.9.3218; Dame C, 2002, BRIT J HAEMATOL, V119, P510, DOI 10.1046/j.1365-2141.2002.03816.x; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Ebert BL, 1999, BLOOD, V94, P1864; ECKHARDT KU, 1992, J CLIN INVEST, V89, P753; FLAKE AW, 1987, BLOOD, V70, P542; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; Hendriks RW, 1999, EUR J IMMUNOL, V29, P1912, DOI 10.1002/(SICI)1521-4141(199906)29:06<1912::AID-IMMU1912>3.3.CO;2-4; IMAGAWA S, 1994, J BIOL CHEM, V269, P9038; Imagawa S, 2002, INT J HEMATOL, V75, P376, DOI 10.1007/BF02982127; Imagawa S, 1997, BLOOD, V89, P1430, DOI 10.1182/blood.V89.4.1430; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Kang SHL, 2002, NUCLEIC ACIDS RES, V30; Kiekhaefer CM, 2002, P NATL ACAD SCI USA, V99, P14309, DOI 10.1073/pnas.212389499; Klemcke HG, 2001, ANIM REPROD SCI, V66, P93, DOI 10.1016/S0378-4320(01)00084-7; Kochling J, 1998, BRIT J HAEMATOL, V103, P960; La Ferla K, 2002, FASEB J, V16, P1811, DOI 10.1096/fj.02-0168fje; Laitinen MPE, 2000, J CLIN ENDOCR METAB, V85, P3476, DOI 10.1210/jc.85.9.3476; Lakshmanan G, 1999, MOL CELL BIOL, V19, P1558; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Leach KM, 2003, NUCLEIC ACIDS RES, V31, P1292, DOI 10.1093/nar/gkg209; Leach KM, 2001, MOL CELL BIOL, V21, P2629, DOI 10.1128/MCB.21.8.2629-2640.2001; LEONARD M, 1993, BLOOD, V82, P1071; Letting DL, 2003, MOL CELL BIOL, V23, P1334, DOI 10.1128/MCB.23.4.1334-1340.2003; LIM GB, 1994, BLOOD, V84, P460; Lim KC, 2000, NAT GENET, V25, P209, DOI 10.1038/76080; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; Lowry JA, 2000, J MOL EVOL, V50, P103, DOI 10.1007/s002399910012; Ma GT, 1997, DEVELOPMENT, V124, P907; MADAN A, 1995, BLOOD, V85, P2735; Masuda S, 1999, INT J HEMATOL, V70, P1; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Moritz KM, 1997, AM J PHYSIOL-REG I, V273, pR1829, DOI 10.1152/ajpregu.1997.273.6.R1829; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Nardelli J, 1999, DEV BIOL, V210, P305, DOI 10.1006/dbio.1999.9278; Nemer G, 2003, DEV BIOL, V254, P131, DOI 10.1016/S0012-1606(02)00026-X; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ozawa Y, 2001, BLOOD, V98, P2116, DOI 10.1182/blood.V98.7.2116; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PESCHLE C, 1975, LIFE SCI, V17, P1325, DOI 10.1016/0024-3205(75)90146-0; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PUGH CW, 1994, BBA-GENE STRUCT EXPR, V1217, P297, DOI 10.1016/0167-4781(94)90289-5; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1990, MOL CELL BIOL, V10, P930, DOI 10.1128/MCB.10.3.930; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P8725, DOI 10.1073/pnas.88.19.8725; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; TAN CC, 1992, AM J PHYSIOL, V263, P474; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; van Doorninck J H, 1999, J Neurosci, V19, pRC12; WEISS MJ, 1995, EXP HEMATOL, V23, P99; ZANJANI ED, 1977, J LAB CLIN MED, V89, P640; Zhou YH, 2000, DEVELOPMENT, V127, P3829; Zhou YH, 1998, EMBO J, V17, P6689, DOI 10.1093/emboj/17.22.6689	65	71	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2955	2961		10.1074/jbc.M310404200	http://dx.doi.org/10.1074/jbc.M310404200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14583613	hybrid			2022-12-25	WOS:000188211300076
J	Ruddy, MJ; Wong, GC; Liu, XKK; Yamamoto, H; Kasayama, S; Kirkwood, KL; Gaffen, SL				Ruddy, MJ; Wong, GC; Liu, XKK; Yamamoto, H; Kasayama, S; Kirkwood, KL; Gaffen, SL			Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PANCREATIC PERIACINAR MYOFIBROBLASTS; TRANSCRIPTION FACTORS NF-IL6; NITRIC-OXIDE PRODUCTION; GENE-EXPRESSION; RHEUMATOID-ARTHRITIS; TNF-ALPHA; CHEMOKINE PRODUCTION; NUCLEAR-FACTOR; MESSENGER-RNA	Interleukin (IL)-17 is a recently described cytokine involved in the amplification of inflammatory responses and pathologies. A hallmark feature of IL-17 is its ability to induce expression of other cytokines and chemokines. In addition, IL-17 potently synergizes with tumor necrosis factor-alpha (TNFalpha) to up-regulate expression of many target genes, particularly IL-6. Despite the many observations of IL-17 signaling synergy observed to date, little is known about the molecular mechanisms that underlie this phenomenon. In the osteoblastic cell line MC-3T3, we have found that IL-17 and TNFalpha exhibit potent synergy in mediating IL-6 secretion. Here, we show that at least part of the functional cooperation between IL-17 and TNFalpha occurs at the level of IL-6 gene transcription. Both the NF-kappaB and CCAAT/enhancer-binding protein (C/EBP; NF-IL6) sites in the IL-6 promoter are important for cooperative gene expression, but NF-kappaB does not appear to be the direct target of the combined signal. Microarray analysis using the Affymetrix mouse MG-U74v2 chip identified C/EBPdelta as another gene target of combined IL-17- and TNFalpha-induced signaling. Because C/EBP family members are known to control IL-6, we examined whether enhanced C/EBPdelta expression is involved in the cooperative up-regulation of IL-6 by IL-17 and TNFalpha. Accordingly, we show that C/EBPdelta (or the related transcription factor C/EBPbeta) is essential for expression of IL-6. Moreover, overexpression of C/EBPdelta (and, to a lesser extent, C/EBPbeta) could substitute for the IL-17 signal at the level of IL-6 transcription. Thus, C/EBP family members, particularly C/EBPdelta, appear to be important for the functional cooperation between IL-17 and TNFalpha.	SUNY Buffalo, Sch Dent Med, Dept Oral Biol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol & Immunol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Dent Med, Dept Periodont & Endodont, Buffalo, NY 14214 USA; Osaka Univ, Grad Sch Med, Dept Mol Med, Osaka 5650871, Japan	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Osaka University	Gaffen, SL (corresponding author), SUNY Buffalo, Sch Dent Med, Dept Oral Biol, 36 Foster Hall,3435 Main St, Buffalo, NY 14214 USA.	sgaffen@buffalo.edu	Gaffen, Sarah L/B-1560-2009; Kirkwood, Keith L/L-4728-2018	Gaffen, Sarah L/0000-0001-8511-2041; Kirkwood, Keith/0000-0003-4519-8973	NIAID NIH HHS [AI49329, AI07614] Funding Source: Medline; NIDCR NIH HHS [DE14460] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI049329, R01AI049329] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE014460] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; Aggarwal S, 2002, J LEUKOCYTE BIOL, V71, P1; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Albanesi C, 1999, J IMMUNOL, V162, P494; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Andoh A, 2002, INT J MOL MED, V10, P631; Andoh A, 2002, BBA-MOL CELL RES, V1591, P69, DOI 10.1016/S0167-4889(02)00250-1; Andoh A, 2002, J IMMUNOL, V169, P1683, DOI 10.4049/jimmunol.169.4.1683; BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Chabaud M, 2001, ARTHRITIS RHEUM, V44, P1293, DOI 10.1002/1529-0131(200106)44:6<1293::AID-ART221>3.0.CO;2-T; de Miguel F, 1999, J AM SOC NEPHROL, V10, P796; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Feldmann M, 1995, ANN NY ACAD SCI, V766, P272, DOI 10.1111/j.1749-6632.1995.tb26675.x; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; Jovanovic DV, 1998, J IMMUNOL, V160, P3513; Kannabiran C, 1997, MOL CELL BIOL, V17, P1, DOI 10.1128/MCB.17.1.1; Katz Y, 2000, CLIN EXP IMMUNOL, V120, P22, DOI 10.1046/j.1365-2249.2000.01199.x; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; Laan M, 1999, J IMMUNOL, V162, P2347; LATCHMAN DS, 1993, TRANSCRIPTION FACTOR, P1; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; Lubberts E, 2003, J IMMUNOL, V170, P2655, DOI 10.4049/jimmunol.170.5.2655; Maertzdorf J, 2002, J IMMUNOL, V169, P5897, DOI 10.4049/jimmunol.169.10.5897; Mann J, 2002, J BIOL CHEM, V277, P17125, DOI 10.1074/jbc.M109250200; Martel-Pelletier J, 1999, ARTHRITIS RHEUM-US, V42, P2399, DOI 10.1002/1529-0131(199911)42:11<2399::AID-ANR19>3.0.CO;2-Y; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Matusevicius D, 1999, MULT SCLER J, V5, P101, DOI 10.1177/135245859900500206; Miossec P, 2003, ARTHRITIS RHEUM-US, V48, P594, DOI 10.1002/art.10816; O'Dell JR, 1999, NEW ENGL J MED, V340, P310, DOI 10.1056/NEJM199901283400411; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Ray P, 1997, FEBS LETT, V409, P79, DOI 10.1016/S0014-5793(97)00487-0; Schwandner R, 2000, J EXP MED, V191, P1233, DOI 10.1084/jem.191.7.1233; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; Shimada M, 2002, J IMMUNOL, V168, P861, DOI 10.4049/jimmunol.168.2.861; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Takaya H, 2002, SCAND J GASTROENTERO, V37, P239, DOI 10.1080/003655202753416948; Teunissen MBM, 1998, J INVEST DERMATOL, V111, P645, DOI 10.1046/j.1523-1747.1998.00347.x; Umayahara Y, 1999, J BIOL CHEM, V274, P10609, DOI 10.1074/jbc.274.15.10609; Vales LD, 2002, J BIOL CHEM, V277, P42438, DOI 10.1074/jbc.M207363200; Van Bezooijen RL, 1999, J BONE MINER RES, V14, P1513, DOI 10.1359/jbmr.1999.14.9.1513; van Bezooijen RL, 2001, BONE, V28, P378, DOI 10.1016/S8756-3282(00)00457-9; Vanden Berghe W, 2000, BIOCHEM PHARMACOL, V60, P1185, DOI 10.1016/S0006-2952(00)00412-3; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Witowski J, 2000, J IMMUNOL, V165, P5814, DOI 10.4049/jimmunol.165.10.5814; Woltman AM, 2000, J AM SOC NEPHROL, V11, P2044, DOI 10.1681/ASN.V11112044; Yamada T, 1998, BIOCHEM BIOPH RES CO, V242, P88, DOI 10.1006/bbrc.1997.7915; Yamamoto H, 2002, J CELL SCI, V115, P3601, DOI 10.1242/jcs.00044; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; YOO ZB, 1995, J IMMUNOL, V155, P5483	52	281	296	4	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2559	2567		10.1074/jbc.M308809200	http://dx.doi.org/10.1074/jbc.M308809200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14600152	hybrid			2022-12-25	WOS:000188211300029
J	Keresztes, G; Martemyanov, KA; Krispel, CM; Mutai, H; Yoo, PJ; Maison, SF; Burns, ME; Arshavsky, VY; Heller, S				Keresztes, G; Martemyanov, KA; Krispel, CM; Mutai, H; Yoo, PJ; Maison, SF; Burns, ME; Arshavsky, VY; Heller, S			Absence of the RGS9 center dot G beta 5 GTPase-activating complex in photoreceptors of the R9AP knockout mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN BETA-SUBUNIT; ACCELERATING PROTEIN; ROD PHOTORESPONSE; MEMBRANE ANCHOR; MICE LACKING; RGS9-1; CELLS; DEACTIVATION; ADAPTATION	Timely termination of the light response in retinal photoreceptors requires rapid inactivation of the G protein transducin. This is achieved through the stimulation of transducin GTPase activity by the complex of the ninth member of the regulator of G protein signaling protein family (RGS9) with type 5 G protein beta subunit (Gbeta5). RGS9.Gbeta5 is anchored to photoreceptor disc membranes by the transmembrane protein, R9AP. In this study, we analyzed visual signaling in the rods of R9AP knockout mice. We found that light responses from R9AP knockout rods were very slow to recover and were indistinguishable from those of RGS9 or Gbeta5 knockout rods. This effect was a consequence of the complete absence of any detectable RGS9 from the retinas of R9AP knockout mice. On the other hand, the level of RGS9 mRNA was not affected by the knockout. These data indicate that in photoreceptors R9AP determines the stability of the RGS9.Gbeta5 complex, and therefore all three proteins, RGS9, Gbeta5, and R9AP, are obligate members of the regulatory complex that speeds the rate at which transducin hydrolyzes GTP.	Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol,Eaton Peabody Lab, Boston, MA 02114 USA; Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Howe Labs, Boston, MA 02114 USA; Univ Calif Davis, Ctr Neurosci, Davis, CA 95616 USA; Univ Calif Davis, Dept Psychiat, Davis, CA 95616 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; University of California System; University of California Davis; University of California System; University of California Davis	Heller, S (corresponding author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol,Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA.	hellers@epl.meei.harvard.edu			NEI NIH HHS [EY 14147, R01 EY014047-03, EY 12859, R01 EY014047] Funding Source: Medline; NIDCD NIH HHS [DC 04563] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012859, R01EY014047] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004563] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; BAYLOR DA, 1973, J PHYSIOL-LONDON, V234, P163, DOI 10.1113/jphysiol.1973.sp010340; Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Chen CK, 2003, P NATL ACAD SCI USA, V100, P6604, DOI 10.1073/pnas.0631825100; Cowan CW, 2001, PROG NUCLEIC ACID RE, V65, P341; Granneman JG, 1998, MOL PHARMACOL, V54, P687; He W, 2000, J BIOL CHEM, V275, P37093, DOI 10.1074/jbc.M006982200; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Hu G, 2003, J BIOL CHEM, V278, P14550, DOI 10.1074/jbc.M212046200; Hu G, 2002, P NATL ACAD SCI USA, V99, P9755, DOI 10.1073/pnas.152094799; Keresztes G, 2003, MOL CELL NEUROSCI, V24, P687, DOI 10.1016/S1044-7431(03)00231-8; Krispel CM, 2003, J NEUROSCI, V23, P6965, DOI 10.1523/JNEUROSCI.23-18-06965.2003; Lishko PV, 2002, J BIOL CHEM, V277, P24376, DOI 10.1074/jbc.M203237200; Maison SF, 2002, J NEUROSCI, V22, P10838; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Martemyanov KA, 2003, J NEUROSCI, V23, P10175; Mendez A, 2000, NEURON, V28, P153, DOI 10.1016/S0896-6273(00)00093-3; PEPPERBERG DR, 1992, VISUAL NEUROSCI, V8, P9, DOI 10.1017/S0952523800006441; Skiba NP, 2001, J BIOL CHEM, V276, P37365, DOI 10.1074/jbc.M106431200	20	76	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1581	1584		10.1074/jbc.C300456200	http://dx.doi.org/10.1074/jbc.C300456200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14625292	hybrid			2022-12-25	WOS:000188005700003
J	Yanagida, M; Hayano, T; Yamauchi, Y; Shinkawa, T; Natsume, T; Isobe, T; Takahashi, N				Yanagida, M; Hayano, T; Yamauchi, Y; Shinkawa, T; Natsume, T; Isobe, T; Takahashi, N			Human fibrillarin forms a sub-complex with splicing factor 2-associated p32, protein arginine methyltransferases, and tubulins alpha 3 and beta 1 that is independent of its association with preribosomal ribonucleoprotein complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEOLAR RNA; RIBOSOMAL-RNA; PROTEOMIC CHARACTERIZATION; MUTATIONAL ANALYSIS; MOLECULAR-CLONING; IN-VITRO; METHYLATION; YEAST; SMN; U3	Fibrillarin (FIB, Nop1p in yeast) is an RNA methyltransferase found not only in the fibrillar region of the nucleolus but also in Cajal bodies. FIB is essential for efficient processing of preribosomal RNA during ribosome biogenesis, although its precise function in this process and its role in Cajal bodies remain uncertain. Here, we demonstrate that the human FIB N-terminal glycine- and arginine-rich domain ( residues 1 - 77) and its spacer region 1 ( 78 - 132) interact with splicing factor 2-associated p32 (SF2A-p32) and that the FIB methyltransferase-like domain ( 133 - 321) interacts with protein-arginine methyltransferase 5 (PRMT5, Janus kinase-binding protein 1). We also show that these proteins associate with several additional proteins, including PRMT1, tubulin alpha3, and tubulin beta1 to form a sub-complex that is principally independent of the association of FIB with preribosomal ribonucleoprotein complexes that co-immunoprecipitate with the sub-complex in human cells expressing FLAG-tagged FIB. Based on the physical association of FIB with SF2A-p32 and PRMTs, as well as the other reported results, we propose that FIB may coordinate both RNA and protein methylation during the processes of ribosome biogenesis in the nucleolus and RNA editing such as small nuclear ( nucleolar) ribonucleoprotein biogenesis in Cajal bodies.	Tokyo Univ Agr & Technol, United Grad Sch Agr, Dept Appl Biol Sci, Fuchu, Tokyo 1838509, Japan; Tokyo Univ Agr & Technol, United Grad Sch Agr, Dept Biotechnol, Fuchu, Tokyo 1838509, Japan; Minist Educ Culture Sports Sci & Technol Japan, Pioneer Res Genome Frontier, Integrated Prote Syst Project, Tokyo, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Biochem Lab, Tokyo 1920397, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Kohtoh Ku, Tokyo 1350064, Japan	Tokyo University of Agriculture & Technology; Tokyo University of Agriculture & Technology; Tokyo Metropolitan University; National Institute of Advanced Industrial Science & Technology (AIST)	Takahashi, N (corresponding author), Tokyo Univ Agr & Technol, United Grad Sch Agr, Dept Appl Biol Sci, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan.	ntakahas@cc.tuat.ac.jp	Natsume, Tohru/M-7627-2018; Isobe, Toshiaki/Q-9279-2017; TAKAHASHI, Nobuhiro/G-1129-2013	Natsume, Tohru/0000-0002-1510-2582; 				Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; ARIS JP, 1991, P NATL ACAD SCI USA, V88, P931, DOI 10.1073/pnas.88.3.931; BASERGA SJ, 1991, EMBO J, V10, P2645, DOI 10.1002/j.1460-2075.1991.tb07807.x; Boisvert FM, 2002, J CELL BIOL, V159, P957, DOI 10.1083/jcb.200207028; David E, 1997, MOL BIOL CELL, V8, P1051, DOI 10.1091/mbc.8.6.1051; EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Fujiyama S, 2002, J BIOL CHEM, V277, P23773, DOI 10.1074/jbc.M201181200; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; Hayano T, 2003, J BIOL CHEM, V278, P34309, DOI 10.1074/jbc.M304304200; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; HOFER L, 1991, J VIROL, V65, P3379, DOI 10.1128/JVI.65.6.3379-3383.1991; JANSEN RP, 1991, J CELL BIOL, V113, P715, DOI 10.1083/jcb.113.4.715; Jones KW, 2001, J BIOL CHEM, V276, P38645, DOI 10.1074/jbc.M106161200; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; LAPEYRE B, 1990, MOL CELL BIOL, V10, P430, DOI 10.1128/MCB.10.1.430; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; Natsume T, 2002, ANAL CHEM, V74, P4725, DOI 10.1021/ac020018n; Nicol SM, 2000, EXP CELL RES, V257, P272, DOI 10.1006/excr.2000.4886; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; Nissan TA, 2002, EMBO J, V21, P5539, DOI 10.1093/emboj/cdf547; Omer AD, 2002, P NATL ACAD SCI USA, V99, P5289, DOI 10.1073/pnas.082101999; Pellizzoni L, 2002, SCIENCE, V298, P1775, DOI 10.1126/science.1074962; Petersen-Mahrt SK, 1999, EMBO J, V18, P1014, DOI 10.1093/emboj/18.4.1014; Pintard L, 2000, MOL CELL BIOL, V20, P1370, DOI 10.1128/MCB.20.4.1370-1381.2000; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; Smith CM, 1997, CELL, V89, P669, DOI 10.1016/S0092-8674(00)80247-0; Snaar S, 2000, J CELL BIOL, V151, P653, DOI 10.1083/jcb.151.3.653; Spector DL, 2001, J CELL SCI, V114, P2891; Takahashi N, 2003, MASS SPECTROM REV, V22, P287, DOI 10.1002/mas.10057; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; TURLEY SJ, 1993, BIOCHIM BIOPHYS ACTA, V1216, P119, DOI 10.1016/0167-4781(93)90046-G; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; Tycowski KT, 1996, P NATL ACAD SCI USA, V93, P14480, DOI 10.1073/pnas.93.25.14480; Wang HM, 2000, EMBO J, V19, P317, DOI 10.1093/emboj/19.3.317; Warner JR, 1990, CURR OPIN CELL BIOL, V2, P521, DOI 10.1016/0955-0674(90)90137-4; Wehner KA, 2002, BRAIN RES, V945, P160, DOI 10.1016/S0006-8993(02)02750-6; Whitehead SE, 2002, J BIOL CHEM, V277, P48087, DOI 10.1074/jbc.M204551200; Yanagida M, 2001, PROTEOMICS, V1, P1390, DOI 10.1002/1615-9861(200111)1:11<1390::AID-PROT1390>3.0.CO;2-Z	42	57	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1607	1614		10.1074/jbc.M305604200	http://dx.doi.org/10.1074/jbc.M305604200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14583623	hybrid			2022-12-25	WOS:000188005700007
J	Schoenfeld, N; Bauer, MKA; Grimm, S				Schoenfeld, N; Bauer, MKA; Grimm, S			The metastasis suppressor gene C33/CD82/KAI1 induces apoptosis through reactive oxygen intermediates	FASEB JOURNAL			English	Article						cell death; metastasis suppressor gene; reactive oxygen intermediates; glutathione; Cdc42		Here we describe the isolation of C33/CD82/KAI1 in a screen for apoptosis-inducing genes. C33 is a gene that is downregulated in many metastatic tumor cells and the expression of which can attenuate the process of metastases formation in a variety of tumors. In accordance, we observed cell death induction by C33 in many different cell types. C33 seems to promote cell death by the generation of reactive oxygen intermediates (ROIs). These ROIs, however, are not derived from the mitochondrial respiratory chain as in most other scenarios leading to apoptosis. We observed that C33 renders cells sensitive to ROIs by causing the specific release of the intracellular antioxidant glutathione (GSH) from cells. Moreover, C33 activates the GTPase Cdc42, which mediates GSH release and apoptosis induction and allows to detect the formation of ROIs.	Max Planck Inst Biochem, D-82152 Martinsried, Germany	Max Planck Society	Grimm, S (corresponding author), Max Planck Inst Biochem, D-82152 Martinsried, Germany.	sgrimm@biochem.mpg.de			Bavarian Government; Roche Diagnostics; Xantos Biomedicine AG	Bavarian Government; Roche Diagnostics; Xantos Biomedicine AG	We thank Drs. Riesenberg, Klinikum Groflhadern (Munich), for providing PC3 and LNCaP cells and T. Mak, Toronto, Canada, for the Apaf-1 negative cells. The expression constructs for PDGF-R, EGF-R, Cdc42 T17N, Rac1 T17N, and HER-2 were a gift of Dr. A. Ullrich, Martinsried. The vectors for catalase, glutathione peroxidase-1 and Cu/Zn superoxide dismutase were from Dr. S. Lenzen, Hannover. The monoclonal antibody C11 against CD82 was a kind gift of H. Conjeaud, Paris, France. Thanks also to A. Gewies and R. Gernert for helpful comments on the manuscript. This work was supported by the Bavarian Government, Roche Diagnostics, and Xantos Biomedicine AG.	Albayrak T, 2003, MOL BIOL CELL, V14, P3082, DOI 10.1091/mbc.e02-10-0631; Albayrak T, 2003, BIOCHEM BIOPH RES CO, V304, P772, DOI 10.1016/S0006-291X(03)00653-3; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; Chandel NS, 1997, J BIOL CHEM, V272, P18808, DOI 10.1074/jbc.272.30.18808; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Delaguillaumie A, 2002, J CELL SCI, V115, P433; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Ellis LM, 1996, EUR J CANCER, V32A, P2451, DOI 10.1016/S0959-8049(96)00389-9; Gewies A, 2003, CANCER RES, V63, P682; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Glinsky GV, 1997, CANCER LETT, V115, P185, DOI 10.1016/S0304-3835(97)04738-1; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grimm S, 1997, J EXP MED, V185, P1137, DOI 10.1084/jem.185.6.1137; Guo XZ, 1996, CANCER RES, V56, P4876; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Jardine H, 2002, J BIOL CHEM, V277, P21158, DOI 10.1074/jbc.M112145200; Jia L, 1997, BRIT J HAEMATOL, V98, P686, DOI 10.1046/j.1365-2141.1997.2683085.x; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Lahiri S, 2000, J APPL PHYSIOL, V88, P1467, DOI 10.1152/jappl.2000.88.4.1467; LEBELBINAY S, 1995, J IMMUNOL, V155, P101; LEBELBINAY S, 1995, J LEUKOCYTE BIOL, V57, P956, DOI 10.1002/jlb.57.6.956; Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Malafa M, 2000, J SURG RES, V88, P130, DOI 10.1006/jsre.1999.5773; Mashimo T, 1998, P NATL ACAD SCI USA, V95, P11307, DOI 10.1073/pnas.95.19.11307; McConkey DJ, 1996, CANCER RES, V56, P5594; McGill Gael, 1997, Frontiers in Bioscience (online), V2, pD353; Mund T, 2003, FASEB J, V17, P696, DOI 10.1096/fj.02-0657fje; Neudecker F, 2000, BIOTECHNIQUES, V28, P107; NONAKA Y, 1993, INT J CANCER, V54, P983, DOI 10.1002/ijc.2910540620; Ono M, 1999, CANCER RES, V59, P2335; Pervaiz S, 2002, METHOD ENZYMOL, V352, P150; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Rokhlin OW, 1997, CANCER RES, V57, P1758; Rottenberg H, 1998, BBA-MOL CELL RES, V1404, P393, DOI 10.1016/S0167-4889(98)00088-3; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; Sidoti-de Fraisse C, 1998, ONCOGENE, V17, P1639, DOI 10.1038/sj.onc.1202094; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Subauste MC, 2000, J BIOL CHEM, V275, P9725, DOI 10.1074/jbc.275.13.9725; Sun IL, 1996, BIOCHEM MOL BIOL INT, V38, P175; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; Takaoka A, 1998, ONCOGENE, V16, P1443, DOI 10.1038/sj.onc.1201648; Thomas A, 2000, ONCOGENE, V19, P5259, DOI 10.1038/sj.onc.1203895; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; White A, 1998, ONCOGENE, V16, P3143, DOI 10.1038/sj.onc.1201852; Yoshida BA, 2000, JNCI-J NATL CANCER I, V92, P1717, DOI 10.1093/jnci/92.21.1717; Yu Y, 1997, CLIN CANCER RES, V3, P1045; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989	57	33	35	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					158	160		10.1096/fj.03-0420fje	http://dx.doi.org/10.1096/fj.03-0420fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597553				2022-12-25	WOS:000188829300060
J	Perani, M; Ingram, CJE; Cooper, CS; Garrett, MD; Goodwin, GH				Perani, M; Ingram, CJE; Cooper, CS; Garrett, MD; Goodwin, GH			Conserved SNH domain of the proto-oncoprotein SYT interacts with components of the human chromatin remodelling complexes, while the QPGY repeat domain forms homo-oligomers	ONCOGENE			English	Article						SYT; SYT-SSX; synovial sarcoma; BRM; BRG1; chromatin remodelling	HUMAN SYNOVIAL SARCOMA; MAMMALIAN SWI/SNF COMPLEXES; CHIMERIC PROTEIN; DNA-BINDING; TRANSCRIPTIONAL ACTIVATOR; CHROMOSOME-TRANSLOCATION; SH3 DOMAINS; CELL-CYCLE; SSX; FUSION	Many studies have now established that the SWI/SNF chromatin remodelling complexes are involved in activation and repression of a variety of genes. In mammalian cells, these complexes contain the BRM and BRG1 helicase-like proteins that are thought to be responsible for nucleosome remodelling. The proto-oncoprotein SYT, involved in the unique translocation t(X;18) found in synovial sarcoma, is known to interact with human BRM (hBRM), thus providing a link between chromatin remodelling factors and human cancer. In this work, we address how SYT interacts with hBRM and BRG1. We demonstrate that the conserved N-terminal SNH domain of SYT, which is also present in the oncoproteins SYT-SSX, binds to both hBRM and BRG1. We have also found that in vivo the C-terminus transactivation QPGY region of SYT can interact with itself. This results in an amplified interaction with hBRM and highlights a possible regulatory function of this domain in cells.	Inst Canc Res, BLB, Sect Mol Carcinogenesis, Sutton SM 5NG, Surrey, England; Inst Canc Res, Canc Res UK Ctr Canc Therapeut, Sutton, Surrey, England	University of London; Institute of Cancer Research - UK; Cancer Research UK; University of London; Institute of Cancer Research - UK	Perani, M (corresponding author), Inst Canc Res, BLB, Sect Mol Carcinogenesis, 15 Cotswold Rd, Sutton SM 5NG, Surrey, England.	michela.perani@icr.ac.uk		Ingram, Catherine/0000-0003-2863-8930	Worldwide Cancer Research [99-0108] Funding Source: Medline	Worldwide Cancer Research		Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; Dallas PB, 2000, MOL CELL BIOL, V20, P3137, DOI 10.1128/MCB.20.9.3137-3146.2000; Dallas PB, 1998, MOL CELL BIOL, V18, P3596, DOI 10.1128/MCB.18.6.3596; de Bruijn DRH, 2001, ONCOGENE, V20, P3281, DOI 10.1038/sj.onc.1204419; deBruijn DRH, 1996, ONCOGENE, V13, P643; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; dos Santos NR, 2000, EXP CELL RES, V256, P192, DOI 10.1006/excr.2000.4813; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; Fisher C, 1998, Ann Diagn Pathol, V2, P401, DOI 10.1016/S1092-9134(98)80042-7; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Hurlstone AFL, 2002, BIOCHEM J, V364, P255, DOI 10.1042/bj3640255; Kato H, 2002, J BIOL CHEM, V277, P5498, DOI 10.1074/jbc.M108702200; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Martens JA, 2002, GENE DEV, V16, P2231, DOI 10.1101/gad.1009902; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; O'Neill D, 1999, P NATL ACAD SCI USA, V96, P349, DOI 10.1073/pnas.96.2.349; OHNO T, 1993, CANCER RES, V53, P5859; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; SMITH S, 1987, CANCER GENET CYTOGEN, V26, P179, DOI 10.1016/0165-4608(87)90147-6; Soulez M, 1999, ONCOGENE, V18, P2739, DOI 10.1038/sj.onc.1202613; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; TREICH I, 1995, MOL CELL BIOL, V15, P4240; Tureci O, 1996, CANCER RES, V56, P4766; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Xie YT, 2002, ONCOGENE, V21, P5791, DOI 10.1038/sj.onc.1205700; Xie YT, 2002, CANCER RES, V62, P3861	41	43	44	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2003	22	50					8156	8167		10.1038/sj.onc.1207031	http://dx.doi.org/10.1038/sj.onc.1207031			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603256				2022-12-25	WOS:000186403400010
J	Swamynathan, SK; Crawford, MA; Robison, WG; Kanungo, J; Piatigorsky, J				Swamynathan, SK; Crawford, MA; Robison, WG; Kanungo, J; Piatigorsky, J			Adaptive differences in the structure and macromolecular compositions of the air and water corneas of the "four-eyed" fish (Anableps anableps)	FASEB JOURNAL			English	Article							DROSOPHILA-MELANOGASTER; PRIMARY SPECTACLE; REFRACTIVE STATE; SEA LAMPREY; GELSOLIN; VISION; GLYCOGEN; EYE; EPITHELIUM; MECHANISMS	The water meniscus bisects the eyes of the "four-eyed" fish Anableps anableps, resulting in simultaneous vision in air and water. We compare the structure and macromolecular compositions of the Anableps dorsal (air) and ventral (water) corneas with the fully aquatic zebrafish cornea. The Anableps dorsal corneal epithelium is thicker (>20 cell layers), flatter (similar to 1. 94 nun radius of curvature), and contains similar to 15-fold more glycogen (0. 16 mug/mug water-soluble protein) than the ventral corneal epithelium (5-7 cell layers; similar to1.63 nun radius of curvature; 0.01 mug glycogen/mug watersoluble protein), which resembles the zebrafish corneal epithelium. Gelsolin is the major water-soluble protein in the zebrafish (similar to50%) and Anableps dorsal (similar to38%) and ventral (similar to21%) corneal epithelia, suggesting that gelsolin was recruited for high corneal expression before these two species diverged at least 100 million years ago and that abundant corneal gelsolin is not limited to aquatic vision. Anableps gelsolin, deduced from its cDNA, is 57% identical to zebrafish gelsolin. Paucity of Anableps corneal F-actin (consistent with high gelsolin) was confirmed by the absence of rhodamine-phalloidin staining. We suggest amphibious refraction and protection from UV irradiation and desiccation in air as selective constraints for the specializations of the Anableps dorsal cornea.	NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA; NEI, Lab Mech Ocular Dis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Piatigorsky, J (corresponding author), NEI, Mol & Dev Biol Lab, NIH, 7 Mem Dr,Bldg 7,Room 100A, Bethesda, MD 20892 USA.	joramp@nei.nih.gov		Swamynathan, Shivalingappa/0000-0002-9158-1511	Intramural NIH HHS [Z01 EY000126-26, Z01 EY000259-18] Funding Source: Medline; NATIONAL EYE INSTITUTE [Z01EY000126, Z01EY000259] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adamo KB, 1998, J APPL PHYSIOL, V84, P908, DOI 10.1152/jappl.1998.84.3.908; AMEMIYA T, 1978, ACTA HISTOCHEM, V62, P302, DOI 10.1016/S0065-1281(78)80096-8; [Anonymous], VERTEBRATE EYE ITS A, DOI 10.1097/00005053-194409000-00057; Folk DG, 2001, J EXP BIOL, V204, P3323; Gibbs AG, 1997, J EXP BIOL, V200, P1821; GRAHAM JB, 1970, SCIENCE, V168, P586, DOI 10.1126/science.168.3931.586; HOWLAND HC, 1984, VISION RES, V24, P1905, DOI 10.1016/0042-6989(84)90024-5; JERMANN T, 1992, EXPERIENTIA, V48, P217, DOI 10.1007/BF01930457; Kanungo J, 2003, P NATL ACAD SCI USA, V100, P3287, DOI 10.1073/pnas.0634473100; Knowles F., 1967, NATURE, V214, P307; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; Land MF, 2002, ANIMAL EYES; LATTIMORE MR, 1989, PHOTOCHEM PHOTOBIOL, V49, P175, DOI 10.1111/j.1751-1097.1989.tb04093.x; Leonard DW, 1997, BIOPHYS J, V72, P1382, DOI 10.1016/S0006-3495(97)78784-8; LEVY B, 1980, J COMP PHYSIOL, V137, P267, DOI 10.1007/BF00657122; LO WK, 1993, EXP EYE RES, V56, P121, DOI 10.1006/exer.1993.1017; Muller F, 2002, BIOESSAYS, V24, P564, DOI 10.1002/bies.10096; MURPHY CJ, 1990, VISION RES, V30, P23, DOI 10.1016/0042-6989(90)90125-5; Nelson JS, 1994, FISHES WORLD, DOI 10.1002/9781119174844; Passonneau JV, 1993, ENZYMATIC ANAL PRACT, P177; PATEL S, 1995, J REFRACT SURG, V11, P100; PATEL S, 1987, OPHTHAL PHYSL OPT, V7, P503, DOI 10.1016/0275-5408(87)90085-8; PEDERSON HJ, 1971, EXP EYE RES, V12, P147, DOI 10.1016/0014-4835(71)90139-4; Piatigorsky J, 1998, PROG RETIN EYE RES, V17, P145, DOI 10.1016/S1350-9462(97)00004-9; Piatigorsky J, 2001, CORNEA, V20, P853, DOI 10.1097/00003226-200111000-00015; Saidel WM, 1998, VISION RES, V38, P2001, DOI 10.1016/S0042-6989(97)00419-7; Schwab I R, 2001, Trans Am Ophthalmol Soc, V99, P145; Schwassmann H O, 1966, Vision Res, V5, P269; SIVAK J, 1987, PROC R SOC SER B-BIO, V229, P467, DOI 10.1098/rspb.1987.0005; SIVAK JG, 1976, VISION RES, V16, P531, DOI 10.1016/0042-6989(76)90035-3; SIVAK JG, 1989, J COMP PHYSIOL A, V165, P771, DOI 10.1007/BF00610875; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; VANHORN DL, 1969, J ULTRA MOL STRUCT R, V26, P454, DOI 10.1016/S0022-5320(69)90051-3; WALLMAN J, 1995, VISION RES, V35, P37, DOI 10.1016/0042-6989(94)E0049-Q; Xu YS, 2000, J BIOL CHEM, V275, P24645, DOI 10.1074/jbc.M001159200; Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6; ZIESKE JD, 1994, EXP CELL RES, V214, P621, DOI 10.1006/excr.1994.1300	37	29	31	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2003	17	14					1996	2005		10.1096/fj.03-0122com	http://dx.doi.org/10.1096/fj.03-0122com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	750AA	14597669	Green Accepted			2022-12-25	WOS:000186961200036
J	Tanaka, K; Shouguchi-Miyata, J; Miyamoto, N; Ikeda, JE				Tanaka, K; Shouguchi-Miyata, J; Miyamoto, N; Ikeda, JE			Novel nuclear shuttle proteins, HDBP1 and HDBP2, bind to neuronal cell-specific cis-regulatory element in the promoter for the human Huntington's disease gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; SACCHAROMYCES-CEREVISIAE; INTRANUCLEAR INCLUSIONS; OXIDATIVE STRESS; IN-VIVO; EXPORT; HD; IDENTIFICATION; DYSFUNCTION; SEQUENCE	Huntington's disease (HD) is a neurodegenerative disease caused by a CAG repeat expansion in exon 1 of the HD gene, and the expression level of either normal or mutant huntingtin is implicated in the pathogenesis of HD. However, a molecular base of the HD gene transcription has not been elucidated as yet. In this study, we identified two proteins, HDBP1 and HDBP2, which bind to the promoter region for the HD gene using a yeast one-hybrid system. Amino acid sequence analysis of the proteins deduced the presence of nuclear localization signal, nuclear export signal, zinc finger, serine/ proline-rich region, and highly conserved C-terminal region. In vitro DNA binding assay indicated that the C-terminal conserved regions of the proteins were responsible for binding to the unique promoter DNA sequences of the HD gene. The DNA sequence protected from DNase I digestion was a 7-bp consensus sequence (GCCGGCG), which resides in triplicate at intervals of 13 bp within and proximal to the 20-bp direct repeat sequences of the HD promoter region. The mutation of 7-bp consensus sequence abolishes the HD promoter function in a neuronal cell line (IMR32). In human cultured cells, ectopically expressed green fluorescent protein-fused HDBP1 and HDBP2 localized in the cytoplasm, but both proteins totally shift from cytoplasm to nucleus by the treatment with an inhibitor of the nuclear export, leptomycin B, and mutagenesis of the putative nuclear export signals. Taken together, HDBP1 and HDBP2 are novel transcription factors shuttling between nucleus and cytoplasm and bind to the specific GCCGGCG, which is an essential cis-element for HD gene expression in neuronal cells.	Tokai Univ, Inst Med Sci, Dept Mol Neurosci, Kanagawa 2591193, Japan; Tokai Univ, Sch Med, Japan Sci & Technol Corp, Solut Oriented Res Sci & Technol, Kanagawa 2591193, Japan; Univ Ottawa, Fac Med, Dept Paediat, Ottawa, ON K1H 8M5, Canada	Tokai University; Japan Science & Technology Agency (JST); Tokai University; University of Ottawa	Ikeda, JE (corresponding author), Tokai Univ, Inst Med Sci, Dept Mol Neurosci, Kanagawa 2591193, Japan.	joh-e@nga.med.u-tokai.ac.jp						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arai N, 1999, GENES GENET SYST, V74, P159, DOI 10.1266/ggs.74.159; Boeckle S, 2002, VIROLOGY, V293, P103, DOI 10.1006/viro.2001.1231; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Carsten H, 2001, MOL BRAIN RES, V92, P85; Cha JHJ, 2000, TRENDS NEUROSCI, V23, P387, DOI 10.1016/S0166-2236(00)01609-X; Coles R, 1998, HUM MOL GENET, V7, P791, DOI 10.1093/hmg/7.5.791; Coles R, 1997, J MED GENET, V34, P371, DOI 10.1136/jmg.34.5.371; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Dawson TM, 2002, NAT MED, V8, P450, DOI 10.1038/nm0502-450; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; Hoshino H, 2000, J BIOL CHEM, V275, P15370, DOI 10.1074/jbc.275.20.15370; Ito E, 1999, GENE, V228, P93, DOI 10.1016/S0378-1119(99)00022-0; Kamura T, 1997, J BIOL CHEM, V272, P11361; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Leavitt BR, 2001, AM J HUM GENET, V68, P313, DOI 10.1086/318207; Li SH, 2002, MOL CELL BIOL, V22, P1277, DOI 10.1128/MCB.22.5.1277-1287.2002; LIN BY, 1995, GENOMICS, V25, P707, DOI 10.1016/0888-7543(95)80014-D; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MARIN JB, 1986, NEW ENGL J MED, V315, P1267; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; NISHI K, 1994, J BIOL CHEM, V269, P6320; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Oshel KM, 2000, J BIOL CHEM, V275, P23666, DOI 10.1074/jbc.M001452200; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Ura S, 2001, P NATL ACAD SCI USA, V98, P10148, DOI 10.1073/pnas.181161698; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Yoshida T, 1997, FEBS LETT, V414, P333, DOI 10.1016/S0014-5793(97)01017-X; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581	35	46	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7275	7286		10.1074/jbc.M310726200	http://dx.doi.org/10.1074/jbc.M310726200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14625278	hybrid			2022-12-25	WOS:000188969200129
J	Li, L; Feng, ZW; Porter, AG				Li, L; Feng, ZW; Porter, AG			JNK-dependent phosphorylation of c-Jun on serine 63 mediates nitric oxide-induced apoptosis of neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; NEURONAL APOPTOSIS; FAS LIGAND; EXPRESSION; PATHWAY; STRESS; P38; SURVIVAL	c-Jun NH2-terminal kinases (JNKs) potentiate transcriptional activity of c-Jun by phosphorylating serines 63 and 73. Moreover, JNK and c-Jun can modulate apoptosis. However, an involvement of nitric oxide (NO)induced phosphorylation of c-Jun on Ser-63 and Ser-73 in apoptosis has not been explored. We report that in SH-Sy5y neuroblastoma cells, NO induced apoptosis following JNK activation and phosphorylation of c-Jun almost exclusively on Ser-63. Importantly, NO-induced apoptosis and caspase-3 activity were inhibited in cells stably transformed with dominant-negative c-Jun in which Ser-63 is mutated to alanine (S63A), but not in cells transformed with dominant-negative c-Jun (S73A). Ser-63 of c-Jun (but not Ser-73) was required for NO-induced, c-Jun-dependent transcriptional activity. NO-induced apoptosis, Ser-63 phosphorylation of c-Jun, and caspase-3 activity were all inhibited in SH-Sy5y cells transformed with dominant-negative jnk. A caspase-3 inhibitor prevented apoptosis but not c-Jun phosphorylation. In a different neuroblastoma cell line, NO-induced Ser-63 phosphorylation of c-Jun and apoptosis were blocked by a specific JNK inhibitor. We conclude that NO-inducible apoptosis is mediated by JNK-dependent Ser-63 phosphorylation of c-Jun upstream of caspase-3 activation in neuroblastoma cells.	Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Porter, AG (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	mcbagp@imcb.a-star.edu.sg						ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; BAKER DL, 1989, CANCER RES, V49, P4142; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; BROWN PH, 1994, ONCOGENE, V9, P791; Brune B, 1999, CELL DEATH DIFFER, V6, P969, DOI 10.1038/sj.cdd.4400582; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Chung KC, 2000, J NEUROCHEM, V75, P9, DOI 10.1046/j.1471-4159.2000.0750009.x; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Feng ZW, 2002, MOL CELL BIOL, V22, P5357, DOI 10.1128/MCB.22.15.5357-5366.2002; Fulda S, 1998, CANCER RES, V58, P4453; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Haas CA, 2000, EUR J NEUROSCI, V12, P4233, DOI 10.1046/j.0953-816X.2000.01329.x; HABY C, 1994, J NEUROCHEM, V62, P496; Harada J, 1999, JPN J PHARMACOL, V79, P369, DOI 10.1254/jjp.79.369; Harris CA, 2001, J BIOL CHEM, V276, P37754; Hentze H, 2002, J BIOL CHEM, V277, P5588, DOI 10.1074/jbc.M110766200; Herdegen T, 2001, ONCOGENE, V20, P2424, DOI 10.1038/sj.onc.1204387; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kataoka K, 1998, NEUROSCI RES, V32, P103, DOI 10.1016/S0168-0102(98)00076-5; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kihiko ME, 1999, J NEUROCHEM, V73, P2609, DOI 10.1046/j.1471-4159.1999.0732609.x; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Kroncke KD, 1997, NITRIC OXIDE-BIOL CH, V1, P107, DOI 10.1006/niox.1997.0118; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Le S, 2001, J BIOL CHEM, V276, P48332, DOI 10.1074/jbc.M106612200; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Leist M, 1998, EXP CELL RES, V239, P183, DOI 10.1006/excr.1997.4026; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Leppa S, 2001, MOL CELL BIOL, V21, P4369, DOI 10.1128/MCB.21.13.4369-4378.2001; Lipton SA, 1999, CELL DEATH DIFFER, V6, P943, DOI 10.1038/sj.cdd.4400580; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Morton S, 2003, EMBO J, V22, P3876, DOI 10.1093/emboj/cdg388; Oh-hashi K, 1999, BIOCHEM BIOPH RES CO, V263, P504, DOI 10.1006/bbrc.1999.1237; Pennypacker K, 1997, HISTOL HISTOPATHOL, V12, P1125; Pennypacker K R, 1995, J Fla Med Assoc, V82, P551; Potapova O, 2001, J BIOL CHEM, V276, P28546, DOI 10.1074/jbc.M102075200; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; Schulz JB, 1995, CURR OPIN NEUROL, V8, P480, DOI 10.1097/00019052-199512000-00016; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Thompson EJ, 2002, MOL CARCINOGEN, V35, P157, DOI 10.1002/mc.10090; Tong LQ, 1998, J NEUROCHEM, V71, P447; Torreilles F, 1999, BRAIN RES REV, V30, P153, DOI 10.1016/S0165-0173(99)00014-4; von Knethen A, 1999, MOL BIOL CELL, V10, P361, DOI 10.1091/mbc.10.2.361; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Yamagishi S, 2001, J BIOL CHEM, V276, P5129, DOI 10.1074/jbc.M007258200; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	64	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4058	4065		10.1074/jbc.M310415200	http://dx.doi.org/10.1074/jbc.M310415200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14617628	hybrid			2022-12-25	WOS:000188554300019
J	Nilsen, T; Slagsvold, T; Skjerpen, CS; Brech, A; Stenmark, H; Olsnes, S				Nilsen, T; Slagsvold, T; Skjerpen, CS; Brech, A; Stenmark, H; Olsnes, S			Peroxisomal targeting as a tool for assaying protein-protein interactions in the living cell - Cytokine-independent survival kinase (CISK) binds PDK-1 in vivo in a phosphorylation-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOCKING-SITE; MEMBRANE; RAT; SGK; IDENTIFICATION; TRANSLOCATION; ACTIVATION; PATHWAY; FAMILY; SERUM	Current methods to detect protein-protein interactions are either laborious to implement or not adaptable for mammalian systems or in vitro methods. By adding a peroxisomal targeting signal (PTS) onto one protein, binding partners lacking a targeting signal were cotransported into the peroxisomes in a "piggy-back" fashion, as visualized by confocal and electron microscopy. A fragment of colicin E2 and its tightly interacting immunity protein, ImmE2, were both expressed in the cytosol. When either one contained a PTS tag, both proteins were co-localized in the peroxisomes. The cytokine-independent survival kinase (CISK) containing a PTS tag was not efficiently targeted to the peroxisomes unless the Phox homology (PX) domain, attaching the protein to endosomal membranes, was removed. However, PTS-tagged CISK with deleted PX domain was able to direct 3-phosphoinositide-dependent protein kinase-1 (PDK-1) into the peroxisomes. This demonstrates that the two proteins interact in vivo. Mutating Ser(486), which is phosphorylated in activated CISK, to Ala prevented the interaction, indicating that CISK and PDK-1 interact in a phosphorylation-dependent manner. The method therefore allows assessment of protein-protein interactions that depend on post-translational modifications that are cell-specific or dependent on the physiological state of the cell.	Norwegian Radium Hosp, Inst Canc Res, Dept Biochem, N-0310 Oslo, Norway	University of Oslo	Olsnes, S (corresponding author), Norwegian Radium Hosp, Inst Canc Res, Dept Biochem, N-0310 Oslo, Norway.	olsnes@radium.uio.no	Stenmark, Harald/B-8868-2008	Christoffersen, Trine Eker/0000-0002-2908-133X; Brech, Andreas/0000-0002-9803-1774				Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Kikuchi M, 2004, J BIOL CHEM, V279, P421, DOI 10.1074/jbc.M305623200; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; LANG F, 2001, SCII STKE; Lawlor MA, 2001, J CELL SCI, V114, P2903; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; PETERS PJ, 1991, J EXP MED, V173, P1099, DOI 10.1084/jem.173.5.1099; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Skjerpen CS, 2002, EMBO J, V21, P4058, DOI 10.1093/emboj/cdf402; Slatin SL, 2002, P NATL ACAD SCI USA, V99, P1286, DOI 10.1073/pnas.022480199; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; Titorenko VI, 2002, J CELL BIOL, V156, P481, DOI 10.1083/jcb.200111075; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Virbasius JV, 2001, P NATL ACAD SCI USA, V98, P12908, DOI 10.1073/pnas.221352898; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151	28	11	14	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4794	4801		10.1074/jbc.M309653200	http://dx.doi.org/10.1074/jbc.M309653200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14604990	hybrid			2022-12-25	WOS:000188554300104
J	Raines, KW; Cao, GL; Porsuphatana, S; Tsai, P; Rosen, GM; Shapiro, P				Raines, KW; Cao, GL; Porsuphatana, S; Tsai, P; Rosen, GM; Shapiro, P			Nitric oxide inhibition of ERK1/2 activity in cells expressing neuronal nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MAP KINASE; CHROMOSOMAL LOCALIZATION; SUPEROXIDE GENERATION; L-ARGININE; SIGNAL-TRANSDUCTION; GLUTAMATE RECEPTORS; RELAXING FACTOR; SPIN TRAPS; APOPTOSIS	Neuronal nitric-oxide synthase (nNOS) is a constitutively expressed enzyme responsible for the production of nitric oxide (NO.) from L-arginine and O-2. Nitric oxide is an intra- and intercellular messenger that mediates a diversity of signaling pathways in target cells. In the absence of L-arginine, nNOS has been shown to generate superoxide (O-2(radical anion)). Superoxide, either directly or through its self-dismutation to H2O2, is likewise believed to be a cell-signaling agent. Because nNOS can generate NO. and O-2(radical anion), we examined the activation of cellular signal transduction pathways in nNOS-transfected cells grown in the presence or absence of L-arginine. Spin trapping/ EPR spectroscopy confirmed that stimulated nNOS-transfected cells grown in an L-arginine environment secreted NO. into the surrounding milieu. Production of NO. blocked Ca2+ ionophore-induced activation of the ERK1/2 through a mechanism involving inhibition of the Ras G-protein and Raf-1 kinase. In contrast, ERK activation was largely unaffected in nNOS-transfected cells grown in L-arginine-free media. Inhibition of nNOS-generated NO. with the competitive NOS inhibitor, N-G-nitro-L-arginine methyl ester, in cells grown in L-arginine restored ERK1/2 activation to levels similar to that found when nNOS was activated in L-arginine-free media. These findings indicate that nNOS can differentially regulate the ERK signal transduction pathway in a manner dependent on the presence of L-arginine and the production of NO..	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, Baltimore, MD 21201 USA; Khon Kaen Univ, Fac Pharmaceut Sci, Dept Toxicol, Khon Kaen 40002, Thailand; Khon Kaen Univ, Ctr Low Frequency EPR In Vivo Physiol, Khon Kaen 40002, Thailand	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Khon Kaen University; Khon Kaen University	Shapiro, P (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, 20 N Pine St, Baltimore, MD 21201 USA.	pshapiro@rx.umaryland.edu			NCRR NIH HHS [RR-12257] Funding Source: Medline; NIBIB NIH HHS [EB-2034] Funding Source: Medline; NIGMS NIH HHS [R25 GM55036] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR012257] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB002034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM055036] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akaike T, 2000, IMMUNOLOGY, V101, P300, DOI 10.1046/j.1365-2567.2000.00142.x; Andreka P, 2001, CIRC RES, V88, P305, DOI 10.1161/01.RES.88.3.305; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; Boyd CS, 2002, BIOL CHEM, V383, P411, DOI 10.1515/BC.2002.045; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BRITTENDEN J, 1994, BRIT J CANCER, V69, P918, DOI 10.1038/bjc.1994.177; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cha H, 2001, J BIOL CHEM, V276, P48494, DOI 10.1074/jbc.M107601200; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; CULCASI M, 1994, J BIOL CHEM, V269, P12589; de Oliveira LCB, 2002, BRAZ J MED BIOL RES, V35, P181, DOI 10.1590/S0100-879X2002000200006; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; Fan X, 2003, J BIOL CHEM, V278, P10232, DOI 10.1074/jbc.M209911200; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; FORMAN HJ, 1973, ARCH BIOCHEM BIOPHYS, V158, P396, DOI 10.1016/0003-9861(73)90636-X; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; Hua LWL, 2002, J NEUROIMMUNOL, V126, P180, DOI 10.1016/S0165-5728(02)00055-3; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; KON H, 1975, BIOCHIM BIOPHYS ACTA, V379, P103, DOI 10.1016/0005-2795(75)90012-4; KURINO M, 1995, J NEUROCHEM, V65, P1282; Lane P, 1999, SEMIN NEPHROL, V19, P215; Lee YJ, 2001, ONCOGENE, V20, P1476, DOI 10.1038/sj.onc.1204225; Levonen AL, 2001, ANTIOXID REDOX SIGN, V3, P215, DOI 10.1089/152308601300185188; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liu XP, 2002, J BIOL CHEM, V277, P26194, DOI 10.1074/jbc.M201939200; Lopez-Ilasaca M, 1998, BIOCHEM PHARMACOL, V56, P269, DOI 10.1016/S0006-2952(98)00059-8; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MCCORD JM, 1969, J BIOL CHEM, V244, P6056; MONCADA S, 1986, P NATL ACAD SCI USA, V83, P9164, DOI 10.1073/pnas.83.23.9164; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Peng TQ, 2003, J BIOL CHEM, V278, P8099, DOI 10.1074/jbc.M207288200; Percival MD, 1999, BIOCHEMISTRY-US, V38, P13574, DOI 10.1021/bi991028u; Pfeilschifter J, 2001, EUR J PHARMACOL, V429, P279, DOI 10.1016/S0014-2999(01)01326-7; Porasuphatana S, 2001, ANAL BIOCHEM, V298, P50, DOI 10.1006/abio.2001.5389; POU S, 1992, J BIOL CHEM, V267, P24173; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; Rincon M, 2000, FREE RADICAL BIO MED, V28, P1328, DOI 10.1016/S0891-5849(00)00219-7; ROBINSON LJ, 1994, GENOMICS, V19, P350, DOI 10.1006/geno.1994.1068; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822, DOI 10.1152/ajpheart.1986.250.5.H822; SANDERS PW, 1995, BLOOD PURIFICAT, V13, P219, DOI 10.1159/000170204; Stolze K, 2003, BIOL CHEM, V384, P493, DOI 10.1515/BC.2003.056; Tierney DL, 1999, BIOCHEMISTRY-US, V38, P3704, DOI 10.1021/bi982904r; Tsai P, 2003, J ORG CHEM, V68, P7811, DOI 10.1021/jo0350413; TSAI P, 2000, J CHEM SOC P2, P983; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Wolin MS, 2000, ARTERIOSCL THROM VAS, V20, P1430, DOI 10.1161/01.ATV.20.6.1430; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XU WM, 1993, CYTOGENET CELL GENET, V64, P62, DOI 10.1159/000133562; Yoneyama H, 2001, BIOCHEM J, V360, P247, DOI 10.1042/0264-6021:3600247; Zaragoza C, 2002, MOL PHARMACOL, V62, P927, DOI 10.1124/mol.62.4.927	63	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					3933	3940		10.1074/jbc.M304813200	http://dx.doi.org/10.1074/jbc.M304813200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14602725	hybrid			2022-12-25	WOS:000188554300006
J	Inaoka, T; Takahashi, K; Yada, H; Yoshida, M; Ochi, K				Inaoka, T; Takahashi, K; Yada, H; Yoshida, M; Ochi, K			RNA polymerase mutation activates the production of a dormant antibiotic 3,3 '-neotrehalosadiamine via an autoinduction mechanism in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RIFAMPICIN RESISTANCE; STRINGENT RESPONSE; GENE-EXPRESSION; RPOB GENE; STREPTOMYCES-LIVIDANS; BETA-SUBUNIT; BIOSYNTHESIS; CHROMOSOME; BACTERIA	Bacillus and Streptomyces species possess the ability to produce a variety of commercially important metabolites and extracellular enzymes. We previously demonstrated that antibiotic production in Streptomyces coelicolor A3(2) and Streptomyces lividans can be enhanced by RNA polymerase (RNAP) mutations selected for the rifampicin-resistant (Rif(r)) phenotype. Here, we have shown that the introduction of a certain Rif(r) rpoB mutation into a B. subtilis strain resulted in cells that overproduce an aminosugar antibiotic 3,3'-neotrehalosadiamine (NTD), the production of which is dormant in the wild-type strain. Mutational and recombinant gene expression analyses have revealed a polycistronic gene ntdABC (formally yhjLKJ) and a monocistronic gene ntdR (formally yhjM) as the NTD biosynthesis operon and a positive regulator for ntdABC, respectively. Analysis of transcriptional fusions to a lacZ reporter revealed that NTD acts as an autoinducer for its own biosynthesis genes via NtdR protein. Our results also showed that the Rif(r) rpoB mutation causes an increase in the activity of sigma(A)-dependent promoters including ntdABC promoter. Therefore, we propose that unlike the wild-type RNAP, the mutant RNAP efficiently recognized the sigma(A)-dependent promoters, resulting in the dramatic activation of the NTD biosynthesis pathway by an autoinduction mechanism.	Natl Food Res Inst, Microbial Funct Lab, Tsukuba, Ibaraki 3058642, Japan; Natl Food Res Inst, Mol Elucidat Lab, Tsukuba, Ibaraki 3058642, Japan	National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan; National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan	Ochi, K (corresponding author), Natl Food Res Inst, Microbial Funct Lab, 2-1-12 Kannondai, Tsukuba, Ibaraki 3058642, Japan.	kochi@affrc.go.jp	Takahashi, Kosaku/B-7760-2012; Inaoka, Takashi/L-3649-2019					Bandow JE, 2002, J BACTERIOL, V184, P459, DOI 10.1128/JB.184.2.459-467.2002; Campbell EA, 2001, CELL, V104, P901, DOI 10.1016/S0092-8674(01)00286-0; CASHEL M, 1996, ESCHERICHIA COLI SAL, V1, P1458; Chang DE, 2002, MOL MICROBIOL, V45, P289, DOI 10.1046/j.1365-2958.2002.03001.x; Eymann C, 2002, J BACTERIOL, V184, P2500, DOI 10.1128/JB.184.9.2500-2520.2002; EZEKIEL DH, 1968, NATURE, V220, P276, DOI 10.1038/220276a0; Fujita M, 1998, GENE, V221, P185, DOI 10.1016/S0378-1119(98)00452-1; Fukuchi K, 2000, MICROBIOL-UK, V146, P1573, DOI 10.1099/00221287-146-7-1573; Fuqua C, 2001, ANNU REV GENET, V35, P439, DOI 10.1146/annurev.genet.35.102401.090913; Hu HF, 2002, J BACTERIOL, V184, P3984, DOI 10.1128/JB.184.14.3984-3991.2002; Hu HF, 2001, APPL ENVIRON MICROB, V67, P1885, DOI 10.1128/AEM.67.4.1885-1892.2001; Inaoka T, 2003, J BIOL CHEM, V278, P2169, DOI 10.1074/jbc.M208722200; Inaoka T, 2002, J BACTERIOL, V184, P3923, DOI 10.1128/JB.184.14.3923-3930.2002; Ingham CJ, 2000, MICROBIOL-UK, V146, P3041, DOI 10.1099/00221287-146-12-3041; ITAYA M, 1989, NUCLEIC ACIDS RES, V17, P4410, DOI 10.1093/nar/17.11.4410; KAISER D, 1993, CELL, V73, P873, DOI 10.1016/0092-8674(93)90268-U; Kleerebezem M, 2001, PEPTIDES, V22, P1579, DOI 10.1016/S0196-9781(01)00493-4; KUIPERS OP, 1995, J BIOL CHEM, V270, P27299, DOI 10.1074/jbc.270.45.27299; Lai CX, 2002, MICROBIOL-SGM, V148, P3365, DOI 10.1099/00221287-148-11-3365; Moriya S, 1998, MOL MICROBIOL, V29, P179, DOI 10.1046/j.1365-2958.1998.00919.x; Nicholson WL, 2002, J BACTERIOL, V184, P4936, DOI 10.1128/JB.184.17.4936-4940.2002; NUMATA KI, 1986, J ANTIBIOT, V39, P1346, DOI 10.7164/antibiotics.39.1346; OCHI K, 1984, J GEN MICROBIOL, V130, P2473; Ohashi Y, 2003, FEMS MICROBIOL LETT, V221, P125, DOI 10.1016/S0378-1097(03)00171-X; Pfeifer BA, 2001, SCIENCE, V291, P1790, DOI 10.1126/science.1058092; Stein T, 2002, MOL MICROBIOL, V44, P403, DOI 10.1046/j.1365-2958.2002.02869.x; STEINMETZ M, 1994, J BACTERIOL, V176, P1761, DOI 10.1128/jb.176.6.1761-1763.1994; TSUNO T, 1986, J ANTIBIOT, V39, P1001, DOI 10.7164/antibiotics.39.1001; WEHRLI W, 1968, BIOCHEM BIOPH RES CO, V32, P284, DOI 10.1016/0006-291X(68)90382-3; WEHRLI W, 1968, P NATL ACAD SCI USA, V61, P667, DOI 10.1073/pnas.61.2.667; Xu J, 2002, MOL GENET GENOMICS, V268, P179, DOI 10.1007/s00438-002-0730-1; Zhou YN, 1998, P NATL ACAD SCI USA, V95, P2908, DOI 10.1073/pnas.95.6.2908	32	73	82	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3885	3892		10.1074/jbc.M309925200	http://dx.doi.org/10.1074/jbc.M309925200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14612444	hybrid			2022-12-25	WOS:000188379600091
J	Ohguchi, K; Banno, Y; Akao, Y; Nozawa, Y				Ohguchi, K; Banno, Y; Akao, Y; Nozawa, Y			Involvement of phospholipase D1 in melanogenesis of mouse B16 melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-INDUCED DIFFERENTIATION; MESSENGER-RNA EXPRESSION; LEUKEMIC HL60 CELLS; D PLD ISOZYMES; TRANSCRIPTION FACTOR; SKIN PIGMENTATION; ERK ACTIVATION; PATHWAY; MELANOCYTES; INHIBITION	In response to alpha-melanocyte-stimulating hormone (alpha-MSH) or cAMP-elevating agents (forskolin and isobutylmethylxanthine), mouse B16 melanoma cells underwent differentiation characterized by increased melanin biosynthesis. However, the mechanism(s) underlying the regulation of melanogenesis during differentiation has not yet been clearly understood. Phospholipase D (PLD) has been reported to be involved in differentiation. This enzyme cleaves phosphatidylcholine upon stimulation with stimuli to generate phosphatidic acid. In the current study, the involvement of PLD in the regulation of melanogenesis characteristic of differentiation was examined using mouse B16 melanoma cells. Treatment of B16 cells with alpha-MSH was found to cause marked decreases in the PLD1 activity concurrent with its reduced protein level. Moreover, treatment of exogenous bacterial PLD also inhibited alpha-MSH-induced melanogenesis. To further investigate the role of PLD1 in the regulation of melanogenesis, we examined the effects of overexpression of PLD1 on melanogenesis in B16 melanoma cells. The B16 cells over-expressing PLD were prepared by transfection with the vector containing the cDNA encoding PLD1. The melanin contents in PLD1-overexpressing cells (B16/PLD1) were observed to be lower compared with those in the vector control cells (B16/Vec), concomitant with the decreases in both activity and protein level of tyrosinase, a key regulatory enzyme in melanogenesis. Moreover, overexpression of PLD1 resulted in a marked inhibition of melanogenesis induced by alpha-MSH. The inhibition of melanogenesis was well correlated with the decrease in the tyrosinase activity associated with its expression. These results indicated that PLD1 negatively regulated the melanogenic signaling by modulating the expression of tyrosinase in mouse B16 melanoma cells.	Gifu Int Inst Biotechnol, Gifu 5040838, Japan; Gifu Univ, Sch Med, Dept Biochem, Gifu 5008705, Japan	Gifu University	Ohguchi, K (corresponding author), Gifu Int Inst Biotechnol, 1-1 Naka Fudogaoka, Gifu 5040838, Japan.	kohguchi@giib.or.jp						Antony P, 2003, FEBS LETT, V541, P93, DOI 10.1016/S0014-5793(03)00313-2; Banno Y, 1999, J BIOL CHEM, V274, P27385, DOI 10.1074/jbc.274.39.27385; Banno Y, 2002, J BIOCHEM, V131, P301, DOI 10.1093/oxfordjournals.jbchem.a003103; BANNO Y, 1995, J BIOL CHEM, V270, P4318, DOI 10.1074/jbc.270.9.4318; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Busca R, 1996, J BIOL CHEM, V271, P31824, DOI 10.1074/jbc.271.50.31824; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cockcroft S, 2001, CELL MOL LIFE SCI, V58, P1674, DOI 10.1007/PL00000805; Englaro W, 1998, J BIOL CHEM, V273, P9966, DOI 10.1074/jbc.273.16.9966; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; Frohman MA, 1999, CHEM PHYS LIPIDS, V98, P127, DOI 10.1016/S0009-3084(99)00025-0; Goding CR, 1997, CELL GROWTH DIFFER, V8, P935; Griner RD, 1999, J BIOL CHEM, V274, P4663, DOI 10.1074/jbc.274.8.4663; Hayakawa K, 1999, NEUROSCI LETT, V265, P127, DOI 10.1016/S0304-3940(99)00228-1; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; HEARING VJ, 1989, PIGM CELL RES, V2, P75, DOI 10.1111/j.1600-0749.1989.tb00166.x; Khaled M, 2002, J BIOL CHEM, V277, P33690, DOI 10.1074/jbc.M202939200; Kim DS, 2003, J CELL SCI, V116, P1699, DOI 10.1242/jcs.00366; Kim DS, 2002, CELL SIGNAL, V14, P779, DOI 10.1016/S0898-6568(02)00024-4; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Madesh M, 1998, CANCER LETT, V132, P141, DOI 10.1016/S0304-3835(98)00172-4; Min DS, 2001, NEUROPHARMACOLOGY, V41, P384, DOI 10.1016/S0028-3908(01)00070-3; MISHIMA Y, 1994, PIGM CELL RES, V7, P376, DOI 10.1111/j.1600-0749.1994.tb00065.x; Nakashima S, 1998, BBA-LIPID LIPID MET, V1389, P173, DOI 10.1016/S0005-2760(97)00153-7; Nakashima S, 1997, IMMUNOBIOLOGY, V196, P588, DOI 10.1016/S0171-2985(97)80074-5; Nozawa Y, 2002, BBA-MOL CELL BIOL L, V1585, P77, DOI 10.1016/S1388-1981(02)00327-X; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; Ohguchi K, 1997, J BIOL CHEM, V272, P1990, DOI 10.1074/jbc.272.3.1990; Ohguchi K, 1999, BBA-MOL CELL BIOL L, V1439, P215, DOI 10.1016/S1388-1981(99)00096-7; Oka M, 2000, J INVEST DERMATOL, V115, P699, DOI 10.1046/j.1523-1747.2000.00095.x; Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298; Tachibana M, 2000, PIGM CELL RES, V13, P230, DOI 10.1034/j.1600-0749.2000.130404.x; Thody AJ, 1998, PIGM CELL RES, V11, P265, DOI 10.1111/j.1600-0749.1998.tb00735.x; Yasumoto K, 1997, J BIOL CHEM, V272, P503; Yoshimura S, 1996, BIOCHEM BIOPH RES CO, V225, P494, DOI 10.1006/bbrc.1996.1201	36	15	15	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3408	3412		10.1074/jbc.M308054200	http://dx.doi.org/10.1074/jbc.M308054200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14615486	hybrid			2022-12-25	WOS:000188379600034
J	Inamori, K; Endo, T; Gu, JG; Matsuo, I; Ito, Y; Fujii, S; Iwasaki, H; Narimatsu, H; Miyoshi, E; Honke, K; Taniguchi, N				Inamori, K; Endo, T; Gu, JG; Matsuo, I; Ito, Y; Fujii, S; Iwasaki, H; Narimatsu, H; Miyoshi, E; Honke, K; Taniguchi, N			N-acetylglucosaminyltransferase IX acts on the GlcNAc beta 1,2-man alpha 1-ser/thr moiety, forming a 2,6-branched structure in brain O-mannosyl glycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL MUSCULAR-DYSTROPHY; HNK-1 CARBOHYDRATE EPITOPE; WALKER-WARBURG-SYNDROME; EXPRESSION CLONING; MOLECULAR-CLONING; ALPHA-DYSTROGLYCAN; FUKUYAMA-TYPE; BIOSYNTHESIS; MUTATIONS; FUCOSE	Mammals contain O-linked mannose residues with 2-mono- and 2,6-di-substitutions by GlcNAc in brain glycoproteins. It has been demonstrated that the transfer of GlcNAc to the 2-OH position of the mannose residue is catalyzed by the enzyme, protein O-mannose beta1,2-N-acetylglucosaminyltransferase (POMGnT1), but the enzymatic basis of the transfer to the 6-OH position is unknown. We recently reported on a brain-specific beta1,6-N- acetylglucosaminyltransferase, GnT-IX, that catalyzes the transfer of GlcNAc to the 6-OH position of the mannose residue of GlcNAcbeta1,2-Manalpha on both the alpha1,3-and alpha1,6-linked mannose arms in the core structure of N-glycan (Inamori, K., Endo, T., Ide, Y., Fujii, S., Gu, J., Honke, K., and Taniguchi, N. (2003) J. Biol. Chem. 278, 43102 - 43109). Here we examined the issue of whether GnT-IX is able to act on the same sequence of the GlcNAcbeta1,2-Manalpha in O-mannosyl glycan. Using three synthetic Ser-linked mannose-containing saccharides, Manalpha1-Ser, GlcNAcbeta1,2-Manalpha1-Ser, and Galbeta1,4-GlcNAc beta1,2-Manalpha1-Ser as acceptor substrates, the findings show that C-14-labeled GlcNAc was incorporated only into GlcNAcbeta1,2-Manalpha1-Ser after separation by thin layer chromatography. To simplify the assay, high performance liquid chromatography was employed, using a fluorescence-labeled acceptor substrate GlcNAcbeta1,2-Man alpha1-Ser-pyridylaminoethylsuccinamyl (PAES). Consistent with the above data, GnT-IX generated a new product which was identified as GlcNAcbeta1,2-(GlcNAc beta1,6-) Manalpha1-Ser-PAES by mass spectrometry and H-1 NMR. Furthermore, incorporation of an additional GlcNAc residue into a synthetic mannosyl peptide Ac-Ala-Ala-Pro-Thr(Man)-Pro-Val-Ala-Ala-Pro-NH2 by GnT-IX was only observed in the presence of POMGnT1. Collectively, these results strongly suggest that GnT-IX may be a novel beta1,6-N-acetylglucosaminyltransferase that is responsible for the formation of the 2,6- branched structure in the brain O-mannosyl glycan.	Kochi Med Sch, Dept Mol Genet, Nanko Ku, Kochi 7838505, Japan; Osaka Univ, Dept Biochem, Suita, Osaka 5650871, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; Kansai Med Univ, Chem Lab, Osaka 5731136, Japan; Natl Inst Adv Ind Sci & Technol, Open Space Lab, Res Ctr Glycosci, Glycogene Funct Team, Tsukuba, Ibaraki 3058568, Japan	Kochi University; Osaka University; RIKEN; Kansai Medical University; National Institute of Advanced Industrial Science & Technology (AIST)	Honke, K (corresponding author), Kochi Med Sch, Dept Mol Genet, Nanko Ku, Oko Cho, Kochi 7838505, Japan.	khonke@med.kochi-ms.ac.jp; proftani@biochem.med.osaka-u.ac.jp	Narimatsu, Hisashi/M-4757-2018; Taniguchi, Naoyuki/I-4182-2014; Gu, Jianguo/ABC-9257-2020; Inamori, Kei-ichiro/ABA-2926-2020; Taniguchi, Naoyuki/A-7086-2016; Ito, Yukishige/M-5119-2014; Ito, Yukishige/ACL-6203-2022	Narimatsu, Hisashi/0000-0002-8402-133X; Taniguchi, Naoyuki/0000-0001-5889-5968; Inamori, Kei-ichiro/0000-0002-5947-3633; Ito, Yukishige/0000-0001-6251-7249; Ito, Yukishige/0000-0001-6251-7249				AMADO M, 1999, BIOCHIM BIOPHYS ACTA, V6, P35; Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; Beltran-Valero de Bernabe D, 2002, AM J HUM GENET, V71, P1033, DOI 10.1086/342975; Brockington M, 2001, AM J HUM GENET, V69, P1198, DOI 10.1086/324412; Chai WG, 1999, EUR J BIOCHEM, V263, P879, DOI 10.1046/j.1432-1327.1999.00572.x; Chiba A, 1997, J BIOL CHEM, V272, P2156; DOBYNS WB, 1989, AM J MED GENET, V32, P195, DOI 10.1002/ajmg.1320320213; ENDO T, 1999, BIOCHIM BIOPHYS ACTA, V6, P237; FUKUYAMA Y, 1981, BRAIN DEV-JPN, V3, P1; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; HASE S, 1988, J BIOCHEM-TOKYO, V104, P867, DOI 10.1093/oxfordjournals.jbchem.a122571; HOLT GD, 1986, J BIOL CHEM, V261, P8049; Inamori K, 2003, J BIOL CHEM, V278, P43102, DOI 10.1074/jbc.M308255200; Kobayashi K, 1998, NATURE, V394, P388, DOI 10.1038/28653; Kudo T, 1998, J BIOL CHEM, V273, P26729, DOI 10.1074/jbc.273.41.26729; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Nishihara S, 2003, GLYCOBIOLOGY, V13, P445, DOI 10.1093/glycob/cwg048; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; Peyrard M, 1999, P NATL ACAD SCI USA, V96, P598, DOI 10.1073/pnas.96.2.598; SANTAVUORI P, 1989, BRAIN DEV-JPN, V11, P147, DOI 10.1016/S0387-7604(89)80088-9; Seifert J, 2000, GLYCOCONJUGATE J, V17, P407, DOI 10.1023/A:1007112232131; Seiki T, 1999, BIOCHEM BIOPH RES CO, V255, P182, DOI 10.1006/bbrc.1999.0151; Shao L, 2003, CELL MOL LIFE SCI, V60, P241, DOI 10.1007/s000180300019; Shimoda Y, 1999, J BIOL CHEM, V274, P17115, DOI 10.1074/jbc.274.24.17115; Smalheiser NR, 1998, J BIOL CHEM, V273, P23698, DOI 10.1074/jbc.273.37.23698; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; Wells L, 2003, BIOCHEM BIOPH RES CO, V302, P435, DOI 10.1016/S0006-291X(03)00175-X; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3; Yuen CT, 1997, J BIOL CHEM, V272, P8924	32	70	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2337	2340		10.1074/jbc.C300480200	http://dx.doi.org/10.1074/jbc.C300480200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14617637	hybrid			2022-12-25	WOS:000188211300003
J	Kuwako, K; Taniura, H; Yoshikawa, K				Kuwako, K; Taniura, H; Yoshikawa, K			Necdin-related MAGE proteins differentially interact with the E2F1 transcription factor and the p75 neurotrophin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRADER-WILLI-SYNDROME; NEURONAL GROWTH SUPPRESSOR; DEVELOPING MOUSE-BRAIN; POSTMITOTIC NEURONS; NUCLEAR-PROTEIN; GENE; EXPRESSION; APOPTOSIS; CELLS; REGION	Necdin is a growth suppressor expressed predominantly in postmitotic neurons and implicated in their terminal differentiation. Necdin shows a moderate homology to the MAGE family proteins, the functional roles of which are largely unknown. Human genes encoding necdin, MAGEL2 (necdin-like 1), and MAGE-G1 (necdin-like 2) are located in proximal chromosome 15q, a region associated with neurodevelopmental disorders such as Prader-Willi syndrome, Angelman syndrome, and autistic disorder. The necdin and MAGEL2 genes are subjected to genomic imprinting and suggested to be involved in the etiology of Prader-Willi syndrome. In this study, we compared biochemical and functional characteristics of murine orthologs of these necdin-related MAGE proteins. The colony formation and bromodeoxyuridine incorporation analyses revealed that necdin and MAGE-G1, but not MAGEL2, induced growth arrest. Necdin and MAGE-G1 interacted with the transcription factor E2F1 via its transactivation domain, repressed E2F1-dependent transcription, and antagonized E2F1-induced apoptosis of N1E-115 neuroblastoma cells. In addition, necdin and MAGE-G1 interacted with the p75 neurotrophin receptor via its distinct intracellular domains. In contrast, MAGEL2 failed to bind to these necdin interactors, suggesting that MAGEL2 has no necdin-like function in developing brain. Overexpression of p75 translocated necdin and MAGE-G1 in the proximity of the plasma membrane and reduced their association with E2F1 to facilitate E2F1-induced death of neuroblastoma cells. These results suggest that necdin and MAGE-G1 target both E2F1 and p75 to regulate cell viability during brain development.	Osaka Univ, Inst Prot Res, Div Regulat Macromol Funct, Osaka 5650871, Japan	Osaka University	Yoshikawa, K (corresponding author), Osaka Univ, Inst Prot Res, Div Regulat Macromol Funct, 3-2 Suita, Osaka 5650871, Japan.	yoshikaw@protein.osaka-u.ac.jp	Kuwako, Ken-ichiro/L-1237-2013	Kuwako, Ken-iihiro/0000-0002-1380-3035				AIZAWA T, 1992, DEV BRAIN RES, V68, P265, DOI 10.1016/0165-3806(92)90069-9; Azuma-Hara N, 1999, EXP CELL RES, V251, P442, DOI 10.1006/excr.1999.4593; Barker PA, 2002, J NEUROSCI RES, V67, P705, DOI 10.1002/jnr.10160; Benzel I, 2001, GENE, V281, P19, DOI 10.1016/S0378-1119(01)00730-2; Boccaccio I, 1999, HUM MOL GENET, V8, P2497, DOI 10.1093/hmg/8.13.2497; Bronfman FC, 2003, J NEUROSCI, V23, P3209; Burke MA, 2003, J NEUROBIOL, V55, P191, DOI 10.1002/neu.10174; Chibuk TK, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-22; Chittka A, 1999, P NATL ACAD SCI USA, V96, P10705, DOI 10.1073/pnas.96.19.10705; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coulson EJ, 2000, J BIOL CHEM, V275, P30537, DOI 10.1074/jbc.M005214200; Gerard M, 1999, NAT GENET, V23, P199, DOI 10.1038/13828; HAYASHI Y, 1995, BIOCHEM BIOPH RES CO, V213, P317, DOI 10.1006/bbrc.1995.2132; Hou ST, 2000, J NEUROCHEM, V75, P91, DOI 10.1046/j.1471-4159.2000.0750091.x; Isles AR, 2000, TRENDS COGN SCI, V4, P309, DOI 10.1016/S1364-6613(00)01504-7; Jay P, 1997, NAT GENET, V17, P357, DOI 10.1038/ng1197-357; Jung KM, 2003, J BIOL CHEM, V278, P42161, DOI 10.1074/jbc.M306028200; Kanning KC, 2003, J NEUROSCI, V23, P5425, DOI 10.1523/jneurosci.23-13-05425.2003; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Kobayashi M, 2002, J BIOL CHEM, V277, P42128, DOI 10.1074/jbc.M205024200; Kuwako K, 2002, MOL BRAIN RES, V107, P166, DOI 10.1016/S0169-328X(02)00489-8; Lee S, 2000, HUM MOL GENET, V9, P1813, DOI 10.1093/hmg/9.12.1813; Lee S, 2003, GENE EXPR PATTERNS, V3, P599, DOI 10.1016/S1567-133X(03)00113-3; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; MacDonald HR, 1997, HUM MOL GENET, V6, P1873, DOI 10.1093/hmg/6.11.1873; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P291, DOI 10.1016/0006-291X(91)91812-Q; Matsumoto K, 2001, GENE, V272, P173, DOI 10.1016/S0378-1119(01)00544-3; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; Muscatelli F, 2000, HUM MOL GENET, V9, P3101, DOI 10.1093/hmg/9.20.3101; Nakada Y, 1998, GENE, V213, P65, DOI 10.1016/S0378-1119(98)00206-6; Niinobe M, 2000, DEV NEUROSCI-BASEL, V22, P310, DOI 10.1159/000017455; Ren J, 2003, J NEUROSCI, V23, P1569; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; Saburi S, 2001, J BIOL CHEM, V276, P49378, DOI 10.1074/jbc.M108584200; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; Sutcliffe JS, 1997, LANCET, V350, P1520, DOI 10.1016/S0140-6736(05)63943-8; Takazaki R, 2002, EXP CELL RES, V277, P220, DOI 10.1006/excr.2002.5558; Taniguchi N, 2000, J BIOL CHEM, V275, P31674, DOI 10.1074/jbc.M005103200; Taniura H, 1999, J BIOL CHEM, V274, P16242, DOI 10.1074/jbc.274.23.16242; Taniura H, 1998, J BIOL CHEM, V273, P720, DOI 10.1074/jbc.273.2.720; Taniura H, 2002, J CELL BIOCHEM, V84, P545, DOI 10.1002/jcb.10047.abs; Tcherpakov M, 2002, J BIOL CHEM, V277, P49101, DOI 10.1074/jbc.C200533200; Tsai TF, 1999, NAT GENET, V22, P15, DOI 10.1038/8722; Uetsuki T, 1996, J BIOL CHEM, V271, P918, DOI 10.1074/jbc.271.2.918; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; YOSHIKAWA K, 1985, P NATL ACAD SCI USA, V82, P589, DOI 10.1073/pnas.82.2.589; Yoshikawa K, 2000, NEUROSCI RES, V37, P1, DOI 10.1016/S0168-0102(00)00101-2	47	81	87	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1703	1712		10.1074/jbc.M308454200	http://dx.doi.org/10.1074/jbc.M308454200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14593116	hybrid			2022-12-25	WOS:000188005700019
J	Prajapati, S; Verma, U; Yamamoto, Y; Kwak, YT; Gaynor, RB				Prajapati, S; Verma, U; Yamamoto, Y; Kwak, YT; Gaynor, RB			Protein phosphatase 2C beta association with the I kappa B kinase complex is involved in regulating NF-kappa B activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IKK-BETA; MEDIATED ACTIVATION; MOLECULAR-CLONING; MICE LACKING; ALPHA; PHOSPHORYLATION; SUBUNIT; GAMMA; IDENTIFICATION; 2C-ALPHA	The NF-kappaB pathway is important in the control of the immune and inflammatory response. One of the critical events in the activation of this pathway is the stimulation of the IkappaB kinases (IKKs) by cytokines such as tumor necrosis factor-alpha and interleukin-1. Although the mechanisms that modulate IKK activation have been studied in detail, much less is known about the processes that down-regulate its activity following cytokine treatment. In this study, we utilized biochemical fractionation and mass spectrometry to demonstrate that protein phosphatase 2Cbeta(PP2Cbeta) can associate with the IKK complex. PP2Cbeta association with the IKK complex led to the dephosphorylation of IKKbeta and decreased its kinase activity. The binding of PP2Cbeta to IKKbeta was decreased at early times post-tumor necrosis factor-alpha treatment and was restored at later times following treatment with this cytokine. Experiments utilizing siRNA directed against PP2Cbeta demonstrated an in vivo role for this phosphatase in decreasing IKK activity at late times following cytokine treatment. These studies are consistent with the ability of PP2Cbeta to down-regulate cytokine-induced NF-kappaB activation by altering IKK activity.	Univ Texas, SW Med Ctr, Dept Med,Harold Simmons Canc Ctr, Div Hematol Oncol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gaynor, RB (corresponding author), Univ Texas, SW Med Ctr, Dept Med,Harold Simmons Canc Ctr, Div Hematol Oncol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	gaynor_richard@lilly.com						Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Chambers RS, 2003, NAT BIOTECHNOL, V21, P1088, DOI 10.1038/nbt858; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Cheng AY, 2000, J BIOL CHEM, V275, P34744, DOI 10.1074/jbc.M006210200; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fu DX, 2003, J BIOL CHEM, V278, P1487, DOI 10.1074/jbc.M210631200; Gatlin CL, 1998, ANAL BIOCHEM, V263, P93, DOI 10.1006/abio.1998.2809; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hanada M, 2001, J BIOL CHEM, V276, P5753, DOI 10.1074/jbc.M007773200; Hanada M, 1998, FEBS LETT, V437, P172, DOI 10.1016/S0014-5793(98)01229-0; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KATO S, 1995, ARCH BIOCHEM BIOPHYS, V318, P387, DOI 10.1006/abbi.1995.1244; Kwak YT, 2000, J BIOL CHEM, V275, P14752, DOI 10.1074/jbc.M001039200; Leonardi A, 2000, P NATL ACAD SCI USA, V97, P10494, DOI 10.1073/pnas.190245697; Li MG, 2003, J BIOL CHEM, V278, P12013, DOI 10.1074/jbc.M211474200; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; MANN DJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P100, DOI 10.1016/0167-4781(92)90471-B; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Pons S, 2000, J BIOL CHEM, V275, P38620, DOI 10.1074/jbc.M004531200; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Strovel ET, 2000, J BIOL CHEM, V275, P2399, DOI 10.1074/jbc.275.4.2399; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; TERASAWA T, 1993, ARCH BIOCHEM BIOPHYS, V307, P342, DOI 10.1006/abbi.1993.1598; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamamoto Y, 2000, MOL CELL BIOL, V20, P3655, DOI 10.1128/MCB.20.10.3655-3666.2000; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang JM, 2001, J BIOL CHEM, V276, P47828, DOI 10.1074/jbc.M106103200; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	53	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1739	1746		10.1074/jbc.M306273200	http://dx.doi.org/10.1074/jbc.M306273200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14585847	hybrid			2022-12-25	WOS:000188005700023
J	Baronas-Lowell, D; Lauer-Fields, JL; Fields, GB				Baronas-Lowell, D; Lauer-Fields, JL; Fields, GB			Induction of endothelial cell activation by a triple helical alpha(2)beta(1) integrin ligand, derived from type I collagen alpha 1(I)496-507	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; MEDIATED SIGNAL-TRANSDUCTION; PEPTIDE-AMPHIPHILES; GENE-EXPRESSION; E-SELECTIN; INTERSTITIAL COLLAGENS; LEUKOCYTE ADHESION; CANCER PATIENTS; BINDING-SITES; GER SEQUENCE	Endothelial cell activation involves the elevated expression of cell adhesion molecules, chemoattractants, chemokines, and cytokines. These expression profiles may be regulated by integrin-mediated cell signaling pathways. In the current study, an alpha(2)beta(1) integrin triple helical peptide ligand derived from type I collagen residues alpha1(I) 496-507 was examined for induction of human aortic endothelial cell (HAEC) activation. In addition, a "miniextracellular matrix" composed of a mixture of the alpha1(I) 496-507 ligand and a second, alpha-helical ligand incorporating the endothelial cell proliferating region of SPARC (secreted protein acidic and rich in cysteine) was studied for induction of HAEC activation. Following HAEC adhesion to alpha1(I) 496-507, mRNA expression of E-selectin-1, vascular and intercellular cell adhesion molecules-1, and monocytic chemoattractant protein-1 was stimulated, whereas that of endothelin-1 was inhibited. Enzyme-linked immunosorbent assay analysis demonstrated that E-selectin-1 and monocytic chemoattractant protein-1 expression was also stimulated, whereas endothelin-1 protein expression diminished. Engagement of the alpha(2)beta(1) integrin initiated a HAEC response similar to that of tumor necrosis factor-alpha-induced HAECs but was not sufficient to induce an inflammatory response. Addition of the SPARC(119-122) region had only a slight effect on HAEC activation. Other cell-extracellular matrix interactions appear to be required to elicit an inflammatory response. The alpha(2)beta(1) integrin specific triple helical peptide ligand described herein represents a more general in vitro model system by which gene expression and protein production profiles induced by binding to a single cellular receptor type can be quantified.	Florida Atlantic Univ, Dept Chem & Biochem, Boca Raton, FL 33431 USA	State University System of Florida; Florida Atlantic University	Fields, GB (corresponding author), Florida Atlantic Univ, Dept Chem & Biochem, 777 Glades Rd, Boca Raton, FL 33431 USA.				NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000289] Funding Source: NIH RePORTER; NIBIB NIH HHS [EB00289] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Alexiou D, 2003, AM J GASTROENTEROL, V98, P478, DOI 10.1016/S0002-9270(02)05927-0; Alexiou D, 2001, EUR J CANCER, V37, P2392, DOI 10.1016/S0959-8049(01)00318-5; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; Bianco-Peled H, 2001, LANGMUIR, V17, P6931, DOI 10.1021/la990383i; Brekken RA, 2000, MATRIX BIOL, V19, P569, DOI 10.1016/S0945-053X(00)00105-0; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COLE WG, 1994, PROG NUCLEIC ACID RE, V47, P29, DOI 10.1016/S0079-6603(08)60249-4; de Fougerolles AR, 2000, J CLIN INVEST, V105, P721, DOI 10.1172/JCI7911; DEFILIPPI P, 1994, CELL ADHES COMMUN, V2, P75, DOI 10.3109/15419069409014203; DEFILIPPI P, 1991, J CELL BIOL, V114, P855, DOI 10.1083/jcb.114.4.855; Di Lullo GA, 2002, J BIOL CHEM, V277, P4223, DOI 10.1074/jbc.M110709200; Dillow AK, 2001, BIOMATERIALS, V22, P1493, DOI 10.1016/S0142-9612(00)00304-5; Dori Y, 2000, J BIOMED MATER RES, V50, P75, DOI 10.1002/(SICI)1097-4636(200004)50:1<75::AID-JBM11>3.0.CO;2-A; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Fields GB, 1995, CONNECT TISSUE RES, V31, P235, DOI 10.3109/03008209509010815; Fields GB, 1998, BIOPOLYMERS, V47, P143, DOI 10.1002/(SICI)1097-0282(1998)47:2<143::AID-BIP3>3.0.CO;2-U; Forns P, 2000, BIOPOLYMERS, V54, P531, DOI 10.1002/1097-0282(200012)54:7<531::AID-BIP60>3.0.CO;2-X; FUNK SE, 1993, J CELL PHYSIOL, V154, P53, DOI 10.1002/jcp.1041540108; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; Gibbons GH, 1996, SCIENCE, V272, P689, DOI 10.1126/science.272.5262.689; Goebeler M, 1999, BLOOD, V93, P857, DOI 10.1182/blood.V93.3.857.403k03_857_865; Gonzalez-Amaro R, 1998, DRUGS, V56, P977, DOI 10.2165/00003495-199856060-00003; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Harari OA, 1999, J IMMUNOL, V163, P6860; HARLAN JM, 1985, BLOOD, V65, P513; Heino J, 2000, MATRIX BIOL, V19, P319, DOI 10.1016/S0945-053X(00)00076-7; Hubbard AK, 2000, FREE RADICAL BIO MED, V28, P1379, DOI 10.1016/S0891-5849(00)00223-9; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; KOSEKI N, 1994, CELL ADHES COMMUN, V1, P355, DOI 10.3109/15419069409097266; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; Kuhn K, 1994, Trends Cell Biol, V4, P256, DOI 10.1016/0962-8924(94)90124-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lafont A, 1999, CIRCULATION, V100, P1109, DOI 10.1161/01.CIR.100.10.1109; Lafrenie RM, 1996, J CELL BIOCHEM, V61, P543, DOI 10.1002/(SICI)1097-4644(19960616)61:4<543::AID-JCB7>3.0.CO;2-O; LANE TF, 1994, J CELL BIOL, V125, P929, DOI 10.1083/jcb.125.4.929; Lauer JL, 1998, BIOCHEMISTRY-US, V37, P5279, DOI 10.1021/bi972958l; Lauer-Fields JL, 2003, J BIOL CHEM, V278, P18140, DOI 10.1074/jbc.M211330200; Lauer-Fields JL, 2003, J BIOL CHEM, V278, P14321, DOI 10.1074/jbc.M212246200; LOBB RR, 1999, GUIDEBOOK EXTRACELLU, P380; Malkar NB, 2003, BIOMACROMOLECULES, V4, P518, DOI 10.1021/bm0256597; Malkar NB, 2002, BIOCHEMISTRY-US, V41, P6054, DOI 10.1021/bi012071w; Mantovani A, 1997, IMMUNOL TODAY, V18, P231, DOI 10.1016/S0167-5699(97)81662-3; Mombouli JV, 1999, J MOL CELL CARDIOL, V31, P61, DOI 10.1006/jmcc.1998.0844; Naito S, 2002, BIOCHEM BIOPH RES CO, V291, P130, DOI 10.1006/bbrc.2002.6418; NEWMAN W, 1993, J IMMUNOL, V150, P644; Nguyen M, 2000, INT J BIOCHEM CELL B, V32, P621, DOI 10.1016/S1357-2725(00)00013-3; Noble KE, 1996, EUR J IMMUNOL, V26, P2944, DOI 10.1002/eji.1830261221; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; Pakalns T, 1999, BIOMATERIALS, V20, P2265, DOI 10.1016/S0142-9612(99)00157-X; Pober JS, 2002, ARTHRITIS RES THER, V4, pS109, DOI 10.1186/ar576; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Sweeney SM, 1998, P NATL ACAD SCI USA, V95, P7275, DOI 10.1073/pnas.95.13.7275; Sweeney SM, 2003, J BIOL CHEM, V278, P30516, DOI 10.1074/jbc.M304237200; Tiger CF, 2001, DEV BIOL, V237, P116, DOI 10.1006/dbio.2001.0363; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; Vogel WF, 2001, EUR J DERMATOL, V11, P506; Werle M, 2002, CARDIOVASC RES, V56, P284, DOI 10.1016/S0008-6363(02)00600-4; Xu JH, 1998, J CELL BIOL, V140, P709, DOI 10.1083/jcb.140.3.709; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; Yu YC, 1997, METHOD ENZYMOL, V289, P571; Zhang WM, 2003, J BIOL CHEM, V278, P7270, DOI 10.1074/jbc.M210313200	68	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					952	962		10.1074/jbc.M305989200	http://dx.doi.org/10.1074/jbc.M305989200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14581484	hybrid			2022-12-25	WOS:000187722800018
J	Jacobs, EH; de Vries, TJ; Smit, AB; Schoffelmeer, ANM				Jacobs, EH; de Vries, TJ; Smit, AB; Schoffelmeer, ANM			Gene transcripts selectively down-regulated in the shell of the nucleus accumbens long after heroin self-administration are up-regulated in the core independent of response contingency	FASEB JOURNAL			English	Article						gene expression; instrumental learning; addiction; relapse	SEEKING BEHAVIOR; COCAINE-SEEKING; ADDICTION; DOPAMINE; RAT; REINFORCEMENT; AMPHETAMINE; SUBTERRITORIES; SENSITIZATION; LESIONS	Long-term drug-induced alterations in neurotransmission within the nucleus accumbens (NAc) shell and core may underlie relapse to drug-seeking behavior and drug-taking upon re-exposure to drugs and drug-associated stimuli (cues) during abstinence. Using an open screening strategy, we recently identified 25 gene transcripts, encoding for proteins involved in neuronal functioning and structure that are down-regulated in rat NAc shell after contingent (active), but not after noncontingent (passive), heroin administration. Studying the expression of the same transcripts in the NAc core by means of quantitative PCR, we now demonstrate that most of these transcripts are up-regulated in that NAc subregion long (3 weeks) after heroin self-administration in rats. A similar up-regulation in gene expression was also apparent in the NAc core of animals with a history of non-contingent heroin administration (yoked controls). These data indicate that heroin self-administration differentially regulates genes in the NAc core as compared with the shell. Moreover, whereas cognitive processes involved in active drug self-administration (e.g., instrumental learning) seems to direct gene expression in the NAc shell, neuroplasticity in the NAc core may be due to the pharmacological effects of heroin (including Pavlovian conditioning), as expressed in rats upon contingent as well as non-contingent administration of heroin.	Vrije Univ Amsterdam, VU Med Ctr, Neurosci Res Inst, Dept Med Pharmacol,Drug Abuse Program, NL-1081 BT Amsterdam, Netherlands; Vrije Univ Amsterdam, Neurosci Res Inst, Fac Earth & Life Sci, Drug Abuse Program,Dept Mol & Cellular Neurobiol, NL-1081 HV Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam	Schoffelmeer, ANM (corresponding author), Vrije Univ Amsterdam, VU Med Ctr, Neurosci Res Inst, Dept Med Pharmacol,Drug Abuse Program, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	anm.schoffelmeer@vumc.nl	Smit, August B/E-8410-2011; De Vries, Taco J/B-2831-2014	De Vries, Taco/0000-0002-0340-4946			We thank Rob Binnekade and Halfdan S. Raaso for their expert technical assistance	Alderson HL, 2001, PSYCHOPHARMACOLOGY, V153, P455, DOI 10.1007/s002130000634; ALHEID GF, 1988, NEUROSCIENCE, V27, P1, DOI 10.1016/0306-4522(88)90217-5; Bassareo V, 1999, NEUROSCIENCE, V89, P637, DOI 10.1016/S0306-4522(98)00583-1; BERENDSE HW, 1992, J NEUROSCI, V12, P2079; Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9; Cadoni C, 2000, EUR J PHARMACOL, V387, pR23, DOI 10.1016/S0014-2999(99)00843-2; Cadoni C, 2000, EUR J PHARMACOL, V388, P69, DOI 10.1016/S0014-2999(99)00824-9; Cadoni C, 1999, NEUROSCIENCE, V90, P447, DOI 10.1016/S0306-4522(98)00466-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Corbit LH, 2001, J NEUROSCI, V21, P3251, DOI 10.1523/JNEUROSCI.21-09-03251.2001; De Vries TJ, 2002, J NEUROSCI, V22, P3321; De Vries TJ, 1998, EUR J NEUROSCI, V10, P3565, DOI 10.1046/j.1460-9568.1998.00368.x; Everitt BJ, 2001, BRAIN RES REV, V36, P129, DOI 10.1016/S0165-0173(01)00088-1; Groenewegen H. J., 1994, BASAL GANGLIA, P81; Haber SN, 2000, J NEUROSCI, V20, P2369; HEIMER L, 1991, PROG BRAIN RES, V87, P109; HEIMER L, 1991, NEUROSCIENCE, V41, P89, DOI 10.1016/0306-4522(91)90202-Y; Hutcheson DM, 2001, PSYCHOPHARMACOLOGY, V153, P464, DOI 10.1007/s002130000635; Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560; Jacobs EH, 2002, FASEB J, V16, P1961, DOI 10.1096/fj.02-0272fje; JONGENRELO AL, 1994, EUR J NEUROSCI, V6, P1255, DOI 10.1111/j.1460-9568.1994.tb00315.x; Kelley AE, 1997, P NATL ACAD SCI USA, V94, P12174, DOI 10.1073/pnas.94.22.12174; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Parkinson JA, 1999, J NEUROSCI, V19, P2401; Pontieri FE, 1995, P NATL ACAD SCI USA, V92, P12304, DOI 10.1073/pnas.92.26.12304; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Weiner I, 1996, BEHAV BRAIN RES, V81, P123, DOI 10.1016/S0166-4328(96)00051-4; Wyvell CL, 2000, J NEUROSCI, V20, P8122; ZAHM DS, 1992, NEUROSCIENCE, V50, P751, DOI 10.1016/0306-4522(92)90202-D; Zahm DS, 1999, ANN NY ACAD SCI, V877, P113, DOI 10.1111/j.1749-6632.1999.tb09264.x; Zahm DS, 2000, NEUROSCI BIOBEHAV R, V24, P85, DOI 10.1016/S0149-7634(99)00065-2	33	27	28	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					200	202		10.1096/fj.03-0317fje	http://dx.doi.org/10.1096/fj.03-0317fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597559				2022-12-25	WOS:000188829300073
J	Florensa, R; Bachs, O; Agell, N				Florensa, R; Bachs, O; Agell, N			ATM/ATR-independent inhibition of cyclin B accumulation in response to hydroxyurea in nontransformed cell lines is altered in tumour cell lines	ONCOGENE			English	Article						hydroxyurea; ATM; ATR; caffeine; cyclin B1; replication checkpoint	DNA-DAMAGE; S-PHASE; REPLICATION CHECKPOINT; POLYMERASE-ALPHA; G2/M TRANSITION; PROTEIN-KINASE; ATR; ACTIVATION; PHOSPHORYLATION; MITOSIS	The DNA replication checkpoint is an inhibitory pathway ensuring that mitosis occurs only after completion of DNA synthesis. Its function may be relevant to the stability of the genome. The essential elements of this checkpoint are ATM/ATR kinases that indirectly lead to the phosphorylation and inhibition of the mitosis-promoting factor (Cdc2/cyclin B1). The function of this checkpoint was analysed in diverse nontransformed and tumour-derived cell lines. All cell lines tested arrested mitosis entry when DNA synthesis was inhibited by hydroxyurea (HU) treatment. But, unlike what has been described in yeast and Xenopus, in normal rat kidney (NRK) cells and NIH 3T3 fibroblasts, the arrest induced by HU treatment was not abrogated by caffeine, an ATM and ATR inhibitor. This indicated the presence of an ATM/ATR-independent response to DNA synthesis inhibition in these nontransformed mammalian cell lines. Interestingly, the behaviour of different tumour cell lines after caffeine treatment varied. While SW480, NP29, NP18 and HeLa cells did not enter mitosis in the presence of caffeine after HU treatment, in CaCo2, DLD1, HCT116 and HT29 caffeine abrogated the checkpoint response. In nontransformed cell lines, lack of cyclin B1 accumulation was observed when DNA synthesis was inhibited. This response was not abrogated by caffeine. In the tumour cell lines, a good correlation between the ability to arrest cell cycle when DNA synthesis was inhibited in the presence of caffeine and the lack of cyclin B1 accumulation was observed. Thus, there is an ATM/ATR-independent checkpoint response that leads to a decrease in cyclin B1 accumulation. However, this response is not functional in some tumour cell lines. Using inhibitors of p38alpha and beta, Mek1, 2 and p53-/- knocked-out fibroblasts, we showed that these proteins were also not involved in this particular checkpoint response. Lack of cyclin B1 accumulation after DNA synthesis inhibition in NRK cells was not due to increased degradation of the protein, but correlated with a decrease in mRNA accumulation.	Univ Barcelona, Fac Med, Dept Biol Cellular & Anat Patol, Inst Invest Biomed August Pi i Sunyer IDIBAPS, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Agell, N (corresponding author), Univ Barcelona, Fac Med, Dept Biol Cellular & Anat Patol, Inst Invest Biomed August Pi i Sunyer IDIBAPS, E-08036 Barcelona, Spain.	agell@medicina.ub.es	Agell, Neus/E-9640-2016	Agell, Neus/0000-0002-1205-6074				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen F, 2002, P NATL ACAD SCI USA, V99, P1990, DOI 10.1073/pnas.032428899; Crawford DF, 2001, J BIOL CHEM, V276, P37166, DOI 10.1074/jbc.M103414200; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; DURSO G, 1995, J CELL SCI, V108, P3109; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hwang A, 1998, J BIOL CHEM, V273, P31505, DOI 10.1074/jbc.273.47.31505; HWANG A, 1995, J BIOL CHEM, V270, P28419; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; KREK W, 1992, NEW BIOL, V4, P323; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Michael WM, 2000, SCIENCE, V289, P2133, DOI 10.1126/science.289.5487.2133; Michael WM, 1998, SCIENCE, V282, P1886, DOI 10.1126/science.282.5395.1886; Myung KJ, 2001, CELL, V104, P397, DOI 10.1016/S0092-8674(01)00227-6; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Rhind N, 1998, MOL CELL BIOL, V18, P3782, DOI 10.1128/MCB.18.7.3782; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Sarkaria JN, 1999, CANCER RES, V59, P4375; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; Stokes MP, 2002, J CELL BIOL, V158, P863, DOI 10.1083/jcb.200204127; TAM SW, 1995, J CELL BIOCHEM, V59, P339, DOI 10.1002/jcb.240590306; Tanaka S, 2002, GENE DEV, V16, P2639, DOI 10.1101/gad.1011002; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Ye X S, 1997, Prog Cell Cycle Res, V3, P221; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; Zeng Y, 1999, MOL CELL BIOL, V19, P7410; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	56	14	14	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2003	22	51					8283	8292		10.1038/sj.onc.1207159	http://dx.doi.org/10.1038/sj.onc.1207159			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614452				2022-12-25	WOS:000186541500007
J	Izumiyama, K; Nakagawa, M; Yonezumi, M; Kasugai, Y; Suzuki, R; Suzuki, H; Tsuzuki, S; Hosokawa, Y; Asaka, M; Seto, M				Izumiyama, K; Nakagawa, M; Yonezumi, M; Kasugai, Y; Suzuki, R; Suzuki, H; Tsuzuki, S; Hosokawa, Y; Asaka, M; Seto, M			Stability and subcellular localization of API2-MALT1 chimeric protein involved in t(11;18) (q21;q21) MALT lymphoma	ONCOGENE			English	Article						MALT lymphoma; chromosome trans location; API2; MALT1; API2-MALT1	B-CELL LYMPHOMA; TISSUE LYMPHOMA; LOW-GRADE; GENE; APOPTOSIS; T(11-18)(Q21-Q21); INHIBITOR; FUSION; LIGASE; BCL10	t(11;18) (q21;q21) is a chromosomal aberration specific to low-grade mucosa-associated lymphoid tissue (MALT) lymphoma, and generates the chimeric product apoptosis inhibitor 2 (API2)-MALT1, which has been suggested to play an important role in MALT lymphomagenesis. However, little is known about the characteristics of API2, MALT1, and API2-MALT1 proteins. We therefore investigated the subcellular localization and stability of these products. API2 was localized in the nucleus and the cytoplasm, and MALT1 and API2-MALT1 in the cytoplasm only. Western blot analysis showed that the products of API2 and MALT1 were unstable, while the API2-MALT1 product was stable. The API2 deletion mutants at the end of the C-terminal and the MALT1 deletion mutants at the end of the N-terminal were stable compared with the full-length products. These results indicate that the domains responsible for protein instability are located in the end of the C-terminal of API2 and in that of the N-terminal of MALT1, and also that API2-MALT1 became stable because it lacks these domains. It has been suggested that NF-kappaB activation plays an important role in the tumorigenesis of MALT lymphoma. Our findings further suggest that the stabilized expression of API2-MALT1 products may continuously stimulate the NF-kappaB activating pathway, thus leading to MALT lymphomagenesis.	Aichi Canc Ctr, Res Inst, Div Mol Med, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hematol, Sapporo, Hokkaido 0608638, Japan	Aichi Cancer Center; Hokkaido University	Seto, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Med, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		Asaka, Masahiro/A-5948-2012	Tsuzuki, Shinobu/0000-0002-3209-3550; Kasugai, Yumiko/0000-0003-4764-4455; Suzuki, Ritsuro/0000-0002-5974-7614				Akagi T, 1999, ONCOGENE, V18, P5785, DOI 10.1038/sj.onc.1203018; Baens M, 2000, AM J PATHOL, V156, P1433, DOI 10.1016/S0002-9440(10)65012-2; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Hozak RR, 2000, MOL CELL BIOL, V20, P1877, DOI 10.1128/MCB.20.5.1877-1885.2000; Huang HK, 2000, J BIOL CHEM, V275, P26661; Inagaki H, 2001, AM J PATHOL, V158, P699, DOI 10.1016/S0002-9440(10)64012-6; Isaacson PG, 1999, SEMIN HEMATOL, V36, P139; ISAACSON PG, 1987, HISTOPATHOLOGY, V11, P445, DOI 10.1111/j.1365-2559.1987.tb02654.x; Kalla J, 2000, LEUKEMIA, V14, P1967, DOI 10.1038/sj.leu.2401918; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; McAllister-Lucas LM, 2001, J BIOL CHEM, V276, P30589, DOI 10.1074/jbc.M103824200; Morgan JA, 1999, CANCER RES, V59, P6205; Motegi M, 2000, AM J PATHOL, V156, P807, DOI 10.1016/S0002-9440(10)64948-6; Ott G, 1997, CANCER RES, V57, P3944; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Remstein ED, 2000, AM J PATHOL, V156, P1183, DOI 10.1016/S0002-9440(10)64988-7; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Suzuki H, 1999, BLOOD, V94, P3270, DOI 10.1182/blood.V94.9.3270.421a44b_3270_3271; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yonezumi M, 2001, BRIT J HAEMATOL, V115, P588, DOI 10.1046/j.1365-2141.2001.03158.x; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767	27	25	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8085	8092		10.1038/sj.onc.1207002	http://dx.doi.org/10.1038/sj.onc.1207002			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603249				2022-12-25	WOS:000186403400003
J	Takebe, K; Oka, Y; Radisky, D; Tsuda, H; Tochigui, K; Koshida, S; Kogo, K; Hirai, Y				Takebe, K; Oka, Y; Radisky, D; Tsuda, H; Tochigui, K; Koshida, S; Kogo, K; Hirai, Y			Epimorphin acts to induce hair follicle anagen in C57BL/6 mice	FASEB JOURNAL			English	Article						morphogenesis; hair cycle; organ culture assay; anagen induction; molecular dynamics	KERATINOCYTE GROWTH-FACTOR; IN-VITRO; EPITHELIAL MORPHOGENESIS; EXTRACELLULAR-MATRIX; VESICULAR TRANSPORT; ALOPECIA-AREATA; DERMAL PAPILLA; CYCLOSPORINE-A; MOUSE SKIN; EXPRESSION	Epimorphin is a mesenchymal morphogen that has been shown to mediate epithelial-mesenchymal signaling interactions in various organs. We now show that epimorphin functions in hair follicle morphogenesis; using a novel ex vivo organ culture assay, we define a mechanism for epimorphin signaling that may provide insight into general developmental processes. We found that epimorphin was produced by follicular mesenchymal cells and bound selectively to follicular epithelial cells, and that treatment with recombinant epimorphin could stimulate procession of hair follicles from telogen (resting stage) to anagen (growing stage). Based on analyses of epimorphin proteolytic digests that suggested a smaller peptide might be able to substitute for the full-length epimorphin molecule, we determined that pep7, a 10-amino acid peptide, was capable of inducing telogen-to-anagen transition both in the culture assay and in the mouse. That pep7 showed maximal activity only when modified with specific sulfhydryl-reactive reagents suggested that a particular structural conformation of the peptide was essential for activity; molecular dynamics studies were pursued to investigate the active peptide structure. These findings define a previously unknown morphogenic process in the hair follicle that may have applications to many other organs.	Sumitomo Elect Ind Ltd, Osaka R&D Labs, Sakae Ku, EPM Project Grp, Yokohama, Kanagawa 2448588, Japan; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	Sumitomo Electric Industries; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Hirai, Y (corresponding author), Sumitomo Elect Ind Ltd, Osaka R&D Labs, Sakae Ku, EPM Project Grp, 1 Taya Cho, Yokohama, Kanagawa 2448588, Japan.	hirai-yohei@sei.co.jp	Radisky, Derek/B-6569-2018	Radisky, Derek/0000-0002-1962-8784				Akiyama M, 1999, BRIT J DERMATOL, V141, P447; Andl T, 2002, DEV CELL, V2, P643, DOI 10.1016/S1534-5807(02)00167-3; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; Bos JD, 2000, EXP DERMATOL, V9, P165, DOI 10.1034/j.1600-0625.2000.009003165.x; BUFFEY JA, 1994, BRIT J DERMATOL, V131, P836, DOI 10.1111/j.1365-2133.1994.tb08586.x; Bull JJ, 2002, J INVEST DERMATOL, V118, P17, DOI 10.1046/j.0022-202x.2001.01629.x; Chanda S, 2000, AM J PHYSIOL-ENDOC M, V278, pE202, DOI 10.1152/ajpendo.2000.278.2.E202; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; Commo S, 1997, BRIT J DERMATOL, V137, P31, DOI 10.1046/j.1365-2133.1997.17641854.x; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; COUCHMAN JR, 1993, J INVEST DERMATOL, V101, pS60, DOI 10.1111/1523-1747.ep12362642; DANILENKO DM, 1995, AM J PATHOL, V147, P145; Davey HW, 1999, AM J HUM GENET, V65, P959, DOI 10.1086/302599; DUCROS DL, 1993, J INVEST DERMATOL, V101, pS106, DOI 10.1111/1523-1747.ep12363020; Fang KC, 2000, AM J RESP CELL MOL, V23, P142, DOI 10.1165/ajrcmb.23.2.f195; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fritsch C, 2002, J CLIN INVEST, V110, P1629, DOI 10.1172/200213588; Galbraith H, 1998, P NUTR SOC, V57, P195, DOI 10.1079/PNS19980032; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; Hamada K, 1996, EXP ANIM TOKYO, V45, P251, DOI 10.1538/expanim.45.251; HARMON CS, 1993, LYMPHOKINE CYTOK RES, V12, P197; HIRAI Y, 1994, EUR J BIOCHEM, V225, P1133, DOI 10.1111/j.1432-1033.1994.1133b.x; HIRAI Y, 1989, DEVELOPMENT, V105, P271; HIRAI Y, 1992, CELL, V69, P471, DOI 10.1016/0092-8674(92)90448-L; Hirai Y, 2001, J CELL BIOL, V153, P785, DOI 10.1083/jcb.153.4.785; Hirai Y, 1998, J CELL BIOL, V140, P159, DOI 10.1083/jcb.140.1.159; Hirai Y, 2001, CELL BIOL INT, V25, P193, DOI 10.1006/cbir.2000.0618; Hirose M, 1996, BIOCHEM BIOPH RES CO, V225, P155, DOI 10.1006/bbrc.1996.1146; Hoffman R, 2001, EUR J DERMATOL, V11, P296; Jahoda CAB, 1996, DERMATOL CLIN, V14, P573, DOI 10.1016/S0733-8635(05)70385-5; Jahoda CAB, 2001, LANCET, V358, P1445, DOI 10.1016/S0140-6736(01)06532-1; Jarrousse F, 2001, INT J DERMATOL, V40, P385, DOI 10.1046/j.1365-4362.2001.01239.x; Jindo T, 1998, J INVEST DERMATOL, V110, P338, DOI 10.1046/j.1523-1747.1998.00144.x; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Jung HS, 1998, DEV BIOL, V196, P11, DOI 10.1006/dbio.1998.8850; KAO J, 1988, TOXICOL APPL PHARM, V94, P93, DOI 10.1016/0041-008X(88)90340-7; Kishimoto J, 1999, P NATL ACAD SCI USA, V96, P7336, DOI 10.1073/pnas.96.13.7336; Kishimoto J, 2000, GENE DEV, V14, P1181; Koshida S, 1997, BIOCHEM BIOPH RES CO, V234, P522, DOI 10.1006/bbrc.1997.6673; Kulessa H, 2000, EMBO J, V19, P6664, DOI 10.1093/emboj/19.24.6664; Lee SC, 1999, J INVEST DERMATOL, V112, P882, DOI 10.1046/j.1523-1747.1999.00602.x; Lehnert L, 2001, J CELL BIOL, V152, P911, DOI 10.1083/jcb.152.5.911; Lerman JC, 2000, BIOCHEMISTRY-US, V39, P8470, DOI 10.1021/bi0003994; Lindner G, 2000, FASEB J, V14, P319, DOI 10.1096/fasebj.14.2.319; LINK RE, 1990, J INVEST DERMATOL, V95, P202, DOI 10.1111/1523-1747.ep12478002; Liu X, 2001, P NATL ACAD SCI USA, V98, P9139, DOI 10.1073/pnas.161016098; McElwee KJ, 1998, PATHOBIOLOGY, V66, P90, DOI 10.1159/000028002; Mori M, 2000, CELL TISSUE RES, V300, P331, DOI 10.1007/s004410000205; MORI O, 1990, Journal of Dermatology (Tokyo), V17, P276; NUCK BA, 1987, ARCH DERMATOL, V123, P59, DOI 10.1001/archderm.123.1.59; Oh HS, 1996, P NATL ACAD SCI USA, V93, P12525, DOI 10.1073/pnas.93.22.12525; Oka Y, 1996, EXP CELL RES, V222, P189, DOI 10.1006/excr.1996.0024; OKEEFE EJ, 1993, J INVEST DERMATOL, V101, P65; Panteleyev AA, 2001, J CELL SCI, V114, P3419; PAUS R, 1989, LAB INVEST, V60, P365; PELHAM HRB, 1993, CELL, V73, P425, DOI 10.1016/0092-8674(93)90128-D; Peters EMJ, 1999, EXP DERMATOL, V8, P274; Peus D, 1996, DERMATOL CLIN, V14, P559, DOI 10.1016/S0733-8635(05)70384-3; PHILPOTT MP, 1994, J INVEST DERMATOL, V102, P857, DOI 10.1111/1523-1747.ep12382494; Sato N, 1999, J CLIN INVEST, V104, P855, DOI 10.1172/JCI7691; Schmidt T, 2000, BBA-GENE STRUCT EXPR, V1493, P249, DOI 10.1016/S0167-4781(00)00163-9; SILVER AF, 1966, NATURE, V210, P1051, DOI 10.1038/2101051a0; Simian M, 2001, DEVELOPMENT, V128, P3117; SLOMINSKI A, 1993, J INVEST DERMATOL, V101, pS90, DOI 10.1111/1523-1747.ep12362991; STENN KS, 1994, J INVEST DERMATOL, V103, P107, DOI 10.1111/1523-1747.ep12391844; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Su H Y, 1999, Dermatol Online J, V5, P1; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TAYLOR M, 1992, BRIT J DERMATOL, V126, P479, DOI 10.1111/j.1365-2133.1992.tb15120.x; THIVOLET J, 1991, PRESSE MED, V20, P2249; Tobin DJ, 1998, EXP DERMATOL, V7, P289; Watanabe S, 1998, BIOCHEM BIOPH RES CO, V250, P486, DOI 10.1006/bbrc.1998.9339; Yano K, 2001, J CLIN INVEST, V107, P409, DOI 10.1172/JCI11317; Zhang LY, 1999, J DERMATOL SCI, V20, P191, DOI 10.1016/S0923-1811(98)00081-4	74	21	25	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2003	17	14					2037	2047		10.1096/fj.03-0386com	http://dx.doi.org/10.1096/fj.03-0386com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	750AA	14597673				2022-12-25	WOS:000186961200040
J	Vetcher, AA; Wells, RD				Vetcher, AA; Wells, RD			Sticky DNA formation in vivo alters the plasmid dimer/monomer ratio	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELIX FORMATION; NUCLEOTIDE EXCISION-REPAIR; DOT-TTC REPEATS; ESCHERICHIA-COLI-CELLS; FRIEDREICHS-ATAXIA; GENETIC INSTABILITIES; MAMMALIAN-CELLS; FORMING OLIGONUCLEOTIDES; TRANSCRIPTION ELONGATION; TARGETED MUTAGENESIS	Our discovery that plasmids containing the Friedreich's ataxia (FRDA) expanded GAA.TTC sequence, which forms sticky DNA, are prone to form dimers compared with monomers in vivo is the basis of an intracellular assay in Escherichia coli for this unusual DNA conformation. Sticky DNA is a single long GAA.GAA.TTC triplex formed in plasmids harboring a pair of long GAA.TTC repeat tracts in the direct repeat orientation. This requirement is fulfilled by either plasmid dimers of DNAs with a single trinucleotide repeat sequence tract or by monomeric DNAs containing a pair of direct repeat GAA.TTC sequences. DNAs harboring a single GAA.TTC repeat are unable to form this type of triplex conformation. An excellent correlation was observed between the ability of a plasmid to adopt the sticky triplex conformation as assayed in vitro and its propensity to form plasmid dimers relative to monomers in vivo. The variables measured that strongly influenced these measurements are as follows: length of the GAA.TTC insert; the extent of periodic interruptions within the repeat sequence; the orientation of the repeat inserts; and the in vivo negative supercoil density. Nitrogen mustard cross-linking studies on a family of GAA.TTC-containing plasmids showed the presence of sticky DNA in vivo and, thus, serves as an important bridge between the in vitro and in vivo determinations. Biochemical genetic studies on FRDA containing DNAs grown in recA or nucleotide excision repair or ruv-deficient cells showed that the in vivo properties of sticky DNA play an important role in the monomer-dimer-sticky DNA intracellular interconversions. Thus, the sticky DNA triplex exists and functions in living cells, strengthening the likelihood of its role in the etiology of FRDA.	Texas A&M Univ Syst Hlth Sci Ctr, Texas Med Ctr, Inst Biosci & Technol, Ctr Genome Res, Houston, TX 77030 USA	Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Wells, RD (corresponding author), Texas A&M Univ, Texas Med Ctr, Inst Biosci & Technol, Ctr Genome Res, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rwells@ibt.tamu.edu		Vetcher, Alexandre/0000-0002-4828-8571	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES11347] Funding Source: Medline; NIGMS NIH HHS [GM52982] Funding Source: Medline; NINDS NIH HHS [NS37554] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bacolla A, 2001, J BIOL CHEM, V276, P18597, DOI 10.1074/jbc.M100845200; Barre FX, 2001, P NATL ACAD SCI USA, V98, P8189, DOI 10.1073/pnas.111008998; Bidichandani SI, 1998, AM J HUM GENET, V62, P111, DOI 10.1086/301680; Bidichandani SI, 1997, AM J HUM GENET, V60, P1251; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Branum ME, 2001, J BIOL CHEM, V276, P25421, DOI 10.1074/jbc.M101032200; BROOKES P, 1961, BIOCHEM J, V80, P496, DOI 10.1042/bj0800496; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; COLLIER DA, 1990, J BIOL CHEM, V265, P10652; Cox MM, 1998, GENES CELLS, V3, P65, DOI 10.1046/j.1365-2443.1998.00175.x; Diviacco S, 2001, FASEB J, V15, P2660, DOI 10.1096/fj.01-0440com; Faria M, 2000, P NATL ACAD SCI USA, V97, P3862, DOI 10.1073/pnas.97.8.3862; Faruqi AF, 2000, MOL CELL BIOL, V20, P990, DOI 10.1128/MCB.20.3.990-1000.2000; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Glazer P M, 1996, Methods Mol Biol, V57, P109; Grabczyk E, 2000, NUCLEIC ACIDS RES, V28, P2815, DOI 10.1093/nar/28.14.2815; Grabczyk E, 2000, NUCLEIC ACIDS RES, V28, P4930, DOI 10.1093/nar/28.24.4930; Guieysse AL, 1996, NUCLEIC ACIDS RES, V24, P4210, DOI 10.1093/nar/24.21.4210; Herbert JM, 1996, J BIOL CHEM, V271, P25928; Jakupciak JP, 2000, J BIOL CHEM, V275, P40003, DOI 10.1074/jbc.M007153200; Jakupciak JP, 1999, J BIOL CHEM, V274, P23468, DOI 10.1074/jbc.274.33.23468; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; JAWORSKI A, 1989, J MOL BIOL, V207, P513, DOI 10.1016/0022-2836(89)90461-0; KARLOVSKY P, 1990, FEBS LETT, V274, P39, DOI 10.1016/0014-5793(90)81324-H; Kochetkov N. K., 1972, ORGANIC CHEM NUCL AC; KOHWI Y, 1993, GENE DEV, V7, P1766, DOI 10.1101/gad.7.9.1766; KOHWI Y, 1992, J MOL BIOL, V223, P817, DOI 10.1016/0022-2836(92)90242-C; LAWLEY PD, 1967, J MOL BIOL, V25, P143, DOI 10.1016/0022-2836(67)90285-9; Lewis RJ, 1996, EMBO J, V15, P1412, DOI 10.1002/j.1460-2075.1996.tb00483.x; Lilley DMJ, 2000, Q REV BIOPHYS, V33, P109, DOI 10.1017/S0033583500003590; MANDAL TN, 1993, J BACTERIOL, V175, P4325, DOI 10.1128/JB.175.14.4325-4334.1993; Michel B, 2000, MOL MICROBIOL, V37, P180, DOI 10.1046/j.1365-2958.2000.01989.x; Montermini L, 1997, HUM MOL GENET, V6, P1261, DOI 10.1093/hmg/6.8.1261; Moolenaar GF, 1998, J BIOL CHEM, V273, P34896, DOI 10.1074/jbc.273.52.34896; Moolenaar GF, 2000, J BIOL CHEM, V275, P8044, DOI 10.1074/jbc.275.11.8044; Moolenaar GF, 1998, NUCLEIC ACIDS RES, V26, P462, DOI 10.1093/nar/26.2.462; Moolenaar GF, 2002, P NATL ACAD SCI USA, V99, P1467, DOI 10.1073/pnas.032584099; Moolenaar GF, 2000, J BACTERIOL, V182, P5706, DOI 10.1128/JB.182.20.5706-5714.2000; Napierala M, 2002, J BIOL CHEM, V277, P34087, DOI 10.1074/jbc.M202128200; Napierala M, 2004, J BIOL CHEM, V279, P6444, DOI 10.1074/jbc.M309596200; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Ohshima K, 1999, NEUROLOGY, V53, P1854, DOI 10.1212/WNL.53.8.1854; Pandolfo M, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P373; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Sakamoto N, 2001, J BIOL CHEM, V276, P27178, DOI 10.1074/jbc.M101852200; Sakamoto N, 2001, J BIOL CHEM, V276, P27171, DOI 10.1074/jbc.M101879200; Sambrook J, 2001, MOL CLONING LAB MANU; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; Soyfer V. N., 1995, TRIPLE HELICAL NUCL; STOLLAR BD, 1992, PROG NUCLEIC ACID RE, V42, P39, DOI 10.1016/S0079-6603(08)60573-5; SUMMERS DK, 1993, MOL MICROBIOL, V8, P1031, DOI 10.1111/j.1365-2958.1993.tb01648.x; Tsai FTF, 1997, PROTEINS, V28, P41; USSERY DW, 1993, BIOCHEMISTRY-US, V32, P6206, DOI 10.1021/bi00075a013; Vasquez KM, 2000, SCIENCE, V290, P530, DOI 10.1126/science.290.5491.530; Vasquez KM, 2002, P NATL ACAD SCI USA, V99, P5848, DOI 10.1073/pnas.082193799; Vasquez KM, 1998, TRENDS BIOCHEM SCI, V23, P4, DOI 10.1016/S0968-0004(97)01158-4; Vetcher AA, 2002, J BIOL CHEM, V277, P39217, DOI 10.1074/jbc.M205209200; Vetcher AA, 2002, J BIOL CHEM, V277, P39228, DOI 10.1074/jbc.M205210200; WANG G, 1995, MOL CELL BIOL, V15, P1759; Wang G, 1996, SCIENCE, V271, P802, DOI 10.1126/science.271.5250.802; Wells R.D., 1998, GENETIC INSTABILITIE; WELLS RD, 1988, J BIOL CHEM, V263, P1095; Wells RD, 1998, J BIOL CHEM, V273, P19532, DOI 10.1074/jbc.273.31.19532; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YUAN JL, 1995, CARCINOGENESIS, V16, P2295, DOI 10.1093/carcin/16.10.2295	68	15	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6434	6443		10.1074/jbc.M309595200	http://dx.doi.org/10.1074/jbc.M309595200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14625291	hybrid			2022-12-25	WOS:000188969200029
J	Yoo, D; Flagg, TP; Olsen, O; Raghuram, V; Foskett, JK; Welling, PA				Yoo, D; Flagg, TP; Olsen, O; Raghuram, V; Foskett, JK; Welling, PA			Assembly and trafficking of a multiprotein ROMK (Kir 1.1) channel complex by PDZ interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CAMP-MEDIATED INHIBITION; PROTEIN-KINASE-A; BASOLATERAL MEMBRANE EXPRESSION; RECTIFYING POTASSIUM CHANNEL; DOMAIN INTERACTION CONTROLS; CORTICAL COLLECTING DUCT; CARBOXYL-TERMINAL REGION; BORDER NA+/H+ EXCHANGER; THICK ASCENDING LIMB	The ROMK subtypes of inward rectifier K+ channels (Kir 1.1, KCNJ1) mediate potassium secretion and regulate NaCl reabsorption in the kidney. In the present study, the role of the PDZ binding motif in ROMK function is explored. Here we identify the Na/H exchange regulatory factors, NHERF-1 and NHERF-2, as PDZ domain interaction partners of the ROMK channel. Characterization of the basis and consequences of NHERF association with ROMK reveals a PDZ interaction-dependent trafficking process and a coupling mechanism for linking ROMK to a channel modifier protein, the cystic fibrosis transmembrane regulator (CFTR). As measured by antibody binding of external epitope-tagged forms of Kir 1.1 in intact cells, NHERF-1 or NHERF-2 coexpression increased cell surface expression of ROMK. Channel interaction with NHERF proteins and effects of NHERF on ROMK localization were dependent on the presence of the PDZ domain binding motif in ROMK. Both NHERF proteins contain two PDZ domains; recombinant protein-protein binding assays and yeast-two-hybrid studies revealed that ROMK preferentially associates with the second PDZ domain of NHERF-1 and with the first PDZ domain of NHERF-2, precisely opposite of what has been reported for CFTR. Consistent with the scaffolding capacity of the NHERF proteins, coexpression of NHERF-2 with ROMK and CFTR dramatically increases the amount of ROMK protein that coimmunopurifies and functionally interacts with CFTR. Thus NHERF facilitates assembly of a ternary complex containing ROMK and CFTR. These observations raise the possibility that PDZ-based interactions may underscore physiological regulation and membrane targeting of ROMK in the kidney.	Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Maryland, Ctr Biotechnol, Baltimore, MD 21201 USA; Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Pennsylvania	Welling, PA (corresponding author), Univ Maryland, Sch Med, Dept Physiol, 655 W Baltimore St, Baltimore, MD 21201 USA.	pwelling@umaryland.edu	Foskett, Kevin/R-2549-2019	Foskett, J. Kevin/0000-0002-8854-0268	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL001286] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063049] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008181] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-63049, DK-54321] Funding Source: Medline; NIGMS NIH HHS [T32GM08181] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; Cahill P, 2000, J BIOL CHEM, V275, P16697, DOI 10.1074/jbc.M910205199; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Ecelbarger CA, 2001, J AM SOC NEPHROL, V12, P10, DOI 10.1681/ASN.V12110; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Flagg TP, 1999, J GEN PHYSIOL, V114, P685, DOI 10.1085/jgp.114.5.685; Flagg TP, 2002, J PHYSIOL-LONDON, V544, P351, DOI 10.1113/jphysiol.2002.027581; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; Giebisch G, 1998, AM J PHYSIOL-RENAL, V274, pF817, DOI 10.1152/ajprenal.1998.274.5.F817; Golemis E A, 1997, Methods Mol Biol, V63, P197; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; HEBERT SC, 1995, KIDNEY INT, V48, P1010, DOI 10.1038/ki.1995.383; Hernando N, 2002, P NATL ACAD SCI USA, V99, P11957, DOI 10.1073/pnas.182412699; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Karolyi L, 1997, HUM MOL GENET, V6, P17; Karthikeyan S, 2002, J BIOL CHEM, V277, P18973, DOI 10.1074/jbc.M201507200; Karthikeyan S, 2001, J BIOL CHEM, V276, P19683, DOI 10.1074/jbc.C100154200; Kohda Y, 1998, KIDNEY INT, V54, P1214, DOI 10.1046/j.1523-1755.1998.00120.x; Konstas AA, 2002, J BIOL CHEM, V277, P25377, DOI 10.1074/jbc.M201925200; Konstas AA, 2002, J BIOL CHEM, V277, P21346, DOI 10.1074/jbc.M202005200; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Ladias JAA, 2003, J MEMBRANE BIOL, V192, P79, DOI 10.1007/s00232-002-1065-x; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; Lamprecht G, 2002, BIOCHEMISTRY-US, V41, P12336, DOI 10.1021/bi0259103; Lau AG, 2001, BIOCHEMISTRY-US, V40, P8572, DOI 10.1021/bi0103516; Le Maout S, 2001, P NATL ACAD SCI USA, V98, P10475, DOI 10.1073/pnas.181481098; Liedtke CM, 2002, J BIOL CHEM, V277, P22925, DOI 10.1074/jbc.M201917200; Lin DH, 2002, AM J PHYSIOL-RENAL, V283, pF671, DOI 10.1152/ajprenal.00160.2002; Lin DH, 2002, J BIOL CHEM, V277, P44278, DOI 10.1074/jbc.M203702200; Lu M, 2002, J BIOL CHEM, V277, P37881, DOI 10.1074/jbc.M206644200; LU M, 2000, J AM SOC NEPHROL, V11, P33; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; McNicholas CM, 1997, AM J PHYSIOL-RENAL, V273, pF843, DOI 10.1152/ajprenal.1997.273.5.F843; Mendelsohn Andrew R., 1994, Current Opinion in Biotechnology, V5, P482, DOI 10.1016/0958-1669(94)90061-2; Mennitt PA, 1997, J AM SOC NEPHROL, V8, P1823; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Moral Z, 2001, J BIOL CHEM, V276, P7156, DOI 10.1074/jbc.M008671200; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Naren AP, 2003, P NATL ACAD SCI USA, V100, P342, DOI 10.1073/pnas.0135434100; Ogura T, 2002, FASEB J, V16, P863, DOI 10.1096/fj.01-0845fje; Olsen O, 2002, AM J PHYSIOL-CELL PH, V282, pC183, DOI 10.1152/ajpcell.00249.2001; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Raghuram V, 2003, P NATL ACAD SCI USA, V100, P9620, DOI 10.1073/pnas.1633250100; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; Reynolds A., 1997, CURRENT PROTOCOLS MO; Ruknudin A, 1998, J BIOL CHEM, V273, P14165, DOI 10.1074/jbc.273.23.14165; Schwappach B, 2000, NEURON, V26, P155, DOI 10.1016/S0896-6273(00)81146-0; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Shenolikar S, 2001, AM J PHYSIOL-RENAL, V280, pF389, DOI 10.1152/ajprenal.2001.280.3.F389; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Shuck ME, 1997, J BIOL CHEM, V272, P586; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Wade JB, 2001, AM J PHYSIOL-CELL PH, V280, pC192, DOI 10.1152/ajpcell.2001.280.1.C192; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; WANG T, 1995, RENAL PHYSIOL BIOCH, V18, P169; WANG WH, 1991, J GEN PHYSIOL, V98, P35, DOI 10.1085/jgp.98.1.35; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; Weinman EJ, 2001, J CLIN INVEST, V108, P185, DOI 10.1172/JCI13518; Welling PA, 1997, AM J PHYSIOL-RENAL, V273, pF825, DOI 10.1152/ajprenal.1997.273.5.F825; Wyszynski M, 1999, Methods Enzymol, V294, P371; Xu JZ, 1997, AM J PHYSIOL-RENAL, V273, pF739, DOI 10.1152/ajprenal.1997.273.5.F739; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7; Yoo D, 2003, J BIOL CHEM, V278, P23066, DOI 10.1074/jbc.M212301200; Yun CC, 2002, J BIOL CHEM, V277, P7676, DOI 10.1074/jbc.M107768200; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; ZHOU H, 1994, AM J PHYSIOL, V266, pC809, DOI 10.1152/ajpcell.1994.266.3.C809	89	58	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6863	6873		10.1074/jbc.M311599200	http://dx.doi.org/10.1074/jbc.M311599200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14604981	hybrid			2022-12-25	WOS:000188969200081
J	Bonnevier, J; Fassler, R; Somlyo, AP; Somlyo, AV; Arner, A				Bonnevier, J; Fassler, R; Somlyo, AP; Somlyo, AV; Arner, A			Modulation of Ca2+ sensitivity by cyclic mucleotides in smooth muscle from protein kinase G-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHATASE; NITRIC-OXIDE; CYTOSOLIC CALCIUM; CORONARY-ARTERIES; CROSS-ACTIVATION; CGMP; CAMP; GMP; CELLS; INHIBITION	The cGMP-dependent protein kinase (PKG) is the main mediator of nitric oxide-induced relaxation of smooth muscle. Although this pathway is well established, the cellular action of PKG, nitric oxide, and cGMP is complex and not fully understood. A cross-talk between the cGMP-PKG and other pathways (e.g. cAMP-protein kinase A) seems to exist. We have explored cGMP- and cAMP-dependent relaxation of smooth muscle using PKG-deficient mice (cGKI-/-). In intact ileum strips of wild type mice (cGKI+/+), 8-Br-cGMP inhibited the sustained phase of carbachol contractions by similar to80%. The initial peak was less inhibited (similar to30%). This relaxation was associated with a reduction in intracellular [Ca2+] and decreased Ca2+ sensitivity. Contractions of cGKI-/- ileum were not influenced by 8-Br-cGMP. EC50 for 8-Br-cGMP for PKG was estimated to be 10 nM. PKG-independent relaxation by 8-Br-cGMP had an EC50 of 10 muM. Relaxation by cAMP (similar to50% at 100 muM), Ca2+ sensitivity of force, and force potentiation by GTPgammaS were similar in cGKI+/+ and cGKI-/- tissues. The results show that PKG is the main target for cGMP- induced relaxation in intestinal smooth muscle. cGMP desensitize the contractile system to Ca2+ via PKG. PKG-independent pathways are activated at 1000-fold higher cGMP concentrations. Relaxation by cAMP can occur independently of PKG. Long term deficiency of PKG does not lead to an apparent up-regulation of the cAMP-dependent pathways or changes in Ca2+ sensitivity.	Dept Physiol Sci, D-82152 Munich, Germany; Max Planck Inst Biochem, Dept Mol Med, D-82152 Munich, Germany; Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA	Max Planck Society; University of Virginia	Arner, A (corresponding author), Lund Univ, Dept Physiol Sci, BMC F11, SE-22184 Lund, Sweden.	Anders.Arner@mphy.lu.se			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242, P01HL048807] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL19242, P01 HL48807] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCHER SL, 1994, P NATL ACAD SCI USA, V91, P7583, DOI 10.1073/pnas.91.16.7583; Arner A, 2002, BIOPHYS J, V82, p424A; Cohen RA, 1999, CIRC RES, V84, P210, DOI 10.1161/01.RES.84.2.210; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; Etter EF, 2001, J BIOL CHEM, V276, P34681, DOI 10.1074/jbc.M104737200; FELBEL J, 1988, J BIOL CHEM, V263, P16764; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hedlund P, 2000, P NATL ACAD SCI USA, V97, P2349, DOI 10.1073/pnas.030419997; HIMPENS B, 1988, J PHYSIOL-LONDON, V395, P507, DOI 10.1113/jphysiol.1988.sp016932; Hofmann F, 2000, J CELL SCI, V113, P1671; JIANG H, 1992, J BIOL CHEM, V267, P1015; Kawada T, 1997, EUR J PHARMACOL, V323, P75, DOI 10.1016/S0014-2999(97)00028-9; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; LINCOLN TM, 1990, AM J PHYSIOL, V258, pC399, DOI 10.1152/ajpcell.1990.258.3.C399; Otto B, 1996, J PHYSIOL-LONDON, V496, P317, DOI 10.1113/jphysiol.1996.sp021687; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; PFITZER G, 1986, PFLUG ARCH EUR J PHY, V407, P87, DOI 10.1007/BF00580726; PFITZER G, 1984, PFLUG ARCH EUR J PHY, V401, P277, DOI 10.1007/BF00582596; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; Ruiz-Velasco V, 1998, CIRC RES, V82, P557, DOI 10.1161/01.RES.82.5.557; Rybalkin SD, 2002, J BIOL CHEM, V277, P3310, DOI 10.1074/jbc.M106562200; SATO K, 1988, J PHARMACOL EXP THER, V246, P294; Sausbier M, 2000, CIRC RES, V87, P825, DOI 10.1161/01.RES.87.9.825; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Schubert R, 2001, TRENDS PHARMACOL SCI, V22, P505, DOI 10.1016/S0165-6147(00)01775-2; Wu XQ, 1996, BIOCHEM BIOPH RES CO, V220, P658, DOI 10.1006/bbrc.1996.0460; Wu XQ, 1998, J BIOL CHEM, V273, P11362, DOI 10.1074/jbc.273.18.11362; YANAGISAWA T, 1989, BRIT J PHARMACOL, V98, P469, DOI 10.1111/j.1476-5381.1989.tb12620.x; Yu JZ, 2000, AM J PHYSIOL-HEART C, V279, pH873, DOI 10.1152/ajpheart.2000.279.3.H873	32	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5146	5151		10.1074/jbc.M306532200	http://dx.doi.org/10.1074/jbc.M306532200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14610087	hybrid			2022-12-25	WOS:000188776500014
J	Cai, XJ; Lytton, J				Cai, XJ; Lytton, J			Molecular cloning of a sixth member of the K+-dependent Na+/Ca2+ exchanger gene family, NCKX6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGER; ALTERNATIVELY SPLICED ISOFORMS; FUNCTIONAL EXPRESSION; NA+-CA2+ EXCHANGER; BRAIN; PROTEIN; STOICHIOMETRY; TOPOLOGY; RESIDUES; SEGMENTS	Bioinformatic and molecular cloning tools were used to identify and isolate cDNA clones from mouse and human tissues that encode the sixth member of the K+-dependent Na+/Ca2+ exchanger family, NCKX6. The mouse NCKX6 protein is 585 amino acids long and shares about 62% sequence similarity with previously identified exchangers in the alpha-repeat regions but has little primary sequence similarity outside these regions. NCKX6 transcripts of 4 kb are abundantly expressed in all tissues examined and are thus more broadly distributed than previously described NC(K)X family members. Two alternatively spliced products of this novel gene were identified that encode proteins of different length. The short isoform differs from the full-length isoform at the C-terminal hydrophobic domain as a result of a shift in the reading frame caused by the deletion of two exons. Both NCKX6 isoforms were expressed in HEK-293 cells. Functional analysis by digital imaging of fura-2 loaded transfected HEK-293 cells demonstrated that the short isoform exhibited K+-dependent Na+/Ca2+ exchange activity whereas the full-length isoform did not. The latter was retained within the endoplasmic reticulum, whereas the short isoform was present at the plasma membrane in transfected cells. Immunofluorescence studies examining NCKX6 expression in native tissue using an NCKX6-specific antibody showed intense labeling of the cardiac sarcolemmal membrane. The discovery of NCKX6 therefore reveals a novel member of the Na+/Ca2+ exchanger superfamily whose ubiquitous expression in all tissues suggests an important role for K+-dependent Na+/Ca2+ exchange in maintaining cellular Ca2+ homeostasis in diverse tissues and cell types.	Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Cardiovasc Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary	Lytton, J (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Cardiovasc Res Grp, Rm 2518,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	jlytton@ucalgary.ca	Cai, Xinjiang/A-9617-2008; Cai, Xinjiang/F-4843-2010	Cai, Xinjiang/0000-0001-8933-7133; Lytton, Jonathan/0000-0003-4770-2512				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ausubel FM, 2003, CURRENT PROTOCOLS MO; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Cai Xinjiang, 2002, Ann N Y Acad Sci, V976, P90; Cai XJ, 2002, J BIOL CHEM, V277, P48923, DOI 10.1074/jbc.M208818200; CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Cooper CB, 1999, BIOCHEMISTRY-US, V38, P6276, DOI 10.1021/bi983068o; DAHAN D, 1991, J BIOL CHEM, V266, P2067; Dong H, 2002, BIOPHYS J, V82, P1943, DOI 10.1016/S0006-3495(02)75543-4; Dong H, 2001, J BIOL CHEM, V276, P25919, DOI 10.1074/jbc.M103401200; Dyck C, 1999, J GEN PHYSIOL, V114, P701, DOI 10.1085/jgp.114.5.701; Fujioka Y, 2000, J PHYSIOL-LONDON, V529, P611, DOI 10.1111/j.1469-7793.2000.00611.x; GABELLINI N, 1995, J BIOL CHEM, V270, P6917, DOI 10.1074/jbc.270.12.6917; Gabellini N, 1996, EUR J BIOCHEM, V239, P897, DOI 10.1111/j.1432-1033.1996.0897u.x; Gamba G, 2001, AM J PHYSIOL-RENAL, V281, pF781, DOI 10.1152/ajprenal.2001.281.5.F781; ISACOFF E, 1990, COLD SPRING HARB SYM, V55, P9; Jakymiw A, 2000, J BIOL CHEM, V275, P4137, DOI 10.1074/jbc.275.6.4137; KIMURA M, 1993, J BIOL CHEM, V268, P6874; Kinjo TG, 2003, BIOCHEMISTRY-US, V42, P2485, DOI 10.1021/bi0270788; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kraev A, 2001, J BIOL CHEM, V276, P23161, DOI 10.1074/jbc.M102314200; Lee SH, 2002, J NEUROSCI, V22, P6891; LEE SL, 1994, J BIOL CHEM, V269, P14849; Li XF, 1999, J BIOL CHEM, V274, P8153, DOI 10.1074/jbc.274.12.8153; Li XF, 2002, J BIOL CHEM, V277, P48410, DOI 10.1074/jbc.M210011200; LI ZP, 1994, J BIOL CHEM, V269, P17434; LOO TW, 1995, J BIOL CHEM, V270, P19345, DOI 10.1074/jbc.270.33.19345; LYTTON J, 1992, J BIOL CHEM, V267, P14483; Lytton J, 2002, ANN NY ACAD SCI, V976, P382; Lytton J, 2002, J PHYSIOL-LONDON, V545, P335, DOI 10.1113/jphysiol.2002.029058; LYTTON J, 2002, ANN NY ACAD SCI, V976, pR1; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Omelchenko A, 1998, J GEN PHYSIOL, V111, P691, DOI 10.1085/jgp.111.5.691; Perelygin AA, 2002, P NATL ACAD SCI USA, V99, P9322, DOI 10.1073/pnas.142287799; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; Philipson KD, 2002, CIRC RES, V90, P118, DOI 10.1161/res.90.2.118; Poon S, 2000, AM J PHYSIOL-CELL PH, V278, pC651, DOI 10.1152/ajpcell.2000.278.4.C651; Prinsen CFM, 2000, J NEUROSCI, V20, P1424; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; REILANDER H, 1992, EMBO J, V11, P1689, DOI 10.1002/j.1460-2075.1992.tb05219.x; Sambrook J, 2001, MOL CLONING LAB MANU; SCHNETKAMP PP, 2004, IN PRESS PFLUEGERS A; SCHNETKAMP PPM, 1995, J BIOL CHEM, V270, P13231, DOI 10.1074/jbc.270.22.13231; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; Schwarzer A, 1997, BIOCHEMISTRY-US, V36, P13667, DOI 10.1021/bi9710232; SLAUGHTER RS, 1983, J BIOL CHEM, V258, P3183; Tsoi M, 1998, J BIOL CHEM, V273, P4155, DOI 10.1074/jbc.273.7.4155; Van Eylen F, 2001, CELL CALCIUM, V30, P191, DOI 10.1054/ceca.2001.0223; Wang L, 1996, CIRC RES, V79, P79, DOI 10.1161/01.RES.79.1.79; Winkfein RJ, 2003, BIOCHEMISTRY-US, V42, P543, DOI 10.1021/bi026982x; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333; Zarei MM, 2001, J BIOL CHEM, V276, P16232, DOI 10.1074/jbc.M008852200	58	82	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5867	5876		10.1074/jbc.M310908200	http://dx.doi.org/10.1074/jbc.M310908200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14625281	hybrid			2022-12-25	WOS:000188776500102
J	Kim, LA; Furst, J; Butler, MH; Xu, SH; Grigorieff, N; Goldstein, SAN				Kim, LA; Furst, J; Butler, MH; Xu, SH; Grigorieff, N; Goldstein, SAN			I-to channels are octomeric complexes with four subunits of each Kv4.2 and K+ channel-interacting protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIENT OUTWARD CURRENT; GATED POTASSIUM CHANNEL; BETA-SUBUNIT; CHARYBDOTOXIN BINDING; HIGH-CONDUCTANCE; ALPHA-SUBUNITS; STOICHIOMETRY; EXPRESSION; MODULATION; RECEPTOR	Mammalian voltage- gated K (+) channels are assemblies of pore- forming alpha- subunits and modulating beta- subunits. To operate correctly, Kv4 alpha- subunits in the heart and central nervous system require recently identified beta- subunits of the neuronal calcium sensing protein family called K (+) channel- interacting proteins ( KChIPs). Here, Kv4.2 . KChIP2 channels are purified, integrity of isolated complexes confirmed, molar ratio of the subunits determined, and subunit valence established. A complex has 4 subunits of each type, a stoichiometry expected for other channels employing neuronal calcium sensing beta- subunits.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pediat, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Cellular & Mol Physiol, New Haven, CT 06536 USA; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Dept Biochem, Waltham, MA 02454 USA; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Howard Hughes Med Inst, Waltham, MA 02454 USA	Yale University; Yale University; Brandeis University; Brandeis University; Howard Hughes Medical Institute	Goldstein, SAN (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pediat, 333 Cedar St, New Haven, CT 06536 USA.	steve.goldstein@yale.edu	Kim, Leo/Y-3323-2018; Goldstein, Steven A./E-9817-2015	Kim, Leo/0000-0001-9106-6416; Goldstein, Steven A./0000-0001-5207-5061; Grigorieff, Nikolaus/0000-0002-1506-909X	NIGMS NIH HHS [GM07205] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott GW, 1998, Q REV BIOPHYS, V31, P357, DOI 10.1017/S0033583599003467; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; Brahmajothi MV, 1999, J GEN PHYSIOL, V113, P581, DOI 10.1085/jgp.113.4.581; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Chen HJ, 2003, NEURON, V40, P15, DOI 10.1016/S0896-6273(03)00570-1; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Deschenes I, 2002, FEBS LETT, V528, P183, DOI 10.1016/S0014-5793(02)03296-9; Ding JP, 1998, BIOPHYS J, V74, P268, DOI 10.1016/S0006-3495(98)77785-9; Dixon JE, 1996, CIRC RES, V79, P659, DOI 10.1161/01.RES.79.4.659; Fiset C, 1997, J PHYSIOL-LONDON, V500, P51, DOI 10.1113/jphysiol.1997.sp021998; GOLDSTEIN SAN, 1992, BIOPHYS J, V62, P5, DOI 10.1016/S0006-3495(92)81760-5; GOLDSTEIN SAN, 1993, BIOPHYS J, V65, P1613, DOI 10.1016/S0006-3495(93)81200-1; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; GROSS A, 1994, NEURON, V13, P961, DOI 10.1016/0896-6273(94)90261-5; Gulbis JM, 2000, SCIENCE, V289, P123, DOI 10.1126/science.289.5476.123; Guo WN, 2002, J BIOL CHEM, V277, P26436, DOI 10.1074/jbc.M201431200; Hoffman DA, 1997, NATURE, V387, P869, DOI 10.1038/43119; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Kaab S, 1998, CIRCULATION, V98, P1383, DOI 10.1161/01.CIR.98.14.1383; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; Kobertz WR, 2000, BIOCHEMISTRY-US, V39, P10347, DOI 10.1021/bi001292j; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; Kuo HC, 2001, CELL, V107, P801, DOI 10.1016/S0092-8674(01)00588-8; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MALETICSAVATIC M, 1995, J NEUROSCI, V15, P3840; Malin SA, 2001, J NEUROSCI, V21, P8004, DOI 10.1523/JNEUROSCI.21-20-08004.2001; Morohashi Y, 2002, J BIOL CHEM, V277, P14965, DOI 10.1074/jbc.M200897200; Nadal MS, 2003, NEURON, V37, P449, DOI 10.1016/S0896-6273(02)01185-6; Nakamura TY, 2001, P NATL ACAD SCI USA, V98, P12808, DOI 10.1073/pnas.221168498; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Rhodes KJ, 1997, J NEUROSCI, V17, P8246; Rosati B, 2001, J PHYSIOL-LONDON, V533, P119, DOI 10.1111/j.1469-7793.2001.0119b.x; Schrader LA, 2002, J NEUROSCI, V22, P10123; Shibata R, 2003, J BIOL CHEM, V278, P36445, DOI 10.1074/jbc.M306142200; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Sokolova O, 2001, STRUCTURE, V9, P215, DOI 10.1016/S0969-2126(01)00578-0; SUN TY, 1994, BIOCHEMISTRY-US, V33, P9992, DOI 10.1021/bi00199a024; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500	43	50	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5549	5554		10.1074/jbc.M311332200	http://dx.doi.org/10.1074/jbc.M311332200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14623880	Green Published, hybrid			2022-12-25	WOS:000188776500063
J	Kunneken, K; Pohlentz, G; Schmidt-Hederich, A; Odenthal, U; Smyth, N; Peter-Katalinic, J; Bruckner, P; Eble, JA				Kunneken, K; Pohlentz, G; Schmidt-Hederich, A; Odenthal, U; Smyth, N; Peter-Katalinic, J; Bruckner, P; Eble, JA			Recombinant human laminin-5 domains - Effects of heterotrimerization, proteolytic processing, and N-glycosylation on alpha(3)beta(1) integrin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES CELL-ADHESION; STRUCTURAL REQUIREMENT; ALPHA-DYSTROGLYCAN; CHAIN; IDENTIFICATION; RECEPTORS; HEPARIN; ALPHA-3-BETA-1; ALPHA-6-BETA-4; KERATINOCYTES	Human laminin-5 fragments, comprising the heterotrimeric C-terminal part of the coiled-coil (CC) domain and the globular (G) domain with defined numbers of LG subdomains, were produced recombinantly. The alpha3' chain with all five LG subdomains was processed proteolytically in a manner similar to the wild-type alpha3 chain. Conditions were established under which the proteolytic cleavage was either inhibited in cell culture or was brought to completion in vitro. The shorter chains of the laminin-5CCG molecule, beta3' and gamma2', produced in a bacterial expression system associated into heterodimers, which then combined spontaneously with the alpha3' chains in vitro to form heterotrimeric laminin-5CCG molecules. Only heterotrimeric laminin-5CCG with at least subdomains LG1-3, but not the single chains, supported binding of soluble alpha(3)beta(1) integrin, proving the coiled-coil domain of laminin- 5 to be essential for its interaction with alpha(3)beta(1) integrin. The N-glycosylation sites in wild-type alpha3 chain were mapped by mass spectrometry. Their location in a structural model of the LG domain suggested that large regions on both faces of the LG1 and LG2 domains are inaccessible by other proteins. However, neither heterotrimerization nor alpha(3)beta(1) integrin binding was affected by the loss of N-linked glycoconjugates. After the proteolytic cleavage between the subdomains LG3 and LG4, the LG4-5 tandem domain dissociated from the rest of the G domain. Further, the laminin-5CCG molecule with the alpha3'LG1-3 chain showed an increased binding affinity for alpha(3)beta(1) integrin, indicating that proteolytic processing of laminin- 5 influences its interaction with alpha(3)beta(1) integrin.	Muenster Univ Hosp, Inst Physiol Chem, D-48149 Munster, Germany; Muenster Univ Hosp, Inst Med Biophys, D-48149 Munster, Germany; Univ Cologne, Inst Biochem, D-50931 Cologne, Germany	University of Munster; University of Munster; University of Cologne	Eble, JA (corresponding author), Muenster Univ Hosp, Inst Physiol Chem, D-48149 Munster, Germany.	eble@uni-muenster.de	Bruckner, Peter/F-4817-2019	Bruckner, Peter/0000-0002-5566-5611; Smyth, Neil/0000-0002-3734-2149				Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; AUMAILLEY M, 1996, LAMININS, V2, P127; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; Belkin AM, 2000, MICROSC RES TECHNIQ, V51, P280, DOI 10.1002/1097-0029(20001101)51:3<280::AID-JEMT7>3.0.CO;2-O; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; Burgeson RE, 1997, CURR OPIN CELL BIOL, V9, P651, DOI 10.1016/S0955-0674(97)80118-4; Champliaud MF, 1996, J CELL BIOL, V132, P1189, DOI 10.1083/jcb.132.6.1189; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Decline F, 2001, J CELL SCI, V114, P811; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; DiPersio CM, 2000, J CELL SCI, V113, P3051; Eble JA, 1998, BIOCHEMISTRY-US, V37, P10945, DOI 10.1021/bi980175+; GERECKE DR, 1994, J BIOL CHEM, V269, P11073; Ghosh S, 2000, MICROSC RES TECHNIQ, V51, P238, DOI 10.1002/1097-0029(20001101)51:3<238::AID-JEMT4>3.0.CO;2-3; Goldfinger LE, 1999, J CELL SCI, V112, P2615; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Hirosaki T, 2000, J BIOL CHEM, V275, P22495, DOI 10.1074/jbc.M001326200; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; HUNTER I, 1992, J BIOL CHEM, V267, P6006; KAMMERER RA, 1995, J MOL BIOL, V250, P64, DOI 10.1006/jmbi.1995.0358; Kariya Y, 2002, J BIOCHEM, V132, P607, DOI 10.1093/oxfordjournals.jbchem.a003263; Kariya Y, 2003, J CELL BIOCHEM, V88, P506, DOI 10.1002/jcb.10350; Kuster B, 1997, ANAL BIOCHEM, V250, P82, DOI 10.1006/abio.1997.2199; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Lohi J, 2001, INT J CANCER, V94, P763, DOI 10.1002/ijc.1539; MATSUI C, 1995, J BIOL CHEM, V270, P23496, DOI 10.1074/jbc.270.40.23496; Mizushima H, 1997, CELL GROWTH DIFFER, V8, P979; Nguyen BP, 2000, CURR OPIN CELL BIOL, V12, P554, DOI 10.1016/S0955-0674(00)00131-9; Nguyen BP, 2001, J BIOL CHEM, V276, P43860, DOI 10.1074/jbc.M103404200; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; ROUSSELLE P, 1995, J BIOL CHEM, V270, P13766, DOI 10.1074/jbc.270.23.13766; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Shang ML, 2001, J BIOL CHEM, V276, P33045, DOI 10.1074/jbc.M100798200; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; Tsubota Y, 2000, BIOCHEM BIOPH RES CO, V278, P614, DOI 10.1006/bbrc.2000.3851; Tsunenaga M, 1998, MATRIX BIOL, V17, P603, DOI 10.1016/S0945-053X(98)90111-1; Tunggal P, 2000, MICROSC RES TECHNIQ, V51, P214, DOI 10.1002/1097-0029(20001101)51:3<214::AID-JEMT2>3.0.CO;2-J; Utani A, 2001, J BIOL CHEM, V276, P28779, DOI 10.1074/jbc.M101420200; VAILLY J, 1994, EUR J BIOCHEM, V219, P209, DOI 10.1111/j.1432-1033.1994.tb19932.x; Veitch DP, 2003, J BIOL CHEM, V278, P15661, DOI 10.1074/jbc.M210588200; VIDAL F, 1995, GENOMICS, V30, P273, DOI 10.1006/geno.1995.9877; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356	46	39	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5184	5193		10.1074/jbc.M310424200	http://dx.doi.org/10.1074/jbc.M310424200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14612440	hybrid			2022-12-25	WOS:000188776500019
J	Kennett, SB; Roberts, JD; Olden, K				Kennett, SB; Roberts, JD; Olden, K			Requirement of protein kinase C mu activation and calpain-mediated proteolysis for arachidonic acid-stimulated adhesion of MDA-MB-435 human mammary carcinoma cells to collagen type IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT NEUTRAL PROTEASE; BREAST-CANCER; PKC-MU; PHOSPHORYLATION SITES; HUMAN-NEUTROPHILS; DOWN-REGULATION; PHORBOL ESTERS; LOOP SER(744); LINOLEIC-ACID; DNA-SYNTHESIS	Arachidonic acid (AA) stimulation of adhesion of human metastatic breast carcinoma cells to collagen type IV depends on the protein kinase C (PKC) pathway(s) and is associated with the translocation of PKCmu from the cytoplasm to the membrane. In the present study, we have further explored the role of PKCmu in AA-stimulated adhesion. PKCmu activation site serines 738/742 and autophosphorylation site serine 910 are rapidly phosphorylated, and in vitro PKCmu kinase activity is enhanced in response to AA treatment. Inhibition of PKCmu activation blocks AA-stimulated adhesion. A phosphorylated, truncated species of PKCmu was detected in AA-treated cells. This 77-kDa protein contains the kinase domain but lacks a significant portion of the regulatory domains. Inhibition of calpain protease activity blocks generation of the truncated protein, promotes accumulation of the activated, full-length protein in the membrane, and blocks the AA-mediated increase in adhesion. p38 MAPK activity is also required for AA-stimulated adhesion. Activation of PKCmu and p38 are independent events. However, inhibition of p38 activity reduces calpain-mediated proteolysis of PKCmu and in vivo calpain activity, suggesting a role for p38 in regulation of calpain activity and a point for cross-talk between the PKC and MAPK pathways. These results support the hypothesis that AA stimulates activation of PKCmu, which is cleaved by calpain at the cell membrane. The resulting truncated kinase, as well as the full-length kinase, may be required for increased cell adhesion to collagen type IV. Additionally, these studies present the first evidence for calpain cleavage of a non-structural protein leading to the promotion of tumor cell adhesion.	NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Roberts, JD (corresponding author), POB 12233,Mail Drop C2-14, Res Triangle Pk, NC 27709 USA.	roberts1@niehs.nih.gov			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES023018] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Brandlin I, 2002, J BIOL CHEM, V277, P45451, DOI 10.1074/jbc.M205299200; Brandlin I, 2002, J BIOL CHEM, V277, P6490, DOI 10.1074/jbc.M106083200; Braun C, 1999, INT J CANCER, V84, P6, DOI 10.1002/(SICI)1097-0215(19990219)84:1<6::AID-IJC2>3.3.CO;2-K; Byzova TV, 1998, J CELL BIOL, V143, P2081, DOI 10.1083/jcb.143.7.2081; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; Cave WT, 1996, NUTRITION, V12, pS39; Disatnik MH, 2002, J CELL SCI, V115, P2151; Ekinci FJ, 1999, BRAIN RES, V850, P207, DOI 10.1016/S0006-8993(99)02146-0; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Forsythe P, 2003, J IMMUNOL, V170, P287, DOI 10.4049/jimmunol.170.1.287; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Guha S, 2002, CANCER RES, V62, P1632; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Hausser A, 2002, J CELL BIOL, V156, P65, DOI 10.1083/jcb.200110047; Hausser A, 2001, FEBS LETT, V492, P39, DOI 10.1016/S0014-5793(01)02219-0; HINCKE MT, 1986, BIOCHEM BIOPH RES CO, V137, P559, DOI 10.1016/0006-291X(86)91247-7; HUBBARD NE, 1987, CANCER RES, V47, P6171; Hurd C, 2002, ONCOGENE, V21, P2154, DOI 10.1038/sj.onc.1205290; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Iglesias T, 1999, FEBS LETT, V454, P53, DOI 10.1016/S0014-5793(99)00772-3; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; JIANG WG, 1995, BRIT J CANCER, V71, P744, DOI 10.1038/bjc.1995.145; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; JOHANNING GL, 1995, NUTR CANCER, V24, P57, DOI 10.1080/01635589509514393; KATZ EB, 1987, J NATL CANCER I, V79, P351; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; LIOTTA LA, 1993, CANC PRINCIPLES PRAC, V1, P134; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; METERISSIAN SH, 1995, CANCER LETT, V89, P145, DOI 10.1016/0304-3835(94)03659-7; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Paine E, 2000, J BIOL CHEM, V275, P11284, DOI 10.1074/jbc.275.15.11284; Palmantier R, 1996, CANCER RES, V56, P2206; Palmantier R, 2001, CANCER RES, V61, P2445; Pandian SS, 2001, BIOCHEM BIOPH RES CO, V283, P806, DOI 10.1006/bbrc.2001.4873; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Paulhe F, 2001, BIOCHEM BIOPH RES CO, V288, P875, DOI 10.1006/bbrc.2001.5859; PONTREMOLI S, 1986, J BIOL CHEM, V261, P8309; PONTREMOLI S, 1990, P NATL ACAD SCI USA, V87, P3705, DOI 10.1073/pnas.87.10.3705; Rennecke J, 1999, INT J CANCER, V80, P98, DOI 10.1002/(SICI)1097-0215(19990105)80:1<98::AID-IJC19>3.3.CO;2-4; Rios-Doria J, 2003, J BIOL CHEM, V278, P1372, DOI 10.1074/jbc.M208772200; Rock MT, 2000, EXP CELL RES, V261, P260, DOI 10.1006/excr.2000.5048; ROSE DP, 1993, JNCI-J NATL CANCER I, V85, P1743, DOI 10.1093/jnci/85.21.1743; ROSE DP, 1994, CANCER RES, V54, P6557; Rozman-Pungercar J, 2003, CELL DEATH DIFFER, V10, P881, DOI 10.1038/sj.cdd.4401247; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SUZUKI K, 1992, ANN NY ACAD SCI, V674, P218, DOI 10.1111/j.1749-6632.1992.tb27490.x; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Vertommen D, 2000, J BIOL CHEM, V275, P19567, DOI 10.1074/jbc.M001357200; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; Zhukova E, 2001, J BIOL CHEM, V276, P40298, DOI 10.1074/jbc.M106512200	60	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3300	3307		10.1074/jbc.M305734200	http://dx.doi.org/10.1074/jbc.M305734200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14607845	hybrid			2022-12-25	WOS:000188379600021
J	Lee, MH; Osaki, T; Lee, JY; Baek, MJ; Zhang, R; Park, JW; Kawabata, S; Soderhall, K; Lee, BL				Lee, MH; Osaki, T; Lee, JY; Baek, MJ; Zhang, R; Park, JW; Kawabata, S; Soderhall, K; Lee, BL			Peptidoglycan recognition proteins involved in 1,3-beta-D-glucan-dependent prophenoloxidase activation system of insect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-PHENOL-OXIDASE; FRESH-WATER CRAYFISH; PATTERN-RECOGNITION; SERINE-PROTEASE; COLEOPTERAN INSECT; MANDUCA-SEXTA; SILKWORM; CDNA; TOLL; PHENOLOXIDASE	The prophenoloxidase (proPO) cascade is a major innate immune response in invertebrates, which is triggered into its active form by elicitors, such as lipopolysaccharide, peptidoglycan, and 1,3-beta-D-glucan. A key question of the proPO system is how pattern recognition proteins recognize pathogenic microbes and subsequently activate the system. To investigate the biological function of 1,3-beta-D-glucan pattern recognition protein in the proPO cascade system, we isolated eight different 1,3-beta-D-glucan-binding proteins from the hemolymph of large beetle (Holotrichia diomphalia) larvae by using 1,3-beta-D-glucan immobilized column. Among them, a 20- and 17-kDa protein ( referred to as Hd-PGRP-1 and Hd-PGRP-2) show high sequence identity with the short forms of peptidoglycan recognition proteins (PGRPs-S) from human and Drosophila melanogaster. To be able to characterize the biochemical properties of these two proteins, we expressed them in Drosophila S2 cells. Hd-PGRP-1 and Hd-PGRP-2 were found to specifically bind both 1,3-beta-D-glucan and peptidoglycan. By BIAcore analysis, the minimal 1,3-beta-D-glucan structure required for binding to Hd-PGRP-1 was found to be laminaritetraose. Hd-PGRP-1 increased serine protease activity upon binding to 1,3-beta-D-glucan and subsequently induced the phenoloxidase activity in the presence of both 1,3-beta-D-glucan and Ca2+, but no phenoloxidase activity was elicited under the same conditions in the presence of peptidoglycan and Ca2+. These results demonstrate that Hd-PGRP-1 can serve as a receptor for 1,3-beta-D-glucan in the insect proPO activation system.	Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea; Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8128581, Japan; Uppsala Univ, Evolutionary Biol Ctr, Dept Comparat Physiol, SE-75236 Uppsala, Sweden	Pusan National University; Kyushu University; Uppsala University	Lee, BL (corresponding author), Pusan Natl Univ, Coll Pharm, Jangjeon Dong, Pusan 609735, South Korea.	brlee@pusan.ac.kr	Baek, Moo-Jun/W-1736-2019	Baek, Moo-Jun/0000-0003-3567-6687; Osaki, Tsukasa/0000-0002-9487-3253				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; ASHIDA M, 1983, BIOCHEM BIOPH RES CO, V113, P562, DOI 10.1016/0006-291X(83)91762-X; ASHIDA M, 1990, EUR J BIOCHEM, V188, P507, DOI 10.1111/j.1432-1033.1990.tb15429.x; Ashida Masaaki, 1998, P135; CHENG XD, 1994, P NATL ACAD SCI USA, V91, P4034, DOI 10.1073/pnas.91.9.4034; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; De Gregorio E, 2002, DEV CELL, V3, P581, DOI 10.1016/S1534-5807(02)00267-8; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Hyuk T, 1997, MOL CELLS, V7, P90; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jiang HB, 2003, J BIOL CHEM, V278, P3552, DOI 10.1074/jbc.M205743200; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kim MS, 2003, NAT IMMUNOL, V4, P787, DOI 10.1038/ni952; Kim MS, 2002, J BIOL CHEM, V277, P39999, DOI 10.1074/jbc.M205508200; Kwon TH, 2000, EUR J BIOCHEM, V267, P6188, DOI 10.1046/j.1432-1327.2000.01695.x; Lee KY, 2002, EUR J BIOCHEM, V269, P4375, DOI 10.1046/j.1432-1033.2002.03155.x; Lee SY, 2000, J BIOL CHEM, V275, P1337, DOI 10.1074/jbc.275.2.1337; Lee SY, 1998, EUR J BIOCHEM, V254, P50, DOI 10.1046/j.1432-1327.1998.2540050.x; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; LEGENDRE N, 1988, BIOTECHNIQUES, V6, P154; LEONARD C, 1985, INSECT BIOCHEM, V15, P803, DOI 10.1016/0020-1790(85)90109-X; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; Ligoxygakis P, 2002, EMBO J, V21, P6330, DOI 10.1093/emboj/cdf661; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Ma CC, 2000, J BIOL CHEM, V275, P7505, DOI 10.1074/jbc.275.11.7505; MCCAULEY R, 1973, MOL CELL BIOCHEM, V1, P73, DOI 10.1007/BF01659940; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Mellroth P, 2003, J BIOL CHEM, V278, P7059, DOI 10.1074/jbc.M208900200; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; Ochiai M, 2000, J BIOL CHEM, V275, P4995, DOI 10.1074/jbc.275.7.4995; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; RAO P, 1989, ANAL BIOCHEM, V181, P18, DOI 10.1016/0003-2697(89)90387-4; Rehman A, 2001, CYTOKINE, V13, P8, DOI 10.1006/cyto.2000.0800; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; SGARAMELLA V, 1972, J MOL BIOL, V72, P427, DOI 10.1016/0022-2836(72)90155-6; SODERHALL K, 1979, CAN J MICROBIOL, V25, P406, DOI 10.1139/m79-062; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; Sugumaran M, 2001, ADV EXP MED BIOL, V484, P289; Takaki Y, 2002, J BIOL CHEM, V277, P14281, DOI 10.1074/jbc.M200177200; Takeda K, 2003, CELL MICROBIOL, V5, P143, DOI 10.1046/j.1462-5822.2003.00264.x; Takehana A, 2002, P NATL ACAD SCI USA, V99, P13705, DOI 10.1073/pnas.212301199; Tydell CC, 2002, J BIOL CHEM, V277, P19658, DOI 10.1074/jbc.M200659200; Wang RG, 2001, EUR J BIOCHEM, V268, P895, DOI 10.1046/j.1432-1327.2001.01945.x; Werner T, 2003, J BIOL CHEM, V278, P26319, DOI 10.1074/jbc.C300184200; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854; Zhang R, 2003, J BIOL CHEM, V278, P42072, DOI 10.1074/jbc.M307475200	53	85	91	0	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3218	3227		10.1074/jbc.M309821200	http://dx.doi.org/10.1074/jbc.M309821200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14583608	hybrid			2022-12-25	WOS:000188379600012
J	Floquet, N; Pasco, S; Ramont, L; Derreumaux, P; Laronze, JY; Nuzillard, JM; Maquart, FX; Alix, AJP; Monboisse, JC				Floquet, N; Pasco, S; Ramont, L; Derreumaux, P; Laronze, JY; Nuzillard, JM; Maquart, FX; Alix, AJP; Monboisse, JC			The antitumor properties of the alpha 3(IV)-(185-203) peptide from the NC1 domain of type IV collagen (tumstatin) are conformation-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; MATRIX METALLOPROTEINASES; BASEMENT-MEMBRANE; NONCOLLAGENOUS DOMAINS; EXTRACELLULAR-MATRIX; TUMOR-GROWTH; CHAIN; ACTIVATION; CELLS; MELANOMA	Tumor progression may be controlled by various fragments derived from noncollagenous 1 (NC1) C-terminal domains of type IV collagen. We demonstrated previously that a peptide sequence from the NC1 domain of the alpha3(IV) collagen chain inhibits the in vitro expression of matrix metalloproteinases in human melanoma cells through RGD-independent binding to alpha(v)beta(3) integrin. In the present paper, we demonstrate that in a mouse melanoma model, the NC1 alpha3(IV)-(185 - 203) peptide inhibits in vivo tumor growth in a conformation-dependent manner. The decrease of tumor growth is the result of an inhibition of cell proliferation and a decrease of cell invasive properties by down-regulation of proteolytic cascades, mainly matrix metalloproteinases and the plasminogen activation system. A shorter peptide comprising the seven N-terminal residues 185 - 191 (CNYYSNS) shares the same inhibitory profile. The three-dimensional structures of the CNYYSNS and NC1 alpha3(IV)-(185 - 203) peptides show a beta-turn at the YSNS ( 188 - 191) sequence level, which is crucial for biological activity. As well, the homologous MNYYSNS heptapeptide keeps the beta-turn and the inhibitory activity. In contrast, the DNYYSNS heptapeptide, which does not form the beta-turn at the YSNS level, is devoid of inhibitory activity. Structural studies indicate a strong structure-function relationship of the peptides and point to the YSNS turn as necessary for biological activity. These peptides could act as potent and specific antitumor antagonists of alpha(v)beta(3) integrin in melanoma progression.	Univ Reims, Lab Spect & Biomol Struct, EA 3305, F-51095 Reims, France; Univ Reims, Lab Med Biochem & Mol Biol, CNRS, Format Rech Evolut 2534, F-51095 Reims, France; Univ Reims, Inst Federat Rech Biomol 53, CNRS, Unite Mixte Rech 6013, F-51095 Reims, France; Univ Aix Marseille 2, CNRS, Unite Propre Rech 2589, F-13402 Marseille, France; Univ Paris 07, CNRS, Unite Propre Rech 9080, Lab Theoret Biochem, F-75005 Paris, France	Universite de Reims Champagne-Ardenne; Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne; Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Monboisse, JC (corresponding author), Fac Med, CNRS, FRE 2534, Lab Med Biochem & Mol Biol, 51 Rue Cognacq Jay, F-51095 Reims, France.	jc.monboisse@univ-reims.fr	Floquet, Nicolas/A-5996-2009; Derreumaux, Philippe/E-9036-2019	Brassart-Pasco, Sylvie/0000-0002-1340-7868; Nuzillard, Jean-Marc/0000-0002-5120-2556				Alix AJP, 1997, NATO ADV SCI I E-APP, V342, P121; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Borza DB, 2002, J BIOL CHEM, V277, P40075, DOI 10.1074/jbc.M207769200; Bouifraden S, 1999, AMINO ACIDS, V16, P345, DOI 10.1007/BF01388176; Boutaud A, 2000, J BIOL CHEM, V275, P30716, DOI 10.1074/jbc.M004569200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Colorado PC, 2000, CANCER RES, V60, P2520; Derreumaux P, 1997, J CHEM PHYS, V107, P1941, DOI 10.1063/1.474546; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; deVries TJ, 1996, MELANOMA RES, V6, P79, DOI 10.1097/00008390-199604000-00001; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fawzi A, 2000, CELL SIGNAL, V12, P327, DOI 10.1016/S0898-6568(00)00074-7; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; Han J, 1997, J BIOL CHEM, V272, P20395, DOI 10.1074/jbc.272.33.20395; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; HORNEBECK W, 2002, SEMIN CANCER BIOL, V439, P1; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; Huet E, 2002, CLIN EXP METASTAS, V19, P107, DOI 10.1023/A:1014547324918; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kamphaus GD, 2000, J BIOL CHEM, V275, P1209, DOI 10.1074/jbc.275.2.1209; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LINDBLOM A, 1996, EXTRACELLULAR MATRIX, V1, P132; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Maeshima Y, 2000, J BIOL CHEM, V275, P23745, DOI 10.1074/jbc.C000186200; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Marneros AG, 2001, MATRIX BIOL, V20, P337, DOI 10.1016/S0945-053X(01)00151-2; MONBOISSE JC, 1994, J BIOL CHEM, V269, P25475; Netzer KO, 1998, PROTEIN SCI, V7, P1340, DOI 10.1002/pro.5560070610; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Ortega N, 2002, J CELL SCI, V115, P4201, DOI 10.1242/jcs.00106; Pasco S, 2000, CANCER RES, V60, P467; Pasco S, 2000, J BIOL CHEM, V275, P32999, DOI 10.1074/jbc.M005235200; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; Shahan TA, 1999, CONNECT TISSUE RES, V40, P221, DOI 10.3109/03008209909005285; Shahan TA, 1999, CANCER RES, V59, P4584; SSAKI T, 2000, J MOL BIOL, V301, P1179; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Than ME, 2002, P NATL ACAD SCI USA, V99, P6607, DOI 10.1073/pnas.062183499; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; Wald M, 2001, CANCER CHEMOTH PHARM, V47, pS16, DOI 10.1007/s002800170004	44	59	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2091	2100		10.1074/jbc.M307736200	http://dx.doi.org/10.1074/jbc.M307736200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14583633	hybrid			2022-12-25	WOS:000188005700065
J	Cohen, M; Stutz, F; Dargemont, C				Cohen, M; Stutz, F; Dargemont, C			Deubiquitination, a new player in Golgi to endoplasmic reticulum retrograde transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; NF-KAPPA-B; GTPASE-ACTIVATING PROTEIN; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; COATED VESICLES; COATOMER; COP; UBIQUITINATION; PROTEASOME	Modification by ubiquitin plays a major role in a broad array of cellular functions. Although reversal of this process, deubiquitination, likely represents an important regulatory step contributing to cellular homeostasis, functions of deubiquitination enzymes still remain poorly characterized. We have previously shown that the ubiquitin protease Ubp3p requires a co-factor, Bre5p, to specifically deubiquitinate the coat protein complex II ( COPII) subunit Sec23p, which is involved in anterograde transport between endoplasmic reticulum and Golgi compartiments. In the present report, we show that disruption of BRE5 gene also led to a defect in the retrograde transport from the Golgi to the endoplasmic reticulum. Further analysis indicate that the COPI subunit beta'-COP represents another substrate of the Ubp3p . Bre5p complex. All together, our results indicate that the Ubp3p . Bre5p deubiquitination complex co-regulates anterograde and retrograde transports between endoplasmic reticulum and Golgi compartments.	Univ Paris 06, CNRS, Unite Mixte Rech 7592, Inst Jacques Monod,Nucleocytoplasm Transport Grp, F-75251 Paris 05, France; Univ Paris 07, CNRS, Unite Mixte Rech 7592, Inst Jacques Monod,Nucleocytoplasm Transport Grp, F-75251 Paris, France; Dept Cell Biol, CH-1211 Geneva 4, Switzerland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; University of Geneva	Dargemont, C (corresponding author), Univ Paris 06, CNRS, Unite Mixte Rech 7592, Inst Jacques Monod,Nucleocytoplasm Transport Grp, 2 Pl Jussieu,Tour 43, F-75251 Paris 05, France.		Cohen, Mickael/P-7148-2019; Cohen, Mickael/F-4122-2011; Stutz, Françoise C/N-4329-2017	Cohen, Mickael/0000-0002-1372-680X; 				Avaro S, 2002, YEAST, V19, P351, DOI 10.1002/yea.838; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880; Cohen M, 2003, NAT CELL BIOL, V5, P661, DOI 10.1038/ncb1003; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Dogic D, 1999, EUR J CELL BIOL, V78, P305, DOI 10.1016/S0171-9335(99)80064-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Faulstich D, 1996, J CELL BIOL, V135, P53, DOI 10.1083/jcb.135.1.53; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Holm Connie, 1993, Methods (Orlando), V5, P102, DOI 10.1006/meth.1993.1014; Kim JH, 2003, J BIOCHEM, V134, P9, DOI 10.1093/jb/mvg107; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Lowe M, 1996, J BIOL CHEM, V271, P30725, DOI 10.1074/jbc.271.48.30725; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Muren E, 2001, YEAST, V18, P163, DOI 10.1002/1097-0061(20010130)18:2<163::AID-YEA659>3.0.CO;2-#; Nickel W, 2002, J CELL SCI, V115, P3235; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Parker F, 1996, MOL CELL BIOL, V16, P2561; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Poon PP, 2001, J CELL BIOL, V155, P1239, DOI 10.1083/jcb.200108075; Reinhard C, 2003, P NATL ACAD SCI USA, V100, P8253, DOI 10.1073/pnas.1432391100; Soncini C, 2001, ONCOGENE, V20, P3869, DOI 10.1038/sj.onc.1204553; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang YQ, 2002, J BIOL CHEM, V277, P15766, DOI 10.1074/jbc.M111733200; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164	36	61	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					51989	51992		10.1074/jbc.C300451200	http://dx.doi.org/10.1074/jbc.C300451200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14593109	hybrid			2022-12-25	WOS:000187480700004
J	Popescu, BO; Cedazo-Minguez, A; Benedikz, E; Nishimura, T; Winblad, B; Ankarcrona, M; Cowburn, RF				Popescu, BO; Cedazo-Minguez, A; Benedikz, E; Nishimura, T; Winblad, B; Ankarcrona, M; Cowburn, RF			gamma-secretase activity of presenilin 1 regulates acetylcholine muscarinic receptor-mediated signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID BETA-PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; PERTURBED CALCIUM HOMEOSTASIS; PRECURSOR PROTEIN; PHOSPHOLIPASE-C; TRANSMEMBRANE ASPARTATES; MUTANT PRESENILIN-1; CORTICAL-NEURONS; PC12 CELLS; MUTATIONS	Familial Alzheimer's disease (FAD) presenilin 1 (PS1) mutations give enhanced calcium responses upon different stimuli, attenuated capacitative calcium entry, an increased sensitivity of cells to undergo apoptosis, and increased gamma-secretase activity. We previously showed that the FAD mutation causing an exon 9 deletion in PS1 results in enhanced basal phospholipase C (PLC) activity (Cedazo-Minguez, A., Popescu, B. O., Ankarcrona, M., Nishimura, T., and Cowburn, R. F. (2002) J. Biol. Chem. 277, 36646-36655). To further elucidate the mechanisms by which PS1 interferes with PLC-calcium signaling, we studied the effect of two other FAD PS1 mutants (M146V and L250S) and two dominant negative PS1 mutants (D257A and D385N) on basal and carbachol-stimulated phosphoinositide (PI) hydrolysis and intracellular calcium concentrations ([Ca2+](i)) in SH-SY5Y neuroblastoma cells. We found a significant increase in basal PI hydrolysis in PS1 M146V cells but not in PS1 L250S cells. Both PS1 M146V and PS1 L250S cells showed a significant increase in carbachol-induced [Ca2+](i) as compared with nontransfected or wild type PS1 transfected cells. The elevated carbachol-induced [Ca2+](i) signals were reversed by the PLC inhibitor neomycin, the ryanodine receptor antagonist dantrolene, the general aspartyl protease inhibitor pepstatin A, and the specific gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester. The cells expressing either PS1 D257A or PS1 D385N had attenuated carbachol-stimulated PI hydrolysis and [Ca2+](i) responses. In nontransfected or PS1 wild type transfected cells, N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester and pepstatin A also attenuated both carbachol-stimulated PI hydrolysis and [Ca2+](i) responses to levels found in PS1 D257A or PS1 D385N dominant negative cells. Our findings suggest that PS1 can regulate PLC activity and that this function is gamma-secretase activity-dependent.	Karolinska Inst, Novum, Kliniskt Forskningsctr, Neurotec Dept,Sect Expt Geriatr, S-14186 Huddinge, Sweden; Karolinska Inst, Novum, Karolinska Inst Sumitomo Pharmaceut Alzheimer Ctr, Neurotec Dept,Sect Expt Geriatr, S-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet	Cedazo-Minguez, A (corresponding author), Karolinska Inst, Novum, Kliniskt Forskningsctr, Neurotec Dept,Sect Expt Geriatr, Plan 4, S-14186 Huddinge, Sweden.	Angel.Cedazo-Minguez@neurotec.ki.se	Cedazo-Minguez, Angel/C-6707-2012	Cedazo-Minguez, Angel/0000-0003-4626-4864; Ankarcrona, Maria/0000-0002-7022-3694; Benedikz, Eirikur/0000-0001-6789-8837				Auld DS, 2002, PROG NEUROBIOL, V68, P209, DOI 10.1016/S0301-0082(02)00079-5; BERRIDGE MJ, 1982, CELL CALCIUM, V3, P385, DOI 10.1016/0143-4160(82)90025-2; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cedazo-Minguez A, 2002, J BIOL CHEM, V277, P36646, DOI 10.1074/jbc.M112117200; Cedazo-Minguez A, 2001, FEBS LETT, V504, P45, DOI 10.1016/S0014-5793(01)02761-2; Chan SL, 2000, J BIOL CHEM, V275, P18195, DOI 10.1074/jbc.M000040200; Chan SL, 2002, NEUROBIOL DIS, V11, P2, DOI 10.1006/nbdi.2002.0542; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Dewji NN, 1997, P NATL ACAD SCI USA, V94, P9926, DOI 10.1073/pnas.94.18.9926; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; FOWLER CJ, 1987, PHARMACOL TOXICOL, V60, P274, DOI 10.1111/j.1600-0773.1987.tb01751.x; Guo Q, 1998, J BIOL CHEM, V273, P12341, DOI 10.1074/jbc.273.20.12341; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; Jo DG, 2003, BIOCHEM BIOPH RES CO, V305, P62, DOI 10.1016/S0006-291X(03)00688-0; Kim D, 1997, NATURE, V389, P290, DOI 10.1038/38508; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Kovacs DM, 1999, J NEUROCHEM, V73, P2278, DOI 10.1046/j.1471-4159.1999.0732278.x; LaFerla FM, 2002, NAT REV NEUROSCI, V3, P862, DOI 10.1038/nrn960; Leissring MA, 2000, P NATL ACAD SCI USA, V97, P8590, DOI 10.1073/pnas.97.15.8590; Leissring MA, 1999, J NEUROCHEM, V72, P1061, DOI 10.1046/j.1471-4159.1999.0721061.x; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Leissring MA, 2002, P NATL ACAD SCI USA, V99, P4697, DOI 10.1073/pnas.072033799; Leissring MA, 2001, NEUROBIOL DIS, V8, P469, DOI 10.1006/nbdi.2001.0382; Mann DMA, 2001, NEUROPATH APPL NEURO, V27, P189, DOI 10.1046/j.1365-2990.2001.00316.x; MARKS AR, 1997, AM J PHYSIOL, V272, P597; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; Mattson MP, 2002, J NEUROVIROL, V8, P539, DOI 10.1080/13550280290100978; MATTSON MP, 1990, NEURON, V4, P105, DOI 10.1016/0896-6273(90)90447-N; Popescu B. O., 2000, J Cell Mol Med, V4, P249, DOI 10.1111/j.1582-4934.2000.tb00124.x; Popescu BO, 2001, J NEUROSCI RES, V66, P122, DOI 10.1002/jnr.1204; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4550, DOI 10.1021/bi00181a016; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schneider I, 2001, J BIOL CHEM, V276, P11539, DOI 10.1074/jbc.M010977200; Selkoe DJ, 2002, J CLIN INVEST, V110, P1375, DOI 10.1172/JCI200216783; Small DH, 2001, NAT REV NEUROSCI, V2, P595, DOI 10.1038/35086072; Smith IF, 2002, BRAIN RES, V949, P105, DOI 10.1016/S0006-8993(02)02970-0; STREB H, 1985, J BIOL CHEM, V260, P7309; Tanii H, 2000, NEUROSCIENCE, V95, P593; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Tian GC, 2002, J BIOL CHEM, V277, P31499, DOI 10.1074/jbc.M112328200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Yu G, 2000, J BIOL CHEM, V275, P27348; Zhao FY, 2001, J BIOL CHEM, V276, P13810, DOI 10.1074/jbc.M006104200	49	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6455	6464		10.1074/jbc.M306041200	http://dx.doi.org/10.1074/jbc.M306041200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14625299	hybrid			2022-12-25	WOS:000188969200031
J	Sleeman, MC; Schofield, CJ				Sleeman, MC; Schofield, CJ			Carboxymethylproline synthase (CarB), an unusual carbon-carbon bond-forming enzyme of the crotonase superfamily involved in carbapenem biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYTANOYL-COA 2-HYDROXYLASE; BETA-LACTAM SYNTHETASE; CRYSTAL-STRUCTURE; CLAVAMINATE SYNTHASE; ANGSTROM RESOLUTION; ACID; THIENAMYCIN; SERRATIA; MECHANISM; EVOLUTION	Carboxymethylproline synthase (CarB) catalyzes the committed step in the biosynthesis of (R)-1-carbapen-2-em-3-carboxylate, the simplest member of the carbapenem family of beta-lactam antibiotics, some of which are used clinically. CarB displays sequence homology with members of the crotonase family including enoyl-CoA hydratase (crotonase) and methylmalonyl-CoA decarboxylase. The CarB reaction has been proposed to comprise condensation of acetyl coenzyme A (AcCoA) and glutamate semi-aldehyde to give (2S,5S)-carboxymethylproline ((2S,5S)-CMP). (2S,5S)-CMP is then cyclized in an ATP-driven reaction catalyzed by CarA to give a carbapenam, which is subsequently epimerized and desaturated to give a carbapenem in a CarC-mediated reaction. Here we report the purification of recombinant CarB and that it exists predominantly in a trimeric form as do other members of the crotonase family. AcCoA was not found to be a substrate for CarB. Instead malonyl-CoA was found to be a substrate, efficiently producing (2S,5S)-CMP in the presence of glutamate semi-aldehyde. In the absence of glutamate semi-aldehyde, mass spectrometric analysis indicated that CarB catalyzed the decarboxylation of malonyl-CoA to AcCoA. The reactions of CarB, CarA, and CarC were coupled in vitro demonstrating the viability of malonyl-CoA as a carbapenem precursor. CarB was also shown to accept methylmalonyl CoA as a substrate to form 6-methyl-(2S,5S)CMP, which in turn is a substrate for CarA. The implications of the results for the biosynthesis of both carbapenem-3-carboxylate and C-2/C-6-substituted carbapenems, such as thienamycin, are discussed.	Univ Oxford, Chem Res Lab, Dept Chem, Oxford OX1 3TA, England	University of Oxford	Schofield, CJ (corresponding author), Univ Oxford, Chem Res Lab, Dept Chem, Mansfield Rd, Oxford OX1 3TA, England.	christopher.schofield@chem.ox.ac.uk		Schofield, Christopher/0000-0002-0290-6565				Bachmann BO, 1998, P NATL ACAD SCI USA, V95, P9082, DOI 10.1073/pnas.95.16.9082; Bahnson BJ, 2002, BIOCHEMISTRY-US, V41, P2621, DOI 10.1021/bi015844p; BALDWIN JE, 1976, J CHEM SOC CHEM COMM, P734, DOI 10.1039/c39760000734; Benning MM, 1996, BIOCHEMISTRY-US, V35, P8103, DOI 10.1021/bi960768p; Benning MM, 2000, BIOCHEMISTRY-US, V39, P4630, DOI 10.1021/bi9928896; Bycroft BW, 2003, TETRAHEDRON LETT, V44, P973, DOI 10.1016/S0040-4039(02)02731-4; BYCROFT BW, 1988, J ANTIBIOT, V41, P1231, DOI 10.7164/antibiotics.41.1231; Caines MEC, 2004, J BIOL CHEM, V279, P5685, DOI 10.1074/jbc.M310803200; Cane DE, 1999, CHEM BIOL, V6, pR319, DOI 10.1016/S1074-5521(00)80001-0; Carreras CW, 1997, TOP CURR CHEM, V188, P85; Clifton IJ, 2003, J BIOL CHEM, V278, P20843, DOI 10.1074/jbc.M213054200; Derzelle S, 2002, APPL ENVIRON MICROB, V68, P3780, DOI 10.1128/AEm.68.8.3780-3789.2002; Farrant RD, 2001, J BIOL CHEM, V276, P15107, DOI 10.1074/jbc.M010860200; Gerlt JA, 2001, ANNU REV BIOCHEM, V70, P209, DOI 10.1146/annurev.biochem.70.1.209; Gerratana B, 2003, BIOCHEMISTRY-US, V42, P7836, DOI 10.1021/bi034361d; Holden HM, 2001, ACCOUNTS CHEM RES, V34, P145, DOI 10.1021/ar000053l; HOUCK DR, 1986, J AM CHEM SOC, V108, P5365, DOI 10.1021/ja00277a063; Iwata-Reuyl D, 1999, J AM CHEM SOC, V121, P11356, DOI 10.1021/ja992649d; Khaleeli N, 1999, J AM CHEM SOC, V121, P9223, DOI 10.1021/ja9923134; Li RF, 2000, J AM CHEM SOC, V122, P9296, DOI 10.1021/ja001723l; Livermore DM, 2000, CURR OPIN MICROBIOL, V3, P489, DOI 10.1016/S1369-5274(00)00128-4; Lloyd MD, 1999, TETRAHEDRON, V55, P10201, DOI 10.1016/S0040-4020(99)00547-5; McGowan SJ, 1996, MOL MICROBIOL, V22, P415, DOI 10.1046/j.1365-2958.1996.00125.x; McGowan SJ, 1998, TRENDS MICROBIOL, V6, P203, DOI 10.1016/S0966-842X(98)01251-7; McNaughton HJ, 1998, CHEM COMMUN, P2325, DOI 10.1039/a806713i; Miller MT, 2003, J BIOL CHEM, V278, P40996, DOI 10.1074/jbc.M307901200; Modis Y, 1998, STRUCTURE, V6, P957, DOI 10.1016/S0969-2126(98)00098-7; Mukherji M, 2002, CHEM BIOL, V9, P597, DOI 10.1016/S1074-5521(02)00139-4; Mukherji M, 2001, HUM MOL GENET, V10, P1971, DOI 10.1093/hmg/10.18.1971; Nunez LE, 2003, CHEM BIOL, V10, P301, DOI 10.1016/S1074-5521(03)00069-3; PAGE MI, 1992, CHEM BETA LACTAMS, P53; PARKER WL, 1982, J ANTIBIOT, V35, P653, DOI 10.7164/antibiotics.35.653; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Sharman GJ, 1999, CHEM COMMUN, P1319, DOI 10.1039/a902459j; Stapon A, 2003, J AM CHEM SOC, V125, P8486, DOI 10.1021/ja034248a; Thomson NR, 2000, MOL MICROBIOL, V36, P539, DOI 10.1046/j.1365-2958.2000.01872.x; WILLIAMSON JM, 1986, CRIT REV BIOTECHNOL, V4, P111, DOI 10.3109/07388558609150792; Xiang H, 1999, BIOCHEMISTRY-US, V38, P7638, DOI 10.1021/bi9901432	38	42	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6730	6736		10.1074/jbc.M311824200	http://dx.doi.org/10.1074/jbc.M311824200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14625287	hybrid			2022-12-25	WOS:000188969200065
J	Arumugam, T; Simeone, DM; Schmidt, AM; Logsdon, CD				Arumugam, T; Simeone, DM; Schmidt, AM; Logsdon, CD			S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-BINDING PROTEIN; MULTILIGAND RECEPTOR; NEURITE OUTGROWTH; EXPRESSION; FAMILY; BINDING; AMPHOTERIN; COMPLICATIONS; DOMAIN; MEMBER	S100P is a member of the S100 protein family that is expressed in several malignant neoplasms. Currently the effects of this molecule on cell function are unknown. In the present study we investigated the biological effects and mechanisms of action of S100P using NIH3T3 cells. Expression of S100P in NIH3T3 cells led to the presence of S100P in the culture medium, increased cellular proliferation, and enhanced survival after detachment from the culture substrate or after exposure to the chemotherapeutic agent 5-flurouracil. The proliferation and survival effects of S100P expression were duplicated in a time- and concentration-dependent manner by the extracellular addition of purified S100P to wild-type NIH3T3 cells and correlated with the activation of extracellular-regulated kinases (Erks) and NF-kappaB. To determine the mechanisms involved in these effects, we tested the hypothesis that S100P activated RAGE (receptor for activated glycation end products). We found that S100P co-immunoprecipitated with RAGE. Furthermore, the effects of S100P on cell signaling, proliferation, and survival were blocked by agents that interfere with RAGE including administration of an amphoterin-derived peptide known to antagonize RAGE activation, anti-RAGE antibodies, and by expression of a dominant negative RAGE. These data suggest that S100P can act in an autocrine manner via RAGE to stimulate cell proliferation and survival.	Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; Columbia Univ, Dept Surg, New York, NY 10032 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Columbia University	Logsdon, CD (corresponding author), Univ Michigan, Dept Physiol, Box 0622,7710 Med Sci Bldg 2, Ann Arbor, MI 48109 USA.	clogsdon@umich.edu			NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA46592] Funding Source: Medline; NIDDK NIH HHS [DK34933] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Averboukh L, 1996, PROSTATE, V29, P350; BECKER T, 1992, EUR J BIOCHEM, V207, P541, DOI 10.1111/j.1432-1033.1992.tb17080.x; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bertram J, 1998, ANTI-CANCER DRUG, V9, P311, DOI 10.1097/00001813-199804000-00004; Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792; Bucciarelli LG, 2002, CELL MOL LIFE SCI, V59, P1117, DOI 10.1007/s00018-002-8491-x; CERAMI A, 1988, DIABETES CARE, V11, P73; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; EMOTO Y, 1992, BIOCHEM BIOPH RES CO, V182, P1246, DOI 10.1016/0006-291X(92)91865-N; Filipek A, 2002, J BIOL CHEM, V277, P28848, DOI 10.1074/jbc.M203602200; Gribenko AV, 2001, BIOCHEMISTRY-US, V40, P15538, DOI 10.1021/bi0114731; GUERREIRO DS, 2000, INT J ONCOL, V16, P231; Han B, 1999, AM J PHYSIOL-CELL PH, V277, pC74, DOI 10.1152/ajpcell.1999.277.1.C74; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Huttunen HJ, 2002, CANCER RES, V62, P4805; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Ishihara K, 2003, FEBS LETT, V550, P107, DOI 10.1016/S0014-5793(03)00846-9; Ji B, 2003, PHYSIOL GENOMICS, V14, P59, DOI 10.1152/physiolgenomics.00174.2002; Koltzscher M, 2003, MOL BIOL CELL, V14, P2372, DOI 10.1091/mbc.E02-09-0553; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Logsdon CD, 2003, CANCER RES, V63, P2649; McNutt NS, 1998, J CUTAN PATHOL, V25, P521, DOI 10.1111/j.1600-0560.1998.tb01735.x; Sato N, 2002, ANAT REC, V267, P60, DOI 10.1002/ar.10085; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002; Schmidt AM, 2001, FRONT BIOSCI-LANDMRK, V6, pD1151, DOI 10.2741/Schmidt; Shanmugam N, 2003, J BIOL CHEM, V278, P34834, DOI 10.1074/jbc.M302828200; Stern DM, 2002, AGEING RES REV, V1, P1, DOI 10.1016/S0047-6374(01)00366-9; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Zhang HM, 2003, J MOL BIOL, V325, P785, DOI 10.1016/S0022-2836(02)01278-0; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	35	228	245	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5059	5065		10.1074/jbc.M310124200	http://dx.doi.org/10.1074/jbc.M310124200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14617629	hybrid			2022-12-25	WOS:000188776500004
J	Wang, HL; Postier, BL; Burnap, RL				Wang, HL; Postier, BL; Burnap, RL			Alterations in global patterns of gene expression in Synechocystis sp PCC 6803 in response to inorganic carbon limitation and the inactivation of ndhR, a LysR family regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAIN PCC 6803; CO2 CONCENTRATING MECHANISMS; NAD(P)H DEHYDROGENASE; PHOTOSYSTEM-I; BICARBONATE TRANSPORTER; ELECTRON-TRANSPORT; NA+/H+ ANTIPORTER; BINDING-PROTEINS; P-II; CYANOBACTERIUM	The cyanobacterium Synechocystis sp. PCC 6803 possesses multiple inorganic carbon (Ci) uptake systems that are regulated by Ci availability. The control mechanisms of these systems and their integration with other cell functions remain to be clarified. An analysis of the changes in global gene expression in response to Ci downshift and the inactivation of ndhR (sll1594), a LysR family regulator of Ci uptake is presented in this report. Mild Ci limitation (3% CO2 (v/v) in air to air alone) induced a dramatic up-regulation of genes encoding both inducible CO2 and HCO3- uptake systems. An induction of ndhD5/ndhD6 and other genes in a probable transcriptional unit was observed, suggesting a function in inducible Ci uptake. The expression of slr1513 and sll1735, physically clustered with sbtA and ndhF3/ndhD3/cupA, respectively, were also coordinated with upstream genes encoding the essential components for HCO3- and CO2 uptake. Ci limitation induced the regulatory genes slr1214, sll1292, slr1594, sigD, sigG, and sigH, among which slr1214, a two-component response regulator, showed the earliest induction, implying a role for the early response to Ci limitation. Opposite regulation of genes encoding the assimilation of carbon and nitrogen demonstrated a striking coordination of expression to balance C- and N-fluxes. The analyses revealed that ndhR inactivation up-regulated the expression of sbtA/sbtB, ndhF3/ndhD3/cupA/sll1735, and slr2006-13 including ndhD5 and ndhD6, indicating a vital role of this regulatory gene in both CO2 and HCO3- acquisition of the cyanobacterium. We therefore suggest that ndhR be renamed ccmR to better represent its broader regulatory characteristics.	Oklahoma State Univ, Dept Microbiol & Mol Genet, Stillwater, OK 74075 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Burnap, RL (corresponding author), Oklahoma State Univ, Dept Microbiol & Mol Genet, 307 Life Sci E, Stillwater, OK 74075 USA.	burnap@biochem.okstate.edu						Aichi M, 1997, J BACTERIOL, V179, P4671, DOI 10.1128/jb.179.15.4671-4675.1997; Aldehni MF, 2003, J BACTERIOL, V185, P2582, DOI 10.1128/JB.185.8.2582-2591.2003; Alfonso M, 2001, PLANT PHYSIOL, V125, P969, DOI 10.1104/pp.125.2.969; ANBUDURAI PR, 1994, P NATL ACAD SCI USA, V91, P8082, DOI 10.1073/pnas.91.17.8082; Badger MR, 2003, J EXP BOT, V54, P609, DOI 10.1093/jxb/erg076; Berry S, 2003, FEBS LETT, V548, P53, DOI 10.1016/S0014-5793(03)00729-4; Buikema WJ, 2001, P NATL ACAD SCI USA, V98, P2729, DOI 10.1073/pnas.051624898; Cashel M., 1996, STRINGENT RESPONSE E; Chelly Jamel, 1994, P97; Deng Y, 2003, PLANT CELL PHYSIOL, V44, P534, DOI 10.1093/pcp/pcg067; DOLGANOV NAM, 1995, P NATL ACAD SCI USA, V92, P636, DOI 10.1073/pnas.92.2.636; Ehira S, 2003, FEMS MICROBIOL LETT, V225, P137, DOI 10.1016/S0378-1097(03)00503-2; ELHAI J, 1988, GENE, V68, P119, DOI 10.1016/0378-1119(88)90605-1; Figge RM, 2001, MOL MICROBIOL, V39, P455, DOI 10.1046/j.1365-2958.2001.02239.x; FORCHHAMMER K, 1995, J BACTERIOL, V177, P5812, DOI 10.1128/jb.177.20.5812-5817.1995; Garcia-Dominguez M, 2000, MOL MICROBIOL, V35, P1192, DOI 10.1046/j.1365-2958.2000.01789.x; Grossman AR, 2001, J BIOL CHEM, V276, P11449, DOI 10.1074/jbc.R100003200; HAMAMOTO T, 1994, MOL MICROBIOL, V14, P939, DOI 10.1111/j.1365-2958.1994.tb01329.x; Harano Y, 1997, J BACTERIOL, V179, P5744, DOI 10.1128/jb.179.18.5744-5750.1997; He QF, 2001, J BIOL CHEM, V276, P306, DOI 10.1074/jbc.M008686200; Helman Y, 2003, CURR BIOL, V13, P230, DOI 10.1016/S0960-9822(03)00046-0; Herrero A, 2001, J BACTERIOL, V183, P411, DOI 10.1128/JB.183.2.411-425.2001; Hihara Y, 2001, PLANT CELL, V13, P793, DOI 10.1105/tpc.13.4.793; Hiramatsu T, 1998, J BACTERIOL, V180, P6642, DOI 10.1128/JB.180.24.6642-6648.1998; Hisbergues M, 1999, FEBS LETT, V463, P216, DOI 10.1016/S0014-5793(99)01624-5; Imamura S, 2003, J MOL BIOL, V325, P857, DOI 10.1016/S0022-2836(02)01242-1; Ito M, 2001, FEBS LETT, V496, P117, DOI 10.1016/S0014-5793(01)02417-6; Kaplan A, 2001, P NATL ACAD SCI USA, V98, P4817, DOI 10.1073/pnas.101119898; Kaplan A, 1999, ANNU REV PLANT PHYS, V50, P539, DOI 10.1146/annurev.arplant.50.1.539; Klughammer B, 1999, MOL MICROBIOL, V32, P1305, DOI 10.1046/j.1365-2958.1999.01457.x; KNOLL AH, 1991, SCI AM, V265, P64, DOI 10.1038/scientificamerican1091-64; Li H, 2000, J BACTERIOL, V182, P4268, DOI 10.1128/JB.182.15.4268-4277.2000; Li LA, 1997, J BACTERIOL, V179, P3793, DOI 10.1128/jb.179.11.3793-3796.1997; LIANG J, 1992, P NATL ACAD SCI USA, V89, P5655, DOI 10.1073/pnas.89.12.5655; Lindahl M, 2000, PLANT CELL, V12, P419, DOI 10.1105/tpc.12.3.419; Lopez-Maury L, 2002, MOL MICROBIOL, V43, P247, DOI 10.1046/j.1365-2958.2002.02741.x; Maeda S, 2002, MOL MICROBIOL, V43, P425, DOI 10.1046/j.1365-2958.2002.02753.x; Mann NH, 2000, FEBS LETT, V479, P72, DOI 10.1016/S0014-5793(00)01871-8; McGinn PJ, 2003, PLANT PHYSIOL, V132, P218, DOI 10.1104/pp.102.019349; Mikami K, 2002, MOL MICROBIOL, V46, P905, DOI 10.1046/j.1365-2958.2002.03202.x; Montesinos ML, 1998, J BIOL CHEM, V273, P31463, DOI 10.1074/jbc.273.47.31463; Muro-Pastor AM, 2001, J BACTERIOL, V183, P1090, DOI 10.1128/JB.183.3.1090-1095.2001; Ohkawa H, 2000, J BIOL CHEM, V275, P31630, DOI 10.1074/jbc.M003706200; Omata T, 1999, P NATL ACAD SCI USA, V96, P13571, DOI 10.1073/pnas.96.23.13571; Omata T, 2002, FUNCT PLANT BIOL, V29, P151, DOI 10.1071/PP01215; Omata T, 2001, J BACTERIOL, V183, P1891, DOI 10.1128/JB.183.6.1891-1898.2001; Postier BL, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-23; Price GD, 1998, CAN J BOT, V76, P973, DOI 10.1139/b98-081; Putnoky P, 1998, MOL MICROBIOL, V28, P1091, DOI 10.1046/j.1365-2958.1998.00868.x; Reyes JC, 1997, J BACTERIOL, V179, P2678, DOI 10.1128/jb.179.8.2678-2689.1997; Shi L, 1999, J BACTERIOL, V181, P4761, DOI 10.1128/JB.181.16.4761-4767.1999; Shibata M, 2002, J BIOL CHEM, V277, P18658, DOI 10.1074/jbc.M112468200; Shibata M, 2001, P NATL ACAD SCI USA, V98, P11789, DOI 10.1073/pnas.191258298; So AKC, 1998, CAN J BOT, V76, P1084, DOI 10.1139/b98-071; Suzuki I, 2001, MOL MICROBIOL, V40, P235, DOI 10.1046/j.1365-2958.2001.02379.x; Suzuki I, 1996, J BACTERIOL, V178, P2688, DOI 10.1128/jb.178.9.2688-2694.1996; Tanigawa R, 2002, P NATL ACAD SCI USA, V99, P4251, DOI 10.1073/pnas.072587199; Tchernov D, 2001, J BIOL CHEM, V276, P23450, DOI 10.1074/jbc.M101973200; Valladares A, 2002, MOL MICROBIOL, V43, P703, DOI 10.1046/j.1365-2958.2002.02778.x; Wang HL, 2002, BIOTECHNIQUES, V33, P26, DOI 10.2144/02331bm02; Wang HL, 2002, MOL MICROBIOL, V44, P1493, DOI 10.1046/j.1365-2958.2002.02983.x; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; WISE AA, 1995, J BACTERIOL, V177, P123, DOI 10.1128/jb.177.1.123-133.1995; Wolk CP, 1996, ANNU REV GENET, V30, P59, DOI 10.1146/annurev.genet.30.1.59; Yoshihara S, 2002, PLANT CELL PHYSIOL, V43, P513, DOI 10.1093/pcp/pcf061	65	9	9	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5739	5751		10.1074/jbc.M311336200	http://dx.doi.org/10.1074/jbc.M311336200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14612435	hybrid			2022-12-25	WOS:000188776500087
J	Brodeur, I; Goulet, I; Tremblay, CS; Charbonneau, C; Delisle, MC; Godin, C; Huard, C; Khandjian, EW; Buchwald, M; Levesque, G; Carreau, M				Brodeur, I; Goulet, I; Tremblay, CS; Charbonneau, C; Delisle, MC; Godin, C; Huard, C; Khandjian, EW; Buchwald, M; Levesque, G; Carreau, M			Regulation of the Fanconi anemia group C protein through proteolytic modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOTIC RESPONSES; ALPHA-SPECTRIN-II; HEMATOPOIETIC-CELLS; NUCLEAR-COMPLEX; POSITIONAL CLONING; HUMAN CASPASES; GENE-PRODUCT; DNA-DAMAGE; ACTIVATION; EXPRESSION	The function of the Fanconi anemia group C protein (FANCC) is still unknown, though many studies point to a role in damage response signaling. Unlike other known FA proteins, FANCC is mainly localized to the cytoplasm and is thought to act as a messenger of cellular damage rather than an effector of repair. FANCC has been shown to interact with several cytoplasmic and nuclear proteins and to delay the onset of apoptosis through redox regulation of GSTP1. We investigated the fate and function of FANCC during apoptosis. Here we show that FANCC undergoes proteolytic modification by a caspase into a predominant 47-kDa ubiquitinated protein fragment. Lack of proteolytic modification at the putative cleavage site delays apoptosis but does not affect MMC complementation. These results suggest that FANCC function is regulated through proteolytic processing.	CHUQ PAvillon St Francois Assise, Unite Genet Humaine & Mol, Quebec City, PQ G1L 3L5, Canada; Univ Laval, Dept Pediat, Quebec City, PQ G1K 7P4, Canada; Univ Laval, Dept Med Biol, Quebec City, PQ G1K 7P4, Canada; Hosp Sick Children, Res Inst, Program Genet & Genom Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1A8, Canada	Laval University; Laval University; Laval University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Carreau, M (corresponding author), CHUQ PAvillon St Francois Assise, Unite Genet Humaine & Mol, Quebec City, PQ G1L 3L5, Canada.	Madeleine.Carreau@crsfa.ulaval.ca		Carreau, Madeleine/0000-0002-0582-6114	Canadian Institutes of Health Research [64309] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Ageta H, 2001, J BIOL CHEM, V276, P15893, DOI 10.1074/jbc.M011097200; Apostolou S, 1996, NAT GENET, V14, P324, DOI 10.1038/ng1196-324; Cumming RC, 2001, NAT MED, V7, P814, DOI 10.1038/89937; Cumming RC, 1996, BLOOD, V88, P4558, DOI 10.1182/blood.V88.12.4558.bloodjournal88124558; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, AM J HUM GENET, V67, P1306, DOI 10.1016/S0002-9297(07)62959-0; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Flygare J, 1998, FEBS LETT, V427, P247, DOI 10.1016/S0014-5793(98)00433-5; Folias A, 2002, HUM MOL GENET, V11, P2591, DOI 10.1093/hmg/11.21.2591; Futaki M, 2002, CARCINOGENESIS, V23, P67, DOI 10.1093/carcin/23.1.67; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Garcia-Higuera I, 2000, BLOOD, V96, P3224, DOI 10.1182/blood.V96.9.3224.h8003224_3224_3230; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Haneline LS, 1998, BLOOD, V91, P4092; Heinrich MC, 2000, BLOOD, V95, P3970; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hoatlin ME, 1998, BLOOD, V91, P1418, DOI 10.1182/blood.V91.4.1418; Hoshino T, 1998, BLOOD, V91, P4379, DOI 10.1182/blood.V91.11.4379.411k14_4379_4386; HOWLETT NG, 2002, SCIENCE, V13, P13; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Kruyt FAE, 1999, J BIOL CHEM, V274, P34212, DOI 10.1074/jbc.274.48.34212; Kruyt FAE, 1998, BLOOD, V92, P3050, DOI 10.1182/blood.V92.9.3050.421k56_3050_3056; Kupfer GM, 1997, BLOOD, V90, P1047, DOI 10.1182/blood.V90.3.1047.1047_1047_1054; Kupfer GM, 1997, NAT GENET, V17, P487, DOI 10.1038/ng1297-487; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McMahon LW, 1999, J BIOL CHEM, V274, P32904, DOI 10.1074/jbc.274.46.32904; McMahon LW, 2001, BIOCHEMISTRY-US, V40, P7025, DOI 10.1021/bi002917g; Medhurst AL, 2001, HUM MOL GENET, V10, P423, DOI 10.1093/hmg/10.4.423; MEETEI AR, 2003, NAT GENET; Otsuki T, 1999, J CELL PHYSIOL, V179, P79, DOI 10.1002/(SICI)1097-4652(199904)179:1<79::AID-JCP10>3.0.CO;2-O; Pang QS, 2000, MOL CELL BIOL, V20, P4724, DOI 10.1128/MCB.20.13.4724-4735.2000; Pang QS, 2001, BLOOD, V98, P1392, DOI 10.1182/blood.V98.5.1392; Pang QS, 2001, EMBO J, V20, P4478, DOI 10.1093/emboj/20.16.4478; Qiao FY, 2001, J BIOL CHEM, V276, P23391, DOI 10.1074/jbc.M101855200; Rathbun RK, 1997, BLOOD, V90, P974, DOI 10.1182/blood.V90.3.974.974_974_985; Rathbun RK, 2000, BLOOD, V96, P4204; Rooimans MA, 1996, NAT GENET, V14, P320; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Song QZ, 1996, J EXP MED, V184, P619, DOI 10.1084/jem.184.2.619; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; STRATHDEE CA, 1992, NATURE, V358, P434, DOI 10.1038/358434a0; Taniguchi T, 2002, BLOOD, V100, P2457, DOI 10.1182/blood-2002-03-0860; Taniguchi T, 2002, INT J HEMATOL, V75, P123, DOI 10.1007/BF02982016; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Waisfisz Q, 1999, P NATL ACAD SCI USA, V96, P10320, DOI 10.1073/pnas.96.18.10320; Wang JX, 1998, CANCER RES, V58, P3538; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; WITT E, 2002, SCIENCE, V13, P13; Yamashita T, 1996, BLOOD, V87, P4424, DOI 10.1182/blood.V87.10.4424.bloodjournal87104424	58	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4713	4720		10.1074/jbc.M301291200	http://dx.doi.org/10.1074/jbc.M301291200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14625294	hybrid			2022-12-25	WOS:000188554300095
J	Kim, S; Jin, JG; Kunapuli, SP				Kim, S; Jin, JG; Kunapuli, SP			Akt activation in platelets depends on G(i) signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; FIBRINOGEN RECEPTOR ACTIVATION; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; ADENOSINE-DIPHOSPHATE; COUPLED RECEPTORS; GLYCOPROTEIN-VI; DUAL REGULATION; RAT ADIPOCYTES; SECRETED ADP	The serine-threonine kinase Akt has been established as an important signaling intermediate in regulating cell survival, cell cycle progression, as well as agonist-induced platelet activation. Stimulation of platelets with various agonists including thrombin results in Akt activation. As thrombin can stimulate multiple G protein signaling pathways, we investigated the mechanism of thrombin-induced activation of Akt. Stimulation of platelets with a PAR1-activating peptide (SFLLRN), PAR4-activating peptide (AYPGKF), and thrombin resulted in Thr(308) and Ser(473) phosphorylation of Akt, which results in its activation. This phosphorylation and activation of Akt were dramatically inhibited in the presence of AR-C69931MX, a P2Y(12) receptor-selective antagonist, or GF 109203X, a protein kinase C inhibitor, but Akt phosphorylation was restored by supplemental G(i) or G(z) signaling. Unlike wild-type mouse platelets, platelets from Galpha(q)-deficient mice failed to trigger Akt phosphorylation by thrombin and AYPGKF, whereas Akt phosphorylation was not affected by these agonists in platelets from mice that lack P2Y(1) receptor. However, ADP caused Akt phosphorylation in Galpha(q) and P2Y(1)-deficient platelets, which was completely blocked by AR-C69931MX. In contrast, ADP failed to cause Akt phosphorylation in platelets from mice treated with clopidogrel, and thrombin and AYPGKF induced minimal phosphorylation of Akt, which was not affected by AR-C69931MX in these platelets. These data demonstrate that G(i), but not G(q) or G(12/13), signaling pathways are required for activation of Akt in platelets, and G(i) signaling pathways, stimulated by secreted ADP, play an essential role in the activation of Akt in platelets.	Temple Univ, Sch Med, Dept Physiol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Kunapuli, SP (corresponding author), Temple Univ, Sch Med, Dept Physiol, 3420 N Broad St, Philadelphia, PA 19140 USA.	spk@temple.edu			NHLBI NIH HHS [HL64943, HL60683] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060683, P01HL064943] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Ballou LM, 2003, J BIOL CHEM, V278, P23472, DOI 10.1074/jbc.M212232200; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; Barry FA, 2002, J BIOL CHEM, V277, P12874, DOI 10.1074/jbc.M200482200; Baurand A, 2001, EUR J PHARMACOL, V412, P213, DOI 10.1016/S0014-2999(01)00733-6; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bommakanti RK, 2000, J BIOL CHEM, V275, P38870, DOI 10.1074/jbc.M007403200; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHAUDHRY A, 1994, CELL SIGNAL, V6, P457, DOI 10.1016/0898-6568(94)90093-0; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cho MJ, 2003, BLOOD, V101, P2646, DOI 10.1182/blood-2002-05-1363; Cho MJ, 2002, BLOOD, V99, P2442, DOI 10.1182/blood.V99.7.2442; Fabre JE, 1999, NAT MED, V5, P1199, DOI 10.1038/13522; Faruqi TR, 2000, J BIOL CHEM, V275, P19728, DOI 10.1074/jbc.M909960199; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Geiger J, 1999, ARTERIOSCL THROM VAS, V19, P2007, DOI 10.1161/01.ATV.19.8.2007; Hirsch E, 2001, FASEB J, V15, P2019, DOI 10.1096/fj.00-0810fje; Hu YH, 2000, J MED CHEM, V43, P3045, DOI 10.1021/jm000117y; Ingall AH, 1999, J MED CHEM, V42, P213, DOI 10.1021/jm981072s; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kim S, 2002, BLOOD, V99, P3629, DOI 10.1182/blood.V99.10.3629; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Kowalska MA, 2000, BLOOD, V96, P50, DOI 10.1182/blood.V96.1.50.013k40_50_57; Kroner C, 2000, J BIOL CHEM, V275, P27790, DOI 10.1074/jbc.M000540200; Leon C, 1999, J CLIN INVEST, V104, P1731, DOI 10.1172/JCI8399; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Phillips-Mason PJ, 2000, J BIOL CHEM, V275, P18046, DOI 10.1074/jbc.M909194199; Quinton TM, 2002, BIOCHEM J, V368, P535, DOI 10.1042/BJ20020226; Quinton TM, 2002, BLOOD, V99, P3228, DOI 10.1182/blood.V99.9.3228; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; SANO K, 1983, J BIOL CHEM, V258, P2010; SAVI P, 1994, J PHARMACOL EXP THER, V269, P772; Smith U, 2000, BIOCHEM BIOPH RES CO, V268, P315, DOI 10.1006/bbrc.2000.2145; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tang XW, 2002, J BIOL CHEM, V277, P338, DOI 10.1074/jbc.M108927200; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Trumel C, 1999, BLOOD, V94, P4156, DOI 10.1182/blood.V94.12.4156.424k29_4156_4165; WALKER TR, 1993, BIOCHEM J, V289, P277, DOI 10.1042/bj2890277; Walker TR, 1998, MOL PHARMACOL, V54, P1007, DOI 10.1124/mol.54.6.1007; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	48	147	152	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4186	4195		10.1074/jbc.M306162200	http://dx.doi.org/10.1074/jbc.M306162200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14623889	hybrid			2022-12-25	WOS:000188554300035
J	Cecchetto, G; Amillis, S; Diallinas, G; Scazzocchio, C; Drevet, C				Cecchetto, G; Amillis, S; Diallinas, G; Scazzocchio, C; Drevet, C			The AzgA purine transporter of Aspergillus nidulans - Characterization of a protein belonging to a new phylogenetic cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN METABOLITE REPRESSION; GATA FACTOR AREA; SACCHAROMYCES-CEREVISIAE; MOLECULAR CHARACTERIZATION; PROLINE TRANSPORTER; SECONDARY STRUCTURE; MEMBRANE-PROTEINS; ACID TRANSPORTERS; REGULATORY GENE; ZINC-FINGER	The azgA gene of Aspergillus nidulans encodes a hypoxanthine-adenine-guanine transporter. It has been cloned by a novel transposon methodology. The null phenotype of azgA was defined by a number of mutations, including a large deletion. In mycelia, the azgA gene is, like other genes of purine catabolism, induced by uric acid and repressed by ammonium. Its transcription depends on the pathway-specific UaY zinc binuclear cluster protein and the broad domain AreA GATA factor. AzgA is not closely related to any other characterized membrane protein, but many close homologues of unknown function are present in fungi, plants, and prokaryotes but not metazoa. Two of three data bases and the phylogeny presented in this article places proteins of this family in a cluster clearly separated (but perhaps phylogenetically related) from the NAT family that includes other eukaryotic and prokaryotic nucleobase transporters. Thus AzgA is the first characterized member of this family or subfamily of membrane proteins.	Univ Paris 11, Inst Genet & Microbiol, CNRS, UMR 8621, F-91405 Orsay, France; Univ Athens, Fac Biol, Dept Bot, Athens 15781, Greece; Univ Republica, Fac Ciencias, Unidad Asociada Microbiol, Montevideo, Uruguay; Inst Univ France, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; National & Kapodistrian University of Athens; Universidad de la Republica, Uruguay; Institut Universitaire de France	Scazzocchio, C (corresponding author), Univ Paris 11, Inst Genet & Microbiol, CNRS, UMR 8621, Batiment 409, F-91405 Orsay, France.	scazzocchio@igmors.u-psud.fr	Diallinas, George/AAE-8457-2019	Diallinas, George/0000-0002-3426-726X				ALTAHO NM, 1984, CURR GENET, V8, P245, DOI 10.1007/BF00419720; Amillis S, 2001, J MOL BIOL, V313, P765, DOI 10.1006/jmbi.2001.5087; Amrani L, 1999, MOL MICROBIOL, V31, P1065, DOI 10.1046/j.1365-2958.1999.01242.x; Argyrou E, 2001, PLANT CELL, V13, P953, DOI 10.1105/tpc.13.4.953; ARST HN, 1975, NATURE, V254, P31, DOI 10.1038/254031a0; ARST HN, 1973, MOL GEN GENET, V126, P111, DOI 10.1007/BF00330988; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Clutterbuck A J, 1994, Prog Ind Microbiol, V29, P791; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; DARLINGTON AJ, 1967, J BACTERIOL, V93, P937, DOI 10.1128/JB.93.3.937-940.1967; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DIALLINAS G, 1995, J BIOL CHEM, V270, P8610; Diallinas G, 1998, EMBO J, V17, P3827, DOI 10.1093/emboj/17.14.3827; FIDEL S, 1988, GENE, V70, P283, DOI 10.1016/0378-1119(88)90200-4; Gillissen B, 2000, PLANT CELL, V12, P291, DOI 10.1105/tpc.12.2.291; Gomez D, 2003, MOL MICROBIOL, V50, P277, DOI 10.1046/j.1365-2958.2003.03682.x; Gomez D, 2002, MOL MICROBIOL, V44, P585, DOI 10.1046/j.1365-2958.2002.02939.x; GORFINKIEL L, 1993, J BIOL CHEM, V268, P23376; Haft DH, 2003, NUCLEIC ACIDS RES, V31, P371, DOI 10.1093/nar/gkg128; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; LEWIS NJ, 1978, EUR J BIOCHEM, V91, P311, DOI 10.1111/j.1432-1033.1978.tb20967.x; LOCKINGTON RA, 1985, GENE, V33, P137, DOI 10.1016/0378-1119(85)90088-5; Meintanis C, 2000, MOL MEMBR BIOL, V17, P47; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; Muro-Pastor MI, 1999, EMBO J, V18, P1584, DOI 10.1093/emboj/18.6.1584; Nicosia MGL, 2001, MOL MICROBIOL, V39, P1330; OCHMAN H, 1988, GENETICS, V120, P621; OESTREICHER N, 1995, J MOL BIOL, V249, P693, DOI 10.1006/jmbi.1995.0329; Paulsen IT, 2000, J MOL BIOL, V301, P75, DOI 10.1006/jmbi.2000.3961; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; Persson BL, 1998, BBA-BIOENERGETICS, V1365, P23, DOI 10.1016/S0005-2728(98)00037-1; Ravagnani A, 1997, EMBO J, V16, P3974, DOI 10.1093/emboj/16.13.3974; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SAMBROOK J, 2000, MOL CLONING LAB MAN; Sanchez MA, 2002, J BIOL CHEM, V277, P21499, DOI 10.1074/jbc.M202319200; SCAZZOCC.C, 1968, BIOCHIM BIOPHYS ACTA, V166, P557, DOI 10.1016/0005-2787(68)90243-8; SCAZZOCCHIO C, 1982, GENETICS, V100, P185; SCAZZOCCHIO C, 1973, MOL GEN GENET, V125, P147, DOI 10.1007/BF00268868; Scazzocchio C, 1994, Prog Ind Microbiol, V29, P221; SEALYLEWIS HM, 1978, MOL GEN GENET, V164, P303, DOI 10.1007/BF00333161; SUAREZ T, 1995, EMBO J, V14, P1453, DOI 10.1002/j.1460-2075.1995.tb07132.x; Tazebay UH, 1997, MOL MICROBIOL, V24, P105, DOI 10.1046/j.1365-2958.1997.3201689.x; TAZEBAY UH, 1995, FEMS MICROBIOL LETT, V132, P27; TILBURN J, 1983, GENE, V26, P205, DOI 10.1016/0378-1119(83)90191-9; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; VERSAW WK, 1995, P NATL ACAD SCI USA, V92, P3884, DOI 10.1073/pnas.92.9.3884; WEBER E, 1990, MOL MICROBIOL, V4, P585, DOI 10.1111/j.1365-2958.1990.tb00627.x; Wipf D, 2002, TRENDS BIOCHEM SCI, V27, P139, DOI 10.1016/S0968-0004(01)02054-0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yao SYM, 2002, J BIOL CHEM, V277, P24938, DOI 10.1074/jbc.M200966200	56	67	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3132	3141		10.1074/jbc.M308826200	http://dx.doi.org/10.1074/jbc.M308826200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14597637	hybrid			2022-12-25	WOS:000188379600002
J	Singh, AB; Harris, RC				Singh, AB; Harris, RC			Epidermal growth factor receptor activation differentially regulates claudin expression and enhances transepithelial resistance in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT JUNCTION STRUCTURE; MOLECULAR-STRUCTURE; THERAPEUTIC TARGET; BARRIER FUNCTION; EGF RECEPTOR; RAT-KIDNEY; KINASE; STRANDS; PERMEABILITY; MODULATION	Tight junctions (TJs) are the most apical cell-cell junctions, and claudins, the recently identified TJ proteins, are critical for maintaining cell-cell adhesion in epithelial cell sheets. Based on their in vivo distribution and the results of overexpression studies, certain claudins, including claudin-1 and -4, are postulated to increase, whereas other claudins, especially claudin-2, are postulated to decrease the overall transcellular resistance. The overall ratio among claudins expressed in a cell/tissue has been hypothesized to define the complexity of TJs. Disruption of the TJs contributes to various human diseases, and a correlation between reduction of TJ function and tumor dedifferentiation has been postulated. The epidermal growth factor (EGF) receptor (EGFR) is overexpressed in a wide spectrum of epithelial cancers, and its expression correlates with a more metastatic cancer phenotype. However, normal functioning of EGFR is essential for normal epithelial cell proliferation and differentiation. The role of EGFR-dependent signaling in the development and maintenance of epithelial TJ integrity has not been studied in detail. This study demonstrates that, in polarized Madin-Darby canine kidney II cells, EGF-induced EGFR activation significantly inhibited claudin-2 expression while simultaneously inducing cellular redistribution and increased expression of claudin-1, -3, and -4. Accompanying these EGF-induced changes in claudin expression was a 3-fold increase in transepithelial resistance, a functional measure of TJs. In contrast, there were no alterations in protein expression and/or intracellular localization of other TJ-related proteins (ZO-1 and occludin) or adherens junction-associated proteins (E-cadherin and beta-catenin), suggesting that EGF regulates TJ function through selective and differential regulation of claudins.	Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA	Vanderbilt University	Harris, RC (corresponding author), Vanderbilt Univ, Dept Med, C-3121 Med Ctr N, Nashville, TN 37232 USA.	ray.harris@vanderbilt.edu			NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, R01DK051265] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593, DK51265] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALROY J, 1979, VET PATHOL, V16, P693, DOI 10.1177/030098587901600608; Amasheh S, 2002, J CELL SCI, V115, P4969, DOI 10.1242/jcs.00165; Anderson JM, 1999, CURR BIOL, V9, pR922, DOI 10.1016/S0960-9822(00)80105-0; Anderson JM, 2001, NEWS PHYSIOL SCI, V16, P126; Arteaga CL, 2003, EXP CELL RES, V284, P122, DOI 10.1016/S0014-4827(02)00104-0; Bonner JA, 2002, SEMIN RADIAT ONCOL, V12, P11, DOI 10.1053/srao.2002.34864; BROWN KD, 1995, EUR J GASTROEN HEPAT, V7, P914, DOI 10.1097/00042737-199510000-00002; Carraway KL, 2001, CURR OPIN CELL BIOL, V13, P125, DOI 10.1016/S0955-0674(00)00188-5; CHOW NH, 1993, EUR UROL, V24, P140; Clarke H, 2000, ADV DRUG DELIVER REV, V41, P283, DOI 10.1016/S0169-409X(00)00047-8; CLAUDE P, 1978, J MEMBRANE BIOL, V39, P219, DOI 10.1007/BF01870332; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; Di Lorenzo G, 2002, CLIN CANCER RES, V8, P3438; Dignass AU, 2001, EUR J GASTROEN HEPAT, V13, P763, DOI 10.1097/00042737-200107000-00002; DOWRICK PG, 1991, CYTOKINE, V3, P299, DOI 10.1016/1043-4666(91)90498-3; Enck AH, 2001, AM J PHYSIOL-RENAL, V281, pF966, DOI 10.1152/ajprenal.0021.2001; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Favit A, 1998, P NATL ACAD SCI USA, V95, P5562, DOI 10.1073/pnas.95.10.5562; Foster DA, 2003, MOL CANCER RES, V1, P789; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Furuse M, 2001, J CELL BIOL, V153, P263, DOI 10.1083/jcb.153.2.263; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; Grant S, 2002, FRONT BIOSCI-LANDMRK, V7, pD376, DOI 10.2741/grant; HARRIS RC, 1991, AM J KIDNEY DIS, V17, P627, DOI 10.1016/S0272-6386(12)80336-2; Hise MK, 2001, NEPHRON, V88, P71, DOI 10.1159/000045962; Hollande F, 2001, AM J PHYSIOL-GASTR L, V280, pG910, DOI 10.1152/ajpgi.2001.280.5.G910; Hollander D, 1999, Curr Gastroenterol Rep, V1, P410, DOI 10.1007/s11894-999-0023-5; Hopkins AM, 2000, ADV DRUG DELIVER REV, V41, P329, DOI 10.1016/S0169-409X(00)00050-8; Inai T, 1999, EUR J CELL BIOL, V78, P849, DOI 10.1016/S0171-9335(99)80086-7; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Jin ML, 2002, INVEST OPHTH VIS SCI, V43, P2782; Kaushal GP, 1998, AM J PHYSIOL-RENAL, V274, pF587, DOI 10.1152/ajprenal.1998.274.3.F587; Kiuchi-Saishin Y, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134875; Liang CC, 2001, J BIOL CHEM, V276, P21146, DOI 10.1074/jbc.M010669200; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; McCarthy KM, 2000, J CELL SCI, V113, P3387; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Mukohara T, 2003, LUNG CANCER, V41, P123, DOI 10.1016/S0169-5002(03)00225-3; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Rao R, 1999, BIOCHEM PHARMACOL, V57, P685, DOI 10.1016/S0006-2952(98)00333-5; Reyes JL, 2002, KIDNEY INT, V62, P476, DOI 10.1046/j.1523-1755.2002.00479.x; Ritter CA, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50027; SAITO T, 1984, Japanese Journal of Clinical Electron Microscopy, V17, P201; SALIDO EC, 1991, HISTOCHEMISTRY, V96, P65, DOI 10.1007/BF00266763; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sasaki H, 2003, P NATL ACAD SCI USA, V100, P3971, DOI 10.1073/pnas.0630649100; SCHNEEBERGER EE, 1992, AM J PHYSIOL, V262, pL647, DOI 10.1152/ajplung.1992.262.6.L647; Shimizu T, 2001, DERMATOLOGY, V202, P203, DOI 10.1159/000051637; Soler AP, 1999, CARCINOGENESIS, V20, P1425, DOI 10.1093/carcin/20.8.1425; STEVENSON BR, 1988, J CELL BIOL, V107, P2401, DOI 10.1083/jcb.107.6.2401; Stravoravdi P, 1996, EUR UROL, V29, P477; STUART RO, 1994, J CELL PHYSIOL, V159, P423, DOI 10.1002/jcp.1041590306; Sun ZW, 1998, SHOCK, V10, P203, DOI 10.1097/00024382-199809000-00009; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsukita S, 2000, J CELL BIOL, V149, P13, DOI 10.1083/jcb.149.1.13; Van Itallie C, 2001, J CLIN INVEST, V107, P1319, DOI 10.1172/JCI12464; Walsh SV, 2000, ADV DRUG DELIVER REV, V41, P303, DOI 10.1016/S0169-409X(00)00048-X; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Wong RWC, 2003, CELL MOL LIFE SCI, V60, P113, DOI 10.1007/s000180300007; Yoo J, 2003, AM J PHYSIOL-CELL PH, V285, pC300, DOI 10.1152/ajpcell.00267.2002; Yu ASL, 2003, J BIOL CHEM, V278, P17350, DOI 10.1074/jbc.M213286200	65	154	159	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3543	3552		10.1074/jbc.M308682200	http://dx.doi.org/10.1074/jbc.M308682200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14593119	hybrid			2022-12-25	WOS:000188379600051
J	Varsanyi, M; Szarka, A; Papp, E; Makai, D; Nardai, G; Fulceri, R; Csermely, P; Mandl, J; Benedetti, A; Banhegyi, G				Varsanyi, M; Szarka, A; Papp, E; Makai, D; Nardai, G; Fulceri, R; Csermely, P; Mandl, J; Benedetti, A; Banhegyi, G			FAD transport and FAD-dependent protein thiol oxidation in rat liver microsomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; FLAVIN-CONTAINING MONOOXYGENASE; ENDOPLASMIC-RETICULUM; REDOX STATE; YEAST; OXIDASE; CYCLE; GLUCOSE-6-PHOSPHATASE; PATHWAYS; BINDING	The transport of FAD and its effect on disulfide bond formation was investigated in rat liver microsomal vesicles. By measuring the intravesicular FAD-accessible space, we observed that FAD permeates across the microsomal membrane and accumulates in the lumen. Rapid filtration experiments also demonstrated the uptake and efflux of the compound, which could be inhibited by atractyloside and 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid. FAD entering the lumen promoted the oxidation of protein thiols and increased the intraluminal oxidation of glucose-6-phosphate. These findings support the notion that, similar to yeast, free FAD may have a decisive role in the mechanism of oxidative protein folding in the endoplasmic reticulum lumen of mammalian cells.	Semmelweis Univ, Dept Med Chem Mol Biol & Pathobiochem, H-1444 Budapest, Hungary; Hungarian Acad Sci, Endoplasm Reticulum Res Grp, H-1444 Budapest, Hungary; Budapest Univ Technol & Econ, Dept Biochem & Food Technol, Budapest, Hungary; Univ Siena, Dept Pathophysiol Expt Med & Publ Hlth, I-53100 Siena, Italy	Semmelweis University; Hungarian Academy of Sciences; Budapest University of Technology & Economics; University of Siena	Banhegyi, G (corresponding author), Semmelweis Univ, Dept Med Chem Mol Biol & Pathobiochem, H-1444 Budapest, Hungary.	banhegyi@puskin.sote.hu	Bánhegyi, Gábor/A-1476-2014; Szarka, Andras/H-8130-2012; Csermely, Peter/J-2067-2017	Csermely, Peter/0000-0001-9234-0659				Banhegyi G, 1997, J BIOL CHEM, V272, P13584, DOI 10.1074/jbc.272.21.13584; Bardwell JCA, 2002, DEV CELL, V3, P758, DOI 10.1016/S1534-5807(02)00370-2; Barile M, 2000, EUR J BIOCHEM, V267, P4888, DOI 10.1046/j.1432-1327.2000.01552.x; Benham AM, 2000, EMBO J, V19, P4493, DOI 10.1093/emboj/19.17.4493; BURCHELL A, 1988, CLIN CHIM ACTA, V173, P183, DOI 10.1016/0009-8981(88)90256-2; Cabibbo A, 2000, J BIOL CHEM, V275, P4827, DOI 10.1074/jbc.275.7.4827; Camporeale G, 2003, J NUTR, V133, P668, DOI 10.1093/jn/133.3.668; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; Csala M, 1999, FEBS LETT, V460, P539, DOI 10.1016/S0014-5793(99)01412-X; Csala M, 2001, ARCH BIOCHEM BIOPHYS, V388, P55, DOI 10.1006/abbi.2000.2260; Debarbieux L, 1999, CELL, V99, P117, DOI 10.1016/S0092-8674(00)81642-6; Fassio A, 2002, HISTOCHEM CELL BIOL, V117, P151, DOI 10.1007/s00418-001-0364-0; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; FULCERI R, 1994, ARCH BIOCHEM BIOPHYS, V309, P43, DOI 10.1006/abbi.1994.1081; Gerber J, 2001, J BIOL CHEM, V276, P23486, DOI 10.1074/jbc.M100134200; Gerin I, 2002, FEBS LETT, V517, P257, DOI 10.1016/S0014-5793(02)02640-6; Gross E, 2002, NAT STRUCT BIOL, V9, P61, DOI 10.1038/nsb740; HENNE V, 1986, FEBS LETT, V202, P267, DOI 10.1016/0014-5793(86)80699-8; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; HORI SH, 1977, BIOCHIM BIOPHYS ACTA, V496, P1, DOI 10.1016/0304-4165(77)90109-X; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; MASER E, 1989, BIOCHEM PHARMACOL, V38, P3049, DOI 10.1016/0006-2952(89)90014-2; Mezghrani A, 2001, EMBO J, V20, P6288, DOI 10.1093/emboj/20.22.6288; Pagani M, 2000, J BIOL CHEM, V275, P23685, DOI 10.1074/jbc.M003061200; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Puskas F, 1999, J BIOL CHEM, V274, P117, DOI 10.1074/jbc.274.1.117; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; SOUTE BAM, 1992, BIOCHEM J, V281, P255, DOI 10.1042/bj2810255; Suh JK, 2000, P NATL ACAD SCI USA, V97, P121, DOI 10.1073/pnas.97.1.121; Suh JK, 1999, P NATL ACAD SCI USA, V96, P2687, DOI 10.1073/pnas.96.6.2687; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2	34	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3370	3374		10.1074/jbc.M307783200	http://dx.doi.org/10.1074/jbc.M307783200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14612450	Green Published, hybrid			2022-12-25	WOS:000188379600029
J	Kasuno, K; Takabuchi, S; Fukuda, K; Kizaka-Kondoh, S; Yodoi, J; Adachi, T; Semenza, GL; Hirota, K				Kasuno, K; Takabuchi, S; Fukuda, K; Kizaka-Kondoh, S; Yodoi, J; Adachi, T; Semenza, GL; Hirota, K			Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR GENE; INITIATION-FACTOR 4E; COLON-CANCER CELLS; TRANSCRIPTIONAL ACTIVITY; FACTOR EXPRESSION; CARBON-MONOXIDE; FACTOR 1-ALPHA; HIF-ALPHA; PROTEIN; INHIBITION	Hypoxia-inducible factor-1 (HIF-1) is a master regulator of cellular adaptive responses to hypoxia. Levels of the HIF-1alpha subunit increase under hypoxic conditions. Exposure of cells to certain nitric oxide (NO) donors also induces HIF-1alpha expression under nonhypoxic conditions. We demonstrate that exposure of cells to the NO donor NOC18 or S-nitrosoglutathione induces HIF-1alpha expression and transcriptional activity. In contrast to hypoxia, NOC18 did not inhibit HIF-1alpha hydroxylation, ubiquitination, and degradation, indicating an effect on HIF-1alpha protein synthesis that was confirmed by pulse labeling studies. NOC18 stimulation of HIF-1alpha protein and HIF-1-dependent gene expression was blocked by treating cells with an inhibitor of the phosphatidylinositol 3-kinase or MAPK-signaling pathway. These inhibitors also blocked NOC18-induced phosphorylation of the translational regulatory proteins 4E-BP1, p70 S6 kinase, and eIF-4E, thus providing a mechanism for the modulation of HIF-1alpha protein synthesis. In addition, expression of a dominant-negative form of Ras significantly suppressed HIF-1 activation by NOC18. We conclude that the NO donor NOC18 induces HIF-1alpha synthesis under conditions of NO formation during normoxia and that hydroxylation of HIF-1alpha is not regulated by NOC18.	Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Anesthesia, Kita Ku, Osaka 5308480, Japan; Natl Inst Adv Ind Sci & Technol, IKEDA, Human Stress Signal Res Ctr, Osaka 5630053, Japan; Kyoto Univ Hosp, Inst Virus Res, Kyoto 6068507, Japan; Kyoto Univ Hosp, Dept Anesthesia, Kyoto 6068507, Japan; Kyoto Univ, Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto 6068507, Japan; Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21287 USA	Kitano Hospital; National Institute of Advanced Industrial Science & Technology (AIST); Kyoto University; Kyoto University; Kyoto University; Johns Hopkins University	Hirota, K (corresponding author), Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Anesthesia, Kita Ku, 2-4-20 Ohgimachi, Osaka 5308480, Japan.	khirota@kuhp.kyoto-u.ac.jp	Kondoh, Shinae/AAF-8745-2020; 高, 雨莉/HGU-8187-2022; Kondoh, Shinae/C-6937-2015; Hirota, Kiichi/E-9181-2010	Kondoh, Shinae/0000-0003-3085-5782; Kondoh, Shinae/0000-0003-3085-5782; Kasuno, Kenji/0000-0002-4371-9109; Hirota, Kiichi/0000-0003-1110-0827				Akaike T, 1996, METHOD ENZYMOL, V268, P211; Ang SO, 2002, NAT GENET, V32, P614, DOI 10.1038/ng1019; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Fukuda R, 2003, CANCER RES, V63, P2330; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Harada H, 2002, CANCER RES, V62, P2013; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; Higaki M, 1996, J BIOL CHEM, V271, P29342, DOI 10.1074/jbc.271.46.29342; Hirota K, 2001, J BIOL CHEM, V276, P21166, DOI 10.1074/jbc.M100677200; Hirota Kiichi, 2002, J Anesth, V16, P150, DOI 10.1007/s005400200011; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; Ignarro LJ, 1999, J CARDIOVASC PHARM, V34, P879, DOI 10.1097/00005344-199912000-00016; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Itoh T, 2001, FEBS LETT, V509, P225, DOI 10.1016/S0014-5793(01)03119-2; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Liu YX, 1998, J BIOL CHEM, V273, P15257, DOI 10.1074/jbc.273.24.15257; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; Morino S, 2000, MOL CELL BIOL, V20, P468, DOI 10.1128/MCB.20.2.468-477.2000; Palmer LA, 2000, MOL PHARMACOL, V58, P1197, DOI 10.1124/mol.58.6.1197; Paulding WR, 2000, ADV EXP MED BIOL, V475, P111; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Sodhi A, 2001, BIOCHEM BIOPH RES CO, V287, P292, DOI 10.1006/bbrc.2001.5532; Sogawa K, 1998, P NATL ACAD SCI USA, V95, P7368, DOI 10.1073/pnas.95.13.7368; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Sumbayev VV, 2003, FEBS LETT, V535, P106, DOI 10.1016/S0014-5793(02)03887-5; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909	47	167	184	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2550	2558		10.1074/jbc.M308197200	http://dx.doi.org/10.1074/jbc.M308197200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14600153	hybrid			2022-12-25	WOS:000188211300028
J	Merluzzi, S; Moretti, M; Altamura, S; Zwollo, P; Sigvardsson, M; Vitale, G; Pucillo, C				Merluzzi, S; Moretti, M; Altamura, S; Zwollo, P; Sigvardsson, M; Vitale, G; Pucillo, C			CD40 stimulation induces Pax5/BSAP and EBF activation through a APE/ref-1-dependent redox mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL FACTOR; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR BSAP; CROSS-LINKING CD40; CHAIN GENE; KAPPA-B; PHOSPHOINOSITIDE 3-KINASE; 3ALPHA ENHANCER; PROTEIN-KINASES; NUCLEAR-PROTEIN	CD40 is a member of the growing tumor necrosis factor receptor family that has been shown to play important roles in T cell-mediated B lymphocyte activation. Ligation of B cell CD40 by CD154, mainly expressed on activated T cells, stimulates B cell proliferation, differentiation, isotype switching, up-regulation of surface molecules contributing to antigen presentation, development of the germinal center, and the humoral memory response. In this study we demonstrate that the redox factor APE/Ref-1 acts as a key signaling intermediate in response to CD40-mediated B cell activation. The transcription factors Pax5a or BSAP ( B cell lineage-specific activator protein) and EBF ( early B cell factor) are constitutively expressed in spleen B cells and CD40 cross-linking induces increases in Pax5a and EBF binding activity compared with nonstimulated B cells. We show that upon CD40 antibody-mediated cross-linking, APE/Ref-1 translocates from the cytoplasm to the nucleus of activated B cells, where it modulates the DNA binding activity of both Pax5a and EBF. Moreover, we show that the repression of APE/Ref-1 protein production is able to block CD40-mediated Pax5a activation. We also provide evidence that APE/Ref-1 can modulate the cooperative activation of the blk promoter operated by Pax5a and EBF and that APE/Ref-1 might directly regulate EBF functional activity. Finally, we show that the interaction between Pax5a and EBF enhances EBF binding activity to its consensus sequence, suggesting that Pax5a can physically interact with EBF and modulate its DNA binding activity.	Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy; Univ Udine, MATI Ctr Excellence, I-33100 Udine, Italy; Coll William & Mary, Dept Biol, Williamsburg, VA 23185 USA; Lund Univ, Dept Stem Cell Biol, Lab Cellular Differentiat, S-22184 Lund, Sweden	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; University of Udine; William & Mary; Lund University	Pucillo, C (corresponding author), Univ Udine, Dipartimento Sci & Tecnol Biomed, Ple Kolbe 4, I-33100 Udine, Italy.	cpucillo@makek.dstb.uniud.it	Pucillo, Carlo/A-5515-2008	Pucillo, Carlo/0000-0002-4872-6156; Sigvardsson, Mikael/0000-0001-8527-7276; Altamura, Sandro/0000-0002-6781-1073				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; Akerblad P, 1999, MOL CELL BIOL, V19, P392; Akerblad P, 1999, J IMMUNOL, V163, P5453; Baron U, 1997, NUCLEIC ACIDS RES, V25, P2723, DOI 10.1093/nar/25.14.2723; BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Daily D, 2001, J BIOL CHEM, V276, P1335, DOI 10.1074/jbc.M008121200; DURIE FH, 1994, RES IMMUNOL, V145, P200, DOI 10.1016/S0923-2494(94)80184-3; FEDYK ER, 1994, INT J IMMUNOPHARMACO, V16, P533, DOI 10.1016/0192-0561(94)90105-8; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HAGMAN J, 1991, EMBO J, V10, P3409, DOI 10.1002/j.1460-2075.1991.tb04905.x; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; HAGMAN J, 1995, EMBO J, V14, P2907, DOI 10.1002/j.1460-2075.1995.tb07290.x; Horcher M, 2001, IMMUNITY, V14, P779, DOI 10.1016/S1074-7613(01)00153-4; Jiricny J, 2002, NATURE, V415, P593, DOI 10.1038/415593a; Kakolyris S, 1998, HISTOPATHOLOGY, V33, P561; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; KUDRYCKI K, 1993, MOL CELL BIOL, V13, P3002, DOI 10.1128/MCB.13.5.3002; Lee JR, 1998, EUR J IMMUNOL, V28, P4188, DOI 10.1002/(SICI)1521-4141(199812)28:12<4188::AID-IMMU4188>3.0.CO;2-B; Li YS, 1996, IMMUNITY, V5, P527, DOI 10.1016/S1074-7613(00)80268-X; LIAO F, 1992, J IMMUNOL, V148, P2909; LIN YH, 1995, J BIOL CHEM, V270, P25968, DOI 10.1074/jbc.270.43.25968; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Martensson A, 1997, EUR J IMMUNOL, V27, P315, DOI 10.1002/eji.1830270145; Michaelson JS, 1996, J IMMUNOL, V156, P2828; NEURATH MF, 1994, J IMMUNOL, V153, P730; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Reimold AM, 1996, J EXP MED, V183, P393, DOI 10.1084/jem.183.2.393; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; Rinkenberger JL, 1996, IMMUNITY, V5, P377, DOI 10.1016/S1074-7613(00)80263-0; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Roque MC, 1996, MOL CELL BIOL, V16, P3138; ROTHMAN P, 1991, MOL CELL BIOL, V11, P5551, DOI 10.1128/MCB.11.11.5551; Shaffer AL, 1997, IMMUNITY, V6, P131, DOI 10.1016/S1074-7613(00)80420-3; Sigvardsson M, 1996, J IMMUNOL, V156, P3788; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; Sigvardsson M, 2002, MOL CELL BIOL, V22, P8539, DOI 10.1128/MCB.22.24.8539-8551.2002; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; Song DL, 1996, DEVELOPMENT, V122, P627; Souabni A, 2002, IMMUNITY, V17, P781, DOI 10.1016/S1074-7613(02)00472-7; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Tell G, 2000, NUCLEIC ACIDS RES, V28, P1099, DOI 10.1093/nar/28.5.1099; Tell G, 1998, BIOCHEM BIOPH RES CO, V252, P178, DOI 10.1006/bbrc.1998.9548; Tell G, 1998, J BIOL CHEM, V273, P25062, DOI 10.1074/jbc.273.39.25062; Thienes CP, 1997, J IMMUNOL, V158, P5874; Tian JY, 1997, EUR J IMMUNOL, V27, P750, DOI 10.1002/eji.1830270325; TRAVIS A, 1993, MOL CELL BIOL, V13, P3392, DOI 10.1128/MCB.13.6.3392; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; WATERS SH, 1989, MOL CELL BIOL, V9, P5594, DOI 10.1128/MCB.9.12.5594; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; XU LZ, 1992, INT IMMUNOL, V4, P875, DOI 10.1093/intimm/4.8.875; ZWOLLO P, 1994, J BIOL CHEM, V269, P15310; Zwollo P, 1997, J BIOL CHEM, V272, P10160, DOI 10.1074/jbc.272.15.10160	63	38	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1777	1786		10.1074/jbc.M305418200	http://dx.doi.org/10.1074/jbc.M305418200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14594818	hybrid			2022-12-25	WOS:000188005700027
J	Torres, VJ; McClain, MS; Cover, TL				Torres, VJ; McClain, MS; Cover, TL			Interactions between p-33 and p-55 domains of the Helicobacter pylori vacuolating cytotoxin (VacA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIN VACA; CELL VACUOLATION; CHANNEL; MEMBRANE; BINDING; ACID; IDENTIFICATION; REVEALS; INTERNALIZATION; ASSOCIATION	The VacA toxin secreted by Helicobacter pylori is considered to be an important virulence factor in the pathogenesis of peptic ulcer disease and gastric cancer. VacA monomers self-assemble into water-soluble oligomeric structures and can form anion-selective membrane channels. The goal of this study was to characterize VacA-VacA interactions that may mediate assembly of VacA monomers into higher order structures. We investigated potential interactions between two domains of VacA (termed p-33 and p-55) by using a yeast two-hybrid system. p-33/p-55 interactions were detected in this system, whereas p-33/p-33 and p-55/p-55 interactions were not detected. Several p-33 proteins containing internal deletion mutations were unable to interact with wildtype p-55 in the yeast two-hybrid system. Introduction of these same deletion mutations into the H. pylori vacA gene resulted in secretion of mutant VacA proteins that failed to assemble into large oligomeric structures and that lacked vacuolating toxic activity for HeLa cells. Additional mapping studies in the yeast two-hybrid system indicated that only the N-terminal portion of the p-55 domain is required for p-33/p-55 interactions. To characterize further p-33/p-55 interactions, we engineered an H. pylori strain that produced a VacA toxin containing an enterokinase cleavage site located between the p-33 and p-55 domains. Enterokinase treatment resulted in complete proteolysis of VacA into p-33 and p-55 domains, which remained physically associated within oligomeric structures and retained vacuolating cytotoxin activity. These results provide evidence that interactions between p-33 and p-55 domains play an important role in VacA assembly into oligomeric structures.	Vanderbilt Univ, Sch Med, Div Infect Dis, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Cover, TL (corresponding author), Vanderbilt Univ, Sch Med, Div Infect Dis, Dept Microbiol & Immunol, A3310 MCN, Nashville, TN 37232 USA.	timothy.L.cover@vanderbilt.edu	Cover, Timothy/I-3814-2015; McClain, Mark S/A-6942-2009	Cover, Timothy/0000-0001-8503-002X; McClain, Mark S/0000-0002-9857-4883; Torres, Victor/0000-0002-7126-0489	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053623] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 39657] Funding Source: Medline; NIDDK NIH HHS [DK 53623] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adrian M, 2002, J MOL BIOL, V318, P121, DOI 10.1016/S0022-2836(02)00047-5; ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771; ATHERTON JC, 2001, HELICOBACTER PYLORI, P97; Bhakdi S, 1996, ARCH MICROBIOL, V165, P73, DOI 10.1007/s002030050300; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Copass M, 1997, INFECT IMMUN, V65, P1949, DOI 10.1128/IAI.65.5.1949-1952.1997; COVER TL, 1991, INFECT IMMUN, V59, P1264, DOI 10.1128/IAI.59.4.1264-1270.1991; Cover TL, 2003, CANCER RES, V63, P951; COVER TL, 1992, J BIOL CHEM, V267, P10570; COVER TL, 1994, J BIOL CHEM, V269, P10566; Cover TL, 1997, J CELL BIOL, V138, P759, DOI 10.1083/jcb.138.4.759; COVER TL, 2001, PRINCIPLES BACTERIAL, P510; Czajkowsky DM, 1999, P NATL ACAD SCI USA, V96, P2001, DOI 10.1073/pnas.96.5.2001; de Bernard M, 1998, INFECT IMMUN, V66, P6014, DOI 10.1128/IAI.66.12.6014-6016.1998; deBernard M, 1997, MOL MICROBIOL, V26, P665, DOI 10.1046/j.1365-2958.1997.5881952.x; DEBERNARD M, 1995, J BIOL CHEM, V270, P23937, DOI 10.1074/jbc.270.41.23937; Dunn BE, 1997, CLIN MICROBIOL REV, V10, P720, DOI 10.1128/CMR.10.4.720; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Figueiredo C, 2002, J NATL CANCER I, V94, P1680, DOI 10.1093/jnci/94.22.1680; Fivaz M, 2001, TOXICON, V39, P1637, DOI 10.1016/S0041-0101(01)00151-9; Fujikawa A, 2003, NAT GENET, V33, P375, DOI 10.1038/ng1112; Galmiche A, 2000, EMBO J, V19, P6361, DOI 10.1093/emboj/19.23.6361; Garner JA, 1996, INFECT IMMUN, V64, P4197, DOI 10.1128/IAI.64.10.4197-4203.1996; Gebert B, 2003, SCIENCE, V301, P1099, DOI 10.1126/science.1086871; GIMBLE FS, 1989, J MOL BIOL, V206, P29, DOI 10.1016/0022-2836(89)90521-4; Gouaux E, 1997, CURR OPIN STRUC BIOL, V7, P566, DOI 10.1016/S0959-440X(97)80123-6; Iwamoto H, 1999, FEBS LETT, V450, P101, DOI 10.1016/S0014-5793(99)00474-3; James P, 2001, METH MOL B, V177, P41; Kuck D, 2001, INFECT IMMUN, V69, P5080, DOI 10.1128/IAI.69.8.5080-5087.2001; Lacy DB, 2002, CURR TOP MICROBIOL, V271, P61; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; Lupetti P, 1996, J CELL BIOL, V133, P801, DOI 10.1083/jcb.133.4.801; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; McClain MS, 2000, MOL MICROBIOL, V37, P433, DOI 10.1046/j.1365-2958.2000.02013.x; Mcclain MS, 2003, J BIOL CHEM, V278, P12101, DOI 10.1074/jbc.M212595200; McClain MS, 2001, J BACTERIOL, V183, P6499, DOI 10.1128/JB.183.22.6499-6508.2001; McClain MS, 2001, INFECT IMMUN, V69, P1181, DOI 10.1128/IAI.69.2.1181-1184.2001; Molinari M, 1998, J EXP MED, V187, P135, DOI 10.1084/jem.187.1.135; Molinari M, 1997, J BIOL CHEM, V272, P25339, DOI 10.1074/jbc.272.40.25339; Montecucco C, 1999, COMPREHENSIVE SOURCE, P264; Moschioni M, 2002, CELL MICROBIOL, V4, P397, DOI 10.1046/j.1462-5822.2002.00199.x; Nguyen VQ, 2001, INFECT IMMUN, V69, P543, DOI 10.1128/IAI.69.1.543-546.2001; Nooren IMA, 2003, EMBO J, V22, P3486, DOI 10.1093/emboj/cdg359; Papini E, 1998, J CLIN INVEST, V102, P813, DOI 10.1172/JCI2764; Papini E, 2001, TOXICON, V39, P1757, DOI 10.1016/S0041-0101(01)00162-3; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; Peek RM, 1999, CANCER RES, V59, P6124; Ramachandran R, 2002, NAT STRUCT BIOL, V9, P823, DOI 10.1038/nsb855; Reyrat JM, 1999, J MOL BIOL, V290, P459, DOI 10.1006/jmbi.1999.2877; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; Schraw W, 2002, J BIOL CHEM, V277, P34642, DOI 10.1074/jbc.M203466200; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; Szabo I, 1999, EMBO J, V18, P5517, DOI 10.1093/emboj/18.20.5517; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; VANDERGOOT FG, 1993, BIOCHEMISTRY-US, V32, P2636, DOI 10.1021/bi00061a023; Vinion-Dubiel AD, 1999, J BIOL CHEM, V274, P37736, DOI 10.1074/jbc.274.53.37736; Wang HJ, 1998, BIOCHEM BIOPH RES CO, V250, P397, DOI 10.1006/bbrc.1998.9228; Wang HJ, 2000, BIOCHEM BIOPH RES CO, V278, P449, DOI 10.1006/bbrc.2000.3820; WARREN JR, 1983, LANCET, V1, P1273; Willhite DC, 2002, INFECT IMMUN, V70, P3824, DOI 10.1128/IAI.70.7.3824-3832.2002; Woods R. A., 2001, METH MOL B, V177, P85; Yahiro K, 1999, J BIOL CHEM, V274, P36693, DOI 10.1074/jbc.274.51.36693; Ye D, 2000, INFECT IMMUN, V68, P4354, DOI 10.1128/IAI.68.7.4354-4357.2000; Ye D, 2002, MOL MICROBIOL, V43, P1243, DOI 10.1046/j.1365-2958.2002.02818.x; Ye D, 1999, J BIOL CHEM, V274, P9277, DOI 10.1074/jbc.274.14.9277	65	43	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2324	2331		10.1074/jbc.M310159200	http://dx.doi.org/10.1074/jbc.M310159200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14593124	hybrid			2022-12-25	WOS:000188005700090
J	Suuronen, EJ; Nakamura, M; Watsky, MA; Stys, PK; Muller, LJ; Munger, RE; Shinozaki, N; Griffith, M				Suuronen, EJ; Nakamura, M; Watsky, MA; Stys, PK; Muller, LJ; Munger, RE; Shinozaki, N; Griffith, M			Innervated human corneal equivalents as in vitro models for nerve-target cell interactions	FASEB JOURNAL			English	Article						extracellular matrix; innervation; cornea; nerve function; tissue engineering	DORSAL-ROOT GANGLIA; GUINEA-PIG CORNEA; GROWTH-FACTOR-I; SUBSTANCE-P; SENSORY DENERVATION; RETINOIC ACID; NEURITE OUTGROWTH; EPITHELIAL-CELLS; RABBIT CORNEA; RAT	A sensory nerve supply is crucial for optimal tissue function. However, the mechanisms for successful innervation and the signaling pathways between nerves and their target tissue are not fully understood. Engineered tissue substitutes can provide controllable environments in which to study tissue innervation. We have therefore engineered human corneal substitutes that promote nerve in-growth in a pattern similar to in vivo re-innervation. We demonstrate that these nerves (a) are morphologically equivalent to natural corneal nerves; (b) make appropriate contact with target cells; (c) can generate action potentials; (d) respond to chemical and physical stimuli; and (e) play an important role in the overall functioning of the bioengineered tissue. This model can be used for studying the more general topics of nerve ingrowth or regeneration and the interaction between nerves and their target cells and, more specifically, the role of nerves in corneal function. This model could also be used as an in vitro alternative to animals for safety and efficacy testing of chemicals and drugs.	Univ Ottawa, Univ Ottawa Eye Inst, Ottawa Hlth Res Inst, Vis Ctr, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8L6, Canada; Santen Pharmaceut Co Ltd, Ikoma, Nara, Japan; Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Ottawa, Div Neurosci, Ottawa Hlth Res Inst, Ottawa, ON, Canada; Netherlands Ophthalm Res Inst, Dept Morphol, NL-1100 AC Amsterdam, Netherlands; Tokyo Dent Coll Ichikawa Gen Hosp, Cornea Ctr, Chiba, Japan	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Santen Pharmaceutical Co Ltd; University of Tennessee System; University of Tennessee Health Science Center; University of Ottawa; Ottawa Hospital Research Institute; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Tokyo Dental College	Griffith, M (corresponding author), Univ Ottawa, Univ Ottawa Eye Inst, Ottawa Hlth Res Inst, Vis Ctr, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	mgriffith@ohri.ca		Griffith, May/0000-0003-1222-6720; Watsky, Mitchell/0000-0003-2079-9887	NSERC Canada; Santen Pharmaceutical Co;  [227212-1999];  [227951-01]	NSERC Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); Santen Pharmaceutical Co; ; 	We thank E. Coderre for technical assistance; Dr. T. Nishida for in vivo confocal images; and Drs. R. Beuerman, D. Carlsson, and I. Spigelman for helpful insights. Supported by grants (227212-1999; 227951-01) and studentship from NSERC Canada and an extramural grant from Santen Pharmaceutical Co. E.J.S. is a Fellow of the International Foundation for Ethical Research.	ARAKI K, 1992, Nippon Ganka Gakkai Zasshi, V96, P710; ARAKI K, 1994, CURR EYE RES, V13, P203, DOI 10.3109/02713689408995778; Araki-Sasaki K, 2000, J CELL PHYSIOL, V182, P189, DOI 10.1002/(SICI)1097-4652(200002)182:2<189::AID-JCP7>3.0.CO;2-9; BAKER KS, 1993, INVEST OPHTH VIS SCI, V34, P137; BELMONTE C, 1991, J PHYSIOL-LONDON, V437, P709, DOI 10.1113/jphysiol.1991.sp018621; Belmonte C, 1997, PROG RETIN EYE RES, V16, P117, DOI 10.1016/S1350-9462(96)00027-4; BEUERMAN RW, 1980, EXP NEUROL, V69, P196, DOI 10.1016/0014-4886(80)90154-5; Bongenhielm U, 1995, REGUL PEPTIDES, V60, P91, DOI 10.1016/0167-0115(95)00115-8; Bowden JJ, 1996, AM J PHYSIOL-LUNG C, V270, pL393; Brock JA, 2001, J PHYSIOL-LONDON, V533, P493, DOI 10.1111/j.1469-7793.2001.0493a.x; Brock JA, 1998, J PHYSIOL-LONDON, V512, P211, DOI 10.1111/j.1469-7793.1998.211bf.x; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; CARR RW, 1993, NEUROREPORT, V4, P467, DOI 10.1097/00001756-199305000-00001; CHAN KY, 1987, EXP EYE RES, V45, P633, DOI 10.1016/S0014-4835(87)80112-4; CHAN KY, 1982, EXP EYE RES, V35, P137, DOI 10.1016/S0014-4835(82)80062-6; Corcoran J, 2000, J CELL SCI, V113, P2567; DASTON GP, 1991, DERMAL OCULAR TOXICO, P509; DELVALLE ME, 1993, CELL MOL BIOL, V39, P801; GALLAR J, 1990, INVEST OPHTH VIS SCI, V31, P1968; Gan L, 2001, ACTA OPHTHALMOL SCAN, V79, P488, DOI 10.1034/j.1600-0420.2001.790512.x; GARCIAHIRSCHFELD J, 1994, EXP EYE RES, V59, P597, DOI 10.1006/exer.1994.1145; Griffith M, 1999, SCIENCE, V286, P2169, DOI 10.1126/science.286.5447.2169; Head H, 1905, BRAIN, V28, P116, DOI 10.1093/brain/28.2.116; HOLZER P, 1988, NEUROSCIENCE, V24, P739, DOI 10.1016/0306-4522(88)90064-4; Jones MA, 1996, INVEST OPHTH VIS SCI, V37, P2535; JUMBLATT MM, 1983, INVEST OPHTH VIS SCI, V24, P1139; KEEN P, 1982, NEUROSCI LETT, V29, P231, DOI 10.1016/0304-3940(82)90322-6; Koopmans SJ, 1998, DIABETOLOGIA, V41, P813, DOI 10.1007/s001250050992; Krarup C, 2002, ANN NEUROL, V51, P69, DOI 10.1002/ana.10054; Li YB, 1997, EXP NEUROL, V147, P452, DOI 10.1006/exnr.1997.6624; LIM C H, 1976, British Journal of Physiological Optics, V31, P38; Liu MX, 1999, CELL TISSUE RES, V297, P423, DOI 10.1007/s004410051369; MACIVER MB, 1993, J NEUROPHYSIOL, V69, P1779, DOI 10.1152/jn.1993.69.5.1779; Maden M, 1996, CURR BIOL, V6, P417, DOI 10.1016/S0960-9822(02)00509-2; Maden M., 1999, HANDB EXP PHARM, P399; MAGGI CA, 1991, J AUTONOM NERV SYST, V33, P1, DOI 10.1016/0165-1838(91)90013-S; Maurer JK, 1999, TOXICOL APPL PHARM, V158, P61, DOI 10.1006/taap.1999.8686; Miller C, 2002, TISSUE ENG, V8, P367, DOI 10.1089/107632702760184646; Mohan R, 2002, J BIOL CHEM, V277, P2065, DOI 10.1074/jbc.M107611200; Muller L, 1996, INVEST OPHTH VIS SCI, V37, P476; Muller LJ, 1997, INVEST OPHTH VIS SCI, V38, P985; Nakamura M, 1997, CURR EYE RES, V16, P275, DOI 10.1076/ceyr.16.3.275.15409; Neubert JK, 2000, BRAIN RES, V871, P181, DOI 10.1016/S0006-8993(00)02440-9; NILSSON J, 1985, NATURE, V315, P61, DOI 10.1038/315061a0; Nishida T, 1996, J CELL PHYSIOL, V169, P159, DOI 10.1002/(SICI)1097-4652(199610)169:1<159::AID-JCP16>3.0.CO;2-8; Obedencio GP, 1999, J INVEST DERMATOL, V113, P851, DOI 10.1046/j.1523-1747.1999.00763.x; PALKAMA A, 1986, EXP EYE RES, V43, P1043, DOI 10.1016/0014-4835(86)90081-3; PAVLIDIS C, 1994, INT J DEV NEUROSCI, V12, P587, DOI 10.1016/0736-5748(94)90066-3; QUINN SDP, 1991, IN VITRO CELL DEV B, V27, P55; RIGGOTT MJ, 1987, J COMP NEUROL, V258, P580, DOI 10.1002/cne.902580408; ROSSINO P, 1991, CELL REGUL, V2, P1021, DOI 10.1091/mbc.2.12.1021; ROY ML, 1992, J NEUROSCI, V12, P2104; ROZSA AJ, 1982, PAIN, V14, P105, DOI 10.1016/0304-3959(82)90092-6; TENTUSSCHER MPM, 1989, BRAIN RES, V494, P95, DOI 10.1016/0006-8993(89)90147-9; Tuori A, 1996, CORNEA, V15, P286, DOI 10.1097/00003226-199605000-00010; UNGER WG, 1990, J OCUL PHARMACOL, V6, P337, DOI 10.1089/jop.1990.6.337; UNGER WG, 1988, CURR EYE RES, V7, P761, DOI 10.3109/02713688809033207; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; Yu XJ, 2003, TISSUE ENG, V9, P421, DOI 10.1089/107632703322066606; Yu XJ, 1999, TISSUE ENG, V5, P291, DOI 10.1089/ten.1999.5.291; ZICHE M, 1990, BRIT J PHARMACOL, V100, P11, DOI 10.1111/j.1476-5381.1990.tb12043.x	61	47	57	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					170	172		10.1096/fj.03-0043fje	http://dx.doi.org/10.1096/fj.03-0043fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597567				2022-12-25	WOS:000188829300064
J	Jacquel, A; Herrant, M; Legros, L; Belhacene, N; Luciano, F; Pages, G; Hofman, P; Auberger, P				Jacquel, A; Herrant, M; Legros, L; Belhacene, N; Luciano, F; Pages, G; Hofman, P; Auberger, P			Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl positive K562 cell line and its differentiation towards the erythroid lineage	FASEB JOURNAL			English	Article						apoptosis; signal transduction; erythroid differentiation; c-DNA array	CHRONIC MYELOGENOUS LEUKEMIA; ENDOTHELIAL GROWTH-FACTOR; CHRONIC MYELOID-LEUKEMIA; FAS-MEDIATED APOPTOSIS; MEGAKARYOCYTIC DIFFERENTIATION; TYROSINE KINASE; HEMATOPOIETIC-CELLS; SIGNALING PATHWAY; IN-VIVO; TRANSCRIPTION FACTORS	Imatinib has emerged as the lead compound for clinical development against chronic myeloid leukemia. Imatinib inhibits the kinase activity of Bcr-Abl, which functions by enhancing the proliferation of hematopoietic precursors and protecting them against apoptosis. Imatinib induces apoptosis of Bcr-Abl positive cells, but how the drug effectively kills these cells remains partially understood. We show here that in K562 cells imatinib i) abolished Bcr-Abl phosphorylation and activity and as a consequence Erk1/2, JNK, and AKT activation; ii) induced mitochondrial transmembrane permeability dissipation; iii) activated caspases 3, 9, and 8, demonstrating that the effect of imatinib is integrated at the mitochondrial level; and iv) triggered caspase-dependent cleavage of Bcr-Abl. Interestingly, imatinib-mediated apoptosis was accompanied by erythroid differentiation of K562 cells. Moreover, phorbol esters inhibited imatinib-induced cell death and promoted differentiation toward the megakaryocytic lineage. Finally, we determined by c-DNA array analysis that more than 20 genes were modulated by imatinib. These genes are involved in both cell death and differentiation programs, and some of them have never been reported before to be expressed or involved in erythroid differentiation. Our results demonstrate that imatinib is responsible for a major modification of the genetic program resulting in death and/or differentiation of K562 cells.	Fac Med, INSERM, U526, Equipe Labellisee Ligue Natl Canc, F-06107 Nice 2, France; Fac Med, EPI 0215, IFR50, F-06107 Nice 2, France; Ctr Antoine Lacassagne, UMR 6543, F-06107 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Auberger, P (corresponding author), Fac Med, INSERM, U526, Equipe Labellisee Ligue Natl Canc, Ave Valombrose, F-06107 Nice 2, France.	auberger@unice.fr	Hofman, Paul/P-7654-2018; Jacquel, Arnaud/O-1928-2017; Pages, Gilles/N-7135-2017; AUBERGER, Patrick/G-1491-2013; luciano, frederic/P-6264-2016	Hofman, Paul/0000-0003-0431-9353; Jacquel, Arnaud/0000-0001-5062-8048; AUBERGER, Patrick/0000-0002-2481-8275; luciano, frederic/0000-0001-9253-4998				Advani AS, 2002, LEUKEMIA RES, V26, P713, DOI 10.1016/S0145-2126(01)00197-7; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Aro ALA, 2002, LEUKEMIA RES, V26, P831, DOI 10.1016/S0145-2126(02)00006-1; Athanasiou M, 2000, LEUKEMIA, V14, P439, DOI 10.1038/sj.leu.2401689; Bartel FO, 2000, ONCOGENE, V19, P6443, DOI 10.1038/sj.onc.1204038; Belhacene N, 1998, FASEB J, V12, P531; Bellamy WT, 1999, CANCER RES, V59, P728; Bellamy WT, 2001, SEMIN ONCOL, V28, P551, DOI 10.1053/sonc.2001.28606; Buchdunger E, 1996, CANCER RES, V56, P100; BURGER SR, 1992, EXP CELL RES, V202, P28, DOI 10.1016/0014-4827(92)90400-3; Burgess GS, 1998, BLOOD, V92, P2450, DOI 10.1182/blood.V92.7.2450.2450_2450_2460; Cortez D, 1996, ONCOGENE, V13, P2589; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Donato NJ, 2001, BLOOD, V97, P2846, DOI 10.1182/blood.V97.9.2846; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Ebos JML, 2002, MOL CANCER RES, V1, P89; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Gillet R, 2002, BIOL CELL, V94, P267, DOI 10.1016/S0248-4900(02)01201-7; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Hong Y, 1996, BLOOD, V87, P123, DOI 10.1182/blood.V87.1.123.bloodjournal871123; Ikonomi P, 2000, EXP HEMATOL, V28, P1423, DOI 10.1016/S0301-472X(00)00553-1; Jain SK, 1996, BLOOD, V88, P1542; Kawabata H, 2001, BLOOD, V98, P2714, DOI 10.1182/blood.V98.9.2714; Kim KW, 2001, J BIOL CHEM, V276, P13186, DOI 10.1074/jbc.M008092200; Lam LT, 2000, J BIOL CHEM, V275, P19676, DOI 10.1074/jbc.M002866200; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Le'Negrate G, 2000, J CELL BIOL, V150, P1479, DOI 10.1083/jcb.150.6.1479; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Luciano F, 2001, ONCOGENE, V20, P4935, DOI 10.1038/sj.onc.1204661; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Maulon L, 1998, BLOOD, V91, P4232, DOI 10.1182/blood.V91.11.4232.411k32_4232_4241; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; NOWELL PC, 1960, SCIENCE, V132, P1497; O'Dwyer ME, 2002, ANNU REV MED, V53, P369, DOI 10.1146/annurev.med.53.082901.103853; Osawa M, 2002, BLOOD, V100, P2769, DOI 10.1182/blood-2002-01-0182; Pane F, 2002, ONCOGENE, V21, P8652, DOI 10.1038/sj.onc.1206094; Park JI, 2001, CELL GROWTH DIFFER, V12, P481; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAKIC P, 1995, NEURON, V14, P1101, DOI 10.1016/0896-6273(95)90258-9; Ricci JE, 1999, ONCOGENE, V18, P3963, DOI 10.1038/sj.onc.1202782; Ricci JE, 2001, FASEB J, V15, P1777, DOI 10.1096/fj.00-0665fje; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Saleque S, 2002, GENE DEV, V16, P301, DOI 10.1101/gad.959102; SAWYERS CL, 1993, LEUKEMIA LYMPHOMA, V11, P101, DOI 10.3109/10428199309064268; Shet AS, 2002, LEUKEMIA, V16, P1402, DOI 10.1038/sj.leu.2402577; Shivdasani RA, 2001, STEM CELLS, V19, P397, DOI 10.1634/stemcells.19-5-397; Sordet O, 1999, CELL DEATH DIFFER, V6, P351, DOI 10.1038/sj.cdd.4400499; Talpaz M, 2002, BLOOD, V99, P1928, DOI 10.1182/blood.V99.6.1928; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Yu CR, 2002, CANCER RES, V62, P188; Yuksel S, 2002, LEUKEMIA RES, V26, P391, DOI 10.1016/S0145-2126(01)00147-3; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zhu J, 2002, ONCOGENE, V21, P3295, DOI 10.1038/sj.onc.1205318; ZUTTER MM, 1992, J BIOL CHEM, V267, P20233	61	102	107	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2160	+		10.1096/fj.03-0322fje	http://dx.doi.org/10.1096/fj.03-0322fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14597677				2022-12-25	WOS:000185925100024
J	Albrecht, DE; Froehner, SC				Albrecht, DE; Froehner, SC			DAMAGE, a novel alpha-dystrobrevin-associated MAGE protein in dystrophin complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P75 NEUROTROPHIN RECEPTOR; DUCHENNE MUSCULAR-DYSTROPHY; WIEACKER-WOLFF-SYNDROME; TORPEDO ELECTRIC ORGAN; CELL-CYCLE PROGRESSION; CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; SKELETAL-MUSCLE; DIFFERENTIAL EXPRESSION; POSTSYNAPTIC PROTEIN	Mice rendered null for a-dystrobrevin, a component of the dystrophin complex, have muscular dystrophy, despite the fact that the sarcolemma remains relatively intact (Grady, R. M., Grange, R. W., Lau, K. S., Maimone, M. M., Nichol, M. C., Stull, J. T., and Sanes, J. R. (1999) Nat. Cell Biol. 1, 215-220) Thus, alpha-dystrobrevin may serve a signaling function that is important for the maintenance of muscle integrity. We have identified a new dystrobrevin-associated protein, DAMAGE, that may play a signaling role in brain, muscle, and peripheral nerve. In humans, DAMAGE is encoded by an intronless gene located at chromosome Xq13.1, a locus that contains genes involved in mental retardation. DAMAGE associates directly with alpha-dystrobrevin, as shown by yeast two-hybrid, and co-immunoprecipitates with the dystrobrevin-syntrophin complex from brain. This co-immunoprecipitation is dependent on the presence of alpha-dystrobrevin but not beta-dystrobrevin. The DAMAGE protein contains a potential nuclear localization signal, 30 12-amino acid repeats, and two MAGE homology domains. The domain structure of DAMAGE is similar to that of NRAGE, a MAGE protein that mediates p75 neurotrophin receptor signaling and neuronal apoptosis (Salehi, A. H., Roux, P. P., Kubu, C. J., Zeindler, C., Bhakar, A., Tannis, L. L., Verdi, J. M., and Barker, P. A. (2000) Neuron 27,279 -288). DAMAGE is highly expressed in brain and is present in the cell bodies and dendrites of hippocampal and Purkinje neurons. In skeletal muscle, DAMAGE is at the postsynaptic membrane and is associated with a subset of myonuclei. DAMAGE is also expressed in peripheral nerve, where it localizes along with other members of the dystrophin complex to the perineurium and myelin. These results expand the role of dystrobrevin and the dystrophin complex in membrane signaling and disease.	Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Froehner, SC (corresponding author), Univ Washington, Dept Physiol & Biophys, Box 357290, Seattle, WA 98195 USA.	froehner@u.washington.edu						Adams ME, 2001, J CELL BIOL, V155, P113, DOI 10.1083/jcb.200106158; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; Balasubramanian S, 1998, FEBS LETT, V432, P133, DOI 10.1016/S0014-5793(98)00804-7; Barker PA, 2002, J NEUROSCI RES, V67, P705, DOI 10.1002/jnr.10160; Benson MA, 2001, J BIOL CHEM, V276, P24232, DOI 10.1074/jbc.M010418200; Blake DJ, 1998, P NATL ACAD SCI USA, V95, P241, DOI 10.1073/pnas.95.1.241; Blake DJ, 1999, J CELL BIOL, V147, P645, DOI 10.1083/jcb.147.3.645; Blake DJ, 1996, J BIOL CHEM, V271, P7802, DOI 10.1074/jbc.271.13.7802; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BUTLER MH, 1992, J BIOL CHEM, V267, P6213; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; Ceccarini M, 2002, NEUROMUSCULAR DISORD, V12, P36, DOI 10.1016/S0960-8966(01)00230-9; Chomez P, 2001, CANCER RES, V61, P5544; DWYER TM, 1995, FEBS LETT, V375, P91, DOI 10.1016/0014-5793(95)01176-F; Enigk RE, 1999, GENE, V238, P479, DOI 10.1016/S0378-1119(99)00358-3; Gee SH, 1998, J NEUROSCI, V18, P128; Gorecki DC, 1997, EUR J NEUROSCI, V9, P965, DOI 10.1111/j.1460-9568.1997.tb01447.x; Grady RM, 2003, J CELL BIOL, V160, P741, DOI 10.1083/jcb.200209045; Grady RM, 1999, NAT CELL BIOL, V1, P215, DOI 10.1038/12034; Hasegawa M, 1999, J BIOL CHEM, V274, P12626, DOI 10.1074/jbc.274.18.12626; Howman EV, 2003, NEUROMUSCULAR DISORD, V13, P42, DOI 10.1016/S0960-8966(02)00181-5; Hwang JJ, 2002, PHYSIOL GENOMICS, V10, P31, DOI 10.1152/physiolgenomics.00122.2001; Ichida F, 2001, CIRCULATION, V103, P1256; Jones KJ, 1998, J MED GENET, V35, P379, DOI 10.1136/jmg.35.5.379; Jordan BWM, 2001, J BIOL CHEM, V276, P39985, DOI 10.1074/jbc.C100171200; KARPATI G, 1993, J NEUROPATH EXP NEUR, V52, P119, DOI 10.1097/00005072-199303000-00004; Kendall SE, 2002, MECH DEVELOP, V117, P187, DOI 10.1016/S0925-4773(02)00204-6; Kloos DU, 1997, HUM GENET, V100, P426, DOI 10.1007/s004390050528; Knuesel I, 2000, J COMP NEUROL, V422, P594, DOI 10.1002/1096-9861(20000710)422:4<594::AID-CNE8>3.0.CO;2-Q; Li W, 2003, NAT GENET, V35, P84, DOI 10.1038/ng1229; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; Liu JW, 1999, J NEUROL SCI, V164, P24, DOI 10.1016/S0022-510X(99)00051-9; Lumeng C, 1999, NAT NEUROSCI, V2, P611, DOI 10.1038/10165; Masuda Y, 2001, J BIOL CHEM, V276, P5331, DOI 10.1074/jbc.M008590200; Mizuno Y, 2001, P NATL ACAD SCI USA, V98, P6156, DOI 10.1073/pnas.111153298; Moukhles H, 2001, J NEUROCHEM, V78, P824, DOI 10.1046/j.1471-4159.2001.00466.x; Mussini I, 1995, ITALIAN JOURNAL OF ANATOMY AND EMBRYOLOGY, VOL 100 - SUPPLEMENT N.1 - 1995, P155; Nawrotzki R, 1998, J CELL SCI, V111, P2595; Newey SE, 2001, J BIOL CHEM, V276, P6645, DOI 10.1074/jbc.M008305200; Peters MF, 1998, J CELL BIOL, V142, P1269, DOI 10.1083/jcb.142.5.1269; Peters MF, 1997, J BIOL CHEM, V272, P31561, DOI 10.1074/jbc.272.50.31561; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rowinski J, 1996, Folia Morphol (Warsz), V55, P428; SadouletPuccio HM, 1997, P NATL ACAD SCI USA, V94, P12413, DOI 10.1073/pnas.94.23.12413; SadouletPuccio HM, 1996, HUM MOL GENET, V5, P489, DOI 10.1093/hmg/5.4.489; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; Salehi AH, 2002, J BIOL CHEM, V277, P48043, DOI 10.1074/jbc.M205324200; Sasaki A, 2002, J BIOL CHEM, V277, P22541, DOI 10.1074/jbc.M109728200; Sherman DL, 2001, NEURON, V30, P677, DOI 10.1016/S0896-6273(01)00327-0; Shiras Anjali, 2001, Molecular Cell Biology Research Communications, V4, P313, DOI 10.1006/mcbr.2001.0298; Sogos V, 2002, MECH AGEING DEV, V123, P455, DOI 10.1016/S0047-6374(01)00360-8; Straub RE, 2002, AM J HUM GENET, V71, P337, DOI 10.1086/341750; Tackels D, 1999, AM J MED GENET, V85, P221; Taniura H, 1999, J BIOL CHEM, V274, P16242, DOI 10.1074/jbc.274.23.16242; Taniura H, 1998, J BIOL CHEM, V273, P720, DOI 10.1074/jbc.273.2.720; Tcherpakov M, 2002, J BIOL CHEM, V277, P49101, DOI 10.1074/jbc.C200533200; Uchino M, 1996, INTERNAL MED, V35, P189, DOI 10.2169/internalmedicine.35.189; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; WIEACKER P, 1987, AM J MED GENET, V28, P245, DOI 10.1002/ajmg.1320280137; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; Zaccaria ML, 2001, NEUROSCIENCE, V104, P311, DOI 10.1016/S0306-4522(01)00092-6	64	24	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7014	7023		10.1074/jbc.M312205200	http://dx.doi.org/10.1074/jbc.M312205200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14623885	hybrid			2022-12-25	WOS:000188969200098
J	Yang, PZ; Fu, HY; Walker, J; Papa, CM; Smalle, J; Ju, YM; Vierstra, RD				Yang, PZ; Fu, HY; Walker, J; Papa, CM; Smalle, J; Ju, YM; Vierstra, RD			Purification of the Arabidopsis 26 S proteasome - Biochemical and molecular analyses revealed the presence of multiple isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PARTICLE SUBUNITS; MULTIUBIQUITIN-CHAIN-BINDING; RABBIT RETICULOCYTE LYSATE; YEAST 26S PROTEASOME; SACCHAROMYCES-CEREVISIAE; 20S PROTEASOME; CELL-CYCLE; FUNCTIONAL-CHARACTERIZATION; DEUBIQUITINATING ENZYME; DEPENDENT PROTEOLYSIS	The 26 S proteasome is a multisubunit protease complex responsible for degrading a wide range of intracellular proteins in eukaryotes, especially those modified with polyubiquitin chains. It is composed of a self-compartmentalized core protease (CP) that houses the peptidase active sites appended on either or both ends by a regulatory particle (RP) that identifies appropriate substrates and translocates them into the lumen of the CP for breakdown. Here, we describe the molecular and biochemical properties of the 26 S proteasome from the plant Arabidopsis thaliana. Like the CP and the ATPase ring of the RP, the RP non-ATPase subunits are often encoded by two transcriptionally active genes with some pairs displaying sufficient sequence divergence to suggest functional differences. Most RPN subunits could functionally replace their yeast counterparts, implying that they have retained their positions and activities within the complex. A method was developed to purify the 26 S proteasome intact from whole Arabidopsis seedlings. These preparations are biochemically indistinguishable from those from yeast and mammals, including the need for ATP to maintain integrity and a strong sensitivity to the inhibitors MG115, MG132, lactacystin, and epoxomicin. Mass spectrometric analysis of the complex detected the presence of almost all CP and RP subunits. In many cases, both products of paralogous genes were detected, demonstrating that each isoform assembles into the mature particle. As with the yeast and animal 26 S proteasomes, attenuation of individual RP genes induces a coordinated up-regulation of many of the other 26 S proteasome genes, suggesting that plants contain a negative feedback mechanism to regulate the 26 S proteasome levels. The incorporation of paralogous subunits into the Arabidopsis holoprotease raises the intriguing possibility that plants synthesize multiple 26 S proteasome types with unique properties and/or target specificities.	Acad Sinica, Inst Bot, Taipei 11529, Taiwan; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA	Academia Sinica - Taiwan; University of Wisconsin System; University of Wisconsin Madison	Fu, HY (corresponding author), Acad Sinica, Inst Bot, 128,Sec 2,Acad Rd, Taipei 11529, Taiwan.	hongyong@gate.sinica.edu.tw; vierstra@wisc.edu	Fu, Hongyong/A-7575-2011; Ju, Yu-Ming/F-7379-2010	Fu, Hongyong/0000-0001-5143-3269; 				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bailly E, 1999, MOL CELL BIOL, V19, P6872; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; CHRISTIANSON AMK, 1992, P NATL ACAD SCI USA, V89, P11503, DOI 10.1073/pnas.89.23.11503; Dahlmann B, 2000, J MOL BIOL, V303, P643, DOI 10.1006/jmbi.2000.4185; de Leon IP, 2002, PLANT J, V29, P61, DOI 10.1046/j.1365-313x.2002.01195.x; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Doelling JH, 2001, PLANT J, V27, P393, DOI 10.1046/j.1365-313X.2001.01106.x; Downes BP, 2003, PLANT J, V35, P729, DOI 10.1046/j.1365-313X.2003.01844.x; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fu HY, 2001, EMBO J, V20, P7096, DOI 10.1093/emboj/20.24.7096; Fu HY, 1999, PLANT J, V18, P529, DOI 10.1046/j.1365-313X.1999.00479.x; Fu HY, 1998, GENETICS, V149, P677; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; FUJINAMI K, 1994, J BIOL CHEM, V269, P25905; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; GENSCHIK P, 1994, PLANT J, V6, P537, DOI 10.1046/j.1365-313X.1994.6040537.x; Genschik P, 1998, PLANT CELL, V10, P2063; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HAASS C, 1989, EXP CELL RES, V180, P243, DOI 10.1016/0014-4827(89)90228-0; Hamberg M, 1999, J BIOL CHEM, V274, P24503, DOI 10.1074/jbc.274.35.24503; Hellmann H, 2002, SCIENCE, V297, P793, DOI 10.1126/science.1072831; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; Holzl H, 2000, J CELL BIOL, V150, P119, DOI 10.1083/jcb.150.1.119; HOUGH R, 1987, J BIOL CHEM, V262, P8303; Kikukawa Y, 2002, BIOL CHEM, V383, P1257, DOI 10.1515/BC.2002.139; KIMMEL AR, 1985, MOL CELL BIOL, V5, P2123, DOI 10.1128/MCB.5.8.2123; Kimura Y, 2003, ARCH BIOCHEM BIOPHYS, V409, P341, DOI 10.1016/S0003-9861(02)00639-2; Kimura Y, 2000, J BIOL CHEM, V275, P4635, DOI 10.1074/jbc.275.7.4635; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Kloetzel PM, 2001, NAT REV MOL CELL BIO, V2, P179, DOI 10.1038/35056572; Kohler A, 2001, MOL CELL, V7, P1143, DOI 10.1016/S1097-2765(01)00274-X; Kominami K, 1997, MOL BIOL CELL, V8, P171, DOI 10.1091/mbc.8.1.171; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Li TW, 2001, FEBS LETT, V488, P201, DOI 10.1016/S0014-5793(00)02436-4; Lopez-Molina L, 2001, P NATL ACAD SCI USA, V98, P4782, DOI 10.1073/pnas.081594298; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P195, DOI 10.1016/S0968-0004(97)01058-X; Meiners S, 2003, J BIOL CHEM, V278, P21517, DOI 10.1074/jbc.M301032200; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Papa FR, 1999, MOL BIOL CELL, V10, P741, DOI 10.1091/mbc.10.3.741; Peng ZH, 2003, CURR BIOL, V13, pR504, DOI 10.1016/S0960-9822(03)00439-1; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rivett AJ, 2001, BIOCHIMIE, V83, P363; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rockel B, 2002, EMBO J, V21, P5979, DOI 10.1093/emboj/cdf601; Satoh K, 2001, BIOCHEMISTRY-US, V40, P314, DOI 10.1021/bi001815n; Seifert U, 2003, NAT IMMUNOL, V4, P375, DOI 10.1038/ni905; Shibahara T, 2002, EUR J BIOCHEM, V269, P1474, DOI 10.1046/j.1432-1033.2002.02792.x; SIKORSKI RS, 1989, GENETICS, V122, P19; Simillion C, 2002, P NATL ACAD SCI USA, V99, P13627, DOI 10.1073/pnas.212522399; Smalle J, 2003, PLANT CELL, V15, P965, DOI 10.1105/tpc.009217; Smalle J, 2002, PLANT CELL, V14, P17, DOI 10.1105/tpc.010381; SMALLE J, 2004, IN PRESS ANN REV PLA, V54; Suty L, 2003, INT J BIOCHEM CELL B, V35, P637, DOI 10.1016/S1357-2725(02)00386-2; Takeuchi J, 1999, MOL CELL BIOL, V19, P6575; Unno M, 2002, STRUCTURE, V10, P609, DOI 10.1016/S0969-2126(02)00748-7; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Walz J, 1998, J STRUCT BIOL, V121, P19, DOI 10.1006/jsbi.1998.3958; Wang EW, 2000, P NATL ACAD SCI USA, V97, P9990, DOI 10.1073/pnas.180328897; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilkinson CRM, 2000, J BIOL CHEM, V275, P15182, DOI 10.1074/jbc.275.20.15182; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Woffenden BJ, 1998, PLANT PHYSIOL, V118, P419, DOI 10.1104/pp.118.2.419; Wojcik C, 2002, J BIOL CHEM, V277, P6188, DOI 10.1074/jbc.M109996200; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497; Xie YM, 2001, P NATL ACAD SCI USA, V98, P3056, DOI 10.1073/pnas.071022298; Yan N, 2000, PLANT PHYSIOL, V124, P1828, DOI 10.1104/pp.124.4.1828; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; Yuan XQ, 1996, GENETICS, V144, P147	79	128	184	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6401	6413		10.1074/jbc.M311977200	http://dx.doi.org/10.1074/jbc.M311977200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14623884	hybrid			2022-12-25	WOS:000188969200026
J	Bartlett, MS; Thomm, M; Geiduschek, EP				Bartlett, MS; Thomm, M; Geiduschek, EP			Topography of the euryarchaeal transcription initiation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; CELL-FREE TRANSCRIPTION; START SITE SELECTION; PHOTOCHEMICAL CROSS-LINKING; 3.3 ANGSTROM RESOLUTION; STRUCTURAL BASIS; ARCHAEAL TRANSCRIPTION; PREINITIATION COMPLEX; PYROCOCCUS-FURIOSUS	Transcription in the Archaea is carried out by RNA polymerases and transcription factors that are highly homologous to their eukaryotic counterparts, but little is known about the structural organization of the archaeal transcription complex. To address this, transcription initiation complexes have been formed with Pyrococcus furiosus transcription factors (TBP and TFB1), RNA polymerase, and a linear DNA fragment containing a strong promoter. The arrangement of proteins from base pair -35 to +20 (relative to the transcriptional start site) has been analyzed by photochemical protein-DNA cross-linking. TBP cross-links to the TATA box and TFB1 cross-links both upstream and downstream of the TATA box, as expected, but the sites of most prominent TFB1 cross-linking are located well downstream of the TATA box, reaching as far as the start site of transcription, suggesting a role for TFB1 in initiation of transcription that extends beyond polymerase recruitment. These cross-links indicate the transcription factor orientation in the initiation complex. The pattern of cross-linking of four RNA polymerase subunits (B, A', A', and H) to the promoter suggests a path for promoter DNA relative to the RNA polymerase surface in this archaeal transcription initiation complex. In addition, an unidentified protein approximately the size of TBP cross-links to the non-transcribed DNA strand near the upstream edge of the transcription bubble. Cross-linking is specific to the polymerase-containing initiation complex and requires the gdh promoter TATA box. The location of this protein suggests that it, like TFB1, could also have a role in transcription initiation following RNA polymerase recruitment.	Univ Calif San Diego, Ctr Mol Genet, Div Biol Sci, La Jolla, CA 92093 USA; Univ Kiel, Inst Allgemeine Mikrobiol, D-24118 Kiel, Germany	University of California System; University of California San Diego; University of Kiel	Bartlett, MS (corresponding author), Portland State Univ, Dept Biol, POB 751, Portland, OR 97207 USA.	micb@pdx.edu						ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; Armache KJ, 2003, P NATL ACAD SCI USA, V100, P6964, DOI 10.1073/pnas.1030608100; BARTHOLOMEW B, 1993, MOL CELL BIOL, V13, P942, DOI 10.1128/MCB.13.2.942; Bartholomew B, 1995, METHOD ENZYMOL, V262, P476; Bartlett MS, 2000, NAT STRUCT BIOL, V7, P782, DOI 10.1038/79020; Bell SD, 2000, J BIOL CHEM, V275, P12934, DOI 10.1074/jbc.275.17.12934; Bell SD, 1999, MOL CELL, V4, P971, DOI 10.1016/S1097-2765(00)80226-9; Bell SD, 2001, EMBO REP, V2, P133, DOI 10.1093/embo-reports/kve021; Chen HT, 2003, MOL CELL, V12, P437, DOI 10.1016/S1097-2765(03)00306-X; Cho EJ, 1999, J BIOL CHEM, V274, P25807, DOI 10.1074/jbc.274.36.25807; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; FREY G, 1990, NUCLEIC ACIDS RES, V18, P1361, DOI 10.1093/nar/18.6.1361; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; HAIN J, 1992, NUCLEIC ACIDS RES, V20, P5423, DOI 10.1093/nar/20.20.5423; Hanzelka BL, 2001, J BACTERIOL, V183, P1813, DOI 10.1128/JB.183.5.1813-1818.2001; HAUSNER W, 1991, J MOL BIOL, V222, P495, DOI 10.1016/0022-2836(91)90492-O; Hausner W, 1996, J BIOL CHEM, V271, P30144, DOI 10.1074/jbc.271.47.30144; Hausner W, 2001, J BACTERIOL, V183, P3025, DOI 10.1128/JB.183.10.3025-3031.2001; Hawkes NA, 1999, J BIOL CHEM, V274, P14337, DOI 10.1074/jbc.274.20.14337; Hethke C, 1996, NUCLEIC ACIDS RES, V24, P2369, DOI 10.1093/nar/24.12.2369; JUE RA, 1985, BIOCHEMISTRY-US, V24, P162, DOI 10.1021/bi00322a023; Juo ZS, 2003, NATURE, V422, P534, DOI 10.1038/nature01534; Kassavetis GA, 2003, J BIOL CHEM, V278, P17912, DOI 10.1074/jbc.M300743200; Kassavetis GA, 2001, EMBO J, V20, P2823, DOI 10.1093/emboj/20.11.2823; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Korzheva N, 1998, COLD SPRING HARB SYM, V63, P337, DOI 10.1101/sqb.1998.63.337; LANGER D, 1995, P NATL ACAD SCI USA, V92, P5768, DOI 10.1073/pnas.92.13.5768; Littlefield O, 1999, P NATL ACAD SCI USA, V96, P13668, DOI 10.1073/pnas.96.24.13668; Magill CP, 2001, J BIOL CHEM, V276, P46693, DOI 10.1074/jbc.C100567200; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Naryshkin N, 2000, CELL, V101, P601, DOI 10.1016/S0092-8674(00)80872-7; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Ouhammouch M, 2003, P NATL ACAD SCI USA, V100, P5097, DOI 10.1073/pnas.0837150100; Pardee TS, 1998, J BIOL CHEM, V273, P17859, DOI 10.1074/jbc.273.28.17859; PINTO I, 1994, J BIOL CHEM, V269, P30569; QURESHI SA, 1995, NUCLEIC ACIDS RES, V23, P1775, DOI 10.1093/nar/23.10.1775; Qureshi SA, 1998, MOL CELL, V1, P389, DOI 10.1016/S1097-2765(00)80039-8; Robb FT, 2001, METHOD ENZYMOL, V330, P134; ROWLANDS T, 1994, SCIENCE, V264, P1326, DOI 10.1126/science.8191287; Shah SMA, 1999, J BIOL CHEM, V274, P28736, DOI 10.1074/jbc.274.40.28736; Sokolenko A. A., 1996, Molekulyarnaya Biologiya (Moscow), V30, P279; Soppa J, 1999, MOL MICROBIOL, V31, P1295, DOI 10.1046/j.1365-2958.1999.01273.x; Spitalny P, 2003, J BIOL CHEM, V278, P30497, DOI 10.1074/jbc.M303633200; Tsai FTF, 2000, EMBO J, V19, P25, DOI 10.1093/emboj/19.1.25; USHNELL DA, 2003, P NATL ACAD SCI USA, V100, P6969; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Werner F, 2002, MOL CELL, V10, P635, DOI 10.1016/S1097-2765(02)00629-9; Woychik NA, 2002, CELL, V108, P453, DOI 10.1016/S0092-8674(02)00646-3; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122; ZILLIG W, 1993, BIOCH ARCHAEA ARCHAE, P367	56	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5894	5903		10.1074/jbc.M311429200	http://dx.doi.org/10.1074/jbc.M311429200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14617625	hybrid			2022-12-25	WOS:000188776500105
J	Gan, L; Ye, SM; Chu, A; Anton, K; Yi, SL; Vincent, VA; von Schack, D; Chin, D; Murray, J; Lohr, S; Patthy, L; Gonzalez-Zulueta, M; Nikolich, K; Urfer, R				Gan, L; Ye, SM; Chu, A; Anton, K; Yi, SL; Vincent, VA; von Schack, D; Chin, D; Murray, J; Lohr, S; Patthy, L; Gonzalez-Zulueta, M; Nikolich, K; Urfer, R			Identification of cathepsin B as a mediator of neuronal death induced by A beta-activated microglial cells using a functional genomics approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; AMYLOID-BETA; ALZHEIMERS-DISEASE; MURINE MICROGLIA; IN-VITRO; PLAQUE-FORMATION; SENILE PLAQUES; NITRIC-OXIDE; BRAIN-INJURY; PEPTIDE	Alzheimer's disease is a progressive neurodegenerative disease characterized by senile plaques, neurofibrillary tangles, dystrophic neurites, and reactive glial cells. Activated microglia are found to be intimately associated with senile plaques and may play a central role in mediating chronic inflammatory conditions in Alzheimer's disease. Activation of cultured murine microglial BV2 cells by freshly sonicated A beta 42 results in the secretion of neurotoxic factors that kill primary cultured neurons. To understand molecular pathways underlying Abeta- induced microglial activation, we analyzed the expression levels of transcripts isolated from Abeta42- activated BV2 cells using high density filter arrays. The analysis of these arrays identified 554 genes that are transcriptionally up- regulated by Abeta42 in a statistically significant manner. Quantitative reverse transcription-PCR was used to confirm the regulation of a subset of genes, including cysteine proteases cathepsin B and cathepsin L, tissue inhibitor of matrix metalloproteinase 2, cytochrome c oxidase, and allograft inflammatory factor 1. Small interfering RNA- mediated silencing of the cathepsin B gene in A beta- activated BV2 cells diminished the microglial activation- mediated neurotoxicity. Moreover, CA- 074, a specific cathepsin B inhibitor, also abolished the neurotoxic effects caused by A beta 42- activated BV2 cells. Our results suggest an essential role for secreted cathepsin B in neuronal death mediated by Abeta-activated inflammatory response.	AGY Therapeut Inc, San Francisco, CA 94080 USA		Gan, L (corresponding author), Gladstone Inst Neurol Dis, POB 419100, San Francisco, CA 94141 USA.	lgan@gladstone.ucsf.edu	Patthy, Laszlo/Q-6058-2019; Patthy, Laszlo/A-2353-2013; Murray, Joseph C/J-8916-2014	Murray, Joseph C/0000-0001-6159-7814				Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bal-Price A, 2001, J NEUROSCI, V21, P6480; BANATI RB, 1993, GLIA, V7, P183, DOI 10.1002/glia.440070208; Berti R, 2002, J CEREBR BLOOD F MET, V22, P1068, DOI 10.1097/00004647-200209000-00004; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P627, DOI 10.1007/s004010000232; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Braak H, 1997, NEUROBIOL AGING, V18, P351, DOI 10.1016/S0197-4580(97)00056-0; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; Chung HY, 1999, J BIOL CHEM, V274, P32301, DOI 10.1074/jbc.274.45.32301; Combs CK, 2001, J NEUROSCI, V21, P1179; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; DelNery E, 1997, J BIOL CHEM, V272, P25713, DOI 10.1074/jbc.272.41.25713; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gasic-Milenkovic J, 2003, EUR J NEUROSCI, V17, P813, DOI 10.1046/j.1460-9568.2003.02506.x; Giulian D, 1996, J NEUROSCI, V16, P6021; GIULIAN D, 1995, NEUROCHEM INT, V27, P119, DOI 10.1016/0197-0186(95)00067-I; Gray J, 2001, J BIOL CHEM, V276, P32750, DOI 10.1074/jbc.M103150200; Hashimoto Y, 2001, BIOCHEM BIOPH RES CO, V283, P334, DOI 10.1006/bbrc.2001.4787; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kingham PJ, 2001, J NEUROCHEM, V76, P1475, DOI 10.1046/j.1471-4159.2001.00146.x; Kingham PJ, 2000, J NEUROCHEM, V74, P1452, DOI 10.1046/j.1471-4159.2000.0741452.x; Klegeris A, 1997, BRAIN RES, V747, P114, DOI 10.1016/S0006-8993(96)01229-2; Kopec KK, 1998, J NEUROCHEM, V71, P2123; Licastro F, 1998, J NEUROIMMUNOL, V88, P105, DOI 10.1016/S0165-5728(98)00096-4; Lorton D, 1996, J NEUROIMMUNOL, V67, P21, DOI 10.1016/S0165-5728(96)00030-6; Mackenzie IRA, 1998, NEUROLOGY, V50, P986, DOI 10.1212/WNL.50.4.986; McDonald DR, 1997, J NEUROSCI, V17, P2284; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; McGeer PL, 2001, NEUROBIOL AGING, V22, P799, DOI 10.1016/S0197-4580(01)00289-5; Mitrasinovic OM, 2002, J BIOL CHEM, V277, P29889, DOI 10.1074/jbc.M200868200; MIYAZONO M, 1991, AM J PATHOL, V139, P589; MURATA M, 1991, FEBS LETT, V280, P307, DOI 10.1016/0014-5793(91)80318-W; Pagenstecher A, 1998, AM J PATHOL, V152, P729; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Phillips JB, 2000, STROKE, V31, P1686, DOI 10.1161/01.STR.31.7.1686; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; Rogers J, 2002, GLIA, V40, P260, DOI 10.1002/glia.10153; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; RYAN RE, 1995, J NEUROCHEM, V65, P1035; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Siao CJ, 2002, CELL MOL BIOL, V48, P151; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Veerhuis R, 2003, ACTA NEUROPATHOL, V105, P135, DOI 10.1007/s00401-002-0624-7; WHITSON JS, 1989, SCIENCE, V243, P1488, DOI 10.1126/science.2928783; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Wyss-Coray T, 2002, P NATL ACAD SCI USA, V99, P10837, DOI 10.1073/pnas.162350199; Yan SQ, 1998, BIOL CHEM, V379, P113; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Yates SL, 2000, J NEUROCHEM, V74, P1017, DOI 10.1046/j.1471-4159.2000.0741017.x; Zandi PP, 2002, NEUROLOGY, V59, P880, DOI 10.1212/WNL.59.6.880	57	113	129	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5565	5572		10.1074/jbc.M306183200	http://dx.doi.org/10.1074/jbc.M306183200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14612454	hybrid			2022-12-25	WOS:000188776500065
J	Alonso, A; Bottini, N; Bruckner, S; Rahmouni, S; Williams, S; Schoenberger, SP; Mustelin, T				Alonso, A; Bottini, N; Bruckner, S; Rahmouni, S; Williams, S; Schoenberger, SP; Mustelin, T			Lck dephosphorylation at Tyr-394 and inhibition of T cell antigen receptor signaling by Yersinia phosphatase YopH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; N-TERMINAL DOMAIN; PHOSPHORYLATION; SUBSTRATE; IDENTIFICATION; SUPPRESSION; ACTIVATION; P130(CAS); PLAGUE; VHR	A key virulence factor for Yersinia pestis, the etiologic agent of plague, is the tyrosine phosphatase YopH, which the bacterium injects into host cells. We report that treatment of human T lymphocytes with a recombinant membrane-permeable YopH resulted in severe reduction in intracellular tyrosine phosphorylation and inhibition of T cell activation. The primary signal transducer for the T cell antigen receptor, the Lck tyrosine kinase, was specifically precipitated by a substrate-trapping YopH mutant, and Lck was dephosphorylated at its positive regulatory site, Tyr-394, in cells containing active YopH. By turning off Lck, YopH blocks T cell antigen receptor signaling at its very first step, effectively preventing the development of a protective immune response against this lethal bacterium.	Burnham Inst, Canc Res Ctr, Program Signal Transduct, La Jolla, CA 92037 USA; La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA	Sanford Burnham Prebys Medical Discovery Institute; La Jolla Institute for Immunology	Mustelin, T (corresponding author), Burnham Inst, Canc Res Ctr, Program Signal Transduct, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	tmustelin@burnham-inst.org	Alonso, Andrés/L-7523-2014; Ingegnoli, Francesca/B-6226-2017	Alonso, Andrés/0000-0001-8674-9378; Mustelin, Tomas/0000-0001-5912-8840; Ingegnoli, Francesca/0000-0002-6727-1273	NIAID NIH HHS [AI53114] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI053114] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aepfelbacher M, 1999, BIOL CHEM, V380, P795, DOI 10.1515/BC.1999.099; Alonso A, 2003, NAT IMMUNOL, V4, P44, DOI 10.1038/ni856; Alonso A, 2001, J BIOL CHEM, V276, P4766, DOI 10.1074/jbc.M006497200; Andersson K, 1996, MOL MICROBIOL, V20, P1057, DOI 10.1111/j.1365-2958.1996.tb02546.x; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; Cheng LW, 2000, J BACTERIOL, V182, P3183, DOI 10.1128/JB.182.11.3183-3190.2000; CHRISTIE A B, 1982, Ecology of Disease, V1, P111; Cleri D J, 1997, Semin Respir Infect, V12, P12; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Cornelis GR, 2000, P NATL ACAD SCI USA, V97, P8778, DOI 10.1073/pnas.97.16.8778; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; Ernst JD, 2000, CELL MICROBIOL, V2, P379, DOI 10.1046/j.1462-5822.2000.00075.x; Evdokimov AG, 2001, ACTA CRYSTALLOGR D, V57, P793, DOI 10.1107/S0907444901004875; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FRIESEN HG, 1995, MRC COMMUNIQUE, V21, P2; Gjorloff-Wingren A, 2000, EUR J IMMUNOL, V30, P2412, DOI 10.1002/1521-4141(2000)30:8<2412::AID-IMMU2412>3.0.CO;2-J; GREEN SP, 1995, J LEUKOCYTE BIOL, V57, P972, DOI 10.1002/jlb.57.6.972; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; Hinnebusch BJ, 1997, J MOL MED, V75, P645, DOI 10.1007/s001090050148; Inglesby TV, 2000, JAMA-J AM MED ASSOC, V283, P2281, DOI 10.1001/jama.283.17.2281; Kholod N, 2001, BIOTECHNIQUES, V31, P322, DOI 10.2144/01312st03; Montagna LG, 2001, J BIOL CHEM, V276, P5005, DOI 10.1074/jbc.M009045200; Mustelin T, 2002, FRONT BIOSCI-LANDMRK, V7, pD918, DOI 10.2741/musteli1; MUSTELIN T, 1994, SRC FAMILY TYROSINE; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; PERSSON C, 1995, MOL MICROBIOL, V18, P135, DOI 10.1111/j.1365-2958.1995.mmi_18010135.x; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Titball RW, 1998, BRIT MED BULL, V54, P625, DOI 10.1093/oxfordjournals.bmb.a011715; Titball RW, 2001, VACCINE, V19, P4175, DOI 10.1016/S0264-410X(01)00163-3; Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7; Wang XD, 2002, J IMMUNOL, V168, P4612, DOI 10.4049/jimmunol.168.9.4612; Yao T, 1999, J EXP MED, V190, P1343, DOI 10.1084/jem.190.9.1343	35	85	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4922	4928		10.1074/jbc.M308978200	http://dx.doi.org/10.1074/jbc.M308978200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14623872	hybrid			2022-12-25	WOS:000188554300118
J	Bergo, MO; Lieu, HD; Gavino, BJ; Ambroziak, P; Otto, JC; Casey, PJ; Walker, QM; Young, SG				Bergo, MO; Lieu, HD; Gavino, BJ; Ambroziak, P; Otto, JC; Casey, PJ; Walker, QM; Young, SG			On the physiological importance of endoproteolysis of CAAX proteins - Heart-specific RCE1 knockout mice develop a lethal cardiomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL METHYLTRANSFERASE; A-FACTOR; TRANSFERASE INHIBITOR; K-RAS; GENE; RECOMBINATION; GROWTH; FARNESYLTRANSFERASE; EXPRESSION; FARNESYL	Proteins terminating with a CAAX motif, such as the Ras proteins and the nuclear lamins, undergo post-translational modification of a C-terminal cysteine with an isoprenyl lipid via a process called protein prenylation. After prenylation, the last three residues of CAAX proteins are clipped off by Rce1, an integral membrane endoprotease of the endoplasmic reticulum. Prenylation is crucial to the function of many CAAX proteins, but the physiologic significance of endoproteolytic processing has remained obscure. To address this issue, we used Cre/loxP recombination techniques to create mice lacking Rce1 in the heart, an organ where Rce1 is expressed at particularly high levels. The hearts from heart-specific Rce1 knockout mice manifested reduced levels of both the Rce1 mRNA and CAAX endoprotease activity, and the hearts manifested an accumulation of CAAX protein substrates. The heart-specific Rce1 knock-out mice initially appeared healthy but died starting at 3-5 months of age. By 10 months of age, similar to70% of the mice had died. Pathological studies revealed that the heart-specific Rce1 knockout mice had a dilated cardiomyopathy. By contrast, liver-specific Rce1 knockout mice appeared healthy, had normal transaminase levels, and had normal liver histology. These studies indicate that the endoproteolytic processing of CAAX proteins is essential for cardiac function but is less important for the liver.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94141 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; Duke University; University of California System; University of California San Francisco	Young, SG (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.	syoung@gladstone.ucsf.edu		Casey, Patrick/0000-0002-7366-9309; Young, Stephen/0000-0001-7270-3176	NATIONAL CANCER INSTITUTE [R01CA099506] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA099506] Funding Source: Medline; NHLBI NIH HHS [HL41633] Funding Source: Medline; NIAMS NIH HHS [R01 AR050200] Funding Source: Medline; NIGMS NIH HHS [GM46372] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agah R, 1997, J CLIN INVEST, V100, P169, DOI 10.1172/JCI119509; AGAH R, 1996, CIRCULATION, V94, P591; Aiyagari AL, 2003, BLOOD, V101, P2250, DOI 10.1182/blood-2002-07-2250; Ambroziak P., 2001, ENZYMES, P155; ANTON M, 1995, J VIROL, V69, P4600, DOI 10.1128/JVI.69.8.4600-4606.1995; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Bergo MO, 2002, MOL CELL BIOL, V22, P171, DOI 10.1128/MCB.22.1.171-181.2002; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; Bergo MO, 2001, J BIOL CHEM, V276, P5841, DOI 10.1074/jbc.C000831200; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Chen J, 1998, J BIOL CHEM, V273, P1252, DOI 10.1074/jbc.273.2.1252; Chen J, 1997, CIRCULATION, V96, P2805; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; Dong G, 1996, J BIOL CHEM, V271, P29969, DOI 10.1074/jbc.271.47.29969; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; GILBERT BA, 1995, METHOD ENZYMOL, V250, P206; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Leung GK, 2001, J BIOL CHEM, V276, P29051, DOI 10.1074/jbc.M102908200; Li XW, 2002, J BIOL CHEM, V277, P15309, DOI 10.1074/jbc.M201253200; Liu M, 1999, CANCER CHEMOTH PHARM, V43, P50, DOI 10.1007/s002800050862; Lobell RB, 2001, CANCER RES, V61, P8758; Maske CP, 2003, J CELL BIOL, V162, P1223, DOI 10.1083/jcb.200303113; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Omer CA, 2000, CANCER RES, V60, P2680; Otto JC, 1999, J BIOL CHEM, V274, P8379, DOI 10.1074/jbc.274.13.8379; Prendergast GC, 2000, SEMIN CANCER BIOL, V10, P443, DOI 10.1006/scbi.2000.0335; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Rajewsky K, 1996, J CLIN INVEST, V98, P600, DOI 10.1172/JCI118828; Redfern CH, 2000, P NATL ACAD SCI USA, V97, P4826, DOI 10.1073/pnas.97.9.4826; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Schlitzer M, 2001, BIOORG MED CHEM LETT, V11, P425, DOI 10.1016/S0960-894X(00)00685-5; Shao F, 2002, CELL, V109, P575, DOI 10.1016/S0092-8674(02)00766-3; Stark WW, 1998, AM J PHYSIOL-LUNG C, V275, pL55, DOI 10.1152/ajplung.1998.275.1.L55; Wang Y, 1996, P NATL ACAD SCI USA, V93, P3932, DOI 10.1073/pnas.93.9.3932; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	45	49	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4729	4736		10.1074/jbc.M310081200	http://dx.doi.org/10.1074/jbc.M310081200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14625273	hybrid			2022-12-25	WOS:000188554300097
J	Kash, TL; Dizon, MJF; Trudell, JR; Harrison, NL				Kash, TL; Dizon, MJF; Trudell, JR; Harrison, NL			Charged residues in the beta(2) subunit involved in GABA(A) receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST BINDING; ACETYLCHOLINE-RECEPTOR; LYSINE RESIDUE; GENERAL-METHOD; CHANNEL; CONFORMATION; EFFICACY; SITE; LOOP; M2	Fast synaptic inhibition in the mammalian central nervous system is mediated primarily via activation of the gamma-aminobutyric acid type A receptor (GABA(A)-R). Upon agonist binding, the receptor undergoes a structural transition from the closed to the open state. This transition, known as gating, is thought to be associated with a sequence of conformational changes originating at the agonist-binding site, ultimately resulting in opening of the channel. Using site-directed mutagenesis and several different GABA(A)-R agonists, we identified a number of highly conserved charged residues in the GABA(A)-R beta(2) subunit that appear to be involved in receptor activation. We then used charge reversal double mutants and disulfide trapping to investigate the interactions between these flexible loops within the beta(2) subunit. The results suggest that interactions between an acidic residue in loop 7 (Asp(146)) and a basic residue in pre-transmembrane domain-1 (Lys(215)) are involved in coupling agonist binding to channel gating.	Cornell Univ, Weill Grad Sch Biomed Sci, Grad Program Neurosci, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Anesthesiol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA; Stanford Univ, Dept Anesthesia, Stanford, CA 94305 USA; Stanford Univ, Beckman Program Mol & Genet Med, Stanford, CA 94305 USA	Cornell University; Cornell University; Cornell University; Stanford University; Stanford University	Kash, TL (corresponding author), Cornell Univ, Weill Grad Sch Biomed Sci, Grad Program Neurosci, 525 E 68th St,A-1040, New York, NY 10021 USA.	tlk2003@med.cornell.edu	Kash, Thomas/G-9625-2013					AMIN J, 1994, MOL PHARMACOL, V45, P317; Baumann SW, 2002, J BIOL CHEM, V277, P46020, DOI 10.1074/jbc.M207663200; Bertaccini E, 2001, INT REV NEUROBIOL, V48, P141, DOI 10.1016/S0074-7742(01)48015-9; Boileau AJ, 2002, J BIOL CHEM, V277, P2931, DOI 10.1074/jbc.M109334200; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; DELCASTILLO J, 1957, PROC R SOC SER B-BIO, V146, P369; DONAHUE PJ, 1999, BIOCHEMISTRY-US, V28, P9366; Fisher JL, 2002, MOL CELL NEUROSCI, V20, P683, DOI 10.1006/mcne.2002.1143; Gomez CM, 1996, ANN NEUROL, V39, P712, DOI 10.1002/ana.410390607; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; Hu XQ, 2003, J BIOL CHEM, V278, P46583, DOI 10.1074/jbc.M308974200; Jensen ML, 2002, J BIOL CHEM, V277, P41438, DOI 10.1074/jbc.M205645200; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Klausberger T, 2003, NATURE, V421, P844, DOI 10.1038/nature01374; Krasowski MD, 2001, NEUROPHARMACOLOGY, V41, P952, DOI 10.1016/S0028-3908(01)00141-1; Leite JF, 2003, P NATL ACAD SCI USA, V100, P13054, DOI 10.1073/pnas.2133028100; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Makhatadze GI, 2003, J MOL BIOL, V327, P1135, DOI 10.1016/S0022-2836(03)00233-X; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Newell JG, 2003, J BIOL CHEM, V278, P13166, DOI 10.1074/jbc.M211905200; O'Shea SM, 2000, J BIOL CHEM, V275, P22764, DOI 10.1074/jbc.M001299200; RAJENDRA S, 1994, J BIOL CHEM, V269, P18739; Schofield CM, 2003, J BIOL CHEM, V278, P34079, DOI 10.1074/jbc.M302416200; Sieghart W, 2000, TRENDS PHARMACOL SCI, V21, P411, DOI 10.1016/S0165-6147(00)01564-9; Sigel E, 1999, J NEUROCHEM, V73, P1758, DOI 10.1046/j.1471-4159.1999.731758.x; SMITH GB, 1994, J BIOL CHEM, V269, P20380; Topf N, 2003, ANESTHESIOLOGY, V98, P306, DOI 10.1097/00000542-200302000-00007; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; Wagner DA, 2001, J NEUROSCI, V21, P67, DOI 10.1523/JNEUROSCI.21-01-00067.2001; Wu JH, 1996, P NATL ACAD SCI USA, V93, P14498, DOI 10.1073/pnas.93.25.14498; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002	34	60	61	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4887	4893		10.1074/jbc.M311441200	http://dx.doi.org/10.1074/jbc.M311441200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14610076	hybrid			2022-12-25	WOS:000188554300114
J	Alvarez, P; Buscaglia, CA; Campetella, O				Alvarez, P; Buscaglia, CA; Campetella, O			Improving protein pharmacokinetics by genetic fusion to simple amino acid sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; TRANS-SIALIDASE; HUMAN ACETYLCHOLINESTERASE; RECOMBINANT HIRUDIN; POLYETHYLENE-GLYCOL; IMMUNOGLOBULIN-G; ACUTE-PHASE; ALBUMIN; CLEARANCE; RECEPTOR	The role of primary amino acid sequences in protein pharmacokinetics, an issue of relevance in both basic knowledge and biotechnology, was addressed here using as a starting point two repetitive antigens from the hemoflagellate Trypanosoma cruzi that are known to stabilize their associated proteins in the bloodstream. A major drawback to their pharmacological application is that these repetitive sequences are highly immunogenic, being therefore the deletion of this characteristic desirable. Based on sequence homology and epitope mapping analyses, an artificial repetitive sequence (PSTAD) was engineered. This motif was tested by genetic fusion to the C terminus of both the trypanosomal trans-sialidase and the rat tyrosine aminotransferase and found to produce a 4.5-6-fold increase in the half-life of the associated proteins in blood while displaying significantly lower immunogenicity. Residues involved in the stabilizing properties of the novel peptide were mapped by a site-directed mutagenesis approach, allowing us to successfully identify another two motifs. Searching databases for sequences displaying some homology, embedded in proline frameworks and associated to shed virulence factors from unrelated microorganisms, resulted in the identification of four other protein extensions. Remarkably, three of them (from Streptococcus pneumoniae, Actinomyces viscosus, and Escherichia coli) revealed similar pharmacokinetic features, suggesting therefore an analogous evolutionarily acquired mechanism to ensure the biodistribution of their corresponding proteins. Our findings indicate that the insertion of defined motifs into a proline-rich framework constitutes a suitable alternative to construct a chimeric protein with extended half-life in blood.	Univ Nacl Gen San Martin, Inst Invest Biotecnol, Predio INTI, San Martin, Buenos Aires, Argentina	Instituto Nacional de Tecnologia Industrial (INTI)	Campetella, O (corresponding author), Univ Nacl Gen San Martin, Inst Invest Biotecnol, Predio INTI, Edificio 24,Av Gen Paz & Constituyentes,B1650WAB, San Martin, Buenos Aires, Argentina.	oscar@iib.unsam.edu.ar		Buscaglia, Carlos/0000-0001-6466-4138; Campetella, Oscar/0000-0002-7018-375X				Adams GP, 1999, J IMMUNOL METHODS, V231, P249, DOI 10.1016/S0022-1759(99)00161-1; AFFRANCHINO JL, 1989, MOL BIOCHEM PARASIT, V34, P221, DOI 10.1016/0166-6851(89)90050-9; Aguero F, 2002, INFECT IMMUN, V70, P7140, DOI 10.1128/IAI.70.12.7140-7144.2002; Alvarez P, 2001, INFECT IMMUN, V69, P7946, DOI 10.1128/IAI.69.12.7946-7949.2001; Ashkenazi A, 1997, CURR OPIN IMMUNOL, V9, P195, DOI 10.1016/S0952-7915(97)80135-5; Buscaglia CA, 1998, J INFECT DIS, V177, P431, DOI 10.1086/514199; Buscaglia CA, 1999, BLOOD, V93, P2025, DOI 10.1182/blood.V93.6.2025.406k19_2025_2032; CAMARA M, 1994, INFECT IMMUN, V62, P3688; CAMPETELLA O, 1992, PARASITOL TODAY, V8, P378, DOI 10.1016/0169-4758(92)90175-2; CAMPETELLA OE, 1994, MOL BIOCHEM PARASIT, V64, P337, DOI 10.1016/0166-6851(94)00036-0; Chapman AP, 1999, NAT BIOTECHNOL, V17, P780, DOI 10.1038/11717; Chitlaru T, 2001, BIOCHEM J, V354, P613, DOI 10.1042/0264-6021:3540613; Chitlaru T, 1998, BIOCHEM J, V336, P647, DOI 10.1042/bj3360647; Clark R, 1996, J BIOL CHEM, V271, P21969, DOI 10.1074/jbc.271.36.21969; Cohen O, 2001, BIOCHEM J, V357, P795, DOI 10.1042/0264-6021:3570795; Dennis MS, 2002, J BIOL CHEM, V277, P35035, DOI 10.1074/jbc.M205854200; Elliott SJ, 2002, INFECT IMMUN, V70, P2271, DOI 10.1128/IAI.70.5.2271-2277.2002; Fallon EM, 2000, J BIOL CHEM, V275, P6790, DOI 10.1074/jbc.275.10.6790; Frank R, 1996, Methods Mol Biol, V66, P149; Frasch ACC, 2000, PARASITOL TODAY, V16, P282, DOI 10.1016/S0169-4758(00)01698-7; FRENCH AR, 1995, J BIOL CHEM, V270, P4334, DOI 10.1074/jbc.270.9.4334; FRICK IM, 1992, P NATL ACAD SCI USA, V89, P8532, DOI 10.1073/pnas.89.18.8532; GANDHI RR, 1992, AM J PHYSIOL, V262, pH999, DOI 10.1152/ajpheart.1992.262.4.H999; Ghetie V, 1997, NAT BIOTECHNOL, V15, P637, DOI 10.1038/nbt0797-637; Ghetie V, 2000, ANNU REV IMMUNOL, V18, P739, DOI 10.1146/annurev.immunol.18.1.739; HENNINGSEN M, 1991, BIOL CHEM H-S, V372, P1065, DOI 10.1515/bchm3.1991.372.2.1065; HOFT DF, 1989, INFECT IMMUN, V57, P1959, DOI 10.1128/IAI.57.7.1959-1967.1989; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KIM JK, 1994, EUR J IMMUNOL, V24, P542, DOI 10.1002/eji.1830240308; KITAMURA K, 1991, CANCER RES, V51, P4310; Leguizamon MS, 1999, J INFECT DIS, V180, P1398, DOI 10.1086/315001; LEGUIZAMON MS, 1994, INFECT IMMUN, V62, P3441; Leguizamon MS, 1997, J INFECT DIS, V175, P1272, DOI 10.1086/593697; MARKWARDT F, 1990, BIOMED BIOCHIM ACTA, V49, P1103; McKean PG, 1997, MOL BIOCHEM PARASIT, V86, P225, DOI 10.1016/S0166-6851(97)00035-2; McNamara BP, 1998, FEMS MICROBIOL LETT, V166, P71, DOI 10.1016/S0378-1097(98)00313-9; Monfardini C, 1998, BIOCONJUGATE CHEM, V9, P418, DOI 10.1021/bc970184f; MORDENTI J, 1991, PHARMACEUT RES, V8, P1351, DOI 10.1023/A:1015836720294; Mucci J, 2002, P NATL ACAD SCI USA, V99, P3896, DOI 10.1073/pnas.052496399; Ni HY, 2000, THROMB RES, V99, P407, DOI 10.1016/S0049-3848(00)00263-2; Osborn BL, 2002, EUR J PHARMACOL, V456, P149, DOI 10.1016/S0014-2999(02)02644-4; Osborn BL, 2002, J PHARMACOL EXP THER, V303, P540, DOI 10.1124/jpet.102.037002; PEDLEY RB, 1994, BRIT J CANCER, V70, P1126, DOI 10.1038/bjc.1994.459; Peters T., 1996, ALL ALBUMIN, P188; POLLOCK RR, 1990, EUR J IMMUNOL, V20, P2021, DOI 10.1002/eji.1830200921; Rifai A, 2000, J EXP MED, V191, P2171, DOI 10.1084/jem.191.12.2171; Sarkar CA, 2002, NAT BIOTECHNOL, V20, P908, DOI 10.1038/nbt725; Syed S, 1997, BLOOD, V89, P3243, DOI 10.1182/blood.V89.9.3243; Talay SR, 1996, BIOCHEM J, V315, P577, DOI 10.1042/bj3150577; Veronese FM, 2002, ADV DRUG DELIVER REV, V54, P453; Verra F, 1999, MOL BIOL EVOL, V16, P627, DOI 10.1093/oxfordjournals.molbev.a026145; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; YEH P, 1992, P NATL ACAD SCI USA, V89, P1904, DOI 10.1073/pnas.89.5.1904; YEUNG MK, 1993, INFECT IMMUN, V61, P109, DOI 10.1128/IAI.61.1.109-116.1993	55	28	54	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3375	3381		10.1074/jbc.M311356200	http://dx.doi.org/10.1074/jbc.M311356200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14612434	hybrid			2022-12-25	WOS:000188379600030
J	Ebert, DH; Kopecky-Bromberg, SA; Dermody, TS				Ebert, DH; Kopecky-Bromberg, SA; Dermody, TS			Cathepsin B is inhibited in mutant cells selected during persistent reovirus infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL CYSTEINE PROTEINASES; MEMBRANE-PENETRATION PROTEIN; RAT PROCATHEPSIN-B; MAMMALIAN REOVIRUSES; IN-VIVO; EPOXYSUCCINYL PEPTIDES; SUBVIRION PARTICLES; INVARIANT CHAIN; VIRAL ENTRY; MUTATIONS	Persistent reovirus infections of murine L929 (L) fibroblast cells select mutant (LX) cells that do not support proteolytic disassembly of reovirus virions within the endocytic pathway. To better understand the function and regulation of endocytic proteases, we conducted experiments to define the block to reovirus disassembly displayed by LX cells. In contrast to parental L cells, mutant LX cells harbor defects that interfere with the maturation and activity of cathepsin B and cathepsin L but not cathepsin H. The cDNAs encoding cathepsin B and cathepsin L in L cells are identical to those in LX cells, indicating that LX cells manifest an extrinsic block to the function of these enzymes. Mixed lysates of L cells and LX cells lack activity of both cathepsin B and cathepsin L, suggesting the presence of an inhibitor of cathepsin function in LX cells. A cathepsin B-green fluorescent protein (GFP) fusion protein expressed in L cells and purified by immunoprecipitation retains cathepsin B activity, whereas cathepsin B-GFP expressed in LX cells does not. However, activity of cathepsin B-GFP expressed in LX cells can be recovered by incubating the immunoprecipitate with L cell lysate followed by immunoprecipitation, providing further evidence that LX cells express a cathepsin inhibitor. Native-gel electrophoresis and gel filtration chromatography demonstrate that, in both cell lines, the double-chain form of cathepsin B is sequestered in a large molecular weight complex that renders this form of the enzyme inactive. Alteration of this sequestration complex appears to be responsible for inhibition of cathepsin B in LX cells. These findings suggest that cathepsins can be regulated within the endocytic pathway. Moreover, this regulation influences host cell susceptibility to intracellular pathogens.	Vanderbilt Univ, Sch Med, Elizabeth B Lamb Ctr Pediat Res, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Dermody, TS (corresponding author), Vanderbilt Univ, Sch Med, Elizabeth B Lamb Ctr Pediat Res, D7235 MCN, Nashville, TN 37232 USA.	terry.dermody@vanderbilt.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032539, T32AI007474] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI32539, T32 AI07474] Funding Source: Medline; NIGMS NIH HHS [T32 GM07347] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED R, 1981, CELL, V25, P325, DOI 10.1016/0092-8674(81)90050-7; ASSFALGMACHLEIDT I, 1990, BIOL CHEM H-S, V371, P211; Baer GS, 1999, J VIROL, V73, P9532, DOI 10.1128/JVI.73.11.9532-9543.1999; Baer GS, 1997, J VIROL, V71, P4921, DOI 10.1128/JVI.71.7.4921-4928.1997; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8; Bevec T, 1996, J EXP MED, V183, P1331, DOI 10.1084/jem.183.4.1331; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; BORSA J, 1979, J GEN VIROL, V45, P161, DOI 10.1099/0022-1317-45-1-161; BORSA J, 1981, VIROLOGY, V111, P191, DOI 10.1016/0042-6822(81)90664-4; BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003-9861(92)90290-D; CALKINS CC, 1995, BIOL CHEM H-S, V376, P71; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; Chandran K, 2002, J VIROL, V76, P9920, DOI 10.1128/JVI.76.19.9920-9933.2002; CHANG CT, 1971, VIROLOGY, V46, P544, DOI 10.1016/0042-6822(71)90058-4; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; Chapman RL, 1997, J BIOL CHEM, V272, P8808, DOI 10.1074/jbc.272.13.8808; Chappell JD, 1997, J VIROL, V71, P1834, DOI 10.1128/JVI.71.3.1834-1841.1997; Chappell JD, 2000, J VIROL, V74, P8472, DOI 10.1128/JVI.74.18.8472-8479.2000; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; Cygler M, 1996, STRUCTURE, V4, P405, DOI 10.1016/S0969-2126(96)00046-9; del Re EC, 2000, BRIT J CANCER, V82, P1317; DERMODY TS, 1993, J VIROL, V67, P2055, DOI 10.1128/JVI.67.4.2055-2063.1993; DERMODY TS, 1995, VIROLOGY, V212, P272, DOI 10.1006/viro.1995.1483; Deussing J, 1998, P NATL ACAD SCI USA, V95, P4516, DOI 10.1073/pnas.95.8.4516; Ebert DH, 2002, J BIOL CHEM, V277, P24609, DOI 10.1074/jbc.M201107200; GAL S, 1986, BIOCHEM BIOPH RES CO, V139, P156, DOI 10.1016/S0006-291X(86)80093-6; GOTTESMAN MM, 1980, CELL, V19, P449, DOI 10.1016/0092-8674(80)90519-X; Honey K, 2001, J BIOL CHEM, V276, P22573, DOI 10.1074/jbc.M101851200; Hooper JW, 1996, J VIROL, V70, P459, DOI 10.1128/JVI.70.1.459-467.1996; Ishidoh K, 1998, BIOCHEM BIOPH RES CO, V252, P202, DOI 10.1006/bbrc.1998.9613; Ishidoh K, 2002, BIOL CHEM, V383, P1827, DOI 10.1515/BC.2002.206; Keppler D, 2000, CELL TISSUE RES, V302, P181, DOI 10.1007/s004410000269; KIRSCHKE H, 1977, EUR J BIOCHEM, V74, P293, DOI 10.1111/j.1432-1033.1977.tb11393.x; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; Lennon-Dumenil AM, 2001, EMBO J, V20, P4055, DOI 10.1093/emboj/20.15.4055; Liemann S, 2002, CELL, V108, P283, DOI 10.1016/S0092-8674(02)00612-8; Linke M, 2002, J CELL SCI, V115, P4877, DOI 10.1242/jcs.00184; MACH L, 1992, BIOCHEM J, V282, P577, DOI 10.1042/bj2820577; MASON RW, 1986, BIOMED BIOCHIM ACTA, V45, P1433; MASON RW, 1989, BIOCHEM J, V257, P125, DOI 10.1042/bj2570125; MASON RW, 1989, ARCH BIOCHEM BIOPHYS, V273, P367, DOI 10.1016/0003-9861(89)90495-5; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MCINTYRE GF, 1993, P NATL ACAD SCI USA, V90, P10588, DOI 10.1073/pnas.90.22.10588; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MOIN K, 1992, BIOCHEM J, V285, P427, DOI 10.1042/bj2850427; Moin K, 2000, ADV EXP MED BIOL, V477, P391; Mort JS, 1997, INT J BIOCHEM CELL B, V29, P715, DOI 10.1016/S1357-2725(96)00152-5; MURATA M, 1991, FEBS LETT, V280, P307, DOI 10.1016/0014-5793(91)80318-W; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; Nathanson CM, 2002, EUR J BIOCHEM, V269, P5502, DOI 10.1046/j.1432-1033.2002.03252.x; NIBERT ML, 1995, J VIROL, V69, P5057, DOI 10.1128/JVI.69.8.5057-5067.1995; NIBERT ML, 1991, J VIROL, V65, P1960, DOI 10.1128/JVI.65.4.1960-1967.1991; NIBERT ML, 1992, J VIROL, V66, P6408, DOI 10.1128/JVI.66.11.6408-6418.1992; NISHIMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V263, P107, DOI 10.1016/0003-9861(88)90618-2; Roshy S, 2003, CANCER METAST REV, V22, P271, DOI 10.1023/A:1023007717757; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; RUBIN DH, 1992, MICROB PATHOGENESIS, V12, P351, DOI 10.1016/0882-4010(92)90098-9; RYAN RE, 1995, J NEUROCHEM, V65, P1035; SALMINEN A, 1990, BIOCHEM J, V272, P39, DOI 10.1042/bj2720039; SHAW E, 1993, FEBS LETT, V334, P340, DOI 10.1016/0014-5793(93)80707-2; SILVERSTEIN SC, 1972, VIROLOGY, V47, P797, DOI 10.1016/0042-6822(72)90571-5; Sims AC, 2000, J VIROL, V74, P5647, DOI 10.1128/JVI.74.12.5647-5654.2000; STURZENBECKER LJ, 1987, J VIROL, V61, P2351, DOI 10.1128/JVI.61.8.2351-2361.1987; TOWATARI T, 1991, FEBS LETT, V280, P311, DOI 10.1016/0014-5793(91)80319-X; Turk D, 1996, FEBS LETT, V384, P211, DOI 10.1016/0014-5793(96)00309-2; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; TYLER KL, 2001, FIELDS VIROLOGY, P199; Waghray A, 2002, J BIOL CHEM, V277, P11533, DOI 10.1074/jbc.M109557200; Wetzel JD, 1997, J VIROL, V71, P1362, DOI 10.1128/JVI.71.2.1362-1369.1997; Wetzel JD, 1997, J VIROL, V71, P299, DOI 10.1128/JVI.71.1.299-306.1997	74	17	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3837	3851		10.1074/jbc.M310048200	http://dx.doi.org/10.1074/jbc.M310048200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14585834	hybrid			2022-12-25	WOS:000188379600086
J	Tringali, C; Papini, N; Fusi, P; Croci, G; Borsani, G; Preti, A; Tortora, P; Tettamanti, G; Venerando, B; Monti, E				Tringali, C; Papini, N; Fusi, P; Croci, G; Borsani, G; Preti, A; Tortora, P; Tettamanti, G; Venerando, B; Monti, E			Properties of recombinant human cytosolic sialidase HsNEU2 - The enzyme hydrolyzes monomerically dispersed GM1 ganglioside molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; SIGNAL-TRANSDUCTION; EXPRESSION; BRAIN; NEURAMINIDASE; PROTEIN; IDENTIFICATION; CLONING; PURIFICATION; TRANSFECTION	Recombinant human cytosolic sialidase (HsNEU2), expressed in Escherichia coli, was purified to homogeneity, and its substrate specificity was studied. HsNEU2 hydrolyzed 4-methylumbelliferyl alpha-NeuAc, alpha2-->3 sialyl-lactose, glycoproteins (fetuin, alpha-acid glycoprotein, transferrin, and bovine submaxillary gland mucin), micellar gangliosides GD1a, GD1b, GT1b, and alpha2-->3 paragloboside, and vesicular GM3. alpha2-->6 sialyllactose, colominic acid, GM1 oligosaccharide, whereas micellar GM2 and GM1 were resistant. The optimal pH was 5.6, kinetics Michaelis-Menten type, V-max varying from 250 IU/mg protein (GD1a) to 0.7 IU/mg protein (alpha(1)-acid glycoprotein), and K-m in the millimolar range. HsNEU2 was activated by detergents (Triton X-100) only with gangliosidic substrates; the change of GM3 from vesicular to mixed micellar aggregation led to a 8.5-fold V-max increase. HsNEU2 acted on gangliosides (GD1a, GM1, and GM2) at nanomolar concentrations. With these dispersions (studied in detailed on GM1), where monomers are bound to the tube wall or dilutedly associated (1:2000, mol/mol) to Triton X-100 micelles, the V-max values were 25 and 72 muIU/mg protein, and K-m was 10 and 15x10(-9) M, respectively. Remarkably, GM1 and GM2 were recognized only as monomers. HsNEU2 worked at pH 7.0 with an efficiency (compared with that at pH 5.6) ranging from 4% (on GD1a) to 64% (on alpha(1)-acid glycoprotein), from 7% (on GD1a) to 45% (on GM3) in the presence of Triton X-100, and from 30 to 40% on GM1 monomeric dispersion. These results show that HsNEU2 differentially recognizes the type of sialosyl linkage, the aglycone part of the substrate, and the supramolecular organization (monomer/micelle/vesicle) of gangliosides. The last ability might be relevant in sialidase interactions with gangliosides under physiological conditions.	Univ Brescia, Dept Biomed Sci & Biotechnol, I-25123 Brescia, Italy; Univ Milan, Fac Med, Dept Med Chem Biochem & Biotechnol, LITA Segrate, I-20090 Milan, Italy; Univ Milano Bicocca, Dept Biotechnol & Biosci, I-20126 Milan, Italy	University of Brescia; University of Milan; University of Milano-Bicocca	Monti, E (corresponding author), Univ Brescia, Dept Biomed Sci & Biotechnol, Viale Europa 11, I-25123 Brescia, Italy.	monti@med.unibs.it	papini, nadia/M-2425-2017; Borsani, Giuseppe/B-1709-2010; Tringali, Cristina Alessandra/Q-7259-2017	papini, nadia/0000-0003-4066-4955; Borsani, Giuseppe/0000-0003-0110-1148; Tringali, Cristina Alessandra/0000-0002-0632-6197; Tortora, Paolo/0000-0001-5234-601X; Fusi, Paola/0000-0002-2746-1742; MONTI, Eugenio/0000-0002-4742-7445				Achyuthan KE, 2001, COMP BIOCHEM PHYS B, V129, P29, DOI 10.1016/S1096-4959(01)00372-4; Bhavanandan V. P., 1995, BIOL SIALIC ACIDS, P145; Bonten E, 1996, GENE DEV, V10, P3156, DOI 10.1101/gad.10.24.3156; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIMI L, 1979, BIOCHIM BIOPHYS ACTA, V571, P137, DOI 10.1016/0005-2744(79)90234-1; CHIGORNO V, 1986, ANAL BIOCHEM, V153, P283, DOI 10.1016/0003-2697(86)90094-1; CRENNELL S, 1994, STRUCTURE, V2, P535, DOI 10.1016/S0969-2126(00)00053-8; CRENNELL SJ, 1993, P NATL ACAD SCI USA, V90, P9852, DOI 10.1073/pnas.90.21.9852; FIORILLI A, 1989, J NEUROCHEM, V53, P672, DOI 10.1111/j.1471-4159.1989.tb11756.x; GHIDONI R, 1976, J NEUROCHEM, V27, P511, DOI 10.1111/j.1471-4159.1976.tb12275.x; GHIDONI R, 1981, J LIPID RES, V22, P1286; GHIDONI R, 1980, J BIOL CHEM, V255, P6990; GILLARD BK, 1991, EXP CELL RES, V192, P433, DOI 10.1016/0014-4827(91)90062-Y; Gravel R. A., 2001, METABOLIC MOL BASES, V3, P3827; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; Hakomori S, 2000, GLYCOCONJUGATE J, V17, P143, DOI 10.1023/A:1026524820177; Hakomori SI, 1998, ANN NY ACAD SCI, V845, P1, DOI 10.1111/j.1749-6632.1998.tb09657.x; IWAMORI M, 1978, BIOCHIM BIOPHYS ACTA, V528, P257; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESKAWA KC, 1984, ANAL BIOCHEM, V140, P172, DOI 10.1016/0003-2697(84)90149-0; Li SC, 2001, BIOCHEM J, V360, P233, DOI 10.1042/0264-6021:3600233; Meuillet EJ, 1999, CANCER RES, V59, P234; Milner CM, 1997, J BIOL CHEM, V272, P4549, DOI 10.1074/jbc.272.7.4549; MIYAGI T, 1986, FEBS LETT, V206, P223, DOI 10.1016/0014-5793(86)80985-1; MIYAGI T, 1985, J BIOL CHEM, V260, P6710; Monti E, 1999, GLYCOBIOLOGY, V9, P1313, DOI 10.1093/glycob/9.12.1313; Monti E, 2000, BIOCHEM J, V349, P343, DOI 10.1042/0264-6021:3490343; Monti E, 1999, GENOMICS, V57, P137, DOI 10.1006/geno.1999.5749; Monti E, 2002, NEUROCHEM RES, V27, P649, DOI 10.1023/A:1020276000901; NAGAI Y, 1995, BEHAV BRAIN RES, V66, P99, DOI 10.1016/0166-4328(94)00130-8; Nagai Y., 1995, BIOL SIALIC ACIDS, P197; Pshezhetsky AV, 1997, NAT GENET, V15, P316, DOI 10.1038/ng0397-316; RIBONI L, 1995, J NEUROCHEM, V64, P451; RICHETTI PG, 1983, ISOELECTRIC FOCUSING; Saito M, 1996, J NEUROCHEM, V66, P2205; SAITO M, 1979, J BIOL CHEM, V254, P7845; Saito M, 1995, BIOL SIALIC ACIDS, P261, DOI [10.1007/978-1-4757-9504-2_8, DOI 10.1007/978-1-4757-9504-2_8]; SAMBROOK J, 2001, MOL CLONING LAB MANA; Sato K, 1996, BIOCHEM BIOPH RES CO, V221, P826, DOI 10.1006/bbrc.1996.0681; Sawada M, 2002, INT J CANCER, V97, P180, DOI 10.1002/ijc.1598; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SONNINO S, 1994, CHEM PHYS LIPIDS, V71, P21, DOI 10.1016/0009-3084(94)02304-2; SONNINO S, 1978, J NEUROCHEM, V31, P947, DOI 10.1111/j.1471-4159.1978.tb00132.x; SONNINO S, 1979, J NEUROCHEM, V33, P117, DOI 10.1111/j.1471-4159.1979.tb11713.x; SONNINO S, 1984, J LIPID RES, V25, P620; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; SWEELEY CC, 1993, ADV LIPID RES, V26, P235; TALLMAN JF, 1972, J BIOL CHEM, V247, P7570; Taylor G, 1996, CURR OPIN STRUC BIOL, V6, P830, DOI 10.1016/S0959-440X(96)80014-5; TETTAMAN.G, 1973, BIOCHIM BIOPHYS ACTA, V296, P160, DOI 10.1016/0005-2760(73)90055-6; Tokuyama S, 1997, INT J CANCER, V73, P410, DOI 10.1002/(SICI)1097-0215(19971104)73:3<410::AID-IJC16>3.0.CO;2-G; USUKI S, 1988, J BIOL CHEM, V263, P6847; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; Venerando B, 1997, BLOOD, V90, P2047, DOI 10.1182/blood.V90.5.2047; VENERANDO B, 1994, BBA-PROTEIN STRUCT M, V1208, P229, DOI 10.1016/0167-4838(94)90108-2; Wada T, 1999, BIOCHEM BIOPH RES CO, V261, P21, DOI 10.1006/bbrc.1999.0973; Wang Y, 2001, EUR J BIOCHEM, V268, P2201, DOI 10.1046/j.1432-1327.2001.02069.x; WARNER TG, 1993, GLYCOBIOLOGY, V3, P455, DOI 10.1093/glycob/3.5.455; WATANABE K, 1979, J BIOL CHEM, V254, P8223; WIEGANDT H, 1970, EUR J BIOCHEM, V15, P287, DOI 10.1111/j.1432-1033.1970.tb01006.x; Wright CS, 2000, J MOL BIOL, V304, P411, DOI 10.1006/jmbi.2000.4225; WU YY, 1994, J BIOL CHEM, V269, P16276	62	70	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3169	3179		10.1074/jbc.M308381200	http://dx.doi.org/10.1074/jbc.M308381200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14613940	hybrid			2022-12-25	WOS:000188379600006
J	Borre, L; Kanner, BI				Borre, L; Kanner, BI			Arginine 445 controls the coupling between glutamate and cations in the neuronal transporter EAAC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; RAT-BRAIN; ESCHERICHIA-COLI; REENTRANT LOOP; MEMBRANE-VESICLES; CHLORIDE CHANNEL; LACTOSE PERMEASE; GLT-1; SUBSTRATE; CARRIER	The substrate-binding sites in membrane transporters are alternately accessible from either side of the membrane, but the molecular basis of how this alternate opening of internal and external gates is achieved is largely unknown. Here we present data indicating that, in the neuronal electrogenic sodium- and potassium-coupled glutamate transporter EAAC-1, the substrate-binding site and one of the gates, or a residue controlling the gating process, are in close physical proximity. Arginine 445, located only two residues away from a residue implicated in glutamate binding (Bendahan, A., Armon, A., Madani, N., Kavanaugh, M. P., and Kanner, B. I. (2000) J. Biol. Chem. 275, 37436 - 37442), has been mutated to serine (R445S). Upon expression in oocytes, measurements of L-[H-3]-glutamate transport under voltage clamp reveal that the charge/flux ratio for L- glutamate at -60 mV is similar to30-fold higher than that of the wild type. Also, with D-aspartate, R445S exhibits an similar to15-fold increase in this ratio. In contrast to the wild type, the reversal potential of the substrate-dependent currents in R445S shifts to more negative potentials when either the external sodium or potassium concentration is decreased. These findings indicate that these two cations are the main current carriers in the R445S mutant. Introduction of a methionine or a glutamine, but not a lysine, at position 445 gives rise to a phenotype similar to R445S. Therefore, it seems that the elimination of a positive charge in the vicinity of the substrate-binding site converts the transporter into a glutamate-gated cation-conducting pathway.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel.	kannerb@cc.huji.ac.il			NINDS NIH HHS [NS16708] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS016708, R01NS016708] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Bendahan A, 2000, J BIOL CHEM, V275, P37436, DOI 10.1074/jbc.M006536200; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; Borre L, 2002, J BIOL CHEM, V277, P13501, DOI 10.1074/jbc.M110861200; Borre L, 2001, J BIOL CHEM, V276, P40396, DOI 10.1074/jbc.M104926200; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; Brocke L, 2002, J BIOL CHEM, V277, P3985, DOI 10.1074/jbc.M107735200; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Grewer C, 2000, P NATL ACAD SCI USA, V97, P9706, DOI 10.1073/pnas.160170397; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; KING SC, 1990, J BIOL CHEM, V265, P9645; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; MATZKE EA, 1992, J BIOL CHEM, V267, P19095; Otis TS, 2000, J NEUROSCI, V20, P2749; PINES G, 1990, BIOCHEMISTRY-US, V29, P11209, DOI 10.1021/bi00503a008; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Ryan RM, 2002, J BIOL CHEM, V277, P13494, DOI 10.1074/jbc.M109970200; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P453, DOI 10.1007/BF00388310; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; Seal RP, 2001, P NATL ACAD SCI USA, V98, P15324, DOI 10.1073/pnas.011400198; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; Slotboom DJ, 2001, J BIOL CHEM, V276, P10775, DOI 10.1074/jbc.M011064200; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Wadiche JI, 1998, J NEUROSCI, V18, P7650; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Yerushalmi H, 2000, J BIOL CHEM, V275, P5264, DOI 10.1074/jbc.275.8.5264; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710; Zhang YM, 1998, P NATL ACAD SCI USA, V95, P751, DOI 10.1073/pnas.95.2.751	40	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2513	2519		10.1074/jbc.M311446200	http://dx.doi.org/10.1074/jbc.M311446200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14594797	hybrid			2022-12-25	WOS:000188211300023
J	Thanawiroon, C; Rice, KG; Toida, T; Linhardt, RJ				Thanawiroon, C; Rice, KG; Toida, T; Linhardt, RJ			Liquid chromatography/mass spectrometry sequencing approach for highly sulfated heparin-derived oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROSPRAY MASS-SPECTROMETRY; MOLECULAR-WEIGHT DETERMINATION; ANION-EXCHANGE CHROMATOGRAPHY; III BINDING-SITE; STRUCTURAL FEATURES; HYALURONIC-ACID; IONIZATION; ELECTROPHORESIS; AMMONIUM; LINKAGE	Liquid chromatography/mass spectrometry (LC/MS) is applied to the analysis of complex mixtures of oligosaccharides obtained through the controlled, heparinase-catalyzed depolymerization of heparin. Reversed-phase ion-pairing chromatography, utilizing a volatile mobile phase, results in the high resolution separation of highly sulfated, heparin-derived oligosaccharides. Simultaneous detection by UV absorbance and electrospray ionization-mass spectrometry (ESI-MS) provides important structural information on the oligosaccharide components of this mixture. Highly sensitive and easily interpretable spectra were obtained through post-column addition of tributylamine in acetonitrile. High resolution mass spectrometry afforded elemental composition of many known and previously unknown heparin-derived oligosaccharides. UV in combination with MS detection led to the identification of oligosaccharides arising from the original non-reducing end (NRE) of the heparin chain. The structural identification of these oligosaccharides provided sequence from a reading frame that begins at the non-reducing terminus of the heparin chain. Interestingly, 16 NRE oligosaccharides are observed, having both an even and an odd number of saccharide residues, most of which are not predicted based on biosynthesis or known pathways of heparin catabolism. Quantification of these NRE oligosaccharides afforded a number-averaged molecular weight consistent with that expected for the pharmaceutical heparin used in this analysis. Molecular ions could be assigned for oligosaccharides as large as a tetradecasaccharide, having a mass of 4625 Da and a net charge of -32. Furthermore, MS detection was demonstrated for oligosaccharides with up to 30 saccharide units having a mass of > 10,000 Da and a net charge of -60.	Univ Iowa, Div Med & Nat Prod Chem, Iowa City, IA 52242 USA; Chiba Univ, Grad Sch Pharmaceut Sci, Dept Bioanalyt Chem, Chiba 263, Japan; Rensselaer Polytech Inst, Dept Chem, Troy, NY 12180 USA; Rensselaer Polytech Inst, Dept Biol, Troy, NY 12180 USA; Rensselaer Polytech Inst, Dept Biol & Chem Engn, Troy, NY 12180 USA	University of Iowa; Chiba University; Rensselaer Polytechnic Institute; Rensselaer Polytechnic Institute; Rensselaer Polytechnic Institute	Linhardt, RJ (corresponding author), Univ Iowa, Div Med & Nat Prod Chem, Iowa City, IA 52242 USA.	linhar@rpi.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038060] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL65262] Funding Source: Medline; NIGMS NIH HHS [GM38060] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAI JY, 1995, J CHROMATOGR A, V703, P667, DOI 10.1016/0021-9673(94)01178-H; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Cataldi TRI, 2000, FRESEN J ANAL CHEM, V368, P739, DOI 10.1007/s002160000588; Chai WG, 1998, ANAL CHEM, V70, P2060, DOI 10.1021/ac9712761; CHENG XH, 1995, ANAL CHEM, V67, P586, DOI 10.1021/ac00099a016; COL RD, 1993, J CHROMATOGR, V647, P289; CONBOY JJ, 1990, ANAL CHEM, V62, P800, DOI 10.1021/ac00207a006; Davies GJ, 2002, BIOCHEM SOC T, V30, P291, DOI 10.1042/BST0300291; Deery MJ, 2001, RAPID COMMUN MASS SP, V15, P2273, DOI 10.1002/rcm.458.abs; Drummond KJ, 2001, PROTEOMICS, V1, P304, DOI 10.1002/1615-9861(200102)1:2<304::AID-PROT304>3.0.CO;2-B; EDENS RE, 1992, J PHARM SCI, V81, P823, DOI 10.1002/jps.2600810821; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; FURA A, 1993, ANAL CHEM, V65, P2805, DOI 10.1021/ac00068a017; Gong F, 2003, J BIOL CHEM, V278, P35152, DOI 10.1074/jbc.M300925200; Griffey RH, 1997, J AM SOC MASS SPECTR, V8, P155, DOI 10.1016/S1044-0305(96)00200-0; Guan FY, 1999, J CHROMATOGR B, V731, P155, DOI 10.1016/S0378-4347(99)00126-7; Harvey DJ, 1996, J CHROMATOGR A, V720, P429, DOI 10.1016/0021-9673(95)00307-X; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Huber CG, 2000, J CHROMATOGR A, V870, P413, DOI 10.1016/S0021-9673(99)00953-X; Imanari T, 1996, J CHROMATOGR A, V720, P275, DOI 10.1016/0021-9673(95)00338-X; Jackson C, 1996, ANAL CHEM, V68, P1303, DOI 10.1021/ac951103g; JANDIK KA, 1994, GLYCOBIOLOGY, V4, P289, DOI 10.1093/glycob/4.3.289; JUHASZ P, 1994, P NATL ACAD SCI USA, V91, P4333, DOI 10.1073/pnas.91.10.4333; KHOO KH, 1993, CARBOHYD RES, V244, P205, DOI 10.1016/0008-6215(83)85002-2; Kim YS, 1998, GLYCOBIOLOGY, V8, P869, DOI 10.1093/glycob/8.9.869; Kinoshita A, 1997, J BIOL CHEM, V272, P19656, DOI 10.1074/jbc.272.32.19656; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; Koketsu M, 2000, ANAL BIOCHEM, V283, P136, DOI 10.1006/abio.2000.4649; Kuberan B, 2002, J AM CHEM SOC, V124, P8707, DOI 10.1021/ja0178867; LAMB DJ, 1992, J AM SOC MASS SPECTR, V3, P797, DOI 10.1016/1044-0305(92)80002-3; Linhardt R. J., 1997, CARBOHYDRATES DRUG D, P277; LINHARDT RJ, 1989, BIOCHEMISTRY-US, V28, P2888, DOI 10.1021/bi00433a021; LINHARDT RJ, 1985, BIOCHEMISTRY-US, V24, P7805, DOI 10.1021/bi00347a045; Linhardt RJ, 1999, SEMIN THROMB HEMOST, V25, P5; Liu J, 1995, GLYCOBIOLOGY, V5, P765, DOI 10.1093/glycob/5.8.765; LOGANATHAN D, 1990, BIOCHEMISTRY-US, V29, P4362, DOI 10.1021/bi00470a015; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; MIDURA RJ, 1995, J BIOL CHEM, V270, P8009, DOI 10.1074/jbc.270.14.8009; Mikhailov D, 1997, BIOCHEM J, V328, P51, DOI 10.1042/bj3280051; Mohsin SB, 2000, J CHROMATOGR A, V884, P23, DOI 10.1016/S0021-9673(00)00280-6; MONSTAUDO G, 1995, RAPID COMMUN MASS SP, V9, P453; Mulloy B, 1996, MOL BIOTECHNOL, V6, P241, DOI 10.1007/BF02761706; NADER HB, 1990, J BIOL CHEM, V265, P16807; Okada Y, 2002, J BIOL CHEM, V277, P42488, DOI 10.1074/jbc.M206510200; Packer NH, 1998, ELECTROPHORESIS, V19, P1872, DOI 10.1002/elps.1150191105; PERVIN A, 1995, GLYCOBIOLOGY, V5, P83, DOI 10.1093/glycob/5.1.83; PETERKATALINIC J, 1994, MASS SPECTROM REV, V13, P77, DOI 10.1002/mas.1280130106; Price KN, 1997, CARBOHYD RES, V303, P303, DOI 10.1016/S0008-6215(97)00171-7; Rabenstein DL, 2002, NAT PROD REP, V19, P312, DOI 10.1039/b100916h; REINHOLD VN, 1995, ANAL CHEM, V67, P1772, DOI 10.1021/ac00107a005; RICE KG, 1985, ANAL BIOCHEM, V150, P325, DOI 10.1016/0003-2697(85)90518-4; RICE KG, 1997, THESIS U IOWA IOWA C; ROSENBERG RD, 1979, P NATL ACAD SCI USA, V76, P1218, DOI 10.1073/pnas.76.3.1218; Shriver Z, 2000, P NATL ACAD SCI USA, V97, P10365, DOI 10.1073/pnas.97.19.10365; Siegel MM, 1997, J MASS SPECTROM, V32, P760, DOI 10.1002/(SICI)1096-9888(199707)32:7<760::AID-JMS529>3.0.CO;2-R; Stephenson JL, 1998, ANAL CHEM, V70, P3533, DOI 10.1021/ac9802832; Storm T, 1999, J CHROMATOGR A, V854, P175, DOI 10.1016/S0021-9673(99)00525-7; Takagaki K, 1998, GLYCOBIOLOGY, V8, P719, DOI 10.1093/glycob/8.7.719; Thanawiroon C, 2003, J CHROMATOGR A, V1014, P215, DOI 10.1016/S0021-9673(03)00779-9; Turnbull JE, 1999, P NATL ACAD SCI USA, V96, P2698, DOI 10.1073/pnas.96.6.2698; Venkataraman G, 1999, SCIENCE, V286, P537, DOI 10.1126/science.286.5439.537; Witters E, 1997, J CHROMATOGR B, V694, P55, DOI 10.1016/S0378-4347(96)00538-5; Yamada S, 1999, BIOCHEMISTRY-US, V38, P838, DOI 10.1021/bi981889n; YAMADA S, 1994, GLYCOBIOLOGY, V4, P69, DOI 10.1093/glycob/4.1.69; Yang HO, 2000, GLYCOBIOLOGY, V10, P1033, DOI 10.1093/glycob/10.10.1033; Yeung B, 1999, J CHROMATOGR A, V852, P573, DOI 10.1016/S0021-9673(99)00647-0; Zaia J, 2001, ANAL CHEM, V73, P233, DOI 10.1021/ac000777a; Zaia J, 2001, ANAL CHEM, V73, P6030, DOI 10.1021/ac015577t	68	130	147	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2608	2615		10.1074/jbc.M304772200	http://dx.doi.org/10.1074/jbc.M304772200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14610083	hybrid			2022-12-25	WOS:000188211300035
J	Guterman, A; Glickman, MH				Guterman, A; Glickman, MH			Complementary roles for Rpn11 and Ubp6 in deubiquitination and proteolysis by the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							26S PROTEASOME; REGULATORY PARTICLE; SACCHAROMYCES-CEREVISIAE; TERMINAL HYDROLASE; UBIQUITIN-ALDEHYDE; CYSTEINE PROTEASES; PROTEIN BREAKDOWN; COP9 SIGNALOSOME; DEGRADATION; COMPLEX	Substrates destined for degradation by the 26 S proteasome are labeled with polyubiquitin chains. These chains can be dismantled by deubiquitinating enzymes (DUBs). A number of reports have identified different DUBs that can hydrolyze ubiquitin from substrates bound to the proteasome. We measured deubiquitination by both isolated lid and base-core particle subcomplexes, suggesting that at least two different DUBs are intrinsic components of 26 S proteasome holoenzymes. In agreement, we find that highly purified proteasomes contain both Rpn11 and Ubp6, situated within the lid and base subcomplexes, respectively. To study their relative contributions, we purified proteasomes from a mutant in the putative metalloprotease domain of Rpn11 and from a ubp6 null. Interestingly, in both preparations we observed slower deubiquitination rates, suggesting that Rpn11 and Ubp6 serve complementary roles. In accord, the double mutant is synthetically lethal. In contrast to WT proteasomes, proteasomes lacking the lid subcomplex or those purified from the rpn11 mutant are less sensitive to metal chelators, supporting the prediction that Rpn11 may be a metalloprotein. Treatment of proteasomes with ubiquitin-aldehyde or with cysteine modifiers also inhibited deubiquitination but simultaneously promoted degradation of a monoubiquitinated substrate along with the ubiquitin tag. Degradation is unique to 26 S proteasome holoenzymes; we could not detect degradation of a ubiquitinated protein by "lidless" proteasomes, although they were competent for deubiquitination. The fascinating observation that a single ubiquitin moiety is sufficient for targeting an otherwise stable substrate to proteasomes exposes how rapid deubiquitination of poorly ubiquitinated substrates may counteract degradation.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Inst Catalysis Sci & Technol, IL-32000 Haifa, Israel	Technion Israel Institute of Technology; Technion Israel Institute of Technology	Glickman, MH (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	glickman@tx.technion.ac.il		Glickman, Michael/0000-0002-1222-8104				Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; Baek KH, 2003, EXP MOL MED, V35, P1; Bajorek M, 2003, CURR BIOL, V13, P1140, DOI 10.1016/S0960-9822(03)00417-2; Balakirev MY, 2003, EMBO REP, V4, P517, DOI 10.1038/sj.embor.embor824; Benaroudj N, 2003, MOL CELL, V11, P69, DOI 10.1016/S1097-2765(02)00775-X; Berndt C, 2002, CURR BIOL, V12, pR815, DOI 10.1016/S0960-9822(02)01317-9; Borodovsky A, 2001, EMBO J, V20, P5187, DOI 10.1093/emboj/20.18.5187; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Evans PC, 2003, J BIOL CHEM, V278, P23180, DOI 10.1074/jbc.M301863200; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; EYTAN E, 1993, J BIOL CHEM, V268, P4668; Finley D, 1998, TRENDS BIOCHEM SCI, V23, P244, DOI 10.1016/S0968-0004(98)01222-5; Fu HY, 2001, EMBO J, V20, P7096, DOI 10.1093/emboj/20.24.7096; Gan-Erdene T, 2003, J BIOL CHEM, V278, P28892, DOI 10.1074/jbc.M302890200; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Glickman MH, 2002, CURR TOP MICROBIOL, V268, P43; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Glickman MH, 2000, SEMIN CELL DEV BIOL, V11, P149, DOI 10.1006/scdb.2000.0161; GLICKMAN MH, 2001, CURRENT PROTOCOLS PR, V24; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; GUTERMAN A, 2004, IN PRESS CURR PROTEI; HAAS A, 1990, J BIOL CHEM, V265, P21664; HADARI T, 1992, J BIOL CHEM, V267, P719; Hartmann-Petersen R, 2003, FEBS LETT, V535, P77, DOI 10.1016/S0014-5793(02)03874-7; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Holzl H, 2000, J CELL BIOL, V150, P119, DOI 10.1083/jcb.150.1.119; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877; Kim JH, 2003, J BIOCHEM, V134, P9, DOI 10.1093/jb/mvg107; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lam YA, 1997, J BIOL CHEM, V272, P28438, DOI 10.1074/jbc.272.45.28438; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Layfield R, 1999, ANAL BIOCHEM, V274, P40, DOI 10.1006/abio.1999.4234; Lee Jae Il, 1998, Biol Proced Online, V1, P92, DOI 10.1251/bpo11; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Li TW, 2000, BIOCHEM BIOPH RES CO, V272, P270, DOI 10.1006/bbrc.2000.2767; Linghu B, 2002, EUKARYOT CELL, V1, P491, DOI 10.1128/EC.1.3.491-494.2002; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Lundgren J, 2003, MOL CELL BIOL, V23, P5320, DOI 10.1128/MCB.23.15.5320-5330.2003; Makarova KS, 2000, TRENDS BIOCHEM SCI, V25, P50, DOI 10.1016/S0968-0004(99)01530-3; Maytal-Kivity V, 2002, EMBO REP, V3, P1215, DOI 10.1093/embo-reports/kvf235; Maytal-Kivity V, 2003, INT J BIOCHEM CELL B, V35, P706, DOI 10.1016/S1357-2725(02)00378-3; Maytal-Kivity V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-28; Mendoza HM, 2003, J BIOL CHEM, V278, P25637, DOI 10.1074/jbc.M212948200; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; Papa FR, 1999, MOL BIOL CELL, V10, P741, DOI 10.1091/mbc.10.3.741; PICKART CM, 1986, J BIOL CHEM, V261, P210; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Rinaldi T, 1998, MOL BIOL CELL, V9, P2917, DOI 10.1091/mbc.9.10.2917; Rinaldi T, 2002, GENE, V286, P43, DOI 10.1016/S0378-1119(01)00799-5; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V296, P813, DOI 10.1016/S0006-291X(02)02002-8; Scheel H, 2003, HUM MOL GENET, V12, P2845, DOI 10.1093/hmg/ddg297; Seeger M, 2003, J BIOL CHEM, V278, P16791, DOI 10.1074/jbc.M208281200; SHAEFFER JR, 1995, BIOCHEMISTRY-US, V34, P4015, DOI 10.1021/bi00012a020; Shaeffer JR, 1996, BIOCHEMISTRY-US, V35, P10886, DOI 10.1021/bi9530705; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Tran HJTT, 2003, BIOCHEMISTRY-US, V42, P11460, DOI 10.1021/bi035033g; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Wee S, 2002, BMC GENET, V3, DOI 10.1186/1471-2156-3-15; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wilkinson KD, 2003, NATURE, V424, P738, DOI 10.1038/424738a; Wing SS, 2003, INT J BIOCHEM CELL B, V35, P590, DOI 10.1016/S1357-2725(02)00392-8; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158; Zwickl P, 2000, CURR OPIN STRUC BIOL, V10, P242, DOI 10.1016/S0959-440X(00)00075-0	82	119	125	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1729	1738		10.1074/jbc.M307050200	http://dx.doi.org/10.1074/jbc.M307050200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14581483	hybrid			2022-12-25	WOS:000188005700022
J	Zhang, HY; Links, PH; Ngsee, JK; Tran, K; Cui, Z; Ko, KWS; Yao, ZM				Zhang, HY; Links, PH; Ngsee, JK; Tran, K; Cui, Z; Ko, KWS; Yao, ZM			Localization of low density lipoprotein receptor-related protein 1 to caveolae in 3T3-L1 adipocytes in response to insulin treatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUCOSE-TRANSPORT; TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; CELL-SURFACE; PLASMA-MEMBRANE; LIPID RAFTS; SIGNAL-TRANSDUCTION; ALPHA-2-MACROGLOBULIN RECEPTOR; ENRICHED LIPOPROTEINS; LINKED PROTEINS	The insulin-induced translocation of low density lipoprotein receptor-related protein 1 (LRP1) from intracellular membranes to the cell surface in 3T3-L1 adipocytes was differentiation-dependent and did not occur in 3T3-L1 fibroblasts. Prompted by findings that the plasma membrane of 3T3-L1 adipocytes was rich in caveolae, we determined whether LRP1 became caveolae-associated upon insulin stimulation. The caveolae domain was isolated by the well characterized detergent solubilization and sucrose density ultracentrifugation methodology. Under basal conditions, only a trace amount of LRP1 was caveolae-associated despite the markedly elevated caveolin-1 and caveolae after adipo-cytic cell differentiation. Upon insulin treatment, the amount of LRP1 associated with caveolae was increased by 4-fold within 10 min, which was blocked completely by pretreatment with wortmannin prior to insulin. The caveolar localization of LRP1 in adipocytes was specific to insulin; treatment with platelet-derived growth factor-bb isoform did not promote but rather decreased caveolar localization of LRP1 below basal levels. The insulin-induced caveolar localization of LRP1 was also observed in 3T3-L1 fibroblasts where translocation of LRP1 from intracellular membranes to the cell surface was absent, suggesting that association of LRP1 with caveolae was achieved, at least in part, through lateral transmigration along the plane of plasma membranes. Immunocytochemistry studies revealed partial co-localization of LRP1 (either endogenous LRP1 or an epitope-tagged minireceptor) with caveolin-1 in cells treated with insulin, which was confirmed by co-immunoprecipitation of LRP1 with caveolin-1 in cells treated with insulin but not platelet-derived growth factor-bb. These results suggest that the localization of LRP1 to caveolae responds selectively to extracellular signals.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada; Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON K1H 8M5, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Wake Forest University; Wake Forest Baptist Medical Center; University of Ottawa	Yao, ZM (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4W7, Canada.	zyao@ottawaheart.ca						Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Avramoglu RK, 1998, J BIOL CHEM, V273, P6057, DOI 10.1074/jbc.273.11.6057; Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Chiang SH, 2002, J BIOL CHEM, V277, P13067, DOI 10.1074/jbc.M109471200; CORVERA S, 1989, J BIOL CHEM, V264, P10133; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; DESCAMPS O, 1993, J BIOL CHEM, V268, P974; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; FAN JY, 1983, J CELL SCI, V61, P219; Fisher MD, 1996, J BIOL CHEM, V271, P11806, DOI 10.1074/jbc.271.20.11806; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; Fridriksson EK, 1999, BIOCHEMISTRY-US, V38, P8056, DOI 10.1021/bi9828324; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1990, J BIOL CHEM, V265, P21355; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Hooper NM, 2001, PROTEOMICS, V1, P748, DOI 10.1002/1615-9861(200106)1:6<748::AID-PROT748>3.3.CO;2-K; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; Ito J, 2000, J LIPID RES, V41, P894; JAMES DE, 1987, J BIOL CHEM, V262, P11817; Ko KWS, 2001, BIOCHEMISTRY-US, V40, P752, DOI 10.1021/bi001797+; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Li WP, 2001, J CELL SCI, V114, P1397; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu LB, 2003, J BIOL CHEM, V278, P30157, DOI 10.1074/jbc.M301511200; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; Molero JC, 2001, J BIOL CHEM, V276, P43829, DOI 10.1074/jbc.M105452200; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; Ness GC, 2003, BIOCHEM BIOPH RES CO, V303, P177, DOI 10.1016/S0006-291X(03)00319-X; Obermoeller-McCormick LM, 2001, J CELL SCI, V114, P899; Parton RG, 2002, J BIOL CHEM, V277, P46769, DOI 10.1074/jbc.M205683200; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P2075, DOI 10.1021/bi0156557; Razani B, 2000, J CELL SCI, V113, P2103; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Riddell DR, 2001, J LIPID RES, V42, P998; Rietveld A, 1999, J BIOL CHEM, V274, P12049, DOI 10.1074/jbc.274.17.12049; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Shigematsu S, 2003, J BIOL CHEM, V278, P10683, DOI 10.1074/jbc.M208563200; Shigematsu S, 2002, MOL ENDOCRINOL, V16, P1060, DOI 10.1210/me.16.5.1060; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simpson F, 2001, TRAFFIC, V2, P2, DOI 10.1034/j.1600-0854.2001.020102.x; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TANNER LI, 1987, J BIOL CHEM, V262, P8975; Tran K, 2000, J BIOL CHEM, V275, P25023, DOI 10.1074/jbc.M908971199; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; Yamabhai M, 2002, J BIOL CHEM, V277, P24843, DOI 10.1074/jbc.C200277200	77	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2221	2230		10.1074/jbc.M310679200	http://dx.doi.org/10.1074/jbc.M310679200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14593097	hybrid			2022-12-25	WOS:000188005700079
J	Jiang, Y; Zhang, YK; Lees, E; Seghezzi, W				Jiang, Y; Zhang, YK; Lees, E; Seghezzi, W			AuroraA overexpression overrides the mitotic spindle checkpoint triggered by nocodazole, a microtubule destabilizer	ONCOGENE			English	Article						mitotic spindle checkpoint; mitotic kinase; cell cycle	ANAPHASE-PROMOTING COMPLEX; CENTROSOME AMPLIFICATION; KINASE AURORA2/AIK; DROSOPHILA-AURORA; BINDING DOMAIN; PROTEIN BUBR1; B KINASE; A KINASE; CANCERS; MITOSIS	AuroraA, a mitotic kinase, is reported to be amplified and overexpressed in a variety of human tumors. Active mutants of AuroraA can transform mouse fibroblasts and form tumors in nude mice. However, the mechanism behind this oncogenic potential remains elusive. In this study, we investigated the consequences of AuroraA overexpression and showed that increased AuroraA levels compromise the mitotic spindle checkpoint triggered by nocodazole, a microtubule polymerization inhibitor. This is accomplished by disrupting the proper assembly of the mitotic checkpoint complex at the level of the Cdc20-BubR1 interaction. As a result, the spindle checkpoint complex fails to form and cells progress through mitosis without proper arrest in response to nocodazole. This ability to override the mitotic spindle checkpoint was found to be independent of AuroraA kinase activity. We conclude that maintenance of a functional balance between AuroraA and mitotic checkpoint proteins is essential for the proper progression through mitosis. This study therefore offers a possible explanation of how deregulation of AuroraA can contribute to genetic instability and tumorigenesis.	DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA; Prot Design Labs Inc, Fremont, CA 94555 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Seghezzi, W (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, 901 Calif Ave, Palo Alto, CA 94304 USA.	wolfgang.seghezzi@dnax.org						Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Bernard M, 1998, GENOMICS, V53, P406, DOI 10.1006/geno.1998.5522; Bin OY, 2002, CLIN ENDOCRINOL, V56, P341, DOI 10.1046/j.1365-2265.2002.01475.x; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; CHAN CSM, 1993, GENETICS, V135, P677; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Farruggio DC, 1999, P NATL ACAD SCI USA, V96, P7306, DOI 10.1073/pnas.96.13.7306; Giet R, 2000, EXP CELL RES, V258, P145, DOI 10.1006/excr.2000.4903; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Hardwick KG, 1998, TRENDS GENET, V14, P1, DOI 10.1016/S0168-9525(97)01340-1; Hernando E, 2001, INT J CANCER, V95, P223, DOI 10.1002/1097-0215(20010720)95:4<223::AID-IJC1038>3.0.CO;2-L; Hixon ML, 2000, FRONT BIOSCI, V5, pD50, DOI 10.2741/Hixon; Imai Y, 1999, JPN J CANCER RES, V90, P837, DOI 10.1111/j.1349-7006.1999.tb00824.x; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kallio MJ, 2002, CURR BIOL, V12, P900, DOI 10.1016/S0960-9822(02)00887-4; Khan SH, 1998, CANCER RES, V58, P396; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li WQ, 1999, CELL GROWTH DIFFER, V10, P769; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Murata-Hori M, 2002, MOL BIOL CELL, V13, P1099, DOI 10.1091/mbc.01-09-0467; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Reis RM, 2001, ACTA NEUROPATHOL, V101, P297; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Sato M, 2000, JPN J CANCER RES, V91, P504, DOI 10.1111/j.1349-7006.2000.tb00974.x; Sen S, 2002, JNCI-J NATL CANCER I, V94, P1320; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Zhang YK, 2001, MOL CELL BIOL, V21, P5190, DOI 10.1128/MCB.21.15.5190-5199.2001; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	40	52	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2003	22	51					8293	8301		10.1038/sj.onc.1206873	http://dx.doi.org/10.1038/sj.onc.1206873			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614453				2022-12-25	WOS:000186541500008
J	Huang, HL; Fang, LW; Lu, SP; Chou, CK; Luh, TY; Lai, MZ				Huang, HL; Fang, LW; Lu, SP; Chou, CK; Luh, TY; Lai, MZ			DNA-damaging reagents induce apoptosis through reactive oxygen species-dependent Fas aggregation	ONCOGENE			English	Article						Fas; DNA damage; ROS; mitochondria; apoptosis	DEATH DOMAIN; CELL-DEATH; MEDIATED APOPTOSIS; T-LYMPHOCYTES; ACTIVATION; LIGAND; PROTEIN; MITOCHONDRIA; MECHANISM; EXPRESSION	DNA-damaging reagents may kill tumor cells through the generation of reactive oxygen species (ROS). Cytotoxic reagents may also induce apoptosis of cancer cells in Fas-FADD-dependent manners. In this study, we explored the possible link between these two apparently distinct pathways in T leukemia cell Jurkat. Our results demonstrated that gamma-irradiation, similar to cisplatin, induced apoptosis by triggering Fas aggregation and activating FADD-caspase-8 apoptotic cascade. The absence of caspase-8 or Fas greatly reduced the sensitivity to apoptosis mediated by DNA-damaging agents. In addition, apoptosis induced by cisplatin and gamma-irradiation, but not by Fas, was inhibited by ROS scavengers, including N-acetyl cysteine, MnTBAP, and C-60. Importantly, these ROS scavengers effectively prevented the clustering of Fas receptor induced by cisplatin and gamma-irradiation. Our results suggest that cisplatin and gamma-irradiation promote ROS production, which in turn contributes to Fas receptor aggregation and cell death. The novel coupling between ROS and Fas clustering likely plays a significant role in apoptosis triggered by DNA-damaging reagents in Fas-expressing leukemia cells.	Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; Natl Def Med Sch, Grad Inst Life Sci, Taipei, Taiwan; Natl Yang Ming Univ, Dept Life Sci, Taipei, Taiwan; Acad Sinica, Inst Chem, Taipei, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Lai, MZ (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan.	mblai@ccvax.sinica.edu.tw	Lai, Ming-Zong/AAA-4408-2021	Luh, Tien-Yau/0000-0002-0415-6454; Lai, Ming-Zong/0000-0002-3237-4803				Alleva R, 2001, FEBS LETT, V503, P46, DOI 10.1016/S0014-5793(01)02694-1; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Aronis A, 2003, CELL DEATH DIFFER, V10, P335, DOI 10.1038/sj.cdd.4401150; Bauer MKA, 1998, J BIOL CHEM, V273, P8048, DOI 10.1074/jbc.273.14.8048; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Chen Y, 2001, J BIOL CHEM, V276, P8350, DOI 10.1074/jbc.M008431200; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Costa GL, 2000, J IMMUNOL, V164, P3581, DOI 10.4049/jimmunol.164.7.3581; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Ferreira CG, 2000, CLIN CANCER RES, V6, P203; Gulbins E, 1996, IMMUNOLOGY, V89, P205, DOI 10.1046/j.1365-2567.1996.d01-743.x; Han ZY, 2001, J BIOL CHEM, V276, P38748, DOI 10.1074/jbc.M106214200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hsu SC, 1998, BLOOD, V91, P2658, DOI 10.1182/blood.V91.8.2658.2658_2658_2663; HUG H, 1994, FEBS LETT, V351, P311, DOI 10.1016/0014-5793(94)00852-3; Hug H, 1997, J BIOL CHEM, V272, P28191, DOI 10.1074/jbc.272.45.28191; Jayanthi S, 1999, MOL BRAIN RES, V72, P158, DOI 10.1016/S0169-328X(99)00216-8; Kamitani T, 1997, J BIOL CHEM, V272, P22307, DOI 10.1074/jbc.272.35.22307; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Landowski TH, 1999, BLOOD, V94, P265, DOI 10.1182/blood.V94.1.265.413k37_265_274; Lavastre V, 2002, J IMMUNOL, V168, P1419, DOI 10.4049/jimmunol.168.3.1419; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Malins DC, 2002, P NATL ACAD SCI USA, V99, P5937, DOI 10.1073/pnas.082111199; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; Simizu S, 1998, J BIOL CHEM, V273, P26900, DOI 10.1074/jbc.273.41.26900; Stegh AH, 2000, MOL CELL BIOL, V20, P5665, DOI 10.1128/MCB.20.15.5665-5679.2000; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Um HD, 1996, J IMMUNOL, V156, P3469; van Wetering S, 2002, J CELL SCI, V115, P1837; Wang J, 2001, J BIOL CHEM, V276, P47763, DOI 10.1074/jbc.C100415200; Wang XD, 2001, GENE DEV, V15, P2922; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795	49	139	145	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2003	22	50					8168	8177		10.1038/sj.onc.1206979	http://dx.doi.org/10.1038/sj.onc.1206979			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603257				2022-12-25	WOS:000186403400011
J	Turner, SD; Tooze, R; Maclennan, K; Alexander, DR				Turner, SD; Tooze, R; Maclennan, K; Alexander, DR			Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase	ONCOGENE			English	Article						NPM-ALK; lymphoma; mouse model; Jun kinase	NON-HODGKINS-LYMPHOMA; RECEPTOR TYROSINE KINASE; ANAPLASTIC LYMPHOMA; C-JUN; T-CELL; SIGNAL-TRANSDUCTION; HELICOBACTER-PYLORI; NH2-TERMINAL KINASE; GENE REARRANGEMENT; EXPRESSION	Anaplastic large-cell lymphoma is associated with a chromosomal translocation generating an oncogenic fusion protein: the nucleophosmin-anaplastic lymphoma kinase (NPM-ALK). We have generated several independent lines of human NPM-ALK transgenic mice using the haematopoietic cell-specific Vav promoter. Lymphomas develop in two transgenic lines in which the Vav promoter regulates NPM-ALK expression. The transgenic line with higher copy number displays an early-onset phenotype in which all mice succumb to aggressive lymph node tumours with intestinal involvement, whereas the second line displays late-onset tumour development in the spleen and/or liver. Lymphomas from both lines are phenotypically distinct and display B-lineage characteristics with aberrant coexpression of myeloid markers. The NPM-ALK kinase is active in primary tumour tissue and forms a multimeric complex with tyrosine-phosphorylated proteins, that is, Shc. Jun and ERK kinase activities in tumours are elevated by up to 30-fold and fivefold, respectively, in comparison with sIgM-stimulated primary B cells. The new transgenic models provide a system for investigating the oncogenic events mediated by NPM-ALK in situ and a physiologically relevant context for developing tyrosine kinase inhibitor therapies of potential use in the clinic.	Babraham Inst, Mol Immunol Programme, Lab Lymphocyte Signalling & Dev, Cambridge CB2 4AT, England; St James Univ Hosp, Canc Med Unit, Leeds LS9 7TF, W Yorkshire, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Saint James's University Hospital	Alexander, DR (corresponding author), Babraham Inst, Mol Immunol Programme, Lab Lymphocyte Signalling & Dev, Cambridge CB2 4AT, England.	denis.alexander@bbsrc.ac.uk	Turner, Suzanne Dawn/K-4405-2013	Turner, Suzanne Dawn/0000-0002-8439-4507; Tooze, Reuben/0000-0003-2915-7119				Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Benharroch D, 1998, BLOOD, V91, P2076, DOI 10.1182/blood.V91.6.2076; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Bost F, 1999, MOL CELL BIOL, V19, P1938; Chan PK, 1997, NUCLEIC ACIDS RES, V25, P1225, DOI 10.1093/nar/25.6.1225; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Corcoran AE, 1998, NATURE, V391, P904, DOI 10.1038/36122; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Delsol G, 1997, BLOOD, V89, P1483, DOI 10.1182/blood.V89.5.1483.1483_1483_1490; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; EHLICH A, 1994, CURR BIOL, V4, P573, DOI 10.1016/S0960-9822(00)00129-9; Falini B, 2002, BLOOD, V99, P409, DOI 10.1182/blood.V99.2.409; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Gascoyne RD, 1999, BLOOD, V93, P3913, DOI 10.1182/blood.V93.11.3913.411k22_3913_3921; Greenland C, 2001, ONCOGENE, V20, P7386, DOI 10.1038/sj.onc.1204870; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; HARIHARAN IK, 1989, MOL CELL BIOL, V9, P2798, DOI 10.1128/MCB.9.7.2798; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; HESTDAL K, 1991, J IMMUNOL, V147, P22; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Jaffe ES, 2001, TUMOURS HAEMATOPOIET; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kanda M, 2001, LEUKEMIA LYMPHOMA, V42, P639, DOI 10.3109/10428190109099324; Katsura Y, 2002, NAT REV IMMUNOL, V2, P127, DOI 10.1038/nri721; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; LANIER LL, 1995, LEUCOCYTE TYPING, V5, P1398; Li YS, 1996, IMMUNITY, V5, P527, DOI 10.1016/S1074-7613(00)80268-X; Maes B, 2001, ANN ONCOL, V12, P853, DOI 10.1023/A:1011195708834; Mason DY, 1998, CANCER RES, V58, P1057; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1995, BLOOD, V86, P647; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Ogilvy S, 2003, J IMMUNOL, V171, P1792, DOI 10.4049/jimmunol.171.4.1792; Ogilvy S, 1999, BLOOD, V94, P1855; Ogilvy S, 1999, P NATL ACAD SCI USA, V96, P14943, DOI 10.1073/pnas.96.26.14943; ONCIU M, 2003, IN PRESS BLOOD; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Pulford K, 1997, BLOOD, V89, P1394, DOI 10.1182/blood.V89.4.1394; Rabbitts TH, 1998, NEW ENGL J MED, V338, P192, DOI 10.1056/NEJM199801153380311; Sanderson RD, 2002, ANN HEMATOL, V81, P125, DOI 10.1007/s00277-002-0437-8; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Sebestyen A, 1999, BRIT J HAEMATOL, V104, P412, DOI 10.1046/j.1365-2141.1999.01211.x; STEWART M, 1993, INT J CANCER, V53, P1023; TENBOEKEL E, 1995, INT IMMUNOL, V7, P1013; Weisenburger DD, 2001, AM J HEMATOL, V67, P172, DOI 10.1002/ajh.1102; Yang YM, 2003, CLIN CANCER RES, V9, P391; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S; ZUKERBERG LR, 1991, AM J PATHOL, V139, P475	56	58	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2003	22	49					7750	7761		10.1038/sj.onc.1207048	http://dx.doi.org/10.1038/sj.onc.1207048			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586401				2022-12-25	WOS:000186240200005
J	Dobo, J; Gettins, PGW				Dobo, J; Gettins, PGW			alpha(1)-proteinase inhibitor forms initial non-covalent and final covalent complexes with elastase analogously to other serpin-proteinase pairs, suggesting a common mechanism of inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; REACTIVE CENTER LOOP; PROTEASE COMPLEX; CONFORMATIONAL-CHANGE; MICHAELIS COMPLEX; PITTSBURGH; TRYPSIN; ENZYME; TRANSLOCATION; CHYMOTRYPSIN	Despite several concordant structural studies on the initial non-covalent complex that serpins form with target proteinases, a recent study on the non-covalent complex between the serpin alpha(1)-proteinase inhibitor (alpha(1)PI) and anhydroelastase (Mellet, P., and Bieth, J. G. ( 2000) J. Biol. Chem. 275, 10788 - 10795) concluded that translocation of the proteinase precedes cleavage of the reactive center loop and formation of the acyl ester. Because this conclusion is diametrically opposite to those of the other structural studies on serpin-proteinase pairs, we proceeded to examine this specific serpin-proteinase complex by the same successful NMR approach used previously on the alpha(1)PI-Pittsburgh-S195A trypsin pair. Both non-covalent complex with anhydroelastase and covalent complex with active elastase were made with N-15-alanine-labeled wild-type alpha(1)PI. The heteronuclear single quantum correlation spectroscopy (HSQC) NMR spectrum of the non-covalent complex showed that the entire reactive center loop remained exposed, and the serpin body maintained a conformation indistinguishable from that of native alpha(1)PI, indicating no movement of the proteinase and no insertion of the reactive center loop into beta-sheet A. In contrast, the HSQC NMR spectrum of the covalent complex showed that the reactive center loop had fully inserted into beta-sheet A, indicating that translocation of the proteinase had occurred. These results agree with previous NMR, fluorescence resonance energy transfer, and x-ray crystallographic studies and suggest that a common mechanism is employed in formation of serpin-proteinase complexes. We found that preparations of anhydroelastase that are not appropriately purified contain material that can regenerate active elastase over time. It is likely that the material used by Mellet and Bieth contained such active elastase, resulting in mistaken attribution of the behavior of covalent complex to that of the non-covalent complex.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gettins, PGW (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, 900 S Ashland,M-C 669, Chicago, IL 60607 USA.	pgettins@uic.edu	Dobo, Jozsef/C-7331-2014	Dobo, Jozsef/0000-0001-9187-8502	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL064013, R37HL049234] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37HL49234, P01HL64013] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKO H, 1972, BIOCHEM BIOPH RES CO, V47, P1402, DOI 10.1016/0006-291X(72)90228-8; AKO H, 1974, BIOCHEMISTRY-US, V13, P132, DOI 10.1021/bi00698a021; Backovic M, 2002, PROTEIN SCI, V11, P1182, DOI 10.1110/ps.4320102; Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; Boudier C, 2001, BIOCHEMISTRY-US, V40, P9962, DOI 10.1021/bi010701o; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dementiev A, 2003, J BIOL CHEM, V278, P37881, DOI 10.1074/jbc.M305195200; Fa M, 2000, STRUCT FOLD DES, V8, P397, DOI 10.1016/S0969-2126(00)00121-0; Futamura A, 1998, BIOCHEMISTRY-US, V37, P13110, DOI 10.1021/bi981234m; Gettins PGW, 2002, FEBS LETT, V523, P2, DOI 10.1016/S0014-5793(02)02924-1; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Im H, 1999, J BIOL CHEM, V274, P11072, DOI 10.1074/jbc.274.16.11072; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; Mellet P, 2000, J BIOL CHEM, V275, P10788, DOI 10.1074/jbc.275.15.10788; O'Malley KM, 2001, J BIOL CHEM, V276, P6631, DOI 10.1074/jbc.M008478200; OLSON ST, 1995, J BIOL CHEM, V270, P30007; Olson ST, 2001, BIOCHEMISTRY-US, V40, P11742, DOI 10.1021/bi0107290; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; Peterson FC, 2000, BIOCHEMISTRY-US, V39, P11884, DOI 10.1021/bi001152+; Peterson FC, 2001, BIOCHEMISTRY-US, V40, P6284, DOI 10.1021/bi010100x; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Stratikos E, 1998, J BIOL CHEM, V273, P15582, DOI 10.1074/jbc.273.25.15582; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; Ye S, 2001, NAT STRUCT BIOL, V8, P979, DOI 10.1038/nsb1101-979	30	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9264	9269		10.1074/jbc.M311731200	http://dx.doi.org/10.1074/jbc.M311731200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14593107	hybrid			2022-12-25	WOS:000189265900088
J	Suzuki, N; Nakano, M; Nozaki, N; Egashira, S; Okazaki, T; Masumoto, H				Suzuki, N; Nakano, M; Nozaki, N; Egashira, S; Okazaki, T; Masumoto, H			CENP-B interacts with CENP-C domains containing Mif2 regions responsible for centromere localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SATELLITE DNA; HISTONE H3; PROTEIN-C; NULL MICE; CHROMATIN; SEQUENCE; GENE; BINDING; IDENTIFICATION; YEAST	Recently, human artificial chromosomes featuring functional centromeres have been generated efficiently from naked synthetic alphoid DNA containing CENP-B boxes as a de novo mechanism in a human cultured cell line, but not from the synthetic alphoid DNA only containing mutations within CENP-B boxes, indicating that CENP-B has some functions in assembling centromere/kinetochore components on alphoid DNA. To investigate whether any interactions exist between CENP-B and the other centromere proteins, we screened a cDNA library by yeast two-hybrid analysis. An interaction between CENP-B and CENP-C was detected, and the CENP-C domains required were determined to overlap with three Mif2 homologous regions, which were also revealed to be involved in the CENP-C assembly of centromeres by expression of truncated polypeptides in cultured cells. Overproduction of truncated CENP-B containing no CENP-C interaction domains caused abnormal duplication of CENP-C domains at G(2) and cell cycle delay at metaphase. These results suggest that the interaction between CENP-B and CENP-C may be involved in the correct assembly of CENP-C on alphoid DNA. In other words, a possible molecular linkage may exist between one of the kinetochore components and human centromere DNA through CENP-B/CENP-B box interaction.	Nagoya Univ, Div Biol Sci, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Kanagawa Dent Coll, Kanagawa 2388580, Japan	Nagoya University; Kanagawa Dental College	Masumoto, H (corresponding author), Nagoya Univ, Div Biol Sci, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.	g44478a@nucc.cc.nagoya-u.ac.jp						Ando S, 2002, MOL CELL BIOL, V22, P2229, DOI 10.1128/MCB.22.7.2229-2241.2002; BAUM M, 1994, MOL BIOL CELL, V5, P747, DOI 10.1091/mbc.5.7.747; BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; BROWN MT, 1993, J CELL BIOL, V123, P387, DOI 10.1083/jcb.123.2.387; BROWN MT, 1995, GENE, V160, P111, DOI 10.1016/0378-1119(95)00163-Z; Buchwitz BJ, 1999, NATURE, V401, P547, DOI 10.1038/44062; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; EARNSHAW WC, 1989, CHROMOSOMA, V98, P1, DOI 10.1007/BF00293329; Fowler KJ, 2000, GENOME RES, V10, P30; Fukagawa T, 1997, HUM MOL GENET, V6, P2301, DOI 10.1093/hmg/6.13.2301; Fukagawa T, 2001, NUCLEIC ACIDS RES, V29, P3796, DOI 10.1093/nar/29.18.3796; Fukagawa T, 2001, EMBO J, V20, P4603, DOI 10.1093/emboj/20.16.4603; Goshima G, 2003, J CELL BIOL, V160, P25, DOI 10.1083/jcb.200210005; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; Henikoff S, 2000, P NATL ACAD SCI USA, V97, P716, DOI 10.1073/pnas.97.2.716; Howman EV, 2000, P NATL ACAD SCI USA, V97, P1148, DOI 10.1073/pnas.97.3.1148; Hudson DF, 1998, J CELL BIOL, V141, P309, DOI 10.1083/jcb.141.2.309; IKENO M, 1994, HUM MOL GENET, V3, P1245, DOI 10.1093/hmg/3.8.1245; Ikeno M, 1998, NAT BIOTECHNOL, V16, P431, DOI 10.1038/nbt0598-431; Irelan JT, 2001, GENETICS, V157, P1191; Kalitsis P, 1998, GENOMICS, V47, P108, DOI 10.1006/geno.1997.5109; Kalitsis P, 1998, P NATL ACAD SCI USA, V95, P1136, DOI 10.1073/pnas.95.3.1136; Kapoor M, 1998, CHROMOSOMA, V107, P570, DOI 10.1007/s004120050343; KITAGAWA K, 1995, MOL CELL BIOL, V15, P1602; LANINI L, 1995, MOL BIOL CELL, V6, P1049, DOI 10.1091/mbc.6.8.1049; Liu ST, 2003, NAT CELL BIOL, V5, P341, DOI 10.1038/ncb953; MASUMOTO H, 1989, EXP CELL RES, V181, P181, DOI 10.1016/0014-4827(89)90192-4; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; Masumoto H, 1998, CHROMOSOMA, V107, P406, DOI 10.1007/s004120050324; MCKAY S, 1994, GENOMICS, V22, P36, DOI 10.1006/geno.1994.1342; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Moore LL, 2001, J CELL BIOL, V153, P1199, DOI 10.1083/jcb.153.6.1199; Murakami Y, 1996, P NATL ACAD SCI USA, V93, P502, DOI 10.1073/pnas.93.1.502; MURO Y, 1992, J CELL BIOL, V116, P585, DOI 10.1083/jcb.116.3.585; MURRAY AW, 1983, NATURE, V305, P189, DOI 10.1038/305189a0; Nakano M, 2003, J CELL SCI, V116, P4021, DOI 10.1242/jcs.00697; Nishihashi A, 2002, DEV CELL, V2, P463, DOI 10.1016/S1534-5807(02)00144-2; Oegema K, 2001, J CELL BIOL, V153, P1209, DOI 10.1083/jcb.153.6.1209; Ohzeki J, 2002, J CELL BIOL, V159, P765, DOI 10.1083/jcb.200207112; PALMER DK, 1987, J CELL BIOL, V104, P805, DOI 10.1083/jcb.104.4.805; Perez-Castro AV, 1998, DEV BIOL, V201, P135, DOI 10.1006/dbio.1998.9005; PLUTA AF, 1992, J CELL BIOL, V116, P1081, DOI 10.1083/jcb.116.5.1081; Pluta AF, 1996, J BIOL CHEM, V271, P18767, DOI 10.1074/jbc.271.31.18767; Politi V, 2002, J CELL SCI, V115, P2317; Saffery R, 2000, HUM MOL GENET, V9, P175, DOI 10.1093/hmg/9.2.175; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; Song K, 2002, EXP CELL RES, V275, P81, DOI 10.1006/excr.2002.5495; STOLER S, 1995, GENE DEV, V9, P573, DOI 10.1101/gad.9.5.573; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; Sugata N, 2000, HUM MOL GENET, V9, P2919, DOI 10.1093/hmg/9.19.2919; SUGIMOTO K, 1994, J BIOCHEM-TOKYO, V116, P877, DOI 10.1093/oxfordjournals.jbchem.a124610; Sugimoto K, 1997, CHROMOSOME RES, V5, P132, DOI 10.1023/A:1018422325569; SULLIVAN KF, 1991, CHROMOSOMA, V100, P360, DOI 10.1007/BF00337514; SULLIVAN KF, 1994, J CELL BIOL, V127, P581, DOI 10.1083/jcb.127.3.581; Takahashi K, 2000, SCIENCE, V288, P2215, DOI 10.1126/science.288.5474.2215; TOMKIEL J, 1994, J CELL BIOL, V125, P531, DOI 10.1083/jcb.125.3.531; Van Hooser AA, 2001, J CELL SCI, V114, P3529; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Warburton PE, 1997, CURR BIOL, V7, P901, DOI 10.1016/S0960-9822(06)00382-4; Yang CH, 1996, MOL CELL BIOL, V16, P3576; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0; YODA K, 1992, J CELL BIOL, V119, P1413, DOI 10.1083/jcb.119.6.1413; Yoda K, 2000, P NATL ACAD SCI USA, V97, P7266, DOI 10.1073/pnas.130189697	63	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5934	5946		10.1074/jbc.M306477200	http://dx.doi.org/10.1074/jbc.M306477200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14612452	hybrid			2022-12-25	WOS:000188776500109
J	de Graaf, K; Hekerman, P; Spelten, O; Herrmann, A; Packman, LC; Bussow, K; Muller-Newen, G; Becker, W				de Graaf, K; Hekerman, P; Spelten, O; Herrmann, A; Packman, LC; Bussow, K; Muller-Newen, G; Becker, W			Characterization of cyclin L2, a novel cyclin with an arginine/serine-rich domain - Phosphorylation by DYRK1A and colocalization with splicing factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; PROTEIN-KINASE; MESSENGER-RNA; IN-VIVO; DUAL-SPECIFICITY; SUBSTRATE-SPECIFICITY; PROGENITOR CELLS; GENE-EXPRESSION; DOWN-SYNDROME; CDNA LIBRARY	A novel method employing filter arrays of a cDNA expression library for the identification of substrates for protein kinases was developed. With this technique, we identified a new member of the cyclin family, cyclin L2, as a substrate of the nuclear protein kinase DYRK1A. Cyclin L2 contains an N-terminal cyclin domain and a C-terminal arginine/serine-rich domain (RS domain), which is a hallmark of many proteins involved in pre-mRNA processing. The gene for cyclin L2 encodes the full-length cyclin L2, which is predominantly expressed in testis, as well as a truncated splicing variant (cyclin US) that lacks the RS domain and is ubiquitously expressed in human tissues. Full-length cyclin L2, but not cyclin L2(S), was associated with the cyclin-dependent kinase PITSLRE. Cyclin L2 interacted with splicing factor 2 in vitro and was co-localized with the splicing factor SC35 in the nuclear speckle compartment. Photobleaching experiments showed that a fusion protein of green fluorescent protein and cyclin L2 in nuclear speckles rapidly exchanged with unbleached molecules in the nucleus, similar to other RS domain-containing proteins. In striking contrast, the closely related green fluorescent protein-cyclin L1 was immobile in the speckle compartment. DYRK1A interacted with cyclin L2 in pull-down assays, and overexpression of DYRK1A stimulated phosphorylation of cyclin L2 in COS-7 cells. These data characterize cyclin L2 as a highly mobile component of nuclear speckles and suggest that DYRK1A may regulate splicing by phosphorylation of cyclin L2.	Rhein Westfal TH Aachen, Fak Med, Inst Pharmakol & Toxikol, D-52074 Aachen, Germany; Rhein Westfal TH Aachen, Fak Med, Inst Biochem, D-52074 Aachen, Germany; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Max Planck Inst Mol Genet, D-14059 Berlin, Germany	RWTH Aachen University; RWTH Aachen University; University of Cambridge; Max Planck Society	Becker, W (corresponding author), Rhein Westfal TH Aachen, Fak Med, Inst Pharmakol & Toxikol, Wendlingweg 2, D-52074 Aachen, Germany.	walter.becker@post.rwth-aachen.de	Becker, Walter/B-8889-2008	Becker, Walter/0000-0002-0347-4768				Airhart N, 2003, J BIOL CHEM, V278, P38693, DOI 10.1074/jbc.M304098200; Altafaj X, 2001, HUM MOL GENET, V10, P1915, DOI 10.1093/hmg/10.18.1915; Alvarez M, 2003, J CELL SCI, V116, P3099, DOI 10.1242/jcs.00618; Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; Beaudoing E, 2000, GENOME RES, V10, P1001, DOI 10.1101/gr.10.7.1001; Becker W, 1999, PROG NUCLEIC ACID RE, V62, P1; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; Becker W, 1996, BBA-MOL CELL RES, V1312, P63, DOI 10.1016/0167-4889(96)00036-5; Beil B, 1997, DNA CELL BIOL, V16, P679, DOI 10.1089/dna.1997.16.679; Berke JD, 2001, NEURON, V32, P277, DOI 10.1016/S0896-6273(01)00465-2; Blencowe BJ, 1999, BIOCHEM CELL BIOL, V77, P277, DOI 10.1139/bcb-77-4-277; Boucher L, 2001, RNA, V7, P1693; Brinkworth RI, 2003, P NATL ACAD SCI USA, V100, P74, DOI 10.1073/pnas.0134224100; Bussow K, 2000, GENOMICS, V65, P1, DOI 10.1006/geno.2000.6141; Bussow K, 1998, NUCLEIC ACIDS RES, V26, P5007, DOI 10.1093/nar/26.21.5007; Campbell LE, 2002, FEBS LETT, V510, P31, DOI 10.1016/S0014-5793(01)03221-5; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; Chen-Hwang MC, 2002, J BIOL CHEM, V277, P17597, DOI 10.1074/jbc.M111101200; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; Dickinson LA, 2002, J BIOL CHEM, V277, P25465, DOI 10.1074/jbc.M202266200; Duncan PI, 1997, MOL CELL BIOL, V17, P5996, DOI 10.1128/MCB.17.10.5996; Fotaki V, 2002, MOL CELL BIOL, V22, P6636, DOI 10.1128/MCB.22.18.6636-6647.2002; FU XD, 1995, RNA, V1, P663; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GALCERAN J, 2003, IN PRESS J NEURAL S; Giese B, 2003, J BIOL CHEM, V278, P39205, DOI 10.1074/jbc.M303347200; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Guimera J, 1996, HUM MOL GENET, V5, P1305, DOI 10.1093/hmg/5.9.1305; Gururajan R, 1998, GENOME RES, V8, P929, DOI 10.1101/gr.8.9.929; Hammerle B, 2002, DEV BIOL, V246, P259, DOI 10.1006/dbio.2002.0675; HAMMERLE B, 2003, IN PRESS J NEURAL S; Herrmann CH, 2001, J CELL SCI, V114, P1491; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Himpel S, 1999, ANAL BIOCHEM, V274, P138, DOI 10.1006/abio.1999.4205; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; Himpel S, 2001, BIOCHEM J, V359, P497, DOI 10.1042/0264-6021:3590497; Hu DL, 2003, J BIOL CHEM, V278, P8623, DOI 10.1074/jbc.M210057200; Jumaa H, 1997, EMBO J, V16, P5077, DOI 10.1093/emboj/16.16.5077; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; Lewis TS, 2000, MOL CELL, V6, P1343, DOI 10.1016/S1097-2765(00)00132-5; Loyer P, 1998, J CELL SCI, V111, P1495; Mao JH, 2002, J BIOL CHEM, V277, P35156, DOI 10.1074/jbc.M206743200; Marti E, 2003, BRAIN RES, V964, P250, DOI 10.1016/S0006-8993(02)04069-6; MATTOX W, 1991, GENE DEV, V5, P786, DOI 10.1101/gad.5.5.786; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; Oelgeschlager T, 2002, J CELL PHYSIOL, V190, P160, DOI 10.1002/JCP.10058; Ohira M, 1997, GENOME RES, V7, P47, DOI 10.1101/gr.7.1.47; Schul W, 1998, EXP CELL RES, V238, P1, DOI 10.1006/excr.1997.3808; Smith DJ, 1997, NAT GENET, V16, P28, DOI 10.1038/ng0597-28; Song WJ, 1997, BIOCHEM BIOPH RES CO, V231, P640, DOI 10.1006/bbrc.1997.6154; Takayama S, 1997, Methods Mol Biol, V69, P171; TEJEDOR F, 1995, NEURON, V14, P287, DOI 10.1016/0896-6273(95)90286-4; Trembley JH, 2002, J BIOL CHEM, V277, P2589, DOI 10.1074/jbc.M109755200; von Groote-Bidlingmaier F, 2003, BIOCHEM BIOPH RES CO, V300, P764, DOI 10.1016/S0006-291X(02)02914-5; Woods YL, 2001, BIOCHEM J, V355, P609, DOI 10.1042/bj3550609; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yang EJ, 2001, J BIOL CHEM, V276, P39819, DOI 10.1074/jbc.M104091200; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382; Zhao ZS, 2001, METHODS, V24, P194, DOI 10.1006/meth.2001.1181; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	66	94	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4612	4624		10.1074/jbc.M310794200	http://dx.doi.org/10.1074/jbc.M310794200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14623875	hybrid			2022-12-25	WOS:000188554300083
J	Hrmova, M; De Gori, R; Smith, BJ; Vasella, A; Varghese, JN; Fincher, GB				Hrmova, M; De Gori, R; Smith, BJ; Vasella, A; Varghese, JN; Fincher, GB			Three-dimensional structure of the barley beta-D-glucan glucohydrolase in complex with a transition state mimic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING DISTORTION; GLYCOSIDASE INHIBITOR; CATALYTIC MECHANISMS; CELLULOMONAS-FIMI; ENDOGLUCANASE I; PROTONATION; INSIGHT; CRYSTALLOGRAPHY; EXOHYDROLASES; CELLOBIOSE	Glucophenylimidazole (PheGlcIm), a tetrahydroimidazopyridine-type inhibitor and H-4(3) conformer mimic of a glucoside, binds very tightly to a barley beta-D-glucan glucohydrolase, with a K-i constant of 2x10(-9) M and a DeltaG of 51 kJ mol(-1). PheGlcIm binds to the barley beta-D-glucan glucohydrolase similar to2x10(5) times tighter than laminarin, which is the best non-synthetic ground-state substrate found so far for this enzyme, 10(6) times tighter than 4-nitrophenyl beta-D-glucopyranoside, and 2x10(7) tighter than glucose. The three-dimensional structure of the beta-D-glucan glucohydrolase with bound PheGlcIm indicates that the complex resembles a hypothetical transition state during the hydrolytic cycle, that the enzyme derives substrate binding energy from the "aglycone" portion of the ligand, and that it also reveals an anti-protonation trajectory for hydrolysis. Continuous electron densities at the 1.6 sigma level form between the three active site residues Asp(95), His(207), and Asp(285), and the C6OH, C7OH, C8OH, and C9OH groups of PheGlcIm. These electron densities correspond to the most favorable interactions in the three-dimensional structure of the beta-D-glucan glucohydrolase-PheGlcIm complex and indicate atomic distances equal to or less than 2.55 Angstrom. The crystallographic data were corroborated with ab initio molecular orbital calculations. The data indicate that the E-4 conformation of the glucose part of PheGlcIm is critical for tight binding and provide the first evidence for probable substrate distortion during catalysis by this enzyme.	Univ Adelaide, Fac Sci, Sch Agr & Wine, Glen Osmond, SA 5064, Australia; CSIRO, Div Hlth Sci & Nutr, Parkville, Vic 3052, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; ETH Zentrum, CH-8092 Zurich, Switzerland	University of Adelaide; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Walter & Eliza Hall Institute; Swiss Federal Institutes of Technology Domain; ETH Zurich	Hrmova, M (corresponding author), Univ Adelaide, Fac Sci, Sch Agr & Wine, Glen Osmond, SA 5064, Australia.	maria.hrmova@adelaide.edu.au; geoff.fincher@adelaide.edu.au	Varghese, Joseph N/A-8191-2012; Smith, Brian J/F-8282-2011; Hrmova, Maria/AAH-3951-2020	Smith, Brian J/0000-0003-0498-1910; Hrmova, Maria/0000-0002-3545-0605				AOYAMA T, 1992, J ANTIBIOT, V45, P1557, DOI 10.7164/antibiotics.45.1557; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRENEMAN CM, 1990, J COMPUT CHEM, V11, P361, DOI 10.1002/jcc.540110311; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cozzini P, 2002, J MED CHEM, V45, P2469, DOI 10.1021/jm0200299; Cutfield SM, 1999, J MOL BIOL, V294, P771, DOI 10.1006/jmbi.1999.3287; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P11707, DOI 10.1021/bi981315i; ERMERT P, 1993, CARBOHYD RES, V250, P113, DOI 10.1016/0008-6215(93)84160-8; FERSHT A, 1999, STRUCTURE MECH PROTE, P1; Fort S, 2001, CHEMBIOCHEM, V2, P319; FRISCH A, 1999, GAUSSIAN 98 USERS RE; Frisch G.W., 2016, GAUSSIAN 16 REVISION; Granier T, 1997, HELV CHIM ACTA, V80, P1443, DOI 10.1002/hlca.19970800509; Gruneberg S, 2002, J MED CHEM, V45, P3588, DOI 10.1021/jm011112j; Heightman TD, 1996, HELV CHIM ACTA, V79, P2190, DOI 10.1002/hlca.19960790814; Heightman TD, 1999, ANGEW CHEM INT EDIT, V38, P750, DOI 10.1002/(SICI)1521-3773(19990315)38:6<750::AID-ANIE750>3.0.CO;2-6; Hrmova M, 1997, CARBOHYD RES, V305, P209, DOI 10.1016/S0008-6215(97)00257-7; Hrmova M, 2002, PLANT CELL, V14, P1033, DOI 10.1105/tpc.010442; Hrmova M, 1996, J BIOL CHEM, V271, P5277, DOI 10.1074/jbc.271.9.5277; Hrmova M, 2001, PLANT MOL BIOL, V47, P73, DOI 10.1023/A:1010619128894; Hrmova M, 2001, STRUCTURE, V9, P1005, DOI 10.1016/S0969-2126(01)00673-6; Hrmova M, 1998, ACTA CRYSTALLOGR D, V54, P687, DOI 10.1107/S0907444997018866; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 2000, J APPL CRYSTALLOGR, V33, P990; LEATHERBARROW RJ, 1998, DATA ANAL GRAPHICS; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Notenboom V, 2000, BIOCHEMISTRY-US, V39, P11553, DOI 10.1021/bi0010625; Notenboom V, 1998, BIOCHEMISTRY-US, V37, P4751, DOI 10.1021/bi9729211; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Panday N, 2000, HELV CHIM ACTA, V83, P58, DOI 10.1002/(SICI)1522-2675(20000119)83:1<58::AID-HLCA58>3.3.CO;2-B; Papanikolau Y, 2001, BIOCHEMISTRY-US, V40, P11338, DOI 10.1021/bi010505h; Ramstrom O, 2002, BBA-GEN SUBJECTS, V1572, P178, DOI 10.1016/S0304-4165(02)00307-0; Roulin S, 2002, PLANTA, V215, P51, DOI 10.1007/s00425-001-0721-1; SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/jcc.540141112; Schneider G, 2002, DRUG DISCOV TODAY, V7, P64, DOI 10.1016/S1359-6446(01)02091-8; Schramm VL, 1998, ANNU REV BIOCHEM, V67, P693, DOI 10.1146/annurev.biochem.67.1.693; SCHRAMM VL, 1991, ENZYME MECH ISOTOPE, P368; Sidhu G, 1999, BIOCHEMISTRY-US, V38, P5346, DOI 10.1021/bi982946f; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Smith BJ, 1998, J COMPUT CHEM, V19, P1482, DOI 10.1002/(SICI)1096-987X(199810)19:13<1482::AID-JCC5>3.0.CO;2-M; Smith BJ, 1997, J AM CHEM SOC, V119, P2699, DOI 10.1021/ja9623020; Smith BJ, 1999, J COMPUT CHEM, V20, P428, DOI 10.1002/(SICI)1096-987X(199903)20:4<428::AID-JCC4>3.0.CO;2-1; Sulzenbacher G, 1997, BIOCHEMISTRY-US, V36, P5902, DOI 10.1021/bi962963+; Sulzenbacher G, 1996, BIOCHEMISTRY-US, V35, P15280, DOI 10.1021/bi961946h; TATSUTA K, 1995, J ANTIBIOT, V48, P286, DOI 10.7164/antibiotics.48.286; Tews I, 1996, NAT STRUCT BIOL, V3, P638, DOI 10.1038/nsb0796-638; Tews I, 1997, J AM CHEM SOC, V119, P7954, DOI 10.1021/ja970674i; Varghese JN, 1999, STRUCTURE, V7, P179, DOI 10.1016/S0969-2126(99)80024-0; Varrot A, 2003, J AM CHEM SOC, V125, P7496, DOI 10.1021/ja034917k; Varrot A, 1999, J AM CHEM SOC, V121, P2621, DOI 10.1021/ja984238n; Vasella A, 2002, CURR OPIN CHEM BIOL, V6, P619, DOI 10.1016/S1367-5931(02)00380-0; Vocadlo DJ, 2002, BIOCHEMISTRY-US, V41, P9736, DOI 10.1021/bi020078n; White A, 1997, CURR OPIN STRUC BIOL, V7, P645, DOI 10.1016/S0959-440X(97)80073-5; Withers S. G., 1999, IMINOSUGARS GLYCOSID, P188; Wolfenden R, 2001, ACCOUNTS CHEM RES, V34, P938, DOI 10.1021/ar000058i; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+; Zou JY, 1999, STRUCTURE, V7, P1035, DOI 10.1016/S0969-2126(99)80171-3	63	31	33	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4970	4980		10.1074/jbc.M307188200	http://dx.doi.org/10.1074/jbc.M307188200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14597633	hybrid			2022-12-25	WOS:000188554300123
J	Koles, K; Irvine, KD; Panin, VM				Koles, K; Irvine, KD; Panin, VM			Functional characterization of Drosophila sialyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; LINKED CARBOHYDRATE CHAINS; LEPIDOPTERAN INSECT CELLS; N-GLYCOSYLATION PATHWAY; MOLECULAR-CLONING; SIALIC-ACID; STRUCTURAL-ANALYSIS; BOVINE COLOSTRUM; MAMMALIAN BETA-1,4-GALACTOSYLTRANSFERASE; ENZYMATIC CHARACTERIZATION	Sialylation is an important carbohydrate modification of glycoconjugates in the deuterostome lineage of animals. By contrast, the evidence for sialylation in protostomes has been scarce and somewhat controversial. In the present study, we characterize a Drosophila sialyltransferase gene, thus providing experimental evidence for the presence of sialylation in protostomes. This gene encodes a functional alpha2-6-sialyltransferase (SiaT) that is closely related to the vertebrate ST6Gal sialyltransferase family, indicating an ancient evolutionary origin for this family. Characterization of recombinant, purified Drosophila SiaT revealed a novel acceptor specificity as it exhibits highest activity toward GalNAcbeta1-4GlcNAc carbohydrate structures at the non-reducing termini of oligosaccharides and glycoprotein glycans. Oligosaccharides are preferred over glycoproteins as acceptors, and no activity toward glycolipid acceptors was detected. Recombinant Drosophila SiaT expressed in cultured insect cells possesses in vivo and in vitro autosialylation activity toward beta-linked GalNAC termini of its own N-linked glycans, thus representing the first example of a sialylated insect glycoconjugate. In situ hybridization revealed that Drosophila SiaT is expressed during embryonic development in a tissue- and stage-specific fashion, with elevated expression in a subset of cells within the central nervous system. The identification of a SiaT in Drosophila provides a new evolutionary perspective for considering the diverse functions of sialylation and, through the powerful genetic tools available in this system, a means of elucidating functions for sialylation in protostomes.	Texas A&M Univ, Dept Biochem & Biophys, TAMU 2128, College Stn, TX 77843 USA; Rutgers State Univ, Waksman Inst, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Texas A&M University System; Texas A&M University College Station; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Panin, VM (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, TAMU 2128, College Stn, TX 77843 USA.	panin@tamu.edu	Panin, Vlad/G-1583-2016	Panin, Vlad/0000-0001-9126-1481	NIGMS NIH HHS [R01-GM54594] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054594] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; Angata T, 2000, J BIOL CHEM, V275, P22127, DOI 10.1074/jbc.M002775200; Aoki N, 1997, BBA-GEN SUBJECTS, V1334, P207, DOI 10.1016/S0304-4165(96)00094-3; BERGWERFF AA, 1995, EUR J BIOCHEM, V228, P1009; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; BUTTERS TD, 1981, BIOCHIM BIOPHYS ACTA, V640, P672, DOI 10.1016/0005-2736(81)90097-3; CODDEVILLE B, 1992, CARBOHYD RES, V236, P145, DOI 10.1016/0008-6215(92)85013-P; Coutinho PM, 1999, ROY SOC CH, P3; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; DAHMS NM, 1983, J NEUROSCI, V3, P806; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; Datta AK, 1997, INDIAN J BIOCHEM BIO, V34, P157; DELL A, 1995, J BIOL CHEM, V270, P24116, DOI 10.1074/jbc.270.41.24116; Fukuda M, 1996, CANCER RES, V56, P2237; GARCIA JV, 1988, BIOCHEMISTRY-US, V27, P4237, DOI 10.1021/bi00412a006; Gelbart W, 2003, NUCLEIC ACIDS RES, V31, P172, DOI 10.1093/nar/gkg094; Geremia RA, 1997, GLYCOBIOLOGY, V7, pR5; GREEN ED, 1988, J BIOL CHEM, V263, P18253; Hamamoto Toshiro, 2002, P295; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; Harduin-Lepers A, 2001, BIOCHIMIE, V83, P727, DOI 10.1016/S0300-9084(01)01301-3; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; HIRUMA K, 1988, DEV BIOL, V130, P87, DOI 10.1016/0012-1606(88)90416-2; Hollister JR, 1998, GLYCOBIOLOGY, V8, P473, DOI 10.1093/glycob/8.5.473; Hollister JR, 2001, GLYCOBIOLOGY, V11, P1; Hooker AD, 1999, BIOTECHNOL BIOENG, V63, P559, DOI 10.1002/(SICI)1097-0290(19990605)63:5<559::AID-BIT6>3.0.CO;2-L; Itoh M, 1999, GLYCOBIOLOGY, V9, P1247, DOI 10.1093/glycob/9.11.1247; Jarvis DL, 1996, NAT BIOTECHNOL, V14, P1288, DOI 10.1038/nbt1096-1288; Joosten JAF, 2003, EUR J ORG CHEM, V2003, P3569, DOI 10.1002/ejoc.200300293; JOZIASSE DH, 1985, J BIOL CHEM, V260, P714; Kawar ZS, 2002, J BIOL CHEM, V277, P34924, DOI 10.1074/jbc.M206112200; Kim K, 2002, GLYCOBIOLOGY, V12, P73, DOI 10.1093/glycob/12.2.73; Kim YJ, 1997, GLYCOCONJUGATE J, V14, P569, DOI 10.1023/A:1018580324971; KIRKPATRICK RB, 1995, J BIOL CHEM, V270, P19800, DOI 10.1074/jbc.270.34.19800; Kitazume-Kawaguchi S, 2001, J BIOL CHEM, V276, P15696, DOI 10.1074/jbc.M010371200; Kobata A., 1993, GLYCOBIOLOGY PRACTIC, P103; Kramerov AA, 1996, FEBS LETT, V378, P213, DOI 10.1016/0014-5793(95)01444-6; Krzewinski-Recchi MA, 2003, EUR J BIOCHEM, V270, P950, DOI 10.1046/j.1432-1033.2003.03458.x; KUBELKA V, 1995, GLYCOCONJUGATE J, V12, P77, DOI 10.1007/BF00731872; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; KUROSAWA N, 1994, EUR J BIOCHEM, V219, P375, DOI 10.1111/j.1432-1033.1994.tb19949.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEHMANN R, 1994, METHOD CELL BIOL, V44, P575, DOI 10.1016/S0091-679X(08)60933-4; Lopez M, 1999, BBA-GEN SUBJECTS, V1427, P49, DOI 10.1016/S0304-4165(98)00176-7; Malykh YN, 1999, GLYCOCONJUGATE J, V16, P731, DOI 10.1023/A:1007115627708; Marchal I, 2001, BIOL CHEM, V382, P151, DOI 10.1515/BC.2001.023; Marz L., 1995, GLYCOPROTEINS, P543; Mercier D, 1999, GLYCOBIOLOGY, V9, P851, DOI 10.1093/glycob/9.9.851; Nakamura Y, 2002, J BIOL CHEM, V277, P46280, DOI 10.1074/jbc.M203873200; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; NEMANSKY M, 1992, BIOCHEM J, V287, P311, DOI 10.1042/bj2870311; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; Ohkura T, 2002, J BIOCHEM, V132, P891, DOI 10.1093/oxfordjournals.jbchem.a003302; Opalka N, 2000, P NATL ACAD SCI USA, V97, P617, DOI 10.1073/pnas.97.2.617; Panin VM, 2002, J BIOL CHEM, V277, P29945, DOI 10.1074/jbc.M204445200; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; PAULSON JC, 1977, J BIOL CHEM, V252, P2356; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Raju TS, 2000, GLYCOBIOLOGY, V10, P477, DOI 10.1093/glycob/10.5.477; ROTH J, 1992, SCIENCE, V256, P673, DOI 10.1126/science.1585182; Rothwell W.F., 2000, DROSOPHILA PROTOCOLS, P141; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; Schauer R, 2000, GLYCOCONJUGATE J, V17, P485, DOI 10.1023/A:1011062223612; Schmid A, 1999, DEVELOPMENT, V126, P4653; Seppo A, 2000, EUR J BIOCHEM, V267, P3549, DOI 10.1046/j.1432-1327.2000.01383.x; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; Sisson JC, 2000, J CELL BIOL, V151, P905, DOI 10.1083/jcb.151.4.905; Sjoberg ER, 1996, J BIOL CHEM, V271, P7450, DOI 10.1074/jbc.271.13.7450; Slangen CJ, 1999, J AGR FOOD CHEM, V47, P4549, DOI 10.1021/jf990212j; Tai MH, 1999, DEV BIOL, V214, P258, DOI 10.1006/dbio.1999.9422; Takashima S, 2002, J BIOL CHEM, V277, P24030, DOI 10.1074/jbc.M112367200; Takashima S, 2003, J BIOCHEM, V134, P287, DOI 10.1093/jb/mvg142; Takashima S, 2002, J BIOL CHEM, V277, P45719, DOI 10.1074/jbc.M206808200; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toivonen S, 2001, J BIOL CHEM, V276, P37141, DOI 10.1074/jbc.M105715200; Tomiya N, 2001, ANAL BIOCHEM, V293, P129, DOI 10.1006/abio.2001.5091; TORRES BV, 1988, ARCH BIOCHEM BIOPHYS, V262, P1, DOI 10.1016/0003-9861(88)90161-0; VADGAMA MR, 1969, HISTOCHEMISTRY, V19, P184, DOI 10.1007/BF00281099; VandenEijnden DH, 1997, BIOCHEM SOC T, V25, P887, DOI 10.1042/bst0250887; vanDie I, 1996, GLYCOBIOLOGY, V6, P157, DOI 10.1093/glycob/6.2.157; VANHALBEEK H, 1981, J BIOL CHEM, V256, P5588; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; Watty A, 2002, J BIOL CHEM, V277, P50457, DOI 10.1074/jbc.M208664200; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEISSHAAR G, 1991, EUR J BIOCHEM, V195, P257, DOI 10.1111/j.1432-1033.1991.tb15702.x; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; WLASICHUK KB, 1993, J BIOL CHEM, V268, P13971	92	101	103	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4346	4357		10.1074/jbc.M309912200	http://dx.doi.org/10.1074/jbc.M309912200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14612445	hybrid			2022-12-25	WOS:000188554300053
J	Amitai, G; Dassa, B; Pietrokovski, S				Amitai, G; Dassa, B; Pietrokovski, S			Protein splicing of inteins with atypical glutamine and aspartate c-terminal residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRANCHED INTERMEDIATE; SUCCINIMIDE FORMATION; DEAMIDATION; ASPARAGINYL; SEQUENCE; CLEAVAGE; MODULATION; MECHANISM; ISOIMIDES; DOMAINS	Inteins are protein-splicing domains present in many proteins. They self-catalyze their excision from the host protein, ligating their former flanks by a peptide bond. The C-terminal residue of inteins is typically an asparagine (Asn). Cyclization of this residue to succinimide causes the final detachment of inteins from their hosts. We studied protein-splicing activity of two inteins with atypical C-terminal residues. One having a C-terminal glutamine (Gln), isolated from Chilo iridescent virus (CIV), and another unique intein, first reported here, with a C-terminal aspartate, isolated from Carboxydothermus hydrogenoformans (Chy). Protein-splicing activity was examined in the wild-type inteins and in several mutants with N- and C-terminal amino acid substitutions. We demonstrate that both wild-type inteins can protein splice, probably by new variations of the typical protein-splicing mechanism. Substituting the atypical C-terminal residue to the typical Asn retained protein-splicing only in the CIV intein. All diverse C-terminal substitutions in the Chy intein (Asp(345) to Asn, Gln, Glu, and Ala) abolished protein-splicing and generated N- and C-terminal cleavage. The observed C-terminal cleavage in the Chy intein ending with Ala cannot be explained by cyclization of this residue. We present and discuss several new models for reactions in the protein-splicing pathway.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Pietrokovski, S (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	shmuel.pietrokovski@weizmann.ac.il		Pietrokovski, Shmuel/0000-0001-8573-5863				Amitai G, 2003, MOL MICROBIOL, V47, P61, DOI 10.1046/j.1365-2958.2003.03283.x; BORNSTEIN P, 1970, J BIOL CHEM, V245, P4854; Chen LX, 2000, J BIOL CHEM, V275, P20431, DOI 10.1074/jbc.M000178200; Chong SR, 1998, J BIOL CHEM, V273, P10567, DOI 10.1074/jbc.273.17.10567; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; CLARKE S, 1987, INT J PEPT PROT RES, V30, P808, DOI 10.1111/j.1399-3011.1987.tb03390.x; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; CREWTHER WG, 1978, BIOCHEM J, V173, P365, DOI 10.1042/bj1730365; DARRINGTON RT, 1994, PHARMACEUT RES, V11, P784, DOI 10.1023/A:1018909220255; ERNST ML, 1966, J AM CHEM SOC, V88, P5001, DOI 10.1021/ja00973a041; GEIGER T, 1987, J BIOL CHEM, V262, P785; INGLIS AS, 1983, METHOD ENZYMOL, V91, P324; Lamed R, 2001, APPL BIOCHEM BIOTECH, V90, P67, DOI 10.1385/ABAB:90:1:67; MEINWALD YC, 1986, INT J PEPT PROT RES, V28, P79; Noren CJ, 2000, ANGEW CHEM INT EDIT, V39, P450; OH IJ, 1995, ARCH PHARM RES, V18, P75, DOI 10.1007/BF02979137; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; Paulus H, 1998, CHEM SOC REV, V27, P375, DOI 10.1039/a827375z; Pietrokovski S, 1998, CURR BIOL, V8, pR634, DOI 10.1016/S0960-9822(07)00409-5; Pietrokovski S, 1998, PROTEIN SCI, V7, P64, DOI 10.1002/pro.5560070106; Robinson A B, 1974, Curr Top Cell Regul, V8, P247; SAUERS CK, 1973, J AM CHEM SOC, V95, P6792, DOI 10.1021/ja00801a044; Shao Y, 1996, BIOCHEMISTRY-US, V35, P3810, DOI 10.1021/bi952592h; SHAO Y, 1995, BIOCHEMISTRY-US, V34, P10844, DOI 10.1021/bi00034a017; Shingledecker K, 2000, ARCH BIOCHEM BIOPHYS, V375, P138, DOI 10.1006/abbi.1999.1645; SONDHEIMER E, 1954, J AM CHEM SOC, V76, P2467, DOI 10.1021/ja01638a047; Southworth MW, 2000, EMBO J, V19, P5019, DOI 10.1093/emboj/19.18.5019; SVETLICHNY VA, 1991, SYST APPL MICROBIOL, V14, P254, DOI 10.1016/S0723-2020(11)80377-2; Wei W, 1999, INT J PHARMACEUT, V185, P129, DOI 10.1016/S0378-5173(99)00152-0; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x	33	39	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3121	3131		10.1074/jbc.M311343200	http://dx.doi.org/10.1074/jbc.M311343200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14593103	hybrid			2022-12-25	WOS:000188379600001
J	Angeloni, D; Danilkovitch-Miagkova, A; Miagkov, A; Leonard, EJ; Lerman, MI				Angeloni, D; Danilkovitch-Miagkova, A; Miagkov, A; Leonard, EJ; Lerman, MI			The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; LEUKOCYTE SEMAPHORIN; INVASIVE GROWTH; CELL-LINES; BETA-CHAIN; GENE; MET; MSP; BINDING	RON is a receptor tyrosine kinase of the MET family that is involved in cell proliferation, cell survival, and cell motility in both normal and disease states. Macrophage-stimulating protein (MSP) is the RON ligand whose binding to RON causes receptor activation. RON is a trans-membrane heterodimer comprised of one alpha- and one beta-chain originating from a single-chain precursor and held together by several disulfide bonds. The intracellular part of RON contains the kinase domain and regulatory elements. The extracellular region is characterized by the presence of a sema domain (a stretch of similar to500 amino acids with several highly conserved cysteine residues), a PSI ((p) under bar lexin, (s) under bar emaphorins, (i) under bar ntegrins) domain, and four immunoglobulin-like folds. Here we show that a soluble, secreted molecule representing the sema domain of RON (referred to as ron-sema) has a dominant negative effect on the ligand-induced receptor activation and is capable of inhibiting RON-dependent signaling pathways and cellular responses. Results suggest that the sema domain of RON participates in ligand binding by the full-length receptor. The ability of ron-sema to suppress growth of MSP-responsive cells in culture, including cancer cells, points to a potential therapeutic use of this molecule, and forced expression of it could potentially be used as a gene therapy tool for treating MSP-dependent types of cancer.	NCI, Immunobiol Lab, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lerman, MI (corresponding author), NCI, Immunobiol Lab, NIH, Bldg 560,Rm 12-68, Frederick, MD 21702 USA.	lerman@ncifcrf.gov		Angeloni, Debora/0000-0002-3850-5392	NATIONAL CANCER INSTITUTE [Z01BC008579] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angeloni D, 2000, GENE CHROMOSOME CANC, V29, P147, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.3.CO;2-E; Artigiani S, 1999, IUBMB LIFE, V48, P477, DOI 10.1080/713803563; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Banu N, 1996, J IMMUNOL, V156, P2933; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; Bork P, 1999, TRENDS BIOCHEM SCI, V24, P261, DOI 10.1016/S0968-0004(99)01416-4; Chen YQ, 2000, EXP CELL RES, V261, P229, DOI 10.1006/excr.2000.5012; Christensen CRL, 1998, CANCER RES, V58, P1238; CREPALDI T, 1994, J BIOL CHEM, V269, P1750; Danilkovitch A, 1999, J BIOL CHEM, V274, P29937, DOI 10.1074/jbc.274.42.29937; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; Danilkovitch-Miagkova A, 2003, P NATL ACAD SCI USA, V100, P4580, DOI 10.1073/pnas.0837136100; Danilkovitch-Miagkova A, 2001, APOPTOSIS, V6, P183, DOI 10.1023/A:1011384609811; Danilkovitch-Miagkova A, 2000, J BIOL CHEM, V275, P14783, DOI 10.1074/jbc.C000028200; Danilkovitch-Miagkova A, 2003, CURR CANCER DRUG TAR, V3, P31, DOI 10.2174/1568009033333745; Delaire S, 1998, CELL MOL LIFE SCI, V54, P1265, DOI 10.1007/s000180050252; Feiner L, 1997, NEURON, V19, P539, DOI 10.1016/S0896-6273(00)80370-0; Follenzi A, 2000, ONCOGENE, V19, P3041, DOI 10.1038/sj.onc.1203620; Gaudino G, 1995, ONCOGENE, V11, P2627; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; Hall KT, 1996, P NATL ACAD SCI USA, V93, P11780, DOI 10.1073/pnas.93.21.11780; IWAMA A, 1995, BLOOD, V86, P3394, DOI 10.1182/blood.V86.9.3394.bloodjournal8693394; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Miller M, 1998, FEBS LETT, V429, P1, DOI 10.1016/S0014-5793(98)00533-X; Muraoka RS, 1999, J CLIN INVEST, V103, P1277, DOI 10.1172/JCI6091; OHTA K, 1995, NEURON, V14, P1189, DOI 10.1016/0896-6273(95)90266-X; Okino T, 1999, INT J ONCOL, V15, P709; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RONSIN C, 1993, ONCOGENE, V8, P1195; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Waltz SE, 2001, J CLIN INVEST, V108, P567, DOI 10.1172/JCI11881; Wang MH, 2003, CARCINOGENESIS, V24, P1291, DOI 10.1093/carcin/bgg089; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WANG MH, 1993, J LEUKOCYTE BIOL, V54, P289, DOI 10.1002/jlb.54.4.289; Wang MH, 1997, J BIOL CHEM, V272, P16999, DOI 10.1074/jbc.272.27.16999; WANG MH, 1994, J BIOL CHEM, V269, P3436; Willett CG, 1998, AM J RESP CELL MOL, V18, P489, DOI 10.1165/ajrcmb.18.4.2978; Willett CG, 1997, J CLIN INVEST, V99, P2979, DOI 10.1172/JCI119493; Yamada T, 1997, P NATL ACAD SCI USA, V94, P14713, DOI 10.1073/pnas.94.26.14713; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461; Zbar B, 2000, SEMIN CANCER BIOL, V10, P313, DOI 10.1006/scbi.2000.0151	46	42	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3726	3732		10.1074/jbc.M309342200	http://dx.doi.org/10.1074/jbc.M309342200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14597639	hybrid			2022-12-25	WOS:000188379600073
J	Chai, YH; Berke, SS; Cohen, RE; Paulson, HL				Chai, YH; Berke, SS; Cohen, RE; Paulson, HL			Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACHADO-JOSEPH-DISEASE; INTRANUCLEAR INCLUSIONS; EXPANDED POLYGLUTAMINE; GLUTAMINE REPEATS; GENE-PRODUCT; CELL-DEATH; IN-VITRO; PROTEASOME; POLYUBIQUITIN; RAD23	In at least nine inherited diseases polyglutamine expansions cause neurodegeneration associated with protein misfolding and the formation of ubiquitin-conjugated aggregates. Although expanded polyglutamine triggers disease, functional properties of host polyglutamine proteins also must influence pathogenesis. Using complementary in vitro and cell-based approaches we establish that the polyglutamine disease protein, ataxin-3, is a poly-ubiquitin-binding protein. In stably transfected neural cell lines, normal and expanded ataxin-3 both co-precipitate with poly-ubiquitinated proteins that accumulate when the proteasome is inhibited. In vitro pull-down assays show that this reflects direct interactions between ataxin-3 and higher order ubiquitin conjugates; ataxin-3 binds K48-linked tetraubiquitin but not di-ubiquitin or mono-ubiquitin. Further studies with domain-deleted and site-directed mutants map tetra-ubiquitin binding to ubiquitin interaction motifs situated near the polyglutamine domain. In surface plasmon resonance binding analyses, normal and expanded ataxin-3 display similar submicromolar dissociation constants for tetra-ubiquitin. Binding kinetics, however, are markedly influenced by the surrounding protein context; ataxin-3 that lacks the highly conserved, amino-terminal josephin domain shows significantly faster association and dissociation rates for tetra-ubiquitin binding. Our results establish ataxin-3 as a poly-ubiquitin-binding protein, thereby linking its normal function to protein surveillance pathways already implicated in polyglutamine pathogenesis.	Univ Iowa, Carver Coll Med, Dept Neurol, Iowa City, IA 52242 USA; Univ Iowa, Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Carver Coll Med, Grad Program Neurosci, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Paulson, HL (corresponding author), Univ Iowa, Carver Coll Med, Dept Neurol, 240 EMRB, Iowa City, IA 52242 USA.	henry-paulson@uiowa.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038712] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38712] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albrecht M, 2003, PROTEINS, V50, P355, DOI 10.1002/prot.10280; Berke SJS, 2003, CURR OPIN GENET DEV, V13, P253, DOI 10.1016/S0959-437X(03)00053-4; Bevivino AE, 2001, P NATL ACAD SCI USA, V98, P11955, DOI 10.1073/pnas.211305198; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bonini NM, 2002, P NATL ACAD SCI USA, V99, P16407, DOI 10.1073/pnas.152330499; Burnett B, 2003, HUM MOL GENET, V12, P3195, DOI 10.1093/hmg/ddg344; Chai YH, 2002, P NATL ACAD SCI USA, V99, P9310, DOI 10.1073/pnas.152101299; Chai YH, 1999, HUM MOL GENET, V8, P673, DOI 10.1093/hmg/8.4.673; Chai YH, 2001, J BIOL CHEM, V276, P44889, DOI 10.1074/jbc.M106575200; Chai YH, 1999, J NEUROSCI, V19, P10338; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Donaldson KM, 2003, P NATL ACAD SCI USA, V100, P8892, DOI 10.1073/pnas.1530212100; Doss-Pepe EW, 2003, MOL CELL BIOL, V23, P6469, DOI 10.1128/MCB.23.18.6469-6483.2003; Evert BO, 1999, HUM MOL GENET, V8, P1169, DOI 10.1093/hmg/8.7.1169; Fisher RD, 2003, J BIOL CHEM, V278, P28976, DOI 10.1074/jbc.M302596200; Fujigasaki H, 2000, EXP NEUROL, V165, P248, DOI 10.1006/exnr.2000.7479; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; La Spada AR, 2003, NEURON, V38, P681, DOI 10.1016/S0896-6273(03)00328-3; Li FS, 2002, J BIOL CHEM, V277, P45004, DOI 10.1074/jbc.M205259200; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; Michalik A, 2003, HUM MOL GENET, V12, pR173, DOI 10.1093/hmg/ddg295; Miller VM, 2003, P NATL ACAD SCI USA, V100, P7195, DOI 10.1073/pnas.1231012100; Opal P, 2002, TRENDS MOL MED, V8, P232, DOI 10.1016/S1471-4914(02)02310-9; Ortolan TG, 2000, NAT CELL BIOL, V2, P601, DOI 10.1038/35023547; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Perez MK, 1999, HUM MOL GENET, V8, P2377, DOI 10.1093/hmg/8.13.2377; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; Piotrowski J, 1997, J BIOL CHEM, V272, P23712, DOI 10.1074/jbc.272.38.23712; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Scheel H, 2003, HUM MOL GENET, V12, P2845, DOI 10.1093/hmg/ddg297; Schmidt T, 1998, BRAIN PATHOL, V8, P669, DOI 10.1111/j.1750-3639.1998.tb00193.x; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Tait D, 1998, HUM MOL GENET, V7, P991, DOI 10.1093/hmg/7.6.991; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Trottier Y, 1998, NEUROBIOL DIS, V5, P335, DOI 10.1006/nbdi.1998.0208; Wang GH, 2000, HUM MOL GENET, V9, P1795, DOI 10.1093/hmg/9.12.1795; Yao TT, 2000, J BIOL CHEM, V275, P36862, DOI 10.1074/jbc.M006050200; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	44	125	131	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3605	3611		10.1074/jbc.M310939200	http://dx.doi.org/10.1074/jbc.M310939200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14602712	hybrid			2022-12-25	WOS:000188379600058
J	Chen, YW; Allen, MD; Veprintsev, DB; Lowe, J; Bycroft, M				Chen, YW; Allen, MD; Veprintsev, DB; Lowe, J; Bycroft, M			The structure of the AXH domain of spinocerebellar ataxin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA TUMOR-SUPPRESSOR; RNA-BINDING DOMAIN; CRYSTAL-STRUCTURE; TRANSCRIPTIONAL REPRESSOR; PROTEIN; IDENTIFICATION; INTERACTS; HBP1; RECOGNITION; EXPRESSION	Spinocerebellar ataxia type 1 is a late-onset neurodegenerative disease caused by the expansion of a CAG triplet repeat in the SCA1 gene. This results in the lengthening of a polyglutamine tract in the gene product ataxin-1. This produces a toxic gain of function that results in specific neuronal death. A region in ataxin-1, the AXH domain, exhibits significant sequence similarity to the transcription factor HBP1. This region of the protein has been implicated in RNA binding and self-association. We have determined the crystal structure of the AXH domain of ataxin-1. The AXH domain is dimeric and contains an OB-fold, a structural motif found in many oligonucleotide-binding proteins, supporting its proposed role in RNA binding. By structure comparison with other proteins that contain an OB-fold, a putative RNA-binding site has been identified. We also identified a cluster of charged surface residues that are well conserved among AXH domains. These residues may constitute a second ligand-binding surface, suggesting that all AXH domains interact with a common yet unidentified partner.	Univ Cambridge, MRC Ctr, Ctr Prot Engn, Cambridge CB2 2QH, England; Univ Cambridge, MRC Ctr, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology; University of Cambridge; MRC Laboratory Molecular Biology; University of Cambridge	Bycroft, M (corresponding author), Univ Cambridge, MRC Ctr, Ctr Prot Engn, Hills Rd, Cambridge CB2 2QH, England.	mb10031@cus.cam.ac.uk	Löwe, Jan/B-3882-2011; Chen, Yu Wai/AAJ-8037-2020; Bycroft, Mark/D-9446-2017; Veprintsev, Dmitry B/H-2228-2012; Löwe, Jan/X-6998-2019	Chen, Yu Wai/0000-0001-7833-7533; Veprintsev, Dmitry B/0000-0002-3583-5409; Bycroft, Mark/0000-0002-0673-2216; Lowe, Jan/0000-0002-5218-6615				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Agrawal V, 2001, BMC Struct Biol, V1, P5, DOI 10.1186/1472-6807-1-5; Andersen AA, 2003, CURR OPIN CELL BIOL, V15, P281, DOI 10.1016/S0955-0674(03)00041-3; Arcus V, 2002, CURR OPIN STRUC BIOL, V12, P794, DOI 10.1016/S0959-440X(02)00392-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Battiste JL, 2000, MOL CELL, V5, P109, DOI 10.1016/S1097-2765(00)80407-4; Bogden CE, 1999, MOL CELL, V3, P487, DOI 10.1016/S1097-2765(00)80476-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burright EN, 1997, HUM MOL GENET, V6, P513, DOI 10.1093/hmg/6.4.513; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; de Chiara C, 2003, FEBS LETT, V551, P107, DOI 10.1016/S0014-5793(03)00818-4; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Deo RC, 2002, CELL, V108, P71, DOI 10.1016/S0092-8674(01)00632-8; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; Hong S, 2002, MOL CELL NEUROSCI, V20, P298, DOI 10.1006/mcne.2002.1103; Hong SG, 2003, BBA-MOL BASIS DIS, V1638, P35, DOI 10.1016/S0925-4439(03)00038-3; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim HY, 2001, EMBO J, V20, P295, DOI 10.1093/emboj/20.1.295; Koshy B, 1996, HUM MOL GENET, V5, P1311, DOI 10.1093/hmg/5.9.1311; La Spada AR, 2003, NEURON, V38, P681, DOI 10.1016/S0896-6273(03)00328-3; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lavender P, 1997, ONCOGENE, V14, P2721, DOI 10.1038/sj.onc.1201243; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LESLIE AG, 1992, JNT CCP4 ESF EACMB N, V26; Lin KM, 2001, LEUKEMIA, V15, P601, DOI 10.1038/sj.leu.2402071; Lin X, 2000, NAT NEUROSCI, V3, P157, DOI 10.1038/72101; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Minor DL, 1996, NATURE, V380, P730, DOI 10.1038/380730a0; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Nakagawa A, 1999, EMBO J, V18, P1459, DOI 10.1093/emboj/18.6.1459; Neuwald AF, 1998, J MOL MED, V76, P3, DOI 10.1007/s109-1998-8098-0; Orr HT, 2001, HUM MOL GENET, V10, P2307, DOI 10.1093/hmg/10.20.2307; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Sampson EM, 2001, EMBO J, V20, P4500, DOI 10.1093/emboj/20.16.4500; Shibata H, 2000, HUM MOL GENET, V9, P1303, DOI 10.1093/hmg/9.9.1303; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Tan S, 1998, NATURE, V391, P660, DOI 10.1038/35563; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; TURK D, 1996, P 1996 M INT UN CRYS; TURK D, 1992, THESIS TU MUNICH MUN; van den Ent F, 1999, STRUCTURE, V7, P1181, DOI 10.1016/S0969-2126(00)80052-0; Yue S, 2001, HUM MOL GENET, V10, P25, DOI 10.1093/hmg/10.1.25	48	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3758	3765		10.1074/jbc.M309817200	http://dx.doi.org/10.1074/jbc.M309817200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14583607	hybrid			2022-12-25	WOS:000188379600077
J	Deo, DD; Bazan, NG; Hunt, JD				Deo, DD; Bazan, NG; Hunt, JD			Activation of platelet-activating factor receptor-coupled G alpha(q) leads to stimulation of Src and focal adhesion kinase via two separate pathways in human umbilical vein endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE-C; PROTEIN-KINASE; GROWTH-FACTOR; DEPENDENT MECHANISM; SIGNALING PATHWAYS; PROMOTES MIGRATION; HUMAN EOSINOPHILS; ALPHA-SUBUNITS	Platelet-activating factor (PAF), a phospholipid second messenger, has diverse physiological functions, including responses in differentiated endothelial cells to external stimuli. We used human umbilical vein endothelial cells (HUVECs) as a model system. We show that PAF activated pertussis toxin-insensitive Galpha(q) protein upon binding to its seven transmembrane receptor. Elevated cAMP levels were observed via activation of adenylate cyclase, which activated protein kinase A (PKA) and was attenuated by a PAF receptor antagonist, blocking downstream activity. Phosphorylation of Src by PAF required Galpha(q) protein and adenylate cyclase activation; there was an absolute requirement of PKA for PAF-induced Src phosphorylation. Immediate (1 min) PAF-induced STAT-3 phosphorylation required the activation of Galpha(q) protein, adenylate cyclase, and PKA, and was independent of these intermediates at delayed (30 min) and prolonged (60 min) PAF exposure. PAF activated PLCbeta3 through its Galpha(q) protein-coupled receptor, whereas activation of phospholipase Cgamma1 (PLCgamma1) by PAF was independent of G proteins but required the involvement of Src at prolonged PAF exposure (60 min). We demonstrate for the first time in vascular endothelial cells: (i) the involvement of signaling intermediates in the PAF-PAF receptor system in the induction of TIMP2 and MT1-MMP expression, resulting in the coordinated proteolytic activation of MMP2, and (ii) a receptor-mediated signal transduction cascade for the tyrosine phosphorylation of FAK by PAF. PAF exposure induced binding of p130(Cas), Src, SHC, and paxillin to FAK. Clearly, PAF-mediated signaling in differentiated endothelial cells is critical to endothelial cell functions, including cell migration and proteolytic activation of MMP2.	Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Neurosci Ctr Excellence, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Hunt, JD (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, Dept Biochem & Mol Biol, 533 Bolivar St,Box CSRB-4-18, New Orleans, LA 70112 USA.	jhunt@lsuhsc.edu	Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444; Hunt, Jay/0000-0002-8838-201X	NIEHS NIH HHS [ES00358-03] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ali H, 1998, J BIOL CHEM, V273, P11012, DOI 10.1074/jbc.273.18.11012; AXELRAD TW, 2004, IN PRESS FASEB J, V18; Barletta E, 2002, BIOL CHEM, V383, P189, DOI 10.1515/BC.2002.019; Bussolati B, 2000, AM J PATHOL, V157, P1713, DOI 10.1016/S0002-9440(10)64808-0; Calcerrada MC, 1999, BRAIN RES, V835, P275, DOI 10.1016/S0006-8993(99)01612-1; Calcerrada MC, 2002, NEUROCHEM RES, V27, P313, DOI 10.1023/A:1014911329489; CAMUSSI G, 1995, J IMMUNOL, V154, P6492; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; Deo DD, 2002, J BIOL CHEM, V277, P21237, DOI 10.1074/jbc.M110955200; DHAR A, 1994, J BIOL CHEM, V269, P9123; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Fukunaga K, 2001, J BIOL CHEM, V276, P43025, DOI 10.1074/jbc.M108288200; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; Haribabu B, 1999, J BIOL CHEM, V274, P37087, DOI 10.1074/jbc.274.52.37087; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Honda Z, 2002, J BIOCHEM, V131, P773, DOI 10.1093/oxfordjournals.jbchem.a003164; Ihida K, 1999, J CELL SCI, V112, P285; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Ishii S, 2002, PROSTAG OTH LIPID M, V68-9, P599, DOI 10.1016/S0090-6980(02)00058-8; Itoh T, 1998, CANCER RES, V58, P1048; Kato M, 2002, J IMMUNOL, V169, P5252, DOI 10.4049/jimmunol.169.9.5252; KURUVILLA A, 1994, J IMMUNOL, V153, P5433; LEE CW, 1993, J BIOL CHEM, V268, P21318; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MONTRUCCHIO G, 1994, J EXP MED, V180, P377, DOI 10.1084/jem.180.1.377; Morrison CJ, 2001, J BIOL CHEM, V276, P47402, DOI 10.1074/jbc.M108643200; MURTHY KS, 1995, MOL PHARMACOL, V47, P1172; NAGAMATSU S, 1992, J BIOL CHEM, V267, P467; Nakao A, 1997, AM J PHYSIOL-RENAL, V273, pF445, DOI 10.1152/ajprenal.1997.273.3.F445; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; Ottino P, 2002, EXP EYE RES, V74, P393, DOI 10.1006/exer.2001.1135; PARK DG, 1993, J BIOL CHEM, V268, P4573; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Prescott S. M., 1999, INFLAMMATION BASIC P, P387; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Sengoku K, 1996, MOL HUM REPROD, V2, P401, DOI 10.1093/molehr/2.6.401; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SNYDER F, 1995, BBA-LIPID LIPID MET, V1254, P231, DOI 10.1016/0005-2760(94)00192-2; Snyder F., 1990, AM J PHYSIOL, V259, P697; Steel HC, 2002, BRIT J PHARMACOL, V136, P81, DOI 10.1038/sj.bjp.0704685; Sugano T, 2000, BIOL REPROD, V62, P540, DOI 10.1095/biolreprod62.3.540; Takizawa T, 2002, J ALLERGY CLIN IMMUN, V110, P241, DOI 10.1067/mai.2002.126303; TAO Y, 1995, INVEST OPHTH VIS SCI, V36, P345; THURSTON AW, 1993, J PHARMACOL EXP THER, V266, P1106; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; Zimmerman GA, 2002, CRIT CARE MED, V30, pS294, DOI 10.1097/00003246-200205001-00020	55	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3497	3508		10.1074/jbc.M304497200	http://dx.doi.org/10.1074/jbc.M304497200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14617636	hybrid			2022-12-25	WOS:000188379600046
J	Fraaije, MW; Kamerbeek, NM; Heidekamp, AJ; Fortin, R; Janssen, DB				Fraaije, MW; Kamerbeek, NM; Heidekamp, AJ; Fortin, R; Janssen, DB			The prodrug activator EtaA from Mycobacterium tuberculosis is a Baeyer-Villiger monooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOLIC ACIDS; 4-HYDROXYACETOPHENONE MONOOXYGENASE; DRUG ETHIONAMIDE; GENE-CLUSTER; IDENTIFICATION; SUBSTRATE; OXIDATION; SEQUENCE; CHEMOTHERAPY; BIOSYNTHESIS	EtaA is a newly identified FAD-containing monooxygenase that is responsible for activation of several thioamide prodrugs in Mycobacterium tuberculosis. It was found that purified EtaA displays a remarkably low activity with the antitubercular prodrug ethionamide. Hinted by the presence of a Baeyer-Villiger monooxygenase sequence motif in the EtaA sequence, we have been able to identify a large number of novel EtaA substrates. It was discovered that the enzyme converts a wide range of ketones to the corresponding esters or lactones via a Baeyer-Villiger reaction, indicating that EtaA represents a Baeyer-Villiger monooxygenase. With the exception of aromatic ketones (phenylacetone and benzylacetone), long-chain ketones (e.g. 2-hexanone and 2-dodecanone) also are converted. EtaA is also able to catalyze enantioselective sulfoxidation of methyl-p-tolylsulfide. Conversion of all of the identified substrates is relatively slow with typical k(cat) values of around 0.02 s(-1). The best substrate identified so far is phenylacetone (K-m=61 muM, k(cat)=0.017 s(-1)). Redox monitoring of the flavin cofactor during turnover of phenylacetone indicates that a step in the reductive half-reaction is limiting the rate of catalysis. Intriguingly, EtaA activity could be increased by one order of magnitude by adding bovine serum albumin. This reactivity and substrate acceptance-profiling study provides valuable information concerning this newly identified prodrug activator from M. tuberculosis.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Biochem Lab, NL-9747 AG Groningen, Netherlands	University of Groningen	Fraaije, MW (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Biochem Lab, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	m.w.fraaije@chem.rug.nl	Fraaije, Marco/E-8421-2014	Fraaije, Marco/0000-0001-6346-5014				Asselineau C, 2002, PROG LIPID RES, V41, P501, DOI 10.1016/S0163-7827(02)00008-5; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Baulard AR, 2000, J BIOL CHEM, V275, P28326; BRITTON LN, 1977, J BIOL CHEM, V252, P8561; Chakraborty S, 2002, J BIOL CHEM, V277, P41507, DOI 10.1074/jbc.M205432200; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; DeBarber AE, 2000, P NATL ACAD SCI USA, V97, P9677, DOI 10.1073/pnas.97.17.9677; Duetz WA, 2001, CURR OPIN BIOTECH, V12, P419, DOI 10.1016/S0958-1669(00)00237-8; Dye C, 2002, SCIENCE, V295, P2042, DOI 10.1126/science.1063814; EINARSDOTTIR GH, 1989, BIOCHEMISTRY-US, V28, P4161, DOI 10.1021/bi00436a006; Fraaije MW, 2002, FEBS LETT, V518, P43, DOI 10.1016/S0014-5793(02)02623-6; Grosset JH, 2001, LEPROSY REV, V72, P429; HARTMANS S, 1986, FEMS MICROBIOL LETT, V36, P155; Howard ST, 2002, MICROBIOL-SGM, V148, P2987, DOI 10.1099/00221287-148-10-2987; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; Kamerbeek NM, 2003, ADV SYNTH CATAL, V345, P667, DOI 10.1002/adsc.200303014; Kamerbeek NM, 2003, APPL ENVIRON MICROB, V69, P419, DOI 10.1128/AEM.69.1.419-426.2003; Kamerbeek NM, 2001, EUR J BIOCHEM, V268, P2547, DOI 10.1046/j.1432-1327.2001.02137.x; Kostichka K, 2001, J BACTERIOL, V183, P6478, DOI 10.1128/JB.183.21.6478-6486.2001; LANEELLE MA, 1970, EUR J BIOCHEM, V12, P296, DOI 10.1111/j.1432-1033.1970.tb00850.x; Larsen MH, 2002, MOL MICROBIOL, V46, P453, DOI 10.1046/j.1365-2958.2002.03162.x; Liang XY, 2001, J BACTERIOL, V183, P843, DOI 10.1128/JB.183.3.843-853.2001; Massey V, 1990, FLAVINS FLAVOPROTEIN, P59; Meyer A, 2002, J BIOL CHEM, V277, P5575, DOI 10.1074/jbc.M110018200; Pattyn S R, 1978, Lepr Rev, V49, P324; Phetsuksiri B, 1999, ANTIMICROB AGENTS CH, V43, P1042, DOI 10.1128/AAC.43.5.1042; POULSEN LL, 1995, CHEM-BIOL INTERACT, V96, P57, DOI 10.1016/0009-2797(94)03583-T; Rivera-Marrero CA, 1998, MICROB PATHOGENESIS, V25, P307, DOI 10.1006/mpat.1998.0235; RYERSON CC, 1982, BIOCHEMISTRY-US, V21, P2644, DOI 10.1021/bi00540a011; Sheng DW, 2001, BIOCHEMISTRY-US, V40, P11156, DOI 10.1021/bi011153h; Souter A, 2000, J CHEM TECHNOL BIOT, V75, P933, DOI 10.1002/1097-4660(200010)75:10<933::AID-JCTB301>3.0.CO;2-C; Suh JK, 2000, ARCH BIOCHEM BIOPHYS, V381, P317, DOI 10.1006/abbi.2000.1965; THIERRY D, 1993, J CLIN MICROBIOL, V31, P1048, DOI 10.1128/JCM.31.5.1048-1054.1993; TORIYAMA S, 1982, BIOCHIM BIOPHYS ACTA, V712, P427, DOI 10.1016/0005-2760(82)90363-0; Vannelli TA, 2002, J BIOL CHEM, V277, P12824, DOI 10.1074/jbc.M110751200; *WHO IUATLD GLOB P, 2002, 2 WHOIUATLD GLOB PRO; Yu J, 2000, APPL MICROBIOL BIOT, V53, P583, DOI 10.1007/s002530051660; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	38	123	128	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3354	3360		10.1074/jbc.M307770200	http://dx.doi.org/10.1074/jbc.M307770200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14610090	Green Published, hybrid			2022-12-25	WOS:000188379600027
J	Garlapati, S; Wang, CC				Garlapati, S; Wang, CC			Identification of a novel internal ribosome entry site in giardiavirus that extends to both sides of the initiation codon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; VIRAL CODING SEQUENCES; STRANDED-RNA GENOME; TRANSLATION INITIATION; MESSENGER-RNA; FIREFLY LUCIFERASE; PROTEIN; REGION; PSEUDOKNOT; EXPRESSION	In Giardia lamblia, enhanced translation of luciferase mRNA, flanked between the 5'-untranslated region (UTR) and 3'-end of giardiavirus transcript, requires the presence of the initial 264-nucleotide (nt) viral capsid-coding region. By introducing the transcripts of dicistronic viral constructs into Giardia, we demonstrated that the 264-nt downstream region alone is insufficient to function as an internal ribosome entry site (IRES) without including a portion of the 5'-UTR as well. Deletion analysis showed that efficient internal initiation requires the last 253 nts (nts 114-367) of the 5'-UTR in combination with the downstream 264 nts. Specific mutations that disrupted the predicted secondary structural elements in either the 5'-UTR or the 264-nt capsid-coding region completely abolished the IRES-mediated translation of downstream cistron, suggesting that the IRES activity requires the presence of these structures in both regions. Mutations that abolished translation of the first cistron did not, however, affect the IRES-mediated translation of the second cistron, indicating that this IRES-mediated translation is independent of the translation of the upstream cistron. This is, to our knowledge, the first reported identification of a viral IRES with an estimated size of 517 nts that extends to both sides of the initiation site.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wang, CC (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	ccwang@cgl.ucsf.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030475] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-30475] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buratti E, 1998, NUCLEIC ACIDS RES, V26, P3179, DOI 10.1093/nar/26.13.3179; Carter MS, 2000, COLD SPRING HARBOR M, V39, P615; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Dmitriev SE, 2003, FEBS LETT, V533, P99, DOI 10.1016/S0014-5793(02)03776-6; EHRENFELD E, 1996, TRANSLATIONAL CONTRO, P549; ENCARNACION M, 2001, J GEN VIROL, V82, P973; Fletcher SP, 2002, RNA, V8, P1558, DOI 10.1017/S1355838202023038; FURFINE ES, 1989, NUCLEIC ACIDS RES, V17, P7453, DOI 10.1093/nar/17.18.7453; Garlapati S, 2002, RNA, V8, P601, DOI 10.1017/S135583820202071X; Garlapati S, 2001, J MOL BIOL, V308, P623, DOI 10.1006/jmbi.2001.4568; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; HUNT SL, 1993, VIROLOGY, V197, P801, DOI 10.1006/viro.1993.1661; Hwang LH, 1998, BIOCHEM BIOPH RES CO, V252, P455, DOI 10.1006/bbrc.1998.9673; Jackson RJ, 2000, COLD SPRING HARBOR M, V39, P127; Jan E, 2002, J MOL BIOL, V324, P889, DOI 10.1016/S0022-2836(02)01099-9; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Komar AA, 2003, EMBO J, V22, P1199, DOI 10.1093/emboj/cdg103; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; Li L, 2001, J VIROL, V75, P10612, DOI 10.1128/JVI.75.22.10612-10622.2001; MEEROVITCH K, 1991, J VIROL, V65, P5895, DOI 10.1128/JVI.65.11.5895-5901.1991; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; POOLE TL, 1995, VIROLOGY, V206, P750, DOI 10.1016/S0042-6822(95)80003-4; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; RIJNBRAND R, 1995, FEBS LETT, V365, P115, DOI 10.1016/0014-5793(95)00458-L; Rijnbrand R, 2001, RNA, V7, P585, DOI 10.1017/S1355838201000589; Sambrook J, 1989, MOL CLONING LAB MANU, P202; Sasaki J, 2000, P NATL ACAD SCI USA, V97, P1512, DOI 10.1073/pnas.010426997; Sizova DV, 1998, J VIROL, V72, P4775, DOI 10.1128/JVI.72.6.4775-4782.1998; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; WANG AL, 1986, MOL BIOCHEM PARASIT, V21, P269, DOI 10.1016/0166-6851(86)90132-5; WANG AL, 1993, P NATL ACAD SCI USA, V90, P8595, DOI 10.1073/pnas.90.18.8595; WANG CY, 1995, RNA, V1, P526; WANG CY, 1993, J VIROL, V67, P3338, DOI 10.1128/JVI.67.6.3338-3344.1993; WU CH, 1995, GENE, V158, P129, DOI 10.1016/0378-1119(95)00092-K; Yu DC, 2000, MOL BIOCHEM PARASIT, V110, P417, DOI 10.1016/S0166-6851(00)00276-0; Yu DC, 1998, MOL BIOCHEM PARASIT, V96, P151, DOI 10.1016/S0166-6851(98)00126-1; Yu DC, 1996, RNA, V2, P824; YU DC, 1995, MOL CELL BIOL, V15, P4867; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	42	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3389	3397		10.1074/jbc.M307565200	http://dx.doi.org/10.1074/jbc.M307565200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14615487	hybrid			2022-12-25	WOS:000188379600032
J	Giraud, J; Leshan, R; Lee, YH; White, MF				Giraud, J; Leshan, R; Lee, YH; White, MF			Nutrient-dependent and insulin-stimulated phosphorylation of insulin receptor substrate-1 on serine 302 correlates with increased insulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; SERINE/THREONINE PHOSPHORYLATION; JUXTAMEMBRANE REGION; TARGETED DISRUPTION; REGULATORY SUBUNIT; 3T3-L1 ADIPOCYTES; IRS-1	Ser/Thr phosphorylation of insulin receptor substrate IRS-1 regulates insulin signaling, but the relevant phosphorylated residues and their potential functions during insulin-stimulated signal transduction are difficult to resolve. We used a sequence-specific polyclonal antibody directed against phosphorylated Ser(302) to study IRS-1-mediated signaling during insulin and insulin-like growth factor IGF-I stimulation. Insulin or IGF-I stimulated phosphorylation of Ser(302) in various cell backgrounds and in murine muscle. Wortmannin or rapamycin inhibited Ser(302) phosphorylation, and amino acids or glucose stimulated Ser(302) phosphorylation, suggesting a role for the mTOR cascade. The Ser(302) kinase associates with IRS-1 during immunoprecipitation, but its identity is unknown. The NH2-terminal c-Jun kinase did not phosphorylate Ser(302). Replacing Ser(302) with alanine significantly reduced insulin-stimulated tyrosine phosphorylation of IRS-1 and p85 binding and reduced insulin-stimulated phosphorylation of p70(S6K), ribosomal S6 protein, and 4E-BP1; however, this mutation had no effect on insulin-stimulated Akt or glycogen synthase kinase 3beta phosphorylation. Replacing Ser(302) with alanine reduced insulin/IGF-I-stimulated DNA synthesis. We conclude that Ser(302) phosphorylation integrates nutrient availability with insulin/IGF-I signaling to promote mitogenesis and cell growth.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Howard Hughes Med Inst,Dept Physiol, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute	White, MF (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Howard Hughes Med Inst,Dept Physiol, 1 Joslin Pl,Rm 620, Boston, MA 02215 USA.	morris.white@joslin.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038712, R55DK038712, R29DK038712] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38712] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; Barthel A, 1998, BIOCHEM BIOPH RES CO, V243, P509, DOI 10.1006/bbrc.1998.8134; Burks DJ, 2000, NATURE, V407, P377, DOI 10.1038/35030105; Coutant A, 2002, HEPATOLOGY, V36, P1079, DOI 10.1053/jhep.2002.36160; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hartley D, 2002, J CELL BIOCHEM, V85, P304, DOI 10.1002/jcb.10135; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Howlett KF, 2002, DIABETES, V51, P479, DOI 10.2337/diabetes.51.2.479; Jakobsen SN, 2001, J BIOL CHEM, V276, P46912, DOI 10.1074/jbc.C100483200; Jhala US, 2003, GENE DEV, V17, P1575, DOI 10.1101/gad.1097103; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Kim YB, 1999, DIABETES, V48, P310, DOI 10.2337/diabetes.48.2.310; Kushner JA, 2002, J CLIN INVEST, V109, P1193, DOI 10.1172/JCI200214439; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Mendez R, 1996, MOL CELL BIOL, V16, P2857; Myers MG, 1996, MOL CELL BIOL, V16, P4147; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Nadler ST, 2001, AM J PHYSIOL-ENDOC M, V281, pE1249, DOI 10.1152/ajpendo.2001.281.6.E1249; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Patel J, 2001, BIOCHEM J, V358, P497, DOI 10.1042/0264-6021:3580497; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; PONS S, 1995, MOL CELL BIOL, V15, P4453; Qiao LY, 2002, J BIOL CHEM, V277, P26530, DOI 10.1074/jbc.M201494200; RICHARDS FM, 1992, IMMUNOLOGY, V76, P642; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Thomas G, 2002, BIOL RES, V35, P305, DOI 10.4067/S0716-97602002000200022; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000	53	79	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3447	3454		10.1074/jbc.M308631200	http://dx.doi.org/10.1074/jbc.M308631200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14623899	hybrid			2022-12-25	WOS:000188379600040
J	Taguchi, S; Matsui, T; Igarashi, J; Sasakura, Y; Araki, Y; Ito, O; Sugiyama, S; Sagami, I; Shimizu, T				Taguchi, S; Matsui, T; Igarashi, J; Sasakura, Y; Araki, Y; Ito, O; Sugiyama, S; Sagami, I; Shimizu, T			Binding of oxygen and carbon monoxide to a heme-regulated phosphodiesterase from Escherichia coli - Kinetics and infrared spectra of the full-length wild-type enzyme, isolated PAS domain, and Met-95 mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; RESONANCE RAMAN-SPECTROSCOPY; IRON COORDINATION STRUCTURES; LIGAND-BINDING; SENSOR FIXL; ELECTRON-TRANSFER; HEMOGLOBIN; PROTEIN; MYOGLOBIN; POCKET	The heme-regulated phosphodiesterase, Ec DOS, is a redox sensor that uses the heme in its PAS domain to regulate catalysis. The rate of O-2 association (k(on)) with full-length Ec DOS is extremely slow at 0.0019 muM(-1) s(-1), compared with >9.5 muM(-1) s(-1) for 6-coordinated globin-type hemoproteins, as determined by the stopped-flow method. This rate is dramatically increased (up to 16-fold) in the isolated heme-bound PAS domain. Dissociation constants (K-d) calculated from the kinetic parameters are 340 and 20 muM for the full-length wild-type enzyme and its isolated PAS domain, respectively. Mutations at Met-95 in the isolated PAS domain, which may be a heme axial ligand in the Fe(II) complex, lead to a further increase in the k(on) value by more than 30-fold, and consequently, a decrease in the K-d value to less than 1 muM. The k(on) value for CO binding to the full-length wild-type enzyme is also very low (0.00081 muM(-1) s(-1)). The kinetics of CO binding to the isolated PAS domain and its mutants are similar to those observed for O-2. However, the K-d values for CO are considerably lower than those for O-2.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan	Tohoku University	Shimizu, T (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.	shimizu@tagen.tohoku.ac.jp	Igarashi, Jotaro/B-4550-2008; Igarashi, Jotaro/ABC-9207-2021; Araki, Yasuyuki/N-5281-2016; Matsui, Toshitaka/B-1570-2008	Igarashi, Jotaro/0000-0002-6165-3350; Igarashi, Jotaro/0000-0002-6165-3350; Araki, Yasuyuki/0000-0002-5627-7776; Matsui, Toshitaka/0000-0003-3865-8468				Amezcua CA, 2002, STRUCTURE, V10, P1349, DOI 10.1016/S0969-2126(02)00857-2; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Aono S, 2002, J BIOL CHEM, V277, P13528, DOI 10.1074/jbc.M112256200; Ballou DP, 2002, P NATL ACAD SCI USA, V99, P12097, DOI 10.1073/pnas.192209799; Chan MK, 2001, CURR OPIN CHEM BIOL, V5, P216, DOI 10.1016/S1367-5931(00)00193-9; Chang AL, 2001, BIOCHEMISTRY-US, V40, P3420, DOI 10.1021/bi0100236; Couture M, 2000, EUR J BIOCHEM, V267, P4770, DOI 10.1046/j.1432-1327.2000.01531.x; Crosson S, 2003, BIOCHEMISTRY-US, V42, P2, DOI 10.1021/bi026978l; Das TK, 2000, BIOCHEMISTRY-US, V39, P14330, DOI 10.1021/bi001681d; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Duff SMG, 1997, J BIOL CHEM, V272, P16746, DOI 10.1074/jbc.272.27.16746; EICHHORN G, 1988, ADV INORGANIC CHEM H, V7; Fukuzumi S, 2001, J AM CHEM SOC, V123, P8459, DOI 10.1021/ja004311l; Gilles-Gonzalez MA, 2001, IUBMB LIFE, V51, P165, DOI 10.1080/152165401753544232; GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011; Gonzalez G, 2002, BIOCHEMISTRY-US, V41, P8414, DOI 10.1021/bi025845x; Hao B, 2002, BIOCHEMISTRY-US, V41, P12952, DOI 10.1021/bi020144l; Hirata S, 2003, EUR J BIOCHEM, V270, P4771, DOI 10.1046/j.1432-1033.2003.03879.x; Hou SB, 2001, P NATL ACAD SCI USA, V98, P9353, DOI 10.1073/pnas.161185598; Hu XH, 1996, BIOCHEMISTRY-US, V35, P13001, DOI 10.1021/bi961522n; Hvitved AN, 2001, J BIOL CHEM, V276, P34714, DOI 10.1074/jbc.M105175200; Jain R, 2003, J BIOL INORG CHEM, V8, P1, DOI 10.1007/s00775-002-0405-8; Lahiri S, 2000, OXYGEN SENSING MOL M; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; Liebl U, 2003, BIOCHEMISTRY-US, V42, P6527, DOI 10.1021/bi027359f; Liebl U, 2002, P NATL ACAD SCI USA, V99, P12771, DOI 10.1073/pnas.192311699; LukatRodgers GS, 1997, BIOCHEMISTRY-US, V36, P4178, DOI 10.1021/bi9628230; Miyatake H, 2000, J MOL BIOL, V301, P415, DOI 10.1006/jmbi.2000.3954; Miyatake H, 1999, J BIOL CHEM, V274, P23176, DOI 10.1074/jbc.274.33.23176; Nakajima H, 2001, J BIOL CHEM, V276, P37895; Nakano R, 1996, J BIOL CHEM, V271, P8570, DOI 10.1074/jbc.271.15.8570; Phillips GN, 1999, J PHYS CHEM B, V103, P8817, DOI 10.1021/jp9918205; Rich PR, 2001, BIOCHEMISTRY-US, V40, P6441, DOI 10.1021/bi0027332; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; Rozhkova EA, 2002, J BIOL CHEM, V277, P16888, DOI 10.1074/jbc.M200642200; Russwurm M, 2002, J BIOL CHEM, V277, P24883, DOI 10.1074/jbc.M110570200; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; Sasakura Y, 2002, J BIOL CHEM, V277, P23821, DOI 10.1074/jbc.M202738200; Sato A, 2002, J BIOL CHEM, V277, P32650, DOI 10.1074/jbc.M204559200; Scheele JS, 1997, J BIOL CHEM, V272, P12523, DOI 10.1074/jbc.272.19.12523; SONO M, 1996, CHEM REV, V96, P2889; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Tamura K, 1996, J AM CHEM SOC, V118, P9434, DOI 10.1021/ja9543457; Tomita T, 2002, BIOCHEMISTRY-US, V41, P4819, DOI 10.1021/bi0158831; Trent JT, 2002, J BIOL CHEM, V277, P19538, DOI 10.1074/jbc.M201934200; Trent JT, 2001, BIOCHEMISTRY-US, V40, P6155, DOI 10.1021/bi0100790; Uchida T, 1998, J BIOL CHEM, V273, P19988, DOI 10.1074/jbc.273.32.19988; Vreede J, 2003, J BIOL CHEM, V278, P18434, DOI 10.1074/jbc.M301701200; Watanabe M, 2002, BIOCHEM BIOPH RES CO, V299, P169, DOI 10.1016/S0006-291X(02)02621-9; Watts RA, 2001, P NATL ACAD SCI USA, V98, P10119, DOI 10.1073/pnas.191349198; Yoshimura T, 2003, J BIOL CHEM, V278, P53105, DOI 10.1074/jbc.M304408200; Youn H, 2001, J BIOL CHEM, V276, P41603, DOI 10.1074/jbc.M106165200	53	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3340	3347		10.1074/jbc.M301013200	http://dx.doi.org/10.1074/jbc.M301013200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14612459	hybrid			2022-12-25	WOS:000188379600025
J	Cenas, N; Nivinskas, H; Anusevicius, Z; Sarlauskas, J; Lederer, F; Arner, ESJ				Cenas, N; Nivinskas, H; Anusevicius, Z; Sarlauskas, J; Lederer, F; Arner, ESJ			Interactions of quinones with thioredoxin reductase - A challenge to the antioxidant role of the mammalian selenoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST GLUTATHIONE-REDUCTASE; STEADY-STATE KINETICS; LIPOAMIDE DEHYDROGENASE; 1,4-NAPHTHOQUINONE DERIVATIVES; ELECTRON-TRANSFER; HUMAN PLACENTA; MECHANISM; SELENOCYSTEINE; INHIBITION; 2-ELECTRON	Mammalian thioredoxin reductases (TrxR) are important selenium-dependent antioxidant enzymes. Quinones, a wide group of natural substances, human drugs, and environmental pollutants may act either as TrxR substrates or inhibitors. Here we systematically analyzed the interactions of TrxR with different classes of quinone compounds. We found that TrxR catalyzed mixed single- and two-electron reduction of quinones, involving both the selenium-containing motif and a second redox center, presumably FAD. Compared with other related pyridine nucleotide-disulfide oxidoreductases such as glutathione reductase or trypanothione reductase, the k(cat)/K-m value for quinone reduction by TrxR was about 1 order of magnitude higher, and it was not directly related to the one-electron reduction potential of the quinones. A number of quinones were reduced about as efficiently as the natural substrate thioredoxin. We show that TrxR mainly cycles between the four-electron reduced (EH4) and two-electron reduced (EH2) states in quinone reduction. The redox potential of the EH2/EH4 couple of TrxR calculated according to the Haldane relationship with NADPH/NADP(+) was -0.294 V at pH 7.0. Antitumor aziridinylbenzoquinones and daunorubicin were poor substrates and almost inactive as reversible TrxR inhibitors. However, phenanthrene quinone was a potent inhibitor (approximate K-i = 6.3 +/- 1 muM). As with other flavoenzymes, quinones could confer superoxide-producing NADPH oxidase activity to mammalian TrxR. A unique feature of this enzyme was, however, the fact that upon selenocysteine-targeted covalent modification, which inactivates its normal activity, reduction of some quinones was not affected, whereas that of others was severely impaired. We conclude that interactions with TrxR may play a considerable role in the complex mechanisms underlying the diverse biological effects of quinones.	Lithuania Acad Sci, Inst Biochem, LT-2600 Vilnius, Lithuania; CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden	Vilnius University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Karolinska Institutet	Arner, ESJ (corresponding author), Lithuania Acad Sci, Inst Biochem, Mokslininku 12, LT-2600 Vilnius, Lithuania.	ncenas@bchi.lt; Arner@mbb.ki.se	Arnér, Elias/K-6737-2019; Arnér, Elias S.J./J-5832-2012; Sarlauskas, Jonas/ACX-5314-2022	Arnér, Elias/0000-0002-4807-6114; Arnér, Elias S.J./0000-0002-4807-6114; Sarlauskas, Jonas/0000-0003-4268-1716; Lederer, Florence/0000-0001-9438-3580				AKINSHOLA BE, 1991, HEPATOLOGY, V13, P509; ANUSEVICIUS ZJ, 1993, ARCH BIOCHEM BIOPHYS, V302, P420, DOI 10.1006/abbi.1993.1234; Argyrou A, 2003, BIOCHEMISTRY-US, V42, P2218, DOI 10.1021/bi020654f; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1999, J MOL BIOL, V292, P1003, DOI 10.1006/jmbi.1999.3085; Arner ESJ, 1996, BIOCHEM BIOPH RES CO, V225, P268, DOI 10.1006/bbrc.1996.1165; Arner ESJ, 2001, FREE RADICAL BIO MED, V31, P1170, DOI 10.1016/S0891-5849(01)00698-0; ARNER ESJ, 2000, CURRENT PROTOCOLS TO; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; Bauer H, 2003, J BIOL CHEM, V278, P33020, DOI 10.1074/jbc.M303762200; Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; Bironaite D, 1998, BBA-PROTEIN STRUCT M, V1383, P82, DOI 10.1016/S0167-4838(97)00190-8; Bohme CC, 2000, J BIOL CHEM, V275, P37317, DOI 10.1074/jbc.M007695200; BUFFINTON GD, 1989, BIOCHEM J, V257, P561, DOI 10.1042/bj2570561; BULGER JE, 1971, J BIOL CHEM, V246, P5570; BULGER JE, 1971, J BIOL CHEM, V246, P5578; CENAS NK, 1994, BIOCHEMISTRY-US, V33, P2509, DOI 10.1021/bi00175a021; CENAS NK, 1989, BIOCHIM BIOPHYS ACTA, V973, P399, DOI 10.1016/S0005-2728(89)80381-0; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; CHOU F, 1976, J MED CHEM, V19, P1302, DOI 10.1021/jm00233a010; Gromer S, 2003, P NATL ACAD SCI USA, V100, P12618, DOI 10.1073/pnas.2134510100; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Gromer S, 1997, FEBS LETT, V412, P318, DOI 10.1016/S0014-5793(97)00816-8; Gromer S, 2002, J BIOL CHEM, V277, P9701, DOI 10.1074/jbc.M109234200; Hargreaves RHJ, 2000, FRONT BIOSCI-LANDMRK, V5, pE172, DOI 10.2741/hargreav; HOLMGREN A, 1980, P NATL ACAD SCI-BIOL, V77, P5149, DOI 10.1073/pnas.77.9.5149; JACQUOT JP, 1994, J MOL BIOL, V235, P1357, DOI 10.1006/jmbi.1994.1091; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; Krimm I, 1998, EUR J BIOCHEM, V255, P185, DOI 10.1046/j.1432-1327.1998.2550185.x; MATTHEWS RG, 1976, J BIOL CHEM, V251, P3956; MAU BL, 1992, BIOCHEM PHARMACOL, V43, P1613, DOI 10.1016/0006-2952(92)90220-D; Maurice MM, 1999, ARTHRITIS RHEUM, V42, P2430, DOI 10.1002/1529-0131(199911)42:11<2430::AID-ANR22>3.0.CO;2-6; NAKAMURA M, 1972, BIOCHIM BIOPHYS ACTA, V267, P249, DOI 10.1016/0005-2728(72)90113-2; Nemeikaite-Ceniene A, 2003, ARCH BIOCHEM BIOPHYS, V416, P110, DOI 10.1016/S0003-9861(03)00281-9; Nordberg J, 1998, J BIOL CHEM, V273, P10835, DOI 10.1074/jbc.273.18.10835; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; OBRIEN PJ, 1991, CHEM-BIOL INTERACT, V80, P1, DOI 10.1016/0009-2797(91)90029-7; PETERSEN S, 1969, Z KREBSFORSCH KLIN O, V72, P162, DOI 10.1007/BF00524772; PORQUE P G, 1970, Journal of Biological Chemistry, V245, P2363; RAKAUSKIENE GA, 1989, FEBS LETT, V243, P33, DOI 10.1016/0014-5793(89)81212-8; Rudolph F B, 1979, Methods Enzymol, V63, P411; Salmon-Chemin L, 2001, J MED CHEM, V44, P548, DOI 10.1021/jm001079l; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; Smith AD, 1999, J NUTR, V129, P194, DOI 10.1093/jn/129.1.194; VIENOZINSKIS J, 1990, BIOCHEM J, V269, P101, DOI 10.1042/bj2690101; WARDMAN P, 1990, FREE RADICAL RES COM, V8, P219, DOI 10.3109/10715769009053355; Wardman P, 2001, CURR MED CHEM, V8, P739, DOI 10.2174/0929867013372959; Winski SL, 1998, CLIN CANCER RES, V4, P3083; Xia L, 2003, J BIOL CHEM, V278, P2141, DOI 10.1074/jbc.M210456200; Zhao R, 2002, J BIOL CHEM, V277, P39456, DOI 10.1074/jbc.M206452200; Zhao R, 2002, P NATL ACAD SCI USA, V99, P8579, DOI 10.1073/pnas.122061399; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897	52	120	123	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2583	2592		10.1074/jbc.M310292200	http://dx.doi.org/10.1074/jbc.M310292200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14604985	hybrid			2022-12-25	WOS:000188211300032
J	Haxhinasto, SA; Bishop, GA				Haxhinasto, SA; Bishop, GA			Synergistic B cell activation by CD40 and the B cell antigen receptor - Role of B lymphocyte antigen receptor-mediated kinase activation and tumor necrosis factor receptor-associated factor regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; CUTTING EDGE; C-MU; DIFFERENTIATION; BTK; MOLECULES; TRAF2; COMPLEX; GENES; MICE	Optimal activation of B-lymphocytes depends both upon expression of various cell surface receptors and adequate integration of signaling pathways. This requires signals generated upon recognition of antigen by the B lymphocyte antigen receptor (BCR) as well as additional signals provided by cognate interaction with T helper cells, including the CD40-CD154 interaction. Engagement of both the BCR and CD40 results in synergistic activation of B cells. Previous studies identified tumor necrosis factor receptor-associated factor (TRAF)-2 and TRAF3 in the CD40-signaling pathway together with BCR-activated protein kinase D (PKD) as important cooperative factors in this synergy. To better understand the role of these factors in bridging the BCR and CD40 signaling pathways, BCR signal regulation of TRAF function was examined. Results show that phosphorylation of TRAF2 is increased upon BCR but not CD40 engagement and that of the potentially phosphorylated residues of TRAF2, tyrosine 484 is crucial for BCR-CD40 synergy. Additionally, wild type or constitutively active Bruton's tyrosine kinase (Btk) enhanced, whereas the xid mutant form of Btk prevented, BCR-CD40 synergy. These effects were dependent upon TRAF2 and PKD activity. These findings suggest a model in which Btk contributes to the enhancement of the CD40 response by TRAF2 in a PKD-dependent manner.	Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Interdisciplinary Grad Program Immunol, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Bishop, GA (corresponding author), Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA.	gail-bishop@uiowa.edu		Bishop, Gail/0000-0002-1291-5078	NCI NIH HHS [CA099997] Funding Source: Medline; NIAID NIH HHS [AI28847, AI49993] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA099997] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI028847, R01AI028847, R01AI049993, R56AI049993, R56AI028847] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baccam M, 1999, EUR J IMMUNOL, V29, P3855, DOI 10.1002/(SICI)1521-4141(199912)29:12<3855::AID-IMMU3855>3.0.CO;2-S; Bishop GA, 2003, CRIT REV IMMUNOL, V23, P149, DOI 10.1615/CritRevImmunol.v23.i3.10; BISHOP GA, 1986, P NATL ACAD SCI USA, V83, P7410, DOI 10.1073/pnas.83.19.7410; BISHOP GA, 1995, EUR J IMMUNOL, V25, P1230, DOI 10.1002/eji.1830250515; BISHOP GA, 1991, J IMMUNOL, V147, P1107; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Brown KD, 2001, J EXP MED, V193, P943, DOI 10.1084/jem.193.8.943; CHEN ZZ, 1986, J IMMUNOL, V136, P2300; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Feldhahn N, 2002, J EXP MED, V196, P1291, DOI 10.1084/jem.20020881; Goldstein MD, 1996, MOL IMMUNOL, V33, P541, DOI 10.1016/0161-5890(96)00005-3; Haxhinasto SA, 2002, J IMMUNOL, V169, P1145, DOI 10.4049/jimmunol.169.3.1145; Haxhinasto SA, 2003, J IMMUNOL, V171, P4655, DOI 10.4049/jimmunol.171.9.4655; Hostager BS, 2003, J BIOL CHEM, V278, P45382, DOI 10.1074/jbc.M306708200; Hostager BS, 2002, J IMMUNOL, V168, P3318, DOI 10.4049/jimmunol.168.7.3318; Hostager BS, 1999, J IMMUNOL, V162, P6307; Hostager BS, 1996, J IMMUNOL, V157, P1047; Hostager BS, 2000, J BIOL CHEM, V275, P15392, DOI 10.1074/jbc.M909520199; Jalukar SV, 2000, J IMMUNOL, V164, P623, DOI 10.4049/jimmunol.164.2.623; Johannes FJ, 1999, FEBS LETT, V461, P68, DOI 10.1016/S0014-5793(99)01424-6; Khan WN, 1997, INT IMMUNOL, V9, P395, DOI 10.1093/intimm/9.3.395; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; McWhirter SM, 1999, P NATL ACAD SCI USA, V96, P8408, DOI 10.1073/pnas.96.15.8408; MERCOLINO TJ, 1986, J EXP MED, V163, P155, DOI 10.1084/jem.163.1.155; MISCHAK H, 1991, J IMMUNOL, V147, P3981; Mizuno T, 2003, J IMMUNOL, V170, P2806, DOI 10.4049/jimmunol.170.6.2806; Nonoyama S, 1998, J IMMUNOL, V161, P3925; Oka Y, 1996, INT IMMUNOL, V8, P1675, DOI 10.1093/intimm/8.11.1675; Satterthwaite AB, 1998, J EXP MED, V188, P833, DOI 10.1084/jem.188.5.833; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6	34	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2575	2582		10.1074/jbc.M310628200	http://dx.doi.org/10.1074/jbc.M310628200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14604983	hybrid			2022-12-25	WOS:000188211300031
J	Kang, SW; Chang, TS; Lee, TH; Kim, ES; Yu, DY; Rhee, SG				Kang, SW; Chang, TS; Lee, TH; Kim, ES; Yu, DY; Rhee, SG			Cytosolic peroxiredoxin attenuates the activation of JNK and p38 but potentiates that of ERK in HeLa cells stimulated with tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-SPECIFIC ANTIOXIDANT; NF-KAPPA-B; CYSTEINE-SULFINIC ACID; PROTEIN-KINASE KINASE; SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; MAMMALIAN PEROXIREDOXIN; TERMINAL KINASE; CELLULAR-RESPONSE	Tumor necrosis factor-alpha (TNF-alpha) induces the activation of all three types of mitogen-activated protein kinase (MAPK): c-Jun NH2-terminal kinase (JNK), p38, and extracellular signal-regulated kinase (ERK). This cytokine also induces the production of several types of reactive oxygen species, including H2O2. With the use both of HeLa cells expressing wild-type or dominant negative forms of the cytosolic peroxidase peroxiredoxin II and of mouse embryonic fibroblasts deficient in this protein, we evaluated the roles of H2O2 in the activation of MAPKs by TNF-alpha. In vitro kinase assays as well as immunoblot analysis with antibodies specific for activated MAPKs indicated that H2O2 produced in response to TNF-alpha potentiates the activation of JNK and p38 induced by this cytokine but inhibits that of ERK. Our results also suggest that cytosolic peroxiredoxins are important regulators of TNF signaling pathways.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA; Ewha Womans Univ, Ctr Cell Signaling Res, Div Mol Life Sci, Seoul 120750, South Korea; Korea Res Inst Biosci & Biotechnol, Funct Prote Lab, Lab Dev & Differentiat, Taejon 305333, South Korea	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Ewha Womans University; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Rhee, SG (corresponding author), Bldg 50,Rm 3523,South Dr,MSC 8015, Bethesda, MD 20892 USA.	sgrhee@nih.gov	Lee, Tae-Hoon/AAR-3708-2021	Lee, Tae-Hoon/0000-0003-0105-1750				Abe MK, 1998, AM J RESP CELL MOL, V18, P562, DOI 10.1165/ajrcmb.18.4.2958; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Chan ED, 1999, J IMMUNOL, V162, P415; Chandel NS, 2001, J BIOL CHEM, V276, P42728, DOI 10.1074/jbc.M103074200; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chang TS, 2002, J BIOL CHEM, V277, P25370, DOI 10.1074/jbc.M110432200; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Chevallet M, 2003, J BIOL CHEM, V278, P37146, DOI 10.1074/jbc.M305161200; Devadas S, 2002, J EXP MED, V195, P59, DOI 10.1084/jem.20010659; Forman HJ, 2002, AM J RESP CRIT CARE, V166, pS4, DOI 10.1164/rccm.2206007; Garg AK, 2002, MOL IMMUNOL, V39, P509, DOI 10.1016/S0161-5890(02)00207-9; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Gu Y, 2002, EXP CELL RES, V272, P62, DOI 10.1006/excr.2001.5404; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HALLIWELL B, 2000, FREE RADICAL BIO MED, P134; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Hildt E, 1999, J EXP MED, V189, P1707, DOI 10.1084/jem.189.11.1707; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Jung H, 2001, J BIOL CHEM, V276, P15504, DOI 10.1074/jbc.M009620200; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lee SL, 2001, AM J PHYSIOL-LUNG C, V281, pL646, DOI 10.1152/ajplung.2001.281.3.L646; Lee TH, 2003, BLOOD, V101, P5033, DOI 10.1182/blood-2002-08-2548; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; Navas TA, 1999, J BIOL CHEM, V274, P33684, DOI 10.1074/jbc.274.47.33684; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; ODONNELL VB, 1995, BIOCHEM J, V310, P133, DOI 10.1042/bj3100133; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sano M, 2001, CIRC RES, V89, P661, DOI 10.1161/hh2001.098873; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; STADLER J, 1991, J IMMUNOL, V147, P3915; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Torres M, 1999, ARCH BIOCHEM BIOPHYS, V366, P231, DOI 10.1006/abbi.1999.1225; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Woo CH, 2000, J BIOL CHEM, V275, P32357, DOI 10.1074/jbc.M005638200; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Yoshizumi M, 2002, BRIT J PHARMACOL, V136, P1023, DOI 10.1038/sj.bjp.0704808; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhou Y, 2002, NEUROBIOL DIS, V9, P126, DOI 10.1006/nbdi.2001.0472	56	69	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2535	2543		10.1074/jbc.M307698200	http://dx.doi.org/10.1074/jbc.M307698200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14597634	hybrid			2022-12-25	WOS:000188211300026
J	Lisman, Q; Pomorski, T; Vogelzangs, C; Urli-Stam, D; van Delwijnen, WD; Holthuis, JCM				Lisman, Q; Pomorski, T; Vogelzangs, C; Urli-Stam, D; van Delwijnen, WD; Holthuis, JCM			Protein sorting in the late Golgi of Saccharomyces cerevisiae does not require mannosylated sphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL PHOSPHORYLCERAMIDE SYNTHASE; EPITHELIAL-CELLS; SECRETORY VESICLES; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; ANCHORED PROTEINS; YEAST; TRANSPORT; SURFACE; TRAFFICKING	Glycosphingolipids are widely viewed as integral components of the Golgi-based machinery by which membrane proteins are targeted to compartments of the endosomal/lysosomal system and to the surface domains of polarized cells. The yeast Saccharomyces cerevisiae creates glycosphingolipids by transferring mannose to the head group of inositol phosphorylceramide (IPC), yielding mannosyl-IPC (MIPC). Addition of an extra phosphoinositol group onto MIPC generates mannosyldi-IPC (M(IP)(2)C), the final and most abundant sphingo-lipid in yeast. Mannosylation of IPC is partially dependent on CSG1, a gene encoding a putative sphingolipid-mannosyltransferase. Here we show that open reading frame YBR161w, renamed CSH1, is functionally homologous to CSG1 and that deletion of both genes abolishes MIPC and M(IP)(2)C synthesis without affecting protein mannosylation. Csg1p and Csh1p are closely related polytopic membrane proteins that co-localize with IPC synthase in the medial-Golgi. Loss of Csg1p and Csh1p has no effect on clathrin- or AP-3 adaptor-mediated protein transport from the Golgi to the vacuole. Moreover, segregation of the periplasmic enzyme invertase, the plasma membrane ATPase Pma1p and the glycosylphosphatidylinositol-anchored protein Gas1p into distinct classes of secretory vesicles occurs independently of Csg1p and Csh1p. Our results indicate that protein sorting in the late Golgi of yeast does not require production of mannosylated sphingolipids.	Univ Utrecht, Fac Chem, Dept Membrane Enzymol, Ctr Biomembranes & Lipid Enzymol, NL-3584 CH Utrecht, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-11085 AZ Amsterdam, Netherlands; Humboldt Univ, Inst Biol, D-10115 Berlin, Germany	Utrecht University; University of Amsterdam; Humboldt University of Berlin	Holthuis, JCM (corresponding author), Univ Utrecht, Fac Chem, Dept Membrane Enzymol, Ctr Biomembranes & Lipid Enzymol, HR Kruytgebouw N605,Padualaan 8, NL-3584 CH Utrecht, Netherlands.		Pomorski, Thomas Günther/G-4804-2014; Holthuis, Joost/AAL-9157-2020	Pomorski, Thomas Günther/0000-0002-4889-0829; Holthuis, Joost/0000-0001-8912-1586				Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; BEELER T, 1994, J BIOL CHEM, V269, P7279; Beeler TJ, 1997, MOL GEN GENET, V255, P570, DOI 10.1007/s004380050530; BONNER WM, 1978, ANAL BIOCHEM, V89, P247, DOI 10.1016/0003-2697(78)90747-9; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Burd CG, 1998, SEMIN CELL DEV BIOL, V9, P527, DOI 10.1006/scdb.1998.0255; Cowles CR, 1997, EMBO J, V16, P2769, DOI 10.1093/emboj/16.10.2769; David D, 1998, J CELL BIOL, V143, P1167, DOI 10.1083/jcb.143.5.1167; Dean N, 1997, J BIOL CHEM, V272, P31908, DOI 10.1074/jbc.272.50.31908; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Gurunathan S, 2002, EMBO J, V21, P602, DOI 10.1093/emboj/21.4.602; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hallstrom TC, 2001, J BIOL CHEM, V276, P23674, DOI 10.1074/jbc.M101568200; HARSAY E, 1995, J CELL BIOL, V131, P297, DOI 10.1083/jcb.131.2.297; Harsay E, 2002, J CELL BIOL, V156, P271, DOI 10.1083/jcb.200109077; HECHTBERGER P, 1994, EUR J BIOCHEM, V225, P641, DOI 10.1111/j.1432-1033.1994.00641.x; Holthuis JCM, 1998, MOL BIOL CELL, V9, P3383, DOI 10.1091/mbc.9.12.3383; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; Jungmann J, 1999, J BIOL CHEM, V274, P6579, DOI 10.1074/jbc.274.10.6579; Keller P, 1997, J CELL SCI, V110, P3001; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Levine TP, 2000, MOL BIOL CELL, V11, P2267, DOI 10.1091/mbc.11.7.2267; Martin-Belmonte F, 2000, J BIOL CHEM, V275, P41074, DOI 10.1074/jbc.M005429200; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Merrill Jr A. H., 1996, BIOCH LIPIDS LIPOPRO, P309; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; PATTON JL, 1991, J BACTERIOL, V173, P3101, DOI 10.1128/JB.173.10.3101-3108.1991; PUOTI A, 1991, J CELL BIOL, V113, P515, DOI 10.1083/jcb.113.3.515; Rayner JC, 1998, J BIOL CHEM, V273, P26836, DOI 10.1074/jbc.273.41.26836; SAUER B, 1987, MOL CELL BIOL, V7, P2087, DOI 10.1128/MCB.7.6.2087; Schmidt K, 2001, J BIOL CHEM, V276, P14315, DOI 10.1074/jbc.M006221200; SIKORSKI RS, 1989, GENETICS, V122, P19; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; Skrzypek M, 1997, J BACTERIOL, V179, P1513, DOI 10.1128/jb.179.5.1513-1520.1997; Sprong H, 2001, J CELL BIOL, V155, P369, DOI 10.1083/jcb.200106104; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; Stepp JD, 1997, J CELL BIOL, V139, P1761, DOI 10.1083/jcb.139.7.1761; Tanida I, 1996, FEBS LETT, V379, P38, DOI 10.1016/0014-5793(95)01478-0; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Uemura S, 2003, J BIOL CHEM, V278, P45049, DOI 10.1074/jbc.M305498200; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247; ZIEGLER FD, 1988, J BIOL CHEM, V263, P6986; Ziman M, 1996, MOL BIOL CELL, V7, P1909, DOI 10.1091/mbc.7.12.1909	54	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1020	1029		10.1074/jbc.M306119200	http://dx.doi.org/10.1074/jbc.M306119200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14583628	hybrid			2022-12-25	WOS:000187722800025
J	Uchida, N; Hoshino, S; Katada, T				Uchida, N; Hoshino, S; Katada, T			Identification of a human cytoplasmic poly(A) nuclease complex stimulated by poly(A)-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEADENYLATION; TRANSLATION INITIATION; BINDING-PROTEIN; POLY(A)-SPECIFIC RIBONUCLEASE; TRANSCRIPTION FACTOR; CAP STRUCTURE; YEAST; TAIL; GENE; CCR4	The poly( A) tail shortening in mRNA, called deadenylation, is the first rate-limiting step in eukaryotic mRNA turnover, and the polyadenylate-binding protein ( PABP) appears to be involved in the regulation of this step. However, the precise role of PABP remains largely unknown in higher eukaryotes. Here we identified and characterized a human PABP-dependent poly( A) nuclease (hPAN) complex consisting of catalytic hPan2 and regulatory hPan3 subunits. hPan2 has intrinsically a 3' to 5' exoribonuclease activity and requires Mg2+ for the enzyme activity. On the other hand, hPan3 interacts with PABP to simulate hPan2 nuclease activity. Interestingly, the hPAN nuclease complex has a higher substrate specificity to poly( A) RNA upon its association with PABP. Consistent with the roles of hPan2 and hPan3 in mRNA decay, the two subunits exhibit cytoplasmic co-localization. Thus, the human PAN complex is a poly(A)-specific exoribonuclease that is stimulated by PABP in the cytoplasm.	Univ Tokyo, Dept Physiol Chem, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Hoshino, S (corresponding author), Univ Tokyo, Dept Physiol Chem, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	hoshino@mol.f.u-tokyo.ac.jp		Uchida, Naoyuki/0000-0002-4123-6154; Hoshino, Shinichi/0000-0001-6135-7896				Baggs JE, 2003, CURR BIOL, V13, P189, DOI 10.1016/S0960-9822(03)00014-9; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; Brown CE, 1996, MOL CELL BIOL, V16, P5744; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; Chekanova JA, 2001, CURR BIOL, V11, P1207, DOI 10.1016/S0960-9822(01)00371-2; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; Chen JJ, 2002, EMBO J, V21, P1414, DOI 10.1093/emboj/21.6.1414; Daugeron MC, 2001, NUCLEIC ACIDS RES, V29, P2448, DOI 10.1093/nar/29.12.2448; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Dehlin E, 2000, EMBO J, V19, P1079, DOI 10.1093/emboj/19.5.1079; Dunckley T, 1999, EMBO J, V18, P5411, DOI 10.1093/emboj/18.19.5411; Dupressoir A, 1999, J BIOL CHEM, V274, P31068, DOI 10.1074/jbc.274.43.31068; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Gao M, 2000, MOL CELL, V5, P479, DOI 10.1016/S1097-2765(00)80442-6; Gao M, 2001, EMBO J, V20, P1134, DOI 10.1093/emboj/20.5.1134; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; Green CB, 1996, P NATL ACAD SCI USA, V93, P14884, DOI 10.1073/pnas.93.25.14884; Hammet A, 2002, J BIOL CHEM, V277, P22469, DOI 10.1074/jbc.M202473200; Hoshino S, 1999, J BIOL CHEM, V274, P16677, DOI 10.1074/jbc.274.24.16677; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; Korner CG, 1997, J BIOL CHEM, V272, P10448; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Kuhn U, 2003, J BIOL CHEM, V278, P16916, DOI 10.1074/jbc.M209886200; LaGrandeur TE, 1998, EMBO J, V17, P1487, DOI 10.1093/emboj/17.5.1487; LOWELL JE, 1992, GENE DEV, V6, P2088, DOI 10.1101/gad.6.11.2088; Lykke-Andersen J, 2002, MOL CELL BIOL, V22, P8114, DOI 10.1128/MCB.22.23.8114-8121.2002; Martinez J, 2001, J BIOL CHEM, V276, P27923, DOI 10.1074/jbc.M102270200; Martinez J, 2000, J BIOL CHEM, V275, P24222, DOI 10.1074/jbc.M001705200; Meyer S, 2002, BIOCHEMISTRY-US, V41, P6082, DOI 10.1021/bi0160866; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; Preiss T, 1998, NATURE, V392, P516, DOI 10.1038/33192; Sachs A, 2000, COLD SPRING HARBOR M, V39, P447; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sonenberg N, 2003, CURR OPIN STRUC BIOL, V13, P56, DOI 10.1016/S0959-440X(03)00009-5; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Tucker M, 2000, ANNU REV BIOCHEM, V69, P571, DOI 10.1146/annurev.biochem.69.1.571; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Uchida N, 2002, J BIOL CHEM, V277, P50286, DOI 10.1074/jbc.M203029200; van Dijk E, 2002, EMBO J, V21, P6915, DOI 10.1093/emboj/cdf678; Viswanathan P, 2003, J BIOL CHEM, V278, P14949, DOI 10.1074/jbc.M211794200; Wang Y, 2001, BMC Dev Biol, V1, P9, DOI 10.1186/1471-213X-1-9; Wang ZR, 2002, P NATL ACAD SCI USA, V99, P12663, DOI 10.1073/pnas.192445599; Wang ZR, 2001, CELL, V107, P751, DOI 10.1016/S0092-8674(01)00592-X; Welch EM, 2000, COLD SPRING HARBOR M, V39, P467; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Wilusz CJ, 2001, RNA, V7, P1416; Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017	54	102	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1383	1391		10.1074/jbc.M309125200	http://dx.doi.org/10.1074/jbc.M309125200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14583602	hybrid			2022-12-25	WOS:000187722800067
J	Beni, SM; Kohen, R; Reiter, RJ; Tan, DX; Shohami, E				Beni, SM; Kohen, R; Reiter, RJ; Tan, DX; Shohami, E			Melatonin-induced neuroprotection after closed head injury is associated with increased brain antioxidants and attenuated late-phase activation of NF-kappa B and AP-1	FASEB JOURNAL			English	Article						ascorbic acid; cyclic voltammetry; reactive oxygen species; traumatic brain injury	TUMOR-NECROSIS-FACTOR; DNA-BINDING ACTIVITIES; REACTIVE OXYGEN; HYDROGEN-PEROXIDE; TRANSCRIPTION FACTORS; OXIDATIVE STRESS; REDOX REGULATION; GENE-EXPRESSION; FACTOR-ALPHA; DAMAGE	Traumatic brain injury (TBI) is followed by massive production of reactive oxygen species (ROS), which mediate secondary cellular damage. Low molecular weight antioxidants (LMWA)constitute one of the defense mechanisms of the brain, and their levels correlate with post-TBI outcome. Melatonin, the main pineal hormone, possesses antioxidant properties. We investigated the effects of melatonin on neurobehavioral recovery, brain LMWA, and activation of the redoxsensitive transcription factors nuclear factor-kappaB (NF-kappa B) and AP-1 in mice subjected to closed head injury (CHI). Given 1 h after CHI, melatonin facilitated recovery during at least 1 wk (P<0.05) and decreased lesion size by similar to twofold (P<0.01). The dose response displayed a bell-shape, i.e., neuroprotection was achieved with 5 but not 1 or 10 mg/kg. At the neuroprotective dose, melatonin treatment was associated with sustained (4 days) elevation of brain LMWA, including ascorbic acid (P<0.05). In contrast, LMWA were unaffected by the administration of the neuroprotective endocannabinoid 2-arachidonoyl glycerol. Furthermore, melatonin did not alter early phase (24 h) CHI-induced activation of NF-kappa B and AP-1; however, it blocked the robust late-phase (8 days) activation of NF-kappa B and decreased that of AP-1 to below basal levels. Our results demonstrate that melatonin induces neuroprotection, presumably via potentiation of brain antioxidants and attenuation of NF-kappa B and AP-1 activation.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, IL-91120 Jerusalem, Israel; Univ Texas, Dept Cellular & Struct Biol, San Antonio, TX USA	Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of Texas System	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il	Kohen, Ron/ABC-2281-2021; tan, dun-xian/E-3610-2010	Kohen, Ron/0000-0001-7268-9845; 	US-Israeli Bi-National Science Foundation [97-00259-2]; Israel Science Foundation [117/00]	US-Israeli Bi-National Science Foundation(US-Israel Binational Science Foundation); Israel Science Foundation(Israel Science Foundation)	This study was supported by the US-Israeli Bi-National Science Foundation (#97-00259-2) and the Israel Science Foundation (117/00). E. Shohami and R. Kohen are affiliated with the David R. Bloom Center for Pharmacy, The Hebrew University School of Pharmacy, Jerusalem.	ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Antunes F, 1999, FREE RADICAL BIO MED, V26, P117, DOI 10.1016/S0891-5849(98)00168-3; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Borlongan CV, 2000, FASEB J, V14, P1307, DOI 10.1096/fj.14.10.1307; Cabrera J, 2000, NEUROPHARMACOLOGY, V39, P507, DOI 10.1016/S0028-3908(99)00128-8; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Chen ST, 1999, EXP BRAIN RES, V124, P241, DOI 10.1007/s002210050619; Cirak B, 1999, PEDIATR NEUROSURG, V31, P298, DOI 10.1159/000028879; Clapp-Lilly KL, 2001, NEUROREPORT, V12, P1277, DOI 10.1097/00001756-200105080-00044; Clemens JA, 1998, STROKE, V29, P677, DOI 10.1161/01.STR.29.3.677; Dabbeni-Sala F, 2001, FASEB J, V15, P164, DOI 10.1096/fj.00-0129com; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; DUGAN LL, 1994, ANN NEUROL, V35, pS17, DOI 10.1002/ana.410350707; Elangovan V, 2000, J NEUROTRAUM, V17, P1013, DOI 10.1089/neu.2000.17.1013; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fowler G, 2003, FREE RADICAL BIO MED, V34, P77, DOI 10.1016/S0891-5849(02)01186-3; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; GARFINKEL D, 1995, LANCET, V346, P541, DOI 10.1016/S0140-6736(95)91382-3; Gilad E, 1997, LIFE SCI, V60, pPL169, DOI 10.1016/S0024-3205(97)00008-8; Gilad E, 1998, FASEB J, V12, P685, DOI 10.1096/fasebj.12.9.685; Ginis I, 2000, MOL MED, V6, P1028, DOI 10.1007/BF03402054; Giusti P, 1996, FASEB J, V10, P891, DOI 10.1096/fasebj.10.8.8666166; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Huang CY, 2001, J CEREBR BLOOD F MET, V21, P163, DOI 10.1097/00004647-200102000-00008; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Kaltschmidt B, 1999, ANTIOXID REDOX SIGN, V1, P129, DOI 10.1089/ars.1999.1.2-129; Kamata H, 2002, ANN NY ACAD SCI, V973, P419, DOI 10.1111/j.1749-6632.2002.tb04675.x; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kaptanoglu E, 2000, J NEUROSURG, V93, P77, DOI 10.3171/spi.2000.93.1.0077; Kohen R, 1999, METHOD ENZYMOL, V300, P428; Kotler M, 1998, J PINEAL RES, V24, P83, DOI 10.1111/j.1600-079X.1998.tb00371.x; Letechipia-Vallejo G, 2001, ARCH MED RES, V32, P186, DOI 10.1016/S0188-4409(01)00268-5; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Livrea MA, 1997, FREE RADICAL BIO MED, V23, P706, DOI 10.1016/S0891-5849(97)00018-X; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; Martin M, 2000, FASEB J, V14, P1677; Martin V, 2002, J PINEAL RES, V33, P204, DOI 10.1034/j.1600-079X.2002.02113.x; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mathews KS, 2000, J NEUROSCI METH, V102, P43, DOI 10.1016/S0165-0270(00)00277-6; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; OGITA K, 1994, J NEUROCHEM, V63, P525; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; Osseni RA, 2000, LIFE SCI, V68, P387, DOI 10.1016/S0024-3205(00)00955-3; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; PIERI C, 1994, LIFE SCI, V55, pPL271, DOI 10.1016/0024-3205(94)00666-0; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; Polidori MC, 2001, STROKE, V32, P898, DOI 10.1161/01.STR.32.4.898; POVLISHOCK JT, 1992, HUM CELL, V4, P345; POZO D, 1994, LIFE SCI, V55, pPL455, DOI 10.1016/0024-3205(94)00532-X; Reiter RJ, 2001, CELL BIOCHEM BIOPHYS, V34, P237, DOI 10.1385/CBB:34:2:237; Sasaki M, 2003, BMC GASTROENTEROL, V3, DOI 10.1186/1471-230X-3-3; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Siushansian R, 1997, J NEUROCHEM, V68, P2378; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Tan DX, 2001, FASEB J, V15, P2294, DOI 10.1096/fj.01-0309fje; Tan DX, 2000, FREE RADICAL BIO MED, V29, P1177, DOI 10.1016/S0891-5849(00)00435-4; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Trembovler V, 1999, J INTERF CYTOK RES, V19, P791, DOI 10.1089/107999099313640; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 2001, NEUROL RES, V23, P129, DOI 10.1179/016164101101198460; YONEDA Y, 1994, BRAIN RES, V667, P54, DOI 10.1016/0006-8993(94)91713-2	73	145	153	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					149	151		10.1096/fj.03-0323fje	http://dx.doi.org/10.1096/fj.03-0323fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597558				2022-12-25	WOS:000188829300057
J	Johnston, JB; Kabore, AF; Strutinsky, J; Hu, XJ; Paul, JT; Kropp, DM; Kuschak, B; Begleiter, A; Gibson, SB				Johnston, JB; Kabore, AF; Strutinsky, J; Hu, XJ; Paul, JT; Kropp, DM; Kuschak, B; Begleiter, A; Gibson, SB			Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia	ONCOGENE			English	Article						apoptosis; death receptors; chronic lymphocytic leukemia; TRAIL; chemotherapeutic drugs	TRAIL-INDUCED APOPTOSIS; LIGAND-INDUCED APOPTOSIS; MULTIPLE-MYELOMA; IN-VITRO; TRAIL/APO2L-INDUCED APOPTOSIS; DRUG-RESISTANCE; CYTOTOXIC DRUGS; TUMOR-CELLS; EXPRESSION; ACTIVATION	The standard treatments for chronic lymphocytic leukemia (CLL) include the alkylating agent chlorambucil (CLB) and the nucleoside analog fludarabine (F-ara-AMP, Flu). Tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL) is a death receptor ligand that induces apoptosis preferentially in tumors. However, CLL cells seem to be resistant to TRAIL-induced apoptosis. The TRAIL apoptotic signaling pathway has also been implicated in genotoxin-induced apoptosis through upregulation of TRAIL death receptors DR4 and DR5. In the present study, we demonstrate that the treatment of primary CLL cells with CLB or Flu increases the mRNA, protein and cell surface expression levels of DR4 and DR5 in a dose-dependent manner. In contrast to CLL cells, drug treatment fails to increase significantly the expression of DR4 or DR5 in normal lymphocytes. CLL cells are, however, resistant to TRAIL-induced apoptosis compared to B-cell lines. In contrast, combinational treatment using CLB or Flu with TRAIL (100 ng/ml) gave a synergistic apoptotic response. Furthermore, TRAIL is readily detectable on the cell surface of CLL cells, but TRAIL expression fails to increase following drug treatment. Preventing TRAIL from interacting with DR4 and DR5 decreases CLB-induced apoptosis in CLL cells. A similar, but less marked effect is observed with Flu. These findings indicate the involvement of the TRAIL apoptotic pathway in the mechanism of action of chemotherapy, and this mechanism could be utilized to sensitize CLL cells to TRAIL-induced apoptosis.	Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, Dept Pharmacol & Therapeut, Winnipeg, MB, Canada; Univ Manitoba, Dept Internal Med, Winnipeg, MB R3E 0V9, Canada	University of Manitoba; University of Manitoba; University of Manitoba; University of Manitoba	Gibson, SB (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.			Gibson, Spencer/0000-0003-0119-732X				Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Begleiter A, 1996, LEUKEMIA LYMPHOMA, V23, P187, DOI 10.3109/10428199609054821; BEGLEITER A, 1995, LEUKEMIA, V9, P1875; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; DELMER A, 1995, BLOOD, V85, P2870, DOI 10.1182/blood.V85.10.2870.bloodjournal85102870; Di Pietro R, 2001, BLOOD, V97, P2596, DOI 10.1182/blood.V97.9.2596; Dighiero G, 2000, NEW ENGL J MED, V343, P1799, DOI 10.1056/NEJM200012143432410; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Friesen C, 1999, LEUKEMIA, V13, P1854, DOI 10.1038/sj.leu.2401333; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; Genini D, 2000, BLOOD, V96, P3537; Genini D, 2000, J BIOL CHEM, V275, P29, DOI 10.1074/jbc.275.1.29; Gibson EM, 2002, CANCER RES, V62, P488; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gottardi D, 1996, BRIT J HAEMATOL, V94, P612, DOI 10.1046/j.1365-2141.1996.d01-1856.x; Guan BX, 2002, ONCOGENE, V21, P3121, DOI 10.1038/sj.onc.1205430; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Johnston JB, 1997, LEUKEMIA LYMPHOMA, V26, P435, DOI 10.3109/10428199709050881; JOHNSTON JB, 1999, WINTROBES CLIN HEMAT, P2405; Jones DT, 2001, BLOOD, V98, P2800, DOI 10.1182/blood.V98.9.2800; Kim EJ, 2001, INT J ONCOL, V18, P187; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Lens D, 1997, BRIT J HAEMATOL, V99, P848, DOI 10.1046/j.1365-2141.1997.4723278.x; Levesque MC, 2001, LEUKEMIA, V15, P1305, DOI 10.1038/sj.leu.2402192; Lincz LF, 2001, LEUKEMIA, V15, P1650, DOI 10.1038/sj.leu.2402251; MacFarlane M, 2002, ONCOGENE, V21, P6809, DOI 10.1038/sj.onc.1205853; Menzel T, 1996, BLOOD, V87, P1056, DOI 10.1182/blood.V87.3.1056.bloodjournal8731056; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Mitsiades N, 2002, BLOOD, V99, P2162, DOI 10.1182/blood.V99.6.2162; Olsson A, 2001, LEUKEMIA, V15, P1868, DOI 10.1038/sj.leu.2402287; Pepper C, 1999, BRIT J HAEMATOL, V107, P611, DOI 10.1046/j.1365-2141.1999.01726.x; Plasilova M, 2002, LEUKEMIA, V16, P67, DOI 10.1038/sj.leu.2402338; Rai KR, 2000, NEW ENGL J MED, V343, P1750, DOI 10.1056/NEJM200012143432402; Ravi R, 2002, CANCER RES, V62, P1583; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Sankar M, 1998, LEUKEMIA, V12, P510, DOI 10.1038/sj.leu.2400973; SAYERS TJ, 2003, BLOOD, V13, P13; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Solary E, 2000, LEUKEMIA, V14, P1833, DOI 10.1038/sj.leu.2401902; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Vrhovac R, 1998, BLOOD, V91, P4694, DOI 10.1182/blood.V91.12.4694.412k09_4694_4700; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Werner AB, 2002, J BIOL CHEM, V277, P40760, DOI 10.1074/jbc.M204351200; Wu GS, 2000, ADV EXP MED BIOL, V465, P143; Zhao HX, 1998, BLOOD, V92, P1031	49	51	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8356	8369		10.1038/sj.onc.1207004	http://dx.doi.org/10.1038/sj.onc.1207004			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614459				2022-12-25	WOS:000186541500014
J	Umehara, S; Higashi, H; Ohnishi, N; Asaka, M; Hatakeyama, M				Umehara, S; Higashi, H; Ohnishi, N; Asaka, M; Hatakeyama, M			Effects of Helicobacter pylori CagA protein on the growth and survival of B lymphocytes, the origin of MALT lymphoma	ONCOGENE			English	Article						H. pylori; CagA; MALT lymphoma; B cell; apoptosis	ATROPHIC GASTRITIS; GENE-EXPRESSION; ULCER DISEASE; LOW-GRADE; IN-VITRO; T(11-18)(Q21-Q21); PHOSPHORYLATION; TRANSLOCATION; STRAINS; KINASE	Helicobacter pylori (H. pylori) is a causative agent of gastrointestinal diseases such as atrophic gastritis and gastroduodenal ulcer. Infection of cagA-positive H. pylori is also associated with gastric carcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. The cagA gene product CagA is directly injected into the bacteria-attached host cells via the bacterial type IV secretion system. The translocated CagA deregulates intracellular signaling pathways and thereby initiates pathogenesis. In this work, we examined the biological effects of CagA on B cells, from which MALT lymphoma arises. Ectopic expression of CagA in interleukin 3-dependent B cells inhibited cell proliferation by suppressing the JAK-STAT signaling. CagA was also capable of preventing hydroxyurea-induced B-cell apoptosis through inhibiting p53 accumulation. In contrast to the effects of CagA in gastric epithelial cells, the observed CagA activities in B cells were independent of its tyrosine phosphorylation. Our results indicate that CagA possesses both phosphorylation-dependent and -independent activities in mammalian cells and that biological impacts of CagA depend on cell-type context. As a result of B-cell growth inhibition, CagA may diminish anti-H. pylori immune responses. Furthermore, CagA may play a role in the development of MALT lymphoma by impairing p53-dependent apoptosis.	Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Grad Sch Sci, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Dept Gastroenterol, Grad Sch Med, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; Hokkaido University; Hokkaido University	Hatakeyama, M (corresponding author), Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Kita-15,Nishi-7, Sapporo, Hokkaido 0600815, Japan.		Higashi, Hideaki/F-6872-2012; OHNISHI, Naomi/F-6914-2012; Asaka, Masahiro/A-5948-2012	OHNISHI, Naomi/0000-0002-2382-3152; 				Auer IA, 1997, ANN ONCOL, V8, P979, DOI 10.1023/A:1008202303666; Baens M, 2000, AM J PATHOL, V156, P1433, DOI 10.1016/S0002-9440(10)65012-2; BLASER MJ, 1995, CANCER RES, V55, P2111; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Du MQ, 2002, LANCET ONCOL, V3, P97, DOI 10.1016/S1470-2045(02)00651-4; Eck M, 1997, GASTROENTEROLOGY, V112, P1482, DOI 10.1016/S0016-5085(97)70028-3; Flores-Morales A, 1998, MOL CELL ENDOCRINOL, V138, P1, DOI 10.1016/S0303-7207(98)00054-9; Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Hoshikawa Y, 1998, ANAL BIOCHEM, V261, P211, DOI 10.1006/abio.1998.2742; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; KUIPERS EJ, 1995, ALIMENT PHARM THERAP, V9, P59; Kuipers EJ, 1997, ALIMENT PHARM THER, V11, P71, DOI 10.1046/j.1365-2036.11.s1.5.x; KUIPERS EJ, 1995, J NATL CANCER I, V87, P1777, DOI 10.1093/jnci/87.23.1777; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Ott G, 1997, CANCER RES, V57, P3944; Palacios C, 2000, ONCOGENE, V19, P3556, DOI 10.1038/sj.onc.1203683; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; Selbach M, 2002, J BIOL CHEM, V277, P6775, DOI 10.1074/jbc.C100754200; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sheu BS, 1999, DIGEST DIS SCI, V44, P868, DOI 10.1023/A:1026627707103; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Stein M, 2002, MOL MICROBIOL, V43, P971, DOI 10.1046/j.1365-2958.2002.02781.x; Tsutsumi R, 2003, J BIOL CHEM, V278, P3664, DOI 10.1074/jbc.M208155200; Wang X, 2000, APMIS, V108, P503, DOI 10.1034/j.1600-0463.2000.d01-89.x; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F	29	72	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8337	8342		10.1038/sj.onc.1207028	http://dx.doi.org/10.1038/sj.onc.1207028			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614457				2022-12-25	WOS:000186541500012
J	Seminario, MC; Precht, P; Wersto, RP; Gorospe, M; Wange, RL				Seminario, MC; Precht, P; Wersto, RP; Gorospe, M; Wange, RL			PTEN expression in PTEN-null leukaemic T cell lines leads to reduced proliferation via slowed cell cycle progression	ONCOGENE			English	Article						PTEN; proliferation; cell cycle; apoptosis	TUMOR-SUPPRESSOR PTEN; ANTIGEN RECEPTOR; CARCINOMA-CELLS; PHOSPHATASE-ACTIVITY; GROWTH ARREST; APOPTOSIS; ACTIVATION; PATHWAY; SIZE; STIMULATION	The balance of activities between the proto-oncogene phosphoinositide 3-kinase (PI3K) and the tumour suppressor gene PTEN has been shown to affect cellular growth and proliferation, as well as tumorigenesis. Previously, PTEN expression in the PTEN-null Jurkat T cell leukaemia line was shown to cause reduced proliferation without cell cycle arrest. Here, we further these investigations by determining the basis for this phenomenon. By BrdU pulse-chase and cell cycle arrest and release assays, we find that PTEN expression reduced proliferation by slowing progression through all phases of the cell cycle. This was associated with reduced levels of cyclins A, B1 and B2, cdk4, and cdc25A and increased p27(KIP1) expression. Apoptosis played no role in the antiproliferative effect of PTEN, since only marginal increases in the rate of apoptosis were detected upon PTEN expression, and inhibitors of effector caspases did not restore proliferative capacity. Active Akt blocked the antiproliferative effects of PTEN, indicating that PTEN mediates its effects through conventional PI3K-linked signalling pathways. Similar results were obtained from a different PTEN-null leukaemia T cell line, CEM. Together, these results show that PTEN expression in leukaemic T cells leads to reduced proliferation via an apoptosis-independent mechanism involving slower passage through the cell cycle.	NIA, Cellular & Mol Biol Lab, IRP, NIH,DHHS, Baltimore, MD 21224 USA; NIA, Flow Cytometry Lab, IRP, NIH,DHHS, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Wange, RL (corresponding author), NIA, Cellular & Mol Biol Lab, IRP, NIH,DHHS, 5600 Nathan Shock Dr,MSC-12, Baltimore, MD 21224 USA.	wanger@grc.nia.nih.gov	Wange, Ronald/AAI-2505-2021	Wange, Ronald/0000-0001-9593-3572	NATIONAL INSTITUTE ON AGING [Z01AG000509] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; ALLEN GD, 1990, BIOPHARM DRUG DISPOS, V11, P477, DOI 10.1002/bdd.2510110603; Appleman LJ, 2002, J IMMUNOL, V168, P2729, DOI 10.4049/jimmunol.168.6.2729; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cheyney IW, 1999, CANCER RES, V59, P2318; Davies MA, 1999, CANCER RES, V59, P2551; DAVIES MA, 2002, CLIN CANCER RES, V8, P1695; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Furnari FB, 1998, CANCER RES, V58, P5002; Genestier L, 1998, J BIOL CHEM, V273, P5060, DOI 10.1074/jbc.273.9.5060; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; GOLD R, 1993, J HISTOCHEM CYTOCHEM, V41, P1023, DOI 10.1177/41.7.8515045; Gorospe M, 1996, MOL CELL BIOL, V16, P762; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; NORDSTROM T, 1992, EXP CELL RES, V202, P487, DOI 10.1016/0014-4827(92)90103-F; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Shan XC, 2001, MOL CELL BIOL, V21, P7137, DOI 10.1128/MCB.21.21.7137-7149.2001; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Wang XD, 2000, J IMMUNOL, V164, P1934, DOI 10.4049/jimmunol.164.4.1934; WANGE RL, 1995, J BIOL CHEM, V270, P944, DOI 10.1074/jbc.270.2.944; Ward SG, 2001, CURR OPIN IMMUNOL, V13, P332, DOI 10.1016/S0952-7915(00)00223-5; Weng LP, 1999, CANCER RES, V59, P5808; Weng LP, 2001, HUM MOL GENET, V10, P251, DOI 10.1093/hmg/10.3.251; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; Wersto RP, 1998, J VIROL, V72, P9491, DOI 10.1128/JVI.72.12.9491-9502.1998; WERSTO RP, 1995, CYTOMETRY, V20, P43, DOI 10.1002/cyto.990200108; Wishart MJ, 2002, TRENDS CELL BIOL, V12, P579, DOI 10.1016/S0962-8924(02)02412-1; Wu RC, 2000, MOL CELL BIOCHEM, V203, P59, DOI 10.1023/A:1007024624967; Xu Z, 2002, CELL GROWTH DIFFER, V13, P285; Yamada KM, 2001, J CELL SCI, V114, P2375; Zhang SM, 2000, J IMMUNOL, V165, P6270, DOI 10.4049/jimmunol.165.11.6270; Zhu XY, 2001, CANCER RES, V61, P4569	47	42	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2003	22	50					8195	8204		10.1038/sj.onc.1206872	http://dx.doi.org/10.1038/sj.onc.1206872			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603260				2022-12-25	WOS:000186403400014
J	Littler, DR; Harrop, SJ; Fairlie, WD; Brown, LJ; Pankhurst, GJ; Pankhurst, S; DeMaere, MZ; Campbell, TJ; Bauskin, AR; Tonini, R; Mazzanti, M; Breit, SN; Curmi, PMG				Littler, DR; Harrop, SJ; Fairlie, WD; Brown, LJ; Pankhurst, GJ; Pankhurst, S; DeMaere, MZ; Campbell, TJ; Bauskin, AR; Tonini, R; Mazzanti, M; Breit, SN; Curmi, PMG			The intracellular chloride ion channel protein CLIC1 undergoes a redox-controlled structural transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; NCC27; REFINEMENT; PROGRAM; FORM	Most proteins adopt a well defined three-dimensional structure; however, it is increasingly recognized that some proteins can exist with at least two stable conformations. Recently, a class of intracellular chloride ion channel proteins (CLICs) has been shown to exist in both soluble and integral membrane forms. The structure of the soluble form of CLIC1 is typical of a soluble glutathione S-transferase superfamily protein but contains a glutaredoxin-like active site. In this study we show that on oxidation CLIC1 undergoes a reversible transition from a monomeric to a non-covalent dimeric state due to the formation of an intramolecular disulfide bond ( Cys-24-Cys-59). We have determined the crystal structure of this oxidized state and show that a major structural transition has occurred, exposing a large hydrophobic surface, which forms the dimer interface. The oxidized CLIC1 dimer maintains its ability to form chloride ion channels in artificial bilayers and vesicles, whereas a reducing environment prevents the formation of ion channels by CLIC1. Mutational studies show that both Cys-24 and Cys-59 are required for channel activity.	Univ New S Wales, Sch Phys, Initiat Biomol Struct, Sydney, NSW 2052, Australia; St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia; Univ New S Wales, Sydney, NSW 2010, Australia; Univ New S Wales, Dept Med, Sydney, NSW 2052, Australia; Univ Roma La Sapienza, Dept Cellular & Dev Biol, I-00185 Rome, Italy	University of New South Wales Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney; University of New South Wales Sydney; Sapienza University Rome	Curmi, PMG (corresponding author), Univ New S Wales, Sch Phys, Initiat Biomol Struct, Sydney, NSW 2052, Australia.	p.curmi@unsw.edu.au	DeMaere, Matthew Zachariah/D-9002-2012; Tonini, Raffaella/J-2960-2012; Mazzanti, Michele/A-8941-2011; Curmi, Paul/G-7185-2011; Fairlie, Walter/M-8401-2015	DeMaere, Matthew Zachariah/0000-0002-7601-5108; Curmi, Paul/0000-0001-5762-7638; Fairlie, Walter/0000-0002-2498-1160; Brown, Louise/0000-0001-8592-2431; Mazzanti, Michele/0000-0002-1819-3811; Littler, Dene/0000-0001-5904-1905; TONINI, Raffaella/0000-0003-1652-4709; Campbell, Terry/0000-0003-0055-4137				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Choi HJ, 2001, CELL, V105, P103, DOI 10.1016/S0092-8674(01)00300-2; Declercq JP, 2001, J MOL BIOL, V311, P751, DOI 10.1006/jmbi.2001.4853; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fernandez-Salas E, 2002, MOL CELL BIOL, V22, P3610, DOI 10.1128/MCB.22.11.3610-3620.2002; Foreman J, 2003, NATURE, V422, P442, DOI 10.1038/nature01485; Gouaux E, 1997, CURR OPIN STRUC BIOL, V7, P566, DOI 10.1016/S0959-440X(97)80123-6; Harrop SJ, 2001, J BIOL CHEM, V276, P44993, DOI 10.1074/jbc.M107804200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LAWRENCE MC, 2000, J APPL CRYSTALLOGR, V33, P990; LESLIE A, 1993, CRYSTALLOGRAPHIC COM, V5; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nilius B, 2003, ACTA PHYSIOL SCAND, V177, P119, DOI 10.1046/j.1365-201X.2003.01060.x; REDHEAD CR, 1992, P NATL ACAD SCI USA, V89, P3716, DOI 10.1073/pnas.89.9.3716; Schlesinger PH, 1997, J BIOL CHEM, V272, P18636, DOI 10.1074/jbc.272.30.18636; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tonini R, 2000, FASEB J, V14, P1171, DOI 10.1096/fasebj.14.9.1171; Tulk BM, 2000, J BIOL CHEM, V275, P26986; Tulk BM, 2002, AM J PHYSIOL-CELL PH, V282, pC1103, DOI 10.1152/ajpcell.00402.2001; Valenzuela SM, 2000, J PHYSIOL-LONDON, V529, P541, DOI 10.1111/j.1469-7793.2000.00541.x; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; Warton K, 2002, J BIOL CHEM, V277, P26003, DOI 10.1074/jbc.M203666200; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8	31	157	159	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9298	9305		10.1074/jbc.M308444200	http://dx.doi.org/10.1074/jbc.M308444200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14613939	hybrid			2022-12-25	WOS:000189265900092
J	Neaud, V; Duplantier, JG; Mazzocco, C; Kisiel, W; Rosenbaum, J				Neaud, V; Duplantier, JG; Mazzocco, C; Kisiel, W; Rosenbaum, J			Thrombin up-regulates tissue factor pathway inhibitor-2 synthesis through a cyclooxygenase-2-dependent, epidermal growth factor receptor-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCELLULAR-CARCINOMA CELLS; SERINE-PROTEASE INHIBITOR; SMOOTH-MUSCLE-CELLS; EGF RECEPTOR; ENDOTHELIAL-CELLS; COUPLED RECEPTORS; GENE-EXPRESSION; KINASE PATHWAY; CDNA CLONING; ACTIVATION	The serine proteinase inhibitor tissue factor pathway inhibitor-2 (TFPI-2) inhibits the tissue factor-factor VIIa complex and thereby impairs factor Xa and subsequently thrombin generation. Here we show that thrombin itself up-regulates TFPI-2 mRNA and protein expression in human liver myofibroblasts, a cell type shown to express high levels of TFPI-2 (Neaud, V., Hisaka, T., Monvoisin,A., Bedin, C., Balabaud, C., Foster, D. C., Desmouliere, A., Kisiel, W., and Rosenbaum, J. (2000) J. Biol. Chem. 275, 35565-35569). This effect required thrombin catalytic activity, as shown by its abolition with hirudin. Although the thrombin effect could be mimicked by agonists of both protease-activated receptor (PAR)-1 and PAR-4, it was largely blocked by a PAR-1 blocking antibody. Transactivation of the epidermal growth factor (EGF) receptor has been reported as a common event in thrombin signaling. However, thrombin did not detectably transactivate the EGF receptor in liver myofibroblasts, and blocking the EGF receptor did not affect TFPI-2 induction. On the other hand, thrombin increased the expression of cyclooxygenase-2 (COX-2) mRNA via a MAPK-dependent pathway, and a specific COX-2 inhibitor abolished the effect of thrombin on TFPI-2 expression. Thus, thrombin, through PAR-1 signaling, up-regulates the synthesis of TFPI-2 via a MAPK/COX-2-dependent pathway. The up-regulation of TFPI-2 expression by thrombin could in turn down-regulate thrombin generation and contribute to limit blood coagulation.	Univ Bordeaux 2, GREF, INSERM E362, F-33076 Bordeaux, France; Univ Bordeaux 2, IFR66, F-33076 Bordeaux, France; Univ New Mexico, Sch Med, Dept Pathol, Albuquerque, NM 87131 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; University of New Mexico	Rosenbaum, J (corresponding author), Univ Bordeaux 2, GREF, INSERM E362, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	jean.rosenbaum@gref.u-bordeaux2.fr	Rosenbaum, Jean/F-5547-2013	Rosenbaum, Jean/0000-0001-8585-5152	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064119] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-64119] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; BLAZEJEWSKI S, 1995, HEPATOLOGY, V22, P788, DOI 10.1016/0270-9139(95)90298-8; CHAND HS, 2003, IN PRESS BLOOD; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DuhamelClerin E, 1997, ARTERIOSCL THROM VAS, V17, P1931, DOI 10.1161/01.ATV.17.10.1931; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; Galis ZS, 1997, ARTERIOSCL THROM VAS, V17, P483, DOI 10.1161/01.ATV.17.3.483; Guo YL, 1997, BIOCHEM BIOPH RES CO, V240, P405, DOI 10.1006/bbrc.1997.7669; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Le Pabic H, 2003, HEPATOLOGY, V37, P1056, DOI 10.1053/jhep.2003.50205; LOTTENBERG R, 1981, METHOD ENZYMOL, V80, P341; Ludwicka-Bradley A, 2000, AM J RESP CELL MOL, V22, P235, DOI 10.1165/ajrcmb.22.2.3642; Madamanchi NR, 2001, J BIOL CHEM, V276, P18915, DOI 10.1074/jbc.M008802200; Mallat A, 1998, J BIOL CHEM, V273, P27300, DOI 10.1074/jbc.273.42.27300; Maulon L, 2001, ONCOGENE, V20, P1964, DOI 10.1038/sj.onc.1204266; MIYAGI Y, 1994, J BIOCHEM-TOKYO, V116, P939, DOI 10.1093/oxfordjournals.jbchem.a124648; Miyata S, 2000, J BIOL CHEM, V275, P4592, DOI 10.1074/jbc.275.7.4592; Molloy CJ, 1996, J CLIN INVEST, V97, P1173, DOI 10.1172/JCI118531; Monvoisin A, 1999, J HEPATOL, V30, P511, DOI 10.1016/S0168-8278(99)80113-5; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; Neaud V, 2000, J BIOL CHEM, V275, P35565, DOI 10.1074/jbc.M006101200; Neaud V, 1997, HEPATOLOGY, V26, P1458, DOI 10.1002/hep.510260612; Ott I, 2000, ARTERIOSCL THROM VAS, V20, P874, DOI 10.1161/01.ATV.20.3.874; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; Phillips-Mason PJ, 2000, J BIOL CHEM, V275, P18046, DOI 10.1074/jbc.M909194199; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rao CN, 1996, ARCH BIOCHEM BIOPHYS, V335, P82, DOI 10.1006/abbi.1996.0484; Rao CN, 1999, BIOCHEM BIOPH RES CO, V255, P94, DOI 10.1006/bbrc.1999.0153; Rao CN, 1998, INT J CANCER, V76, P749, DOI 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y; Raza SL, 2000, J BIOL CHEM, V275, P41243, DOI 10.1074/jbc.M005788200; Shimizu S, 2000, AM J PHYSIOL-LUNG C, V279, pL503, DOI 10.1152/ajplung.2000.279.3.L503; Sower LE, 1999, EXP CELL RES, V247, P422, DOI 10.1006/excr.1998.4372; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; WIN KM, 1993, HEPATOLOGY, V18, P137, DOI 10.1002/hep.1840180121; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730	39	28	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5200	5206		10.1074/jbc.M306679200	http://dx.doi.org/10.1074/jbc.M306679200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14623891	hybrid			2022-12-25	WOS:000188776500021
J	Park, SJ; Ciccone, SLM; Freie, B; Kurimasa, A; Chen, DJ; Li, GC; Clapp, DW; Lee, SH				Park, SJ; Ciccone, SLM; Freie, B; Kurimasa, A; Chen, DJ; Li, GC; Clapp, DW; Lee, SH			A positive role for the Ku complex in DNA replication following strand break damage in mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CELL NUCLEAR ANTIGEN; S-PHASE CHECKPOINT; CATALYTIC SUBUNIT; POLYMERASE-DELTA; REPAIR PROTEIN; PHOSPHORYLATION; BINDING; MRE11; YEAST	Ku70-Ku80 complex is the regulatory subunit of DNA-dependent protein kinase (DNA-PK) and plays an essential role in double-strand break repair following ionizing radiation (IR). It preferentially interacts with chromosomal breaks and protects DNA ends from nuclease attack. Here we show evidence that cells defective in Ku80 exhibit a significantly slow S phase progression following DNA damage. IR-induced retardation in S phase progression in Ku80-/- cells was not due to the lack of DNA-PK kinase activity because both wild-type cells and DNA-PKcs-deficient cells showed no such symptom. Instead, proliferating cell nuclear antigen (PCNA) dissociated from chromosomes following IR in Ku80-deficient cells but not in wild-type or DNA-PKcs-deficient cells. Treatment of HeLa cells with IR induced colocalization of the Ku complex with PCNA on chromosomes. Together, these results suggest that binding of the Ku complex at chromosomal breaks may be necessary to maintain the sliding clamps (PCNA) on chromatin, which would allow cells to resume DNA replication without a major delay following IR.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Canc Inst, Indianapolis, IN 46202 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Memorial Sloan Kettering Cancer Center	Lee, SH (corresponding author), IU Canc Res Inst, 1044 W Walnut St,Rm 153, Indianapolis, IN 46202 USA.	slee@iupui.edu			NATIONAL CANCER INSTITUTE [R37CA050519, R01CA050519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM020167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018949] Funding Source: NIH RePORTER; NCI NIH HHS [CA92111, CA50519] Funding Source: Medline; NIA NIH HHS [AG18949] Funding Source: Medline; NIGMS NIH HHS [F32 GM20167-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balajee AS, 2001, NUCLEIC ACIDS RES, V29, P1341, DOI 10.1093/nar/29.6.1341; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Brush GS, 2000, NUCLEIC ACIDS RES, V28, P3725, DOI 10.1093/nar/28.19.3725; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; Chiu CY, 1998, J MOL BIOL, V284, P1075, DOI 10.1006/jmbi.1998.2212; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; D'Amours D, 2001, GENE DEV, V15, P2238, DOI 10.1101/gad.208701; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Dibiase SJ, 2000, CANCER RES, V60, P1245; Espejel S, 2002, EMBO J, V21, P6275, DOI 10.1093/emboj/cdf593; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hingorani MM, 2000, CURR BIOL, V10, pR25, DOI 10.1016/S0960-9822(99)00252-3; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; JOHZUKA K, 1995, GENETICS, V139, P1521; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; Kim CH, 2002, J PHARMACOL EXP THER, V303, P753, DOI 10.1124/jpet.102.038505; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; Lee SH, 2002, MOL CELLS, V13, P159; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Maga G, 2001, P NATL ACAD SCI USA, V98, P14298, DOI 10.1073/pnas.251193198; Matheos D, 2002, BBA-GENE STRUCT EXPR, V1578, P59, DOI 10.1016/S0167-4781(02)00497-9; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Murti KG, 1996, EXP CELL RES, V223, P279, DOI 10.1006/excr.1996.0083; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Park JS, 1999, J BIOL CHEM, V274, P32520, DOI 10.1074/jbc.274.45.32520; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; POLTORATSKY VP, 1995, J IMMUNOL, V155, P4529; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang HY, 2001, CANCER RES, V61, P8554; Wang S, 2000, P NATL ACAD SCI USA, V97, P1584, DOI 10.1073/pnas.97.4.1584; Wang Y, 1999, J BIOL CHEM, V274, P22060, DOI 10.1074/jbc.274.31.22060; WATSON JV, 1987, CYTOMETRY, V8, P1, DOI 10.1002/cyto.990080101; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	58	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6046	6055		10.1074/jbc.M311054200	http://dx.doi.org/10.1074/jbc.M311054200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14617623	hybrid			2022-12-25	WOS:000188776500120
J	Elkabetz, Y; Shapira, I; Rabinovich, E; Bar-Nun, S				Elkabetz, Y; Shapira, I; Rabinovich, E; Bar-Nun, S			Distinct steps in dislocation of luminal endoplasmic reticulum-associated degradation substrates - Roles of endoplasmic reticulum-bound p97/Cdc48p and proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER QUALITY-CONTROL; IMMUNOGLOBULIN LIGHT-CHAINS; VALOSIN-CONTAINING PROTEIN; I HEAVY-CHAINS; AAA-ATPASE; B-LYMPHOCYTES; SYNTAXIN 5; UBIQUITIN; RETROTRANSLOCATION; TRANSPORT	Dislocation of endoplasmic reticulum-associated degradation (ERAD) substrates from the endoplasmic reticulum (ER) lumen to cytosol is considered to occur in a single step that is tightly coupled to proteasomal degradation. Here we show that dislocation of luminal ERAD substrates occurs in two distinct consecutive steps. The first is passage across ER membrane to the ER cytosolic face, where substrates can accumulate as ubiquitin conjugates. In vivo, this step occurs despite proteasome inhibition but requires p97/Cdc48p because substrates remain entrapped in ER lumen and are prevented from ubiquitination in cdc48 yeast strain. The second dislocation step is the release of accumulated substrates to the cytosol. In vitro, this release requires active proteasome, consumes ATP, and relies on salt-removable ER-bound components, among them the ER-bound p97 and ER-bound proteasome, which specifically interact with the cytosol-facing substrates. An additional role for Cdc48p subsequent to ubiquitination is revealed in the cdc48 strain at permissive temperature, consistent with our finding that p97 recognizes luminal ERAD substrates through multiubiquitin. BiP interacts exclusively with ERAD substrates, suggesting a role for this chaperone in ERAD. We propose a model that assigns the cytosolic face of the ER as a midpoint to which luminal ERAD substrates emerge and p97/Cdc48p and the proteasome are recruited. Although p97/Cdc48p plays a dual role in dislocation and is involved both in passage of the substrate across ER membrane and subsequent to its ubiquitination, the proteasome takes part in the release of the substrate from the ER face to the cytosol en route to degradation.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel	Tel Aviv University	Bar-Nun, S (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel.	sbnun@post.tau.ac.il						AMITAY R, 1991, J BIOL CHEM, V266, P12568; AMITAY R, 1992, J BIOL CHEM, V267, P20694; Ausubel F. M., 2001, CURRENT PROTOCOLS MO; Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Bays NW, 2002, CURR BIOL, V12, pR366, DOI 10.1016/S0960-9822(02)00862-X; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Brooks P, 2000, BIOCHEM J, V346, P155, DOI 10.1042/0264-6021:3460155; Caldwell SR, 2001, J BIOL CHEM, V276, P23296, DOI 10.1074/jbc.M102962200; Chillaron J, 2000, MOL BIOL CELL, V11, P217, DOI 10.1091/mbc.11.1.217; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; Elkabetz Y, 2003, J BIOL CHEM, V278, P18922, DOI 10.1074/jbc.M208730200; Enenkel C, 1998, EMBO J, V17, P6144, DOI 10.1093/emboj/17.21.6144; Flierman D, 2003, J BIOL CHEM, V278, P34774, DOI 10.1074/jbc.M303360200; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; Golbik R, 1999, BIOL CHEM, V380, P1049, DOI 10.1515/BC.1999.131; Hampton RY, 1997, P NATL ACAD SCI USA, V94, P12944, DOI 10.1073/pnas.94.24.12944; Haynes CM, 2002, J CELL BIOL, V158, P91, DOI 10.1083/jcb.200201053; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hirsch C, 2000, TRENDS CELL BIOL, V10, P268, DOI 10.1016/S0962-8924(00)01768-2; Hori H, 1999, J BIOCHEM-TOKYO, V126, P722, DOI 10.1093/oxfordjournals.jbchem.a022509; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Kikkert M, 2001, BIOCHEM J, V358, P369, DOI 10.1042/0264-6021:3580369; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Lavoie C, 2000, P NATL ACAD SCI USA, V97, P13637, DOI 10.1073/pnas.240278097; Lord JM, 2002, CURR BIOL, V12, pR182, DOI 10.1016/S0960-9822(02)00738-8; Mancini R, 2000, FASEB J, V14, P769, DOI 10.1096/fasebj.14.5.769; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; RABINOVICH E, 1993, J BIOL CHEM, V268, P24145; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Ravid T, 2000, J BIOL CHEM, V275, P35840, DOI 10.1074/jbc.M004793200; Rivett AJ, 1998, CURR OPIN IMMUNOL, V10, P110, DOI 10.1016/S0952-7915(98)80040-X; Rouiller I, 2000, MOL CELL, V6, P1485, DOI 10.1016/S1097-2765(00)00144-1; Roy L, 2000, MOL BIOL CELL, V11, P2529, DOI 10.1091/mbc.11.8.2529; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Wang B, 2003, J BIOL CHEM, V278, P20225, DOI 10.1074/jbc.M300459200; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Winitz D, 1996, J BIOL CHEM, V271, P27645, DOI 10.1074/jbc.271.44.27645; Xiong XM, 1999, J BIOL CHEM, V274, P2616, DOI 10.1074/jbc.274.5.2616; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Zhou MY, 1999, MOL CELL, V4, P925, DOI 10.1016/S1097-2765(00)80222-1	65	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					3980	3989		10.1074/jbc.M309938200	http://dx.doi.org/10.1074/jbc.M309938200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14607830	hybrid			2022-12-25	WOS:000188554300010
J	Wagner, C; Ehresmann, C; Ehresmann, B; Brunel, C				Wagner, C; Ehresmann, C; Ehresmann, B; Brunel, C			Mechanism of dimerization of bicoid mRNA - Initiation and stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX	Dimerization of bcd mRNA was shown to be important for the formation of ribonucleoprotein particles and their localization in Drosophila embryo. The cis-element responsible for dimerization is localized in a stem-loop domain (domain III) containing two essential complementary 6-nucleotide sequences in a hairpin loop (LIIIb) and an interior loop (LIIIa). Such an RNA element can potentially generate single or double "hand-by-arm" interactions leading to open and closed complexes, respectively. The former retains the possibility of forming multimers, whereas the latter does not. We showed previously that dimerization proceeds through a two-step mechanism, which includes a transition from the reversible initiation complex into a very stable one. Here we have addressed the nature of the initial interactions and the mechanism of transition. We engineered a series of different RNA fragments with the capacity to form defined open dimers, multimers, or closed dimers. We compared their thermodynamic and kinetic behavior and mapped nucleotides involved in intermolecular interactions by enzymatic and chemical footprinting experiments and chemical modification interference. Our results indicate that the initiation step leads to a reversible open dimer, involving a more limited number of intermolecular base pairs than expected. The two loops play distinct roles in this process, and the structure of loop IIIb is more constrained than that of loop IIIa. Thus, loop IIIa appears to be the driving element of the recognition process. The initial open dimer is then converted into a stable closed dimer, possibly through a kinetically controlled mechanism.	Inst Biol Mol & Cellulaire, CNRS, Unite Propre Rech 9002, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Brunel, C (corresponding author), Inst Biol Mol & Cellulaire, CNRS, Unite Propre Rech 9002, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	C.Brunel@ibmc.u-strasbg.fr			NIGMS NIH HHS [GM54447] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054447] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asano K, 2000, J BIOL CHEM, V275, P1269, DOI 10.1074/jbc.275.2.1269; BRUNEL C, 1991, J MOL BIOL, V221, P293; Brunel C, 2002, BIOCHIMIE, V84, P925, DOI 10.1016/S0300-9084(02)01401-3; Brunel C, 2000, METHOD ENZYMOL, V318, P3; Chen CP, 2000, J BIOL CHEM, V275, P17510, DOI 10.1074/jbc.M909662199; Chen CP, 1999, RNA, V5, P805, DOI 10.1017/S1355838299990350; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; Ferrandon D, 1997, EMBO J, V16, P1751, DOI 10.1093/emboj/16.7.1751; Franch T, 1999, J MOL BIOL, V294, P1115, DOI 10.1006/jmbi.1999.3306; Grosjean H., 1998, MODULATION ROLE MODI, P113; Jossinet F, 1999, RNA, V5, P1222, DOI 10.1017/S1355838299990982; Kolb FA, 2000, EMBO J, V19, P5905, DOI 10.1093/emboj/19.21.5905; Lodmell JS, 2000, RNA, V6, P1267, DOI 10.1017/S1355838200000698; Macdonald PM, 1997, RNA, V3, P1413; Rist MJ, 2001, NUCLEIC ACIDS RES, V29, P2401, DOI 10.1093/nar/29.11.2401; Wagner C, 2001, J MOL BIOL, V313, P511, DOI 10.1006/jmbi.2001.5057; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433; Zeiler BN, 1998, COLD SPRING HARBOR M, P437	18	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4560	4569		10.1074/jbc.M306511200	http://dx.doi.org/10.1074/jbc.M306511200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14607826	hybrid			2022-12-25	WOS:000188554300077
J	Chandrasekar, B; Bysani, S; Mummidi, S				Chandrasekar, B; Bysani, S; Mummidi, S			CXCL16 signals via G(i), phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CONVERTING-ENZYME; CHEMOKINE RECEPTOR EXPRESSION; SCAVENGER RECEPTOR; SR-PSOX; FRACTALKINE CX3CL1; CUTTING EDGE; CLEAVAGE; SUBSETS; TRAFFICKING; ACTIVATION	CXCL16, a recently discovered transmembrane chemokine, is expressed in human aortic smooth muscle cell (ASMC). It facilitates uptake of low density lipoproteins by macrophages, resulting in foam cell formation. However, it is not known whether ASMC express CXCR6, the receptor for CXCL16, or whether CXCL16 affects ASMC biology. To dissect the biological and signal transduction pathways elicited by CXCL16, human aortic smooth muscle cells (HASMC) were treated with pharmacological inhibitors or transiently transfected with pathway-specific dominant-negative or kinase-dead expression vectors prior to the addition of CXCL16. HASMC expressed CXCR6 at basal conditions. Exposure of HASMC to CXCL16 increased NF-kappaB DNA binding activity, induced kappaB-driven luciferase activity, and up-regulated tumor necrosis factor-alpha expression in an NF-kappaB-dependent manner. However, treatment with pertussis toxin (G(i) inhibitor), wortmannin or LY294002 (phosphatidylinositol 3-kinase (PI3K inhibitors)), or Akt inhibitor or overexpression of dominant-negative (dn) PI3Kgamma, dnPDK-1, kinase-dead (kd) Akt, kdIKK-beta, dnIKK-gamma, dnIkappaB-alpha, or dnIkappaB-beta significantly attenuated CXCL16-induced NF-kappaB activation. Furthermore, CXCL16 increased cell-cell adhesion and induced cellular proliferation in an NF-kappaB-dependent manner. In conclusion, CXCL16 is a potent and direct activator of NF-kappaB and induces kappaB-dependent proinflammatory gene transcription. CXCL16-mediated NF-kappaB activation occurred via heterotrimeric G proteins, PI3K, PDK-1, Akt, and IkappaB kinase (IKK). CXCL16 induced IkappaB phosphorylation and degradation. Most importantly, CXCL16 increased cell-cell adhesion and induced kappaB-dependent ASMC proliferation, indicating that CXCL16 may play an important role in the development and progression of atherosclerotic vascular disease.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Chandrasekar, B (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	chandraseka@uthscsa.edu	Mummidi, Srinivas/C-1004-2008; Mummidi, Srinivas/H-3335-2017	Mummidi, Srinivas/0000-0002-4068-6380; Mummidi, Srinivas/0000-0002-4068-6380	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068020] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68020] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chandrasekar B, 2003, J BIOL CHEM, V278, P4675, DOI 10.1074/jbc.M207006200; Chandrasekar B, 2003, BIOCHEM J, V373, P547, DOI 10.1042/BJ20030207; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Garton KJ, 2001, J BIOL CHEM, V276, P37993; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Han YL, 2001, J CLIN INVEST, V108, P425, DOI 10.1172/JCI12629; Heydtmann M, 2002, GUT, V50, P150, DOI 10.1136/gut.50.2.150; Hofnagel O, 2002, ARTERIOSCL THROM VAS, V22, P710, DOI 10.1161/01.ATV.0000012402.85056.45; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kim CH, 2001, J CLIN INVEST, V107, P595, DOI 10.1172/JCI11902; Kim CH, 2002, BLOOD, V100, P11, DOI 10.1182/blood-2001-12-0196; Matloubian M, 2000, NAT IMMUNOL, V1, P298, DOI 10.1038/79738; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Minami M, 2001, ARTERIOSCL THROM VAS, V21, P1796, DOI 10.1161/hq1001.096652; Nakayama T, 2003, J IMMUNOL, V170, P1136, DOI 10.4049/jimmunol.170.3.1136; Onuffer JJ, 2002, TRENDS PHARMACOL SCI, V23, P459, DOI 10.1016/S0165-6147(02)02064-3; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Shashkin P, 2003, ARTERIOSCL THROM VAS, V23, P148, DOI 10.1161/01.ATV.0000043906.61088.4B; Shimaoka T, 2003, J IMMUNOL, V171, P1647, DOI 10.4049/jimmunol.171.4.1647; Shimaoka T, 2000, J BIOL CHEM, V275, P40663, DOI 10.1074/jbc.C000761200; Terkeltaub R, 1998, CURR OPIN LIPIDOL, V9, P397, DOI 10.1097/00041433-199810000-00003; Troyer DA, 1997, CLIN EXP IMMUNOL, V108, P58, DOI 10.1046/j.1365-2249.1997.d01-970.x; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; Unutmaz D, 2000, J IMMUNOL, V165, P3284, DOI 10.4049/jimmunol.165.6.3284; Wilbanks A, 2001, J IMMUNOL, V166, P5145, DOI 10.4049/jimmunol.166.8.5145	29	128	142	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3188	3196		10.1074/jbc.M311660200	http://dx.doi.org/10.1074/jbc.M311660200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14625285	hybrid			2022-12-25	WOS:000188379600008
J	Papoucheva, E; Dumuis, A; Sebben, M; Richter, DW; Ponimaskin, EG				Papoucheva, E; Dumuis, A; Sebben, M; Richter, DW; Ponimaskin, EG			The 5-hydroxytryptamine(1A) receptor is stably palmitoylated, and acylation is critical for communication of receptor with G(i) protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTOR; CARBOXYL-TERMINAL DOMAIN; 5-HT1A RECEPTOR; SIGNALING PATHWAYS; COUPLED RECEPTORS; ADENYLYL-CYCLASE; SF9 CELLS; MEDIATED INHIBITION; LIPID MODIFICATIONS	In the present study, we verified that the mouse 5-hydroxytryptamine(1A) (5-HT1A) receptor is modified by palmitic acid, which is covalently attached to the protein through a thioester-type bond. Palmitoylation efficiency was not modulated by receptor stimulation with agonists. Block of protein synthesis by cycloheximide resulted in a significant reduction of receptor acylation, suggesting that palmitoylation occurs early after synthesis of the 5-HT1A receptor. Furthermore, pulse-chase experiments demonstrated that fatty acids are stably attached to the receptor. Two conserved cysteine residues 417 and 420 located in the proximal C-terminal domain were identified as acylation sites by site-directed mutagenesis. To address the functional role of 5-HT1A receptor acylation, we have analyzed the ability of acylation-deficient mutants to interact with heterotrimeric G(i) protein and to modulate downstream effectors. Replacement of individual cysteine residues (417 or 420) resulted in a significantly reduced coupling of receptor with G(i) protein and impaired inhibition of adenylyl cyclase activity. When both palmitoylated cysteines were replaced, the communication of receptors with Galpha(i) subunits was completely abolished. Moreover, non-palmitoylated mutants were no longer able to inhibit forskolin-stimulated cAMP formation, indicating that palmitoylation of the 5-HT1A receptor is critical for the enabling of G(i) protein coupling/effector signaling. The receptor-dependent activation of extracellular signal-regulated kinase was also affected by acylation-deficient mutants, suggesting the importance of receptor palmitoylation for the signaling through the Gbetagamma-mediated pathway, in addition to the Galpha(i)-mediated signaling.	Univ Gottingen, Inst Physiol, Abt Neuro & Sinnesphysiol, D-37073 Gottingen, Germany; CNRS, UPR 9023, F-34094 Montpellier 5, France	University of Gottingen; Centre National de la Recherche Scientifique (CNRS)	Ponimaskin, EG (corresponding author), Univ Gottingen, Inst Physiol, Abt Neuro & Sinnesphysiol, Humboldtallee 23, D-37073 Gottingen, Germany.	evgeni@ukps.gwdg.de		Ponimaskin, evgeni/0000-0002-4570-5130				ALBERT PR, 1994, VITAM HORM, V48, P59, DOI 10.1016/S0083-6729(08)60496-3; ANDRADE R, 1986, SCIENCE, V234, P1261, DOI 10.1126/science.2430334; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; BIJMAKERS MJ, 2003, TRENDS CELL BIOL, V13, P32; Blanpain C, 2001, J BIOL CHEM, V276, P23795, DOI 10.1074/jbc.M100583200; BOESS FG, 1994, NEUROPHARMACOLOGY, V33, P275, DOI 10.1016/0028-3908(94)90059-0; Boutin JA, 1997, CELL SIGNAL, V9, P15, DOI 10.1016/S0898-6568(96)00100-3; BOUVIER M, 1995, BIOCHEM SOC T, V23, P577, DOI 10.1042/bst0230577; BOUVIER M, 1995, METHOD ENZYMOL, V250, P300; BOUVIER M, 1995, BIOCHEM SOC T, V23, P116, DOI 10.1042/bst0230116; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; Chen CA, 2000, J BIOL CHEM, V275, P23516, DOI 10.1074/jbc.M003439200; Clarke WP, 1996, J PHARMACOL EXP THER, V277, P1259; Clawges HM, 1997, BIOCHEMISTRY-US, V36, P12930, DOI 10.1021/bi970112b; Cramer H, 2001, EUR J BIOCHEM, V268, P5449, DOI 10.1046/j.0014-2956.2001.02486.x; DEVIVO M, 1986, J PHARMACOL EXP THER, V238, P248; DUMUIS A, 1988, MOL PHARMACOL, V33, P178; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; FARGIN A, 1989, J BIOL CHEM, V264, P14848; Fragoso R, 2003, J IMMUNOL, V170, P913, DOI 10.4049/jimmunol.170.2.913; Gao ZH, 1999, BIOCHEM J, V342, P387, DOI 10.1042/0264-6021:3420387; Garnovskaya MN, 1996, BIOCHEMISTRY-US, V35, P13716, DOI 10.1021/bi961764n; Gurdal H, 1997, MOL PHARMACOL, V52, P1064, DOI 10.1124/mol.52.6.1064; HALL MD, 1985, J NEUROCHEM, V44, P1685, DOI 10.1111/j.1471-4159.1985.tb07155.x; HAMON M, 1984, EUR J PHARMACOL, V100, P263, DOI 10.1016/0014-2999(84)90002-5; Hawtin SR, 2001, J BIOL CHEM, V276, P38139; Hayashi MK, 1997, ARCH BIOCHEM BIOPHYS, V340, P376, DOI 10.1006/abbi.1997.9906; Heisler LK, 1998, P NATL ACAD SCI USA, V95, P15049, DOI 10.1073/pnas.95.25.15049; Hiol A, 2003, J BIOL CHEM, V278, P19301, DOI 10.1074/jbc.M210123200; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Kalinina EV, 2003, J BIOL CHEM, V278, P9244, DOI 10.1074/jbc.M209379200; KARSCHIN A, 1991, P NATL ACAD SCI USA, V88, P5694, DOI 10.1073/pnas.88.13.5694; KENNEDY ME, 1994, J BIOL CHEM, V269, P31915; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; Li M, 2002, J VIROL, V76, P11845, DOI 10.1128/JVI.76.23.11845-11852.2002; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; LIU YF, 1991, J BIOL CHEM, V266, P23689; Liu YF, 1999, J BIOL CHEM, V274, P16444, DOI 10.1074/jbc.274.23.16444; Loisel TP, 1996, BIOCHEMISTRY-US, V35, P15923, DOI 10.1021/bi9611321; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Miggin SM, 2003, J BIOL CHEM, V278, P6947, DOI 10.1074/jbc.M210637200; MOENCH SJ, 1994, BIOCHEMISTRY-US, V33, P5791, DOI 10.1021/bi00185a017; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; MULHERON JG, 1994, J BIOL CHEM, V269, P12954; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; MUMBY SM, 1995, BIOCHEM SOC T, V23, P156, DOI 10.1042/bst0230156; NEBIGIL CG, 1995, BIOCHEMISTRY-US, V34, P11954, DOI 10.1021/bi00037a037; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; Niethammer P, 2002, J CELL BIOL, V157, P521, DOI 10.1083/jcb.200109059; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; Okamoto Y, 1998, J CARDIOVASC PHARM, V31, pS230, DOI 10.1097/00005344-199800001-00064; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parks CL, 1998, P NATL ACAD SCI USA, V95, P10734, DOI 10.1073/pnas.95.18.10734; Patterson SI, 2002, BIOL RES, V35, P139, DOI 10.4067/S0716-97602002000200005; Ponimaskin E, 1998, FEBS LETT, V429, P370, DOI 10.1016/S0014-5793(98)00638-3; Ponimaskin EG, 2002, J BIOL CHEM, V277, P2534, DOI 10.1074/jbc.M106529200; Ponimaskin EG, 2001, BIOCHEM J, V353, P627, DOI 10.1042/0264-6021:3530627; Qanbar R, 2003, PHARMACOL THERAPEUT, V97, P1, DOI 10.1016/S0163-7258(02)00300-5; Ramboz S, 1998, P NATL ACAD SCI USA, V95, P14476, DOI 10.1073/pnas.95.24.14476; Raymond JR, 1999, BRIT J PHARMACOL, V127, P1751, DOI 10.1038/sj.bjp.0702723; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; *SPSS INC, 2002, SIGMAPLOT 8 02; Stevens PA, 2001, J BIOL CHEM, V276, P35883, DOI 10.1074/jbc.M103816200; VANKOPPEN CJ, 1991, J NEUROCHEM, V57, P1873, DOI 10.1111/j.1471-4159.1991.tb06397.x; VARRAULT A, 1992, MOL PHARMACOL, V41, P999; VEIT M, 1994, FEBS LETT, V339, P160, DOI 10.1016/0014-5793(94)80406-0; Wedegaertner PB, 1998, BIOL SIGNAL RECEPT, V7, P125; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; ZGOMBICK JM, 1989, MOL PHARMACOL, V35, P484	72	62	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3280	3291		10.1074/jbc.M308177200	http://dx.doi.org/10.1074/jbc.M308177200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14604995	hybrid			2022-12-25	WOS:000188379600019
J	Vrabioiu, AM; Gerber, SA; Gygi, SP; Field, CM; Mitchison, TJ				Vrabioiu, AM; Gerber, SA; Gygi, SP; Field, CM; Mitchison, TJ			The majority of the Saccharomyces cerevisiae septin complexes do not exchange guanine nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; GENE-PRODUCT; MICROTUBULE DYNAMICS; POLYACRYLAMIDE-GELS; MAMMALIAN SEPTIN; BUDDING YEAST; BUD NECK; FILAMENTS; GTP; LOCALIZATION	We show here that affinity-purified Saccharomyces cerevisiae septin complexes contain stoichiometric amounts of guanine nucleotides, specifically GTP and GDP. Using a N-15-dilution assay read-out by liquid chromatography-tandem mass spectrometry, we determined that the majority of the bound guanine nucleotides do not turn over in vivo during one cell cycle period. In vitro, the isolated S. cerevisiae septin complexes have similar GTP binding and hydrolytic properties to the Drosophila septin complexes (Field, C. M., al-Awar, O., Rosenblatt, J., Wong, M. L., Alberts, B., and Mitchison, T. J. (1996) J. Cell Biol. 133, 605-616). In particular, the GTP turnover of septins is very slow when compared with the GTP turnover for Ras-like GTPases. We conclude that bound GTP and GDP play a structural, rather then regulatory, role for the majority of septins in proliferating cells as GTP does for alpha-tubulin.	Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Taplin Biol Mass Spectrometry Facil, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Vrabioiu, AM (corresponding author), Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.	alina_vrabioiu@student.hms.harvard.edu		Gerber, Scott/0000-0002-2964-5051	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023928] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23928] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGELASTRO JM, 1992, J BIOL CHEM, V267, P25685; ANGELASTRO JM, 1992, ANAL BIOCHEM, V204, P47, DOI 10.1016/0003-2697(92)90137-V; Beites CL, 1999, NAT NEUROSCI, V2, P434, DOI 10.1038/8100; Bi EF, 1996, MOL CELL BIOL, V16, P5264; BYERS B, 1976, J CELL BIOL, V69, P717, DOI 10.1083/jcb.69.3.717; Carroll CW, 1998, J CELL BIOL, V143, P709, DOI 10.1083/jcb.143.3.709; Casamayor A, 2003, MOL CELL BIOL, V23, P2762, DOI 10.1128/MCB.23.8.2762-2777.2003; Castillon GA, 2003, CURR BIOL, V13, P654, DOI 10.1016/S0960-9822(03)00247-1; DAVIS A, 1994, SCIENCE, V264, P839, DOI 10.1126/science.8171338; DeMarini DJ, 1997, J CELL BIOL, V139, P75, DOI 10.1083/jcb.139.1.75; Dent J, 2002, P NATL ACAD SCI USA, V99, P3064, DOI 10.1073/pnas.052715199; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Field CM, 1996, J CELL BIOL, V133, P605, DOI 10.1083/jcb.133.3.605; FORD SK, 1991, DEV GENET, V12, P281, DOI 10.1002/dvg.1020120405; Frazier JA, 1998, J CELL BIOL, V143, P737, DOI 10.1083/jcb.143.3.737; HAARER BK, 1987, MOL CELL BIOL, V7, P3678, DOI 10.1128/MCB.7.10.3678; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; Hsu SC, 1998, NEURON, V20, P1111, DOI 10.1016/S0896-6273(00)80493-6; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; KIM HB, 1991, J CELL BIOL, V112, P535, DOI 10.1083/jcb.112.4.535; Kinoshita M, 2002, DEV CELL, V3, P791, DOI 10.1016/S1534-5807(02)00366-0; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Longtine MS, 2003, TRENDS CELL BIOL, V13, P403, DOI 10.1016/S0962-8924(03)00151-X; Mendoza M, 2002, CURR BIOL, V12, P1858, DOI 10.1016/S0960-9822(02)01258-7; Mingorance J, 2001, MOL MICROBIOL, V41, P83, DOI 10.1046/j.1365-2958.2001.02498.x; Mortensen EM, 2002, MOL BIOL CELL, V13, P2091, DOI 10.1091/mbc.01-10-0500; NATH JP, 1985, BIOCHEMISTRY-US, V24, P1555, DOI 10.1021/bi00327a040; NEUFELD TP, 1994, CELL, V77, P371, DOI 10.1016/0092-8674(94)90152-X; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Nguyen TQ, 2000, J CELL SCI, V113, P3825; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; ROSENBLATT J, 1995, MOL BIOL CELL, V6, P227, DOI 10.1091/mbc.6.2.227; Sanders SL, 1996, J CELL BIOL, V134, P413, DOI 10.1083/jcb.134.2.413; Sheffield PJ, 2003, J BIOL CHEM, V278, P3483, DOI 10.1074/jbc.M209701200; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SPIEGELMAN BM, 1977, CELL, V12, P587, DOI 10.1016/0092-8674(77)90259-8; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Stensballe A, 2001, PROTEOMICS, V1, P207, DOI 10.1002/1615-9861(200102)1:2<207::AID-PROT207>3.3.CO;2-V; VARMA A, 1985, MOL GEN GENET, V201, P1, DOI 10.1007/BF00397977; Yates JR, 1998, ANAL CHEM, V70, P3557, DOI 10.1021/ac980122y	40	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					3111	3118		10.1074/jbc.M310941200	http://dx.doi.org/10.1074/jbc.M310941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14597621	hybrid			2022-12-25	WOS:000188211300092
J	Fischer, DF; De Vos, RAI; Van Dijk, R; De Vrij, FMS; Proper, EA; Sonnemans, MAF; Verhage, MC; Sluijs, JA; Hobo, B; Zouambia, M; Steur, ENHJ; Kamphorst, W; Hol, EM; Van Leeuwen, FW				Fischer, DF; De Vos, RAI; Van Dijk, R; De Vrij, FMS; Proper, EA; Sonnemans, MAF; Verhage, MC; Sluijs, JA; Hobo, B; Zouambia, M; Steur, ENHJ; Kamphorst, W; Hol, EM; Van Leeuwen, FW			Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain	FASEB JOURNAL			English	Article						tauopathies; synucleinopathies; molecular misreading; UBB+1; lentivirus	ALPHA-SYNUCLEIN INCLUSIONS; TAU GENE-MUTATIONS; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; FRAMESHIFT MUTATIONS; DEGRADATION; FREQUENCY; PROTEIN; SYSTEM; PATHOGENESIS	Molecular misreading of the ubiquitin-B (UBB) gene results in a dinucleotide deletion in UBB mRNA. The resulting mutant protein, UBB+1, accumulates in the neuropathological hallmarks of Alzheimer disease. In vitro, UBB+1 inhibits proteasomal proteolysis, although it is also an ubiquitin fusion degradation substrate for the proteasome. Using the ligase chain reaction to detect dinucleotide deletions, we report here that UBB+1 transcripts are present in each neurodegenerative disease studied (tauo- and synucleinopathies) and even in control brain samples. In contrast to UBB+1 transcripts, UBB+1 protein accumulation in the ubiquitin-containing neuropathological hallmarks is restricted to the tauopathies such as Pick disease, frontotemporal dementia, progressive supranuclear palsy, and argyrophilic grain disease. Remarkably, UBB+1 protein is not detected in the major forms of synucleinopathies (Lewy body disease and multiple system atrophy). The neurologically intact brain can cope with UBB+1 as lentivirally delivered UBB+1 protein is rapidly degraded in rat hippocampus, whereas the K29,48R mutant of UBB+1, which is not ubiquitinated, is abundantly expressed. The finding that UBB+1 protein only accumulates in tauopathies thus implies that the ubiquitin-proteasome system is impaired specifically in this group of neurodegenerative diseases and not in synucleinopathies and that the presence of UBB+1 protein reports proteasomal dysfunction in the brain.	Netherlands Inst Brain Res, NL-1105 AZ Amsterdam, Netherlands; Grad Sch Neurosci Amsterdam, Amsterdam, Netherlands; Pathol Lab Oost Nederland & Med Spectrum Twente, Enschede, Netherlands; Utrecht Med Ctr, Rudolf Magnus Inst Neurosci, Utrecht, Netherlands; Univ Hosp Free Univ, Dept Neuropathol, Amsterdam, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Amsterdam; Medical Spectrum Twente; Utrecht University; Utrecht University Medical Center	Van Leeuwen, FW (corresponding author), Netherlands Inst Brain Res, Meibergdreef 33, NL-1105 AZ Amsterdam, Netherlands.	f.van.leeuwen@nih.knaw.nl	Hol, Elly M/F-1891-2013; de Vrij, Femke M.S./O-9706-2019; Hol, Elly/J-2025-2019	Hol, Elly M/0000-0001-5604-2603; de Vrij, Femke M.S./0000-0003-0825-3806; Hol, Elly/0000-0001-5604-2603; Fischer, David/0000-0002-6690-0197				Alves-Rodrigues A, 1998, TRENDS NEUROSCI, V21, P516, DOI 10.1016/S0166-2236(98)01276-4; BARANY F, 1991, P NATL ACAD SCI USA, V88, P189, DOI 10.1073/pnas.88.1.189; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Braak H, 1998, J NEURAL TRANSM, V105, P801, DOI 10.1007/s007020050096; Braak H, 2000, ANN NY ACAD SCI, V911, P221; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; De Vrij FMS, 2001, FASEB J, V15, P2680, DOI 10.1096/fj.01-0438com; EVANS DAP, 1994, P NATL ACAD SCI USA, V91, P6059, DOI 10.1073/pnas.91.13.6059; Fergusson J, 2000, NEUROSCI LETT, V279, P69, DOI 10.1016/S0304-3940(99)00917-9; Furukawa Y, 2002, ANN NEUROL, V51, P779, DOI 10.1002/ana.10207; Goedert M, 2001, CURR OPIN GENET DEV, V11, P343, DOI 10.1016/S0959-437X(00)00200-8; Hasegawa M, 2002, J BIOL CHEM, V277, P49071, DOI 10.1074/jbc.M208046200; Huitinga I, 2001, J NEUROPATH EXP NEUR, V60, P1208, DOI 10.1093/jnen/60.12.1208; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Ingram EM, 2002, TRENDS MOL MED, V8, P555, DOI 10.1016/S1471-4914(02)02440-1; Jicha GA, 1997, J NEUROSCI RES, V48, P128, DOI 10.1002/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E; Keck S, 2003, J NEUROCHEM, V85, P115, DOI 10.1046/j.1471-4159.2003.01642.x; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Lam YA, 2000, P NATL ACAD SCI USA, V97, P9902, DOI 10.1073/pnas.170173897; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Lindsten K, 2002, J CELL BIOL, V157, P417, DOI 10.1083/jcb.200111034; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; McNaught KSP, 2002, NEUROSCI LETT, V326, P155, DOI 10.1016/S0304-3940(02)00296-3; McPhaul LW, 2002, GASTROENTEROLOGY, V122, P1878, DOI 10.1053/gast.2002.33629; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Poorkaj P, 2001, ARCH NEUROL-CHICAGO, V58, P383, DOI 10.1001/archneur.58.3.383; Schwartz AL, 1999, ANNU REV MED, V50, P57; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shringarpure R, 2003, J BIOL CHEM, V278, P311, DOI 10.1074/jbc.M206279200; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Swaab DF, 1998, PROG BRAIN RES, V117, P343; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Van Broeckhoven C, 1998, PROG BRAIN RES, V117, P315; van den Hurk WH, 2001, J BIOL CHEM, V276, P11496, DOI 10.1074/jbc.M011040200; van Leeuwen FW, 2000, NEUROBIOL AGING, V21, P879, DOI 10.1016/S0197-4580(00)00151-2; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; van Leeuwen FW, 1998, TRENDS NEUROSCI, V21, P331, DOI 10.1016/S0166-2236(98)01280-6; WIEDMANN M, 1994, PCR METH APPL, V3, pS51	46	99	103	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2003	17	14					2014	2024		10.1096/fj.03-0205com	http://dx.doi.org/10.1096/fj.03-0205com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	750AA	14597671				2022-12-25	WOS:000186961200038
J	Eichmuller, S; Vezzoli, V; Bazzini, C; Ritter, M; Furst, J; Jakab, M; Ravasio, A; Chwatal, S; Dossena, S; Botta, G; Meyer, G; Maier, B; Valenti, G; Lang, F; Paulmichl, M				Eichmuller, S; Vezzoli, V; Bazzini, C; Ritter, M; Furst, J; Jakab, M; Ravasio, A; Chwatal, S; Dossena, S; Botta, G; Meyer, G; Maier, B; Valenti, G; Lang, F; Paulmichl, M			A new gene-finding tool - Using the Caenorhabditis elegans operons for identifying functional partner proteins in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA; ORGANIZATION	How can a large number of different phenotypes be generated by a limited number of genotypes? Promiscuity between different, structurally related and/or unrelated proteins seems to provide a plausible explanation to this pertinent question. Strategies able to predict such functional interrelations between different proteins are important to restrict the number of putative candidate proteins, which can then be subjected to time-consuming functional tests. Here we describe the use of the operon structure of the nematode genome to identify partner proteins in human cells. In this work we focus on ion channels proteins, which build an interface between the cell and the outside world and are responsible for a growing number of diseases in humans. However, the proposed strategy for the partner protein quest is not restricted to this scientific area but can be adopted in virtually every field of human biology where protein-protein interactions are assumed.	Univ Innsbruck, Inst Physiol, A-6020 Innsbruck, Austria; Univ Tubingen, Dept Physiol, D-72076 Tubingen, Germany; Univ Bari, Dept Gen & Environm Physiol, I-70100 Bari, Italy; Univ Milan, Dept Biomol Sci & Biotechnol, I-20133 Milan, Italy	University of Innsbruck; Eberhard Karls University of Tubingen; Universita degli Studi di Bari Aldo Moro; University of Milan	Paulmichl, M (corresponding author), Univ Innsbruck, Inst Physiol, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	markus.paulmichl@unimi.it	Meyer, Giuliano/G-8062-2011; Ritter, Markus/AAG-4987-2020; Ravasio, Andrea/G-6167-2011; Bazzini, Claudia/G-8214-2011; Ravasio, Andrea/H-6722-2012; Dossena, Silvia/G-1437-2018	Ritter, Markus/0000-0001-7346-7750; Ravasio, Andrea/0000-0001-7835-5133; VALENTI, GIOVANNA/0000-0003-0233-0778; Vezzoli, Valeria/0000-0001-6396-7284				Ahringer J, 1997, CURR OPIN GENET DEV, V7, P410, DOI 10.1016/S0959-437X(97)80157-8; Ashcroft FM, 2000, ION CHANNELS DIS; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Blumenthal T, 2002, NATURE, V417, P851, DOI 10.1038/nature00831; Blumenthal Thomas, 2003, Nature Reviews Genetics, V4, P112; Culetto E, 2000, HUM MOL GENET, V9, P869, DOI 10.1093/hmg/9.6.869; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Furst J, 2002, J BIOL CHEM, V277, P4435, DOI 10.1074/jbc.M107372200; Hille B., 1992, IONIC CHANNELS EXCIT; Huang T, 2001, MOL CELL BIOL, V21, P1111, DOI 10.1128/MCB.21.4.1111-1120.2001; Hubner CA, 2002, HUM MOL GENET, V11, P2435, DOI 10.1093/hmg/11.20.2435; Jobin CM, 2003, BIOCHEMISTRY-US, V42, P11716, DOI 10.1021/bi035066w; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kato Y, 2002, BIOCHEM J, V361, P221, DOI 10.1042/0264-6021:3610221; Lawrence JG, 2002, CELL, V110, P407, DOI 10.1016/S0092-8674(02)00900-5; Maniatis T., 1982, MOL CLONING LAB MANU; MILLER C, 2000, GENOME BIOL; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; Nilsen TW, 2001, TRENDS GENET, V17, P678, DOI 10.1016/S0168-9525(01)02499-4; NOMURA M, 1976, CELL, V9, P633, DOI 10.1016/0092-8674(76)90127-6; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; Ritter M, 2003, J BIOL CHEM, V278, P50163, DOI 10.1074/jbc.M300374200; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; Treinin M, 1998, P NATL ACAD SCI USA, V95, P15492, DOI 10.1073/pnas.95.26.15492; Wheelan SJ, 1999, GENE, V238, P163, DOI 10.1016/S0378-1119(99)00298-X	25	7	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7136	7146		10.1074/jbc.M307347200	http://dx.doi.org/10.1074/jbc.M307347200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14615488	hybrid			2022-12-25	WOS:000188969200113
J	Schwarz, A; Tutsch, E; Ludwig, B; Schwarz, EC; Stallmach, A; Hoth, M				Schwarz, A; Tutsch, E; Ludwig, B; Schwarz, EC; Stallmach, A; Hoth, M			Ca2+ signaling in identified T-lymphocytes from human intestinal mucosa - Relation to hyporeactivity, proliferation, and inflammatory bowel disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMINA PROPRIA LYMPHOCYTES; CAPACITATIVE CALCIUM-ENTRY; CROHNS-DISEASE; STORE DEPLETION; CRAC CHANNELS; IN-VIVO; CELLS; ACTIVATION; MECHANISMS; TOLERANCE	Ca2+ entry across the plasma membrane is necessary for the activation and proliferation of T- lymphocytes. Human intestinal lamina propria lymphocytes physiologically exhibit minimal proliferation in response to antigen receptor stimulation when compared with peripheral blood T- lymphocytes. This hyporeactivity is partially abolished in inflammatory bowel disease. We hypothesized that differences in Ca2+ signaling could be related to the disease. To test this possibility, we measured Ca2+ signals in identified lymphocytes from human blood and human intestinal mucosa. Ca2+ signals in lamina propria T- lymphocytes from non- inflamed tissue were drastically reduced when compared with Ca2+ signals of blood T- lymphocytes from the same persons. However, Ca2+ signals in T- lymphocytes from inflamed intestinal mucosa were much higher than the ones from non- inflamed mucosa and almost reached levels of Ca2+ signals in peripheral blood T- cells. Furthermore, Ca2+ influx was closely linked to cell proliferation in both peripheral blood T- lymphocytes and lamina propria lymphocytes cells. We conclude that differences in Ca2+ signaling can explain the differences of T- lymphocyte reactivity in blood versus lamina propria and, importantly, also between T- lymphocytes from inflamed and non- inflamed intestinal mucosa. Ca2+ channels in the plasma membrane of T- lymphocytes might thus prove an excellent target to screen for immunosuppressiva to potentially treat the symptoms of inflammatory bowel disease.	Univ Saarland, Dept Physiol, D-66421 Homburg, Germany; Univ Saarland, Dept Internal Med 2, D-66421 Homburg, Germany	Saarland University; Saarland University	Hoth, M (corresponding author), Univ Saarland, Inst Physiol, Gebaude 58, D-66421 Homburg, Germany.	markus.hoth@uniklinik-saarland.de		Hoth, Markus/0000-0001-7080-4643; Schwarz, Eva C./0000-0002-6503-4864				Asai K, 2002, J IMMUNOL, V169, P4723, DOI 10.4049/jimmunol.169.9.4723; AUTSCHBACH F, 1995, VIRCHOWS ARCH, V426, P51; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; DEMARIA R, 1993, EUR J IMMUNOL, V23, P3104, DOI 10.1002/eji.1830231209; Duchmann R, 1995, CLIN EXP IMMUNOL, V102, P448; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; HOTH M, 1995, PFLUG ARCH EUR J PHY, V430, P315, DOI 10.1007/BF00373905; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Ina K, 1999, J IMMUNOL, V163, P1081; Kellermann SA, 2001, J IMMUNOL, V167, P682, DOI 10.4049/jimmunol.167.2.682; LEDEIST F, 1995, BLOOD, V85, P1053, DOI 10.1182/blood.V85.4.1053.bloodjournal8541053; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Liu ZJ, 2000, J IMMUNOL, V164, P3608, DOI 10.4049/jimmunol.164.7.3608; Macian F, 2002, CELL, V109, P719, DOI 10.1016/S0092-8674(02)00767-5; Mowat AM, 2003, NAT REV IMMUNOL, V3, P331, DOI 10.1038/nri1057; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PARTISETI M, 1994, J BIOL CHEM, V269, P32327; PIRZER U, 1991, LANCET, V338, P1238, DOI 10.1016/0140-6736(91)92104-A; PIRZER UC, 1990, EUR J IMMUNOL, V20, P2339, DOI 10.1002/eji.1830201025; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; QIAO L, 1993, GASTROENTEROLOGY, V105, P814, DOI 10.1016/0016-5085(93)90899-N; QIAO L, 1991, GASTROENTEROLOGY, V101, P1529, DOI 10.1016/0016-5085(91)90388-2; Schwartz RH, 2003, ANNU REV IMMUNOL, V21, P305, DOI 10.1146/annurev.immunol.21.120601.141110; Stallmach A, 2001, EUR J IMMUNOL, V31, P1228, DOI 10.1002/1521-4141(200104)31:4<1228::AID-IMMU1228>3.0.CO;2-K; ULLRICH R, 1995, ADV EXP MED BIOL, V371, P1281; Westermann J, 2001, ANN INTERN MED, V135, P279, DOI 10.7326/0003-4819-135-4-200108210-00013; ZEITZ M, 1988, GASTROENTEROLOGY, V94, P353, DOI 10.1016/0016-5085(88)90422-2; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	31	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5641	5647		10.1074/jbc.M309317200	http://dx.doi.org/10.1074/jbc.M309317200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14585840	hybrid			2022-12-25	WOS:000188776500074
J	Wei, SJ; Trempus, CS; Ali, RC; Hansen, LA; Tennant, RW				Wei, SJ; Trempus, CS; Ali, RC; Hansen, LA; Tennant, RW			12-O-tetradecanoylphorbol-13-acetate and UV radiation-induced nucleoside diphosphate protein kinase B mediates neoplastic transformation of epidermal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METASTASIS-SUPPRESSOR GENES; ENERGY PHOSPHATE TRANSFER; HETEROTRIMERIC G-PROTEINS; MYELOID-LEUKEMIA CELLS; TRANSGENIC TG.AC MICE; STEM-CELLS; NM23 GENE; PAPILLOMA DEVELOPMENT; SKIN CARCINOGENESIS; FUNCTIONAL-ANALYSIS	The molecular changes associated with early skin carcinogenesis are largely unknown. We have previously identified 11 genes whose expression was up- or down-regulated by 12-O-tetradecanoylphorbol-13-acetate (TPA) in mouse skin keratinocyte progenitor cells (Wei, S.-J., Trempus, C. S., Cannon, R. E., Bortner, C. D., and Tennant, R. W. (2003) J. Biol. Chem. 278, 1758-1768). Here, we show an induction of a nucleoside diphosphate protein kinase B (NDPK-B) gene in response to TPA or UV radiation (UVR). TPA or UVR significantly induced the expression of NDPK-B both in vivo hyperplastic mouse skin and in vitro mouse JB6 Cl 41-5a epidermal cells. Indeed, this gene was also up- regulated in TPA or UVR-mediated skin tumors including papillomas, spindle cell tumors, and squamous cell carcinomas, relative to adjacent normal skins. Functional studies by constitutive expression of nm23-M2/NDPK-B in TPA susceptible JB6 Cl 41-5a and TPA-resistant JB6 Cl 30-7b preneoplastic epidermal cell lines showed a remarkable gene dosage-dependent increase in foci-forming activity, as well as an enhancement in the efficiency of neoplastic transformation of these cells in soft agar but no effect on proliferation in monolayer cultures. Interestingly, stable transfection of the nm23-M2/NDPK-B delRGD or G106A mutant gene in JB6 Cl 41-5a cells selectively abrogated NDPK-B-induced cellular transformation, implicating a possible Arg(105)-Gly(106)-Asp(107) regulatory role in early skin carcinogenesis.	NIEHS, Natl Ctr Toxicogenom, NIH, Res Triangle Pk, NC 27709 USA; Creighton Univ, Sch Med, Dept Biomed Sci, Omaha, NE 68178 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Creighton University	Wei, SJ (corresponding author), NIEHS, Natl Ctr Toxicogenom, NIH, Bldg 101,Rm F-149,MD F1-05,POB 12233, Res Triangle Pk, NC 27709 USA.	wei2@niehs.nih.gov		Wei, Sung Jen/0000-0002-9810-9041	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES021175, K22ES000365] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agou F, 1999, J BIOL CHEM, V274, P19630, DOI 10.1074/jbc.274.28.19630; Anzinger J, 2001, P W PHARMACOL SOC, V44, P61; Arnold I, 2001, CURR BIOL, V11, P558, DOI 10.1016/S0960-9822(01)00154-3; BACKER JM, 1993, ONCOGENE, V8, P497; BERBERICH SJ, 1995, ONCOGENE, V10, P2343; BOMINAAR AA, 1993, EMBO J, V12, P2275, DOI 10.1002/j.1460-2075.1993.tb05881.x; Caligo MA, 1996, LEUKEMIA RES, V20, P161, DOI 10.1016/0145-2126(95)00122-0; CALIGO MA, 1995, INT J CANCER, V60, P837, DOI 10.1002/ijc.2910600619; Cannon RE, 1997, MOL CARCINOGEN, V20, P108, DOI 10.1002/(SICI)1098-2744(199709)20:1<108::AID-MC12>3.0.CO;2-5; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; COX AD, 1994, METHOD ENZYMOL, V238, P277; Crackower MA, 1996, HUM MOL GENET, V5, P571, DOI 10.1093/hmg/5.5.571; Cuello F, 2003, J BIOL CHEM, V278, P7220, DOI 10.1074/jbc.M210304200; DEAROLF CR, 1988, DEV BIOL, V129, P169, DOI 10.1016/0012-1606(88)90171-6; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FRENCH JE, 1994, MOL CARCINOGEN, V11, P215, DOI 10.1002/mc.2940110407; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; HANSEN LA, 1994, MOL CARCINOGEN, V9, P143, DOI 10.1002/mc.2940090306; Hippe HJ, 2003, J BIOL CHEM, V278, P7227, DOI 10.1074/jbc.M210305200; IZUMIYA H, 1995, J BIOL CHEM, V270, P27859, DOI 10.1074/jbc.270.46.27859; Joosten M, 2002, ONCOGENE, V21, P7247, DOI 10.1038/sj.onc.1205813; KANTOR JD, 1993, CANCER RES, V53, P1971; KEIM D, 1992, J CLIN INVEST, V89, P919, DOI 10.1172/JCI115672; KIMURA N, 1990, J BIOL CHEM, V265, P15744; Kojic M, 2003, MOL CELL, V12, P1043, DOI 10.1016/S1097-2765(03)00367-8; Kraeft SK, 1996, EXP CELL RES, V227, P63, DOI 10.1006/excr.1996.0250; LACOMBE ML, 1991, EUR J CANCER, V27, P1302, DOI 10.1016/0277-5379(91)90101-I; Lascu I, 2000, J BIOENERG BIOMEMBR, V32, P237, DOI 10.1023/A:1005532912212; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; Lu Q, 1996, J BIOL CHEM, V271, P32886, DOI 10.1074/jbc.271.51.32886; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; Masse K, 2002, GENE, V296, P87, DOI 10.1016/S0378-1119(02)00836-3; Munier A, 1998, FEBS LETT, V434, P289, DOI 10.1016/S0014-5793(98)00996-X; Okabe-Kado J, 2002, LEUKEMIA RES, V26, P569, DOI 10.1016/S0145-2126(01)00171-0; OKABEKADO J, 1988, J BIOL CHEM, V263, P10994; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; OKABEKADO J, 1995, FEBS LETT, V363, P311, DOI 10.1016/0014-5793(95)00338-A; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; Postel EH, 2002, BIOCHEMISTRY-US, V41, P6330, DOI 10.1021/bi025606+; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Postel EH, 1996, P NATL ACAD SCI USA, V93, P6892, DOI 10.1073/pnas.93.14.6892; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; Postel EH, 2000, P NATL ACAD SCI USA, V97, P14194, DOI 10.1073/pnas.97.26.14194; Schaertl S, 1999, J BIOL CHEM, V274, P20159, DOI 10.1074/jbc.274.29.20159; SHIMADA N, 1993, J BIOL CHEM, V268, P2583; SPALDING JW, 1993, CARCINOGENESIS, V14, P1335, DOI 10.1093/carcin/14.7.1335; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1993, BREAST CANCER RES TR, V25, P175, DOI 10.1007/BF00662142; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEEG PS, 1989, INVAS METAST, V9, P351; Timmons L, 2000, J BIOENERG BIOMEMBR, V32, P293, DOI 10.1023/A:1005545214937; Trempus CS, 2003, J INVEST DERMATOL, V120, P501, DOI 10.1046/j.1523-1747.2003.12088.x; Trempus CS, 1998, J INVEST DERMATOL, V111, P445, DOI 10.1046/j.1523-1747.1998.00237.x; Tsuiki H, 2000, J CELL BIOCHEM, V76, P254, DOI 10.1002/(SICI)1097-4644(20000201)76:2<254::AID-JCB9>3.0.CO;2-G; URANO T, 1993, ONCOGENE, V8, P1371; URANO T, 1992, FEBS LETT, V309, P358, DOI 10.1016/0014-5793(92)80807-S; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; Waikel RL, 2001, NAT GENET, V28, P165, DOI 10.1038/88889; Wei SJ, 2003, J BIOL CHEM, V278, P1758, DOI 10.1074/jbc.M206328200; Willems R, 2002, EXP HEMATOL, V30, P640, DOI 10.1016/S0301-472X(02)00809-3; Willems R, 1998, J BIOL CHEM, V273, P13663, DOI 10.1074/jbc.273.22.13663; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	71	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5993	6004		10.1074/jbc.M310820200	http://dx.doi.org/10.1074/jbc.M310820200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14623877	hybrid			2022-12-25	WOS:000188776500115
J	Hartner, JC; Schmittwolf, C; Kispert, A; Muller, AM; Higuchi, M; Seeburg, PH				Hartner, JC; Schmittwolf, C; Kispert, A; Muller, AM; Higuchi, M; Seeburg, PH			Liver disintegration in the mouse embryo caused by deficiency in the RNA-editing enzyme ADAR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOXP SPACER REGION; ADENOSINE-DEAMINASE; TRANSCRIPTION FACTOR; FETAL LIVER; CANDIDATE ENZYME; MICE DEFICIENT; BINDING-FACTOR; STEM-CELLS; HEMATOPOIESIS; GENE	ADAR1 (adenosine deaminase acting on RNA-1) is widely expressed in mammals, but its biological role is unknown. We show here by gene targeting that ADAR1 selectively edits in vivo two of five closely spaced adenosines in the serotonin 5-hydroxytryptamine subtype 2C receptor pre-mRNA of nervous tissue; and hence, site-selective adenosine-to-inosine editing is indeed a function of ADAR1. Remarkably, homozygosity for two different null alleles of ADAR1 caused a consistent embryonic phenotype appearing early at embryonic day 11 and leading to death between embryonic days 11.5 and 12.5. This phenotype manifests a rapidly disintegrating liver structure, along with severe defects in definitive hematopoiesis, encompassing both erythroid and myeloid/granuloid progenitors as well as spleen colony-forming activity from the aorta-gonad-mesonephros region and fetal liver. Probably as a consequence of these developmental impairments, ADAR1-deficient embryonic stem cells failed to contribute to liver, bone marrow, spleen, thymus, and blood in adult chimeric mice. Thus, ADAR1 subserves critical steps in developing non-nervous tissue, which are likely to include transcript editing.	Max Planck Inst Med Res, Dept Mol Neurobiol, D-69120 Heidelberg, Germany; Univ Wurzburg, Inst Med Radiat & Cell Res, D-97078 Wurzburg, Germany; Hannover Med Sch, Inst Mol Biol, D-30625 Hannover, Germany	Max Planck Society; University of Wurzburg; Hannover Medical School	Seeburg, PH (corresponding author), Max Planck Inst Med Res, Dept Mol Neurobiol, Jahnstr 29, D-69120 Heidelberg, Germany.	seeburg@mpimf-heidelberg.mpg.de						Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Cai ZL, 2000, IMMUNITY, V13, P423, DOI 10.1016/S1074-7613(00)00042-X; Cho DSC, 2003, J BIOL CHEM, V278, P17093, DOI 10.1074/jbc.M213127200; Duncan SA, 2000, DEV DYNAM, V219, P131, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1051>3.3.CO;2-E; DZIERZAK E, 1995, TRENDS GENET, V11, P359, DOI 10.1016/S0168-9525(00)89107-6; FOWLER JH, 1967, J CELL PHYSIOL, V69, P65, DOI 10.1002/jcp.1040690109; Gallo A, 2003, EMBO J, V22, P3421, DOI 10.1093/emboj/cdg327; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; George CX, 1999, P NATL ACAD SCI USA, V96, P4621, DOI 10.1073/pnas.96.8.4621; Godin I, 2002, NAT REV IMMUNOL, V2, P593, DOI 10.1038/nri857; Herbert A, 1997, P NATL ACAD SCI USA, V94, P8421, DOI 10.1073/pnas.94.16.8421; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; HOESS RH, 1986, NUCLEIC ACIDS RES, V14, P2287, DOI 10.1093/nar/14.5.2287; Hogan B, 1994, MANIPULATING MOUSE E; JOHNSON GR, 1975, NATURE, V258, P726, DOI 10.1038/258726a0; Kask K, 1998, P NATL ACAD SCI USA, V95, P13777, DOI 10.1073/pnas.95.23.13777; Kaufman M.H., 1992, ATLAS MOUSE DEV; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; Lee G, 1998, GENE, V216, P55, DOI 10.1016/S0378-1119(98)00325-4; Liu Y, 1998, METHODS, V15, P199, DOI 10.1006/meth.1998.0624; Maas S, 1996, J BIOL CHEM, V271, P12221, DOI 10.1074/jbc.271.21.12221; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; Melcher T, 1996, J BIOL CHEM, V271, P31795, DOI 10.1074/jbc.271.50.31795; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; Nishina H, 1999, DEVELOPMENT, V126, P505; North T, 1999, DEVELOPMENT, V126, P2563; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; OGAWA M, 1993, DEVELOPMENT, V117, P1089; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Reimold AM, 2000, GENE DEV, V14, P152; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Seeburg PH, 2002, NEURON, V35, P17, DOI 10.1016/S0896-6273(02)00760-2; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Sumner R, 2000, ONCOGENE, V19, P3335, DOI 10.1038/sj.onc.1203660; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Wang Q, 2000, SCIENCE, V290, P1765, DOI 10.1126/science.290.5497.1765; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wang QD, 2000, J NEUROCHEM, V74, P1290; Watanabe T, 2002, DEV BIOL, V250, P332, DOI 10.1006/dbio.2002.0781; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Zaret KS, 2002, NAT REV GENET, V3, P499, DOI 10.1038/nrg837	50	352	362	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4894	4902		10.1074/jbc.M311347200	http://dx.doi.org/10.1074/jbc.M311347200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14615479	hybrid			2022-12-25	WOS:000188554300115
J	Johnson, DJD; Huntington, JA				Johnson, DJD; Huntington, JA			The influence of hinge region residue Glu-381 on antithrombin allostery and metastability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY HEPARIN; CONFORMATIONAL-CHANGE; BETA-ANTITHROMBIN; IN-VIVO; BINDING; ACTIVATION; PENTASACCHARIDE; PROTEINASES; ENHANCEMENT; THROMBOSIS	Antithrombin becomes an efficient inhibitor of factor Xa and thrombin by binding a specific pentasaccharide sequence found on a small fraction of the heparan sulfate proteoglycans lining the microvaculature. In the structure of native antithrombin, the reactive center loop is restrained due to the insertion of its hinge region into the main beta-sheet A, whereas in the heparin-activated state the reactive center loop is freed from beta-sheet A. In both structures, hinge region residue Glu-381 makes several stabilizing contacts. To determine the role of these contacts in the allosteric mechanism of antithrombin activation, we replaced Glu-381 with an alanine. This variant is less active toward its target proteases than control antithrombin, due to a perturbation of the equilibrium between the two forms, and to an increase in stoichiometry of inhibition. Pentasaccharide binding affinity is reduced 4-fold due to an increase in the off-rate. These data suggest that the main role of Glu-381 is to stabilize the activated conformation. Stability studies also showed that the E381A variant is resistant to continued insertion of its reactive center loop upon incubation at 50 degreesC, suggesting new stabilizing interactions in the native structure. To test this hypothesis, and to aid in the interpretation of the kinetic data we solved to 2.6 Angstrom the structure of the variant. We conclude that wild-type Glu-381 interactions stabilize the activated state and decreases the energy barrier to full loop insertion.	Univ Cambridge, Dept Haematol, Cambridge Inst Med Res, Div Struct Med,Thrombosis Res Unit, Cambridge CB2 2XY, England	University of Cambridge	Huntington, JA (corresponding author), Univ Cambridge, Dept Haematol, Cambridge Inst Med Res, Div Struct Med,Thrombosis Res Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	jah52@cam.ac.uk			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068629] Funding Source: NIH RePORTER; MRC [G117/444] Funding Source: UKRI; Medical Research Council [G117/444] Funding Source: Medline; NHLBI NIH HHS [R01 HL68629] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arocas V, 1999, BIOCHEMISTRY-US, V38, P10196, DOI 10.1021/bi990686b; Arocas V, 2001, J BIOL CHEM, V276, P43809, DOI 10.1074/jbc.M105294200; Beauchamp NJ, 1998, BLOOD, V92, P2696, DOI 10.1182/blood.V92.8.2696.420a43_2696_2706; Belzar KJ, 2000, J BIOL CHEM, V275, P8733, DOI 10.1074/jbc.275.12.8733; Belzar KJ, 2002, J BIOL CHEM, V277, P8551, DOI 10.1074/jbc.M110807200; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Desai U, 2000, J BIOL CHEM, V275, P18976, DOI 10.1074/jbc.M001340200; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Garone L, 1996, BIOCHEMISTRY-US, V35, P8881, DOI 10.1021/bi960542m; Huntington JA, 2000, J BIOL CHEM, V275, P15377, DOI 10.1074/jbc.275.20.15377; Huntington JA, 2003, J THROMB HAEMOST, V1, P1535, DOI 10.1046/j.1538-7836.2003.00305.x; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Johnson DJD, 2003, BIOCHEMISTRY-US, V42, P8712, DOI 10.1021/bi034524y; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; McCoy AJ, 2003, J MOL BIOL, V326, P823, DOI 10.1016/S0022-2836(02)01382-7; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mushunje A, 2003, BLOOD, V102, P4028, DOI 10.1182/blood-2003-05-1560; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1981, J BIOL CHEM, V256, P1073; Olson ST, 2002, TRENDS CARDIOVAS MED, V12, P331, DOI 10.1016/S1050-1738(02)00183-4; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Pike RN, 1997, J BIOL CHEM, V272, P19652, DOI 10.1074/jbc.272.32.19652; Quinsey NS, 2003, BIOCHEMISTRY-US, V42, P10169, DOI 10.1021/bi0349322; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; THUNBERG L, 1982, J BIOL CHEM, V257, P278; Turk B, 1997, BIOCHEMISTRY-US, V36, P6682, DOI 10.1021/bi9702492; Whisstock JC, 2000, J MOL BIOL, V301, P1287, DOI 10.1006/jmbi.2000.3982; Zettlmeissl G, 1988, Behring Inst Mitt, P26; Zhou AW, 2003, J BIOL CHEM, V278, P15116, DOI 10.1074/jbc.M211663200; Zhou AW, 1999, BLOOD, V94, P3388, DOI 10.1182/blood.V94.10.3388.422k20_3388_3396	34	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4913	4921		10.1074/jbc.M311644200	http://dx.doi.org/10.1074/jbc.M311644200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14623882	hybrid			2022-12-25	WOS:000188554300117
J	Kotera, J; Sasaki, T; Kobayashi, T; Fujishige, K; Yamashita, Y; Omori, K				Kotera, J; Sasaki, T; Kobayashi, T; Fujishige, K; Yamashita, Y; Omori, K			Subcellular localization of cyclic nucleotide phosphodiesterase type 10A variants, and alteration of the localization by cAMP-dependent protein kinase-dependent phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICE VARIANT; MESSENGER-RNA; PC12 CELLS; ACTIVATION; PDE10A; CGMP; DOPAMINE; RECEPTOR; GENE; TRANSLOCATION	Our previous studies have suggested that two phosphodiesterase type 10A (PDE10A) variants, PDE10A1 and PDE10A2 transcripts, are mainly expressed in humans and that PDE10A2 and PDE10A3 transcripts are major variants in rats. In the present study, immunoblot analysis demonstrated that PDE10A proteins, especially PDE10A2, are more abundant in membrane fractions than in cytosolic fractions of rat striatum. Recombinant PDE10A1 and PDE10A3 were produced only in cytosolic fractions of transfected PC12h cells. By contrast, recombinant PDE10A2 was present mainly in membrane fractions. This finding agreed well with the result of subcellular fractionation of PDE10A in rat striatum. Immunocytochemical analysis showed that PDE10A2 was localized in the Golgi apparatus of transfected PC12h cells. PDE10A2 was phosphorylated by cAMP-dependent protein kinase (PKA) at Thr(16). Interestingly, recombinant protein of wild-type PDE10A2, but not PDE10A2 mutant with an Ala replacement at Thr(16), was distributed to cytosolic fractions by co-transfection with a plasmid encoding the catalytic subunit of PKA. A PDE10A2 mutant with Glu substitution at Thr(16), which can be a mimic of phosphorylation, was localized in the cytosolic fractions of transfected PC12h cells. These observations implied that phosphorylation of PDE10A2 at Thr(16) by PKA caused alteration of subcellular localization of PDE10A2 from the Golgi apparatus to cytosol. It is hypothesized that cAMP signaling in the Golgi area and the cytosol in neurons is controlled through alteration of subcellular localization of PDE10A brought by activation of PKA in response to intracellular elevations of cAMP.	Tanabe Seiyaku Co Ltd, Discovery Res Lab, Toda, Saitama 3358505, Japan; Tanabe Seiyaku Co Ltd, Pharmacol Res Lab, Toda, Saitama 3358505, Japan; Tanabe Seiyaku Co Ltd, Discovery Res Lab, Yodogawa Ku, Osaka 5328505, Japan; Tanabe Seiyaku Co Ltd, Pharmacol Res Lab, Yodogawa Ku, Osaka 5328505, Japan	Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation	Omori, K (corresponding author), Tanabe Seiyaku Co Ltd, Discovery Res Lab, 2-50 Kawagishi 2 Chome, Toda, Saitama 3358505, Japan.	k-omori@tanabe.co.jp						Baillie GS, 2002, J BIOL CHEM, V277, P28298, DOI 10.1074/jbc.M108353200; BENELLI C, 1988, DIABETES, V37, P717, DOI 10.2337/diabetes.37.6.717; Bolger GB, 1996, J BIOL CHEM, V271, P1065, DOI 10.1074/jbc.271.2.1065; Cassano S, 1999, J BIOL CHEM, V274, P32574, DOI 10.1074/jbc.274.46.32574; Chang YH, 1997, J NEUROCHEM, V69, P1300; Constantinescu A, 1999, J BIOL CHEM, V274, P26985, DOI 10.1074/jbc.274.38.26985; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; Dohrman DP, 1996, P NATL ACAD SCI USA, V93, P10217, DOI 10.1073/pnas.93.19.10217; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; Fujishige K, 1999, EUR J BIOCHEM, V266, P1118, DOI 10.1046/j.1432-1327.1999.00963.x; Fujishige K, 2000, EUR J BIOCHEM, V267, P5943, DOI 10.1046/j.1432-1327.2000.01661.x; Fujishige K, 1999, J BIOL CHEM, V274, P18438, DOI 10.1074/jbc.274.26.18438; Geoffroy V, 1999, EUR J BIOCHEM, V259, P892, DOI 10.1046/j.1432-1327.1999.00123.x; Greengard P, 1998, BRAIN RES REV, V26, P274, DOI 10.1016/S0165-0173(97)00057-X; Han P, 1997, J BIOL CHEM, V272, P16152, DOI 10.1074/jbc.272.26.16152; HATANAKA H, 1981, BRAIN RES, V222, P225, DOI 10.1016/0006-8993(81)91029-5; Hoffmann R, 1999, EMBO J, V18, P893, DOI 10.1093/emboj/18.4.893; Huston E, 2000, J BIOL CHEM, V275, P28063; Jin SLC, 1998, J BIOL CHEM, V273, P19672, DOI 10.1074/jbc.273.31.19672; Kotera J, 1999, BIOCHEM BIOPH RES CO, V261, P551, DOI 10.1006/bbrc.1999.1013; LAEMMLI UK, 1974, NATURE, V222, P680; LEMOINE C, 1995, J COMP NEUROL, V355, P418, DOI 10.1002/cne.903550308; Lim J, 1999, J BIOL CHEM, V274, P19677, DOI 10.1074/jbc.274.28.19677; LIPPINCOTTSCHWARTZ J, 1991, J CELL BIOL, V112, P567, DOI 10.1083/jcb.112.4.567; Liu HG, 1999, J BIOL CHEM, V274, P10557, DOI 10.1074/jbc.274.15.10557; MARTINEZMIR MI, 1991, NEUROSCIENCE, V42, P697, DOI 10.1016/0306-4522(91)90038-P; Pooley L, 1997, BIOCHEM J, V321, P177, DOI 10.1042/bj3210177; Price CJ, 1999, J NEUROCHEM, V73, P2441, DOI 10.1046/j.1471-4159.1999.0732441.x; Seeger TF, 2003, BRAIN RES, V985, P113, DOI 10.1016/S0006-8993(03)02754-9; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; Shakur Y, 2000, J BIOL CHEM, V275, P38749, DOI 10.1074/jbc.M001734200; SHAKUR Y, 1995, BIOCHEM J, V306, P801, DOI 10.1042/bj3060801; Snyder GL, 1998, J NEUROSCI, V18, P10297; Soderling SH, 1999, P NATL ACAD SCI USA, V96, P7071, DOI 10.1073/pnas.96.12.7071; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; Verde I, 2001, J BIOL CHEM, V276, P11189, DOI 10.1074/jbc.M006546200; Wang XL, 2000, J NEUROSCI, V20, P8551; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Yuasa K, 2000, J BIOL CHEM, V275, P31469, DOI 10.1074/jbc.M003041200; Yuasa K, 1999, J BIOL CHEM, V274, P37429, DOI 10.1074/jbc.274.52.37429	42	74	77	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4366	4375		10.1074/jbc.M308471200	http://dx.doi.org/10.1074/jbc.M308471200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14604994	hybrid			2022-12-25	WOS:000188554300055
J	Ibarra, CA; Blouse, GE; Christian, TD; Shore, JD				Ibarra, CA; Blouse, GE; Christian, TD; Shore, JD			The contribution of the exosite residues of plasminogen activator inhibitor-1 to proteinase inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; SERPIN-PROTEASE COMPLEXES; VARIABLE REGION-1; CRYSTAL-STRUCTURE; BETA-SHEET; MECHANISM; INSERTION; SPECIFICITY; THROMBIN; TARGET	The binding of plasminogen activator inhibitor-1 (PAI-1) to serine proteinases, such as tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), is mediated by the exosite interactions between the surface-exposed variable region-1, or 37-loop, of the proteinase and the distal reactive center loop (RCL) of PAI-1. Although the contribution of such interactions to the inhibitory activity of PAI-1 has been established, the specific mechanistic steps affected by interactions at the distal RCL remain unknown. We have used protein engineering, stopped-flow fluorimetry, and rapid acid quenching techniques to elucidate the role of exosite interactions in the neutralization of tPA, uPA, and beta-trypsin by PAI-1. Alanine substitutions at the distal P4' (Glu-350) and P5' (Glu-351) residues of PAI-1 reduced the rates of Michaelis complex formation (k(a)) and overall inhibition (k(app)) with tPA by 13.4- and 4.7-fold, respectively, whereas the rate of loop insertion or final acyl-enzyme formation (k(lim)) increased by 3.3-fold. The effects of double mutations on k(a), k(lim), and k(app) were small with uPA and nonexistent with beta-trypsin. We provide the first kinetic evidence that the removal of exosite interactions significantly alters the formation of the noncovalent Michaelis complex, facilitating the release of the primed side of the distal loop from the active-site pocket of tPA and the subsequent insertion of the cleaved reactive center loop into beta-sheet A. Moreover, mutational analysis indicates that the P5' residue contributes more to the mechanism of tPA inhibition, notably by promoting the formation of a final Michaelis complex.	Henry Ford Hlth Sci Ctr, Dept Pathol, Div Biochem Res, Detroit, MI 48202 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Henry Ford Health System; Henry Ford Hospital; Wayne State University	Blouse, GE (corresponding author), Henry Ford Hlth Sci Ctr, Dept Pathol, Div Biochem Res, 1 Ford Pl,5-D, Detroit, MI 48202 USA.	gblouse1@hfhs.org		Christian, Thomas/0000-0002-3822-7097	NHLBI NIH HHS [HL54930] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS DS, 1991, J BIOL CHEM, V266, P8476; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bijnens AP, 2001, J BIOL CHEM, V276, P44912, DOI 10.1074/jbc.M103077200; Blouse GE, 2003, BIOCHEMISTRY-US, V42, P12260, DOI 10.1021/bi034737n; Blouse GE, 2002, BIOCHEMISTRY-US, V41, P11997, DOI 10.1021/bi025967p; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; Carrell RW, 1992, CURR OPIN STRUC BIOL, V2, P438; Dekker RJ, 1999, J MOL BIOL, V293, P613, DOI 10.1006/jmbi.1999.3178; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; FA M, 1995, BIOCHEMISTRY-US, V34, P13833, DOI 10.1021/bi00042a015; Gettins PGW, 2002, FEBS LETT, V523, P2, DOI 10.1016/S0014-5793(02)02924-1; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; HOPKINS PCR, 1995, J BIOL CHEM, V270, P11866, DOI 10.1074/jbc.270.20.11866; HORREVOETS AJG, 1993, J BIOL CHEM, V268, P779; Huber K, 2001, THROMB RES, V103, pS7, DOI 10.1016/S0049-3848(01)00293-6; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Komissarov AA, 2002, J BIOL CHEM, V277, P43858, DOI 10.1074/jbc.M204110200; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; Kvassman JO, 1998, BIOCHEMISTRY-US, V37, P15491, DOI 10.1021/bi9814787; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MOORE JW, 1981, KINETICS MECHANISM, P159; Olson ST, 2001, BIOCHEMISTRY-US, V40, P11742, DOI 10.1021/bi0107290; PERRON MJ, 2003, IN PRESS J BIOL CHEM; Renatus M, 1997, EMBO J, V16, P4797, DOI 10.1093/emboj/16.16.4797; Renatus M, 1997, J BIOL CHEM, V272, P21713, DOI 10.1074/jbc.272.35.21713; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Sipley JD, 1997, P NATL ACAD SCI USA, V94, P2933, DOI 10.1073/pnas.94.7.2933; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Tachias K, 1997, J BIOL CHEM, V272, P14580, DOI 10.1074/jbc.272.23.14580; VAUGHAN DE, 1993, BIOCHIM BIOPHYS ACTA, V1202, P221, DOI 10.1016/0167-4838(93)90008-F; WANG Q, 2003, BMC BIOMED CENTRAL B, V4, P1; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; Ye S, 2001, NAT STRUCT BIOL, V8, P979, DOI 10.1038/nsb1101-979; [No title captured]	45	32	33	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3643	3650		10.1074/jbc.M310601200	http://dx.doi.org/10.1074/jbc.M310601200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14594804	hybrid			2022-12-25	WOS:000188379600063
J	Severin, A; Tabei, K; Tenover, F; Chung, M; Clarke, N; Tomasz, A				Severin, A; Tabei, K; Tenover, F; Chung, M; Clarke, N; Tomasz, A			High level oxacillin and vancomycin resistance and altered cell wall composition in Staphylococcus aureus carrying the staphylococcal mecA and the enterococcal vanA gene complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING PROTEIN; BETA-LACTAM RESISTANCE; METHICILLIN-RESISTANT; PEPTIDOGLYCAN COMPOSITION; GLYCOPEPTIDE RESISTANCE; ANTIBIOTIC-RESISTANCE; LIQUID-CHROMATOGRAPHY; MASS-SPECTROMETRY; ELECTROSPRAY-IONIZATION; SEQUENCE INFORMATION	Recently, for the first time in the history of this bacterial species,methicillin- resistant Staphylococcus aureus (MRSA) carrying the enterococcal vanA gene complex and expressing high level resistance to vancomycin was identified in clinical specimens (CDC (2002) MMWR 51, 565-567). The purpose of our studies was to understand how vanA is expressed in the heterologous background of S. aureus and how it interacts with the mecA-based resistance mechanism, which is also present in these strains and is targeted on cell wall biosynthesis. The vanA-containing staphylococcal plasmid was transferred from the clinical vancomycin-resistant S. aureus (VRSA) strain HIP11714 (CDC (2002) MMWR 51, 565-567) to the methicillin- resistant S. aureus (MRSA) strain COL for which extensive genetic and biochemical information is available on staphylococcal cell wall biochemistry and drug resistance mechanisms. The transconjugant named COLVA showed high and homogeneous resistance to both oxacillin and vancomycin. COLVA grown in vancomycin-containing medium produced an abnormal peptidoglycan: all pentapeptides were replaced by tetrapeptides, and the peptidoglycan contained at least 22 novel muropeptide species that frequently showed a deficit or complete absence of pentaglycine branches. The UDP-MurNAc-pentapeptide, the major component of the cell wall precursor pool in vancomycin-sensitive cells was replaced by UDP-MurNAc-depsipeptide and UDP-MurNAc-tetrapeptide. Transposon inactivation of the beta-lactam resistance gene mecA caused complete loss of beta-lactam resistance but had no effect on the expression of vancomycin resistance. The two major antibiotic resistance mechanisms encoded by mecA and vanA residing in the same S. aureus appear to use different sets of enzymes for the assembly of cell walls.	Rockefeller Univ, New York, NY 10021 USA; Wyeth Res, Pearl River, NY 10965 USA; Ctr Dis Control & Prevent, Div Healthcare Qual Promot G08, Atlanta, GA 30333 USA	Rockefeller University; Pfizer; Centers for Disease Control & Prevention - USA	Tomasz, A (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	tomasz@mail.rockefeller.edu	Tomasz, Alexander/B-9939-2011	Tomasz, Alexander/0000-0003-1520-1983	NIAID NIH HHS [1-R01-AI45738] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045738] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALOBEID S, 1992, FEMS MICROBIOL LETT, V91, P79, DOI 10.1111/j.1574-6968.1992.tb05187.x; Arthur M, 1996, MOL MICROBIOL, V21, P33, DOI 10.1046/j.1365-2958.1996.00617.x; Arthur M, 1998, MOL MICROBIOL, V30, P819, DOI 10.1046/j.1365-2958.1998.01114.x; Arthur M, 2001, ANTIMICROB AGENTS CH, V45, P375, DOI 10.1128/AAC.45.2.375-381.2001; BillotKlein D, 1996, J BACTERIOL, V178, P4696, DOI 10.1128/jb.178.15.4696-4703.1996; BillotKlein D, 1996, BIOCHEM J, V313, P711, DOI 10.1042/bj3130711; BILLOTKLEIN D, 1992, ANTIMICROB AGENTS CH, V36, P1487, DOI 10.1128/AAC.36.7.1487; Boneca IG, 2000, J BIOL CHEM, V275, P9910, DOI 10.1074/jbc.275.14.9910; Boneca IG, 2003, EXPERT OPIN THER TAR, V7, P311, DOI 10.1517/14728222.7.3.311; Bouhss A, 2002, J BIOL CHEM, V277, P45935, DOI 10.1074/jbc.M207449200; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P10408, DOI 10.1021/bi00107a007; Centers for Disease Control and Prevention, 2002, MMWR-MORBID MORTAL W, V51, P565; Chang S, 2003, NEW ENGL J MED, V348, P1342, DOI 10.1056/NEJMoa025025; COVEY TR, 1991, ANAL CHEM, V63, P1193, DOI 10.1021/ac00013a003; de Jonge BLM, 2002, ANTIMICROB AGENTS CH, V46, P3151, DOI 10.1128/AAC.46.10.3151-3155.2002; De Lencastre H, 1999, MICROB DRUG RESIST, V5, P163, DOI 10.1089/mdr.1999.5.163; deJonge BLM, 1996, MICROB DRUG RESIST, V2, P225, DOI 10.1089/mdr.1996.2.225; DeJonge BLM, 1996, ANTIMICROB AGENTS CH, V40, P863, DOI 10.1128/AAC.40.4.863; deJonge BLM, 1996, ANTIMICROB AGENTS CH, V40, P1498, DOI 10.1128/AAC.40.6.1498; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; DELENCASTRE H, 1994, ANTIMICROB AGENTS CH, V38, P2590, DOI 10.1128/AAC.38.11.2590; ESHRAGHI J, 1993, ANAL CHEM, V65, P3528, DOI 10.1021/ac00071a035; FLOURET B, 1981, ANAL BIOCHEM, V114, P59, DOI 10.1016/0003-2697(81)90451-6; Gonzalez-Zorn B, 2003, LANCET INFECT DIS, V3, P67, DOI 10.1016/S1473-3099(03)00510-3; HANDWERGER S, 1992, J BACTERIOL, V174, P5982, DOI 10.1128/jb.174.18.5982-5984.1992; HARTMAN BJ, 1984, J BACTERIOL, V158, P513, DOI 10.1128/JB.158.2.513-516.1984; HEMLING ME, 1990, BIOMED ENVIRON MASS, V19, P677, DOI 10.1002/bms.1200191107; Hunt DF, 1989, RAPID COMMUN MASS SP, V3, P122, DOI 10.1002/rcm.1290030408; Ito T, 1999, ANTIMICROB AGENTS CH, V43, P1449, DOI 10.1128/AAC.43.6.1449; KOBAYASHI T, 1987, J BACTERIOL, V169, P3873, DOI 10.1128/jb.169.9.3873-3878.1987; LOO JA, 1991, ANAL CHEM, V63, P2488, DOI 10.1021/ac00021a018; LOO JA, 1990, SCIENCE, V248, P201, DOI 10.1126/science.2326633; MATTHEWS P, 1990, ANTIMICROB AGENTS CH, V34, P1777, DOI 10.1128/AAC.34.9.1777; MENGINLECREULX D, 1982, J BACTERIOL, V151, P1109, DOI 10.1128/JB.151.3.1109-1117.1982; ORNELASSOARES A, 1993, J BIOL CHEM, V268, P26268; Pinho MG, 2001, P NATL ACAD SCI USA, V98, P10886, DOI 10.1073/pnas.191260798; Pinho MG, 2001, J BACTERIOL, V183, P6525, DOI 10.1128/JB.183.22.6525-6531.2001; Ray SS, 2002, STRUCTURE, V10, P1499, DOI 10.1016/S0969-2126(02)00880-8; Ray SS, 2003, PROTEINS, V50, P170, DOI 10.1002/prot.10272; REYNOLDS PE, 1985, FEBS LETT, V192, P28, DOI 10.1016/0014-5793(85)80036-3; Rohrer S, 2003, ANTIMICROB AGENTS CH, V47, P837, DOI 10.1128/AAC.47.3.837-846.2003; Sieradzki K, 1997, J BACTERIOL, V179, P2557, DOI 10.1128/jb.179.8.2557-2566.1997; Sobral RG, 2003, MICROB DRUG RESIST, V9, P231, DOI 10.1089/107662903322286436; STONE KJ, 1971, P NATL ACAD SCI USA, V68, P3223, DOI 10.1073/pnas.68.12.3223; STORM DR, 1974, ANN NY ACAD SCI, V235, P387, DOI 10.1111/j.1749-6632.1974.tb43278.x; TOMASZ A, 1991, ANTIMICROB AGENTS CH, V35, P124, DOI 10.1128/AAC.35.1.124; Ton-That H, 1998, J BIOL CHEM, V273, P29143, DOI 10.1074/jbc.273.44.29143; UTSUI Y, 1985, ANTIMICROB AGENTS CH, V28, P397, DOI 10.1128/AAC.28.3.397; Walsh TR, 2002, ANNU REV MICROBIOL, V56, P657, DOI 10.1146/annurev.micro.56.012302.160806; Weller TMA, 1999, J ANTIMICROB CHEMOTH, V43, P15, DOI 10.1093/jac/43.1.15; [No title captured]	51	83	89	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3398	3407		10.1074/jbc.M309593200	http://dx.doi.org/10.1074/jbc.M309593200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14613936	hybrid			2022-12-25	WOS:000188379600033
J	Tisne, C; Roques, BP; Dardel, F				Tisne, C; Roques, BP; Dardel, F			The annealing mechanism of HIV-1 reverse transcription primer onto the viral genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RETROVIRAL NUCLEOCAPSID PROTEINS; TRANSFER-RNA; EFFICIENT INITIATION; SECONDARY STRUCTURE; ZINC FINGERS; COMPLEX; TRNA(3)(LYS); NMR; RECOGNITION	Reverse transcription of human immunodeficiency virus-1 viral RNA uses human tRNA(3)(Lys) as a primer. The first step of viral replication is, thus, the annealing of the primer tRNA onto the primer binding site located in the 5' leader region of the viral RNA. This involves large rearrangements of both RNA structures and requires the chaperone activity of the viral nucleocapsid protein. We have developed a novel approach to analyze dynamically such RNA refolding events using heteronuclear NMR spectroscopy of mixtures of N-15-labeled and unlabeled large RNA fragments (up to 50 kDa). We have thus been able to characterize the detailed mechanisms of both heat- and nucleocapsid-mediated annealing and to identify previously unknown key steps. The role played by the nucleocapsid is 2-fold; it facilitates strand exchange at the level of the tRNA acceptor stem, presumably via its basic N- and C-terminal extensions, and it unlocks the highly stable tertiary interactions at the level of the TPsiC loop, most likely by specific interactions involving its two zinc knuckles.	Fac Pharm, CNRS, UMR 8015, Lab Cristallog & Resonance Magnet Nucl Biol, F-75006 Paris, France; Fac Pharm, CNRS, FRE2463, INSERM,U266, F-75006 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Dardel, F (corresponding author), Fac Pharm, CNRS, UMR 8015, Lab Cristallog & Resonance Magnet Nucl Biol, 4 Ave Observ, F-75006 Paris, France.	dardel@pharmacie.univ-paris5.fr	Dardel, Frédéric/E-5805-2010	Dardel, Frédéric/0000-0002-9397-3965; Tisne, Carine/0000-0001-5534-4650				Amarasinghe GK, 2000, J MOL BIOL, V301, P491, DOI 10.1006/jmbi.2000.3979; Bajji AC, 2002, J AM CHEM SOC, V124, P14302, DOI 10.1021/ja028015f; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; Beerens N, 2000, J BIOL CHEM, V275, P15474, DOI 10.1074/jbc.275.20.15474; Beerens N, 2000, NUCLEIC ACIDS RES, V28, P4130, DOI 10.1093/nar/28.21.4130; Bernacchi S, 2002, J MOL BIOL, V317, P385, DOI 10.1006/jmbi.2002.5429; Brule F, 2002, RNA, V8, P8, DOI 10.1017/S1355838202010981; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DIBHAJJ F, 1993, PROTEIN SCI, V2, P231; Gregoire CJ, 1997, J BIOL CHEM, V272, P25143, DOI 10.1074/jbc.272.40.25143; Hargittai MRS, 2001, J MOL BIOL, V312, P985, DOI 10.1006/jmbi.2001.5021; ISEL C, 1993, J BIOL CHEM, V268, P25269; Isel C, 1999, EMBO J, V18, P1038, DOI 10.1093/emboj/18.4.1038; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; JIANG M, 1993, J VIROL, V67, P3246, DOI 10.1128/JVI.67.6.3246-3253.1993; Khan R, 1996, NUCLEIC ACIDS RES, V24, P3568, DOI 10.1093/nar/24.18.3568; KHAN R, 1992, J BIOL CHEM, V267, P6689; Morellet N, 1998, J MOL BIOL, V283, P419, DOI 10.1006/jmbi.1998.2098; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; Raghunathan PL, 1998, SCIENCE, V279, P857, DOI 10.1126/science.279.5352.857; Rist MJ, 2002, BIOCHEMISTRY-US, V41, P14762, DOI 10.1021/bi0267240; Rong LW, 1998, J VIROL, V72, P9353, DOI 10.1128/JVI.72.11.9353-9358.1998; Staley JP, 1999, MOL CELL, V3, P55, DOI 10.1016/S1097-2765(00)80174-4; Tisne C, 2000, RNA, V6, P1403, DOI 10.1017/S1355838200000947; Tisne C, 2003, BIOCHIMIE, V85, P557, DOI 10.1016/S0300-9084(03)00034-8; Tisne C, 2001, J MOL BIOL, V306, P443, DOI 10.1006/jmbi.2000.4391; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; Weigelt J, 1998, J AM CHEM SOC, V120, P10778, DOI 10.1021/ja982649y; Zhang ZJ, 1998, AIDS RES HUM RETROV, V14, P979, DOI 10.1089/aid.1998.14.979	32	52	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3588	3595		10.1074/jbc.M310368200	http://dx.doi.org/10.1074/jbc.M310368200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14602716	Green Submitted, hybrid			2022-12-25	WOS:000188379600056
J	Young, EC; Krougliak, N				Young, EC; Krougliak, N			Distinct structural determinants of efficacy and sensitivity in the ligand-binding domain of cyclic nucleotide-gated channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATFISH OLFACTORY NEURONS; MOLECULAR MECHANISM; REGULATORY SUBUNIT; PROTEIN-KINASE; ION CHANNELS; C-ELEGANS; CAMP; SPECIFICITY; ACTIVATION; SITE	Cyclic nucleotide-gated (CNG) channels open in response to direct binding of cyclic nucleotide messengers. Every subunit in a tetrameric CNG channel contains a cytoplasmic ligand-binding domain (BD) that includes a beta-roll (flanked by short helices) and a single C-terminal helix called the C-helix that was previously found to control efficacy (maximal open probability) and selectivity for cGMP versus cAMP. We constructed a series of chimeric CNG channel subunits, each containing a distinct BD sequence (chosen from among six phylogenetically divergent isoforms) fused to an invariant non-BD sequence. We assayed these "BD substitution" chimeras as homomeric CNG channels in Xenopus oocytes to compare their functions and found that the most efficient activation by both cAMP and cGMP derived from the BD of the catfish CNGA4 olfactory modulatory subunit (fCNGA4). We then tested the effects of replacing subregions of the bovine CNGA1 BD with corresponding fCNGA4 sequence and hence identified parts of the fCNGA4 BD producing efficient activation. For instance, replacing either the "hinge" that connects the roll and C-helix subdomains or the BD sequence N-terminal to the hinge greatly enhanced cAMP efficacy. Replacing the "loop-beta8" region (the C-terminal end of the beta-roll) improved agonist sensitivity for cGMP selectively over cAMP. Our results thus identify multiple BD elements outside the C-helix that control selective ligand interaction and channel gating steps by distinct mechanisms. This suggests that the purine ring of the cyclic nucleotide may interact with both the beta-roll and the C-helix at different points in the mechanism.	Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University	Young, EC (corresponding author), Columbia Univ, Ctr Neurobiol & Behav, 722 W 168th St, New York, NY 10032 USA.	ecy4@columbia.edu		Young, Edgar C./0000-0002-8453-088X				ALTENHOFEN W, 1991, P NATL ACAD SCI USA, V88, P9868, DOI 10.1073/pnas.88.21.9868; Biel M, 1999, Rev Physiol Biochem Pharmacol, V135, P151, DOI 10.1007/BFb0033672; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; Bradley J, 2001, SCIENCE, V294, P2095, DOI 10.1126/science.294.5549.2095; Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Diller TC, 2001, STRUCTURE, V9, P73, DOI 10.1016/S0969-2126(00)00556-6; Gordon SE, 1996, BIOCHEMISTRY-US, V35, P3994, DOI 10.1021/bi952607b; GOULDING EH, 1993, NATURE, V364, P61, DOI 10.1038/364061a0; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; KRAMER RH, 1990, NEURON, V4, P335, DOI 10.1016/0896-6273(90)90046-I; Li J, 1999, MOL PHARMACOL, V55, P873; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; Liu DT, 1998, NEURON, V21, P235, DOI 10.1016/S0896-6273(00)80530-9; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; Matulef K, 1999, NEURON, V24, P443, DOI 10.1016/S0896-6273(00)80857-0; Molokanova E, 1999, J NEUROSCI, V19, P4786; Pages F, 2000, BIOPHYS J, V78, P1227, DOI 10.1016/S0006-3495(00)76680-X; Paoletti P, 1999, J GEN PHYSIOL, V113, P17, DOI 10.1085/jgp.113.1.17; Rehmann H, 2003, NAT STRUCT BIOL, V10, P26, DOI 10.1038/nsb878; Scott SP, 1998, BIOCHEMISTRY-US, V37, P17239, DOI 10.1021/bi981185d; Shapiro MS, 2000, BIOPHYS J, V78, P2307, DOI 10.1016/S0006-3495(00)76777-4; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Sunderman ER, 1999, J GEN PHYSIOL, V113, P621, DOI 10.1085/jgp.113.5.621; Tibbs GR, 1997, NATURE, V386, P612, DOI 10.1038/386612a0; Tibbs GR, 1998, J BIOL CHEM, V273, P4497, DOI 10.1074/jbc.273.8.4497; VARNUM MD, 1995, NEURON, V15, P619, DOI 10.1016/0896-6273(95)90150-7; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; Young EC, 2002, BIOPHYS J, V82, p275A; Young EC, 2001, J GEN PHYSIOL, V118, P523, DOI 10.1085/jgp.118.5.523; Zagotta WN, 2003, NATURE, V425, P200, DOI 10.1038/nature01922; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315; ZUFALL F, 1994, ANNU REV BIOPH BIOM, V23, P577, DOI 10.1146/annurev.bb.23.060194.003045	38	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3553	3562		10.1074/jbc.M310545200	http://dx.doi.org/10.1074/jbc.M310545200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14594805	hybrid			2022-12-25	WOS:000188379600052
J	Renfrow, MB; Naryshkin, N; Lewis, LM; Chen, HT; Ebright, RH; Scott, RA				Renfrow, MB; Naryshkin, N; Lewis, LM; Chen, HT; Ebright, RH; Scott, RA			Transcription factor B contacts promoter DNA near the transcription start site of the archaeal transcription initiation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; CELL-FREE TRANSCRIPTION; N-TERMINAL REGION; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; PREINITIATION COMPLEX; FUNCTIONAL DOMAINS; ZINC RIBBON; TFIIB	Transcription initiation in all three domains of life requires the assembly of large multiprotein complexes at DNA promoters before RNA polymerase ( RNAP)-catalyzed transcript synthesis. Core RNAP subunits show homology among the three domains of life, and recent structural information supports this homology. General transcription factors are required for productive transcription initiation complex formation. The archaeal general transcription factors TATA-element-binding protein (TBP), which mediates promoter recognition, and transcription factor B (TFB), which mediates recruitment of RNAP, show extensive homology to eukaryal TBP and TFIIB. Crystallographic information is becoming available for fragments of transcription initiation complexes (e.g. RNAP, TBP-TFB-DNA, TBP-TFIIB-DNA), but understanding the molecular topography of complete initiation complexes still requires biochemical and biophysical characterization of protein-protein and protein-DNA interactions. In published work, systematic site-specific protein-DNA photocrosslinking has been used to define positions of RNAP subunits and general transcription factors in bacterial and eukaryal initiation complexes. In this work, we have used systematic site-specific protein-DNA photocrosslinking to define positions of RNAP subunits and general transcription factors in an archaeal initiation complex. Employing a set of 41 derivatized DNA fragments, each having a phenyl azide photoactivable crosslinking agent incorporated at a single, defined site within positions - 40 to + 1 of the gdh promoter of the hyperthermophilic marine archaea, Pyrococcus furiosus (Pf), we have determined the locations of PfRNAP subunits PfTBP and PfTFB relative to promoter DNA. The resulting topographical information supports the striking homology with the eukaryal initiation complex and permits one major new conclusion, which is that PfTFB interacts with promoter DNA not only in the TATA-element region but also in the transcription-bubble region, near the transcription start site. Comparison with crystallographic information implicates the PfTFB N-terminal domain in the interaction with the transcription-bubble region. The results are discussed in relation to the known effects of substitutions in the TFB and TFIIB N-terminal domains on transcription initiation and transcription start-site selection.	Univ Georgia, Dept Chem, Athens, GA 30602 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Univ Georgia, Ctr Metalloenzyme Studies, Athens, GA 30602 USA; Rutgers State Univ, Howard Hughes Med Inst, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Chem, Piscataway, NJ 08854 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Scott, RA (corresponding author), Univ Georgia, Dept Chem, Athens, GA 30602 USA.	scott@chem.uga.edu	Chen, Hung-Ta/ABC-8094-2021; Ebright, Richard/O-3321-2019	Chen, Hung-Ta/0000-0003-1192-0382; Ebright, Richard/0000-0001-8915-7140; Scott, Robert/0000-0003-2236-1336; Renfrow, Matthew B./0000-0002-4193-7305	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042025, R01GM041376] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42025, GM41376] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armache KJ, 2003, P NATL ACAD SCI USA, V100, P6964, DOI 10.1073/pnas.1030608100; Bangur CS, 1997, MOL CELL BIOL, V17, P6784, DOI 10.1128/MCB.17.12.6784; BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; Bartlett MS, 2000, NAT STRUCT BIOL, V7, P782, DOI 10.1038/79020; Bell SD, 2000, J BIOL CHEM, V275, P12934, DOI 10.1074/jbc.275.17.12934; Bell SD, 1998, TRENDS MICROBIOL, V6, P222, DOI 10.1016/S0966-842X(98)01281-5; Bell SD, 1999, P NATL ACAD SCI USA, V96, P13662, DOI 10.1073/pnas.96.24.13662; Bell SD, 2001, BIOCHEM SOC T, V29, P392, DOI 10.1042/BST0290392; Bell SD, 2000, NAT STRUCT BIOL, V7, P703, DOI 10.1038/78907; BRYANT FO, 1989, J BIOL CHEM, V264, P5070; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Bushnell DA, 2003, P NATL ACAD SCI USA, V100, P6969, DOI 10.1073/pnas.1130601100; Campbell EA, 2002, MOL CELL, V9, P527, DOI 10.1016/S1097-2765(02)00470-7; CECH CL, 1980, BIOCHEMISTRY-US, V19, P2440, DOI 10.1021/bi00552a023; Chen HT, 2000, PROTEIN SCI, V9, P1743, DOI 10.1110/ps.9.9.1743; Chen HT, 2003, MOL CELL, V12, P437, DOI 10.1016/S1097-2765(03)00306-X; CHEN HT, 2000, THESIS U GEORGIA ATH; Cho EJ, 1999, J BIOL CHEM, V274, P25807, DOI 10.1074/jbc.274.36.25807; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Ebright RH, 2000, J MOL BIOL, V304, P687, DOI 10.1006/jmbi.2000.4309; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Hausner W, 1996, J BIOL CHEM, V271, P30144, DOI 10.1074/jbc.271.47.30144; Hausner W, 2001, J BACTERIOL, V183, P3025, DOI 10.1128/JB.183.10.3025-3031.2001; Hawkes NA, 1999, J BIOL CHEM, V274, P14337, DOI 10.1074/jbc.274.20.14337; Hethke C, 1999, GENETICS, V152, P1325; Hethke C, 1996, NUCLEIC ACIDS RES, V24, P2369, DOI 10.1093/nar/24.12.2369; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Kosa PF, 1997, P NATL ACAD SCI USA, V94, P6042, DOI 10.1073/pnas.94.12.6042; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; Lagrange T, 1996, P NATL ACAD SCI USA, V93, P10620, DOI 10.1073/pnas.93.20.10620; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; LEWIS LM, 2000, THESIS U GEORGIA ATH; Littlefield O, 1999, P NATL ACAD SCI USA, V96, P13668, DOI 10.1073/pnas.96.24.13668; Magill CP, 2001, J BIOL CHEM, V276, P46693, DOI 10.1074/jbc.C100567200; Mekler V, 2002, CELL, V108, P599, DOI 10.1016/S0092-8674(02)00667-0; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Naryshkin N, 2000, METH MOL B, V148, P337; Naryshkin N, 2000, CELL, V101, P601, DOI 10.1016/S0092-8674(00)80872-7; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Pardee TS, 1998, J BIOL CHEM, V273, P17859, DOI 10.1074/jbc.273.28.17859; PINTO I, 1994, J BIOL CHEM, V269, P30569; Qureshi SA, 1998, MOL CELL, V1, P389, DOI 10.1016/S1097-2765(00)80039-8; ROWLANDS T, 1994, SCIENCE, V264, P1326, DOI 10.1126/science.8191287; SEVERINOV K, 1994, J BIOL CHEM, V269, P20826; Soppa J, 1999, MOL MICROBIOL, V31, P1295, DOI 10.1046/j.1365-2958.1999.01273.x; Spitalny P, 2003, J BIOL CHEM, V278, P30497, DOI 10.1074/jbc.M303633200; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THOMM M, 1990, ARCHAEA LAB MANUAL, P297; Thomsen J, 2001, J MOL BIOL, V309, P589, DOI 10.1006/jmbi.2001.4705; Todone F, 2001, MOL CELL, V8, P1137, DOI 10.1016/S1097-2765(01)00379-3; Tsai FTF, 2000, EMBO J, V19, P25, DOI 10.1093/emboj/19.1.25; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Woychik NA, 2002, CELL, V108, P453, DOI 10.1016/S0092-8674(02)00646-3; Zeng QD, 1996, J BIOL INORG CHEM, V1, P162, DOI 10.1007/s007750050035; Zhang DY, 2002, NUCLEIC ACIDS RES, V30, P3078, DOI 10.1093/nar/gkf422; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122	64	48	48	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2825	2831		10.1074/jbc.M311433200	http://dx.doi.org/10.1074/jbc.M311433200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14597623	hybrid			2022-12-25	WOS:000188211300061
J	Skurat, AV; Dietrich, AD				Skurat, AV; Dietrich, AD			Phosphorylation of Ser(640) in muscle glycogen synthase by DYRK family protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; WD-REPEAT; CRYSTAL-STRUCTURE; MULTISITE PHOSPHORYLATION; SUBSTRATE-SPECIFICITY; MOLECULAR-MECHANISM; GLUCOSE-METABOLISM; INSULIN; SITES; EXPRESSION	Glycogen synthase, a key enzyme in the regulation of glycogen synthesis by insulin, is controlled by multisite phosphorylation. Glycogen synthase kinase-3 (GSK-3) phosphorylates four serine residues in the COOH terminus of glycogen synthase. Phosphorylation of one of these residues, Ser(640) ( site 3a), causes strong inactivation of glycogen synthase. In previous work, we demonstrated in cell models that site 3a can be phosphorylated by an as yet unidentified protein kinase (3a-kinase) distinct from GSK-3. In the present study, we purified the 3a-kinase from rabbit skeletal muscle and identified one constituent polypeptide as HAN11, a WD40 domain protein with unknown function. Another polypeptide was identified as DYRK1A, a member of the dual-specificity tyrosine phosphorylated and regulated protein kinase (DYRK) family. Two isoforms of DYRK, DYRK1A and DYRK1B, co-immunoprecipitate with HAN11 when coexpressed in COS cells indicating that the proteins interact in mammalian cells. Co-expression of DYRK1A, DYRK1B, or DYRK2 with a series of glycogen synthase mutants with Ser/Ala substitutions at the phosphorylation sites in COS cells revealed that protein kinases cause phosphorylation of site 3a in glycogen synthase. To confirm that DYRKs directly phosphorylate glycogen synthase, recombinant DYRK1A, DYRK2, and glycogen synthase were produced in bacterial cells. In the presence of Mg-ATP, both DYRKs inactivated glycogen synthase by more than 10-fold. The inactivation correlated with phosphorylation of site 3a in glycogen synthase. These results indicate that protein kinase(s) from the DYRK family may be involved in a new mechanism for the regulation of glycogen synthesis.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Skurat, AV (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.	askurat@iupui.edu						Altafaj X, 2001, HUM MOL GENET, V10, P1915, DOI 10.1093/hmg/10.18.1915; Becker W, 1999, PROG NUCLEIC ACID RE, V62, P1; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; Campbell LE, 2002, FEBS LETT, V510, P31, DOI 10.1016/S0014-5793(01)03221-5; Chen-Hwang MC, 2002, J BIOL CHEM, V277, P17597, DOI 10.1074/jbc.M111101200; Cline GW, 2002, DIABETES, V51, P2903, DOI 10.2337/diabetes.51.10.2903; Cohen P., 1986, ENZYMES, VXVII, P461; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; DEPAOLIROACH AA, 1983, J BIOL CHEM, V258, P702; deVetten N, 1997, GENE DEV, V11, P1422, DOI 10.1101/gad.11.11.1422; Ferrer JC, 1997, FEBS LETT, V415, P249, DOI 10.1016/S0014-5793(97)01136-8; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; Fotaki V, 2002, MOL CELL BIOL, V22, P6636, DOI 10.1128/MCB.22.18.6636-6647.2002; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; Geiger JN, 2001, BLOOD, V97, P901, DOI 10.1182/blood.V97.4.901; Guimera J, 1999, GENOMICS, V57, P407, DOI 10.1006/geno.1999.5775; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; James P, 1996, GENETICS, V144, P1425; JUE T, 1989, P NATL ACAD SCI USA, V86, P1439, DOI 10.1073/pnas.86.5.1439; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; Leder S, 1999, BIOCHEM BIOPH RES CO, V254, P474, DOI 10.1006/bbrc.1998.9967; Lee K, 2000, CANCER RES, V60, P3631; Matsuo R, 2001, J IMMUNOL METHODS, V247, P141, DOI 10.1016/S0022-1759(00)00313-6; Miyata Y, 1999, BIOCHEM BIOPH RES CO, V266, P291, DOI 10.1006/bbrc.1999.1705; Moriya H, 2001, GENE DEV, V15, P1217, DOI 10.1101/gad.884001; NAKIELNY S, 1991, EUR J BIOCHEM, V199, P713, DOI 10.1111/j.1432-1033.1991.tb16175.x; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 2000, P NATL ACAD SCI USA, V97, P960, DOI 10.1073/pnas.97.3.960; Nikoulina SE, 2002, DIABETES, V51, P2190, DOI 10.2337/diabetes.51.7.2190; Okui M, 1999, GENOMICS, V62, P165, DOI 10.1006/geno.1999.5998; PICTON C, 1982, EUR J BIOCHEM, V124, P37, DOI 10.1111/j.1432-1033.1982.tb05903.x; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; Shindoh N, 1996, BIOCHEM BIOPH RES CO, V225, P92, DOI 10.1006/bbrc.1996.1135; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; SKURAT AV, 1994, J BIOL CHEM, V269, P25534; Skurat AV, 1996, BIOCHEM J, V313, P45, DOI 10.1042/bj3130045; SKURAT AV, 1995, J BIOL CHEM, V270, P12491, DOI 10.1074/jbc.270.21.12491; SKURAT AV, 1993, J BIOL CHEM, V268, P14701; Skurat AV, 2000, DIABETES, V49, P1096, DOI 10.2337/diabetes.49.7.1096; SKURAT AV, 2000, DIABETES MELLITUS FU, P251; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; Walker AR, 1999, PLANT CELL, V11, P1337, DOI 10.1105/tpc.11.7.1337; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wang J, 1998, BIOCHEM BIOPH RES CO, V250, P704, DOI 10.1006/bbrc.1998.9392; Woods YL, 2001, BIOCHEM J, V355, P609, DOI 10.1042/bj3550609; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; ZHANG WM, 1993, ARCH BIOCHEM BIOPHYS, V304, P219, DOI 10.1006/abbi.1993.1342	53	79	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2490	2498		10.1074/jbc.M301769200	http://dx.doi.org/10.1074/jbc.M301769200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14593110	hybrid			2022-12-25	WOS:000188211300020
J	Kumagai, M; Makioka, A; Takeuchi, T; Nozaki, T				Kumagai, M; Makioka, A; Takeuchi, T; Nozaki, T			Molecular cloning and characterization of a protein farnesyltransferase from the enteric protozoan parasite Entamoeba histolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS; FARNESYL; GENES; TRANSFERASE; IDENTIFICATION; PRENYLATION; INHIBITION; MECHANISM; SUBUNIT; BINDING	Genes encoding alpha- and beta-subunits of a putative protein farnesyltransferase (FT) from the enteric protozoan parasite Entamoeba histolytica were obtained and their biochemical properties were characterized. Deduced amino acid sequences of the alpha- and beta-subunit of E. histolytica FT (EhFT) were 298- and 375-residues long with a molecular mass of 35.6 and 42.6 kDa, and a pI of 5.43 and 5.65, respectively. They showed 24% to 36% identity to and shared common signature domains and repeats with those from other organisms. Recombinant alpha- and beta-subunits, co-expressed in Escherichia coli, formed a heterodimer and showed activity to transfer farnesyl using farnesylpyrophosphate as a donor to human H-Ras possessing a C-terminal CVLS, but not a mutant H-Ras possessing CVLL. Among a number of small GTPases that belong to the Ras superfamily from this parasite, we identified EhRas4, which possesses CVVA at the C terminus, as a sole farnesyl acceptor for EhFT. This is in contrast to mammalian FT, which utilizes a variety of small GTPases that possess a C-terminal CaaX motif, where X is serine, methionine, glutamine, cysteine, or alanine. EhFT also showed remarkable resistance against a variety of known inhibitors of mammalian FT. These results suggest that remarkable biochemical differences in binding to substrates and inhibitors exist between amebic and mammalian FTs, which highlights this enzyme as a novel target for the development of new chemotherapeutics against amebiasis.	Natl Inst Infect Dis, Dept Parasitol, Shinjuku Ku, Tokyo 1628640, Japan; Jikei Univ, Sch Med, Dept Trop Med, Minato Ku, Tokyo 1058461, Japan; Keio Univ, Sch Med, Dept Trop Med & Parasitol, Shinjuku Ku, Tokyo 1608582, Japan; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Tokyo 1900012, Japan	National Institute of Infectious Diseases (NIID); Jikei University; Keio University; Japan Science & Technology Agency (JST)	Nozaki, T (corresponding author), Natl Inst Infect Dis, Dept Parasitol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.	nozaki@nih.go.jp						[Anonymous], 1997, B WORLD HEALTH ORGAN, V75, P291; ARMSTRONG SA, 1995, J BIOL CHEM, V270, P7864, DOI 10.1074/jbc.270.14.7864; BOGUSKI MS, 1992, NEW BIOL, V4, P408; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; DIAMOND LS, 1972, J VIROL, V9, P326, DOI 10.1128/JVI.9.2.326-341.1972; Dunten P, 1998, BIOCHEMISTRY-US, V37, P7907, DOI 10.1021/bi980531o; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Gelb MH, 2003, MOL BIOCHEM PARASIT, V126, P155, DOI 10.1016/S0166-6851(02)00282-7; Ghosh SK, 1997, INFECT IMMUN, V65, P4243, DOI 10.1128/IAI.65.10.4243-4249.1997; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; Guillen N, 1997, Arch Med Res, V28 Spec No, P129; Guillen N, 1998, J CELL SCI, V111, P1729; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; Juarez P, 2000, ARCH MED RES, V31, pS157, DOI 10.1016/S0188-4409(00)00111-9; Kral AM, 1997, J BIOL CHEM, V272, P27319, DOI 10.1074/jbc.272.43.27319; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LOHIA A, 1993, MOL BIOCHEM PARASIT, V58, P177, DOI 10.1016/0166-6851(93)90104-6; Lohia A, 1996, GENE, V173, P205, DOI 10.1016/0378-1119(96)00232-6; MANNE V, 1995, DRUG DEVELOP RES, V34, P121, DOI 10.1002/ddr.430340205; MANNE V, 1984, P NATL ACAD SCI-BIOL, V81, P6953, DOI 10.1073/pnas.81.22.6953; Micali E, 2001, BIOCHEMISTRY-US, V40, P12254, DOI 10.1021/bi011133f; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Nepomuceno-Silva JL, 2001, J BIOL CHEM, V276, P29711, DOI 10.1074/jbc.M102920200; Nozaki T, 1998, MOL BIOCHEM PARASIT, V97, P33, DOI 10.1016/S0166-6851(98)00129-7; OMER CA, 1995, METHOD ENZYMOL, V250, P3; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; Rodriguez MA, 2000, MOL BIOCHEM PARASIT, V108, P199, DOI 10.1016/S0166-6851(00)00216-4; Saito-Nakano Y, 2001, MOL BIOCHEM PARASIT, V116, P219, DOI 10.1016/S0166-6851(01)00318-8; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAMBROOK J, 1989, MOL CLONING LAB MANU, V18, P47; Shen PS, 1996, EXP PARASITOL, V82, P65, DOI 10.1006/expr.1996.0008; SHEN PS, 1994, MOL BIOCHEM PARASIT, V64, P111, DOI 10.1016/0166-6851(94)90139-2; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; Temesvari LA, 1999, MOL BIOCHEM PARASIT, V103, P225, DOI 10.1016/S0166-6851(99)00133-4; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANDERPYL D, 1992, J ANTIBIOT, V45, P1802; Yokoyama K, 1997, MOL BIOCHEM PARASIT, V87, P61, DOI 10.1016/S0166-6851(97)00043-1; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	50	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2316	2323		10.1074/jbc.M311478200	http://dx.doi.org/10.1074/jbc.M311478200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14583615	hybrid			2022-12-25	WOS:000188005700089
J	McLaughlin, JP; Myers, LC; Zarek, PE; Caron, MG; Lefkowitz, RJ; Czyzyk, TA; Pintar, JE; Chavkin, C				McLaughlin, JP; Myers, LC; Zarek, PE; Caron, MG; Lefkowitz, RJ; Czyzyk, TA; Pintar, JE; Chavkin, C			Prolonged kappa opioid receptor phosphorylation mediated by G-protein receptor kinase underlies sustained analgesic tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; MOLECULAR-MECHANISMS; DESENSITIZATION; MU; INTERNALIZATION; INVOLVEMENT; DISRUPTION; ROLES; GENE	Kappa opioid receptor (KOR) desensitization was previously shown to follow agonist-dependent phosphorylation of serine 369 by G-protein receptor kinase (GRK) and beta-arrestin binding in transfected cells. To study the in vivo effects induced by phosphorylation of KOR(S369), C57Bl/6 mice were administered single or repeated doses of the KOR agonist, U50,488, and isolated brain glycoprotein was probed with an antibody, KOR-P, that specifically recognized phosphoserine 369 KOR. Western blot analysis using KOR-P antibody showed that labeling intensity increased after either single or repeated treatment of mice with U50,488 by 59 +/- 22% and 101 +/- 29%, respectively. In contrast, there was no change in labeling intensity by nonphosphoselective KOR antibodies following acute or chronic in vivo treatment with kappa agonist. Moreover, mice lacking GRK3 showed no increase in KOR-P labeling and developed significantly less analgesic tolerance following treatment with kappa agonist. The result suggests that tolerance to kappa agonists includes phosphorylation of serine 369 within KOR by GRK3. Recovery of analgesic potency and reduction of elevated KOR-P labeling in wild-type mice both required 2 weeks to return to base line. Consistent with these results, in vitro phosphorylation by GRK3 of KOR isolated from tolerant mice resulted in 46 +/- 7% less P-32 incorporation than in KOR isolated from untreated mice. In addition, in vitro P-32 incorporation returned to base line levels only in KOR isolated from tolerant mice allowed to recover for 2 weeks. The coincident reversal of analgesic tolerance and slow return to a basal phosphorylation state matched the regeneration rate of functional kappa receptors following irreversible antagonism and suggested that receptor replacement rather than dephosphorylation was required to restore sensitivity.	Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Med, Durham, NC 27710 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA	University of Washington; University of Washington Seattle; Duke University; Duke University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Chavkin, C (corresponding author), Univ Washington, Sch Med, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.	cchavkin@u.washington.edu	Lefkowitz, Robert/AAW-2649-2021; Chavkin, Charles/G-2797-2010	Czyzyk, Traci/0000-0002-3888-8338	NIDA NIH HHS [P01 DA015916-05, T32 DA007278, T32 DA 07278, R01 DA 11672, P01 DA015916-010001, R03 DA 16656, R01 DA011672-05, P01 DA015916-03, T32 DA007278-05, T32 DA007278-07, P01 DA015916-01, R01 DA 09040, P01 DA015916-04, P01 DA015916, R01 DA011672-04, T32 DA007278-06, T32 DA007278-08, R01 DA011672-03, R01 DA011672, P01 DA015916-02, R01 DA011672-02, R01 DA011672-01A1] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007278, P01DA015916, R03DA016656, R01DA011672, R01DA009040] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Appleyard SM, 1999, J BIOL CHEM, V274, P23802, DOI 10.1074/jbc.274.34.23802; Appleyard SM, 1997, J NEUROCHEM, V69, P2405; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Bohn LM, 2002, J NEUROSCI, V22, P10494; Chavkin C, 2001, MOL PHARMACOL, V60, P20, DOI 10.1124/mol.60.1.20; Clarke S, 2002, EUR J NEUROSCI, V16, P1705, DOI 10.1046/j.1460-9568.2002.02239.x; COX BM, 1993, OPIOIDS 1 HDB EXPT P, V104; Deng HB, 2001, BRAIN RES, V898, P204, DOI 10.1016/S0006-8993(01)02179-5; Drake CT, 1996, J COMP NEUROL, V370, P377; Gutstein HB, 2001, GOODMAN GILMANS PHAR, P569; Hasbi A, 2000, J PHARMACOL EXP THER, V293, P237; Hasbi A, 1998, J NEUROCHEM, V70, P2129; HORAN P, 1992, J PHARMACOL EXP THER, V260, P1237; JAMES IF, 1982, P NATL ACAD SCI-BIOL, V79, P7570, DOI 10.1073/pnas.79.23.7570; Jin WZ, 1997, J PHARMACOL EXP THER, V281, P123; JOSEPH DB, 1995, J PHARMACOL EXP THER, V272, P970; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; Li JG, 2000, MOL PHARMACOL, V58, P795, DOI 10.1124/mol.58.4.795; McLaughlin JP, 2003, J BIOL CHEM, V278, P34631, DOI 10.1074/jbc.M304022200; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Nestler EJ, 1997, CURR OPIN NEUROBIOL, V7, P713, DOI 10.1016/S0959-4388(97)80094-3; PEI G, 1995, MOL PHARMACOL, V48, P173; Peppel K, 1997, J BIOL CHEM, V272, P25425, DOI 10.1074/jbc.272.41.25425; PORTOGHESE PS, 1978, J MED CHEM, V21, P598, DOI 10.1021/jm00205a002; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886; VAUGHT JL, 1979, J PHARMACOL EXP THER, V208, P86; VILLAR VM, 1992, PHARMACOLOGY, V45, P319, DOI 10.1159/000139017; XIE GX, 1994, P NATL ACAD SCI USA, V91, P3779, DOI 10.1073/pnas.91.9.3779	36	89	93	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1810	1818		10.1074/jbc.M305796200	http://dx.doi.org/10.1074/jbc.M305796200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14597630	hybrid, Green Accepted			2022-12-25	WOS:000188005700031
J	Jin, P; Zhang, J; Rowe-Teeter, C; Yang, JM; Stuve, LL; Fu, GK				Jin, P; Zhang, J; Rowe-Teeter, C; Yang, JM; Stuve, LL; Fu, GK			Cloning and characterization of a GABA(A) receptor gamma(2) subunit variant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICE-MEDIATED INSERTION; A RECEPTORS; PROTEIN GABARAP; ALU SEQUENCE; MUTATION; GAMMA-2-SUBUNIT; EXPRESSION; SUBTYPES; EPILEPSY; EXON	We have cloned a novel gamma-aminobutyric acid type A (GABA(A)) receptor gamma(2) subunit variant named gamma(2)XL. gamma(2)XL contains an alternatively spliced exon, resulting in the addition of 40 amino acids to the N-terminal extracellular domain between Ser(171) and Tyr(172). We show that gamma(2)XL failed to localize to the cell surface when it was coexpressed with the alpha(2) and beta(1) subunits in human embryonic kidney 293 cells. Expression of beta(2)XL in 293 cells suppressed GABA(A) receptor binding in a dose-dependent manner by preventing GABA(A) receptor cell-surface localization. We also generated a gamma(2) mutant with Ser(171) and Tyr(172) converted to glycine and threonine, respectively. We demonstrate that this mutant has a significantly lower affinity for the alpha(2) and beta(1) subunits and failed to reach the cell surface when coexpressed with these subunits. Together, our results indicate that Ser(171) and Tyr(172) in the gamma(2) subunit constitute a critical motif. When this motif is disrupted by insertion of the alternative exon, access of the gamma(2) subunit to the cell surface is prevented.	Incyte Corp, Palo Alto, CA 94304 USA	Incyte	Jin, P (corresponding author), Incyte Corp, 3160 Porter Dr, Palo Alto, CA 94304 USA.	pjin@incyte.com						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARAKI T, 1992, NEUROSCIENCE, V47, P45, DOI 10.1016/0306-4522(92)90119-M; Baulac S, 2001, NAT GENET, V28, P46, DOI 10.1038/88254; Bedford FK, 2001, NAT NEUROSCI, V4, P908, DOI 10.1038/nn0901-908; BLOOM FE, 2001, GOODMAN GILMANS PHAR; Bowser DN, 2002, P NATL ACAD SCI USA, V99, P15170, DOI 10.1073/pnas.212320199; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Connolly CN, 1999, J BIOL CHEM, V274, P36565, DOI 10.1074/jbc.274.51.36565; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; Deininger PL, 1999, MOL GENET METAB, V67, P183, DOI 10.1006/mgme.1999.2864; Deininger PL, 2002, GENOME RES, V12, P1455, DOI 10.1101/gr.282402; Dredge BK, 2003, MOL CELL BIOL, V23, P4687, DOI 10.1128/MCB.23.13.4687-4700.2003; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; Florea L, 1998, GENOME RES, V8, P967, DOI 10.1101/gr.8.9.967; GUTIERREZ A, 1994, J NEUROSCI, V14, P7168; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; Kittler JT, 2001, MOL CELL NEUROSCI, V18, P13, DOI 10.1006/mcne.2001.1005; Kittler JT, 2000, J NEUROSCI, V20, P7972; Klausberger T, 2001, J BIOL CHEM, V276, P16024, DOI 10.1074/jbc.M009508200; Klausberger T, 2001, J NEUROSCI, V21, P9124, DOI 10.1523/JNEUROSCI.21-23-09124.2001; KNEBELMANN B, 1995, HUM MOL GENET, V4, P675, DOI 10.1093/hmg/4.4.675; Kneussel M, 2000, P NATL ACAD SCI USA, V97, P8594, DOI 10.1073/pnas.97.15.8594; Kneussel M, 2002, BRAIN RES REV, V39, P74, DOI 10.1016/S0165-0173(02)00159-5; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lev-Maor G, 2003, SCIENCE, V300, P1288, DOI 10.1126/science.1082588; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; Mighell AJ, 1997, FEBS LETT, V417, P1, DOI 10.1016/S0014-5793(97)01259-3; MITCHELL GA, 1991, P NATL ACAD SCI USA, V88, P815, DOI 10.1073/pnas.88.3.815; NAYEEM N, 1994, J NEUROCHEM, V62, P815; PREGENZER JF, 1993, MOL PHARMACOL, V43, P801; Quinlan JJ, 2000, PHARMACOL BIOCHEM BE, V66, P371, DOI 10.1016/S0091-3057(00)00225-2; Roy-Engel AM, 2002, GENOME RES, V12, P1333, DOI 10.1101/gr.384802; Roy-Engel AM, 2001, GENETICS, V159, P279; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Sorek R, 2002, GENOME RES, V12, P1060, DOI 10.1101/gr.229302; Stangler T, 2002, J BIOL CHEM, V277, P13363, DOI 10.1074/jbc.C200050200; Taylor PM, 2000, J NEUROSCI, V20, P1297; Thanaraj TA, 2001, NUCLEIC ACIDS RES, V29, P2581, DOI 10.1093/nar/29.12.2581; Vervoort R, 1998, HUM GENET, V103, P686, DOI 10.1007/PL00008709; Wallace RH, 2001, NAT GENET, V28, P49, DOI 10.1038/ng0501-49; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966; Whiting PJ, 1997, J NEUROSCI, V17, P5027	44	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1408	1414		10.1074/jbc.M308656200	http://dx.doi.org/10.1074/jbc.M308656200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14593118	hybrid			2022-12-25	WOS:000187722800070
J	Shin, D; Park, C				Shin, D; Park, C			N-terminal extension of canine glutamine synthetase created by splicing alters its enzymatic property	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; HUMAN BRAIN; PROTEIN; EXPRESSION; PURIFICATION; TRANSLATION; SULFOXIMINE; BINDING; BOVINE	It was found that an extra exon exists in the first intron of glutamine synthetase gene, generated by means of alternative splicing ( Shin, D., Park, S., and Park, C. (2003) Biochem. J. 374, 175 - 184). Inclusion of this exon decreased the translation of glutamine synthetase (GS) in human, dog, and mouse. When translated in vitro with the canine GS transcript containing the exon, we obtained two different species of GS enzymes. Besides the known 45-kDa protein, the extended form of GS was identified with additional 40 amino acids on its N-terminal end. An upstream ATG in the extra exon served as a translation initiator for the long form of GS. When the long transcript was translated in vivo in animal cells, only the long GS was expressed. On the other hand, the long GS is less predominant relative to the short one in canine tissues including brain and liver. Subcellular fractionation of canine brain revealed that the long GS is present in all cellular compartments as is the short one, which is consistent with fluorescence microscopy data obtained with green fluorescent protein fused to GS. The short (SGS) and long (LGS) forms of canine GS were purified in Escherichia coli and shown to have similar K-m values for L-glutamate and hydroxylamine. However, the K-m values for ATP were slightly altered, 1.3 and 1.9 mM for the short and long GSs, respectively. The K(i)s for L-methionine-S-sulfoximine (MSOX), a highly potent ATP-dependent inactivator of GS, were considerably different such that the values are 0.067 and 0.124 mM for the short and long forms, respectively. When the intrinsic fluorescences of tryptophans were monitored upon bindings of chloride and metal ions without any effect on the oligomeric state, the pattern of quenching in LGS was significantly different from that of SGS. Taken together, the N-terminal extension in the long isoform of GS induces a conformational change of core enzyme, leading to a change in affinity to its substrates as well as in the effector-induced conformational alterations.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Ctr Behav Genet, Natl Creat Res Initiat, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Park, C (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Ctr Behav Genet, Natl Creat Res Initiat, Taejon 305701, South Korea.	ckpark@kaist.ac.kr	Park, Chankyu/C-1936-2011					Boksha IS, 2000, J NEUROCHEM, V75, P2574, DOI 10.1046/j.1471-4159.2000.0752574.x; Boksha IS, 2002, BIOCHEMISTRY-MOSCOW+, V67, P1012, DOI 10.1023/A:1020574003027; CAMPBELL JW, 1992, MOL BIOL EVOL, V9, P787; CARLSSON M, 1990, TRENDS NEUROSCI, V13, P272, DOI 10.1016/0166-2236(90)90108-M; Eisenberg D, 2000, BBA-PROTEIN STRUCT M, V1477, P122, DOI 10.1016/S0167-4838(99)00270-8; Gorovits R, 1997, P NATL ACAD SCI USA, V94, P7024, DOI 10.1073/pnas.94.13.7024; GRIFFITH OW, 1978, J BIOL CHEM, V253, P2333; GUNNERSEN D, 1992, P NATL ACAD SCI USA, V89, P11949, DOI 10.1073/pnas.89.24.11949; HASCHEMEYER RH, 1968, T NEW YORK ACAD SCI, V30, P875, DOI 10.1111/j.2164-0947.1968.tb02531.x; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Kim KS, 1998, MOL PHYLOGENET EVOL, V10, P210, DOI 10.1006/mpev.1998.0513; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; LAUD PR, 1994, J MOL EVOL, V39, P93; Lie-Venema H, 1998, PROG NUCLEIC ACID RE, V61, P243, DOI 10.1016/S0079-6603(08)60829-6; Listrom CD, 1997, BIOCHEM J, V328, P159; MAURIZI MR, 1987, BIOCHEMISTRY-US, V26, P5023, DOI 10.1021/bi00390a021; MAURIZI MR, 1986, ARCH BIOCHEM BIOPHYS, V246, P494, DOI 10.1016/0003-9861(86)90496-0; MEISTER A, 1985, METHOD ENZYMOL, V113, P185; MEISTER A, 1974, ENZYMES, V10, P699; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Oyama R, 2000, BBA-PROTEIN STRUCT M, V1479, P91, DOI 10.1016/S0167-4838(00)00057-1; Robinson SR, 2000, NEUROCHEM INT, V36, P471, DOI 10.1016/S0197-0186(99)00150-3; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; Sambrook J, 2001, MOL CLONING LAB MANU; Santoro JC, 2001, ANAL BIOCHEM, V289, P18, DOI 10.1006/abio.2000.4911; Shin D, 2003, BIOCHEM J, V374, P175, DOI 10.1042/BJ20030132; Takeda A, 2003, BRAIN RES REV, V41, P79, DOI 10.1016/S0165-0173(02)00234-5; Uhlmann-Schiffler H, 2002, J BIOL CHEM, V277, P1066, DOI 10.1074/jbc.M107535200; Wang YM, 1996, GENOMICS, V37, P195, DOI 10.1006/geno.1996.0542	30	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1184	1190		10.1074/jbc.M309940200	http://dx.doi.org/10.1074/jbc.M309940200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14583610	hybrid			2022-12-25	WOS:000187722800043
J	Crnkovic-Mertens, I; Hoppe-Seyler, F; Butz, K				Crnkovic-Mertens, I; Hoppe-Seyler, F; Butz, K			Induction of apoptosis in tumor cells by siRNA-mediated silencing of the livin/ML-IAP/KIAP gene	ONCOGENE			English	Article						RNA interference; inhibitors of apoptosis; chemotherapy; HeLa; melanoma	SMALL INTERFERING RNAS; POSITIVE CANCER-CELLS; MAMMALIAN-CELLS; IN-VIVO; PROTEIN FAMILY; IAP PROTEINS; EXPRESSION; INHIBITOR; DELIVERY; DEATH	Increased resistance to apoptosis is a hallmark of many tumor cells. The functional inhibition of specific antiapoptotic factors may provide a rational basis for the development of novel therapeutic strategies. We investigated here whether the RNA interference (RNAi) technology could be used to increase the apoptotic susceptibility of cancer cells. As a molecular target, we chose the antiapoptotic livin (ML-IAP, KIAP) gene, which is expressed in a subset of human tumors. We identified vector-borne small interfering (si)RNAs, which could efficiently block endogenous livin gene expression. Silencing of livin was associated with caspase-3 activation and a strongly increased apoptotic rate in response to different proapoptotic stimuli, such as doxorubicin, UV-irradiation, or TNFalpha. The effects were specific for Livin-expressing tumor cells. Our results (i) provide direct evidence that the intracellular interference with livin gene expression resensitizes human tumor cells to apoptosis, (ii) define the livin gene as a promising molecular target for therapeutic inhibition, and (iii) show that the livin gene is susceptible to efficient and specific silencing by the siRNA technology.	Deutsch Krebsforschungszentrum, Angewandte Tumorvirol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Butz, K (corresponding author), Deutsch Krebsforschungszentrum, Angewandte Tumorvirol, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.			Hoppe-Seyler, Felix/0000-0002-1864-300X				Agami R, 2002, CURR OPIN CHEM BIOL, V6, P829, DOI 10.1016/S1367-5931(02)00378-2; Ashhab Y, 2001, FEBS LETT, V495, P56, DOI 10.1016/S0014-5793(01)02366-3; Borkhardt A, 2002, CANCER CELL, V2, P167, DOI 10.1016/S1535-6108(02)00129-0; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; BUTZ K, 1993, J VIROL, V67, P6476, DOI 10.1128/JVI.67.11.6476-6486.1993; Butz K, 1999, ONCOGENE, V18, P2381, DOI 10.1038/sj.onc.1202557; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Gazzaniga P, 2003, ANN ONCOL, V14, P85, DOI 10.1093/annonc/mdg002; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944; Lin JH, 2000, BIOCHEM BIOPH RES CO, V279, P820, DOI 10.1006/bbrc.2000.4027; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Rittner K, 2002, MOL THER, V5, P104, DOI 10.1006/mthe.2002.0523; Rothbard JB, 2002, J MED CHEM, V45, P3612, DOI 10.1021/jm0105676; Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; SONG E, 2003, NAT MED, V10, P2002; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, APOPTOSIS, V7, P163, DOI 10.1023/A:1014318615955; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Wilda M, 2002, ONCOGENE, V21, P5716, DOI 10.1038/sj.onc.1205653; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739	48	81	125	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8330	8336		10.1038/sj.onc.1206973	http://dx.doi.org/10.1038/sj.onc.1206973			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614456				2022-12-25	WOS:000186541500011
J	Ricaud, S; Vernus, B; Duclos, M; Bernardi, H; Ritvos, O; Carnac, G; Bonnieu, A				Ricaud, S; Vernus, B; Duclos, M; Bernardi, H; Ritvos, O; Carnac, G; Bonnieu, A			Inhibition of autocrine secretion of myostatin enhances terminal differentiation in human rhabdomyosarcoma cells	ONCOGENE			English	Article						myostatin; rhabdomyosarcoma; autocrine secretion; inhibition of myostatin; inhibition of differentiation; MyoD activity	HUMAN ALVEOLAR RHABDOMYOSARCOMA; FIBROBLAST GROWTH-FACTOR; MYOGENIC DIFFERENTIATION; GENE-EXPRESSION; MUSCLE-CELLS; REGULATORY FACTORS; PROTEIN-SYNTHESIS; PROLIFERATION; MYOD; INDUCTION	Rhabdomyosarcomas (RMSs) are one of the most common solid tumor of childhood. Rhabdomyosarcoma (RMS) cells fail to both complete the skeletal muscle differentiation program and irreversibly exit the cell cycle as a consequence of an active repression exerted on the muscle-promoting factor MyoD. Myostatin is a negative regulator of normal muscle growth, we have thus studied its possible role in RMS cells. Here, we present evidence that overexpression of myostatin is a common feature of RMS since both subtypes of RMS (embryonal RD and alveolar Rh30 cells) express high levels of myostatin when compared to nontumoral skeletal muscle cells. Interestingly, we found that inactivation of myostatin through overexpression of antisense myostatin or of follistatin (a myostatin antagonist) constructs enhanced differentiation of RD cells. In addition, RD and Rh30 cells treated with blocking antimyostatin antibodies progress into the myogenic terminal differentiation program. Finally, our results suggest that high levels of myostatin could impair MyoD function in RMS cells. These results show that an autocrine myostatin loopcontributes to maintain RMS cells in an undifferentiating stage and suggest that new therapeutic approaches could be exploited for the treatment of RMS based on inactivation of myostatin protein.	INRA, UMR Differenciat Cellulaire & Croissance 866, F-34060 Montpellier 1, France; INRA, Rech Avicoles Stn, F-37380 Nouzilly, France; Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, FIN-00014 Helsinki, Finland; Univ Helsinki, Programme Dev & Reprod Biol, Biomedicum Helsinki, FIN-00014 Helsinki, Finland; CNRS, FRE 2593, CRBM, F-34293 Montpellier 5, France	INRAE; INRAE; University of Helsinki; University of Helsinki; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Bonnieu, A (corresponding author), INRA, UMR Differenciat Cellulaire & Croissance 866, F-34060 Montpellier 1, France.		DUCLOS, Michel/AAQ-3957-2021; Bonnieu, Anne/ABA-7182-2020; Ritvos, Olli/GWC-2442-2022; Carnac, Gilles/N-6744-2018	DUCLOS, Michel/0000-0002-9305-3982; Carnac, Gilles/0000-0002-3518-8774; Bernardi, Henri/0000-0003-3570-8925; Ritvos, Olli/0000-0001-7017-6931				Alric S, 1998, ONCOGENE, V16, P273, DOI 10.1038/sj.onc.1201484; Artaza JN, 2002, J CELL PHYSIOL, V190, P170, DOI 10.1002/JCP.10044; Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; Bouche M, 2000, FASEB J, V14, P1147, DOI 10.1096/fasebj.14.9.1147; BOUCHE M, 1993, EXP CELL RES, V208, P209, DOI 10.1006/excr.1993.1239; DeGiovanni C, 1996, CANCER RES, V56, P3898; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; Froeschle A, 1998, ONCOGENE, V16, P3369, DOI 10.1038/sj.onc.1201894; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Gonzalez-Cadavid NF, 1998, P NATL ACAD SCI USA, V95, P14938, DOI 10.1073/pnas.95.25.14938; Grobet L, 1997, NAT GENET, V17, P71, DOI 10.1038/ng0997-71; JIN P, 1991, J BIOL CHEM, V266, P1245; Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910; Kitzmann M, 1998, J CELL BIOL, V142, P1447, DOI 10.1083/jcb.142.6.1447; Knudsen ES, 1998, CANCER RES, V58, P2042; Langley B, 2002, J BIOL CHEM, V277, P49831, DOI 10.1074/jbc.M204291200; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; Puri PL, 2000, GENE DEV, V14, P574; Rios R, 2002, AM J PHYSIOL-CELL PH, V282, pC993, DOI 10.1152/ajpcell.00372.2001; Rios R, 2001, BIOCHEM BIOPH RES CO, V280, P561, DOI 10.1006/bbrc.2000.4159; SCHWEIGERER L, 1987, P NATL ACAD SCI USA, V84, P842, DOI 10.1073/pnas.84.3.842; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Taylor WE, 2001, AM J PHYSIOL-ENDOC M, V280, pE221, DOI 10.1152/ajpendo.2001.280.2.E221; Thies RS, 2001, GROWTH FACTORS, V18, P251; Thomas M, 2000, J BIOL CHEM, V275, P40235, DOI 10.1074/jbc.M004356200; TONIN PN, 1991, CANCER RES, V51, P5100; Vandromme M, 2001, J BIOL CHEM, V276, P8173, DOI 10.1074/jbc.M005587200; Wagner KR, 2002, ANN NEUROL, V52, P832, DOI 10.1002/ana.10385; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525	44	23	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8221	8232		10.1038/sj.onc.1207177	http://dx.doi.org/10.1038/sj.onc.1207177			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614446				2022-12-25	WOS:000186541500001
J	Suno, R; Taguchi, H; Masui, R; Odaka, M; Yoshida, M				Suno, R; Taguchi, H; Masui, R; Odaka, M; Yoshida, M			Trigger factor from Thermus thermophilus is a Zn2+-dependent chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL ISOMERASE; MOLECULAR CHAPERONES; BINDING-SITE; DNAK; PROTEINS; DOMAIN; SPECIFICITY; DISTINCT	The ribosome-associated chaperone trigger factor (TF) of Escherichia coli interacts with a variety of newly synthesized polypeptides to assist their correct folding. Here, we report that the TF of thermophilic eubacterium, Thermus thermophilus, arrested spontaneous folding of green fluorescent protein by forming a 1:1 binary complex. The complex was isolable by gel-filtration but was shown to be dynamic because green fluorescent protein was released by a-casein in large excess. Unexpectedly, EDTA completely abolished the folding-arrest activity of TF, and analysis revealed that the TF from our preparation contained similar to0.5 mol Zn2+/mol TF. The folding-arrest activity of TF that was saturated with Zn2+ (similar to1 mol/mol TF) was twice as efficient as that of untreated TF. Thus, chaperone activity of thermophilic TF is Zn2+-dependent.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; Japan Sci & Technol Corp, PRESTO, Osaka 5600043, Japan; Osaka Univ, Dept Biol, Osaka 5600043, Japan; RIKEN, Inst Phys & Chem Res, Bioengn Lab, Wako, Saitama 3510198, Japan	Tokyo Institute of Technology; Japan Science & Technology Agency (JST); Osaka University; RIKEN	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, 4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.	myoshida@res.titech.ac.jp	Taguchi, Hideki/B-6946-2009; Odaka, Masafumi/C-2378-2013; taguchi, hideki/AAM-2663-2021	Taguchi, Hideki/0000-0002-6612-9339; taguchi, hideki/0000-0002-6612-9339; Suno, Ryoji/0000-0003-2378-236X				Banecki B, 2001, J BIOL CHEM, V276, P18843, DOI 10.1074/jbc.M007507200; Blaha G, 2003, J MOL BIOL, V326, P887, DOI 10.1016/S0022-2836(02)01436-5; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; CALLEBAUT I, 1995, FEBS LETT, V374, P211, DOI 10.1016/0014-5793(95)01109-R; Craig EA, 2003, CURR OPIN MICROBIOL, V6, P157, DOI 10.1016/S1369-5274(03)00030-4; CROSS RL, 1982, J BIOL CHEM, V257, P2874; Deuerling E, 2003, MOL MICROBIOL, V47, P1317, DOI 10.1046/j.1365-2958.2003.03370.x; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Fekkes P, 1999, BIOCHEMISTRY-US, V38, P5111, DOI 10.1021/bi982818r; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hesterkamp T, 1996, FEBS LETT, V385, P67, DOI 10.1016/0014-5793(96)00351-1; Hesterkamp T, 1997, J BIOL CHEM, V272, P21865, DOI 10.1074/jbc.272.35.21865; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; Huang GC, 2000, BBA-PROTEIN STRUCT M, V1480, P77, DOI 10.1016/S0167-4838(00)00094-7; Huang GC, 2000, PROTEIN SCI, V9, P1254, DOI 10.1110/ps.9.6.1254; Jakob U, 2000, J BIOL CHEM, V275, P38302, DOI 10.1074/jbc.M005957200; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; Li ZY, 2001, FEBS LETT, V506, P108, DOI 10.1016/S0014-5793(01)02896-4; Lyon WR, 2003, J BACTERIOL, V185, P3661, DOI 10.1128/JB.185.12.3661-3667.2003; Maier R, 2003, J MOL BIOL, V326, P585, DOI 10.1016/S0022-2836(02)01427-4; Maier R, 2001, J MOL BIOL, V314, P1181, DOI 10.1006/jmbi.2000.5192; Makino Y, 1997, J BIOL CHEM, V272, P12468, DOI 10.1074/jbc.272.19.12468; Motohashi K, 1996, J BIOL CHEM, V271, P17343, DOI 10.1074/jbc.271.29.17343; Patzelt H, 2001, P NATL ACAD SCI USA, V98, P14244, DOI 10.1073/pnas.261432298; Sakikawa C, 1999, J BIOL CHEM, V274, P21251, DOI 10.1074/jbc.274.30.21251; Scholz C, 1998, J MOL BIOL, V277, P723, DOI 10.1006/jmbi.1997.1604; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; Stoller G, 1996, FEBS LETT, V384, P117, DOI 10.1016/0014-5793(96)00282-7; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; TAGUCHI H, 1991, J BIOL CHEM, V266, P22411; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4	32	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6380	6384		10.1074/jbc.M311572200	http://dx.doi.org/10.1074/jbc.M311572200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14602709	hybrid			2022-12-25	WOS:000188969200023
J	Brown, VM; Krynetski, EY; Krynetskaia, NF; Grieger, D; Mukatira, ST; Murti, KG; Slaughter, CA; Park, HW; Evans, WE				Brown, VM; Krynetski, EY; Krynetskaia, NF; Grieger, D; Mukatira, ST; Murti, KG; Slaughter, CA; Park, HW; Evans, WE			A novel CRM1-mediated nuclear export signal governs nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase following genotoxic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FELINE IMMUNODEFICIENCY VIRUS; CEREBELLAR GRANULE CELLS; INFECTIOUS-ANEMIA VIRUS; INDUCED APOPTOSIS; LEPTOMYCIN B; PROTEIN COMPLEX; TRANSLOCATION; REV; INHIBITOR; RNA	Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a multifunctional protein with glycolytic and non-glycolytic functions, including pro-apoptotic activity. GAPDH accumulates in the nucleus after cells are treated with genotoxic drugs, and it is present in a protein complex that binds DNA modified by thioguanine incorporation. We identified a novel CRM1-dependent nuclear export signal (NES) comprising 13 amino acids (KKVVKQASEGPLK) in the C-terminal domain of GAPDH, truncation or mutation of which abrogated CRM1 binding and caused nuclear accumulation of GAPDH. Alanine scanning of the sequence encompassing the putative NES demonstrated at least two regions important for nuclear export. Site mutagenesis of Lys(259) did not affect oligomerization but impaired nuclear efflux of GAPDH, indicating that this amino acid residue is essential for proper functioning of this NES. This novel NES does not contain multiple leucine residues unlike other CRM1-interacting NES, is conserved in GAPDH from multiple species, and has sequence similarities to the export signal found in feline immunodeficiency virus Rev protein. Similar sequences (KKVV*7-13PLK) were found in two other human proteins, U5 small nuclear ribonucleoprotein, and transcription factor BT3.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Sci Imaging Shared Resource, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; Univ Tennessee, Dept Pharmaceut Sci, Memphis, TN 38163 USA; Univ Tennessee, Dept Pharm, Memphis, TN 38163 USA; Univ Tennessee, Dept Pediat, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Evans, WE (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.	william.evans@stjude.org	Evans, William E./C-2069-2012	Evans, William E./0000-0002-9333-5322	NCI NIH HHS [R25 CA023944, CA-21765, R37-CA36401] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R25CA023944, R37CA036401, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bear J, 1999, MOL CELL BIOL, V19, P6306; Berry MD, 2000, J NEUROSCI RES, V60, P150, DOI 10.1002/(SICI)1097-4547(20000415)60:2<150::AID-JNR3>3.0.CO;2-4; Carlile GW, 2000, MOL PHARMACOL, V57, P2; Daelemans D, 2002, P NATL ACAD SCI USA, V99, P14440, DOI 10.1073/pnas.212285299; Dastoor Z, 2001, J CELL SCI, V114, P1643; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fornerod M, 1997, GENOMICS, V42, P538, DOI 10.1006/geno.1997.4767; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Hope TJ, 1997, CHEM BIOL, V4, P335, DOI 10.1016/S1074-5521(97)90124-1; Ishitani R, 1997, MOL PHARMACOL, V51, P542, DOI 10.1124/mol.51.4.542; Ishitani R, 1996, J PHARMACOL EXP THER, V278, P447; Ishitani R, 2003, PROG NEURO-PSYCHOPH, V27, P291, DOI 10.1016/S0278-5846(03)00024-1; Ishitani R, 1998, MOL PHARMACOL, V53, P701, DOI 10.1124/mol.53.4.701; *J WIL SONS INC, 1991, CURR PROT MOL BIOL, V1; Krynetskaia NF, 2003, MOL PHARMACOL, V64, P456, DOI 10.1124/mol.64.2.456; Krynetski EY, 2001, MOL PHARMACOL, V59, P367, DOI 10.1124/mol.59.2.367; Krynetski EY, 2003, CANCER RES, V63, P100; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Lischka P, 2001, EMBO J, V20, P7271, DOI 10.1093/emboj/20.24.7271; MANCUSO VA, 1994, J VIROL, V68, P1998, DOI 10.1128/JVI.68.3.1998-2001.1994; Mazzola JL, 2002, NEUROTOXICOLOGY, V23, P603, DOI 10.1016/S0161-813X(02)00062-1; Murai N, 2003, J BIOL CHEM, V278, P44791, DOI 10.1074/jbc.M308059200; Otero GC, 1998, J VIROL, V72, P7593, DOI 10.1128/JVI.72.9.7593-7597.1998; Palmeri D, 1996, J VIROL, V70, P6442, DOI 10.1128/JVI.70.9.6442-6445.1996; PIETERS R, 1988, CANCER LETT, V41, P323, DOI 10.1016/0304-3835(88)90294-7; Saunders PA, 1997, J NEUROCHEM, V69, P1820; Saunders PA, 1999, J NEUROCHEM, V72, P925, DOI 10.1046/j.1471-4159.1999.0720925.x; Sawa A, 1997, P NATL ACAD SCI USA, V94, P11669, DOI 10.1073/pnas.94.21.11669; Schmitz HD, 2002, CELL BIOL INT, V26, P155, DOI 10.1006/cbir.2001.0819; Schmitz HD, 2001, EUR J CELL BIOL, V80, P419, DOI 10.1078/0171-9335-00174; Sirover MA, 1997, J CELL BIOCHEM, V66, P133, DOI 10.1002/(SICI)1097-4644(19970801)66:2<133::AID-JCB1>3.3.CO;2-V; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; Vaudry D, 2003, SCIENCE, V300, P1532, DOI 10.1126/science.1085260; WEN W, 1995, J BIOL CHEM, V270, P2041, DOI 10.1074/jbc.270.5.2041; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	35	71	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5984	5992		10.1074/jbc.M307071200	http://dx.doi.org/10.1074/jbc.M307071200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14617633	hybrid			2022-12-25	WOS:000188776500114
J	Iwai, S; Ishiji, A; Mabuchi, I; Sutoh, K				Iwai, S; Ishiji, A; Mabuchi, I; Sutoh, K			A novel actin-bundling kinesin-related protein from Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; CROSS-LINKING; ORGANELLE TRANSPORT; TARGETED DISRUPTION; MOTOR PROTEIN; F-ACTIN; MYOSIN; DOMAIN; MICROTUBULES; MELANOPHORES	Actin filaments and microtubules are two major cytoskeletal systems involved in wide cellular processes, and the organizations of their filamentous networks are regulated by a large number of associated proteins. Recently, evidence has accumulated for the functional cooperation between the two filament systems via associated proteins. However, little is known about the interactions of the kinesin superfamily proteins, a class of microtubule-based motor proteins, with actin filaments. Here, we describe the identification and characterization of a novel kinesin-related protein named DdKin5 from Dictyostelium. DdKin5 consists of an N-terminal conserved motor domain, a central stalk region, and a C-terminal tail domain. The motor domain showed binding to microtubules in an ATP-dependent manner that is characteristic of kinesin-related proteins. We found that the C-terminal tail domain directly interacts with actin filaments and bundles them in vitro. Immunofluorescence studies showed that DdKin5 is specifically enriched at the actin-rich surface protrusions in cells. Overexpression of the DdKin5 protein affected the organization of actin filaments in cells. We propose that a kinesin-related protein, DdKin5, is a novel actin-bundling protein and a potential cross-linker of actin filaments and microtubules associated with specific actin-based structures in Dictyostelium.	Univ Tokyo, Dept Life Sci, Meguro Ku, Tokyo 1538902, Japan	University of Tokyo	Sutoh, K (corresponding author), Univ Tokyo, Dept Life Sci, Meguro Ku, 3-8-1 Komaba, Tokyo 1538902, Japan.	sutoh@bio.c.u-tokyo.ac.jp		Iwai, Sosuke/0000-0002-0794-9767				ADACHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1808, DOI 10.1006/bbrc.1994.2880; Barth C, 1998, NUCLEIC ACIDS RES, V26, P3317, DOI 10.1093/nar/26.13.3317; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Brazill DT, 2000, J BIOL CHEM, V275, P19231, DOI 10.1074/jbc.M000900200; BROWN SS, 1982, J CELL BIOL, V93, P205, DOI 10.1083/jcb.93.1.205; COX D, 1992, J CELL BIOL, V116, P943, DOI 10.1083/jcb.116.4.943; COX D, 1995, J CELL BIOL, V128, P819, DOI 10.1083/jcb.128.5.819; de Hostos EL, 1998, MOL BIOL CELL, V9, P2093, DOI 10.1091/mbc.9.8.2093; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DHARMAWARDHANE S, 1989, CELL MOTIL CYTOSKEL, V13, P57, DOI 10.1002/cm.970130107; ELZINGA M, 1973, P NATL ACAD SCI USA, V70, P2687, DOI 10.1073/pnas.70.9.2687; Firtel RA, 2000, BIOESSAYS, V22, P603, DOI 10.1002/1521-1878(200007)22:7<603::AID-BIES3>3.0.CO;2-#; FUKUI Y, 1987, METHOD CELL BIOL, V28, P347; GIFFARD RG, 1983, J MUSCLE RES CELL M, V4, P115, DOI 10.1007/BF00711962; Goldstein LSB, 2001, TRENDS CELL BIOL, V11, P477, DOI 10.1016/S0962-8924(01)02143-2; HAUGWITZ M, 1994, CELL, V79, P303, DOI 10.1016/0092-8674(94)90199-6; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; HOWARD PK, 1988, NUCLEIC ACIDS RES, V16, P2613, DOI 10.1093/nar/16.6.2613; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; HUANG TG, 1994, J BIOL CHEM, V269, P16502; Iwai S, 2000, FEBS LETT, V475, P47, DOI 10.1016/S0014-5793(00)01619-7; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; Jung G, 2001, J CELL BIOL, V153, P1479, DOI 10.1083/jcb.153.7.1479; JUNG G, 1994, FEBS LETT, V342, P197, DOI 10.1016/0014-5793(94)80500-8; Klopfenstein DR, 2002, J MUSCLE RES CELL M, V23, P631, DOI 10.1023/A:1024403006680; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; Koonce MP, 1999, EMBO J, V18, P6786, DOI 10.1093/emboj/18.23.6786; Koonce MP, 1996, MOL BIOL CELL, V7, P935, DOI 10.1091/mbc.7.6.935; Krylyshkina O, 2002, J CELL BIOL, V156, P349, DOI 10.1083/jcb.200105051; Kuriyama R, 2002, J CELL BIOL, V156, P783, DOI 10.1083/jcb.200109090; Lee EY, 2001, BBA-GEN SUBJECTS, V1525, P217, DOI 10.1016/S0304-4165(01)00107-6; Maselli AG, 2002, J CELL SCI, V115, P1939; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; Nilsson H, 1997, CELL MOTIL CYTOSKEL, V38, P397, DOI 10.1002/(SICI)1097-0169(1997)38:4<397::AID-CM9>3.3.CO;2-5; Noegel AA, 2000, J CELL SCI, V113, P759; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; Pollock N, 1999, J CELL BIOL, V147, P493, DOI 10.1083/jcb.147.3.493; Prahlad V, 1998, J CELL BIOL, V143, P159, DOI 10.1083/jcb.143.1.159; Puius YA, 1998, CURR OPIN CELL BIOL, V10, P23, DOI 10.1016/S0955-0674(98)80083-5; Rivero F, 1999, J CELL SCI, V112, P2737; Rodionov VI, 1998, CURR BIOL, V8, P165, DOI 10.1016/S0960-9822(98)70064-8; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; Rogers SL, 1998, CURR BIOL, V8, P161, DOI 10.1016/S0960-9822(98)70063-6; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; SHAW DR, 1989, MOL GEN GENET, V218, P453, DOI 10.1007/BF00332409; Steck TL, 1997, J EUKARYOT MICROBIOL, V44, P503, DOI 10.1111/j.1550-7408.1997.tb05731.x; STEINBERG G, 1995, MOL BIOL CELL, V6, P1605, DOI 10.1091/mbc.6.11.1605; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; Terada S, 2000, CELL, V103, P141, DOI 10.1016/S0092-8674(00)00094-5; Tuma MC, 1998, J CELL BIOL, V143, P1547, DOI 10.1083/jcb.143.6.1547; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; Waterman-Storer C, 2000, J CELL BIOL, V150, P361, DOI 10.1083/jcb.150.2.361; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WHITE E, 1983, J CELL BIOL, V97, P1011, DOI 10.1083/jcb.97.4.1011; Xia CH, 2003, J CELL BIOL, V161, P55, DOI 10.1083/jcb.200301026; Yabe JT, 1999, J CELL SCI, V112, P3799	62	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4696	4704		10.1074/jbc.M308022200	http://dx.doi.org/10.1074/jbc.M308022200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14623897	hybrid			2022-12-25	WOS:000188554300093
J	Lai, YR; Tse, CM; Unadkat, JD				Lai, YR; Tse, CM; Unadkat, JD			Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EQUILIBRATIVE NUCLEOSIDE TRANSPORTERS; REVERSE-TRANSCRIPTASE INHIBITORS; DNA-POLYMERASE-GAMMA; CANCER-CELL LINES; HEPATITIS-B; DEOXYCYTIDINE KINASE; THYMIDINE KINASE; RAT TESTIS; ANALOGS; CYTOTOXICITY	Many antiviral drugs (e.g. fialuridine; FIAU) produce clinically significant mitochondrial toxicity that limits their dose or prevents their use in the clinic. Because the majority of nucleoside drugs is too hydrophilic to cross the highly impermeable mitochondrial membrane, we have hypothesized that they must be transported into the mitochondria to produce their toxicity. To test this hypothesis, we have sought to determine whether the nucleoside transporters, human equilibrative nucleoside transporter 1 (hENT1) or human concentrative nucleoside transporter 1 (hCNT1), when stably expressed in Madin-Darby canine kidney cells as yellow fluorescent fusion protein (YFP), are localized to the mitochondria. By using organelle-selective dyes and confocal microscopy, we have found that hENT1-YFP is localized to the mitochondria as well as the plasma membrane, whereas hCNT1-YFP was found predominantly on the plasma membrane. hENT1-YFP was not localized to the nuclear envelope, endosomes, lysosomes, or Golgi complex. Western blotting confirmed the presence of hENT1-YFP or endogenous hENT1 in mitochondria isolated from hENT1-YFP-expressing cells and human livers, respectively. In agreement with these localization data, [C-14]FIAU was efficiently transported into the mitochondria of cells expressing hENT1-YFP but not of cells expressing hCNT1-YFP. The mitochondrial toxicity of FIAU to Madin-Darby canine kidney cells was enhanced by hENT1-YFP, even when hENT1 activity on the plasma membrane was selectively blocked by 10 nM nitrobenzylthioinosine. Moreover, FIAU (50 mum) produced significant mitochondrial toxicity (similar to70% decrease in mitochondrial DNA synthesis) when it was directly incubated with mitochondria isolated from hENT1-expressing cells. In conclusion, we have identified for the first time that hENT1 is expressed on the mitochondrial membrane and that this expression enhances the mitochondrial toxicity of nucleoside drugs such as FIAU. Mitochondrial expression of hENTs may explain the clinically significant mitochondrial toxicity caused by the anti-HIV nucleoside drugs such as zidovudine, stavudine, and didanosine.	Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21205 USA	University of Washington; University of Washington Seattle; Johns Hopkins University	Unadkat, JD (corresponding author), Univ Washington, Dept Pharmaceut, Box 357610, Seattle, WA 98195 USA.	jash@u.washington.edu	Lai, Yurong/ABG-4485-2021; Lai, Yurong/GWV-6243-2022	Lai, Yurong/0000-0001-9505-333X; 	NIGMS NIH HHS [GM54447] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054447] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANKI K, 1989, CARCINOGENESIS, V10, P767, DOI 10.1093/carcin/10.4.767; Barile M, 1997, BIOCHEM PHARMACOL, V53, P913, DOI 10.1016/S0006-2952(96)00831-3; Beausejour CM, 2002, BIOCHEM BIOPH RES CO, V293, P1478, DOI 10.1016/S0006-291X(02)00413-8; Benbrik E, 1997, J NEUROL SCI, V149, P19, DOI 10.1016/S0022-510X(97)05376-8; Bridges EG, 1999, J BIOL CHEM, V274, P4620, DOI 10.1074/jbc.274.8.4620; Brinkman K, 1998, AIDS, V12, P1735, DOI 10.1097/00002030-199814000-00004; Camins A, 1996, LIFE SCI, V58, P753, DOI 10.1016/0024-3205(95)02353-4; CASS CE, 1973, BIOCHIM BIOPHYS ACTA, V291, P734, DOI 10.1016/0005-2736(73)90477-X; DALUGE SM, 1994, ANTIMICROB AGENTS CH, V38, P1590, DOI 10.1128/AAC.38.7.1590; Davis AF, 1996, NUCLEIC ACIDS RES, V24, P2753, DOI 10.1093/nar/24.14.2753; Dolce V, 2001, P NATL ACAD SCI USA, V98, P2284, DOI 10.1073/pnas.031430998; Feng JY, 2001, J BIOL CHEM, V276, P23832, DOI 10.1074/jbc.M101156200; Genini D, 2000, BLOOD, V96, P3537; Groschel B, 2002, BIOCHEM PHARMACOL, V64, P239, DOI 10.1016/S0006-2952(02)01109-7; Hickman D, 1998, DRUG METAB DISPOS, V26, P207; Horn DM, 1997, ANTIVIR RES, V34, P71, DOI 10.1016/S0166-3542(96)01027-3; Hyde RJ, 2001, MOL MEMBR BIOL, V18, P53, DOI 10.1080/09687680110033765; Jimenez A, 2000, EUR J PHARMACOL, V398, P31, DOI 10.1016/S0014-2999(00)00297-1; Kakuda TN, 1999, AIDS, V13, P2311, DOI 10.1097/00002030-199911120-00019; Kakuda TN, 2000, CLIN THER, V22, P685, DOI 10.1016/S0149-2918(00)90004-3; KLECKER RW, 1994, MOL PHARMACOL, V46, P1204; Lai YR, 2002, J BIOL CHEM, V277, P37711, DOI 10.1074/jbc.M204986200; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; Lum PY, 2000, CANCER CHEMOTH PHARM, V45, P273, DOI 10.1007/s002800050040; Mackey JR, 1998, CANCER RES, V58, P4349; Mangravite LM, 2003, AM J PHYSIOL-RENAL, V284, pF902, DOI 10.1152/ajprenal.00215.2002; Mani RS, 1998, J BIOL CHEM, V273, P30818, DOI 10.1074/jbc.273.46.30818; MARTIN JL, 1994, ANTIMICROB AGENTS CH, V38, P2743, DOI 10.1128/AAC.38.12.2743; MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702; PARKER WB, 1994, CANCER RES, V54, P1742; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; RETTIE AE, 1989, DRUG METAB DISPOS, V17, P265; Riddler SA, 1996, ANTIMICROB AGENTS CH, V40, P2842, DOI 10.1128/AAC.40.12.2842; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; STASCHKE KA, 1994, ANTIVIR RES, V23, P45, DOI 10.1016/0166-3542(94)90032-9; Walker UA, 2000, LANCET, V355, P1096, DOI 10.1016/S0140-6736(05)72215-7; Wang JH, 1996, ANTIMICROB AGENTS CH, V40, P1555, DOI 10.1128/AAC.40.6.1555; Wang JH, 2000, BIOCHEM PHARMACOL, V59, P1583, DOI 10.1016/S0006-2952(00)00285-9; Wang L, 1999, FEBS LETT, V443, P170, DOI 10.1016/S0014-5793(98)01711-6; Ward JL, 2000, J BIOL CHEM, V275, P8375, DOI 10.1074/jbc.275.12.8375; White AJ, 2001, SEX TRANSM INFECT, V77, P158, DOI 10.1136/sti.77.3.158; Yao SYM, 2001, MOL MEMBR BIOL, V18, P161, DOI 10.1080/09687680110048318; Zhu CY, 1998, J BIOL CHEM, V273, P14707, DOI 10.1074/jbc.273.24.14707	44	107	110	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4490	4497		10.1074/jbc.M307938200	http://dx.doi.org/10.1074/jbc.M307938200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14607828	hybrid			2022-12-25	WOS:000188554300069
J	Li, G; Niu, L				Li, G; Niu, L			How fast does the G1uR1Q(flip) channel open?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LASER-PULSE PHOTOLYSIS; MICROSECOND TIME REGION; LIGAND-BINDING CORE; GLUTAMATE-RECEPTOR DESENSITIZATION; NICOTINIC ACETYLCHOLINE-RECEPTOR; AMPA RECEPTOR; HIPPOCAMPAL-NEURONS; KINETIC INVESTIGATIONS; LOCAL-ANESTHETICS; OPEN PROBABILITY	Opening of a ligand-gated ion channel is the step at which the binding of a neurotransmitter is transduced into the electrical signal by allowing ions to flow through the transmembrane channel, thereby altering the postsynaptic membrane potential. We report the kinetics for the opening of the GluR1Q(flip) channel, an alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor subunit of the ionotropic glutamate receptors. Using a laser-pulse photolysis technique that permits glutamate to be liberated photolytically from gamma-O-(alpha-carboxy-2-nitrobenzyl)glutamate (caged glutamate) with a time constant of similar to30 mus, we show that, after the binding of glutamate, the channel opened with a rate constant of (2.9 +/- 0.2) x 10(4) s(-1) and closed with a rate constant of (2.1 +/- 0.1) x 10(3) s(-1). The observed shortest rise time (20-80% of the receptor current response), i.e. the fastest time by which the GluR1Q(flip) channel can open, was predicted to be 35 mus. This value is three times shorter than those previously reported. The minimal kinetic mechanism for channel opening consists of binding of two glutamate molecules, with the channel-opening probability being 0.93 +/- 0.10. These findings identify GluR1Q(flip) as one of the temporally efficient receptors that transduce the binding of chemical signals (i.e. glutamate) into an electrical impulse.	SUNY Albany, Dept Chem, Albany, NY 12222 USA; SUNY Albany, Neurosci Res Ctr, Albany, NY 12222 USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Niu, L (corresponding author), SUNY Albany, Dept Chem, 1400 Washington Ave, Albany, NY 12222 USA.	lniu@albany.edu						Abele R, 2000, J BIOL CHEM, V275, P21355, DOI 10.1074/jbc.M909883199; Armstrong N, 2003, P NATL ACAD SCI USA, V100, P5736, DOI 10.1073/pnas.1037393100; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; AUERBACH A, 1984, BIOPHYS J, V45, P187, DOI 10.1016/S0006-3495(84)84147-8; Banke TG, 2000, J NEUROSCI, V20, P89, DOI 10.1523/JNEUROSCI.20-01-00089.2000; Banke TG, 2001, J NEUROSCI, V21, P3052, DOI 10.1523/JNEUROSCI.21-09-03052.2001; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Carlezon WA, 2001, NEUROPSYCHOPHARMACOL, V25, P234, DOI 10.1016/S0893-133X(01)00232-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Clements JD, 1998, J NEUROSCI, V18, P119; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; COLQUHOUN D, 1985, J PHYSIOL-LONDON, V369, P501, DOI 10.1113/jphysiol.1985.sp015912; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; CONNORS KA, 1990, CHEM KINETICS STUDY, P245; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; Dingledine R, 1999, PHARMACOL REV, V51, P7; Fitzgerald LW, 1996, J NEUROSCI, V16, P274; Fleck MW, 1996, J NEUROPHYSIOL, V75, P2322, DOI 10.1152/jn.1996.75.6.2322; FRANKE C, 1991, BIOPHYS J, V60, P1008, DOI 10.1016/S0006-3495(91)82138-5; Grewer C, 1999, BIOCHEMISTRY-US, V38, P7837, DOI 10.1021/bi9827767; Grosskreutz J, 2003, EUR J NEUROSCI, V17, P1173, DOI 10.1046/j.1460-9568.2003.02531.x; Heckmann M, 1996, BIOPHYS J, V71, P1743, DOI 10.1016/S0006-3495(96)79375-X; Hess G P, 1998, Methods Enzymol, V291, P443; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Inglis FM, 2002, J NEUROSCI, V22, P8042; Jayaraman V, 1998, BIOCHEMISTRY-US, V37, P16735, DOI 10.1021/bi9813328; Jayaraman V, 1999, BIOCHEMISTRY-US, V38, P11406, DOI 10.1021/bi991219x; Jayaraman V, 1999, BIOCHEMISTRY-US, V38, P11372, DOI 10.1021/bi990454c; Jin RS, 2002, BIOCHEMISTRY-US, V41, P15635, DOI 10.1021/bi020583k; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838; Koike M, 2000, J NEUROSCI, V20, P2166; Lee HK, 2003, CELL, V112, P631, DOI 10.1016/S0092-8674(03)00122-3; Li G, 2003, BIOCHEMISTRY-US, V42, P12367, DOI 10.1021/bi034797t; Li G, 2003, BIOCHEMISTRY-US, V42, P12358, DOI 10.1021/bi0347961; Li HY, 2002, BIOCHEMISTRY-US, V41, P4753, DOI 10.1021/bi0118916; Liao DH, 1999, NAT NEUROSCI, V2, P37, DOI 10.1038/4540; MATSUBARA N, 1992, BIOCHEMISTRY-US, V31, P5507, DOI 10.1021/bi00139a012; McFeeters RL, 2002, BIOCHEMISTRY-US, V41, P10472, DOI 10.1021/bi026010p; MOSBACHER J, 1994, SCIENCE, V266, P1059, DOI 10.1126/science.7973663; NEHER E, 1983, J PHYSIOL-LONDON, V339, P663, DOI 10.1113/jphysiol.1983.sp014741; NEHER E, 1978, J PHYSIOL-LONDON, V277, P153, DOI 10.1113/jphysiol.1978.sp012267; NEHER E, 1976, NATURE, V260, P799, DOI 10.1038/260799a0; Niu L, 1995, P NATL ACAD SCI USA, V92, P12008, DOI 10.1073/pnas.92.26.12008; NIU L, 1996, TECHNIQUES PROTEIN C, V7, P139; Niu Li, 1993, Biochemistry, V32, P3831, DOI 10.1021/bi00066a001; Partin KM, 1996, J NEUROSCI, V16, P6634, DOI 10.1523/jneurosci.16-21-06634.1996; PATNEAU DK, 1991, NEURON, V6, P785, DOI 10.1016/0896-6273(91)90175-Y; PATNEAU DK, 1993, J NEUROSCI, V13, P3496; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; Petralia RS, 1999, NAT NEUROSCI, V2, P31, DOI 10.1038/4532; RAMAN IM, 1995, BIOPHYS J, V68, P137, DOI 10.1016/S0006-3495(95)80168-2; RAMAN IM, 1992, NEURON, V9, P173, DOI 10.1016/0896-6273(92)90232-3; Reisel D, 2002, NAT NEUROSCI, V5, P868, DOI 10.1038/nn910; Robert A, 2001, J NEUROSCI, V21, P5574, DOI 10.1523/JNEUROSCI.21-15-05574.2001; SINE SM, 1986, J PHYSIOL-LONDON, V373, P129, DOI 10.1113/jphysiol.1986.sp016039; Stern-Bach Y, 1998, NEURON, V21, P907, DOI 10.1016/S0896-6273(00)80605-4; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; Sutton MA, 2003, NATURE, V421, P70, DOI 10.1038/nature01249; Takahashi T, 2003, SCIENCE, V299, P1585, DOI 10.1126/science.1079886; TONG G, 1994, J NEUROPHYSIOL, V72, P754, DOI 10.1152/jn.1994.72.2.754; Traynelis SF, 1997, J PHYSIOL-LONDON, V503, P513, DOI 10.1111/j.1469-7793.1997.513bg.x; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; UDGAONKAR JB, 1987, P NATL ACAD SCI USA, V84, P8758, DOI 10.1073/pnas.84.24.8758; UDGAONKAR JB, 1986, J MEMBRANE BIOL, V93, P93, DOI 10.1007/BF01870803; Wahl P, 1998, MOL PHARMACOL, V53, P590, DOI 10.1124/mol.53.3.590; WIEBOLDT R, 1994, P NATL ACAD SCI USA, V91, P8752, DOI 10.1073/pnas.91.19.8752; Yu ZF, 2002, NEUROBIOL DIS, V11, P199, DOI 10.1006/nbdi.2002.0530	69	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					3990	3997		10.1074/jbc.M310410200	http://dx.doi.org/10.1074/jbc.M310410200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14610080	hybrid			2022-12-25	WOS:000188554300011
J	Murai, T; Miyazaki, Y; Nishinakamura, H; Sugahara, KN; Miyauchi, T; Sako, Y; Yanagida, T; Miyasaka, M				Murai, T; Miyazaki, Y; Nishinakamura, H; Sugahara, KN; Miyauchi, T; Sako, Y; Yanagida, T; Miyasaka, M			Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MATRIX-METALLOPROTEINASE CLEAVES; RESONANCE ENERGY-TRANSFER; SULFATE PROTEOGLYCAN; PROGELATINASE-A; GROWTH-FACTOR; RHO GTPASES; L-SELECTIN; BINDING; HYALURONAN	CD44 is a major cell surface adhesion molecule for hyaluronan, a component of the extracellular matrix, and is implicated in tumor metastasis and invasion. We reported previously that hyaluronan oligosaccharides induce CD44 cleavage from tumor cells. Here we show that engagement of CD44 promotes CD44 cleavage and tumor cell migration, both of which were suppressed by a metalloproteinase inhibitor KB-R7785 and tissue inhibitor of metalloproteinases-1 (TIMP-1) but not by TIMP-2. We also present evidence that blockade of metalloproteinase-disintegrin ADAM10 (a disintegrin and metalloproteinase 10 by RNA interference suppresses CD44 cleavage induced by its ligation. Engagement of CD44 concurrently induced activation of the small GTPase Rac1 and led to drastic changes in cell morphology and actin cytoskeleton with redistribution of CD44 to newly generated membrane ruffling areas. A fluorescence resonance energy transfer approach to visualize GTP-bound Rac1 in living cells revealed the localization of the active Rac1 in the leading edge of the membrane ruffling areas upon ligation of CD44. Taken together, our results indicate that the cleavage of CD44 catalyzed by ADAM10 is augmented by the intracellular signaling elicited by engagement of CD44, through Rac-mediated cytoskeletal rearrangement, and suggest that CD44 cleavage contributes to the migration and invasion of tumor cells.	Osaka Univ, Grad Sch Med, Lab Mol & Cellular Recognit, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Nanobiol Labs, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Murai, T (corresponding author), Osaka Univ, Grad Sch Med, Lab Mol & Cellular Recognit, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	murai@orgct1.med.osaka-u.ac.jp	Miyasaka, Masayuki/AAM-6343-2020; Yanagida, Toshio/D-1919-2009; Sako, Yasushi/B-3253-2015	Sako, Yasushi/0000-0002-5707-5455				Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; BORREGO F, 1994, CELL IMMUNOL, V158, P208, DOI 10.1006/cimm.1994.1268; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Gunthert AR, 1996, J CELL BIOL, V134, P1089, DOI 10.1083/jcb.134.4.1089; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Hirayama R, 1997, BIOORGAN MED CHEM, V5, P765, DOI 10.1016/S0968-0896(97)00028-X; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kawano Y, 2000, J BIOL CHEM, V275, P29628, DOI 10.1074/jbc.M002440200; Kawashima H, 1999, INT IMMUNOL, V11, P393, DOI 10.1093/intimm/11.3.393; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LIAO HX, 1993, J IMMUNOL, V151, P6490; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIKECZ K, 1995, NAT MED, V1, P558, DOI 10.1038/nm0695-558; Mikecz K, 1999, ARTHRITIS RHEUM, V42, P659, DOI 10.1002/1529-0131(199904)42:4<659::AID-ANR8>3.0.CO;2-Z; Mitra RD, 1996, GENE, V173, P13, DOI 10.1016/0378-1119(95)00768-7; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Okamoto I, 1999, J BIOL CHEM, V274, P25525, DOI 10.1074/jbc.274.36.25525; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; Oliferenko S, 2000, J CELL BIOL, V148, P1159, DOI 10.1083/jcb.148.6.1159; PATEL DD, 1997, LEUKOCYTE TYPING, V6, P373; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Shi M, 2001, J IMMUNOL, V167, P123, DOI 10.4049/jimmunol.167.1.123; Sugahara KN, 2003, J BIOL CHEM, V278, P32259, DOI 10.1074/jbc.M300347200; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; Tsuji T, 2002, J CELL BIOL, V157, P819, DOI 10.1083/jcb.200112107; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; YOUVAN DC, 1997, BIOTECHNOLOGY ALIA, V1, P1	48	118	124	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4541	4550		10.1074/jbc.M307356200	http://dx.doi.org/10.1074/jbc.M307356200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14623895	hybrid			2022-12-25	WOS:000188554300075
J	Shimura, H; Schwartz, D; Gygi, SP; Kosik, KS				Shimura, H; Schwartz, D; Gygi, SP; Kosik, KS			CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; PROTEIN PHOSPHATASE 2A; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; MICROTUBULE-BINDING; UNFOLDED PROTEIN; TRANSGENIC MICE; LIGASE; CHIP; NEURODEGENERATION	The microtubule-binding protein tau has been implicated in the neurofibrillary pathology of Alzheimer's disease. Within affected cells, ubiquitinated and hyperphosphorylated tau assembles into massive filamentous polymers. Eventually these tangle-bearing neurons die. The formation of neurofibrillary tangles closely parallels the progression and anatomic distribution of neuronal loss in Alzheimer's disease, suggesting that these lesions play a role in the disease pathogenesis. Mutations in the human tau gene cause autosomal dominant neurodegenerative disorders. These and other neurodegenerative conditions are also characterized by extensive neurofibrillary pathology. The mechanisms underlying tau-mediated neurotoxicity remain unclear; however, phosphorylated tau is a strong candidate for a toxic molecule, particularly those isoforms phosphorylated by the kinases glycogen synthase kinase 3beta and Cdk5. Here we show that Alzheimer tau binds to Hsc70, and its phosphorylation is a recognition requirement for the addition of ubiquitin (Ub) by the E3 Ub ligase CHIP (carboxyl terminus of the Hsc70-interacting protein) and the E2 conjugating enzyme UbcH5B. Other E3 Ub ligases including parkin and Cbl failed to ubiquitinate phosphorylated tau. CHIP could rescue phosphorylated tau-induced cell death, and therefore the CHIP-Hsc70 complex may provide a new therapeutic target for the tauopathies.	Brigham & Womens Hosp, Harvard Inst Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Kosik, KS (corresponding author), Brigham & Womens Hosp, Harvard Inst Med, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	kkosik@rics.bwh.harvard.edu	shimura, hideki/AAA-2864-2020					Ahlijanian MK, 2000, P NATL ACAD SCI USA, V97, P2910, DOI 10.1073/pnas.040577797; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; De Vrij FMS, 2001, FASEB J, V15, P2680, DOI 10.1096/fj.01-0438com; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; Dou F, 2003, P NATL ACAD SCI USA, V100, P721, DOI 10.1073/pnas.242720499; Fath T, 2002, J NEUROSCI, V22, P9733; Gong CX, 2000, BRAIN RES, V853, P299, DOI 10.1016/S0006-8993(99)02294-5; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; Illenberger S, 1998, MOL BIOL CELL, V9, P1495, DOI 10.1091/mbc.9.6.1495; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Jellinger KA, 2003, J NEURAL TRANSM-SUPP, P101; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; JOACHIM CL, 1987, J NEUROPATH EXP NEUR, V46, P611, DOI 10.1097/00005072-198711000-00001; Johnson G V, 1999, J Alzheimers Dis, V1, P307; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; Kosik KS, 1997, BRAIN MICROTUBULE AS, P43; Lansbury PT, 2000, CHEM BIOL, V7, pR9, DOI 10.1016/S1074-5521(00)00068-5; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Lu M, 2001, MOL BIOL CELL, V12, P171, DOI 10.1091/mbc.12.1.171; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Maraganore DM, 2003, MOVEMENT DISORD, V18, P631, DOI 10.1002/mds.10431; McNaught KS, 2003, EXP NEUROL, V179, P38, DOI 10.1006/exnr.2002.8050; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; NOLE W, 2003, NEURON, V38, P555; PAPASOZOMENOS SC, 1995, J NEUROCHEM, V65, P396; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Sontag E, 1999, J BIOL CHEM, V274, P25490, DOI 10.1074/jbc.274.36.25490; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Spittaels K, 2000, J BIOL CHEM, V275, P41340, DOI 10.1074/jbc.M006219200; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200	40	367	393	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4869	4876		10.1074/jbc.M305838200	http://dx.doi.org/10.1074/jbc.M305838200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14612456	hybrid			2022-12-25	WOS:000188554300112
J	Takemoto, A; Kimura, K; Yokoyama, S; Hanaoka, F				Takemoto, A; Kimura, K; Yokoyama, S; Hanaoka, F			Cell cycle-dependent phosphorylation, nuclear localization, and activation of human condensin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC CHROMOSOME CONDENSATION; XENOPUS EGG EXTRACTS; NON-SMC SUBUNITS; AURORA-B KINASE; 13S CONDENSIN; CHROMATID SEGREGATION; PROTEIN COMPLEXES; TOPOISOMERASE-II; DUAL ROLES; HISTONE H3	Condensin, one of the most abundant components of mitotic chromosomes, is a conserved protein complex composed of two structural maintenance of chromosomes (SMC) subunits (SMC2- and SMC4-type) and three non-SMC subunits, and it plays an essential role in mitotic chromosome condensation. Purified condensin reconfigures DNA structure using energy provided by ATP hydrolysis. To know the regulation of condensin in somatic cells, the expression level, subcellular localization, and phosphorylation status of human condensin were examined during the cell cycle. The levels of condensin subunits were almost constant throughout the cell cycle, and the three non-SMC subunits were phosphorylated at specific sites in mitosis and dephosphorylated upon the completion of mitosis. Subcellular fractionation studies revealed that a proportion of condensin was tightly bound to mitotic chromosomes and that this form was phosphorylated at specific sites. Condensin purified from mitotic cells had much stronger supercoiling activity than that purified from interphase cells. These results suggest that condensin functions in somatic cells are regulated by phosphorylation in two ways during the cell cycle; the phosphorylation of specific sites correlates with the chromosomal targeting of condensin, and its biochemical activity is stimulated by phosphorylation.	Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; RIKEN, Discovery Res Inst, Cellular Physiol Lab, Wako, Saitama 3510198, Japan; Japan Sci & Technol Corp, CREST, Wako, Saitama 3510198, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan	Osaka University; RIKEN; Japan Science & Technology Agency (JST); University of Tokyo; RIKEN	Hanaoka, F (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, 1-3 Yamada Oka, Suita, Osaka 5650871, Japan.	fhanaoka@fbs.osaka-u.ac.jp	Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338				Anderson DE, 2002, J CELL BIOL, V156, P419, DOI 10.1083/jcb.200111002; Aono N, 2002, NATURE, V417, P197, DOI 10.1038/417197a; Ball AR, 2002, MOL CELL BIOL, V22, P5769, DOI 10.1128/MCB.22.16.5769-5781.2002; Bazett-Jones DP, 2002, MOL CELL, V9, P1183, DOI 10.1016/S1097-2765(02)00546-4; Bhalla N, 2002, MOL BIOL CELL, V13, P632, DOI 10.1091/mbc.01-05-0264; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; Cabello OA, 1997, GENOMICS, V46, P311, DOI 10.1006/geno.1997.5021; Cabello OA, 2001, MOL BIOL CELL, V12, P3527, DOI 10.1091/mbc.12.11.3527; Cobbe N, 2000, J STRUCT BIOL, V129, P123, DOI 10.1006/jsbi.2000.4255; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Freeman L, 2000, J CELL BIOL, V149, P811, DOI 10.1083/jcb.149.4.811; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; Hagstrom KA, 2003, NAT REV GENET, V4, P520, DOI 10.1038/nrg1110; Hagstrom KA, 2002, GENE DEV, V16, P729, DOI 10.1101/gad.968302; Hirano T, 2000, ANNU REV BIOCHEM, V69, P115, DOI 10.1146/annurev.biochem.69.1.115; Hirano T, 2002, GENE DEV, V16, P399, DOI 10.1101/gad.955102; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Kaitna S, 2002, CURR BIOL, V12, P798, DOI 10.1016/S0960-9822(02)00820-5; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Kimura K, 1996, J BIOL CHEM, V271, P21439, DOI 10.1074/jbc.271.35.21439; Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Kimura K, 2000, P NATL ACAD SCI USA, V97, P11972, DOI 10.1073/pnas.220326097; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Lavoie BD, 2000, MOL BIOL CELL, V11, P1293, DOI 10.1091/mbc.11.4.1293; Lieb JD, 1998, CELL, V92, P265, DOI 10.1016/S0092-8674(00)80920-4; MacCallum DE, 2002, MOL BIOL CELL, V13, P25, DOI 10.1091/mbc.01-09-0441; Maeshima K, 2003, DEV CELL, V4, P467, DOI 10.1016/S1534-5807(03)00092-3; Ouspenski II, 2000, MOL BIOL CELL, V11, P1305, DOI 10.1091/mbc.11.4.1305; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; Schmiesing JA, 1998, P NATL ACAD SCI USA, V95, P12906, DOI 10.1073/pnas.95.22.12906; Schmiesing JA, 2000, MOL CELL BIOL, V20, P6996, DOI 10.1128/MCB.20.18.6996-7006.2000; Steffensen S, 2001, CURR BIOL, V11, P295, DOI 10.1016/S0960-9822(01)00096-3; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; Sutani T, 1997, NATURE, V388, P798, DOI 10.1038/42062; Sutani T, 1999, GENE DEV, V13, P2271, DOI 10.1101/gad.13.17.2271; Swedlow JR, 2003, MOL CELL, V11, P557, DOI 10.1016/S1097-2765(03)00103-5; Yoshimura SH, 2002, CURR BIOL, V12, P508, DOI 10.1016/S0960-9822(02)00719-4	41	46	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4551	4559		10.1074/jbc.M310925200	http://dx.doi.org/10.1074/jbc.M310925200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14607834	hybrid			2022-12-25	WOS:000188554300076
J	Lynch, M; Fitzgerald, C; Johnston, KA; Wang, SP; Schmidt, EV				Lynch, M; Fitzgerald, C; Johnston, KA; Wang, SP; Schmidt, EV			Activated eIF4E-binding protein slows G(1) progression and blocks transformation by c-myc without inhibiting cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; MESSENGER-RNA TRANSLATION; ORNITHINE-DECARBOXYLASE; INDUCED APOPTOSIS; FACTOR EIF-4E; TARGET GENE; PHOSPHORYLATION; CYCLE; FIBROBLASTS; INDUCTION	Translation initiation is poised between global regulation of cell growth and specific regulation of cell division. The mRNA cap-binding protein (eIF4E) is a critical integrator of cell growth and division because it is rate-limiting for translation initiation and is also rate-limiting for G(1) progression. Translation initiation factor eIF4E is also oncogenic and a candidate target of c-myc. Recently, an activated inhibitory 4E-binding protein (4EBP) that blocks eIF4E was used to study its regulation of Drosophila growth. We adopted this approach in mammalian cells after identifying an autosensing mechanism that protects against increased levels of 4EBP1. Increased 4EBP1 induced a quantitative increase in the inactivated phosphorylated form of 4EBP1 in vitro and in vivo. To overcome this protective mechanism, we introduced alanine substitutions at four phosphorylation/inactivation sites in 4EBP1 to constitutively activate a 4EBPmu to block eIF4E. Overexpression of activated 4EBPmu inhibited cell proliferation and completely blocked transformation by both eIF4E and c-myc, although it did not block all tested oncogenes. Surprisingly, expression of the activated 4EBPmu increased cell size and protein content. Activated 4EBPmu blocked both cell proliferation and c-myc transformation by inhibiting G(1) progression and increasing apoptosis, without decreasing protein synthesis. Our results identify mammalian eIF4E as rate-limiting for cell cycle progression before it regulates cell growth. It further identifies G(1) control by translation initiation factors as an essential genetic target of c-myc that is necessary for its ability to transform cells.	Massachusetts Gen Hosp, Serv Pediat, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Schmidt, EV (corresponding author), Massachusetts Gen Hosp, Serv Pediat, Fruit St, Boston, MA 02114 USA.	Schmidt@helix.mgh.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA063117] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA63117] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P5923, DOI 10.1093/nar/17.15.5923; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Barth-Baus D, 2002, NUCLEIC ACIDS RES, V30, P1919, DOI 10.1093/nar/30.9.1919; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Bernal A, 2000, P NATL ACAD SCI USA, V97, P6019, DOI 10.1073/pnas.100391597; Blackshear PJ, 1997, J BIOL CHEM, V272, P31510, DOI 10.1074/jbc.272.50.31510; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; CARR R, 2000, XLSTATISTICS VERSION; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; Clemens MJ, 1998, ONCOGENE, V17, P2921, DOI 10.1038/sj.onc.1202227; Clemens MJ, 2001, J CELL MOL MED, V5, P221, DOI 10.1111/j.1582-4934.2001.tb00157.x; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Dang CV, 1999, MOL CELL BIOL, V19, P1; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DUNCAN R, 1985, J BIOL CHEM, V260, P5486; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FREDERICKSON RM, 1992, MOL CELL BIOL, V12, P1239, DOI 10.1128/MCB.12.3.1239; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446; Greco A, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P135; Guo QM, 2000, CANCER RES, V60, P5922; HANICJOYCE PJ, 1987, EXP CELL RES, V172, P134, DOI 10.1016/0014-4827(87)90100-5; Heesom KJ, 2001, CURR BIOL, V11, P1374, DOI 10.1016/S0960-9822(01)00422-5; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li SN, 2002, MOL CELL BIOL, V22, P2853, DOI 10.1128/MCB.22.8.2853-2861.2002; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Mac SM, 2000, MOL CARCINOGEN, V27, P84; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Meyuhas Oded, 1996, P65; Miron M, 2001, NAT CELL BIOL, V3, P596, DOI 10.1038/35078571; Morley SJ, 1998, FEBS LETT, V438, P41, DOI 10.1016/S0014-5793(98)01269-1; MOSHIER JA, 1993, CANCER RES, V53, P2618; Neufeld TP, 1998, CURR OPIN CELL BIOL, V10, P784, DOI 10.1016/S0955-0674(98)80122-1; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Polymenis M, 1999, CURR OPIN GENET DEV, V9, P76, DOI 10.1016/S0959-437X(99)80011-2; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; Prescott JE, 2001, J BIOL CHEM, V276, P48276, DOI 10.1074/jbc.M107357200; PROUTY SM, 1993, ONCOGENE, V8, P899; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Shama Silvian, 1995, Gene Expression, V4, P241; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Tsukiyama-Kohara K, 2001, NAT MED, V7, P1128, DOI 10.1038/nm1001-1128; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Wonsey DR, 2002, P NATL ACAD SCI USA, V99, P6649, DOI 10.1073/pnas.102523299; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Zaffran S, 1998, DEVELOPMENT, V125, P3571; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000	80	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3327	3339		10.1074/jbc.M310872200	http://dx.doi.org/10.1074/jbc.M310872200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14607835	hybrid			2022-12-25	WOS:000188379600024
J	Meador, MG; Rajagopalan, L; Lloyd, RS; Dodson, ML				Meador, MG; Rajagopalan, L; Lloyd, RS; Dodson, ML			Role of His-16 in turnover of T4 pyrimidine dimer glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDONUCLEASE-V; EXCISION-REPAIR; ABASIC SITES; MECHANISM; INTERMEDIATE; RECOGNITION; SUBSTRATE; BINDING	Previously, the histidine residue at position 16 in the mature T4 pyrimidine dimer glycosylase (T4-PDG) protein has been suggested to be involved in general (non-target) DNA binding. This interpretation is likely correct, but, in and of itself, cannot account for the most dramatic phenotype of mutants at this position: their inability to restore ultraviolet light resistance to a DNA repair-deficient Escherichia coli strain. Accordingly, this residue has been mutated to serine, glutamic, aspartic acid, lysine, cysteine, and alanine. The mutant proteins were expressed, purified, and their abilities to carry out several functions of T4-PDG were assessed. The mutant proteins were able to perform most functions tested in vitro, albeit at reduced rates compared with the wild type protein. The most likely explanation for the biochemical phenotypes of the mutants is that the histidine residue is required for rapid turnover of the enzyme. This role is interpreted and discussed in the context of a reaction mechanism able to account for the complete spectrum of products generated by T4-PDG during a single turnover cycle.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Dodson, ML (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA.	bdodson@scms.utmb.edu		Lloyd, R. Stephen/0000-0001-7273-372X	NIEHS NIH HHS [R01ES04091, P30ES06676] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004091, P30ES006676] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUGUSTINE ML, 1991, BIOCHEMISTRY-US, V30, P8052, DOI 10.1021/bi00246a025; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; Dodson ML, 2002, METHOD ENZYMOL, V354, P202; Gerlt J. A., 1993, NUCLEASES, P1; GRUSKIN EA, 1986, J BIOL CHEM, V261, P9607; Kurtz AJ, 2002, BIOCHEMISTRY-US, V41, P7054, DOI 10.1021/bi020026y; McCullough AK, 1999, ANNU REV BIOCHEM, V68, P255, DOI 10.1146/annurev.biochem.68.1.255; McCullough AK, 1996, J BIOL CHEM, V271, P32147, DOI 10.1074/jbc.271.50.32147; McCullough AK, 2001, BIOCHEMISTRY-US, V40, P561, DOI 10.1021/bi002404+; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6	12	3	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3348	3353		10.1074/jbc.M304714200	http://dx.doi.org/10.1074/jbc.M304714200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14610082	hybrid			2022-12-25	WOS:000188379600026
J	Cho, DH; Choi, YJ; Jo, SA; Jo, I				Cho, DH; Choi, YJ; Jo, SA; Jo, I			Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone - Evidence for involvement of peroxisome proliferator-activated receptor (PPAR)gamma-dependent and PPAR gamma-independent signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR EXPRESSION; STRESS STIMULATES PHOSPHORYLATION; PROTEIN-KINASE-C; BLOOD-PRESSURE; INSULIN SENSITIZER; KDR/FLK-1 RECEPTOR; UP-REGULATION; CELLS; INCREASE; LIGANDS	Recently, peroxisome proliferator-activated receptor gamma (PPARgamma) ligands have been reported to increase endothelial NO, but the signaling mechanisms involved are unknown. Using troglitazone, a PPARgamma ligand known as an antidiabetic compound, we investigated the molecular mechanism of its effect on NO production in bovine aortic endothelial cells. Troglitazone increased endothelial NO production in a dose- and time-dependent manner with no alteration in endothelial nitric-oxide synthase ( eNOS) expression. The maximal increase (similar to3.1-fold) was achieved with 20 muM troglitazone treatment for 12 h, and this increase was accompanied by increases in the expression of vascular endothelial growth factor ( VEGF) and its receptor, KDR/Flk-1, and in Akt phosphorylation. Analysis with antibodies specific for each phosphorylated site demonstrated that troglitazone (20 muM treatment for 12 h) significantly increased both the phosphorylation of Ser(1179) of eNOS (eNOS-Ser(1179)) and the dephosphorylation of eNOS-Ser(116) but did not alter eNOS-Thr(497) phosphorylation. Treatment with anti-VEGF antibody to scavenge the increased VEGF induced by troglitazone partially inhibited troglitazone-stimulated NO production. This was accompanied by the attenuation of troglitazone-stimulated increases in the phosphorylation of Akt and eNOS-Ser(1179) with no alteration in eNOS-Ser(116) dephosphorylation. We also found that bisphenol A diglycidyl ether, a PPARgamma antagonist, partially inhibited troglitazone-stimulated NO production with a concomitant reduction in VEGF-KDR/Flk-1-Akt-mediated eNOS-Ser(1179) phosphorylation but with no alteration in eNOS-Ser(116) dephosphorylation induced by troglitazone. Taken together, our results demonstrate that prolonged treatment with troglitazone increases endothelial NO production by at least two independent signaling pathways: PPARgamma-dependent, VEGF-KDR/Flk-1-Akt-mediated eNOS-Ser(1179) phosphorylation and PPARgamma-independent, eNOS-Ser(116) dephosphorylation.	NIH, Dept Biomed Sci, Seoul 122701, South Korea	Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH)	Jo, I (corresponding author), NIH, Dept Biomed Sci, 5 Nokbun Dong, Seoul 122701, South Korea.	inhojo@nih.go.kr	Cho, Du-Hyong/AAE-7570-2022; Jo, Inho/R-3581-2019	Cho, Du-Hyong/0000-0002-9891-1464; 				Baba T, 2001, DIABETES CARE, V24, P953, DOI 10.2337/diacare.24.5.953; Babaei S, 2003, AM J PATHOL, V162, P1927, DOI 10.1016/S0002-9440(10)64326-X; Bae SW, 2003, BIOCHEM BIOPH RES CO, V306, P981, DOI 10.1016/S0006-291X(03)01086-6; Bonora E, 2001, DIABETOLOGIA, V44, P2107, DOI 10.1007/s001250100020; Boo YC, 2002, AM J PHYSIOL-HEART C, V283, pH1819, DOI 10.1152/ajpheart.00214.2002; Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200; BUCHANAN TA, 1995, J CLIN INVEST, V96, P354, DOI 10.1172/JCI118041; Calnek DS, 2003, ARTERIOSCL THROM VAS, V23, P52, DOI 10.1161/01.ATV.0000044461.01844.C9; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; de Dios ST, 2001, J DIABETES COMPLICAT, V15, P120, DOI 10.1016/S1056-8727(01)00141-6; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dobashi K, 2000, LIFE SCI, V67, P2093, DOI 10.1016/S0024-3205(00)00796-7; Emoto M, 2001, DIABETES, V50, P1166, DOI 10.2337/diabetes.50.5.1166; Fauconnet S, 2002, J BIOL CHEM, V277, P23534, DOI 10.1074/jbc.M200172200; Feron O, 1998, BIOCHEMISTRY-US, V37, P193, DOI 10.1021/bi972307p; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Fujishima S, 1998, AM J HYPERTENS, V11, P1134, DOI 10.1016/S0895-7061(98)00130-7; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Gelinas DS, 2002, BRIT J PHARMACOL, V137, P1021, DOI 10.1038/sj.bjp.0704956; Gonzalez E, 2002, J BIOL CHEM, V277, P39554, DOI 10.1074/jbc.M207299200; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; Hattori M, 2002, CAN J PHYSIOL PHARM, V80, P777, DOI 10.1139/Y02-099; Hattori Y, 2000, BIOCHEM BIOPH RES CO, V273, P1144, DOI 10.1006/bbrc.2000.3084; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054; Ikeda U, 2000, HYPERTENSION, V35, P1232, DOI 10.1161/01.HYP.35.6.1232; Inoue M, 2001, ARTERIOSCL THROM VAS, V21, P560, DOI 10.1161/01.ATV.21.4.560; Iwamoto Y, 1996, DIABETES CARE, V19, P151, DOI 10.2337/diacare.19.2.151; Jozkowicz A, 2000, ACTA BIOCHIM POL, V47, P1147, DOI 10.18388/abp.2000_3967; Kang MA, 2000, J GENE MED, V2, P289; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; Kone BC, 2000, ACTA PHYSIOL SCAND, V168, P27; Kou RQ, 2002, J BIOL CHEM, V277, P29669, DOI 10.1074/jbc.M204519200; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Michell BJ, 2002, J BIOL CHEM, V277, P42344, DOI 10.1074/jbc.M205144200; Mineo C, 2003, J BIOL CHEM, V278, P9142, DOI 10.1074/jbc.M211394200; Moon J, 2002, THROMB RES, V107, P129, DOI 10.1016/S0049-3848(02)00208-6; Niimi Y, 2001, HEPATOL RES, V21, P261, DOI 10.1016/S1386-6346(01)00091-2; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; OGIHARA T, 1995, AM J HYPERTENS, V8, P316, DOI 10.1016/0895-7061(95)96214-5; Perrault LP, 2003, J HEART LUNG TRANSPL, V22, P439, DOI 10.1016/S1053-2498(02)00494-1; Rosenfeld CR, 2003, J SOC GYNECOL INVEST, V10, P205, DOI 10.1016/S1071-5576(03)00049-2; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Schwartz S, 1998, NEW ENGL J MED, V338, P861, DOI 10.1056/NEJM199803263381302; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; van Haperen R, 2002, J BIOL CHEM, V277, P48803, DOI 10.1074/jbc.M209477200; Watkins PB, 1998, NEW ENGL J MED, V338, P916, DOI 10.1056/NEJM199803263381314; Wright HM, 2000, J BIOL CHEM, V275, P1873, DOI 10.1074/jbc.275.3.1873; Yamakawa K, 2000, BIOCHEM BIOPH RES CO, V271, P571, DOI 10.1006/bbrc.2000.2665; Zander T, 2002, J NEUROCHEM, V81, P1052, DOI 10.1046/j.1471-4159.2002.00899.x; ZHANG F, 1994, HYPERTENSION, V24, P170, DOI 10.1161/01.HYP.24.2.170	58	136	151	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2499	2506		10.1074/jbc.M309451200	http://dx.doi.org/10.1074/jbc.M309451200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14593122	hybrid			2022-12-25	WOS:000188211300021
J	Kao, SC; Krichevsky, AM; Kosik, KS; Tsai, LH				Kao, SC; Krichevsky, AM; Kosik, KS; Tsai, LH			BACE1 suppression by RNA interference in primary cortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS BETA-SECRETASE; HYDROGEN-PEROXIDE; DISEASE; EXPRESSION; SITE; ACCUMULATION; CLEAVAGE; BRAIN; MICE	Extracellular deposition of amyloid-beta (Abeta) aggregates in the brain represents one of the histopathological hallmarks of Alzheimer's disease (AD). Abeta peptides are generated from proteolysis of the amyloid precursor proteins (APPs) by beta- and gamma-secretases. beta-Secretase (BACE1) is a type I integral membrane glycoprotein that can cleave APP first to generate C-terminal 99- or 89-amino acid membrane-bound fragments containing the N terminus of Abeta peptides (betaCTF). As BACE1 cleavage is an essential step for Abeta generation, it is proposed as a key therapeutic target for treating AD. In this study, we show that small interfering RNA ( siRNA) specifically targeted to BACE1 can suppress BACE1 ( but not BACE2) protein expression in different cell systems. Furthermore, BACE1 siRNA reduced APP betaCTF and Abeta production in primary cortical neurons derived from both wildtype and transgenic mice harboring the Swedish APP mutant. The subcellular distribution of APP and presenilin-1 did not appear to differ in BACE1 suppressed cells. Importantly, pretreating neurons with BACE1 siRNA reduced the neurotoxicity induced by H2O2 oxidative stress. Our results indicate that BACE1 siRNA specifically impacts on beta-cleavage of APP and may be a potential therapeutic approach for treating AD.	Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Kosik, KS (corresponding author), Brigham & Womens Hosp, Dept Neurol, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	kosik@cnd.bwh.harvard.edu; li-huei_tsai@hms.harvard.edu		Krichevsky, Anna/0000-0002-5080-5507; Kao, Shih-chu/0000-0002-6294-5494				Basi G, 2003, J BIOL CHEM, V278, P31512, DOI 10.1074/jbc.M300169200; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Fowler CJ, 1998, NEUROCHEM INT, V33, P161, DOI 10.1016/S0197-0186(98)00013-8; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Kitazume S, 2003, J BIOL CHEM, V278, P14865, DOI 10.1074/jbc.M206262200; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; Krichevsky AM, 2002, P NATL ACAD SCI USA, V99, P11926, DOI 10.1073/pnas.182272699; Lim F, 1996, BIOTECHNIQUES, V20, P460; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Mark RJ, 1997, J NEUROCHEM, V68, P255; Markesbery WR, 1999, BRAIN PATHOL, V9, P133; Misonou H, 2000, BIOCHEMISTRY-US, V39, P6951, DOI 10.1021/bi000169p; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Paola D, 2000, BIOCHEM BIOPH RES CO, V268, P642, DOI 10.1006/bbrc.2000.2164; PRICE DL, 1995, CURR OPIN NEUROL, V8, P268, DOI 10.1097/00019052-199508000-00004; Price DL, 1998, ANNU REV GENET, V32, P461, DOI 10.1146/annurev.genet.32.1.461; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SURI C, 1993, J NEUROSCI, V13, P1280; Tamagno E, 2002, NEUROBIOL DIS, V10, P279, DOI 10.1006/nbdi.2002.0515; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WHITEHOUSE PJ, 1985, CRC CR REV CL NEUROB, V1, P319; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3	35	130	157	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1942	1949		10.1074/jbc.M309219200	http://dx.doi.org/10.1074/jbc.M309219200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14600149	hybrid			2022-12-25	WOS:000188005700048
J	Mukhin, YV; Garnovskaya, MN; Ullian, ME; Raymond, JR				Mukhin, YV; Garnovskaya, MN; Ullian, ME; Raymond, JR			ERK is regulated by sodium-proton exchanger in rat aortic vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NA+-H+ EXCHANGER; GROWTH-FACTOR RECEPTOR; RENAL MESANGIAL CELLS; ASCITES TUMOR-CELLS; ANGIOTENSIN-II; INTRACELLULAR PH; COUPLED RECEPTORS; HEART-FAILURE; VENTRICULAR MYOCYTES	The purposes of this study were to test 1) the relationship between two widely studied mitogenic effector pathways, and 2) the hypothesis that sodium-proton exchanger type 1 (NHE-1) is a regulator of extracellular signal-regulated protein kinase (ERK) activation in rat aortic smooth muscle (RASM) cells. Angiotensin II (Ang II) and 5-hydroxytryptamine (5-HT) stimulated both ERK and NHE-1 activities, with activation of NHE-1 preceding that of ERK. The concentration-response curves for 5-HT and Ang II were superimposable for both processes. Inhibition of NHE-1 with pharmacological agents or by isotonic replacement of sodium in the perfusate with choline or tetramethylammonium greatly attenuated ERK activation by 5-HT or Ang II. Similar maneuvers significantly attenuated 5-HT- or Ang II-mediated activation of MEK and Ras but not transphosphorylation of the epidermal growth factor (EGF) receptor. EGF receptor blockade attenuated ERK activation, but not NHE-1 activation by 5-HT and Ang II, suggesting that the EGF receptor and NHE-1 work in parallel to stimulate ERK activity in RASM cells, converging distal to the EGF receptor but at or above the level of Ras in the Ras-MEK-ERK pathway. Receptor- independent activation of NHE-1 by acute acid loading of RASM cells resulted in the rapid phosphorylation of ERK, which could be blocked by pharmacological inhibitors of NHE-1 or by isotonic replacement of sodium, closely linking the proton transport function of NHE-1 to ERK activation. These studies identify NHE as a new regulator of ERK activity in RASM cells.	Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Med Serv, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29425 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Mukhin, YV (corresponding author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas St,Rm 829 CSB,POB 250623, Charleston, SC 29425 USA.	mukhinyv@musc.edu		Garnovskaya, Maria/0000-0002-6216-038X	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002694, R01DK052448, R56DK052448] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR 013005] Funding Source: Medline; NIDDK NIH HHS [DK 02694, DK 52448] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aharonovitz O, 1996, J BIOL CHEM, V271, P16494, DOI 10.1074/jbc.271.28.16494; Avkiran M, 2002, J AM COLL CARDIOL, V39, P747, DOI 10.1016/S0735-1097(02)01693-5; Bianchini L, 1997, J BIOL CHEM, V272, P271; BORON WF, 1977, AM J PHYSIOL, V233, pC61, DOI 10.1152/ajpcell.1977.233.3.C61; Bouaboula M, 1999, FEBS LETT, V449, P61, DOI 10.1016/S0014-5793(99)00395-6; Chen L, 2001, J PHARMACOL EXP THER, V298, P469; Chen R, 2000, AM J PHYSIOL-RENAL, V279, pF440, DOI 10.1152/ajprenal.2000.279.3.F440; Denker SP, 2002, J CELL BIOL, V159, P1087, DOI 10.1083/jcb.200208050; Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8; Di Sario A, 2003, HEPATOLOGY, V37, P256, DOI 10.1053/jhep.2003.50028; DOPPLER W, 1987, GENE, V54, P145; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; GARNOVSKAYA MN, 1995, MOL PHARMACOL, V48, P230; Garnovskaya MN, 2003, BIOCHEMISTRY-US, V42, P7178, DOI 10.1021/bi034563+; Garnovskaya MN, 1998, BIOCHEM J, V330, P489; Gavras H, 2001, HYPERTENSION, V37, P342, DOI 10.1161/01.HYP.37.2.342; Gazmuri RJ, 2001, J LAB CLIN MED, V137, P43, DOI 10.1067/mlc.2001.111693; Gekle M, 2001, PFLUG ARCH EUR J PHY, V441, P781, DOI 10.1007/s004240000507; Gillis D, 2001, J MEMBRANE BIOL, V181, P205, DOI 10.1007/s00232-001-0023-3; Greene EL, 2000, AM J PHYSIOL-RENAL, V278, pF650, DOI 10.1152/ajprenal.2000.278.4.F650; Grewal JS, 2001, J BIOL CHEM, V276, P27335, DOI 10.1074/jbc.M103578200; Gunasegaram S, 1999, CIRC RES, V85, P919; HAGAG N, 1987, MOL CELL BIOL, V7, P1984, DOI 10.1128/MCB.7.5.1984; Kalmes A, 2001, ANN NY ACAD SCI, V947, P42; Kanda Y, 1999, EUR J PHARMACOL, V371, P69, DOI 10.1016/S0014-2999(99)00162-4; Kang MG, 1998, BIOL CELL, V90, P477, DOI 10.1016/S0248-4900(99)80006-9; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; KAPUS A, 1994, J BIOL CHEM, V269, P23544; Krump E, 1997, J BIOL CHEM, V272, P17303, DOI 10.1074/jbc.272.28.17303; Kusuhara M, 1998, CIRC RES, V83, P824, DOI 10.1161/01.RES.83.8.824; Kusumoto K, 2001, AM J PHYSIOL-HEART C, V280, pH738, DOI 10.1152/ajpheart.2001.280.2.H738; Liu FM, 2001, AM J PHYSIOL-RENAL, V280, pF415, DOI 10.1152/ajprenal.2001.280.3.F415; LUCCHESI PA, 1994, HYPERTENSION, V24, P734, DOI 10.1161/01.HYP.24.6.734; Luttrell DK, 2003, ASSAY DRUG DEV TECHN, V1, P327, DOI 10.1089/15406580360545143; MALY K, 1989, J BIOL CHEM, V264, P11839; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; MITSUKA M, 1993, CIRC RES, V73, P269, DOI 10.1161/01.RES.73.2.269; Moor AN, 2001, J BIOL CHEM, V276, P16113, DOI 10.1074/jbc.M100519200; Mukhin YV, 2003, J PHARMACOL EXP THER, V304, P968, DOI 10.1124/jpet.102.043943; Nemeth ZH, 2002, AM J PHYSIOL-GASTR L, V283, pG122, DOI 10.1152/ajpgi.00015.2002; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; Pedersen SF, 2002, J MEMBRANE BIOL, V189, P67, DOI 10.1007/s00232-001-0190-2; Phan VN, 1997, HYPERTENSION, V29, P1265, DOI 10.1161/01.HYP.29.6.1265; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; Rothstein EC, 2002, AM J PHYSIOL-HEART C, V283, pH598, DOI 10.1152/ajpheart.00198.2002; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Sabri A, 1998, CIRC RES, V82, P1053, DOI 10.1161/01.RES.82.10.1053; Sartori M, 1999, BBA-BIOMEMBRANES, V1421, P140, DOI 10.1016/S0005-2736(99)00121-2; Schroeder K.S., 1996, J BIOMOL SCREEN, V1, P75, DOI DOI 10.1177/108705719600100205; Seta K, 2003, J BIOL CHEM, V278, P9019, DOI 10.1074/jbc.M208017200; Snabaitis AK, 2000, CIRC RES, V86, P214, DOI 10.1161/01.RES.86.2.214; Snabaitis AK, 2002, CARDIOVASC RES, V53, P470, DOI 10.1016/S0008-6363(01)00464-3; Takahashi E, 1997, CIRC RES, V81, P268, DOI 10.1161/01.RES.81.2.268; Takahashi E, 1999, J BIOL CHEM, V274, P20206, DOI 10.1074/jbc.274.29.20206; TAKEWAKI S, 1995, J MOL CELL CARDIOL, V27, P729, DOI 10.1016/S0022-2828(08)80063-6; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Tominaga T, 1998, MOL BIOL CELL, V9, P2287, DOI 10.1091/mbc.9.8.2287; Touyz RM, 2000, PHARMACOL REV, V52, P639; Tsuganezawa H, 2002, KIDNEY INT, V62, P41, DOI 10.1046/j.1523-1755.2002.00418.x; Ullian ME, 1996, CARDIOVASC RES, V32, P266, DOI 10.1016/0008-6363(96)00053-3; Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489; Voisin L, 2002, AM J PHYSIOL-CELL PH, V283, pC446, DOI 10.1152/ajpcell.00261.2001; Wang H, 1997, BIOCHEMISTRY-US, V36, P9151, DOI 10.1021/bi970802f; Watanabe T, 2001, J VASC RES, V38, P341, DOI 10.1159/000051065; Watts BA, 2002, AM J PHYSIOL-RENAL, V282, pF1056, DOI 10.1152/ajprenal.00133.2001; Watts SW, 1996, J PHARMACOL EXP THER, V279, P1541; Wei S, 2001, AM J PHYSIOL-CELL PH, V281, pC1542, DOI 10.1152/ajpcell.2001.281.5.C1542	67	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1845	1852		10.1074/jbc.M304907200	http://dx.doi.org/10.1074/jbc.M304907200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14600156	hybrid			2022-12-25	WOS:000188005700035
J	Hamada, K; Terauchi, A; Mikoshiba, K				Hamada, K; Terauchi, A; Mikoshiba, K			Three-dimensional rearrangements within inositol 1,4,5-trisphosphate receptor by calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED POTASSIUM CHANNEL; SMOOTH-MUSCLE CELLS; LIGAND-BINDING SITE; PIG TAENIA CECI; TRISPHOSPHATE RECEPTOR; IP3 RECEPTORS; (1,4,5)-TRISPHOSPHATE RECEPTOR; CONFORMATIONAL STATES; ENDOPLASMIC-RETICULUM; ANGSTROM RESOLUTION	Allosteric binding of calcium ion (Ca2+) to inositol 1,4,5-trisphosphate (IP3) receptor (IP3R) controls channel gating within IP3R. Here, we present biochemical and electron microscopic evidence of Ca2+-sensitive structural changes in the three-dimensional structure of type 1 IP3R (IP(3)R1). Low concentrations of Ca2+ and high concentrations of Sr2+ and Ba2+ were shown to be effective for the limited proteolysis of IP(3)R1, but Mg2+ had no effect on the proteolysis. The electron microscopy and the limited proteolysis consistently demonstrated that the effective concentration of Ca2+ for conformational changes in IP(3)R1 was <10(-7) M and that the IP3 scarcely affected the conformational states. The structure of IP(3)R1 without Ca2+, as reconstructed by three-dimensional electron microscopy, had a "mushroom-like" appearance consisting of a large square-shaped head and a small channel domain linked by four thin bridges. The projection image of the "head-to-head" assembly comprising two particles confirmed the mushroom-like side view. The "windmill-like" form of IP(3)R1 with Ca2+ also contains the four bridges connecting from the IP3-binding domain toward the channel domain. These data suggest that the Ca2+-specific conformational change structurally regulates the IP3-triggered channel opening within IP(3)R1.	RIKEN, Inst Phys & Chem Res, Dev Neurobiol Lab, Brain Sci Inst, Wako, Saitama 3510198, Japan; JST, ICORP, Calcium Oscillation Project, Minato Ku, Tokyo 1080071, Japan; Univ Tokyo, Inst Med Sci, Div Mol Neurobiol, Dept Basic Med Sci,Minato Ku, Tokyo 1088639, Japan	RIKEN; Japan Science & Technology Agency (JST); University of Tokyo	Hamada, K (corresponding author), RIKEN, Inst Phys & Chem Res, Dev Neurobiol Lab, Brain Sci Inst, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	hamada@ims.u-tokyo.ac.jp; mikosiba@ims.u-tokyo.ac.jp	Mikoshiba, Katsuhiko/N-7943-2015	Hamada, Kozo/0000-0002-2795-802X				Adkins CE, 1999, CURR BIOL, V9, P1115, DOI 10.1016/S0960-9822(99)80481-3; Ando H, 2003, J BIOL CHEM, V278, P10602, DOI 10.1074/jbc.M210119200; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Boehning D, 2000, EMBO J, V19, P5450, DOI 10.1093/emboj/19.20.5450; Boehning D, 2001, J BIOL CHEM, V276, P13509, DOI 10.1074/jbc.C100094200; Bosanac I, 2002, NATURE, V420, P696, DOI 10.1038/nature01268; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; da Fonseca PCA, 2003, P NATL ACAD SCI USA, V100, P3936, DOI 10.1073/pnas.0536251100; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; Galvan DL, 1999, J BIOL CHEM, V274, P29483, DOI 10.1074/jbc.274.41.29483; Gu C, 2000, J BIOL CHEM, V275, P6980, DOI 10.1074/jbc.275.10.6980; Hamada K, 2002, J BIOL CHEM, V277, P21115, DOI 10.1074/jbc.C200244200; Hirota J, 2003, BIOCHEM J, V372, P435, DOI 10.1042/BJ20030110; IINO M, 1991, J GEN PHYSIOL, V98, P681, DOI 10.1085/jgp.98.4.681; IINO M, 1987, BIOCHEM BIOPH RES CO, V142, P47, DOI 10.1016/0006-291X(87)90449-9; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; Jiang QX, 2002, EMBO J, V21, P3575, DOI 10.1093/emboj/cdf380; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Joseph SK, 1997, J BIOL CHEM, V272, P1579, DOI 10.1074/jbc.272.3.1579; JOSEPH SK, 1995, BIOCHEM J, V307, P859, DOI 10.1042/bj3070859; Kanaseki T, 1998, CELL STRUCT FUNCT, V23, P373, DOI 10.1247/csf.23.373; LI C, 1995, J BIOL CHEM, V270, P24898, DOI 10.1074/jbc.270.42.24898; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Ludtke SJ, 2001, J MOL BIOL, V314, P253, DOI 10.1006/jmbi.2001.5133; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; Maes K, 2001, J BIOL CHEM, V276, P3492, DOI 10.1074/jbc.M006082200; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Marchant JS, 1997, CURR BIOL, V7, P510, DOI 10.1016/S0960-9822(06)00222-3; MARSHALL ICB, 1994, BIOCHEM J, V301, P591, DOI 10.1042/bj3010591; Maximov A, 2003, MOL CELL NEUROSCI, V22, P271, DOI 10.1016/S1044-7431(02)00027-1; MEYER T, 1988, SCIENCE, V240, P653, DOI 10.1126/science.2452482; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; Miyakawa T, 2001, EMBO J, V20, P1674, DOI 10.1093/emboj/20.7.1674; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; Ozawa T, 1999, BBA-PROTEIN STRUCT M, V1434, P211, DOI 10.1016/S0167-4838(99)00185-5; Ramos-Franco J, 1999, J GEN PHYSIOL, V114, P243, DOI 10.1085/jgp.114.2.243; Riley AM, 2002, J BIOL CHEM, V277, P40290, DOI 10.1074/jbc.M206925200; Serysheva II, 2003, J BIOL CHEM, V278, P21319, DOI 10.1074/jbc.C300148200; Shah PK, 2001, PROTEIN ENG, V14, P867, DOI 10.1093/protein/14.11.867; Sharma MR, 2000, J BIOL CHEM, V275, P9485, DOI 10.1074/jbc.275.13.9485; Sienaert I, 1997, J BIOL CHEM, V272, P25899, DOI 10.1074/jbc.272.41.25899; Sienaert I, 1996, J BIOL CHEM, V271, P27005, DOI 10.1074/jbc.271.43.27005; Sokolova O, 2001, STRUCTURE, V9, P215, DOI 10.1016/S0969-2126(01)00578-0; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; Swatton JE, 2002, J BIOL CHEM, V277, P17571, DOI 10.1074/jbc.M200524200; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Tu HP, 2003, BIOPHYS J, V85, P290, DOI 10.1016/S0006-3495(03)74474-9; Uchida K, 2003, J BIOL CHEM, V278, P16551, DOI 10.1074/jbc.M300646200; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; YAMADA M, 1995, BIOCHEM J, V308, P83, DOI 10.1042/bj3080083; Yoneshima H, 1997, BIOCHEM J, V322, P591, DOI 10.1042/bj3220591; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277; Yoshikawa F, 1999, J BIOL CHEM, V274, P316, DOI 10.1074/jbc.274.1.316; YOSHIKAWA S, 1992, J BIOL CHEM, V267, P16613; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zhang SB, 2003, J BIOL CHEM, V278, P4048, DOI 10.1074/jbc.M209960200	66	77	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52881	52889		10.1074/jbc.M309743200	http://dx.doi.org/10.1074/jbc.M309743200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14593123	hybrid			2022-12-25	WOS:000187480700109
J	Horiguchi, K; Tomizawa, Y; Tosaka, M; Ishiuchi, S; Kurihara, H; Mori, M; Saito, N				Horiguchi, K; Tomizawa, Y; Tosaka, M; Ishiuchi, S; Kurihara, H; Mori, M; Saito, N			Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors	ONCOGENE			English	Article						3p21.3; methylation; glioma; medulloblastoma; meningioma; schwannoma	PRIMITIVE NEUROECTODERMAL TUMORS; CHROMOSOME 3P; PROMOTER HYPERMETHYLATION; CPG ISLAND; LUNG; METHYLATION; BREAST; CELL; HETEROZYGOSITY; HYBRIDIZATION	The human Ras association domain family 1A (RASS-F1A) gene, recently isolated from the lung and breast tumor suppressor locus 3p21.3, is highly methylated in primary lung, breast, nasopharyngeal and other tumors, and re-expression of RASSF1A suppresses the growth of several types of cancer cells. Epigenetic inactivation of RASSF1A by promoter hypermethylation is also important in the development of several human cancers. The methylation status of the promoter region of RASSF1A was analysed in primary brain tumors and glioma cell lines by methylation-specific polymerase chain reaction. In primary brain tumors, 25 of 46 ( 54.3%) gliomas and five of five (100%) medulloblastomas showed RASSF1A methylation. In benign tumors, only one of 10 (10%) schwannomas and two of 12 (16.7%) meningiomas showed RASSF1A methylation. The RASSF1A promoter region was methylated in all four glioma cell lines. RASSF1A was re-expressed in all methylated cell lines after treatment with the demethylating agent 5-aza-2'-deoxycytidine. Methylation of the promoter CpG islands of the RASSF1A may play an important role in the pathogenesis of glioma and medulloblastoma.	Gunma Univ, Sch Med, Dept Neurosurg, Gunma 3718511, Japan; Gunma Univ, Sch Med, Dept Internal Med 1, Gunma 3718511, Japan	Gunma University; Gunma University	Horiguchi, K (corresponding author), Gunma Univ, Sch Med, Dept Neurosurg, 3-39-22 Showa Machi, Gunma 3718511, Japan.							Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Avet-Loiseau H, 1999, BRIT J CANCER, V79, P1843, DOI 10.1038/sj.bjc.6690293; Bayani J, 2000, J NEUROSURG, V93, P437, DOI 10.3171/jns.2000.93.3.0437; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; FULTS D, 1990, CANCER RES, V50, P5784; Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ishiuchi S, 2002, NAT MED, V8, P971, DOI 10.1038/nm746; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kanno H, 1997, CANCER RES, V57, P1035; Kleihues P, 2000, PATHOLOGY GENETICS T; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Lee MG, 2001, CANCER RES, V61, P6688; Lo KW, 2001, CANCER RES, V61, P3877; Lusher ME, 2002, CANCER RES, V62, P5906; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3; Mollerup S, 1999, CANCER RES, V59, P3317; Morrissey C, 2001, CANCER RES, V61, P7277; Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362; Toyooka S, 2001, CANCER RES, V61, P5727; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835	28	57	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7862	7865		10.1038/sj.onc.1207082	http://dx.doi.org/10.1038/sj.onc.1207082			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586413				2022-12-25	WOS:000186240200017
J	Pometun, MS; Chekmenev, EY; Wittebort, RJ				Pometun, MS; Chekmenev, EY; Wittebort, RJ			Quantitative observation of backbone disorder in native elastin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; INVERSE TEMPERATURE TRANSITION; ANGLE-SPINNING NMR; SOLID-STATE NMR; MOLECULAR-BASIS; HYDROPHOBIC HYDRATION; PROTEIN MECHANISMS; VASCULAR-DISEASE; C-13; RELAXATION	Elastin is a key protein in soft tissue function and pathology. Establishing a structural basis for understanding its reversible elasticity has proven to be difficult. Complementary to structure is the important aspect of flexibility and disorder in elastin. We have used solid-state NMR methods to examine polypeptide and hydrate ordering in both elastic ( hydrated) and brittle (dry) elastin fibers and conclude (i) that tightly bound waters are absent in both dry and hydrated elastin and (ii) that the backbone in the hydrated protein is highly disordered with large amplitude motions. The hydrate was studied by H-2 and O-17 NMR, and the polypeptide by C-13 and H-2 NMR. Using a two-dimensional C-13 MAS method, an upper limit of S < 0.1 was determined for the backbone carbonyl group order parameter in hydrated elastin. For comparison, S similar to 0.9 in most proteins. The former result is substantiated by two additional observations: the absence of the characteristic 2H spectrum for stationary amides and "solution-like" C-13 magic angle spinning spectra at 75 degrees C, at which the material retains elasticity. Comparison of the observed shifts with accepted values for alpha-helices, beta-sheets, or random coils indicates a random coil structure at all carbons. These conclusions are discussed in the context of known thermodynamic properties of elastin and, more generally, protein folding. Because coacervation is an entropy-driven process, it is enhanced by the observed backbone disorder, which, we suggest, is the result of high proline content. This view is supported by recent studies of recombinant elastin polypeptides with systematic proline substitutions.	Univ Louisville, Dept Chem, Louisville, KY 40208 USA	University of Louisville	Wittebort, RJ (corresponding author), Univ Louisville, Dept Chem, 2320 S Brook St, Louisville, KY 40208 USA.	rjwitt01@louisville.edu	Chekmenev, Eduard Y/J-5908-2013	Chekmenev, Eduard Y/0000-0002-8745-8801				AARON BB, 1981, BIOPOLYMERS, V20, P1247, DOI 10.1002/bip.1981.360200611; AARON BB, 1980, NATURE, V287, P865, DOI 10.1038/287865a0; AKKE M, 1993, J AM CHEM SOC, V115, P9832, DOI 10.1021/ja00074a073; ANTZUTKIN ON, 1995, J MAGN RESON SER A, V115, P7, DOI 10.1006/jmra.1995.1142; BALDWIN RL, 1989, TRENDS BIOCHEM SCI, V14, P291, DOI 10.1016/0968-0004(89)90067-4; Brooke BS, 2003, TRENDS CARDIOVAS MED, V13, P176, DOI 10.1016/S1050-1738(03)00065-3; CHAN HS, 1990, P NATL ACAD SCI USA, V87, P6388, DOI 10.1073/pnas.87.16.6388; DEBELLE L, 1995, J BIOL CHEM, V270, P26099, DOI 10.1074/jbc.270.44.26099; DUNCAN TM, 1997, PRINCIPAL COMPONENTS, P40; FLEMING WW, 1978, BIOPHYS J, V21, pA39; GOSLINE JM, 1978, BIOPOLYMERS, V17, P677, DOI 10.1002/bip.1978.360170311; HAHN EL, 1950, PHYS REV, V80, P580, DOI 10.1103/PhysRev.80.580; HOEVE CAJ, 1974, BIOPOLYMERS, V13, P677, DOI 10.1002/bip.1974.360130404; Hong M, 2003, BIOPOLYMERS, V70, P158, DOI 10.1002/bip.10431; KARPLUS M, 1994, PROTEIN SCI, V3, P650; Kumashiro KK, 2003, BIOPOLYMERS, V70, P221, DOI 10.1002/bip.10470; Kumashiro KK, 2001, BIOPOLYMERS, V59, P266, DOI 10.1002/1097-0282(20011005)59:4<266::AID-BIP1023>3.0.CO;2-2; Lee AL, 2001, NATURE, V411, P501, DOI 10.1038/35078119; Li B, 2001, J AM CHEM SOC, V123, P11991, DOI 10.1021/ja010363e; Li B, 2002, J MUSCLE RES CELL M, V23, P561, DOI 10.1023/A:1023474909980; Li B, 2003, BIOPOLYMERS, V68, P121, DOI 10.1002/bip.10204; Li B, 2001, J MOL BIOL, V305, P581, DOI 10.1006/jmbi.2000.4306; Li DY, 1997, HUM MOL GENET, V6, P1021, DOI 10.1093/hmg/6.7.1021; Li ZG, 1996, PROTEIN SCI, V5, P2647, DOI 10.1002/pro.5560051228; LIPARI G, 1980, BIOPHYS J, V30, P489, DOI 10.1016/S0006-3495(80)85109-5; Lorch M, 1999, BIOCHEMISTRY-US, V38, P1377, DOI 10.1021/bi9817820; LYERLA JR, 1975, BIOCHEMISTRY-US, V14, P5175, DOI 10.1021/bi00694a024; Mack JW, 2000, BIOPOLYMERS, V53, P9, DOI 10.1002/(SICI)1097-0282(200001)53:1<9::AID-BIP2>3.3.CO;2-Y; Meyer DE, 2001, J CONTROL RELEASE, V74, P213, DOI 10.1016/S0168-3659(01)00319-4; Meyer DE, 1999, NAT BIOTECHNOL, V17, P1112, DOI 10.1038/15100; Miao M, 2003, J BIOL CHEM, V278, P48553, DOI 10.1074/jbc.M308465200; PARTRIDGE SM, 1955, BIOCHEM J, V61, P11, DOI 10.1042/bj0610011; Perry A, 2002, BIOPHYS J, V82, P1086, DOI 10.1016/S0006-3495(02)75468-4; Pometun MS, 2002, J AM CHEM SOC, V124, P2345, DOI 10.1021/ja017364r; Reiersen H, 2001, TRENDS BIOCHEM SCI, V26, P679, DOI 10.1016/S0968-0004(01)01957-0; REIS IR, 1976, ZH FIZ KHIM, V50, P736; SEELIG J, 1980, Q REV BIOPHYS, V13, P19, DOI 10.1017/S0033583500000305; Tanford C., 1973, HYDROPHOBIC EFFECT, P16; TORCHIA DA, 1973, J MOL BIOL, V76, P419, DOI 10.1016/0022-2836(73)90514-7; URRY DW, 1988, J PROTEIN CHEM, V7, P81, DOI 10.1007/BF01025240; Urry DW, 1997, J AM CHEM SOC, V119, P1161, DOI 10.1021/ja962374r; URRY DW, 1985, BIOPOLYMERS, V24, P2345, DOI 10.1002/bip.360241212; URRY DW, 1992, BIOPOLYMERS, V32, P373, DOI 10.1002/bip.360320413; Urry DW, 2002, PHILOS T R SOC B, V357, P169, DOI 10.1098/rstb.2001.1023; URRY DW, 1995, SCI AM, V272, P64, DOI 10.1038/scientificamerican0195-64; URRY DW, 1988, J PROTEIN CHEM, V7, P1, DOI 10.1007/BF01025411; USHA MG, 1991, BIOCHEMISTRY-US, V30, P3955, DOI 10.1021/bi00230a022; Vrhovski B, 1997, EUR J BIOCHEM, V250, P92, DOI 10.1111/j.1432-1033.1997.00092.x; Wand AJ, 2001, NAT STRUCT BIOL, V8, P926, DOI 10.1038/nsb1101-926; Welsh ER, 2000, BIOMACROMOLECULES, V1, P23, DOI 10.1021/bm0002914; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WITTEBORT RJ, 1987, J CHEM PHYS, V86, P5411, DOI 10.1063/1.452565; WITTEBORT RJ, 1988, J AM CHEM SOC, V110, P5668, DOI 10.1021/ja00225a013; Zhang HY, 2003, J BIOMOL NMR, V25, P173, DOI 10.1023/A:1022836027055	54	81	86	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7982	7987		10.1074/jbc.M310948200	http://dx.doi.org/10.1074/jbc.M310948200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14625282	hybrid			2022-12-25	WOS:000189103300076
J	Vaysse, L; Harbottle, R; Bigger, B; Bergau, A; Tolmachov, O; Coutelle, C				Vaysse, L; Harbottle, R; Bigger, B; Bergau, A; Tolmachov, O; Coutelle, C			Development of a self-assembling nuclear targeting vector system based on the tetracycline repressor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED GENE DELIVERY; PLASMID DNA; LOCALIZATION SIGNAL; MAMMALIAN-CELLS; ACID PNA; IMPORT PATHWAY; DUPLEX DNA; PEPTIDE; EXPRESSION; TRANSPORT	The ultimate destination for most gene therapy vectors is the nucleus and nuclear import of potentially therapeutic DNA is one of the major barriers for nonviral vectors. We have developed a novel approach of attaching a nuclear localization sequence ( NLS) peptide to DNA in a non- essential position, by generating a fusion between the tetracycline repressor protein TetR and the SV40- derived NLS peptide. The high affinity and specificity of TetR for the short DNA sequence tetO was used in these studies to bind the NLS to DNA as demonstrated by the reduced electrophoretic mobility of the TetR . tetO- DNA complexes. The protein TetR- NLS, but not control protein TetR, specifically enhances gene expression from lipofected tetO- containing DNA between 4- and 16- fold. The specific enhancement is observed in a variety of cell types, including primary and growth- arrested cells. Intracellular trafficking studies demonstrate an increased accumulation of fluorescence labeled DNA in the nucleus after TetR- NLS binding. In comparison, binding studies using the similar fusion of peptide nucleic acid ( PNA) with NLS peptide, demonstrate specific binding of PNA to plasmid DNA. However, although we observed a 2 - 8.5- fold increase in plasmid-mediated luciferase activity with bis- PNA- NLS, control bis- PNA without an NLS sequence gave a similar increase, suggesting that the effect may not be because of a specific bis- PNA- NLS- mediated enhancement of nuclear transfer of the plasmid. Overall, we found TetR-NLS-enhanced plasmid- mediated transgene expression at a similar level to that by bis- PNA- NLS or bis- PNA alone but specific to nuclear uptake and significantly more reliable and reproducible.	Univ London Imperial Coll Sci Technol & Med, Div Biomed Sci, Gene Therapy Res Grp, London SW7 2AZ, England	Imperial College London	Coutelle, C (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Biomed Sci, Gene Therapy Res Grp, Sir Alexander Fleming Bldg,Exhibit Rd, London SW7 2AZ, England.	c.coutelle@imperial.ac.uk	; Bigger, Brian/I-3553-2012	Harbottle, Richard/0000-0002-3332-8024; Bigger, Brian/0000-0002-9708-1112; Tolmachov, Oleg/0000-0002-6926-4229; Rose, Anna/0000-0003-2854-7377; Vaysse, Laurence/0000-0001-6371-9360	Medical Research Council [G0300705, G9805886] Funding Source: Medline; MRC [G0300705, G9805886] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Baron U, 2000, METHOD ENZYMOL, V327, P401, DOI 10.1016/S0076-6879(00)27292-3; Bigger BW, 2001, J BIOL CHEM, V276, P23018, DOI 10.1074/jbc.M010873200; Branden LJ, 2001, GENE THER, V8, P84, DOI 10.1038/sj.gt.3301345; Branden LJ, 1999, NAT BIOTECHNOL, V17, P784, DOI 10.1038/11726; Cartier R, 2002, GENE THER, V9, P157, DOI 10.1038/sj.gt.3301635; Chan CK, 1998, GENE THER, V5, P1204, DOI 10.1038/sj.gt.3300708; Chan CK, 2001, GENE THER, V8, P166, DOI 10.1038/sj.gt.3301366; Christophe D, 2000, CELL SIGNAL, V12, P337, DOI 10.1016/S0898-6568(00)00077-2; Collas P, 1996, MOL REPROD DEV, V45, P431, DOI 10.1002/(SICI)1098-2795(199612)45:4<431::AID-MRD4>3.0.CO;2-S; Devine SM, 2002, J CELL BIOCHEM, P73, DOI 10.1002/jcb.10046; Escriou V, 2001, J GENE MED, V3, P179, DOI 10.1002/jgm.174; Fritz JD, 1996, HUM GENE THER, V7, P1395, DOI 10.1089/hum.1996.7.12-1395; Gao X, 1996, BIOCHEMISTRY-US, V35, P1027, DOI 10.1021/bi952436a; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hansen GI, 2001, J MOL BIOL, V307, P67, DOI 10.1006/jmbi.2000.4487; Harel A, 2001, NAT CELL BIOL, V3, pE267, DOI 10.1038/ncb1201-e267; HILLEN W, 1982, NUCLEIC ACIDS RES, V10, P6085, DOI 10.1093/nar/10.19.6085; HILLEN W, 1983, J MOL BIOL, V169, P707, DOI 10.1016/S0022-2836(83)80166-1; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kuhn H, 1999, J MOL BIOL, V286, P1337, DOI 10.1006/jmbi.1998.2578; LabatMoleur F, 1996, GENE THER, V3, P1010; Larsen HJ, 1996, NUCLEIC ACIDS RES, V24, P458, DOI 10.1093/nar/24.3.458; Ludtke JJ, 1999, J CELL SCI, V112, P2033; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; McKenzie DL, 1999, J PEPT RES, V54, P311, DOI 10.1034/j.1399-3011.1999.00104.x; Nakielny S, 1996, EXP CELL RES, V229, P261, DOI 10.1006/excr.1996.0369; Neves C, 1999, FEBS LETT, V453, P41, DOI 10.1016/S0014-5793(99)00674-2; Neves C, 1999, CELL BIOL TOXICOL, V15, P193, DOI 10.1023/A:1007693805849; Nielsen P E, 1999, Curr Issues Mol Biol, V1, P89; NIELSEN PE, 1993, NUCLEIC ACIDS RES, V21, P197, DOI 10.1093/nar/21.2.197; Nishikawa M, 2001, HUM GENE THER, V12, P861, DOI 10.1089/104303401750195836; Orth P, 1998, ACTA CRYSTALLOGR D, V54, P99, DOI 10.1107/S0907444997007646; Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507; Saenger W, 2000, ANGEW CHEM INT EDIT, V39, P2042, DOI 10.1002/1521-3773(20000616)39:12<2042::AID-ANIE2042>3.0.CO;2-C; Sebestyen MG, 1998, NAT BIOTECHNOL, V16, P80, DOI 10.1038/nbt0198-80; Subramanian A, 1999, NAT BIOTECHNOL, V17, P873, DOI 10.1038/12860; Uherek C, 2000, ADV DRUG DELIVER REV, V44, P153, DOI 10.1016/S0169-409X(00)00092-2; Vitiello L, 1996, GENE THER, V3, P396; Wadhwa MS, 1997, BIOCONJUGATE CHEM, V8, P81, DOI 10.1021/bc960079q; Wilke M, 1996, GENE THER, V3, P1133; Wittung P, 1997, BIOCHEMISTRY-US, V36, P7973, DOI 10.1021/bi963136b; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; Zanta MA, 1999, P NATL ACAD SCI USA, V96, P91, DOI 10.1073/pnas.96.1.91	45	31	34	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5555	5564		10.1074/jbc.M311894200	http://dx.doi.org/10.1074/jbc.M311894200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14607832	hybrid			2022-12-25	WOS:000188776500064
J	Carattino, MD; Sheng, SH; Kleyman, TR				Carattino, MD; Sheng, SH; Kleyman, TR			Epithelial Na+ channels are activated by laminar shear stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL COLLECTING DUCT; PLANAR LIPID-BILAYERS; SODIUM-CHANNEL; ALPHA-SUBUNIT; CONFORMATIONAL-CHANGE; STRETCH ACTIVATION; XENOPUS OOCYTES; BINDING REGION; GAMMA-SUBUNIT; ION CHANNELS	The degenerin/epithelial Na+ channel (ENaC) superfamily is a group of structurally related ion channels that are involved in diverse biological processes, including responses to mechanical stimuli. In renal cortical collecting ducts, changes in rates of perfusion affect Na+ reabsorption through an amiloride-sensitive pathway, suggesting that ENaC may be a mechanosensitive channel. In this study, we examined whether ENaC expressed in oocytes is regulated by laminar shear stress (LSS). A 1.8-mm (internal diameter) perfusion pipette was placed within 0.5-1.0 mm of the oocyte to provide laminar flow across the oocyte surface. LSS induced a dose-dependent and reversible increase in benzamil-sensitive whole cell Na+ currents in oocytes expressing alphabetagamma ENaC. The half-time for activation by LSS was similar to5 s. Repetitive stimulation by LSS of oocytes expressing ENaC was associated with a reduction in the response to LSS. Oocytes expressing alphabetaS518Kgamma, a pore region mutant with a high open probability, were insensitive to LSS. We demonstrated previously that channels with a Cys residue introduced at position alphaSer-580 had a low open probability, but, following modification by [2-(trimethylammonium)ethyl]methanethiosulfonate bromide (MTSET), channels exhibited a high open probability. Oocytes expressing alphaS580Cbetagamma ENaC respond to LSS similar to wild type; however, covalent modification by MTSET largely eliminated the response to LSS. Our results suggest that shear stress activates ENaC by modifying the gating properties of the channel.	Univ Pittsburgh, Renal Electrolyte Div, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kleyman, TR (corresponding author), Univ Pittsburgh, Renal Electrolyte Div, Dept Med, A919 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	kleyman@pitt.edu	Sheng, Shaohu/G-7052-2016	Sheng, Shaohu/0000-0002-7198-1702	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK051391, R29DK038470, R01DK051391, R01DK054354, R01DK038470] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54354, DK51391, DK38470] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CM, 1998, J BIOL CHEM, V273, P30204, DOI 10.1074/jbc.273.46.30204; Awayda MS, 1998, J GEN PHYSIOL, V112, P97, DOI 10.1085/jgp.112.2.97; AWAYDA MS, 1995, AM J PHYSIOL-CELL PH, V268, pC1450, DOI 10.1152/ajpcell.1995.268.6.C1450; Babini E, 2003, J BIOL CHEM, V278, P28418, DOI 10.1074/jbc.M301315200; Chalfant ML, 1996, AM J PHYSIOL-CELL PH, V270, pC998, DOI 10.1152/ajpcell.1996.270.4.C998; Coric T, 2003, J BIOL CHEM, V278, P45240, DOI 10.1074/jbc.M304441200; Dinudom A, 2001, J BIOL CHEM, V276, P13744, DOI 10.1074/jbc.M011273200; Ernstrom GG, 2002, ANNU REV GENET, V36, P411, DOI 10.1146/annurev.genet.36.061802.101708; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Garcia-Anoveros J, 1998, NEURON, V20, P1231, DOI 10.1016/S0896-6273(00)80503-6; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; HAMILL OP, 1992, P NATL ACAD SCI USA, V89, P7462, DOI 10.1073/pnas.89.16.7462; Hoger JH, 2002, P NATL ACAD SCI USA, V99, P7780, DOI 10.1073/pnas.102184999; Holt JR, 1997, J NEUROSCI, V17, P8739; Ismailov II, 1997, BIOPHYS J, V72, P1182, DOI 10.1016/S0006-3495(97)78766-6; Ji HL, 1998, AM J PHYSIOL-CELL PH, V275, pC1182; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Kelly O, 2003, AM J PHYSIOL-RENAL, V285, pF1279, DOI 10.1152/ajprenal.00094.2003; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Liu W, 2003, AM J PHYSIOL-RENAL, V285, pF998, DOI 10.1152/ajprenal.00067.2003; Ma HP, 2002, AM J PHYSIOL-RENAL, V282, pF501, DOI 10.1152/ajprenal.00147.2001; Mano I, 1999, BIOESSAYS, V21, P568, DOI 10.1002/(SICI)1521-1878(199907)21:7&lt;568::AID-BIES5&gt;3.0.CO;2-L; MCNAUGHTON KJ, 1966, J FLUID MECH, V25, P367, DOI 10.1017/S0022112066001708; Palmer LG, 1996, J GEN PHYSIOL, V107, P35, DOI 10.1085/jgp.107.1.35; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; Satlin LM, 2001, AM J PHYSIOL-RENAL, V280, pF1010, DOI 10.1152/ajprenal.2001.280.6.F1010; SATLIN LM, 1994, AM J PHYSIOL, V266, pF57, DOI 10.1152/ajprenal.1994.266.1.F57; Sheng SH, 2000, J BIOL CHEM, V275, P8572, DOI 10.1074/jbc.275.12.8572; Sheng SH, 2002, J BIOL CHEM, V277, P50098, DOI 10.1074/jbc.M209975200; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Snyder PM, 2000, J GEN PHYSIOL, V116, P781, DOI 10.1085/jgp.116.6.781; Suzuki H, 2003, NEURON, V39, P1005, DOI 10.1016/j.neuron.2003.08.015; WODA CB, 2003, AM J PHYSIOL, V85, pF629	36	111	114	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4120	4126		10.1074/jbc.M311783200	http://dx.doi.org/10.1074/jbc.M311783200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14625286	hybrid			2022-12-25	WOS:000188554300026
J	Chen, XH; Zhang, B; Harmon, PM; Schaffner, W; Peterson, DO; Giedroc, DP				Chen, XH; Zhang, B; Harmon, PM; Schaffner, W; Peterson, DO; Giedroc, DP			A novel cysteine cluster in human metal-responsive transcription factor 1 is required for heavy metal-induced transcriptional activation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGERS; FACTOR MTF-1; DNA-BINDING; FUNCTIONAL-HETEROGENEITY; ACTIVE-SITE; METALLOTHIONEIN; ELEMENT; GENE; PROTEIN; MOUSE	Metal-responsive transcription factor 1 (MTF-1) specifically binds to metal response elements (MREs) associated with a number of metal- and stress-responsive genes. Human MTF-1 contains a cysteine-rich cluster, -(632)Cys-Gln-Cys-Gln-Cys-Ala-Cys(638)-, conserved from pufferfish to humans far removed from the MRE-binding zinc finger domain and just C-terminal to a previously mapped serine/threonine-rich transcriptional activation domain. MTF-1 proteins containing two Cys-->Ala substitutions (C632A/C634A) or a deletion in this region altogether (Delta(632-644)) are significantly impaired in their ability to induce Zn(II)- and Cd(II)-responsive transcription of a MRE-linked reporter gene in transiently transfected mouse dko7 (MTF-1-/-) cells in culture under moderate metal stress but retain the ability to drive basal levels of transcription in a MRE-dependent manner in vivo and in vitro. In addition, the mutated proteins respond to induction by Zn(H) or Cd(H) with nuclear translocation and MRE binding activities comparable with wild-type MTF-1. Attempts to rescue the 0(632-644) deletion mutant phenotype by inserting similar Cys-rich sequences from Drosophila MTF-1 were unsuccessful, suggesting that the structure of this motif within intact human MTF-1, rather than the simple presence of multiple closely spaced Cys residues, is required for function. This cysteine cluster therefore functions at a step subsequent to nuclear translocation and MRE-binding DNA to naked promoter-containing DNA and appears to be specifically required for MTF-1 to activate transcription in the presence of inducing heavy metal ions.	Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	University of Zurich; Texas A&M University System; Texas A&M University College Station	Schaffner, W (corresponding author), Univ Zurich, Inst Mol Biol, Winterhurer Str 190, CH-8057 Zurich, Switzerland.	walter.schaffner@molbio.unizh.ch; giedroc@tamu.edu	Zhang, Bo/K-7162-2012; Giedroc, David/A-8608-2018	Giedroc, David/0000-0002-2342-1620	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042569, R29GM042569] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM042569] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apuy JL, 2001, BIOCHEMISTRY-US, V40, P15164, DOI 10.1021/bi0112208; Bird A, 2000, J BIOL CHEM, V275, P16160, DOI 10.1074/jbc.M000664200; Bird AJ, 2000, EMBO J, V19, P3704, DOI 10.1093/emboj/19.14.3704; Bird AJ, 2003, EMBO J, V22, P5137, DOI 10.1093/emboj/cdg484; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; Bittel DC, 2000, J BIOL CHEM, V275, P37194, DOI 10.1074/jbc.M003863200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown KR, 2002, BIOCHEMISTRY-US, V41, P6469, DOI 10.1021/bi0160664; BRUGNERA E, 1994, NUCLEIC ACIDS RES, V22, P3167, DOI 10.1093/nar/22.15.3167; Chen WY, 2002, BIOCHEM BIOPH RES CO, V291, P798, DOI 10.1006/bbrc.2002.6517; Chen XH, 1999, BIOCHEMISTRY-US, V38, P12915, DOI 10.1021/bi9913000; Chen XH, 1998, BIOCHEMISTRY-US, V37, P11152, DOI 10.1021/bi980843r; Coleman JE, 1998, CURR OPIN CHEM BIOL, V2, P222, DOI 10.1016/S1367-5931(98)80064-1; Cousins RJ, 2003, P NATL ACAD SCI USA, V100, P6952, DOI 10.1073/pnas.0732111100; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; DISTEFANO MD, 1990, BIOCHEMISTRY-US, V29, P2703, DOI 10.1021/bi00463a013; Domenech J, 2003, FEBS LETT, V533, P72, DOI 10.1016/S0014-5793(02)03754-7; Egli D, 2003, EMBO J, V22, P100, DOI 10.1093/emboj/cdg012; ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6; Engst S, 1999, BIOCHEMISTRY-US, V38, P3519, DOI 10.1021/bi982680c; Evans-Galea MV, 2003, BIOCHEMISTRY-US, V42, P1053, DOI 10.1021/bi0263199; Giedroc DP, 2001, ANTIOXID REDOX SIGN, V3, P577, DOI 10.1089/15230860152542943; Giedroc DP, 2001, J BIOL CHEM, V276, P42322, DOI 10.1074/jbc.M106517200; Graden JA, 1996, BIOCHEMISTRY-US, V35, P14583, DOI 10.1021/bi961642v; Gunes C, 1998, EMBO J, V17, P2846, DOI 10.1093/emboj/17.10.2846; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Jensen LT, 1998, EMBO J, V17, P5400, DOI 10.1093/emboj/17.18.5400; Jiang HM, 2003, J BIOL CHEM, V278, P30394, DOI 10.1074/jbc.M303598200; Kim CA, 1996, NAT STRUCT BIOL, V3, P940, DOI 10.1038/nsb1196-940; Koizumi S, 2000, J CELL PHYSIOL, V185, P464, DOI 10.1002/1097-4652(200012)185:3<464::AID-JCP18>3.0.CO;2-4; Koizumi S, 1999, EUR J BIOCHEM, V259, P635, DOI 10.1046/j.1432-1327.1999.00069.x; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Langmade SJ, 2000, J BIOL CHEM, V275, P34803, DOI 10.1074/jbc.M007339200; LaRochelle O, 2001, BIOCHEM J, V353, P591, DOI 10.1042/0264-6021:3530591; Lichtlen P, 2001, NUCLEIC ACIDS RES, V29, P1514, DOI 10.1093/nar/29.7.1514; Maur AAD, 2000, CELL STRESS CHAPERON, V5, P196; McCall KA, 2000, J NUTR, V130, p1437S, DOI 10.1093/jn/130.5.1437S; Muller HP, 1995, SOMAT CELL MOLEC GEN, V21, P289, DOI 10.1007/BF02257464; MULLER HP, 1989, CELL, V58, P767, DOI 10.1016/0092-8674(89)90110-4; OTSUKA F, 1994, J BIOL CHEM, V269, P23700; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RADTKE F, 1995, NUCLEIC ACIDS RES, V23, P2277, DOI 10.1093/nar/23.12.2277; Saydam N, 2002, J BIOL CHEM, V277, P20438, DOI 10.1074/jbc.M110631200; Saydam N, 2001, J BIOL CHEM, V276, P25487, DOI 10.1074/jbc.M009154200; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Smirnova IV, 2000, J BIOL CHEM, V275, P9377, DOI 10.1074/jbc.275.13.9377; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; Suhy DA, 1999, J BIOL CHEM, V274, P9183, DOI 10.1074/jbc.274.14.9183; Vanacore RM, 2000, ANTIOXID REDOX SIGN, V2, P739, DOI 10.1089/ars.2000.2.4-739; Vasak M, 2000, CURR OPIN CHEM BIOL, V4, P177, DOI 10.1016/S1367-5931(00)00082-X; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; Wuttke DS, 1997, J MOL BIOL, V273, P183, DOI 10.1006/jmbi.1997.1291; Zhang B, 2003, MOL CELL BIOL, V23, P8471, DOI 10.1128/MCB.23.23.8471-8485.2003; Zhang B, 2001, MOL CELL BIOL, V21, P4505, DOI 10.1128/MCB.21.14.4505-4514.2001	57	42	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4515	4522		10.1074/jbc.M308924200	http://dx.doi.org/10.1074/jbc.M308924200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14610091	hybrid			2022-12-25	WOS:000188554300072
J	Krieg, AJ; Krieg, SA; Ahn, BS; Shapiro, DJ				Krieg, AJ; Krieg, SA; Ahn, BS; Shapiro, DJ			Interplay between estrogen response element sequence and ligands controls in vivo binding of estrogen receptor to regulated genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE-INHIBITOR 9; B-MEDIATED APOPTOSIS; PROGESTERONE-RECEPTOR; MOLECULAR-BASIS; CELL-DEATH; TAMOXIFEN; PROMOTER; ALPHA; TRANSCRIPTION; CONFORMATION	To examine the role of the estrogen response element (ERE) sequence in binding of liganded estrogen receptor (ER) to promoters, we analyzed in vivo interaction of liganded ER with the imperfect ERE in the pS2 gene and the composite estrogen-responsive unit (ERU) in the proteinase inhibitor 9 (PI-9) gene. In transient transfections of ER-positive HepG2-ER7 cells, PI-9 was strongly induced by estrogen, moxestrol (MOX), and 4-hydroxytamoxifen (OHT). PI-9 was not induced by raloxifene or ICI 182,780. Quantitative reverse transcriptase-PCR showed that moxestrol strongly induced cellular PI-9 and pS2 mRNAs, whereas OHT moderately induced PI-9 mRNA and weakly induced pS2 mRNA. Chromatin immunoprecipitation experiments demonstrated strong and similar association of 17beta-estradiol-hERalpha and MOX-hERalpha with the PI-9 ERU and with the pS2 ERE. Binding of MOX-hERalpha to the PI-9 ERU and the pS2 ERE was rapid and continuous. Although MOX-hERalpha bound strongly to the PI-9 ERU and less well to the pS2 ERE in chromatin immunoprecipitation, gel shift assays showed that estrogen-hERalpha binds with higher affinity to the deproteinized pS2 ERE than to the PI-9 ERU. Across a broad range of OHT concentrations, OHT-hERalpha associated strongly with the pS2 ERE and weakly with the PI-9 ERU. ICI-hERalpha bound poorly to the PI-9 ERU and effectively to the pS2 ERE. Raloxifene-hERalpha and MOX-hERalpha exhibited similar binding to the PI-9 ERU and the pS2 ERE. These studies demonstrate that ER ligand and ERE sequence work together to regulate in vivo binding of ER to estrogen-responsive promoters.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Shapiro, DJ (corresponding author), Univ Illinois, Dept Biochem, 600 S Mathews Ave, Urbana, IL 61801 USA.	djshapir@uiuc.edu		Krieg, Adam/0000-0002-3069-0378	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016720] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-16720] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Annand RR, 1999, BIOCHEM J, V342, P655, DOI 10.1042/0264-6021:3420655; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Barkhem T, 1997, J STEROID BIOCHEM, V62, P53, DOI 10.1016/S0960-0760(97)00017-4; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; Bird CH, 2001, MOL CELL BIOL, V21, P5396, DOI 10.1128/MCB.21.16.5396-5407.2001; BIRD PI, 2002, MOD ASP IMMUNOBIOL, V2, P136; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Burakov D, 2002, J BIOL CHEM, V277, P14359, DOI 10.1074/jbc.C200099200; Di Croce L, 1999, MOL ENDOCRINOL, V13, P1225, DOI 10.1210/me.13.8.1225; Driscoll MD, 1998, J BIOL CHEM, V273, P29321, DOI 10.1074/jbc.273.45.29321; Ediger TR, 2002, MOL ENDOCRINOL, V16, P1828, DOI 10.1210/me.2001-0290; FARSETTI A, 1995, ENDOCRINOLOGY, V136, P5076, DOI 10.1210/en.136.11.5076; Hall JM, 2002, MOL ENDOCRINOL, V16, P469, DOI 10.1210/me.16.3.469; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; Kanamori H, 2000, J BIOL CHEM, V275, P5867, DOI 10.1074/jbc.275.8.5867; Kannan-Thulasiraman P, 2002, J BIOL CHEM, V277, P41230, DOI 10.1074/jbc.M200379200; Klinge CM, 1999, J STEROID BIOCHEM, V71, P1, DOI 10.1016/S0960-0760(99)00124-7; Klinge CM, 2001, MOL CELL ENDOCRINOL, V174, P151, DOI 10.1016/S0303-7207(01)00382-3; Kloosterboer HJ, 2002, J STEROID BIOCHEM, V83, P157, DOI 10.1016/S0960-0760(03)00055-4; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; Krieg SA, 2001, MOL ENDOCRINOL, V15, P1971, DOI 10.1210/me.15.11.1971; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1997, BASIC PATHOLOGY, P283; Mattick S, 1997, J STEROID BIOCHEM, V60, P285, DOI 10.1016/S0960-0760(96)00198-7; McEwan IJ, 2000, BIOCHEM SOC T, V28, P369, DOI 10.1042/0300-5127:0280369; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Medema JP, 2001, P NATL ACAD SCI USA, V98, P11515, DOI 10.1073/pnas.201398198; Metivier R, 2002, MOL CELL, V10, P1019, DOI 10.1016/S1097-2765(02)00746-3; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; Obrero M, 2002, J BIOL CHEM, V277, P45695, DOI 10.1074/jbc.M208092200; Petz LN, 2002, ENDOCRINOLOGY, V143, P4583, DOI 10.1210/en.2002-220369; Petz LN, 2000, MOL ENDOCRINOL, V14, P972, DOI 10.1210/me.14.7.972; Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90; Pike ACW, 2000, BIOCHEM SOC T, V28, P396, DOI 10.1042/0300-5127:0280396; Pike ACW, 2001, STRUCTURE, V9, P145, DOI 10.1016/S0969-2126(01)00568-8; Ramsey TL, 2001, J MOL ENDOCRINOL, V27, P275, DOI 10.1677/jme.0.0270275; Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219; Sandberg K, 2002, TRENDS ENDOCRIN MET, V13, P317, DOI 10.1016/S1043-2760(02)00674-4; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shiau AK, 2002, NAT STRUCT BIOL, V9, P359, DOI 10.1038/nsb787; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; TAM SP, 1985, J BIOL CHEM, V260, P1670; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Wood JR, 1998, MOL CELL BIOL, V18, P1927, DOI 10.1128/MCB.18.4.1927; Wood JR, 2001, MOL ENDOCRINOL, V15, P1114, DOI 10.1210/me.15.7.1114; Young JL, 2000, J EXP MED, V191, P1535, DOI 10.1084/jem.191.9.1535; Zajchowski DA, 2000, J BIOL CHEM, V275, P15885, DOI 10.1074/jbc.M909865199; Zhang CC, 1999, MOL ENDOCRINOL, V13, P632, DOI 10.1210/me.13.4.632	54	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					5025	5034		10.1074/jbc.M307076200	http://dx.doi.org/10.1074/jbc.M307076200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14617632	hybrid			2022-12-25	WOS:000188554300129
J	McMullen, JR; Shioi, T; Huang, WY; Zhang, L; Tarnavski, O; Bisping, E; Schinke, M; Kong, S; Sherwood, MC; Brown, J; Riggi, L; Kang, PM; Izumo, S				McMullen, JR; Shioi, T; Huang, WY; Zhang, L; Tarnavski, O; Bisping, E; Schinke, M; Kong, S; Sherwood, MC; Brown, J; Riggi, L; Kang, PM; Izumo, S			The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110 alpha) pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN CAPPING PROTEIN; RAT CARDIAC MYOCYTES; FACTOR-I; TRANSGENIC MICE; GENE-EXPRESSION; PRESSURE-OVERLOAD; BETA-TROPOMYOSIN; MYOCARDIAL HYPERTROPHY; SIGNALING PATHWAY; POSTNATAL-GROWTH	Insulin-like growth factor 1 (IGF1) was considered a potential candidate for the treatment of heart failure. However, some animal studies and clinical trials have questioned whether elevating IGF1 chronically is beneficial. Secondary effects of increased serum IGF1 levels on other tissues may explain these unfavorable results. The aim of the current study was to examine the role of IGF1 in cardiac myocytes in the absence of secondary effects, and to elucidate downstream signaling pathways and transcriptional regulatory effects of the IGF1 receptor (IGF1R). Transgenic mice overexpressing IGF1R in the heart displayed cardiac hypertrophy, which was the result of an increase in myocyte size, and there was no evidence of histopathology. IGF1R transgenics also displayed enhanced systolic function at 3 months of age, and this was maintained at 12-16 months of age. The phosphoinositide 3-kinase (PI3K)-Akt-p70S6K1 pathway was significantly activated in hearts from IGF1R transgenics. Cardiac hypertrophy induced by overexpression of IGF1R was completely blocked by a dominant negative PI3K(p110alpha) mutant, suggesting IGF1R promotes compensated cardiac hypertrophy in a PI3K(p110alpha)-dependent manner. This study suggests that targeting the cardiac IGF1R-PI3K(p110alpha) pathway could be a potential therapeutic strategy for the treatment of heart failure.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc, Boston, MA 02215 USA; Boston Childrens Hosp, Dept Cardiol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Boston Children's Hospital	McMullen, JR (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc, Boston, MA 02215 USA.	jmcmulle@bidmc.harvard.edu		Kong, Sek Won/0000-0003-4877-7567	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065742, U01HL066582] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL65742, U01-HL66582] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; Bergo MO, 2002, J BIOL CHEM, V277, P47701, DOI 10.1074/jbc.M207734200; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; CANNON RO, 1987, CIRCULATION, V75, P163, DOI 10.1161/01.CIR.75.1.163; CITTADINI A, 1994, AM J PHYSIOL, V267, pE219, DOI 10.1152/ajpendo.1994.267.2.E219; Clemmons DR, 1998, MOL CELL ENDOCRINOL, V140, P19, DOI 10.1016/S0303-7207(98)00024-0; Cohn JN, 1997, CIRCULATION, V95, P766; Colao A, 2001, CLIN ENDOCRINOL, V54, P137, DOI 10.1046/j.1365-2265.2001.01218.x; Cook SA, 2002, J BIOL CHEM, V277, P22528, DOI 10.1074/jbc.M201462200; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; Delaughter MC, 1999, FASEB J, V13, P1923, DOI 10.1096/fasebj.13.14.1923; DONATH MY, 1994, P NATL ACAD SCI USA, V91, P1686, DOI 10.1073/pnas.91.5.1686; Duan CM, 1999, J BIOL CHEM, V274, P37147, DOI 10.1074/jbc.274.52.37147; DUERR RL, 1995, J CLIN INVEST, V95, P619, DOI 10.1172/JCI117706; Fagard Robert H., 1997, Cardiology Clinics, V15, P397; Fiorotto M, 2003, FASEB J, V17, pA700, DOI 10.1096/fj.02-0289fje; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Geenen DL, 1996, J APPL PHYSIOL, V81, P816, DOI 10.1152/jappl.1996.81.2.816; GULICK J, 1991, J BIOL CHEM, V266, P9180; GUSE AH, 1992, ENDOCRINOLOGY, V130, P145, DOI 10.1210/en.130.1.145; Hao JM, 1997, AM J PHYSIOL-HEART C, V272, pH2885, DOI 10.1152/ajpheart.1997.272.6.H2885; Hart MC, 1997, GENOMICS, V39, P264, DOI 10.1006/geno.1996.4506; Hart MC, 1997, CELL MOTIL CYTOSKEL, V38, P120, DOI 10.1002/(SICI)1097-0169(1997)38:2<120::AID-CM2>3.0.CO;2-B; IEMITSU M, 2001, AM J PHYSIOL, V281, pH1167; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; ITO H, 1993, CIRCULATION, V87, P1715, DOI 10.1161/01.CIR.87.5.1715; Iwamoto R, 2003, P NATL ACAD SCI USA, V100, P3221, DOI 10.1073/pnas.0537588100; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KAJSTURA J, 1994, EXP CELL RES, V215, P273, DOI 10.1006/excr.1994.1343; Kasahara H, 1998, CIRC RES, V82, P936, DOI 10.1161/01.RES.82.9.936; KUGE O, 1986, J BIOL CHEM, V261, P5795; Lembo G, 1996, J CLIN INVEST, V98, P2648, DOI 10.1172/JCI119086; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Li BS, 1999, CIRC RES, V84, P1007, DOI 10.1161/01.RES.84.9.1007; Lim HW, 1999, NAT MED, V5, P246, DOI 10.1038/6430; Lim HW, 2000, CIRCULATION, V101, P2431, DOI 10.1161/01.CIR.101.20.2431; Littlefield R, 2001, NAT CELL BIOL, V3, P544, DOI 10.1038/35078517; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Liu TJ, 2001, CIRC RES, V88, P1231, DOI 10.1161/hh1201.092036; Lupu F, 2001, DEV BIOL, V229, P141, DOI 10.1006/dbio.2000.9975; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; McCaig C, 2002, J CELL BIOCHEM, V84, P784, DOI 10.1002/jcb.10093; Mclaughlin L, 2000, J CLIN INVEST, V106, P1105, DOI 10.1172/JCI9037; McMullen JR, 2003, P NATL ACAD SCI USA, V100, P12355, DOI 10.1073/pnas.1934654100; MEROLA B, 1993, J CLIN ENDOCR METAB, V77, P1658, DOI 10.1210/jc.77.6.1658; Muthuchamy M, 1998, J MOL CELL CARDIOL, V30, P1545, DOI 10.1006/jmcc.1998.0720; Muthuchamy M, 1995, J BIOL CHEM, V270, P30593, DOI 10.1074/jbc.270.51.30593; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Okubo S, 2001, CIRCULATION, V103, P877, DOI 10.1161/01.CIR.103.6.877; Oldham S, 2003, TRENDS CELL BIOL, V13, P79, DOI 10.1016/S0962-8924(02)00042-9; Packer M, 2002, J CARD FAIL, V8, P193, DOI 10.1054/jcaf.2002.128001; Pieples K, 2002, AM J PHYSIOL-HEART C, V283, pH1344, DOI 10.1152/ajpheart.00351.2002; Pyle WG, 2002, CIRC RES, V90, P1299, DOI 10.1161/01.RES.0000024389.03152.22; REINACH FC, 1986, NATURE, V322, P648, DOI 10.1038/322648a0; Reiss K, 1996, P NATL ACAD SCI USA, V93, P8630, DOI 10.1073/pnas.93.16.8630; Ren J, 1999, J MOL CELL CARDIOL, V31, P2049, DOI 10.1006/jmcc.1999.1036; Roschier M, 2001, J NEUROCHEM, V76, P11, DOI 10.1046/j.1471-4159.2001.00002.x; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Schadt EE, 2001, J CELL BIOCHEM, V84, P120, DOI 10.1002/jcb.10073; SCHAFER DA, 1994, J CELL BIOL, V127, P453, DOI 10.1083/jcb.127.2.453; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; Serneri GGN, 2001, J AM COLL CARDIOL, V38, P49, DOI 10.1016/S0735-1097(01)01368-7; Serneri GGN, 2001, CIRC RES, V89, P977, DOI 10.1161/hh2301.100982; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Shioi T, 2003, CIRCULATION, V107, P1664, DOI 10.1161/01.CIR.0000057979.36322.88; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Sturbois-Balcerzak B, 2001, J BIOL CHEM, V276, P8205, DOI 10.1074/jbc.M009776200; Tanaka M, 1999, DEVELOPMENT, V126, P1269; Tanaka N, 1998, AM J PHYSIOL-HEART C, V275, pH393, DOI 10.1152/ajpheart.1998.275.2.H393; TAYLOR V, 1995, J BIOL CHEM, V270, P28824, DOI 10.1074/jbc.270.48.28824; Thomas DP, 2000, J APPL PHYSIOL, V89, P1462, DOI 10.1152/jappl.2000.89.4.1462; VOELKER DR, 1986, J BIOL CHEM, V261, P1002; von Lewinski D, 2003, CIRC RES, V92, P169, DOI 10.1161/01.RES.0000051885.70159.12; Welch S, 2002, CIRC RES, V90, P641, DOI 10.1161/01.RES.0000013780.77774.75; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Wolska BM, 1999, CIRC RES, V84, P745; Wolska BM, 2003, PFLUG ARCH EUR J PHY, V446, P1, DOI 10.1007/s00424-002-0900-3; Younes A, 2000, AM J PHYSIOL-HEART C, V279, pH1989, DOI 10.1152/ajpheart.2000.279.4.H1989	84	310	325	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4782	4793		10.1074/jbc.M310405200	http://dx.doi.org/10.1074/jbc.M310405200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14597618	hybrid			2022-12-25	WOS:000188554300103
J	Serbec, VC; Bresjanac, M; Popovic, M; Hartman, KP; Galvani, V; Rupreht, R; Cernilec, M; Vranac, T; Hafner, I; Jerala, R				Serbec, VC; Bresjanac, M; Popovic, M; Hartman, KP; Galvani, V; Rupreht, R; Cernilec, M; Vranac, T; Hafner, I; Jerala, R			Monoclonal antibody against a peptide of human prion protein discriminates between Creutzfeldt-Jacob's disease-affected and normal brain tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JAKOB-DISEASE; SCRAPIE; EPITOPE; HELIX; CONFORMATIONS; REPLICATION; PROPAGATION; INHIBITION; CONVERSION; TRANSITION	Current methods for diagnosing transmissible spongiform encephalopathies rely on the degradation of the cellular prion protein (PrPC) and the subsequent detection of the protease-resistant remnant of the pathological prion isoform PrPSc by antibodies that react with all forms of PrP. We report on a monoclonal antibody, V5B2, raised against a peptide from the C-terminal part of PrP, which recognizes an epitope specific to PrPSc. In cryostat sections from Creutzfeldt-Jacob's disease (CJD) patients' brains, V5B2 selectively labels various deposits of PrPSc without any pretreatment for removal of PrPC. V5B2 does not bind to non-CJD brain samples or to recombinant PrP, either in its native or denatured form. Specificity for PrP is confirmed by a sandwich enzyme-linked immunosorbent assay utilizing V5B2, which discriminates between CJD and normal samples without proteinase K treatment, and by immunoprecipitation from CJD brain homogenate. The PrPSc-specific epitope is disrupted by denaturation. We conclude that the C-terminal part of PrP in disease-associated PrPSc aggregates forms a structural epitope whose conformation is distinct from that of PrPC.	Blood Transfus Ctr Slovenia, Ljubljana 1000, Slovenia; Natl Inst Chem, Biotechnol Lab, Ljubljana 1000, Slovenia; Natl Inst Chem, Sch Med, Inst Pathophysiol, Ljubljana 1000, Slovenia; Natl Inst Chem, Sch Med, Inst Pathol, Ljubljana 1000, Slovenia	National Institute of Chemistry - Slovenia; National Institute of Chemistry - Slovenia; National Institute of Chemistry - Slovenia	Serbec, VC (corresponding author), Blood Transfus Ctr Slovenia, Slajmerjeva 6, Ljubljana 1000, Slovenia.	vladka.curin@ztm.si	Jerala, Roman/H-9850-2015	Jerala, Roman/0000-0002-6337-5251				Billeter M, 1997, P NATL ACAD SCI USA, V94, P7281, DOI 10.1073/pnas.94.14.7281; Bresjanac M, 2000, EXP NEUROL, V164, P53, DOI 10.1006/exnr.2000.7416; Dima RI, 2002, BIOPHYS J, V83, P1268, DOI 10.1016/S0006-3495(02)73899-X; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; Giaccone G, 2000, BRAIN PATHOL, V10, P31, DOI 10.1111/j.1750-3639.2000.tb00240.x; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; Horiuchi M, 2001, J BIOL CHEM, V276, P15489, DOI 10.1074/jbc.M100288200; Hosszu LLP, 1999, NAT STRUCT BIOL, V6, P740, DOI 10.1038/11507; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; Korth C, 1999, METHOD ENZYMOL, V309, P106; KULIOPULOS A, 1994, J AM CHEM SOC, V116, P4599, DOI 10.1021/ja00090a008; Lu BY, 2002, BIOCHEM J, V364, P81, DOI 10.1042/bj3640081; Lu BY, 2001, BIOCHEMISTRY-US, V40, P13390, DOI 10.1021/bi011111t; Morillas M, 2001, BIOCHEMISTRY-US, V40, P6982, DOI 10.1021/bi010232q; MUNOZ V, 1995, J MOL BIOL, V245, P275, DOI 10.1006/jmbi.1994.0023; Paramithiotis E, 2003, NAT MED, V9, P893, DOI 10.1038/nm883; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; Perrier V, 2002, P NATL ACAD SCI USA, V99, P13079, DOI 10.1073/pnas.182425299; PRICE KM, 1995, MONOCLONAL ANTIBODIE, P60; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1997, ANNU REV GENET, V31, P139, DOI 10.1146/annurev.genet.31.1.139; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Shibuya S, 1998, ANN NEUROL, V43, P826, DOI 10.1002/ana.410430618; Swietnicki W, 2000, BIOCHEMISTRY-US, V39, P424, DOI 10.1021/bi991967m; Takahashi H, 1999, J NEUROVIROL, V5, P300, DOI 10.3109/13550289909015816; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Vogtherr M, 2003, J MED CHEM, V46, P3563, DOI 10.1021/jm034093h; Will RG, 1999, P NATL ACAD SCI USA, V96, P4738, DOI 10.1073/pnas.96.9.4738; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zahn R, 1997, FEBS LETT, V417, P400, DOI 10.1016/S0014-5793(97)01330-6	34	70	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3694	3698		10.1074/jbc.M310868200	http://dx.doi.org/10.1074/jbc.M310868200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14593100	hybrid			2022-12-25	WOS:000188379600069
J	Shitamukai, A; Hirata, D; Sonobe, S; Miyakawa, T				Shitamukai, A; Hirata, D; Sonobe, S; Miyakawa, T			Evidence for antagonistic regulation of cell growth by the calcineurin and high osmolarity glycerol pathways in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; VACUOLAR H+-ATPASE; OSMOTIC-STRESS; MORPHOGENESIS CHECKPOINT; PHOSPHATASE CALCINEURIN; TYROSINE PHOSPHATASES; TRANSCRIPTION FACTOR; RESPONSE PATHWAY; GENE-EXPRESSION; MAPK PATHWAYS	Because Ca2+ signaling of budding yeast, through the activation of calcineurin and the Mpk1/Slt2 mitogen-activated protein kinase cascade, performs redundant function(s) in the events essential for growth, the simultaneous deletion of both these pathways (Deltacnb1 Deltampk1) leads to lethality. A PTC4 cDNA that encodes a protein phosphatase belonging to the PP2C family was obtained as a high dosage suppressor of the lethality of Deltacnb1 Deltampk1 strain. Overexpression of PTC4 led to a decrease in the high osmolarity-induced Hog1 phosphorylation, and HOG1 deletion remarkably suppressed the synthetic lethality, indicating an antagonistic role of the high osmolarity glycerol (HOG) pathway and the Ca2+ signaling pathway in growth regulation. The calcineurin-Crz1 pathway was required for the down-regulation of the HOG pathway. Analysis of the time course of actin polarization, bud formation, and the onset of mitosis in synchronous cell cultures demonstrated that calcineurin negatively regulates actin polarization at the bud site, whereas the HOG pathway positively regulates bud formation at a later step after actin has polarized.	Hiroshima Univ, Grad Sch Adv Sci Matter, Dept Mol Biotechnol, Higashihiroshima 7398530, Japan	Hiroshima University	Miyakawa, T (corresponding author), Hiroshima Univ, Grad Sch Adv Sci Matter, Dept Mol Biotechnol, Higashihiroshima 7398530, Japan.	tmiyaka@hiroshima-u.ac.jp	Shitamukai, Atsunori/AAT-8802-2021; Shitamukai, Atsunori/C-6817-2014	Shitamukai, Atsunori/0000-0003-4216-927X; 				ADAMS AEM, 1991, METHOD ENZYMOL, V194, P729; ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Alexander MR, 2001, MOL BIOL CELL, V12, P53, DOI 10.1091/mbc.12.1.53; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; BREWSTER JL, 1994, YEAST, V10, P425, DOI 10.1002/yea.320100402; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CHANG HY, 1995, NATURE, V376, P686, DOI 10.1038/376686a0; Cheng AY, 1999, GENE DEV, V13, P2946, DOI 10.1101/gad.13.22.2946; Cruz MC, 2001, EMBO J, V20, P1020, DOI 10.1093/emboj/20.5.1020; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; Denis V, 2002, J CELL BIOL, V156, P29, DOI 10.1083/jcb.200111004; FARCASANU IC, 1995, EUR J BIOCHEM, V232, P712, DOI 10.1111/j.1432-1033.1995.tb20865.x; Gaits F, 1997, J BIOL CHEM, V272, P17873, DOI 10.1074/jbc.272.28.17873; GARRETTENGELE P, 1995, MOL CELL BIOL, V15, P4103; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Jacoby T, 1997, J BIOL CHEM, V272, P17749, DOI 10.1074/jbc.272.28.17749; Lee BN, 1999, P NATL ACAD SCI USA, V96, P12679, DOI 10.1073/pnas.96.22.12679; Lim HW, 2001, J BIOL CHEM, V276, P15913, DOI 10.1074/jbc.M100452200; Ma XJ, 1996, GENE DEV, V10, P1327, DOI 10.1101/gad.10.11.1327; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; McMillan JN, 1998, J CELL BIOL, V142, P1487, DOI 10.1083/jcb.142.6.1487; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; Mizunuma M, 1998, NATURE, V392, P303, DOI 10.1038/32695; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; Nakamura T, 1996, MOL GEN GENET, V251, P211; O'Rourke SM, 1998, GENE DEV, V12, P2874, DOI 10.1101/gad.12.18.2874; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; Sagasti A, 2001, CELL, V105, P221, DOI 10.1016/S0092-8674(01)00313-0; Sakumoto NM, 1999, YEAST, V15, P1669, DOI 10.1002/(SICI)1097-0061(199911)15:15<1669::AID-YEA480>3.0.CO;2-6; Sia RAL, 1998, EMBO J, V17, P6678, DOI 10.1093/emboj/17.22.6678; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; TANIDA I, 1995, J BIOL CHEM, V270, P10113, DOI 10.1074/jbc.270.17.10113; Uesono Y, 2002, J BIOL CHEM, V277, P13848, DOI 10.1074/jbc.M108848200; Warmka J, 2001, MOL CELL BIOL, V21, P51, DOI 10.1128/MCB.21.1.51-60.2001; Withee JL, 1997, MOL BIOL CELL, V8, P263, DOI 10.1091/mbc.8.2.263; Withee JL, 1998, GENETICS, V149, P865; WurglerMurphy SM, 1997, MOL CELL BIOL, V17, P1289, DOI 10.1128/MCB.17.3.1289	43	48	51	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3651	3661		10.1074/jbc.M306098200	http://dx.doi.org/10.1074/jbc.M306098200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14583627	hybrid			2022-12-25	WOS:000188379600064
J	Zayzafoon, M; Abdulkadir, SA; McDonald, JM				Zayzafoon, M; Abdulkadir, SA; McDonald, JM			Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; OSTEOCALCIN GENE; GAMMA-SECRETASE; STEM-CELLS; EXPRESSION; PROTEIN; DIFFERENTIATION; PATHWAY; CBFA1; TRANSFORMATION	Prostate cancer bone metastases are characterized by their ability to induce osteoblastic lesions and local bone formation. It has been suggested that bone metastatic prostate cancer cells are osteomimetic and capable of expressing genes and proteins typically expressed by osteoblasts. The ability of preosteoblasts to differentiate and express osteoblastic genes depends on several pathways, including Notch and MAPK. Here we show that notch1 expression is increased 4-5 times in C4-2B and MDA PCa 2b cells (osteoblastic skeletal prostate metastatic cancer cell lines) when compared with non-skeletal metastatic cell lines (LNCaP and DU145). Notch1 ligand, dll1, is expressed only in C4-2B cells. Immunohistochemical studies demonstrate that Notch1 is present in both human clinical samples from prostate cancer bone metastases and the C4-2B cell line. To determine whether prostate cancer bone metastases respond to osteogenic induction similar to osteoblasts, C4-2B cells were cultured in osteogenic medium that promotes mineralization. C4-2B cells mineralize and express HES- 1 (a downstream target of Notch), an effect that is completely inhibited by L-685,458, a Notch activity inhibitor. Furthermore, osteogenic induction increases ERK activation, runx2 expression, and nuclear localization, independent of Notch signaling. Finally, we show that Notch and ERK activation are essential for Runx2 DNA binding activity and osteocalcin gene expression in C4-2B cells in response to osteogenic induction. These studies demonstrate that prostate cancer bone metastatic cell lines acquire osteoblastic properties through independent activation of ERK and Notch signaling; presumably, both pathways are activated in the bone microenvironment.	Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35233 USA; Vet Affairs Med Ctr, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	McDonald, JM (corresponding author), Univ Alabama Birmingham, Dept Pathol, 220 W Pavil,619 S 19th St, Birmingham, AL 35233 USA.	mcdonald@path.uab.edu			NIAMS NIH HHS [R01 AR4325, P30 AR 46031] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR046031] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Barrack ER, 1997, PROSTATE, V31, P61; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; BENTLEY H, 1992, BRIT J CANCER, V66, P1159, DOI 10.1038/bjc.1992.427; Brown JM, 2001, UROLOGY, V57, P611, DOI 10.1016/S0090-4295(00)01122-5; Bruder SP, 1998, CLIN ORTHOP RELAT R, pS247; Christiansen JH, 2000, CURR OPIN CELL BIOL, V12, P719, DOI 10.1016/S0955-0674(00)00158-7; Chu JL, 2002, J BIOL CHEM, V277, P7587, DOI 10.1074/jbc.M111044200; DUCY P, 1995, MOL CELL BIOL, V15, P1858; DUCY P, 2000, DEV DYN S, P247; Dumont P., 1993, In Vivo (Attiki), V7, P167; Eandi JA, 2001, BIOCHEM BIOPH RES CO, V288, P521, DOI 10.1006/bbrc.2001.5803; Fitzgerald K, 2000, ONCOGENE, V19, P4191, DOI 10.1038/sj.onc.1203766; Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369; HARRIS SE, 1994, PROSTATE, V24, P204, DOI 10.1002/pros.2990240406; IWAMURA M, 1993, CANCER RES, V53, P1724; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Jung CY, 2001, GENE, V271, P143, DOI 10.1016/S0378-1119(01)00513-3; Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037; Kiefer JA, 2001, MATRIX BIOL, V20, P429, DOI 10.1016/S0945-053X(01)00159-7; KOUTSILIERIS M, 1993, ANTICANCER RES, V13, P443; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Lardelli M, 1995, INT J DEV BIOL, V39, P769; Lin DL, 2001, PROSTATE, V47, P212, DOI 10.1002/pros.1065; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; McLarrent FW, 2001, J BIOL CHEM, V276, P1578, DOI 10.1074/jbc.M007629200; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Nair P, 2003, J VIROL, V77, P7106, DOI 10.1128/JVI.77.12.7106-7112.2003; Navone NM, 1997, CLIN CANCER RES, V3, P2493; Nelson JB, 2000, BJU INT, V85, P45, DOI 10.1046/j.1464-410X.2000.00063.x; Nofziger D, 1999, DEVELOPMENT, V126, P1689; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; Park BJ, 2000, CANCER RES, V60, P3031; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Rabbani SA, 1998, INT J ONCOL, V12, P911; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Shou JY, 2001, CANCER RES, V61, P7291; Sriuranpong V, 2001, CANCER RES, V61, P3200; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Tezuka K, 2002, J BONE MINER RES, V17, P231, DOI 10.1359/jbmr.2002.17.2.231; Tian GC, 2002, J BIOL CHEM, V277, P31499, DOI 10.1074/jbc.M112328200; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200; Yeung F, 2002, J BIOL CHEM, V277, P2468, DOI 10.1074/jbc.M105947200; Zayzafoon M, 2002, J BIOL CHEM, V277, P37212, DOI 10.1074/jbc.M200129200; Ziros PG, 2002, J BIOL CHEM, V277, P23934, DOI 10.1074/jbc.M109881200	49	114	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3662	3670		10.1074/jbc.M308158200	http://dx.doi.org/10.1074/jbc.M308158200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14602722	hybrid			2022-12-25	WOS:000188379600065
J	Cheng, NH; Pittman, JK; Zhu, JK; Hirschi, KD				Cheng, NH; Pittman, JK; Zhu, JK; Hirschi, KD			The protein kinase SOS2 activates the Arabidopsis H+/Ca2+ antiporter CAX1 to integrate calcium transport and salt tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ION HOMEOSTASIS; CALCINEURIN; STRESS; YEAST; IDENTIFICATION; EXCHANGER; DOMAIN; PLANTS	The regulation of ions within cells is an indispensable component of growth and adaptation. The plant SOS2 protein kinase and its associated Ca2+ sensor, SOS3, have been demonstrated to modulate the plasma membrane H+/ Na+ antiporter SOS1; however, how these regulators modulate Ca2+ levels within cells is poorly understood. Here we demonstrate that SOS2 regulates the vacuolar H+/Ca2+ antiporter CAX1. Using a yeast growth assay, co-expression of SOS2 specifically activated CAX1, whereas SOS3 did not. CAX1-like chimeric transporters were activated by SOS2 if the chimeric proteins contained the N terminus of CAX1. Vacuolar membranes from CAX1-expressing cells were made to be H+/Ca2+-competent by the addition of SOS2 protein in a dose-dependent manner. Using a yeast two-hybrid assay, SOS2 interacted with the N terminus of CAX1. In each of these yeast assays, the activation of CAX1 by SOS2 was SOS3-independent. In planta, the high level of expression of a deregulated version of CAX1 caused salt sensitivity. These findings suggest multiple functions for SOS2 and provide a mechanistic link between Ca2+ and Na+ homeostasis in plants.	Baylor Coll Med, USDA ARS, Childrens Nutr Res Ctr, Plant Physiol Grp, Houston, TX 77030 USA; Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA; Baylor Coll Med, Dept Human & Mol Genet, Houston, TX 77030 USA; Texas A&M Univ, Vegetable & Fruit Improvement Ctr, College Stn, TX 77845 USA	Baylor College of Medicine; United States Department of Agriculture (USDA); University of Arizona; Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station	Hirschi, KD (corresponding author), Baylor Coll Med, USDA ARS, Childrens Nutr Res Ctr, Plant Physiol Grp, 1100 Bates St, Houston, TX 77030 USA.	kendalh@bcm.tmc.edu	hirschi, kendal/GNP-0351-2022; Zhu, Jian-Kang/F-7658-2011	Zhu, Jian-Kang/0000-0001-5134-731X; Pittman, Jon/0000-0001-7197-1494				Bressan RA, 1998, TRENDS PLANT SCI, V3, P411, DOI 10.1016/S1360-1385(98)01331-4; Cheng NH, 2003, J BIOL CHEM, V278, P6503, DOI 10.1074/jbc.M210883200; Cheng NH, 2003, PLANT CELL, V15, P347, DOI 10.1105/tpc.007385; Cheng NH, 2002, PLANT PHYSIOL, V128, P1245, DOI 10.1104/pp.010857; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; Gong DM, 2002, PLANT PHYSIOL, V130, P256, DOI 10.1104/pp.004507; Guo Y, 2001, PLANT CELL, V13, P1383, DOI 10.1105/tpc.13.6.1383; Halfter U, 2000, P NATL ACAD SCI USA, V97, P3735, DOI 10.1073/pnas.040577697; HARPER JW, 1993, CELL, V75, P805; Hirschi KD, 1996, P NATL ACAD SCI USA, V93, P8782, DOI 10.1073/pnas.93.16.8782; Hirschi KD, 1999, PLANT CELL, V11, P2113, DOI 10.1105/tpc.11.11.2113; Hrabak EM, 2003, PLANT PHYSIOL, V132, P666, DOI 10.1104/pp.102.011999; LAUCHLI A, 1990, CUR TOP PL, V4, P26; Liu JP, 2000, P NATL ACAD SCI USA, V97, P3730, DOI 10.1073/pnas.060034197; Liu JP, 1998, SCIENCE, V280, P1943, DOI 10.1126/science.280.5371.1943; Maser P, 2001, PLANT PHYSIOL, V126, P1646, DOI 10.1104/pp.126.4.1646; Matsumoto TK, 2002, J BIOL CHEM, V277, P33075, DOI 10.1074/jbc.M205037200; Mendoza I, 1996, J BIOL CHEM, V271, P23061, DOI 10.1074/jbc.271.38.23061; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; Miseta A, 1999, FEBS LETT, V451, P132, DOI 10.1016/S0014-5793(99)00519-0; Nathan DF, 1999, P NATL ACAD SCI USA, V96, P1409, DOI 10.1073/pnas.96.4.1409; Pittman JK, 2002, J BIOL CHEM, V277, P26452, DOI 10.1074/jbc.M202563200; Pittman JK, 2001, PLANT PHYSIOL, V127, P1020, DOI 10.1104/pp.010409; Qiu QS, 2002, P NATL ACAD SCI USA, V99, P8436, DOI 10.1073/pnas.122224699; Quintero FJ, 2002, P NATL ACAD SCI USA, V99, P9061, DOI 10.1073/pnas.132092099; Sherman F., 1986, METHODS YEAST GENETI; Shigaki T, 2001, J BIOL CHEM, V276, P43152, DOI 10.1074/jbc.M106637200; Shigaki T, 2000, GENE, V257, P291, DOI 10.1016/S0378-1119(00)00390-5; Zhu JK, 2000, PLANT PHYSIOL, V124, P941, DOI 10.1104/pp.124.3.941; Zhu JK, 2001, TRENDS PLANT SCI, V6, P66, DOI 10.1016/S1360-1385(00)01838-0	31	179	202	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2922	2926		10.1074/jbc.M309084200	http://dx.doi.org/10.1074/jbc.M309084200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14583601	hybrid			2022-12-25	WOS:000188211300072
J	Lencesova, L; O'Neill, A; Resneck, WG; Bloch, RJ; Blaustein, MP				Lencesova, L; O'Neill, A; Resneck, WG; Bloch, RJ; Blaustein, MP			Plasma membrane-cytoskeleton-endoplasmic reticulum complexes in neurons and astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE ALPHA-2 ISOFORM; SUBUNIT ISOFORMS; SMOOTH-MUSCLE; CA2+ RELEASE; ANKYRIN-B; RECEPTOR; SPECTRIN; CALCIUM; EXPRESSION; PROTEINS	The possibility that certain integral plasma membrane (PM) proteins involved in Ca2+ homeostasis form junctional units with adjacent endoplasmic reticulum (ER) in neurons and glia was explored using immunoprecipitation and immunocytochemistry. Rat brain membranes were solubilized with the mild, non-ionic detergent, IGEPAL CA-630. Na+/Ca2+ exchanger type 1 (NCX1), a key PM Ca2+ transporter, was immunoprecipitated from the detergent-soluble fraction. Several abundant PM proteins co-immunoprecipitated with NCX1, including the alpha2 and alpha3 isoforms of the Na+ pump catalytic (alpha) subunit, and the alpha2 subunit of the dihydropyridine receptor. The adaptor protein, ankyrin 2 (Ank 2), and the cytoskeletal proteins, alpha-fodrin and beta-spectrin, also selectively co-immunoprecipitated with NCX1, as did the ER proteins, Ca2+ pump type 2 (SERCA 2), and inositol-trisphosphate receptor type 1 (IP3R-1). In contrast, a number of other abundant PMs, adaptors, and cytoskeletal proteins did not co-immunoprecipitate with NCX1, including the Na+ pump alpha1 isoform, PM Ca2+ pump type 1 (PMCA1), beta-fodrin, and Ank 3. In reciprocal experiments, immunoprecipitation with antibodies to the Na+ pump alpha2 and alpha3 isoforms, but not alpha1, co-immunoprecipitated NCX1; the antibodies to alpha1 did, however, co-immunoprecipitate PMCA1. Antibodies to Ank 2, alpha-fodrin, beta-spectrin and IP3R-1 all co-immunoprecipitated NCX1. Immunocytochemistry revealed partial co-localization of beta-spectrin with NCX1, Na+ pump alpha3, and IP3R-1 in neurons and of alpha-fodrin with NCX1 and SERCA2 in astrocytes. The data support the idea that in neurons and glia PM microdomains containing NCX1 and Na+ pumps with alpha2 or alpha3 subunits form Ca2+ signaling complexes with underlying ER containing SERCA2 and IP3R-1. These PM and ER components appear to be linked through the cytoskeletal spectrin network, to which they are probably tethered by Ank 2.	Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Blaustein, MP (corresponding author), Univ Maryland, Sch Med, Dept Physiol, 655 W Baltimore St, Baltimore, MD 21201 USA.	mblauste@umaryland.edu	Lencesova, Lubomira/H-7335-2018		NHLBI NIH HHS [HL-45215, HL-64304] Funding Source: Medline; NINDS NIH HHS [NS-16106, NS-17282] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064304, R01HL045215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016106, R01NS017282] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arnon A, 2000, AM J PHYSIOL-HEART C, V279, pH679, DOI 10.1152/ajpheart.2000.279.2.H679; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; Bennett V, 2001, CURR OPIN CELL BIOL, V13, P61, DOI 10.1016/S0955-0674(00)00175-7; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Blaustein MR, 2001, TRENDS NEUROSCI, V24, P602, DOI 10.1016/S0166-2236(00)01891-9; BLOCH RJ, 1989, J CELL BIOL, V108, P481, DOI 10.1083/jcb.108.2.481; BOOHER J, 1972, Neurobiology (Copenhagen), V2, P97; Bootman MD, 2001, J CELL SCI, V114, P2213; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P17917, DOI 10.1074/jbc.270.30.17917; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BUSH KT, 1994, J BIOL CHEM, V269, P23694; Delmas P, 2002, NEURON, V36, P787, DOI 10.1016/S0896-6273(02)01097-8; Doctor RB, 1998, AM J PHYSIOL-RENAL, V274, pF129, DOI 10.1152/ajprenal.1998.274.1.F129; Franzini-Armstrong C, 1998, ANN NY ACAD SCI, V853, P20, DOI 10.1111/j.1749-6632.1998.tb08253.x; Golovina VA, 2002, BIOPHYS J, V82, p61A; Golovina VA, 2003, AM J PHYSIOL-CELL PH, V284, pC475, DOI 10.1152/ajpcell.00383.2002; He SW, 2001, AM J PHYSIOL-REG I, V281, pR917, DOI 10.1152/ajpregu.2001.281.3.R917; HENKART M, 1976, J CELL BIOL, V70, P338, DOI 10.1083/jcb.70.2.338; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; James PF, 1999, MOL CELL, V3, P555, DOI 10.1016/S1097-2765(00)80349-4; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; Juhaszova M, 1997, ANN NY ACAD SCI, V834, P524, DOI 10.1111/j.1749-6632.1997.tb52310.x; Juhaszova M, 1997, P NATL ACAD SCI USA, V94, P1800, DOI 10.1073/pnas.94.5.1800; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1998, J CELL BIOCHEM, V27, P423; Lencesova L, 2002, FASEB J, V16, pA466; LI ZP, 1993, J BIOL CHEM, V268, P11489; LIU SC, 1984, CELL, V37, P587, DOI 10.1016/0092-8674(84)90389-1; LOMBARDO CR, 1994, J BIOL CHEM, V269, P29212; Lytton J, 2002, ANN NY ACAD SCI, V976, P382; MALCHIODIALBEDI F, 1993, J CELL SCI, V106, P67; MCDONOUGH AA, 1994, AM J PHYSIOL-CELL PH, V267, pC901, DOI 10.1152/ajpcell.1994.267.4.C901; Michaely P, 2002, EMBO J, V21, P6387, DOI 10.1093/emboj/cdf651; Miyakawa-Naito A, 2003, J BIOL CHEM, V278, P50355, DOI 10.1074/jbc.M305378200; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Mohler PJ, 2002, J CELL SCI, V115, P1565; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Morrow JS, 1989, CURR OPIN CELL BIOL, V1, P23, DOI 10.1016/S0955-0674(89)80032-8; Moseley AE, 2003, J BIOL CHEM, V278, P5317, DOI 10.1074/jbc.M211315200; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; OBRIEN WJ, 1994, ARCH BIOCHEM BIOPHYS, V310, P32, DOI 10.1006/abbi.1994.1136; Papa M, 2003, J COMP NEUROL, V461, P31, DOI 10.1002/cne.10665; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; PRESSLEY TA, 1992, AM J PHYSIOL, V262, pC743, DOI 10.1152/ajpcell.1992.262.3.C743; Putney JW, 2000, CELL MOL LIFE SCI, V57, P1272, DOI 10.1007/PL00000765; Santacruz-Toloza L, 2000, J BIOL CHEM, V275, P182, DOI 10.1074/jbc.275.1.182; Scotland P, 1998, J CELL BIOL, V143, P1305, DOI 10.1083/jcb.143.5.1305; SOMLYO AV, 1985, EXPERIENTIA, V41, P841, DOI 10.1007/BF01970000; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; SWEADNER KJ, 2000, CAN J PHYSIOL PHARM, V70, P255; Thevananther S, 1998, J BIOL CHEM, V273, P23952, DOI 10.1074/jbc.273.37.23952; Thurneysen T, 2002, MOL BRAIN RES, V107, P145, DOI 10.1016/S0169-328X(02)00461-8; Tuvia S, 1999, J CELL BIOL, V147, P995, DOI 10.1083/jcb.147.5.995; Ursitti JA, 2001, DEV BRAIN RES, V129, P81, DOI 10.1016/S0165-3806(01)00160-2; URSITTI JA, 2002, ENCY MOL MED, V2, P2965; WATANABE H, 1976, J NEUROCYTOL, V5, P125, DOI 10.1007/BF01176186; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8; Zhang ZS, 1998, J BIOL CHEM, V273, P18681, DOI 10.1074/jbc.273.30.18681	58	101	104	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2885	2893		10.1074/jbc.M310365200	http://dx.doi.org/10.1074/jbc.M310365200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14593108	hybrid			2022-12-25	WOS:000188211300068
J	Rosenkilde, MM; Gerlach, LO; Jakobsen, JS; Skerlj, RT; Bridger, GJ; Schwartz, TW				Rosenkilde, MM; Gerlach, LO; Jakobsen, JS; Skerlj, RT; Bridger, GJ; Schwartz, TW			Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor - Transfer of binding site to the CXCR3 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLENEBIS(METHYLENE)-LINKED BIS-TETRAAZAMACROCYCLES; CHEMOKINE RECEPTOR; HIV-1 ENTRY; BICYCLAM DERIVATIVES; POTENT; IDENTIFICATION; INHIBITION; REPLICATION; MUTAGENESIS; CORECEPTOR	AMD3100 is a symmetric bicyclam, prototype non-peptide antagonist of the CXCR4 chemokine receptor. Mutational substitutions at 16 positions located in TM-III, -IV, -V, -VI, and -VII lining the main ligand-binding pocket of the CXCR4 receptor identified three acid residues: Asp(171) (AspIV:20), Asp(262) (AspVI:23), and Glu(288) (GluVII:06) as the main interaction points for AMD3100. Molecular modeling suggests that one cyclam ring of AMD3100 interacts with Asp(171) in TM-IV, whereas the other ring is sandwiched between the carboxylic acid groups of Asp(262) and Glu(288) from TM-VI and -VII, respectively. Metal ion binding in the cyclam rings of AMD3100 increased its dependence on Asp(262) and provided a tighter molecular map of the binding site, where borderline mutational hits became clear hits for the Zn(II)-loaded analog. The proposed binding site for AMD3100 was confirmed by a gradual build-up in the rather distinct CXCR3 receptor, for which the compound normally had no effect. Introduction of only a Glu at position VII:06 and the removal of a neutralizing Lys residue at position VII:02 resulted in a 1000-fold increase in affinity of AMD3100 to within 10-fold of its affinity in CXCR4. We conclude that AMD3100 binds through interactions with essentially only three acidic anchor-point residues, two of which are located at one end and the third at the opposite end of the main ligand-binding pocket of the CXCR4 receptor. We suggest that non-peptide antagonists with, for example, improved oral bioavailability can be designed to mimic this interaction and thereby efficiently and selectively block the CXCR4 receptor.	Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Pharmacol Lab, DK-2200 Copenhagen, Denmark; AnorMED, Langley, BC V2Y 1N5, Canada; 7TM Pharma AS, DK-2970 Horsholm, Denmark	University of Copenhagen	Rosenkilde, MM (corresponding author), Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Pharmacol Lab, Blegdamsvej 3, DK-2200 Copenhagen, Denmark.	rosenkilde@molpharm.dk; gbridger@anormed.com; schwartz@molpharm.dk	Jakobsen, Janus Schou/P-1679-2014	Jakobsen, Janus Schou/0000-0001-6135-5815; Schwartz, Thue W./0000-0002-0261-6904; Rosenkilde, Mette Marie/0000-0001-9600-3254				ADAM KR, 1994, J CHEM SOC CHEM COMM, P1539, DOI 10.1039/c39940001539; Balzarini J, 2001, ANTIVIR CHEM CHEMOTH, V12, P301, DOI 10.1177/095632020101200505; BAREFIELD EK, 1981, J CHEM SOC CHEM COMM, P302, DOI 10.1039/c39810000302; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BOSNICH B, 1965, INORG CHEM, V4, P1102, DOI 10.1021/ic50030a003; Bridger GJ, 1996, J MED CHEM, V39, P109, DOI 10.1021/jm950584t; BRIDGER GJ, 1995, J MED CHEM, V38, P366, DOI 10.1021/jm00002a019; BRIDGER GJ, 1999, ADV ANTIV D, V3, P161; Castonguay LA, 2003, BIOCHEMISTRY-US, V42, P1544, DOI 10.1021/bi026639s; Cho C, 2002, J NEUROVIROL, V8, P573, DOI 10.1080/13550280290101003; Choi HJ, 1998, J AM CHEM SOC, V120, P10622, DOI 10.1021/ja980504l; De Clercq E, 2000, MOL PHARMACOL, V57, P833; DECLERCO E, 1992, P NATL ACAD SCI USA, V89, P5286, DOI 10.1073/pnas.89.12.5286; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Este JA, 1999, MOL PHARMACOL, V55, P67, DOI 10.1124/mol.55.1.67; Gerlach LO, 2003, BIOCHEMISTRY-US, V42, P710, DOI 10.1021/bi0264770; Gerlach LO, 2001, J BIOL CHEM, V276, P14153, DOI 10.1074/jbc.M010429200; Hatse S, 2002, FEBS LETT, V527, P255, DOI 10.1016/S0014-5793(02)03143-5; Hemmerich S, 1999, BIOCHEMISTRY-US, V38, P13013, DOI 10.1021/bi991029m; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holst B, 1998, MOL PHARMACOL, V53, P166, DOI 10.1124/mol.53.1.166; Horn F, 1998, NUCLEIC ACIDS RES, V26, P275, DOI 10.1093/nar/26.1.275; IZATT RM, 1991, CHEM REV, V91, P1721, DOI 10.1021/cr00008a003; KAJIWARA T, 1993, INORG CHEM, V32, P4990, DOI 10.1021/ic00075a003; Kostenis E, 2001, TRENDS PHARMACOL SCI, V22, P560, DOI 10.1016/S0165-6147(00)01810-1; Labrosse B, 1998, J VIROL, V72, P6381, DOI 10.1128/JVI.72.8.6381-6388.1998; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; Liang XY, 2002, J AM CHEM SOC, V124, P9105, DOI 10.1021/ja0260723; Mirzadegan T, 2000, J BIOL CHEM, V275, P25562, DOI 10.1074/jbc.M000692200; Murphy PM, 2000, PHARMACOL REV, V52, P145; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Sabroe I, 2000, J BIOL CHEM, V275, P25985, DOI 10.1074/jbc.M908864199; Signoret N, 1998, J CELL SCI, V111, P2819; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; TASKER PA, 1975, J CRYST MOL STRUCT, V5, P329, DOI 10.1007/BF01270621; Tsamis F, 2003, J VIROL, V77, P5201, DOI 10.1128/JVI.77.9.5201-5208.2003; Unutmaz D, 1997, P NATL ACAD SCI USA, V94, P1615, DOI 10.1073/pnas.94.5.1615; White JR, 1998, J BIOL CHEM, V273, P10095, DOI 10.1074/jbc.273.17.10095; White JR, 2000, J BIOL CHEM, V275, P36626, DOI 10.1074/jbc.M006613200; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	43	193	195	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					3033	3041		10.1074/jbc.M309546200	http://dx.doi.org/10.1074/jbc.M309546200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14585837	hybrid			2022-12-25	WOS:000188211300084
J	Aerbajinai, W; Lee, YT; Wojda, U; Barr, VA; Miller, JL				Aerbajinai, W; Lee, YT; Wojda, U; Barr, VA; Miller, JL			Cloning and characterization of a gene expressed during terminal differentiation that encodes a novel inhibitor of growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; PROTEINS; DOMAIN	We report here the cloning and initial characterization of a novel growth-related gene (EEG-1) that is located on the short arm of chromosome 12. Two spliced transcripts were cloned from human bone marrow and human erythroid progenitor cells: EEG-1L containing a 4350-nucleotide open reading frame encoding a putative protein of 1077 amino acids including a C1q-like globular domain, and an alternatively spliced transcript lacking exon 5 (EEG-1S) encodes a significantly smaller coding region and no C1q-like domain. Quantitative PCR revealed expression of both EEG-1 transcripts in all analyzed tissues. Plasmids encoding green fluorescent protein-tagged genes (GFP-EEG-1) were transfected into Chinese hamster ovary cells for localization and functional assays. In contrast to the diffuse cellular localization of the GFP control, GFP-EEG-1L was detected throughout the cytoplasm and excluded from the nucleus, and GFP-EEG-1S co-localized with aggregated mitochondria. Transfection of both isoforms was associated with significantly increased levels of apoptosis. Stable transfection assays additionally demonstrated decreased growth in those cells expressing EEG-1 at higher levels. Quantitative PCR analyses of mRNA obtained from differentiating erythroid cells from blood donors were performed to determine the transcriptional pattern of EEG-1 during erythropoiesis. EEG-1 expression was highly regulated with increased expression at the stage of differentiation associated with the onset of global nuclear condensation and reduced cell proliferation. We propose that the regulated expression of EEG-1 is involved in the orchestrated regulation of growth that occurs as erythroblasts shift from a highly proliferative state toward their terminal phase of differentiation.	NIDDK, Biol Chem Lab, NIH, Bethesda, MD 20892 USA; NCI, Cellular & Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Miller, JL (corresponding author), NIDDK, Biol Chem Lab, NIH, Bldg 10,Rm 9B17, Bethesda, MD 20892 USA.	jm7f@nih.gov	Wojda, Urszula/M-6079-2015	Wojda, Urszula/0000-0002-4525-2004	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK025089] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; De Maria R, 1999, BLOOD, V93, P796, DOI 10.1182/blood.V93.3.796.403k23_796_803; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; Eggleton P, 1998, TRENDS CELL BIOL, V8, P428, DOI 10.1016/S0962-8924(98)01373-7; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Gubin AN, 1999, GENOMICS, V59, P168, DOI 10.1006/geno.1999.5855; Gupta M, 2000, BLOOD, V96, P491; Israels LG, 1999, STEM CELLS, V17, P306, DOI 10.1002/stem.170306; Kavety B, 1998, MOL BRAIN RES, V63, P98, DOI 10.1016/S0169-328X(98)00264-2; Kishore U, 1999, IMMUNOPHARMACOLOGY, V42, P15, DOI 10.1016/S0162-3109(99)00011-9; Mhawech P, 2001, CRIT REV ONCOL HEMAT, V40, P229, DOI 10.1016/S1040-8428(01)00101-9; Miller JL, 2002, CURR OPIN HEMATOL, V9, P87, DOI 10.1097/00062752-200203000-00001; Palis J, 1998, BLOOD REV, V12, P106, DOI 10.1016/S0268-960X(98)90022-4; Panzenbock B, 1998, BLOOD, V92, P3658, DOI 10.1182/blood.V92.10.3658.422k18_3658_3668; Prigent M, 2000, J BIOL CHEM, V275, P36441, DOI 10.1074/jbc.M004751200; Soltys BJ, 2000, HISTOCHEM CELL BIOL, V114, P245; TAKAMATSU N, 1993, MOL CELL BIOL, V13, P1516, DOI 10.1128/MCB.13.3.1516; Taniguchi T, 1999, BLOOD, V93, P4167, DOI 10.1182/blood.V93.12.4167.412k05_4167_4178; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Watanabe M, 2002, MICROSC MICROANAL, V8, P375, DOI 10.1017/S1431927602010346; Wojda U, 2002, BLOOD, V99, P3005, DOI 10.1182/blood.V99.8.3005.h8003005_3005_3013; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247	22	30	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1916	1921		10.1074/jbc.M305634200	http://dx.doi.org/10.1074/jbc.M305634200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14593112	hybrid			2022-12-25	WOS:000188005700045
J	Dong, MQ; Pinon, DI; Cox, RF; Miller, LJ				Dong, MQ; Pinon, DI; Cox, RF; Miller, LJ			Importance of the amino terminus in secretin family G protein-coupled receptors - Intrinsic photoaffinity labeling establishes initial docking constraints for the calcitonin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENT CROSS-LINKING; PARATHYROID-HORMONE; EXTRACELLULAR DOMAIN; BINDING DOMAIN; CHOLECYSTOKININ RECEPTOR; AGONIST-BINDING; MOLECULAR PHARMACOLOGY; SPATIAL APPROXIMATION; DIRECT IDENTIFICATION; CHIMERIC RECEPTORS	The calcitonin receptor is a member of the class B family of G protein-coupled receptors, closely related to secretin and parathyroid hormone receptors. Although mechanisms of ligand binding have been directly explored for those receptors, current knowledge of the molecular basis of calcitonin binding to its receptor is based only on receptor mutagenesis. In this work we have utilized the more direct approach of photoaffinity labeling to explore spatial approximations between distinct residues within calcitonin and its receptor. For this we have developed two human calcitonin analogues incorporating a photolabile p-benzoyl-L-phenylalanine residue in the mid-region and carboxyl-terminal half of the peptide in positions 16 and 26, respectively. Both probes specifically bound to the human calcitonin receptor with high affinity and were potent stimulants of cAMP accumulation in calcitonin receptor-bearing human embryonic kidney 293 cells. They covalently labeled the calcitonin receptor in a saturable and specific manner. Further purification, deglycosylation, specific chemical and enzymatic cleavage, and sequencing of labeled wild type and mutant calcitonin receptors identified the sites of labeling for the position 16 and 26 probes as receptor residues Phe(137) and Thr(30), respectively. Both were within the extracellular amino terminus of the calcitonin receptor, with the former adjacent to the first transmembrane segment and the latter within the distal amino-terminal tail of the receptor. These data are consistent with affinity labeling of other members of the class B G protein-coupled receptors using analogous probes and may suggest a common ligand binding mechanism for this family.	Mayo Clin Scottsdale, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA; GlaxoSmithKline, Res Triangle Pk, NC 27709 USA	Mayo Clinic; Mayo Clinic Phoenix; GlaxoSmithKline	Dong, MQ (corresponding author), Mayo Clin Scottsdale, Dept Mol Pharmacol & Expt Therapeut, Johnson Res Bldg,13400 E Shea Blvd, Scottsdale, AZ 85259 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046577] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46577] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams AE, 1998, MOL ENDOCRINOL, V12, P1673, DOI 10.1210/me.12.11.1673; Asmann YW, 2000, MOL PHARMACOL, V58, P911, DOI 10.1124/mol.58.5.911; Bazarsuren A, 2002, BIOPHYS CHEM, V96, P305, DOI 10.1016/S0301-4622(02)00023-6; Behar V, 2000, J BIOL CHEM, V275, P9, DOI 10.1074/jbc.275.1.9; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; BOUIZAR Z, 1986, EUR J BIOCHEM, V155, P141, DOI 10.1111/j.1432-1033.1986.tb09469.x; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; Chorev M, 2002, RECEPTOR CHANNEL, V8, P219, DOI 10.1080/10606820213685; Coulie B, 2001, J BIOL CHEM, V276, P35518, DOI 10.1074/jbc.M104489200; Ding XQ, 2001, J BIOL CHEM, V276, P4236, DOI 10.1074/jbc.M003798200; Dong MQ, 2000, J BIOL CHEM, V275, P26032, DOI 10.1074/jbc.M000612200; Dong MQ, 2003, J BIOL CHEM, V278, P48300, DOI 10.1074/jbc.M309166200; Dong MQ, 1999, J BIOL CHEM, V274, P19161, DOI 10.1074/jbc.274.27.19161; Dong MQ, 2002, REGUL PEPTIDES, V109, P181, DOI 10.1016/S0167-0115(02)00202-1; Dong MQ, 2002, MOL ENDOCRINOL, V16, P2490, DOI 10.1210/me.2002-0111; Dong MQ, 2002, RECEPTOR CHANNEL, V8, P189, DOI 10.1080/10606820213686; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; DSANTOS CS, 1988, ENDOCRINOLOGY, V123, P1483, DOI 10.1210/endo-123-3-1483; FEYEN JHM, 1992, BIOCHEM BIOPH RES CO, V187, P8, DOI 10.1016/S0006-291X(05)81450-0; Ganguli SC, 1998, J PHARMACOL EXP THER, V286, P593; Gensure RC, 2001, J BIOL CHEM, V276, P42692, DOI 10.1074/jbc.M106215200; Gensure RC, 2001, J BIOL CHEM, V276, P28650, DOI 10.1074/jbc.M100717200; Gourlet P, 1996, EUR J BIOCHEM, V239, P349, DOI 10.1111/j.1432-1033.1996.0349u.x; Gourlet P, 1996, PEPTIDES, V17, P825, DOI 10.1016/0196-9781(96)00107-6; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; Greenberg Z, 2000, BIOCHEMISTRY-US, V39, P8142, DOI 10.1021/bi000195n; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; MOSELEY JM, 1987, PHARMACOL THERAPEUT, V34, P51, DOI 10.1016/0163-7258(87)90091-X; MOSELEY JM, 1982, J BIOL CHEM, V257, P5846; MOSELEY JM, 1986, J BONE MINER RES, V1, P293; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Pantaloni C, 1996, J BIOL CHEM, V271, P22146, DOI 10.1074/jbc.271.36.22146; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; Perrin MH, 2001, J BIOL CHEM, V276, P31528, DOI 10.1074/jbc.M101838200; Pondel M, 2000, INT J EXP PATHOL, V81, P405, DOI 10.1046/j.1365-2613.2000.00176.x; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; Pozvek G, 1997, MOL PHARMACOL, V51, P658, DOI 10.1124/mol.51.4.658; Purdue BW, 2002, RECEPTOR CHANNEL, V8, P243, DOI 10.1080/10606820213681; Quiza M, 1997, ENDOCRINOLOGY, V138, P530, DOI 10.1210/en.138.2.530; RITTEL W, 1976, EXPERIENTIA, V32, P246, DOI 10.1007/BF01937791; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sexton PM, 1999, CURR MED CHEM, V6, P1067; Stroop SD, 1996, ENDOCRINOLOGY, V137, P4752, DOI 10.1210/en.137.11.4752; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; Suva LJ, 1997, J PHARMACOL EXP THER, V283, P876; Tan YV, 2003, J BIOL CHEM, V278, P36531, DOI 10.1074/jbc.M304770200; VILARDAGA JP, 1995, BIOCHEM BIOPH RES CO, V211, P885, DOI 10.1006/bbrc.1995.1895; Zang MW, 2003, MOL PHARMACOL, V63, P993, DOI 10.1124/mol.63.5.993; Zhou AT, 1997, P NATL ACAD SCI USA, V94, P3644, DOI 10.1073/pnas.94.8.3644	57	43	44	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1167	1175		10.1074/jbc.M305719200	http://dx.doi.org/10.1074/jbc.M305719200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14583624	hybrid			2022-12-25	WOS:000187722800041
J	Sullivan, M; Hornig, NCD; Porstmann, T; Uhlmann, F				Sullivan, M; Hornig, NCD; Porstmann, T; Uhlmann, F			Studies on substrate recognition by the budding yeast separase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER-CHROMATID SEPARATION; ANAPHASE-PROMOTING COMPLEX; COHESIN SUBUNIT SCC1; MEIOSIS-I DEPENDS; MITOTIC EXIT; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; MEDIATED PROTEOLYSIS; CELL-CYCLE; CLEAVAGE	Sister chromatid cohesion is resolved at anaphase onset when separase, a site-specific protease, cleaves the Scc1 subunit of the chromosomal cohesin complex that is responsible for holding sister chromatids together. This mechanism to initiate anaphase is conserved in eukaryotes from budding yeast to man. Budding yeast separase recognizes and cleaves two conserved peptide motifs within Scc1. In addition, separase cleaves a similar motif in the kinetochore and spindle protein Slk19. Separase may cleave further substrate proteins to orchestrate multiple cellular events that take place during anaphase. To investigate substrate recognition by budding yeast separase we analyzed the sequence requirements at one of the Scc1 cleavage site motifs by systematic mutagenesis. We derived a cleavage site consensus motif (not( FKRWY))(ACFHILMPVWY)(DE) X(AGSV) R/X. This motif is found in 1,139 of 5,889 predicted yeast proteins. We analyzed 28 candidate proteins containing this motif as well as 35 proteins that contain a core (DE) XXR motif. We could so far not confirm new separase substrates, but we have uncovered other forms of mitotic regulation of some of the proteins. We studied whether determinants other than the cleavage site motif mediate separase-substrate interaction. When the separase active site was occupied with a peptide inhibitor covering the cleavage site motif, separase still efficiently interacted with its substrate Scc1. This suggests that separase recognizes both a cleavage site consensus sequence as well as features outside the cleavage site.	Canc Res UK London Res Inst, Lincolns Inn Fields Labs, Chromosome Segregat Lab, London WC2A 3PX, England	Cancer Research UK	Uhlmann, F (corresponding author), Canc Res UK London Res Inst, Lincolns Inn Fields Labs, Chromosome Segregat Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Hornig, Nadine/AAO-2648-2021	Uhlmann, Frank/0000-0002-3527-6619				Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Buonomo SBC, 2000, CELL, V103, P387, DOI 10.1016/S0092-8674(00)00131-8; Buonomo SBC, 2003, DEV CELL, V4, P727, DOI 10.1016/S1534-5807(03)00129-1; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; Cohen-Fix O, 1999, GENE DEV, V13, P1950, DOI 10.1101/gad.13.15.1950; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gordon DM, 2001, P NATL ACAD SCI USA, V98, P12515, DOI 10.1073/pnas.231212498; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Herzig A, 2002, GENE DEV, V16, P2443, DOI 10.1101/gad.242202; Hornig NCD, 2002, CURR BIOL, V12, P973, DOI 10.1016/S0960-9822(02)00847-3; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Lee SE, 2001, J CELL SCI, V114, P2345; Li YM, 2003, CELL CYCLE, V2, P143, DOI 10.4161/cc.2.2.336; Lim HH, 1998, CURR BIOL, V8, P231, DOI 10.1016/S0960-9822(98)70088-0; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Nakamura T, 2002, GENES CELLS, V7, P1113, DOI 10.1046/j.1365-2443.2002.00586.x; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Rao H, 2001, NATURE, V410, P955, DOI 10.1038/35073627; Rappleye CA, 2002, DEV CELL, V2, P195, DOI 10.1016/S1534-5807(02)00114-4; Shah R, 2001, GENETICS, V159, P965; Siomos MF, 2001, CURR BIOL, V11, P1825, DOI 10.1016/S0960-9822(01)00588-7; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Sullivan M, 2003, NAT CELL BIOL, V5, P249, DOI 10.1038/ncb940; Sullivan M, 2001, NAT CELL BIOL, V3, P771, DOI 10.1038/ncb0901-771; Tinker-Kulberg RL, 1999, GENE DEV, V13, P1936, DOI 10.1101/gad.13.15.1936; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 2001, EMBO REP, V2, P487, DOI 10.1093/embo-reports/kve113; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; Vallen EA, 2000, MOL BIOL CELL, V11, P593, DOI 10.1091/mbc.11.2.593; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Waizenegger IC, 2002, CURR BIOL, V12, P1368, DOI 10.1016/S0960-9822(02)01073-4; Yoshida S, 2002, BIOCHEM BIOPH RES CO, V294, P687, DOI 10.1016/S0006-291X(02)00544-2; Zou H, 2002, FEBS LETT, V528, P246, DOI 10.1016/S0014-5793(02)03238-6	39	46	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1191	1196		10.1074/jbc.M309761200	http://dx.doi.org/10.1074/jbc.M309761200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14585836	hybrid			2022-12-25	WOS:000187722800044
J	Fuller, W; Eaton, P; Bell, JR; Shattock, MJ				Fuller, W; Eaton, P; Bell, JR; Shattock, MJ			Ischemia-induced phosphorylation of phospholemman directly activates rat cardiac Na/K ATPase	FASEB JOURNAL			English	Article						ischemia; phospholemman; protein kinase; isolated heart	PROTEIN-KINASE-C; NA+-K+-ATPASE; PIG VENTRICULAR MYOCYTES; GAMMA-SUBUNIT; ALPHA-SUBUNITS; SODIUM-PUMP; NA,K-ATPASE; MEMBRANE; BINDING; HEARTS	Regulation of the Na/K ATPase by protein kinases is model-specific. We have observed a profound activation of the sarcolemmal Na/K ATPase during cardiac ischemia, which is masked by an inhibitor of the enzyme in the cytosol. The aim of these studies was to characterize the pathways involved in this activation in the Langendorff-perfused rat heart. Na/K ATPase activity was determined by measuring ouabain-sensitive phosphate generation by cardiac homogenates at 37degreesC. In isolated sarcolemma, ischemia (30 min) caused a substantial activation of the Na/K ATPase compared with aerobic controls, which was abolished by perfusing the heart with staurosporine or H89. However, the alpha1 subunit of the Na/K ATPase was not phosphorylated during ischemia. The sarcolemmal protein phospholemman (PLM) was found associated with the Na/K ATPase alpha1 and beta1 but not alpha2 subunits, and PLM increased its association with the catalytic subunit of PKA following ischemia. In vitro 14-3-3 binding assays indicated that PLM was phosphorylated following ischemia. These results indicate that the ischemia-induced activation of the Na/K ATPase is indirect, through phosphorylation of PLM, which is an integral part of the Na/K ATPase enzyme complex in the heart. The role of PLM is analogous to phospholamban in regulating the sarcoplasmic reticulum calcium ATPase.	Kings Coll London, St Thomas Hosp, Rayne Inst, Ctr Cardiovasc Biol & Med, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Shattock, MJ (corresponding author), Kings Coll London, St Thomas Hosp, Rayne Inst, Ctr Cardiovasc Biol & Med, London SE1 7EH, England.	shattock@kcl.ac.uk	Eaton, Philip/I-5444-2015	Eaton, Philip/0000-0003-0748-2367; Shattock, Michael/0000-0001-6242-7585; Fuller, William/0000-0002-5883-4433	British Heart Foundation; the Wellcome Trust	British Heart Foundation(British Heart Foundation); the Wellcome Trust(Wellcome TrustEuropean Commission)	This work was supported by grants from the British Heart Foundation and the Wellcome Trust. All authors have no conflicts of interest to disclose. The technical assistance of Semjidmaa Dashnyam is gratefully acknowledged	Albert CJ, 1999, AM J PHYSIOL-HEART C, V276, pH642, DOI 10.1152/ajpheart.1999.276.2.H642; Arystarkhova E, 1996, J BIOL CHEM, V271, P23407, DOI 10.1074/jbc.271.38.23407; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Chen ZH, 1998, CIRC RES, V82, P367, DOI 10.1161/01.RES.82.3.367; Cheng SXJ, 1999, J PHYSIOL-LONDON, V518, P37, DOI 10.1111/j.1469-7793.1999.0037r.x; Cheng XJ, 1997, AM J PHYSIOL-CELL PH, V273, pC893, DOI 10.1152/ajpcell.1997.273.3.C893; Cornelius F, 2001, J BIOENERG BIOMEMBR, V33, P415, DOI 10.1023/A:1010671607911; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; Feschenko MS, 2000, J BIOL CHEM, V275, P34693, DOI 10.1074/jbc.M005869200; Feschenko MS, 2003, J NEUROSCI, V23, P2161; Feschenko MS, 1997, J BIOL CHEM, V272, P17726, DOI 10.1074/jbc.272.28.17726; Fotis H, 1999, EUR J BIOCHEM, V260, P904, DOI 10.1046/j.1432-1327.1999.00237.x; Fuller W, 2003, CARDIOVASC RES, V57, P1044, DOI 10.1016/S0008-6363(02)00810-6; Fuller W, 2001, ANAL BIOCHEM, V293, P216, DOI 10.1006/abio.2001.5127; GAO J, 1994, J PHYSIOL-LONDON, V477, P373, DOI 10.1113/jphysiol.1994.sp020199; James AF, 2001, BIOCHEM BIOPH RES CO, V284, P1048, DOI 10.1006/bbrc.2001.5083; KAKAR SS, 1987, J BIOL CHEM, V262, P42; KIHARA Y, 1989, CIRC RES, V65, P1029, DOI 10.1161/01.RES.65.4.1029; Kockskamper J, 2000, J PHYSIOL-LONDON, V523, P561, DOI 10.1111/j.1469-7793.2000.t01-2-00561.x; Kurihara K, 2000, AM J PHYSIOL-CELL PH, V279, pC1516, DOI 10.1152/ajpcell.2000.279.5.C1516; LEFER AM, 1974, ARCH INT PHARMACOD T, V211, P225; Lehoux S, 2001, J BIOL CHEM, V276, P15794, DOI 10.1074/jbc.M100410200; Mahmmoud YA, 2000, J BIOL CHEM, V275, P35969, DOI 10.1074/jbc.M005168200; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; Minor NT, 1998, P NATL ACAD SCI USA, V95, P6521, DOI 10.1073/pnas.95.11.6521; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Netticadan T, 1997, BIOCHEM BIOPH RES CO, V238, P544, DOI 10.1006/bbrc.1997.7305; OWENS K, 1982, AM J PHYSIOL, V242, pH456, DOI 10.1152/ajpheart.1982.242.3.H456; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PITTS BJR, 1984, AM J PHYSIOL, V247, pH840, DOI 10.1152/ajpheart.1984.247.5.H840; PRESTI CF, 1985, J BIOL CHEM, V260, P3879; PRESTI CF, 1985, J BIOL CHEM, V260, P3860; Rice WJ, 2001, BIOPHYS J, V80, P2187, DOI 10.1016/S0006-3495(01)76191-7; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; SILVERMAN BDZ, 2002, BIOPHYS J, V82; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Song JL, 2002, AM J PHYSIOL-HEART C, V283, pH576, DOI 10.1152/ajpheart.00197.2002; STEENBERGEN C, 1977, CIRC RES, V41, P849, DOI 10.1161/01.RES.41.6.849; Sweadner KJ, 2001, AM J PHYSIOL-CELL PH, V280, pC1017, DOI 10.1152/ajpcell.2001.280.4.C1017; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Van Emous JG, 1998, J MOL CELL CARDIOL, V30, P337, DOI 10.1006/jmcc.1997.0597; VANECHTELD CJA, 1991, J MOL CELL CARDIOL, V23, P297, DOI 10.1016/0022-2828(91)90066-U; Vittone L, 2002, J MOL CELL CARDIOL, V34, P39, DOI 10.1006/jmcc.2001.1488; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YAMAGUCHI M, 1983, J BIOL CHEM, V258, P5260	46	95	95	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					197	199		10.1096/fj.03-0213fje	http://dx.doi.org/10.1096/fj.03-0213fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597563				2022-12-25	WOS:000188829300072
J	Ghoshal, K; Majumder, S; Datta, J; Motiwala, T; Bai, S; Sharma, SM; Frankel, W; Jacob, ST				Ghoshal, K; Majumder, S; Datta, J; Motiwala, T; Bai, S; Sharma, SM; Frankel, W; Jacob, ST			Role of human ribosomal RNA (rRNA) promoter methylation and of Methyl-CpG-binding protein MBD2 in the suppression of rRNA gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLTRANSFERASE GENE; METALLOTHIONEIN-I PROMOTER; DE-NOVO METHYLATION; POLYMERASE-I; HEPATOCELLULAR-CARCINOMA; HISTONE DEACETYLASE; IMMUNODEFICIENCY SYNDROME; SPECIES-SPECIFICITY; TRANSCRIPTION; CHROMATIN	The methylation status of the CpG island located within the ribosomal RNA (rRNA) promoter in human hepatocellular carcinomas and pair-matched liver tissues was analyzed by bisulfite genomic sequencing. Significant hypomethylation of methyl-CpGs in the rRNA promoter was observed in the tumor samples compared with matching normal tissues, which was consistent with the relatively high level of rRNA synthesis in rapidly proliferating tumors. To study the effect of CpG methylation on RNA polymerase I (pol I)-transcribed rRNA genes, we constructed pHrD-IRES-Luc (human rRNA promoter-luciferase reporter). In this plasmid, Kozak sequence of the pGL3-basic vector was replaced by the internal ribosome entry site (IRES) of encephalomyocarditis viral genome to optimize pol I-driven reporter gene expression. Transfection of this plasmid into HepG2 (human) cells revealed reduced pol I-driven luciferase activity with an increase in methylation density at the promoter. Markedly reduced luciferase activity in Hepa (mouse) cells compared with HepG2 (human) cells showed that pHrD-IRES-Luc is transcribed by pol I. Site-specific methylation of human rRNA promoter demonstrated that methylation of CpG at the complementary strands located in the promoter (-9, -102, -347 with respect to the + 1 site) inhibited luciferase activity, whereas symmetrical methylation of a CpG in the transcribed region (+152) did not affect the promoter activity. Immunofluorescence studies showed that the methyl-CpG-binding proteins, MBD1, MBD2, MBD3, and MeCP2, are localized both in the nuclei and nucleoli of HepG2 cells. Transient overexpression of MBD2 suppressed luciferase activity specifically from the methylated rRNA promoter, whereas MBD1 and MBD3 inhibited rRNA promoter activity irrespective of the methylation status. Chromatin immunoprecipitation analysis confirmed predominant association of MBD2 with the endogenous methylated rRNA promoter, which suggests a selective role for MBD2 in the methylation-mediated inhibition of ribosomal RNA gene expression.	Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Dept Pathol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Ghoshal, K (corresponding author), Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.	ghoshal.1@osu.edu; jacob.42@osu.edu	Motiwala, Tasneem/AAB-9067-2021; Jacob, Samson/H-3135-2011	Frankel, Wendy/0000-0003-1658-1009; Sharma, Sudarshana/0000-0002-9745-0061	NCI NIH HHS [R01 CA081024-04, CA 81024, R01 CA081024-02, R01 CA086978-01A2, R01 CA086978-06A1, R01 CA081024-01A2, R01 CA081024, R01 CA086978, R01 CA081024-03, R01 CA086978-04, R01 CA086978-05, R01 CA086978-03, CA 86978, R01 CA086978-02] Funding Source: Medline; NIEHS NIH HHS [R01 ES010874-04, R01 ES010874-03, ES 10874, R01 ES010874-02, R01 ES010874-05, R01 ES010874-01, R01 ES010874] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081024, R01CA086978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010874] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Detich N, 2003, J BIOL CHEM, V278, P27586, DOI 10.1074/jbc.M303740200; Ehrlich M, 2001, HUM MOL GENET, V10, P2917, DOI 10.1093/hmg/10.25.2917; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Ghosh AK, 1996, BIOCHEM BIOPH RES CO, V225, P890, DOI 10.1006/bbrc.1996.1268; GHOSH AK, 1994, GENE, V141, P271, DOI 10.1016/0378-1119(94)90584-3; Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002; Ghoshal K, 2002, METHOD ENZYMOL, V353, P476; Gibbons RJ, 2000, NAT GENET, V24, P368, DOI 10.1038/74191; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; Hannan KM, 1998, FRONT BIOSCI, V3, P376, DOI [10.2741/A282, DOI 10.2741/A282]; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Heix J, 1997, P NATL ACAD SCI USA, V94, P1733, DOI 10.1073/pnas.94.5.1733; HEIX J, 1995, CURR OPIN GENET DEV, V5, P652, DOI 10.1016/0959-437X(95)80035-2; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 2000, CURR TOP MICROBIOL, V249, P55; Holliday R, 1996, CANCER SURV, V28, P103; Huang RM, 2002, FASEB J, V16, DOI 10.1096/fj.01-0687com; JACOB ST, 1995, BIOCHEM J, V306, P617, DOI 10.1042/bj3060617; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; Leary DJ, 2001, FEBS LETT, V509, P145, DOI 10.1016/S0014-5793(01)03143-X; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Lin CH, 2001, CANCER RES, V61, P4238; Machwe A, 2000, FASEB J, V14, P1715, DOI 10.1096/fj.99-0926com; Majumder S, 1999, J BIOL CHEM, V274, P28584, DOI 10.1074/jbc.274.40.28584; Majumder S, 2002, J BIOL CHEM, V277, P16048, DOI 10.1074/jbc.M111662200; Majumder S, 2001, GENE EXPRESSION, V9, P203, DOI 10.3727/000000001783992588; Matsukura S, 2003, BRIT J CANCER, V88, P521, DOI 10.1038/sj.bjc.6600743; McStay B, 2002, GENE EXPRESSION, V10, P263, DOI 10.3727/000000002783992415; Millar CB, 2002, SCIENCE, V297, P403, DOI 10.1126/science.1073354; Motiwala T, 2003, ONCOGENE, V22, P6319, DOI 10.1038/sj.onc.1206750; Nakao M, 2001, BRAIN DEV-JPN, V23, pS174, DOI 10.1016/S0387-7604(01)00348-5; Nan XH, 2001, BRAIN DEV-JPN, V23, pS32, DOI 10.1016/S0387-7604(01)00333-3; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; PALMER TD, 1993, NUCLEIC ACIDS RES, V21, P3451, DOI 10.1093/nar/21.15.3451; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Plass C, 2002, HUM MOL GENET, V11, P2479, DOI 10.1093/hmg/11.20.2479; Pogribny IP, 2002, CANCER LETT, V187, P69, DOI 10.1016/S0304-3835(02)00408-1; Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501; REEDER RH, 1984, CELL, V38, P349, DOI 10.1016/0092-8674(84)90489-6; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Santoro R, 2001, MOL CELL, V8, P719, DOI 10.1016/S1097-2765(01)00317-3; Schagdarsurengin U, 2003, ONCOGENE, V22, P1866, DOI 10.1038/sj.onc.1206338; Valdez BC, 1995, MOL IMMUNOL, V32, P1207, DOI 10.1016/0161-5890(95)00093-3; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yu J, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-29; ZAPISEK WF, 1992, CARCINOGENESIS, V13, P1869, DOI 10.1093/carcin/13.10.1869; Zhao XY, 2003, P NATL ACAD SCI USA, V100, P6777, DOI 10.1073/pnas.1131928100; Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440	63	149	153	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6783	6793		10.1074/jbc.M309393200	http://dx.doi.org/10.1074/jbc.M309393200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14610093	Green Accepted, hybrid			2022-12-25	WOS:000188969200072
J	Sacrist n, C; Tussie-Luna, MI; Logan, SM; Roy, AL				Sacrist n, C; Tussie-Luna, MI; Logan, SM; Roy, AL			Mechanism of Bruton's tyrosine kinase-mediated recruitment and regulation of TFII-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; SRC FAMILY; B-CELLS; ACTIVATION; BTK; PHOSPHORYLATION; ENGAGEMENT; REGION; MICE; GENE	TFII-I is a ubiquitously expressed multifunctional transcription factor with broad biological roles in transcription and signal transduction in a variety of cell types. We and others have shown that TFII-I can interact physically and functionally with Bruton's tyrosine kinase (Btk), a hematopoietic non-receptor protein tyrosine kinase that is critical for B lymphocyte development. Although TFII-I-Btk interactions are impaired in B cells from X-linked immunodeficient mice, the precise molecular determinants governing TFII-I-Btk complex formation remain unknown. To this end, we have conducted a structural analysis of TFII-I-Btk interactions by using a panel of TFII-I mutants. These studies have revealed that a region within the N-terminal 90 amino acids of TFII-I, which includes a putative leucine zipper motif, is primarily responsible for its interaction with Btk. Mutations in the leucine zipper region itself were not sufficient to abrogate binding of TFII-I to Btk, suggesting that regions/residues outside the leucine zipper are responsible for such interactions. Because the first 90 amino acids of TFII-I are required for its dimerization, we propose that Btk tethers TFII-I to the cytoplasm by preventing its dimerization and its subsequent nuclear localization. We further examined the requirement of tyrosine phosphorylation for TFII-I-Btk complex formation. Our data showed that Src-dependent tyrosine phosphorylation sites in TFII-I are not targeted by Btk, suggesting that multiple kinases can independently target TFII-I via distinct signaling pathways. Our results provide a beginning step toward understanding the functional importance of the TFII-I-Btk pathway in B cell signaling and gene expression.	Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Tufts Univ, Sch Med, Program Immunol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Genet Program, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts University; Tufts University	Roy, AL (corresponding author), Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA.	ananda.roy@tufts.edu		Sacristan, Catarina/0000-0001-9643-7650; Tussie-Luna, Maria Isabel/0000-0002-5033-408X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045150, R56AI045150] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45150] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bajpai UD, 2000, J EXP MED, V191, P1735, DOI 10.1084/jem.191.10.1735; Cheriyath V, 2000, J BIOL CHEM, V275, P26300, DOI 10.1074/jbc.M002980200; Cheriyath V, 2002, J BIOL CHEM, V277, P22798, DOI 10.1074/jbc.M202956200; Cheriyath V, 1998, MOL CELL BIOL, V18, P4444, DOI 10.1128/MCB.18.8.4444; Cheriyath V, 2001, J BIOL CHEM, V276, P8377, DOI 10.1074/jbc.M008411200; Chiu CW, 2002, EMBO J, V21, P6461, DOI 10.1093/emboj/cdf658; Egloff AM, 2001, J BIOL CHEM, V276, P27806, DOI 10.1074/jbc.M103692200; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Guo BC, 2000, IMMUNITY, V13, P243, DOI 10.1016/S1074-7613(00)00024-8; Jurado LAP, 1998, HUM MOL GENET, V7, P325, DOI 10.1093/hmg/7.3.325; Kang SW, 2001, EMBO J, V20, P5692, DOI 10.1093/emboj/20.20.5692; Khan WN, 1997, INT IMMUNOL, V9, P395, DOI 10.1093/intimm/9.3.395; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; Kim DW, 2001, MOL CELL BIOL, V21, P3387, DOI 10.1128/MCB.21.10.3387-3397.2000; Mahajan S, 2001, J BIOL CHEM, V276, P31216, DOI 10.1074/jbc.M104874200; Novina CD, 1998, J BIOL CHEM, V273, P33443, DOI 10.1074/jbc.273.50.33443; Novina CD, 1999, MOL CELL BIOL, V19, P5014; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Roy AL, 2001, GENE, V274, P1, DOI 10.1016/S0378-1119(01)00625-4; Saijo K, 2002, J EXP MED, V195, P1647, DOI 10.1084/jem.20020408; SANTOSARGUMEDO L, 1995, INT IMMUNOL, V7, P163, DOI 10.1093/intimm/7.2.163; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; Smith CIE, 2001, BIOESSAYS, V23, P436, DOI 10.1002/bies.1062; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Wang YK, 1998, GENOMICS, V48, P163, DOI 10.1006/geno.1997.5182; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604	32	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7147	7158		10.1074/jbc.M303724200	http://dx.doi.org/10.1074/jbc.M303724200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14623887	hybrid			2022-12-25	WOS:000188969200114
J	Fortna, RR; Crystal, AS; Morais, VA; Pijak, DS; Lee, VMY; Doms, RW				Fortna, RR; Crystal, AS; Morais, VA; Pijak, DS; Lee, VMY; Doms, RW			Membrane topology and nicastrin-enhanced endoproteolysis of APH-1, a component of the gamma-secretase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; INTRAMEMBRANE PROTEOLYSIS; CAENORHABDITIS-ELEGANS; SIGNAL-TRANSDUCTION; ALZHEIMERS-DISEASE; BETA-APP; PRESENILIN; NOTCH; CLEAVAGE; PEN-2	APH-1, presenilin, nicastrin, and Pen-2 are proteins with varying membrane topologies that compose the gamma-secretase complex, which is responsible for the intramembrane proteolysis of several substrates including the amyloid precursor protein. APH-1 is known to be necessary for gamma-secretase activity, but its precise function in the complex is not fully understood, and its membrane topology has not been described, although it is predicted to traverse the membrane seven times. To investigate this, we used selective permeabilization of the plasma membrane and immunofluorescence microscopy to show that the C terminus of the APH-1 resides in the cytosolic space. Insertion of N-linked glycosylation sites into each of the hydrophilic loop domains and the N terminus of APH-1 showed that the N-terminal domain as well as loops 2, 4, and 6 could be glycosylated, whereas loops 1, 3, and 5 were not. Thus, APH-1 topologically resembles a seven-transmembrane domain receptor with the N terminus and even-numbered loops facing the endoplasmic reticulum lumen, and the C terminus and odd-numbered loops reside in the cytosolic space. By using these glycosylation mutants, we provide evidence that the association between nicastrin and APH-1 may occur very soon after APH-1 synthesis and that the interaction between these two proteins may rely more heavily on the transmembrane domains of APH-1 than on the loop domains. Furthermore, we found that APH-1 can be processed by several endoproteolytic events. One of these cleavages is strongly up-regulated by co-expression of nicastrin and generates a stable C-terminal fragment that associates with nicastrin.	Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780 Oeiras, Portugal; Inst Biol Expt & Tecol, P-2780 Oeiras, Portugal	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Universidade Nova de Lisboa	Doms, RW (corresponding author), Univ Penn, Sch Med, Dept Microbiol, 225 Johnson Pavil,3610 Hamilton Walk, Philadelphia, PA 19104 USA.	doms@mail.med.upenn.edu	Fortna, Ryan/ABC-9700-2021	Morais, Vanessa/0000-0002-0830-0548; Crystal, Adam/0000-0002-2302-2654	NIA NIH HHS [AG-00255-07, AG-00256] Funding Source: Medline; PHS HHS [P01 11542] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Audoly L, 1997, MOL PHARMACOL, V51, P61, DOI 10.1124/mol.51.1.61; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CHANG XB, 1994, J BIOL CHEM, V269, P18572; Chung HM, 2001, NAT CELL BIOL, V3, P1129, DOI 10.1038/ncb1201-1129; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Crystal AS, 2003, J BIOL CHEM, V278, P20117, DOI 10.1074/jbc.M213107200; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Hamilton SR, 2001, J BIOL CHEM, V276, P27981, DOI 10.1074/jbc.M100518200; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Li T, 2003, J NEUROSCI, V23, P3272; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lopez-Schier H, 2002, DEV CELL, V2, P79, DOI 10.1016/S1534-5807(01)00109-5; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Morais VA, 2003, J BIOL CHEM, V278, P43284, DOI 10.1074/jbc.M305685200; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; Slack BE, 2001, BIOCHEM J, V357, P787, DOI 10.1042/0264-6021:3570787; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vannier B, 1998, J BIOL CHEM, V273, P8675, DOI 10.1074/jbc.273.15.8675; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	43	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3685	3693		10.1074/jbc.M310505200	http://dx.doi.org/10.1074/jbc.M310505200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14593096	hybrid			2022-12-25	WOS:000188379600068
J	Skinner, GM; Baumann, CG; Quinn, DM; Molloy, JE; Hoggett, JG				Skinner, GM; Baumann, CG; Quinn, DM; Molloy, JE; Hoggett, JG			Promoter binding, initiation, and elongation by bacteriophage T7 RNA polymerase - A single-molecule view of the transcription cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN COMPLEX-FORMATION; T7-RNA POLYMERASE; REAL-TIME; KINETIC MECHANISM; DNA; PURIFICATION; FORCE; PROCESSIVITY; FLUORESCENCE; SPECIFICITY	A single-molecule transcription assay has been developed that allows, for the first time, the direct observation of promoter binding, initiation, and elongation by a single RNA polymerase (RNAP) molecule in real-time. To promote DNA binding and transcription initiation, a DNA molecule tethered between two optically trapped beads was held near a third immobile surface bead sparsely coated with RNAP. By driving the optical trap holding the upstream bead with a triangular oscillation while measuring the position of both trapped beads, we observed the onset of promoter binding, promoter escape (productive initiation), and processive elongation by individual RNAP molecules. After DNA template release, transcription re-initiation on the same DNA template is possible; thus, multiple enzymatic turnovers by an individual RNAP molecule can be observed. Using bacteriophage T7 RNAP, a commonly used RNAP paradigm, we observed the association and dissociation (k(off)=2.9 s(-1)) of T7 RNAP and promoter DNA, the transition to the elongation mode (k(for)=0.36 s(-1)), and the processive synthesis (k(pol)=43 nt s(-1)) and release of a gene-length RNA transcript (similar to1200 nt). The transition from initiation to elongation is much longer than the mean lifetime of the binary T7 RNAP-promoter DNA complex (k(off)>k(for)), identifying a rate-limiting step between promoter DNA binding and promoter escape.	Univ York, Dept Biol, Area 10, York YO10 5YW, N Yorkshire, England; Natl Inst Med Res, London NW7 1AA, England	University of York - UK; MRC National Institute for Medical Research	Hoggett, JG (corresponding author), Univ York, Dept Biol, Area 10, POB 373, York YO10 5YW, N Yorkshire, England.	jgh1@york.ac.uk		Molloy, Justin/0000-0002-8307-2450	MRC [MC_U117570592] Funding Source: UKRI; Medical Research Council [MC_U117570592] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; CHAMBERL.M, 1970, NATURE, V228, P227, DOI 10.1038/228227a0; CHAMBERL.M, 1973, J BIOL CHEM, V248, P2235; CHAMBERLIN MJ, 1979, J BIOL CHEM, V254, P61; Cheetham GMT, 2000, CURR OPIN STRUC BIOL, V10, P117, DOI 10.1016/S0959-440X(99)00058-5; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; Davenport RJ, 2000, SCIENCE, V287, P2497, DOI 10.1126/science.287.5462.2497; Diaz GA, 1996, BIOCHEMISTRY-US, V35, P10837, DOI 10.1021/bi960488+; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; Harada Y, 1999, BIOPHYS J, V76, P709, DOI 10.1016/S0006-3495(99)77237-1; Harada Y, 2001, NATURE, V409, P113, DOI 10.1038/35051126; He B, 1997, PROTEIN EXPRES PURIF, V9, P142, DOI 10.1006/prep.1996.0663; IKEDA RA, 1992, J BIOL CHEM, V267, P2640; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; Jia YP, 1996, J BIOL CHEM, V271, P30451, DOI 10.1074/jbc.271.48.30451; Jia YP, 1997, J BIOL CHEM, V272, P30147, DOI 10.1074/jbc.272.48.30147; Kubori T, 1996, J MOL BIOL, V256, P449, DOI 10.1006/jmbi.1996.0100; Liu CH, 2002, J BIOL CHEM, V277, P2725, DOI 10.1074/jbc.M108856200; Lopez PJ, 1997, J MOL BIOL, V269, P41, DOI 10.1006/jmbi.1997.1039; Ma KY, 2002, J BIOL CHEM, V277, P43206, DOI 10.1074/jbc.M206658200; MARTIN CT, 1989, BIOCHEMISTRY-US, V28, P2760, DOI 10.1021/bi00433a002; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MASLAK M, 1993, BIOCHEMISTRY-US, V32, P4281, DOI 10.1021/bi00067a017; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; Mukherjee S, 2002, CELL, V110, P81, DOI 10.1016/S0092-8674(02)00815-2; Nelson P, 1999, P NATL ACAD SCI USA, V96, P14342, DOI 10.1073/pnas.96.25.14342; Protacio RU, 1996, J MOL BIOL, V256, P458, DOI 10.1006/jmbi.1996.0101; Sastry S, 1999, BIOCHEMISTRY-US, V38, P4972, DOI 10.1021/bi9823941; Sastry SS, 1997, BIOCHEMISTRY-US, V36, P3133, DOI 10.1021/bi961793y; Sastry SS, 1996, BIOCHEMISTRY-US, V35, P15715, DOI 10.1021/bi960729d; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; SOUSA R, 1992, J MOL BIOL, V224, P319, DOI 10.1016/0022-2836(92)90997-X; Stano NM, 2002, J BIOL CHEM, V277, P37292, DOI 10.1074/jbc.M201600200; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Temiakov D, 2000, P NATL ACAD SCI USA, V97, P14109, DOI 10.1073/pnas.250473197; Ujvari A, 1996, BIOCHEMISTRY-US, V35, P14574, DOI 10.1021/bi961165g; Ujvari A, 2000, J MOL BIOL, V295, P1173, DOI 10.1006/jmbi.1999.3418; Veigel C, 1998, BIOPHYS J, V75, P1424, DOI 10.1016/S0006-3495(98)74061-5; Villemain J, 1997, J MOL BIOL, V273, P958, DOI 10.1006/jmbi.1997.1358; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653; Yin H, 1999, P NATL ACAD SCI USA, V96, P13124, DOI 10.1073/pnas.96.23.13124; YIN H, 1994, BIOPHYS J, V67, P2468, DOI 10.1016/S0006-3495(94)80735-0; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464; ZAWADZKI V, 1991, NUCLEIC ACIDS RES, V19, P1948, DOI 10.1093/nar/19.8.1948	48	70	74	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3239	3244		10.1074/jbc.M310471200	http://dx.doi.org/10.1074/jbc.M310471200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14597619	hybrid			2022-12-25	WOS:000188379600014
J	Tolic-Norrelykke, SF; Engh, AM; Landick, R; Gelles, J				Tolic-Norrelykke, SF; Engh, AM; Landick, R; Gelles, J			Diversity in the rates of transcript elongation by single RNA polymerase molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CHAIN ELONGATION; REGULATES TRANSCRIPTION; TERMINATION EFFICIENCY; DNA-POLYMERASE; PROTEINS; MECHANISM; DYNAMICS; ENERGY; ENZYME	Single-molecule measurements of the activities of a variety of enzymes show that rates of catalysis may vary markedly between different molecules in putatively homogenous enzyme preparations. We measured the rate at which purified Escherichia coli RNA polymerase moves along a similar to2650-bp DNA during transcript elongation in vitro at 0.5 mM nucleoside triphosphates. Individual molecules of a specifically biotinated RNA polymerase derivative were tagged with 199-nm diameter avidin-coated polystyrene beads; enzyme movement along a surface-linked DNA molecule was monitored by observing changes in bead Brownian motion by light microscopy. The DNA was derived from a naturally occurring transcription unit and was selected for the absence of regulatory sequences that induce lengthy pausing or termination of transcription. With rare exceptions, individual enzyme molecules moved at a constant velocity throughout the transcription reaction; the distribution of velocities across a population of 140 molecules was unimodal and was well fit by a Gaussian. However, the width of the Gaussian, sigma=6.7 bp/s, was considerably larger than the precision of the velocity measurement (1 bp/s). The observations show that different transcription complexes have differences in catalytic rate (and thus differences in structure) that persist for thousands of catalytic turnovers. These differences may provide a parsimonious explanation for the complex transcription kinetics observed in bulk solution.	Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA; Niels Bohr Inst, DK-2100 Copenhagen, Denmark; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	Brandeis University; University of Copenhagen; Niels Bohr Institute; University of Wisconsin System; University of Wisconsin Madison	Gelles, J (corresponding author), Brandeis Univ, Dept Biochem, MS009,POB 549110, Waltham, MA 02454 USA.	jeff@brandeis.edu	Nørrelykke, Simon/C-9405-2009; Nørrelykke, Simon F/M-4722-2014	Nørrelykke, Simon F/0000-0001-8302-526X				Adelman K, 2002, P NATL ACAD SCI USA, V99, P13538, DOI 10.1073/pnas.212358999; Artsimovitch I, 1998, GENE DEV, V12, P3110, DOI 10.1101/gad.12.19.3110; Bevington P R, 1992, DATA REDUCTION ERROR, P58; Bianco PR, 2001, NATURE, V409, P374, DOI 10.1038/35053131; Campbell EA, 2001, CELL, V104, P901, DOI 10.1016/S0092-8674(01)00286-0; Chan CL, 1997, J MOL BIOL, V268, P37, DOI 10.1006/jmbi.1997.0934; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; Craig DB, 1996, J AM CHEM SOC, V118, P5245, DOI 10.1021/ja9540839; Cramer P, 2002, CURR OPIN STRUC BIOL, V12, P89, DOI 10.1016/S0959-440X(02)00294-4; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; Darst SA, 2001, CURR OPIN STRUC BIOL, V11, P155; Davenport RJ, 2000, SCIENCE, V287, P2497, DOI 10.1126/science.287.5462.2497; Dohoney KM, 2001, NATURE, V409, P370, DOI 10.1038/35053124; EDWARDS RA, 1992, BIOCHEM CELL BIOL, V70, P63, DOI 10.1139/o92-009; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; FIIL NP, 1979, MOL GEN GENET, V173, P39, DOI 10.1007/BF00267689; FINZI L, 1995, SCIENCE, V267, P378, DOI 10.1126/science.7824935; Forde NR, 2002, P NATL ACAD SCI USA, V99, P11682, DOI 10.1073/pnas.142417799; Foster JE, 2001, CELL, V106, P243, DOI 10.1016/S0092-8674(01)00420-2; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Frauenfelder H, 2001, P NATL ACAD SCI USA, V98, P2370, DOI 10.1073/pnas.041614298; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; GOLIGER JA, 1989, J MOL BIOL, V205, P331, DOI 10.1016/0022-2836(89)90344-6; Guthold M, 1999, BIOPHYS J, V77, P2284, DOI 10.1016/S0006-3495(99)77067-0; Guthold M, 2001, CHEMBIOCHEM, V2, P167; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; Harada Y, 2001, NATURE, V409, P113, DOI 10.1038/35051126; Harrington KJ, 2001, P NATL ACAD SCI USA, V98, P5019, DOI 10.1073/pnas.240431598; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Hubley MJ, 1996, BBA-GEN SUBJECTS, V1291, P115, DOI 10.1016/0304-4165(96)00053-0; Johnson RS, 2002, J MOL BIOL, V318, P305, DOI 10.1016/S0022-2836(02)00042-6; KHAZAIE K, 1984, EUR J BIOCHEM, V144, P485, DOI 10.1111/j.1432-1033.1984.tb08491.x; King RA, 1996, CELL, V87, P893, DOI 10.1016/S0092-8674(00)81996-0; KIRKWOOD TBL, 1984, INT REV CYTOL, V92, P93; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Landick R, 1996, METHOD ENZYMOL, V274, P334; Landick R, 2001, CELL, V105, P567, DOI 10.1016/S0092-8674(01)00381-6; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Lu HP, 1998, SCIENCE, V282, P1877, DOI 10.1126/science.282.5395.1877; Maier B, 2000, P NATL ACAD SCI USA, V97, P12002, DOI 10.1073/pnas.97.22.12002; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MCDOWELL JC, 1994, SCIENCE, V266, P822, DOI 10.1126/science.7526463; MILLER JH, 1992, LAB MANUAL HDB ESCHE, P268; Mooney RA, 1998, J BACTERIOL, V180, P3265, DOI 10.1128/JB.180.13.3265-3275.1998; Neuman KC, 2003, CELL, V115, P437, DOI 10.1016/S0092-8674(03)00845-6; ODEN KL, 1990, GENE, V96, P29, DOI 10.1016/0378-1119(90)90337-Q; OZAKI M, 1991, MOL GEN GENET, V230, P17, DOI 10.1007/BF00290644; Pasman Z, 2002, J MOL BIOL, V322, P505, DOI 10.1016/S0022-2836(02)00814-8; Peterman EJG, 2003, BIOPHYS J, V84, P1308, DOI 10.1016/S0006-3495(03)74946-7; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; Shaner S L, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 1, P463; SHANER SL, 1982, BIOCHEMISTRY-US, V21, P5539, DOI 10.1021/bi00265a025; SHAW SY, 1993, SCIENCE, V260, P533, DOI 10.1126/science.8475384; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; Strick TR, 2000, NATURE, V404, P901, DOI 10.1038/35009144; TELESNITSKY APW, 1989, J MOL BIOL, V205, P315, DOI 10.1016/0022-2836(89)90343-4; Toulokhonov I, 2001, SCIENCE, V292, P730, DOI 10.1126/science.1057738; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; von Hippel PH, 2002, BIOPHYS CHEM, V101, P401, DOI 10.1016/S0301-4622(02)00160-6; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; Wuite GJL, 2000, NATURE, V404, P103, DOI 10.1038/35003614; XUE QF, 1995, NATURE, V373, P681, DOI 10.1038/373681a0; YANOFSKY C, 1981, J BACTERIOL, V145, P1334, DOI 10.1128/JB.145.3.1334-1341.1981; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653; Yin H, 1999, P NATL ACAD SCI USA, V96, P13124, DOI 10.1073/pnas.96.23.13124; YIN H, 1994, BIOPHYS J, V67, P2468, DOI 10.1016/S0006-3495(94)80735-0; Zhuang XW, 2002, SCIENCE, V296, P1473, DOI 10.1126/science.1069013; Zhuang XW, 2000, SCIENCE, V288, P2048, DOI 10.1126/science.288.5473.2048	71	83	83	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3292	3299		10.1074/jbc.M310290200	http://dx.doi.org/10.1074/jbc.M310290200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14604986	hybrid			2022-12-25	WOS:000188379600020
J	Bauer, JA; Bennett, EM; Begley, TP; Ealick, SE				Bauer, JA; Bennett, EM; Begley, TP; Ealick, SE			Three-dimensional structure of YaaE from Bacillus subtilis, a glutaminase implicated in pyridoxal-5 '-phosphate biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCEROL PHOSPHATE SYNTHASE; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; VITAMIN-B-6; PYRIDOXINE; GENE; SYNTHETASE; RESISTANCE; PROGRAM; BARREL	The structure of YaaE from Bacillus subtilis was determined at 2.5-Angstrom resolution. YaaE is a member of the triad glutamine aminotransferase family and functions in a recently identified alternate pathway for the biosynthesis of vitamin B-6. Proposed active residues include conserved Cys-79, His-170, and Glu-172. YaaE shows similarity to HisH, a glutaminase involved in histidine biosynthesis. YaaD associates with YaaE. A homology model of this protein was constructed. YaaD is predicted to be a (beta/alpha)(8) barrel on the basis of sequence comparisons. The predicted active site includes highly conserved residues 211-216 and 233-235. Finally, a homology model of a putative YaaD-YaaE complex was prepared using the structure of HisH-F as a model. This model predicts that the ammonia molecule generated by YaaE is channeled through the center of the YaaD barrel to the putative YaaD active site.	Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University	Ealick, SE (corresponding author), Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA.	see3@cornell.edu	Begley, Tadhg/B-5801-2015		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR015301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK044083, R01DK044083] Funding Source: NIH RePORTER	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMURO N, 1985, J BIOL CHEM, V260, P4844; Antelmann H, 1997, ELECTROPHORESIS, V18, P1451, DOI 10.1002/elps.1150180820; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bean LE, 2001, GENETICS, V157, P1067; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Braun EL, 1996, J BACTERIOL, V178, P6865, DOI 10.1128/jb.178.23.6865-6872.1996; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cane DE, 2003, CHIMIA, V57, P75; Chaudhuri BN, 2001, STRUCTURE, V9, P987, DOI 10.1016/S0969-2126(01)00661-X; CHRISTOPHER JA, 1998, SPOCK; Douangamath A, 2002, STRUCTURE, V10, P185, DOI 10.1016/S0969-2126(02)00702-5; Drewke C, 2001, VITAM HORM, V61, P121; Ehrenshaft M, 1999, CURR GENET, V34, P478, DOI 10.1007/s002940050423; Ehrenshaft M, 2001, J BACTERIOL, V183, P3383, DOI 10.1128/JB.183.11.3383-3390.2001; EVANS L, 1993, ELECT J DIFFERENTIAL, V3, P1; FUGE EK, 1994, J BACTERIOL, V176, P5802, DOI 10.1128/JB.176.18.5802-5813.1994; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1997, MOSFLM VERSION 6 2 2; MARTIN AC, 1998, PROFIT VERSION 1 8; MARTIRENOM MA, 2002, CURRENT PROTOCOLS PR; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mittenhuber G, 2001, J MOL MICROB BIOTECH, V3, P1; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Osmani AH, 1999, J BIOL CHEM, V274, P23565, DOI 10.1074/jbc.274.33.23565; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Padilla PA, 1998, J BACTERIOL, V180, P5718, DOI 10.1128/JB.180.21.5718-5726.1998; Qiu D, 1997, J PHYS CHEM A, V101, P3005, DOI 10.1021/jp961992r; Sakai A, 2002, J BIOSCI BIOENG, V93, P309, DOI 10.1263/jbb.93.309; Sakai A, 2001, J BIOSCI BIOENG, V91, P147, DOI 10.1263/jbb.91.147; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; Spraggon G, 2001, P NATL ACAD SCI USA, V98, P6021, DOI 10.1073/pnas.111150298; TAZUYA K, 1995, BBA-GEN SUBJECTS, V1244, P113, DOI 10.1016/0304-4165(94)00205-C; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P8825, DOI 10.1021/bi9807761; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Zeidler J, 2003, J ORG CHEM, V68, P3486, DOI 10.1021/jo020730k; Zeidler J, 2002, J AM CHEM SOC, V124, P4542, DOI 10.1021/ja012708z	44	39	46	0	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2704	2711		10.1074/jbc.M310311200	http://dx.doi.org/10.1074/jbc.M310311200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14585832	hybrid			2022-12-25	WOS:000188211300047
J	Kimsey, HH; Waldor, MK				Kimsey, HH; Waldor, MK			The CTX phi repressor RstR binds DNA cooperatively to form tetrameric repressor-operator complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMBDA-REPRESSOR; FILAMENTOUS PHAGE; ARC REPRESSOR; PROTEIN; REGION; SITE; RECOGNITION; PROMOTER; IMMUNITY; DOMAINS	CTXphi is a filamentous bacteriophage that encodes cholera toxin and integrates into the Vibrio cholerae genome to form stable lysogens. In CTXphi lysogens, gene expression originating from the rstA phage promoter is repressed by the phage-encoded repressor RstR. The N-terminal region of RstR contains a helix-turn-helix DNA-binding element similar to the helix-turn-helix of the cI/Cro family of phage repressors, whereas the short C-terminal region is unrelated to the oligomerization domain of cI repressor. Purified His-tagged RstR bound to three extended 50-bp operator sites in the rstA promoter region. Each of the RstR footprints exhibited a characteristic staggered pattern of DNase I-accessible regions that suggested RstR binds DNA as a dimer-of-dimers. In gel permeation chromatography and crosslinking experiments, RstR oligomerized to form dimers and tetramers. RstR was shown to be tetrameric when bound to operator DNA by performing mobility shift experiments with mixtures of RstR and a lengthened active variant of RstR. Binding of RstR to the high affinity O1 site could be fit to a cooperative model of operator binding in which two RstR dimers associate to form tetrameric RstR-operator complexes. The binding of RstR dimers to the left or right halves of O1 operator DNA was not observed in mobility shift assays. These observations support a model in which protein-protein contacts between neighboring RstR dimers contribute to strong operator binding.	Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; Howard Hughes Med Inst, Boston, MA 02111 USA	Tufts University; Howard Hughes Medical Institute	Kimsey, HH (corresponding author), Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA.	harveykimsey@yahoo.com		Waldor, Matthew/0000-0003-1843-7000				ADHYA S, 1989, ANNU REV GENET, V23, P227, DOI 10.1146/annurev.genet.23.1.227; Bell CE, 2000, CELL, V101, P801, DOI 10.1016/S0092-8674(00)80891-0; BROWN BM, 1990, BIOCHEMISTRY-US, V29, P11189, DOI 10.1021/bi00503a006; BRUIST MF, 1987, GENE DEV, V1, P762, DOI 10.1101/gad.1.8.762; CARLSON NG, 1993, J MOL BIOL, V230, P1108, DOI 10.1006/jmbi.1993.1229; Davis BM, 1999, J BACTERIOL, V181, P6779, DOI 10.1128/JB.181.21.6779-6787.1999; Davis BM, 2000, SCIENCE, V288, P333, DOI 10.1126/science.288.5464.333; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; JOHNSON AD, 1981, NATURE, V294, P217, DOI 10.1038/294217a0; JOHNSON AD, 1979, P NATL ACAD SCI USA, V76, P5061, DOI 10.1073/pnas.76.10.5061; KIM B, 1992, SCIENCE, V255, P203, DOI 10.1126/science.1553548; Kimsey HH, 1998, LANCET, V352, P457, DOI 10.1016/S0140-6736(05)79193-5; Kimsey HH, 1998, P NATL ACAD SCI USA, V95, P7035, DOI 10.1073/pnas.95.12.7035; MAJUMDAR A, 1987, J BIOL CHEM, V262, P13258; Maxam A M, 1980, Methods Enzymol, V65, P499; Munson GP, 1999, J BACTERIOL, V181, P2110, DOI 10.1128/JB.181.7.2110-2117.1999; OBERTO J, 1989, J MOL BIOL, V207, P675, DOI 10.1016/0022-2836(89)90237-4; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; OGAWA T, 1988, J MOL BIOL, V202, P537, DOI 10.1016/0022-2836(88)90284-7; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; Ptashne M., 1992, A GENETIC SWITCH; SAHA S, 1987, EMBO J, V6, P809, DOI 10.1002/j.1460-2075.1987.tb04823.x; Sambrook J, 2001, MOL CLONING LAB MANU; Schleif R, 2003, BIOESSAYS, V25, P274, DOI 10.1002/bies.10237; Shirra MK, 1998, J BIOL CHEM, V273, P19260, DOI 10.1074/jbc.273.30.19260; SMITH TL, 1995, J MOL BIOL, V249, P729, DOI 10.1006/jmbi.1995.0332; SUSSKIND MM, 1983, LAMBDA, V2, P347; TINOCO I, 1985, PHYSICAL CHEM PRINCI, P573; TOLEDANO MB, 1994, CELL, V78, P897, DOI 10.1016/S0092-8674(94)90702-1; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; WALDBURGER CD, 1995, BIOCHEMISTRY-US, V34, P13109, DOI 10.1021/bi00040a023; Waldor MK, 1997, MOL MICROBIOL, V24, P917, DOI 10.1046/j.1365-2958.1997.3911758.x; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910; WANG L, 1992, CELL, V69, P659, DOI 10.1016/0092-8674(92)90229-6; Wintjens R, 1996, J MOL BIOL, V262, P294, DOI 10.1006/jmbi.1996.0514	38	38	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2640	2647		10.1074/jbc.M311109200	http://dx.doi.org/10.1074/jbc.M311109200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14610071	hybrid			2022-12-25	WOS:000188211300039
J	Pedchenko, V; Zent, R; Hudson, BG				Pedchenko, V; Zent, R; Hudson, BG			alpha(v)beta(3) and alpha(v)beta(5) integrins bind both the proximal RGD site and non-RGD motifs within noncollagenous (NC1) domain of the alpha 3 chain of type IV collagen - Implication for the mechanism of endothelial cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; DISTINCT ANTITUMOR PROPERTIES; ARG-GLY-ASP; IN-VIVO; EXTRACELLULAR-MATRIX; TUMOR VASCULATURE; LIGAND-BINDING; MELANOMA-CELLS; ANGIOGENESIS; PEPTIDE	The NC1 domains of human type IV collagen, in particular alpha3NC1, are inhibitors of angiogenesis and tumor growth (Petitclerc, E., Boutaud, A., Prestayko, A., Xu, J., Sado, Y., Ninomiya, Y., Sarras, M. P., Jr., Hudson, B. G., and Brooks, P. C. ( 2000) J. Biol. Chem. 275, 8051 - 8061). The recombinant alpha3NC1 domain contained a RGD site as part of a short collagenous sequence at the N terminus, designated herein as RGD-alpha3NC1. Others, using synthetic peptides, have concluded that this RGD site is nonfunctional in cell adhesion, and therefore, the antiangiogenic activity is attributed exclusively to alpha(v)beta(3) integrin interactions with non-RGD motifs of the RGDalpha3NC1 domain (Maeshima, Y., Colorado, P. C., and Kalluri, R. ( 2000) J. Biol. Chem. 275, 23745 - 23750). This nonfunctionality is surprising given that RGD is a binding site for alpha(v)beta(3) integrin in several proteins. In the present study, we used the alpha3NC1 domain with or without the RGD site, expressed in HEK 293 cells for native conformation, as an alternative approach to synthetic peptides to assess the functionality of the RGD site and non-RGD motifs. Our results demonstrate a predominant role of the RGD site for endothelial adhesion and for binding of alpha(v)beta(3) and alpha(v)beta(5) integrins. Moreover, we demonstrate that the two non-RGD peptides, previously identified as the alpha(v)beta(3) integrin-binding sites of the alpha3NC1 domain, are 10-fold less potent in competing for integrin binding than the native protein, indicating the importance of additional structural and/or conformational features of the alpha3NC1 domain for integrin binding. Therefore, the RGD site, in addition to non-RGD motifs, may contribute to the mechanisms of endothelial cell adhesion in the human vasculature and the antiangiogenic activity of the RGD-alpha3NC1 domain.	Vanderbilt Univ, Med Ctr, Div Nephrol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Ctr Matrix Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vet Affairs Hosp, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Pedchenko, V (corresponding author), Vanderbilt Univ, Med Ctr, Div Nephrol, S-3223 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	vadim.pedchenko@vanderbilt.edu; billy.hudson@vanderbilt.edu	Pedchenko, Vadim/A-6873-2009	Hudson, Billy/0000-0002-5420-4100	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018381, R01DK018381, P01DK065123, P50DK039261] Funding Source: NIH RePORTER; NIDDK NIH HHS [P50 DK39261-16, DK18381, DK065123] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABECASSIS J, 1987, INT J CANCER, V40, P525, DOI 10.1002/ijc.2910400416; ADLER S, 1993, KIDNEY INT, V44, P278, DOI 10.1038/ki.1993.242; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Aznavoorian S, 1996, J BIOL CHEM, V271, P3247, DOI 10.1074/jbc.271.6.3247; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Buerkle MA, 2002, BRIT J CANCER, V86, P788, DOI 10.1038/sj.bjc.6600141; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; CHENG YF, 1989, J CELL PHYSIOL, V139, P275, DOI 10.1002/jcp.1041390209; CHERNY RC, 1993, J BIOL CHEM, V268, P9725; Cierniewski CS, 1999, J BIOL CHEM, V274, P16923, DOI 10.1074/jbc.274.24.16923; Colorado PC, 2000, CANCER RES, V60, P2520; CONFORTI G, 1994, CELL ADHES COMMUN, V1, P279, DOI 10.3109/15419069409097260; DEDHAR S, 1993, CLIN EXP METASTAS, V11, P391, DOI 10.1007/BF00132982; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; Eble JA, 1996, J BIOL CHEM, V271, P30964, DOI 10.1074/jbc.271.48.30964; Hamano Y, 2003, CANCER CELL, V3, P589, DOI 10.1016/S1535-6108(03)00133-8; Han J, 1997, J BIOL CHEM, V272, P20395, DOI 10.1074/jbc.272.33.20395; HERBST TJ, 1988, J CELL BIOL, V106, P1365, DOI 10.1083/jcb.106.4.1365; Hu DD, 1999, J BIOL CHEM, V274, P4633, DOI 10.1074/jbc.274.8.4633; Hudson BG, 2003, NEW ENGL J MED, V348, P2543, DOI 10.1056/NEJMra022296; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Krishnamurti U, 1996, LAB INVEST, V74, P650; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; Maeshima Y, 2000, J BIOL CHEM, V275, P23745, DOI 10.1074/jbc.C000186200; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Maeshima Y, 2001, J BIOL CHEM, V276, P31959, DOI 10.1074/jbc.M103024200; MILES AJ, 1995, J BIOL CHEM, V270, P29047, DOI 10.1074/jbc.270.49.29047; MURRAY JC, 1979, J CELL BIOL, V80, P197, DOI 10.1083/jcb.80.1.197; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; Netzer KO, 1999, J BIOL CHEM, V274, P11267, DOI 10.1074/jbc.274.16.11267; NICOSIA RF, 1991, AM J PATHOL, V138, P829; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; REVERT F, 1995, J BIOL CHEM, V270, P13254, DOI 10.1074/jbc.270.22.13254; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Rupp PA, 2001, CIRC RES, V89, P566, DOI 10.1161/hh1901.097747; Sado Y, 1998, KIDNEY INT, V53, P664, DOI 10.1046/j.1523-1755.1998.00795.x; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; Schraa AJ, 2002, INT J CANCER, V102, P469, DOI 10.1002/ijc.10727; Setty S, 1998, J BIOL CHEM, V273, P12244, DOI 10.1074/jbc.273.20.12244; Shahan TA, 1999, CANCER RES, V59, P4584; Sheu JR, 1997, BBA-GEN SUBJECTS, V1336, P445, DOI 10.1016/S0304-4165(97)00057-3; Sudhakar A, 2003, P NATL ACAD SCI USA, V100, P4766, DOI 10.1073/pnas.0730882100; Sundaramoorthy M, 2002, J BIOL CHEM, V277, P31142, DOI 10.1074/jbc.M201740200; Tarui T, 2002, J BIOL CHEM, V277, P33564, DOI 10.1074/jbc.M205514200; Tarui T, 2001, J BIOL CHEM, V276, P39562, DOI 10.1074/jbc.M101815200; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; ZHANG XM, 1994, DEV BIOL, V164, P10, DOI 10.1006/dbio.1994.1176	52	93	100	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2772	2780		10.1074/jbc.M311901200	http://dx.doi.org/10.1074/jbc.M311901200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14610079	hybrid			2022-12-25	WOS:000188211300055
J	Sade, H; Krishna, S; Sarin, A				Sade, H; Krishna, S; Sarin, A			The anti-apoptotic effect of Notch-1 requires p56(lck)-dependent, Akt/PKB-mediated signaling in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; FACTOR RECEPTOR; DEATH; ACTIVATION; SURVIVAL; BINDING; KINASE; TRANSFORMATION; LOCALIZATION; HOMEOSTASIS	The Notch family of transmembrane receptors have been implicated in a variety of cellular decisions in different cell types. Here we investigate the mechanism underlying Notch-1-mediated anti-apoptotic function in T cells using model cell lines as the experimental system. Ectopic expression of the intracellular domain of Notch1/activated Notch (AcN1) increases expression of antiapoptotic proteins of the inhibitors of apoptosis (IAP) family, the Bcl-2 family, and the FLICE-like inhibitor protein (FLIP) and inhibits death triggered by multiple stimuli that activate intrinsic or extrinsic pathways of apoptosis in human and murine T cell lines. Numb inhibited the AcN1-dependent induction of anti-apoptotic proteins and anti-apoptotic function. Using pharmacological inhibitors and dominant-negative approaches, we describe a functional role for phosphatidylinositol 3-kinase (PI3K)-dependent activation of the serine-threonine kinase Akt/PKB in the regulation of AcN1-mediated anti-apoptotic function and the expression of FLIP and IAP family proteins. Using a cell line deficient for the T cell-specific, Src family protein, the tyrosine kinase p56(lck) and by reconstitution approaches we demonstrate that p56lck is required for the Notch-1-mediated activation of Akt/PKB function. Furthermore, the Src tyrosine kinase inhibitor, PP2, abrogated ectopically expressed AcN1-mediated anti-apoptotic function and phosphorylation of p56(lck). We present evidence that endogenous Notch-1 associates with p56(lck) and PI3K but that Akt/PKB does not co-immunoprecipitate with the Notch1.p56(lck).PI3K complex. Finally, we demonstrate that the Notch1.p56(lck).PI3K complex is present in primary T cells that have been activated in vitro and sustained in culture with the cytokine interleukin-2.	Univ Agr Sci Bangalore, Natl Ctr Biol Sci, Bangalore 560065, Karnataka, India	Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS); University of Agricultural Sciences Bangalore	Sarin, A (corresponding author), Univ Agr Sci Bangalore, Natl Ctr Biol Sci, GKVK Campus,New Bellary Rd, Bangalore 560065, Karnataka, India.	sarina@ncbs.res.in						Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Aster JC, 1997, J BIOL CHEM, V272, P11336; Boehme SA, 1996, J IMMUNOL, V156, P4075; Carmena A, 2002, DEV BIOL, V244, P226, DOI 10.1006/dbio.2002.0606; Ceponis PJM, 2000, J BIOL CHEM, V275, P29132, DOI 10.1074/jbc.M003516200; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Goldrath AW, 1999, NATURE, V402, P255, DOI 10.1038/35005508; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Izon DJ, 2002, CURR OPIN IMMUNOL, V14, P192, DOI 10.1016/S0952-7915(02)00321-7; Jehn BM, 1999, J IMMUNOL, V162, P635; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057; Nair P, 2003, J VIROL, V77, P7106, DOI 10.1128/JVI.77.12.7106-7112.2003; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; Perez OD, 2002, IMMUNITY, V16, P51, DOI 10.1016/S1074-7613(02)00266-2; Plas DR, 2002, NAT IMMUNOL, V3, P515, DOI 10.1038/ni0602-515; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; Radtke F, 2002, IMMUNOL REV, V187, P65, DOI 10.1034/j.1600-065X.2002.18706.x; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Sade H, 2003, EUR J IMMUNOL, V33, P913, DOI 10.1002/eji.200323782; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; Schmitt TM, 2002, IMMUNITY, V17, P749, DOI 10.1016/S1074-7613(02)00474-0; Seddon B, 2000, SCIENCE, V290, P127, DOI 10.1126/science.290.5489.127; Sohn SJ, 2001, J IMMUNOL, V166, P2209, DOI 10.4049/jimmunol.166.4.2209; Sprent J, 2002, ANNU REV IMMUNOL, V20, P551, DOI 10.1146/annurev.immunol.20.100101.151926; Van Parijs L, 1998, SCIENCE, V280, P243; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; Yang YL, 1997, BLOOD, V89, P550, DOI 10.1182/blood.V89.2.550; YANO H, 1993, J BIOL CHEM, V268, P25846; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2	43	207	219	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2937	2944		10.1074/jbc.M309924200	http://dx.doi.org/10.1074/jbc.M309924200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14583609	hybrid			2022-12-25	WOS:000188211300074
J	Ali, M; Hicks, AER; Hellewell, PG; Thoma, G; Norman, KE				Ali, M; Hicks, AER; Hellewell, PG; Thoma, G; Norman, KE			Polymers carrying sLe(x)-mimetics are superior inhibitors of E-selectin-dependent leukocyte rolling in vivo	FASEB JOURNAL			English	Article						multivalency; microcirculation; neutrophil; inflammation; intravital microscopy	P-SELECTIN; DEFICIENT MICE; ADHESION; LIGANDS; SLE(X); PATHOGENESIS; VENULES	Selectins mediate leukocyte rolling and may represent good anti-inflammatory drug targets. Detailed knowledge regarding the structure of selectin ligands has permitted development of selectin antagonists with varying specificities and activity. Efficacy of monovalent selectin antagonists may be increased by presenting them on a polymer backbone. We have synthesized a range of multivalent selectin antagonists and characterized their activity by using intravital microscopy of the mouse cremaster muscle. The monovalent inhibitor CGP77175A inhibited E-selectin-dependent leukocyte rolling at a dose of 3 mg/kg. Multivalent presentation of CGP77175A on a modified polylysine backbone (degree of polymerization = 1200; 50% of the polylysines carry the inhibitor) greatly enhanced in vivo activity giving an inhibitor that produced an equivalent effect at 0.1 mg/kg. The polylysine conjugate was also longer acting than the monovalent antagonist. In spite of greatly enhanced activity against E-selectin compared with monovalent inhibitor, the multivalent inhibitor had no measurable effect on P- or L-selectin-dependent leukocyte rolling.	Univ Sheffield, Div Clin Sci N, Cardiovasc Res Grp, Sheffield, S Yorkshire, England; Novartis Pharma AG, CH-4002 Basel, Switzerland	University of Sheffield; Novartis	Norman, KE (corresponding author), No Gen Hosp, Clin Sci Ctr, Cardiovasc Res Grp, Sheffield S5 7AU, S Yorkshire, England.	k.norman@shef.ac.uk			Medical Research Council of the United Kingdom; British Heart Foundation [FS/98051]	Medical Research Council of the United Kingdom(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation)	K.E.N. is the recipient of a Career Establishment Grant from the Medical Research Council of the United Kingdom, which supported this study. A.E.R.H. was supported by a studentship (FS/98051) from the British Heart Foundation.	ALTAVILLA D, 1994, EUR J PHARM-ENVIRON, V270, P45, DOI 10.1016/0926-6917(94)90079-5; ALTAVILLA D, 1995, EUR J PHARMACOL, V272, P223, DOI 10.1016/0014-2999(94)00658-T; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Damiano ER, 1996, CIRC RES, V79, P1122, DOI 10.1161/01.RES.79.6.1122; Dunne JL, 2002, BLOOD, V99, P336, DOI 10.1182/blood.V99.1.336; Ernst B, 2001, CHIMIA, V55, P268; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; Hicks AER, 2003, BLOOD, V101, P3249, DOI 10.1182/blood-2002-07-2329; HICKS AER, 2002, FASEB J; Johnston B, 1996, J EXP MED, V183, P1995, DOI 10.1084/jem.183.5.1995; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Katopodis AG, 2002, J CLIN INVEST, V110, P1869, DOI 10.1172/JCI200216526; Kunkel EJ, 1996, CIRC RES, V79, P1196, DOI 10.1161/01.RES.79.6.1196; Kunkel EJ, 1996, J EXP MED, V183, P57, DOI 10.1084/jem.183.1.57; LABOW MA, 1994, IMMUNITY, V1, P709, DOI 10.1016/1074-7613(94)90041-8; LEES WJ, 1994, J MED CHEM, V37, P3419, DOI 10.1021/jm00046a027; Lefer DJ, 2000, ANNU REV PHARMACOL, V40, P283, DOI 10.1146/annurev.pharmtox.40.1.283; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Marquardt T, 1999, BLOOD, V94, P3976, DOI 10.1182/blood.V94.12.3976.424k06_3976_3985; McEver RP, 2001, THROMB HAEMOSTASIS, V86, P746; Mocco J, 2002, CIRC RES, V91, P907, DOI 10.1161/01.RES.0000042063.15901.20; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; Norman KE, 1998, BLOOD, V91, P475, DOI 10.1182/blood.V91.2.475.475_475_483; Owen RM, 2002, ORG LETT, V4, P2293, DOI 10.1021/ol0259239; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; Ridger VC, 2002, FASEB J, V16, pA1213; Sanders WJ, 1999, J BIOL CHEM, V274, P5271, DOI 10.1074/jbc.274.9.5271; Setiadi H, 1998, J CELL BIOL, V142, P859, DOI 10.1083/jcb.142.3.859; Singbartl K, 2000, CRIT CARE MED, V28, P2507, DOI 10.1097/00003246-200007000-00053; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Sperandio M, 2001, BLOOD, V97, P3812, DOI 10.1182/blood.V97.12.3812; Stahn R, 1998, GLYCOBIOLOGY, V8, P311, DOI 10.1093/glycob/8.4.311; Thoma G, 2001, J AM CHEM SOC, V123, P10113, DOI 10.1021/ja0164430; Thoma G, 1999, J MED CHEM, V42, P4909, DOI 10.1021/jm990422n; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; WELPLY JK, 1994, GLYCOBIOLOGY, V4, P259, DOI 10.1093/glycob/4.3.259; Weninger W, 2000, IMMUNITY, V12, P665, DOI 10.1016/S1074-7613(00)80217-4	41	19	31	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					152	154		10.1096/fj.03-0346fje	http://dx.doi.org/10.1096/fj.03-0346fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597557				2022-12-25	WOS:000188829300058
J	Alzghoul, MB; Gerrard, D; Watkins, BA; Hannon, K				Alzghoul, MB; Gerrard, D; Watkins, BA; Hannon, K			Ectopic expression of IGF-1 and Shh by skeletal muscle inhibits disuse-mediated skeletal muscle atrophy and bone osteopenia in vivo	FASEB JOURNAL			English	Article						spaceflight; insulin growth factor-1; growth hormone	GROWTH-FACTOR; SOLEUS MUSCLE; SONIC HEDGEHOG; INSULIN; MICE; RAT; DENSITY; SPACE; MODEL	The loss of normal weight-bearing activity, which occurs during bed rest, limb immobilization, and spaceflight, stimulates a catabolic response within the musculoskeletal system, which results in a loss of skeletal muscle mass and bone mineral. The mechanism by which loading of muscle and bone is sensed and translated into signals controlling tissue formation remains a major question in the field of musculoskeletal research. In this investigation, we have examined the ability of two potentially anti-atrophic proteins, IGF-I and Shh, to inhibit disuse atrophy within muscle and bone, when electroporated into skeletal muscle. We have found that electroporation and ectopic expression of IGF-I and/or Shh within the gastrocnemius/soleus muscle significantly stimulated muscle fiber hypertrophy and increases in muscle size. In addition, we report that electroporation and ectopic expression of IGF-I and/or Shh within the gastrocnemius/soleus muscle attenuated the lost of muscle fiber area, muscle mass, and muscle mass density that normally occurs during disuse muscle atrophy. Finally, we found that ectopic expression of IGF-I and Shh within the gastrocnemius/soleus muscle inhibits parameters of osteopenia within the tibia and fibula associated with hindlimb unloading. These results support the theory that skeletal muscle can regulate bone maintenance and could offer potentially novel and efficient therapeutic options for attenuating muscle and bone atrophy during aging, illness and spaceflight.	Purdue Univ, Sch Vet Med, Dept Basic Med Sci, W Lafayette, IN 47907 USA; Purdue Univ, Dept Anim Sci, W Lafayette, IN 47907 USA; Purdue Univ, Dept Food Sci, Lipid Chem & Mol Biol Lab, W Lafayette, IN 47907 USA; Sch Vet Med, Irbid, Jordan	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Hannon, K (corresponding author), Purdue Univ, Sch Vet Med, Dept Basic Med Sci, W Lafayette, IN 47907 USA.	kmh@vet.purdue.edu	Alzghoul, Mohammad/ABE-8281-2021; gerrard, david/AAG-7507-2019	Watkins, Bruce/0000-0002-2793-4538; gerrard, david/0000-0002-3482-1400				Allen DL, 1997, J APPL PHYSIOL, V83, P1857, DOI 10.1152/jappl.1997.83.6.1857; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; Bikle DD, 1999, J BONE MINER METAB, V17, P233, DOI 10.1007/s007740050090; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Borrelli J, 2002, J ORTHOP TRAUMA, V16, P691, DOI 10.1097/00005131-200211000-00002; Borycki AG, 1998, DEVELOPMENT, V125, P777; Carmeliet G, 2001, CRIT REV EUKAR GENE, V11, P131; Conover CA, 2002, GROWTH HORM IGF RES, V12, P178, DOI 10.1016/S1096-6374(02)00044-8; Criswell DS, 1998, AM J PHYSIOL-ENDOC M, V275, pE373; Day CS, 2001, J RECONSTR MICROSURG, V17, P51, DOI 10.1055/s-2001-12689; Draghia-Akli R, 2003, FASEB J, V17, P526, DOI 10.1096/fj.02-0671fje; Duprez D, 1998, DEVELOPMENT, V125, P495; HANNON K, 1992, DEV BIOL, V151, P137, DOI 10.1016/0012-1606(92)90221-2; Hannon K, 1996, J CELL BIOL, V132, P1151, DOI 10.1083/jcb.132.6.1151; Hikida RS, 1997, ANAT REC, V247, P350, DOI 10.1002/(SICI)1097-0185(199703)247:3<350::AID-AR6>3.0.CO;2-Y; Kraemer WJ, 2000, HISTOCHEM CELL BIOL, V114, P349; KU Z, 1994, AM J PHYSIOL, V267, pC115, DOI 10.1152/ajpcell.1994.267.1.C115; LeBlanc A, 1998, BONE, V22, p113S, DOI 10.1016/S8756-3282(98)00013-1; Lee SJ, 1999, CURR OPIN GENET DEV, V9, P604, DOI 10.1016/S0959-437X(99)00004-0; Marchetti M E, 1996, J Shoulder Elbow Surg, V5, P471, DOI 10.1016/S1058-2746(96)80020-6; Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262; Morey E.R., 1979, PHYSIOLOGIST, V22, P23; PARK E, 1993, AVIAT SPACE ENVIR MD, V64, P401; Pirskanen A, 2000, DEV BIOL, V224, P189, DOI 10.1006/dbio.2000.9784; Rabinovsky ED, 2002, FASEB J, V16, P53, DOI 10.1096/fj.02-0183fje; Rantakokko J, 1999, J BONE MINER RES, V14, P1934, DOI 10.1359/jbmr.1999.14.11.1934; Reichel CL, 2000, DOMEST ANIM ENDOCRIN, V18, P337, DOI 10.1016/S0739-7240(00)00054-0; RILEY DA, 1990, J APPL PHYSIOL, V69, P58, DOI 10.1152/jappl.1990.69.1.58; Rubin C, 2001, FASEB J, V15, P2225, DOI 10.1096/fj.01-0166com; Sjogren K, 2001, J NUTR, V131, P2963, DOI 10.1093/jn/131.11.2963; Stabnov L, 2002, BONE, V30, P909, DOI 10.1016/S8756-3282(02)00738-X; THOMASON DB, 1990, J APPL PHYSIOL, V68, P1, DOI 10.1152/jappl.1990.68.1.1; Young BH, 2002, CLIN ORTHOP RELAT R, pS243, DOI 10.1097/01.blo.0000031984.92980.5d	33	80	84	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					221	223		10.1096/fj.03-0293fje	http://dx.doi.org/10.1096/fj.03-0293fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597562				2022-12-25	WOS:000188829300079
J	Bar, D; Apte, RN; Voronov, E; Dinarello, CA; Cohen, S				Bar, D; Apte, RN; Voronov, E; Dinarello, CA; Cohen, S			A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development	FASEB JOURNAL			English	Article						tumor inhibition; controlled delivery; proinflammatory cytokine; genetically engineered cells; microencapsulated cells	IN-VIVO; INTERLEUKIN-1; MELANOMA; GROWTH; INVASIVENESS; METASTASIS; IL-1-BETA; CARCINOMA; ARTHRITIS; GENE	The involvement of interleukin-1 (IL-1) in inflammation, tumor growth, and metastasis makes it an attractive target for therapeutic intervention. Here, we show that a continuous delivery of a low, but steady-state level of the naturally occurring IL-I receptor antagonist (IL-IRa) reduced inflammatory responses and inhibited tumor development in mice, phenomena that are induced by IL-1, mainly secretable IL-1 beta. The IL-IRa was delivered from microencapsulated genetically engineered cells, which overexpress and secrete this mediator. For a tumor model, we used fibrosarcoma cell line, which secretes high levels of IL-1 beta; when injected s.c. into mice, the cells developed into large tumors characterized by very active angiogenic patterns. The proangiogenic features of IL-1 beta were manifested at low levels of the cytokine, and release of 25 ng per day of the IL-IRa was needed to oppose its effects and inhibit tumor development. The continuous delivery of the IL-IRa contributed to improved biocompatibility of the microencapsulated cell systems; the fibrotic sac surrounding the systems was much thinner with significantly less blood capillaries and inflammatory cells. Not only do our findings point to the antiangiogenic properties of IL-1Ra in inflammation and tumor growth, but they also provide a more efficient and convenient way for treating diseases involving IL- 1.	Ben Gurion Univ Negev, Dept Biotechnol Engn, Fac Engn Sci, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Inst Appl Biosci, Fac Engn Sci, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, Ctr Canc, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel; Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA	Ben Gurion University; Ben Gurion University; Ben Gurion University; Ben Gurion University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cohen, S (corresponding author), Ben Gurion Univ Negev, Dept Biotechnol Engn, Fac Engn Sci, Bldg 39,Room 222, IL-84105 Beer Sheva, Israel.	scohen@bgumail.bgu.ac.il	Dinarello, Charles/C-8524-2013		Israel Science Foundation; Israel Science Foundation and the Association for International Cancer Research; Kamea Program of the Israel Ministry of Immigrant Absorption; Israel Cancer Association; NIH [AI-15614]	Israel Science Foundation(Israel Science Foundation); Israel Science Foundation and the Association for International Cancer Research; Kamea Program of the Israel Ministry of Immigrant Absorption; Israel Cancer Association; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Ms. Parvin Zerin for excellent assistance in tissue embedding and processing and Prof. Daniel Benharroch for his advice and assistance in histology assessment. S.C. is supported by The Israel Science Foundation; R.N.A. is supported by The Israel Science Foundation and the Association for International Cancer Research; E.V. is supported by the Kamea Program of the Israel Ministry of Immigrant Absorption, The Israel Science Foundation, and the Israel Cancer Association; and C.A.D. is supported by NIH grant AI-15614	Apte RN, 2000, ADV EXP MED BIOL, V479, P277; Apte RN, 2002, SEMIN CANCER BIOL, V12, P277, DOI 10.1016/S1044-579X(02)00014-7; Bar D, 2001, J CONTROL RELEASE, V72, P228; BAR D, THESIS BEN GURION U; Bendele A, 1999, ARTHRITIS RHEUM, V42, P498, DOI 10.1002/1529-0131(199904)42:3<498::AID-ANR15>3.0.CO;2-A; Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.3.CO;2-U; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Douvdevani A, 1991, Eur Cytokine Netw, V2, P257; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; GIAVAZZI R, 1990, CANCER RES, V50, P4771; GRANOWTIZ EV, 1992, CYTOKINE, V4, P353, DOI 10.1016/1043-4666(92)90078-6; Horai R, 2000, J EXP MED, V191, P313, DOI 10.1084/jem.191.2.313; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; Machluf M, 1997, J CONTROL RELEASE, V43, P35, DOI 10.1016/S0168-3659(96)01466-6; Nicklin MJH, 2000, J EXP MED, V191, P303, DOI 10.1084/jem.191.2.303; Saijo Y, 2002, J IMMUNOL, V169, P469, DOI 10.4049/jimmunol.169.1.469; ULUDAG H, 1990, BIOMATERIALS, V11, P708, DOI 10.1016/0142-9612(90)90032-L; VIDALVANACLOCHA F, 1994, CANCER RES, V54, P2667; VidalVanaclocha F, 1996, JNCI-J NATL CANCER I, V88, P198, DOI 10.1093/jnci/88.3-4.198; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Wingren AG, 1996, CELL IMMUNOL, V169, P226, DOI 10.1006/cimm.1996.0113	22	83	85	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					161	163		10.1096/fj.03-0483fje	http://dx.doi.org/10.1096/fj.03-0483fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597552				2022-12-25	WOS:000188829300061
J	Krysan, K; Merchant, FH; Zhu, L; Dohadwala, M; Luo, J; Lin, Y; Heuze-Vourc'h, N; Pold, M; Seligson, D; Chia, D; Goodglick, L; Wang, HJ; Strieter, R; Sharma, S; Dubinett, S				Krysan, K; Merchant, FH; Zhu, L; Dohadwala, M; Luo, J; Lin, Y; Heuze-Vourc'h, N; Pold, M; Seligson, D; Chia, D; Goodglick, L; Wang, HJ; Strieter, R; Sharma, S; Dubinett, S			COX-2-dependent stabilization of survivin in non-small cell lung cancer	FASEB JOURNAL			English	Article						cyclooxygenase 2; prostaglandin; NSCLC cells	CASPASE ACTIVATION; PROSTAGLANDIN E-2; CYTOCHROME-C; CYCLOOXYGENASE-2; APOPTOSIS; PROTEIN; EXPRESSION; INHIBITOR; INVOLVEMENT; DEATH	Elevated tumor cyclooxygenase 2 (COX-2) expression is associated with increased angiogenesis, tumor invasion and promotion of tumor cell resistance to apoptosis. The mechanism(s) by which COX-2 exerts its cytoprotective effects are not completely understood but may be due to an imbalance of pro- and anti-apoptotic gene expression. To analyze COX-2-dependent gene expression and apoptosis, we created cell lines constitutively expressing COX-2 cDNA in sense and antisense orientations. Whereas COX-2 sense cells have significantly heightened resistance to radiation and drug-induced apoptosis, COX-2 antisense cells are highly sensitive to apoptosis induction. We found that the expression of the anti-apoptotic protein survivin correlated positively with COX-2 expression. A COX-2-dependent modulation of survivin ubiquitination led to its stabilization in COX-2 overexpressing cells, and this effect was replicated by exogenous PGE2 treatment of parental tumor cells. In contrast to previous studies in other cell types, in nonsmall cell lung cancer cells survivin was expressed in a cell cycle-independent manner. When established in SCID mice in vivo, COX-2 antisense-derived tumors had significantly decreased survivin levels while COX-2 sense-derived tumors demonstrated elevated levels compared with controls. In accord with these findings, survivin and COX-2 were frequently upregulated and co-expressed in human lung cancers in situ.	Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Lung Canc Res Program, Los Angeles, CA 90024 USA; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA; Univ Calif Los Angeles, Defined Tumor Marker Evaluat Ctr, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles	Dubinett, S (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, 37-131 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	sdubinett@mednet.ucla.edu	HEUZE-VOURC'H, Nathalie/P-8081-2016	Heuze-Vourc'h, Nathalie/0000-0003-4929-5068	UCLA SPORE In Lung Cancer NIH [P50 CA90388]; TRDRP grant [12FT-0061]; Early Detection Research Network [NCI CA-99-008]; NATIONAL CANCER INSTITUTE [U24CA086366] Funding Source: NIH RePORTER	UCLA SPORE In Lung Cancer NIH; TRDRP grant; Early Detection Research Network; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the UCLA SPORE In Lung Cancer NIH P50 CA90388, TRDRP grant #12FT-0061 (K. Krysan) and the Early Detection Research Network (NCI CA-99-008; L. Goodglick, D. Chia, D. Seligson, and F. Merchant).	ALTORKI N, 2002, ASCO, V21, P101; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; CARBONE D, 2002, ASCO, V21, P1270; Chang HC, 2001, ONCOL REP, V8, P1321; Chang YWE, 2000, MOL CELL BIOL, V20, P8571, DOI 10.1128/MCB.20.22.8571-8579.2000; CSIKI I, 2002, ASCO, V21, P1187; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dohadwala M, 2001, J BIOL CHEM, V276, P20809, DOI 10.1074/jbc.C100140200; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fujita T, 1998, CANCER RES, V58, P4823; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hida T, 2000, CLIN CANCER RES, V6, P2006; Hosomi Y, 2000, LUNG CANCER, V30, P73, DOI 10.1016/S0169-5002(00)00132-X; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Huang M, 1998, CANCER RES, V58, P1208; Kirschenbaum A, 2001, UROLOGY, V58, P127, DOI 10.1016/S0090-4295(01)01255-9; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lin MT, 2001, J BIOL CHEM, V276, P48997, DOI 10.1074/jbc.M107829200; Milas L, 1999, J NATL CANCER I, V91, P1501, DOI 10.1093/jnci/91.17.1501; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Piazza GA, 1997, CANCER RES, V57, P2452; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Turini ME, 2002, ANNU REV MED, V53, P35, DOI 10.1146/annurev.med.53.082901.103952; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wolff H, 1998, CANCER RES, V58, P4997; Yu J, 2002, BRIT J CANCER, V87, P91, DOI 10.1038/sj.bjc.6600421; Zhao J, 2000, J CELL SCI, V113, P4363	45	111	138	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					205	206		10.1096/fj.03-0369fje	http://dx.doi.org/10.1096/fj.03-0369fje			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597555				2022-12-25	WOS:000188829300075
J	Agarwal, C; Singh, RP; Dhanalakshmi, S; Tyagi, AK; Tecklenburg, M; Sclafani, RA; Agarwal, R				Agarwal, C; Singh, RP; Dhanalakshmi, S; Tyagi, AK; Tecklenburg, M; Sclafani, RA; Agarwal, R			Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells	ONCOGENE			English	Article						cyclin-dependent kinase inhibitor; apoptosis; colon cancer; silibinin	FLAVONOID ANTIOXIDANT SILYMARIN; CANCER CELLS; PROTEIN-KINASE; DU145 CELLS; PROGNOSTIC-SIGNIFICANCE; P27(KIP1) PROTEIN; GROWTH-INHIBITION; COLORECTAL-CANCER; SILYBUM-MARIANUM; MAMMALIAN-CELLS	Silymarin, a defined mixture of natural flavonoid, has recently been shown to have potent cancer chemopreventive efficacy against colon carcinogenesis in rat model; however, the mechanism of such efficacy is not elucidated. Here, using pure active agent in silymarin, namely silibinin, we show its antiproliferative and apoptotic effects, and associated molecular alterations in human colon carcinoma HT-29 cells. Silibinin treatment of cells at 50-100 mug/ml doses resulted in a moderate to very strong growth inhibition in a dose- and a time-dependent manner, which was largely due to a G0/G1 arrest in cell cycle progression; higher dose and longer treatment time also caused a G2/M arrest. In mechanistic studies related its effect on cell cycle progression, silibinin treatment resulted in an upregulation of Kip1/p27 and Cip1/p21 protein as well as mRNA levels, and decreased CDK2, CDK4, cyclin E and cyclin D1 protein levels together with an inhibition in CDK2 and CDK4 kinase activities. In other studies, we observed that G2/M arrest by silibinin was associated with a decrease in cdc25C, cdc2/p34 and cyclin B1 protein levels, as well as cdc2/p34 kinase activity. In the studies assessing biological fate of silibinin-treated cells, silibinin-induced cell cycle arrest and growth inhibition were not associated with cellular differentiation, but caused apoptotic death. The quantitative apoptosis analysis showed up to 15% apoptotic cell death after 48 h of silibinin treatment. Interestingly, silibinin-induced apoptosis in HT-29 cells was independent of caspases activation, as all caspases inhibitor did not reverse silibinin-induced apoptosis. This observation was further confirmed by the findings showing a lack in caspases activity increase and caspases and PARP cleavage as well as a lack in cytochrome c release in cytosol following silibinin treatment of HT-29 cells. Additional studies conducted in mice showed that doses found effective in HT-29 cells are achievable in plasma, which increases the significance of the present findings and their possible translation in in vivo anticancer efficacy of silibinin against colon cancer. Together, these results identify molecular mechanisms of silibinin efficacy as a cell cycle regulator and apoptosis inducer in human colon carcinoma HT-29 cells, and justify further studies to investigate potential usefulness of this nontoxic agent in colon cancer prevention and intervention.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Univ Colorado Canc Ctr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Agarwal, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 4200 E 9th St,Box C238, Denver, CO 80262 USA.	Rajesh.Agarwal@UCHSC.edu		Sclafani, Robert/0000-0002-1100-6489; Singh, Rana Pratap/0000-0003-4261-7044	NATIONAL CANCER INSTITUTE [R03CA099079, R01CA064514, R29CA064514, R01CA091883] Funding Source: NIH RePORTER; NCI NIH HHS [CA91883, CA99079, CA64514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad N, 1998, BIOCHEM BIOPH RES CO, V247, P294, DOI 10.1006/bbrc.1998.8748; Bhatia N, 1999, CANCER LETT, V147, P77, DOI 10.1016/S0304-3835(99)00276-1; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chinni SR, 2001, ONCOGENE, V20, P2927, DOI 10.1038/sj.onc.1204365; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; DING QM, 1998, AM J PHYSIOL, V275, pC1191; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Esposito V, 1997, CANCER RES, V57, P3381; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Flora K, 1998, AM J GASTROENTEROL, V93, P139, DOI 10.1111/j.1572-0241.1998.00139.x; GILFIX BM, 1985, J BIOL CHEM, V260, P4026; GRANA X, 1995, ONCOGENE, V11, P211; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Guo YP, 1997, CLIN CANCER RES, V3, P2269; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; HAHN G, 1968, ARZNEI-FORSCHUNG, V18, P698; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Jordan RCK, 1998, AM J PATHOL, V152, P585; Katiyar SK, 1997, JNCI-J NATL CANCER I, V89, P556, DOI 10.1093/jnci/89.8.556; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kitamura S, 1999, JPN J CANCER RES, V90, P75, DOI 10.1111/j.1349-7006.1999.tb00668.x; Kohno H, 2002, INT J CANCER, V101, P461, DOI 10.1002/ijc.10625; Lahiri-Chatterjee M, 1999, CANCER RES, V59, P622; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Moragoda L, 2001, ANTICANCER RES, V21, P873; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Samowitz WS, 2002, INT J CANCER, V99, P597, DOI 10.1002/ijc.10405; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Singh RP, 2002, CARCINOGENESIS, V23, P499, DOI 10.1093/carcin/23.3.499; Singh RP, 2002, CANCER RES, V62, P3063; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; TSAI LH, 1993, ONCOGENE, V8, P1593; Tyagi AK, 2002, CLIN CANCER RES, V8, P3512; VOGEL G, 1975, ARZNEIMITTEL-FORSCH, V25, P82; Wellington K, 2001, BIODRUGS, V15, P465, DOI 10.2165/00063030-200115070-00005; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zi XL, 1998, CANCER RES, V58, P1920; Zi XL, 1997, BIOCHEM BIOPH RES CO, V239, P334, DOI 10.1006/bbrc.1997.7375; Zi XL, 1998, CLIN CANCER RES, V4, P1055; Zi XL, 1999, BIOCHEM BIOPH RES CO, V263, P528, DOI 10.1006/bbrc.1999.1398; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	51	198	212	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2003	22	51					8271	8282		10.1038/sj.onc.1207158	http://dx.doi.org/10.1038/sj.onc.1207158			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614451				2022-12-25	WOS:000186541500006
J	Frelin, C; Imbert, V; Griessinger, E; Loubat, A; Dreano, M; Peyron, JF				Frelin, C; Imbert, V; Griessinger, E; Loubat, A; Dreano, M; Peyron, JF			AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-alpha in Jurkat leukemic cells	ONCOGENE			English	Article						NF-kappa B; IKK2 inhibitor; TNF; apoptosis	NF-KAPPA-B; CANCER-THERAPY; ACTIVATION; DEATH; CHEMORESISTANCE; EXPRESSION; BLOCKING; BLOCKADE; PATHWAY; C-IAP2	NF-kappaB transcription factors promote survival in numerous cell types via induction of antiapoptotic genes. Pharmacological blockade of the IKK2 kinase with AS602868, a specific inhibitor that competes with ATP binding, prevented TNF-alpha-induced NF-kappaB activation in Jurkat leukemic T cells. While TNF-alpha by itself had no effect on Jurkat survival, the addition of AS602868 induced cell death, visualized by DNA fragmentation and sub-G1 analysis. A disruption of the mitochondrial potential followed by activation of caspases 9 and 3 was observed in cells treated by the combination TNF-alpha+AS602868. Quantitative real-time PCR demonstrated that AS602868 prevented TNF-alpha induction of the antiapoptotic genes coding for c-IAP-2, Bclx, Bfl-1/A1 and Traf-1. The use of a specific IKK2 inhibitor appears, therefore, as an interesting pharmaceutical strategy to increase the cell's sensitivity towards apoptotic effectors.	Fac Med Pasteur, INSERM, U526, UFR Genet & Signalisat Mol 50, F-06107 Nice 02, France; Fac Med Pasteur, INSERM, U364, UFR Genet & Signalisat Mol 50, F-06107 Nice, France; Serono Int SA, Geneva, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Merck & Company; Serono International S.A.	Peyron, JF (corresponding author), Fac Med Pasteur, INSERM, U526, UFR Genet & Signalisat Mol 50, F-06107 Nice 02, France.		Griessinger, Emmanuel/G-5574-2018; Imbert, Véronique/I-6093-2016; Jean-Francois, Peyron/AAA-9496-2022; Peyron, Jean-Francois/M-5682-2016	Imbert, Véronique/0000-0003-2103-6718; Jean-Francois, Peyron/0000-0001-6113-916X; Peyron, Jean-Francois/0000-0001-6113-916X				Adams J, 2002, TRENDS MOL MED, V8, pS49, DOI 10.1016/S1471-4914(02)02315-8; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Burke JR, 1998, J BIOL CHEM, V273, P12041, DOI 10.1074/jbc.273.20.12041; Busuttil V, 2002, ONCOGENE, V21, P3213, DOI 10.1038/sj.onc.1205433; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Cheng QW, 2000, ONCOGENE, V19, P4936, DOI 10.1038/sj.onc.1203861; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Foo SY, 1999, TRENDS GENET, V15, P229; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hideshima T, 2001, CANCER RES, V61, P3071; Jones BE, 2000, J BIOL CHEM, V275, P705, DOI 10.1074/jbc.275.1.705; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Keane MM, 2000, BREAST CANCER RES TR, V64, P211, DOI 10.1023/A:1006458407515; Pagliari LJ, 2000, MOL CELL BIOL, V20, P8855, DOI 10.1128/MCB.20.23.8855-8865.2000; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sugiyama H, 1999, J BIOL CHEM, V274, P19532, DOI 10.1074/jbc.274.28.19532; VAN AD, 1996, SCIENCE, V274, P787; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	35	68	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8187	8194		10.1038/sj.onc.1206963	http://dx.doi.org/10.1038/sj.onc.1206963			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603259				2022-12-25	WOS:000186403400013
J	Walther, T; Menrad, A; Orzechowski, HD; Siemeister, G; Paul, M; Schirner, M				Walther, T; Menrad, A; Orzechowski, HD; Siemeister, G; Paul, M; Schirner, M			Differential regulation of in vivo angiogenesis by angiotensin II receptors	FASEB JOURNAL			English	Article						alginate implant angiogenesis; angiotensin receptor AT1; angiotensin receptor AT2	CONVERTING ENZYME-INHIBITION; TYPE-2 RECEPTOR; BLOOD-PRESSURE; TUMOR-CELLS; GROWTH; EXPRESSION; MICE; GENE; ALGINATE; MODEL	Angiotensin II (ANG II), a key regulator of blood pressure and body fluid homeostasis, exerts mitogenic effects on endothelial cells. We therefore hypothesized that ANG 11 could be a mediator between homeostatic changes within the vascular perfusion bed and growth factor-driven angiogenesis. In the present study, we applied the alginate implant angiogenesis model in mice with normal ANG 11 levels, elevated ANG 11 levels by transgenic overexpression of angiotensinogen (AOGEN), or in AT2 receptor-deficient mice. We demonstrate that a decrease in the amount of circulating ANG 11 by the angiotensin-converting enzyme (ACE) inhibitor enalapril or the AT1 receptor antagonist losartan induced a stimulation of in vivo angiogenesis implying an inhibitory function of ANG 11 through the AT1 receptor. However, the strong increase of angiogenesis in AOGEN-transgenic mice compared with mice with normal ANG 11 levels suggests additional stimulatory activity. We showed that the ANG 11-induced stimulation of angiogenesis is linked to the AT2 receptor as an impaired induction of angiogenesis was obtained in AT2 receptor knockout mice. These findings provide the first evidence that the AT2 receptor mediates a stimulation of in vivo angiogenesis and indicate that ANG 11 is a humoral regulator of peripheral angiogenesis involving two receptor subtypes with opposing actions.	Free Univ Berlin, Benjamin Franklin Med Ctr, Dept Cardiol & Pneumol, D-12200 Berlin, Germany; Schering AG, Res Labs, Expt Oncol, D-13342 Berlin, Germany; Free Univ Berlin, Benjamin Franklin Med Ctr, Inst Clin Pharmacol & Toxicol, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Schering AG; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Walther, T (corresponding author), Free Univ Berlin, Benjamin Franklin Med Ctr, Dept Cardiol & Pneumol, Hindenburgdamm 30, D-12200 Berlin, Germany.	thomas.walther@ukbf.fu-berlin.de	Paul, Martin/K-5425-2015	, Gerhard/0000-0002-4712-0531				AHMED A, 1995, J CLIN INVEST, V96, P848, DOI 10.1172/JCI118131; CURNOW KM, 1995, MOL ENDOCRINOL, V9, P1250, DOI 10.1210/me.9.9.1250; Fabre JE, 1999, CIRCULATION, V99, P3043, DOI 10.1161/01.CIR.99.23.3043; FERNANDEZ LA, 1985, J LAB INVEST CLIN, V105, pR141; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; HEIN L, 1995, NATURE, V377, P744, DOI 10.1038/377744a0; Hoffmann J, 1997, CANCER RES, V57, P3847; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; LENOBLE FAC, 1993, AM J PHYSIOL, V264, pR460, DOI 10.1152/ajpregu.1993.264.2.R460; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MINCHENKO A, 1994, LAB INVEST, V71, P374; NAKAJIMA M, 1995, P NATL ACAD SCI USA, V92, P10663, DOI 10.1073/pnas.92.23.10663; Ozawa Y, 1996, BIOCHEM BIOPH RES CO, V228, P328, DOI 10.1006/bbrc.1996.1661; PLUNKETT ML, 1990, LAB INVEST, V62, P510; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Schirner M, 1998, CLIN CANCER RES, V4, P1331; Silvestre JS, 2002, CIRC RES, V90, P1072, DOI 10.1161/01.RES.0000019892.41157.24; Silvestre JS, 2001, CIRC RES, V89, P678, DOI 10.1161/hh2001.097691; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; UNGER T, 1992, HYPERTENSION, V20, P478, DOI 10.1161/01.HYP.20.4.478; VISWANATHAN M, 1992, PEPTIDES, V13, P783, DOI 10.1016/0196-9781(92)90187-8; Walsh DA, 1997, BRIT J PHARMACOL, V120, P1302, DOI 10.1038/sj.bjp.0701062	25	97	106	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2003	17	14					2061	2067		10.1096/fj.03-0129com	http://dx.doi.org/10.1096/fj.03-0129com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	750AA	14597675				2022-12-25	WOS:000186961200042
J	Croce, M; De Ambrosis, A; Corrias, MV; Pistoia, V; Occhino, M; Meazza, R; Giron-Michel, J; Azzarone, B; Accolla, RS; Ferrini, S				Croce, M; De Ambrosis, A; Corrias, MV; Pistoia, V; Occhino, M; Meazza, R; Giron-Michel, J; Azzarone, B; Accolla, RS; Ferrini, S			Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells	ONCOGENE			English	Article						HLA class II; CIITA; neuroblastoma; promoter methylation	BARE-LYMPHOCYTE-SYNDROME; HISTOCOMPATIBILITY COMPLEX EXPRESSION; PROMOTER BINDING-PROTEIN; TRANSACTIVATOR CIITA; ANTIGEN PRESENTATION; DERMAL FIBROBLASTS; TROPHOBLAST CELLS; REGULATORY FACTOR; GENE-EXPRESSION; NF-Y	The HLA class II expression is controlled by the transcriptional activator CIITA. The transcription of CIITA is controlled by different promoters, among which promoter-IV is inducible by IFN-gamma. We analysed the regulation of HLA class II molecules by IFN-gamma in a large series of human neuroblastoma cell lines. No induction of surface or intracellular HLA class II molecules and of specific mRNA was observed, in all neuroblastomas, with the exception of a nonprototypic cell line, ACN. In a large subset of neuroblastomas IFN-gamma induced expression of CIITA mRNA, derived from promoter-IV, which was not methylated. In contrast, in another subset of neuroblastomas, CIITA was not inducible by IFN-gamma and CIITA promoter-IV was either completely or partially methylated. Interestingly, the use of DNA demethylating agents restored CIITA gene transcriptional activation by IFN-gamma, but not HLA class II expression. The defect of HLA class II was not related to alterations in RFX or NF-Y transcription factors, as suggested by EMSA or RFX gene transfection experiments. In addition, the transfection of a functional CIITA cDNA failed to induce HLA class II expression in typical neuroblastoma cells. Confocal microscopy and Western blot analysis suggested a defective nuclear translocation and/or reduced protein synthesis in CIITA-transfected NB cells. Altogether, these data point to multiple mechanisms preventing HLA class II expression in the neuroblastoma, either involving CIITA promoter-IV silencing, or acting at the CIITA post-transcriptional level.	Ist Nazl Ric Canc, I-16132 Genoa, Italy; Ist Giannina Gaslini, I-16148 Genoa, Italy; Univ Insubria, Dipartimento Sci Clin & Biol, I-21100 Varese, Italy; Hop Paul Brousse, INSERM, U506, F-94807 Villejuif, France	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Insubria; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Ferrini, S (corresponding author), Ctr Biotecnol Avanzate, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.		Azzarone, Bruno/AAH-9251-2019; Giron-Michel, Julien/Q-4503-2018; Corrias, Maria Valeria/E-4571-2011; Croce, Michela/AAA-8966-2020; Meazza, Raffaella/AAC-2425-2019; Giron-michel, Julien/GNP-7299-2022	Azzarone, Bruno/0000-0002-5962-3849; Giron-Michel, Julien/0000-0001-6613-6099; Corrias, Maria Valeria/0000-0002-7316-0772; Croce, Michela/0000-0003-4683-4951; Meazza, Raffaella/0000-0003-0242-3157; Giron-michel, Julien/0000-0001-6613-6099; Accolla, Roberto/0000-0003-2493-7378; Ferrini, Silvano/0000-0001-7254-2616				Accolla RS, 2002, EUR J IMMUNOL, V32, P2783, DOI 10.1002/1521-4141(2002010)32:10<2783::AID-IMMU2783>3.0.CO;2-E; ACCOLLA RS, 1986, J EXP MED, V164, P369, DOI 10.1084/jem.164.1.369; Antunes NL, 2000, J PEDIAT HEMATOL ONC, V22, P315, DOI 10.1097/00043426-200007000-00007; Armstrong TD, 1997, P NATL ACAD SCI USA, V94, P6886, DOI 10.1073/pnas.94.13.6886; Barbieri G, 2002, INT IMMUNOL, V14, P839, DOI 10.1093/intimm/dxf060; Blanck G, 1999, MICROBES INFECT, V1, P913, DOI 10.1016/S1286-4579(99)00226-9; BLANCK G, 1990, HUM IMMUNOL, V29, P150, DOI 10.1016/0198-8859(90)90078-4; BROCKER EB, 1984, J INVEST DERMATOL, V82, P244, DOI 10.1111/1523-1747.ep12260181; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; COOPER MJ, 1990, CANCER RES, V50, P3694; Corrias MV, 2001, TISSUE ANTIGENS, V57, P110, DOI 10.1034/j.1399-0039.2001.057002110.x; Cressman DE, 2001, J IMMUNOL, V167, P3626, DOI 10.4049/jimmunol.167.7.3626; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Durand B, 1997, EMBO J, V16, P1045, DOI 10.1093/emboj/16.5.1045; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Garrido F, 2001, ADV CANCER RES, V83, P117, DOI 10.1016/S0065-230X(01)83005-0; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GOBLIN S, 1997, IMMUNITY, V6, P601; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Hake SB, 2000, MOL CELL BIOL, V20, P7716, DOI 10.1128/MCB.20.20.7716-7725.2000; Harton JA, 2000, MOL CELL BIOL, V20, P6185, DOI 10.1128/MCB.20.17.6185-6194.2000; KHAN R, 1988, J BIOL CHEM, V263, P14374; LAMPSON LA, 1990, J IMMUNOL, V144, P512; Lennon AM, 1997, IMMUNOGENETICS, V45, P266, DOI 10.1007/s002510050202; Li GX, 2001, MOL CELL BIOL, V21, P4626, DOI 10.1128/MCB.21.14.4626-4635.2001; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Martin BK, 1999, J IMMUNOL, V162, P6663; Meazza R, 2003, EUR J IMMUNOL, V33, P1183, DOI 10.1002/eji.200323712; MORENO CS, 1995, J IMMUNOL, V155, P4313; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; Morris AC, 2000, J IMMUNOL, V164, P4143, DOI 10.4049/jimmunol.164.8.4143; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Nagarajan UM, 1999, IMMUNITY, V10, P153, DOI 10.1016/S1074-7613(00)80016-3; Naves R, 2002, INT IMMUNOL, V14, P481, DOI 10.1093/intimm/14.5.481; Nekrep N, 2000, MOL CELL BIOL, V20, P4455, DOI 10.1128/MCB.20.12.4455-4461.2000; Piskurich JF, 1999, MOL CELL BIOL, V19, P431; Redwine JM, 2001, AM J PATHOL, V159, P1219, DOI 10.1016/S0002-9440(10)62507-2; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; REITH W, 1989, P NATL ACAD SCI USA, V86, P4200, DOI 10.1073/pnas.86.11.4200; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; Rodriguez AM, 1997, EUR J IMMUNOL, V27, P45, DOI 10.1002/eji.1830270108; Sartoris S, 1998, J IMMUNOL, V161, P814; SHEENCHEN SM, 1994, SURGERY, V116, P510; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; TEMPONI M, 1993, J IMMUNOL METHODS, V161, P239, DOI 10.1016/0022-1759(93)90300-V; Ting JPY, 2002, CELL, V109, pS21, DOI 10.1016/S0092-8674(02)00696-7; Tosi G, 2002, EMBO J, V21, P5467, DOI 10.1093/emboj/cdf557; van den Elsen PJ, 2000, HUM IMMUNOL, V61, P850, DOI 10.1016/S0198-8859(00)00159-2; van der Stoep N, 2002, INT J CANCER, V97, P501, DOI 10.1002/ijc.1623	57	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7848	7857		10.1038/sj.onc.1207054	http://dx.doi.org/10.1038/sj.onc.1207054			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586411				2022-12-25	WOS:000186240200015
J	van Bruggen, R; Anthony, E; Fernandez-Borja, M; Roos, D				van Bruggen, R; Anthony, E; Fernandez-Borja, M; Roos, D			Continuous translocation of Rac2 and the NADPH oxidase component p67(phox) during phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; CELL-FREE SYSTEM; FLAVOCYTOCHROME B(558); RESPIRATORY BURST; ACTIVATION; NEUTROPHILS; P47(PHOX); ACTIN; PROTEINS; DOMAIN	In this study, the translocation of the NADPH oxidase components p67(phox) and Rac2 was studied during phagocytosis in living cells. For this purpose, green fluorescent protein (GFP)-tagged versions of these proteins were expressed in the myeloid cell line PLB-985. First, the correct localization of p67GFP and GFP-Rac2 was shown during phagocytosis of serum-treated zymosan by wild-type PLB-985 cells and PLB-985 X-CGD ( chronic granulomatous disease) cells, which lack expression of flavocytochrome b(558). Subsequently, these constructs were used for fluorescence recovery after photobleaching studies to elucidate the turnover of these proteins on the phagosomal membrane. The turnover of p67GFP and GFP-Rac2 proved to be very high, indicating a continuous exchange of flavocytochrome b(558)-bound p67GFP and GFP-Rac2 for cytosolic, free p67GFP and GFP-Rac2. Furthermore, the importance of an intact actin cytoskeleton for correct localization of these proteins was investigated by disrupting the actin cytoskeleton with cytochalasin B. However, cytochalasin B treatment of PLB-985 cells did not alter the localization of p67GFP and GFP-Rac2 once phagocytosis was initiated. In addition, the continuous exchange of flavocytochrome b(558)-bound p67GFP and GFP-Rac2 for cytosolic p67GFP and GFP-Rac2 was still intact in cytochalasin B-treated cells, indicating that the translocation of these proteins does not depend on a rearrangement of the actin cytoskeleton.	Sanquin Res, Dept Expt Immunohematol, NL-1066 CX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, NL-1066 CX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, NL-1105 A2 Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Roos, D (corresponding author), Sanquin Res, Dept Expt Immunohematol, Plasmanlaan 125, NL-1066 CX Amsterdam, Netherlands.	d.roos@sanquin.nl						AKARD LP, 1988, BLOOD, V72, P322; Allen LAH, 1999, BLOOD, V93, P3521, DOI 10.1182/blood.V93.10.3521.410k21_3521_3530; ANDO S, 1992, J BIOL CHEM, V267, P25709; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Babior BM, 2002, ANTIOXID REDOX SIGN, V4, P35, DOI 10.1089/152308602753625834; Biberstine-Kinkade KJ, 1999, J BIOL CHEM, V274, P10451, DOI 10.1074/jbc.274.15.10451; Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149; Coppolino MG, 2002, J BIOL CHEM, V277, P43849, DOI 10.1074/jbc.M209046200; Cross AR, 1999, BIOCHEM J, V341, P251, DOI 10.1042/0264-6021:3410251; DeLeo FR, 1999, J IMMUNOL, V163, P6732; DEMENDEZ I, 1995, BLOOD, V85, P1104, DOI 10.1182/blood.V85.4.1104.bloodjournal8541104; Dusi S, 1996, BIOCHEM J, V314, P409, DOI 10.1042/bj3140409; Granfeldt D, 2001, INFLAMMATION, V25, P165, DOI 10.1023/A:1011084330283; Grogan A, 1997, J CELL SCI, V110, P3071; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lapouge K, 2002, J BIOL CHEM, V277, P10121, DOI 10.1074/jbc.M112065200; Lekstrom-Himes JA, 2000, NEW ENGL J MED, V343, P1703, DOI 10.1056/NEJM200012073432307; Lowry MB, 1998, J EXP MED, V187, P161, DOI 10.1084/jem.187.2.161; Morimatsu T, 1997, BIOCHEM BIOPH RES CO, V230, P206, DOI 10.1006/bbrc.1996.5881; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; Roos D, 1996, BLOOD, V87, P1663; STAHELIN RV, 2003, J BIOL CHEM; Tamura M, 2000, BIOCHEM BIOPH RES CO, V276, P1186, DOI 10.1006/bbrc.2000.3598; Tamura M, 2000, BIOCHEM J, V349, P369, DOI 10.1042/0264-6021:3490369; Tao W, 2002, BLOOD, V100, P1679, DOI 10.1182/blood.V100.5.1679.h81702001679_1679_1688; Tse SML, 2003, J BIOL CHEM, V278, P3331, DOI 10.1074/jbc.M207966200; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	35	52	53	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9097	9102		10.1074/jbc.M309284200	http://dx.doi.org/10.1074/jbc.M309284200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14623873	hybrid			2022-12-25	WOS:000189265900071
J	De Simone, G; Mandrich, L; Menchise, V; Giordano, V; Febbraio, F; Rossi, M; Pedone, C; Manco, G				De Simone, G; Mandrich, L; Menchise, V; Giordano, V; Febbraio, F; Rossi, M; Pedone, C; Manco, G			A substrate-induced switch in the reaction mechanism of a thermophilic esterase - Kinetic evidences and structural basis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; ALICYCLOBACILLUS-ACIDOCALDARIUS; BACILLUS-ACIDOCALDARIUS; SEQUENCE SIMILARITY; CRYSTAL-STRUCTURE; ARCHAEOGLOBUS-FULGIDUS; LIPOPROTEIN-LIPASE; ACTIVE-SITE; SUBFAMILY; IDENTIFICATION	The reaction mechanism of the esterase 2 (EST2) from Alicyclobacillus acidocaldarius was studied at the kinetic and structural level to shed light on the mechanism of activity and substrate specificity increase previously observed in its double mutant M211S/R215L. In particular, the values of kinetic constants (k(1), k(-1), k(2), and k(3)) along with activation energies (E-1, E-1, E-2, and E-3) were measured for wild type and mutant enzyme. The previously suggested substrate-induced switch in the reaction mechanism from k(cat) = k(3) with a short acyl chain substrate (p-nitrophenyl hexanoate) to k(cat) = k(2) with a long acyl chain substrate (p-nitrophenyl dodecanoate) was validated. The inhibition afforded by an irreversible inhibitor (1-hexadecanesulfonyl chloride), structurally related to p-nitrophenyl dodecanoate, was studied by kinetic analysis. Moreover the three-dimensional structure of the double mutant bound to this inhibitor was determined, providing essential information on the enzyme mechanism. In fact, structural analysis explained the observed substrate-induced switch because of an inversion in the binding mode of the long acyl chain derivatives with respect to the acyl- and alcohol-binding sites.	CNR, Ist Biostrutture & Bioimmagini, I-80134 Naples, Italy; CNR, Ist Biochim Prot, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biostrutture e Bioimmagini (IBB-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	Pedone, C (corresponding author), CNR, Ist Biostrutture & Bioimmagini, Via Mezzocannone 6, I-80134 Naples, Italy.	pedone@chemistry.unina.it; g.manco@ibp.cnr.it	Manco, Giuseppe/AAL-3777-2020; MANDRICH, Luigi/L-7198-2019; De Simone, Giuseppina/AAJ-4964-2021; Febbraio, Ferdinando/AAX-8255-2020; Mandrich, Luigi/AAH-9328-2020	Manco, Giuseppe/0000-0001-6191-3952; MANDRICH, Luigi/0000-0002-0025-9544; Febbraio, Ferdinando/0000-0002-3653-9847; Mandrich, Luigi/0000-0002-0025-9544; De Simone, Giuseppina/0000-0001-9783-5431				Ayala YM, 2000, PROTEIN SCI, V9, P1589, DOI 10.1110/ps.9.8.1589; Bencharit S, 2003, NAT STRUCT BIOL, V10, P349, DOI 10.1038/nsb919; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; D'Auria S, 2000, PROTEINS, V40, P473, DOI 10.1002/1097-0134(20000815)40:3<473::AID-PROT140>3.0.CO;2-8; De Simone G, 2000, J MOL BIOL, V303, P761, DOI 10.1006/jmbi.2000.4195; De Simone G, 2001, J MOL BIOL, V314, P507, DOI 10.1006/jmbi.2001.5152; GROCHULSKI P, 1994, BIOCHEMISTRY-US, V33, P3494, DOI 10.1021/bi00178a005; HEMILA H, 1994, BBA-LIPID LIPID MET, V1210, P249, DOI 10.1016/0005-2760(94)90129-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAZLAUSKAS RJ, 1994, TRENDS BIOTECHNOL, V12, P464, DOI 10.1016/0167-7799(94)90022-1; Kokotos G, 2000, BIOORG MED CHEM LETT, V10, P2803, DOI 10.1016/S0960-894X(00)00566-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; Manco G, 1997, PROTEIN PEPTIDE LETT, V4, P375; Manco G, 1999, PROTEIN SCI, V8, P1789, DOI 10.1110/ps.8.9.1789; Manco G, 1998, BIOCHEM J, V332, P203, DOI 10.1042/bj3320203; Manco G, 2002, EXTREMOPHILES, V6, P325, DOI 10.1007/s00792-001-0261-4; Manco G, 2001, J BIOL CHEM, V276, P37482, DOI 10.1074/jbc.M103017200; Nardini M, 2000, J BIOL CHEM, V275, P31219, DOI 10.1074/jbc.M003903200; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Osterlund T, 2001, EUR J BIOCHEM, V268, P1899, DOI 10.1046/j.1432-1327.2001.02097.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PROBST MR, 1994, J BIOL CHEM, V269, P21650; Wei YY, 1999, NAT STRUCT BIOL, V6, P340	24	41	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6815	6823		10.1074/jbc.M307738200	http://dx.doi.org/10.1074/jbc.M307738200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14617621	hybrid			2022-12-25	WOS:000188969200075
J	Heiring, C; Dahlback, B; Muller, YA				Heiring, C; Dahlback, B; Muller, YA			Ligand recognition and homophilic interactions in Tyro3 - Structural insights into the Axl/Tyro3 receptor tyrosine kinase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; CELL-ADHESION; ANGSTROM RESOLUTION; SURFACE-RECEPTORS; CRYSTAL-STRUCTURE; PROTEIN-S; GENE 6; GROWTH; AXL; GAS6	The receptor Tyro3 together with Axl and Mer form the Axl/Tyro3 family of receptor tyrosine kinases. Members of this family play essential roles in spermatogenesis, immunoregulation, and phagocytosis. Gas6, the product of growth arrest-specific gene, activates the kinase activity of all three receptors. Here, we report the first biochemical and structural characterization of a member of this family, namely of a fragment spanning the two N-terminal Ig domains of the extracellular part of human Tyro3. Its ligand binding specificity profile is identical to the activation profile of the native receptor. The 1.95-Angstrom crystal structure suggests a common ligand-binding site in this receptor family located at the interface of the Ig domains and unusually rich in cis-prolines. Furthermore, both in the crystal and in solution we observed the ligand-independent dimerization of the receptor fragment. This homophilic interaction emphasizes previous functional reports, which hinted that in addition to signal transduction, members of this family of receptors might participate in cell adhesion.	Univ Erlangen Nurnberg, Lehrstuhl Biotech, Inst Mikrobiol Biochem & Genet, D-91052 Erlangen, Germany; Free Univ Berlin, Grad Sch, Fachbereich Biol Chem & Pharm, D-14195 Berlin, Germany; Lund Univ, Univ Hosp, Dept Lab Med, Div Clin Chem, S-20502 Malmo, Sweden	University of Erlangen Nuremberg; Free University of Berlin; Lund University; Skane University Hospital	Muller, YA (corresponding author), Univ Erlangen Nurnberg, Lehrstuhl Biotech, Inst Mikrobiol Biochem & Genet, Henkestr 91, D-91052 Erlangen, Germany.	ymuller@biologie.uni-erlangen.de	Muller, Yves A/R-5397-2016	Muller, Yves A/0000-0003-0519-8928; Dahlback, Bjorn/0000-0003-1546-0328				Angelillo-Scherrer A, 2001, NAT MED, V7, P215, DOI 10.1038/84667; Bellosta P, 1997, ONCOGENE, V15, P2387, DOI 10.1038/sj.onc.1201419; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUDISA N, 1995, EUR J BIOCHEM, V230, P788; Burchert A, 1998, ONCOGENE, V16, P3177, DOI 10.1038/sj.onc.1201865; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; Crosier KE, 1997, PATHOLOGY, V29, P131, DOI 10.1080/00313029700169744; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HEIDENREICH KA, 1986, ENDOCRINOLOGY, V118, P1835, DOI 10.1210/endo-118-5-1835; Heiring C, 2001, PROTEIN ENG, V14, P183, DOI 10.1093/protein/14.3.183; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard TJP, 1997, NUCLEIC ACIDS RES, V25, P236, DOI 10.1093/nar/25.1.236; JIA R, 1994, J BIOL CHEM, V269, P1839; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Kasper C, 2000, NAT STRUCT BIOL, V7, P389; Katagiri M, 2001, J BIOL CHEM, V276, P7376, DOI 10.1074/jbc.M007393200; Kostrewa D, 2001, EMBO J, V20, P4391, DOI 10.1093/emboj/20.16.4391; LAI C, 1994, ONCOGENE, V9, P2567; Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554; Lu QX, 2001, SCIENCE, V293, P306, DOI 10.1126/science.1061663; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; MARK MR, 1994, J BIOL CHEM, V269, P10720; McCloskey P, 1997, J BIOL CHEM, V272, P23285, DOI 10.1074/jbc.272.37.23285; Muller D, 2002, ENDOCRINOLOGY, V143, P23, DOI 10.1210/en.143.1.23; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; Nakano T, 1997, J BIOL CHEM, V272, P29411, DOI 10.1074/jbc.272.47.29411; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RESCIGNO J, 1991, ONCOGENE, V6, P1909; Rudenko G, 2001, TRENDS BIOCHEM SCI, V26, P363, DOI 10.1016/S0968-0004(01)01832-1; Sasaki T, 2002, J BIOL CHEM, V277, P44164, DOI 10.1074/jbc.M207340200; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J; Taylor ICA, 1995, ONCOGENE, V11, P2619; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Wang JH, 2002, TRENDS BIOCHEM SCI, V27, P122, DOI 10.1016/S0968-0004(01)02038-2; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wimmel A, 2001, EUR J CANCER, V37, P2264, DOI 10.1016/S0959-8049(01)00271-4; Yanagita M, 2001, AM J PATHOL, V158, P1423, DOI 10.1016/S0002-9440(10)64093-X	50	53	55	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6952	6958		10.1074/jbc.M311750200	http://dx.doi.org/10.1074/jbc.M311750200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14623883	hybrid			2022-12-25	WOS:000188969200090
J	Pham, V; Wade, JD; Purdue, BW; Sexton, PM				Pham, V; Wade, JD; Purdue, BW; Sexton, PM			Spatial proximity between a photolabile residue in position 19 of salmon calcitonin and the amino terminus of the human calcitonin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOAFFINITY CROSS-LINKING; FIRST EXTRACELLULAR DOMAIN; SECRETIN RECEPTOR; PARATHYROID-HORMONE; BINDING DOMAIN; MOLECULAR PHARMACOLOGY; PROTEIN-RECEPTOR; LIGAND-BINDING; MUTATIONAL ANALYSIS; CHIMERIC RECEPTORS	Calcitonins are 32-amino acid peptide hormones with both peripheral and central actions mediated via specific cell surface receptors, which belong to the class II subfamily of G protein-coupled receptors. Understanding receptor function, particularly in terms of ligand recognition by calcitonin receptors, may aid in the rational design of calcitonin analogs with increased potency and improved selectivity. To directly identify sites of proximity between calcitonin and its receptor, we carried out photoaffinity labeling studies followed by protein digestion and mapping of the radiolabeled photoconjugated receptor. A fully active salmon calcitonin analog [Arg(11,18),Bpa(19)]sCT, incorporating a photolabile p-benzoyl-L-phenylalanine into position 19 of the ligand, has been used to demonstrate spatial proximity between residue 19 of the peptide and the amino-terminal extracellular domain of the receptor. Cyanogen bromide cleavage together with endoproteinase Asp-N digestion indicated that binding was predominantly to the region delimited by receptor residues Cys(134) and Met(187). Binding to this fragment was supported further by cyanogen bromide-digestion of receptors that were mutated to remove the predicted cleavage site at Met(133) (M133A, M133L). Binding within the 54-amino acid fragment was refined further by digestion with endoproteinase Lys-C to the 8-amino acid region corresponding to Cys(134)- Lys(141). These results provide the first direct demonstration of a contact domain between salmon calcitonin and its receptor and will contribute toward modeling of the calcitonin-receptor interface.	Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Parkville, Vic 3010, Australia	Florey Institute of Neuroscience & Mental Health; University of Melbourne	Sexton, PM (corresponding author), Univ Melbourne, Howard Florey Inst, Gate 11,Royal Parade, Parkville, Vic 3010, Australia.	p.sexton@hfi.unimelb.edu.au	Sexton, Patrick M/B-1319-2008	Sexton, Patrick M/0000-0001-8902-2473; Wade, John/0000-0002-1352-6568; Purdue, Brooke/0000-0001-7618-7180				Adams AE, 1998, MOL ENDOCRINOL, V12, P1673, DOI 10.1210/me.12.11.1673; Amodeo P, 1999, J BIOMOL NMR, V13, P161, DOI 10.1023/A:1008365322148; Asmann YW, 2000, MOL PHARMACOL, V58, P911, DOI 10.1124/mol.58.5.911; Behar V, 2000, J BIOL CHEM, V275, P9, DOI 10.1074/jbc.275.1.9; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; Chorev M, 2002, RECEPTOR CHANNEL, V8, P219, DOI 10.1080/10606820213685; CLORE GM, 1988, EUR J BIOCHEM, V171, P479, DOI 10.1111/j.1432-1033.1988.tb13814.x; Dawson NF, 1999, J PEPT RES, V53, P542, DOI 10.1034/j.1399-3011.1999.00060.x; Dong MQ, 2000, J BIOL CHEM, V275, P26032, DOI 10.1074/jbc.M000612200; Dong MQ, 1999, J BIOL CHEM, V274, P19161, DOI 10.1074/jbc.274.27.19161; Dong MQ, 2002, MOL ENDOCRINOL, V16, P2490, DOI 10.1210/me.2002-0111; Dong MQ, 2002, RECEPTOR CHANNEL, V8, P189, DOI 10.1080/10606820213686; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; DSANTOS CS, 1988, ENDOCRINOLOGY, V123, P1483, DOI 10.1210/endo-123-3-1483; EPAND RM, 1985, INT J PEPT PROT RES, V25, P105; EPAND RM, 1988, BIOCHEM BIOPH RES CO, V152, P203, DOI 10.1016/S0006-291X(88)80700-9; Gelling RW, 1997, ENDOCRINOLOGY, V138, P2640, DOI 10.1210/en.138.6.2640; Gensure RC, 2001, J BIOL CHEM, V276, P42692, DOI 10.1074/jbc.M106215200; Gensure RC, 2001, J BIOL CHEM, V276, P28650, DOI 10.1074/jbc.M100717200; GORN AH, 1995, J CLIN INVEST, V95, P2680, DOI 10.1172/JCI117970; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; Greenberg Z, 2000, BIOCHEMISTRY-US, V39, P8142, DOI 10.1021/bi000195n; GRONENBORN AM, 1987, FEBS LETT, V215, P88, DOI 10.1016/0014-5793(87)80119-9; Hilton JM, 2000, J ENDOCRINOL, V166, P213, DOI 10.1677/joe.0.1660213; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; HOUSSAMI S, 1995, MOL PHARMACOL, V47, P798; KUESTNER RE, 1994, MOL PHARMACOL, V46, P246; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; MEADOWS RP, 1991, BIOCHEMISTRY-US, V30, P1247, DOI 10.1021/bi00219a012; NICHOLSON GC, 1986, J CLIN INVEST, V78, P355, DOI 10.1172/JCI112584; Olde B, 1998, J MOL NEUROSCI, V11, P127, DOI 10.1385/JMN:11:2:127; Perrin MH, 2001, J BIOL CHEM, V276, P31528, DOI 10.1074/jbc.M101838200; Perrin MH, 1998, ENDOCRINOLOGY, V139, P566, DOI 10.1210/en.139.2.566; Pondel M, 2000, INT J EXP PATHOL, V81, P405, DOI 10.1046/j.1365-2613.2000.00176.x; Poyner DR, 2002, PHARMACOL REV, V54, P233, DOI 10.1124/pr.54.2.233; Purdue BW, 2002, RECEPTOR CHANNEL, V8, P243, DOI 10.1080/10606820213681; Quiza M, 1997, ENDOCRINOLOGY, V138, P530, DOI 10.1210/en.138.2.530; SENGSTAG C, 1990, MOL CELL BIOL, V10, P672, DOI 10.1128/MCB.10.2.672; Servant G, 1997, J BIOL CHEM, V272, P8653, DOI 10.1074/jbc.272.13.8653; Sexton PM, 1999, CURR MED CHEM, V6, P1067; Sexton PM, 2002, RECEPTOR CHANNEL, V8, P135, DOI 10.1080/10606820290005056; Stroop SD, 1996, ENDOCRINOLOGY, V137, P4752, DOI 10.1210/en.137.11.4752; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; Suva LJ, 1997, J PHARMACOL EXP THER, V283, P876; Sydow S, 1999, EUR J BIOCHEM, V259, P55, DOI 10.1046/j.1432-1327.1999.00007.x; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; Tan YV, 2003, J BIOL CHEM, V278, P36531, DOI 10.1074/jbc.M304770200; Vilardaga JP, 1997, EUR J BIOCHEM, V246, P173, DOI 10.1111/j.1432-1033.1997.00173.x; Zang MW, 2003, MOL PHARMACOL, V63, P993, DOI 10.1124/mol.63.5.993; Zhou AT, 1997, P NATL ACAD SCI USA, V94, P3644, DOI 10.1073/pnas.94.8.3644	53	32	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6720	6729		10.1074/jbc.M307214200	http://dx.doi.org/10.1074/jbc.M307214200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14623894	hybrid			2022-12-25	WOS:000188969200064
J	Caines, MEC; Elkins, JM; Hewitson, KS; Schofield, CJ				Caines, MEC; Elkins, JM; Hewitson, KS; Schofield, CJ			Crystal structure and mechanistic implications of N-2-(2-carboxyethyl)arginine synthase, the first enzyme in the clavulanic acid biosynthesis pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHATE-DEPENDENT ENZYME; BETA-LACTAM SYNTHETASE; STREPTOMYCES-CLAVULIGERUS; PYRUVATE DECARBOXYLASE; SUBSTRATE ACTIVATION; AMIDINO HYDROLASE; ESCHERICHIA-COLI; GENE-CLUSTER; THIAMIN; CLONING	The initial step in the biosynthesis of the clinically important beta-lactamase inhibitor clavulanic acid involves condensation of two primary metabolites, D-glyceraldehyde 3-phosphate and L-arginine, to give N-2-(2-carboxyethyl) arginine, a beta-amino acid. This unusual N-C bond forming reaction is catalyzed by the thiamin diphosphate (ThP2)-dependent enzyme N-2-(2-carboxyethyl) arginine synthase. Here we report the crystal structure of N-2-(2-carboxyethyl) arginine synthase, complexed with ThP2 and Mg2+, to 2.35-Angstrom resolution. The structure was solved in two space groups, P2(1)2(1)2(1) and P2(1)2(1)2. In both, the enzyme is observed in a tetrameric form, composed of a dimer of two more tightly associated dimers, consistent with both mass spectrometric and gel filtration chromatography studies. Both ThP2 and Mg2+ cofactors are present at the active site, with ThP2 in a "V" conformation as in related enzymes. A sulfate anion is observed in the active site of the enzyme in a location proposed as a binding site for the phosphate group of the D-glyceraldehyde 3-phosphate substrate. The mechanistic implications of the active site arrangement are discussed, including the potential role of the aminopyrimidine ring of the ThP2. The structure will form a basis for future mechanistic and structural studies, as well as engineering aimed at production of alternative beta-amino acids.	Univ Oxford, Dept Chem, Chem Res Lab, Oxford OX1 3TA, England	University of Oxford	Schofield, CJ (corresponding author), Univ Oxford, Dept Chem, Chem Res Lab, Mansfield Rd, Oxford OX1 3TA, England.	christopher.schofield@chem.ox.ac.uk		Elkins, Jon/0000-0003-2858-8929; Schofield, Christopher/0000-0002-0290-6565				AIDOO KA, 1994, GENE, V147, P41, DOI 10.1016/0378-1119(94)90036-1; Arjunan P, 1996, J MOL BIOL, V256, P590, DOI 10.1006/jmbi.1996.0111; Bachmann BO, 1998, P NATL ACAD SCI USA, V95, P9082, DOI 10.1073/pnas.95.16.9082; Baggaley KH, 1997, NAT PROD REP, V14, P309, DOI 10.1039/np9971400309; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALDWIN JE, 1991, TETRAHEDRON, V47, P4089, DOI 10.1016/S0040-4020(01)86446-2; BASAK A, 1990, J AM CHEM SOC, V112, P1654, DOI 10.1021/ja00160a069; BENTLEY PH, 1979, TETRAHEDRON LETT, P1889; BERTAGNOLLI BL, 1991, J BIOL CHEM, V266, P10168; Brown RPA, 1996, BIOCHEMISTRY-US, V35, P12421, DOI 10.1021/bi961044g; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dobritzsch D, 1998, J BIOL CHEM, V273, P20196, DOI 10.1074/jbc.273.32.20196; Elkins JM, 2002, BIOCHEM J, V366, P423, DOI 10.1042/BJ20020125; ELSON SW, 1993, J CHEM SOC CHEM COMM, P1212, DOI 10.1039/c39930001212; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fiedler E, 2002, P NATL ACAD SCI USA, V99, P591, DOI 10.1073/pnas.022510999; Foulon V, 1999, P NATL ACAD SCI USA, V96, P10039, DOI 10.1073/pnas.96.18.10039; GOLBIK R, 1991, BIOORG CHEM, V19, P10, DOI 10.1016/0045-2068(91)90039-R; Guo FS, 1998, BIOCHEMISTRY-US, V37, P13379, DOI 10.1021/bi9807097; Hasson MS, 1998, BIOCHEMISTRY-US, V37, P9918, DOI 10.1021/bi973047e; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; HODGSON JE, 1995, GENE, V166, P49, DOI 10.1016/0378-1119(95)00560-9; JENSEN SE, 1993, INDUSTRIAL MICROORGANISMS: BASIC AND APPLIED MOLECULAR GENETICS, P169; Jensen SE, 1999, ANTON LEEUW INT J G, V75, P125, DOI 10.1023/A:1001755724055; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jordan F, 2003, NAT PROD REP, V20, P184, DOI 10.1039/b111348h; Kern D, 1997, SCIENCE, V275, P67, DOI 10.1126/science.275.5296.67; Kershaw NJ, 2002, EUR J BIOCHEM, V269, P2052, DOI 10.1046/j.1432-1033.2002.02853.x; Khaleeli N, 1999, J AM CHEM SOC, V121, P9223, DOI 10.1021/ja9923134; KNOWLES JR, 1985, ACCOUNTS CHEM RES, V18, P97, DOI 10.1021/ar00112a001; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Li RF, 2000, J BACTERIOL, V182, P4087, DOI 10.1128/JB.182.14.4087-4095.2000; Lobell M, 1996, J AM CHEM SOC, V118, P1867, DOI 10.1021/ja951830t; Lu GG, 2000, EUR J BIOCHEM, V267, P861, DOI 10.1046/j.1432-1327.2000.01070.x; Matagne A, 1999, NAT PROD REP, V16, P1, DOI 10.1039/a705983c; MCILWAINE DB, 1993, J CHEM SOC CHEM COMM, V17, P1346; McNaughton HJ, 1998, CHEM COMMUN, P2325, DOI 10.1039/a806713i; Mellado E, 2002, MICROBIOL-SGM, V148, P1427, DOI 10.1099/00221287-148-5-1427; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miller MT, 2001, NAT STRUCT BIOL, V8, P684, DOI 10.1038/90394; MULLER YA, 1993, SCIENCE, V259, P965, DOI 10.1126/science.8438155; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NICHOLSON NH, 1994, J CHEM SOC CHEM COMM, P1281, DOI 10.1039/c39940001281; Nilsson U, 1997, J BIOL CHEM, V272, P1864, DOI 10.1074/jbc.272.3.1864; Pang SS, 2002, J MOL BIOL, V317, P249, DOI 10.1006/jmbi.2001.5419; Polovnikova ES, 2003, BIOCHEMISTRY-US, V42, P1820, DOI 10.1021/bi026490k; Schellenberger A, 1998, BBA-PROTEIN STRUCT M, V1385, P177, DOI 10.1016/S0167-4838(98)00067-3; SCHELLENBERGER A, 1990, CHEM BER, V123, P1489, DOI 10.1002/cber.19901230709; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; WU TK, 1995, J BACTERIOL, V177, P3714, DOI 10.1128/jb.177.13.3714-3720.1995; Zhang ZH, 2000, NAT STRUCT BIOL, V7, P127	53	34	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5685	5692		10.1074/jbc.M310803200	http://dx.doi.org/10.1074/jbc.M310803200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14623876	hybrid			2022-12-25	WOS:000188776500080
J	Eda, S; Yamanaka, M; Beppu, M				Eda, S; Yamanaka, M; Beppu, M			Carbohydrate-mediated phagocytic recognition of early apoptotic cells undergoing transient capping of CD43 glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLLACTOSAMINYL SACCHARIDE CHAINS; 3 AUTOANTIBODY BINDING; MACROPHAGE RECOGNITION; HUMAN-LEUKOCYTES; ANTI-BAND-3 AUTOANTIBODY; MAJOR SIALOGLYCOPROTEIN; OXIDIZED ERYTHROCYTES; VITRONECTIN RECEPTOR; BAND-3 GLYCOPROTEIN; SENESCENT ANTIGEN	A novel mechanism of phagocytic recognition of apoptotic cells was found and characterized. Jurkat cells incubated with appropriate concentrations of etoposide or anti-Fas antibody transiently became susceptible to binding and phagocytosis by THP-1 cell-derived macrophages at 2 h. The bound Jurkat cells showed no chromatin condensation, but the binding was prevented by a caspase inhibitor, indicating that they were recognized at an early stage of apoptosis. The ligands recognized on the apoptotic cells were sialylpolylactosaminyl sugar chains because 1) the binding was inhibited by an oligosaccharide preparation of erythrocyte membrane, and its inhibitory activity was destroyed by polylactosaminoglycan-specific endo-beta-galactosidase or neuraminidase; 2) Jurkat cells pretreated with endo-beta-galactosidase or neuraminidase failed to be recognized; and 3) treatment of the apoptotic cells with polylactosaminoglycan-binding Datura stramonium agglutinin prevented recognition. The sialylpolylactosaminyl chains involved were most likely those of a major sialoglycoprotein CD43 because anti-CD43 antibody inhibited recognition. CD43 on apoptotic Jurkat cells was found to form a cap at 2 h, and the cap disappeared at 4 h. This transient capping of CD43 coincided with the transient increase in the susceptibility of the cells to macrophage recognition, suggesting that CD43 capping is responsible for generation of the carbohydrate ligands for recognition. Furthermore, microscopic observation suggested that the apoptotic cells were recognized at the CD43 cap. Taken together, we conclude that apoptotic Jurkat cells transiently undergo CD43 capping at an early stage of apoptosis and are recognized by macrophages through the cluster of sialylpolylactosaminyl chains of the capped CD43.	Tokyo Univ Pharm & Life Sci, Sch Pharm, Tokyo 1920392, Japan	Tokyo University of Pharmacy & Life Sciences	Beppu, M (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Pharm, 1432-1 Horinouchi, Tokyo 1920392, Japan.	beppum@ps.toyaku.ac.jp						ANDO K, 1994, J BIOL CHEM, V269, P19394; Ando K, 1997, ARCH BIOCHEM BIOPHYS, V339, P250, DOI 10.1006/abbi.1996.9831; BAZIL V, 1993, P NATL ACAD SCI USA, V90, P3792, DOI 10.1073/pnas.90.9.3792; BAZIL V, 1994, J IMMUNOL, V152, P1314; BEPPU M, 1994, ARCH BIOCHEM BIOPHYS, V312, P189, DOI 10.1006/abbi.1994.1298; BEPPU M, 1992, J BIOL CHEM, V267, P14691; BEPPU M, 1990, J BIOL CHEM, V265, P3226; Beppu M, 2001, BIOL PHARM BULL, V24, P19, DOI 10.1248/bpb.24.19; Beppu M, 2000, ARCH BIOCHEM BIOPHYS, V384, P368, DOI 10.1006/abbi.2000.2122; Beppu M, 1996, BIOL PHARM BULL, V19, P188; Beppu M, 1996, CELL MOL BIOL, V42, P1007; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; DESMET W, 1993, IMMUNOLOGY, V79, P46; DINI L, 1992, FEBS LETT, V296, P174, DOI 10.1016/0014-5793(92)80373-O; DUVALL E, 1985, IMMUNOLOGY, V56, P351; Eda S, 2001, ARCH BIOCHEM BIOPHYS, V385, P186, DOI 10.1006/abbi.2000.2142; Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Falasca L, 1996, EXP CELL RES, V224, P152, DOI 10.1006/excr.1996.0123; Fukuda M, 1996, CANCER RES, V56, P2237; FUKUDA MN, 1979, J BIOL CHEM, V254, P5458; Gregory CD, 2000, CURR OPIN IMMUNOL, V12, P27, DOI 10.1016/S0952-7915(99)00047-3; HALL SE, 1994, J IMMUNOL, V153, P3218; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Kondo T, 1997, J CELL BIOL, V139, P749, DOI 10.1083/jcb.139.3.749; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mevorach D, 1998, J EXP MED, V188, P2313, DOI 10.1084/jem.188.12.2313; MORRIS RG, 1984, AM J PATHOL, V115, P426; Nakamura K, 1999, CELL IMMUNOL, V193, P147, DOI 10.1006/cimm.1999.1459; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Ostberg JR, 1998, IMMUNOL TODAY, V19, P546, DOI 10.1016/S0167-5699(98)01343-7; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; REMOLDODONNELL E, 1994, J IMMUNOL, V152, P3595; Ren Y, 1998, CELL DEATH DIFFER, V5, P563, DOI 10.1038/sj.cdd.4400407; RIEU P, 1992, EUR J IMMUNOL, V22, P3021, DOI 10.1002/eji.1830221138; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SCHMID K, 1992, P NATL ACAD SCI USA, V89, P663, DOI 10.1073/pnas.89.2.663; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; Stern M, 1996, AM J PATHOL, V149, P911; Takizawa F, 1996, FEBS LETT, V397, P269, DOI 10.1016/S0014-5793(96)01197-0; TARENTINO AL, 1974, J BIOL CHEM, V249, P818; Taylor PR, 2000, J EXP MED, V192, P359, DOI 10.1084/jem.192.3.359; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; VOL RE, 1997, NATURE, V390, P350; YAMASHITA K, 1987, J BIOL CHEM, V262, P1602; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885	53	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5967	5974		10.1074/jbc.M310805200	http://dx.doi.org/10.1074/jbc.M310805200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14613931	hybrid			2022-12-25	WOS:000188776500112
J	Olofsson, A; Ippel, JH; Wijmenga, SS; Lundgren, E; Ohman, A				Olofsson, A; Ippel, JH; Wijmenga, SS; Lundgren, E; Ohman, A			Probing solvent accessibility of transthyretin amyloid by solution NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-EXCHANGE; TETRAMER DISSOCIATION; SUBUNIT INTERFACE; X-RAY; FIBRILS; CORE; INTERMEDIATE; PROTEINS; VARIANTS; MUTANTS	The human plasma protein transthyretin (TTR) may form fibrillar protein deposits that are associated with both inherited and idiopathic amyloidosis. The present study utilizes solution nuclear magnetic resonance spectroscopy, in combination with hydrogen/deuterium exchange, to determine residue-specific solvent protection factors within the fibrillar structure of the clinically relevant variant, TTRY114C. This novel approach suggests a fibril core comprised of the six beta-strands, A-B-E-F-G-H, which retains a native-like conformation. Strands C and D are dislocated from their native edge region and become solvent-exposed, leaving a new interface involving strands A and B open for intermolecular interactions. Our results further support a native-like intermolecular association between strands F-F' and H-H' with a prolongation of these beta-strands and, interestingly, with a possible shift in beta-strand register of the subunit assembly. This finding may explain previous observations of a monomeric intermediate preceding fibril formation. A structural model based on our results is presented.	Umea Univ, Dept Biochem, SE-90187 Umea, Sweden; Umea Univ, Dept Mol Biol, SE-90187 Umea, Sweden; Univ Wageningen & Res Ctr, Biochem Lab, NL-6703 HA Wageningen, Netherlands; Univ Nijmegen, Dept Biophys Chem, NL-6500 GL Nijmegen, Netherlands	Umea University; Umea University; Wageningen University & Research; Radboud University Nijmegen	Ohman, A (corresponding author), Umea Univ, Dept Biochem, SE-90187 Umea, Sweden.	anders.ohman@chem.umu.se	Ippel, Hans/D-6917-2016					ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Blake C, 1996, STRUCTURE, V4, P989, DOI 10.1016/S0969-2126(96)00104-9; Blake CCF, 1978, BIOCHEM SOC T, V6, P1114, DOI 10.1042/bst0061114; COLON W, 1992, BIOCHEMISTRY-US, V31, P8654, DOI 10.1021/bi00151a036; Connors LH, 2000, AMYLOID, V7, P54, DOI 10.3109/13506120009146826; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Eneqvist T, 2002, BIOCHEMISTRY-US, V41, P13143, DOI 10.1021/bi025800w; Eneqvist T, 2000, MOL CELL, V6, P1207, DOI 10.1016/S1097-2765(00)00117-9; Goldsteins G, 1997, BIOCHEMISTRY-US, V36, P5346, DOI 10.1021/bi961649c; Goldsteins G, 1999, P NATL ACAD SCI USA, V96, P3108, DOI 10.1073/pnas.96.6.3108; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Helgstrand M, 2000, J BIOMOL NMR, V18, P329, DOI 10.1023/A:1026729404698; Hornberg A, 2000, J MOL BIOL, V302, P649, DOI 10.1006/jmbi.2000.4078; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; Ippel JH, 2002, P NATL ACAD SCI USA, V99, P8648, DOI 10.1073/pnas.132098999; Jiang X, 2001, P NATL ACAD SCI USA, V98, P14943, DOI 10.1073/pnas.261419998; Jiang X, 2001, BIOCHEMISTRY-US, V40, P11442, DOI 10.1021/bi011194d; Jimenez JL, 1999, EMBO J, V18, P815, DOI 10.1093/emboj/18.4.815; Kheterpal I, 2000, P NATL ACAD SCI USA, V97, P13597, DOI 10.1073/pnas.250288897; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; Larsson G, 1999, J BIOMOL NMR, V14, P169, DOI 10.1023/A:1008308307363; Lashuel HA, 1999, BIOCHEMISTRY-US, V38, P13560, DOI 10.1021/bi991021c; Liu K, 2000, NAT STRUCT BIOL, V7, P754; Liu K, 2002, J MOL BIOL, V320, P821, DOI 10.1016/S0022-2836(02)00471-0; Liu K, 2000, J MOL BIOL, V303, P555, DOI 10.1006/jmbi.2000.4164; Nettleton EJ, 1999, METHOD ENZYMOL, V309, P633; Olofsson A, 2001, J BIOL CHEM, V276, P39592, DOI 10.1074/jbc.M103599200; Quintas A, 2001, J BIOL CHEM, V276, P27207, DOI 10.1074/jbc.M101024200; Redondo C, 2000, BIOCHEM J, V348, P167, DOI 10.1042/0264-6021:3480167; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Sebastiao MP, 1998, J BIOL CHEM, V273, P24715, DOI 10.1074/jbc.273.38.24715; Serag AA, 2002, NAT STRUCT BIOL, V9, P734, DOI 10.1038/nsb838; Serag AA, 2001, BIOCHEMISTRY-US, V40, P9089, DOI 10.1021/bi010655s; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; THYLEN C, 1993, EMBO J, V12, P743, DOI 10.1002/j.1460-2075.1993.tb05708.x; Tycko R, 2001, ANNU REV PHYS CHEM, V52, P575, DOI 10.1146/annurev.physchem.52.1.575; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P2843, DOI 10.1073/pnas.87.7.2843	39	93	93	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5699	5707		10.1074/jbc.M310605200	http://dx.doi.org/10.1074/jbc.M310605200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14604984	Green Published, hybrid			2022-12-25	WOS:000188776500082
J	Schneider, C; Boeglin, WE; Brash, AR				Schneider, C; Boeglin, WE; Brash, AR			Identification of two cyclooxygenase active site residues, leucine 384 and glycine 526, that control carbon ring cyclization in prostaglandin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE-H SYNTHASE-1; ARACHIDONIC-ACID; SENSITIVE METHOD; EPOXY ALCOHOLS; STEREOCHEMISTRY; OXYGENATION; MECHANISM; COX-2; BINDING; HYDROPEROXIDES	The cyclooxygenase (COX) reaction of prostaglandin (PG) biosynthesis begins with the highly specific oxygenation of arachidonic acid in the 11R configuration and ends with a 15S oxygenation to form PGG(2). To obtain new insights into the mechanisms of stereocontrol of oxygenation, we mutated active site residues of human COX-2 that have potential contacts with C-11 of the reacting substrate. Although the 11R oxygenation was not perturbed, changing Leu-384 (into Phe, Trp), Trp-387 (Phe, Tyr), Phe-518 (Ile, Trp, Tyr), and Gly-526 (Ala, Ser, Thr, Val) impaired or abrogated PGG2 synthesis, and typically 11R-HETE was the main product formed. The Gly-526 and Leu-384 mutants formed, in addition, three novel products identified by LC-MS, NMR, and circular dichroism as 8,9-11,12-diepoxy-13R-(or 15R)-hydro(pero)xy derivatives of arachidonic acid. Mechanistically, we propose these arise from a free radical intermediate in which a C-8 carbon radical displaces the 9,11-endoperoxide O-O bond to yield an 8,9-11,12-diepoxide that is finally oxygenated stereospecifically in the 13R or 15R configuration. Formation of these novel products signals an arrest in the normal course of prostaglandin synthesis just prior to closing of the 5-membered carbon ring, and points to a crucial role for Leu-384 and Gly-526 in the correct positioning of the reacting fatty acid intermediate. Some of the Gly-526 and Leu-384 mutants catalyzed both formation of PGG(2) (with the normal 15S configuration) and the 13R- or 15R-oxygenated diepoxides. This result suggests that oxygenation specificity can be determined by the orientation of the reacting fatty acid radical and is not a predetermined outcome based solely on the structure of the cyclooxygenase active site.	Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University	Brash, AR (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, 23rd Ave & Pierce, Nashville, TN 37232 USA.	alan.brash@vanderbilt.edu			NIGMS NIH HHS [GM-53638, GM-15431] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, P01GM015431, R01GM053638] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNART MW, 1994, PHYTOCHEMISTRY, V36, P1233, DOI 10.1016/S0031-9422(00)89643-0; Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; Blomberg LM, 2003, J PHYS CHEM B, V107, P3297, DOI 10.1021/jp027204h; Brash AR, 2000, LIPIDS, V35, P947, DOI 10.1007/s11745-000-0604-0; Chang MS, 1996, BIOCHEMISTRY-US, V35, P464, DOI 10.1021/bi952081v; COREY EJ, 1983, TETRAHEDRON LETT, V24, P4921, DOI 10.1016/S0040-4039(01)99811-9; FALCK JR, 1992, TETRAHEDRON LETT, V33, P4893, DOI 10.1016/S0040-4039(00)61226-1; Garavito RM, 2002, PROSTAG OTH LIPID M, V68-9, P129; GARSSEN GJ, 1976, EUR J BIOCHEM, V62, P33, DOI 10.1111/j.1432-1033.1976.tb10094.x; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; GONNELLA NC, 1982, J AM CHEM SOC, V104, P3775, DOI 10.1021/ja00377a063; Goodwin DC, 2000, BIOCHEMISTRY-US, V39, P5422, DOI 10.1021/bi992752f; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HAMBERG M, 1967, J BIOL CHEM, V242, P5344; HAMBERG M, 1986, BIOCHIM BIOPHYS ACTA, V879, P410, DOI 10.1016/0005-2760(86)90233-X; HAWKINS DJ, 1987, J BIOL CHEM, V262, P7629; HECKER M, 1987, EUR J BIOCHEM, V169, P113, DOI 10.1111/j.1432-1033.1987.tb13587.x; HUMPF HU, 1995, J ORG CHEM, V60, P3539, DOI 10.1021/jo00116a048; Kiefer JR, 2000, NATURE, V405, P97, DOI 10.1038/35011103; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903; MERCIER J, 1974, CHEM PHYS LIPIDS, V12, P239, DOI 10.1016/0009-3084(74)90078-4; OCONNOR DE, 1984, J AM CHEM SOC, V106, P3577, DOI 10.1021/ja00324a028; OLIW EH, 1993, ARCH BIOCHEM BIOPHYS, V305, P288, DOI 10.1006/abbi.1993.1425; Peng S, 2002, J AM CHEM SOC, V124, P10785, DOI 10.1021/ja026880u; PIERRE JL, 1968, CHIM ANAL-PARIS, V50, P494; PORTER NA, 1984, TETRAHEDRON LETT, V25, P807, DOI 10.1016/S0040-4039(01)80032-0; PRATICO D, 1995, J BIOL CHEM, V270, P9800, DOI 10.1074/jbc.270.17.9800; Pratico D, 1996, J BIOL CHEM, V271, P8919, DOI 10.1074/jbc.271.15.8919; Rowlinson SW, 2000, J BIOL CHEM, V275, P6586, DOI 10.1074/jbc.275.9.6586; Rowlinson SW, 1999, J BIOL CHEM, V274, P23305, DOI 10.1074/jbc.274.33.23305; Schneider C, 1997, CHIRALITY, V9, P563, DOI 10.1002/(SICI)1520-636X(1997)9:5/6<563::AID-CHIR25>3.0.CO;2-L; Schneider C, 2000, ANAL BIOCHEM, V287, P186, DOI 10.1006/abio.2000.4847; Schneider C, 2000, J BIOL CHEM, V275, P4743, DOI 10.1074/jbc.275.7.4743; Schneider C, 2002, J BIOL CHEM, V277, P478, DOI 10.1074/jbc.M107471200; Schneider C, 2001, J BIOL CHEM, V276, P20831, DOI 10.1074/jbc.M101821200; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; Silverstein R.M., 1981, SPECTROMETRIC IDENTI, P181; Smith T, 2000, ARCH BIOCHEM BIOPHYS, V375, P195, DOI 10.1006/abbi.1999.1659; Smith WL, 2002, PROSTAG OTH LIPID M, V68-9, P115, DOI 10.1016/S0090-6980(02)00025-4; Thuresson ED, 2000, J BIOL CHEM, V275, P8501, DOI 10.1074/jbc.275.12.8501; Thuresson ED, 2001, J BIOL CHEM, V276, P10347, DOI 10.1074/jbc.M009377200; Tsai AL, 2002, J BIOL CHEM, V277, P38311, DOI 10.1074/jbc.M206961200; van der Donk WA, 2002, BIOCHEMISTRY-US, V41, P15451, DOI 10.1021/bi026938h; VANOS CPA, 1982, BIOCHIM BIOPHYS ACTA, V713, P173; VASILJEVA LL, 1993, TETRAHEDRON, V49, P4099, DOI 10.1016/S0040-4020(01)89921-X; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u	48	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4404	4414		10.1074/jbc.M307431200	http://dx.doi.org/10.1074/jbc.M307431200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14594816	hybrid			2022-12-25	WOS:000188554300059
J	Thevissen, K; Warnecke, DC; Francois, EJA; Leipelt, M; Heinz, E; Ott, C; Zahringer, U; Thomma, BPHJ; Ferkel, KKA; Cammue, BPA				Thevissen, K; Warnecke, DC; Francois, EJA; Leipelt, M; Heinz, E; Ott, C; Zahringer, U; Thomma, BPHJ; Ferkel, KKA; Cammue, BPA			Defensins from insects and plants interact with fungal glucosylceramides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; DAHLIA DAHLIA-MERCKII; SACCHAROMYCES-CEREVISIAE; ANTIFUNGAL ACTIVITY; PROTEIN-SYNTHESIS; CANDIDA-ALBICANS; BARLEY ENDOSPERM; BINDING-SITES; CEREBROSIDES; CELLS	Growth of the yeast species Candida albicans and Pichia pastoris is inhibited by RSAFP2, a plant defensin isolated from radish seed (Raphanus sativus), at micromolar concentrations. In contrast, gcs-deletion mutants of both yeast species are resistant toward RsAFP2. GCS genes encode UDP-glucose:ceramide glucosyltransferases, which catalyze the final step in the biosynthesis of the membrane lipid glucosylceramide. In an enzyme-linked immunosorbent assay-based binding assay, RSAFP2 was found to interact with glucosylceramides isolated from P. pastoris but not with soybean nor human glucosylceramides. Furthermore, the P. pastoris parental strain is sensitive toward RSAFP2-induced membrane permeabilization, whereas the corresponding gcs-deletion mutant is highly resistant to RsAFP2-mediated membrane permeabilization. A model for the mode of action of RsAFP2 is presented in which all of these findings are linked. Similarly to RSAFP2, heliomicin, a defensin-like peptide from the insect Hehothis virescens, is active on C. albicans and P. pastoris parental strains but displays no activity on the gcs-deletion mutants of both yeast species. Furthermore, heliomicin interacts with glucosylceramides isolated from P. pastoris and soybean but not with human glucosylceramides. These data indicate that structurally homologous antifungal peptides present in species from different eukaryotic kingdoms interact with the same target in the fungal plasma membrane, namely glucosylceramides, and as such support the hypothesis that defensins from plants and insects have evolved from a single precursor.	Ctr Microbial & Plant Genet, B-3001 Heverlee, Belgium; Univ Hamburg, Inst Allgemeine Bot, D-22609 Hamburg, Germany; Res Ctr Borstel, Ctr Med & Biosci, D-23845 Borstel, Germany	University of Hamburg; Forschungszentrum Borstel	Thevissen, K (corresponding author), Ctr Microbial & Plant Genet, Kasteelpk Arenberg 20, B-3001 Heverlee, Belgium.	karin.thevissen@agr.kuleuven.ac.be	Thevissen, Karin/B-7003-2015; Thomma, Bart/E-5959-2011; Thomma, Bart/ABH-6344-2020; Cammue, Bruno/M-9575-2013	Thevissen, Karin/0000-0003-0275-9072; Thomma, Bart/0000-0003-4125-4181; Thomma, Bart/0000-0003-4125-4181; 				Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Banzet N, 2002, PLANT SCI, V162, P995, DOI 10.1016/S0168-9452(02)00053-5; BONMATIN JM, 1992, J BIOMOL NMR, V2, P235, DOI 10.1007/BF01875319; Brade L, 2000, GLYCOBIOLOGY, V10, P629, DOI 10.1093/glycob/10.6.629; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; DeSamblanx GW, 1997, J BIOL CHEM, V272, P1171, DOI 10.1074/jbc.272.2.1171; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; Dickson RC, 1999, BBA-GEN SUBJECTS, V1426, P347, DOI 10.1016/S0304-4165(98)00135-4; FONZI WA, 1993, GENETICS, V134, P717; Gordon J, 2000, CELL DEATH DIFFER, V7, P785, DOI 10.1038/sj.cdd.4400710; KAWAI G, 1985, J LIPID RES, V26, P338; Kiyokawa N, 1998, J INFECT DIS, V178, P178, DOI 10.1086/515592; Lamberty M, 2001, BIOCHEMISTRY-US, V40, P11995, DOI 10.1021/bi0103563; Lamberty M, 1999, J BIOL CHEM, V274, P9320, DOI 10.1074/jbc.274.14.9320; Leipelt M, 2001, J BIOL CHEM, V276, P33621, DOI 10.1074/jbc.M104952200; Levery SB, 2000, RAPID COMMUN MASS SP, V14, P551, DOI 10.1002/(SICI)1097-0231(20000415)14:7<551::AID-RCM909>3.3.CO;2-C; LINGWOOD CA, 1994, NEPHRON, V66, P21, DOI 10.1159/000187761; Mamelak D, 2001, J BIOL CHEM, V276, P449, DOI 10.1074/jbc.M006732200; Mamelak D, 2001, CARBOHYD RES, V335, P91, DOI 10.1016/S0008-6215(01)00209-9; MATSUBARA T, 1987, CHEM PHYS LIPIDS, V43, P1, DOI 10.1016/0009-3084(87)90012-0; Mendez E, 1996, EUR J BIOCHEM, V239, P67, DOI 10.1111/j.1432-1033.1996.0067u.x; MENDEZ E, 1990, EUR J BIOCHEM, V194, P533, DOI 10.1111/j.1432-1033.1990.tb15649.x; Mori T, 2000, EXP HEMATOL, V28, P1260, DOI 10.1016/S0301-472X(00)00538-5; MORRIS DL, 1948, SCIENCE, V107, P254, DOI 10.1126/science.107.2775.254; Mylvaganam M, 2002, BIOCHEM J, V368, P769, DOI 10.1042/BJ20020225; OSBORN RW, 1995, FEBS LETT, V368, P257, DOI 10.1016/0014-5793(95)00666-W; Pinto MR, 2002, GLYCOBIOLOGY, V12, P251, DOI 10.1093/glycob/12.4.251; Rodrigues ML, 2000, INFECT IMMUN, V68, P7049, DOI 10.1128/IAI.68.12.7049-7060.2000; Roth BL, 1997, APPL ENVIRON MICROB, V63, P2421, DOI 10.1128/AEM.63.6.2421-2431.1997; Sakaki T, 2001, YEAST, V18, P679, DOI 10.1002/yea.720; SANDVIG K, 1989, J CELL BIOL, V108, P1331, DOI 10.1083/jcb.108.4.1331; Schneiter R, 1999, J CELL BIOL, V146, P741, DOI 10.1083/jcb.146.4.741; Sperling P, 1998, J BIOL CHEM, V273, P28590, DOI 10.1074/jbc.273.44.28590; Sullards MC, 2000, J MASS SPECTROM, V35, P347, DOI 10.1002/(SICI)1096-9888(200003)35:3<347::AID-JMS941>3.0.CO;2-3; Ternes P, 2002, J BIOL CHEM, V277, P25512, DOI 10.1074/jbc.M202947200; TERRAS FRG, 1992, J BIOL CHEM, V267, P15301; Thevissen K, 1999, APPL ENVIRON MICROB, V65, P5451; Thevissen K, 2000, MOL PLANT MICROBE IN, V13, P54, DOI 10.1094/MPMI.2000.13.1.54; Thevissen K, 2000, P NATL ACAD SCI USA, V97, P9531, DOI 10.1073/pnas.160077797; Thevissen K, 1997, J BIOL CHEM, V272, P32176, DOI 10.1074/jbc.272.51.32176; Thevissen K, 2003, FEMS MICROBIOL LETT, V226, P169, DOI 10.1016/S0378-1097(03)00590-1; Thomma BPHJ, 2002, PLANTA, V216, P193, DOI 10.1007/s00425-002-0902-6; Toledo MS, 2000, J LIPID RES, V41, P797; Toledo MS, 2001, GLYCOBIOLOGY, V11, P105, DOI 10.1093/glycob/11.2.105; Toledo MS, 2001, GLYCOBIOLOGY, V11, P113, DOI 10.1093/glycob/11.2.113; WADDELL T, 1990, P NATL ACAD SCI USA, V87, P7898, DOI 10.1073/pnas.87.20.7898; Warnecke D, 2003, CELL MOL LIFE SCI, V60, P919, DOI 10.1007/s00018-003-2243-4; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200	48	293	319	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					3900	3905		10.1074/jbc.M311165200	http://dx.doi.org/10.1074/jbc.M311165200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14604982	hybrid			2022-12-25	WOS:000188554300002
J	Tomashek, JJ; Glagoleva, OB; Brusilow, WSA				Tomashek, JJ; Glagoleva, OB; Brusilow, WSA			The Escherichia coli F1F0 ATP synthase displays biphasic synthesis kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SITE COOPERATIVITY; OXIDATIVE-PHOSPHORYLATION; ADENOSINE-TRIPHOSPHATASE; MECHANISM; HYDROLYSIS; BINDING; OCCURS; ADP; PH	The F1F0 proton-translocating ATPase/synthase is the primary generator of ATP in most organisms growing aerobically. Kinetic assays of ATP synthesis have been conducted using enzymes from mitochondria and chloroplasts. However, limited data on ATP synthesis by the model Escherichia coli enzyme are available, mostly because of the lack of an efficient and reproducible assay. We have developed an optimized assay and have collected synthase kinetic data over a substrate concentration range of 2 orders of magnitude for both ADP and Pi from the synthase enzyme of E. coli. Negative and positive cooperativity of substrate binding and positive catalytic cooperativity were all observed. ATP synthesis displayed biphasic kinetics for ADP indicating that 1) the enzyme is capable of catalyzing efficient ATP synthesis when only two of three catalytic sites are occupied by ADP; and 2) occupation of the third site further activates the rate of catalysis.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Brusilow, WSA (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.	wbrusilo@med.wayne.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054108, R01GM061272] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61272, GM54108] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AlShawi MK, 1997, BIOCHEMISTRY-US, V36, P12961, DOI 10.1021/bi971478r; BOOTH IR, 1985, MICROBIOL REV, V49, P359, DOI 10.1128/MMBR.49.4.359-378.1985; BOYER PD, 1973, P NATL ACAD SCI USA, V70, P2837, DOI 10.1073/pnas.70.10.2837; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Boyer PD, 2002, FEBS LETT, V512, P29, DOI 10.1016/S0014-5793(02)02293-7; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; Etzold C, 1997, EUR J BIOCHEM, V243, P336, DOI 10.1111/j.1432-1033.1997.0336a.x; FISCHER S, 1994, EUR J BIOCHEM, V225, P167, DOI 10.1111/j.1432-1033.1994.00167.x; GRESSER MJ, 1982, J BIOL CHEM, V257, P2030; JENSEN PR, 1993, EMBO J, V12, P1277, DOI 10.1002/j.1460-2075.1993.tb05772.x; MATSUNOYAGI A, 1985, J BIOL CHEM, V260, P4424; Milgrom YM, 1998, BIOCHEM J, V330, P1037; PENEFSKY HS, 1991, ADV ENZYMOL RAMB, V64, P173; PEREZ JA, 1990, BIOCHEMISTRY-US, V29, P10503, DOI 10.1021/bi00498a013; SEGEL IH, 1975, ENZYME KINETICS, P18; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; STROOP SD, 1985, BIOCHEMISTRY-US, V24, P2304, DOI 10.1021/bi00330a027; STROTMANN H, 1990, EUR J BIOCHEM, V193, P879, DOI 10.1111/j.1432-1033.1990.tb19412.x; Tomashek JJ, 2001, ARCH BIOCHEM BIOPHYS, V387, P180, DOI 10.1006/abbi.2000.2251; Weber J, 2000, BBA-BIOENERGETICS, V1458, P300, DOI 10.1016/S0005-2728(00)00082-7; WEBER J, 1993, J BIOL CHEM, V268, P20126; Weber J, 2001, J BIOL CHEM, V276, P35422, DOI 10.1074/jbc.M104946200; WISE JG, 1985, BIOCHEMISTRY-US, V24, P6949, DOI 10.1021/bi00345a030; YAGI T, 1984, BIOCHEMISTRY-US, V23, P1029, DOI 10.1021/bi00300a035; ZHOU JM, 1993, J BIOL CHEM, V268, P1531	25	15	16	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4465	4470		10.1074/jbc.M310826200	http://dx.doi.org/10.1074/jbc.M310826200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14602713	hybrid			2022-12-25	WOS:000188554300066
J	Walford, GA; Moussignac, RL; Scribner, AW; Loscalzo, J; Leopold, JA				Walford, GA; Moussignac, RL; Scribner, AW; Loscalzo, J; Leopold, JA			Hypoxia potentiates nitric oxide-mediated apoptosis in endothelial cells via peroxynitrite-induced activation of mitochondria-dependent and -independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CYTOCHROME-C; INHIBITION; DAMAGE	Nitric oxide (NO.) at low concentrations is cytoprotective for endothelial cells; however, elevated concentrations of NO. (greater than or equal to1 mumol/liter), as may be achieved during inflammatory states, can induce apoptosis and cell death. Hypoxia is associated with tissue inflammation and ischemia and, therefore, may modulate the effects of NO. on endothelial function. To examine the influence of hypoxia on NO.-mediated apoptosis, we exposed bovine aortic endothelial cells (BAEC) to (Z)-1-[N-(2-aminoethyl)-N- (2-ammonioethyl) amino]diazen-1-ium-1,2-diolate (diethylenetriamine NONOate, DETA-NO) (1 mmol/liter) under normoxic or hypoxic conditions (pO(2) = 35 mm of Hg) and measured the indices of apoptotic cell death. BAEC treated with DETA-NO under normoxic conditions demonstrated increased levels of histone-associated DNA fragments, which was confirmed by terminal dUTP nick-end labeling assay, and hypoxic conditions augmented this response. To determine whether mitochondrial dysfunction was one mechanism by which NO. initiated apoptosis under hypoxic conditions, we evaluated mitochondrial membrane potential in (psi(m)). Exposure to DETA-NO resulted in a decrease in psi(m) and concomitant release of cytochrome c and caspase-9 activation, which were enhanced by hypoxia. By utilizing Rho(0) BAEC (Rho(0)-EC), which lack functional mitochondria, we demonstrated that dissipation of psi(m) was associated with increased reactive oxygen species generation and peroxynitrite formation. Moreover, in Rho(0)-EC we identified activation of caspase-8 as part of the mitochondrial-independent pathway of apoptosis. To establish that peroxynitrite mediated mitochondrial damage and apoptosis, we treated BAEC and Rho(0)-EC with the peroxynitrite scavenger uric acid and found that the indices of apoptosis were decreased significantly. These findings confirm that high flux of NO. under hypoxic conditions promotes cell death via mitochondrial damage and mitochondrial-independent mechanisms by peroxynitrite.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Sch Med, Evans Dept Med, Boston, MA 02118 USA	Boston University; Boston University	Leopold, JA (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 700 Albany St,CABR W-507, Boston, MA 02118 USA.	Jane.Leopold@bmc.org	Loscalzo, Joseph/ABD-8980-2021		DIVISION OF HEART AND VASCULAR DISEASES [N01HV028178] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061795, R01HL058976, P50HL055993, K08HL004399, R37HL061795] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01HV28178, P01HL55993, HL04399, HL58976, HL61795] Funding Source: Medline	DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ameredes BT, 2001, J LEUKOCYTE BIOL, V70, P730; Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960; Barone MC, 2003, J BIOL CHEM, V278, P27520, DOI 10.1074/jbc.M304129200; BOCHATONPIALLAT ML, 1995, AM J PATHOL, V146, P1059; Borutaite V, 2001, BBA-MOL BASIS DIS, V1537, P101, DOI 10.1016/S0925-4439(01)00062-X; Boyd CS, 2002, BIOL CHEM, V383, P411, DOI 10.1515/BC.2002.045; Brookes PS, 2002, FREE RADICAL BIO MED, V33, P755, DOI 10.1016/S0891-5849(02)00901-2; Brown GC, 2001, IUBMB LIFE, V52, P189, DOI 10.1080/15216540152845993; Brown GC, 2003, MOL NEUROBIOL, V27, P325, DOI 10.1385/MN:27:3:325; Choy JC, 2001, J MOL CELL CARDIOL, V33, P1673, DOI 10.1006/jmcc.2001.1419; Chung HT, 2001, BIOCHEM BIOPH RES CO, V282, P1075, DOI 10.1006/bbrc.2001.4670; de la Monte SM, 2003, LAB INVEST, V83, P287, DOI 10.1097/01.LAB.0000056995.07053.C0; Dong CM, 1996, LAB INVEST, V74, P921; GENG YJ, 1995, AM J PATHOL, V147, P251; Hoffmann J, 2001, CIRC RES, V89, P709, DOI 10.1161/hh2001.097796; Jekabsone A, 2003, J MOL CELL CARDIOL, V35, P803, DOI 10.1016/S0022-2828(03)00137-8; Joshi MS, 1999, FREE RADICAL BIO MED, V27, P1357, DOI 10.1016/S0891-5849(99)00179-3; Krause MM, 2003, ARTHRITIS RHEUM, V48, P1438, DOI 10.1002/art.10969; Lee VY, 2002, J BIOL CHEM, V277, P16067, DOI 10.1074/jbc.M111177200; Li CQ, 2002, CHEM RES TOXICOL, V15, P527, DOI 10.1021/tx010171x; Marshall HE, 2002, J BIOL CHEM, V277, P34223, DOI 10.1074/jbc.M201638200; Matsushita H, 2000, CIRC RES, V86, P974, DOI 10.1161/01.RES.86.9.974; Pearlstein DP, 2002, ARTERIOSCL THROM VAS, V22, P566, DOI 10.1161/01.ATV.0000012262.76205.6A; Ramachandran A, 2002, P NATL ACAD SCI USA, V99, P6643, DOI 10.1073/pnas.102019899; Ramachandran A, 2002, FREE RADICAL BIO MED, V33, P1465, DOI 10.1016/S0891-5849(02)01142-5; Riobo NA, 2001, BIOCHEM J, V359, P139, DOI 10.1042/0264-6021:3590139; Santore MT, 2002, AM J PHYSIOL-LUNG C, V282, pL727, DOI 10.1152/ajplung.00281.2001; Shen YH, 1998, FEBS LETT, V433, P125, DOI 10.1016/S0014-5793(98)00844-8; Stempien-Otero A, 1999, J BIOL CHEM, V274, P8039, DOI 10.1074/jbc.274.12.8039; UMEKI S, 1990, BIOCHEM PHARMACOL, V40, P559, DOI 10.1016/0006-2952(90)90556-Z; Zhuang SG, 2000, AM J PHYSIOL-CELL PH, V279, pC341, DOI 10.1152/ajpcell.2000.279.2.C341	31	75	78	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4425	4432		10.1074/jbc.M310582200	http://dx.doi.org/10.1074/jbc.M310582200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14597620	hybrid			2022-12-25	WOS:000188554300061
J	Pendrak, ML; Chao, MP; Yan, SS; Roberts, DD				Pendrak, ML; Chao, MP; Yan, SS; Roberts, DD			Heme oxygenase in Candida albicans is regulated by hemoglobin and is necessary for metabolism of exogenous heme and hemoglobin to alpha-biliverdin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; IRON SOURCES; IX-ALPHA; YEAST; EXPRESSION; GENE; BINDING; FIBRONECTIN; PROTEINS; IDENTIFICATION	Candida albicans is an opportunistic pathogen that has adapted uniquely to life in mammalian hosts. One of the host factors recognized by this yeast is hemoglobin, which binds to a specific cell surface receptor. In addition to its regulating the expression of adhesion receptors on the yeast, we have found that hemoglobin induces the expression of a C. albicans heme oxygenase (CaHmx1p). Hemoglobin transcriptionally induces the CaHMX1 gene independent of the presence of inorganic iron in the medium. A Renilla luciferase reporter driven by the CaHMX1 promoter demonstrated rapid activation of transcription by hemoglobin and (cobalt protoporphyrin IX) globin but not by apoglobin or other proteins. In contrast, iron deficiency or exogenous hemin did not activate the reporter until after 3 h, suggesting that induction of the promoter by hemoglobin is mediated by receptor signaling rather than heme or iron flux into the cell. As observed following disruption of the Saccharomyces cerevisiae ortholog, HMX1, a CaHMX1 null mutant was unable to grow under iron restriction. This suggests a role for CaHmx1p in inorganic iron acquisition. CaHMX1 encodes a functional heme oxygenase. Exogenous heme or hemoglobin is exclusively metabolized to alpha-biliverdin. CaHMX1 is required for utilization of these exogenous substrates, indicating that C. albicans heme oxygenase confers a nutritional advantage for growth in mammalian hosts.	NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Roberts, DD (corresponding author), NCI, Pathol Lab, NIH, Bldg 10 Rm 2A33,10 Ctr Dr MSC 1500, Bethesda, MD 20892 USA.	mxc107@po.cwru.edu; syan@cvm.fda.gov; droberts@helix.nih.gov	Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981	NATIONAL CANCER INSTITUTE [Z01SC009173, ZIASC009173] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM NG, 1988, INT J BIOCHEM, V20, P543, DOI 10.1016/0020-711X(88)90093-6; Auclair K, 2003, PROTEIN EXPRES PURIF, V28, P340, DOI 10.1016/S1046-5928(02)00699-X; Ausubel FM., 1988, CURRENT PROTOCOLS MO; Benson ES, 2002, EUKARYOT CELL, V1, P787, DOI 10.1128/EC.1.5.787-798.2002; Care RS, 1999, MOL MICROBIOL, V34, P792, DOI 10.1046/j.1365-2958.1999.01641.x; CHANEY RL, 1988, J PLANT NUTR, V11, P1033, DOI 10.1080/01904168809363867; Durante W, 2003, J CELL PHYSIOL, V195, P373, DOI 10.1002/jcp.10274; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438, DOI 10.1111/paa.1999.111.5.438; FONZI WA, 1993, GENETICS, V134, P717; Fujita T, 2001, NAT MED, V7, P598, DOI 10.1038/87929; Genco CA, 2001, MOL MICROBIOL, V39, P1, DOI 10.1046/j.1365-2958.2001.02231.x; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Groll AH, 2001, CLIN MICROBIOL INFEC, V7, P8, DOI 10.1111/j.1469-0691.2001.tb00005.x; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; Luo G, 2001, J CLIN MICROBIOL, V39, P2971, DOI 10.1128/JCM.39.8.2971-2974.2001; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MANNS JM, 1994, INFECT IMMUN, V62, P5154, DOI 10.1128/IAI.62.11.5154-5156.1994; MAYER SA, 1991, MOL CELL BIOL, V11, P813, DOI 10.1128/MCB.11.2.813; MCDONAGH AF, 1980, BIOCHEM J, V189, P193, DOI 10.1042/bj1890193; McDonagh AF, 2001, NAT STRUCT BIOL, V8, P198, DOI 10.1038/84915; Muramoto T, 2002, PLANT PHYSIOL, V130, P1958, DOI 10.1104/pp.008128; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; OCARRA P, 1969, FEBS LETT, V5, P295; Odds FC., 1988, CANDIDA CANDIDOSIS; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Pendrak ML, 2000, BIOCHEMISTRY-US, V39, P16110, DOI 10.1021/bi0012585; Philpott CC, 1998, EMBO J, V17, P5026, DOI 10.1093/emboj/17.17.5026; Philpott CC, 2002, BIOCHEM SOC T, V30, P698, DOI 10.1042/bst0300698; Protchenko O, 2003, J BIOL CHEM, V278, P36582, DOI 10.1074/jbc.M306584200; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Rodrigues RG, 1998, J INFECT DIS, V178, P497, DOI 10.1086/515639; SAITO S, 1982, P NATL ACAD SCI-BIOL, V79, P1393, DOI 10.1073/pnas.79.5.1393; SANO S, 1986, P NATL ACAD SCI USA, V83, P531, DOI 10.1073/pnas.83.3.531; Santos R, 2003, MICROBIOL-SGM, V149, P579, DOI 10.1099/mic.0.26108-0; SCHACTER BA, 1988, SEMIN HEMATOL, V25, P349; Schmitt MP, 1997, J BACTERIOL, V179, P838, DOI 10.1128/jb.179.3.838-845.1997; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; SHERMAN F, 1991, METHOD ENZYMOL, V191, P1; SRIKANTHA T, 1995, MOL GEN GENET, V246, P342, DOI 10.1007/BF00288607; Srikantha T, 1996, J BACTERIOL, V178, P121, DOI 10.1128/jb.178.1.121-129.1996; Stojiljkovic I, 2002, DNA CELL BIOL, V21, P281, DOI 10.1089/104454902753759708; SUN J, 1994, BIOCHEMISTRY-US, V33, P13734, DOI 10.1021/bi00250a026; Weinberg ED, 1999, J EUKARYOT MICROBIOL, V46, P231, DOI 10.1111/j.1550-7408.1999.tb05119.x; Weissman Z, 2002, MOL MICROBIOL, V44, P1551, DOI 10.1046/j.1365-2958.2002.02976.x; Wilson RB, 1999, J BACTERIOL, V181, P1868, DOI 10.1128/JB.181.6.1868-1874.1999; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yan SH, 1996, INFECT IMMUN, V64, P2930, DOI 10.1128/IAI.64.8.2930-2935.1996; ZHANG L, 1994, GENE DEV, V8, P2110, DOI 10.1101/gad.8.17.2110; Zhu WM, 2000, J BACTERIOL, V182, P439, DOI 10.1128/JB.182.2.439-447.2000	50	80	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3426	3433		10.1074/jbc.M311550200	http://dx.doi.org/10.1074/jbc.M311550200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14615478	hybrid			2022-12-25	WOS:000188379600037
J	Wang, RW; Bolstad, J; Kong, HH; Zhang, L; Brown, C; Chen, SRW				Wang, RW; Bolstad, J; Kong, HH; Zhang, L; Brown, C; Chen, SRW			The predicted TM10 transmembrane sequence of the cardiac Ca2+ release channel (ryanodine receptor) is crucial for channel activation and gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; POTASSIUM CHANNEL; CALCIUM-RELEASE; MOLECULAR-IDENTIFICATION; K+ CHANNEL; INACTIVATION; CONTRACTION; CONDUCTION; MECHANISM; CATIONS	The predicted TM10 transmembrane sequence, (4844)IIFDITFFFFVIVILLAIIQGLII(4867), has been proposed to be the pore inner helix of the ryanodine receptor (RyR) and to play a crucial role in channel activation and gating, as with the inner helix of bacterial potassium channels. However, experimental evidence for the involvement of the TM10 sequence in RyR channel activation and gating is lacking. In the present study, we have systematically investigated the effects of mutations of each residue within the 24-amino acid TM10 sequence of the mouse cardiac ryanodine receptor (RyR2) on channel activation by caffeine and Ca2+. Intracellular Ca2+ release measurements in human embryonic kidney 293 cells expressing the RyR2 wild type and TM10 mutants revealed that several mutations in the TM10 sequence either abolished caffeine response or markedly reduced the sensitivity of the RyR2 channel to activation by caffeine. By assessing the Ca2+ dependence of [H-3] ryanodine binding to RyR2 wild type and TM10 mutants we also found that mutations in the TM10 sequence altered the sensitivity of the channel to activation by Ca2+ and enhanced the basal activity of [H-3] ryanodine binding. Furthermore, single I4862A mutant channels exhibited considerable channel openings and altered gating at very low concentrations of Ca2+. Our data indicate that the TM10 sequence constitutes an essential determinant for channel activation and gating, in keeping with the proposed role of TM10 as an inner helix of RyR. Our results also shed insight into the orientation of the TM10 helix within the RyR channel pore.	Univ Calgary, Dept Physiol & Biophys, Cardiovasc Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Chen, SRW (corresponding author), Univ Calgary, Dept Physiol & Biophys, Cardiovasc Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	swchen@ucalgary.ca	Kong, Huihui/F-9024-2012					Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Bers DM, 2002, CIRC RES, V90, P14, DOI 10.1161/res.90.1.14; Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; Chen SRW, 1998, J BIOL CHEM, V273, P14675, DOI 10.1074/jbc.273.24.14675; CHEN SRW, 1994, J BIOL CHEM, V269, P22698; CHU A, 1990, MOL PHARMACOL, V37, P735; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Du GC, 2000, J BIOL CHEM, V275, P11778, DOI 10.1074/jbc.275.16.11778; Du GG, 2001, J BIOL CHEM, V276, P31760, DOI 10.1074/jbc.M102751200; EBASHI S, 1991, ANNU REV PHYSIOL, V53, P1, DOI 10.1146/annurev.ph.53.030191.000245; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; Gao L, 2000, BIOPHYS J, V79, P828, DOI 10.1016/S0006-3495(00)76339-9; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Li P, 2001, J GEN PHYSIOL, V118, P33, DOI 10.1085/jgp.118.1.33; Marks AR, 2002, J CELL PHYSIOL, V190, P1, DOI 10.1002/jcp.10031; Masumiya H, 2001, J BIOL CHEM, V276, P39727, DOI 10.1074/jbc.M106557200; Mead FC, 1998, J MEMBRANE BIOL, V163, P225, DOI 10.1007/s002329900386; MEISSNER G, 1992, MOL CELL BIOCHEM, V114, P119; Meissner G, 1997, J BIOL CHEM, V272, P1628, DOI 10.1074/jbc.272.3.1628; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; Scoote M, 2002, CARDIOVASC RES, V56, P359, DOI 10.1016/S0008-6363(02)00574-6; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Tanna B, 1998, J GEN PHYSIOL, V112, P55, DOI 10.1085/jgp.112.1.55; TINKER A, 1992, J MEMBRANE BIOL, V127, P149; WANG R, 2003, J BIOL CHEM     1013; Williams AJ, 2001, Q REV BIOPHYS, V34, P61, DOI 10.1017/S0033583501003675; Xiong H, 1998, BIOCHEMISTRY-US, V37, P4804, DOI 10.1021/bi971198b; Zhao MC, 1999, J BIOL CHEM, V274, P25971, DOI 10.1074/jbc.274.37.25971; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	34	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3635	3642		10.1074/jbc.M311367200	http://dx.doi.org/10.1074/jbc.M311367200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14593104	hybrid			2022-12-25	WOS:000188379600062
J	Kraiczy, P; Hellwage, J; Skerka, C; Becker, H; Kirschfink, M; Simon, MM; Brade, V; Zipfel, PF; Wallich, R				Kraiczy, P; Hellwage, J; Skerka, C; Becker, H; Kirschfink, M; Simon, MM; Brade, V; Zipfel, PF; Wallich, R			Complement resistance of Borrelia burgdorferi correlates with the expression of BbCRASP-1, a novel linear plasmid-encoded surface protein that interacts with human factor H and FHL-1 and is unrelated to Erp proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITOR FACTOR-H; LYME-DISEASE; BINDING-SITE; IMMUNE EVASION; SERUM RESISTANCE; IDENTIFICATION; REGULATOR; ACTIVATION; FAMILY; C3B	The etiologic agent of Lyme disease, Borrelia burgdorferi, is capable of circumventing the immune defense of a variety of potential vertebrate hosts. Previous work has shown that interaction of host-derived complement regulators, factor H and factor H-like protein 1 (FHL-1), with up to five complement regulator-acquiring surface proteins ( CRASPs) expressed by resistant B. burgdorferi sensu lato isolates conferred complement resistance. In addition expression of CRASP-1 is directly correlated with complement resistance of Borrelia species. This work describes the functional characterization of BbCRASP-1 as the dominant factor H and FHL-1-binding protein of B. burgdorferi. The corresponding gene, zs7.a68, is located on the linear plasmid lp54 and is different from factor H-binding Erp proteins that are encoded by genes localized on circular plasmids (cp32). Deletion mutants of BbCRASP-1 were generated, and a high affinity binding site for factor H and FHL-1 was mapped to the C terminus of BbCRASP-1. Similarly, the predominant binding site of factor H and FHL-1 was localized to the short consensus repeat 7. Factor H and FHL-1 maintain their cofactor activity for factor I-mediated C3b inactivation when bound to BbCRASP-1, and factor H is up to 6-fold more efficient in mediating C3b conversion than FHL-1. In conclusion, BbCRASP-1 ( i) binds the host complement regulators factor H and FHL-1 with high affinity, (ii) is the key molecule of the complement resistance of spirochetes, and (iii) is distinct from the Erp protein family. Thus, BbCRASP-1 most likely contributes to persistence of B. burgdorferi and to pathogenesis of Lyme disease.	Univ Hosp Frankfurt, Inst Med Microbiol, D-60596 Frankfurt, Germany; Hans Knoell Inst Nat Prod Res, Dept Infect Biol, D-07745 Jena, Germany; Hans Knoell Inst Nat Prod Res, Mol Immunobiol Grp, D-07745 Jena, Germany; Heidelberg Univ, Dept Immunol, D-69120 Heidelberg, Germany; Max Planck Inst Immunobiol, D-79108 Freiburg, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Hans Knoll Institute (HKI); Hans Knoll Institute (HKI); Ruprecht Karls University Heidelberg; Max Planck Society	Kraiczy, P (corresponding author), Univ Hosp Frankfurt, Inst Med Microbiol, Paul Ehrlich Str 40, D-60596 Frankfurt, Germany.	Kraiczy@em.unifrankfurt.de	Kirschfink, Michael/AAG-5410-2020					Alitalo A, 2002, J IMMUNOL, V169, P3847, DOI 10.4049/jimmunol.169.7.3847; Alitalo A, 2001, INFECT IMMUN, V69, P3685, DOI 10.1128/IAI.69.6.3685-3691.2001; Areschoug T, 2002, J BIOL CHEM, V277, P12642, DOI 10.1074/jbc.M112072200; Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998; BRADE V, 1992, IMMUNOBIOLOGY, V185, P453, DOI 10.1016/S0171-2985(11)80087-2; BreitnerRuddock S, 1997, MED MICROBIOL IMMUN, V185, P253, DOI 10.1007/s004300050038; Bunikis J, 1999, INFECT IMMUN, V67, P2874, DOI 10.1128/IAI.67.6.2874-2883.1999; Casjens S, 1997, J BACTERIOL, V179, P217, DOI 10.1128/jb.179.1.217-227.1997; Dave S, 2001, INFECT IMMUN, V69, P3435, DOI 10.1128/IAI.69.5.3435-3437.2001; FISCHETTI VA, 1995, INFECT IMMUN, V63, P149, DOI 10.1128/IAI.63.1.149-153.1995; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541; Hellwage J, 2002, J IMMUNOL, V169, P6935, DOI 10.4049/jimmunol.169.12.6935; Hellwage J, 2001, J BIOL CHEM, V276, P8427, DOI 10.1074/jbc.M007994200; HORSTMANN RD, 1988, P NATL ACAD SCI USA, V85, P1657, DOI 10.1073/pnas.85.5.1657; Janulczyk R, 2000, J BIOL CHEM, V275, P37257, DOI 10.1074/jbc.M004572200; Jarva H, 2002, J IMMUNOL, V168, P1886, DOI 10.4049/jimmunol.168.4.1886; Johnsson E, 1998, J IMMUNOL, V161, P4894; Kotarsky H, 1998, J IMMUNOL, V160, P3349; Kraiczy P, 2003, EUR J IMMUNOL, V33, P697, DOI 10.1002/eji.200323571; Kraiczy P, 2002, WIEN KLIN WOCHENSCHR, V114, P568; Kraiczy P, 2001, EUR J IMMUNOL, V31, P1674, DOI 10.1002/1521-4141(200106)31:6&lt;1674::AID-IMMU1674&gt;3.0.CO;2-2; Kraiczy P, 2001, INFECT IMMUN, V69, P7800, DOI 10.1128/IAI.69.12.7800-7809.2001; KRAMER MD, 1990, IMMUNOBIOLOGY, V181, P357, DOI 10.1016/S0171-2985(11)80504-8; KUHN S, 1995, GENE, V162, P225, DOI 10.1016/0378-1119(95)00360-I; Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017; KUHN S, 1995, J IMMUNOL, V155, P5663; Kurtenbach K, 2002, TRENDS MICROBIOL, V10, P74, DOI 10.1016/S0966-842X(01)02298-3; Liang FT, 2002, J EXP MED, V195, P415, DOI 10.1084/jem.20011870; MA Y, 1991, INFECT IMMUN, V59, P671, DOI 10.1128/IAI.59.2.671-678.1991; McDowell JV, 2003, INFECT IMMUN, V71, P3597, DOI 10.1128/IAI.71.6.3597-3602.2003; Metts MS, 2003, INFECT IMMUN, V71, P3587, DOI 10.1128/IAI.71.6.3587-3596.2003; MONTGOMERY RR, 1993, J IMMUNOL, V150, P909; Neeleman C, 1999, INFECT IMMUN, V67, P4517, DOI 10.1128/IAI.67.9.4517-4524.1999; Pandiripally V, 2002, INFECT IMMUN, V70, P6206, DOI 10.1128/IAI.70.11.6206-6214.2002; PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257; Patarakul K, 1999, MICROB PATHOGENESIS, V27, P25, DOI 10.1006/mpat.1999.0280; Perez-Caballero D, 2000, EUR J IMMUNOL, V30, P1243, DOI 10.1002/(SICI)1521-4141(200004)30:4<1243::AID-IMMU1243>3.0.CO;2-D; PROBERT WS, 1995, INFECT IMMUN, V63, P1933, DOI 10.1128/IAI.63.5.1933-1939.1995; Prodinger WM, 1998, BIOCHEM J, V331, P41, DOI 10.1042/bj3310041; Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743; Ram S, 1998, J EXP MED, V188, P671, DOI 10.1084/jem.188.4.671; Ram S, 1999, MOL IMMUNOL, V36, P915, DOI 10.1016/S0161-5890(99)00114-5; SADZIENE A, 1995, INFECT IMMUN, V63, P1573, DOI 10.1128/IAI.63.4.1573-1580.1995; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; Stevenson B, 2002, INFECT IMMUN, V70, P491, DOI 10.1128/IAI.70.2.491-497.2002; Stevenson B, 1998, INFECT IMMUN, V66, P2648, DOI 10.1128/IAI.66.6.2648-2654.1998; Stevenson B, 2000, J MOL MICROB BIOTECH, V2, P411; STOIBER H, 1995, AIDS, V9, P19, DOI 10.1097/00002030-199501000-00003; VanDam AP, 1997, INFECT IMMUN, V65, P1228, DOI 10.1128/IAI.65.4.1228-1236.1997; Wallich R, 2003, EUR J IMMUNOL, V33, P708, DOI 10.1002/eji.200323620; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147; Zhang JR, 1997, CELL, V89, P275, DOI 10.1016/S0092-8674(00)80206-8; Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971; Zipfel PF, 1999, IMMUNOL TODAY, V20, P135, DOI 10.1016/S0167-5699(98)01432-7; ZIPFEL PF, 1994, IMMUNOL TODAY, V15, P121, DOI 10.1016/0167-5699(94)90155-4	58	177	178	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2421	2429		10.1074/jbc.M308343200	http://dx.doi.org/10.1074/jbc.M308343200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14607842	hybrid			2022-12-25	WOS:000188211300013
J	Zoidl, G; Bruzzone, R; Weickert, S; Kremer, M; Zoidl, C; Mitropoulou, G; Srinivas, M; Spray, DC; Dermietzel, R				Zoidl, G; Bruzzone, R; Weickert, S; Kremer, M; Zoidl, C; Mitropoulou, G; Srinivas, M; Spray, DC; Dermietzel, R			Molecular cloning and functional expression of zfCx52.6 - A novel connexin with hemichannel-forming properties expressed in horizontal cells of the zebrafish retina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION CHANNELS; AII AMACRINE CELLS; MAMMALIAN RETINA; NEURONAL CONNEXIN36; DOPAMINERGIC MODULATION; ELECTRICAL SYNAPSES; GENE CONNEXIN36; SKATE RETINA; CYCLIC-AMP; PROTEIN	Gap junction-mediated electrical coupling contributes to synchronous oscillatory activities of neurons, and considerable progress has been made in defining the molecular composition of gap junction channels. In particular, cloning and functional expression of gap junction proteins (connexins (Cx)) from zebrafish retina have shown that this part of the brain possesses a high degree of connexin diversity that may account for differential functional properties of electrical synapses. Here, we report the cloning and functional characterization of a new connexin, designated zebrafish Cx52.6 (zfCx52.6). This connexin shows little similarity to known connexins from fish and higher vertebrates. By combining in situ hybridization with Laser Capture Microdissection and RT-PCR, we found that this novel fish connexin is expressed in horizontal cells in the inner nuclear layer of the retina. Functional expression of zfCx52.6 in neuroblastoma cells and Xenopus oocytes led to functional gap junctional channels and, in single oocytes, induced large non-junctional membrane currents indicative of the formation of hemichannels, which were inhibited in reversible fashion by raising extracellular Ca2+ concentrations.	Ruhr Univ Bochum, Dept Neuroanat & Mol Brain Res, D-44801 Bochum, Germany; Inst Pasteur, Dept Neurosci, F-75015 Paris, France; Interdisciplinary Ctr Neurosci IZN, Dept Clin Neurobiol, D-69120 Heidelberg, Germany; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Rose F Kennedy Ctr, Bronx, NY 10461 USA	Ruhr University Bochum; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Ruprecht Karls University Heidelberg; Yeshiva University; Albert Einstein College of Medicine	Dermietzel, R (corresponding author), Ruhr Univ Bochum, Dept Neuroanat & Mol Brain Res, Univ St 150, D-44801 Bochum, Germany.	rolf.dermietzel@ruhr-uni-bochum.de	Bruzzone, Roberto/C-4719-2009; Bruzzone, Roberto/G-9355-2017	Bruzzone, Roberto/0000-0003-4373-1447; Bruzzone, Roberto/0000-0003-4373-1447; Spray, David/0000-0001-8368-5073	NIMH NIH HHS [MH65495] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH065495] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Al-Ubaidi MR, 2000, J NEUROSCI RES, V59, P813, DOI 10.1002/(SICI)1097-4547(20000315)59:6<813::AID-JNR14>3.3.CO;2-R; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARRIO LC, 1991, P NATL ACAD SCI USA, V88, P8410, DOI 10.1073/pnas.88.19.8410; Becker D, 1998, CELL BIOL INT, V22, P781, DOI 10.1006/cbir.1998.0390; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BRUZZONE R, 1993, MOL BIOL CELL, V4, P7, DOI 10.1091/mbc.4.1.7; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Castro C, 1999, J NEUROSCI, V19, P3752; Condorelli DF, 1998, EUR J NEUROSCI, V10, P1202, DOI 10.1046/j.1460-9568.1998.00163.x; Deans MR, 2002, NEURON, V36, P703, DOI 10.1016/S0896-6273(02)01046-2; Dermietzel R, 2000, J NEUROSCI, V20, P8331, DOI 10.1523/JNEUROSCI.20-22-08331.2000; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P186, DOI 10.1016/0166-2236(93)90151-B; DEVRIES SH, 1992, J PHYSIOL-LONDON, V445, P201, DOI 10.1113/jphysiol.1992.sp018920; DEVRIES SH, 1989, J PHYSIOL-LONDON, V414, P351, DOI 10.1113/jphysiol.1989.sp017692; Feigenspan A, 2001, J NEUROSCI, V21, P230, DOI 10.1523/JNEUROSCI.21-01-00230.2001; Galarreta M, 1999, NATURE, V402, P72, DOI 10.1038/47029; Gibson JR, 1999, NATURE, V402, P75, DOI 10.1038/47035; Gillen C, 1996, EUR J NEUROSCI, V8, P405, DOI 10.1111/j.1460-9568.1996.tb01223.x; Guldenagel M, 2001, J NEUROSCI, V21, P6036, DOI 10.1523/JNEUROSCI.21-16-06036.2001; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HAMPSON ECGM, 1994, P ROY SOC B-BIOL SCI, V255, P67, DOI 10.1098/rspb.1994.0010; HAMPSON ECGM, 1992, J NEUROSCI, V12, P4911; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; HENNEMANN H, 1992, J CELL BIOL, V117, P1299, DOI 10.1083/jcb.117.6.1299; Hopperstad MG, 2000, BIOPHYS J, V79, P1954, DOI 10.1016/S0006-3495(00)76444-7; Hormuzdi SG, 2001, NEURON, V31, P487, DOI 10.1016/S0896-6273(01)00387-7; JANSSENBIENHOLD U, 1993, EUR J NEUROSCI, V5, P584, DOI 10.1111/j.1460-9568.1993.tb00524.x; Kamermans M, 2001, SCIENCE, V292, P1178, DOI 10.1126/science.1060101; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; LASATER EM, 1987, P NATL ACAD SCI USA, V84, P7319, DOI 10.1073/pnas.84.20.7319; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; Lu CB, 1999, VISUAL NEUROSCI, V16, P811, DOI 10.1017/S0952523899165015; Masai I, 2000, NEURON, V27, P251, DOI 10.1016/S0896-6273(00)00034-9; MCMAHON DG, 1994, J NEUROSCI, V14, P1722, DOI 10.1523/JNEUROSCI.14-03-01722.1994; Meier C, 2002, HISTOCHEM CELL BIOL, V117, P461, DOI 10.1007/s00418-002-0417-z; Mergia E, 2003, CELL SIGNAL, V15, P189, DOI 10.1016/S0898-6568(02)00078-5; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; MILLS SL, 1995, NATURE, V377, P734, DOI 10.1038/377734a0; MIYACHI EI, 1989, J PHYSIOL-LONDON, V419, P213, DOI 10.1113/jphysiol.1989.sp017870; Mueller T, 2003, DEV BRAIN RES, V140, P137, DOI 10.1016/S0165-3806(02)00583-7; NITROPOULOU G, 2003, J NEUROSCI RES, V15, P147; O'Brien J, 1998, J NEUROSCI, V18, P7625; OBrien J, 1996, MOL BIOL CELL, V7, P233, DOI 10.1091/mbc.7.2.233; OLMSTED JB, 1970, P NATL ACAD SCI USA, V65, P129, DOI 10.1073/pnas.65.1.129; PEREDA AE, 1995, J NEUROSCI, V15, P5943; PICCOLINO M, 1982, P NATL ACAD SCI-BIOL, V79, P3671, DOI 10.1073/pnas.79.11.3671; QIAN HH, 1992, J GEN PHYSIOL, V100, P457, DOI 10.1085/jgp.100.3.457; Quist AP, 2000, J CELL BIOL, V148, P1063, DOI 10.1083/jcb.148.5.1063; Scheer N, 2001, DEVELOPMENT, V128, P1099; Sohl G, 1998, FEBS LETT, V428, P27, DOI 10.1016/S0014-5793(98)00479-7; Sohl G, 2000, BRAIN RES REV, V32, P138, DOI 10.1016/S0165-0173(99)00074-0; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; Taylor JS, 2003, GENOME RES, V13, P382, DOI 10.1101/gr.640303; Van de Peer Yves, 2003, Journal of Structural and Functional Genomics, V3, P65, DOI 10.1023/A:1022652814749; VANEY DI, 1994, PROG RETIN EYE RES, V13, P301, DOI 10.1016/1350-9462(94)90014-0; VANEY DI, 1993, P ROY SOC B-BIOL SCI, V252, P93, DOI 10.1098/rspb.1993.0051; VANEY DI, 1991, NEUROSCI LETT, V125, P187, DOI 10.1016/0304-3940(91)90024-N; Vaney DI, 1998, J NEUROSCI, V18, P10594; VANEY DI, 1996, GAP JUNCTIONS NERVOU, P79; Veruki ML, 2002, J NEUROSCI, V22, P10558; Veruki ML, 2002, NEURON, V33, P935, DOI 10.1016/S0896-6273(02)00609-8; Vetter ML, 2001, SEMIN CELL DEV BIOL, V12, P491, DOI 10.1006/scdb.2001.0273; WAGNER TL, 1998, VISUAL NEUROSCI, V15, P1173; WEILER R, 1996, GAP JUNCTIONS NERVOU, P103; White TW, 1999, EUR J NEUROSCI, V11, P1883, DOI 10.1046/j.1460-9568.1999.00607.x; White TW, 2000, BRAIN RES REV, V32, P130, DOI 10.1016/S0165-0173(99)00072-7; WILDERS R, 1992, BIOPHYS J, V63, P942, DOI 10.1016/S0006-3495(92)81664-8; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Yeager M, 1998, CURR OPIN STRUC BIOL, V8, P517, DOI 10.1016/S0959-440X(98)80131-0; Zoidl G, 2002, CELL TISSUE RES, V310, P137, DOI 10.1007/s00441-002-0632-x; Zoidl G, 2002, J NEUROSCI RES, V69, P448, DOI 10.1002/jnr.10284	73	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2913	2921		10.1074/jbc.M304850200	http://dx.doi.org/10.1074/jbc.M304850200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14583621	hybrid			2022-12-25	WOS:000188211300071
J	Grechez-Cassiau, A; Panda, S; Lacoche, S; Teboul, M; Azmi, S; Laudet, V; Hogenesch, JB; Taneja, R; Delaunay, F				Grechez-Cassiau, A; Panda, S; Lacoche, S; Teboul, M; Azmi, S; Laudet, V; Hogenesch, JB; Taneja, R; Delaunay, F			The transcriptional repressor STRA13 regulates a subset of peripheral circadian outputs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MOUSE-LIVER; SERUM-FREE; E-BOX; CLOCK; PROTEIN; DEC1; MECHANISM; PACEMAKER; RECEPTOR	Central and peripheral mammalian circadian clocks regulate a variety of behavioral and physiological processes through the rhythmic transcription of hundreds of clock-controlled genes. The circadian expression of many transcriptional regulators suggests that a major part of this circadian gene network is indirectly regulated by clock genes. Here we show that the basic helix-loop-helix transcriptional repressor Stra13 is rhythmically expressed in mouse peripheral organs. The circadian transcription of Stra13 is mediated by a response element recognized by the CLOCK-BMAL1 heterodimer and located in the proximal promoter region. CLOCK-BMAL1-dependent activation of Stra13 is strongly repressed by CRY1 and also by STRA13 itself. To determine putative Stra13 output genes, we performed microarray analyses of differential gene expression in the liver between wild type and Stra13(-/-) mice and identified 42 target genes including a subset of 20 previously known as clock-controlled genes. Importantly, we demonstrate that circadian gene expression of the serum protein insulin-like growth factor-binding protein 1 and of the NKG2D receptor ligand retinoic acid early transcript was suppressed in Stra13(-/-) mice. These biochemical and genetic data establish a role for the basic helix-loop-helix repressor STRA13 as a circadian output regulator in the periphery.	Univ Nice Sophia Antipolis, CNRS, UMR 6078, F-06230 Villefranche Sur Mer, France; Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Mt Sinai Sch Med, Brookdale Dept Mol Cell & Dev Biol, New York, NY 10029 USA; Ecole Normale Super Lyon, CNRS, UMR 5665, F-69364 Lyon, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Novartis; Scripps Research Institute; Icahn School of Medicine at Mount Sinai; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)	Delaunay, F (corresponding author), Univ Nice Sophia Antipolis, CNRS, UMR 6078, 284 Chemin Lazaret, F-06230 Villefranche Sur Mer, France.	delaunay@obs-vlfr.fr	Taneja, Reshma/F-9658-2014; Panda, Satchidananda/J-6891-2012	Taneja, Reshma/0000-0002-2151-2094; Reshma, Taneja/0000-0001-6214-6177; Delaunay, Franck/0000-0003-4927-1701; Teboul, Michele/0000-0002-3418-4384				Akhtar RA, 2002, CURR BIOL, V12, P540, DOI 10.1016/S0960-9822(02)00759-5; Azmi S, 2003, J BIOL CHEM, V278, P20098, DOI 10.1074/jbc.M210427200; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Baxter RC, 2000, AM J PHYSIOL-ENDOC M, V278, pE967, DOI 10.1152/ajpendo.2000.278.6.E967; Bek MJ, 2003, FASEB J, V17, P682, DOI 10.1096/fj.02-0250fje; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Ceriani MF, 2002, J NEUROSCI, V22, P9305, DOI 10.1523/jneurosci.22-21-09305.2002; Cerwenka A, 2000, IMMUNITY, V12, P721, DOI 10.1016/S1074-7613(00)80222-8; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Delaunay F, 2002, TRENDS GENET, V18, P595, DOI 10.1016/S0168-9525(02)02794-4; Diefenbach A, 2002, IMMUNOL REV, V188, P9, DOI 10.1034/j.1600-065X.2002.18802.x; Fraser DJ, 2003, J BIOL CHEM, V278, P39392, DOI 10.1074/jbc.M306148200; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Grundschober C, 2001, J BIOL CHEM, V276, P46751, DOI 10.1074/jbc.M107499200; Haus E, 1999, CHRONOBIOL INT, V16, P581, DOI 10.3109/07420529908998730; Heuck C, 1999, PEDIATR RES, V45, P733, DOI 10.1203/00006450-199905010-00021; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Hsieh CS, 2002, J IMMUNOL, V168, P2618, DOI 10.4049/jimmunol.168.6.2618; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kornmann B, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.11.e51; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lavery DJ, 1999, MOL CELL BIOL, V19, P6488; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; Li YX, 2003, J BIOL CHEM, V278, P16899, DOI 10.1074/jbc.M300596200; Matsuo T, 2003, SCIENCE, V302, P255, DOI 10.1126/science.1086271; McDonald MJ, 2001, CELL, V107, P567, DOI 10.1016/S0092-8674(01)00545-1; McNamara P, 2001, CELL, V105, P877, DOI 10.1016/S0092-8674(01)00401-9; Munoz E, 2002, J BIOL CHEM, V277, P36009, DOI 10.1074/jbc.M203909200; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Panda S, 2002, NATURE, V417, P329, DOI 10.1038/417329a; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Ripperger JA, 2000, GENE DEV, V14, P679; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; SHAPIRO DJ, 1969, BIOCHEM BIOPH RES CO, V37, P867, DOI 10.1016/0006-291X(69)90972-3; Shen M, 2001, EUR J CELL BIOL, V80, P329, DOI 10.1078/0171-9335-00167; Skjaerbaek C, 2000, CLIN ENDOCRINOL, V52, P25, DOI 10.1046/j.1365-2265.2000.00876.x; Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Sun H, 2001, NAT IMMUNOL, V2, P1040, DOI 10.1038/ni721; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Ueda HR, 2002, NATURE, V418, P534, DOI 10.1038/nature00906; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Yagita K, 2000, GENE DEV, V14, P1353; Zawel L, 2002, P NATL ACAD SCI USA, V99, P2848, DOI 10.1073/pnas.261714999	50	66	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1141	1150		10.1074/jbc.M305369200	http://dx.doi.org/10.1074/jbc.M305369200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14581485	hybrid, Green Published			2022-12-25	WOS:000187722800038
J	Korfali, N; Ruchaud, S; Loegering, D; Bernard, D; Dingwall, C; Kaufmann, SH; Earnshaw, WC				Korfali, N; Ruchaud, S; Loegering, D; Bernard, D; Dingwall, C; Kaufmann, SH; Earnshaw, WC			Caspase-7 gene disruption reveals an involvement of the enzyme during the early stages of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-DELTA; CELL-DEATH; CHROMATIN CONDENSATION; POLY(ADP-RIBOSE) POLYMERASE; PHOSPHATIDYLSERINE EXPOSURE; DNA FRAGMENTATION; FODRIN CLEAVAGE; ENDONUCLEASE-G; IN-VITRO; B-CELLS	Caspases play a key role during apoptotic execution. In an attempt to elucidate the specific role of caspase-7 we generated a chicken DT40 cell line in which both alleles of the gene were disrupted. Viability assays showed that caspase-7(-/-) clones are more resistant to the common apoptosis-inducing drugs etoposide and staurosporine. Caspase-7(-/-) cells show a delay in phosphatidylserine externalization and DNA fragmentation as well as cleavage of the caspase substrates poly(ADP-ribose) polymerase 1 and lamins B1 and B2. Caspase affinity labeling and activity assays indicated that deficient cells exhibit a delay in caspase activation compared with wild type DT40 cells, providing an explanation for the differences in apoptotic execution between caspase-7 null and wild type DT40 cells. These results strongly suggest that caspase-7 is involved earlier than other effector caspases in the apoptotic execution process in DT40 B lymphocytes.	Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Mayo Clin, Div Oncol Res, Rochester, MN 55905 USA; Univ Paris 07, Unite Format Rech Biol & Sci Nat, Magistere Genet, F-75005 Paris, France; GlaxoSmithKline, Neurol Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England	University of Edinburgh; Mayo Clinic; UDICE-French Research Universities; Universite Paris Cite; GlaxoSmithKline	Earnshaw, WC (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Swann Bldg,Mayfield Rd, Edinburgh EH9 3JR, Midlothian, Scotland.		Earnshaw, William/AAY-7438-2020; Ruchaud, Sandrine/AAJ-2179-2021	Earnshaw, William/0000-0002-7191-0621; Kaufmann, Scott/0000-0002-4900-7145	NATIONAL CANCER INSTITUTE [R01CA069008] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA069008, R01 CA69008] Funding Source: Medline; Wellcome Trust [073915] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		Allsopp TE, 2000, CELL DEATH DIFFER, V7, P984, DOI 10.1038/sj.cdd.4400733; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bourdon JC, 2002, J CELL BIOL, V158, P235, DOI 10.1083/jcb.200203006; Bras A, 1999, FASEB J, V13, P931, DOI 10.1096/fasebj.13.8.931; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Coelho D, 2000, BRIT J CANCER, V83, P642, DOI 10.1054/bjoc.2000.1322; Creagh EM, 2001, BIOCHEM SOC T, V29, P696, DOI 10.1042/0300-5127:0290696; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; Ferraro-Peyret C, 2002, J IMMUNOL, V169, P4805, DOI 10.4049/jimmunol.169.9.4805; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kottke TJ, 2002, J BIOL CHEM, V277, P804, DOI 10.1074/jbc.M108419200; Kottke TJ, 1999, J BIOL CHEM, V274, P15927, DOI 10.1074/jbc.274.22.15927; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lane JD, 2001, J CELL BIOL, V153, P1415, DOI 10.1083/jcb.153.7.1415; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; Le DA, 2002, P NATL ACAD SCI USA, V99, P15188, DOI 10.1073/pnas.232473399; Le XF, 2001, ONCOGENE, V20, P8258, DOI 10.1038/sj.onc.1205039; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; Mc Gee MM, 2002, FEBS LETT, V515, P66, DOI 10.1016/S0014-5793(02)02440-7; McIlroy D, 1999, ONCOGENE, V18, P4401, DOI 10.1038/sj.onc.1202868; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nitta T, 2001, EXP CELL RES, V265, P174, DOI 10.1006/excr.2001.5177; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Ruchaud S, 2002, EMBO J, V21, P1967, DOI 10.1093/emboj/21.8.1967; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samejima K, 2001, J BIOL CHEM, V276, P45427, DOI 10.1074/jbc.M108844200; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	63	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1030	1039		10.1074/jbc.M306277200	http://dx.doi.org/10.1074/jbc.M306277200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14583630	hybrid			2022-12-25	WOS:000187722800026
J	Loffler, H; Syljuasen, RG; Bartkova, J; Worm, J; Lukas, J; Bartek, J				Loffler, H; Syljuasen, RG; Bartkova, J; Worm, J; Lukas, J; Bartek, J			Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines	ONCOGENE			English	Article						DNA damage; cell cycle checkpoints; Cdc25A; proteolysis; breast cancer	DNA-DAMAGE; S-PHASE; CYCLIN D1; C-MYC; CHECKPOINT; EXPRESSION; PROTEIN; GENE; ATM; OVEREXPRESSION	The rapid cell cycle arrest in response to DNA damage is mediated by degradation of the Cdc25A phosphatase, a proto-oncogene whose mRNA is frequently overexpressed in human tumours. Here, we study the occurrence and mechanisms of Cdc25A deregulation in human breast cancer cell lines. We demonstrate aberrantly elevated Cdc25A protein abundance and phosphatase activity in eight out of 15 cell lines, in some cases resulting in abrogation of the Cdc25A-mediated checkpoint response to ionizing radiation (IR), and this defect correlated with hypersensitivity to IR. Furthermore, we present evidence that deregulation of Cdc25A occurs predominantly on the post-transcriptional level, as overabundant Cdc25A protein was usually not accompanied by adequate mRNA overexpression. Instead, we demonstrate that aberrantly enhanced protein stability is an important mechanism underlying Cdc25A overabundance in a subset of breast cancer cell lines. Given the frequency of this mechanism, we propose that the DNA integrity checkpoint controlling Cdc25A protein stability might be a common target for deregulation in breast cancer.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.		Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Mondesert O, 2002, BIOCHEM BIOPH RES CO, V295, P673, DOI 10.1016/S0006-291X(02)00739-8; Moynahan ME, 2002, ONCOGENE, V21, P8994, DOI 10.1038/sj.onc.1206177; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Nishioka K, 2001, BRIT J CANCER, V85, P412, DOI 10.1054/bjoc.2001.1934; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Sorensen CS, 2000, MOL CELL BIOL, V20, P7613, DOI 10.1128/MCB.20.20.7613-7623.2000; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Tauchi H, 2002, ONCOGENE, V21, P8967, DOI 10.1038/sj.onc.1206136; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wu WG, 1998, CANCER RES, V58, P4082; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	40	36	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8063	8071		10.1038/sj.onc.1206976	http://dx.doi.org/10.1038/sj.onc.1206976			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603247				2022-12-25	WOS:000186403400001
J	Ando, K; Kanazawa, S; Tetsuka, T; Ohta, S; Jiang, X; Tada, T; Kobayashi, M; Matsui, N; Okamoto, T				Ando, K; Kanazawa, S; Tetsuka, T; Ohta, S; Jiang, X; Tada, T; Kobayashi, M; Matsui, N; Okamoto, T			Induction of Notch signaling by tumor necrosis factor in rheumatoid synovial fibroblasts	ONCOGENE			English	Article						rheumatoid arthritis; transformation; notch; Jagged; gene expression; TNF	NF-KAPPA-B; INTRACELLULAR DOMAIN; GENE-EXPRESSION; ARTHRITIS; ALPHA; ACTIVATION; KINASE; MICE; IL-6; SYNOVIOCYTES	Rheumatoid arthritis ( RA) is characterized by progressive inflammation associated with abberrant proliferation of synoviocytes. In order to explore the characteristics of rheumatoid synovial fibroblasts (RSF), we performed the comparative gene expression profile analysis between RSF and normal synovial. broblasts (NSF) upon tumor necrosis factor (TNF) stimulation. As an initial screening for the genes preferentially induced by TNF in RSF compared with NSF, we have adopted a cDNA array containing well-defined sets of genes responsible for cell growth, cell fate determination, and cellular invasiveness. Differentially expressed genes of interest were confirmed using real-time RT-PCR. We found that TNF induced the expression of Notch-1, Notch-4, and Jagged-2 in RSF. The expression of these proteins was detected in the RA synovial tissues. The nucleus of RA synoviocytes showed strong staining with anti-Notch-1 and Notch-4 antibody. TNF induced the nuclear translocation of Notch intracellular domain in RSF, indicating the elicitation of the Notch signaling. Notch-1, Notch-4, and Jagged-2 proteins were also detected in the developing synovium of mouse embryo. Thus, RSF may have re-acquired the primordial phenotype, accounting for the hyperproliferation and aggressive invasiveness, exhibiting tumor-like phenotype.	Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Sch Med, Dept Orthoped, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Sch Nursing, Dept Pathol, Nagoya, Aichi 4678601, Japan	Nagoya City University; Nagoya City University; Nagoya City University	Okamoto, T (corresponding author), Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.							ALVAROGRACIA JM, 1991, J IMMUNOL, V146, P3365; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Constantin A, 2002, ARTHRITIS RHEUM, V46, P1754, DOI 10.1002/art.10336; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fassbender H G, 1980, Verh Dtsch Ges Pathol, V64, P193; FASSBENDER HG, 1983, J PATHOL, V139, P399, DOI 10.1002/path.1711390314; Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092-8674(00)81109-5; Feldmann M, 2001, J CLIN INVEST, V107, P1353, DOI 10.1172/JCI13209; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Jiang RL, 1998, GENE DEV, V12, P1046, DOI 10.1101/gad.12.7.1046; Kajino S, 2000, ONCOGENE, V19, P2233, DOI 10.1038/sj.onc.1203560; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MullerLadner U, 1996, AM J PATHOL, V149, P1607; MULLERLADNER U, 1995, RHEUM DIS CLIN N AM, V21, P675; Nakazawa M, 2001, ARTHRITIS RHEUM-US, V44, P1545, DOI 10.1002/1529-0131(200107)44:7<1545::AID-ART278>3.0.CO;2-Q; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Okamoto T, 1997, CURR TOP CELL REGUL, V35, P149, DOI 10.1016/S0070-2137(97)80006-4; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Sen M, 2002, ARTHRITIS RHEUM, V46, P2867, DOI 10.1002/art.10593; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Suzuki M, 2000, FEBS LETT, V465, P23, DOI 10.1016/S0014-5793(99)01717-2; Uyttendaele H, 2001, P NATL ACAD SCI USA, V98, P5643, DOI 10.1073/pnas.091584598; Watanabe N, 2002, BIOCHEM BIOPH RES CO, V294, P1121, DOI 10.1016/S0006-291X(02)00608-3; Wolfer A, 2001, NAT IMMUNOL, V2, P235, DOI 10.1038/85294; Yamanishi Y, 2002, P NATL ACAD SCI USA, V99, P10025, DOI 10.1073/pnas.152333199; Yoshida S, 1999, INT IMMUNOL, V11, P151, DOI 10.1093/intimm/11.2.151; Yoshida S, 1999, J IMMUNOL, V163, P351	31	93	100	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7796	7803		10.1038/sj.onc.1206965	http://dx.doi.org/10.1038/sj.onc.1206965			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586405				2022-12-25	WOS:000186240200009
J	Nawata, R; Yujiri, T; Nakamura, Y; Ariyoshi, K; Takahashi, T; Sato, Y; Oka, Y; Tanizawa, Y				Nawata, R; Yujiri, T; Nakamura, Y; Ariyoshi, K; Takahashi, T; Sato, Y; Oka, Y; Tanizawa, Y			MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF-kappa B activation	ONCOGENE			English	Article						MEK kinase 1; Bcr-Abl; NF-kappa B	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE; DNA-DAMAGE; GENE DISRUPTION; APOPTOSIS; TRANSFORMATION; EXPRESSION; CELLS; JUN; PROTEIN	Bcr-Abl tyrosine kinase, a chimeric oncoprotein responsible for chronic myelogenous leukemia, constitutively activates several signal transduction pathways that stimulate cell proliferation and prevent apoptosis in hematopoietic cells. The antiapoptotic function of Bcr-Abl is necessary for hematopoietic transformation, and also contributes to leukemogenesis. Herein, we show for the first time that cell transformation induced by Bcr-Abl leads to increased expression and kinase activity of MEK kinase 1 (MEKK1), which acts upstream of the c-Jun N-terminal kinase (JNK), extracellular signal regulated kinase (ERK) and NF-kappaB signaling pathways. Inhibition of MEKK1 activity using a dominant-negative MEKK1 mutant (MEKK1km) diminished the ability of Bcr-Abl to protect cells from genotoxin-induced apoptosis, but had no effect on the proliferation of Bcr-Abl-transformed cells. Expression of MEKK1km also reduced NF-kappaB activation, and inhibited antiapoptotic c-IAP1 and c-IAP2 mRNA expression in response to the genotoxin. By contrast, neither JNK nor ERK activation was affected. These results indicate that MEKK1 is a downstream target of Bcr-Abl, and that the antiapoptotic effect of Bcr-Abl in chronic myelogenous leukemia cells is mediated via the MEKK1-NF-kappaB pathway.	Yamaguchi Univ, Grad Sch Med, Dept Biosignal Anal, Yamaguchi 7558505, Japan; Tohoku Univ, Grad Sch Med, Dept Internal Med, Div Mol Metab & Diabet, Sendai, Miyagi 9808575, Japan	Yamaguchi University; Tohoku University	Yujiri, T (corresponding author), Yamaguchi Univ, Grad Sch Med, Dept Biosignal Anal, 1-1-1 Minami Kogushi, Yamaguchi 7558505, Japan.		Yujiri, Toshiaki/AAY-8150-2020	Yujiri, Toshiaki/0000-0001-6838-3456				Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Burgess GS, 1998, BLOOD, V92, P2450, DOI 10.1182/blood.V92.7.2450.2450_2450_2460; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Dubrez L, 1998, BLOOD, V91, P2415, DOI 10.1182/blood.V91.7.2415.2415_2415_2422; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hirano T, 2002, ONCOGENE, V21, P5923, DOI 10.1038/sj.onc.1205643; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Makin G, 2001, TRENDS CELL BIOL, V11, pS22, DOI 10.1016/S0962-8924(01)82111-5; ODA T, 1994, J BIOL CHEM, V269, P22925; Onishi M, 1996, EXP HEMATOL, V24, P324; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Shuai K, 1996, ONCOGENE, V13, P247; Skorski T, 2002, ONCOGENE, V21, P8591, DOI 10.1038/sj.onc.1206087; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Yujiri T, 2003, J BIOL CHEM, V278, P3846, DOI 10.1074/jbc.M206087200; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	38	36	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7774	7780		10.1038/sj.onc.1206901	http://dx.doi.org/10.1038/sj.onc.1206901			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586403				2022-12-25	WOS:000186240200007
J	Alarcon-Vargas, D; Ronai, Z				Alarcon-Vargas, D; Ronai, Z			c-Jun-NH2 kinase (JNK) contributes to the regulation of c-Myc protein stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; IN-VIVO; PHOSPHORYLATION; DEGRADATION; JUN; UBIQUITINATION; PROTEASOME; TRANSACTIVATION; STABILIZATION; MUTATIONS	In accord with the central role c-Myc plays in control of cell growth and death, the stability of this protein is tightly regulated. Although the NH2-terminal domain of c-Myc has been implicated in the regulation of its stability, c-Myc-S, which lacks this domain, is equally unstable, pointing to the role of additional domains in the regulation of c-Myc stability. Our former studies revealed that amino acids (aa) 127-189 of c-Myc are responsible for stress-induced stability of the c-Myc protein. This region of c-Myc shares homology with the delta domain of c-Jun, which is required for JNK association and subsequent targeting of c-Jun for ubiquitination under non-stressed growth conditions. Here we demonstrate that JNK associates with, and mediates, cMyc ubiquitination and degradation. Addition of JNK increased the degree of c-Myc ubiquitination in in vitro ubiquitination reactions. Increased c-Myc stability following MEKK1/JNK stimuli is abolished upon mutation within the delta-like domain of c-Myc (aa 166-181), as well as deletion of as 127-189. Significantly, inhibition of JNK expression via small interfering RNA increased c-Myc protein expression. Similarly, squelching JNK association with c-Myc by overexpression of a peptide corresponding to as 127-189 of c-Myc increased endogenous c-Myc stability and elevated the fraction of cells within the G(2)/M phase of the cell cycle. In all, these findings point to the contribution of JNK to the regulation of c-Myc protein stability under normal growth conditions.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA.	zeev.ronai@mssm.edu		RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA78419, CA85197] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F31CA085197, R01CA078419] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi S, 2001, MOL CELL BIOL, V21, P4929, DOI 10.1128/MCB.21.15.4929-4937.2001; Alarcon-Vargas D, 2002, ONCOGENE, V21, P4384, DOI 10.1038/sj.onc.1205543; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Bonvini P, 1998, ONCOGENE, V16, P1131, DOI 10.1038/sj.onc.1201625; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chen L, 2000, ARCH BIOCHEM BIOPHYS, V374, P306, DOI 10.1006/abbi.1999.1603; Cheng M, 1999, J BIOL CHEM, V274, P6553, DOI 10.1074/jbc.274.10.6553; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; Gavine PR, 1999, ONCOGENE, V18, P7552, DOI 10.1038/sj.onc.1203102; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002; Henikoff S, 1998, NUCLEIC ACIDS RES, V26, P309, DOI 10.1093/nar/26.1.309; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Kuttler F, 2001, ONCOGENE, V20, P6084, DOI 10.1038/sj.onc.1204827; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; Potter M, 1997, CURR TOP MICROBIOL, V224, P1; PULVERER BJ, 1994, ONCOGENE, V9, P59; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SETH A, 1991, J BIOL CHEM, V266, P23521; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803	44	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					5008	5016		10.1074/jbc.M312054200	http://dx.doi.org/10.1074/jbc.M312054200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14625288	hybrid			2022-12-25	WOS:000188554300127
J	Neid, M; Datta, K; Stephan, S; Khanna, I; Pal, S; Shaw, L; White, M; Mukhopadhyay, D				Neid, M; Datta, K; Stephan, S; Khanna, I; Pal, S; Shaw, L; White, M; Mukhopadhyay, D			Role of insulin receptor substrates and protein kinase C-zeta in vascular permeability factor/vascular endothelial growth factor expression in pancreatic cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PLECKSTRIN HOMOLOGY; SIGNALING PATHWAYS; IGF-IR; ACTIVATION; INDUCTION; CARCINOMA; HYPOXIA; IRS-1	Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF), the critical molecule in tumor angiogenesis, is regulated by different stimuli, such as hypoxia and oncogenes, and also by growth factors. Previously we have shown that in AsPC-1 pancreatic adenocarcinoma cells, insulin-like growth factor receptor (IGF-IR) regulates VPF/VEGF expression. Insulin receptor substrate-1 and -2 (IRS-1 and IRS-2), two major downstream molecules of IGF-1R, are known to be important in the genesis of diabetes. In this study, we have defined a new role of IRS in angiogenesis. Both of the IRS proteins modulate VPF/VEGF expression in pancreatic cancer cells by different mechanistic pathways. The Sp1-dependent VPF/VEGF transcription is regulated mainly by IRS-2. Protein kinase C-zeta (PKC-zeta) plays a central role in VPF/VEGF expression and acts as a switching element. Furthermore, we have also demonstrated that the phosphatidylinositol 3-kinase pathway, but not the Ras pathway, is a downstream event of IRS proteins for VPF/VEGF expression in AsPC-1 cells. Interestingly, like renal cancer cells, in AsPC-1 cells PKC-zeta leads to direct Sp1-dependent VPF/VEGF transcription; in addition, it also promotes a negative feedback loop to IRS-2 that decreases the association of IRS-2/IGF-1R and IRS-2/p85. Taken together, our results show that in AsPC-1 pancreatic carcinoma cells, Sp1-dependent VPF/VEGF transcription is controlled by IGF-1R signaling through IRS-2 proteins and modulated by a negative feedback loop of PKC-zeta to IRS-2. Our data also suggest that IRS proteins, which are known to play crucial roles in IGF-1R signaling, are also important mediators for tumor angiogenesis.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Rochester, MN 55905 USA; Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Biol Sci, Boston, MA 02115 USA; Childrens Hosp, Dept Med, Div Nephrol, Boston, MA 02115 USA	Mayo Clinic; Mayo Clinic; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Mukhopadhyay, D (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Gugg 1401A,200 1st St SW, Rochester, MN 55905 USA.	mukhopadhyay.debabrata@mayo.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070567] Funding Source: NIH RePORTER; NCI NIH HHS [CA7838] Funding Source: Medline; NHLBI NIH HHS [HL70567] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akagi Y, 1998, CANCER RES, V58, P4008; Akeno N, 2002, ENDOCRINOLOGY, V143, P420, DOI 10.1210/en.143.2.420; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; BERGMANN U, 1995, CANCER RES, V55, P2007; Bergmann U, 1996, BIOCHEM BIOPH RES CO, V220, P886, DOI 10.1006/bbrc.1996.0500; Bermont L, 2000, INT J CANCER, V85, P117, DOI 10.1002/(SICI)1097-0215(20000101)85:1<117::AID-IJC21>3.3.CO;2-O; Berra E, 2000, CANCER METAST REV, V19, P139, DOI 10.1023/A:1026506011458; Blakesley VA, 1997, J ENDOCRINOL, V152, P339, DOI 10.1677/joe.0.1520339; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; Chang Q, 2002, CANCER RES, V62, P6035; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Dunn SE, 2000, GROWTH HORM IGF RES, V10, pS41, DOI 10.1016/S1096-6374(00)90020-0; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; FICKLE T, 2000, CANCER RES, V60, P203; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 1996, SCI AM, V275, P150, DOI 10.1038/scientificamerican0996-150; Fujioka T, 2001, EUR J BIOCHEM, V268, P4158, DOI 10.1046/j.1432-1327.2001.02327.x; Giovannone B, 2000, DIABETES-METAB RES, V16, P434, DOI 10.1002/1520-7560(2000)9999:9999<::AID-DMRR159>3.0.CO;2-8; Greene MW, 2002, BIOCHEMISTRY-US, V41, P7082, DOI 10.1021/bi015992f; Jackson JG, 2001, ONCOGENE, V20, P7318, DOI 10.1038/sj.onc.1204920; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; Khandwala HM, 2000, ENDOCR REV, V21, P215, DOI 10.1210/er.21.3.215; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kornmann M, 1998, CANCER RES, V58, P4250; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; Nair PN, 2001, ONCOGENE, V20, P8203, DOI 10.1038/sj.onc.1205044; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pal S, 2001, J BIOL CHEM, V276, P2395, DOI 10.1074/jbc.M007818200; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Punglia RS, 1997, DIABETES, V46, P1619, DOI 10.2337/diabetes.46.10.1619; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Reiss K, 2001, ONCOGENE, V20, P490, DOI 10.1038/sj.onc.1204112; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Schnarr B, 2000, INT J CANCER, V89, P506, DOI 10.1002/1097-0215(20001120)89:6<506::AID-IJC7>3.0.CO;2-F; Seo Y, 2000, CANCER, V88, P2239, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2239::AID-CNCR6>3.0.CO;2-V; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; Shi Q, 2001, CANCER RES, V61, P4143; Shih SC, 1999, J BIOL CHEM, V274, P15407, DOI 10.1074/jbc.274.22.15407; Simpson L, 2001, MOL CELL BIOL, V21, P3947, DOI 10.1128/MCB.21.12.3947-3958.2001; Sohn TA, 2000, SURG ONCOL, V9, P95, DOI 10.1016/S0960-7404(00)00041-4; Tanaka S, 1996, J CLIN INVEST, V98, P2100, DOI 10.1172/JCI119016; TANNO S, 2001, CANCER RES, V61, P689; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Wang JY, 2001, ONCOGENE, V20, P3857, DOI 10.1038/sj.onc.1204532; Warren RS, 1996, J BIOL CHEM, V271, P29483, DOI 10.1074/jbc.271.46.29483; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Woods SA, 2002, NEURO-ONCOLOGY, V4, P242, DOI 10.1093/neuonc/4.4.242; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Zeng HY, 2003, BIOCHEM BIOPH RES CO, V302, P46, DOI 10.1016/S0006-291X(03)00107-4; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Zheng WH, 2000, J BIOL CHEM, V275, P13377, DOI 10.1074/jbc.275.18.13377	60	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					3941	3948		10.1074/jbc.M303975200	http://dx.doi.org/10.1074/jbc.M303975200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14604996	hybrid			2022-12-25	WOS:000188554300007
J	Obsilova, V; Herman, P; Vecer, J; Sulc, M; Teisinger, J; Obsil, T				Obsilova, V; Herman, P; Vecer, J; Sulc, M; Teisinger, J; Obsil, T			14-3-3 zeta C-terminal stretch changes its conformation upon ligand binding and phosphorylation at Thr(232)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIME-RESOLVED FLUORESCENCE; PROTEIN-KINASE-C; BACKBONE DYNAMICS; CRYSTAL-STRUCTURE; IDENTIFICATION; ACTIVATION; SUBSTRATE; COMPLEX; ENTROPY; SITE	14-3-3 proteins are abundant binding proteins involved in many biologically important processes. 14-3-3 proteins bind to other proteins in a phosphorylation-dependent manner and function as scaffold molecules modulating the activity of their binding partners. In this work, we studied the conformational changes of 14-3-3 C-terminal stretch, a region implicated in playing a role in the regulation of 14-3-3. Time-resolved fluorescence and molecular dynamics were used to investigate structural changes of the C-terminal stretch induced by phosphopeptide binding and phosphorylation at Thr(232), a casein kinase I phosphorylation site located within this region. A tryptophan residue placed at position 242 was exploited as an intrinsic fluorescence probe of the C-terminal stretch dynamics. Other tryptophan residues were mutated to phenylalanine. Time-resolved fluorescence measurements revealed that phosphopeptide binding changes the conformation and increases the flexibility of 14-3-3 C-terminal stretch, demonstrating that this region is directly involved in ligand binding. Phosphorylation of 14-3-3 at Thr(232) resulted in inhibition of phosphopeptide binding and suppression of 14-3-3-mediated enhancement of serotonin N-acetyltransferase activity. Time-resolved fluorescence of Trp(242) also revealed that phosphorylation at Thr(232) induces significant changes of the C-terminal stretch conformation. In addition, molecular dynamic simulations suggest that phosphorylation at Thr(232) induces a more extended conformation of 14-3-3 C-terminal stretch and changes its interaction with the rest of the 14-3-3 molecule. These results indicate that the conformation of the C-terminal stretch plays an important role in the regulation of 14-3-3 binding properties.	Acad Sci Czech Republ, Inst Physiol, CR-14220 Prague, Czech Republic; Charles Univ Prague, Fac Sci, Dept Phys & Macromol Chem, Prague 12843, Czech Republic; Charles Univ Prague, Fac Math & Phys, Inst Phys, Prague 12843, Czech Republic; Acad Sci Czech Republ, Inst Microbiol, CR-14220 Prague, Czech Republic	Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Charles University Prague; Charles University Prague; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Obsil, T (corresponding author), Acad Sci Czech Republ, Inst Physiol, Videnska 1083, CR-14220 Prague, Czech Republic.	obsil@natur.cuni.cz	Herman, Petr/A-2626-2008; Obsil, Tomas/B-7142-2012; Sulc, Miroslav/K-1029-2014; Obsilova, Veronika/B-7116-2012; Teisinger, Jan/B-7122-2012	Herman, Petr/0000-0001-6918-2576; Obsil, Tomas/0000-0003-4602-1272; Sulc, Miroslav/0000-0002-2659-0489; Obsilova, Veronika/0000-0003-4887-0323; 				AITKEN A, 1995, MOL CELL BIOCHEM, V149, P41, DOI 10.1007/BF01076562; AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BROCHON JC, 1994, METHOD ENZYMOL, V240, P262; BROCHON JC, 1999, FLUORESCENCE ANISOTR, P33; BRYAN RK, 1990, EUR BIOPHYS J, V18, P165, DOI 10.1007/BF02427376; Chi YH, 2000, J BIOL CHEM, V275, P39444, DOI 10.1074/jbc.M007205200; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Daura X, 1999, ANGEW CHEM INT EDIT, V38, P236, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<236::AID-ANIE236>3.3.CO;2-D; De Angelis J, 1998, J BIOL CHEM, V273, P3045, DOI 10.1074/jbc.273.5.3045; Dubois T, 1997, J BIOL CHEM, V272, P28882, DOI 10.1074/jbc.272.46.28882; Eftink M.R., 2000, TOPICS FLUORESCENCE, P1, DOI DOI 10.1007/0-306-47102-7_1; EFTINK MR, 1990, J PHYS CHEM-US, V94, P3469, DOI 10.1021/j100372a022; Finerty PJ, 2002, J MOL BIOL, V322, P605, DOI 10.1016/S0022-2836(02)00803-3; Forman-Kay JD, 1999, NAT STRUCT BIOL, V6, P1086, DOI 10.1038/70008; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Ganguly S, 2001, P NATL ACAD SCI USA, V98, P8083, DOI 10.1073/pnas.141118798; Graves JD, 1999, PHARMACOL THERAPEUT, V82, P111, DOI 10.1016/S0163-7258(98)00056-4; Hansson T, 1997, J MOL BIOL, V265, P118, DOI 10.1006/jmbi.1996.0716; Harper CC, 2003, J BIOL CHEM, V278, P7897, DOI 10.1074/jbc.M206651200; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; Kohler JJ, 2001, BIOCHEMISTRY-US, V40, P130, DOI 10.1021/bi001881p; Lin K, 1996, SCIENCE, V273, P1539, DOI 10.1126/science.273.5281.1539; LIPARI G, 1980, BIOPHYS J, V30, P489, DOI 10.1016/S0006-3495(80)85109-5; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Megidish T, 1998, J BIOL CHEM, V273, P21834, DOI 10.1074/jbc.273.34.21834; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Powell DW, 2003, MOL CELL BIOL, V23, P5376, DOI 10.1128/MCB.23.15.5376-5387.2003; Rischel C, 1996, J MOL BIOL, V257, P877, DOI 10.1006/jmbi.1996.0208; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Rommel C, 1996, ONCOGENE, V12, P609; Schutkowski M, 1998, BIOCHEMISTRY-US, V37, P5566, DOI 10.1021/bi973060z; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Stultz CM, 2002, J BIOL CHEM, V277, P47653, DOI 10.1074/jbc.M208755200; Truong AB, 2002, PROTEINS, V49, P321, DOI 10.1002/prot.10210; Van der Hoeven PCJ, 2000, BIOCHEM J, V345, P297, DOI 10.1042/0264-6021:3450297; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; VECER J, 1993, REV SCI INSTRUM, V64, P3413, DOI 10.1063/1.1144312; Wurtele M, 2003, EMBO J, V22, P987, DOI 10.1093/emboj/cdg104; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YGUERABIDE J, 1970, J MOL BIOL, V51, P573, DOI 10.1016/0022-2836(70)90009-4; Yu LP, 1996, BIOCHEMISTRY-US, V35, P9661, DOI 10.1021/bi960507f; Zidek L, 1999, NAT STRUCT BIOL, V6, P1118	50	64	66	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4531	4540		10.1074/jbc.M306939200	http://dx.doi.org/10.1074/jbc.M306939200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14613942	hybrid			2022-12-25	WOS:000188554300074
J	Gray, MO; Zhou, HZ; Schafhalter-Zoppoth, I; Zhu, PL; Mochly-Rosen, D; Messing, RO				Gray, MO; Zhou, HZ; Schafhalter-Zoppoth, I; Zhu, PL; Mochly-Rosen, D; Messing, RO			Preservation of base-line hemodynamic function and loss of inducible cardioprotection in adult mice lacking protein kinase C-epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT-HEART; K-ATP CHANNELS; CARDIAC MYOCYTES; PKC-EPSILON; SIGNALING PATHWAY; INFARCT SIZE; MOUSE HEARTS; DELTA-PKC; PROTECTION; ACTIVATION	Signaling pathways involving protein kinase C isozymes are modulators of cardiovascular development and response to injury. Protein kinase Cepsilon activation in cardiac myocytes reduces necrosis caused by coronary artery disease. However, it is unclear whether protein kinase Cepsilon function is required for normal cardiac development or inducible protection against oxidative stress. Protein kinase Cdelta activation is also observed during cardiac preconditioning. However, its role as a promoter or inhibitor of injury is controversial. We examined hearts from protein kinase Cepsilon knock-out mice under physiological conditions and during acute ischemia reperfusion. Null-mutant and wild-type mice displayed equivalent base-line morphology and hemodynamic function. Targeted disruption of the protein kinase Cepsilon gene blocked cardioprotection caused by ischemic preconditioning and alpha(1)-adrenergic receptor stimulation. Protein kinase Cdelta activation increased in protein kinase Cepsilon knock-out myocytes without altering resistance to injury. These observations support protein kinase Cepsilon activation as an essential component of cardioprotective signaling. Our results favor protein kinase Cdelta activation as a mediator of normal growth. This study advances the understanding of cellular mechanisms responsible for preservation of myocardial integrity as potential targets for prevention and treatment of ischemic heart disease.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94110 USA; Univ Calif San Francisco, Ernest Gallo Res Ctr, San Francisco, CA 94110 USA; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; Stanford University	Gray, MO (corresponding author), San Francisco Gen Hosp, Div Cardiol 5G1, 1001 Potrero Ave, San Francisco, CA 94110 USA.	gray@medicine.ucsf.edu	Messing, Robert/D-3642-2015	Messing, Robert/0000-0002-5345-4431; Mochly-Rosen, Daria/0000-0002-6691-8733	NIAAA NIH HHS [5R01AA011135] Funding Source: Medline; NIGMS NIH HHS [5T32GM007546] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA011135] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Burkart EM, 2003, J BIOL CHEM, V278, P11265, DOI 10.1074/jbc.M210712200; Caruso M, 2001, J BIOL CHEM, V276, P45088, DOI 10.1074/jbc.M105451200; Castrillo A, 2001, J EXP MED, V194, P1231, DOI 10.1084/jem.194.9.1231; Chen CH, 1999, P NATL ACAD SCI USA, V96, P12784, DOI 10.1073/pnas.96.22.12784; Chen L, 2001, P NATL ACAD SCI USA, V98, P11114, DOI 10.1073/pnas.191369098; Cohen MV, 1999, AM J PHYSIOL-HEART C, V277, pH1754, DOI 10.1152/ajpheart.1999.277.5.H1754; Cohen MV, 2001, CIRC RES, V89, P273, DOI 10.1161/hh1501.094266; Dorn GW, 2002, ANNU REV PHYSIOL, V64, P407, DOI 10.1146/annurev.physiol.64.081501.155903; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798; Fryer RM, 2001, AM J PHYSIOL-HEART C, V280, pH1346, DOI 10.1152/ajpheart.2001.280.3.H1346; Gerlai R, 1996, TRENDS NEUROSCI, V19, P177, DOI 10.1016/S0166-2236(96)20020-7; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Gustafsson AB, 2002, CIRCULATION, V106, P735, DOI 10.1161/01.CIR.0000023943.50821.F7; Hahn HS, 2002, CIRC RES, V91, P741, DOI 10.1161/01.RES.0000037091.64492.69; Hodge CW, 2002, J CLIN INVEST, V110, P1003, DOI 10.1172/JCI200215903; Huh J, 2001, AM J PHYSIOL-HEART C, V280, pH377, DOI 10.1152/ajpheart.2001.280.1.H377; Jin ZQ, 2002, AM J PHYSIOL-HEART C, V282, pH1970, DOI 10.1152/ajpheart.01029.2001; Kawamura S, 1998, AM J PHYSIOL-HEART C, V275, pH2266; Khasar SG, 1999, NEURON, V24, P253, DOI 10.1016/S0896-6273(00)80837-5; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Kudo M, 2002, AM J PHYSIOL-HEART C, V283, pH296, DOI 10.1152/ajpheart.01087.2001; Lee SK, 1998, J BIOL CHEM, V273, P19829, DOI 10.1074/jbc.273.31.19829; Littler CM, 2003, AM J PHYSIOL-HEART C, V284, pH1321, DOI 10.1152/ajpheart.00795.2002; Maklashina E, 2002, BBA-BIOENERGETICS, V1556, P6, DOI 10.1016/S0005-2728(02)00280-3; MITCHELL MB, 1995, CIRC RES, V76, P73, DOI 10.1161/01.RES.76.1.73; Mochly-Rosen D, 2000, CIRC RES, V86, P1173; Ping PP, 2001, CIRC RES, V88, P59, DOI 10.1161/01.RES.88.1.59; Ping PP, 1999, AM J PHYSIOL-HEART C, V276, pH1468, DOI 10.1152/ajpheart.1999.276.5.H1468; Rokosh DG, 2002, P NATL ACAD SCI USA, V99, P9474, DOI 10.1073/pnas.132552699; Said S, 1998, BIOTECHNIQUES, V25, P522, DOI 10.2144/98253pf02; Salvi S, 2001, CHEST, V119, P1242, DOI 10.1378/chest.119.4.1242; Saurin AT, 2002, CARDIOVASC RES, V55, P672, DOI 10.1016/S0008-6363(02)00325-5; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Silva AJ, 1997, NEURON, V19, P755, DOI 10.1016/S0896-6273(00)80958-7; Soeller C, 1999, CIRC RES, V84, P266, DOI 10.1161/01.RES.84.3.266; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Tsuchimochi H, 2002, AM J PHYSIOL-HEART C, V283, pH1896, DOI 10.1152/ajpheart.00112.2002; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Wu GY, 2000, J BIOL CHEM, V275, P29927, DOI 10.1074/jbc.C000380200; Xi L, 1998, MOL CELL BIOCHEM, V186, P69, DOI 10.1023/A:1006811128561; Yu R, 2000, J BIOL CHEM, V275, P9612, DOI 10.1074/jbc.275.13.9612; Zhao J, 1998, J BIOL CHEM, V273, P23072, DOI 10.1074/jbc.273.36.23072; Zhou HZ, 2002, AM J PHYSIOL-HEART C, V283, pH165, DOI 10.1152/ajpheart.00408.2001; Zhou YY, 2000, AM J PHYSIOL-HEART C, V279, pH429	44	95	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3596	3604		10.1074/jbc.M311459200	http://dx.doi.org/10.1074/jbc.M311459200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14600145	hybrid			2022-12-25	WOS:000188379600057
J	Hernandez, F; Perez, M; Lucas, JJ; Mata, AM; Bhat, R; Avila, J				Hernandez, F; Perez, M; Lucas, JJ; Mata, AM; Bhat, R; Avila, J			Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35 - Implications for Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRONTOTEMPORAL DEMENTIA; PROTEIN-TAU; MICROTUBULE-BINDING; NEURODEGENERATIVE DISORDERS; LIVING CELLS; DNA-BINDING; HEAT-SHOCK; PHOSPHORYLATION; MUTATIONS; 3-BETA	Tauopathies, including Alzheimer's disease, are neurodegenerative disorders in which tau protein accumulates as a consequence of alterations in its metabolism. At least three different types of alterations have been described; in some cases, an aberrant mRNA splicing of tau exon 10 occurs; in other cases, the disorder is a consequence of missense mutations and, in most cases, aberrant tau hyperphosphorylation takes place. Glycogen synthase kinase-3 (GSK-3) has emerged as a key kinase that is able to interact with several proteins involved in the ethiology of Alzheimer's disease and other tauopathies. Here, we have evaluated whether GSK-3 is also able to modulate tau-mRNA splicing. Our data demonstrate that GSK-3 inhibition in cultured neurons affects tau splicing resulting in an increase in tau mRNA containing exon 10. Pre-mRNA splicing is catalyzed by a multimolecular complex including members of the serine/arginine-rich (SR) family of splicing factors. Immunofluorescence studies showed that after GSK-3 inhibition, SC35, a member of the SR family, is redistributed and enriched in nuclear speckles and colocalizes with the kinase. Furthermore, immunoprecipitated SC35 is phosphorylated by recombinant GSK-3beta. Phosphorylation of a peptide from the SR domain by GSK-3 revealed that the peptide needs to be prephosphorylated, suggesting the involvement of a priming kinase. Our results demonstrate that GSK-3 plays a crucial role in tau exon 10 splicing, raising the possibility that GSK3 could contribute to tauopathies via aberrant tau splicing.	Univ Autonoma Madrid, Fac Ciencias, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; AstraZeneca R&D, SE-15185 Sodertalje, Sweden	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); AstraZeneca	Avila, J (corresponding author), Univ Autonoma Madrid, Fac Ciencias, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.	javila@cbm.uam.es	Mar, Perez/Y-2055-2019; Hernandez, Felix/L-2114-2015; Lucas, Jose J./U-6543-2019; Avila, Jesus/I-2610-2015; Mata, Ana M./J-8460-2014	Mar, Perez/0000-0002-8477-9554; Hernandez, Felix/0000-0001-8753-8249; Avila, Jesus/0000-0002-6288-0571; Mata, Ana M./0000-0002-2887-7854; Lucas, Jose J./0000-0003-1597-3916				ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; Arrasate M, 2000, NEUROCHEM RES, V25, P43, DOI 10.1023/A:1007583214722; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Bhat R, 2003, J BIOL CHEM, V278, P45937, DOI 10.1074/jbc.M306268200; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Bijur GN, 2000, J NEUROCHEM, V75, P2401, DOI 10.1046/j.1471-4159.2000.0752401.x; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; D'Souza I, 2000, J BIOL CHEM, V275, P17700, DOI 10.1074/jbc.M909470199; D'Souza I, 2002, J BIOL CHEM, V277, P26587, DOI 10.1074/jbc.M203794200; DEANCOS JG, 1993, J BIOL CHEM, V268, P7976; DEGARCINI EM, 1992, FEBS LETT, V299, P10, DOI 10.1016/0014-5793(92)80088-X; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; Ferrer I, 2002, ACTA NEUROPATHOL, V104, P583, DOI 10.1007/s00401-002-002-0587-8; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; Goedert M, 1996, COLD SPRING HARB SYM, V61, P565; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; Goedert M, 2001, BIOCHEM SOC SYMP, V67, P59, DOI 10.1042/bss0670059; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; Hartmann AM, 2001, MOL CELL NEUROSCI, V18, P80, DOI 10.1006/mcne.2001.1000; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; Heutink P, 2000, HUM MOL GENET, V9, P979, DOI 10.1093/hmg/9.6.979; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; ISHIGURO K, 1993, FEBS LETT, V325, P167, DOI 10.1016/0014-5793(93)81066-9; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KOSIK KS, 1992, SCIENCE, V256, P780, DOI 10.1126/science.1589757; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Lovestone S, 1997, NEUROSCIENCE, V78, P309; Lu M, 2001, MOL BIOL CELL, V12, P171, DOI 10.1091/mbc.12.1.171; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Martin-Aparicio E, 2001, J NEUROSCI, V21, P8772, DOI 10.1523/JNEUROSCI.21-22-08772.2001; Misteli T, 1999, CURR BIOL, V9, pR198, DOI 10.1016/S0960-9822(99)80128-6; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014-5793(97)00688-1; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Rizzu P, 1999, AM J HUM GENET, V64, P414, DOI 10.1086/302256; Ryves WJ, 1998, ANAL BIOCHEM, V264, P124, DOI 10.1006/abio.1998.2832; SCHOENFELD TA, 1994, INT REV CYTOL, V151, P67, DOI 10.1016/S0074-7696(08)62631-5; Shiurba RA, 1996, BRAIN RES, V737, P119, DOI 10.1016/0006-8993(96)00717-2; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Stanford PM, 2003, BRAIN, V126, P814, DOI 10.1093/brain/awg090; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Varani L, 1999, P NATL ACAD SCI USA, V96, P8229, DOI 10.1073/pnas.96.14.8229; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Xavier IJ, 2000, J BIOL CHEM, V275, P29147, DOI 10.1074/jbc.M002169200; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799	64	104	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3801	3806		10.1074/jbc.M311512200	http://dx.doi.org/10.1074/jbc.M311512200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14602710	hybrid, Green Published			2022-12-25	WOS:000188379600082
J	Guillot, L; Medjane, S; Le-Barillec, K; Balloy, V; Danel, C; Chignard, M; Si-Tahar, M				Guillot, L; Medjane, S; Le-Barillec, K; Balloy, V; Danel, C; Chignard, M; Si-Tahar, M			Response of human pulmonary epithelial cells to lipopolysaccharide involves Toll-like receptor 4 (TLR4)-dependent signaling pathways - Evidence for an intracellular compartmentalization of TLR4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVASIVE SHIGELLA-FLEXNERI; NF-KAPPA-B; BACTERIAL LIPOPOLYSACCHARIDE; INTESTINAL EPITHELIUM; GOLGI-APPARATUS; GENE-EXPRESSION; ACTIVATION; ENDOTOXIN; LPS; TRANSDUCTION	Pulmonary epithelial cells are continuously exposed to microbial challenges as a result of breathing. It is recognized that immune myeloid cells express Toll-like receptors (TLRs), which play a major role in detecting microbes and initiating innate immune responses. In contrast, little is known concerning the expression of TLR in pulmonary epithelial cells per se, their distribution within the cell, their function, and the signaling pathways involved. In this work, we demonstrated by reverse transcription-PCR and/or immunoblot that TLR4 and the accessory molecule MD-2 are constitutively expressed in distinct human alveolar and bronchial epithelial cells. We further characterized by flow cytometry, biotinylation/precipitation, and confocal microscopy the intracellular localization of TLR4 in these cells. Despite this intracellular compartmentalization of TLR4, pulmonary epithelial cells were responsive to the TLR4 activator lipopolysaccharide (LPS), a potent Gram-negative bacteria-associated molecular pattern. Using respiratory epithelial cells isolated from TLR4 knock-out and wild type mice, we demonstrated that TLR4 is the actual activating receptor for LPS in these cells. Furthermore we showed that this cell response to LPS involves a signaling complex including the kinases interleukin-1 receptor-associated kinase (IRAK), p38, Jnk, and ERK1/2. Moreover, using vectors expressing dominant-negative forms of MyD88 and TRAF6, we established that LPS-induced activation of respiratory epithelial cells is largely dependent on TLR4 signaling intermediates. Altogether these data demonstrate that TLR4 is a key element in the response of pulmonary epithelial cells to molecules derived from Gram-negative bacteria. The intracellular localization of TLR4 in lung epithelia is expected to play an important role in the prevention of the development of chronic inflammatory disease.	Inst Pasteur, INSERM, Unite Def Innee & Inflammat, F-75015 Paris, France; Inst Pasteur, INSERM, Unite Cytokines & Dev Lymphoide, F-75015 Paris, France; Hop Europeen Georges Pompidou, Dept Anat Pathol, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Si-Tahar, M (corresponding author), Inst Pasteur, INSERM, Unite Def Innee & Inflammat, E336,25 Rue Dr Roux, F-75015 Paris, France.	sitahar@pasteur.fr	Guillot, Loic/D-8893-2011; SI-TAHAR, Mustapha/L-4149-2014; Si-Tahar, Mustapha/W-8034-2019; Balloy, Viviane/B-8551-2014; Chignard, Michel/B-4351-2008	Guillot, Loic/0000-0001-6853-7945; SI-TAHAR, Mustapha/0000-0002-5792-7742; Si-Tahar, Mustapha/0000-0002-5792-7742; Balloy, Viviane/0000-0001-9093-9676; Chignard, Michel/0000-0003-3810-6575				Abreu MT, 2002, J BIOL CHEM, V277, P20431, DOI 10.1074/jbc.M110333200; Barton GM, 2002, CURR TOP MICROBIOL, V270, P81; Becker MN, 2000, J BIOL CHEM, V275, P29731, DOI 10.1074/jbc.M000184200; Beutler B, 2002, CURR TOP MICROBIOL, V270, P109; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Cario E, 2002, AM J PATHOL, V160, P165, DOI 10.1016/S0002-9440(10)64360-X; Cario E, 2000, J IMMUNOL, V164, P966, DOI 10.4049/jimmunol.164.2.966; Chung JY, 2002, J CELL SCI, V115, P679; COOPERSTOCK MS, 1974, ANTIMICROB AGENTS CH, V6, P422, DOI 10.1128/AAC.6.4.422; Corti M, 1996, AM J RESP CELL MOL, V14, P309, DOI 10.1165/ajrcmb.14.4.8600933; Detmers PA, 1996, J IMMUNOL, V157, P5589; Diamond G, 2000, IMMUNOL REV, V173, P27, DOI 10.1034/j.1600-065X.2000.917304.x; Drapkin PT, 2000, J CLIN INVEST, V105, P589, DOI 10.1172/JCI8858; Fenton MJ, 1998, J LEUKOCYTE BIOL, V64, P25, DOI 10.1002/jlb.64.1.25; Foster WM, 2002, PULM PHARMACOL THER, V15, P277, DOI 10.1006/pupt.2002.0351; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Hedlund M, 2001, MOL MICROBIOL, V39, P542, DOI 10.1046/j.1365-2958.2001.02205.x; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Hornef MW, 2002, J EXP MED, V195, P559, DOI 10.1084/jem.20011788; Hume D A, 2001, BMC Immunol, V2, P11, DOI 10.1186/1471-2172-2-11; Koyama S, 2000, AM J PHYSIOL-LUNG C, V278, pL658, DOI 10.1152/ajplung.2000.278.4.L658; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; LEMNAOUAR M, 1993, EUR J CLIN INVEST, V23, P151, DOI 10.1111/j.1365-2362.1993.tb00754.x; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Naik S, 2001, J PEDIATR GASTR NUTR, V32, P449, DOI 10.1097/00005176-200104000-00011; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Philpott DJ, 2000, J IMMUNOL, V165, P903, DOI 10.4049/jimmunol.165.2.903; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; Rehli M, 2002, TRENDS IMMUNOL, V23, P375, DOI 10.1016/S1471-4906(02)02259-7; Schulz C, 2002, SCAND J IMMUNOL, V56, P294, DOI 10.1046/j.1365-3083.2002.01137.x; Simpson JCG, 1999, ANN OCCUP HYG, V43, P107, DOI 10.1093/annhyg/43.2.107; Takeda K, 2001, GENES CELLS, V6, P733, DOI 10.1046/j.1365-2443.2001.00458.x; Takeuchi O, 2002, CURR TOP MICROBIOL, V270, P155; Thieblemont N, 1998, IMMUNITY, V8, P771, DOI 10.1016/S1074-7613(00)80582-8; Uehara A, 2001, MED MICROBIOL IMMUN, V189, P185, DOI 10.1007/s004300100063; Vasselon T, 1999, J EXP MED, V190, P509, DOI 10.1084/jem.190.4.509; Wolfs TGAM, 2002, J IMMUNOL, V168, P1286, DOI 10.4049/jimmunol.168.3.1286; Wyllie DH, 2000, J IMMUNOL, V165, P7125, DOI 10.4049/jimmunol.165.12.7125; Zarember KA, 2002, J IMMUNOL, V168, P554, DOI 10.4049/jimmunol.168.2.554; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	41	294	306	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2712	2718		10.1074/jbc.M305790200	http://dx.doi.org/10.1074/jbc.M305790200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14600154	hybrid			2022-12-25	WOS:000188211300048
J	Hoshi, H; Nakagawa, H; Nishiguchi, S; Iwata, K; Niikura, K; Monde, K; Nishimura, SI				Hoshi, H; Nakagawa, H; Nishiguchi, S; Iwata, K; Niikura, K; Monde, K; Nishimura, SI			An engineered hyaluronan synthase - Characterization of recombinant human hyaluronan synthase 2 expressed in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATED TERATOCARCINOMA CELLS; PASTEURELLA-MULTOCIDA; MOLECULAR-CLONING; STREPTOCOCCUS-PYOGENES; IN-VITRO; PROTEIN; ACID; CDNA; IDENTIFICATION; GENE	The Class I hyaluronan synthase ( HAS) is a unique glycosyltransferase synthesizing hyaluronan ( HA), a polysaccharide composed of GlcUA and GlcNAc, by using one catalytic domain that elongates two different monosaccharides. As for the synthetic mechanism, there are two alternative manners for the sugar elongation process. Some bacterial HASs add new sugars to the non-reducing end of the acceptor to grow polymers. On the other hand, some vertebrate enzymes seem to transfer sugars to the reducing end. Expression of vertebrate HASs as active and soluble proteins will accelerate further precise insight into mechanisms of sugar elongation reactions by natural HASs. Since large scale production of HA polymers and oligomers would become powerful tools both for basic studies and new biotechnology to create functional carbohydrates in medicinal purposes, advent of an efficient method for the expression of HASs in Escherichia coli is strongly expected. Here we communicate the first success of the production of recombinant human HAS2 proteins composed of only the catalytic region in E. coli as the active form. It was demonstrated that an engineered HAS2 expressed in E. coli exhibited significant activity to synthesize a mixture of HAS oligomers from 8-mer (HA8) to 16-mer (HA16). Engineered HAS2 prepared herein elongated sugars from exogenous tetrasaccharide to form polymers with a direction to the non-reducing end. According to the present results, large scale production of engineered recombinant HASs is to be performed using E. coli that will provide practical and economic advantages in manufacturing enzymes for use in the synthesis of various oligomeric HA molecules and their industrial applications.	Hokkaido Univ, Grad Sch Sci, Div Biol Sci,Frontier Res Ctr Postgenom Sci & Tech, Lab Biomacromol Chem,Kita Ku, Sapporo, Hokkaido 0010021, Japan; Hokkaido Univ, Japan Bioind Assoc, Sapporo Lab Glycocluster Project, Sapporo, Hokkaido 0010021, Japan; Natl Inst Adv Ind Sci & Technol Res AIST, Res Ctr Glycosci, Glycochemosynth Team, Sapporo, Hokkaido 0628517, Japan	Hokkaido University; Hokkaido University; National Institute of Advanced Industrial Science & Technology (AIST)	Nishimura, SI (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Biol Sci,Frontier Res Ctr Postgenom Sci & Tech, Lab Biomacromol Chem,Kita Ku, N21,W11, Sapporo, Hokkaido 0010021, Japan.	shin@glyco.sci.hokudai.ac.jp	Nishimura, Shinichiro/F-5277-2011; Monde, Kenji/F-5286-2011	Monde, Kenji/0000-0002-1424-1054				Asplund T, 1998, BBA-GEN SUBJECTS, V1380, P377, DOI 10.1016/S0304-4165(98)00010-5; DeAngelis PL, 1999, CELL MOL LIFE SCI, V56, P670, DOI 10.1007/s000180050461; DeAngelis PL, 1998, J BIOL CHEM, V273, P8454, DOI 10.1074/jbc.273.14.8454; Deangelis PL, 2003, J BIOL CHEM, V278, P35199, DOI 10.1074/jbc.M306431200; DeAngelis PL, 1999, J BIOL CHEM, V274, P26557, DOI 10.1074/jbc.274.37.26557; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; DeAngelis PL, 1996, BIOCHEMISTRY-US, V35, P9768, DOI 10.1021/bi960154k; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; Heldermon C, 2001, J BIOL CHEM, V276, P2037, DOI 10.1074/jbc.M002276200; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; Jing W, 2000, GLYCOBIOLOGY, V10, P883, DOI 10.1093/glycob/10.9.883; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Nickel V, 1998, J BIOL CHEM, V273, P23668, DOI 10.1074/jbc.273.37.23668; Nishimura S, 1997, J AM CHEM SOC, V119, P10555, DOI 10.1021/ja971786c; Nishimura S, 2001, CURR OPIN CHEM BIOL, V5, P325, DOI 10.1016/S1367-5931(00)00209-X; Ohno S, 2001, BBA-GENE STRUCT EXPR, V1520, P71, DOI 10.1016/S0167-4781(01)00256-1; PREHM P, 1983, BIOCHEM J, V211, P181, DOI 10.1042/bj2110181; PREHM P, 1983, BIOCHEM J, V211, P191, DOI 10.1042/bj2110191; Pummill PE, 2001, J BIOL CHEM, V276, P39832, DOI 10.1074/jbc.M105489200; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Spicer AP, 1997, J BIOL CHEM, V272, P8957; STOOLMILLER AC, 1969, J BIOL CHEM, V244, P236; TAYLOR KA, 1992, ANAL BIOCHEM, V201, P190, DOI 10.1016/0003-2697(92)90194-C; Tlapak-Simmons VL, 1998, J BIOL CHEM, V273, P26100, DOI 10.1074/jbc.273.40.26100; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4239, DOI 10.1074/jbc.274.7.4239; Toda A, 2002, ADV SYNTH CATAL, V344, P61; UEJIMA T, 1992, CANCER RES, V52, P6158; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Yanagidani S, 1997, J BIOCHEM-TOKYO, V121, P626; Yoshida M, 2000, J BIOL CHEM, V275, P497, DOI 10.1074/jbc.275.1.497	34	15	16	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2341	2349		10.1074/jbc.M305723200	http://dx.doi.org/10.1074/jbc.M305723200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14583625	hybrid			2022-12-25	WOS:000188211300004
J	Inoue, Y; Yu, AM; Inoue, J; Gonzalez, FJ				Inoue, Y; Yu, AM; Inoue, J; Gonzalez, FJ			Hepatocyte nuclear factor 4 alpha is a central regulator of bile acid conjugation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA SYNTHETASE; N-ACYLTRANSFERASE; MOLECULAR-CLONING; SALT TRANSPORTERS; GENE-EXPRESSION; HNF4-ALPHA; PROMOTER; LIGASE	Hepatocyte nuclear factor 4alpha (HNF4alpha) has an important role in regulating the expression of liver-specific genes. Because bile acids are produced from cholesterol in liver and many enzymes involved in their biosynthesis are preferentially expressed in liver, the role of HNF4alpha in the regulation of bile acid production was examined. In mice, unconjugated bile acids are conjugated with taurine by the liver-specific enzymes, bile acid-CoA ligase and bile acid-CoA: amino acid N-acyl-transferase ( BAT). Mice lacking hepatic HNF4alpha expression exhibited markedly decreased expression of the very long chain acyl-CoA synthase-related gene ( VLACSR), a mouse candidate for bile acid-CoA ligase, and BAT. This was associated with markedly elevated levels of unconjugated and glycine-conjugated bile acids in gallbladder. HNF4alpha was found to bind directly to the mouse VLACSR and BAT gene promoters, and the promoter activities were dependent on HNF4alpha-binding sites and HNF4alpha expression. In conclusion, HNF4alpha plays a central role in bile acid conjugation by direct regulation of VLACSR and BAT in vivo.	NCI, Lab Metab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gonzalez, FJ (corresponding author), NCI, Lab Metab, Ctr Canc Res, NIH, 9000 Rockville Pike,Bldg 37,Rm 3106, Bethesda, MD 20892 USA.	fjgonz@helix.nih.gov	Inoue, Yusuke/O-6207-2018	Inoue, Yusuke/0000-0002-9710-7482; Yu, Aiming/0000-0003-1441-4012				[Anonymous], 2001, NUCL RECEPTORS GENET; Bahar RJ, 1999, GASTROENTEROL CLIN N, V28, P27, DOI 10.1016/S0889-8553(05)70042-X; Berger J, 1998, BIOCHEM BIOPH RES CO, V247, P255, DOI 10.1006/bbrc.1998.8770; Bjorkhem I, 2001, CURR OPIN LIPIDOL, V12, P97, DOI 10.1097/00041433-200104000-00002; CAPOCACCIA L, 1981, DIGEST DIS SCI, V26, P513, DOI 10.1007/BF01308099; Carlton VEH, 2003, NAT GENET, V34, P91, DOI 10.1038/ng1147; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; Falany CN, 2002, J LIPID RES, V43, P2062, DOI 10.1194/jlr.M200260-JLR200; FALANY CN, 1994, J BIOL CHEM, V269, P19375; Falany CN, 1997, J LIPID RES, V38, P1139; FURUTANI M, 1995, BIOCHEM J, V311, P203, DOI 10.1042/bj3110203; Garuti R, 2002, GENE, V283, P133, DOI 10.1016/S0378-1119(01)00874-5; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Inoue Y, 2002, J BIOL CHEM, V277, P25257, DOI 10.1074/jbc.M203126200; Kardassis D, 2002, BIOCHEMISTRY-US, V41, P1217, DOI 10.1021/bi015618f; Meier PJ, 2002, ANNU REV PHYSIOL, V64, P635, DOI 10.1146/annurev.physiol.64.082201.100300; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; Pircher PC, 2003, J BIOL CHEM, V278, P27703, DOI 10.1074/jbc.M302128200; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Schrem H, 2002, PHARMACOL REV, V54, P129, DOI 10.1124/pr.54.1.129; St-Pierre MV, 2001, J EXP BIOL, V204, P1673; Steinberg SJ, 2000, J BIOL CHEM, V275, P15605, DOI 10.1074/jbc.C000015200; Tirona RG, 2003, NAT MED, V9, P220, DOI 10.1038/nm815; Trauner M, 2003, PHYSIOL REV, V83, P633, DOI 10.1152/physrev.00027.2002; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8; Wang DQH, 1999, AM J PHYSIOL-GASTR L, V276, pG751, DOI 10.1152/ajpgi.1999.276.3.G751	26	73	74	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2480	2489		10.1074/jbc.M311015200	http://dx.doi.org/10.1074/jbc.M311015200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14583614	hybrid			2022-12-25	WOS:000188211300019
J	James, ES; Cronan, JE				James, ES; Cronan, JE			Expression of two Escherichia coli acetyl-CoA carboxylase subunits is autoregulated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; ACYL CARRIER PROTEIN; FATTY-ACID SYNTHESIS; BIOTIN HOLOENZYME SYNTHETASE; OPERON ENCODING SUBUNITS; GROWTH-RATE REGULATION; BACILLUS-SUBTILIS; PHOSPHOLIPID-SYNTHESIS; FIRST ENZYME; BIRA GENE	Acetyl-CoA carboxylase (ACC) catalyzes the first step of fatty acid biosynthesis, the synthesis of malonyl-CoA from acetyl-CoA using ATP and bicarbonate. In Escherichia coli and most other bacteria, ACC is composed of four subunits encoded by accA, accB, accC, and accD. Prior work from this laboratory showed that the in vivo expression of the accBC operon had a strikingly nonlinear response to gene copy number (Li, S.- J, and Cronan, J. E., Jr. ( 1993) J. Bacteriol. 175, 332 - 340) in that the presence of 50 or more copies of the accBC operon resulted in only a 2-3-fold increase in AccB and AccC. We now report that AccB functions to negatively regulate transcription of the accBC operon. Expression of a chimeric protein consisting of the N terminus of E. coli AccB and the C-terminal bioinylation domain of Bacillus subtilis AccB down-regulated transcription of the E. coli accBC operon. A truncated form of AccB consisting of the N-terminal 68 amino acids of E. coli AccB was sufficient to negatively regulate the accBC operon. In vivo bypass of acetyl-CoA carboxylase activity by expression of a malonyl-CoA synthase from Rhizobium trifolii allowed construction of strain deleted for the accA and accB genes. Unexpectedly, the DeltaaccB mutation could not be resolved from the DeltaaccA mutation. Transcription of the accBC operon in the DeltaaccB DeltaaccA strain continued well into stationary phase under growth conditions that normally result in greatly decreased transcription. These data support a model in which AccB acts as an autoregulator of accBC operon transcription.	Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Cronan, JE (corresponding author), Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, 601 S Goodwin Ave, Urbana, IL 61801 USA.	j-cronan@life.uiuc.edu	Cronan, John/V-6626-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015650, R37AI015650] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15650] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADHYA S, 1968, P NATL ACAD SCI USA, V61, P956, DOI 10.1073/pnas.61.3.956; ALIX JH, 1989, DNA-J MOLEC CELL BIO, V8, P779, DOI 10.1089/dna.1989.8.779; BARKER DF, 1981, J MOL BIOL, V146, P451, DOI 10.1016/0022-2836(81)90042-5; BARKER DF, 1981, J MOL BIOL, V146, P469, DOI 10.1016/0022-2836(81)90043-7; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P881, DOI 10.1042/bj3020881; Choi-Rhee E, 2003, J BIOL CHEM, V278, P30806, DOI 10.1074/jbc.M302507200; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; Cronan JE, 2002, PROG LIPID RES, V41, P407, DOI 10.1016/S0163-7827(02)00007-3; CRONAN JE, 1989, CELL, V58, P427, DOI 10.1016/0092-8674(89)90421-2; Cronan JE, 2001, J BIOL CHEM, V276, P37355, DOI 10.1074/jbc.M106353200; CRONAN JE, 1988, J BIOL CHEM, V263, P10332; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Davis MS, 2000, J BIOL CHEM, V275, P28593, DOI 10.1074/jbc.M004756200; Davis MS, 2001, J BACTERIOL, V183, P1499, DOI 10.1128/JB.183.4.1499-1503.2001; Dennis JJ, 1998, APPL ENVIRON MICROB, V64, P2710; FALL RR, 1972, J BIOL CHEM, V247, P8005; FALL RR, 1971, P NATL ACAD SCI USA, V68, P1512, DOI 10.1073/pnas.68.7.1512; HEATH RJ, 1994, J BIOL CHEM, V269, P26584; Heath RJ, 1996, J BIOL CHEM, V271, P1833, DOI 10.1074/jbc.271.4.1833; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; JACKOWSKI S, 1991, BIOCH LIPIDS LIPOPRO, P43; JIANG P, 1994, J BACTERIOL, V176, P2814, DOI 10.1128/JB.176.10.2814-2821.1994; KORNBLUM JS, 1988, GENE, V63, P75, DOI 10.1016/0378-1119(88)90547-1; LI SJ, 1992, J BIOL CHEM, V267, P855; LI SJ, 1993, J BACTERIOL, V175, P332, DOI 10.1128/JB.175.2.332-340.1993; Lombo F, 2001, BIOTECHNOL PROGR, V17, P612, DOI 10.1021/bp010045j; MARINI P, 1995, J BACTERIOL, V177, P7003, DOI 10.1128/jb.177.23.7003-7006.1995; Marini PE, 2001, ARCH MICROBIOL, V175, P234, DOI 10.1007/s002030100256; Nenortas E, 1996, J BIOL CHEM, V271, P7559, DOI 10.1074/jbc.271.13.7559; Perez CA, 1998, MICROBIOL-SGM, V144, P895, DOI 10.1099/00221287-144-4-895; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; Snel B, 2002, P NATL ACAD SCI USA, V99, P5890, DOI 10.1073/pnas.092632599; VANDYK TK, 1994, APPL ENVIRON MICROB, V60, P1414, DOI 10.1128/AEM.60.5.1414-1420.1994; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597	35	46	79	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2520	2527		10.1074/jbc.M311584200	http://dx.doi.org/10.1074/jbc.M311584200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14594796	hybrid			2022-12-25	WOS:000188211300024
J	Gustin, JA; Ozes, ON; Akca, H; Pincheira, R; Mayo, LD; Li, QT; Guzman, JR; Korgaonkar, CK; Donner, DB				Gustin, JA; Ozes, ON; Akca, H; Pincheira, R; Mayo, LD; Li, QT; Guzman, JR; Korgaonkar, CK; Donner, DB			Cell type-specific expression of the I kappa B kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; UBIQUITIN-PROTEASOME PATHWAY; IKK-ALPHA; MICE LACKING; PHOSPHOINOSITIDE 3-KINASE; INDUCED PHOSPHORYLATION; TRANSCRIPTION FACTOR; LIVER DEGENERATION; BETA; AKT	Phosphatidylinositol (PI) 3-kinase/Akt signaling activates NF-kappaB through pleiotropic, cell type-specific mechanisms. This study investigated the significance of PI 3-kinase/Akt signaling to tumor necrosis factor (TNF)-induced NF-kappaB activation in transformed, immortalized, and primary cells. Pharmacological inhibition of PI 3-kinase blocked TNF-induced NF-kappaB DNA binding in the 293 line of embryonic kidney cells, partially affected binding in MCF-7 breast cancer cells, HeLa and ME-180 cervical carcinoma cells, and NIH 3T3 cells but was without significant effect in H1299 and human umbilical vein endothelial cells, cell types in which TNF activated Akt. NF-kappaB is retained in the cytoplasm by inhibitory proteins, IkappaBs, which are phosphorylated and targeted for degradation by IkappaB kinases (IKKalpha and IKKbeta). Expression and the ratios of IKKalpha and IKKbeta, which homo- and heterodimerize, varied among cell types. Cells with a high proportion of IKKalpha ( the IKK kinase activated by Akt) to IKKbeta were most sensitive to PI 3-kinase inhibitors. Consequently, transient expression of IKKbeta diminished the capacity of the inhibitors to block NF-kappaB DNA binding in 293 cells. Also, inhibitors of PI 3-kinase blocked NF-kappaB DNA binding in Ikkbeta-/- but not Ikkalpha-/- or wild-type cells in which the ratio of IKKalpha to IKKbeta is low. Thus, noncoordinate expression of IkappaB kinases plays a role in determining the cell type-specific role of Akt in NF-kappaB activation.	Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46208 USA; Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Salk Institute	Donner, DB (corresponding author), Indiana Univ, Sch Med, Walther Oncol Ctr, 950 W Walnut St, Indianapolis, IN 46202 USA.	ddonner@iupui.edu		Rivera Guzman, Javier/0000-0001-9004-6739; Pincheira, Roxana/0000-0003-4277-5245	NATIONAL CANCER INSTITUTE [R55CA067891, R01CA073023, R01CA067891] Funding Source: NIH RePORTER; NCI NIH HHS [CA 73023, CA 67891] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andjelic S, 2000, J IMMUNOL, V165, P3860, DOI 10.4049/jimmunol.165.7.3860; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gustin JA, 2001, J BIOL CHEM, V276, P27740, DOI 10.1074/jbc.M102559200; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Kane LP, 2002, MOL CELL BIOL, V22, P5962, DOI 10.1128/MCB.22.16.5962-5974.2002; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2000, Tanpakushitsu Kakusan Koso, V45, P2405; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Manna SK, 2000, FEBS LETT, V473, P113, DOI 10.1016/S0014-5793(00)01501-5; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Ozes ON, 1999, NATURE, V401, P82; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Traenckner EBM, 1995, J CELL SCI, P79; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	71	164	186	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1615	1620		10.1074/jbc.M306976200	http://dx.doi.org/10.1074/jbc.M306976200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14585846	hybrid			2022-12-25	WOS:000188005700008
J	Watanabe, H; Shimizu, T; Nishihira, J; Abe, R; Nakayama, T; Taniguchi, M; Sabe, H; Ishibashi, T; Shimizu, H				Watanabe, H; Shimizu, T; Nishihira, J; Abe, R; Nakayama, T; Taniguchi, M; Sabe, H; Ishibashi, T; Shimizu, H			Ultraviolet A-induced production of matrix metalloproteinase-1 is mediated by macrophage migration inhibitory factor (MIF) in human dermal fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; IMMUNOHISTOCHEMICAL LOCALIZATION; CELL-GROWTH; RAT-BRAIN; IN-VITRO; EXPRESSION; COLLAGENASE; CYTOKINE; SKIN; GENE	Matrix metalloproteinases ( MMPs) are thought to be responsible for dermal photoaging in human skin. In the present study, we evaluated the involvement of macrophage migration inhibitory factor (MIF) in MMP-1 expression under ultraviolet A (UVA) irradiation in cultured human dermal fibroblasts. UVA ( 20 J/cm(2)) up-regulates MIF production, and UVA-induced MMP-1 mRNA production is inhibited by an anti-MIF antibody. MIF ( 100 ng/ml) was shown to induce MMP-1 in cultured human dermal fibroblasts. We found that MIF ( 100 ng/ml) enhanced MMP-1 activity in cultured fibroblasts assessed by zymography. Moreover, we observed that fibroblasts obtained from MIF-deficient mice were much less sensitive to UVA regarding MMP-13 expression than those from wild-type BALB/c mice. Furthermore, after UVA irradiation ( 10 J/cm(2)), dermal fibroblasts of MIF-deficient mice produced significantly decreased levels of MMP-13 compared with fibroblasts of wild-type mice. Next we investigated the signal transduction pathway of MIF. The up-regulation of MMP-1 mRNA by MIF stimulation was found to be inhibited by a PKC inhibitor (GF109203X), a Src-family tyrosine kinase inhibitor ( herbimycin A), a tyrosine kinase inhibitor ( genistein), a PKA inhibitor (H89), a MEK inhibitor (PD98089), and a JNK inhibitor (SP600125). In contrast, the p38 inhibitor (SB203580) was found to have little effect on expression of MMP-1 mRNA. We found that PKC-pan, PKCalpha/betaII, PKCdelta (Thr505), PKCdelta (Ser(643)), Raf, and MAPK were phosphorylated by MIF. Moreover, we demonstrated that phosphorylation of PKCalpha/betaII and MAPK in response to MIF was suppressed by genistein, and herbimycin A as well as by transfection of the plasmid of C-terminal Src kinase. The DNA binding activity of AP-1 was significantly up-regulated 2 h after MIF stimulation. Taken together, these results suggest that MIF is involved in the up-regulation of UVA-induced MMP-1 in dermal fibroblasts through PKC-, PKA-, Src family tyrosine kinase, MAPK-,c-Jun-, and AP-1-dependent pathways.	Hokkaido Univ, Grad Sch Med, Dept Dermatol, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Grad Sch Med, Dept Mol Biochem, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Chiba Univ, Grad Sch Med, Dept Med Immunol, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Mol Immunol, Chuo Ku, Chiba 2608670, Japan; RIKEN, Res Ctr Allergy & Immunol, Lab Immune Regulat, Yokohama, Kanagawa 2300045, Japan; Osaka Biosci Inst, Dept Mol Biol, Osaka 5650874, Japan	Hokkaido University; Hokkaido University; Chiba University; Chiba University; RIKEN	Shimizu, H (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Dermatol, Kita Ku, Sapporo, Hokkaido 0608638, Japan.	shimizu@med.hokudai.ac.jp	Shimizu, Hiroshi/A-5193-2012; Sabe, Hisataka/GPF-4385-2022; Abe, Riichiro/A-5450-2012; Nakayama, Toshinori/E-1067-2017; Sabe, Hisataka/A-4066-2012	Nakayama, Toshinori/0000-0002-1434-2007; Shimizu, Tadamichi/0000-0002-3231-0279				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Alexander JP, 2001, INVEST OPHTH VIS SCI, V42, P2831; Bacher M, 1998, MOL MED, V4, P217, DOI 10.1007/BF03401919; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Brauchle M, 2000, EXP CELL RES, V258, P135, DOI 10.1006/excr.2000.4913; Brenneisen P, 1996, PHOTOCHEM PHOTOBIOL, V64, P877, DOI 10.1111/j.1751-1097.1996.tb01851.x; Bucala R, 1996, FASEB J, V10, P1607, DOI 10.1096/fasebj.10.14.9002552; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Choi SW, 1998, J DERMATOL SCI, V18, P54; CHURCHILL WH, 1975, J IMMUNOL, V115, P781; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Fisher GJ, 1997, NEW ENGL J MED, V337, P1419, DOI 10.1056/NEJM199711133372003; Herrmann G, 1993, Exp Dermatol, V2, P92, DOI 10.1111/j.1600-0625.1993.tb00015.x; Honma N, 2000, IMMUNOLOGY, V100, P84, DOI 10.1046/j.1365-2567.2000.00011.x; Imamura K, 1996, BIOCHEM MOL BIOL INT, V40, P1233; Kawaguchi Y, 1996, ARCH DERMATOL RES, V288, P39, DOI 10.1007/BF02505041; Lan HY, 1996, AM J PATHOL, V149, P1119; Lan HY, 1998, TRANSPLANTATION, V66, P1465, DOI 10.1097/00007890-199812150-00009; NATHAN CF, 1971, J EXP MED, V133, P1356, DOI 10.1084/jem.133.6.1356; Nishibori M, 1996, NEUROSCI LETT, V213, P193; Nishihira J, 2000, J INTERF CYTOK RES, V20, P751, DOI 10.1089/10799900050151012; Nishihira J, 1998, INT J MOL MED, V2, P17; NISHIHIRA J, 1995, BBA-PROTEIN STRUCT M, V1247, P159, DOI 10.1016/0167-4838(94)00215-3; NISHINO T, 1995, MOL MED, V1, P781, DOI 10.1007/BF03401892; Ohnishi Y, 2000, ARCH DERMATOL RES, V292, P27, DOI 10.1007/PL00007457; Onodera S, 2000, J BIOL CHEM, V275, P444, DOI 10.1074/jbc.275.1.444; Rutter JL, 1997, J CELL BIOCHEM, V66, P322, DOI 10.1002/(SICI)1097-4644(19970901)66:3<322::AID-JCB5>3.3.CO;2-D; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Shimizu T, 1997, BIOCHEM BIOPH RES CO, V240, P173, DOI 10.1006/bbrc.1997.7633; Shimizu T, 1996, FEBS LETT, V381, P199, DOI 10.1016/0014-5793(96)00120-2; Suzuki T, 1999, BRAIN RES, V816, P457, DOI 10.1016/S0006-8993(98)01179-2; Takahashi N, 1998, MOL MED, V4, P707, DOI 10.1007/BF03401765; Tesch GH, 1998, J AM SOC NEPHROL, V9, P417; WLASCHEK M, 1994, PHOTOCHEM PHOTOBIOL, V59, P550, DOI 10.1111/j.1751-1097.1994.tb02982.x; Wlaschek M, 1997, FEBS LETT, V413, P239, DOI 10.1016/S0014-5793(97)00919-8; Yu WH, 2001, ANAL BIOCHEM, V293, P38, DOI 10.1006/abio.2001.5099	38	77	77	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1676	1683		10.1074/jbc.M303650200	http://dx.doi.org/10.1074/jbc.M303650200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14581488	hybrid			2022-12-25	WOS:000188005700016
J	Xu, ZX; Zhao, RX; Ding, T; Tran, TT; Zhang, W; Pandolfi, PP; Chang, KS				Xu, ZX; Zhao, RX; Ding, T; Tran, TT; Zhang, W; Pandolfi, PP; Chang, KS			Promyelocytic leukemia protein 4 induces apoptosis by inhibition of survivin expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PML-RAR-ALPHA; TRANSCRIPTIONAL REPRESSION; ALTERED EXPRESSION; GROWTH-SUPPRESSOR; MESSENGER-RNA; CANCER CELLS; DNA-DAMAGE; GENE; P53; LOCALIZATION	The promyelocytic leukemia protein (PML) plays an essential role in multiple pathways of apoptosis. Our previous study showed that PML enhances tumor necrosis factor-induced apoptosis by inhibiting the NFkappaB survival pathway. To continue exploring the mechanism of PML-induced apoptosis, we performed a DNA microarray screening of PML target genes using a PML-inducible stable cell line. We found that Survivin was one of the downstream target genes of PML. Cotransfection experiments demonstrated that PML4 repressed transactivation of the Survivin promoter in an isoform-specific manner. Western blot analysis demonstrated that induced PML expression down-regulated Survivin. Inversely, PML knockdown by siRNA up-regulated Survivin expression. A substantial increase in Survivin expression was found in PML-deficient cells. Re-expression of PML in PML-/- mouse embryo fibroblasts downregulated the expression of Survivin. Furthermore, cells arrested at the G(2)/M cell cycle phase expressed a high level of Survivin and a significantly lower level of PML. Overexpression of PML in A549 cells reduced Survivin expression leading to massive apoptotic cell death associated with activation of procaspase 9, caspase 3, and caspase 7. Together, our results demonstrate a novel mechanism of PML-induced apoptosis by down-regulation of Survivin.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center	Chang, KS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd,Unit 89, Houston, TX 77030 USA.	kchang@mail.mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA099963, R01CA055577] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16627, CA 55577, CA 099963] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adida C, 1998, LANCET, V351, P882, DOI 10.1016/S0140-6736(05)70294-4; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Carter BZ, 2001, BLOOD, V97, P2784, DOI 10.1182/blood.V97.9.2784; Chan JYH, 1998, EUR J CANCER, V34, P1015, DOI 10.1016/S0959-8049(97)10138-1; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Cohen N, 2001, EMBO J, V20, P4547, DOI 10.1093/emboj/20.16.4547; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Ferbeyre G, 2000, GENE DEV, V14, P2015; Gambacorta M, 1996, AM J PATHOL, V149, P2023; Grobelny JV, 2000, J CELL SCI, V113, P4577; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; He DL, 1997, CANCER RES, V57, P1868; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kawasaki H, 1998, CANCER RES, V58, P5071; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; KOKEN MHM, 1995, ONCOGENE, V10, P1315; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Lin RJ, 2001, ONCOGENE, V20, P7204, DOI 10.1038/sj.onc.1204853; Marusawa H, 2003, EMBO J, V22, P2729, DOI 10.1093/emboj/cdg263; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100; Mu ZM, 1997, CARCINOGENESIS, V18, P2063, DOI 10.1093/carcin/18.11.2063; Olie RA, 2000, CANCER RES, V60, P2805; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Reed JC, 2001, J CLIN INVEST, V108, P965, DOI 10.1172/JCI14123; Reed JC, 2000, CELL, V102, P545, DOI 10.1016/S0092-8674(00)00076-3; TERRIS B, 1995, CANCER RES, V55, P1590; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; Wang ZG, 1998, SCIENCE, V279, P1547; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wu GK, 2003, CANCER RES, V63, P2589; Wu WS, 2003, J BIOL CHEM, V278, P12294, DOI 10.1074/jbc.M211849200; Wu WS, 2002, J BIOL CHEM, V277, P31734, DOI 10.1074/jbc.M201648200; Wu WS, 2002, ONCOGENE, V21, P3925, DOI 10.1038/sj.onc.1205491; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Xu ZX, 2003, MOL CELL BIOL, V23, P4247, DOI 10.1128/MCB.23.12.4247-4256.2003; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Yeager TR, 1999, CANCER RES, V59, P4175; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; ZHONG S, 1999, ONCOGENE, V18, P7841	54	39	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1838	1844		10.1074/jbc.M310987200	http://dx.doi.org/10.1074/jbc.M310987200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14597622	hybrid			2022-12-25	WOS:000188005700034
J	Napierala, M; Dere, R; Vetcher, A; Wells, RD				Napierala, M; Dere, R; Vetcher, A; Wells, RD			Structure-dependent recombination hot spot activity of GAA center dot TTC sequences from intron 1 of the Friedreich's ataxia gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAK; TRIPLET REPEAT SEQUENCES; CTG-CAG REPEATS; HOMOLOGOUS RECOMBINATION; ESCHERICHIA-COLI; STICKY DNA; TRINUCLEOTIDE REPEAT; MYCOPLASMA-GALLISEPTICUM; MEIOTIC RECOMBINATION; MYOTONIC-DYSTROPHY	The recombinational properties of long GAA.TTC repeating sequences were analyzed in Escherichia coh to gain further insights into the molecular mechanisms of the genetic instability of this tract as possibly related to the etiology of Friedreich's ataxia. Intramolecular and intermolecular recombination studies showed that the frequency of recombination between the GAA.TTC tracts was as much as 15 times higher than the nonrepeating control sequences. Homologous, intramolecular recombination between GAA.TTC tracts and GAAGGA.TCCTTC repeats also occurred with a very high frequency (similar to 0.8%). Biochemical analyses of the recombination products demonstrated the expansions and deletions of the GAA.TTC repeats. These results, together with our previous studies on the CTG.CAG sequences, suggest that the recombinational hot spot characteristics may be a common feature of all triplet repeat sequences. Unexpectedly, we found that the recombination properties of the GAA.TTC tracts were unique, compared with CTG.CAG repeats, because they depended on the DNA secondary structure polymorphism. Increasing the length of the GAA.TTC repeats decreased the intramolecular recombination frequency between these tracts. Also, a correlation was found between the propensity of the GAA.TTC tracts to adopt the sticky DNA conformation and the inhibition of intramolecular recombination. The use of novobiocin to modulate the intracellular DNA topology, ie. the lowering of the negative superhelical density, repressed the formation of the sticky DNA structure, thereby restoring the expected positive correlation between the length of the GAA.TTC tracts and the frequency of intramolecular recombination. Hence, our results demonstrate that sticky DNA exists and functions in E. coli.	Texas A&M Univ Syst Hlth Sci Ctr, Texas Med Ctr, Ctr Genome Res, Inst Biosci & Technol, Houston, TX 77030 USA	Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Wells, RD (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Genome Res, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rwells@ibt.tamu.edu		Vetcher, Alexandre/0000-0002-4828-8571	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES11347] Funding Source: Medline; NINDS NIH HHS [NS37554] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bacolla A, 2001, J BIOL CHEM, V276, P18597, DOI 10.1074/jbc.M100845200; Benet A, 1999, J MOL BIOL, V294, P851, DOI 10.1006/jmbi.1999.3295; Benet A, 2000, NUCLEIC ACIDS RES, V28, P4617, DOI 10.1093/nar/28.23.4617; Bidichandani SI, 1998, AM J HUM GENET, V62, P111, DOI 10.1086/301680; BLAHO JA, 1989, PROG NUCLEIC ACID RE, V37, P107; Boan F, 1998, J MOL BIOL, V278, P499, DOI 10.1006/jmbi.1998.1714; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Chauhan C, 2002, J BIOMOL STRUCT DYN, V20, P253, DOI 10.1080/07391102.2002.10506841; Chen CR, 1996, J MOL BIOL, V258, P627, DOI 10.1006/jmbi.1996.0274; Cossee M, 1997, NAT GENET, V15, P337, DOI 10.1038/ng0497-337; Cox MM, 1998, GENES CELLS, V3, P65, DOI 10.1046/j.1365-2443.1998.00175.x; Dutreix M, 1997, J MOL BIOL, V273, P105, DOI 10.1006/jmbi.1997.1293; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Gendrel CG, 2000, GENE DEV, V14, P1261; Glew MD, 1998, INFECT IMMUN, V66, P5833, DOI 10.1128/IAI.66.12.5833-5841.1998; Grabczyk E, 2000, NUCLEIC ACIDS RES, V28, P2815, DOI 10.1093/nar/28.14.2815; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Hardy CD, 2003, ANTIMICROB AGENTS CH, V47, P941, DOI 10.1128/AAC.47.3.941-947.2003; HEARNE CM, 1992, TRENDS GENET, V8, P288, DOI 10.1016/0168-9525(92)90256-4; Hiasa H, 1996, J BIOL CHEM, V271, P26424, DOI 10.1074/jbc.271.42.26424; HOWARD MT, 1994, P NATL ACAD SCI USA, V91, P12031, DOI 10.1073/pnas.91.25.12031; Jakupciak JP, 2000, J BIOL CHEM, V275, P40003, DOI 10.1074/jbc.M007153200; Jakupciak JP, 2000, IUBMB LIFE, V50, P355, DOI 10.1080/152165400300089358; Jakupciak JP, 1999, J BIOL CHEM, V274, P23468, DOI 10.1074/jbc.274.33.23468; Jankowski C, 2000, P NATL ACAD SCI USA, V97, P2134, DOI 10.1073/pnas.040460297; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; Kirkpatrick DT, 1999, MOL CELL BIOL, V19, P7661; KOHWI Y, 1993, GENE DEV, V7, P1766, DOI 10.1101/gad.7.9.1766; Kruger R, 2000, J BACTERIOL, V182, P2461, DOI 10.1128/JB.182.9.2461-2467.2000; Kuzminov A, 2001, P NATL ACAD SCI USA, V98, P8241, DOI 10.1073/pnas.131009198; LAPIDOT A, 1989, NUCLEIC ACIDS RES, V17, P883, DOI 10.1093/nar/17.3.883; LeProust EM, 2000, J MOL BIOL, V302, P1063, DOI 10.1006/jmbi.2000.4073; Lewis RJ, 1996, EMBO J, V15, P1412, DOI 10.1002/j.1460-2075.1996.tb00483.x; Liu L, 2000, INFECT IMMUN, V68, P871, DOI 10.1128/IAI.68.2.871-876.2000; Lovett ST, 1996, P NATL ACAD SCI USA, V93, P7120, DOI 10.1073/pnas.93.14.7120; Marcadier JL, 2003, J BIOL CHEM, V278, P33848, DOI 10.1074/jbc.M304284200; Mariappan SVS, 1999, J MOL BIOL, V285, P2035, DOI 10.1006/jmbi.1998.2435; Mariappan SVS, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P647; Maurer DJ, 1996, MOL CELL BIOL, V16, P6617; Meservy JL, 2003, MOL CELL BIOL, V23, P3152, DOI 10.1128/MCB.23.9.3152-3162.2003; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; Napierala M, 2002, J BIOL CHEM, V277, P34087, DOI 10.1074/jbc.M202128200; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Ohshima K, 1999, NEUROLOGY, V53, P1854, DOI 10.1212/WNL.53.8.1854; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; Petes TD, 2001, NAT REV GENET, V2, P360, DOI 10.1038/35072078; Pluciennik A, 2002, J BIOL CHEM, V277, P34074, DOI 10.1074/jbc.M202127200; Pluciennik A, 2000, J BIOL CHEM, V275, P28386, DOI 10.1074/jbc.M000154200; Richard GF, 1999, MOL GEN GENET, V261, P871, DOI 10.1007/s004380050031; Richard GF, 2000, EMBO J, V19, P2381, DOI 10.1093/emboj/19.10.2381; ROONEY SM, 1995, P NATL ACAD SCI USA, V92, P2141, DOI 10.1073/pnas.92.6.2141; RUBNITZ J, 1984, MOL CELL BIOL, V4, P2253, DOI 10.1128/MCB.4.11.2253; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Sakamoto N, 2001, J BIOL CHEM, V276, P27178, DOI 10.1074/jbc.M101852200; Sakamoto N, 2001, J BIOL CHEM, V276, P27171, DOI 10.1074/jbc.M101879200; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; Soyfer V.N., 1996, TRIPLE HELICAL NUCL; Subramanian S, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-r13; Subramanian S, 2003, BIOINFORMATICS, V19, P549, DOI 10.1093/bioinformatics/btg029; TRECO D, 1986, MOL CELL BIOL, V6, P3934, DOI 10.1128/MCB.6.11.3934; Tsai FTF, 1997, PROTEINS, V28, P41; Vetcher AA, 2004, J BIOL CHEM, V279, P6434, DOI 10.1074/jbc.M309595200; Vetcher AA, 2002, J BIOL CHEM, V277, P39217, DOI 10.1074/jbc.M205209200; Vetcher AA, 2002, J BIOL CHEM, V277, P39228, DOI 10.1074/jbc.M205210200; WAHLS WP, 1990, CELL, V60, P95, DOI 10.1016/0092-8674(90)90719-U; WATT VM, 1985, P NATL ACAD SCI USA, V82, P4768, DOI 10.1073/pnas.82.14.4768; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; WEINREB A, 1990, J BIOL CHEM, V265, P1352; Wells R.D., 1998, GENETIC INSTABILITIE; Wells RD, 1998, J BIOL CHEM, V273, P19532, DOI 10.1074/jbc.273.31.19532; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307	76	53	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6444	6454		10.1074/jbc.M309596200	http://dx.doi.org/10.1074/jbc.M309596200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14625270	hybrid			2022-12-25	WOS:000188969200030
J	Mensah, JK; Ogawa, T; Kapadia, H; Cavender, AC; D'Souza, RN				Mensah, JK; Ogawa, T; Kapadia, H; Cavender, AC; D'Souza, RN			Functional analysis of a mutation in PAX9 associated with familial tooth agenesis in humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-DNA COMPLEX; PAIRED DOMAIN; SEQUENCE RECOGNITION; CRYSTAL-STRUCTURE; BINDING; PROTEINS; MSX1; HAPLOINSUFFICIENCY; OLIGODONTIA; ENCODES	Pax9 is a paired domain-containing transcription factor that plays an essential role in the patterning of murine dentition. In humans, mutations in PAX9 are associated with unique phenotypes of familial tooth agenesis that mainly involve posterior teeth. Among these, a frameshift mutation (219InsG) within the paired domain of PAX9 produces a protein product associated with a severe form of molar agenesis in a single family. The objectives of this study were to gain new insights into the molecular pathogenesis of the 219InsG mutation and its role in tooth agenesis. Here we describe functional defects in DNA binding and transactivation of mutant 219InsGPax9. Although wild type Pax9 binds to the high affinity paired domain recognition sequences, e5 and CD19-2(A-ins), the 219InsGPax9 mutant protein was unable to bind to these cognate DNA-binding sites. In co-transfection assays, wild type Pax9 activated reporter gene transcription although the mutant was transcriptionally inactive. Immunolocalization data show that Pax9 and 219InsGPax9 proteins are synthesized in mammalian cells but that the nuclear localization of the mutant Pax9 protein is altered. Furthermore, transactivation by the full-length Pax9 protein from paired domain binding sites was not impaired by the 219InsGPax9 mutant. The latter did not alter the DNA binding activities of wild type Pax9 in gel mobility shift assays. The combined defects in DNA binding activities and transactivation function of mutant 219InsGPAX9 likely alter the selective activation and/or repression of PAX9 effector genes during odontogenesis. This loss-of-function of PAX9 most likely results in its haploinsufficiency during the patterning of dentition and the subsequent loss of posterior teeth.	Univ Texas, Hlth Sci Ctr, Dept Orthodont, Dent Branch, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	D'Souza, RN (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Orthodont, Dent Branch, Rm 346,6516 MD Anderson Blvd, Houston, TX 77030 USA.	rena.n.dsouza@uth.tmc.edu		D'Souza, Rena/0000-0002-1505-5173	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K08DE014237, R01DE011663] Funding Source: NIH RePORTER; NIDCR NIH HHS [K08-DE14237, DE011663] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bei M, 1998, DEVELOPMENT, V125, P4325; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; Das P, 2002, HUM GENET, V110, P371, DOI 10.1007/s00439-002-0699-1; El Ghouzzi V, 2000, HUM MOL GENET, V9, P813, DOI 10.1093/hmg/9.5.813; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Frazier-Bowers SA, 2002, CONNECT TISSUE RES, V43, P296, DOI 10.1080/03008200290000961; Hu GZ, 1998, MOL CELL BIOL, V18, P6044, DOI 10.1128/MCB.18.10.6044; LI J, 1995, CANCER RES, V55, P5540; Mostowska A, 2003, EUR J ORAL SCI, V111, P365, DOI 10.1034/j.1600-0722.2003.00069.x; NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; Nornes S, 1996, J BIOL CHEM, V271, P26914, DOI 10.1074/jbc.271.43.26914; Pellizzari L, 1999, BIOCHEM J, V337, P253, DOI 10.1042/0264-6021:3370253; Peters H, 1999, TRENDS GENET, V15, P59, DOI 10.1016/S0168-9525(98)01662-X; Peters H, 1998, GENE DEV, V12, P2735, DOI 10.1101/gad.12.17.2735; Stockton DW, 2000, NAT GENET, V24, P18, DOI 10.1038/71634; Tell G, 1999, BIOCHEM J, V341, P89, DOI 10.1042/0264-6021:3410089; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; Vastardis H, 1996, NAT GENET, V13, P417, DOI 10.1038/ng0896-417; Xu HE, 1999, GENE DEV, V13, P1263, DOI 10.1101/gad.13.10.1263; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9	22	42	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5924	5933		10.1074/jbc.M305648200	http://dx.doi.org/10.1074/jbc.M305648200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14607846	hybrid			2022-12-25	WOS:000188776500108
J	Barbier, J; Lamthanh, H; Le Gall, F; Favreau, P; Benoit, E; Chen, HJ; Gilles, N; Ilan, N; Heinemann, SH; Gordon, D; Menez, A; Molgo, J				Barbier, J; Lamthanh, H; Le Gall, F; Favreau, P; Benoit, E; Chen, HJ; Gilles, N; Ilan, N; Heinemann, SH; Gordon, D; Menez, A; Molgo, J			A delta-conotoxin from Conus ermineus venom inhibits inactivation in vertebrate neuronal Na+ channels but not in skeletal and cardiac muscles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED SODIUM-CHANNELS; ALPHA-LIKE TOXIN; RAT-BRAIN; MOLECULAR-MECHANISMS; RECEPTOR-SITE; SEA-ANEMONE; LQH-III; PEPTIDE; SUBTYPES; CURRENTS	We have isolated delta-conotoxin EVIA (delta-EVIA) a conopeptide in Conus ermineus venom that contains 32 amino acid residues and a six-cysteine/four-loop framework similar to that of previously described omega-, delta-, muO-, and kappa-conotoxins. However, it displays low sequence homology with the latter conotoxins. delta-EVIA inhibits Na+ channel inactivation with unique tissue specificity upon binding to receptor site 6 of neuronal Na+ channels. Using amphibian myelinated axons and spinal neurons, we showed that delta-EVIA increases the duration of action potentials by inhibiting Na+ channel inactivation. delta-EVIA considerably enhanced nerve terminal excitability and synaptic efficacy at the frog neuromuscular junction but did not affect directly elicited muscle action potentials. The neuronally selective property of delta-EVIA was confirmed by showing that a fluorescent derivative of delta-EVIA labeled motor nerve endings but not skeletal muscle fibers. In a heterologous expression system, delta-EVIA inhibited inactivation of rat neuronal Na+ channel subtypes (rNa(V)1.2a, rNa(V)1.3, and rNa(V)1.6) but did not affect rat skeletal (rNa(V)1.4) and human cardiac muscle (hNa(V)1.5) Na+ channel subtypes. delta-EVIA, in the range of concentrations used, is the first conotoxin found to affect neuronal Na+ channels without acting on Na+ channels of skeletal and cardiac muscle. Therefore, it is a unique tool for discriminating voltage-sensitive Na+ channel subtypes and for studying the distribution and modulation mechanisms of neuronal Na+ channels, and it may serve as a lead to design new drugs adapted to treat diseases characterized by defective nerve conduction.	CNRS, UPR 9040, Neurobiol Cellulaire & Mol Lab, F-91198 Gif Sur Yvette, France; CENS, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France; Univ Jena, Fac Med, Res Unit Mol & Cellular Biophys, D-07747 Jena, Germany; Tel Aviv Univ, Dept Plant Sci, IL-69978 Tel Aviv, Israel	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; Friedrich Schiller University of Jena; Tel Aviv University	Molgo, J (corresponding author), CNRS, UPR 9040, Neurobiol Cellulaire & Mol Lab, F-91198 Gif Sur Yvette, France.	Jordi.Molgo@nbcm.cnrs-gif.fr	Chen, Haijun/C-7334-2011	barbier, julien/0000-0003-2187-4973; BENOIT, Evelyne/0000-0001-5501-0888; Heinemann, Stefan H./0000-0002-4144-0251				Benoit E, 2001, NEUROSCIENCE, V104, P551, DOI 10.1016/S0306-4522(01)00073-2; BERGMAN C, 1976, BIOCHIM BIOPHYS ACTA, V455, P173, DOI 10.1016/0005-2736(76)90162-0; Bulaj G, 2001, BIOCHEMISTRY-US, V40, P13201, DOI 10.1021/bi010683a; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Cestele S, 2000, BIOCHIMIE, V82, P883, DOI 10.1016/S0300-9084(00)01174-3; Chahine M, 1996, J MEMBRANE BIOL, V152, P39, DOI 10.1007/s002329900083; Chen HJ, 2000, PFLUG ARCH EUR J PHY, V439, P423, DOI 10.1007/s004240050959; CRUZ LJ, 1985, J BIOL CHEM, V260, P9280; FAINZILBER M, 1991, EUR J BIOCHEM, V202, P589, DOI 10.1111/j.1432-1033.1991.tb16412.x; FAINZILBER M, 1994, J BIOL CHEM, V269, P2574; FAINZILBER M, 1995, J BIOL CHEM, V270, P1123, DOI 10.1074/jbc.270.3.1123; Favreau P, 1999, Acta Physiol Pharmacol Ther Latinoam, V49, P257; French R J, 1999, Methods Enzymol, V294, P575; Gilles N, 1999, J NEUROSCI, V19, P8730, DOI 10.1523/JNEUROSCI.19-20-08730.1999; Goldin AL, 2001, ANNU REV PHYSIOL, V63, P871, DOI 10.1146/annurev.physiol.63.1.871; Gordon D, 2003, EUR J BIOCHEM, V270, P2663, DOI 10.1046/j.1432-1033.2003.03643.x; Hamon A, 2002, EUR J BIOCHEM, V269, P3920, DOI 10.1046/j.1432-1033.2002.03065.x; HASSON A, 1993, EUR J NEUROSCI, V5, P56, DOI 10.1111/j.1460-9568.1993.tb00205.x; Hattori N, 2003, BRAIN, V126, P134, DOI 10.1093/brain/awg012; HILLYARD DR, 1989, BIOCHEMISTRY-US, V28, P358, DOI 10.1021/bi00427a049; Kaji R, 2003, MUSCLE NERVE, V27, P285, DOI 10.1002/mus.10273; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P1207, DOI 10.1021/bi00600a011; Kits KS, 1996, J NEUROCHEM, V67, P2155; Le Gall F, 1999, TOXICON, V37, P985, DOI 10.1016/S0041-0101(98)00227-X; Le Gall F, 1999, EUR J NEUROSCI, V11, P3134, DOI 10.1046/j.1460-9568.1999.00732.x; Li RA, 2001, J BIOL CHEM, V276, P11072, DOI 10.1074/jbc.M010862200; Little MJ, 1998, J BIOL CHEM, V273, P27076, DOI 10.1074/jbc.273.42.27076; MALLART A, 1984, PFLUG ARCH EUR J PHY, V400, P8, DOI 10.1007/BF00670529; MCINTOSH JM, 1995, J BIOL CHEM, V270, P16796, DOI 10.1074/jbc.270.28.16796; Nakamura T, 1996, PROTEIN SCI, V5, P524; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; OLIVERA BM, 1987, BIOCHEMISTRY-US, V26, P2086, DOI 10.1021/bi00382a004; Olivera BM, 1997, MOL BIOL CELL, V8, P2101, DOI 10.1091/mbc.8.11.2101; Safo P, 2000, J NEUROSCI, V20, P76, DOI 10.1523/JNEUROSCI.20-01-00076.2000; Shichor I, 1996, J NEUROCHEM, V67, P2451; SHON KJ, 1995, BIOCHEMISTRY-US, V34, P4913, DOI 10.1021/bi00015a002; Shon KJ, 1998, J NEUROSCI, V18, P4473; SHON KJ, 1994, BIOCHEMISTRY-US, V33, P11420, DOI 10.1021/bi00204a003; SPITZER NC, 1976, P NATL ACAD SCI USA, V73, P1641, DOI 10.1073/pnas.73.5.1641; Szeto TH, 2000, FEBS LETT, V470, P293, DOI 10.1016/S0014-5793(00)01339-9; Tabti N., 1991, CULTURING NERVE CELL, P137; Terlau H, 1996, NATURE, V381, P148, DOI 10.1038/381148a0; Terlau H, 1996, J NEUROPHYSIOL, V76, P1423, DOI 10.1152/jn.1996.76.3.1423; VOLPON L, 2003, J BIOL CHEM	44	52	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4680	4685		10.1074/jbc.M309576200	http://dx.doi.org/10.1074/jbc.M309576200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14615484	hybrid			2022-12-25	WOS:000188554300091
J	Bian, X; Giordano, TD; Lin, HJ; Solomon, G; Castle, VP; Opipari, AW				Bian, X; Giordano, TD; Lin, HJ; Solomon, G; Castle, VP; Opipari, AW			Chemotherapy-induced apoptosis of S-type neuroblastoma cells requires caspase-9 and is augmented by CD95/Fas stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEURO-BLASTOMA; SURFACE-ANTIGEN EXPRESSION; NF-KAPPA-B; FAS LIGAND; CYTO-TOXICITY; DEATH; TUMOR; LINES; ACTIVATION; PROTEASE	Stromal or S-type tumor cells are a distinct lineage found in neuroblastoma tumors and have an important role in the biology of this disease. Anticancer agents induce apoptosis through death receptor- and mitochondria-initiated pathways. The object of this work was to determine the involvement of these pathways in the response to doxorubicin (Dox) and cisplatin (CDDP) in S-type neuroblastoma cells. Both drugs activated caspase-9 and caspase-3 but not caspase-8. Caspase-9-specific inhibition blocked S-type cell death induced by Dox. SH-EP1 cells transfected to express dominant negative mutant caspase-9, but not those expressing DN caspase-8, were resistant to Dox- and CDDP-induced apoptosis. The lack of caspase-8 involvement in chemotherapy-induced death was not the result of an intrinsic inability of these cells to activate this enzyme because when they were treated with tumor necrosis factor-related apoptosis-inducing ligand, caspase-8 was activated. We also found that both drugs up-regulated CD95/Fas expression but that CD95/Fas signaling was not necessary for cell killing. Experiments testing the response of chemotherapy-treated cells to agonists of the CD95/Fas receptor established that Dox and CDDP treatment sensitizes cells to CD95/Fas killing. Together, these results are consistent with a model in which caspase-9 is of central importance in the death mechanism utilized by these drugs in S-type cells. Although the death response is not dependent on CD95/Fas, concomitant stimulation of this receptor amplifies the death response in drug-treated cells.	Univ Michigan, Ctr Comprehens Canc, Dept Pediat, Sch Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Castle, VP (corresponding author), Univ Michigan, Ctr Comprehens Canc, Dept Pediat, Sch Med, 1500 E Med Ctr Dr,Rm 4302, Ann Arbor, MI 48109 USA.	vcastle@umich.edu	Lin, Huey-Jen/E-3514-2011	Giordano, Thomas/0000-0003-0641-8873	NCI NIH HHS [CA69276-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069276] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Backus HHJ, 2003, EUR J CANCER, V39, P1310, DOI 10.1016/S0959-8049(03)00204-1; Bian X, 2002, J BIOL CHEM, V277, P42144, DOI 10.1074/jbc.M203891200; Bian X, 2001, J BIOL CHEM, V276, P48921, DOI 10.1074/jbc.M108674200; BIEDLER JL, 1973, CANCER RES, V33, P2643; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOLIVAR R, 1980, CANCER, V46, P1555, DOI 10.1002/1097-0142(19801001)46:7<1555::AID-CNCR2820460710>3.0.CO;2-4; Chen SH, 2000, AM J PATHOL, V156, P1085, DOI 10.1016/S0002-9440(10)64976-0; Chen TA, 2003, CANCER RES, V63, P4368; CICCARONE V, 1989, CANCER RES, V49, P219; Clement MV, 1998, BLOOD, V92, P996; DECLERCK YA, 1987, CANCER RES, V47, P6505; DOLE M, 1994, CANCER RES, V54, P3253; DOLE MG, 1995, CANCER RES, V55, P2576; Fulda S, 1997, CANCER RES, V57, P3823; Gross N, 2001, MED PEDIATR ONCOL, V36, P111, DOI 10.1002/1096-911X(20010101)36:1<111::AID-MPO1026>3.0.CO;2-3; HELSON L, 1984, CANC DRUG DEL, V1, P303, DOI 10.1089/cdd.1984.1.303; Hopkins-Donaldson S, 2002, ONCOGENE, V21, P6132, DOI 10.1038/sj.onc.1205879; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Iolascon A, 2003, CANCER GENET CYTOGEN, V146, P41, DOI 10.1016/S0165-4608(03)00125-0; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Kuwahara D, 2000, CANCER LETT, V148, P65, DOI 10.1016/S0304-3835(99)00315-8; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Muthumani K, 2002, ONCOGENE, V21, P4613, DOI 10.1038/sj.onc.1205549; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nitobe J, 2003, CARDIOVASC RES, V57, P119, DOI 10.1016/S0008-6363(02)00646-6; OGITA S, 1988, ONCOLOGY, V45, P117, DOI 10.1159/000226544; PARK JG, 1987, CANCER RES, V47, P5875; RETTIG WJ, 1987, CANCER RES, V47, P1383; ROSS RA, 1985, CANCER RES, V45, P1628; ROSS RA, 1980, ADV NEUROBLASTOMA RE, P151; Schlesinger M, 2000, BIOCHEM PHARMACOL, V60, P1693, DOI 10.1016/S0006-2952(00)00484-6; Schwartz PS, 2001, MOL PHARMACOL, V60, P1268, DOI 10.1124/mol.60.6.1268; SEEGER RC, 1977, CANCER RES, V37, P1364; Shivapurkar N, 2002, CANCER BIOL THER, V1, P65, DOI 10.4161/cbt.1.1.45; Strater J, 2001, CELL DEATH DIFFER, V8, P273, DOI 10.1038/sj.cdd.4400813; SUMIMOTO SI, 1994, CELL IMMUNOL, V153, P184, DOI 10.1006/cimm.1994.1016; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Teitz T, 2002, ONCOGENE, V21, P1848, DOI 10.1038/sj.onc.1205180; Verbeke CS, 1999, J PATHOL, V189, P155, DOI 10.1002/(SICI)1096-9896(199910)189:2<155::AID-PATH442>3.0.CO;2-9; Wu GS, 2002, ONCOGENE, V21, P1, DOI 10.1038/sj.onc.1205020	44	33	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4663	4669		10.1074/jbc.M306905200	http://dx.doi.org/10.1074/jbc.M306905200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14617634	hybrid			2022-12-25	WOS:000188554300089
J	He, JL; Baum, LG				He, JL; Baum, LG			Presentation of galectin-1 by extracellular matrix triggers T cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTIN; HAMSTER OVARY CELLS; PROLIFERATION; EXPRESSION; APOPTOSIS; CANCER; MODULATORS; ADHESION; RECEPTOR; PROTEIN	Apoptotic elimination of T cells at sites of inflammation or infiltration into tumors limits an effective immune response. T cell apoptosis can be initiated by a variety of triggers, including galectin-1, a soluble, secreted lectin that binds to oligosaccharide ligands on cell surface glycoproteins, or to oligosaccharide ligands on extracellular matrix glycoproteins in tissue stroma. Although galectin-1 has no transmembrane domain and is secreted from cells that make it, it is not clear if galectin-1 functions as a soluble death trigger in vivo. We examined the ability of stromal cells secreting galectin-1 to kill T cells. Although the stromal cells synthesized abundant galectin-1, the majority of the galectin-1 remained bound to the cell surface, and stromal cell-associated galectin-1 killed bound T cells. In contrast, insufficient amounts of functional galectin-1 were released from the stromal cells into the media to kill T cells in the absence of contact with stromal cells. However, when stromal cells were grown on Matrigel, a mixture of extracellular matrix proteins, or on permeable membranes above Matrigel, secreted galectin-1 bound to Matrigel and killed T cells without stromal cell contact. Ten-fold less galectin-1 on Matrigel was sufficient to kill adherent T cells compared with soluble galectin-1. These results demonstrate that galectin-1 in extracellular matrix is able to directly kill susceptible T cells. Because increased galectin-1 deposition in tumor stroma occurs with tumor progression in various types of cancer, galectin-1 in stroma may act locally in the apoptotic elimination of infiltrating T cells during an immune response.	Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Baum, LG (corresponding author), Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.	lbaum@mednet.ucla.edu			NIGMS NIH HHS [GM63281] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063281] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed H, 1996, J BIOCHEM, V120, P1007; ALLEN HJ, 1993, TUMOR BIOL, V14, P360, DOI 10.1159/000217851; Almkvist J, 2002, J IMMUNOL, V168, P4034, DOI 10.4049/jimmunol.168.8.4034; Amano M, 2003, J BIOL CHEM, V278, P7469, DOI 10.1074/jbc.M209595200; Blaser C, 1998, EUR J IMMUNOL, V28, P2311, DOI 10.1002/(SICI)1521-4141(199808)28:08<2311::AID-IMMU2311>3.0.CO;2-G; Brewer CF, 2002, CURR OPIN STRUC BIOL, V12, P616, DOI 10.1016/S0959-440X(02)00364-0; CHO MJ, 1995, J BIOL CHEM, V270, P5198, DOI 10.1074/jbc.270.10.5198; CHO MJ, 1995, J BIOL CHEM, V270, P5207, DOI 10.1074/jbc.270.10.5207; Correa SG, 2003, GLYCOBIOLOGY, V13, P119, DOI 10.1093/glycob/cwg010; Danguy A, 2002, BBA-GEN SUBJECTS, V1572, P285, DOI 10.1016/S0304-4165(02)00315-X; Dias-Baruffi M, 2003, J BIOL CHEM, V278, P41282, DOI 10.1074/jbc.M306624200; Fukaya K, 2003, J NEUROPATH EXP NEUR, V62, P162, DOI 10.1093/jnen/62.2.162; Gauthier L, 2002, P NATL ACAD SCI USA, V99, P13014, DOI 10.1073/pnas.202323999; Harjacek M, 2001, J RHEUMATOL, V28, P1914; Hernandez JD, 2002, GLYCOBIOLOGY, V12, p127R, DOI 10.1093/glycob/cwf081; Hughes RC, 2001, BIOCHIMIE, V83, P667; Liu FT, 2002, BBA-GEN SUBJECTS, V1572, P263, DOI 10.1016/S0304-4165(02)00313-6; Maeda N, 2003, J BIOL CHEM, V278, P18938, DOI 10.1074/jbc.M209673200; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; McHugh RS, 2002, J ALLERGY CLIN IMMUN, V110, P693, DOI 10.1067/mai.2002.129339; Nguyen JT, 2001, J IMMUNOL, V167, P5697, DOI 10.4049/jimmunol.167.10.5697; Palmer E, 2003, NAT REV IMMUNOL, V3, P383, DOI 10.1038/nri1085; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Rabinovich GA, 1998, J IMMUNOL, V160, P4831; Rabinovich GA, 2002, TRENDS IMMUNOL, V23, P313, DOI 10.1016/S1471-4906(02)02232-9; Rivoltini L, 2002, IMMUNOL REV, V188, P97, DOI 10.1034/j.1600-065X.2002.18809.x; Santucci L, 2003, GASTROENTEROLOGY, V124, P1381, DOI 10.1016/S0016-5085(03)00267-1; Seelenmeyer C, 2003, J CELL SCI, V116, P1305, DOI 10.1242/jcs.00312; STANLEY P, 1991, Glycobiology, V1, P307, DOI 10.1093/glycob/1.3.307; van den Brule F, 2003, LAB INVEST, V83, P377, DOI 10.1097/01.LAB.0000059949.01480.40; van den Brule FA, 2001, J PATHOL, V193, P80, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH730>3.0.CO;2-2	32	158	166	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4705	4712		10.1074/jbc.M311183200	http://dx.doi.org/10.1074/jbc.M311183200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14617626	hybrid			2022-12-25	WOS:000188554300094
J	Peltier, JB; Ripoll, DR; Friso, G; Rudella, A; Cai, Y; Ytterberg, J; Giacomelli, L; Pillardy, J; van Wijk, KJ				Peltier, JB; Ripoll, DR; Friso, G; Rudella, A; Cai, Y; Ytterberg, J; Giacomelli, L; Pillardy, J; van Wijk, KJ			Clp protease complexes from photosynthetic and non-photosynthetic plastids and mitochondria of plants, their predicted three-dimensional structures, and functional implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; ESCHERICHIA-COLI CLPP; CRYSTAL-STRUCTURE; ARABIDOPSIS-THALIANA; DEGRADE PROTEINS; CHLOROPLAST; IDENTIFICATION; GENE; ELECTROPHORESIS; PROTEOLYSIS	Tetradecameric Clp protease core complexes in nonphotosynthetic plastids of roots, flower petals, and in chloroplasts of leaves of Arabidopsis thaliana were purified based on native mass and isoelectric point and identified by mass spectrometry. The stoichiometry between the subunits was determined. The protease complex consisted of one to three copies of five different serine-type protease Clp proteins (ClpP1,3-6) and four non-proteolytic ClpR proteins (ClpR1-4). Three-dimensional homology modeling showed that the ClpP/R proteins fit well together in a tetradecameric complex and also indicated unique contributions for each protein. Lateral exit gates for proteolysis products are proposed. In addition, ClpS1,2, unique to land plants, tightly interacted with this core complex, with one copy of each per complex. The three-dimensional modeling show that they do fit well on the axial sites of the ClpPR cores. In contrast to plastids, plant mitochondria contained a single similar to320-kDa homo-tetradecameric ClpP2 complex, without association of ClpR or ClpS proteins. It is surprising that the Clp core composition appears identical in all three plastid types, despite the remarkable differences in plastid proteome composition. This suggests that regulation of plastid proteolysis by the Clp machinery is not through differential regulation of ClpP/R/S gene expression, but rather through substrate recognition mechanisms and regulated interaction of chaperone-like molecules (ClpS1,2 and others) to the ClpP/R core.	Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA; Cornell Univ, Cornell Theory Ctr, Computat Biol Serv Unit, Ithaca, NY 14853 USA	Cornell University; Cornell University	Peltier, JB (corresponding author), Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA.	jp269@cornell.edu; kv35@Cornell.edu	Giacomelli, Lisa/AAA-6266-2022; Ytterberg, Anders/E-1773-2016	Giacomelli, Lisa/0000-0002-0697-037X; Ytterberg, Anders/0000-0002-1485-2314; Peltier, Jean-Benoit/0000-0001-6656-6072				Adam Z, 2001, PLANT PHYSIOL, V125, P1912, DOI 10.1104/pp.125.4.1912; Baker D, 2001, SCIENCE, V294, P93, DOI 10.1126/science.1065659; Burton BM, 2001, MOL CELL, V8, P449, DOI 10.1016/S1097-2765(01)00307-0; Dougan DA, 2002, MOL CELL, V9, P673, DOI 10.1016/S1097-2765(02)00485-9; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Guo FS, 2002, J BIOL CHEM, V277, P46753, DOI 10.1074/jbc.M208104200; Halperin T, 2001, PLANTA, V213, P614, DOI 10.1007/s004250100527; Halperin T, 2001, PLANT MOL BIOL, V45, P461, DOI 10.1023/A:1010677220323; Herman C, 1998, GENE DEV, V12, P1348, DOI 10.1101/gad.12.9.1348; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Hoskins JR, 2002, P NATL ACAD SCI USA, V99, P11037, DOI 10.1073/pnas.172378899; HUANG CZ, 1994, MOL GEN GENET, V244, P151, DOI 10.1007/BF00283516; Kang SG, 2002, J BIOL CHEM, V277, P21095, DOI 10.1074/jbc.M201642200; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kim YI, 2001, NAT STRUCT BIOL, V8, P230, DOI 10.1038/84967; KO K, 1994, PLANT PHYSIOL, V104, P1087, DOI 10.1104/pp.104.3.1087; Kohler RH, 1997, PLANT J, V11, P613, DOI 10.1046/j.1365-313X.1997.11030613.x; Kuroda H, 2003, NATURE, V425, P86, DOI 10.1038/nature01909; Majeran W, 2000, PLANT CELL, V12, P137; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; Missiakas D, 1996, EMBO J, V15, P6899, DOI 10.1002/j.1460-2075.1996.tb01082.x; MOORE T, 1993, PLANT MOL BIOL, V21, P525, DOI 10.1007/BF00028809; Nakabayashi K, 1999, PLANT CELL PHYSIOL, V40, P504, DOI 10.1093/oxfordjournals.pcp.a029571; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Peltier JB, 2000, PLANT CELL, V12, P319, DOI 10.1105/tpc.12.3.319; Peltier JB, 2002, PLANT CELL, V14, P211, DOI 10.1105/tpc.010304; Peltier JB, 2001, J BIOL CHEM, V276, P16318, DOI 10.1074/jbc.M010503200; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; Sanchez R, 1998, P NATL ACAD SCI USA, V95, P13597, DOI 10.1073/pnas.95.23.13597; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schelin J, 2002, MICROBIOL-SGM, V148, P2255, DOI 10.1099/00221287-148-7-2255; SHANKLIN J, 1995, PLANT CELL, V7, P1713, DOI 10.1105/tpc.7.10.1713; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shikanai T, 2001, PLANT CELL PHYSIOL, V42, P264, DOI 10.1093/pcp/pce031; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; Sokolenko A, 2002, CURR GENET, V41, P291, DOI 10.1007/s00294-002-0309-8; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang JM, 1998, J STRUCT BIOL, V124, P151, DOI 10.1006/jsbi.1998.4058; Weaver LM, 1999, PLANT PHYSIOL, V119, P1209, DOI 10.1104/pp.119.4.1209; Wickner S, 1999, P NATL ACAD SCI USA, V96, P8318, DOI 10.1073/pnas.96.15.8318; Zabrouskov V, 2002, ARCH BIOCHEM BIOPHYS, V402, P136, DOI 10.1016/S0003-9861(02)00069-3; Zheng B, 2002, PHYSIOL PLANTARUM, V114, P92, DOI 10.1034/j.1399-3054.2002.1140113.x	49	165	191	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4768	4781		10.1074/jbc.M309212200	http://dx.doi.org/10.1074/jbc.M309212200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14593120	hybrid			2022-12-25	WOS:000188554300102
J	Suenaga, A; Kiyatkin, AB; Hatakeyama, M; Futatsugi, N; Okimoto, N; Hirano, Y; Narumi, T; Kawai, A; Susukita, R; Koishi, T; Furusawa, H; Yasuoka, K; Takada, N; Ohno, Y; Taiji, M; Ebisuzaki, T; Hoek, JB; Konagaya, A; Kholodenko, BN				Suenaga, A; Kiyatkin, AB; Hatakeyama, M; Futatsugi, N; Okimoto, N; Hirano, Y; Narumi, T; Kawai, A; Susukita, R; Koishi, T; Furusawa, H; Yasuoka, K; Takada, N; Ohno, Y; Taiji, M; Ebisuzaki, T; Hoek, JB; Konagaya, A; Kholodenko, BN			Tyr-317 phosphorylation increases shc structural rigidity and reduces coupling of domain motions remote from the phosphorylation site as revealed by molecular dynamics simulations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; PROTEIN DYNAMICS; ADAPTER PROTEIN; SWISS-MODEL; GRB2; COMPLEX; LYSOZYME; AFFINITY; NETWORK	Activated receptor tyrosine kinases bind the She adaptor protein through its N-terminal phosphotyrosine-binding (PTB) and C-terminal Src homology 2 (SH2) domains. After binding, Shc is phosphorylated within the central collagen-homology (CH) linker region on Tyr-317, a residue remote to both the PTB and SH2 domains. Shc phosphorylation plays a pivotal role in the initiation of mitogenic signaling through the Ras/Raf/MEK/ERK pathway, but it is unclear if Tyr-317 phosphorylation affects Shc-receptor interactions through the PTB and SH2 domains. To investigate the structural impact of Shc phosphorylation, molecular dynamics simulations were carried out using special-purpose Molecular Dynamics Machine-Grape computers. After a 1-nanosecond equilibration, atomic motions in the structures of unphosphorylated Shc and Shc phosphorylated on Tyr-317 were calculated during a 2-nanosecond period. The results reveal larger phosphotyrosine-binding domain fluctuations and more structural flexibility of unphosphorylated Shc compared with phosphorylated Shc. Collective motions between the PTB-SH2, PTB-CH, and CH-SH2 domains were highly correlated only in unphosphorylated Shc. Dramatic changes in domain coupling and structural rigidity, induced by Tyr-317 phosphorylation, may alter Shc function, bringing about marked differences in the association of unphosphorylated and phosphorylated Shc with its numerous partners, including activated membrane receptors.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; RIKEN Genom Sci Ctr, Bioinformat Grp, Tsurumi Ku, Kanagawa 2300045, Japan; RIKEN, Adv Comp Ctr, Computat Sci Div, Wako, Saitama 3510198, Japan; Keio Univ, Dept Mech Engn, Kouhoku Ku, Kanagawa 2238521, Japan	Jefferson University; RIKEN; RIKEN; Keio University	Kholodenko, BN (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, 1020 Locust St, Philadelphia, PA 19107 USA.	Boris.Kholodenko@jefferson.edu	Okimoto, Noriaki/AAI-4656-2020; Admin, SBI/HGB-2738-2022; Susukita, Ryutaro/AAH-2264-2019; Ebisuzaki, Toshikazu/N-6998-2014; Yasuoka, Kenji/F-7643-2014; Okada, Mariko/N-6933-2015; Kiyatkin, Anatoly/A-8707-2009; Konagaya, Akihiko/F-9302-2014; Taiji, Makoto/N-1077-2014	Okimoto, Noriaki/0000-0002-2956-1317; Ebisuzaki, Toshikazu/0000-0002-3918-1166; Kiyatkin, Anatoly/0000-0002-5060-6081; Taiji, Makoto/0000-0002-5317-0500; Kholodenko, Boris/0000-0002-9483-4975; Hoek, Jan/0000-0001-7127-4218	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008714] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA08714] Funding Source: Medline; NIGMS NIH HHS [GM59570] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CASE DA, 1999, COMPUTER SIMULATIONS; Chook YM, 1996, J BIOL CHEM, V271, P30472, DOI 10.1074/jbc.271.48.30472; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Fujii Y, 2003, J PHYS CHEM B, V107, P10274, DOI 10.1021/jp034536t; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guy GR, 2002, CELL SIGNAL, V14, P11, DOI 10.1016/S0898-6568(01)00227-3; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Hayward S, 1999, PROTEINS, V36, P425, DOI 10.1002/(SICI)1097-0134(19990901)36:4<425::AID-PROT6>3.3.CO;2-J; Hayward S, 1997, PROTEINS, V27, P425, DOI 10.1002/(SICI)1097-0134(199703)27:3<425::AID-PROT10>3.0.CO;2-N; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kholodenko BN, 2000, TRENDS CELL BIOL, V10, P173, DOI 10.1016/S0962-8924(00)01741-4; Kholodenko BN, 1999, J BIOL CHEM, V274, P30169, DOI 10.1074/jbc.274.42.30169; Kitao A, 1999, CURR OPIN STRUC BIOL, V9, P164, DOI 10.1016/S0959-440X(99)80023-2; MCCAMMON JA, 1984, REP PROG PHYS, V47, P1, DOI 10.1088/0034-4885/47/1/001; Moehren G, 2002, BIOCHEMISTRY-US, V41, P306, DOI 10.1021/bi011506c; Narumi E, 1999, MOL SIMULAT, V21, P401; OKIMOTO N, 2003, CHEM BIO INFORMATICS, V3, P1; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASTRY L, 1995, ONCOGENE, V11, P1107; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Suenaga A, 2003, BIOCHEMISTRY-US, V42, P5195, DOI 10.1021/bi034113h; SWAMINATHAN S, 1991, J AM CHEM SOC, V106, P765; Ugi S, 2002, J BIOL CHEM, V277, P18592, DOI 10.1074/jbc.M201019200; Ugi S, 2002, MOL CELL BIOL, V22, P2375, DOI 10.1128/MCB.22.7.2375-2387.2002; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4; ZHOU MM, 1995, P NATL ACAD SCI USA, V92, P7784, DOI 10.1073/pnas.92.17.7784; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	36	26	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4657	4662		10.1074/jbc.M310598200	http://dx.doi.org/10.1074/jbc.M310598200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14613932	hybrid			2022-12-25	WOS:000188554300088
J	Walther, M; Wiesner, R; Kuhn, H				Walther, M; Wiesner, R; Kuhn, H			Investigations into calcium-dependent membrane association of 15-lipoxygenase-1 - Mechanistic roles of surface-exposed hydrophobic amino acids and calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; CYTOSOLIC PHOSPHOLIPASE-A2; PANCREATIC ELASTASE; MODEL MEMBRANES; BINDING-SITE; C2 DOMAIN; 5-LIPOXYGENASE; LIPOXYGENASE; TRANSLOCATION; 12-LIPOXYGENASE	Among mammalian lipoxygenases the 15-lipoxygenase-1 is somewhat special because of its capability of oxygenating complex lipid-protein assemblies (biomembranes, lipoproteins) and previous investigations have implicated calcium in enzyme/membrane interaction. We investigated the mechanism of calcium-dependent membrane association and obtained the following results. (i) Membrane binding of 15-lipoxygenase-1 involves electrostatic forces as well as hydrophobic interactions of solvent-exposed apolar amino acids (Tyr(15), Phe(70), Leu(71), Trp(181), and Leu(195)) with the hydrophobic core of membrane phospholipids. These sequence determinants of membrane association are clustered at the membrane contact plane of the enzyme that also involves the entrance to the substrate binding pocket. Site-directed mutagenesis of these determinants to negatively charged residues strongly impaired membrane binding. (ii) Calcium at micromolar concentrations (5-50 muM) is required for efficient membrane binding. For direct 15-lipoxygenase/calcium interaction a dissociation constant of 2-5x10(-4) M was determined (low affinity binding) and we failed to detect high affinity calcium-binding sites at the enzyme. Reversible low affinity calcium binding induces subtle structural alterations of the enzyme, which did not impact catalytic activity. (iii) Increasing calcium concentrations failed to reverse impairment of membrane binding induced by mutagenesis of the sequence determinants indicating the priority of hydrophobic interactions. Taken together these data suggest that 15-lipoxygenase-1 associates to biomembranes primarily via hydrophobic interactions between surface-exposed apolar amino acid side chains and membrane lipids. Calcium supports membrane binding probably by forming salt bridges between the negatively charged head groups of membrane phospholipids and acidic surface amino acids of the membrane contact plane and this interaction might contribute to overcome repulsive forces.	Humboldt Univ, Univ Clin Cahrite, Inst Biochem, D-10117 Berlin, Germany	Humboldt University of Berlin	Kuhn, H (corresponding author), Humboldt Univ, Univ Clin Cahrite, Inst Biochem, Monbijoustr 2, D-10117 Berlin, Germany.	hartmut.kuehn@charite.de						Aliberti J, 2002, NAT IMMUNOL, V3, P76, DOI 10.1038/ni745; BABA A, 1989, J BIOL CHEM, V264, P15790; BELKNER J, 1993, EUR J BIOCHEM, V213, P251, DOI 10.1111/j.1432-1033.1993.tb17755.x; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Brinckmann R, 1998, BLOOD, V91, P64, DOI 10.1182/blood.V91.1.64.64_64_74; Cathcart MK, 2000, FREE RADICAL BIO MED, V28, P1726, DOI 10.1016/S0891-5849(00)00230-6; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; CRANE FL, 1956, BIOCHIM BIOPHYS ACTA, V22, P475, DOI 10.1016/0006-3002(56)90058-0; Cyrus T, 1999, J CLIN INVEST, V103, P1597, DOI 10.1172/JCI5897; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; DEJERSEY J, 1980, BIOCHEMISTRY-US, V19, P1127, DOI 10.1021/bi00547a014; DIMICOLI JL, 1977, BIOCHEMISTRY-US, V16, P5532, DOI 10.1021/bi00644a022; Feussner I, 2002, ANNU REV PLANT BIOL, V53, P275, DOI 10.1146/annurev.arplant.53.100301.135248; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; GILMORE SA, 1998, NAT STRUCT BIOL, V5, P414; HAGMANN W, 1993, PROSTAGLANDINS, V46, P471, DOI 10.1016/0090-6980(93)90066-G; HAMASAKI Y, 1984, BIOCHIM BIOPHYS ACTA, V793, P393; Hammarberg T, 1999, BIOCHEMISTRY-US, V38, P4441, DOI 10.1021/bi9824700; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; IZUMI T, 1991, EUR J BIOCHEM, V202, P1231, DOI 10.1111/j.1432-1033.1991.tb16495.x; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; LAKOVICZ JR, 1983, PRINCIPLES FLUORESCE; May C, 2000, EUR J BIOCHEM, V267, P1100, DOI 10.1046/j.1432-1327.2000.01105.x; Muller K, 2002, CANCER RES, V62, P4610; MURRAY JJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P514, DOI 10.1016/0003-9861(88)90156-7; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; Pidgeon GP, 2002, CANCER RES, V62, P2721; RAPOPORT SM, 1979, EUR J BIOCHEM, V96, P545, DOI 10.1111/j.1432-1033.1979.tb13068.x; RAPOPORT SM, 1990, BLOOD CELL BIOCH, V1, P151; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; SCHEWE T, 1975, FEBS LETT, V60, P149, DOI 10.1016/0014-5793(75)80439-X; SMAAL EB, 1987, BIOCHIM BIOPHYS ACTA, V897, P180, DOI 10.1016/0005-2736(87)90326-9; SMAAL EB, 1986, BIOCHIM BIOPHYS ACTA, V860, P99, DOI 10.1016/0005-2736(86)90503-1; SMAAL EB, 1987, BIOCHIM BIOPHYS ACTA, V897, P453, DOI 10.1016/0005-2736(87)90442-1; Tatulian SA, 1998, BIOCHEMISTRY-US, V37, P15481, DOI 10.1021/bi981062t; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; Walther M, 2002, J BIOL CHEM, V277, P27360, DOI 10.1074/jbc.M203234200; WATSON A, 1994, BIOCHEM J, V298, P377, DOI 10.1042/bj2980377; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; YAMAMOTO S, 2002, PROSTAG OTH LIPID M, V68, P211	44	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3717	3725		10.1074/jbc.M309564200	http://dx.doi.org/10.1074/jbc.M309564200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14594811	hybrid			2022-12-25	WOS:000188379600072
J	Hiraoka, N; Kawashima, H; Petryniak, B; Nakayama, J; Mitoma, J; Marth, JD; Lowe, JB; Fukuda, M				Hiraoka, N; Kawashima, H; Petryniak, B; Nakayama, J; Mitoma, J; Marth, JD; Lowe, JB; Fukuda, M			Core 2 branching beta 1,6-N-acetylglucosaminyltransferase and high endothelial venule-restricted sulfotransferase collaboratively control lymphocyte homing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-SELECTIN LIGANDS; SIALYL-LEWIS-X; ALPHA(1,3)FUCOSYLTRANSFERASE FUC-TVII; NONOBESE DIABETIC MICE; O-GLYCANS; P-SELECTIN; MOLECULAR-CLONING; VASCULAR ADDRESSIN; TYROSINE SULFATION; GOLGI RETENTION	L-selectin mediates lymphocyte homing by facilitating lymphocyte adhesion to carbohydrate ligands expressed on high endothelial venules (HEV) of the secondary lymphoid organs. Previous studies demonstrated that L-selectin ligand sulfotransferase ( LSST) forms 6-sulfo sialyl Lewis x (sLe(x)) on both core 2 branch and MECA-79-positive extended core 1 O-glycans, but the chemical nature and roles of HEV ligands elaborated by LSST and core 2 beta1,6-N-acetylglucosaminyltransferase-1 (Core2GlcNAcT) have been undefined. In the present study, we have generated mutant mice with deficient LSST and show that inactivation of LSST gene alone leads to only partial impairment of lymphocyte homing to peripheral lymph nodes and moderate reduction in lymphocyte counts in the peripheral lymph nodes, despite the fact that L-selectin ligands that contain 6-sulfo sLe(x) are reduced at HEV. By contrast, LSST/Core2GlcNAcT double null mice exhibited a markedly reduced lymphocyte homing and reduced lymphocyte counts as a result of significantly decreased 6-sulfo sLe(x) on HEV L-selectin counterreceptors, relative to LSST-or Core2GlcNAcT-single null mice. Moreover, induction of LSST and Core2GlcNAcT transcripts was observed in HEV-like structure formed in the salivary gland of the non-obese diabetic mouse, which displays chronic inflammation. These results indicate that LSST and Core2GlcNAcT cooperatively synthesize HEV-specific L-selectin ligands required for lymphocyte homing and suggest that LSST and Core2GlcNAcT play a critical role in lymphocyte trafficking during chronic inflammation.	Burnham Inst, Ctr Canc Res, Glycobiol Program, La Jolla, CA 92037 USA; Univ Michigan, Sch Med, Dept Pathol, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Shinshu Univ, Sch Med, Dept Pathol, Matsumoto, Nagano 3908621, Japan; Univ Calif San Diego, Howard Hughes Med Inst, Div Cellular & Mol Med, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Shinshu University; Howard Hughes Medical Institute; University of California System; University of California San Diego	Fukuda, M (corresponding author), Burnham Inst, Ctr Canc Res, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	minoru@burnham.org			NATIONAL CANCER INSTITUTE [P01CA071932, R37CA033000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048247] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA71932, R37CA33000] Funding Source: Medline; NIDDK NIH HHS [DK48247] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Bruehl RE, 2000, J BIOL CHEM, V275, P32642, DOI 10.1074/jbc.M001703200; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Clark RA, 1998, J CELL BIOL, V140, P721, DOI 10.1083/jcb.140.3.721; Ellies LG, 1998, IMMUNITY, V9, P881, DOI 10.1016/S1074-7613(00)80653-6; FAVEEUW C, 1994, J IMMUNOL, V152, P5969; Fieger CB, 2003, J BIOL CHEM, V278, P27390, DOI 10.1074/jbc.M304204200; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; Fukuda M, 1999, J CELL BIOL, V147, P467, DOI 10.1083/jcb.147.3.467; Fukuda M, 2001, J BIOL CHEM, V276, P47747, DOI 10.1074/jbc.R100049200; HANNINEN A, 1993, J CLIN INVEST, V92, P2509, DOI 10.1172/JCI116859; Hemmerich S, 2001, IMMUNITY, V15, P237, DOI 10.1016/S1074-7613(01)00188-1; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Homeister JW, 2001, IMMUNITY, V15, P115, DOI 10.1016/S1074-7613(01)00166-2; IMAI Y, 1993, NATURE, V361, P555; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kawashima H, 2003, J BIOL CHEM, V278, P13069, DOI 10.1074/jbc.M212244200; Kimura N, 1999, P NATL ACAD SCI USA, V96, P4530, DOI 10.1073/pnas.96.8.4530; Kunkel EJ, 1998, J IMMUNOL, V161, P2449; KYTZIA HJ, 1985, J BIOL CHEM, V260, P7568; Leppanen A, 2003, J BIOL CHEM, V278, P26391, DOI 10.1074/jbc.M303551200; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MICHIE SA, 1995, AM J PATHOL, V147, P412; MICHIE SA, 1993, AM J PATHOL, V143, P1688; Mitoma J, 2003, J BIOL CHEM, V278, P9953, DOI 10.1074/jbc.M212756200; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; Priatel JJ, 2000, IMMUNITY, V12, P273, DOI 10.1016/S1074-7613(00)80180-6; Rosen SD, 1999, AM J PATHOL, V155, P1013, DOI 10.1016/S0002-9440(10)65201-7; SALMI M, 1994, GASTROENTEROLOGY, V106, P596, DOI 10.1016/0016-5085(94)90691-2; Satomaa T, 2002, BLOOD, V99, P2609, DOI 10.1182/blood.V99.7.2609; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; Suzuki A, 1996, BLOOD, V87, P3550, DOI 10.1182/blood.V87.9.3550.bloodjournal8793550; Tangemann K, 1999, J EXP MED, V190, P935, DOI 10.1084/jem.190.7.935; Toppila S, 1999, AM J PATHOL, V155, P1303, DOI 10.1016/S0002-9440(10)65232-7; TURUNEN JP, 1995, J EXP MED, V182, P1133, DOI 10.1084/jem.182.4.1133; Uchimura K, 2002, J BIOL CHEM, V277, P3979, DOI 10.1074/jbc.M106587200; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; VANDINTHERJANSSEN ACHM, 1990, J RHEUMATOL, V17, P11; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407; Wang LC, 2002, J CLIN INVEST, V110, P127, DOI 10.1172/JCI200214996; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215	53	60	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					3058	3067		10.1074/jbc.M311150200	http://dx.doi.org/10.1074/jbc.M311150200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14593101	hybrid			2022-12-25	WOS:000188211300087
J	Kettritz, R; Choi, M; Rolle, S; Wellner, M; Luft, FC				Kettritz, R; Choi, M; Rolle, S; Wellner, M; Luft, FC			Integrins and cytokines activate nuclear transcription factor-kappa B in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; CONSTITUTIVE APOPTOSIS; GRANULOCYTE APOPTOSIS; BETA(2) INTEGRINS; GENE-EXPRESSION; KINASE PATHWAY; SYK; INHIBITION; ALPHA; ADHERENT	Neutrophil adhesion to extracellular matrix is necessary for an effective inflammatory response. Adhesion may accelerate neutrophil activation by affecting intracellular signaling pathways. The nuclear transcription factor kappaB (NF-kappaB) controls several cellular functions, including inflammation, proliferation, and cell survival. We explored the role of adhesion in NF-kappaB activation in human neutrophils. Cells were stimulated with tumor necrosis factor-alpha (TNF-alpha), granulocyte macrophage-colony-stimulating factor (GM-CSF), interleukin-8 (IL-8), and formyl-methionyl-leucyl-phenylalanine (fMLP). All four initiated neutrophil adherence to and spreading on fibronectin. GM-CSF and IL-8 did not activate NF-kappaB in suspended neutrophils but rapidly activated NF-kappaB under adherent conditions on matrix, as shown by IkappaB kinase activity assay, IkappaBalpha degradation, electromobility shift assay, and quantitative reverse transcriptase-PCR. In contrast, TNF-alpha activated NF-kappaB both in suspended cells and adherent cells. fMLP did not activate NF-kappaB in either suspended or adherent cells. Specific beta(2) integrin blockade prevented NF-kappaB activation by GM-CSF and IL-8 on fibronectin. Co-stimulating CD18 and CD11b with activating antibodies resulted in NF-kappaB activation by GM-CSF and IL-8 in suspended cells. We inhibited actin polymerization with cytochalasin and blocked the non-receptor kinase Syk with piceatannol. Both maneuvers prevented the co-stimulatory NF-kappaB-activating signal by beta(2) integrins. Thus, in addition to beta(2) integrin ligand binding, NF-kappaB activation depended on the formation of the receptor-associated intracellular focal adhesion complex. We conclude that beta(2) integrins may provide co-stimulatory signals allowing some soluble mediators to activate the NF-kappaB pathway even when they are not capable of doing so in suspension. This effect may become important when human neutrophils leave the circulating blood and migrate through extracellular matrix during inflammation.	HELIOS Klin, Franz Volhard Clin, Dept Hypertens & Nephrol, Charite,Fac Med, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany	Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helios Kliniken; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kettritz, R (corresponding author), Wiltberg Str 50, D-13125 Berlin, Germany.	kettritz@fvk-berlin.de		Luft, Friedrich/0000-0002-8635-1199; Kettritz, Ralph/0000-0001-5821-6718; Choi, Mira/0000-0002-0286-1491				Akgul C, 2001, FEBS LETT, V487, P318, DOI 10.1016/S0014-5793(00)02324-3; ATHENS JW, 1961, J CLIN INVEST, V40, P989, DOI 10.1172/JCI104338; Avdi NJ, 2001, J BIOL CHEM, V276, P2189, DOI 10.1074/jbc.M007527200; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; Bhullar IS, 1998, J BIOL CHEM, V273, P30544, DOI 10.1074/jbc.273.46.30544; Castro-Alcaraz S, 2002, J IMMUNOL, V169, P3947, DOI 10.4049/jimmunol.169.7.3947; Choi M, 2003, BLOOD, V102, P2259, DOI 10.1182/blood-2002-09-2960; Fernandez R, 1998, J IMMUNOL, V160, P5154; FUORTES M, 1993, J CELL BIOL, V120, P777, DOI 10.1083/jcb.120.3.777; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; Harris ES, 2000, J BIOL CHEM, V275, P23409, DOI 10.1074/jbc.R000004200; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Hogg N, 2002, IMMUNOL REV, V186, P164, DOI 10.1034/j.1600-065X.2002.18614.x; KARIN M, 1998, CANC J SCI AM S1, V4, P92; Kettritz R, 2001, J AM SOC NEPHROL, V12, P37, DOI 10.1681/ASN.V12137; Klein JB, 2000, J IMMUNOL, V164, P4286, DOI 10.4049/jimmunol.164.8.4286; Klein S, 2002, MOL CELL BIOL, V22, P5912, DOI 10.1128/MCB.22.16.5912-5922.2002; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Law DA, 1999, BLOOD, V93, P2645, DOI 10.1182/blood.V93.8.2645.408k13_2645_2652; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; McDonald PP, 1997, BLOOD, V89, P3421, DOI 10.1182/blood.V89.9.3421; McDonald PP, 1997, FEBS LETT, V412, P583, DOI 10.1016/S0014-5793(97)00857-0; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P537, DOI 10.1002/jlb.64.4.537; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Mocsai A, 2002, IMMUNITY, V16, P547, DOI 10.1016/S1074-7613(02)00303-5; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; Niwa M, 2000, EUR J PHARMACOL, V407, P211, DOI 10.1016/S0014-2999(00)00735-4; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Renshaw SA, 2003, J IMMUNOL, V170, P1027, DOI 10.4049/jimmunol.170.2.1027; Rezzonico R, 2001, BLOOD, V97, P2932, DOI 10.1182/blood.V97.10.2932; RICHTER J, 1990, P NATL ACAD SCI USA, V87, P9472, DOI 10.1073/pnas.87.23.9472; Rossetti G, 2002, IMMUNOL REV, V186, P189, DOI 10.1034/j.1600-065X.2002.18616.x; Rubel C, 2003, EUR J IMMUNOL, V33, P1429, DOI 10.1002/eji.200323512; Sabroe I, 2003, J IMMUNOL, V170, P5268, DOI 10.4049/jimmunol.170.10.5268; Schnitzler N, 1999, NAT MED, V5, P231, DOI 10.1038/5597; Schwartz MA, 2001, TRENDS CELL BIOL, V11, P466, DOI 10.1016/S0962-8924(01)02152-3; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; Sitrin RG, 1998, J IMMUNOL, V161, P1462; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; Tsubata T, 2001, Int Rev Immunol, V20, P675, DOI 10.3109/08830180109045584; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; Wang KQ, 2003, J IMMUNOL, V171, P1035, DOI 10.4049/jimmunol.171.2.1035; Ward C, 2002, J IMMUNOL, V168, P6232, DOI 10.4049/jimmunol.168.12.6232; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; Whitlock BB, 2000, J CELL BIOL, V151, P1305, DOI 10.1083/jcb.151.6.1305; Willeke T, 2003, J LEUKOCYTE BIOL, V74, P260, DOI 10.1189/jlb.0102016; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; Yan SR, 1997, J IMMUNOL, V158, P1902	53	69	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2657	2665		10.1074/jbc.M309778200	http://dx.doi.org/10.1074/jbc.M309778200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14613935	hybrid			2022-12-25	WOS:000188211300041
J	Lehtonen, J; Shen, BR; Vihinen, M; Casini, A; Scozzafava, A; Supuran, CT; Parkkila, AK; Saarnio, J; Kivela, AJ; Waheed, A; Sly, WS; Parkkila, S				Lehtonen, J; Shen, BR; Vihinen, M; Casini, A; Scozzafava, A; Supuran, CT; Parkkila, AK; Saarnio, J; Kivela, AJ; Waheed, A; Sly, WS; Parkkila, S			Characterization of CA XIII, a novel member of the carbonic anhydrase isozyme family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; IMMUNOHISTOCHEMICAL LOCALIZATION; CATALYTIC-PROPERTIES; INHIBITORS; IDENTIFICATION; TRANSMEMBRANE; SEQUENCE; BINDING; DOMAIN	The carbonic anhydrase (CA) gene family has been reported to consist of at least 11 enzymatically active members and a few inactive homologous proteins. Recent analyses of human and mouse databases provided evidence that human and mouse genomes contain genes for still another novel CA isozyme hereby named CA XIII. In the present study, we modeled the structure of human CA XIII. This model revealed a globular molecule with high structural similarity to cytosolic isozymes, CA I, II, and III. Recombinant mouse CA XIII showed catalytic activity similar to those of mitochondrial CA V and cytosolic CA I, with k(cat)/K-m of 4.3 x 10(7) M-1 s(-1), and k(cat) of 8.3 x 10(4) s(-1). It is very susceptible to inhibition by sulfonamide and anionic inhibitors, with inhibition constants of 17 nM for acetazolamide, a clinically used sulfonamide, and of 0.25 muM, for cyanate, respectively. Using panels of cDNAs we evaluated human and mouse CA13 gene expression in a number of different tissues. In human tissues, positive signals were identified in the thymus, small intestine, spleen, prostate, ovary, colon, and testis. In mouse, positive tissues included the spleen, lung, kidney, heart, brain, skeletal muscle, and testis. We also investigated the cellular and subcellular localization of CA XIII in human and mouse tissues using an antibody raised against a polypeptide of 14 amino acids common for both human and mouse orthologues. Immunohistochemical staining showed a unique and widespread distribution pattern for CA XIII compared with the other cytosolic CA isozymes. In conclusion, the predicted amino acid sequence, structural model, distribution, and activity data suggest that CA XIII represents a novel enzyme, which may play important physiological roles in several organs.	Univ Tampere, Inst Med Technol, Tampere 33520, Finland; Univ Tampere, Dept Neurol, Tampere 33520, Finland; Tampere Univ Hosp, Tampere 33520, Finland; Univ Florence, Dipartimento Chim, Lab Chim Bioinorgan, I-50019 Florence, Italy; Univ Oulu, Dept Surg, SF-90220 Oulu, Finland; Univ Oulu, Dept Anat & Cell Biol, SF-90220 Oulu, Finland; Univ Oulu, Dept Clin Chem, SF-90220 Oulu, Finland; St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Tampere University; Tampere University; Tampere University; Tampere University Hospital; University of Florence; University of Oulu; University of Oulu; University of Oulu; Saint Louis University	Parkkila, S (corresponding author), Univ Tampere, Inst Med Technol, Lenkkeilijankatu 8, Tampere 33520, Finland.	Seppo.Parkkila@uta.fi	Shen, Bairong/E-6431-2012; Supuran, Claudiu T/A-5151-2008; Casini, Angela/E-6731-2014; Vihinen, Mauno/A-8452-2012; Shen, Bairong/W-1254-2019; Casini, Angela/Q-1701-2019	Shen, Bairong/0000-0003-2899-1531; Casini, Angela/0000-0003-1599-9542; Vihinen, Mauno/0000-0002-9614-7976; Shen, Bairong/0000-0003-2899-1531; Casini, Angela/0000-0003-1599-9542; Scozzafava, Andrea/0000-0001-5020-3322; Supuran, Claudiu/0000-0003-4262-0323; Parkkila, Seppo/0000-0001-7323-8536	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034182, R37GM034182] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40163] Funding Source: Medline; NIGMS NIH HHS [GM34182] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; BEHRAVAN G, 1991, EUR J BIOCHEM, V195, P393, DOI 10.1111/j.1432-1033.1991.tb15718.x; CHAKRAVARTY S, 1994, J MOL BIOL, V243, P298, DOI 10.1006/jmbi.1994.1655; Ferraroni M, 2002, BIOCHEMISTRY-US, V41, P6237, DOI 10.1021/bi0120446; Ferraroni M, 2002, INORG CHIM ACTA, V339, P135, DOI 10.1016/S0020-1693(02)00959-3; FLEMING RE, 1994, AM J RESP CELL MOL, V10, P499, DOI 10.1165/ajrcmb.10.5.7514010; Franchi M, 2003, BIOORG MED CHEM LETT, V13, P2857, DOI 10.1016/S0960-894X(03)00581-X; FRIEDLEY NJ, 1975, BIOL REPROD, V12, P293, DOI 10.1095/biolreprod12.2.293; GHANDOUR MS, 1989, J NEUROSCI RES, V23, P180, DOI 10.1002/jnr.490230208; HewettEmmett D, 1996, MOL PHYLOGENET EVOL, V5, P50, DOI 10.1006/mpev.1996.0006; Karhumaa P, 2000, MOL HUM REPROD, V6, P68, DOI 10.1093/molehr/6.1.68; KAUNISTO K, 1990, HISTOCHEMISTRY, V94, P381; KHALIFAH RG, 1971, J BIOL CHEM, V246, P2561; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; KUMPULAINEN T, 1982, J HISTOCHEM CYTOCHEM, V30, P283, DOI 10.1177/30.4.6801110; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY JB, 1993, J BIOL CHEM, V268, P10573; LOGRASSO PV, 1993, BIOCHEMISTRY-US, V32, P5786, DOI 10.1021/bi00073a010; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; OKAMURA N, 1985, J BIOL CHEM, V260, P9699; PARKKILA AK, 1993, HISTOCHEMISTRY, V99, P37, DOI 10.1007/BF00268018; Parkkila S, 1996, SCAND J GASTROENTERO, V31, P305, DOI 10.3109/00365529609006403; PARKKILA S, 1991, HISTOCHEMISTRY, V95, P477, DOI 10.1007/BF00315743; Rodriguez R, 1998, BIOINFORMATICS, V14, P523, DOI 10.1093/bioinformatics/14.6.523; Sanchez R, 1997, CURR OPIN STRUC BIOL, V7, P206, DOI 10.1016/S0959-440X(97)80027-9; Scozzafava A, 2000, J MED CHEM, V43, P4542, DOI 10.1021/jm000296j; SKAGGS LA, 1993, GENE, V126, P291, DOI 10.1016/0378-1119(93)90385-G; SLY WS, 1995, ANNU REV BIOCHEM, V64, P375, DOI 10.1146/annurev.bi.64.070195.002111; Supuran CT, 2003, MED RES REV, V23, P146, DOI 10.1002/med.10025; Swofford D., 2001, PAUP 4 0; Tashian RE, 2000, EXS, V90, P105; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vullo D, 2003, J ENZYM INHIB MED CH, V18, P403, DOI 10.1080/1475636031000138732; ZHEN HG, 1988, BIOL REPROD, V38, P439, DOI 10.1095/biolreprod38.2.439	34	195	203	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2719	2727		10.1074/jbc.M308984200	http://dx.doi.org/10.1074/jbc.M308984200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14600151	hybrid, Green Accepted			2022-12-25	WOS:000188211300049
J	Marion, S; Weiner, DM; Caron, MG				Marion, S; Weiner, DM; Caron, MG			RNA editing induces variation in desensitization and trafficking of 5-hydroxytryptamine 2c receptor isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; CONSTITUTIVE ACTIVATION; ADRENERGIC-RECEPTOR; MEDIATED DESENSITIZATION; 5-HT2C RECEPTOR; IN-VITRO; AGONIST; PHOSPHORYLATION	The 5-hydroxytryptamine2c receptor (5-HT2cR) is subjected to RNA editing, in the second intracellular loop, generating 14 different isoforms in human brain. This post-transcriptional event markedly alters the signaling properties of the receptor by reducing its ability to couple to G-proteins. Although the non-edited form of the receptor is essentially fully constitutively active, edited forms show lesser degrees of constitutive activity. We have used two extensively edited receptor isoforms, VGV and VSV, and the non-edited INI isoform to investigate how variations in constitutive receptor activity affect the trafficking and the interaction of these isoforms with components of the desensitization machinery in HEK 293 cells. We found that cell surface expression of the 5-HT2cR decreased in parallel with increased constitutive activity of the isoforms. The subcellular distribution of the various isoforms was dependent of their ability to interact with betaarrestin2, which correlated with the constitutive activity level of each isoform. We observed that the agonist-independent interaction of betaarrestin2 with constitutively active 5-HT2cR isoforms was reversed by inverse agonist treatments promoting receptor redistribution to the cell surface. Overexpression of a G-protein-coupled receptor kinase (GRK2) was able to stabilize the interaction of betaarrestin2 with constitutively active 5-HT2cR isoforms even in the presence of inverse agonists. Taken together, our observations indicate that the constitutively active 5-HT2cR isoforms are spontaneously internalized in an agonist-independent manner. This endocytosis process is mediated by a GRK/betaarrestin-dependent mechanism and is directly correlated with the constitutive activity status of the RNA edited receptor variants. Thus the ultimate physiological output of constitutively active receptors may be determined not only by their agonist-independent activity but also by their interactions with GRKs and betaarrestin.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Univ Calif San Diego, ACADIA Pharmaceut, San Diego, CA 92121 USA; Univ Calif San Diego, Dept Neurosci, San Diego, CA 92121 USA; Univ Calif San Diego, Dept Psychiat, San Diego, CA 92121 USA	Duke University; Duke University; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Caron, MG (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Box 3287, Durham, NC 27710 USA.	caron002@mc.duke.edu		Marion, Sebastien/0000-0002-3302-3845	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER; NINDS NIH HHS [NS19576] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Barak LS, 2001, P NATL ACAD SCI USA, V98, P93, DOI 10.1073/pnas.011303698; Bennett TA, 2000, J BIOL CHEM, V275, P24590, DOI 10.1074/jbc.C000314200; Berg KA, 2001, J PHARMACOL EXP THER, V299, P593; Blaukat A, 2001, J BIOL CHEM, V276, P40431, DOI 10.1074/jbc.M107024200; Bouaboula M, 1999, J BIOL CHEM, V274, P20397, DOI 10.1074/jbc.274.29.20397; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Chang M, 2000, J BIOL CHEM, V275, P7021, DOI 10.1074/jbc.275.10.7021; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; DAUTRYVARSAT A, 1986, BIOCHIMIE, V68, P375, DOI 10.1016/S0300-9084(86)80004-9; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Kennett GA, 1996, BRIT J PHARMACOL, V117, P427, DOI 10.1111/j.1476-5381.1996.tb15208.x; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KONG GH, 1994, J BIOL CHEM, V269, P13084; Liu Y, 1999, J BIOL CHEM, V274, P18351, DOI 10.1074/jbc.274.26.18351; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Miller WE, 2003, J BIOL CHEM, V278, P21663, DOI 10.1074/jbc.M303219200; Morin D, 1998, FEBS LETT, V441, P470, DOI 10.1016/S0014-5793(98)01585-3; Niswender CM, 1999, J BIOL CHEM, V274, P9472, DOI 10.1074/jbc.274.14.9472; Niswender CM, 1998, ANN NY ACAD SCI, V861, P38, DOI 10.1111/j.1749-6632.1998.tb10171.x; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Prezeau L, 1996, MOL PHARMACOL, V49, P422; Price RD, 2001, J BIOL CHEM, V276, P44663, DOI 10.1074/jbc.M106745200; Prioleau C, 2002, J BIOL CHEM, V277, P36577, DOI 10.1074/jbc.M206223200; Quitterer U, 1996, BIOCHEMISTRY-US, V35, P13368, DOI 10.1021/bi961163w; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; Sallese M, 2000, MOL PHARMACOL, V57, P826, DOI 10.1124/mol.57.4.826; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; van Dam EM, 2002, MOL BIOL CELL, V13, P169, DOI 10.1091/mbc.01-07-0380; Weiner DM, 2001, J PHARMACOL EXP THER, V299, P268; WESTPHAL RS, 1995, MOL PHARMACOL, V48, P200; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999	45	123	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2945	2954		10.1074/jbc.M308742200	http://dx.doi.org/10.1074/jbc.M308742200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14602721	hybrid			2022-12-25	WOS:000188211300075
J	Oestergaard, VH; Bjergbaek, L; Skouboe, C; Giangiacomo, L; Knudsen, BR; Andersen, AH				Oestergaard, VH; Bjergbaek, L; Skouboe, C; Giangiacomo, L; Knudsen, BR; Andersen, AH			The transducer domain is important for clamp operation in human DNA topoisomerase II alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; CRYSTAL-STRUCTURE; ONE ATP; MECHANISM; TRANSPORT; PROTEIN; ENZYME; SITE; RELIGATION	DNA topoisomerase II is a multidomain homodimeric enzyme that changes DNA topology by coupling ATP hydrolysis to the transport of one DNA helix through a transient double-stranded break in another. The process requires dramatic conformational changes including closure of an ATP-operated clamp, which is comprised of two N-terminal domains from each protomer. The most N-terminal domain contains the ATP-binding site and is directly involved in clamp closure, undergoing dimerization upon ATP binding. The second domain, the transducer domain, forms the walls of the N-terminal clamp and connects the clamp to the enzyme core. Although structurally conserved, it is unclear whether the transducer domain is involved in clamp mechanism. We have purified and characterized a human topoisomerase IIalpha enzyme with a two-amino acid insertion at position 408 in the transducer domain. The enzyme retains both ATPase and DNA cleavage activities. However, the insertion, which is situated far from the N-terminal dimerization area, severely disrupts the function of the N-terminal clamp. The clamp-deficient enzyme is catalytically inactive and lacks most aspects of interdomain communication. Surprisingly, it seems to have retained the intersubunit communication, allowing it to bind ATP cooperatively in the presence of DNA. The results show that even distal parts of the transducer domain are important for the dynamics of the N-terminal clamp and furthermore indicate that stable clamp closure is not required for cooperative binding of ATP.	Univ Aarhus, Dept Mol Biol, DK-8000 Aarhus C, Denmark	Aarhus University	Andersen, AH (corresponding author), Univ Aarhus, Dept Mol Biol, CF Mollers Alle,Bldg 130, DK-8000 Aarhus C, Denmark.	aha@mb.au.dk	Bjergbæk, Lotte/AAW-6302-2021; Oestergaard, Vibe Hallundbæk/B-7254-2015; Andersen, Anni/O-1162-2017	Oestergaard, Vibe Hallundbæk/0000-0002-1633-0560; Bjergbaek, Lotte/0000-0002-8233-3356				ANDERSEN AH, 1991, J BIOL CHEM, V266, P9203; Baird CL, 1999, P NATL ACAD SCI USA, V96, P13685, DOI 10.1073/pnas.96.24.13685; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Berger JM, 1998, P NATL ACAD SCI USA, V95, P7876, DOI 10.1073/pnas.95.14.7876; Biersack H, 1996, P NATL ACAD SCI USA, V93, P8288, DOI 10.1073/pnas.93.16.8288; Bjergbaek L, 2000, J BIOL CHEM, V275, P13041, DOI 10.1074/jbc.275.17.13041; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; CLASSEN S, 2003, P NATL ACAD SCI US; Corbett KD, 2003, EMBO J, V22, P151, DOI 10.1093/emboj/cdg008; CRENSHAW DG, 1993, J BIOL CHEM, V268, P21335; DeLano W, 2002, PYMOL 0 99; Fass D, 1999, NAT STRUCT BIOL, V6, P322; GOCKE E, 1983, NUCLEIC ACIDS RES, V11, P7661, DOI 10.1093/nar/11.22.7661; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Hu T, 1998, J BIOL CHEM, V273, P9586, DOI 10.1074/jbc.273.16.9586; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jensen S, 1996, MOL CELL BIOL, V16, P3866; Lamour V, 2002, J BIOL CHEM, V277, P18947, DOI 10.1074/jbc.M111740200; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; Mao Y, 1999, BIOCHEMISTRY-US, V38, P10793, DOI 10.1021/bi9909804; Morris SNK, 1999, J BIOL CHEM, V274, P3446, DOI 10.1074/jbc.274.6.3446; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; REECE RJ, 1989, J BIOL CHEM, V264, P19648; ROBINSON MJ, 1990, BIOCHEMISTRY-US, V29, P2511, DOI 10.1021/bi00462a012; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SHIOZAKI K, 1991, MOL CELL BIOL, V11, P6093, DOI 10.1128/MCB.11.12.6093; Skouboe C, 2003, J BIOL CHEM, V278, P5768, DOI 10.1074/jbc.M210332200; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	34	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1684	1691		10.1074/jbc.M309624200	http://dx.doi.org/10.1074/jbc.M309624200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14583603	hybrid			2022-12-25	WOS:000188005700017
J	Falcone, G; Ciuffini, L; Gauzzi, MC; Provenzano, C; Strano, S; Gallo, R; Castellani, L; Alema, S				Falcone, G; Ciuffini, L; Gauzzi, MC; Provenzano, C; Strano, S; Gallo, R; Castellani, L; Alema, S			V-Src inhibits myogenic differentiation by interfering with the regulatory network of muscle-specific transcriptional activators at multiple levels	ONCOGENE			English	Article						myogenesis; MyoD; cell cycle; tyrosine kinase; p300	CELL-CYCLE ARREST; HELIX-LOOP-HELIX; CHROMATIN REMODELING ENZYMES; TERMINAL DIFFERENTIATION; SKELETAL-MUSCLE; QUAIL MYOTUBES; DNA-BINDING; MOLECULAR-MECHANISMS; GENE-TRANSCRIPTION; TYROSINE KINASE	The conversion of skeletal myoblasts to terminally differentiated myocytes is negatively controlled by several growth factors and oncoproteins. In this study, we have investigated the molecular mechanisms by which v-Src, a prototypic tyrosine kinase, perturbs myogenesis in primary avian myoblasts and in established murine C2C12 satellite cells. We determined the expression levels of the cell cycle regulators pRb, cyclin D1 and D3 and cyclin-dependent kinase inhibitors p21 and p27 in v-Src-transformed myoblasts and found that, in contrast to myogenin, they are normally modulated by differentiative cues, implying that v-Src affects myogenesis independent of cell proliferation. We then examined the levels of expression, DNA-binding ability and transcription-activation potentials of myogenic regulatory factors in transformed myoblasts and in myotubes after reactivation of a temperature-sensitive allele of v-Src. Our results reveal two distinct potential modes of repression targeted to myogenic factors. On the one hand, we show that v-Src reversibly inhibits the expression of MyoD and myogenin in C2C12 cells and of myogenin in quail myoblasts. Remarkably, these loci become resistant to activation of the kinase in the postmitotic compartment. On the other hand, we demonstrate that v-Src efficiently inhibits muscle gene expression by repressing the transcriptional activity of myogenic factors without affecting MyoD DNA-binding activity. Indeed, forced expression of MyoD and myogenin allows terminal differentiation of transformed myoblasts. Finally, we found that ectopic expression of the coactivator p300 restores transcription from extrachromosomal muscle-specific promoters.	CNR, Ist Biol Cellulare, I-00016 Monterotondo, Italy; Univ Cassino, I-03043 Cassino, Italy; INFM, SezB, Cassino, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Cassino; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR)	Falcone, G (corresponding author), CNR, Ist Biol Cellulare, Via Ramarini 32, I-00016 Monterotondo, Italy.	gfalcone@ibc.cnr.it; alema@ibc.cnr.it	Gauzzi, Maria Cristina/N-7038-2017; strano, sabrina/B-6743-2013; Falcone, Germana/A-3735-2016; Strano, Sabrina/K-9654-2016	Gauzzi, Maria Cristina/0000-0002-2996-5231; strano, sabrina/0000-0002-6341-4230; Castellani, Loriana/0000-0002-8519-3504; Falcone, Germana/0000-0002-3508-7623; Alema, Stefano/0000-0002-9869-6354				Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BOETTIGER D, 1989, CURR TOP MICROBIOL, V147, P31; CARUSO M, 1993, ONCOGENE, V8, P267; CASTELLANI L, 1995, J CELL BIOL, V130, P871, DOI 10.1083/jcb.130.4.871; Castellani L, 1996, J CELL SCI, V109, P1335; Chan HM, 2001, J CELL SCI, V114, P2363; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FALCONE G, 1984, EMBO J, V3, P1327, DOI 10.1002/j.1460-2075.1984.tb01971.x; Gallo R, 1997, ONCOGENE, V15, P1929, DOI 10.1038/sj.onc.1201344; Gallo R, 1999, MOL BIOL CELL, V10, P3137, DOI 10.1091/mbc.10.10.3137; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Iezzi S, 2002, P NATL ACAD SCI USA, V99, P7757, DOI 10.1073/pnas.112218599; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Johnson SE, 2002, J BIOL CHEM, V277, P28742, DOI 10.1074/jbc.M203680200; JOHNSTON LA, 1992, MOL CELL BIOL, V12, P5123, DOI 10.1128/MCB.12.11.5123; KIESS M, 1995, ONCOGENE, V10, P159; KONG YF, 1995, MOL CELL BIOL, V15, P5205; KONIECZNY SF, 1989, ONCOGENE, V4, P473; La Rocca SA, 2002, ONCOGENE, V21, P4838, DOI 10.1038/sj.onc.1205586; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Lazaro JB, 2002, GENE DEV, V16, P1792, DOI 10.1101/gad.U-9988R; Liu LN, 1998, CELL GROWTH DIFFER, V9, P699; MAIONE R, 1997, BIOCHIM BIOPHYS ACTA, V1332, P19; MARTELLI F, 1994, ONCOGENE, V9, P3579; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Perry RLS, 2001, MOL CELL, V8, P291, DOI 10.1016/S1097-2765(01)00302-1; PINNEY DF, 1995, DEV BIOL, V170, P21, DOI 10.1006/dbio.1995.1192; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; POWNALL ME, 1992, DEV BIOL, V151, P67, DOI 10.1016/0012-1606(92)90214-2; Puri PL, 2002, NAT GENET, V32, P585, DOI 10.1038/ng1023; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Roy K, 2002, J BIOL CHEM, V277, P33818, DOI 10.1074/jbc.M205159200; Russo S, 1997, ONCOGENE, V14, P63, DOI 10.1038/sj.onc.1200805; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wei Q, 2001, FEBS LETT, V490, P171, DOI 10.1016/S0014-5793(01)02120-2; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WELHAM MJ, 1990, ONCOGENE, V5, P161; Winter B, 2000, J CELL SCI, V113, P4211; YOON HY, 1994, ONCOGENE, V9, P801; Zabludoff SD, 1998, CELL GROWTH DIFFER, V9, P1; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926	63	11	12	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2003	22	51					8302	8315		10.1038/sj.onc.1206915	http://dx.doi.org/10.1038/sj.onc.1206915			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614454				2022-12-25	WOS:000186541500009
J	Kartasheva, NN; Lenz-Bauer, C; Hartmann, O; Schafer, H; Eilers, M; Dobbelstein, M				Kartasheva, NN; Lenz-Bauer, C; Hartmann, O; Schafer, H; Eilers, M; Dobbelstein, M			Delta Np73 can modulate the expression of various genes in a p53-independent fashion	ONCOGENE			English	Article						p53; p73; EGR1; NF-kappa B; c-MYC	WILD-TYPE P53; NF-KAPPA-B; P73 GENE; C-MYC; TRANSCRIPTION; MICROARRAY; INHIBITOR; CANCER; OVEREXPRESSION; NEUROBLASTOMA	DeltaNp73alpha is an isoform of the p53 homologue p73 that lacks an amino-terminal transactivation domain and antagonizes the induction of gene expression by p53. Here, we examined whether DeltaNp73alpha might also modulate cellular transcription in the absence of p53. The expression of DeltaNp73alpha in the p53-/- cell line H1299 reduced the mRNA levels of p21/CDKN1A, but did not affect other p53-responsive genes. Correspondingly, the p21/CDKN1A promoter was downregulated by DeltaNp73alpha in reporter assays, whereas other p53-responsive promoters were not inhibited. To identify additional genes that respond to DeltaNp73alpha in the absence of p53, microarrays carrying 4600 cDNA clones were hybridized. The expression of 30 genes was found to be altered more than threefold by overexpressed DeltaNp73alpha. For instance, DeltaNp73alpha increased the expression of EGR1 and CDC6, whereas it decreased the mRNA levels of c-MYC, cyclin A2/CCNA2, NF-kappaB1, ODC1, and RET finger protein/RFP. Semiquantitative reverse transcription-PCR confirmed these results and further revealed that the influence of DeltaNp73alpha on the regulation of these genes differs from other p73 isoforms and p53. We conclude that the impact of DeltaNp73alpha on gene expression is not limited to p53-responsive genes. Rather, DeltaNp73alpha can regulate the expression of a variety of genes independently of p53.	Univ Marburg, Inst Virol, D-35037 Marburg, Germany; Univ Marburg, Inst Mol Biol & Tumor Res IMT, D-35033 Marburg, Germany; Univ Marburg, Inst Med Biometrie & Epidemiol, D-35037 Marburg, Germany; Russian Acad Sci, Inst Mol Genet, Moscow 123182, Russia	Philipps University Marburg; Philipps University Marburg; Philipps University Marburg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Russian Academy of Sciences	Dobbelstein, M (corresponding author), Univ Marburg, Inst Virol, Robert Koch Str 17, D-35037 Marburg, Germany.	dobbelst@mailer.uni-marburg.de		Dobbelstein, Matthias/0000-0001-5052-3967; Eilers, Martin/0000-0002-0376-6533				Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Adamson ED, 2002, TUMOR BIOL, V23, P93, DOI 10.1159/000059711; Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Douc-Rasy S, 2002, AM J PATHOL, V160, P631, DOI 10.1016/S0002-9440(10)64883-3; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Koch P, 2001, CANCER RES, V61, P5941; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; Lagger G, 2003, MOL CELL BIOL, V23, P2669, DOI 10.1128/MCB.23.8.2669-2679.2003; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Ng SW, 2000, ONCOGENE, V19, P1885, DOI 10.1038/sj.onc.1203512; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Roth J, 2000, ONCOGENE, V19, P1834, DOI 10.1038/sj.onc.1203500; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; STIEWE T, 2002, J BIOL CHEM, V13, P13; Takahashi H, 1998, CANCER RES, V58, P2076; Tokuchi Y, 1999, BRIT J CANCER, V80, P1623, DOI 10.1038/sj.bjc.6690572; Weigel S, 2000, J VIROL, V74, P764, DOI 10.1128/JVI.74.2.764-772.2000; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zaika AI, 1999, CANCER RES, V59, P3257; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179	44	34	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2003	22	51					8246	8254		10.1038/sj.onc.1207138	http://dx.doi.org/10.1038/sj.onc.1207138			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614448				2022-12-25	WOS:000186541500003
J	Leu, CM; Wong, FH; Chang, CM; Huang, SF; Hu, CP				Leu, CM; Wong, FH; Chang, CM; Huang, SF; Hu, CP			Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways	ONCOGENE			English	Article						IL-6; esophageal carcinoma; apoptosis; MAPK; STAT3	PROSTATE-CANCER CELLS; GROWTH-FACTOR-I; SERINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; INDUCED APOPTOSIS; IMMUNE-RESPONSE; MYELOMA CELLS; RISK-FACTORS; EXPRESSION; RECEPTOR	The production of interleukin-6 (IL-6) has been discovered in a variety of human tumors. Here we report the expression of IL-6, IL-6 receptor alpha (IL- 6Ralpha), and gp130 in human esophageal carcinoma tissues. We further demonstrate that IL- 6 protects an esophageal carcinoma cell line CE48T/VGH from apoptosis induced by staurosporine. IL-6 stimulation induced a rapid phosphorylation of gp130 and STAT3, and a dominant-negative STAT3 completely abolished the antiapoptotic effect. IL-6 also activated ERK 1/2 in CE48T/VGH cells. Inhibition of the ERK activation by PD98059 and transfection of a dominant-negative ERK2 completely blocked the protection of IL- 6 against apoptosis. Thus, both STAT and MAP kinase pathways are responsible for the IL-6-delivered survival signal in human esophageal carcinoma cells. In contrast, PI3-K inhibitors only partially attenuated the effect of IL-6, suggesting that PI3-K does not play a major role in the antiapoptotic signal of IL- 6 in our system. To investigate whether IL- 6 could induce the production of antiapoptotic molecules, proteins of the Bcl-2 family were measured. While Bcl-2, Bcl- x(L),, and Bax were not affected, Mcl-1 was induced by IL-6 in human esophageal carcinoma cells. Our results suggest that IL- 6 may contribute to the progression of esophageal cancers in an autocrine or paracrine manner.	Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Publ Hlth, Taipei 112, Taiwan; Natl Hlth Res Inst, Dept Intramural Res Affairs, Taipei, Taiwan; Natl Hlth Res Inst, Div Mol & Gen Med, Taipei, Taiwan; Chang Gung Mem Hosp, Dept Pathol, Taipei 10591, Taiwan	Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; Chang Gung Memorial Hospital	Hu, CP (corresponding author), Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 112, Taiwan.	cphu@vghtpe.gov.tw	Huang, Shiu-Feng Kathy/E-3977-2010; Chang, Chung-Ming/E-3945-2010					Abe K, 2001, ONCOGENE, V20, P3464, DOI 10.1038/sj.onc.1204461; BLOT WJ, 1994, SEMIN ONCOL, V21, P403; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; CHEN T, 2001, CANCER RES, V60, P2132; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Enzinger PC, 1999, SEMIN ONCOL, V26, P12; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gallo RL, 1997, J INVEST DERMATOL, V109, P597, DOI 10.1111/1523-1747.ep12337529; Halapi E, 1998, MED ONCOL, V15, P203, DOI 10.1007/BF02787202; Hirano T, 1998, Int Rev Immunol, V16, P249; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; HU CP, 1984, J NATL CANCER I, V72, P577; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kuo ML, 2001, ONCOGENE, V20, P677, DOI 10.1038/sj.onc.1204140; Lauta VM, 2001, CYTOKINE, V16, P79, DOI 10.1006/cyto.2001.0982; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Ma YX, 1999, APMIS, V107, P514, DOI 10.1111/j.1699-0463.1999.tb01587.x; MATEO RB, 1994, AM J PHYSIOL, V266, pR1840, DOI 10.1152/ajpregu.1994.266.6.R1840; MEIR EV, 1990, CANCER RES, V50, P6683; Minshall C, 1996, J IMMUNOL, V156, P939; Mocellin S, 2001, J IMMUNOTHER, V24, P392, DOI 10.1097/00002371-200109000-00002; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Oka M, 1996, CANCER RES, V56, P2776; OKA M, 1995, J INTERF CYTOK RES, V15, P1005, DOI 10.1089/jir.1995.15.1005; Okamoto M, 1997, CANCER RES, V57, P141; Park J, 1999, HEPATOLOGY, V30, P1128, DOI 10.1002/hep.510300522; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Ribeiro U, 1996, BRIT J SURG, V83, P1174, DOI 10.1002/bjs.1800830905; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Smith PC, 2001, CYTOKINE GROWTH F R, V12, P33, DOI 10.1016/S1359-6101(00)00021-6; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Takeda K, 1998, J IMMUNOL, V161, P4652; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WONG FH, 1994, CANCER INVEST, V12, P121, DOI 10.3109/07357909409024867; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhang YG, 2001, J BIOL CHEM, V276, P42534, DOI 10.1074/jbc.M106044200	46	137	147	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2003	22	49					7809	7818		10.1038/sj.onc.1207084	http://dx.doi.org/10.1038/sj.onc.1207084			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586407				2022-12-25	WOS:000186240200011
J	Watabe, M; Hishikawa, K; Takayanagi, A; Shimizu, N; Nakaki, T				Watabe, M; Hishikawa, K; Takayanagi, A; Shimizu, N; Nakaki, T			Caffeic acid phenethyl ester induces apoptosis by inhibition of NF kappa B and activation of Fas in human breast cancer MCF-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA U937 CELLS; CYTOCHROME-C; SIGNAL-TRANSDUCTION; MEDIATED APOPTOSIS; ULTRAVIOLET-LIGHT; KINASE COMPLEX; PROTEIN; PHOSPHORYLATION; RADIATION; PATHWAY	The transcription factor NFkappaB plays a role in cell survival. Apoptosis, programmed cell death, via numerous triggers including death receptor ligand binding is antagonized by NFkappaB activation and potentiated by its inhibition. In the present study, we found that caffeic acid phenethyl ester (CAPE), known to inhibit NFkappaB, induced apoptosis via Fas signal activation in human breast cancer MCF-7 cells. CAPE activated Fas by a Fas ligand (Fas-L)-independent mechanism, induced p53-regulated Bax protein, and activated caspases. CAPE also activated MAPK family proteins p38 and JNK. SB203580, a specific inhibitor of p38 MAPK, partially suppressed CAPE-induced p53 activation, Bax expression, and apoptosis, consistent with a mechanism by which CAPE leads to Bax activation, known to be regulated by p38 and p53. The expression of dominant negative c-Jun, which inhibits the JNK signal, also suppresses CAPE-induced apoptosis, suggesting MAPKs are involved in CAPE-induced apoptosis. The expression of Fas antisense oligomers significantly suppressed the CAPE-induced activations of JNK and p38 and apoptosis as compared with Fas sense oligomers. To ascertain whether these phenomena are attributable to the inhibition of NFkappaB by CAPE, we examined the effect of a truncated form of IkappaBalpha (IkappaBDeltaN) lacking the phosphorylation sites essential for NFkappaB activation. IkappaBDeltaN expression not only inhibited NFkappaB activity but also induced Fas activation, Bax expression, and apoptosis. Our findings demonstrate that NFkappaB inhibition is sufficient to induce apoptosis and that Fas activation plays a role in NFkappaB inhibition-induced apoptosis in MCF-7 cells.	Univ Tokyo, Dept Clin Renal Regenerat, Grad Sch Med, Tokyo 1138655, Japan; Teikyo Univ, Sch Med, Dept Pharmacol, Tokyo 1738605, Japan; Keio Univ, Sch Med, Dept Mol Biol, Tokyo 1608582, Japan	University of Tokyo; Teikyo University; Keio University	Hishikawa, K (corresponding author), Univ Tokyo, Dept Clin Renal Regenerat, Grad Sch Med, Tokyo 1138655, Japan.	hishikawa-tky@umin.ac.jp	Hishikawa, Keiichi/A-8661-2011; Nakaki, Toshio/C-4832-2009					Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bellas RE, 1997, AM J PATHOL, V151, P891; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hirahashi J, 2000, KIDNEY INT, V57, P959, DOI 10.1046/j.1523-1755.2000.00924.x; Hishikawa Keiichi, 2002, HeartDrug, V2, P303, DOI 10.1159/000069669; Kamitani T, 1997, J BIOL CHEM, V272, P22307, DOI 10.1074/jbc.272.35.22307; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LUO J, 1997, J BIOL CHEM, V278, P4542; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Muromoto R, 2003, FEBS LETT, V540, P223, DOI 10.1016/S0014-5793(03)00269-2; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Watabe M, 1999, ONCOGENE, V18, P5211, DOI 10.1038/sj.onc.1202901; Watabe M, 2000, CANCER RES, V60, P5214; Watabe M, 1997, CELL GROWTH DIFFER, V8, P871; Watabe M, 1996, J BIOL CHEM, V271, P14067, DOI 10.1074/jbc.271.24.14067; Watabe M, 1998, ONCOGENE, V16, P779, DOI 10.1038/sj.onc.1201592; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	35	185	196	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6017	6026		10.1074/jbc.M306040200	http://dx.doi.org/10.1074/jbc.M306040200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14625298	hybrid			2022-12-25	WOS:000188776500117
J	Chen, D; Purohit, A; Halilovic, E; Doxsey, SJ; Newton, AC				Chen, D; Purohit, A; Halilovic, E; Doxsey, SJ; Newton, AC			Centrosomal anchoring of protein kinase C beta II by pericentrin controls microtubule organization, spindle function, and cytokinesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; COLON CARCINOGENESIS; GRANULE EXOCYTOSIS; CYTOPLASMIC DYNEIN; ENDOTHELIAL-CELLS; PHASE-TRANSITION; BINDING DOMAIN; GAMMA-TUBULIN; T-CELLS	Location is a critical determinant in dictating the cellular function of protein kinase C (PKC). Scaffold proteins contribute to localization by poising PKC at specific intracellular sites. Using a yeast two-hybrid screen, we identified the centrosomal protein pericentrin as a scaffold that tethers PKC betaII to centrosomes. Co-immunoprecipitation studies reveal that the native proteins interact in cells. Co-overexpression studies show that the interaction is mediated by the C1A domain of PKC and a segment of pericentrin within residues 494-593. Immunofluorescence analysis reveals that endogenous PKC betaII colocalizes with pericentrin at centrosomes. Disruption of this interaction by expression of the interacting region of pericentrin results in release of PKC from the centrosome, microtubule disorganization, and cytokinesis failure. Overexpression of this disrupting fragment has no effect in cells lacking PKC betaII, indicating a specific regulatory role of this isozyme in centrosome function. These results reveal a novel role for PKC betaII in cytokinesis and indicate that this function is mediated by an interaction with pericentrin at centrosomes.	Univ Massachusetts, Sch Med, Dept Mol Med, Worcester, MA 01605 USA; Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Mol Pathol Grad Program, La Jolla, CA 92093 USA	University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California San Diego; University of California System; University of California San Diego	Newton, AC (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Med, Worcester, MA 01605 USA.	anewton@ucsd.edu			NIDDK NIH HHS [DK54441] Funding Source: Medline; NIGMS NIH HHS [GM51994] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051994, R56GM051994] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashton AW, 1999, J BIOL CHEM, V274, P20805, DOI 10.1074/jbc.274.30.20805; BEMENT WM, 1989, J CELL BIOL, V108, P885, DOI 10.1083/jcb.108.3.885; BEMENT WM, 1991, CELL MOTIL CYTOSKEL, V20, P145, DOI 10.1002/cm.970200207; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; CORREAS I, 1992, J BIOL CHEM, V267, P15721; Cox DN, 2001, P NATL ACAD SCI USA, V98, P14475, DOI 10.1073/pnas.261565198; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; Diviani D, 2000, CURR BIOL, V10, P417, DOI 10.1016/S0960-9822(00)00422-X; Diviani D, 2001, J CELL SCI, V114, P1431; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; Flory MR, 2000, P NATL ACAD SCI USA, V97, P5919, DOI 10.1073/pnas.97.11.5919; Gillingham AK, 2000, EMBO REP, V1, P524; Gokmen-Polar Y, 2001, CANCER RES, V61, P1375; Hosotani T, 2001, GENES CELLS, V6, P775, DOI 10.1046/j.1365-2443.2001.00461.x; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Khalfan W, 2000, GENETICS, V155, P1543; KILEY SC, 1995, J CELL SCI, V108, P1003; Kiley SC, 1997, CELL GROWTH DIFFER, V8, P231; KILEY SC, 1995, BIOCHEM SOC T, V23, P601, DOI 10.1042/bst0230601; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; Liu QQ, 2001, J CELL SCI, V114, P797; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; Nakhost A, 2002, J BIOL CHEM, V277, P40633, DOI 10.1074/jbc.M205099200; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ORR JW, 1994, J BIOL CHEM, V269, P27715; ORR JW, 1992, J BIOL CHEM, V267, P15263; Parissenti AM, 1996, J CELL PHYSIOL, V166, P609, DOI 10.1002/(SICI)1097-4652(199603)166:3<609::AID-JCP16>3.0.CO;2-1; Pihan GA, 2001, CANCER RES, V61, P2212; Pihan GA, 2003, CANCER RES, V63, P1398; Pihan GA, 1998, CANCER RES, V58, P3974; Purohit A, 1999, J CELL BIOL, V147, P481, DOI 10.1083/jcb.147.3.481; Radoja S, 2001, J IMMUNOL, V167, P5042, DOI 10.4049/jimmunol.167.9.5042; ROBINSON PJ, 1991, MOL NEUROBIOL, V5, P87, DOI 10.1007/BF02935541; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; Takahashi M, 2000, J BIOL CHEM, V275, P34592, DOI 10.1074/jbc.M005285200; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; Tynan SH, 2000, J BIOL CHEM, V275, P32763, DOI 10.1074/jbc.M001536200; Vanzela APDC, 2002, MICROBIOL RES, V157, P239, DOI 10.1078/0944-5013-00156; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Volkov Y, 1998, J IMMUNOL, V161, P6487; Volkov Y, 2001, NAT IMMUNOL, V2, P508, DOI 10.1038/88700; YAMAGUCHI K, 1995, BIOCHEM BIOPH RES CO, V210, P639, DOI 10.1006/bbrc.1995.1708; Yu WS, 2003, J BIOL CHEM, V278, P11167, DOI 10.1074/jbc.M211424200; Zezula J, 1997, J BIOL CHEM, V272, P29967, DOI 10.1074/jbc.272.47.29967; ZONG ZP, 1994, BIOCHEM BIOPH RES CO, V205, P746, DOI 10.1006/bbrc.1994.2728	54	83	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4829	4839		10.1074/jbc.M311196200	http://dx.doi.org/10.1074/jbc.M311196200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14594954	hybrid			2022-12-25	WOS:000188554300108
J	Li, WP; Tsiokas, L; Sansom, SC; Ma, R				Li, WP; Tsiokas, L; Sansom, SC; Ma, R			Epidermal growth factor activates store-operated Ca2+ channels through an inositol 1,4,5-trisphosphate-independent pathway in human glomerular mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; CATION CHANNELS; A431 CELLS; TRISPHOSPHATE RECEPTOR; SIGNAL-TRANSDUCTION; INTRACELLULAR CA2+; ANGIOTENSIN-II; HTRP3 CHANNELS; SMOOTH-MUSCLE; B-LYMPHOCYTES	One of the fastest cellular responses following activation of epidermal growth factor receptor is an increase in intracellular Ca2+ concentration. This event is attributed to a transient Ca2+ release from internal stores and Ca2+ entry from extracellular compartment. Store-operated Ca2+ channels are defined the channels activated in response to store depletion. In the present study, we determined whether epidermal growth factor activated store-operated Ca2+ channels and further, whether depletion of internal Ca2+ stores was required for the epidermal growth factor-induced Ca2+ entry in human glomerular mesangial cells. We found that 100 nM epidermal growth factor activated a Ca2+-permeable channel that had identical biophysical and pharmacological properties to channels activated by 1 muM thapsigargin in human glomerular mesangial cells or A431 cells. The epidermal growth factor-induced Ca2+ currents were completely abolished by a selective phospholipase C inhibitor, U73122. However, xestospongin C, a specific inositol 1,4,5-trisphosphate receptor inhibitor, did not affect the membrane currents elicited by epidermal growth factor despite a slight reduction in background currents. Following emptying of internal Ca2+ stores by thapsigargin, epidermal growth factor still potentiated the Ca2+ currents as determined by the whole-cell patch configuration. Furthermore, epidermal growth factor failed to trigger measurable Ca2+ release from endoplasmic reticulum. However, another physiological agent linked to phospholipase C and inositol 1,4,5-trisphosphate cascade, angiotensin II, produced a striking Ca2+ transient. These results indicate that epidermal growth factor activates store-operated Ca2+ channels through an inositol 1,4,5-trisphosphate-independent, but phospholipase C-dependent, pathway in human glomerular mesangial cells.	Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73190 USA; Anhui Med Univ, Dept Pharmacol, Hefei, Peoples R China; Univ Nebraska, Med Ctr, Dept Physiol & Biophys, Omaha, NE 68198 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Anhui Medical University; University of Nebraska System; University of Nebraska Medical Center	Tsiokas, L (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, 940 Stanton L Young Blvd, Oklahoma City, OK 73190 USA.	leonidas-tsiokas@ouhsc.edu; rong-ma@ouhsc.edu		Tsiokas, Leonidas/0000-0002-3659-1813	NIDDK NIH HHS [DK-49561, DK59599] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049561, R01DK059599, R56DK059599] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Broad LM, 1999, J PHYSIOL-LONDON, V517, P121, DOI 10.1111/j.1469-7793.1999.0121z.x; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074/jbc.M011571200; Cahalan MD, 2001, NATURE, V411, P542, DOI 10.1038/35079231; CARMINES PK, 1993, AM J PHYSIOL, V265, pF677, DOI 10.1152/ajprenal.1993.265.5.F677; Carroll RC, 1998, EMBO J, V17, P3036, DOI 10.1093/emboj/17.11.3036; Clapham DE, 2002, J GEN PHYSIOL, V120, P217, DOI 10.1085/jgp.20028618; Elliott AC, 2001, CELL CALCIUM, V30, P73, DOI 10.1054/ceca.2001.0215; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; GONZALEZ FA, 1988, J CELL PHYSIOL, V135, P269, DOI 10.1002/jcp.1041350214; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hall DA, 2000, AM J PHYSIOL-RENAL, V278, pF97, DOI 10.1152/ajprenal.2000.278.1.F97; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; LUCKHOFF A, 1994, BIOPHYS J, V67, P177, DOI 10.1016/S0006-3495(94)80467-9; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2001, J BIOL CHEM, V276, P18888, DOI 10.1074/jbc.M100944200; Ma R, 2001, J AM SOC NEPHROL, V12, P47, DOI 10.1681/ASN.V12147; Ma R, 2000, AM J PHYSIOL-RENAL, V278, pF954, DOI 10.1152/ajprenal.2000.278.6.F954; MADHUN ZT, 1993, REGUL PEPTIDES, V44, P149, DOI 10.1016/0167-0115(93)90238-4; MAGNI M, 1991, J BIOL CHEM, V266, P6329; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Miyamoto S, 2000, BRIT J PHARMACOL, V130, P650, DOI 10.1038/sj.bjp.0703358; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; PANDIELLA A, 1989, J BIOL CHEM, V264, P12914; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; PEPPELENBOSCH MP, 1991, J BIOL CHEM, V266, P19938; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 2001, J CELL SCI, V114, P2223; Rane SG, 1999, ADV SEC MESS PHOSPH, V33, P107; RUEGG UT, 1989, J CARDIOVASC PHARM, V14, pS49; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Shen JP, 2003, AM J PHYSIOL-RENAL, V284, pF57, DOI 10.1152/ajprenal.00028.2002; STOCKAND JD, 1994, AM J PHYSIOL-CELL PH, V267, pC1080, DOI 10.1152/ajpcell.1994.267.4.C1080; Vazquez G, 2002, EMBO J, V21, P4531, DOI 10.1093/emboj/cdf467; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; WAHL M, 1988, J BIOL CHEM, V263, P7581; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zhang BX, 2002, J BIOL CHEM, V277, P48165, DOI 10.1074/jbc.M208077200	44	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4570	4577		10.1074/jbc.M304334200	http://dx.doi.org/10.1074/jbc.M304334200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14612458	hybrid			2022-12-25	WOS:000188554300078
J	Bianchini, EP; Pike, RN; Le Bonniec, BF				Bianchini, EP; Pike, RN; Le Bonniec, BF			The elusive role of the potential factor X cation-binding exosite-1 in substrate and inhibitor interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR VA BINDING; PLASMINOGEN-ACTIVATOR INHIBITOR-1; BLOOD-COAGULATION FACTOR; FACTOR PATHWAY INHIBITOR; AMINO-ACID-RESIDUES; MACROMOLECULAR SUBSTRATE; HEPARIN-BINDING; TISSUE FACTOR; FACTOR IXA; PROTHROMBINASE COMPLEX	number of studies suggest that blood-clotting factor X (FX) uses secondary site(s) to interact (as a substrate) with its activators. Numerous pieces of evidence also imply that, within prothrombinase (as an enzyme), activated FX (FXa) uses exosite(s) for cofactor Va and/or prothrombin recognition. Similarly, FXa exosite(s) seem to govern interaction with inhibitors. An obvious difference between FXa and thrombin resides within a region called exosite-1: positively charged in thrombin and clearly of opposite polarity in FXa. To investigate the role of this potential cation-binding exosite, we prepared a series of mutants within loops 34-40 and 70-80 of FX. Overall, the mutations induced relatively subtle, non-synergistic modulation. The potential exosite was dispensable for FX activation and is unlikely to constitute a critical region for factor Va binding, albeit it is clearly important for prothrombin activation. Our data also implicate loop 34-40 of FXa in the interaction with the tissue factor pathway inhibitor, in prevention of plasminogen activator inhibitor-1 binding, and in tempering inhibition by heparin-activated antithrombin. Compared with FX, mutants with reduced electrostatic potential potentiated thrombin production in FX-depleted plasma, whereas mutants with inverted electrostatic potential impeded clotting. Despite the definite consequences observed, disruption of the potential cation-binding exosite of FX had rather weak effects, far from what would be expected if this region was as crucial as in thrombin.	Univ Paris 05, Fac Pharm, INSERM, U428, F-75270 Paris 06, France; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Monash University	Le Bonniec, BF (corresponding author), Univ Paris 05, Fac Pharm, INSERM, U428, 4 Av Observ, F-75270 Paris 06, France.	lebonnie@infobiogen.fr	Le Bonniec, Bernard/ABA-1366-2020; Le Bonniec, Bernard/S-5756-2016	Le Bonniec, Bernard/0000-0002-8432-7363; Le Bonniec, Bernard/0000-0002-8432-7363; Pike, Robert/0000-0002-2083-0269; BIANCHINI, Elsa/0000-0002-1370-5312				Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; Bajaj SP, 1999, THROMB HAEMOSTASIS, V82, P218; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bianchini EP, 2002, J BIOL CHEM, V277, P20527, DOI 10.1074/jbc.M201139200; Bode W, 1997, THROMB HAEMOSTASIS, V78, P501; Boskovic DS, 2000, J BIOL CHEM, V275, P38561, DOI 10.1074/jbc.M006637200; Braud S, 2002, BIOCHEMISTRY-US, V41, P8478, DOI 10.1021/bi016069g; Burgering MJM, 1997, J MOL BIOL, V269, P395, DOI 10.1006/jmbi.1997.1029; Camire RM, 2000, BIOCHEMISTRY-US, V39, P14322, DOI 10.1021/bi001074q; Chen L, 2003, J BIOL CHEM, V278, P27564, DOI 10.1074/jbc.M302707200; Chuang YJ, 2001, J BIOL CHEM, V276, P14961, DOI 10.1074/jbc.M011550200; Dekker RJ, 1999, J MOL BIOL, V293, P613, DOI 10.1006/jmbi.1999.3178; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; Djie MZ, 1996, BIOCHEMISTRY-US, V35, P11461, DOI 10.1021/bi952717i; DRAPIER JC, 1979, BIOCHIMIE, V61, P463, DOI 10.1016/S0300-9084(79)80202-3; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; HORREVOETS AJG, 1993, J BIOL CHEM, V268, P779; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; JONES DH, 1990, BIOTECHNIQUES, V8, P178; Kalafatis M, 2002, BIOCHEMISTRY-US, V41, P12715, DOI 10.1021/bi026208+; Kolkman JA, 1999, J BIOL CHEM, V274, P29087, DOI 10.1074/jbc.274.41.29087; KOSOW DP, 1974, THROMB RES, V4, P219, DOI 10.1016/0049-3848(74)90087-5; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; LAUDANO AP, 1980, BIOCHEMISTRY-US, V19, P1013, DOI 10.1021/bi00546a028; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; LEBONNIEC BF, 1993, J BIOL CHEM, V268, P19055; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; Manithody C, 2002, BIOCHEMISTRY-US, V41, P6780, DOI 10.1021/bi0255367; Mathur A, 1997, J BIOL CHEM, V272, P23418, DOI 10.1074/jbc.272.37.23418; Mine S, 2002, BIOCHEMISTRY-US, V41, P78, DOI 10.1021/bi011299g; Myles T, 1998, J BIOL CHEM, V273, P31203, DOI 10.1074/jbc.273.47.31203; Olson ST, 2002, TRENDS CARDIOVAS MED, V12, P331, DOI 10.1016/S1050-1738(02)00183-4; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Picard V, 1999, J BIOL CHEM, V274, P4586, DOI 10.1074/jbc.274.8.4586; Quinsey NS, 2002, J BIOL CHEM, V277, P15971, DOI 10.1074/jbc.M108131200; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P12083, DOI 10.1021/bi0011126; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; Rezaie AR, 2001, BBA-GEN SUBJECTS, V1528, P167, DOI 10.1016/S0304-4165(01)00189-1; Rijkers DTS, 1998, THROMB RES, V89, P161, DOI 10.1016/S0049-3848(97)00312-5; Rudolph AE, 2000, BIOCHEMISTRY-US, V39, P2861, DOI 10.1021/bi992379b; Rudolph AE, 2001, J BIOL CHEM, V276, P5123, DOI 10.1074/jbc.M006961200; Sabharwal AK, 1997, J BIOL CHEM, V272, P22037, DOI 10.1074/jbc.272.35.22037; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; Shobe J, 1999, J BIOL CHEM, V274, P24171, DOI 10.1074/jbc.274.34.24171; Stanley TB, 1999, J BIOL CHEM, V274, P16940, DOI 10.1074/jbc.274.24.16940; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; Wilkens M, 2002, J BIOL CHEM, V277, P9366, DOI 10.1074/jbc.M110848200; Williams J W, 1979, Methods Enzymol, V63, P437; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; Yang LK, 2002, J BIOL CHEM, V277, P50756, DOI 10.1074/jbc.M208485200	57	15	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3671	3679		10.1074/jbc.M309691200	http://dx.doi.org/10.1074/jbc.M309691200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14583605	hybrid			2022-12-25	WOS:000188379600066
J	Harris, FM; Tesseur, I; Brecht, WJ; Xu, Q; Mullendorff, K; Chang, SJ; Wyss-Coray, T; Mahley, RW; Huang, YD				Harris, FM; Tesseur, I; Brecht, WJ; Xu, Q; Mullendorff, K; Chang, SJ; Wyss-Coray, T; Mahley, RW; Huang, YD			Astroglial regulation of apolipoprotein E expression in neuronal cells - Implications for Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							E PROMOTER POLYMORPHISM; AMYLOID-BETA-PEPTIDE; PAIRED HELICAL FILAMENTS; MOUSE CORTICAL-NEURONS; CENTRAL-NERVOUS-SYSTEM; E APOE LEVELS; TRANSGENIC MICE; E GENE; HUMAN BRAIN; MESSENGER-RNA	Although apolipoprotein (apo) E is synthesized in the brain primarily by astrocytes, neurons in the central nervous system express apoE, albeit at lower levels than astrocytes, in response to various physiological and pathological conditions, including excitotoxic stress. To investigate how apoE expression is regulated in neurons, we transfected Neuro-2a cells with a 17-kilobase human apoE genomic DNA construct encoding apoE3 or apoE4 along with upstream and downstream regulatory elements. The baseline expression of apoE was low. However, conditioned medium from an astrocytic cell line (C6) or from apoE-null mouse primary astrocytes increased the expression of both isoforms by 3-4-fold at the mRNA level and by 4-10-fold at the protein level. These findings suggest that astrocytes secrete a factor or factors that regulate apoE expression in neuronal cells. The increased expression of apoE was almost completely abolished by incubating neurons with U0126, an inhibitor of extracellular signal-regulated kinase (Erk), suggesting that the Erk pathway controls astroglial regulation of apoE expression in neuronal cells. Human neuronal precursor NT2/D1 cells expressed apoE constitutively; however, after treatment of these cells with retinoic acid to induce differentiation, apoE expression diminished. Cultured mouse primary cortical and hippocampal neurons also expressed low levels of apoE. Astrocyte-conditioned medium rapidly up-regulated apoE expression in fully differentiated NT2 neurons and in cultured mouse primary cortical and hippocampal neurons. Thus, neuronal expression of apoE is regulated by a diffusible factor or factors released from astrocytes, and this regulation depends on the activity of the Erk kinase pathway in neurons.	Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Huang, YD (corresponding author), Univ Calif San Francisco, Gladstone Inst Neurol Dis, POB 419100, San Francisco, CA 94141 USA.	yhuang@gladstone.ucsf.edu	Wyss-Coray, Tony/AAF-3380-2019	Wyss-Coray, Tony/0000-0001-5893-0831	NHLBI NIH HHS [R01 HL37063] Funding Source: Medline; NIA NIH HHS [P01 AG022074] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG022074] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alvarez-Arcaya A, 2001, NEUROSCI LETT, V304, P204, DOI 10.1016/S0304-3940(01)01790-6; Aoki K, 2003, STROKE, V34, P875, DOI 10.1161/01.STR.0000064320.73388.C6; Arendt T, 1996, NEUROREPORT, V7, P3047; Artiga MJ, 1998, HUM MOL GENET, V7, P1887, DOI 10.1093/hmg/7.12.1887; Artiga MJ, 1998, FEBS LETT, V421, P105, DOI 10.1016/S0014-5793(97)01543-3; Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; Bao F, 1996, NEUROREPORT, V7, P1733, DOI 10.1097/00001756-199607290-00008; BAUER J, 1991, FEBS LETT, V285, P111, DOI 10.1016/0014-5793(91)80737-N; Beffert U, 1999, BRAIN RES, V843, P87, DOI 10.1016/S0006-8993(99)01894-6; Beffert U, 1996, ANN NY ACAD SCI, V777, P166, DOI 10.1111/j.1749-6632.1996.tb34415.x; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; BERG DT, 1995, J BIOL CHEM, V270, P15447, DOI 10.1074/jbc.270.26.15447; BERTRAND P, 1995, MOL BRAIN RES, V33, P174, DOI 10.1016/0169-328X(95)00097-C; Boschert U, 1999, NEUROBIOL DIS, V6, P508, DOI 10.1006/nbdi.1999.0251; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; Bullido MJ, 1998, NAT GENET, V18, P69, DOI 10.1038/ng0198-69; Buttini M, 2002, J NEUROSCI, V22, P10539; Buttini M, 1999, J NEUROSCI, V19, P4867; Casadei VM, 1999, NEUROLOGY, V53, P1888, DOI 10.1212/WNL.53.8.1888; Chen L, 1999, NEUROSCI LETT, V269, P173, DOI 10.1016/S0304-3940(99)00421-8; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CROWTHER RA, 1993, CURR OPIN STRUC BIOL, V3, P202, DOI 10.1016/S0959-440X(05)80153-8; David JP, 1997, NEUROSCI LETT, V235, P53, DOI 10.1016/S0304-3940(97)00708-8; Dekroon RM, 2001, GLIA, V33, P298, DOI 10.1002/1098-1136(20010315)33:4<298::AID-GLIA1028>3.0.CO;2-N; DIEDRICH JF, 1991, J VIROL, V65, P4759, DOI 10.1128/JVI.65.9.4759-4768.1991; Dunn PF, 1996, CIRCULATION, V93, P1439, DOI 10.1161/01.CIR.93.7.1439; Dupont-Wallois L, 1997, NEUROBIOL DIS, V4, P356, DOI 10.1006/nbdi.1997.0155; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Fagan KA, 1999, J CLIN INVEST, V103, P291, DOI 10.1172/JCI3862; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Ferreira S, 2000, EXP NEUROL, V166, P415, DOI 10.1006/exnr.2000.7510; Ferrer I, 2001, BRAIN PATHOL, V11, P144; Fiumelli H, 1999, EUR J NEUROSCI, V11, P1639, DOI 10.1046/j.1460-9568.1999.00580.x; Fiumelli H, 2000, J NEUROCHEM, V74, P1870, DOI 10.1046/j.1471-4159.2000.0741870.x; Garcia MA, 1996, J NEUROSCI, V16, P7550; Gong JS, 2002, J BIOL CHEM, V277, P29919, DOI 10.1074/jbc.M203934200; GREENBERG SM, 1994, P NATL ACAD SCI USA, V91, P7104, DOI 10.1073/pnas.91.15.7104; Grehan S, 2001, J INVEST DERMATOL, V116, P77, DOI 10.1046/j.1523-1747.2001.00213.x; Grehan S, 2001, J NEUROSCI, V21, P812, DOI 10.1523/JNEUROSCI.21-03-00812.2001; Griffin WST, 1998, BRAIN PATHOL, V8, P65; HAN SH, 1994, J NEUROPATH EXP NEUR, V53, P535, DOI 10.1097/00005072-199409000-00013; Harr SD, 1996, J NEUROCHEM, V66, P2429; Harris FM, 2003, P NATL ACAD SCI USA, V100, P10966, DOI 10.1073/pnas.1434398100; Hartman RE, 2001, EXP NEUROL, V170, P326, DOI 10.1006/exnr.2001.7715; Helisalmi S, 1999, J NEUROL, V246, P821, DOI 10.1007/s004150050461; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; HYMAN BT, 1994, AM J PATHOL, V144, P565; Irizarry MC, 2000, ACTA NEUROPATHOL, V100, P451, DOI 10.1007/s004010000263; Ishigami M, 1998, J BIOL CHEM, V273, P20156, DOI 10.1074/jbc.273.32.20156; Ji Y, 2001, J ALZHEIMERS DIS, V3, P23, DOI 10.3233/JAD-2001-3105; Ji ZS, 2002, J BIOL CHEM, V277, P21821, DOI 10.1074/jbc.M112109200; LADU MJ, 1994, J BIOL CHEM, V269, P23403; Lambert JC, 1998, HUM MOL GENET, V7, P533, DOI 10.1093/hmg/7.3.533; Laws SM, 1999, NEUROREPORT, V10, P879, DOI 10.1097/00001756-199903170-00038; Laws SM, 2003, J NEUROCHEM, V84, P1215, DOI 10.1046/j.1471-4159.2003.01615.x; Laws SM, 2002, MOL PSYCHIATR, V7, P886, DOI 10.1038/sj.mp.4001097; Liu XY, 1996, DEMENTIA, V7, P128, DOI 10.1159/000106867; Ljungberg MC, 2002, NEUROREPORT, V13, P867, DOI 10.1097/00001756-200205070-00026; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MASLIAH E, 1993, NEUROLOGY, V43, P192, DOI 10.1212/WNL.43.1_Part_1.192; McShea A, 1997, AM J PATHOL, V150, P1933; Metzger RE, 1996, J NEUROPATH EXP NEUR, V55, P372, DOI 10.1097/00005072-199603000-00013; MILNE RW, 1984, J CLIN INVEST, V73, P816, DOI 10.1172/JCI111276; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Mrak RE, 1996, J NEUROPATH EXP NEUR, V55, P273, DOI 10.1097/00005072-199603000-00002; MUCKE L, 1993, TRANSGENE, V1, P3; Nagy Z, 1998, NEUROSCIENCE, V87, P731; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NIETOSAMPEDRO M, 1994, NEUROREPORT, V5, P375, DOI 10.1097/00001756-199401120-00001; Ohkubo N, 2001, J BIOL CHEM, V276, P3046, DOI 10.1074/jbc.M005070200; PAIK YK, 1988, J BIOL CHEM, V263, P13340; Perry G, 1999, NEUROREPORT, V10, P2411, DOI 10.1097/00001756-199908020-00035; PIKE CJ, 1995, EXP NEUROL, V132, P172, DOI 10.1016/0014-4886(95)90022-5; Pirttila T, 1996, BRAIN RES, V722, P71, DOI 10.1016/0006-8993(96)00183-7; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; POIRIER J, 1991, MOL BRAIN RES, V11, P97, DOI 10.1016/0169-328X(91)90111-A; PROBST A, 1982, ACTA NEUROPATHOL, V57, P75, DOI 10.1007/BF00688880; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Raber J, 2000, NATURE, V404, P352, DOI 10.1038/35006165; Raber J, 2002, J NEUROSCI, V22, P5204, DOI 10.1523/JNEUROSCI.22-12-05204.2002; Romas SN, 2002, ARCH NEUROL-CHICAGO, V59, P87, DOI 10.1001/archneur.59.1.87; Roses AD, 1996, ANNU REV MED, V47, P387, DOI 10.1146/annurev.med.47.1.387; ROSES AD, 1994, CURR NEUROL, V14, P111; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Sheng JG, 1996, NEUROBIOL AGING, V17, P359, DOI 10.1016/0197-4580(96)00037-1; Shih SJ, 2000, J BIOL CHEM, V275, P31567, DOI 10.1074/jbc.M005468200; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SIMONET WS, 1991, J BIOL CHEM, V266, P8651; SIMONET WS, 1990, J BIOL CHEM, V265, P10809; SMITH JD, 1988, J BIOL CHEM, V263, P8300; Smith MZ, 1999, NEUROSCI LETT, V271, P45, DOI 10.1016/S0304-3940(99)00509-1; SMITH TW, 1995, J NEUROPATH EXP NEUR, V54, P297, DOI 10.1097/00005072-199505000-00002; Song YQ, 1998, NEUROSCI LETT, V250, P189, DOI 10.1016/S0304-3940(98)00470-4; STELLA N, 1995, J NEUROSCI, V15, P3307; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Swertfeger DK, 2001, J BIOL CHEM, V276, P25043, DOI 10.1074/jbc.M102357200; Taddei K, 1997, NEUROSCI LETT, V223, P29, DOI 10.1016/S0304-3940(97)13394-8; Tang MX, 1998, JAMA-J AM MED ASSOC, V279, P751, DOI 10.1001/jama.279.10.751; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; Tesseur I, 2000, AM J PATHOL, V156, P951, DOI 10.1016/S0002-9440(10)64963-2; Tesseur I, 2000, AM J PATHOL, V157, P1495, DOI 10.1016/S0002-9440(10)64788-8; Toji H, 1999, NEUROSCI LETT, V259, P56, DOI 10.1016/S0304-3940(98)00855-6; Town T, 1998, NEUROSCI LETT, V252, P95, DOI 10.1016/S0304-3940(98)00567-9; Vincent B, 2001, EUR J NEUROSCI, V14, P256, DOI 10.1046/j.0953-816x.2001.01643.x; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; Vincent I, 1997, J NEUROSCI, V17, P3588; Wang JC, 2000, NEUROLOGY, V55, P1644, DOI 10.1212/WNL.55.11.1644; WEIS JR, 1991, FASEB J, V5, P2459, DOI 10.1096/fasebj.5.10.2065893; WEST MJ, 1993, NEUROBIOL AGING, V14, P287, DOI 10.1016/0197-4580(93)90113-P; Wilczynski GM, 2000, AM J PATHOL, V156, P1835, DOI 10.1016/S0002-9440(10)65056-0; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; Xu PT, 1998, NEUROSCI LETT, V246, P65, DOI 10.1016/S0304-3940(98)00247-X; Xu PT, 1999, AM J PATHOL, V154, P601, DOI 10.1016/S0002-9440(10)65305-9; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023; Xu PT, 1999, NEUROBIOL DIS, V6, P63, DOI 10.1006/nbdi.1998.0213; Yang Y, 2001, J NEUROSCI, V21, P2661, DOI 10.1523/JNEUROSCI.21-08-02661.2001; Yang Y, 2003, J NEUROSCI, V23, P2557; YOUNKIN DP, 1993, P NATL ACAD SCI USA, V90, P2174, DOI 10.1073/pnas.90.6.2174; Zeleny M, 2002, BIOCHEMISTRY-US, V41, P11820, DOI 10.1021/bi026202k	134	95	98	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3862	3868		10.1074/jbc.M309475200	http://dx.doi.org/10.1074/jbc.M309475200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14585838	hybrid			2022-12-25	WOS:000188379600088
J	Wang, X; Thomson, SR; Starkey, JD; Page, JL; Ealy, AD; Johnson, SE				Wang, X; Thomson, SR; Starkey, JD; Page, JL; Ealy, AD; Johnson, SE			Transforming growth factor beta 1 is up-regulated by activated Raf in skeletal myoblasts but does not contribute to the differentiation-defective phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOGENIC DIFFERENTIATION; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MUSCLE DIFFERENTIATION; INHIBITS MYOGENESIS; AVIAN MYOGENESIS; EPITHELIAL-CELLS; C2C12 MYOGENESIS; MYOSTATIN; INSULIN	The Raf/MEK/MAPK signaling module elicits a strong negative impact on skeletal myogenesis that is reflected by a complete loss of muscle gene transcription and differentiation in multinucleated myocytes. Recent evidence indicates that Raf signaling also may contribute to myoblast cell cycle exit and cytoprotection. To further define the mechanisms by which Raf participates in cellular responses, a stable line of myoblasts expressing an estrogen receptor-Raf chimeric protein was created. The cells (23A2RafER(DD)) demonstrate a strict concentration-dependent increase in chimeric Raf protein synthesis and downstream phosphoMAPK activation. Initiation of low-level Raf activity in these cells augments contractile protein expression and myocyte fusion. By contrast, induction of high level Raf activity in 23A2RafERDD myoblasts inhibits the formation of myocytes and muscle reporter gene expression. Interestingly, treatment of myoblasts with conditioned medium isolated from Raf-repressive cells inhibits all of the aspects of myogenesis. Closer examination indicates that the transforming growth factor-beta(1) (TGF-beta(1)) gene is up-regulated in Raf-repressive myoblasts. The cells also direct elevated levels of Smad transcriptional activity, suggesting the existence of a TGF-beta(1) autocrine loop. However, extinguishing the biological activity of TGF-beta(1) does not restore the myogenic program. Our results provide evidence for the involvement of Raf signal transmission during myocyte formation as well as during inhibition of myogenesis.	Penn State Univ, Dept Poultry Sci, University Pk, PA 16802 USA; Penn State Univ, Dept Dairy & Anim Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Johnson, SE (corresponding author), Penn State Univ, Dept Poultry Sci, 213 Henning, University Pk, PA 16802 USA.	sej4@psu.edu						Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; Bouche M, 2000, FASEB J, V14, P1147, DOI 10.1096/fasebj.14.9.1147; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Crown AL, 2000, J ENDOCRINOL, V167, P403, DOI 10.1677/joe.0.1670403; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; DeChant AK, 2002, ONCOGENE, V21, P5268, DOI 10.1038/sj.onc.1205648; Dorman CM, 2000, J BIOL CHEM, V275, P27481; Dorman CM, 1999, ONCOGENE, V18, P5167, DOI 10.1038/sj.onc.1202907; Fedorov YV, 1998, MOL CELL BIOL, V18, P5780, DOI 10.1128/MCB.18.10.5780; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; Grobet L, 1997, NAT GENET, V17, P71, DOI 10.1038/ng0997-71; Herrera R, 2002, TRENDS MOL MED, V8, pS27, DOI 10.1016/S1471-4914(02)02307-9; Hindley A, 2002, J CELL SCI, V115, P1575; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Johnson SE, 2002, J BIOL CHEM, V277, P28742, DOI 10.1074/jbc.M203680200; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910; Kerkhoff E, 1998, CANCER RES, V58, P1636; Komesli S, 1998, EUR J BIOCHEM, V254, P505, DOI 10.1046/j.1432-1327.1998.2540505.x; KONG YF, 1995, MOL CELL BIOL, V15, P5205; Langley B, 2002, J BIOL CHEM, V277, P49831, DOI 10.1074/jbc.M204291200; Lee SJ, 1999, CURR OPIN GENET DEV, V9, P604, DOI 10.1016/S0959-437X(99)00004-0; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Li YQ, 2000, CELL SIGNAL, V12, P751, DOI 10.1016/S0898-6568(00)00120-0; Lin J, 2002, BIOCHEM BIOPH RES CO, V291, P701, DOI 10.1006/bbrc.2002.6500; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; McLennan IS, 2002, INT J DEV BIOL, V46, P559; Mitchell PJ, 2002, DEV DYNAM, V223, P12, DOI 10.1002/dvdy.1227; Olwin Bradley B., 1994, Progress in Growth Factor Research, V5, P145, DOI 10.1016/0955-2235(94)90002-7; Pearson G, 2000, J BIOL CHEM, V275, P37303, DOI 10.1074/jbc.C000570200; Perry RLS, 2001, MOL CELL, V8, P291, DOI 10.1016/S1097-2765(01)00302-1; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Rios R, 2002, AM J PHYSIOL-CELL PH, V282, pC993, DOI 10.1152/ajpcell.00372.2001; Rios R, 2001, BIOCHEM BIOPH RES CO, V280, P561, DOI 10.1006/bbrc.2000.4159; Samuel DS, 1999, HORM METAB RES, V31, P55, DOI 10.1055/s-2007-978699; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Taylor WE, 2001, AM J PHYSIOL-ENDOC M, V280, pE221, DOI 10.1152/ajpendo.2001.280.2.E221; Thomas M, 2000, J BIOL CHEM, V275, P40235, DOI 10.1074/jbc.M004356200; TSANG MLS, 1995, CYTOKINE, V7, P389, DOI 10.1006/cyto.1995.0054; Tureckova J, 2001, J BIOL CHEM, V276, P39264, DOI 10.1074/jbc.M104991200; Weyman CM, 1997, ONCOGENE, V15, P2521, DOI 10.1038/sj.onc.1201423; Winter B, 2000, J CELL SCI, V113, P4211; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	48	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2528	2534		10.1074/jbc.M306489200	http://dx.doi.org/10.1074/jbc.M306489200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14594948	hybrid			2022-12-25	WOS:000188211300025
J	Karring, H; Mathu, SGJ; van Duin, J; Clark, BFC; Kraal, B; Knudsen, CR				Karring, H; Mathu, SGJ; van Duin, J; Clark, BFC; Kraal, B; Knudsen, CR			Q beta-phage resistance by deletion of the coiled-coil motif in elongation factor Ts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-Q-BETA; RIBONUCLEIC-ACID REPLICASE; EF-TU; RNA REPLICATION; HOST FACTOR; POLYMERASE; MUTANT; GENE; RECONSTITUTION; RENATURATION	Elongation factor Ts (EF-Ts) is the guanine-nucleotide exchange factor of elongation factor Tu (EF-Tu), which promotes the binding of aminoacyl-tRNA to the mRNA-programmed ribosome in prokaryotes. The EF-Tu.EF-Ts complex, one of the EF-Tu complexes during protein synthesis, is also a component of RNA-dependent RNA polymerases like the polymerase from coliphage Qbeta. The present study shows that the Escherichia coli mutant GRd.tsf lacking the coiled-coil motif of EF-Ts is completely resistant to phage Qbeta and that Qbeta-polymerase complex formation is not observed. GRd.tsf is the first E. coli mutant ever described that is unable to form a Qbeta-polymerase complex while still maintaining an almost normal growth behavior. The phage resistance correlates with an observed instability of the mutant EF-Tu.EF-Ts complex in the presence of guanine nucleotides. Thus, the mutant EF-Tu.EF-Ts is the first EF-Tu.EF-Ts complex ever described that is completely inactive in the Qbeta-polymerase complex despite its almost full activity in protein synthesis. We propose that the role of EF-Ts in the Qbeta-polymerase complex is to control and trap EF-Tu in a stable conformation with affinity for RNA templates while unable to bind aminoacyl-tRNA.	Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark; Leiden Univ, Leiden Inst Chem, Dept Biochem, NL-2300 RA Leiden, Netherlands	Aarhus University; Leiden University; Leiden University - Excl LUMC	Knudsen, CR (corresponding author), Aarhus Univ, Dept Mol Biol, Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.	crk@imsb.au.dk		Knudsen, Charlotte/0000-0003-2356-4821; Karring, Henrik/0000-0002-4672-1503				AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; ARMSTRONGMAJOR J, 1985, BIOCHIM BIOPHYS ACTA, V824, P140, DOI 10.1016/0167-4781(85)90090-9; BARRERA I, 1993, J MOL BIOL, V232, P512, DOI 10.1006/jmbi.1993.1407; Bjornsson A, 1998, METH MOL B, V77, P75; BLUMENTHAL T, 1972, P NATL ACAD SCI USA, V69, P1313, DOI 10.1073/pnas.69.5.1313; BLUMENTHAL T, 1976, BIOCHEMISTRY-US, V15, P422, DOI 10.1021/bi00647a028; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; BONI IV, 1991, NUCLEIC ACIDS RES, V19, P155, DOI 10.1093/nar/19.1.155; Brown D, 1996, P NATL ACAD SCI USA, V93, P11558, DOI 10.1073/pnas.93.21.11558; BROWN D, 1995, BIOCHEMISTRY-US, V34, P14765, DOI 10.1021/bi00045a018; Brown L, 1997, J BACTERIOL, V179, P656, DOI 10.1128/jb.179.3.656-662.1997; BROWN S, 1976, J BIOL CHEM, V251, P2749; BROWN S, 1976, P NATL ACAD SCI USA, V73, P1131, DOI 10.1073/pnas.73.4.1131; Caldas TD, 1998, J BIOL CHEM, V273, P11478, DOI 10.1074/jbc.273.19.11478; EGGEN K, 1967, BIOCHEM BIOPH RES CO, V28, P587, DOI 10.1016/0006-291X(67)90354-3; Franze de Fernandez M T, 1972, J Biol Chem, V247, P824; FRANZE MT, 1968, NATURE, V219, P588, DOI 10.1038/219588a0; GARWES D, 1969, BIOCHIM BIOPHYS ACTA, V186, P166, DOI 10.1016/0005-2787(69)90499-7; HARUNA I, 1965, SCIENCE, V150, P884, DOI 10.1126/science.150.3698.884; HORI K, 1967, P NATL ACAD SCI USA, V57, P1790, DOI 10.1073/pnas.57.6.1790; HORIUCHI K, 1971, VIROLOGY, V45, P429, DOI 10.1016/0042-6822(71)90343-6; KAMEN R, 1972, EUR J BIOCHEM, V31, P44, DOI 10.1111/j.1432-1033.1972.tb02498.x; KAMEN R, 1970, NATURE, V228, P527, DOI 10.1038/228527a0; KARNIK S, 1983, EMBO J, V2, P1521, DOI 10.1002/j.1460-2075.1983.tb01617.x; Karring H, 2003, EUR J BIOCHEM, V270, P4294, DOI 10.1046/j.1432-1033.2003.03822.x; Karring H, 2002, BBA-PROTEINS PROTEOM, V1601, P172, DOI 10.1016/S1570-9639(02)00460-0; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KNUDSEN CR, 1992, BIOCHEM INT, V28, P353; KONDO M, 1970, NATURE, V228, P525, DOI 10.1038/228525a0; Krab IM, 1998, BBA-GENE STRUCT EXPR, V1443, P1, DOI 10.1016/S0167-4781(98)00169-9; Krab IM, 2001, BIOCHEMISTRY-US, V40, P8531, DOI 10.1021/bi0104930; KUWANO M, 1972, J BACTERIOL, V112, P1150, DOI 10.1128/JB.112.3.1150-1156.1972; KUWANO M, 1973, NATURE-NEW BIOL, V244, P107, DOI 10.1038/newbio244107a0; LANDERS TA, 1974, J BIOL CHEM, V249, P5801; MANDAL NC, 1977, P NATL ACAD SCI USA, V74, P1657, DOI 10.1073/pnas.74.4.1657; Mathu SGJ, 2003, J CHROMATOGR B, V786, P279, DOI 10.1016/S1570-0232(02)00811-5; Miller DL, 1977, MOL MECH PROTEIN BIO, P323; MILLS DR, 1990, J VIROL, V64, P3872, DOI 10.1128/JVI.64.8.3872-3881.1990; MOODY MD, 1994, BIOCHEMISTRY-US, V33, P13836, DOI 10.1021/bi00250a038; Muffler A, 1996, GENE DEV, V10, P1143, DOI 10.1101/gad.10.9.1143; Nesper M, 1998, EUR J BIOCHEM, V255, P81, DOI 10.1046/j.1432-1327.1998.2550081.x; Neuhard J., 1987, ESCHERICHIA COLI SAL; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schuppli D, 1997, P NATL ACAD SCI USA, V94, P10239, DOI 10.1073/pnas.94.19.10239; SHAKLEE PN, 1988, VIROLOGY, V163, P209, DOI 10.1016/0042-6822(88)90250-4; Su Q, 1997, VIROLOGY, V227, P211, DOI 10.1006/viro.1996.8302; TANIGUCHI T, 1978, NATURE, V274, P223, DOI 10.1038/274223a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANDIEIJEN G, 1975, J MOL BIOL, V93, P351, DOI 10.1016/0022-2836(75)90282-X; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; WEINER AM, 1971, NATURE-NEW BIOL, V234, P206, DOI 10.1038/newbio234206a0; WEISSMANN C, 1974, FEBS LETT, V43, pS10	52	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1878	1884		10.1074/jbc.M306605200	http://dx.doi.org/10.1074/jbc.M306605200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14583631	hybrid			2022-12-25	WOS:000188005700040
J	Le Chatelier, E; Becherel, OJ; d'Alencon, E; Canceill, D; Ehrlich, SD; Fuchs, RPP; Janniere, L				Le Chatelier, E; Becherel, OJ; d'Alencon, E; Canceill, D; Ehrlich, SD; Fuchs, RPP; Janniere, L			Involvement of DnaE, the second replicative DNA polymerase from Bacillus subtilis, in DNA mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; III HOLOENZYME; FRAMESHIFT MUTATIONS; ERROR-PRONE; CIS-SYN; REPLICATION; PURIFICATION; EXONUCLEASE; EXPRESSION; REPAIR	In a large group of organisms including low G + C bacteria and eukaryotic cells, DNA synthesis at the replication fork strictly requires two distinct replicative DNA polymerases. These are designated pol C and DnaE in Bacillus subtilis. We recently proposed that DnaE might be preferentially involved in lagging strand synthesis, whereas pol C would mainly carry out leading strand synthesis. The biochemical analysis of DnaE reported here is consistent with its postulated function, as it is a highly potent enzyme, replicating as fast as 240 nucleotides/s, and stalling for more than 30 s when encountering annealed 5'-DNA end. DnaE is devoid of 3' --> 3 5'-proofreading exonuclease activity and has a low processivity ( 1 - 75 nucleotides), suggesting that it requires additional factors to fulfill its role in replication. Interestingly, we found that (i) DnaE is SOS-inducible; (ii) variation in DnaE or pol C concentration has no effect on spontaneous mutagenesis; (iii) depletion of pol C or DnaE prevents UV-induced mutagenesis; and (iv) purified DnaE has a rather relaxed active site as it can bypass lesions that generally block other replicative polymerases. These results suggest that DnaE and possibly pol C have a function in DNA repair/mutagenesis, in addition to their role in DNA replication.	INRA, F-78352 Jouy En Josas, France; Univ Strasbourg, Ecole Super Bioechnol Strasbourg, UPR 9003, CNRS,UPR Convent, F-67400 Strasbourg, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Le Chatelier, E (corresponding author), INRA, Domaine Vilvert, F-78352 Jouy En Josas, France.	lechat@jouy.inra.fr	d'Alençon, Emmanuelle/AAD-3069-2020; LE CHATELIER, Emmanuelle/O-1243-2017; Ehrlich, S./Y-2423-2019	LE CHATELIER, Emmanuelle/0000-0002-2724-0536; Ehrlich, S./0000-0002-7563-4046; Janniere, Laurent/0000-0003-2353-3160				BARNES MH, 1992, GENE, V111, P43, DOI 10.1016/0378-1119(92)90601-K; Becherel OJ, 1999, J MOL BIOL, V294, P299, DOI 10.1006/jmbi.1999.3272; BELGUISEVALLADIER P, 1994, J MOL BIOL, V236, P151, DOI 10.1006/jmbi.1994.1125; Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; Bloom LB, 1997, J BIOL CHEM, V272, P27919, DOI 10.1074/jbc.272.44.27919; Borden A, 2002, J BACTERIOL, V184, P2674, DOI 10.1128/JB.184.10.2674-2681.2002; Boshoff HIM, 2003, CELL, V113, P183, DOI 10.1016/S0092-8674(03)00270-8; Bruck I, 2000, J BIOL CHEM, V275, P28971, DOI 10.1074/jbc.M003565200; Bruck I, 2003, J BIOL CHEM, V278, P44361, DOI 10.1074/jbc.M308307200; Bruck I, 2002, J BIOL CHEM, V277, P17334, DOI 10.1074/jbc.M110198200; Bullard JM, 2002, J BIOL CHEM, V277, P13401, DOI 10.1074/jbc.M110833200; Bullock PA, 1997, CRIT REV BIOCHEM MOL, V32, P503, DOI 10.3109/10409239709082001; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Burnouf D, 1997, Recent Results Cancer Res, V143, P1; Canceill D, 1999, J BIOL CHEM, V274, P27481, DOI 10.1074/jbc.274.39.27481; Cordonnier AM, 1999, MOL CELL BIOL, V19, P2206; Creighton S, 1995, METHOD ENZYMOL, V262, P232; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; Davis EO, 2002, J BACTERIOL, V184, P3287, DOI 10.1128/JB.184.12.3287-3295.2002; Dervyn E, 2001, SCIENCE, V294, P1716, DOI 10.1126/science.1066351; Fabret C, 2002, MOL MICROBIOL, V46, P25, DOI 10.1046/j.1365-2958.2002.03140.x; FAY PJ, 1981, J BIOL CHEM, V256, P976; Foster KA, 2003, PROTEIN EXPRES PURIF, V27, P90, DOI 10.1016/S1046-5928(02)00577-6; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; FUCHS RPP, 1981, NATURE, V294, P657, DOI 10.1038/294657a0; GARCIA A, 1993, P NATL ACAD SCI USA, V90, P5989, DOI 10.1073/pnas.90.13.5989; GASS KB, 1973, P NATL ACAD SCI USA, V70, P103, DOI 10.1073/pnas.70.1.103; GASS KB, 1973, J BIOL CHEM, V248, P7688; GOODMAN MF, 1994, ANN NY ACAD SCI, V726, P132, DOI 10.1111/j.1749-6632.1994.tb52804.x; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Inoue R, 2001, MOL GENET GENOMICS, V266, P564, DOI 10.1007/s004380100564; KELVIN Z, 1995, ANNU REV BIOCHEM, V64, P171; Kim DR, 1996, J BIOL CHEM, V271, P20681, DOI 10.1074/jbc.271.34.20681; Kim SR, 1997, P NATL ACAD SCI USA, V94, P13792, DOI 10.1073/pnas.94.25.13792; Klemperer N, 2000, J BIOL CHEM, V275, P26136, DOI 10.1074/jbc.M002566200; KoffelSchwartz N, 1996, P NATL ACAD SCI USA, V93, P7805, DOI 10.1073/pnas.93.15.7805; KOFFELSCHWARTZ N, 1984, J MOL BIOL, V177, P33, DOI 10.1016/0022-2836(84)90056-1; KORNBERG A, 1992, DNA REPLICATION, P494; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LADUCA RJ, 1983, BIOCHEMISTRY-US, V22, P5177, DOI 10.1021/bi00291a018; LAMBERT IB, 1992, P NATL ACAD SCI USA, V89, P1310, DOI 10.1073/pnas.89.4.1310; Lenne-Samuel N, 2000, MOL MICROBIOL, V38, P299, DOI 10.1046/j.1365-2958.2000.02116.x; LOW RL, 1976, J BIOL CHEM, V251, P1311; LOW RL, 1976, MICROBIOLOGY 1976, P185; MACKENZIE JM, 1973, P NATL ACAD SCI USA, V70, P512, DOI 10.1073/pnas.70.2.512; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; MAKI H, 1985, J BIOL CHEM, V260, P2987; McHenry CS, 2003, MOL MICROBIOL, V49, P1157, DOI 10.1046/j.1365-2958.2003.03645.x; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; MSADEK T, 1990, J BACTERIOL, V172, P824, DOI 10.1128/jb.172.2.824-834.1990; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; NAPOLITANO RL, 1994, BIOCHEMISTRY-US, V33, P1311, DOI 10.1021/bi00172a004; Napolitano RL, 1997, CHEM RES TOXICOL, V10, P667, DOI 10.1021/tx970018w; Noirot-Gros MF, 2002, P NATL ACAD SCI USA, V99, P8342, DOI 10.1073/pnas.122040799; PazElizur T, 1996, J BIOL CHEM, V271, P24662, DOI 10.1074/jbc.271.40.24662; Petit MA, 1998, MOL MICROBIOL, V29, P261, DOI 10.1046/j.1365-2958.1998.00927.x; Petit MA, 2002, EMBO J, V21, P3137, DOI 10.1093/emboj/cdf317; Pham PT, 1999, J BIOL CHEM, V274, P3705, DOI 10.1074/jbc.274.6.3705; Reuven NB, 1998, MOL CELL, V2, P191, DOI 10.1016/S1097-2765(00)80129-X; Rocha EPC, 2002, TRENDS MICROBIOL, V10, P393, DOI 10.1016/S0966-842X(02)02420-4; SHCHERBAKOVA PV, 2003, SCI AGING KNOWLEDGE, V8; Shen X, 2002, J BIOL CHEM, V277, P5265, DOI 10.1074/jbc.M109575200; Shibutani S, 1997, J BIOL CHEM, V272, P13916, DOI 10.1074/jbc.272.21.13916; Smith CA, 1998, J BIOL CHEM, V273, P21933, DOI 10.1074/jbc.273.34.21933; Stucki M, 2001, PROG NUCLEIC ACID RE, V65, P261; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; Sung HM, 2003, J BACTERIOL, V185, P2153, DOI 10.1128/JB.185.7.2153-2160.2003; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Tomer G, 1998, P NATL ACAD SCI USA, V95, P14106, DOI 10.1073/pnas.95.24.14106; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; VEAUTE X, 1993, SCIENCE, V261, P598, DOI 10.1126/science.8342022; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Wagner J, 2000, J BACTERIOL, V182, P4587, DOI 10.1128/JB.182.16.4587-4595.2000; Winterling KW, 1997, J BACTERIOL, V179, P1698, DOI 10.1128/jb.179.5.1698-1703.1997	76	45	47	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1757	1767		10.1074/jbc.M310719200	http://dx.doi.org/10.1074/jbc.M310719200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14593098	hybrid, Green Published			2022-12-25	WOS:000188005700025
J	Wolfe, MD; Ahmed, F; Lacourciere, GM; Lauhon, CT; Stadtman, TC; Larson, TJ				Wolfe, MD; Ahmed, F; Lacourciere, GM; Lauhon, CT; Stadtman, TC; Larson, TJ			Functional diversity of the rhodanese homology domain - The Escherichia coli ybbB gene encodes a selenophosphate-dependent tRNA 2-selenouridine synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; 1ST POSITION; BIOSYNTHESIS; SELENIUM; 4-THIOURIDINE; ENZYME; ISCS; SULFURTRANSFERASE; AMINOACYLATION; SYNTHETASE	Escherichia coli has eight genes predicted to encode sulfurtransferases having the active site consensus sequence Cys-Xaa-Xaa-Gly. One of these genes, ybbB, is frequently found within bacterial operons that contain selD, the selenophosphate synthetase gene, suggesting a role in selenium metabolism. We show that ybbB is required in vivo for the specific substitution of selenium for sulfur in 2-thiouridine residues in E. coli tRNA. This modified tRNA nucleoside, 5-methylaminomethyl-2-selenouridine (mnm(5)se(2)U), is located at the wobble position of the anticodons of tRNALys, tRNAGlu, and tRNA(1)(Gln). Nucleoside analysis of tRNAs from wild-type and ybbB mutant strains revealed that production of mnm(5)se(2)U is lost in the ybbB mutant but that 5-methylaminomethyl-2- thiouridine, the mnm(5)se(2)U precursor, is unaffected by deletion of ybbB. Thus, ybbB is not required for the initial sulfurtransferase reaction but rather encodes a 2-selenouridine synthase that replaces a sulfur atom in 2-thiouridine in tRNA with selenium. Purified 2-selenouridine synthase containing a C-terminal His(6) tag exhibited spectral properties consistent with tRNA bound to the enzyme. In vitro mnm(5)se(2)U synthesis is shown to be dependent on 2-selenouridine synthase, SePO3, and tRNA. Finally, we demonstrate that the conserved Cys(97) ( but not Cys(96)) in the rhodanese sequence motif Cys(96)-Cys(97)-Xaa-Xaa-Gly is required for 2-selenouridine synthase in vivo activity. These data are consistent with the ybbB gene encoding a tRNA 2-selenouridine synthase and identifies a new role for the rhodanese homology domain in enzymes.	Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA; NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA	Virginia Polytechnic Institute & State University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Wisconsin System; University of Wisconsin Madison	Larson, TJ (corresponding author), Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA.	tilarson@vt.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000205] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams H, 2002, FEBS LETT, V518, P173, DOI 10.1016/S0014-5793(02)02695-9; Allan Christian B., 2000, Biofactors, V11, P87; Alphey MS, 2003, J BIOL CHEM, V278, P48219, DOI 10.1074/jbc.M307187200; Ashraf SS, 1999, RNA, V5, P188, DOI 10.1017/S1355838299981529; Begley TP, 1999, ARCH MICROBIOL, V171, P293, DOI 10.1007/s002030050713; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bordo D, 2002, EMBO REP, V3, P741, DOI 10.1093/embo-reports/kvf150; CHEREPANOV PP, 1995, GENE, V158, P9, DOI 10.1016/0378-1119(95)00193-A; CHING WM, 1985, P NATL ACAD SCI USA, V82, P347, DOI 10.1073/pnas.82.2.347; CHING WM, 1985, CURR TOP CELL REGUL, V27, P497; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Donahue JL, 2000, J BACTERIOL, V182, P5624, DOI 10.1128/JB.182.19.5624-5627.2000; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; GEHRKE CW, 1982, J CHROMATOGR, V230, P297, DOI 10.1016/S0378-4347(00)80479-X; IKEMURA T, 1981, J MOL BIOL, V146, P1, DOI 10.1016/0022-2836(81)90363-6; Kambampati R, 2000, J BIOL CHEM, V275, P10727, DOI 10.1074/jbc.275.15.10727; Kambampati R, 2003, BIOCHEMISTRY-US, V42, P1109, DOI 10.1021/bi026536+; KLAYMAN DL, 1973, J AM CHEM SOC, V95, P197, DOI 10.1021/ja00782a034; KOONIN EV, 1993, J MOL BIOL, V229, P1165, DOI 10.1006/jmbi.1993.1115; KRAMER GF, 1988, J BACTERIOL, V170, P736, DOI 10.1128/jb.170.2.736-743.1988; Kruger MK, 1998, J MOL BIOL, V284, P609, DOI 10.1006/jmbi.1998.2197; Kruger MK, 1998, J MOL BIOL, V284, P621, DOI 10.1006/jmbi.1998.2196; Lauhon CT, 2002, J BACTERIOL, V184, P6820, DOI 10.1128/JB.184.24.6820-6829.2002; Lima CD, 2002, J MOL BIOL, V315, P1199, DOI 10.1006/jmbi.2001.5308; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; Madore E, 1999, EUR J BIOCHEM, V266, P1128, DOI 10.1046/j.1432-1327.1999.00965.x; Mihara H, 2002, P NATL ACAD SCI USA, V99, P6679, DOI 10.1073/pnas.102176099; Mueller EG, 2001, J BIOL CHEM, V276, P33588, DOI 10.1074/jbc.M104067200; Nichols BP, 1998, J BACTERIOL, V180, P6408; Ogasawara Y, 2001, P NATL ACAD SCI USA, V98, P9494, DOI 10.1073/pnas.171320998; Palenchar PM, 2000, J BIOL CHEM, V275, P8283, DOI 10.1074/jbc.275.12.8283; Ray WK, 2000, J BACTERIOL, V182, P2277, DOI 10.1128/JB.182.8.2277-2284.2000; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; Spallarossa A, 2001, STRUCTURE, V9, P1117, DOI 10.1016/S0969-2126(01)00666-9; Stadtman T C, 1994, Adv Inorg Biochem, V10, P157; STADTMAN T C, 1989, Biofactors, V2, P35; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SULLIVAN MA, 1985, J BACTERIOL, V161, P368, DOI 10.1128/JB.161.1.368-376.1985; SYLVERS LA, 1993, BIOCHEMISTRY-US, V32, P3836, DOI 10.1021/bi00066a002; Urbonavicius J, 2001, EMBO J, V20, P4863, DOI 10.1093/emboj/20.17.4863; VERES Z, 1994, J BIOL CHEM, V269, P10597; VERES Z, 1994, P NATL ACAD SCI USA, V91, P8092, DOI 10.1073/pnas.91.17.8092; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WITTWER A J, 1989, Biofactors, V2, P27; WITTWER AJ, 1983, J BIOL CHEM, V258, P8637; WITTWER AJ, 1986, ARCH BIOCHEM BIOPHYS, V248, P540, DOI 10.1016/0003-9861(86)90507-2; Wright CM, 2002, CHEM COMMUN, P2708, DOI 10.1039/b208626c; Yarian C, 2002, J BIOL CHEM, V277, P16391, DOI 10.1074/jbc.M200253200; YOKOYAMA S, 1985, P NATL ACAD SCI USA, V82, P4905, DOI 10.1073/pnas.82.15.4905; Zeng G, 1996, BIOTECHNIQUES, V21, P822	51	82	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1801	1809		10.1074/jbc.M310442200	http://dx.doi.org/10.1074/jbc.M310442200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14594807	hybrid			2022-12-25	WOS:000188005700030
J	Deng, QD; Liao, R; Wu, BL; Sun, PQ				Deng, QD; Liao, R; Wu, BL; Sun, PQ			High intensity ras signaling induces premature senescence by activating p38 pathway in primary human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE DISSOCIATION STIMULATOR; HUMAN-PAPILLOMAVIRUS TYPE-16; HUMAN EPITHELIAL-CELLS; MAP-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; TUMOR-SUPPRESSOR; DNA-SYNTHESIS; CYCLE ARREST; E7 PROTEIN; CANCER	Although oncogenic ras plays a pivotal role in neoplastic transformation, it triggers an anti-oncogenic defense mechanism known as premature senescence in normal cells. In this study, we investigated the induction of cellular responses by different expression levels of oncogenic ras in primary human fibroblasts. We found that a moderate, severalfold increase in ras expression promoted cell growth. Further elevation of ras expression initially enhanced proliferation but eventually induced p16(INK4A) expression and senescence. The induction of these opposing cellular responses by ras signals of different intensity was achieved through differential activation of the MAPK pathways that mediated these responses. Whereas moderate ras activities only stimulated the mitogenic MEK-ERK pathway, high intensity ras signals induced MEK and ERK to higher levels, leading to stimulation of the MKK3/6-p38 pathway, which had been shown previously to act downstream of Ras-MEK to trigger the senescence response. Thus, these studies have revealed a mechanism for the differential effects of ras on cell proliferation. Furthermore, moderate ras activity mediated transformation in cooperation with E6E7 and hTERT, suggesting that a moderate intensity ras signal can provide sufficient oncogenic activities for tumorigenesis. This result also implies that the ability of ras to promote proliferation and oncogenic transformation can be uncoupled with that to induce senescence in cell culture and that the development of tumors with relatively low ras activities may not need to acquire genetic alterations that bypass premature senescence.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 91037 USA; Childrens Hosp, Dept Pathol & Lab Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02115 USA	Scripps Research Institute; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Sun, PQ (corresponding author), Scripps Res Inst, Dept Mol Biol, MB-41,10550 N Torrey Pines Rd, La Jolla, CA 91037 USA.							BANKS L, 1990, ONCOGENE, V5, P1383; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1989, CANCER RES, V49, P4682; Boyer SN, 1996, CANCER RES, V56, P4620; BROKAW JL, 1994, VIROLOGY, V205, P603, DOI 10.1006/viro.1994.1688; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dokianakis DN, 1999, ONCOL REP, V6, P1327; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; GARRETT LR, 1993, CARCINOGENESIS, V14, P329, DOI 10.1093/carcin/14.2.329; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Graves LM, 2000, NATURE, V403, P328, DOI 10.1038/35002111; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Huibregtse JM, 1996, SEMIN CANCER BIOL, V7, P317, DOI 10.1006/scbi.1996.0041; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Roh JW, 2001, CANCER LETT, V165, P59, DOI 10.1016/S0304-3835(01)00401-3; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SEABRIGH.M, 1971, LANCET, V2, P971; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Treinies I, 1999, MOL CELL BIOL, V19, P321; Tremain R, 2000, ONCOGENE, V19, P1698, DOI 10.1038/sj.onc.1203471; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Wei S, 1999, CANCER RES, V59, P1539; WEINBERG RA, 1989, CANCER RES, V49, P3713; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wu BL, 1996, AM J MED GENET, V62, P77, DOI 10.1002/(SICI)1096-8628(19960301)62:1<77::AID-AJMG16>3.0.CO;2-S; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; ZUR HH, 1996, BIOCHIM BIOPHYS ACTA, V1288, pF55	58	140	148	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1050	1059		10.1074/jbc.M308644200	http://dx.doi.org/10.1074/jbc.M308644200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14593117	hybrid			2022-12-25	WOS:000187722800028
J	Fassbender, K; Walter, S; Kuhl, S; Landmann, R; Ishii, K; Bertsch, T; Stalder, AK; Muehlhauser, F; Liu, Y; Ulmer, AJ; Rivest, S; Lentschat, A; Gulbins, E; Jucker, M; Staufenbiel, M; Brechtel, K; Walter, J; Multhaup, G; Penke, B; Adachi, Y; Hartmann, T; Beyreuther, K				Fassbender, K; Walter, S; Kuhl, S; Landmann, R; Ishii, K; Bertsch, T; Stalder, AK; Muehlhauser, F; Liu, Y; Ulmer, AJ; Rivest, S; Lentschat, A; Gulbins, E; Jucker, M; Staufenbiel, M; Brechtel, K; Walter, J; Multhaup, G; Penke, B; Adachi, Y; Hartmann, T; Beyreuther, K			The LPS receptor (CD14) links innate immunity with Alzheimer's disease	FASEB JOURNAL			English	Article						AD; lipopolysaccharide; A beta	CENTRAL-NERVOUS-SYSTEM; AMYLOID-BETA; LIPOPOLYSACCHARIDE LPS; MICROGLIAL CELLS; MOUSE MODEL; ACTIVATION; EXPRESSION; PATHOLOGY; BINDING; ENDOTOXIN	To rapidly respond to invading microorganisms, humans call on their innate immune system. This occurs by microbe-detecting receptors, such as CD14, that activate immune cells to eliminate the pathogens. Here, we link the lipopolysaccharide receptor CD14 with Alzheimer's disease, a severe neurodegenerative disease resulting in dementia. We demonstrate that this key innate immunity receptor interacts with fibrils of Alzheimer amyloid peptide. Neutralization with antibodies against CD14 and genetic deficiency for this receptor significantly reduced amyloid peptide induced microglial activation and microglial toxicity. The observation of strongly enhanced microglial expression of the LPS receptor in brains of animal models of Alzheimer's disease indicates a clinical relevance of these findings. These data suggest that CD14 may significantly contribute to the overall neuroinflammatory response to amyloid peptide, highlighting the possibility that the enormous progress currently being made in the field of innate immunity could be extended to research on Alzheimer's disease.	Univ Gottingen, Dept Neurol, D-37075 Gottingen, Germany; Heidelberg Univ, Ctr Mol Biol, D-69120 Heidelberg, Germany; Univ Basel Hosp, Dept Res, Div Infect Dis, CH-4031 Basel, Switzerland; Heidelberg Univ, Dept Clin Chem, D-68167 Mannheim, Germany; Univ Basel Hosp, Div Neuropathol, CH-4031 Basel, Switzerland; Novartis Inst BioMed Res, Basel, Switzerland; Borstel Res Ctr, Ctr Med & Biosci, D-23845 Borstel, Germany; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; Univ Laval, Mol Endocrinol Lab, Quebec City, PQ PQ G1V 4G2, Canada; Albert Szent Gyorgyi Med Univ, Dept Med Chem, H-6720 Szeged, Hungary; Tokyo Univ Pharm & Life Sci, Sch Pharm, Tokyo 1920392, Japan	University of Gottingen; Ruprecht Karls University Heidelberg; University of Basel; Ruprecht Karls University Heidelberg; University of Basel; Novartis; Forschungszentrum Borstel; St Jude Children's Research Hospital; Laval University; Szeged University; Tokyo University of Pharmacy & Life Sciences	Fassbender, K (corresponding author), Univ Gottingen, Dept Neurol, D-37075 Gottingen, Germany.	klaus.fassbender@med.uni-goettingen.de	Hartmann, Tobias/AAB-8297-2022; Ishii, Ken J/B-1685-2012; Gulbins, Erich/L-6989-2014	Ishii, Ken J/0000-0002-6728-3872; Gulbins, Erich/0000-0002-3117-1342; Hartmann, Tobias/0000-0001-7481-6430; Fassbender, Klaus/0000-0003-3596-868X; Walter, Silke/0000-0002-1176-2911; Rivest, Serge/0000-0002-6082-770X			We thank M. Freeman and D. Golenbock (Boston) for providing CD14-/- mice and Y. Imai(Kodaira, Japan) for providing the iba1 mAb	Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bendelac A, 2000, CURR OPIN IMMUNOL, V12, P11, DOI 10.1016/S0952-7915(99)00044-8; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; Calhoun ME, 1998, NATURE, V395, P755, DOI 10.1038/27351; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; El Khoury JB, 2003, J EXP MED, V197, P1657, DOI 10.1084/jem.20021546; ElKhoury J, 1996, NATURE, V382, P716; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; GOLENBOCK DT, 1993, J BIOL CHEM, V268, P22055; Goodwin JL, 1997, BRAIN RES, V768, P279, DOI 10.1016/S0006-8993(97)00653-7; Hamann L, 2000, EUR J IMMUNOL, V30, P211, DOI 10.1002/1521-4141(200001)30:1<211::AID-IMMU211>3.3.CO;2-F; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; Ishii K, 2000, FASEB J, V14, P1485, DOI 10.1096/fj.14.11.1485; Kaisho T, 2001, NATURE, V414, P701, DOI 10.1038/414701a; KIRKLAND TN, 1993, J BIOL CHEM, V268, P24818; Laflamme N, 2001, FASEB J, V15, P155, DOI 10.1096/fj.00-0339com; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; Mackenzie IRA, 1998, NEUROLOGY, V50, P986, DOI 10.1212/WNL.50.4.986; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Nagaoka I, 2001, J IMMUNOL, V167, P3329, DOI 10.4049/jimmunol.167.6.3329; Perera PY, 2001, J IMMUNOL, V166, P574, DOI 10.4049/jimmunol.166.1.574; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Sellati TJ, 1998, J IMMUNOL, V160, P5455; Sheng JG, 1997, ACTA NEUROPATHOL, V94, P1, DOI 10.1007/s004010050664; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; Wang JE, 2001, INFECT IMMUN, V69, P2402, DOI 10.1128/IAI.69.4.2402-2406.2001; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yates SL, 2000, J NEUROCHEM, V74, P1017, DOI 10.1046/j.1471-4159.2000.0741017.x; Younkin SG, 2001, NAT MED, V7, P18, DOI 10.1038/83292	36	259	276	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					203	205		10.1096/fj.03-0364fje	http://dx.doi.org/10.1096/fj.03-0364fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597556				2022-12-25	WOS:000188829300074
J	Hardaker, EL; Bacon, AM; Carlson, K; Roshak, AK; Foley, JJ; Schmidt, DB; Buckley, PT; Comegys, M; Panettieri, RA; Sarau, HM; Belmonte, KE				Hardaker, EL; Bacon, AM; Carlson, K; Roshak, AK; Foley, JJ; Schmidt, DB; Buckley, PT; Comegys, M; Panettieri, RA; Sarau, HM; Belmonte, KE			Regulation of TNF-alpha and IFN-gamma induced CXCL10 expression: participation of the airway smooth muscle in the pulmonary inflammatory response in chronic obstructive pulmonary disease	FASEB JOURNAL			English	Article						chemokines; inflammation; respiratory; NF-kappa B	NECROSIS-FACTOR-ALPHA; CHEMOKINE RECEPTOR CXCR3; INDUCIBLE PROTEIN-10; INTERFERON-GAMMA; T-LYMPHOCYTES; PERIPHERAL AIRWAYS; GENE-EXPRESSION; I-TAC; CELLS; IP-10	The chemokine CXCL 10 is produced by many inflammatory cells found in the diseased lung and has been implicated in the pathogenesis of chronic obstructive pulmonary disease (COPD). The present study demonstrates elevated CXCL10 protein in the lungs of COPD patients, which appears histologically in airway smooth muscle (hASM). In primary cultured hASM cells taken from normal donors, CXCL10 protein expression was induced by IFN-gamma and TNF-alpha., cytokines reported as elevated in COPD, and a synergistic response was obtained when they were combined. TNF-alpha. stimulation of hASM enhanced accumulation of CXCL10 mRNA, indicating regulation at the transcriptional level, while IFN-gamma stimulation resulted in a smaller accumulation of CXCL10 mRNA. When these cytokines were applied simultaneously, an additive effect was obtained. TNF-alpha-induced CXCL 10 expression in hASM was dependent on NFkappaB activation, and a salicylanilide NF kappa B inhibitor blocked the CXCL10 expression. In contrast, IFN-gamma stimulation resulted in transient NF kappa B activation, and the inhibitor had little effect on CXCL 10 expression. When these cytokines were added simultaneously, NF kappa B was activated earlier and lasted longer, and the effect was blocked by the inhibitor. These data demonstrate a potential active role for hASM in pulmonary inflammatory diseases such as COPD by producing CXCL10.	GlaxoSmithKline Inc, Ctr Excellence Drug Discovery, King Of Prussia, PA 19406 USA; Univ Penn, Med Ctr, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA	GlaxoSmithKline; University of Pennsylvania	Belmonte, KE (corresponding author), GlaxoSmithKline Inc, Ctr Excellence Drug Discovery, King Of Prussia, PA 19406 USA.	Kristen.E.Belmonte@GSK.com	panettieri, reynold/AAG-9485-2019		Airways Biology Institute at the University of Pennsylvania GlaxoSmithKline; National Institutes of Health [HL-67663]	Airways Biology Institute at the University of Pennsylvania GlaxoSmithKline; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors wish to thank Andrew Eszterhas in Dr. Reynold Panettieri's laboratory (University of Pennsylvania) for the primary cultured hASM cells, GlaxoSmithKline employee Roseanna Frankowski for assistance with the immunohistochemistry methods, and James F. Callahan for his guidance regarding use of the NF-kB inhibitor. This work was supported by the Airways Biology Institute at the University of Pennsylvania in cooperation with a grant from GlaxoSmithKline and a grant from the National Institutes of Health (HL-67663 to R. A. Panettieri, Jr.).	Ammit AJ, 2000, AM J RESP CELL MOL, V23, P794, DOI 10.1165/ajrcmb.23.6.4184; Barnes PJ, 2000, CHEST, V117, P10; Boorsma DM, 1998, ARCH DERMATOL RES, V290, P335, DOI 10.1007/s004030050314; Bukowski RM, 1999, CLIN CANCER RES, V5, P2780; CALLAHAN JF, 2000, KEYSTONE S, V369; CALLAHAN JF, 1999, Patent No. 9965449; Campbell JJ, 2000, CURR OPIN IMMUNOL, V12, P336, DOI 10.1016/S0952-7915(00)00096-0; Carayol N, 2002, AM J RESP CELL MOL, V26, P341, DOI 10.1165/ajrcmb.26.3.4684; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dixon AE, 2000, AM J PHYSIOL-LUNG C, V279, pL592, DOI 10.1152/ajplung.2000.279.3.L592; Ebert LM, 2001, J IMMUNOL, V166, P4870, DOI 10.4049/jimmunol.166.8.4870; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; Frangogiannis NG, 2000, CELL TISSUE RES, V302, P365, DOI 10.1007/s004410000274; Gasperini S, 1999, J IMMUNOL, V162, P4928; Hamerman JA, 2001, J IMMUNOL, V167, P2227, DOI 10.4049/jimmunol.167.4.2227; HayGlass KT, 2000, IMMUNOPHARMACOLOGY, V48, P283, DOI 10.1016/S0162-3109(00)00225-3; Hozumi A, 2001, AM J PHYSIOL-LUNG C, V281, pL1444, DOI 10.1152/ajplung.2001.281.6.L1444; John M, 1998, AM J RESP CELL MOL, V18, P84, DOI 10.1165/ajrcmb.18.1.2813; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; Kronke M, 1992, Immunol Ser, V56, P189; Lamkhioued B, 2000, AM J RESP CRIT CARE, V162, P723, DOI 10.1164/ajrccm.162.2.9901080; Loetscher M, 1998, EUR J IMMUNOL, V28, P3696, DOI 10.1002/(SICI)1521-4141(199811)28:11<3696::AID-IMMU3696>3.0.CO;2-W; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; Majumder S, 1998, J IMMUNOL, V161, P4736; Majumder S, 1998, J NEUROSCI RES, V54, P169, DOI 10.1002/(SICI)1097-4547(19981015)54:2<169::AID-JNR5>3.0.CO;2-C; Miotto D, 2001, J ALLERGY CLIN IMMUN, V107, P664, DOI 10.1067/mai.2001.113524; Mueller R, 1996, RESP MED, V90, P79, DOI 10.1016/S0954-6111(96)90202-4; Neville Lewis F., 1997, Cytokine and Growth Factor Reviews, V8, P207, DOI 10.1016/S1359-6101(97)00015-4; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Piali L, 1998, EUR J IMMUNOL, V28, P961, DOI 10.1002/(SICI)1521-4141(199803)28:03<961::AID-IMMU961>3.0.CO;2-4; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Rabin RL, 1999, J IMMUNOL, V162, P3840; Ren XD, 2002, SHOCK, V17, P513, DOI 10.1097/00024382-200206000-00013; Romagnani P, 2002, J AM SOC NEPHROL, V13, P53, DOI 10.1681/ASN.V13153; Saetta M, 1998, AM J RESP CRIT CARE, V157, P822, DOI 10.1164/ajrccm.157.3.9709027; Saetta M, 2002, AM J RESP CRIT CARE, V165, P1404, DOI 10.1164/rccm.2107139; Saetta M, 1999, AM J RESP CRIT CARE, V160, pS17, DOI 10.1164/ajrccm.160.supplement_1.6; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Sauty A, 1999, J IMMUNOL, V162, P3549; SCHUTZE S, 1992, SEMIN ONCOL, V19, P16; Soejima K, 2001, J IMMUNOL, V167, P6576, DOI 10.4049/jimmunol.167.11.6576; Soler N, 1999, EUR RESPIR J, V14, P1015, DOI 10.1183/09031936.99.14510159; Tan JQ, 2000, BLOOD, V96, P1230, DOI 10.1182/blood.V96.4.1230.h8001230_1230_1238; Tensen CP, 1999, J INVEST DERMATOL, V112, P716, DOI 10.1046/j.1523-1747.1999.00581.x; Wang XK, 1996, J BIOL CHEM, V271, P24286, DOI 10.1074/jbc.271.39.24286	49	96	100	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					191	193		10.1096/fj.03-0170fje	http://dx.doi.org/10.1096/fj.03-0170fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597565				2022-12-25	WOS:000188829300070
J	Kim, E; Gunther, W; Yoshizato, K; Meissner, H; Zapf, S; Nusing, RM; Yamamoto, H; Van Meir, EG; Deppert, W; Giese, A				Kim, E; Gunther, W; Yoshizato, K; Meissner, H; Zapf, S; Nusing, RM; Yamamoto, H; Van Meir, EG; Deppert, W; Giese, A			Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1	ONCOGENE			English	Article						invasion genes; glioma; p53; ets-1; thromboxane synthase; transcription	HUMAN COLON-CANCER; GROWTH-FACTOR; CELL-GROWTH; PLASMINOGEN-ACTIVATOR; GLIOBLASTOMA CELLS; INDUCE APOPTOSIS; EPITHELIAL-CELLS; DOWN-REGULATION; BREAST-CANCER; HUMAN GLIOMAS	Cancer formation and progression is a complex process determined by several mechanisms that promote cell growth, invasiveness, neo-angiogenesis, and render neoplastic cells resistant to apoptosis. The tumor suppressor p53 and the proto-oncogenic factor ets-1 are important regulators of such mechanisms. While it is well established that p53 and ets-1 influence various aspects of cell behavior by regulating the transcription of specific genes, little is known about the functional relationship between these transcription factors. We found that the gene encoding thromboxane synthase (TXSA), which we recently identified as a factor promoting invasion and resistance to apoptosis in gliomas, is a novel target gene for both p53 and ets-1. We demonstrate that p53 and ets-1 coregulate TXSA in an antagonistic and interrelated manner, with ets-1 being a potent transcriptional activator and p53 inhibiting ets-1-dependent transcription. Negative interference with ets-1 transcription requires functional p53 and is lost in mutant p53 proteins. We show that ets-1 and p53 associate physically in vitro and in vivo and that their interaction, rather than a direct binding of p53 to the TXSA promoter, is required for transcriptional repression of TXSA by wild-type p53. An important implication of our findings is that the loss of p53-mediated negative control over ets-1-dependent transcription may lead to the acquisition of an invasive phenotype in tumor cells.	Univ Hosp Lubeck, Dept Neurosurg, D-23538 Lubeck, Germany; Univ Hosp Eppendorf, Dept Neurosurg, Hamburg, Germany; Univ Childrens Hosp, Ctr Sci Res, Marburg, Germany; Inst Neurosurg & Neurores, Chicago, IL USA; Emory Univ, Sch Med, Winship Canc Inst, Dept Neurosurg, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol Oncol, Atlanta, GA 30322 USA; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Dept Tumor Virol, D-2000 Hamburg, Germany	University of Lubeck; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Emory University; Emory University; Heinrich Pette Institute; University of Hamburg	Giese, A (corresponding author), Univ Hosp Lubeck, Dept Neurosurg, Ratzeburger Allee 160, D-23538 Lubeck, Germany.			Van Meir, Erwin G./0000-0003-2444-7707				Albertoni M, 1998, ONCOGENE, V16, P321, DOI 10.1038/sj.onc.1201544; Albertoni M, 2002, ONCOGENE, V21, P4212, DOI 10.1038/sj.onc.1205610; ANKER L, 1993, INT J CANCER, V55, P982, DOI 10.1002/ijc.2910550618; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Behrens P, 2001, J PATHOL, V194, P43, DOI 10.1002/path.844; BENNETT A, 1986, PROG LIPID RES, V25, P539, DOI 10.1016/0163-7827(86)90109-8; BENNETT A, 1977, LANCET, V2, P624; BENNETT A, 1987, GUT, V28, P315, DOI 10.1136/gut.28.3.315; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; CASTELLI MG, 1989, CANCER RES, V49, P1505; Daniel TO, 1999, CANCER RES, V59, P4574; Deininger MH, 1999, ACTA NEUROPATHOL, V98, P240, DOI 10.1007/s004010051075; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Fritsche M, 1998, MOL CELL ENDOCRINOL, V143, P143, DOI 10.1016/S0303-7207(98)00140-3; Giese A, 1999, Neuro Oncol, V1, P3, DOI 10.1093/neuonc/1.1.3; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; Gohler T, 2002, J BIOL CHEM, V277, P41192, DOI 10.1074/jbc.M202344200; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Hong TM, 2001, J BIOL CHEM, V276, P1510, DOI 10.1074/jbc.M008231200; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Jayaraman G, 1999, J BIOL CHEM, V274, P17869, DOI 10.1074/jbc.274.25.17869; Jiang Y, 2001, BIOCHEM BIOPH RES CO, V286, P1123, DOI 10.1006/bbrc.2001.5521; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kim E, 1999, ONCOGENE, V18, P7310, DOI 10.1038/sj.onc.1203139; Kim E, 2003, BIOCHEM CELL BIOL, V81, P141, DOI 10.1139/o03-046; Kita D, 2001, CANCER RES, V61, P7985; Kitange G, 2000, CANCER, V89, P2292, DOI 10.1002/1097-0142(20001201)89:11<2292::AID-CNCR18>3.0.CO;2-0; Kurzel F, 2002, ACTA NEUROCHIR, V144, P71, DOI 10.1007/s701-002-8276-9; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu XH, 2000, J UROLOGY, V164, P820, DOI 10.1016/S0022-5347(05)67321-1; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; McDonough W, 1998, J NEUROPATH EXP NEUR, V57, P449, DOI 10.1097/00005072-199805000-00008; MIYATA A, 1994, EUR J BIOCHEM, V224, P273, DOI 10.1111/j.1432-1033.1994.00273.x; Modugno M, 2002, ONCOGENE, V21, P7478, DOI 10.1038/sj.onc.1205957; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nakada M, 1999, J NEUROPATH EXP NEUR, V58, P329, DOI 10.1097/00005072-199904000-00003; Nie DT, 2000, BIOCHEM BIOPH RES CO, V267, P245, DOI 10.1006/bbrc.1999.1840; Pastorcic M, 2000, J BIOL CHEM, V275, P34938, DOI 10.1074/jbc.M005411200; Pica F, 1996, J PHARMACOL EXP THER, V277, P1793; Pradono P, 2002, CANCER RES, V62, P63; Reisdorff J, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015617.39974.FB; Ristimaki A, 1997, CANCER RES, V57, P1276; Rodrigues S, 2001, FASEB J, V15, P1517, DOI 10.1096/fj.00-0802com; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; SANO H, 1995, CANCER RES, V55, P3785; Sato Y, 2001, ANN NY ACAD SCI, V947, P117; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Surette ME, 1999, CARCINOGENESIS, V20, P757, DOI 10.1093/carcin/20.5.757; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Valter MM, 1999, CANCER RES, V59, P5608; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang XJ, 1997, J RADIAT RES, V38, P179, DOI 10.1269/jrr.38.179; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Wasylyk C, 2002, MOL CELL BIOL, V22, P2687, DOI 10.1128/MCB.22.8.2687-2702.2002; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Xu DK, 2002, EMBO J, V21, P4081, DOI 10.1093/emboj/cdf413; Yamamoto H, 2000, CANCER RES, V60, P134; Yoshizato K, 2002, NEUROSURGERY, V50, P343, DOI 10.1097/00006123-200202000-00021; ZHOU Y, 2002, J BIOL CHEM, V25, P25	70	45	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7716	7727		10.1038/sj.onc.1207155	http://dx.doi.org/10.1038/sj.onc.1207155			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586398				2022-12-25	WOS:000186240200002
J	Muntoni, A; Fleming, J; Gordon, KE; Hunter, K; McGregor, F; Parkinson, EK; Harrison, PR				Muntoni, A; Fleming, J; Gordon, KE; Hunter, K; McGregor, F; Parkinson, EK; Harrison, PR			Senescing oral dysplasias are not immortalized by ectopic expression of hTERT alone without other molecular changes, such as loss of INK4A and/or retinoic acid receptor-beta: but p53 mutations are not necessarily required	ONCOGENE			English	Article						head and neck cancer; preneoplasia; immortalization; RAR-beta; INK4A; telomerase	KERATINOCYTE SENESCENCE; REPLICATIVE SENESCENCE; P16(INK4A); TELOMERASE; INACTIVATION; ACQUISITION; PROTEINS	Our previous work showed that acquisition of immortality at the dysplasia stage of oral cancer progression was consistently associated with four changes: loss of retinoic acid receptor (RAR)-beta and p16(INK4A) expression, p53 mutations and activation of telomerase. One atypical dysplasia (D17) that underwent delayed senescence after an extended lifespan showed loss of RAR-beta and p16(INK4A)/ p14(ARF) expression, but retained functional wild-type p53 and telomerase was not activated. We now demonstrate that retroviral delivery of hTERT results in telomere lengthening and immortalization of D17 without loss of functional wild-type p53 activity. In contrast, the expression of hTERT in two other typical mortal dyplasia cultures (that retain RAR-beta and p16(INK4A) expression) does not extend their lifespan, even though telomeres are lengthened.	CRC Beatson Labs, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Harrison, PR (corresponding author), CRC Beatson Labs, Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	p.r.harrison@beatson.gla.ac.uk	Hunter, Keith D/B-5670-2009; Hunter, Keith/M-9784-2019	Hunter, Keith/0000-0002-7873-0877				Campisi J, 2000, IN VIVO, V14, P183; Ghose A, 2001, CANCER RES, V61, P7479; Gordon KE, 2003, CANCER RES, V63, P458; Kresty LA, 2002, CANCER RES, V62, P5295; Lustig AJ, 1999, P NATL ACAD SCI USA, V96, P3339, DOI 10.1073/pnas.96.7.3339; McGregor F, 1997, CANCER RES, V57, P3886; McGregor F, 2002, CANCER RES, V62, P4757; Morris M, 2002, ONCOGENE, V21, P4277, DOI 10.1038/sj.onc.1205492; Munro J, 1999, CANCER RES, V59, P2516; Munro J, 2001, ONCOGENE, V20, P3541, DOI 10.1038/sj.onc.1204460; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Papadimitrakopoulou V, 1997, ONCOGENE, V14, P1799, DOI 10.1038/sj.onc.1201010; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Stewart SA, 2002, ONCOGENE, V21, P627, DOI 10.1038/sj.onc.1205062; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; XU XC, 1994, CANCER RES, V54, P3580	24	25	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2003	22	49					7804	7808		10.1038/sj.onc.1207085	http://dx.doi.org/10.1038/sj.onc.1207085			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586406				2022-12-25	WOS:000186240200010
J	Tujague, M; Thomsen, JS; Mizuki, K; Sadek, CM; Gustafsson, JA				Tujague, M; Thomsen, JS; Mizuki, K; Sadek, CM; Gustafsson, JA			The focal adhesion protein vinexin alpha regulates the phosphorylation and activity of estrogen receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDEPENDENT ACTIVATION; EPIDERMAL-GROWTH-FACTOR; HUMAN GLUCOCORTICOID-RECEPTOR; VINCULIN-BINDING PROTEIN; HUMAN ANDROGEN RECEPTOR; NUCLEAR RECEPTORS; IN-VITRO; TRANSACTIVATION FUNCTION; P21-ACTIVATED KINASE; INTERACTING PROTEIN	Steroid receptors are transcription factors that regulate hormone-responsive genes and whose activity is controlled by their interaction with numerous other proteins. Observations reported here reveal that estrogen receptors alpha and beta (ERalpha and ERbeta), androgen receptor, and glucocorticoid receptor bind in vitro to vinexin alpha, a multiple SH3 motif-containing protein associated with the cytoskeleton. The SH3 domains are not involved in this interaction. Furthermore, we demonstrate that vinexin alpha stimulates the ligand-induced transactivation function of these receptors, although it is devoid of intrinsic transcriptional activity when tethered to DNA. In addition, the ectopic coexpression of vinexin alpha and ERalpha results in a loss of ERalpha phosphorylation on serines and the partial redistribution of vinexin alpha into the nucleus, where it colocalizes with ERalpha. These results establish a new model of transcriptional regulation where components of the cell-cell and cell-substrate adhesion complexes can regulate the phosphorylation and activity of steroid receptors.	Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden	Karolinska Institutet	Tujague, M (corresponding author), Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden.	michel.tujague@biosci.ki.se	Sadek, Christine/A-7356-2010	thomsen, jane/0000-0002-9336-5695				Akamatsu M, 1999, J BIOL CHEM, V274, P35933, DOI 10.1074/jbc.274.50.35933; ALMLOF T, 1995, J BIOL CHEM, V270, P17535, DOI 10.1074/jbc.270.29.17535; ARNOLD SF, 1995, J STEROID BIOCHEM, V55, P163, DOI 10.1016/0960-0760(95)00177-2; ARNOLD SF, 1995, J STEROID BIOCHEM, V52, P159, DOI 10.1016/0960-0760(94)00166-J; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bevan C, 1999, EXP CELL RES, V253, P349, DOI 10.1006/excr.1999.4719; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; Cenni B, 1999, TRENDS ENDOCRIN MET, V10, P41, DOI 10.1016/S1043-2760(98)00121-0; Chen DS, 1999, MOL CELL BIOL, V19, P1002; CULIG Z, 1994, CANCER RES, V54, P5474; Delaunay F, 2000, MOL PHARMACOL, V58, P584, DOI 10.1124/mol.58.3.584; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; Ford J, 1997, MOL ENDOCRINOL, V11, P1467, DOI 10.1210/me.11.10.1467; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kawauchi T, 2001, MECH DEVELOP, V106, P147, DOI 10.1016/S0925-4773(01)00421-X; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lee SR, 2002, MOL ENDOCRINOL, V16, P85, DOI 10.1210/me.16.1.85; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Lu Q, 2003, J BIOL CHEM, V278, P4639, DOI 10.1074/jbc.M210949200; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Moggs JG, 2001, EMBO REP, V2, P775, DOI 10.1093/embo-reports/kve185; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Ogawa S, 1998, BIOCHEM BIOPH RES CO, V243, P122, DOI 10.1006/bbrc.1997.7893; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; Patrone C, 1998, MOL ENDOCRINOL, V12, P835, DOI 10.1210/me.12.6.835; Reinikainen P, 1996, ENDOCRINOLOGY, V137, P4351, DOI 10.1210/en.137.10.4351; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; SADEK CM, 1994, J BIOL CHEM, V269, P16067; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; SCHWERK C, 1995, J BIOL CHEM, V270, P21331, DOI 10.1074/jbc.270.36.21331; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Suwa A, 2002, J BIOL CHEM, V277, P13053, DOI 10.1074/jbc.M108644200; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Townson SM, 2003, J BIOL CHEM, V278, P20059, DOI 10.1074/jbc.M212988200; Treuter E, 1999, J BIOL CHEM, V274, P6667, DOI 10.1074/jbc.274.10.6667; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Wang BL, 1997, J BIOL CHEM, V272, P17542, DOI 10.1074/jbc.272.28.17542; Warnmark A, 2003, MOL ENDOCRINOL, V17, P1901, DOI 10.1210/me.2002-0384; Wiebel FF, 1997, MOL CELL BIOL, V17, P3977, DOI 10.1128/MCB.17.7.3977; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Windahl SH, 1999, J STEROID BIOCHEM, V71, P93, DOI 10.1016/S0960-0760(99)00128-4; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Zhang H, 2000, J BIOL CHEM, V275, P39855, DOI 10.1074/jbc.C000567200	61	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9255	9263		10.1074/jbc.M312160200	http://dx.doi.org/10.1074/jbc.M312160200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14625289	hybrid			2022-12-25	WOS:000189265900087
J	Valentin, FO; Field, MC; Tippins, JR				Valentin, FO; Field, MC; Tippins, JR			The mechanism of oxidative stress stabilization of the thromboxane receptor in COS-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; N-GLYCOSYLATION; A(2) RECEPTOR; ISOPROSTANE; DISEASE; RAT; EXPRESSION; HEART	The 8-iso-prostaglandin F-2alpha, a prostanoid produced in vivo by cyclooxygenase-independent free-radical-catalyzed lipid peroxidation, acts as a partial agonist on the thromboxane receptor (TXA(2)R) and is a potent vasoconstrictor in the oxidatively stressed isolated perfused rat heart. We hypothesized that the response in the isolated heart may be due to augmentation of TXA(2)R density, which may be initiated by the presence of oxidative radicals. Previous studies have shown that TXA(2)R density is increased during atherosclerosis on both the medial and intimal smooth muscle layers in human coronary arteries. Here we describe the effect of oxidative stress on TXA(2)R. The thromboxane A(2) receptor beta isoform (TXA(2)Rbeta) was transiently expressed in COS-7 cells. Immunofluorescence suggested that the presence of H2O2 increased translocation of TXA(2)Rbeta from the endoplasmic reticulum (ER) to the Golgi complex. H2O2 treatment also increased binding of a TXA(2)R antagonist ([H-3] SQ29548) to membranes. Degradation kinetics of TXA(2)Rbeta following cycloheximide treatment, a protein synthesis inhibitor, suggested not only that TXA(2)Rbeta is a short-lived protein predominantly localized to the ER but also that TXA(2)Rbeta degradation is modulated in the presence of H2O2. Our results indicate that oxidative stress induces maturation and stabilization of the TXA(2)Rbeta protein probably by intracellular translocation. Importantly, these observations also suggest that TXA(2)Rbeta levels are modulated by ER-associated degradation and controlled by the efficiency of transport to post-ER compartments. Stabilization of the TXA(2)Rbeta by translocation from a degradative compartment, i.e. the ER, can account for the augmentation of receptor density observed in vivo.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Wellcome Trust Labs Mol Parasitol, London SW7 2AZ, England	Imperial College London; Imperial College London	Tippins, JR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Exhibit Rd, London SW7 2AZ, England.	j.tippins@imperial.ac.uk	Field, Mark/AAD-6455-2021	Field, Mark/0000-0002-4866-2885				Audoly LP, 2000, CIRCULATION, V101, P2833, DOI 10.1161/01.CIR.101.24.2833; BECKER KP, 1998, BIOCHIM BIOPHYS ACTA, V27, P109; Benedetti C, 2000, BIOCHEM BIOPH RES CO, V278, P530, DOI 10.1006/bbrc.2000.3838; Boer U, 2000, BIOCHEM J, V350, P839, DOI 10.1042/0264-6021:3500839; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Chiang N, 1998, ARCH BIOCHEM BIOPHYS, V352, P207, DOI 10.1006/abbi.1998.0620; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FITZGERALD GA, 1987, FASEB J, V46, P154; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Halaban R, 2001, J BIOL CHEM, V276, P11933, DOI 10.1074/jbc.M008703200; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; John GW, 1997, BRIT J PHARMACOL, V122, P899, DOI 10.1038/sj.bjp.0701441; Kamekura I, 1999, J CARDIOVASC PHARM, V33, P836, DOI 10.1097/00005344-199906000-00002; Katugampola SD, 2002, CLIN SCI, V103, p171S, DOI 10.1042/CS103S171S; Katugampola SD, 2001, BRIT J PHARMACOL, V134, P1385, DOI 10.1038/sj.bjp.0704416; KOPITO RR, 1999, PHYSIOL REV, V79, P167; Kromer BM, 1999, BRIT J PHARMACOL, V126, P1171, DOI 10.1038/sj.bjp.0702433; Kromer BM, 1996, BRIT J PHARMACOL, V119, P1276, DOI 10.1111/j.1476-5381.1996.tb16033.x; Mehrabi MR, 1999, CARDIOVASC RES, V43, P492; MODESTI PA, 1995, AM HEART J, V129, P873, DOI 10.1016/0002-8703(95)90106-X; MORINELLI TA, 1994, J BIOL CHEM, V269, P5693; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; RICKWOOD D, 1982, ANAL BIOCHEM, V123, P23, DOI 10.1016/0003-2697(82)90618-2; Sato N, 2000, NAT CELL BIOL, V2, P863, DOI 10.1038/35046500; Shang J, 2002, GLYCOBIOLOGY, V12, P307, DOI 10.1093/glycob/12.5.307; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; SUN DQ, 1994, CIRCULATION, V89, P793, DOI 10.1161/01.CIR.89.2.793; YATSUNAMI K, 1990, BIOCHIM BIOPHYS ACTA, V1051, P94, DOI 10.1016/0167-4889(90)90178-G; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139	33	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8316	8324		10.1074/jbc.M306761200	http://dx.doi.org/10.1074/jbc.M306761200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14583632	hybrid			2022-12-25	WOS:000189103300113
J	Blazyk, JL; Lippard, SJ				Blazyk, JL; Lippard, SJ			Domain engineering of the reductase component of soluble methane monooxygenase from Methylococcus capsulatus (Bath)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOSINUS-TRICHOSPORIUM OB3B; ELECTRON-TRANSFER REACTIONS; MONO-OXYGENASE; DIOXYGEN ACTIVATION; ACCEPTOR REDUCTASE; FERREDOXIN; IRON; PURIFICATION; COPPER; HYDROXYLASE	Soluble methane monooxygenase ( sMMO) from Methylococcus capsulatus ( Bath) is a three- component enzyme system that catalyzes the conversion of methane to methanol. A reductase ( MMOR), which contains [ 2Fe- 2S] and FAD cofactors, facilitates electron transfer from NADH to the hydroxylase diiron active sites where dioxygen activation and substrate hydroxylation take place. By separately expressing the ferredoxin ( MMOR-Fd, MMOR residues 1 - 98) and FAD/ NADH ( MMOR- FAD, MMOR residues 99 - 348) domains of the reductase, nearly all biochemical properties of full- length MMOR are retained, except for interdomain electron transfer rates. To investigate the extent to which rapid electron transfer between domains might be restored and further to explore the modularity of MMOR, MMOR- Fd and MMOR- FAD were connected in a non- native fashion. Four different linker sequences were employed to create MMOR reversed- domain ( MMOR- RD) constructs, MMOR( 99 - 342)- linker- MMOR( 2 - 98), with a domain connectivity observed in other homologous oxidoreductases. The optical, redox, and electron transfer properties of the four MMOR- RD proteins were characterized and compared with those of wild- type MMOR. The linker sequence plays a key role in controlling solvent accessibility to the FAD cofactor, as evidenced by perturbed flavin optical spectra, decreased FAD(ox)/ FAD(sq) redox potentials, and increased steady- state oxidase activities in three of the constructs. Stopped- flow optical spectroscopy revealed slow interdomain electron transfer ( k < 0.04 s(-1) at 4 degrees C, compared with 90 s(-1) for wild- type MMOR) for all three MMOR- RD proteins with 7- residue linkers. A long ( 14- residue), flexible linker afforded much faster electron transfer between the FAD and [ 2Fe- 2S] cofactors ( k = 0.9 s(-1) at 4 degrees C).	MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lippard, SJ (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	lippard@lippard.mit.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032134, R37GM032134] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32134] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDREWS SC, 1992, FEBS LETT, V302, P247, DOI 10.1016/0014-5793(92)80452-M; Blazyk JL, 2002, BIOCHEMISTRY-US, V41, P15780, DOI 10.1021/bi026757f; COLBY J, 1978, BIOCHEM J, V171, P461, DOI 10.1042/bj1710461; COLBY J, 1979, BIOCHEM J, V177, P903, DOI 10.1042/bj1770903; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; Coufal DE, 2000, EUR J BIOCHEM, V267, P2174, DOI 10.1046/j.1432-1327.2000.01210.x; Crasto CJ, 2000, PROTEIN ENG, V13, P309, DOI 10.1093/protein/13.5.309; FEIG AL, 1994, CHEM REV, V94, P759, DOI 10.1021/cr00027a011; FOX BG, 1989, J BIOL CHEM, V264, P10023; FOX BG, 1993, J AM CHEM SOC, V115, P3688, DOI 10.1021/ja00062a039; FOX BG, 1990, METHOD ENZYMOL, V188, P191; Gassner GT, 1999, BIOCHEMISTRY-US, V38, P12768, DOI 10.1021/bi990841m; GREEN J, 1989, BIOCHEM J, V259, P167, DOI 10.1042/bj2590167; Hanson RS, 1996, MICROBIOL REV, V60, P439, DOI 10.1128/MMBR.60.2.439-471.1996; HIGGINS IJ, 1981, MICROBIOL REV, V45, P556, DOI 10.1128/MMBR.45.4.556-590.1981; Karlsson A, 2002, J MOL BIOL, V318, P261, DOI 10.1016/S0022-2836(02)00039-6; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; Kopp DA, 2001, BIOCHEMISTRY-US, V40, P14932, DOI 10.1021/bi015556t; Kurisu G, 2001, NAT STRUCT BIOL, V8, P117, DOI 10.1038/84097; Lieberman RL, 2003, P NATL ACAD SCI USA, V100, P3820, DOI 10.1073/pnas.0536703100; LIU KE, 1995, ADV INORG CHEM RAD, V42, P263; LUND J, 1985, EUR J BIOCHEM, V147, P291, DOI 10.1111/j.1432-1033.1985.tb08749.x; LUND J, 1985, EUR J BIOCHEM, V147, P297, DOI 10.1111/j.1432-1033.1985.tb08750.x; MASSEY V, 1957, J BIOL CHEM, V229, P763; Merkx M, 2001, ANGEW CHEM INT EDIT, V40, P2782, DOI 10.1002/1521-3773(20010803)40:15<2782::AID-ANIE2782>3.0.CO;2-P; Muller J, 2002, BIOCHEMISTRY-US, V41, P42, DOI 10.1021/bi015668k; Murrell J. Colin, 1994, Biodegradation, V5, P145, DOI 10.1007/BF00696456; Nguyen HHT, 1998, J BIOL CHEM, V273, P7957, DOI 10.1074/jbc.273.14.7957; PILKINGTON SJ, 1990, METHOD ENZYMOL, V188, P181; PRIOR SD, 1985, J GEN MICROBIOL, V131, P155; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275; STAINTHORPE AC, 1989, ARCH MICROBIOL, V152, P154, DOI 10.1007/BF00456094; STAINTHORPE AC, 1990, GENE, V91, P27, DOI 10.1016/0378-1119(90)90158-N; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VALENTINE AM, 1997, J CHEM SOC DA, V21, P3925; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; WHITTINGTON DA, 2001, HDB METALLOPROTEINS, P712; WOODLAND MP, 1984, J BIOL CHEM, V259, P53	41	16	18	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5630	5640		10.1074/jbc.M308940200	http://dx.doi.org/10.1074/jbc.M308940200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14613937	hybrid			2022-12-25	WOS:000188776500073
J	Cheng, GJ; Lambeth, JD				Cheng, GJ; Lambeth, JD			NOXO1, regulation of lipid binding, localization, and activation of Nox1 by the phox homology (PX) domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; PHOSPHORYLATION-INDUCED ACTIVATION; PHAGOCYTE NADPH OXIDASE; PROTEIN-KINASE-C; PHOSPHATIDIC-ACID; HUMAN NEUTROPHILS; SH3 DOMAIN; INTRAMOLECULAR INTERACTION; SUPEROXIDE GENERATION	NOXO1 (Nox organizing protein 1) and NOXA1 (Nox activating protein 1) are homologs of p47(phox) and p67(phox). p47(phox) functions in phagocytes as an essential organizing protein mediating the binding of other regulatory proteins during activation of the phagocyte oxidase, and its translocation to the membrane is triggered upon cell activation by hyperphosphorylation, which relieves autoinhibition of SH3 and PX domains. NOXO1 lacks an autoinhibitory region and phosphorylation sites that are present in p47(phox). Co-transfection of Nox1, NOXO1, and NOXA1 reconstitutes ROS (reactive oxygen species) generation in HEK293 cells in the absence of cell stimulation. NOXO1 binds to the phosphatidylinositol (PtdIns) lipids PtdIns 3,5-P-2, PtdIns 5-P, and PtdIns 4-P. Unlike p47(phox), which is located in the cytosol of resting cells and translocates to the plasma membrane where gp91(phox) is located, NOXO1 co-localizes with Nox1 in the membranes of resting cells. This localization of NOXO1 is dictated by its PX domain, since this domain but not the remainder of the molecule localizes to membranes. A point mutation in the PX domain of holo-NOXO1 decreases lipid binding resulting in cytosolic localization and also inhibits NOXO1-activation of Nox1. Thus, in transfected HEK293 cells, NOXO1 and NOXA1 activate Nox1 without the need for agonist activation, and this is mediated in part by binding of the NOXO1 PX domain to membrane lipids.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Emory University	Lambeth, JD (corresponding author), Emory Univ, Sch Med, Dept Pathol, 148 whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA.			Cheng, Guangjie/0000-0002-9368-379X				Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Ago T, 2003, P NATL ACAD SCI USA, V100, P4474, DOI 10.1073/pnas.0735712100; Ago T, 2001, BIOCHEM BIOPH RES CO, V287, P733, DOI 10.1006/bbrc.2001.5629; ALLEN RC, 1976, BIOCHEM BIOPH RES CO, V69, P245, DOI 10.1016/S0006-291X(76)80299-9; Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; BABIOR BM, 1984, BLOOD, V64, P959; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; Brar SS, 2003, AM J PHYSIOL-CELL PH, V285, pC353, DOI 10.1152/ajpcell.00525.2002; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; DING JB, 1993, BLOOD, V82, P940; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; ElBenna J, 1997, J BIOL CHEM, V272, P17204, DOI 10.1074/jbc.272.27.17204; Ellson CD, 2002, J CELL SCI, V115, P1099; Geiszt M, 2003, J BIOL CHEM, V278, P20006, DOI 10.1074/jbc.M301289200; Groemping Y, 2003, CELL, V113, P343, DOI 10.1016/S0092-8674(03)00314-3; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; Hoyal CR, 2003, P NATL ACAD SCI USA, V100, P5130, DOI 10.1073/pnas.1031526100; Inanami O, 1998, J BIOL CHEM, V273, P9539, DOI 10.1074/jbc.273.16.9539; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lambeth JD, 2000, J BIOCHEM MOL BIOL, V33, P427; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; Roos D, 1996, BLOOD, V87, P1663; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; Segal AW, 1996, MOL MED TODAY, V2, P129, DOI 10.1016/1357-4310(96)88723-5; Sorescu D, 2002, CIRCULATION, V105, P1429, DOI 10.1161/01.CIR.0000012917.74432.66; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Szocs K, 2002, ARTERIOSCL THROM VAS, V22, P21, DOI 10.1161/hq0102.102189; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Wientjes FB, 2001, BIOCHEM BIOPH RES CO, V289, P382, DOI 10.1006/bbrc.2001.5982; Yaffe MB, 2002, STRUCTURE, V10, P1288, DOI 10.1016/S0969-2126(02)00860-2; Zhan Y, 2002, J BIOL CHEM, V277, P4512, DOI 10.1074/jbc.M109520200	45	169	174	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4737	4742		10.1074/jbc.M305968200	http://dx.doi.org/10.1074/jbc.M305968200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14617635	hybrid			2022-12-25	WOS:000188554300098
J	Fiegen, D; Haeusler, LC; Blumenstein, L; Herbrand, U; Dvorsky, R; Vetter, IR; Ahmadian, MR				Fiegen, D; Haeusler, LC; Blumenstein, L; Herbrand, U; Dvorsky, R; Vetter, IR; Ahmadian, MR			Alternative splicing of Rac1 generates Rac1b, a self-activating GTPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; NUCLEOTIDE-BINDING; DISSOCIATION INHIBITORS; SIGNAL-TRANSDUCTION; BREAST-CANCER; RHO GTPASES; H-RAS; COMPLEX; PROTEIN; CDC42	Rac1b was recently identified in malignant colorectal tumors as an alternative splice variant of Rac1 containing a 19-amino acid insertion next to the switch II region. The structures of Rac1b in the GDP- and the GppNHp-bound forms, determined at a resolution of 1.75 Angstrom, reveal that the insertion induces an open switch I conformation and a highly mobile switch II. As a consequence, Rac1b has an accelerated GEF-independent GDP/GTP exchange and an impaired GTP hydrolysis, which is restored partially by GTPase-activating proteins. Interestingly, Rac1b is able to bind the GTPase-binding domain of PAK but not full-length PAK in a GTP-dependent manner, suggesting that the insertion does not completely abolish effector interaction. The presented study provides insights into the structural and biochemical mechanism of a self-activating GTPase.	Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44227 Dortmund, Germany	Max Planck Society	Ahmadian, MR (corresponding author), Max Planck Inst Mol Physiol, Abt Strukturelle Biol, Otto Hahn Str 11, D-44227 Dortmund, Germany.	reza.ahmadian@mpi-dortmund.mpg.de	Dvorsky, Radovan/ABE-3042-2020	Fiegen, Dennis/0000-0003-3396-5274				Ahmadian Mohammad Reza, 2002, Methods Mol Biol, V189, P45; Ahmadian MR, 1999, P NATL ACAD SCI USA, V96, P7065, DOI 10.1073/pnas.96.12.7065; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Buchwald G, 2001, MOL CELL BIOL, V21, P5179, DOI 10.1128/MCB.21.15.5179-5189.2001; Corbett KD, 2001, TRENDS BIOCHEM SCI, V26, P710, DOI 10.1016/S0968-0004(01)01974-0; Fiegen D, 2002, FEBS LETT, V525, P100, DOI 10.1016/S0014-5793(02)03094-6; Gamblin SJ, 1998, CURR OPIN STRUC BIOL, V8, P195, DOI 10.1016/S0959-440X(98)80038-9; Grizot S, 2001, BIOCHEMISTRY-US, V40, P10007, DOI 10.1021/bi010288k; Haeusler LC, 2003, FEBS LETT, V555, P556, DOI 10.1016/S0014-5793(03)01351-6; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Hwang MCC, 1996, J BIOL CHEM, V271, P8196, DOI 10.1074/jbc.271.14.8196; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; JOHN J, 1993, J BIOL CHEM, V268, P923; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Matos P, 2003, J BIOL CHEM, V278, P50442, DOI 10.1074/jbc.M308215200; Menetrey J, 1999, PROTEINS, V37, P465, DOI 10.1002/(SICI)1097-0134(19991115)37:3<465::AID-PROT13>3.0.CO;2-O; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Owen D, 2000, BIOCHEMISTRY-US, V39, P1243, DOI 10.1021/bi991567z; Pan JY, 1998, BIOESSAYS, V20, P516, DOI 10.1002/(SICI)1521-1878(199806)20:6<516::AID-BIES11>3.0.CO;2-3; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Reid T, 1999, J BIOL CHEM, V274, P33587, DOI 10.1074/jbc.274.47.33587; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Robbe K, 2003, J BIOL CHEM, V278, P4756, DOI 10.1074/jbc.M210412200; Rudolph MG, 1999, PROTEIN SCI, V8, P778; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schmidt G, 1996, ONCOGENE, V12, P87; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Spoerner M, 2001, P NATL ACAD SCI USA, V98, P4944, DOI 10.1073/pnas.081441398; Thompson G, 1998, BIOCHEMISTRY-US, V37, P7885, DOI 10.1021/bi980140+; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Xu XM, 1997, BIOCHEMISTRY-US, V36, P626, DOI 10.1021/bi962059h; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225	51	111	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4743	4749		10.1074/jbc.M310281200	http://dx.doi.org/10.1074/jbc.M310281200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14625275	hybrid			2022-12-25	WOS:000188554300099
J	Williams, CR; Snyder, AK; Kuzmic, P; O'Donnell, M; Bloom, LB				Williams, CR; Snyder, AK; Kuzmic, P; O'Donnell, M; Bloom, LB			Mechanism of loading the Escherichia coli DNA polymerase III sliding clamp - I. Two distinct activities for individual ATP sites in the gamma complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION MACHINE; ONE HOLOENZYME PARTICLE; LAGGING-STRAND SYNTHESIS; BINDING PROTEIN; DELTA-SUBUNIT; BETA-SUBUNIT; LOADER; TAU; FORK; PURIFICATION	The Escherichia coli DNA polymerase III gamma complex loads the beta clamp onto DNA, and the clamp tethers the core polymerase to DNA to increase the processivity of synthesis. ATP binding and hydrolysis promote conformational changes within the gamma complex that modulate its affinity for the clamp and DNA, allowing it to accomplish the mechanical task of assembling clamps on DNA. This is the first of two reports (Snyder, A. K., Williams, C. R., Johnson, A., O'Donnell, M., and Bloom, L. B. (2004) J. Biol. Chem. 279,4386-4393) addressing the question of how ATP binding and hydrolysis modulate specific interactions with DNA and beta. Pre-steady-state rates of ATP hydrolysis were slower when reactions were initiated by addition of ATP than when the gamma complex was equilibrated with ATP and were limited by the rate of an intramolecular reaction, possibly ATP-induced conformational changes. Kinetic modeling of assays in which the gamma complex was incubated with ATP for different periods of time prior to adding DNA to trigger hydrolysis suggests a mechanism in which a relatively slow conformational change step (k(forward) = 6.5 s(-1)) produces a species of the gamma complex that is activated for DNA (and beta) binding. In the absence of beta, 2 of the 3 molecules of ATP are hydrolyzed rapidly prior to releasing DNA, and the 3rd molecule is hydrolyzed slowly. In the presence of beta, all 3 molecules of ATP are hydrolyzed rapidly. These results suggest that hydrolysis of 2 molecules of ATP may be coupled to conformational changes that reduce interactions with DNA, whereas hydrolysis of the 3rd is coupled to changes that result in release of beta.	Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Biokin Ltd, Pullman, WA 99163 USA; Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA	State University System of Florida; University of Florida; Rockefeller University; Howard Hughes Medical Institute	Bloom, LB (corresponding author), Univ Florida, Dept Biochem & Mol Biol, POB 100245, Gainesville, FL 32610 USA.	lbloom@ufl.edu	Bloom, Linda B/F-3684-2014	Kuzmic, Petr/0000-0001-5250-8381	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM055596, GM55596, GM38839] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ason B, 2000, J BIOL CHEM, V275, P3006, DOI 10.1074/jbc.275.4.3006; Ason B, 2003, J BIOL CHEM, V278, P10033, DOI 10.1074/jbc.M211741200; BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; Bertram JG, 2000, J BIOL CHEM, V275, P28413, DOI 10.1074/jbc.M910441199; Bertram JG, 1998, J BIOL CHEM, V273, P24564, DOI 10.1074/jbc.273.38.24564; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; Bloom LB, 1996, J BIOL CHEM, V271, P30699, DOI 10.1074/jbc.271.48.30699; Brune M, 1998, BIOCHEMISTRY-US, V37, P10370, DOI 10.1021/bi9804277; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; Davey MJ, 2002, NAT REV MOL CELL BIO, V3, P826, DOI 10.1038/nrm949; FAY PJ, 1981, J BIOL CHEM, V256, P976; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; Gao DX, 2001, J BIOL CHEM, V276, P4441, DOI 10.1074/jbc.M009830200; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HAWKER JR, 1987, J BIOL CHEM, V262, P12722; Hingorani MM, 1999, EMBO J, V18, P5131, DOI 10.1093/emboj/18.18.5131; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P291, DOI 10.1007/978-1-4757-3061-6; Leu FP, 2000, J BIOL CHEM, V275, P34609, DOI 10.1074/jbc.M005495200; Leu FP, 2003, MOL CELL, V11, P315, DOI 10.1016/S1097-2765(03)00042-X; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; Podobnik M, 2003, STRUCTURE, V11, P253, DOI 10.1016/S0969-2126(03)00027-3; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; Snyder AK, 2004, J BIOL CHEM, V279, P4386, DOI 10.1074/jbc.M310430200; Stewart J, 2001, J BIOL CHEM, V276, P19182, DOI 10.1074/jbc.M100592200; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; WU CA, 1992, J BIOL CHEM, V267, P4064; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	46	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4376	4385		10.1074/jbc.M310429200	http://dx.doi.org/10.1074/jbc.M310429200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14610067	hybrid			2022-12-25	WOS:000188554300056
J	Yang, G; Cai, KQ; Thompson-Lanza, JA; Bast, RC; Liu, JS				Yang, G; Cai, KQ; Thompson-Lanza, JA; Bast, RC; Liu, JS			Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; CANCER-CELLS; FACTOR RECEPTOR; NEU ONCOGENE; STABLE SUPPRESSION; INDUCED APOPTOSIS; KINASE INHIBITOR; HAIRPIN RNAS; TRANSFORMATION; DELIVERY	The Her-2/neu oncogene is overexpressed in similar to30% of breast and ovarian cancer cases and often indicates a poor prognosis. Therapeutic agents against Her-2/neu have been intensively sought over the past decade. Here we show that small interfering RNA (siRNA) can silence the expression of Her-2/neu in models of human breast or ovarian cancer through retrovirus-mediated transfer of an siRNA against Her-2/neu. Cells infected with retrovirus expressing anti-Her-2/neu siRNA exhibit slower proliferation, increased apoptosis, increased G(0)/G(1) arrest, and decreased tumor growth. Changes in cell cycle-associated factors included decreased levels of phosphatidylinositol 3-kinase, pAkt, and cyclin D1 and increased levels of p27 and phosphorylated retinoblastoma protein. Knockdown of Her-2/neu expression by siRNA is also associated with increased expression of the anti-angiogenic factor thrombospondin-1 and decreased expression of the pro-angiogenic vascular endothelial growth factor, suggesting that Her-2/neu stimulates tumor growth at least in part by regulating angiogenesis. siRNA-mediated gene silencing of Her-2/neu and increasing the expression of thrombospondin-1 may be a useful therapeutic strategy for Her-2/neu-overexpressing breast or ovarian cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Liu, JS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Box 85,1515 Holcombe Blvd, Houston, TX 77030 USA.	jliu@mdanderson.org	Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NATIONAL CANCER INSTITUTE [P50CA083639] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA83639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; Bartkova J, 1997, Prog Cell Cycle Res, V3, P211; Barton GM, 2002, P NATL ACAD SCI USA, V99, P14943, DOI 10.1073/pnas.242594499; BERCHUCK A, 1990, CANCER RES, V50, P4087; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Chang JY, 1996, ONCOGENE, V13, P1405; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hong RL, 1999, CLIN CANCER RES, V5, P1884; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kumar R, 2001, SEMIN ONCOL, V28, P27, DOI 10.1016/S0093-7754(01)90279-9; Lee S, 2002, CANCER RES, V62, P5703; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liu JS, 2000, ONCOGENE, V19, P2767, DOI 10.1038/sj.onc.1203599; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Moulder SL, 2001, CANCER RES, V61, P8887; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pegram MD, 2000, SEMIN ONCOL, V27, P21; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Roh H, 2000, CANCER RES, V60, P560; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; SWIFT S, 1999, CURRENT PROTOCOLS IM; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Yang G, 2003, ONCOGENE, V22, P5694, DOI 10.1038/sj.onc.1206858; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; Yu DH, 2000, BIOESSAYS, V22, P673, DOI 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; ZHANG LS, 1995, CANCER RES, V55, P3890; ZHANG YJ, 1995, ONCOGENE, V10, P1947; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	47	98	116	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4339	4345		10.1074/jbc.M311153200	http://dx.doi.org/10.1074/jbc.M311153200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14625284	hybrid			2022-12-25	WOS:000188554300052
J	Golomb, E; Ma, XF; Jana, SS; Preston, YA; Kawamoto, S; Shoham, NG; Goldin, E; Conti, MA; Sellers, JR; Adelstein, RS				Golomb, E; Ma, XF; Jana, SS; Preston, YA; Kawamoto, S; Shoham, NG; Goldin, E; Conti, MA; Sellers, JR; Adelstein, RS			Identification and characterization of nonmuscle myosin II-C, a new member of the myosin II family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; HEAVY-CHAIN ISOFORMS; IN-VITRO; MUSCLE-CONTRACTION; NEURITE OUTGROWTH; MOUSE HEART; LOCALIZATION; GENE; CLONING; CELLS	A previously unrecognized nonmuscle myosin II heavy chain (NMHC II), which constitutes a distinct branch of the nonmuscle/ smooth muscle myosin II family, has recently been revealed in genome data bases. We characterized the biochemical properties and expression patterns of this myosin. Using nucleotide probes and affinity-purified antibodies, we found that the distribution of NMHC II-C mRNA and protein (MYH14) is widespread in human and mouse organs but is quantitatively and qualitatively distinct from NMHC II-A and II-B. In contrast to NMHC II-A and II-B, the mRNA level in human fetal tissues is substantially lower than in adult tissues. Immunofluorescence microscopy showed distinct patterns of expression for all three NMHC isoforms. NMHC II-C contains an alternatively spliced exon of 24 nucleotides in loop I at a location analogous to where a spliced exon appears in NMHC II-B and in the smooth muscle myosin heavy chain. However, unlike neuron-specific expression of the NMHC II-B insert, the NMHC II-C inserted isoform has widespread tissue distribution. Baculovirus expression of noninserted and inserted NMHC II-C heavy meromyosin (HMMII-C/HMM II-C1) resulted in significant quantities of expressed protein (mg of protein) for HMM II-C1 but not for HMM II-C. Functional characterization of HMM II-C1 by actin-activated MgATPase activity demonstrated a V-max of 0.55 + 0.18 s(-1), which was half-maximally activated at an actin concentration of 16.5 + 7.2 muM. HMM II-C1 translocated actin filaments at a rate of 0.05 + 0.011 mum/s in the absence of tropomyosin and at 0.072 + 0.019 mum/s in the presence of tropomyosin in an in vitro motility assay.	Shaare Zedek Med Ctr, Dept Pathol, IL-91031 Jerusalem, Israel; NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA; NIAMS, Genet & Gen Branch, NIH, Bethesda, MD 20892 USA; NINDS, Dev Metab Neurol Branch, NIH, Bethesda, MD 20892 USA	Hebrew University of Jerusalem; Shaare Zedek Medical Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Golomb, E (corresponding author), Shaare Zedek Med Ctr, Dept Pathol, IL-91031 Jerusalem, Israel.	golomb@szmc.org.il		Adelstein, Robert/0000-0002-8683-2144	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL004230, ZIAHL004230] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Buxton DB, 2003, J BIOL CHEM, V278, P15449, DOI 10.1074/jbc.M210145200; CHENEY RE, 1993, CELL MOTIL CYTOSKEL, V24, P215, DOI 10.1002/cm.970240402; Cuda G, 1997, BIOPHYS J, V72, P1767, DOI 10.1016/S0006-3495(97)78823-4; Du AP, 2003, DEV BIOL, V257, P382, DOI 10.1016/S0012-1606(03)00104-0; FALLON JR, 1980, J CELL BIOL, V87, P237, DOI 10.1083/jcb.87.1.237; Ford HL, 1997, BIOCHEMISTRY-US, V36, P16321, DOI 10.1021/bi971182l; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Heath KE, 2001, AM J HUM GENET, V69, P1033, DOI 10.1086/324267; Hu AH, 2002, J BIOL CHEM, V277, P46512, DOI 10.1074/jbc.M208506200; Huang H, 2003, MOL CELL BIOL, V23, P3636, DOI 10.1128/MCB.23.10.3636-3645.2003; ITOH K, 1995, J BIOL CHEM, V270, P14533, DOI 10.1074/jbc.270.24.14533; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; Kolega J, 1998, J CELL SCI, V111, P2085; Kovacs M, 2003, J BIOL CHEM, V278, P38132, DOI 10.1074/jbc.M305453200; Leal A, 2003, GENE, V312, P165, DOI 10.1016/S0378-1119(03)00613-9; LITTEN RZ, 1982, CIRC RES, V50, P856, DOI 10.1161/01.RES.50.6.856; MAUPIN P, 1994, J CELL SCI, V107, P3077; Morano I, 2000, NAT CELL BIOL, V2, P371, DOI 10.1038/35014065; MURAKAMI N, 1993, DEV BIOL, V157, P19, DOI 10.1006/dbio.1993.1108; NG WA, 1991, CIRC RES, V68, P1742, DOI 10.1161/01.RES.68.6.1742; Obungu VH, 2003, ONCOGENE, V22, P6347, DOI 10.1038/sj.onc.1206658; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; PHILLIPS CL, 1995, J MUSCLE RES CELL M, V16, P379, DOI 10.1007/BF00114503; Rey M, 2002, J IMMUNOL, V169, P5410, DOI 10.4049/jimmunol.169.10.5410; ROCHLIN MW, 1995, J CELL SCI, V108, P3661; Rosenfeld SS, 2003, J BIOL CHEM, V278, P27449, DOI 10.1074/jbc.M302555200; SATA M, 1993, CIRC RES, V73, P696, DOI 10.1161/01.RES.73.4.696; Sellers J. R., 1999, MYOSINS; SELLERS JR, 1993, METHOD CELL BIOL, V39, P23, DOI 10.1016/S0091-679X(08)60159-4; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; Takeda K, 2000, CELL MOTIL CYTOSKEL, V46, P59, DOI 10.1002/(SICI)1097-0169(200005)46:1<59::AID-CM6>3.0.CO;2-Q; Tullio AN, 1997, P NATL ACAD SCI USA, V94, P12407, DOI 10.1073/pnas.94.23.12407; Tullio AN, 2001, J COMP NEUROL, V433, P62, DOI 10.1002/cne.1125; Uren D, 2000, J CLIN INVEST, V105, P663, DOI 10.1172/JCI8199; VANBUREN P, 1995, CIRC RES, V77, P439, DOI 10.1161/01.RES.77.2.439; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Wang F, 2000, J BIOL CHEM, V275, P4329, DOI 10.1074/jbc.275.6.4329; Wang F, 2000, BIOCHEMISTRY-US, V39, P5555, DOI 10.1021/bi000133x; Wylie SR, 1998, P NATL ACAD SCI USA, V95, P12967, DOI 10.1073/pnas.95.22.12967; Wylie SR, 2001, NAT CELL BIOL, V3, P88, DOI 10.1038/35050613	46	256	277	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2800	2808		10.1074/jbc.M309981200	http://dx.doi.org/10.1074/jbc.M309981200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14594953	hybrid			2022-12-25	WOS:000188211300058
J	Herrmann, JM; Bonnefoy, N				Herrmann, JM; Bonnefoy, N			Protein export across the inner membrane of mitochondria - The nature of translocated domains determines the dependence on the Oxa1 translocase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVELY CHARGED RESIDUES; CYTOCHROME-C-OXIDASE; YEAST SACCHAROMYCES-CEREVISIAE; N-TERMINAL TAIL; ESCHERICHIA-COLI; LEADER PEPTIDE; BC(1) COMPLEX; SUBUNIT II; IN-VIVO; INSERTION	The biogenesis of mitochondria requires the insertion of both nuclear and mitochondrially encoded proteins into the inner membrane. The inner membrane protein Oxa1 plays an important role in this process. Translocation of the terminal intermembrane space domains of subunit 2 of the cytochrome oxidase complex, Cox2, strictly depends on Oxa1. In contrast, other Oxa1 substrates can be inserted independently of Oxa1 function, although at reduced efficiency. A Saccharomyces cerevisiae mutant containing a large deletion in its mitochondrial genome allowed us to analyze the insertion process of a fusion protein of cytochrome b and Cox2. In this mutant, the N-terminal domain of Cox2 is synthesized as a hairpin loop that is flanked by hydrophobic transmembrane segments on both sides. Both genetic and biochemical evidences indicate that translocation of this region across the inner membrane still requires Oxa1 function. Thus, the position of intermembrane space domains within protein sequences does not appear to determine their dependence on the Oxa1 translocase. Our observations rather suggest that the dependence on Oxa1 correlates with the net charge of the domain that has to be translocated across the lipid bilayer.	Univ Munich, Inst Physiol Chem, D-81377 Munich, Germany; CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France	University of Munich; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Herrmann, JM (corresponding author), Univ Munich, Inst Physiol Chem, Butenandtstr 5, D-81377 Munich, Germany.	hannes.herrmann@bio.med.unimuenchen.de	Bonnefoy, Nathalie/GYD-2949-2022	Bonnefoy, Nathalie/0000-0002-5068-8849				ANDERSSON H, 1994, FEBS LETT, V347, P169, DOI 10.1016/0014-5793(94)00530-3; BAUER M, 1994, MOL GEN GENET, V245, P272, DOI 10.1007/BF00290106; Bonnefoy N, 2001, MOL CELL BIOL, V21, P2359, DOI 10.1128/MCB.21.7.2359-2372.2001; Bonnefoy N, 2001, METHOD CELL BIOL, V65, P381, DOI 10.1016/S0091-679X(01)65022-2; Bonnefoy N, 2000, MOL GEN GENET, V262, P1036, DOI 10.1007/PL00008646; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; diRago JP, 1997, J BIOL CHEM, V272, P4699, DOI 10.1074/jbc.272.8.4699; GAVEL Y, 1992, EUR J BIOCHEM, V205, P1207, DOI 10.1111/j.1432-1033.1992.tb16892.x; He SC, 1997, MOL BIOL CELL, V8, P1449, DOI 10.1091/mbc.8.8.1449; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; Herrmann JM, 2003, IUBMB LIFE, V55, P219, DOI 10.1080/1521654031000123349; Herrmann JM, 2001, METHOD CELL BIOL, V65, P217, DOI 10.1016/S0091-679X(01)65013-1; HERRMANN JM, 1995, J BIOL CHEM, V270, P27079, DOI 10.1074/jbc.270.45.27079; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Kuhn A, 2003, TRENDS CELL BIOL, V13, P510, DOI 10.1016/j.tcb.2003.08.005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leonhard K, 1996, EMBO J, V15, P4218, DOI 10.1002/j.1460-2075.1996.tb00796.x; Lonergan KM, 1996, J MOL BIOL, V257, P1019, DOI 10.1006/jmbi.1996.0220; Luirink J, 2001, FEBS LETT, V501, P1, DOI 10.1016/S0014-5793(01)02616-3; Preuss M, 2001, J CELL BIOL, V153, P1085, DOI 10.1083/jcb.153.5.1085; Rojo EE, 1999, J BIOL CHEM, V274, P19617, DOI 10.1074/jbc.274.28.19617; Ryan MT, 2001, METHOD CELL BIOL, V65, P189, DOI 10.1016/S0091-679X(01)65012-X; Saint-Georges Y, 2001, P NATL ACAD SCI USA, V98, P13814, DOI 10.1073/pnas.251503098; Samuelson JC, 2001, J BIOL CHEM, V276, P34847, DOI 10.1074/jbc.M105793200; Schuenemann TA, 1999, J BIOL CHEM, V274, P6855, DOI 10.1074/jbc.274.11.6855; SIKORSKI RS, 1989, GENETICS, V122, P19; Torello AT, 1997, GENETICS, V145, P903; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; Westermann B, 2001, METHOD CELL BIOL, V65, P429, DOI 10.1016/S0091-679X(01)65025-8; WHITLEY P, 1995, J BIOL CHEM, V270, P29831; Yen MR, 2001, FEMS MICROBIOL LETT, V204, P223, DOI 10.1111/j.1574-6968.2001.tb10889.x	36	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2507	2512		10.1074/jbc.M310468200	http://dx.doi.org/10.1074/jbc.M310468200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14593095	hybrid			2022-12-25	WOS:000188211300022
J	Roth, U; Curth, K; Unterman, TG; Kietzmann, T				Roth, U; Curth, K; Unterman, TG; Kietzmann, T			The transcription factors HIF-1 and HNF-4 and the coactivator p300 are involved in insulin-regulated glucokinase gene expression via the phosphatidylinositol 3-kinase/protein kinase B pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR; ELEMENT-BINDING-PROTEIN; SMOOTH-MUSCLE-CELLS; FACTOR-I; SIGNALING PATHWAY; STRUCTURAL BASIS; RAT HEPATOCYTES; FACTOR 1-ALPHA; PHOSPHOINOSITIDE 3-KINASE; RESPONSE ELEMENTS	Glucokinase plays a key role in the regulation of glucose utilization in liver and its expression is strongly enhanced by insulin and modulated by venous pO(2). In primary rat hepatocytes, pO(2) modulated insulin-dependent glucokinase (GK) gene expression was abolished by wortmannin an inhibitor of phosphatidylinositol 3-kinase (PI3K). Transfection of vectors encoding the p110 catalytic subunit of PI3K or constitutively active proteinkinase B (PKB) stimulated GK mRNA and protein expression. The transfection of GK promoter constructs together with expression vectors for p110 or constitutively active PKB revealed that the GK promoter region -87/-80 mediates the response to PI3K/PKB. Transfection experiments and gel shift assays show that this element is able to bind hypoxia-inducible factor-1 (HIF-1) in a hypoxia- and PKB-dependent manner. The ability of HIF-1alpha to activate the GK promoter was enhanced by hepatocyte nuclear factor-4alpha (HNF-4alpha), acting via the sequence -52/-39, and by the coactivator p300. Stimulation of the GK promoter by insulin was dependent on the intact -87/-80 region and maximal stimulation was achieved when HIF-1alpha, HNF-4, and p300 were co-transfected with the -1430 GK promoter Luc construct in primary hepatocytes. Maximal stimulation of GK promoter activity by insulin was inhibited when a p300 vector was used containing a mutation within a PKB phosphorylation site. Thus, a regulatory transcriptional complex consisting of HIF-1, HNF-4, and p300 appears to be involved in insulin-dependent GK gene activation.	Univ Gottingen, Inst Biochem & Mol Zellbiol, D-37073 Gottingen, Germany; Univ Illinois, Dept Med, Chicago, IL 60612 USA; Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA; Vet Affair Chicago Healthcare Syst, Chicago, IL 60612 USA	University of Gottingen; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kietzmann, T (corresponding author), Univ Gottingen, Inst Biochem & Mol Zellbiol, Humboldtallee 23, D-37073 Gottingen, Germany.	tkietzm@gwdg.de		Kietzmann, Thomas/0000-0003-0242-8636	NIDDK NIH HHS [DKK1430] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK001430] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Feldser D, 1999, CANCER RES, V59, P3915; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Fleischmann M, 2000, BIOCHEM J, V349, P13, DOI 10.1042/bj3490013; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Huang LE, 1997, KIDNEY INT, V51, P548, DOI 10.1038/ki.1997.76; Immenschuh S, 1998, BIOCHEM J, V334, P141, DOI 10.1042/bj3340141; Iynedjian PB, 2000, BIOCHEM J, V351, P621, DOI 10.1042/0264-6021:3510621; Iynedjian PB, 1998, BIOCHEM J, V333, P705, DOI 10.1042/bj3330705; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; JETTON TL, 1994, J BIOL CHEM, V269, P3641; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jungermann K, 1996, ANNU REV NUTR, V16, P179, DOI 10.1146/annurev.nu.16.070196.001143; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Kietzmann T, 1999, BLOOD, V94, P4177, DOI 10.1182/blood.V94.12.4177.424k14_4177_4185; Kietzmann T, 2003, BLOOD, V101, P907, DOI 10.1182/blood-2002-06-1693; Kietzmann T, 1997, BIOCHEM J, V321, P17, DOI 10.1042/bj3210017; Kietzmann T, 2001, BIOCHEM J, V354, P531, DOI 10.1042/0264-6021:3540531; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; MADAN A, 1993, P NATL ACAD SCI USA, V90, P3928, DOI 10.1073/pnas.90.9.3928; Maxwell PH, 2002, SEMIN CELL DEV BIOL, V13, P29, DOI 10.1006/scdb.2001.0287; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; PRINTZ RL, 1993, ANNU REV NUTR, V13, P463, DOI 10.1146/annurev.nu.13.070193.002335; Richard DE, 2000, J BIOL CHEM, V275, P26765; Roth U, 2002, BIOCHEM J, V365, P223, DOI 10.1042/BJ20020340; Ruas JL, 2002, J BIOL CHEM, V277, P38723, DOI 10.1074/jbc.M205051200; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Samoylenko A, 2001, BLOOD, V97, P2657, DOI 10.1182/blood.V97.9.2657; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; Semenza CL, 2001, PEDIATR RES, V49, P614, DOI 10.1203/00006450-200105000-00002; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Shepherd PR, 1997, DIABETOLOGIA, V40, P1172, DOI 10.1007/s001250050803; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; SLADEK FM, 1993, RECEPTOR, V3, P223; Stiehl DP, 2002, FEBS LETT, V512, P157, DOI 10.1016/S0014-5793(02)02247-0; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; VANDERCAMMEN A, 1991, EUR J BIOCHEM, V200, P545, DOI 10.1111/j.1432-1033.1991.tb16217.x; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Yeagley D, 2001, J BIOL CHEM, V276, P33705, DOI 10.1074/jbc.M101215200; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 2000, CANCER RES, V60, P1541	69	85	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2623	2631		10.1074/jbc.M308391200	http://dx.doi.org/10.1074/jbc.M308391200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14612449	hybrid			2022-12-25	WOS:000188211300037
J	Rubio-Aliaga, I; Boll, M; Weisenhorn, DMV; Foltz, M; Kottra, G; Daniel, H				Rubio-Aliaga, I; Boll, M; Weisenhorn, DMV; Foltz, M; Kottra, G; Daniel, H			The proton/amino acid cotransporter PAT2 is expressed in neurons with a different subcellular localization than its paralog PAT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTOR SUBUNITS; HIGH-AFFINITY UPTAKE; GLYCINE TRANSPORTER; SYSTEM-N; FUNCTIONAL-CHARACTERIZATION; HIPPOCAMPAL-NEURONS; NERVOUS-SYSTEM; VESICULAR GABA; AMINO-ACIDS; CLONING	The new member of the mammalian amino acid/auxin permease family, PAT2, has been cloned recently and represents an electrogenic proton/amino acid symporter. PAT2 and its paralog, PAT1/LYAAT-1, are transporters for small amino acids such as glycine, alanine, and proline. Our immunodetection studies revealed that the PAT2 protein is expressed in spinal cord and brain. It is found in neuronal cell bodies in the anterior horn in spinal cord and in brain stem, cerebellum, hippocampus, hypothalamus, rhinencephalon, cerebral cortex, and olfactory bulb in the brain. PAT2 is expressed in neurons positive for the N-methyl-D-aspartate subtype glutamate receptor subunit NR1. PAT2 is not found in lysosomes, unlike its paralog PAT1, but is present in the endoplasmic reticulum and recycling endosomes in neurons. PAT2 has a high external proton affinity causing half-maximal transport activation already at a pH of 8.3, suggesting that its activity is most likely not altered by physiological pH changes. Transport of amino acids by PAT2 activity is dependent on membrane potential and can occur bidirectionally; membrane depolarization causes net glycine outward currents. Our data suggest that PAT2 contributes to neuronal transport and sequestration of amino acids such as glycine, alanine, and/or proline, whereby the transport direction is dependent on the sum of the driving forces such as substrate concentration, pH gradient, and membrane potential.	Tech Univ Munich, Mol Nutr Unit, D-85350 Freising Weihenstephan, Germany; Natl Res Ctr, Inst Dev Genet, D-85764 Neuherberg, Germany	Technical University of Munich	Daniel, H (corresponding author), Tech Univ Munich, Mol Nutr Unit, Hochfeldweg 2, D-85350 Freising Weihenstephan, Germany.	daniel@wzw.tum.de	Daniel, Hannelore/B-8982-2009	Vogt Weisenhorn, Daniela/0000-0002-4566-6506; Rubio-Aliaga, Isabel/0000-0003-1051-9511				Agulhon C, 2003, J COMP NEUROL, V462, P71, DOI 10.1002/cne.10712; Armano S, 2002, J BIOL CHEM, V277, P10467, DOI 10.1074/jbc.M110942200; ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; BENNETT JP, 1972, SCIENCE, V178, P997, DOI 10.1126/science.178.4064.997; Bermingham JR, 2002, J NEUROSCI, V22, P10217; Boll M, 2003, MOL MEMBR BIOL, V20, P261, DOI 10.1080/0968768031000100759; Boll M, 2003, GENOMICS, V82, P47, DOI 10.1016/S0888-7543(03)00099-5; Boll M, 2002, J BIOL CHEM, V277, P22966, DOI 10.1074/jbc.M200374200; BOLL M, 2004, PFLUGERS ARCH; Chatterton JE, 2002, NATURE, V415, P793, DOI 10.1038/nature715; Chaudhry FA, 2002, J CELL BIOL, V157, P349, DOI 10.1083/jcb.200201070; Chaudhry FA, 2002, J NEUROSCI, V22, P62, DOI 10.1523/JNEUROSCI.22-01-00062.2002; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; Chen Z, 2003, J PHYSIOL-LONDON, V546, P349, DOI 10.1113/jphysiol.2002.026500; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; DUMOLIN A, 1999, J CELL SCI, V112, P22802; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; Kottra G, 2001, J PHYSIOL-LONDON, V536, P495, DOI 10.1111/j.1469-7793.2001.0495c.xd; LIU QR, 1993, J BIOL CHEM, V268, P22802; LIU QR, 1992, FEBS LETT, V305, P110, DOI 10.1016/0014-5793(92)80875-H; LOGAN WJ, 1971, NATURE, V234, P297, DOI 10.1038/234297b0; McIntire SL, 1997, NATURE, V389, P870, DOI 10.1038/39908; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Nakanishi T, 2001, BIOCHEM BIOPH RES CO, V281, P1343, DOI 10.1006/bbrc.2001.4504; Nakanishi T, 2001, AM J PHYSIOL-CELL PH, V281, pC1757, DOI 10.1152/ajpcell.2001.281.6.C1757; PETRALIA RS, 1994, J NEUROSCI, V14, P667; Reimer RJ, 2000, P NATL ACAD SCI USA, V97, P7715, DOI 10.1073/pnas.140152797; Sagne C, 2001, P NATL ACAD SCI USA, V98, P7206, DOI 10.1073/pnas.121183498; Sagne C, 1997, FEBS LETT, V417, P177, DOI 10.1016/S0014-5793(97)01279-9; Saier MH, 2000, MICROBIOL-SGM, V146, P1775, DOI 10.1099/00221287-146-8-1775; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; Sugawara M, 2000, BBA-BIOMEMBRANES, V1509, P7, DOI 10.1016/S0005-2736(00)00349-7; Sugawara M, 2000, J BIOL CHEM, V275, P16473, DOI 10.1074/jbc.C000205200; Supplisson S, 1997, J NEUROSCI, V17, P4580; Varoqui H, 2000, J BIOL CHEM, V275, P4049, DOI 10.1074/jbc.275.6.4049; Wreden CC, 2003, J NEUROSCI, V23, P1265, DOI 10.1523/JNEUROSCI.23-04-01265.2003; Young GB, 1999, BBA-BIOMEMBRANES, V1415, P306, DOI 10.1016/S0005-2736(98)00196-5; ZAFRA F, 1995, J NEUROSCI, V15, P3952	39	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2754	2760		10.1074/jbc.M305556200	http://dx.doi.org/10.1074/jbc.M305556200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14600155	hybrid			2022-12-25	WOS:000188211300053
J	Wong, GW; Yasuda, S; Morokawa, N; Li, LX; Stevens, RL				Wong, GW; Yasuda, S; Morokawa, N; Li, LX; Stevens, RL			Mouse chromosome 17A3.3 contains 13 genes that encode functional tryptic-like serine proteases with distinct tissue and cell expression patterns	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MAST-CELL; SUBSTRATE-SPECIFICITY; COMPLEMENTARY-DNA; MESSENGER-RNA; TRYPTASES; CLONING; PROTEIN; FAMILY; MEMBER; DIFFERENTIATION	Probing of the mouse EST data base at GenBank(TM) with known tryptase cDNAs resulted in the identification of undiscovered serine protease transcripts whose genes reside at a 1.5-Mb complex on mouse chromosome 17A3.3. Mouse tryptase-5 (mT5), tryptase-6 (mT6), and mast cell protease-11 (mMCP-11) are new members of this serine protease superfamily whose amino acid sequences are 36 - 54% identical to each other and to their other 10 family members. The 13 functional mouse proteases can be subdivided into two subgroups based on conserved features in their propeptides. Of the three new serine proteases, mT6 is most widely expressed in tissues. mT5 is preferentially expressed in smooth muscle, whereas mMCP-11 is preferentially expressed in the spleen and bone marrow. In contrast to mT5 and mT6, mMCP-11 is also expressed in mast cells. Although mT6 and mMCP-11 are constitutively secreted when expressed in mammalian and insect cells, mT5 remains membrane-associated. The fact that recombinant mT5, mT6, and mMCP-11 possess non-identical expression patterns and substrate specificities suggests that each protease has a unique function in vivo. Of the 13 functional mouse tryptase genes identified at the complex, 12 have orthologs that reside in the syntenic region of human chromosome 16p13.3. The establishment of these ortholog pairs helps clarify the evolutionary relationship of the serine protease locus in the two species. This information provides a useful framework for the functional analysis of each protease using gene targeting and other molecular approaches.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Stevens, RL (corresponding author), Brigham & Womens Hosp, Dept Med, Smith Bldg,Rm 616B,1 Jimmy Fund Way, Boston, MA 02115 USA.	rstevens@rics.bwh.harvard.edu	Yasuda, Shinsuke/A-4369-2012	Wong, G. William/0000-0002-5286-6506	NHLBI NIH HHS [HL-63284, HL-36110] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110, R01HL063284] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Badge RM, 2000, HUM MOL GENET, V9, P1239, DOI 10.1093/hmg/9.8.1239; BENYON RC, 1991, INT ARCH ALLER A IMM, V94, P218, DOI 10.1159/000235364; Bhagwandin VJ, 2003, J BIOL CHEM, V278, P3363, DOI 10.1074/jbc.M209353200; CAMPANELLI D, 1990, J CLIN INVEST, V85, P904, DOI 10.1172/JCI114518; Caughey GH, 2000, J IMMUNOL, V164, P6566, DOI 10.4049/jimmunol.164.12.6566; Chen C, 2003, BIOCHEM J, V374, P97, DOI 10.1042/BJ20030242; Chertov O, 1997, J EXP MED, V186, P739, DOI 10.1084/jem.186.5.739; CROMLISH JA, 1987, J BIOL CHEM, V262, P1363; EKLUND KK, 1993, J IMMUNOL, V151, P4266; GHILDYAL N, 1994, J IMMUNOL, V153, P2624; GHILDYAL N, 1993, J IMMUNOL, V151, P3206; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; Hallgren J, 2000, BIOCHEMISTRY-US, V39, P13068, DOI 10.1021/bi000973b; Harris JL, 2001, J BIOL CHEM, V276, P34941, DOI 10.1074/jbc.M102997200; Honda A, 2002, J BIOL CHEM, V277, P16976, DOI 10.1074/jbc.M112470200; Hooper JD, 1999, CANCER RES, V59, P3199; Huang C, 2000, J BIOL CHEM, V275, P351, DOI 10.1074/jbc.275.1.351; Huang CF, 1997, J BIOL CHEM, V272, P31885, DOI 10.1074/jbc.272.50.31885; Huang CF, 1998, J IMMUNOL, V160, P1910; Huang CF, 1999, J BIOL CHEM, V274, P19670, DOI 10.1074/jbc.274.28.19670; Huang CF, 2001, J BIOL CHEM, V276, P26276, DOI 10.1074/jbc.M102356200; Inoue M, 1998, BIOCHEM BIOPH RES CO, V252, P307, DOI 10.1006/bbrc.1998.9645; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; Mekori YA, 1999, J ALLERGY CLIN IMMUN, V104, P517, DOI 10.1016/S0091-6749(99)70316-7; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; MORGAN JG, 1991, J IMMUNOL, V147, P3210; O'Sullivan CM, 2001, REPRODUCTION, V122, P235, DOI 10.1530/rep.0.1220235; O'Sullivan CM, 2001, REPRODUCTION, V122, P61, DOI 10.1530/rep.0.1220061; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Oh SW, 2002, J IMMUNOL, V168, P1992, DOI 10.4049/jimmunol.168.4.1992; Pallaoro M, 1999, J BIOL CHEM, V274, P3355, DOI 10.1074/jbc.274.6.3355; PEREIRA HA, 1995, J LEUKOCYTE BIOL, V57, P805, DOI 10.1002/jlb.57.6.805; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; RAZIN E, 1984, J IMMUNOL, V132, P1479; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; Scarman AL, 2001, EUR J BIOCHEM, V268, P1250, DOI 10.1046/j.1432-1327.2001.01986.x; Shaw-Smith CJ, 2000, BBA-GENE STRUCT EXPR, V1490, P131, DOI 10.1016/S0167-4781(99)00226-2; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; Wang HW, 2002, J IMMUNOL, V169, P5145, DOI 10.4049/jimmunol.169.9.5145; WILLIAMS EB, 1989, J BIOL CHEM, V264, P7536; Wong GW, 2001, J BIOL CHEM, V276, P49169, DOI 10.1074/jbc.M108677200; Wong GW, 2002, J BIOL CHEM, V277, P41906, DOI 10.1074/jbc.M205868200; Wong GW, 2001, J BIOL CHEM, V276, P20648, DOI 10.1074/jbc.M010422200; Wong UW, 1999, J BIOL CHEM, V274, P30784, DOI 10.1074/jbc.274.43.30784; Xia ZN, 1996, J BIOL CHEM, V271, P8747, DOI 10.1074/jbc.271.15.8747; Yasuda S, 2003, FASEB J, V17, pC12	48	59	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2438	2452		10.1074/jbc.M308209200	http://dx.doi.org/10.1074/jbc.M308209200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14583634	hybrid			2022-12-25	WOS:000188211300015
J	Ogawa, D; Shikata, K; Honke, K; Sato, S; Matsuda, M; Nagase, R; Tone, A; Okada, S; Usui, H; Wada, J; Miyasaka, M; Kawashima, H; Suzuki, Y; Suzuki, T; Taniguchi, N; Hirahara, Y; Tadano-Aritomi, K; Ishizuka, I; Tedder, TF; Makino, H				Ogawa, D; Shikata, K; Honke, K; Sato, S; Matsuda, M; Nagase, R; Tone, A; Okada, S; Usui, H; Wada, J; Miyasaka, M; Kawashima, H; Suzuki, Y; Suzuki, T; Taniguchi, N; Hirahara, Y; Tadano-Aritomi, K; Ishizuka, I; Tedder, TF; Makino, H			Cerebroside sulfotransferase deficiency ameliorates L-selectin-dependent monocyte infiltration in the kidney after ureteral obstruction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE HOMING RECEPTOR; LEUKOCYTE ADHESION MOLECULE; ACUTE-RENAL-FAILURE; P-SELECTIN; LIGANDS; SULFOGLYCOLIPIDS; OLIGOSACCHARIDES; MACROPHAGES; GLYCOLIPIDS; EXPRESSION	Mononuclear cells infiltrating the interstitium are involved in renal tubulointerstitial injury. The unilateral ureteral obstruction (UUO) is an established experimental model of renal interstitial inflammation. In our previous study, we postulated that L-selectin on monocytes is involved in their infiltration into the interstitium by UUO and that a sulfated glycolipid, sulfatide, is the physiological L-selectin ligand in the kidney. Here we tested the above hypothesis using sulfatide-and L-selectin-deficient mice. Sulfatide-deficient mice were generated by gene targeting of the cerebroside sulfotransferase (Cst) gene. Although the L-selectin-IgG chimera protein specifically bound to sulfatide fraction in acidic lipids from wild-type kidney, it did not show such binding in fractions of Cst(-/-) mice kidney, indicating that sulfatide is the major L-selectin-binding glycolipid in the kidney. The distribution of L-selectin ligand in wildtype mice changed after UUO; sulfatide was relocated from the distal tubules to the peritubular capillaries where monocytes infiltrate, suggesting that sulfatide relocated to the endothelium after UUO interacted with L-selectin on monocytes. In contrast, L-selectin ligand was not detected in Cst(-/-) mice irrespective of UUO treatment. Compared with wild-type mice, Cst(-/-) mice showed a considerable reduction in the number of monocytes/macrophages that infiltrated the interstitium after UUO. The number of monocytes/macrophages was also reduced to a similar extent in L-selectin(-/-) mice. Our results suggest that sulfatide is a major L-selectin-binding molecule in the kidney and that the interaction between L-selectin and sulfatide plays a critical role in monocyte infiltration into the kidney interstitium.	Okayama Univ, Grad Sch Med & Dent, Dept Med & Clin Sci, Okayama 7008558, Japan; Kochi Med Sch, Dept Mol Genet, Kochi 7838505, Japan; Kanazawa Univ, Grad Sch Med Sci, Dept Dermatol, Kanazawa, Ishikawa 9208641, Japan; Osaka Univ, Grad Sch Med, Lab Mol & Cellular Recognit, Suita, Osaka 5650871, Japan; Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem, Shizuoka 4228526, Japan; CREST, Shizuoka 4228526, Japan; Osaka Univ, Grad Sch Med, Dept Biochem, CREST, Suita, Osaka 5650871, Japan; Osaka Med Ctr Maternal & Child Hlth, Res Inst, Dept Mol Med, Osaka 5441101, Japan; Teikyo Univ, Sch Med, Dept Biochem, Tokyo 1738605, Japan; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Okayama University; Kochi University; Kanazawa University; Osaka University; University of Shizuoka; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Osaka University; Teikyo University; Duke University	Shikata, K (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Med & Clin Sci, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	shikata@md.okayama-u.ac.jp	Taniguchi, Naoyuki/A-7086-2016; WADA, Jun/B-2023-2011; Taniguchi, Naoyuki/I-4182-2014	WADA, Jun/0000-0003-1468-5170; Taniguchi, Naoyuki/0000-0001-5889-5968; Yasuo, Suzuki/0000-0003-3518-5642				Aliprantis AO, 1996, IMMUNOL TODAY, V17, P573, DOI 10.1016/S0167-5699(96)10071-2; ALON R, 1995, J IMMUNOL, V154, P5356; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; Borsig L, 2002, P NATL ACAD SCI USA, V99, P2193, DOI 10.1073/pnas.261704098; DIAMOND JR, 1995, AM J KIDNEY DIS, V26, P133, DOI 10.1016/0272-6386(95)90166-3; DZIUKAS LJ, 1982, LAB INVEST, V47, P185; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; GREEN PJ, 1995, GLYCOBIOLOGY, V5, P29, DOI 10.1093/glycob/5.1.29; Hickey MJ, 2000, J IMMUNOL, V165, P7164, DOI 10.4049/jimmunol.165.12.7164; Hirata K, 1998, DIABETOLOGIA, V41, P185, DOI 10.1007/s001250050888; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; Honke K, 2002, P NATL ACAD SCI USA, V99, P4227, DOI 10.1073/pnas.032068299; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; IMAI Y, 1993, NATURE, V361, P555; Ishibashi T, 2002, J NEUROSCI, V22, P6507; Ishizuka I, 1997, PROG LIPID RES, V36, P245, DOI 10.1016/S0163-7827(97)00011-8; Kawashima H, 2003, J BIOL CHEM, V278, P13069, DOI 10.1074/jbc.M212244200; Kirveskari J, 2000, J AM SOC NEPHROL, V11, P2358, DOI 10.1681/ASN.V11122358; Lange-Sperandio B, 2002, KIDNEY INT, V61, P516, DOI 10.1046/j.1523-1755.2002.00162.x; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; Li YF, 1999, FEBS LETT, V444, P201, DOI 10.1016/S0014-5793(99)00046-0; MULLIGAN MS, 1995, INT IMMUNOL, V7, P1107, DOI 10.1093/intimm/7.7.1107; Naruse T, 2002, KIDNEY INT, V62, P94, DOI 10.1046/j.1523-1755.2002.00419.x; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; NELSON RM, 1993, BLOOD, V82, P3253; Nikolic-Paterson DJ, 2001, NEPHROL DIAL TRANSPL, V16, P3, DOI 10.1093/ndt/16.suppl_5.3; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; SAITO T, 1990, KIDNEY INT, V37, P1076, DOI 10.1038/ki.1990.88; SCHREINER GF, 1988, KIDNEY INT, V34, P487, DOI 10.1038/ki.1988.207; Shikata K, 1999, J PATHOL, V188, P93, DOI 10.1002/(SICI)1096-9896(199905)188:1<93::AID-PATH305>3.0.CO;2-#; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; Singbartl K, 2000, FASEB J, V14, P48, DOI 10.1096/fasebj.14.1.48; Singbartl K, 2000, CRIT CARE MED, V28, P2507, DOI 10.1097/00003246-200007000-00053; SUZUKI Y, 1991, J BIOCHEM-TOKYO, V109, P354; SUZUKI Y, 1993, BIOCHEM BIOPH RES CO, V190, P426, DOI 10.1006/bbrc.1993.1065; Tadano-Aritomi K, 2000, J LIPID RES, V41, P1237; TAKI T, 1994, ANAL BIOCHEM, V221, P312, DOI 10.1006/abio.1994.1418; TAMATANI T, 1993, J IMMUNOL, V150, P1735	41	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2085	2090		10.1074/jbc.M305809200	http://dx.doi.org/10.1074/jbc.M305809200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14583626	hybrid			2022-12-25	WOS:000188005700064
J	Samino, Y; Lopez, D; Guil, S; de Leon, P; Del Val, M				Samino, Y; Lopez, D; Guil, S; de Leon, P; Del Val, M			An endogenous HIV envelope-derived peptide without the terminal NH3+ group anchor is physiologically presented by major histocompatibility complex class I molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CYTOTOXIC-T-CELLS; PROCESSED VIRAL PEPTIDES; ANTIGEN PRESENTATION; 3-DIMENSIONAL STRUCTURE; ENDOPLASMIC-RETICULUM; LYMPHOCYTE EPITOPES; TYPE-1 INFECTION; IMMUNE-RESPONSES; BINDING-SITE	Cytotoxic T lymphocytes (CTL) recognize viral peptidic antigens presented by major histocompatibility complex (MHC) class I molecules on the surface of infected cells. The CTL response is critical in clearance and prevention of HIV infection. Yet, there are no descriptions of physiological peptides derived from the viral envelope protein. In the few reports on endogenous MHC class I viral peptidic ligands from HIV internal proteins, definitive positive identification by mass spectrometry is lacking. The HIV-1 envelope glycoprotein gp160 induces a strong specific CTL response restricted by several human and murine MHC class I molecules, including H-2D(d). Previous analyses showed that this response can be optimally mimicked with the synthetic decameric peptide (318)RGPGRAFVTI(327). We aim to identify the endogenous natural peptides mediating the response to this epitope. Our data indicate the presence of, at least, two peptidic species of different length and sharing the same antigenic core, which are associated with the D-d presenting molecule in infected cells. One species is at least, probably, the optimal decapeptide. The second species, identified by mass spectrometry for the first time in HIV, is, unexpectedly, a nonamer, which lacks the correctly positioned N-terminal group to bind to Dd. And yet, it is present in similar amounts and, notably, is equally antigenic. Thus, the physiological set of HIV-derived MHC class I ligands is richer and different than expected from studies with synthetic peptides. This may help raise the plasticity and thus the effectiveness of the immune response against the viral infection. These data have implications for HIV vaccine development.	Inst Salud Carlos III, Ctr Nacl Microbiol, E-28220 Madrid, Spain	Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM)	Del Val, M (corresponding author), Inst Salud Carlos III, Ctr Nacl Microbiol, Ctra Pozuelo,Km 2, E-28220 Madrid, Spain.	mdval@isciii.es	Del Val, Margarita/E-4769-2010; López, Daniel/I-2632-2014	Del Val, Margarita/0000-0001-6769-4279; López, Daniel/0000-0003-0268-5878; de Leon, Patricia/0000-0003-2518-2245				ABASTADO JP, 1987, J EXP MED, V166, P327, DOI 10.1084/jem.166.2.327; Achour A, 1998, IMMUNITY, V9, P199, DOI 10.1016/S1074-7613(00)80602-0; BERGMANN C, 1993, EUR J IMMUNOL, V23, P2777, DOI 10.1002/eji.1830231109; BERGMANN CC, 1994, J IMMUNOL, V152, P5603; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748; CHAKRABARTI S, 1986, NATURE, V320, P535, DOI 10.1038/320535a0; Chen WS, 2000, IMMUNITY, V12, P83, DOI 10.1016/S1074-7613(00)80161-2; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; CORR M, 1993, J EXP MED, V178, P1877, DOI 10.1084/jem.178.6.1877; DEL VM, 1991, CELL, V66, P1145; Del-Val M, 2002, MOL IMMUNOL, V39, P235, DOI 10.1016/S0161-5890(02)00104-9; DELVAL M, 1988, J VIROL, V62, P3965, DOI 10.1128/JVI.62.11.3965-3972.1988; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; Flyer DC, 2002, INFECT IMMUN, V70, P2926, DOI 10.1128/IAI.70.6.2926-2932.2002; FRUMENTO G, 1993, CELL IMMUNOL, V152, P623, DOI 10.1006/cimm.1993.1318; Gil-Torregrosa BC, 2000, TRAFFIC, V1, P641, DOI 10.1034/j.1600-0854.2000.010808.x; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; Herr W, 1999, P NATL ACAD SCI USA, V96, P12033, DOI 10.1073/pnas.96.21.12033; Hogan CM, 2001, ANN INTERN MED, V134, P761, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00013; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; Knuehl C, 2001, J IMMUNOL, V167, P1515, DOI 10.4049/jimmunol.167.3.1515; KORBER BTM, 2001, THEORETICAL BIOL BIO; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KOZLOWSKI S, 1992, J EXP MED, V175, P1417, DOI 10.1084/jem.175.6.1417; KULKARNI AB, 1993, J VIROL, V67, P4086, DOI 10.1128/JVI.67.7.4086-4092.1993; Li HM, 1998, J MOL BIOL, V283, P179, DOI 10.1006/jmbi.1998.2091; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Lopez D, 2000, J IMMUNOL, V164, P5070, DOI 10.4049/jimmunol.164.10.5070; Lopez D, 2001, J IMMUNOL, V167, P4238, DOI 10.4049/jimmunol.167.8.4238; Lucchiari-Hartz M, 2000, J EXP MED, V191, P239, DOI 10.1084/jem.191.2.239; McMichael AJ, 1997, ANNU REV IMMUNOL, V15, P271, DOI 10.1146/annurev.immunol.15.1.271; Montoya M, 1999, J IMMUNOL, V163, P1914; NEEFJES J, 1995, EUR J IMMUNOL, V25, P1133, DOI 10.1002/eji.1830250444; NEISIG A, 1995, J IMMUNOL, V154, P1273; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; Paz P, 1999, IMMUNITY, V11, P241, DOI 10.1016/S1074-7613(00)80099-0; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Serwold T, 2001, NAT IMMUNOL, V2, P644, DOI 10.1038/89800; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; SHIRAI M, 1992, J IMMUNOL, V148, P1657; Shirai M, 1996, J IMMUNOL, V157, P4399; Stryhn A, 2000, EUR J IMMUNOL, V30, P3089, DOI 10.1002/1521-4141(200011)30:11<3089::AID-IMMU3089>3.0.CO;2-5; TAKAHASHI H, 1988, P NATL ACAD SCI USA, V85, P3105, DOI 10.1073/pnas.85.9.3105; TAKESHITA T, 1995, J IMMUNOL, V154, P1973; TAYLOR PM, 1987, IMMUNOGENETICS, V26, P267, DOI 10.1007/BF00346521; Tomiyama H, 2000, EUR J IMMUNOL, V30, P2521, DOI 10.1002/1521-4141(200009)30:9<2521::AID-IMMU2521>3.0.CO;2-Q; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TSOMIDES TJ, 1994, J EXP MED, V180, P1283, DOI 10.1084/jem.180.4.1283; Yague J, 2001, J BIOL CHEM, V276, P43699, DOI 10.1074/jbc.M105981200; York IA, 2002, NAT IMMUNOL, V3, P1177, DOI 10.1038/ni860; Yusim K, 2002, J VIROL, V76, P8757, DOI 10.1128/JVI.76.17.8757-8768.2002	59	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1151	1160		10.1074/jbc.M305343200	http://dx.doi.org/10.1074/jbc.M305343200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14583622	hybrid, Green Published			2022-12-25	WOS:000187722800039
J	Capell, A; Kaether, C; Edbauer, D; Shirotani, K; Merkl, S; Steiner, H; Haass, C				Capell, A; Kaether, C; Edbauer, D; Shirotani, K; Merkl, S; Steiner, H; Haass, C			Nicastrin interacts with gamma-secretase complex components via the N-terminal part of its transmembrane domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; BETA-APP; A-BETA; PRESENILIN; APH-1; NOTCH; PEN-2; ACCUMULATION; TRAFFICKING	Two secretases are involved in the generation of amyloid beta-peptide, the principal component of amyloid plaques in the brains of Alzheimer's disease patients. While beta-secretase is a classical aspartyl protease, gamma-secretase activity is associated with a high molecular weight complex. One of the complex components, which is critically required for gamma-secretase activity is nicastrin (NCT). Here we investigate the assembly of NCT into the gamma-secretase complex. NCT mutants either lacking the entire cytoplasmic tail, the cytoplasmic tail, and the transmembrane domain (TMD), or containing a set of heterologous TMDs were expressed in cells with strongly reduced levels of endogenous NCT. Maturation of exogenous NCT, gamma-secretase complex formation and proteolytic function was then investigated. This revealed that the cytoplasmic tail of NCT is dispensable for gamma-secretase complex assembly and function. In contrast, the authentic TMD of NCT is critically required for the interaction with gamma-secretase complex components and for formation of an active gamma-secretase complex. Neither soluble NCT lacking any membrane anchor nor NCT containing a heterologous TMD were inserted into the gamma-secretase complex. We identified the N-terminal region of the NCT TMD as a functionally important entity of NCT. These data thus demonstrate that NCT interacts with other gamma-secretase complex components via its TMD.	Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany	University of Munich	Haass, C (corresponding author), Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, Schillerstr 44, D-80336 Munich, Germany.		Edbauer, Dieter/M-9906-2019	Edbauer, Dieter/0000-0002-7186-4653				Capell A, 1997, J NEUROCHEM, V69, P2432; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kimberly WT, 2002, J BIOL CHEM, V277, P35113, DOI 10.1074/jbc.M204446200; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Morais VA, 2003, J BIOL CHEM, V278, P43284, DOI 10.1074/jbc.M305685200; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shirotani K, 2003, J BIOL CHEM, V278, P16474, DOI 10.1074/jbc.C300095200; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	34	52	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52519	52523		10.1074/jbc.C300435200	http://dx.doi.org/10.1074/jbc.C300435200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14602727	hybrid			2022-12-25	WOS:000187480700067
J	Liu, LT; Peng, JP; Chang, HC; Hung, WC				Liu, LT; Peng, JP; Chang, HC; Hung, WC			RECK is a target of Epstein-Barr virus latent membrane protein 1	ONCOGENE			English	Article						RECK; Epstein-Barr virus; latent membrane protein 1; extracellular signal-regulated kinases; small interference RNA	MEMBRANE-PROTEIN 1; CANCER-CELL INVASION; NASOPHARYNGEAL CARCINOMA; EXTRACELLULAR-MATRIX; B-CELLS; EXPRESSION; ACTIVATION; MATRIX-METALLOPROTEINASE-9; TRANSFORMATION; METASTASIS	Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) has been suggested to be involved in tumor metastasis. However, the molecular mechanism of LMP1-induced metastasis is largely unknown. In this study, we investigated the effect of LMP1 on the expression of RECK, a metastasis suppressor gene, in an EBV-negative nasopharyngeal carcinoma (NPC) cell line. Our data demonstrated that LMP1 induced downregulation of RECK via transcription repression in TW04 cells. In addition, we found that LMP1 acted via an Sp1 site to inhibit RECK promoter activity. We next studied the signaling pathway that mediated the effect of LMP1 on RECK expression. Our results showed that LMP1 potently stimulated the activity of extracellular signal-regulated kinases (ERKs) and inhibition of ERK activity by PD98059 antagonized LMP1-induced downregulation of RECK. Conversely, the c-Jun N-terminal kinase inhibitor SP600125 and p38(HOG) kinase inhibitor SB203580 had little effect. We also found that the expression of LMP1 increased the invasive ability of TW04 cells. The importance of RECK in LMP1-induced invasiveness was supported by three observations. First, restoration of RECK expression by PD98059 reduced LMP1-induced release of active MMP-9. Second, suppression of PD98059-induced RECK expression by small interference RNA abolished the inhibitory action of PD98059 on LMP1-induced invasiveness. Third, coexpression of RECK with LMP1 in TW04 cells effectively suppressed cell invasiveness induced by LMP1. Taken together, these results suggest that LMP1 inhibits RECK expression via the ERK/Sp1 signaling pathway and this inhibition is a critical step for LMP1-induced tumor metastasis.	Kaohsiung Med Univ, Sch Technol Med Sci, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Dept Physiol, Kaohsiung, Taiwan; Cang Gung Univ, Chang Gung Mem Hosp, Dept Otolaryngol, Kaohsiung Med Ctr, Kaohsiung, Taiwan; Kaohsiung Med Univ, Grad Inst Med, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Chang Gung Memorial Hospital; Kaohsiung Medical University	Hung, WC (corresponding author), Kaohsiung Med Univ, Sch Technol Med Sci, No 100,Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.			Liu, Li-Teh/0000-0002-7993-7263				DERRICO A, 1991, MODERN PATHOL, V4, P239; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; Horikawa T, 2000, CANCER-AM CANCER SOC, V89, P715, DOI 10.1002/1097-0142(20000815)89:4<715::AID-CNCR1>3.0.CO;2-9; HU LF, 1995, EUR J CANCER, V31A, P658, DOI 10.1016/0959-8049(94)00468-K; KIEFF E, 1995, NEW ENGL J MED, V333, P724, DOI 10.1056/NEJM199509143331110; KIEFF E, 1990, VIROLOGY, P1889; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Kim KR, 2000, ONCOGENE, V19, P1764, DOI 10.1038/sj.onc.1203502; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Lee TH, 2000, ONCOGENE, V19, P3766, DOI 10.1038/sj.onc.1203715; LIN CT, 1990, LAB INVEST, V62, P713; LIN CT, 1993, LAB INVEST, V68, P716; Liu LT, 2003, CANCER RES, V63, P3069; MILLER G, 1990, VIROLOGY, P1921; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; PALLESEN G, 1991, J PATHOL, V165, P289, DOI 10.1002/path.1711650404; Pan MR, 2002, J BIOL CHEM, V277, P32775, DOI 10.1074/jbc.M202334200; PENG M, 1992, ONCOGENE, V7, P1775; Roberts ML, 1998, VIROLOGY, V240, P93, DOI 10.1006/viro.1997.8901; Sasahara RM, 1999, BIOCHEM BIOPH RES CO, V264, P668, DOI 10.1006/bbrc.1999.1552; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WEISS LM, 1991, AM J PATHOL, V139, P1259; Yang XH, 2000, ONCOGENE, V19, P2002, DOI 10.1038/sj.onc.1203515; Yoshizaki T, 1998, P NATL ACAD SCI USA, V95, P3621, DOI 10.1073/pnas.95.7.3621	31	54	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8263	8270		10.1038/sj.onc.1207157	http://dx.doi.org/10.1038/sj.onc.1207157			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614450				2022-12-25	WOS:000186541500005
J	Quaranta, MG; Mattioli, B; Spadaro, F; Straface, E; Giordani, L; Ramoni, C; Malorni, W; Viora, M				Quaranta, MG; Mattioli, B; Spadaro, F; Straface, E; Giordani, L; Ramoni, C; Malorni, W; Viora, M			HIV-1 Nef triggers Vav-mediated signaling pathway leading to functional and morphological differentiation of dendritic cells	FASEB JOURNAL			English	Article						ATDS immunopathogenesis; exogenous Nef; signal transduction; cytoskeleton rearrangement	HUMAN-IMMUNODEFICIENCY-VIRUS; NF-KAPPA-B; CYTOTOXIC T-LYMPHOCYTES; HUMAN IMMUNE-RESPONSE; TYPE-1 NEF; IMMUNOLOGICAL SYNAPSE; CHEMOKINE PRODUCTION; ACTIN CYTOSKELETON; DOWN-REGULATION; EXOGENOUS NEF	The accessory HIV-1 Nef protein plays a key role in AIDS pathogenesis. We recently demonstrated that exogenous Nef triggers phenotypic and functional differentiation of immature dendritic cells (DCs). Here we investigated whether the Nef-induced DC differentiation occurs with morphological remodeling and have focused on the interference of Nef in the signaling pathways that regulates DC maturation. We found that exogenous Nef enters immature DCs, promoting their functional and morphological differentiation. Specifically, Nef promotes interleukin (IL) -12 release, which closely fits with nuclear factor (NF) -kappaB activation. Nef induces rearrangement of actin microfilaments, leading to uropod and ruffle formation. Moreover, Nef increases the capacity of DCs to form clusters with allogeneic CD4(+) T cells, improving immunological synapse formation. Searching for molecules involved in Nef-triggered signaling pathways driving the DC maturation, we found that Nef targets Vav and promotes its tyrosine phosphorylation, associated with its nucleus-to-cytoplasm redistribution. This has a direct effect on Vav guanine nucleotide exchange factor activity for the small GTPase Racl. We hypothesize that targeting Vav, Nef modulates both early signaling events (such as cytoskeletal rearrangement) and delayed responses (such as transcriptional regulation), promoting DC differentiation. Our results highlight how Nef may enhance T lymphocyte activation, thus fostering virus dissemination, manipulating the DC arm of the immune response.	Ist Super Sanita, Dept Immunol, I-00161 Rome, Italy; Ist Super Sanita, Dept Ultrastruct, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS)	Viora, M (corresponding author), Ist Super Sanita, Dept Immunol, Viale Regina Elena 299, I-00161 Rome, Italy.	viora@iss.it	Malorni, Walter/G-5874-2016; Spadaro, Francesca/M-7512-2017	Spadaro, Francesca/0000-0002-6610-350X; Quaranta, Maria Giovanna/0000-0002-1077-1488; malorni, walter/0000-0002-1223-7000				Al-Alwan MM, 2001, J IMMUNOL, V166, P1452, DOI 10.4049/jimmunol.166.3.1452; Andrieu M, 2001, AIDS RES HUM RETROV, V17, P1365, DOI 10.1089/08892220152596623; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; Burns S, 2001, BLOOD, V98, P1142, DOI 10.1182/blood.V98.4.1142; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; CHEINGSONGPOPOV R, 1990, AIDS RES HUM RETROV, V6, P1099, DOI 10.1089/aid.1990.6.1099; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Dienz O, 2000, J BIOL CHEM, V275, P24547, DOI 10.1074/jbc.C000177200; Engering A, 2002, BLOOD, V100, P1780, DOI 10.1182/blood-2001-12-0179; Fackler OT, 2002, IMMUNITY, V16, P493, DOI 10.1016/S1074-7613(02)00307-2; Fackler OT, 1997, EUR J BIOCHEM, V247, P843, DOI 10.1111/j.1432-1033.1997.00843.x; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; Federico M, 2001, BLOOD, V98, P2752, DOI 10.1182/blood.V98.9.2752; Frank I., 2002, Current Molecular Medicine (Hilversum), V2, P229, DOI 10.2174/1566524024605716; Fujii Y, 1996, FEBS LETT, V393, P93, DOI 10.1016/0014-5793(96)00859-9; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Giordani L, 2000, CLIN EXP IMMUNOL, V122, P358, DOI 10.1046/j.1365-2249.2000.01388.x; GRANELLIPIPERNO A, 1995, P NATL ACAD SCI USA, V92, P10944, DOI 10.1073/pnas.92.24.10944; Granucci F, 2001, NAT IMMUNOL, V2, P882, DOI 10.1038/ni0901-882; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Houlard M, 2002, J EXP MED, V195, P1115, DOI 10.1084/jem.20011701; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Kobayashi M, 2001, J IMMUNOL, V167, P3585, DOI 10.4049/jimmunol.167.7.3585; Kohleisen B, 2001, J NEUROVIROL, V7, P52; Kranewitter WJ, 2001, CELL MOTIL CYTOSKEL, V49, P154, DOI 10.1002/cm.1029; LUCCHIARI M, 1994, INT IMMUNOL, V6, P1739, DOI 10.1093/intimm/6.11.1739; LucchiariHartz M, 1996, INT IMMUNOL, V8, P577, DOI 10.1093/intimm/8.4.577; Manninen A, 2002, J EXP MED, V195, P1023, DOI 10.1084/jem.20012039; Messmer D, 2002, J IMMUNOL, V169, P4172, DOI 10.4049/jimmunol.169.8.4172; Messmer D, 2002, AIDS RES HUM RETROV, V18, P1043, DOI 10.1089/08892220260235407; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Ouaaz F, 2002, IMMUNITY, V16, P257, DOI 10.1016/S1074-7613(02)00272-8; Pandori MW, 1996, J VIROL, V70, P4283, DOI 10.1128/JVI.70.7.4283-4290.1996; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Papkalla A, 2002, J VIROL, V76, P8455, DOI 10.1128/JVI.76.16.8455-8459.2002; Parlato S, 2000, EMBO J, V19, P5123, DOI 10.1093/emboj/19.19.5123; Peter F, 1998, IMMUNITY, V9, P433, DOI 10.1016/S1074-7613(00)80626-3; Peters JH, 1996, IMMUNOL TODAY, V17, P273, DOI 10.1016/0167-5699(96)80544-5; Piguet V, 1999, REV MED VIROL, V9, P111, DOI 10.1002/(SICI)1099-1654(199904/06)9:2&lt;111::AID-RMV245&gt;3.0.CO;2-P; Quaranta MG, 1999, EXP CELL RES, V250, P112, DOI 10.1006/excr.1999.4494; Quaranta MG, 2002, EXP CELL RES, V275, P243, DOI 10.1006/excr.2002.5497; Rescigno M, 1998, J EXP MED, V188, P2175, DOI 10.1084/jem.188.11.2175; Romero F, 1996, CELL SIGNAL, V8, P545, DOI 10.1016/S0898-6568(96)00118-0; Romero F, 1996, MOL CELL BIOL, V16, P37; Saksela Kalle, 1997, Frontiers in Bioscience, V2, pD606; Sallusto F, 1999, EUR J IMMUNOL, V29, P1617, DOI 10.1002/(SICI)1521-4141(199905)29:05<1617::AID-IMMU1617>3.0.CO;2-3; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; Sewell AK, 2001, TRENDS IMMUNOL, V22, P173, DOI 10.1016/S1471-4906(01)01866-X; Shutt DC, 2000, CELL MOTIL CYTOSKEL, V46, P200, DOI 10.1002/1097-0169(200007)46:3<200::AID-CM5>3.0.CO;2-M; Sims TN, 2002, IMMUNOL REV, V186, P100, DOI 10.1034/j.1600-065X.2002.18610.x; Sol-Foulon N, 2002, IMMUNITY, V16, P145, DOI 10.1016/S1074-7613(02)00260-1; Steinman R. M, 1999, FUNDAMENTAL IMMUNOLO, P547; STEINMAN RM, 1999, DENDRITIC CELLS BIOL, P421; Swetman CA, 2002, EUR J IMMUNOL, V32, P2074, DOI 10.1002/1521-4141(200207)32:7<2074::AID-IMMU2074>3.0.CO;2-S; Tobiume M, 2002, AIDS RES HUM RETROV, V18, P461, DOI 10.1089/088922202753614227; Torres BA, 1996, AIDS, V10, P1042, DOI 10.1097/00002030-199610090-00017; Varin A, 2003, J BIOL CHEM, V278, P2219, DOI 10.1074/jbc.M209622200; Verhasselt B, 1999, BLOOD, V94, P2809, DOI 10.1182/blood.V94.8.2809.420k11_2809_2818; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; Welker R, 1996, VIROLOGY, V219, P228, DOI 10.1006/viro.1996.0240; West MA, 2000, CURR BIOL, V10, P839, DOI 10.1016/S0960-9822(00)00595-9; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317	66	60	61	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2003	17	14					2025	2036		10.1096/fj.03-0272com	http://dx.doi.org/10.1096/fj.03-0272com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	750AA	14597672				2022-12-25	WOS:000186961200039
J	Delia, D; Fontanella, E; Ferrario, C; Chessa, L; Mizutani, S				Delia, D; Fontanella, E; Ferrario, C; Chessa, L; Mizutani, S			DNA damage-induced cell-cycle phase regulation of p53 and p21(waf1) in normal and ATM-defective cells	ONCOGENE			English	Article							DEPENDENT PROTEIN-KINASE; ATAXIA-TELANGIECTASIA; INDUCED PHOSPHORYLATION; RADIOSENSITIZING AGENT; CHECKPOINT; APOPTOSIS; INHIBITION; G(1); DISSOCIATION; ARREST	The ATM-dependent accumulation of p53 and induction of p21(waf1) are key events for G1 cell-cycle checkpoint arrest following DNA damage. In ATM-null AT cells, even though the p53 and p21(waf1) responses are kinetically delayed and quantitatively reduced, the G1 checkpoint is virtually disrupted, suggesting that these proteins arrive too late in G1 to enforce the arrest. As the precise mechanism remains unclear, we examined the response to DNA double-strand breaks generated by gamma-radiation (IR), to determine if ATM deficiency affects the cell-cycle phase regulation of these molecules. We find that, after irradiation, whereas normal LCL-N cells markedly increase their levels of p53 in all phases of the cell cycle, AT cells fail to show any p53 increase in the G1 phase. In addition, whereas in LCL-N p21(waf1) is induced in G1 and G2-M, in AT cells this induction is partly seen in G2-M, but not in G1, indicating a different cell-cycle phase regulation of p53 and p21(waf1) as a result of ATM deficiency. The levels and catalytic activity of the p53-targeting kinases ATR and DNA-PK in LCL-N and AT cells are very similar throughout the cell cycle, both before and after IR, thus excluding a phase-specific activity for these kinases. Collectively, our findings demonstrate that, in ATM-deficient cells, the p53-dependent p21(waf1) response to DNA damage is not only quantitatively reduced, but also specifically suppressed in the G1 phase, thus providing a mechanistic explanation for the severe disruption of the G1 checkpoint in AT cells.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; IFOM, I-20139 Milan, Italy; Osped S Andrea, I-00189 Rome, Italy; Tokyo Med & Dent Univ, Postgrad Med Sch, Dept Pediat & Dev Biol, Bunkyo Ku, Tokyo 1138519, Japan	Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; Tokyo Medical & Dental University (TMDU)	Delia, D (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.				Telethon [GP0205Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; CANMAN CE, 1994, CANCER RES, V54, P5054; Chehab NH, 2000, GENE DEV, V14, P278; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; Delia D, 2000, BRIT J CANCER, V82, P1938; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Goi K, 1997, CANCER RES, V57, P1895; Jhappan C, 2000, MOL CELL BIOL, V20, P4075, DOI 10.1128/MCB.20.11.4075-4083.2000; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; KHANNA KK, 1995, ONCOGENE, V11, P609; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Takagi M, 1998, CANCER RES, V58, P4923; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Yoshida M, 2002, INT J RADIAT BIOL, V78, P503, DOI [10.1080/095530002317577321, 10.1080/09553000210123685]	28	34	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7866	7869		10.1038/sj.onc.1207086	http://dx.doi.org/10.1038/sj.onc.1207086			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586414				2022-12-25	WOS:000186240200018
J	Qiu, Y; Ogawa, H; Miyagi, M; Misono, KS				Qiu, Y; Ogawa, H; Miyagi, M; Misono, KS			Constitutive activation and uncoupling of the atrial natriuretic peptide receptor by mutations at the dimer interface - Role of the dimer structure in signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLYL-CYCLASE; VASORELAXANT ACTIVITY; BINDING DOMAIN; EXPRESSION; HYPERTENSION; PURIFICATION; HYPERTROPHY; APOPTOSIS; PROGRAM; HORMONE	The crystal packing of the extracellular hormone binding domain of the atrial natriuretic peptide (ANP) receptor contains two possible dimer pairs, the head-to-head (hh) and tail-to-tail (tt) dimer pairs associated through the membrane-distal and membrane-proximal subdomains, respectively. The tt-dimer structure has been proposed previously (van den Akker, F., Zhang, X., Miyagi, M., Huo, X., Misono, K. S., and Yee, V. C. (2000) Nature 406, 101-104). However, no direct evidence is available to identify the physiological dimer form. Here we report site-directed mutagenesis studies of residues at the two alternative dimer interfaces in the full-length receptor expressed on COS cells. The Trp(74) to Arg mutation (W74R) or D71R at the hh-dimer interface caused partial constitutive guanylate cyclase activation, whereas mutation F96D or H99D caused receptor uncoupling. In contrast, mutation Y196D or L225D at the tt-interface had no such effect. His(99) modification at the hh-dimer interface by ethoxyformic anhydride abolished ANP binding. These results suggest that the hh-dimer represents the physiological structure. Recently, we determined the crystal structure of ANPR complexed with ANP and proposed a hormone-induced rotation mechanism mediating transmembrane signaling (H. Ogawa, Y. Qiu, C. M. Ogata, and K. S. Misono, submitted for publication). The observed effects of mutations are consistent with the ANP-induced structural change identified from the crystal structures with and without ANP and support the proposed rotation mechanism for ANP receptor signaling.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Misono, KS (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, NB50,9500 Euclid Ave, Cleveland, OH 44195 USA.	misonok@ccf.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054329] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54329] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; Chrisman TD, 1999, J BIOL CHEM, V274, P4293, DOI 10.1074/jbc.274.7.4293; Cohen D, 1996, J BIOL CHEM, V271, P9863, DOI 10.1074/jbc.271.16.9863; CURRIE MG, 1983, SCIENCE, V221, P71, DOI 10.1126/science.6857267; De Lean A, 2003, J BIOL CHEM, V278, P11159, DOI 10.1074/jbc.M212862200; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; FULLE HJ, 1995, P NATL ACAD SCI USA, V92, P3571, DOI 10.1073/pnas.92.8.3571; FULLER F, 1988, J BIOL CHEM, V263, P9395; GRAMMER RT, 1983, BIOCHEM BIOPH RES CO, V116, P696, DOI 10.1016/0006-291X(83)90581-8; HE XL, 1995, BIOCONJUGATE CHEM, V6, P541, DOI 10.1021/bc00035a007; He XL, 2001, SCIENCE, V293, P1657, DOI 10.1126/science.1062246; Huo XW, 1999, BIOCHEMISTRY-US, V38, P16941, DOI 10.1021/bi9919448; ITOH H, 1990, J CLIN INVEST, V86, P1690, DOI 10.1172/JCI114893; JOHN SWM, 1995, SCIENCE, V267, P679, DOI 10.1126/science.7839143; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LINCOLN TM, 1994, CYCLIC GMP BIOCH PHY, P57; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Misono KS, 1999, BIOCHEMISTRY-US, V38, P516, DOI 10.1021/bi982127v; Oliver PM, 1997, P NATL ACAD SCI USA, V94, P14730, DOI 10.1073/pnas.94.26.14730; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; Suenobu N, 1999, ARTERIOSCL THROM VAS, V19, P140, DOI 10.1161/01.ATV.19.1.140; van den Akker F, 2000, NATURE, V406, P101, DOI 10.1038/35017602; van den Akker F, 2001, J MOL BIOL, V311, P923, DOI 10.1006/jmbi.2001.4922; Wu CF, 1997, J BIOL CHEM, V272, P14860, DOI 10.1074/jbc.272.23.14860	30	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6115	6123		10.1074/jbc.M310225200	http://dx.doi.org/10.1074/jbc.M310225200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14600147	hybrid			2022-12-25	WOS:000188776500127
J	Akgul, B; Tu, CPD				Akgul, B; Tu, CPD			Pentobarbital-mediated regulation of alternative polyadenylation in Drosophila glutathione S-transferase D21 mRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPERGENE FAMILY; MELANOGASTER; ELEMENT; MECHANISM; SEQUENCE; CLEAVAGE; GENES; EXPRESSION; STABILITY; REGION	Two nearly identical, gstD21(L) and gstD21(S) mRNAs, whose polyadenylation sites differ by 19 nucleotides, are transcribed from the intronless glutathione S-transferase D21 gene in Drosophila. Both mRNAs are intrinsically very labile, but exposure to pentobarbital renders them stabilized beyond what can be attributed to transcriptional activation. We have reconstituted this PB-mediated mRNA stabilization in a transgene (D21L) that contains the full-length gstD21(L) sequence. We have also constructed a similar transgene (D21L-UTR), which matches D21L but excluded the native 3'-UTR. D21L-UTR produces a relatively stable RNA, whose stability is unaffected by pentobarbital. Following pentobarbital treatment of wild-type flies, the levels of gstD21(L) and gstD21(S) mRNAs hold at a relatively constant ratio (L/S) of 1.4 +/- 0.2. In transgenic flies, heat shock induction of D21L mRNA changed the L/S ratio to 0.6 +/- 0.1, and it was further reduced to 0.3 +/- 0.1 as D21L mRNA accumulated in the presence of PB. The ratio returned nearly normal (1.1 +/- 0.1) as the D21L mRNA decayed over 12 h after terminating induction. In constrast, when D21L-UTR was present, the ratio remained constant (1.7 +/- 0.2) even under various induction conditions and during recovery. Thus, the 3'-UTR, which was the critical difference between these two transgenes, must have some role in determining the L/S ratio. Induced D21L mRNA alone is not sufficient to cause reversible changes in the ratio. Such changes require the presence of pentobarbital. Therefore, pentobarbital may regulate this L/S ratio by affecting the choice of polyadenylation sites for the gstD21 mRNAs through sensing the concentrations of the native 3'-UTR sequences.	Penn State Univ, Dept Biochem & Mol Biol, Paul M Althouse Lab 106, Intercoll Grad Program Genet, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Tu, CPD (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Paul M Althouse Lab 106, Intercoll Grad Program Genet, University Pk, PA 16802 USA.	unh@psu.edu	Akgül, Bünyamin/AAY-2958-2020	Akgül, Bünyamin/0000-0001-9877-9689	NIEHS NIH HHS [ES 02678] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002678] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Akgul B, 2002, J BIOL CHEM, V277, P34700, DOI 10.1074/jbc.M200985200; CHEN F, 1995, NUCLEIC ACIDS RES, V23, P2614, DOI 10.1093/nar/23.14.2614; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; Edmonds M, 2002, PROG NUCLEIC ACID RE, V71, P285, DOI 10.1016/S0079-6603(02)71046-5; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; KAUFMAN RJ, 1983, MOL CELL BIOL, V3, P1598, DOI 10.1128/MCB.3.9.1598; LAI HCJ, 1986, J BIOL CHEM, V261, P3793; LEE MP, 1993, P NATL ACAD SCI USA, V90, P6656, DOI 10.1073/pnas.90.14.6656; Miyamoto S, 1996, BIOCHEM J, V315, P791, DOI 10.1042/bj3150791; PRESCOTT J, 1994, MOL CELL BIOL, V14, P4682, DOI 10.1128/MCB.14.7.4682; Proudfoot N, 2002, CURR BIOL, V12, pR855, DOI 10.1016/S0960-9822(02)01353-2; ROBERTSON HM, 1988, GENETICS, V118, P461; Sambrook J., 1989, MOL CLONING LAB MANU, V2; TANG AH, 1995, J BIOL CHEM, V270, P13819, DOI 10.1074/jbc.270.23.13819; TANG AH, 1994, J BIOL CHEM, V269, P27876; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TOUNG YPS, 1993, J BIOL CHEM, V268, P9737; TOUNG YPS, 1990, P NATL ACAD SCI USA, V87, P31, DOI 10.1073/pnas.87.1.31; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; Wahle E, 1997, PROG NUCLEIC ACID RE, V57, P41, DOI 10.1016/S0079-6603(08)60277-9; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; WEISS EA, 1991, EMBO J, V10, P215, DOI 10.1002/j.1460-2075.1991.tb07938.x; Zarudnaya MI, 2003, NUCLEIC ACIDS RES, V31, P1375, DOI 10.1093/nar/gkg241; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	26	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4027	4033		10.1074/jbc.M310151200	http://dx.doi.org/10.1074/jbc.M310151200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14612442	hybrid, Green Published			2022-12-25	WOS:000188554300015
J	Kudin, AP; Bimpong-Buta, NYB; Vielhaber, S; Elger, CE; Kunz, WS				Kudin, AP; Bimpong-Buta, NYB; Vielhaber, S; Elger, CE; Kunz, WS			Characterization of superoxide-producing sites in isolated brain mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSPORT CHAIN; HUMAN SKELETAL-MUSCLE; HYDROGEN-PEROXIDE; COMPLEX-I; CYTOCHROME-C; HEART-MITOCHONDRIA; OXYGEN; GENERATION; ISCHEMIA; RAT	Mitochondrial respiratory chain complexes I and III have been shown to produce superoxide but the exact contribution and localization of individual sites have remained unclear. We approached this question investigating the effects of oxygen, substrates, inhibitors, and of the NAD(+)/NADH redox couple on H2O2 and superoxide production of isolated mitochondria from rat and human brain. Although rat brain mitochondria in the presence of glutamate+malate alone do generate only small amounts of H2O2 (0.04+/-0.02 nmol H2O2/min/mg), a substantial production is observed after the addition of the complex I inhibitor rotenone (0.68+/-0.25 nmol H2O2/min/mg) or in the presence of the respiratory substrate succinate alone (0.80+/-0.27 nmol H2O2/min/mg). The maximal rate of H2O2 generation by respiratory chain complex III observed in the presence of antimycin A was considerably lower (0.14+/-0.07 nmol H2O2/min/mg). Similar observations were made for mitochondria isolated from human parahippocampal gyrus. This is an indication that most of the superoxide radicals are produced at complex I and that high rates of production of reactive oxygen species are features of respiratory chain-inhibited mitochondria and of reversed electron flow, respectively. We determined the redox potential of the superoxide production site at complex I to be equal to -295 mV. This and the sensitivity to inhibitors suggest that the site of superoxide generation at complex I is most likely the flavine mononucleotide moiety. Because short-term incubation of rat brain mitochondria with H2O2 induced increased H2O2 production at this site we propose that reactive oxygen species can activate a self-accelerating vicious cycle causing mitochondrial damage and neuronal cell death.	Univ Bonn, Med Ctr, Dept Epileptol, D-53105 Bonn, Germany; Univ Magdeburg, Med Ctr, Dept Neurol, D-39120 Magdeburg, Germany	University of Bonn; Otto von Guericke University	Kunz, WS (corresponding author), Univ Bonn, Med Ctr, Dept Epileptol, Sigmund Freud Str 25, D-53105 Bonn, Germany.	wolfram.kunz@ukb.uni-bonn.de	Kunz, Wolfram/K-1232-2019	Kunz, Wolfram/0000-0003-1113-3493				Alvarez S, 2003, BIOCHEM BIOPH RES CO, V305, P771, DOI 10.1016/S0006-291X(03)00818-0; Beal MF, 1996, CURR OPIN NEUROBIOL, V6, P661, DOI 10.1016/S0959-4388(96)80100-0; BEAL MF, 1997, MITOCHONDRIA FREE RA; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; CINO M, 1989, ARCH BIOCHEM BIOPHYS, V269, P623, DOI 10.1016/0003-9861(89)90148-3; FLINT DH, 1993, J BIOL CHEM, V268, P22369; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; Genova ML, 2001, FEBS LETT, V505, P364, DOI 10.1016/S0014-5793(01)02850-2; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HYSLOP PA, 1995, BRAIN RES, V671, P181, DOI 10.1016/0006-8993(94)01291-O; JENSEN MA, 1984, BIOCHIM BIOPHYS ACTA, V764, P310, DOI 10.1016/0005-2728(84)90101-4; Kamencic H, 2000, ANAL BIOCHEM, V286, P35, DOI 10.1006/abio.2000.4765; Kunz WS, 2000, ANN NEUROL, V48, P766, DOI 10.1002/1531-8249(200011)48:5<766::AID-ANA10>3.0.CO;2-M; Kunz WS, 2000, J BIOL CHEM, V275, P27741; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; NOHL H, 1986, BIOCHEM BIOPH RES CO, V138, P533, DOI 10.1016/S0006-291X(86)80529-0; ROSENTHAL RE, 1987, J CEREBR BLOOD F MET, V7, P752, DOI 10.1038/jcbfm.1987.130; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Wiedemann FR, 2000, ANAL BIOCHEM, V279, P55, DOI 10.1006/abio.1999.4434	27	406	415	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4127	4135		10.1074/jbc.M310341200	http://dx.doi.org/10.1074/jbc.M310341200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14625276	hybrid			2022-12-25	WOS:000188554300027
J	Lartigue, A; Gruez, A; Briand, L; Blon, F; Bezirard, V; Walsh, M; Pernollet, JC; Tegoni, M; Cambillau, C				Lartigue, A; Gruez, A; Briand, L; Blon, F; Bezirard, V; Walsh, M; Pernollet, JC; Tegoni, M; Cambillau, C			Sulfur single-wavelength anomalous diffraction crystal structure of a pheromone-binding protein from the honeybee Apis mellifera L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTHERAEA-POLYPHEMUS; LIGAND-BINDING; NMR STRUCTURE; CRYSTALLIZATION; MOTH; LUSH	Pheromone binding proteins (PBPs) are small helical proteins (similar to13-17 kDa) present in several sensory organs from moth and other insect species. They are involved in the transport of pheromones from the sensillar lymph to the olfactory receptors. We report here the crystal structure of a PBP (Amel-ASP1) originating from the honeybee (Apis mellifera) antennae and expressed as recombinant protein in the yeast Pichia pastoris. Crystals of Amel-ASP1 were obtained at pH 5.5 using the nanodrops technique of crystallization with a novel optimization procedure, and the structure was solved initially with the single-wavelength anomalous diffraction technique using sulfur anomalous dispersion. The structure of Amel-ASP1 has been refined at 1.6-Angstrom resolution. Its fold is roughly similar to that of other PBP/odorant binding proteins, presenting six helices and three disulfide bridges. Contrary to the PBPs from Bombyx mori (Sandler, B. H., Nikonova, L., Leal, W. S., and Clardy, J. (2000) Chem. Biol. 7, 143-151) and Leucophea maderae (Lartigue, A., Gruez, A., Spinelli, S., Riviere, S., Brossut, R., Tegoni, M., and Cambillau, C. (2003) J. Biol. Chem. 278,30213-30218), the extended C terminus folds into the protein and forms a wall of the internal hydrophobic cavity. Its backbone groups establish two hydrogen bonds with a serendipitous ligand, n-butyl-benzene-sulfonamide, an additive used in plastics. This mode of binding might, however, mimic that used by one of the pheromonal blend components and illustrates the binding versatility of PBPs.	CNRS, Unite Mixte Rech 6098, F-13402 Marseille 20, France; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France; INRA, Unite Rech 477, F-78352 Jouy En Josas, France; European Synchrotron Radiat Facil, Med Res Council France, F-38043 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; INRAE; UDICE-French Research Universities; Universite Paris Saclay; European Synchrotron Radiation Facility (ESRF)	Cambillau, C (corresponding author), CNRS, Unite Mixte Rech 6098, F-13402 Marseille 20, France.	cambillau@afmb.cnrs-mrs.fr	Walsh, Martin A/I-1566-2013	Walsh, Martin A/0000-0001-5683-1151				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bette S, 2002, INSECT BIOCHEM MOLEC, V32, P241, DOI 10.1016/S0965-1748(01)00171-0; Briand L, 2001, EUR J BIOCHEM, V268, P752, DOI 10.1046/j.1432-1327.2001.01927.x; Briand L, 2002, EUR J BIOCHEM, V269, P4586, DOI 10.1046/j.1432-1033.2002.03156.x; Campanacci V, 2001, J BIOL CHEM, V276, P20078, DOI 10.1074/jbc.M100713200; Danty E, 1999, J NEUROSCI, V19, P7468, DOI 10.1523/JNEUROSCI.19-17-07468.1999; Danty E, 1998, CHEM SENSES, V23, P83, DOI 10.1093/chemse/23.1.83; Debreczeni JE, 2003, ACTA CRYSTALLOGR D, V59, P688, DOI 10.1107/S0907444903002646; Debreczeni JE, 2003, ACTA CRYSTALLOGR D, V59, P393, DOI 10.1107/S0907444902020917; Horst R, 2001, P NATL ACAD SCI USA, V98, P14374, DOI 10.1073/pnas.251532998; Horst R, 2001, J BIOMOL NMR, V19, P79, DOI 10.1023/A:1008394615895; Kim MS, 2001, CHEM SENSES, V26, P195, DOI 10.1093/chemse/26.2.195; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krieger J, 1996, INSECT BIOCHEM MOLEC, V26, P297, DOI 10.1016/0965-1748(95)00096-8; Krieger MJB, 2002, SCIENCE, V295, P328, DOI 10.1126/science.1065247; Kruse SW, 2003, NAT STRUCT BIOL, V10, P694, DOI 10.1038/nsb960; Larsson AM, 2002, ACTA CRYSTALLOGR D, V58, P346, DOI 10.1107/S0907444901020406; Lartigue A, 2003, J BIOL CHEM, V278, P30213, DOI 10.1074/jbc.M304688200; Lartigue A, 2003, ACTA CRYSTALLOGR D, V59, P919, DOI 10.1107/S090744490300413X; Lee D, 2002, FEBS LETT, V531, P314, DOI 10.1016/S0014-5793(02)03548-2; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mohl Claudia, 2002, Invertebrate Neuroscience, V4, P165, DOI 10.1007/s10158-002-0018-5; Mueller U, 2001, J BIOTECHNOL, V85, P7, DOI 10.1016/S0168-1656(00)00349-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Potier N, 2003, PROTEIN SCI, V12, P725, DOI 10.1110/ps.0232503; Ramagopal UA, 2003, ACTA CRYSTALLOGR D, V59, P868, DOI 10.1107/S0907444903005663; Ramon R, 2001, J BIOL CHEM, V276, P7150, DOI 10.1074/jbc.M010368200; ROUSSEL A, 1991, SILICON GRAPHICS GEO; Sandler BH, 2000, CHEM BIOL, V7, P143, DOI 10.1016/S1074-5521(00)00078-8; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; SHELDRICK GM, 2001, METHODS MACROMOLECUL; SLESSOR KN, 1988, NATURE, V332, P354, DOI 10.1038/332354a0; Sulzenbacher G, 2002, ACTA CRYSTALLOGR D, V58, P2109, DOI 10.1107/S0907444902013938; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; VOGT RG, 1981, NATURE, V293, P161, DOI 10.1038/293161a0; VOGT RG, 1991, J NEUROBIOL, V22, P74, DOI 10.1002/neu.480220108	38	74	91	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4459	4464		10.1074/jbc.M311212200	http://dx.doi.org/10.1074/jbc.M311212200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14594955	Green Published, hybrid			2022-12-25	WOS:000188554300065
J	Landree, LE; Hanlon, AL; Strong, DW; Rumbaugh, G; Miller, IM; Thupari, JN; Connolly, EC; Huganir, RL; Richardson, C; Witters, LA; Kuhajda, FP; Ronnett, GV				Landree, LE; Hanlon, AL; Strong, DW; Rumbaugh, G; Miller, IM; Thupari, JN; Connolly, EC; Huganir, RL; Richardson, C; Witters, LA; Kuhajda, FP; Ronnett, GV			C75, a fatty acid synthase inhibitor, modulates AMP-activated protein kinase to alter neuronal energy metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARNITINE PALMITOYLTRANSFERASE-I; ACETYL-COA CARBOXYLASE; CENTRAL-NERVOUS-SYSTEM; CHAIN ACYL-COA; FOOD-INTAKE; MALONYL-COA; SKELETAL-MUSCLE; BETA-OXIDATION; BODY-WEIGHT; RAT-BRAIN	C75, a synthetic inhibitor of fatty acid synthase (FAS), is hypothesized to alter the metabolism of neurons in the hypothalamus that regulate feeding behavior to contribute to the decreased food intake and profound weight loss seen with C75 treatment. In the present study, we characterize the suitability of primary cultures of cortical neurons for studies designed to investigate the consequences of C75 treatment and the alteration of fatty acid metabolism in neurons. We demonstrate that in primary cortical neurons, C75 inhibits FAS activity and stimulates carnitine palmitoyltransferase-1 (CPT-1), consistent with its effects in peripheral tissues. C75 alters neuronal ATP levels and AMP-activated protein kinase (AMPK) activity. Neuronal ATP levels are affected in a biphasic manner with C75 treatment, decreasing initially, followed by a prolonged increase above control levels. Cerulenin, a FAS inhibitor, causes a similar biphasic change in ATP levels, although levels do not exceed control. C75 and cerulenin modulate AMPK phosphorylation and activity. TOFA, an inhibitor of acetyl-CoA carboxylase, increases ATP levels, but does not affect AMPK activity. Several downstream pathways are affected by C75 treatment, including glucose metabolism and acetyl-CoA carboxylase (ACC) phosphorylation. These data demonstrate that C75 modulates the levels of energy intermediates, thus, affecting the energy sensor AMPK. Similar effects in hypothalamic neurons could form the basis for the effects of C75 on feeding behavior.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Dartmouth Coll, Dartmouth Med Sch, Dept Med, Endocrine Metab Div, Hanover, NH 03755 USA; Dartmouth Coll, Dartmouth Med Sch, Dept Biochem, Endocrine Metab Div, Hanover, NH 03755 USA; Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Dartmouth College; Dartmouth College; Dartmouth College	Ronnett, GV (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 1006B Preclin Teaching Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.	gronnett@jhmi.edu	Hanlon, Alexandra L/J-9585-2013					Abbud W, 2000, ARCH BIOCHEM BIOPHYS, V380, P347, DOI 10.1006/abbi.2000.1935; Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; Attwell D, 2001, J CEREBR BLOOD F MET, V21, P1133, DOI 10.1097/00004647-200110000-00001; BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5; BEKKERS JM, 1995, J NEUROPHYSIOL, V73, P1145, DOI 10.1152/jn.1995.73.3.1145; Campfield LA, 2003, PHYSIOL REV, V83, P25, DOI 10.1152/physrev.00019.2002; CARLSON CA, 1973, J BIOL CHEM, V248, P378; Clegg DJ, 2002, DIABETES, V51, P3196, DOI 10.2337/diabetes.51.11.3196; Culmsee C, 2001, J MOL NEUROSCI, V17, P45, DOI 10.1385/JMN:17:1:45; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; DAWSON VL, 1993, J NEUROSCI, V13, P2651; Eaton S, 2001, BIOCHEM BIOPH RES CO, V285, P537, DOI 10.1006/bbrc.2001.5201; EDMOND J, 1987, J NEUROSCI RES, V18, P551, DOI 10.1002/jnr.490180407; FUNABASHI H, 1989, J BIOCHEM-TOKYO, V105, P751, DOI 10.1093/oxfordjournals.jbchem.a122739; Gao S, 2003, P NATL ACAD SCI USA, V100, P5628, DOI 10.1073/pnas.1031698100; Gribble FM, 1998, J BIOL CHEM, V273, P26383, DOI 10.1074/jbc.273.41.26383; Habinowski SA, 2001, ARCH BIOCHEM BIOPHYS, V396, P71, DOI 10.1006/abbi.2001.2589; HALVORSON DL, 1984, LIPIDS, V19, P851, DOI 10.1007/BF02534514; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857; JAYAKUMAR A, 1995, P NATL ACAD SCI USA, V92, P8695, DOI 10.1073/pnas.92.19.8695; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Kim EK, 2002, AM J PHYSIOL-ENDOC M, V283, pE867, DOI 10.1152/ajpendo.00178.2002; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Kuhajda F. P., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P121; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Kumar MV, 2002, P NATL ACAD SCI USA, V99, P1921, DOI 10.1073/pnas.042683699; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; Kusakabe T, 2000, J HISTOCHEM CYTOCHEM, V48, P613, DOI 10.1177/002215540004800505; Larsson O, 1996, J BIOL CHEM, V271, P10623, DOI 10.1074/jbc.271.18.10623; Liu GX, 2001, CIRC RES, V88, P918, DOI 10.1161/hh0901.089881; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Miki T, 2001, NAT NEUROSCI, V4, P507, DOI 10.1038/87455; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; Obici S, 2003, NAT MED, V9, P756, DOI 10.1038/nm873; Pellerin L, 2003, J PHYSIOL-LONDON, V546, P325, DOI 10.1113/jphysiol.2002.035105; Pizer ES, 1996, CANCER RES, V56, P745; Rubi B, 2002, BIOCHEM J, V364, P219, DOI 10.1042/bj3640219; RUTTER GA, 2003, BIOCH J; SAGGERSON ED, 1982, BIOCHEM J, V202, P397, DOI 10.1042/bj2020397; Salles J, 2002, MOL BRAIN RES, V101, P52, DOI 10.1016/S0169-328X(02)00161-4; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Shimokawa T, 2002, P NATL ACAD SCI USA, V99, P66, DOI 10.1073/pnas.012606199; Sleboda J, 1999, BBA-MOL CELL BIOL L, V1436, P541, DOI 10.1016/S0005-2760(98)00164-7; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; STOCCHI V, 1987, ANAL BIOCHEM, V167, P181, DOI 10.1016/0003-2697(87)90150-3; TAKAHASHI KA, 2003, ENDOCRINOLOGY; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; Thupari JN, 2001, BIOCHEM BIOPH RES CO, V285, P217, DOI 10.1006/bbrc.2001.5146; Turnley AM, 1999, J NEUROCHEM, V72, P1707, DOI 10.1046/j.1471-4159.1999.721707.x; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WATKINS PA, 1991, ARCH BIOCHEM BIOPHYS, V289, P329, DOI 10.1016/0003-9861(91)90419-J; Winder WW, 2001, J APPL PHYSIOL, V91, P1017, DOI 10.1152/jappl.2001.91.3.1017; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; WITTERS LA, 1992, J BIOL CHEM, V267, P2864; Woods SC, 2000, NUTRITION, V16, P894, DOI 10.1016/S0899-9007(00)00454-8; Wortman MD, 2003, NAT MED, V9, P483, DOI 10.1038/nm0503-483; YANG SY, 1987, J BIOL CHEM, V262, P13027; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505	66	99	110	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3817	3827		10.1074/jbc.M310991200	http://dx.doi.org/10.1074/jbc.M310991200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14615481	hybrid			2022-12-25	WOS:000188379600084
J	Gould, WR; Silveira, JR; Tracy, PB				Gould, WR; Silveira, JR; Tracy, PB			Unique in vivo modifications of coagulation factor V produce a physically and functionally distinct platelet-derived cofactor - Characterization of purified platelet-derived factor V/Va	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-CATALYZED ACTIVATION; O-LINKED GLCNAC; BOVINE FACTOR-V; PROTEIN-C; TETRATRICOPEPTIDE REPEATS; PARTIAL GLYCOSYLATION; POLYACRYLAMIDE GELS; CYTOSOLIC PROTEINS; HUMAN-PROTHROMBIN; HUMAN-PLASMA	Platelet- and plasma-derived factor Va (FVa) serve essential cofactor roles in prothrombinase-catalyzed thrombin generation. Platelet- derived FV/Va, purified from Triton X-100 platelet lysates was composed of a mixture of polypeptides ranging from similar to 40 to 330 kDa, mimicking those visualized by Western blotting of platelet lysates and releasates with anti-FV antibodies. The purified, platelet-derived protein expressed significant cofactor activity such that thrombin activation led to only a 2-3-fold increase in cofactor activity yet expression of a specific activity identical to that of purified, plasma-derived FVa. Physical and functional differences between the two cofactors were identified. Purified, platelet-derived FVa was 2-3-fold more resistant to activated protein C-catalyzed inactivation than purified plasma-derived FVa on the thrombin-activated platelet surface. The heavy chain subunit of purified, platelet-derived FVa contained only a fraction ( similar to 10 - 15%) of the intrinsic phosphoserine present in the plasma-derived FVa heavy chain and was resistant to phosphorylation at Ser(692) catalyzed by either casein kinase II or thrombin-activated platelets. MALDI-TOF mass spectrometric analyses of tryptic digests of platelet-derived FV peptides detected an intact heavy chain uniquely modified on Thr(402) with an N-acetylglucosamine or N-acetylgalactosamine, whereas Ser(692) remained unmodified. N-terminal sequencing and MALDI-TOF analyses of platelet-derived FV/Va peptides identified the presence of a full-length heavy chain subunit, as well as a light chain subunit formed by cleavage at Tyr(1543) rather than Arg(1545) accounting for the intrinsic levels of cofactor activity exhibited by native platelet-derived FVa. These collective data are the first to demonstrate physical differences between the two FV cofactor pools and support the hypothesis that, subsequent to its endocytosis by megakaryocytes, FV is modified to yield a platelet-derived cofactor distinct from its plasma counterpart.	Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA	University of Vermont	Tracy, PB (corresponding author), Univ Vermont, Coll Med, Dept Biochem, Given Bldg,Rm C409,89 Beaumont Ave, Burlington, VT 05405 USA.	paula.tracy@uvm.edu			NCRR NIH HHS [M01RR00109] Funding Source: Medline; NHLBI NIH HHS [P01 HL47603] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000109] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Bouchard BA, 2001, BLOOD, V98, p516A; Bouchard BA, 2000, BLOOD, V96, p625A; BRADFORD HN, 1988, BLOOD, V71, P388; CAMIRE RM, 1995, J BIOL CHEM, V270, P20794, DOI 10.1074/jbc.270.35.20794; Camire RM, 1998, BLOOD, V91, P2818, DOI 10.1182/blood.V91.8.2818.2818_2818_2829; Camire RM, 1998, BLOOD, V92, P3035, DOI 10.1182/blood.V92.9.3035.421k54_3035_3041; Camire RM, 1998, BIOCHEMISTRY-US, V37, P11896, DOI 10.1021/bi980520v; CHEDIAK J, 1980, BLOOD, V56, P835; CHIU HC, 1985, BLOOD, V65, P810; Colman RW, 1999, BLOOD, V93, P3152; Conlon S. J., 1997, THROMB HAEMOST S, V77, P616; COOTS MC, 1978, AM J HEMATOL, V4, P193, DOI 10.1002/ajh.2830040212; DAHLBACK B, 1980, J CLIN INVEST, V66, P583, DOI 10.1172/JCI109890; FENTON JW, 1977, CHEM BIOL THROMBIN; FOSTER WB, 1983, BLOOD, V61, P1060; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Gomori G, 1942, J LAB CLIN MED, V27, P955; Gould WR, 2002, BLOOD, V100, p126A; Gould WR, 2001, BLOOD, V98, p703A; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; HART GW, 1989, CIBA F SYMP, V145, P102; Hockin MF, 1997, ARTERIOSCL THROM VAS, V17, P2765, DOI 10.1161/01.ATV.17.11.2765; HOLT GD, 1987, J BIOL CHEM, V262, P14847; HONGMIN S, 2001, BLOOD, V91, pA823; HORTIN GL, 1990, BLOOD, V76, P946; Huang XL, 1996, FEBS LETT, V393, P280, DOI 10.1016/0014-5793(96)00912-X; JENNY RJ, 1994, HAEMOSTASIS THROMBOS; Jesty J, 1976, Methods Enzymol, V45, P95; Kalafatis M, 1998, J BIOL CHEM, V273, P8459, DOI 10.1074/jbc.273.14.8459; KANE WH, 1982, J CLIN INVEST, V70, P1092, DOI 10.1172/JCI110697; KANE WH, 1990, BIOCHEMISTRY-US, V29, P6762, DOI 10.1021/bi00481a003; KANE WH, 1981, J BIOL CHEM, V256, P1002; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KELLER FG, 1995, BIOCHEMISTRY-US, V34, P4118, DOI 10.1021/bi00012a030; Kim SW, 1999, BIOCHEMISTRY-US, V38, P11448, DOI 10.1021/bi991275y; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; Kumar HPM, 1999, THROMB HAEMOSTASIS, P35; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lubas WA, 1997, J BIOL CHEM, V272, P9316; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1990, BLOOD, V76, P1; Medzihradszky KF, 1997, ANAL CHEM, V69, P3986, DOI 10.1021/ac970372z; MERRIL CR, 1981, ANAL BIOCHEM, V110, P201, DOI 10.1016/0003-2697(81)90136-6; MONKOVIC DD, 1990, J BIOL CHEM, V265, P17132; MONROE DM, 2001, THROMB HAEMOSTASIS, V81, P617; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; NAKAMURA M, 1992, THROMB RES, V66, P757, DOI 10.1016/0049-3848(92)90051-B; NESHEIM ME, 1979, J BIOL CHEM, V254, P508; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1986, J CLIN INVEST, V77, P405, DOI 10.1172/JCI112318; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; Nicolaes GAF, 1999, BIOCHEMISTRY-US, V38, P13584, DOI 10.1021/bi991165r; Nicolas G, 2002, MOL CELL BIOL, V22, P3527, DOI 10.1128/MCB.22.10.3527-3536.2002; ONUORA CA, 1973, AM J MED SCI, V265, P407, DOI 10.1097/00000441-197305000-00008; OSTERUD B, 1977, BLOOD, V49, P819; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; PITTMAN DD, 1994, BIOCHEMISTRY-US, V33, P6952, DOI 10.1021/bi00188a026; RAND MD, 1994, BLOOD, V83, P2180; Rapak A, 1997, P NATL ACAD SCI USA, V94, P3783, DOI 10.1073/pnas.94.8.3783; SCHINDLER M, 1987, J BIOL CHEM, V262, P1254; Silveira JR, 2000, BLOOD, V96, p635A; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRACY PB, 1984, J CLIN INVEST, V74, P1221, DOI 10.1172/JCI111531; TRACY PB, 1982, BLOOD, V60, P59; vantVeer C, 1997, J BIOL CHEM, V272, P7983, DOI 10.1074/jbc.272.12.7983; VICIC WJ, 1980, BLOOD, V56, P448; VISKUP RW, 1987, BLOOD, V69, P1188	72	71	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2383	2393		10.1074/jbc.M308600200	http://dx.doi.org/10.1074/jbc.M308600200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14594814	hybrid			2022-12-25	WOS:000188211300009
J	Lee, HJ; Lee, JK; Miyake, S; Kim, SJ				Lee, HJ; Lee, JK; Miyake, S; Kim, SJ			A novel E1A-like inhibitor of differentiation (EID) family member, EID-2, suppresses transforming growth factor (TGF)-beta signaling by blocking TGF-beta-induced formation of Smad3-Smad4 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMAD PROTEINS; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; COACTIVATORS; SEQUENCE; CBP/P300; DOMAIN	Smad proteins play key roles in intracellular signaling of the transforming growth factor-beta (TGF-beta) superfamily. E1A, an adenoviral oncoprotein, is known to inhibit TGF-beta-induced transactivation through binding to Smad proteins. Recently, an EID-1 (E1A-like inhibitor of differentiation-1) and EID-2 (EID-1-like inhibitor of differentiation-2) were identified. In this study, we examined the effect of EID-2 on Smad-mediated TGF-beta signaling. Here, we show that EID-2 inhibits TGF-beta/Smad transcriptional responses. EID-2 interacts constitutively with Smad proteins, and most strongly with Smad3. Stable expression of EID-2 in the TGF-beta1-responsive cell line inhibits endogenous Smad3-Smad4 complex formation and TGF-beta1-induced expression of p21 and p15. These results suggest that EID-2 may function as an endogenous suppressor of TGF-beta signaling.	NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; Tohoku Univ, Grad Sch Med, Dept Dev Genet, Ctr Translat & Adv Anim Res Human Dis, Sendai, Miyagi 9808575, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tohoku University	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA.	kims@mail.nih.gov			NATIONAL CANCER INSTITUTE [Z01BC005617] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Felici A, 2003, EMBO J, V22, P4465, DOI 10.1093/emboj/cdg428; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; KIM SJ, 1991, MOL CELL BIOL, V11, P5222, DOI 10.1128/MCB.11.10.5222; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MacLellan WR, 2000, MOL CELL BIOL, V20, P8903, DOI 10.1128/MCB.20.23.8903-8915.2000; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, GENE DEV, V14, P627; Miyake S, 2003, J BIOL CHEM, V278, P17060, DOI 10.1074/jbc.M212212200; Miyake S, 2000, MOL CELL BIOL, V20, P8889, DOI 10.1128/MCB.20.23.8889-8902.2000; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Yahata T, 2000, J BIOL CHEM, V275, P8825, DOI 10.1074/jbc.275.12.8825; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	28	22	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2666	2672		10.1074/jbc.M310591200	http://dx.doi.org/10.1074/jbc.M310591200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14612439	hybrid			2022-12-25	WOS:000188211300042
J	Park, MY; Jang, HD; Lee, SY; Lee, KJ; Kim, E				Park, MY; Jang, HD; Lee, SY; Lee, KJ; Kim, E			Fas-associated factor-1 inhibits nuclear factor-kappa B (NF-kappa B) activity by interfering with nuclear translocation of the RelA (p65) subunit of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; DOMAIN-CONTAINING RECEPTOR; DEATH-DOMAIN; CELL-DEATH; SIGNAL-TRANSDUCTION; BCL-2 EXPRESSION; PROTEIN; ACTIVATION; APOPTOSIS; GENE	Fas-associated factor-1 (FAF1) is a Fas-binding proapoptotic protein that is a component of the death-inducing signaling complex in Fas-mediated apoptosis. Here, we show that FAF1 is involved in negative regulation of NF-kappaB activation. Overexpression of FAF1 decreased the basal level of NF-kappaB activity in 293 cells. NF-kappaB activation induced by tumor necrosis factor (TNF)-alpha, interleukin-1beta, and lipopolysaccharide was also inhibited by FAF1 overexpression. Moreover, FAF1 suppressed NF-kappaB activation induced by transducers of diverse NF-kappaB-activating signals such as TNF receptor-associated factor-2 and -6, MEKK1, and IkappaB kinase-beta as well as NF-kappaB p65, one of the end point molecules in the NF-kappaB activation pathway, suggesting that NF-kappaB p65 might be a target molecule upon which FAF1 acts. Subsequent study disclosed that FAF1 physically interacts with NF-kappaB p65 and that the binding domain of FAF1 is the death effector domain (DED)-interacting domain ( amino acids 181 - 381), where DEDs of the Fas-associated death domain protein and caspase-8 interact. The NF-kappaB activity-modulating potential of FAF1 was also mapped to the DED-interacting domain. Finally, overexpression of FAF1 prevented translocation of NF-kappaB p65 into the nucleus and decreased its DNA-binding activity upon TNFalpha treatment. This study presents a novel function of FAF1, in addition to the previously known function as a component of the Fas death-inducing signaling complex, i.e. NF-kappaB activity suppressor by cytoplasmic retention of NF-kappaB p65 via physical interaction.	PaiChai Univ, Res Ctr Biomed Resources, Taejon 302735, South Korea; PaiChai Univ, Div Life Sci, Taejon 302735, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea	Pai Chai University; Pai Chai University; Ewha Womans University; Ewha Womans University	Kim, E (corresponding author), PaiChai Univ, Res Ctr Biomed Resources, 439-6 Doma 2 Dong, Taejon 302735, South Korea.	ehkim@mail.pcu.ac.kr		Lee, Kong-Joo/0000-0001-7972-6020				Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Becker K, 1997, FEBS LETT, V412, P102, DOI 10.1016/S0014-5793(97)00758-8; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Buchberger A, 2001, J MOL BIOL, V307, P17, DOI 10.1006/jmbi.2000.4462; Camandola S, 2000, J NEUROSCI RES, V61, P134, DOI 10.1002/1097-4547(20000715)61:2<134::AID-JNR3>3.0.CO;2-P; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chendil D, 2002, CANCER BIOL THER, V1, P152, DOI 10.4161/cbt.61; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Choi YH, 2001, J BIOL CHEM, V276, P25073, DOI 10.1074/jbc.M102941200; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Hong SY, 2000, J BIOL CHEM, V275, P18022, DOI 10.1074/jbc.M001202200; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Min W, 1996, MOL CELL BIOL, V16, P359; Mochida Y, 2000, J BIOL CHEM, V275, P32747, DOI 10.1074/jbc.M003042200; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Park KJ, 2002, J BIOL CHEM, V277, P13122, DOI 10.1074/jbc.M111599200; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Ryu SW, 2003, J BIOL CHEM, V278, P24003, DOI 10.1074/jbc.M302200200; Ryu SW, 2001, BIOCHEM BIOPH RES CO, V286, P1027, DOI 10.1006/bbrc.2001.5505; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Strasser A, 1999, INT J BIOCHEM CELL B, V31, P533, DOI 10.1016/S1357-2725(99)00003-5; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Wu WS, 2003, J BIOL CHEM, V278, P12294, DOI 10.1074/jbc.M211849200; Young PP, 1997, MOL ENDOCRINOL, V11, P1082, DOI 10.1210/me.11.8.1082; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	38	70	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2544	2549		10.1074/jbc.M304565200	http://dx.doi.org/10.1074/jbc.M304565200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14600157	hybrid			2022-12-25	WOS:000188211300027
J	Shalabi, A; Zamudio, F; Wu, XY; Scaloni, A; Possani, LD; Villereal, ML				Shalabi, A; Zamudio, F; Wu, XY; Scaloni, A; Possani, LD; Villereal, ML			Tetrapandins, a new class of scorpion toxins that specifically inhibit store-operated calcium entry in human embryonic kidney-293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-AMINOETHOXYDIPHENYL BORATE 2-APB; CA2+ ENTRY; INTRACELLULAR CALCIUM; RECEPTOR; CHANNELS; PATHWAYS; OSCILLATIONS; MECHANISMS; CURRENTS; RELEASE	Venoms from 14 snakes and four scorpions were screened for inhibitory activities toward store-operated Ca2+ entry (SOCE) in human embryonic kidney-293 cells. An inhibitory activity was found in venom from the African scorpion Pandinus imperator. The active agent of this venom was purified by gel filtration and reverse-phase high pressure liquid chromatography methods. Sequence information on the purified fraction, by automatic Edman degradation and mass spectrometry analysis, identified the activity as being contained in two tetrapeptides, which we have named tetrapandins. We demonstrate that synthesized tetrapandins have inhibitory activity for SOCE in human embryonic kidney-293 cells while having no effect on either thapsigarginor carbachol-stimulated release of Ca2+ stores. These toxins should be extremely useful in future studies to determine downstream events regulated by SOCE as well as to determine whether multiple pathways exist for thapsigargin-stimulated Ca2+ entry.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Univ Nacl Autonoma Mexico, Inst Biotechnol, Dept Mol Med & Bioproc, Cuernavaca 62210, Morelos, Mexico; CNR, Ist Sistema Prod Anim Ambiente Mediterraneo, Proteom & Mass Spectrometry Lab, I-80147 Naples, Italy	University of Chicago; Universidad Nacional Autonoma de Mexico; Consiglio Nazionale delle Ricerche (CNR); Istituto Per Il Sistema Produzione Animale In Ambiente Mediterraneo (ISPAAM-CNR)	Villereal, ML (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 947 E 58th St, Chicago, IL 60637 USA.	mitch@drugs.bsd.uchicago.edu	Possani, Lourival D/J-2397-2013	Scaloni, Andrea/0000-0001-9362-8515	NIGMS NIH HHS [GM-54500] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessandro R, 1996, IN VIVO, V10, P153; Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; Bilmen JG, 2002, EUR J BIOCHEM, V269, P3678, DOI 10.1046/j.1432-1033.2002.03060.x; Bootman MD, 2002, CURR BIOL, V12, pR563, DOI 10.1016/S0960-9822(02)01055-2; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; Braun FJ, 2003, MOL PHARMACOL, V63, P1304, DOI 10.1124/mol.63.6.1304; CARBONE E, 1982, NATURE, V296, P90, DOI 10.1038/296090a0; Chinopoulos C, 2003, J BIOL CHEM, V278, P27382, DOI 10.1074/jbc.M303808200; Conde R, 2000, FEBS LETT, V471, P165, DOI 10.1016/S0014-5793(00)01384-3; de la Rosa LA, 2001, CELL SIGNAL, V13, P711, DOI 10.1016/S0898-6568(01)00200-5; Dietl P, 1996, CELL CALCIUM, V20, P11, DOI 10.1016/S0143-4160(96)90046-9; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; Harks EGA, 2003, FASEB J, V17, P941, DOI 10.1096/fj.02-0786fje; Hong S. J., 1994, Journal of Biomedical Science, V1, P172, DOI 10.1007/BF02253347; HONG SJ, 1994, EUR J PHARMACOL, V265, P35, DOI 10.1016/0014-2999(94)90220-8; HUPE DJ, 1991, J BIOL CHEM, V266, P10136; Jenkins RE, 2001, PROTEOMICS, V1, P1092, DOI 10.1002/1615-9861(200109)1:9<1092::AID-PROT1092>3.0.CO;2-S; KAO CY, 1966, PHARMACOL REV, V18, P997; KEITH RA, 1989, BRIT J PHARMACOL, V98, P767, DOI 10.1111/j.1476-5381.1989.tb14604.x; KWAN CY, 1990, J BIOL CHEM, V265, P678; Luo D, 2001, J BIOL CHEM, V276, P5613, DOI 10.1074/jbc.M007524200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; OLIVERA BM, 1991, ANN NY ACAD SCI, V635, P114, DOI 10.1111/j.1749-6632.1991.tb36486.x; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Peppiatt CM, 2003, CELL CALCIUM, V34, P97, DOI 10.1016/S0143-4160(03)00026-5; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; Possani LD, 2000, BIOCHIMIE, V82, P861, DOI 10.1016/S0300-9084(00)01167-6; Possani Lourival D., 1999, Perspectives in Drug Discovery and Design, V15-16, P15, DOI 10.1023/A:1017062613503; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 2001, J CELL SCI, V114, P2223; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; SCHWARZ G, 1994, CELL CALCIUM, V15, P45, DOI 10.1016/0143-4160(94)90103-1; SOERGEL DG, 1992, MOL PHARMACOL, V41, P487; Valdivia HH, 1998, TRENDS CARDIOVAS MED, V8, P111, DOI 10.1016/S1050-1738(97)00138-2; Wang Y, 2002, CELL CALCIUM, V32, P209, DOI 10.1016/S0143416002001562; Wu XY, 2000, AM J PHYSIOL-CELL PH, V278, pC526, DOI 10.1152/ajpcell.2000.278.3.C526; Wu XY, 2002, J BIOL CHEM, V277, P13597, DOI 10.1074/jbc.M110881200; Zamudio FZ, 1997, J BIOL CHEM, V272, P11886, DOI 10.1074/jbc.272.18.11886; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3	40	9	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1040	1049		10.1074/jbc.M308234200	http://dx.doi.org/10.1074/jbc.M308234200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14583617	hybrid			2022-12-25	WOS:000187722800027
J	Artwohl, M; Roden, M; Waldhausl, W; Freudenthaler, A; Baumgartner-Parzer, SM				Artwohl, M; Roden, M; Waldhausl, W; Freudenthaler, A; Baumgartner-Parzer, SM			Free fatty acids trigger apoptosis and inhibit cell cycle progression in human vascular endothelial cells	FASEB JOURNAL			English	Article						endothelial dysfunction; vascular complications; diabetes	NF-KAPPA-B; OXIDATIVE STRESS; LINOLEIC-ACID; OLEIC-ACID; INSULIN-RESISTANCE; INDUCE APOPTOSIS; GLUCOSE; ACTIVATION; PROTEIN; EXPRESSION	Plasma free fatty acid (FFA) concentrations are increased in states of insulin resistance and impair endothelial function. Because the underlying mechanisms are largely unknown, we examined selected, purified FFAs. (100.300 mu mol/l, 24.48 h) action on apoptosis, cell cycle distribution, and associated gene/protein expression in human umbilical vein endothelial cells (HUVECs). Stearic acid, but not oleic acid, time and concentration dependently increased endothelial apoptosis by fivefold (n=6, P<0.01), whereas polyunsaturated FFAs (PUFAs; linoleic, gamma-linolenic, and arachidonic acid) exerted proapoptotic activity only at 300 mu mol/l (P<0.05). Proapoptotic FFA action increased with FFAs' number of double bonds and with protein expression of the apoptosis promotor bak. The G(0)/G(1) cell cycle arrest (n=6, P<0.05) induced by stearic acid (+14%) and PUFAs (+30%) is reflected by up-regulation of p21(WAF-1/Cip1). In addition, all FFAs concentration dependently reduced (P<0.05) gene/protein expression of clusterin (-54%), NF-kappa B's inhibitor, I kappa B alpha (-50%), endothelin-1 (-44%), and endothelial NO synthase (-44%). Plasma samples obtained from individuals with elevated plasma FFAs (372 +/- 22 mu mol/l) increased endothelial apoptosis by 4.2-fold (P<0.001, n=10) compared with intraindividually matched low plasma FFA (56 +/- 21 mu mol/l) conditions, underlining the results obtained by defined FFA stimulation. In conclusion, FFA structure differently affects endothelial cell proliferation and apoptosis, both representing key factors in the development of micro- and macrovascular dysfunction.	Univ Vienna, Dept Internal Med 3, Div Endocrinol & Metab, A-1090 Vienna, Austria	University of Vienna	Baumgartner-Parzer, SM (corresponding author), Univ Vienna, Dept Internal Med 3, Div Endocrinol & Metab, A-1090 Vienna, Austria.	sabina.baumgartner-parzer@akh-wien.ac.at	Roden, Michael/AAD-3843-2019		European foundation for the study of diabetes (EFSD); Austrian Science Fonds [P 15656]; Austrian National Bank [10510]	European foundation for the study of diabetes (EFSD); Austrian Science Fonds(Austrian Science Fund (FWF)); Austrian National Bank	The study was supported in part by the European foundation for the study of diabetes (EFSD 2002) and the Austrian Science Fonds (P 15656) and the Jubilaumsfondsprojekt No.10510 of the Austrian National Bank.	Akimoto S, 2000, CIRC RES, V86, P185, DOI 10.1161/01.RES.86.2.185; Aoki M, 2001, HYPERTENSION, V38, P48, DOI 10.1161/01.HYP.38.1.48; Artwohl M, 2003, DIABETES, V52, P1240, DOI 10.2337/diabetes.52.5.1240; Artwohl M, 2002, INT J OBESITY, V26, P577, DOI 10.1038/sj.ijo.0801947; Artwohl M, 2000, BRIT J PHARMACOL, V131, P1577, DOI 10.1038/sj.bjp.0703660; BATES EJ, 1995, ATHEROSCLEROSIS, V116, P247, DOI 10.1016/0021-9150(95)05553-9; Baumgartner-Parzer SM, 2001, EXP CLIN ENDOCR DIAB, V109, pS166, DOI 10.1055/s-2001-18579; BAUMGARTNERPARZER SM, 1995, DIABETES, V44, P1323, DOI 10.2337/diabetes.44.11.1323; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Carluccio MA, 1999, ARTERIOSCL THROM VAS, V19, P220, DOI 10.1161/01.ATV.19.2.220; Chung BH, 1998, ATHEROSCLEROSIS, V141, P321; CRISSMAN HA, 1995, CELL GROWTH APOPTOSI, P21; DAVDA RK, 1995, HYPERTENSION, V26, P764, DOI 10.1161/01.HYP.26.5.764; de Martin R, 2000, ARTERIOSCL THROM VAS, V20, pE83; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dimmeler S, 2000, CIRC RES, V87, P434; Dimmeler S, 2002, CURR OPIN LIPIDOL, V13, P531, DOI 10.1097/00041433-200210000-00009; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Eitel K, 2003, DIABETES, V52, P991, DOI 10.2337/diabetes.52.4.991; Evans JL, 2003, DIABETES, V52, P1, DOI 10.2337/diabetes.52.1.1; Fagot-Campagna A, 1998, INT J EPIDEMIOL, V27, P808, DOI 10.1093/ije/27.5.808; Henning B, 2001, J AM COLL NUTR, V20, P97, DOI 10.1080/07315724.2001.10719021; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875; Im EO, 2001, CANCER LETT, V163, P83, DOI 10.1016/S0304-3835(00)00671-6; Jiang WG, 1998, BIOCHEM BIOPH RES CO, V244, P414, DOI 10.1006/bbrc.1998.8288; KASTAN MB, 1991, CANCER RES, V51, P6304; Kiessling F, 2000, BASIC RES CARDIOL, V95, P299, DOI 10.1007/s003950070049; Lupi R, 2002, DIABETES, V51, P1437, DOI 10.2337/diabetes.51.5.1437; Mackness B, 1997, ARTERIOSCL THROM VAS, V17, P1233, DOI 10.1161/01.ATV.17.7.1233; Massaro M, 2002, NUTR METAB CARDIOVAS, V12, P42; Meerarani P, 2000, AM J CLIN NUTR, V71, P81; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746; Nilsson L, 1998, ARTERIOSCL THROM VAS, V18, P1679, DOI 10.1161/01.ATV.18.11.1679; OPIE LH, 1963, NEW ENGL J MED, V268, P757, DOI 10.1056/NEJM196304042681404; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; Pleiner J, 2002, J CLIN ENDOCR METAB, V87, P2913, DOI 10.1210/jc.87.6.2913; REAVEN GM, 1988, DIABETES, V37, P1020, DOI 10.2337/diabetes.37.8.1020; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; Roden M, 1999, DIABETES, V48, P358, DOI 10.2337/diabetes.48.2.358; Romeo G, 2002, DIABETES, V51, P2241, DOI 10.2337/diabetes.51.7.2241; Sata M, 2000, HYPERTENSION, V36, P83, DOI 10.1161/01.HYP.36.1.83; Shichiri M, 1997, HYPERTENSION, V30, P1198, DOI 10.1161/01.HYP.30.5.1198; SHULMAN GI, 2000, J CLIN INVEST, V106, P171, DOI DOI 10.1172/JCI10583; Simopoulos AP, 1999, AM J CLIN NUTR, V70, p560S, DOI 10.1093/ajcn/70.3.560s; Sivamurthy N, 2001, SURGERY, V130, P204, DOI 10.1067/msy.2001.115823; Steinberg HO, 1997, J CLIN INVEST, V100, P1230, DOI 10.1172/JCI119636; Steinberg HO, 2000, DIABETES, V49, P1231, DOI 10.2337/diabetes.49.7.1231; Steinberg HO, 2002, DIABETOLOGIA, V45, P623, DOI 10.1007/s00125-002-0800-2; Stingl H, 2002, OBES RES, V10, P1111, DOI 10.1038/oby.2002.151; Surette ME, 1999, CARCINOGENESIS, V20, P757, DOI 10.1093/carcin/20.5.757; Toborek M, 1997, J LIPID RES, V38, P2155; Urbich C, 2000, CIRCULATION, V101, P352, DOI 10.1161/01.CIR.101.4.352; WALDHAUSL WK, 2000, CURR OPIN ENDOCRINOL, V71, P211; Warren MC, 2000, FREE RADICAL BIO MED, V29, P537, DOI 10.1016/S0891-5849(00)00353-1; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wong SCC, 2001, J PATHOL, V194, P35, DOI 10.1002/path.838; Yam D, 1996, ISRAEL J MED SCI, V32, P1134; Young VM, 1998, METABOLISM, V47, P566, DOI 10.1016/S0026-0495(98)90241-4	62	129	143	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					146	148		10.1096/fj.03-0301fje	http://dx.doi.org/10.1096/fj.03-0301fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597560				2022-12-25	WOS:000188829300056
J	Pendaries, V; Verrecchia, F; Michel, S; Mauviel, A				Pendaries, V; Verrecchia, F; Michel, S; Mauviel, A			Retinoic acid receptors interfere with the TGF-beta/Smad signaling pathway in a ligand-specific manner	ONCOGENE			English	Article						transforming growth factor-beta; nuclear receptors; RAR; Smad; promoter region; gene expression	GROWTH-FACTOR-BETA; CANCER-CELL-LINES; TRANSCRIPTION FACTORS; HL-60 CELLS; PROMOTER; SMAD; GENE; DIFFERENTIATION; PROLIFERATION; ELEMENTS	Transforming growth factor-beta (TGF-beta) and retinoic acid (RA) are important regulators of cell growth and differentiation. The TGF-beta receptors utilize Smad proteins to transduce signals intracellularly and regulate transcription of target genes, either directly or in combination with other sequence-specific transcription factors. Two classes of nuclear receptors, the retinoic acid receptors (RARs) and the retinoic X receptors, are involved in mediating transcriptional responses to RA. Given the known interactions between the TGF-beta and RAR pathways, we have investigated the role played by RAR ligands in modulating functional interactions between Smad3 and RARs. Using transient cell transfection experiments with an artificial Smad3/Smad4-dependent reporter construct, we demonstrate that RAR overexpression enhances Smad-driven transactivation, an effect that requires both Smad3 and Smad4. We provide evidence that RAR effect on Smad3/Smad4-driven transcription is prevented by natural and synthetic RAR agonists, and potentiated by synthetic RAR antagonists. The activity of two TGF-beta-responsive human gene promoter constructs was regulated in a parallel fashion. Using both mammalian two-hybrid and immunoprecipitation/Western methods, we demonstrate a direct interaction between the region DEF of RARgamma and the MH2 domain of Smad3, inhibited by RAR agonists and enhanced by their antagonists. We propose that RARs may function as coactivators of the Smad pathway in the absence of RAR agonists or in the presence of their antagonists, a phenomenon that contrasts with their known role as agonist-activated transcriptional regulators of RA-dependent genes.	Univ Paris 07, Inst Rech Peau, Hop St Louis, INSERM,U532, F-75475 Paris 10, France; Galderma R&D, F-06902 Sophia Antipolis, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Galderma R&D SNC	Mauviel, A (corresponding author), Univ Paris 07, Inst Rech Peau, Hop St Louis, INSERM,U532, Pavillon Bazin,Ave Claude Vellefaux, F-75475 Paris 10, France.		MAUVIEL, Alain/F-6251-2013; Verrecchia, Franck/G-5535-2018	Verrecchia, Franck/0000-0003-4920-2554; Mauviel, Alain/0000-0002-0438-2793				Allenby G, 1995, Hum Exp Toxicol, V14, P226; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Borger DR, 2000, VIROLOGY, V270, P397, DOI 10.1006/viro.2000.0282; Cao ZH, 2003, BLOOD, V101, P498, DOI 10.1182/blood-2002-05-1549; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; CHIPUK JE, 2001, J BIOL CHEM, V13, P13; Datto M, 2000, CYTOKINE GROWTH F R, V11, P37, DOI 10.1016/S1359-6101(99)00027-1; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Defacque H, 1997, LEUKEMIA, V11, P221, DOI 10.1038/sj.leu.2400568; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Fink SP, 2003, ONCOGENE, V22, P1317, DOI 10.1038/sj.onc.1206128; Fu MG, 2001, J BIOL CHEM, V276, P45888, DOI 10.1074/jbc.M105490200; Germain S, 2000, GENE DEV, V14, P435; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; Jetten AM, 2001, PROG NUCLEIC ACID RE, V69, P205, DOI 10.1016/S0079-6603(01)69048-2; Kumar R, 1999, STEROIDS, V64, P310, DOI 10.1016/S0039-128X(99)00014-8; La P, 2003, ONCOGENE, V22, P198, DOI 10.1038/sj.onc.1206100; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 1999, J BIOL CHEM, V274, P31229, DOI 10.1074/jbc.274.44.31229; Nunes I, 1996, CANCER RES, V56, P495; PEMRICK SM, 1994, LEUKEMIA, V8, P1797; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; ROBERTS AB, 1992, CANCER SURV, V14, P205; Rodeck U, 1999, CANCER RES, V59, P547; Schutte M, 1996, CANCER RES, V56, P2527; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; Toma S, 1998, INT J CANCER, V78, P86, DOI 10.1002/(SICI)1097-0215(19980925)78:1<86::AID-IJC14>3.0.CO;2-3; Verrecchia F, 2001, ONCOGENE, V20, P3332, DOI 10.1038/sj.onc.1204448; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317	42	62	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8212	8220		10.1038/sj.onc.1206913	http://dx.doi.org/10.1038/sj.onc.1206913			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603262				2022-12-25	WOS:000186403400016
J	Lanigan, TM; Liu, A; Huang, YZ; Mei, L; Margolis, B; Guan, KL				Lanigan, TM; Liu, A; Huang, YZ; Mei, L; Margolis, B; Guan, KL			Human homologue of Drosophila CNK interacts with Ras effector proteins Raf and Rlf	FASEB JOURNAL			English	Article							MAP KINASE ACTIVATION; KSR-1 GENE ENCODES; SIGNAL-TRANSDUCTION; C-ELEGANS; CELL-TRANSFORMATION; GROWTH-FACTOR; PATHWAY; BINDING; MEK; SCAFFOLD	Connector enhancer of KSR (CNK) is a multidomain protein that participates in Ras signaling in Drosophila eye development. In this report we identify the human homologue of CNK, termed CNK2A, and a truncated alternatively spliced variant, CNK2B. We characterize CNK2 phosphorylation, membrane localization, and interaction with Ras effector molecules. Our results show that MAPK signaling appears to play a role in the phosphorylation of CNK2 in vivo. CNK2 is found in both membrane and cytoplasmic fractions of the cell. In MDCK cells, full-length CNK2 is localized to the lateral plasma membrane. Consistent with previous reports, we show CNK2 interacts with Raf. CNK2 interaction was mapped to the regulatory and kinase domains of Raf, as well as to the carboxyl-terminal half of CNK2. CNK2 also interacts with the Ral signaling components, Ral GTPase, and the Ral-GDS family member R1f. CNK2 interaction was mapped to the GEF domain of R1f. The ability of CNK2 to interact with both Ras effector proteins Raf and R1f suggests that CNK2 may integrate signals between MAPK and Ral pathways through a complex interplay of components.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Inst Gerontol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Alabama, Dept Neurobiol, Birmingham, AL USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL 35294 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Guan, KL (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	kunliang@umich.edu	Mei, Lin/G-8755-2012		NIA NIH HHS [5T32AG00114-17] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [T32AG000114] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anselmo AN, 2002, J BIOL CHEM, V277, P5940, DOI 10.1074/jbc.M110498200; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; Huang YZ, 2000, NEURON, V26, P443, DOI 10.1016/S0896-6273(00)81176-9; Joneson T, 1998, J BIOL CHEM, V273, P7743, DOI 10.1074/jbc.273.13.7743; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; Li WQ, 2000, GENE DEV, V14, P895; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; Mirey G, 2003, MOL CELL BIOL, V23, P1112, DOI 10.1128/MCB.23.3.1112-1124.2003; Morrison DK, 2001, J CELL SCI, V114, P1609; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Prober DA, 2002, GENE DEV, V16, P2286, DOI 10.1101/gad.991102; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Roy F, 2002, GENE DEV, V16, P427, DOI 10.1101/gad.962902; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Sieburth DS, 1998, CELL, V94, P119, DOI 10.1016/S0092-8674(00)81227-1; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; Sundaram M, 1996, BIOESSAYS, V18, P473, DOI 10.1002/bies.950180609; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Therrien M, 1999, P NATL ACAD SCI USA, V96, P13259, DOI 10.1073/pnas.96.23.13259; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Verheijen MHG, 1999, ONCOGENE, V18, P4435, DOI 10.1038/sj.onc.1202834; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Yao I, 1999, J BIOL CHEM, V274, P11889, DOI 10.1074/jbc.274.17.11889; Yao I, 2000, BIOCHEM BIOPH RES CO, V270, P538, DOI 10.1006/bbrc.2000.2475; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	43	42	44	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2003	17	14					2048	2060		10.1096/fj.02-1096com	http://dx.doi.org/10.1096/fj.02-1096com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	750AA	14597674	Green Submitted			2022-12-25	WOS:000186961200041
J	Kobayashi, H; Suzuki, M; Kanayama, N; Terao, T				Kobayashi, H; Suzuki, M; Kanayama, N; Terao, T			Genetic down-regulation of phosphoinositide 3-kinase by bikunin correlates with suppression of invasion and metastasis in human ovarian cancer HRA cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URINARY TRYPSIN-INHIBITOR; GROWTH-FACTOR-I; PLASMINOGEN-ACTIVATOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; PROTEASE INHIBITOR; BINDING-PROTEIN; EXPRESSION; KINASE; INVASIVENESS	Using a cDNA microarray analysis, we previously found that exposure of a highly invasive ovarian cancer cell line HRA with bikunin, a Kunitz-type protease inhibitor, or bikunin gene overexpression markedly reduced phosphoinositide kinase (PI3K) p85 gene expression, demonstrating that PI3K may be a candidate bikunin target gene. To clarify how reduced levels of PI3K may confer repressed invasiveness, we transfected HRA cells with PI3K p85 antisense-oligodeoxynucleotide (AS-ODN) and compared the properties of the transfected cells with those of parental cells and sense (S)-ODN cells. We have also demonstrated previously that transforming growth factor-beta1 (TGF-beta1) stimulates urokinase-type plasminogen activator (uPA)-dependent invasion and metastasis of HRA cells. Here, we show that 1) TGF-beta1 induced a rapid increase of the PI3K activity that was accompanied by increased expression (5-fold) of the uPA mRNA; 2) pharmacological inhibition of PI3K or AS-PI3K ODN transfection inhibited TGF-beta1-stimulated Akt phosphorylation; 3) both PI3K pharmacological inhibitors and forced expression of AS-PI3K ODN reduced TGF-beta1-stimulated uPA mRNA and protein expression by similar to70% compared with controls; 4) concentrations of PI3K inhibitors, sufficient to inhibit uPA up-regulation, inhibited TGF-beta1-dependent HRA cell invasion; 5) the AS-PI3K ODN cells had a decreased ability to invade the extracellular matrix layer as compared with controls; and 6) when the AS-PI3K ODN cells were injected intraperitoneally into nude mice, the mice developed smaller intraperitoneal tumors and showed longer survival. We conclude that PI3K plays an essential role in promoting uPA-mediated invasive phenotype in HRA cells. Our data identify a novel role for PI3K as a bikunin target gene on uPA up-regulation and invasion.	Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Shizuoka 4313192, Japan	Hamamatsu University School of Medicine	Kobayashi, H (corresponding author), Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Handayama 1-20-1, Shizuoka 4313192, Japan.	hirokoba@hama-med.ac.jp						Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Biwa T, 1998, J BIOL CHEM, V273, P28305, DOI 10.1074/jbc.273.43.28305; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Duffy MJ, 2002, BIOCHEM SOC T, V30, P207, DOI 10.1042/BST0300207; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Dunn SE, 2001, CANCER RES, V61, P1367; Eandi JA, 2001, BIOCHEM BIOPH RES CO, V288, P521, DOI 10.1006/bbrc.2001.5803; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; Hirashima Y, 2001, J BIOL CHEM, V276, P13650, DOI 10.1074/jbc.M009906200; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kobayashi H, 2000, BBA-PROTEIN STRUCT M, V1481, P310, DOI 10.1016/S0167-4838(00)00173-4; Kobayashi H, 2003, J BIOL CHEM, V278, P7790, DOI 10.1074/jbc.M210407200; Kobayashi H, 2002, EUR J BIOCHEM, V269, P3945, DOI 10.1046/j.1432-1033.2002.03068.x; Kobayashi H, 2001, Hum Cell, V14, P233; Kobayashi H, 1998, BBA-PROTEIN STRUCT M, V1383, P253, DOI 10.1016/S0167-4838(97)00215-X; Kobayashi H, 2001, J BIOL CHEM, V276, P2015, DOI 10.1074/jbc.M007650200; Kobayashi H, 2000, J BIOL CHEM, V275, P21185, DOI 10.1074/jbc.M907862199; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LIOTTA LA, 1992, CELL, V71, P411; Liu Q, 1998, J IMMUNOL, V160, P1393; Metzner B, 1996, J INVEST DERMATOL, V107, P597, DOI 10.1111/1523-1747.ep12583096; Muehlenweg B, 2001, EXPERT OPIN BIOL TH, V1, P683; Santibanez JF, 2000, NUTR CANCER, V37, P49, DOI 10.1207/S15327914NC3701_6; Santibanez JF, 2000, BIOCHEM BIOPH RES CO, V273, P521, DOI 10.1006/bbrc.2000.2946; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Sturge J, 2002, J CELL SCI, V115, P699; Suzuki M, 2003, INT J CANCER, V104, P289, DOI 10.1002/ijc.10950; Suzuki M, 2003, J BIOL CHEM, V278, P14640, DOI 10.1074/jbc.M300239200; Suzuki M, 2002, J BIOL CHEM, V277, P8022, DOI 10.1074/jbc.M108545200; Suzuki M, 2001, BBA-PROTEIN STRUCT M, V1547, P26, DOI 10.1016/S0167-4838(01)00167-4; Tanaka Y, 2003, CANCER-AM CANCER SOC, V98, P424, DOI 10.1002/cncr.11506; Turner SJ, 1998, J BIOL CHEM, V273, P25987, DOI 10.1074/jbc.273.40.25987; Weng LP, 2002, HUM MOL GENET, V11, P1687, DOI 10.1093/hmg/11.15.1687; Yart A, 2002, J BIOL CHEM, V277, P21167, DOI 10.1074/jbc.M110411200	36	16	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6371	6379		10.1074/jbc.M305749200	http://dx.doi.org/10.1074/jbc.M305749200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14597629	hybrid			2022-12-25	WOS:000188969200022
J	Roh, J; Chang, CL; Bhalla, A; Klein, C; Hsu, SYT				Roh, J; Chang, CL; Bhalla, A; Klein, C; Hsu, SYT			Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; HYPOTENSIVE PEPTIDE; BLOOD-PRESSURE; ADRENOMEDULLIN; EXPRESSION; HORMONE; CGRP; RAT; AMYLIN; POTENT	Calcitonin, calcitonin gene-related peptide (CGRP), adrenomedullin (ADM), and amylin belong to a unique group of peptide hormones important for homeostasis in diverse tissues. Calcitonin is essential for calcium balance, whereas CGRP and ADM are important for neurotransmission and cardiovascular and respiratory regulation. Based on phylogenetic analysis, we identified intermedin as a novel member of the calcitonin/CGRP peptide family. Analysis of intermedin expression indicated that intermedin is expressed primarily in the pituitary and gastrointestinal tract. Intermedin increased cAMP production in SK-N-MC and L6 cells expressing endogenous CGRP receptors and competed with labeled CGRP for binding to its receptors in these cells. In addition, treatment of 293T cells expressing recombinant calcitonin receptor-like receptor (CRLR) and one of the three receptor activity-modifying proteins (RAMPs) showed that a CRLR/RAMP receptor complex is required for intermedin signaling. In contrast to CGRP and ADM, which exhibited a preferential stimulation of CRLR when co-expressed with RAMP1 and RAMP2 or RAMP3, respectively, intermedin represents a nonselective agonist for the RAMP coreceptors. In vivo studies demonstrated that intermedin treatment led to blood pressure reduction in both normal and spontaneously hypertensive rats via interactions with the CRLR/RAMP receptor complexes. Furthermore, in vivo treatment in mice with intermedin led to suppression of gastric emptying activity and food intake. Thus, identification of intermedin as a novel member of the calcitonin/CGRP peptide family capable of signaling through CRLR/ RAMP receptor complexes provides an additional player in the regulation of peripheral tissues by CRLR and will allow development of new therapeutic agents for pathologies associated with diverse vascular and gastrointestinal disorders.	Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA	Stanford University	Hsu, SYT (corresponding author), Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, A344E,300 Pasteur Dr, Stanford, CA 94305 USA.	teddyhsu@stanford.edu	Roh, Jaesook/P-1689-2015	Roh, Jaesook/0000-0002-6286-1071				AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; Autelitano DJ, 1998, BIOCHEM BIOPH RES CO, V250, P689, DOI 10.1006/bbrc.1998.9375; CHIBA T, 1989, AM J PHYSIOL, V256, pE331, DOI 10.1152/ajpendo.1989.256.2.E331; Choksi T, 2002, BRIT J PHARMACOL, V136, P784, DOI 10.1038/sj.bjp.0704761; Christopoulos G, 1999, MOL PHARMACOL, V56, P235, DOI 10.1124/mol.56.1.235; COPP DH, 1994, CLIN INVEST MED, V17, P268; DUNNING BE, 1987, ENDOCRINOLOGY, V120, P1774, DOI 10.1210/endo-120-5-1774; Dvorakova M, 2003, ANAT EMBRYOL, V207, P307, DOI 10.1007/s00429-003-0344-3; EGUCHI S, 1994, ENDOCRINOLOGY, V135, P2454, DOI 10.1210/en.135.6.2454; Eto T, 2001, PEPTIDES, V22, P1693, DOI 10.1016/S0196-9781(01)00513-7; FISHER LA, 1983, NATURE, V305, P534, DOI 10.1038/305534a0; Hagner S, 2002, CELL TISSUE RES, V310, P41, DOI 10.1007/s00441-002-0616-x; HARGIS GK, 1966, SCIENCE, V152, P73, DOI 10.1126/science.152.3718.73; Hay D L, 2001, Trends Pharmacol Sci, V22, P57, DOI 10.1016/S0165-6147(00)01617-5; Hsu SY, 1999, MOL ENDOCRINOL, V13, P2163, DOI 10.1210/me.13.12.2163; Hsu SY, 2002, MOL ENDOCRINOL, V16, P1538, DOI 10.1210/me.16.7.1538; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Hsu SY, 2001, NAT MED, V7, P605, DOI 10.1038/87936; KANAZAWA H, 1994, BIOCHEM BIOPH RES CO, V205, P251, DOI 10.1006/bbrc.1994.2657; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V194, P720, DOI 10.1006/bbrc.1993.1881; KRUGER L, 1988, BRAIN RES, V463, P223, DOI 10.1016/0006-8993(88)90395-2; Kuwasako K, 2000, J BIOL CHEM, V275, P29602, DOI 10.1074/jbc.M004534200; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Meeran K, 1997, J CLIN ENDOCR METAB, V82, P95, DOI 10.1210/jc.82.1.95; Mulder H, 2000, AM J PHYSIOL-ENDOC M, V278, pE684, DOI 10.1152/ajpendo.2000.278.4.E684; Pinto A, 1996, BRIT J PHARMACOL, V119, P1477, DOI 10.1111/j.1476-5381.1996.tb16061.x; POYNER DR, 1992, BRIT J PHARMACOL, V105, P441, DOI 10.1111/j.1476-5381.1992.tb14272.x; Poyner DR, 2002, PHARMACOL REV, V54, P233, DOI 10.1124/pr.54.2.233; RAYBOULD HE, 1992, ANN NY ACAD SCI, V657, P248, DOI 10.1111/j.1749-6632.1992.tb22773.x; REIDELBERGER RD, 2002, AM J PHYSIOL, V282, pE1395; Reyes TM, 2001, P NATL ACAD SCI USA, V98, P2843, DOI 10.1073/pnas.051626398; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; Rossowski WJ, 1997, EUR J PHARMACOL, V336, P51, DOI 10.1016/S0014-2999(97)01252-1; Salmon AM, 1999, NEUROREPORT, V10, P849, DOI 10.1097/00001756-199903170-00033; Salmon AM, 2001, NAT NEUROSCI, V4, P357, DOI 10.1038/86001; Samson WK, 1997, ENDOCRINOLOGY, V138, P613, DOI 10.1210/en.138.2.613; Shindo T, 2001, CIRCULATION, V104, P1964, DOI 10.1161/hc4101.097111; Troughton RW, 2000, HYPERTENSION, V36, P588, DOI 10.1161/01.HYP.36.4.588; WASHIMINE H, 1994, BIOCHEM BIOPH RES CO, V202, P1081, DOI 10.1006/bbrc.1994.2039; Zhang LP, 2001, PAIN, V89, P265, DOI 10.1016/S0304-3959(00)00378-X	41	379	442	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7264	7274		10.1074/jbc.M305332200	http://dx.doi.org/10.1074/jbc.M305332200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14615490	hybrid			2022-12-25	WOS:000188969200128
J	Atkinson, SJ; Hosford, MA; Molitoris, BA				Atkinson, SJ; Hosford, MA; Molitoris, BA			Mechanism of actin polymerization in cellular ATP depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACANTHAMOEBA-PROFILIN; FILAMENTS; INJURY; CELLS; INTEGRITY; MONOMERS; ISCHEMIA; DYNAMICS; THYMOSIN-BETA-4; MICROFILAMENTS	Cellular ATP depletion in diverse cell types results in the net conversion of monomeric G-actin to polymeric F-actin and is an important aspect of cellular injury in tissue ischemia. We propose that this conversion results from altering the ratio of ATP-G-actin and ADP-G-actin, causing a net decrease in the concentration of thymosin-actin complexes as a consequence of the differential affinity of thymosin beta(4) for ATP- and ADP-G-actin. To test this hypothesis we examined the effect of ATP depletion induced by antimycin A and substrate depletion on actin polymerization, the nucleotide state of the monomer pool, and the association of actin monomers with thymosin and profilin in the kidney epithelial cell line LLC-PK1. ATP depletion for 30 min increased F-actin content to 145% of the levels under physiological conditions, accompanied by a corresponding decrease in G-actin content. Cytochalasin D treatment did not reduce F-actin formation during ATP depletion, indicating that it was predominantly not because of barbed end monomer addition. ATP-G-actin levels decreased rapidly during depletion, but there was no change in the concentration of ADP-G-actin monomers. The decrease in ATP-G-actin levels could be accounted for by dissociation of the thymosin-G-actin binary complex, resulting in a rise in the concentration of free thymosin beta(4) from 4 to 11 muM. Increased detection of profilin-actin complexes during depletion indicated that profilin may participate in catalyzing nucleotide exchange during depletion. This mechanism provides a biochemical basis for the accumulation of F-actin aggregates in ischemic cells.	Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Atkinson, SJ (corresponding author), Indiana Univ, Sch Med, Dept Med Nephrol, 950 W Walnut St,R2-202, Indianapolis, IN 46202 USA.	satkinso@iupui.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053465, R01DK053194] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK53194, P01 DK53465] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashworth SL, 2003, AM J PHYSIOL-RENAL, V284, pF852, DOI 10.1152/ajprenal.00210.2002; ATKINSON SJ, 2001, ACUTE RENAL FAILURE; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Blanchoin L, 1998, J BIOL CHEM, V273, P25106, DOI 10.1074/jbc.273.39.25106; CANFIELD PE, 1991, AM J PHYSIOL, V261, pF1038, DOI 10.1152/ajprenal.1991.261.6.F1038; CANO ML, 1991, J CELL BIOL, V115, P677, DOI 10.1083/jcb.115.3.677; CARLIER MF, 1993, P NATL ACAD SCI USA, V90, P5034, DOI 10.1073/pnas.90.11.5034; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; COOPER JA, 1991, ANNU REV PHYSIOL, V53, P585, DOI 10.1146/annurev.ph.53.030191.003101; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Dagher PC, 2000, AM J PHYSIOL-CELL PH, V279, pC1270, DOI 10.1152/ajpcell.2000.279.4.C1270; De La Cruz EM, 2000, BIOPHYS J, V78, P2516, DOI 10.1016/S0006-3495(00)76797-X; GERLACH E, 1963, PFLUG ARCH EUR J PHY, V278, P296, DOI 10.1007/BF00363494; GLASCOTT PA, 1987, CELL MOTIL CYTOSKEL, V8, P118, DOI 10.1002/cm.970080204; Herget-Rosenthal S, 2001, AM J PHYSIOL-CELL PH, V281, pC1858, DOI 10.1152/ajpcell.2001.281.6.C1858; HINSHAW DB, 1988, J SURG RES, V44, P527, DOI 10.1016/0022-4804(88)90158-8; HINSHAW DB, 1988, AM J PATHOL, V132, P479; Iguchi K, 1999, BIOCHEM PHARMACOL, V57, P1105, DOI 10.1016/S0006-2952(99)00030-1; Jahraus A, 2001, MOL BIOL CELL, V12, P155, DOI 10.1091/mbc.12.1.155; Kaiser DA, 1999, J CELL SCI, V112, P3779; KELLERMAN PS, 1990, AM J PHYSIOL, V259, pF279, DOI 10.1152/ajprenal.1990.259.2.F279; KUHNE W, 1993, AM J PHYSIOL, V264, pH1599, DOI 10.1152/ajpheart.1993.264.5.H1599; Kwon O, 2002, AM J PHYSIOL-RENAL, V282, pF1012, DOI 10.1152/ajprenal.00294.2001; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; MOLITORIS BA, 1991, J CLIN INVEST, V88, P462, DOI 10.1172/JCI115326; MOLITORIS BA, 1996, AM J PHYSIOL, V271, P790; Nachmias VT, 1993, CURR OPIN CELL BIOL, V5, P56, DOI 10.1016/S0955-0674(05)80008-0; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; ROSENBLATT J, 1995, MOL BIOL CELL, V6, P227, DOI 10.1091/mbc.6.2.227; SAFER D, 1989, ANAL BIOCHEM, V178, P32, DOI 10.1016/0003-2697(89)90351-5; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; SAFER D, 1994, BIOESSAYS, V16, P473, DOI 10.1002/bies.950160706; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; Shelden EA, 2002, J AM SOC NEPHROL, V13, P2667, DOI 10.1097/01.ASN.0000033353.21502.31; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; Sutton TA, 1998, SEMIN NEPHROL, V18, P490; VENKATACHALAM MA, 1988, J CLIN INVEST, V81, P745, DOI 10.1172/JCI113380; Vinson VK, 1998, BIOCHEMISTRY-US, V37, P10871, DOI 10.1021/bi980093l; WEINBERG JM, 1991, KIDNEY INT, V39, P476, DOI 10.1038/ki.1991.58; WEINBERG JM, 1985, J CLIN INVEST, V76, P1193, DOI 10.1172/JCI112075	44	102	107	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5194	5199		10.1074/jbc.M306973200	http://dx.doi.org/10.1074/jbc.M306973200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14623892	Green Published, hybrid			2022-12-25	WOS:000188776500020
J	Hayakawa, A; Hayes, SJ; Lawe, DC; Sudharshan, E; Tuft, R; Fogarty, K; Lambright, D; Corvera, S				Hayakawa, A; Hayes, SJ; Lawe, DC; Sudharshan, E; Tuft, R; Fogarty, K; Lambright, D; Corvera, S			Structural basis for endosomal targeting by FYVE domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; NUCLEOTIDE EXCHANGE FACTOR; TYROSINE KINASE SUBSTRATE; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; FACIOGENITAL DYSPLASIA; MEMBRANE TRAFFICKING; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; AUTOANTIGEN EEA1; RECEPTOR	The FYVE domain is a conserved protein motif characterized by its ability to bind with high affinity and specificity to phosphatidylinositol 3-phosphate (PI(3)P), a phosphoinositide highly enriched in early endosomes. The PI(3)P polar head group contacts specific amino acid residues that are conserved among FYVE domains. Despite full conservation of these residues, the ability of different FYVE domains to bind to endosomes in cells is highly variable. Here we show that the endosomal localization in intact cells absolutely requires structural features intrinsic to the FYVE domain in addition to the PI(3)P binding pocket. These features are involved in FYVE domain dimerization and in interaction with the membrane bilayer. These interactions, which are determined by non-conserved residues, are likely to be essential for the temporal and spatial control of protein associations at the membrane-cytosol interface within the endocytic pathway.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Interdisciplinary Grad Program, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Mol Pharmacol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Corvera, S (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St,Ste 107, Worcester, MA 01605 USA.	silvia.corvera@umassmed.edu			NIDDK NIH HHS [DK60564, DK54479] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054479, P01DK060564] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; Diraviyam K, 2003, J MOL BIOL, V328, P721, DOI 10.1016/S0022-2836(03)00325-5; Dumas JJ, 2001, MOL CELL, V8, P947, DOI 10.1016/S1097-2765(01)00385-9; Estrada L, 2001, HUM MOL GENET, V10, P485, DOI 10.1093/hmg/10.5.485; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Hayakawa A, 2000, J BIOL CHEM, V275, P29636, DOI 10.1074/jbc.M002696200; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; HEBERT CD, 1989, CANCER RES, V49, P3196; Itoh T, 2002, CELL SIGNAL, V14, P733, DOI 10.1016/S0898-6568(02)00028-1; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Kim Y, 2002, GENES CELLS, V7, P413, DOI 10.1046/j.1365-2443.2002.00524.x; Komada M, 1999, GENE DEV, V13, P1475, DOI 10.1101/gad.13.11.1475; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Kutateladze TG, 1999, MOL CELL, V3, P805, DOI 10.1016/S1097-2765(01)80013-7; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; Lawe DC, 2002, J BIOL CHEM, V277, P8611, DOI 10.1074/jbc.M109239200; Mao YX, 2000, CELL, V100, P447, DOI 10.1016/S0092-8674(00)80680-7; Mari M, 2001, J BIOL CHEM, V276, P42501, DOI 10.1074/jbc.M104885200; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Mills IG, 1998, CURR BIOL, V8, P881, DOI 10.1016/S0960-9822(07)00351-X; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Obaishi H, 1998, J BIOL CHEM, V273, P18697, DOI 10.1074/jbc.273.30.18697; Panopoulou E, 2002, J BIOL CHEM, V277, P18046, DOI 10.1074/jbc.M107983200; PASTERIS NG, 1994, CELL, V79, P669; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Patki V, 2001, MOL BIOL CELL, V12, P129, DOI 10.1091/mbc.12.1.129; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Raiborg C, 2001, J CELL SCI, V114, P2255; Ridley SH, 2001, J CELL SCI, V114, P3991; Rizzuto R, 1998, TRENDS CELL BIOL, V8, P288, DOI 10.1016/S0962-8924(98)01301-4; Sankaran VG, 2001, BIOCHEMISTRY-US, V40, P8581, DOI 10.1021/bi010425d; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Stahelin RV, 2002, J BIOL CHEM, V277, P26379, DOI 10.1074/jbc.M201106200; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Urbe S, 2000, MOL CELL BIOL, V20, P7685, DOI 10.1128/MCB.20.20.7685-7692.2000; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Yang W, 2000, J MED CHEM, V43, P1135, DOI 10.1021/jm9904396	44	90	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5958	5966		10.1074/jbc.M310503200	http://dx.doi.org/10.1074/jbc.M310503200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14594806	hybrid			2022-12-25	WOS:000188776500111
J	de Almodovar, CR; Ruiz-Ruiz, C; Rodriguez, A; Ortiz-Ferron, G; Redondo, JM; Lopez-Rivas, A				de Almodovar, CR; Ruiz-Ruiz, C; Rodriguez, A; Ortiz-Ferron, G; Redondo, JM; Lopez-Rivas, A			Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD95 GENE-EXPRESSION; NF-KAPPA-B; DEATH DOMAIN; DNA-DAMAGE; KILLER/DR5 GENE; BINDING-SITE; FAMILY; IDENTIFICATION; APO2L/TRAIL; INHIBITION	Tumor necrosis factor-related apoptosis-inducing ligand receptor 3 (TRAIL-R3) is a decoy receptor for TRAIL, a member of the tumor necrosis factor family. In several cell types decoy receptors inhibit TRAIL-induced apoptosis by binding TRAIL and thus preventing its binding to proapoptotic TRAIL receptors. We studied the regulation of TRAIL-R3 gene expression in breast tumor cells treated with the genotoxic drug doxorubicin (DXR). The breast tumor cell line MCF-7 (p53 wild type) responded to DXR with a marked elevation of TRAIL-R3 expression at the mRNA, total protein, and cell surface levels. In contrast, in EVSA-T cells (p53 mutant) DXR did not induce increased expression of TRAIL-R3. In MCF-7 cells overexpressing the human papillomavirus protein E6, which causes p53 degradation, DXR-induced TRAIL-R3 expression was notably reduced. Furthermore, in MCF-7 cells overexpressing a temperature-sensitive p53 mutant (Val(135)), shifting the cultures to the permissive temperature was sufficient to induce the expression of TRAIL-R3. We also cloned and characterized a p53 consensus element located within the first intron of the human TRAIL-R3 gene. This element binds p53 and confers responsiveness to genotoxic damage to constructs of the TRAIL-R3 promoter in transient transfection experiments. Our results indicate that genotoxic treatments such as DXR, frequently used in cancer therapy, may also induce genes such as TRAIL-R3 that potentially have antiapoptotic actions and thus interfere with the TRAIL signaling system. This is particularly important in view of the proposed use of TRAIL in antitumor therapy.	CSIC, Inst Parasitol & Biomed, Granada 18001, Spain; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; CNIC, Madrid 28049, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Centro Nacional de Investigaciones Cardiovasculares (CNIC)	Lopez-Rivas, A (corresponding author), CSIC, Inst Parasitol & Biomed, Calle Ventanilla 11, Granada 18001, Spain.	alrivas@ipb.csic.es	Redondo, Juan Miguel/H-6351-2015; Marquez, Antonio A. Rodriguez/L-2422-2013; Ruiz-Ruiz, Carmen/I-8792-2017; Lopez-Rivas, Abelardo/E-5115-2015	Redondo, Juan Miguel/0000-0001-5779-9122; Marquez, Antonio A. Rodriguez/0000-0003-2455-6583; Ruiz-Ruiz, Carmen/0000-0002-6243-6227; Ruiz de Almodovar, Carmen/0000-0001-5975-7815; Lopez-Rivas, Abelardo/0000-0002-9351-9690				Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; Bernard D, 2001, J BIOL CHEM, V276, P27322, DOI 10.1074/jbc.M011183200; BORRESEN AL, 1995, GENE CHROMOSOME CANC, V14, P71, DOI 10.1002/gcc.2870140113; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; de Almodovar CR, 2002, FEBS LETT, V531, P304, DOI 10.1016/S0014-5793(02)03544-5; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Guan BX, 2001, J CELL PHYSIOL, V188, P98, DOI 10.1002/jcp.1101; Keane MM, 1999, CANCER RES, V59, P734; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lorenzo E, 2002, J BIOL CHEM, V277, P10883, DOI 10.1074/jbc.M107442200; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Meng RD, 2000, MOL THER, V1, P130, DOI 10.1006/mthe.2000.0025; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Ruiz-Ruiz C, 2003, J BIOL CHEM, V278, P31667, DOI 10.1074/jbc.M304397200; Ruiz-Ruiz MD, 1999, CELL DEATH DIFFER, V6, P271, DOI 10.1038/sj.cdd.4400490; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Sheikh MS, 1999, ONCOGENE, V18, P4153, DOI 10.1038/sj.onc.1202763; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; van Noesel MM, 2002, CANCER RES, V62, P2157; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Zhang XD, 2000, FEBS LETT, V482, P193, DOI 10.1016/S0014-5793(00)02042-1; Zhang XD, 2000, J IMMUNOL, V164, P3961, DOI 10.4049/jimmunol.164.8.3961	41	37	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4093	4101		10.1074/jbc.M311243200	http://dx.doi.org/10.1074/jbc.M311243200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14623878	hybrid			2022-12-25	WOS:000188554300023
J	Fujiwara, K; Tenno, T; Sugasawa, K; Jee, JG; Ohki, I; Kojima, C; Tochio, H; Hiroaki, H; Hanaoka, F; Shirakawa, M				Fujiwara, K; Tenno, T; Sugasawa, K; Jee, JG; Ohki, I; Kojima, C; Tochio, H; Hiroaki, H; Hanaoka, F; Shirakawa, M			Structure of the ubiquitin-interacting motif of S5a bound to the ubiquitin-like domain of HR23B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; DNA-REPAIR; MOLECULAR-DYNAMICS; BINDS UBIQUITIN; RAD23 PROTEINS; NMR STRUCTURE; SUBUNIT; PROTEASOME; SURFACE; RECEPTOR	Ubiquitination, a modification in which single or multiple ubiquitin molecules are attached to a protein, serves signaling functions that control several cellular processes. The ubiquitination signal is recognized by downstream effectors, many of which carry a ubiquitin-interacting motif (UIM). Such interactions can be modulated by regulators carrying a ubiquitin-like (UbL) domain, which binds UIM by mimicking ubiquitination. Of them, HR23B regulates the proteasomal targeting of ubiquitinated substrates, DNA repair factors, and other proteins. Here we report the structure of the UIM of the proteasome subunit S5a bound to the UbL domain of HR23B. The UbL domain presents one hydrophobic and two polar contact sites for interaction with UIM. The residues in these contact sites are well conserved in ubiquitin, but ubiquitin also presents a histidine at the interface. The pH-dependent protonation of this residue interferes with the access of ubiquitin to the UIM and the ubiquitin-associated domain (UBA), and its mutation to a smaller residue increases the affinity of ubiquitin for UIM.	Yokohama City Univ, Grad Sch Integrated Sci, Kanagawa 2300045, Japan; Ehime Univ, Grad Sch Sci & Engn, Matsuyama, Ehime 7908577, Japan; RIKEN, Discovery Res Inst, Cellular Physiol Lab, Wako, Saitama 35101, Japan; RIKEN, Genom Sci Ctr, Kanagawa 2300045, Japan; Biomol Engn Res Inst, Dept Biol Struct, Osaka 5650874, Japan; Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan	Yokohama City University; Ehime University; RIKEN; RIKEN; Nara Institute of Science & Technology; Osaka University	Shirakawa, M (corresponding author), Yokohama City Univ, Grad Sch Integrated Sci, 1-7-29 Suehiro, Kanagawa 2300045, Japan.	shirakawa@tsurumi.yokohama-cu.ac.jp	Tochio, Hidehito/F-6109-2011; Kojima, Chojiro/AFV-4592-2022; Hiroaki, Hidekazu/G-9564-2012; Ohki, Izuru/C-7883-2013; HIROAKI, HIDEKAZU/N-1658-2019; Ohki, Izuru/O-4816-2019	HIROAKI, HIDEKAZU/0000-0003-1621-5893; Ohki, Izuru/0000-0002-0667-5936; Tochio, Hidehito/0000-0003-3843-3330; Kojima, Chojiro/0000-0003-2723-8249				Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Beal RE, 1998, BIOCHEMISTRY-US, V37, P2925, DOI 10.1021/bi972514p; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchberger A, 2002, TRENDS CELL BIOL, V12, P216, DOI 10.1016/S0962-8924(02)02269-9; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; COOK WJ, 1992, J BIOL CHEM, V267, P16467; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cornilescu G, 1998, J AM CHEM SOC, V120, P6836, DOI 10.1021/ja9812610; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Fisher RD, 2003, J BIOL CHEM, V278, P28976, DOI 10.1074/jbc.M302596200; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Gillette TG, 2001, GENE DEV, V15, P1528, DOI 10.1101/gad.869601; Guzder SN, 1998, J BIOL CHEM, V273, P31541, DOI 10.1074/jbc.273.47.31541; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Horst R, 2001, P NATL ACAD SCI USA, V98, P14374, DOI 10.1073/pnas.251532998; Johnson ES, 2002, NAT CELL BIOL, V4, pE295, DOI 10.1038/ncb1202-e295; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Merrill AR, 1997, BIOCHEMISTRY-US, V36, P6874, DOI 10.1021/bi970222i; Mueller TD, 2003, EMBO J, V22, P4634, DOI 10.1093/emboj/cdg467; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; Olson LJ, 2002, J BIOL CHEM, V277, P10156, DOI 10.1074/jbc.M112230200; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Ryu KS, 2003, J BIOL CHEM, V278, P36621, DOI 10.1074/jbc.M304628200; Sakata E, 2003, EMBO REP, V4, P301, DOI 10.1038/sj.embor.embor764; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Shekhtman A, 2002, BIOCHEM BIOPH RES CO, V296, P1222, DOI 10.1016/S0006-291X(02)02006-5; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Suzuki T, 2001, J BIOL CHEM, V276, P21601, DOI 10.1074/jbc.M100826200; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; Takahashi H, 2000, NAT STRUCT BIOL, V7, P220; Tashiro M, 2003, J BIOMOL NMR, V25, P153, DOI 10.1023/A:1022254432039; van Laar T, 2002, MUTAT RES-FUND MOL M, V499, P53, DOI 10.1016/S0027-5107(01)00291-3; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Varadan R, 2002, J MOL BIOL, V324, P637, DOI 10.1016/S0022-2836(02)01198-1; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; Withers-Ward ES, 2000, BIOCHEMISTRY-US, V39, P14103, DOI 10.1021/bi0017071; Xia B, 2002, J BIOMOL NMR, V22, P317, DOI 10.1023/A:1014929925008; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	54	73	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4760	4767		10.1074/jbc.M309448200	http://dx.doi.org/10.1074/jbc.M309448200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14585839	hybrid			2022-12-25	WOS:000188554300101
J	Hanna, E; Ng, KF; MacRae, IJ; Bley, CJ; Fisher, AJ; Segel, IH				Hanna, E; Ng, KF; MacRae, IJ; Bley, CJ; Fisher, AJ; Segel, IH			Kinetic and stability properties of Penicillium chrysogenum ATP sulfurylase missing the C-terminal regulatory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE 5'-PHOSPHOSULFATE KINASE; SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; ALLOSTERIC TRANSITIONS; FILAMENTOUS FUNGI; HXGH MOTIF; BINDING; ENZYME; PURIFICATION; INHIBITION	ATP sulfurylase from Penicillium chrysogenum is a homohexameric enzyme that is subject to allosteric inhibition by 3'-phosphoadenosine 5'-phosphosulfate. In contrast to the wild type enzyme, recombinant ATP sulfurylase lacking the C-terminal allosteric domain was monomeric and noncooperative. All k(cat) values were decreased (the adenosine 5'-phosphosulfate (adenylylsulfate) (APS) synthesis reaction to 17% of the wild type value). Additionally, the Michaelis constants for MgATP and sulfate (or molybdate), the dissociation constant of E-APS, and the monovalent oxyanion dissociation constants of dead end E-MgATP-oxyanion complexes were all increased. APS release (the h, step) was rate-limiting in the wild type enzyme. Without the C-terminal domain, the composite k(5) step (isomerization of the central complex and MgPPi release) became rate-limiting. The cumulative results indicate that besides (a) serving as a receptor for the allosteric inhibitor, the C-terminal domain (b) stabilizes the hexameric structure and indirectly, individual subunits. Additionally, (c) the domain interacts with and perfects the catalytic site such that one or more steps following the formation of the binary E-MgATP and E-SO42- complexes and preceding the release of MgPPi are optimized. The more negative entropy of activation of the truncated enzyme for APS synthesis is consistent with a role of the C-terminal domain in promoting the effective orientation of MgATP and sulfate at the active site.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Davis, Dept Chem, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Segel, IH (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, 1 Shields Ave, Davis, CA 95616 USA.	ihsegel@ucdavis.edu	Hanna, Ehab Y/B-1593-2017	Hanna, Ehab Y/0000-0003-3241-2440; Bley, Christopher/0000-0003-2301-1290; Fisher, Andrew/0000-0003-3488-6594				BALLIO A, 1959, SSPISS, V2, P343; BORK P, 1995, PROTEINS, V22, P259, DOI 10.1002/prot.340220306; CLELAND WW, 1967, ANNU REV BIOCHEM, V36, P77, DOI 10.1146/annurev.bi.36.070167.000453; Cox JM, 2003, BIOCHEMISTRY-US, V42, P1863, DOI 10.1021/bi027083b; DALEY LA, 1986, ANAL BIOCHEM, V157, P385, DOI 10.1016/0003-2697(86)90642-1; Daniels F., 1966, PHYS CHEM, P612; Deyrup AT, 1999, J BIOL CHEM, V274, P28929, DOI 10.1074/jbc.274.41.28929; FOSTER BA, 1994, J BIOL CHEM, V269, P19777; Hanna E, 2002, ARCH BIOCHEM BIOPHYS, V406, P275, DOI 10.1016/S0003-9861(02)00428-9; HANSON AD, 1994, P NATL ACAD SCI USA, V91, P306, DOI 10.1073/pnas.91.1.306; ITAHASHI M, 1961, J BIOCHEM, V50, P52, DOI 10.1093/oxfordjournals.jbchem.a127408; Lansdon EB, 2002, BIOCHEMISTRY-US, V41, P13672, DOI 10.1021/bi026556b; MacRae I, 1997, ARCH BIOCHEM BIOPHYS, V337, P17, DOI 10.1006/abbi.1996.9751; MacRae IJ, 1998, J BIOL CHEM, V273, P28583, DOI 10.1074/jbc.273.44.28583; MacRae IJ, 2000, J BIOL CHEM, V275, P36303, DOI 10.1074/jbc.M005992200; MacRae IJ, 2000, BIOCHEMISTRY-US, V39, P1613, DOI 10.1021/bi9924157; MacRae IJ, 2002, NAT STRUCT BIOL, V9, P945, DOI 10.1038/nsb868; MacRae IJ, 2001, FASEB J, V15, pA203; MacRae IJ, 2001, BIOCHEMISTRY-US, V40, P6795, DOI 10.1021/bi010367w; MEANS G E, 1971, P254; Medina DC, 2001, ARCH BIOCHEM BIOPHYS, V393, P51, DOI 10.1006/abbi.2001.2490; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PETTIGREW DW, 1977, J BIOL CHEM, V252, P4546; PIERCE, 1989, PIERCE HDB CATALOG, P210; RENOSTO F, 1985, J BIOL CHEM, V260, P1535; RENOSTO F, 1987, J BIOL CHEM, V262, P16279; RENOSTO F, 1977, ARCH BIOCHEM BIOPHYS, V180, P416, DOI 10.1016/0003-9861(77)90056-X; RENOSTO F, 1991, ARCH BIOCHEM BIOPHYS, V290, P66, DOI 10.1016/0003-9861(91)90592-7; RENOSTO F, 1990, J BIOL CHEM, V265, P10300; RENOSTO F, 1984, J BIOL CHEM, V259, P2113; RENOSTO F, 1993, ARCH BIOCHEM BIOPHYS, V307, P272, DOI 10.1006/abbi.1993.1590; RUBIN MM, 1966, J MOL BIOL, V21, P265, DOI 10.1016/0022-2836(66)90097-0; SATISHCHANDRAN C, 1992, BIOORG CHEM, V20, P107, DOI 10.1016/0045-2068(92)90031-W; SEGEL IH, 1987, METHOD ENZYMOL, V143, P334; SEGEL IH, 1976, BIOCH CALCULATIONS, P334; Segel IH., 1993, ENZYME KINETICS BEHA; SEUBERT PA, 1983, ARCH BIOCHEM BIOPHYS, V225, P679, DOI 10.1016/0003-9861(83)90079-6; SEUBERT PA, 1985, ARCH BIOCHEM BIOPHYS, V240, P509, DOI 10.1016/0003-9861(85)90057-8; STORER AC, 1976, BIOCHEM J, V159, P1; Ullrich TC, 2001, J MOL BIOL, V313, P1117, DOI 10.1006/jmbi.2001.5098; Ullrich TC, 2001, EMBO J, V20, P316, DOI 10.1093/emboj/20.3.316; Veitch DP, 1996, BIOCHEMISTRY-US, V35, P10743, DOI 10.1021/bi960402c; Venkatachalam KV, 1999, J BIOL CHEM, V274, P2601, DOI 10.1074/jbc.274.5.2601; WHITAKER JR, 1980, ANAL BIOCHEM, V109, P156, DOI 10.1016/0003-2697(80)90024-X; WOOD HG, 1966, J BIOL CHEM, V241, P5692; YU M, 1989, ARCH BIOCHEM BIOPHYS, V269, P156, DOI 10.1016/0003-9861(89)90096-9	46	17	18	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4415	4424		10.1074/jbc.M311317200	http://dx.doi.org/10.1074/jbc.M311317200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14613928	hybrid			2022-12-25	WOS:000188554300060
J	Shi, N; Ye, S; Bartlam, M; Yang, MJ; Wu, J; Liu, YW; Sun, F; Han, XQ; Peng, XZ; Qiang, BQ; Yuan, JG; Rao, ZH				Shi, N; Ye, S; Bartlam, M; Yang, MJ; Wu, J; Liu, YW; Sun, F; Han, XQ; Peng, XZ; Qiang, BQ; Yuan, JG; Rao, ZH			Structural basis for the specific recognition of RET by the Dok1 phosphotyrosine binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICING VARIANTS; PROTEIN; DISTINCT; KINASE; SHC; REGION; IRS-1	Dok1 is a common substrate of activated protein-tyrosine kinases. It is rapidly tyrosine-phosphorylated in response to receptor tyrosine activation and interacts with ras GTPase-activating protein and Nck, leading to inhibition of ras signaling pathway activation and the c-Jun N-terminal kinase (JNK) and c-Jun activation, respectively. In chronic myelogenous leukemia cells, it has shown constitutive phosphorylation. The N-terminal phosphotyrosine binding (PTB) domain of Dok1 can recognize and bind specifically to phosphotyrosine-containing motifs of receptors. Here we report the crystal structure of the Dok1 PTB domain alone and in complex with a phosphopeptide derived from RET receptor tyrosine kinase. The structure consists of a beta-sandwich composed of two nearly orthogonal, 7-stranded, antiparallel beta-sheets, and it is capped at one side by a C-terminal alpha-helix. The RET phosphopeptide binds to Dok1 via a surface groove formed between strand beta5 and the C-terminal alpha-helix of the PTB domain. The structures reveal the molecular basis for the specific recognition of RET by the Dok1 PTB domain. We also show that Dok1 does not recognize peptide sequences from TrkA and IL-4, which are recognized by She and IRS1, respectively.	Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol,Natl Human Genome Ctr, Inst Basic Med Sci,Peking Union Med Coll, Beijing 100005, Peoples R China; Tsinghua Univ, Struct Biol Lab, Beijing 100084, Peoples R China; Chinese Acad Sci, Natl Lab Biomacromol, Inst Biophys, Beijing 100084, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Tsinghua University; Chinese Academy of Sciences; Institute of Biophysics, CAS	Yuan, JG (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol,Natl Human Genome Ctr, Inst Basic Med Sci,Peking Union Med Coll, Beijing 100005, Peoples R China.	yuanjiangang@pumc.edu.cn; raozh@xtal.tsinghua.edu.cn	Sun, Fei/C-4190-2015; Sun, Fei/AAR-3186-2020; Rao, Zihe/HCH-6944-2022	Sun, Fei/0000-0002-0351-5144; Sun, Fei/0000-0002-0351-5144; Yang, Maojun/0000-0002-6798-3094; Bartlam, Mark/0000-0001-5173-5080				Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Carter MT, 2001, CYTOGENET CELL GENET, V95, P169, DOI 10.1159/000059341; Dhe-Paganon S, 1999, P NATL ACAD SCI USA, V96, P8378, DOI 10.1073/pnas.96.15.8378; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; Ivanchuk SM, 1998, ONCOGENE, V16, P991, DOI 10.1038/sj.onc.1201622; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kato I, 2002, J IMMUNOL, V168, P629, DOI 10.4049/jimmunol.168.2.629; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee DCW, 2002, ONCOGENE, V21, P5582, DOI 10.1038/sj.onc.1205741; Melillo RM, 2001, ONCOGENE, V20, P209, DOI 10.1038/sj.onc.1204049; Murakami H, 2002, J BIOL CHEM, V277, P32781, DOI 10.1074/jbc.M202336200; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Shah K, 2002, CHEM BIOL, V9, P35, DOI 10.1016/S1074-5521(02)00086-8; Songyang Z, 2001, J BIOL CHEM, V276, P2459, DOI 10.1074/jbc.M005504200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Watanabe T, 2002, AM J PATHOL, V161, P249, DOI 10.1016/S0002-9440(10)64176-4; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	28	27	30	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4962	4969		10.1074/jbc.M311030200	http://dx.doi.org/10.1074/jbc.M311030200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14607833	hybrid			2022-12-25	WOS:000188554300122
J	Uchida, Y; Ohba, K; Yoshioka, T; Irie, K; Muraki, T; Maru, Y				Uchida, Y; Ohba, K; Yoshioka, T; Irie, K; Muraki, T; Maru, Y			Cellular carbonyl stress enhances the expression of plasminogen activator inhibitor-1 in rat white adipocytes via reactive oxygen species-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; MOUSE MESANGIAL CELLS; SMOOTH-MUSCLE-CELLS; ENDOTHELIAL-CELLS; ADVANCED GLYCOSYLATION; OXIDATIVE STRESS; LIPID-PEROXIDATION; DIABETES-MELLITUS; VASCULAR-DISEASE; BINDING-PROTEINS	Carbonyl stress is one of the important mechanisms of tissue damage in vascular complications of diabetes. In the present study, we observed that the plasminogen activator inhibitor-1 (PAI-1) levels in serum and its gene expression in adipose tissue were up-regulated in aged OLETF rats, model animals of obese type 2 diabetes. To study the mechanism of PAI-1 up-regulation, we examined the effect of advanced glycation end products (AGES) and the product of lipid peroxidation (4-hydroxy-2-nonenal (HNE)), both of which are endogenously generated under carbonyl stress. Stimulation of primary white adipocytes by either AGE or HNE resulted in the elevation of PAI-1 in culture medium and at mRNA levels. The up-regulation of PAI-1 was also observed by incubating the cells in high glucose medium (30 mm, 48 h). The stimulatory effects by AGE or high glucose were inhibited by antioxidant, pyrrolidine dithiocarbamate, and reactive oxygen scavenger, probucol, suggesting a pivotal role of oxidative stress in white adipocytes. We also found that the effect by HNE was inhibited by antioxidant, N-acetylcysteine and that a specific inhibitor of glutathione biosynthesis, L-buthionine-S,R-sulfoximine, augmented the effect of subthreshold effect of HNE. Bioimaging of reactive oxygen species (ROS) by a fluorescent indicator, 6-carboxy-2',7'dichlorodihydrofluorescein diacetate, revealed ROS production in white adipocytes treated with AGE or HNE. These results suggest that cellular carbonyl stress induced by AGES or HNE may stimulate PAI-1 synthesis in and release from adipose tissues through ROS formation.	Tokyo Womens Med Univ, Sch Med, Dept Pharmacol, Shinjuku Ku, Tokyo 1628666, Japan; Tokyo Womens Med Univ, Sch Med, Dept Med Educ, Shinjuku Ku, Tokyo 1628666, Japan; Natl Inst Ind Hlth, Dept Work Stress Control, Tama Ku, Kawasaki, Kanagawa 2148585, Japan	Tokyo Women's Medical University; Tokyo Women's Medical University	Uchida, Y (corresponding author), Tokyo Womens Med Univ, Sch Med, Dept Pharmacol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	uchiy@research.twmu.ac.jp						Alessi MC, 1997, DIABETES, V46, P860, DOI 10.2337/diabetes.46.5.860; AUWERX J, 1988, ARTERIOSCLEROSIS, V8, P68, DOI 10.1161/01.ATV.8.1.68; Bierhaus A, 1997, CIRCULATION, V96, P2262; Bonnefont-Rousselot D, 2002, CURR OPIN CLIN NUTR, V5, P561, DOI 10.1097/00075197-200209000-00016; BRETT J, 1993, AM J PATHOL, V143, P1699; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Chen YQ, 1998, J BIOL CHEM, V273, P8225, DOI 10.1074/jbc.273.14.8225; Dandona P, 1996, LANCET, V347, P444, DOI 10.1016/S0140-6736(96)90013-6; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Eriksson P, 1998, DIABETOLOGIA, V41, P65, DOI 10.1007/s001250050868; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257; Higashi T, 1997, DIABETES, V46, P463, DOI 10.2337/diabetes.46.3.463; Hinokio Y, 1999, DIABETOLOGIA, V42, P995, DOI 10.1007/s001250051258; Huttunen HJ, 2002, J BIOL CHEM, V277, P38635, DOI 10.1074/jbc.M202515200; Ihara Y, 1999, DIABETES, V48, P927, DOI 10.2337/diabetes.48.4.927; KAWANO K, 1992, DIABETES, V41, P1422, DOI 10.2337/diabetes.41.11.1422; Keller JN, 1997, NEUROSCIENCE, V80, P685, DOI 10.1016/S0306-4522(97)00065-1; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; LANDIN K, 1990, METABOLISM, V39, P1044, DOI 10.1016/0026-0495(90)90164-8; Li JF, 1998, J BIOL CHEM, V273, P30870, DOI 10.1074/jbc.273.47.30870; Lin CH, 2002, EUR J PHARMACOL, V438, P143, DOI 10.1016/S0014-2999(02)01285-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGILL JB, 1994, DIABETES, V43, P104, DOI 10.2337/diabetes.43.1.104; Nakamura S, 1997, DIABETES, V46, P895, DOI 10.2337/diabetes.46.5.895; NouroozZadeh J, 1997, DIABETOLOGIA, V40, P647, DOI 10.1007/s001250050729; Page S, 1999, J BIOL CHEM, V274, P11611, DOI 10.1074/jbc.274.17.11611; PRYOR WA, 1990, FREE RADICAL BIO MED, V8, P541, DOI 10.1016/0891-5849(90)90153-A; Samad F, 1996, J CLIN INVEST, V97, P37, DOI 10.1172/JCI118404; Samad F, 1996, MOL MED, V2, P568, DOI 10.1007/BF03401641; SCHMIDT AM, 1994, P NATL ACAD SCI USA, V91, P8807, DOI 10.1073/pnas.91.19.8807; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SCHMIDT AM, 1993, J CLIN INVEST, V91, P2155, DOI 10.1172/JCI116442; Schneider C, 2001, J BIOL CHEM, V276, P20831, DOI 10.1074/jbc.M101821200; Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800; Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591; SPIEGELMAN BM, 1993, J BIOL CHEM, V268, P6823; Stitt AW, 1999, BIOCHEM BIOPH RES CO, V256, P549, DOI 10.1006/bbrc.1999.0291; Suzuki D, 2001, CONTRIB NEPHROL, V134, P36; Takahara N, 1997, DIABETOLOGIA, V40, P662, DOI 10.1007/s001250050731; Thornalley PJ, 1999, BIOCHEM J, V344, P109, DOI 10.1042/0264-6021:3440109; Tsuji H, 1998, BIOCHEM BIOPH RES CO, V245, P583, DOI 10.1006/bbrc.1998.8489; Tsuji T, 2001, J CARDIOVASC PHARM, V38, P868, DOI 10.1097/00005344-200112000-00008; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; VAGUE P, 1989, METABOLISM, V38, P913, DOI 10.1016/0026-0495(89)90241-2; VANLOON BJP, 1993, METABOLISM, V42, P945, DOI 10.1016/0026-0495(93)90005-9; Vlassara H, 1996, ANN MED, V28, P419, DOI 10.3109/07853899608999102; VLASSARA H, 1994, LAB INVEST, V70, P138; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; Yamagishi S, 1997, J BIOL CHEM, V272, P8723, DOI 10.1074/jbc.272.13.8723; Yamagishi S, 1998, DIABETOLOGIA, V41, P1435, DOI 10.1007/s001250051089; Yamagishi S, 1996, FEBS LETT, V384, P103, DOI 10.1016/0014-5793(96)00279-7	58	72	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4075	4083		10.1074/jbc.M304222200	http://dx.doi.org/10.1074/jbc.M304222200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14610081	hybrid			2022-12-25	WOS:000188554300021
J	Zaika, EI; Perlow, RA; Matz, E; Broyde, S; Gilboa, R; Grollman, AP; Zharkov, DO				Zaika, EI; Perlow, RA; Matz, E; Broyde, S; Gilboa, R; Grollman, AP; Zharkov, DO			Substrate discrimination by formamidopyrimidine-DNA glycosylase - A mutational analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ENDONUCLEASE-VIII; OXIDATIVELY DAMAGED DNA; DIFFUSION-DRIVEN MECHANISMS; REPRESSOR-OPERATOR INTERACTION; APURINIC APYRIMIDINIC SITES; BASE EXCISION-REPAIR; ESCHERICHIA-COLI; FPG PROTEIN; NUCLEIC-ACIDS; CRYSTAL-STRUCTURE	Formamidopyrimidine-DNA glycosylase (Fpg) is a primary participant in the repair of 8-oxoguanine, an abundant oxidative DNA lesion. Although the structure of Fpg has been established, amino acid residues that define damage recognition have not been identified. We have combined molecular dynamics and bioinformatics approaches to address this issue. Site-specific mutagenesis coupled with enzyme kinetics was used to test our predictions. On the basis of molecular dynamics simulations, Lys-217 was predicted to interact with the O(8) of extrahelical 8-oxoguanine accommodated in the binding pocket. Consistent with our computational studies, mutation of Lys-217 selectively reduced the ability of Fpg to excise 8-oxoguanine from DNA. Dihydrouracil, also a substrate for Fpg, served as a nonspecific control. Other residues involved in damage recognition (His-89, Arg-108, and Arg-109) were identified by combined conservation/structure analysis. Arg-108, which forms two hydrogen bonds with cytosine in Fpg-DNA, is a major determinant of opposite-base specificity. Mutation of this residue reduced excision of 8-oxoguanine from thermally unstable mispairs with guanine or thymine, while excision from the stable cytosine and adenine base pairs was less affected. Mutation of His-89 selectively diminished the rate of excision of 8-oxoguanine, whereas mutation of Arg-109 nearly abolished binding of Fpg to damaged DNA. Taken together, these results suggest that His-89 and Arg-109 form part of a reading head, a structural feature used by the enzyme to scan DNA for damage. His-89 and Lys-217 help determine the specificity of Fpg in recognizing the oxidatively damaged base, while Arg-108 provides specificity for bases positioned opposite the lesion.	SUNY Stony Brook, Dept Pharmacol Sci, Biol Chem Lab, Stony Brook, NY 11794 USA; NYU, Dept Biol, New York, NY 10003 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; Hebrew Univ Jerusalem, Dept Inorgan Chem, IL-91904 Jerusalem, Israel; Russian Acad Sci, SB, Inst Chem Biol & Fundamental Med, Novosibirsk 630090, Russia	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; New York University; United States Department of Energy (DOE); Brookhaven National Laboratory; Hebrew University of Jerusalem; Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences	Zharkov, DO (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Biol Chem Lab, Stony Brook, NY 11794 USA.	dzharkov@niboch.nsc.ru	Zharkov, Dmitry/K-2158-2012	Zharkov, Dmitry/0000-0001-5013-0194	NATIONAL CANCER INSTITUTE [R01CA017395, R37CA017395] Funding Source: NIH RePORTER; NCI NIH HHS [CA-17395] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Asagoshi K, 2002, J BIOL CHEM, V277, P14589, DOI 10.1074/jbc.M200316200; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; Bhagwat M, 1996, BIOCHEMISTRY-US, V35, P659, DOI 10.1021/bi9522662; Blaisdell JO, 1999, J BACTERIOL, V181, P6396, DOI 10.1128/JB.181.20.6396-6402.1999; BODEPUDI V, 1992, CHEM RES TOXICOL, V5, P608, DOI 10.1021/tx00029a004; BOITEUX S, 1983, BIOCHEM BIOPH RES CO, V110, P552, DOI 10.1016/0006-291X(83)91185-3; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; Buchko GW, 2002, J BIOMOL NMR, V22, P301, DOI 10.1023/A:1014903518628; Burgess S, 2002, J BIOL CHEM, V277, P2938, DOI 10.1074/jbc.M110499200; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; Cheatham TE, 1999, J BIOMOL STRUCT DYN, V16, P845, DOI 10.1080/07391102.1999.10508297; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; CULP SJ, 1989, CHEM RES TOXICOL, V2, P416, DOI 10.1021/tx00012a010; D'Ham C, 1999, BIOCHEMISTRY-US, V38, P3335, DOI 10.1021/bi981982b; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Dherin C, 1999, NUCLEIC ACIDS RES, V27, P4001, DOI 10.1093/nar/27.20.4001; Dinner AR, 2001, NATURE, V413, P752, DOI 10.1038/35099587; Dizdaroglu M, 2001, BIOCHEMISTRY-US, V40, P12150, DOI 10.1021/bi015552o; Fedorova OS, 2002, BIOCHEMISTRY-US, V41, P1520, DOI 10.1021/bi011524u; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Frisch M. J., 2001, GAUSSIAN; Fromme JC, 2003, J BIOL CHEM, V278, P51543, DOI 10.1074/jbc.M307768200; Fromme JC, 2002, NAT STRUCT BIOL, V9, P544, DOI 10.1038/nsb809; Fuxreiter M, 1999, BIOCHEMISTRY-US, V38, P9577, DOI 10.1021/bi9901937; Fuxreiter M, 2002, J MOL BIOL, V323, P823, DOI 10.1016/S0022-2836(02)00999-3; Gasparutto D, 2000, CHEM RES TOXICOL, V13, P575, DOI 10.1021/tx000005+; Gilboa R, 2002, J BIOL CHEM, V277, P19811, DOI 10.1074/jbc.M202058200; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; Guliaev AB, 2002, NUCLEIC ACIDS RES, V30, P3778, DOI 10.1093/nar/gkf494; Hang B, 2002, BIOCHEMISTRY-US, V41, P2158, DOI 10.1021/bi011542b; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; Hazra TK, 2002, J BIOL CHEM, V277, P30417, DOI 10.1074/jbc.C200355200; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; Hazra TK, 2000, J BIOL CHEM, V275, P27762; HINGERTY BE, 1985, BIOPOLYMERS, V24, P427, DOI 10.1002/bip.360240302; Ishchenko AA, 2002, BIOCHEMISTRY-US, V41, P7540, DOI 10.1021/bi0121297; Jiang DY, 1997, J BACTERIOL, V179, P3773, DOI 10.1128/jb.179.11.3773-3782.1997; Jiang DY, 1997, J BIOL CHEM, V272, P32230, DOI 10.1074/jbc.272.51.32230; Jiang YL, 2003, BIOCHEMISTRY-US, V42, P1922, DOI 10.1021/bi027014x; Karakaya A, 1997, NUCLEIC ACIDS RES, V25, P474, DOI 10.1093/nar/25.3.474; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; Lavrukhin OV, 2000, BIOCHEMISTRY-US, V39, P15266, DOI 10.1021/bi001587x; LIVINGSTONE CD, 1993, COMPUT APPL BIOSCI, V9, P745; Luscombe NM, 2001, NUCLEIC ACIDS RES, V29, P2860, DOI 10.1093/nar/29.13.2860; Mezei M, 1997, J COMPUT CHEM, V18, P812, DOI 10.1002/(SICI)1096-987X(19970430)18:6<812::AID-JCC6>3.0.CO;2-V; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; OCONNOR TR, 1988, NUCLEIC ACIDS RES, V16, P5879, DOI 10.1093/nar/16.13.5879; Parikh SS, 2000, P NATL ACAD SCI USA, V97, P5083, DOI 10.1073/pnas.97.10.5083; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Plum GE, 1995, BIOCHEMISTRY-US, V34, P16148, DOI 10.1021/bi00049a030; Purmal AA, 1998, J BIOL CHEM, V273, P10026, DOI 10.1074/jbc.273.16.10026; Rieger RA, 2000, J AM SOC MASS SPECTR, V11, P505, DOI 10.1016/S1044-0305(00)00117-3; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 2003, DNA REPAIR, V2, P581, DOI 10.1016/S1568-7864(03)00025-9; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Seibert E, 2002, BIOCHEMISTRY-US, V41, P10976, DOI 10.1021/bi026121o; Serre L, 2002, EMBO J, V21, P2854, DOI 10.1093/emboj/cdf304; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Sidorkina OM, 1998, NUCLEIC ACIDS RES, V26, P5351, DOI 10.1093/nar/26.23.5351; Sponer J, 2001, BIOPOLYMERS, V61, P3, DOI 10.1002/1097-0282(2001)61:1<3::AID-BIP10048>3.0.CO;2-4; STEENKEN S, 1989, CHEM REV, V89, P503, DOI 10.1021/cr00093a003; Sugahara M, 2000, EMBO J, V19, P3857, DOI 10.1093/emboj/19.15.3857; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; TCHOU J, 1994, J BIOL CHEM, V269, P15318; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; Wallace SS, 2002, FREE RADICAL BIO MED, V33, P1, DOI 10.1016/S0891-5849(02)00827-4; Wallace SS, 2003, DNA REPAIR, V2, P441, DOI 10.1016/S1568-7864(02)00182-9; Wiederholt CJ, 2002, J AM CHEM SOC, V124, P7278, DOI 10.1021/ja026522r; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6948, DOI 10.1021/bi00527a029; Wu XY, 1999, CHEM RES TOXICOL, V12, P895, DOI 10.1021/tx990108w; Zharkov DO, 1998, BIOCHEMISTRY-US, V37, P12384, DOI 10.1021/bi981066y; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335; Zharkov DO, 2002, EMBO J, V21, P789, DOI 10.1093/emboj/21.4.789; Zharkov DO, 2002, FREE RADICAL BIO MED, V32, P1254, DOI 10.1016/S0891-5849(02)00828-6	92	62	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4849	4861		10.1074/jbc.M310262200	http://dx.doi.org/10.1074/jbc.M310262200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14607836	hybrid			2022-12-25	WOS:000188554300110
J	Auster, AS; Joshua-Tor, L				Auster, AS; Joshua-Tor, L			The DNA-binding domain of human papillomavirus type 18 E1 - Crystal structure, dimerization, and DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E2 PROTEINS; REPLICATION; ORIGIN; INHIBITION; MOLSCRIPT; PROGRAM	High risk types of human papillomavirus, such as type 18 (HPV-18), cause cervical carcinoma, one of the most frequent causes of cancer death in women worldwide. DNA replication is one of the central processes in viral maintenance, and the machinery involved is an excellent target for the design of antiviral therapy. The papillomaviral DNA replication initiation protein E1 has origin recognition and ATP-dependent DNA melting and helicase activities, and it consists of a DNA-binding domain and an ATPase/helicase domain. While monomeric in solution, E1 binds DNA as a dimer. Dimerization occurs via an interaction of hydrophobic residues on a single alpha-helix of each monomer. Here we present the crystal structure of the monomeric HPV-18 E1 DNA-binding domain refined to 1.8-Angstrom resolution. The structure reveals that the dimerization helix is significantly different from that of bovine papillomavirus type 1 (BPV-1). However, we demonstrate that the analogous residues required for E1 dimerization in BPV-1 and the low risk HPV-11 are also required for HPV-18 E1. We also present evidence that the HPV-18 E1 DNA-binding domain does not share the same nucleotide and amino acid requirements for specific DNA recognition as BPV-1 and HPV-11 E1.	Cold Spring Harbor Lab, WM Keck Struct Biol Lab, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Grad Program Genet, Stony Brook, NY 11794 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Joshua-Tor, L (corresponding author), Cold Spring Harbor Lab, WM Keck Struct Biol Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	leemor@cshl.edu		Joshua-Tor, Leemor/0000-0001-8185-8049	NIAID NIH HHS [AI46724] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046724] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Berg M, 1997, J VIROL, V71, P3853, DOI 10.1128/JVI.71.5.3853-3863.1997; Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campos-Olivas R, 2002, P NATL ACAD SCI USA, V99, P10310, DOI 10.1073/pnas.152342699; CAREY M, 2000, TRANSCRIPTIONAL REGU, P257; Case D. A., 2002, AMBER 7; Chen G, 2002, MOL CELL BIOL, V22, P7712, DOI 10.1128/MCB.22.21.7712-7720.2002; Chen G, 2001, J VIROL, V75, P292, DOI 10.1128/JVI.75.1.292-302.2001; Chen G, 1998, J VIROL, V72, P2567, DOI 10.1128/JVI.72.4.2567-2576.1998; CRUM CP, 2003, J CLIN ONCOL, V21, P224; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; Dickerson RE, 1998, NUCLEIC ACIDS RES, V26, P1906, DOI 10.1093/nar/26.8.1906; Enemark EJ, 2000, MOL CELL, V6, P149, DOI 10.1016/S1097-2765(00)00016-2; Enemark EJ, 2002, EMBO J, V21, P1487, DOI 10.1093/emboj/21.6.1487; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fouts ET, 1999, J BIOL CHEM, V274, P4447, DOI 10.1074/jbc.274.7.4447; Gillitzer E, 2000, EMBO J, V19, P3069, DOI 10.1093/emboj/19.12.3069; Gonzalez A, 2000, J VIROL, V74, P245, DOI 10.1128/JVI.74.1.245-253.2000; Hickman AB, 2002, MOL CELL, V10, P327, DOI 10.1016/S1097-2765(02)00592-0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt G. J., 2001, INT TABLES CRYSTALLO, VF, P353, DOI DOI 10.1107/97809553602060000111; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LUSKY M, 1994, P NATL ACAD SCI USA, V91, P8895, DOI 10.1073/pnas.91.19.8895; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Sanders CM, 1998, EMBO J, V17, P7044, DOI 10.1093/emboj/17.23.7044; Sanders CM, 2000, J BIOL CHEM, V275, P3522, DOI 10.1074/jbc.275.5.3522; Sedman T, 1997, J VIROL, V71, P2887, DOI 10.1128/JVI.71.4.2887-2896.1997; Stenlund A, 2003, EMBO J, V22, P954, DOI 10.1093/emboj/cdg091; Titolo S, 2003, J VIROL, V77, P5178, DOI 10.1128/JVI.77.9.5178-5191.2003; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; West M, 2001, J VIROL, V75, P11948, DOI 10.1128/JVI.75.24.11948-11960.2001; White PW, 2003, J BIOL CHEM, V278, P26765, DOI 10.1074/jbc.M303608200; Wilson VG, 2002, VIRUS GENES, V24, P275, DOI 10.1023/A:1015336817836; Zimmerman JM, 2003, NUCLEIC ACIDS RES, V31, P5134, DOI 10.1093/nar/gkg697	39	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3733	3742		10.1074/jbc.M311681200	http://dx.doi.org/10.1074/jbc.M311681200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14593106	hybrid			2022-12-25	WOS:000188379600074
J	Liu, PS; Ying, YS; Zhao, YM; Mundy, DI; Zhu, MF; Anderson, RGW				Liu, PS; Ying, YS; Zhao, YM; Mundy, DI; Zhu, MF; Anderson, RGW			Chinese hamster ovary K2 cell lipid droplets appear to be metabolic organelles involved in membrane traffic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTERYL ESTER CYCLE; PLASMA-MEMBRANE; RAB GTPASES; PROTEINS; IDENTIFICATION; LOCALIZATION; CAVEOLIN; GENE; TRANSPORT; ENCODES	The principal lipids in animal cell lipid droplets are cholesterol, cholesterol ester, and triglyceride, but the protein composition of this compartment is largely unknown. Here we report on the proteomic analysis of lipid droplets. Using a combination of mass spectrometry and immunoblotting, we identify nearly 40 specifically associated proteins in droplets isolated from Chinese hamster ovary K2 cells grown in normal medium. The proteins fall in to five groups: structural molecules of the droplet-like adipose differentiation-related protein; multiple enzymes involved in the synthesis, storage, utilization, and degradation of cholesterol esters and triglycerides; multiple, different Rab GTPases known to be involved in regulating membrane traffic; signaling molecules such as p50RhoGAP; and a group of proteins that do not fit any classification but include proteins often found in caveolae/rafts such as caveolin-1 and 2 and flotillin-1. The proteome of droplets isolated from cells grown in the presence of oleate is largely the same except for an increase in the amount of adipose differentiation-related protein, caveolin-1, and a protein thought to be involved in phospholipid recycling called CGI-58. Based on the protein profile, the lipid droplet appears to be a complex, metabolically active organelle that is directly involved in membrane traffic and possibly phospholipid recycling. We propose the name adiposome for this organelle.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Anderson, RGW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA.	richard.anderson@utsouthwestern.edu	Liu, Pingsheng/B-7124-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052016] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline; NIGMS NIH HHS [GM 52016] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Athenstaedt K, 2003, J BIOL CHEM, V278, P23317, DOI 10.1074/jbc.M302577200; Athenstaedt K, 1999, J BACTERIOL, V181, P6441, DOI 10.1128/JB.181.20.6441-6448.1999; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; Bathori G, 1999, J BIOL CHEM, V274, P29607, DOI 10.1074/jbc.274.42.29607; Baulande S, 2001, J BIOL CHEM, V276, P33336, DOI 10.1074/jbc.M105193200; BROWN MS, 1980, J BIOL CHEM, V255, P9344; Buettner R, 2000, P NATL ACAD SCI USA, V97, P3201, DOI 10.1073/pnas.060242297; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; FAWCETT DW, 1981, CELL, P655; Ferl RJ, 2002, GENOME BIOL, V3; Fivaz M, 2000, ELECTROPHORESIS, V21, P3351, DOI 10.1002/1522-2683(20001001)21:16<3351::AID-ELPS3351>3.3.CO;2-B; Hammer JA, 2002, CURR OPIN CELL BIOL, V14, P69, DOI 10.1016/S0955-0674(01)00296-4; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Igal RA, 1998, J LIPID RES, V39, P31; Imai Y, 2002, BIOCHEM BIOPH RES CO, V297, P1282, DOI 10.1016/S0006-291X(02)02380-X; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; Lefevre C, 2001, AM J HUM GENET, V69, P1002, DOI 10.1086/324121; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; May C, 1998, BBA-LIPID LIPID MET, V1393, P267, DOI 10.1016/S0005-2760(98)00081-2; MCGOOKEY DJ, 1983, J CELL BIOL, V97, P1156, DOI 10.1083/jcb.97.4.1156; McManaman JL, 2003, J LIPID RES, V44, P668, DOI 10.1194/jlr.C200021-JLR200; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; MUNDY DI, 1992, J CELL BIOL, V116, P135, DOI 10.1083/jcb.116.1.135; Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3; Ohashi M, 2003, J BIOL CHEM, V278, P36819, DOI 10.1074/jbc.M301408200; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Schnabl M, 2003, EUR J BIOCHEM, V270, P3133, DOI 10.1046/j.1432-1033.2003.03688.x; Seabra MC, 2002, TRENDS MOL MED, V8, P23, DOI 10.1016/S1471-4914(01)02227-4; Shewry PR, 2003, ANN BOT-LONDON, V91, P755, DOI 10.1093/aob/mcg084; Tauchi-Sato K, 2002, J BIOL CHEM, V277, P44507, DOI 10.1074/jbc.M207712200; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; van Meer G, 2001, J CELL BIOL, V152, pF29, DOI 10.1083/jcb.152.5.F29; Wu CC, 2000, ELECTROPHORESIS, V21, P3470, DOI 10.1002/1522-2683(20001001)21:16<3470::AID-ELPS3470>3.3.CO;2-7; Zhang W, 2003, ELECTROPHORESIS, V24, P2855, DOI 10.1002/elps.200305569	38	426	447	4	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3787	3792		10.1074/jbc.M311945200	http://dx.doi.org/10.1074/jbc.M311945200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14597625	hybrid			2022-12-25	WOS:000188379600080
J	Zhang, SP; Scheller, HV				Zhang, SP; Scheller, HV			Light-harvesting complex II binds to several small Subunits of photosystem I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL-A/B-PROTEIN; PHOTOSYNTHETIC STATE TRANSITIONS; CYANOBACTERIUM SYNECHOCYSTIS SP; PSI-H SUBUNIT; LHC-II; ARABIDOPSIS-THALIANA; THYLAKOID STRUCTURE; EXCITATION-ENERGY; ELECTRON FLOW; BARLEY LEAVES	Mobile light-harvesting complex II (LHCII) is implicated in the regulation of excitation energy distribution between Photosystem I (PSI) and Photosystem II (PSII) during state transitions. To investigate how LHCII interacts with PSI during state transitions, PSI was isolated from Arabidopsis thaliana plants treated with PSII or PSI light. The PSI preparations were made using digitonin. Chemical cross-linking using dithio-bis(succinimidylpropionate) followed by diagonal electrophoresis and immunoblotting showed that the docking site of LHCII (Lhcb1) on PSI is comprised of the PSI-H, -L, and -I subunits. This was confirmed by the lack of energy transfer from LHCII to PSI in the digitonin-PSI isolated from plants lacking PSI-H and -L. Digitonin-PSI was purified further to obtain an LHCII.PSI complex, and two to three times more LHCII was associated with PSI in the wild type in State 2 than in State 1. Lhcb1 was also associated with PSI from plants lacking PSI-K, but PSI from PSI-H, -L, or -O mutants contained only about 30% of Lhcb1 compared with the wild type. Surprisingly, a significant fraction of the LHCII bound to PSI in State 2 was not phosphorylated. Cross-linking prior to sucrose gradient purification resulted in copurification of phosphorylated LHCII in the wild type, but not with PSI from the PSI-H, -L, and -O mutants. The data suggest that migration of LHCII during state transitions cannot be explained sufficiently by different affinity of phosphorylated and unphosphorylated LHCII for PSI but is likely to involve structural changes in thylakoid organization.	Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, DK-1871 Frederiksberg C, Denmark	University of Copenhagen	Scheller, HV (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, 40 Thorvaldsensvej, DK-1871 Frederiksberg C, Denmark.	hvs@kvl.dk	Scheller, Henrik/AAH-4770-2020; Scheller, Henrik V/A-8106-2008	Scheller, Henrik/0000-0002-6702-3560; Scheller, Henrik V/0000-0002-6702-3560				ALLEN JF, 1981, NATURE, V291, P25, DOI 10.1038/291025a0; Allen JF, 2001, TRENDS PLANT SCI, V6, P317, DOI 10.1016/S1360-1385(01)02010-6; Allen JF, 2003, SCIENCE, V299, P1530, DOI 10.1126/science.1082833; ANDERSEN B, 1992, PHYSIOL PLANTARUM, V84, P154, DOI 10.1111/j.1399-3054.1992.tb08778.x; BARBER J, 1982, ANNU REV PLANT PHYS, V33, P261, DOI 10.1146/annurev.pp.33.060182.001401; BASSI R, 1987, EUR J BIOCHEM, V163, P221, DOI 10.1111/j.1432-1033.1987.tb10791.x; BENNETT J, 1983, BIOCHEM J, V212, P1; BENNETT J, 1984, PHYSIOL PLANTARUM, V60, P583, DOI 10.1111/j.1399-3054.1984.tb04932.x; Boekema EJ, 2000, J MOL BIOL, V301, P1123, DOI 10.1006/jmbi.2000.4037; Boekema EJ, 1999, BIOCHEMISTRY-US, V38, P2233, DOI 10.1021/bi9827161; Boekema EJ, 1999, EUR J BIOCHEM, V266, P444, DOI 10.1046/j.1432-1327.1999.00876.x; Boekema EJ, 2001, BIOCHEMISTRY-US, V40, P1029, DOI 10.1021/bi0015358; BONAVENTURA C, 1969, BIOCHIM BIOPHYS ACTA, V189, P366, DOI 10.1016/0005-2728(69)90168-6; Bukhov N, 2002, PLANTA, V215, P812, DOI 10.1007/s00425-002-0808-3; Chitnis PR, 2001, ANNU REV PLANT PHYS, V52, P593, DOI 10.1146/annurev.arplant.52.1.593; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; Depege N, 2003, SCIENCE, V299, P1572, DOI 10.1126/science.1081397; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Haldrup A, 2001, TRENDS PLANT SCI, V6, P301, DOI 10.1016/S1360-1385(01)01953-7; Haldrup A, 1999, PLANT J, V17, P689, DOI 10.1046/j.1365-313X.1999.00419.x; Jackowski G, 2001, BBA-BIOENERGETICS, V1504, P340, DOI 10.1016/S0005-2728(00)00262-0; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; Jensen PE, 2000, J BIOL CHEM, V275, P24701, DOI 10.1074/jbc.M000550200; Jensen PE, 2002, J BIOL CHEM, V277, P2798, DOI 10.1074/jbc.M110448200; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Knoetzel H, 2002, FEBS LETT, V510, P145, DOI 10.1016/S0014-5793(01)03253-7; LARSSON UK, 1987, BIOCHIM BIOPHYS ACTA, V894, P69, DOI 10.1016/0005-2728(87)90213-1; LARSSON UK, 1983, EUR J BIOCHEM, V136, P25, DOI 10.1111/j.1432-1033.1983.tb07700.x; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; Lunde C, 2000, NATURE, V408, P613, DOI 10.1038/35046121; Lunde C, 2003, PLANT CELL PHYSIOL, V44, P44, DOI 10.1093/pcp/pcg012; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; Munekage Y, 2002, CELL, V110, P361, DOI 10.1016/S0092-8674(02)00867-X; MURATA N, 1969, BIOCHIM BIOPHYS ACTA, V172, P242, DOI 10.1016/0005-2728(69)90067-X; Naver H, 1999, J BIOL CHEM, V274, P10784, DOI 10.1074/jbc.274.16.10784; Pesaresi P, 2002, PLANTA, V215, P940, DOI 10.1007/s00425-002-0835-0; Pfannschmidt T, 1999, NATURE, V397, P625, DOI 10.1038/17624; QUICK WP, 1989, BIOCHIM BIOPHYS ACTA, V977, P287, DOI 10.1016/S0005-2728(89)80082-9; Rintamaki E, 1997, J BIOL CHEM, V272, P30476, DOI 10.1074/jbc.272.48.30476; Scheller HV, 2001, BBA-BIOENERGETICS, V1507, P41, DOI 10.1016/S0005-2728(01)00196-7; Snyders S, 2001, J BIOL CHEM, V276, P32169, DOI 10.1074/jbc.M102539200; Snyders S, 1999, J BIOL CHEM, V274, P9137, DOI 10.1074/jbc.274.14.9137; WALTERS RG, 1991, PHOTOSYNTH RES, V27, P121, DOI 10.1007/BF00033251; WILLIAMS RS, 1987, FEBS LETT, V225, P59, DOI 10.1016/0014-5793(87)81131-6; XU Q, 1995, J BIOL CHEM, V270, P16243, DOI 10.1074/jbc.270.27.16243; Yakushevska AE, 2001, EUR J BIOCHEM, V268, P6020, DOI 10.1046/j.0014-2956.2001.02505.x; Yang DH, 1998, PLANT PHYSIOL, V118, P827, DOI 10.1104/pp.118.3.827	47	99	108	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3180	3187		10.1074/jbc.M311640200	http://dx.doi.org/10.1074/jbc.M311640200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14617624	hybrid			2022-12-25	WOS:000188379600007
J	Sun, XK; Fontaine, JM; Rest, JS; Shelden, EA; Welsh, MJ; Benndorf, R				Sun, XK; Fontaine, JM; Rest, JS; Shelden, EA; Welsh, MJ; Benndorf, R			Interaction of human HSP22 (HSPB8) with other small heat shock proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; RESONANCE ENERGY-TRANSFER; NECROSIS-FACTOR-ALPHA; SMALL STRESS-PROTEIN; A-CRYSTALLIN; PHOSPHORYLATION; CELLS; IDENTIFICATION; KINASE; MEMBER	Mammalian small heat shock proteins ( sHSP) are abundant in muscles and are implicated in both muscle function and myopathies. Recently a new sHSP, HSP22 (HSPB8, H11), was identified in the human heart by its interaction with HSP27 (HSPB1). Using phylogenetic analysis we show that HSP22 is a true member of the sHSP superfamily. sHSPs interact with each other and form homo- and hetero-oligomeric complexes. The function of these complexes is poorly understood. Using gel filtration HPLC, the yeast two-hybrid method, immunoprecipitation, cross-linking, and fluorescence resonance energy transfer microscopy, we report that (i) HSP22 forms high molecular mass complexes in the heart, (ii) HSP22 interacts with itself, cvHSP (HSPB7), MKBP (HSPB2) and HSP27, and (iii) HSP22 has two binding domains (N- and C-terminal) that are specific for different binding partners. HSP22 homo- dimers are formed through N- N and N- C interactions, and HSP22-cvHSP hetero-dimers through C-C interaction. HSP22-MKBP and HSP22-HSP27 hetero-dimers involve the N and C termini of HSP22 and HSP27, respectively, but appear to require full-length protein as a binding partner.	Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Museum Zool, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Benndorf, R (corresponding author), Univ Michigan, Sch Med, Dept Cell & Dev Biol, 1335 Catherine St, Ann Arbor, MI 48109 USA.	rbenndo@umich.edu	, Eric/GWC-7636-2022; Welsh, Michael/B-1968-2008	Rest, Joshua/0000-0002-9582-1041	NIEHS NIH HHS [P01ES11188, 5R01ES011196-02] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011196, P01ES011188] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; AUGUSTEYN RC, 1993, BIOCHIM BIOPHYS ACTA, V1162, P61, DOI 10.1016/0167-4838(93)90128-E; Aurelian L, 2001, J INVEST DERMATOL, V116, P286, DOI 10.1046/j.1523-1747.2001.00191.x; Beall A, 1999, J BIOL CHEM, V274, P11344, DOI 10.1074/jbc.274.16.11344; Benndorf R, 2001, J BIOL CHEM, V276, P26753, DOI 10.1074/jbc.M103001200; Boelens WC, 1998, J BIOL CHEM, V273, P28085, DOI 10.1074/jbc.273.43.28085; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Charpentier AH, 2000, CANCER RES, V60, P5977; Depre C, 2002, CIRC RES, V91, P1007, DOI 10.1161/01.RES.0000044380.54893.4B; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Fontaine JM, 2003, CELL STRESS CHAPERON, V8, P62, DOI 10.1379/1466-1268(2003)8<62:TSODFP>2.0.CO;2; Hoppe A, 2002, BIOPHYS J, V83, P3652, DOI 10.1016/S0006-3495(02)75365-4; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; Kappe G, 2001, BBA-GENE STRUCT EXPR, V1520, P1, DOI 10.1016/S0167-4781(01)00237-8; KATO K, 1994, J BIOL CHEM, V269, P11274; Krief S, 1999, J BIOL CHEM, V274, P36592, DOI 10.1074/jbc.274.51.36592; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; Liu CH, 1999, BIOCHEM BIOPH RES CO, V255, P256, DOI 10.1006/bbrc.1999.0174; Lutsch G, 1997, CIRCULATION, V96, P3466; Martin JL, 1997, CIRCULATION, V96, P4343; Maslov S, 2002, SCIENCE, V296, P910, DOI 10.1126/science.1065103; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; SIEGEL RM, 2000, SCI STKE, V38, P1; Smith CC, 2000, J BIOL CHEM, V275, P25690, DOI 10.1074/jbc.M002140200; Sugiyama Y, 2000, J BIOL CHEM, V275, P1095, DOI 10.1074/jbc.275.2.1095; Sun TX, 1998, J BIOL CHEM, V273, P286, DOI 10.1074/jbc.273.1.286; Suzuki A, 1998, J CELL BIOL, V140, P1113, DOI 10.1083/jcb.140.5.1113; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wotton D, 1996, J BIOL CHEM, V271, P2717, DOI 10.1074/jbc.271.5.2717; Yamboliev IA, 2000, AM J PHYSIOL-HEART C, V278, pH1899, DOI 10.1152/ajpheart.2000.278.6.H1899; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	34	116	126	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2394	2402		10.1074/jbc.M311324200	http://dx.doi.org/10.1074/jbc.M311324200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14594798	hybrid			2022-12-25	WOS:000188211300010
J	Nishitai, G; Shimizu, N; Negishi, T; Kishimoto, H; Nakagawa, K; Kitagawa, D; Watanabe, T; Momose, H; Ohata, S; Tanemura, S; Asaka, S; Kubota, J; Saito, R; Yoshida, H; Mak, TW; Wada, T; Penninger, JM; Azuma, N; Nishina, H; Katada, T				Nishitai, G; Shimizu, N; Negishi, T; Kishimoto, H; Nakagawa, K; Kitagawa, D; Watanabe, T; Momose, H; Ohata, S; Tanemura, S; Asaka, S; Kubota, J; Saito, R; Yoshida, H; Mak, TW; Wada, T; Penninger, JM; Azuma, N; Nishina, H; Katada, T			Stress induces mitochondria-mediated apoptosis independent of SAPK/JNK activation in embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE SAPK/JNK; N-TERMINAL KINASE; SYNERGISTIC ACTIVATION; SIGNAL-TRANSDUCTION; JNK; SEK1; PHOSPHORYLATION; PROLIFERATION; RECEPTOR; LACKING	SAPK/JNK, which belongs to the family of mitogen-activated protein kinase ( MAPK), is activated by many types of cellular stresses or extracellular signals and is involved in embryonic development, immune responses, and cell survival or apoptosis. However, the physiological roles of SAPK/JNK in the signaling of stress-induced apoptosis are still controversial. To evaluate the precise function, SAPK/JNK-inactivated mouse embryonic stem (ES) cells were generated by disrupting genes of the MAPK activators, SEK1 and MKK7. Although SAPK/JNK activation by various stresses was completely abolished in sek1(-/-) mkk7(-/-) ES cells, apoptotic responses including DNA fragmentation and caspase 3 activation still occurred normally, which displays a sharp contrast to apaf1(-/-) ES cells exhibiting profound defects in the mitochondria-dependent apoptosis. These normal apoptotic responses without SAPK/JNK activation were also observed in fibroblasts derived from sek1(-/-) mkk7(-/-) ES cells. Instead, interleukin-1beta (IL-1beta)- induced IL-6 gene expression was greatly suppressed in sek1(-/-) mkk7(-/-) fibroblasts. These results clearly show that SAPK/JNK activation is responsible for the inflammatory cytokine-induced gene expression but not essentially required for the mitochondria-dependent apoptosis at least in ES or fibroblast-like cells, which are prototypes of all cell lineages.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, Tokyo 1130033, Japan; Saga Med Sch, Dept Biomol Sci, Saga 8498501, Japan; Univ Turin, Univ Hlth Network, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Turin, Univ Hlth Network, Dept Immunol, Toronto, ON M5G 2C1, Canada; Natl Ctr Child Hlth & Dev, Dept Ophthalmol, Setagaya Ku, Tokyo 1578535, Japan	University of Tokyo; Saga University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Turin; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Turin; National Center for Child Health & Development - Japan	Nishina, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	nishina@mol.f.u-tokyo.ac.jp	Ohata, Shinya/S-2320-2018; Penninger, Josef M/I-6860-2013	Ohata, Shinya/0000-0003-4333-4433; Penninger, Josef M/0000-0002-8194-3777				Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Conze D, 2002, J EXP MED, V195, P811, DOI 10.1084/jem.20011508; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Holtmann H, 2001, J BIOL CHEM, V276, P3508, DOI 10.1074/jbc.M004376200; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kishimoto H, 2003, J BIOL CHEM, V278, P16595, DOI 10.1074/jbc.M213182200; Kitagawa D, 2002, J BIOL CHEM, V277, P366, DOI 10.1074/jbc.M107110200; Krause A, 1998, J BIOL CHEM, V273, P23681, DOI 10.1074/jbc.273.37.23681; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Nishina H, 1997, J EXP MED, V186, P941, DOI 10.1084/jem.186.6.941; Nishina H, 1999, DEVELOPMENT, V126, P505; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Wada T, 2001, J BIOL CHEM, V276, P30892, DOI 10.1074/jbc.M011780200; Watanabe T, 2002, DEV BIOL, V250, P332, DOI 10.1006/dbio.2002.0781; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	32	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1621	1626		10.1074/jbc.M310335200	http://dx.doi.org/10.1074/jbc.M310335200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14585831	hybrid			2022-12-25	WOS:000188005700009
J	Frick, DN; Rypma, RS; Lam, AMI; Gu, BH				Frick, DN; Rypma, RS; Lam, AMI; Gu, BH			The nonstructural protein 3 protease/helicase requires an intact protease domain to unwind duplex RNA efficiently	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; HELICASES DISPLACE STREPTAVIDIN; CELL-CULTURE ADAPTATION; ESCHERICHIA-COLI UVRD; NS3 PROTEIN; CRYSTAL-STRUCTURE; NUCLEOSIDE TRIPHOSPHATASE; ENZYMATIC-ACTIVITIES; KINETIC-ANALYSIS; DNA HELICASE	The nonstructural 3 (NS3) protein encoded by the hepatitis C virus possesses both an N-terminal serine protease activity and a C-terminal 3'-5' helicase activity. This study examines the effects of the protease on the helicase by comparing the enzymatic properties of the full-length NS3 protein with truncated versions in which the protease is either deleted or replaced by a polyhistidine (His tag) or a glutathione S-transferase fusion protein (GST tag). When the NS3 protein lacks the protease domain it unwinds RNA more slowly and does not unwind RNA in the presence of excess nucleic acid that acts as an enzyme trap. Some but not all of the RNA helicase activity can be restored by adding a His tag or GST tag to the N terminus of the truncated helicase, suggesting that the effects of the protease are both specific and nonspecific. Similar but smaller effects are also seen in DNA helicase and translocation assays. While translocating on RNA ( or DNA) the full-length protein hydrolyzes ATP more slowly than the truncated protein, suggesting that the protease allows for more efficient ATP usage. Binding assays reveal that the full-length protein assembles on single-stranded DNA as a higher order oligomer than the truncated fragment, and the binding appears to be more cooperative. The data suggest that hepatitis C virus RNA helicase, and therefore viral replication, could be influenced by the rotations of the protease domain which likely occur during polyprotein processing.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA; Jefferson Ctr Biomed Res, Dept Biochem & Mol Biol, Doylestown, PA 18901 USA	New York Medical College; Jefferson University	Frick, DN (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.	David_Frick@NYMC.edu		Frick, David/0000-0002-2434-7223	NIAID NIH HHS [R01 AI052395-01A1, R01 AI052395-03, R01 AI052395, AI052395, R01 AI052395-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052395] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; Banerjee R, 2001, J VIROL, V75, P1708, DOI 10.1128/JVI.75.4.1708-1721.2001; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Bukh J, 2002, P NATL ACAD SCI USA, V99, P14416, DOI 10.1073/pnas.212532699; Chao L, 1999, J VIROL, V73, P8798, DOI 10.1128/JVI.73.10.8798-8807.1999; Cho HS, 1998, J BIOL CHEM, V273, P15045, DOI 10.1074/jbc.273.24.15045; Du MX, 2002, BIOCHEM J, V363, P147, DOI 10.1042/0264-6021:3630147; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; Flajolet M, 2000, GENE, V242, P369, DOI 10.1016/S0378-1119(99)00511-9; FRICK DN, 2003, IN PRESS CURR ORG CH, V7; Gallinari P, 1999, BIOCHEMISTRY-US, V38, P5620, DOI 10.1021/bi982892+; Gallinari P, 1998, J VIROL, V72, P6758, DOI 10.1128/JVI.72.8.6758-6769.1998; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; Grobler JA, 2003, J BIOL CHEM, V278, P16741, DOI 10.1074/jbc.M212602200; Gu BH, 2003, J VIROL, V77, P5352, DOI 10.1128/JVI.77.9.5352-5359.2003; Gwack Y, 1997, EUR J BIOCHEM, V250, P47, DOI 10.1111/j.1432-1033.1997.00047.x; Heilek GM, 1997, J VIROL, V71, P6264, DOI 10.1128/JVI.71.8.6264-6266.1997; Howe AYM, 1999, PROTEIN SCI, V8, P1332, DOI 10.1110/ps.8.6.1332; JIN L, 1995, ARCH BIOCHEM BIOPHYS, V323, P47, DOI 10.1006/abbi.1995.0008; Khu YL, 2001, J VIROL, V75, P205, DOI 10.1128/JVI.75.1.205-214.2001; Kim DW, 1997, VIRUS RES, V49, P17, DOI 10.1016/S0168-1702(97)01452-4; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Lam AMI, 2003, J BIOL CHEM, V278, P44514, DOI 10.1074/jbc.M306444200; Lam AMI, 2003, J VIROL, V77, P3950, DOI 10.1128/JVI.77.7.3950-3961.2003; Levin MK, 1999, J BIOL CHEM, V274, P31839, DOI 10.1074/jbc.274.45.31839; Levin MK, 2003, J BIOL CHEM, V278, P23311, DOI 10.1074/jbc.M301283200; Levin MK, 2002, J BIOL CHEM, V277, P29377, DOI 10.1074/jbc.M112315200; Locatelli GA, 2002, BIOCHEMISTRY-US, V41, P10332, DOI 10.1021/bi026082g; Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001; Maluf NK, 2003, J MOL BIOL, V325, P913, DOI 10.1016/S0022-2836(02)01277-9; Morris PD, 1999, BIOCHEMISTRY-US, V38, P5164, DOI 10.1021/bi9822269; Morris PD, 2002, BIOCHEMISTRY-US, V41, P2372, DOI 10.1021/bi012058b; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pang PS, 2002, EMBO J, V21, P1168, DOI 10.1093/emboj/21.5.1168; Paolini C, 2000, J GEN VIROL, V81, P1335, DOI 10.1099/0022-1317-81-5-1335; Piccininni S, 2002, J BIOL CHEM, V277, P45670, DOI 10.1074/jbc.M204124200; Porter DJT, 1998, J BIOL CHEM, V273, P18906, DOI 10.1074/jbc.273.30.18906; Preugschat F, 2000, BIOCHEMISTRY-US, V39, P5174, DOI 10.1021/bi9923860; Preugschat F, 1996, J BIOL CHEM, V271, P24449, DOI 10.1074/jbc.271.40.24449; Sali DL, 1998, BIOCHEMISTRY-US, V37, P3392, DOI 10.1021/bi972010r; Silverman E, 2003, GENE, V312, P1, DOI 10.1016/S0378-1119(03)00626-7; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; Tan SL, 2002, NAT REV DRUG DISCOV, V1, P867, DOI 10.1038/nrd937; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463	48	87	91	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1269	1280		10.1074/jbc.M310630200	http://dx.doi.org/10.1074/jbc.M310630200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14585830	Green Accepted, hybrid			2022-12-25	WOS:000187722800053
J	Wischhusen, J; Naumann, U; Ohgaki, H; Rastinejad, F; Weller, M				Wischhusen, J; Naumann, U; Ohgaki, H; Rastinejad, F; Weller, M			CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death	ONCOGENE			English	Article						p53; glioma; CP-31398; conformation; drug engineering	WILD-TYPE P53; IN-VITRO; P53-INDUCED APOPTOSIS; CANCER-CELLS; MUTANT P53; DNA-DAMAGE; GENE; EXPRESSION; DRUG; PROTEIN	CP-31398 is a prototype small molecule that stabilizes the active conformation of p53 and promotes p53 activity in cancer cell lines with mutant or wild-type p53. Here, we report that CP-31398 induces p53 reporter gene activity and p21 expression in all of 11 glioma cell lines harboring wild-type or mutant p53, but not in p53-null LN-308 cells. Upon prolonged exposure to CP-31398, all glioma cell lines undergo caspase-independent and bcl-x(L)-insensitive cell death with EC50 concentrations of 10-36 muM. By comparing p53 wild-type U87MG and p53-null LN-308 cells expressing the temperature-sensitive p53(V135A) mutant, we delineate two pathways of CP-31398-induced cell death: an early, p53-dependent pathway that requires (new p53) protein synthesis and a late, p53-independent pathway characterized by aurintricarboxylic acid -sensitive calcium release and epiphenomenal free radical formation. Post-transcriptional repression of p53 synthesis by an intracellularly transcribed short interfering RNA confirmed the presence of these two pathways of cell death. These observations point out some of the liabilities of CP-31398 as a prototype p53-based therapeutic and de. ne a rationale for further refinement of small molecules that specifically target the p53 pathway, but lack the p53-independent effects.	Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany; Int Agcy Res Canc, F-69372 Lyon 08, France; Pfizer Inc, Global Res & Dev, Canc Drug Discovery Grp, Groton, CT 06340 USA	Eberhard Karls University of Tubingen; World Health Organization; International Agency for Research on Cancer (IARC); Pfizer	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany.	michael.weller@uni-tuebingen.de		Weller, Michael/0000-0002-1748-174X				Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Dringen R, 1998, BRAIN RES PROTOC, V2, P223, DOI 10.1016/S1385-299X(97)00047-0; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Glaser T, 1999, ONCOGENE, V18, P5044, DOI 10.1038/sj.onc.1202882; Glaser T, 2001, ONCOGENE, V20, P4757, DOI 10.1038/sj.onc.1204498; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Haupt Ygal, 1997, Leukemia (Basingstoke), V11, P337; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; JIANG ZY, 1991, LIPIDS, V26, P853, DOI 10.1007/BF02536169; Kaku S, 2001, BIOCHEM BIOPH RES CO, V280, P204, DOI 10.1006/bbrc.2000.4060; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lotem J, 1996, P NATL ACAD SCI USA, V93, P9166, DOI 10.1073/pnas.93.17.9166; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Naumann U, 1998, ONCOGENE, V17, P1567, DOI 10.1038/sj.onc.1202071; Naumann U, 1998, INT J CANCER, V77, P645, DOI 10.1002/(SICI)1097-0215(19980812)77:4<645::AID-IJC27>3.0.CO;2-3; Naumann U, 2001, CANCER RES, V61, P5833; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rippin TM, 2002, ONCOGENE, V21, P2119, DOI 10.1038/sj.onc.1205362; Schmidt F, 2001, EUR J PHARMACOL, V412, P21, DOI 10.1016/S0014-2999(00)00923-7; Takimoto R, 2002, CANCER BIOL THER, V1, P47, DOI 10.4161/cbt.1.1.41; Takuma K, 1999, EUR J NEUROSCI, V11, P4204, DOI 10.1046/j.1460-9568.1999.00850.x; VAN MEIR EG, 1994, CANCER RES, V54, P649; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; WELLER M, 1992, BRAIN RES, V594, P160, DOI 10.1016/0006-8993(92)91043-E; Weller M, 1998, INT J CANCER, V79, P640; Wick W, 1999, J PHARMACOL EXP THER, V289, P1306; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	34	125	129	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2003	22	51					8233	8245		10.1038/sj.onc.1207198	http://dx.doi.org/10.1038/sj.onc.1207198			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614447				2022-12-25	WOS:000186541500002
J	Liu, LM; Tommasi, S; Lee, DH; Dammann, R; Pfeifer, GP				Liu, LM; Tommasi, S; Lee, DH; Dammann, R; Pfeifer, GP			Control of microtubule stability by the RASSF1A tumor suppressor	ONCOGENE			English	Article						RASSF1A; mitosis; DNA methylation; microtubules; taxol	FREQUENT EPIGENETIC INACTIVATION; HUMAN-CHROMOSOME 3P21.3; PROMOTER HYPERMETHYLATION; CPG ISLAND; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; BREAST CANCERS; BLADDER-CANCER; MITOTIC BLOCK; K-RAS	The RAS association domain family 1A ( RASSF1A) gene is silenced by DNA methylation in over 50% of all solid tumors of different histological types. However, the biochemical function of the RASSF1A protein is unknown. We show that RASSF1A colocalizes with microtubules in interphase and decorates spindles and centrosomes during mitosis. RASSF1A has a strong cytoprotective activity against the microtubule-destabilizing drug nocodazole, and against cold-treatment in vivo. Conversely, loss of RASSF1 in RASSF1(-/-) mouse embryonic fibroblasts renders the cells more sensitive to nocodazole-induced depolymerization of microtubules. The domain required for both microtubule association and stabilization was mapped to a 169 amino-acid fragment that contains the RAS association domain. Overexpression of RASSF1A induces mitotic arrest at metaphase with aberrant mitotic cells reminiscent of such produced by the microtubule-stabilizing drug paclitaxel (taxol), including monopolar spindles, or complete lack of a mitotic spindle. Altered microtubule stability in cells lacking RASSF1A is likely to affect spindle assembly and chromosome attachment, processes that need to be carefully controlled to protect cells from genomic instability and transformation. In addition, knowledge of the microtubule-targeting function of RASSF1 may aid in the development of new anticancer drugs.	City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA; Univ Halle Wittenberg, Inst Humangenet & Med Biol, D-06097 Halle Saale, Germany	City of Hope; Beckman Research Institute of City of Hope; Martin Luther University Halle Wittenberg	Pfeifer, GP (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.			Tommasi, Stella/0000-0001-6897-4985	NCI NIH HHS [CA88873] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088873] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBONDANZO SJ, 1993, METHOD ENZYMOL, V225, P803; Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan MWY, 2003, INT J CANCER, V104, P611, DOI 10.1002/ijc.10971; Chen Z, 2000, J BIOL CHEM, V275, P41251, DOI 10.1074/jbc.M006687200; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Honorio S, 2003, ONCOGENE, V22, P461, DOI 10.1038/sj.onc.1206119; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Jordan MA, 1996, CANCER RES, V56, P816; JORDAN MA, 1992, J CELL SCI, V102, P401; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kuzmin I, 2003, CANCER RES, V63, P1888; Kuzmin I, 2002, CANCER RES, V62, P3498; Lee MG, 2001, CANCER RES, V61, P6688; Lerman MI, 2000, CANCER RES, V60, P6116; Li YC, 2000, GENETICS, V156, P995; Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814; Lo KW, 2001, CANCER RES, V61, P3877; Lotti LV, 2002, GENE CHROMOSOME CANC, V35, P193, DOI 10.1002/gcc.10105; Lusher ME, 2002, CANCER RES, V62, P5906; Maruyama R, 2001, CANCER RES, V61, P8659; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Morrissey C, 2001, CANCER RES, V61, P7277; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Schagdarsurengin U, 2002, CANCER RES, V62, P3698; Schagdarsurengin U, 2003, ONCOGENE, V22, P1866, DOI 10.1038/sj.onc.1206338; Segal M, 2001, BIOESSAYS, V23, P307, DOI 10.1002/bies.1044; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Spugnardi M, 2003, CANCER RES, V63, P1639; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; Toyooka S, 2002, ONCOGENE, V21, P4340, DOI 10.1038/sj.onc.1205381; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Wagner KJ, 2002, ONCOGENE, V21, P7277, DOI 10.1038/sj.onc.1205922; Zhang YJ, 2002, MOL CARCINOGEN, V35, P85, DOI 10.1002/mc.10076; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	53	160	170	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8125	8136		10.1038/sj.onc.1206984	http://dx.doi.org/10.1038/sj.onc.1206984			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603253				2022-12-25	WOS:000186403400007
J	Hoornaert, I; Marynen, P; Goris, J; Sciot, R; Baens, M				Hoornaert, I; Marynen, P; Goris, J; Sciot, R; Baens, M			MAPK phosphatase DUSP16/MKP-7, a candidate tumor suppressor for chromosome region 12p12-13, reduces BCR-ABL-induced transformation	ONCOGENE			English	Article						tumor suppressor gene; MAPK phosphatase; chromosome 12p12-13; transformation	ACUTE LYMPHOBLASTIC-LEUKEMIA; DUAL-SPECIFICITY PHOSPHATASES; LUNG-CARCINOMA CELLS; SIGNAL-TRANSDUCTION; KINASE PHOSPHATASE; PROSTATE-CANCER; FREQUENT LOSS; GENE FAMILY; JUN KINASE; SHORT ARM	Recurrent chromosome 12p deletions are associated with distinct tumor types and suggest the presence of a tumor suppressor gene (TSG). Previously, we mapped an EST with similarity to a protein tyrosine phosphatase to the minimally deleted region for all these neoplasms. The corresponding gene, DUSP16/MKP-7, was recently shown to code for a mitogen-activated protein kinase phosphatase, suggestive for a function as tumor suppressor. Overexpression of DUSP16 in BCR-ABL-transformed Rat-1. broblasts reduces their transforming capacity in vitro and in vivo via downregulation of BCR-ABL-induced JNK activation. A role for DUSP16 as a regulator of JNK signaling was further demonstrated via overexpression in Ba/F3 cells, which increased their antiapoptosis. However, no inactivating mutations could be detected in leukemia patients hemizygous for DUSP16, and the effect of hemizygosity on DUSP16 expression level could not be assessed due to the variability of DUSP16 transcript levels observed in leukaemia cell lines and in patients. Taken together, the functional data point to a context-dependent role for DUSP16 on cell transformation and apoptosis, reflecting the dual role of JNK, and therefore suggest that DUSP16 might be haploinsufficient for tumor suppression.	Katholieke Univ Leuven VIB, Dept Human Genet, Human Genome Lab, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Dept Mol Cell Biol, Div Biochem, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Dept Pathol, B-3000 Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; KU Leuven; KU Leuven	Baens, M (corresponding author), Katholieke Univ Leuven VIB, Dept Human Genet, Human Genome Lab, Herestr 49, B-3000 Louvain, Belgium.	Mathijs.Baens@med.kuleuven.ac.be		sciot, raf/0000-0003-2244-5839				Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Baens M, 1999, GENOMICS, V56, P40, DOI 10.1006/geno.1998.5685; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Cools J, 2002, BLOOD, V99, P1776, DOI 10.1182/blood.V99.5.1776; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Furukawa T, 1998, CYTOGENET CELL GENET, V82, P156, DOI 10.1159/000015091; Guo B, 2001, J BIOL CHEM, V276, P2780, DOI 10.1074/jbc.M005889200; Hatta Y, 1997, BRIT J CANCER, V75, P1256, DOI 10.1038/bjc.1997.214; Hetet G, 2000, Hematol J, V1, P42, DOI 10.1038/sj.thj.6200008; Hoshino R, 2001, J BIOL CHEM, V276, P2686, DOI 10.1074/jbc.M006132200; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Kibel AS, 1998, CANCER RES, V58, P5652; Kibel AS, 2000, J UROLOGY, V164, P192, DOI 10.1016/S0022-5347(05)67493-9; Kibel AS, 1999, GENE CHROMOSOME CANC, V25, P270, DOI 10.1002/(SICI)1098-2264(199907)25:3<270::AID-GCC9>3.3.CO;2-Q; Latil A, 2001, GENE CHROMOSOME CANC, V31, P199; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIU Q, 1995, BIOTECHNIQUES, V18, P470; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; Masuda K, 2001, J BIOL CHEM, V276, P39002, DOI 10.1074/jbc.M104600200; Montpetit A, 2002, EUR J HUM GENET, V10, P62, DOI 10.1038/sj.ejhg.5200766; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Nesbit MA, 1997, GENOMICS, V42, P284, DOI 10.1006/geno.1997.4737; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; Romana SP, 1996, LEUKEMIA, V10, P167; SATO Y, 1995, BLOOD, V86, P1525, DOI 10.1182/blood.V86.4.1525.bloodjournal8641525; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; Spirin KS, 1996, CANCER RES, V56, P2400; Stegmaier K, 1996, CANCER RES, V56, P1413; Takeuchi S, 1996, CANCER RES, V56, P738; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Wlodarska I, 1996, CYTOGENET CELL GENET, V72, P229, DOI 10.1159/000134197; Xiao L, 2000, CANCER RES, V60, P400	42	42	43	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7728	7736		10.1038/sj.onc.1207089	http://dx.doi.org/10.1038/sj.onc.1207089			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586399				2022-12-25	WOS:000186240200003
J	Venkateswarlu, K; Brandom, KG; Lawrence, JL				Venkateswarlu, K; Brandom, KG; Lawrence, JL			Centaurin-alpha(1) is an in vivo phosphatidylinositol 3,4,5-trisphosphate-dependent GTPase-activating protein for ARF6 that is involved in actin cytoskeleton organization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; DOWNSTREAM; CLONING; ALPHA	The ADP-ribosylation factor (ARF) 6 small GTPase regulates vesicle trafficking and cytoskeletal actin reorganization. The GTPase-activating proteins (GAPs) catalyze the formation of inactive ARF6(GDP). Centaurin-alpha(1) contains an ARF GAP and two pleckstrin homology (PH) domains, which bind the second messenger phosphatidylinositol 3,4,5-trisphosphate (PIP3). Here, we show that centaurin-alpha(1) specifically inhibits in vivo GTP loading of ARF6 and redistribution of ARF6 from the endosomal compartment to the plasma membrane, which are indicative of its activation. Centaurin-alpha(1) also inhibited cortical actin formation in a PIP3-dependent manner. Moreover, the constitutively active mutant of ARF6, but not that of ARF1, reverses the inhibition of cortical actin formation by centaurin-alpha(1). An artificially plasma membrane-targeted centaurin-alpha(1) bypasses the requirement of PIP3 for its involvement in ARF6 inactivation, suggesting that PIP3 is required for recruitment of centaurin-alpha(1) to the plasma membrane but not for its activity. Together, these data suggest that centaurin-alpha(1) negatively regulates ARF6 activity by functioning as an in Vivo PIP3-dependent ARF6 GAP.	Univ Bristol, Sch Med Sci, Dept Pharmacol, Bristol BS8 1TD, Avon, England	University of Bristol	Venkateswarlu, K (corresponding author), Univ Bristol, Sch Med Sci, Dept Pharmacol, Univ Walk, Bristol BS8 1TD, Avon, England.	k.venkateswarlu@bristol.ac.uk	Kanamarlapudi, Venkateswarlu/A-9864-2011	Kanamarlapudi, Venkateswarlu/0000-0002-8739-1483; Brandom, Kevin/0000-0002-0312-360X				Cullen PJ, 1999, BIOCHEM SOC T, V27, P683, DOI 10.1042/bst0270683; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; Hawadle MA, 2002, BIOL RES, V35, P247, DOI 10.4067/S0716-97602002000200017; Jackson TR, 2000, J CELL BIOL, V151, P627, DOI 10.1083/jcb.151.3.627; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; RANDAZZO P, 2000, SCI STKE; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Tanaka K, 1997, EUR J BIOCHEM, V245, P512, DOI 10.1111/j.1432-1033.1997.00512.x; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Venkateswarlu K, 2003, J BIOL CHEM, V278, P43460, DOI 10.1074/jbc.M304078200; Venkateswarlu K, 1999, BIOCHEM BIOPH RES CO, V262, P237, DOI 10.1006/bbrc.1999.1065; Venkateswarlu K, 2000, BIOCHEM J, V345, P719, DOI 10.1042/0264-6021:3450719; Venkateswarlu K, 1999, BIOCHEM J, V340, P359, DOI 10.1042/0264-6021:3400359; Vitale N, 2000, J BIOL CHEM, V275, P13901, DOI 10.1074/jbc.275.18.13901	15	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6205	6208		10.1074/jbc.C300482200	http://dx.doi.org/10.1074/jbc.C300482200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14625293	hybrid			2022-12-25	WOS:000188969200001
J	Perera, NM; Michell, RH; Dove, SK				Perera, NM; Michell, RH; Dove, SK			Hypo-osmotic stress activates Plc1p-dependent phosphatidylinositol 4,5-bisphosphate hydrolysis and inositol hexakisphosphate accumulation in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE C-DELTA; SPONTANEOUSLY HYPERTENSIVE RAT; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; PROTEIN-KINASE; LIPID KINASE; CELL-GROWTH; 4-KINASE; GENE; STT4	Polyphosphoinositide-specific phospholipases (PICs) of the delta-subfamily are ubiquitous in eukaryotes, but an inability to control these enzymes physiologically has been a major obstacle to understanding their cellular function(s). Plc1p is similar to metazoan delta-PICs and is the only PIC in Saccharomyces cerevisiae. Genetic studies have implicated Plc1p in several cell functions, both nuclear and cytoplasmic. Here we show that a brief hypo-osmotic episode provokes rapid Plc1p-catalyzed hydrolysis of PtdIns(4,5)P-2 in intact yeast by a mechanism independent of extracellular Ca2+. Much of this PtdIns(4,5)P-2 hydrolysis occurs at the plasma membrane. The hydrolyzed PtdIns(4,5)P-2 is mainly derived from PtdIns4P made by the PtdIns 4-kinase Stt4p. PtdIns(4,5)P-2 hydrolysis occurs normally in mutants lacking Arg82p or Ipk1p, but they accumulate no InsP(6), showing that these enzymes normally convert the liberated Ins(1,4,5)P-3 rapidly and quantitatively to InsP6. We conclude that hypo-osmotic stress activates Plc1p-catalyzed PtdIns(4,5)P-2 at the yeast plasma membrane and the liberated Ins(1,4,5)P-3 is speedily converted to InsP6. This ability routinely to activate Plc1p-catalyed PtdIns(4,5)P-2 hydrolysis in vivo opens up new opportunities for molecular and genetic scrutiny of the regulation and functions of phosphoinositidases C of the delta-subfamily.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Michell, RH (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	r.h.michell@bham.ac.uk	Michell, Robert H/AAT-4974-2020	Michell, Robert H/0000-0001-9422-9858				Allen V, 1997, BIOCHEM J, V327, P545, DOI 10.1042/bj3270545; Andoh T, 1998, MOL GEN GENET, V258, P139, DOI 10.1007/s004380050716; Audhya A, 2003, EMBO J, V22, P4223, DOI 10.1093/emboj/cdg397; Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; Audhya A, 2002, DEV CELL, V2, P593, DOI 10.1016/S1534-5807(02)00168-5; Batiza AF, 1996, J BIOL CHEM, V271, P23357, DOI 10.1074/jbc.271.38.23357; Bergsma JCT, 2001, BIOCHEM J, V359, P517, DOI 10.1042/0264-6021:3590517; BLEASDALE JE, 1989, ADV PROSTAG THROMB L, V19, P590; BOMINAAR AA, 1994, BIOCHEM J, V297, P189, DOI 10.1042/bj2970189; Brazill DT, 1998, J BIOL CHEM, V273, P8161, DOI 10.1074/jbc.273.14.8161; Coccetti P, 1998, BBA-MOL CELL RES, V1405, P147, DOI 10.1016/S0167-4889(98)00099-8; Cooper KF, 1999, MOL CELL BIOL, V19, P3338; Cox LJ, 2002, REPRODUCTION, V124, P611, DOI 10.1530/rep.0.1240611; Cutler NS, 1997, J BIOL CHEM, V272, P27671, DOI 10.1074/jbc.272.44.27671; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; DOVE SK, 1999, SIGNAL TRANSDUCTION, P255; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; DOWNES P, 1982, CELL CALCIUM, V3, P467, DOI 10.1016/0143-4160(82)90031-8; Dubois E, 2002, J BIOL CHEM, V277, P23755, DOI 10.1074/jbc.M202206200; EINSPAHR KJ, 1988, J BIOL CHEM, V263, P5775; ESTEVEZ F, 1994, BIOCHEM J, V302, P709, DOI 10.1042/bj3020709; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; Flick JS, 1998, GENETICS, V148, P33; Foti M, 2001, MOL BIOL CELL, V12, P2396, DOI 10.1091/mbc.12.8.2396; Fujii M, 1999, BIOCHEM BIOPH RES CO, V254, P284, DOI 10.1006/bbrc.1998.9936; Fukami K, 2001, SCIENCE, V292, P920, DOI 10.1126/science.1059042; GARCIABUSTOS JF, 1994, EMBO J, V13, P2352, DOI 10.1002/j.1460-2075.1994.tb06519.x; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; Han GS, 2002, J BIOL CHEM, V277, P47709, DOI 10.1074/jbc.M207996200; HARRISON SM, 1987, BIOCHIM BIOPHYS ACTA, V925, P133, DOI 10.1016/0304-4165(87)90102-4; HAWKINS PT, 1993, J BIOL CHEM, V268, P3374; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Ives EB, 2000, J BIOL CHEM, V275, P36575, DOI 10.1074/jbc.M007586200; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; Katan M, 1998, BBA-MOL CELL BIOL L, V1436, P5, DOI 10.1016/S0005-2760(98)00125-8; KATSUYA T, 1992, BIOCHEM BIOPH RES CO, V187, P1359, DOI 10.1016/0006-291X(92)90452-Q; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Lin H, 2002, MOL GENET GENOMICS, V267, P313, DOI 10.1007/s00438-002-0647-8; Lin HY, 1998, BIOCHEM BIOPH RES CO, V252, P285, DOI 10.1006/bbrc.1998.9639; Lin HY, 2000, MOL CELL BIOL, V20, P3597, DOI 10.1128/MCB.20.10.3597-3607.2000; MICHELL RH, 1987, PERSPECTIVES RECEPTO, P95; Minogue S, 2001, J BIOL CHEM, V276, P16635, DOI 10.1074/jbc.M100982200; Mitchell CA, 2002, IUBMB LIFE, V53, P25, DOI 10.1080/15216540210815; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Ongusaha P. P., 1997, Biochemical Society Transactions, V25, p105S; Ongusaha PP, 1998, BIOCHEM J, V335, P671, DOI 10.1042/bj3350671; PAYNE WE, 1993, MOL CELL BIOL, V13, P4351, DOI 10.1128/MCB.13.7.4351; PETHIG R, 1989, CELL CALCIUM, V10, P491, DOI 10.1016/0143-4160(89)90026-2; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rodrigues F, 2001, J BACTERIOL, V183, P3791, DOI 10.1128/JB.183.12.3791-3794.2001; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; SCHOMERUS C, 1992, FEBS LETT, V307, P249, DOI 10.1016/0014-5793(92)80688-D; Seeley ES, 2002, MOL BIOL CELL, V13, P782, DOI 10.1091/mbc.01-10-0512; Shelton SN, 2003, BIOCHEM J, V371, P533, DOI 10.1042/BJ20021407; Shen XT, 2003, SCIENCE, V299, P112, DOI 10.1126/science.1078068; SHIMOHAMA S, 1995, BRAIN RES, V669, P217, DOI 10.1016/0006-8993(94)01239-E; SHIMOHAMA S, 1991, AM J PATHOL, V139, P737; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; STUART JA, 1994, BIOCHEM J, V303, P517, DOI 10.1042/bj3030517; Tanino H, 2000, BIOCHEM BIOPH RES CO, V271, P620, DOI 10.1006/bbrc.2000.2679; Tanino H, 2001, BIOL PHARM BULL, V24, P1241, DOI 10.1248/bpb.24.1241; Trotter PJ, 1998, J BIOL CHEM, V273, P13189, DOI 10.1074/jbc.273.21.13189; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Van Dijken P, 2001, BMC CELL BIOL, V2, part. no., DOI 10.1186/1471-2121-2-25; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Watt SA, 2002, BIOCHEM J, V363, P657, DOI 10.1042/0264-6021:3630657; YAGISAWA H, 1991, J HYPERTENS, V9, P997, DOI 10.1097/00004872-199111000-00004; Yagisawa H, 1999, BIOCHEM SOC T, V27, P652, DOI 10.1042/bst0270652; YOKOO T, 1993, P NATL ACAD SCI USA, V90, P1804, DOI 10.1073/pnas.90.5.1804; YOKOO T, 1995, MOL GEN GENET, V247, P148, DOI 10.1007/BF00705644; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; York JD, 2001, ADV ENZYME REGUL, V41, P57, DOI 10.1016/S0065-2571(00)00025-X; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166; Zhang T, 2001, FEBS LETT, V494, P208, DOI 10.1016/S0014-5793(01)02351-1	78	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5216	5226		10.1074/jbc.M305068200	http://dx.doi.org/10.1074/jbc.M305068200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14625296	hybrid			2022-12-25	WOS:000188776500023
J	Schiefner, A; Breed, J; Bosser, L; Kneip, S; Gade, J; Holtmann, G; Diederichs, K; Welte, W; Bremer, E				Schiefner, A; Breed, J; Bosser, L; Kneip, S; Gade, J; Holtmann, G; Diederichs, K; Welte, W; Bremer, E			Cation-pi interactions as determinants for binding of the compatible solutes glycine betaine and proline betaine by the periplasmic ligand-binding protein ProX from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT-SYSTEM PROU; DEPENDENT TRANSPORT; CRYSTAL-STRUCTURE; DIFFRACTION DATA; STRESS; WATER; ACETYLCHOLINESTERASE; OSMOREGULATION; STABILIZATION; MICROORGANISMS	Compatible solutes such as glycine betaine and proline betaine are accumulated to exceedingly high intracellular levels by many organisms in response to high osmolarity to offset the loss of cell water. They are excluded from the immediate hydration shell of proteins and thereby stabilize their native structure. Despite their exclusion from protein surfaces, the periplasmic ligand- binding protein ProX from the Escherichia coli ATP- binding cassette transport system ProU binds the compatible solutes glycine betaine and proline betaine with high affinity and specificity. To understand the mechanism of compatible solute binding, we determined the high resolution structure of ProX in complex with its ligands glycine betaine and proline betaine. This crystallographic study revealed that cation-pi interactions between the positive charge of the quaternary amine of the ligands and three tryptophan residues forming a rectangular aromatic box are the key determinants of the high affinity binding of compatible solutes by ProX. The structural analysis was combined with site- directed mutagenesis of the ligand binding pocket to estimate the contributions of the tryptophan residues involved in binding.	Univ Konstanz, Fachbereich Biol, D-78457 Constance, Germany; Univ Marburg, Mikrobiol Lab, Fachbereich Biol, D-35032 Marburg, Germany	University of Konstanz; Philipps University Marburg	Welte, W (corresponding author), Univ Konstanz, Fachbereich Biol, Univ Str 10, D-78457 Constance, Germany.	wolfram.welte@uni-konstanz.de	Holtmann, Gerald/S-4065-2019; Holtmann, Gerald/I-5341-2014	Holtmann, Gerald/0000-0002-0206-2358; Schiefner, Andre/0000-0001-5215-4122				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARAKAWA T, 1985, BIOPHYS J, V47, P411, DOI 10.1016/S0006-3495(85)83932-1; BARRON A, 1987, J BIOL CHEM, V262, P11841; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bjorkman AJ, 1998, J MOL BIOL, V279, P651, DOI 10.1006/jmbi.1998.1785; Bolen DW, 2001, J MOL BIOL, V310, P955, DOI 10.1006/jmbi.2001.4819; BOOS W, 1996, ESCHERICHIA COLI SAL, P1175; Booth IR, 1999, CURR OPIN MICROBIOL, V2, P166, DOI 10.1016/S1369-5274(99)80029-0; Borths EL, 2002, P NATL ACAD SCI USA, V99, P16642, DOI 10.1073/pnas.262659699; Bourot S, 2000, J BIOL CHEM, V275, P1050, DOI 10.1074/jbc.275.2.1050; Breed J, 2001, ACTA CRYSTALLOGR D, V57, P448, DOI 10.1107/S0907444901000397; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; BREMER E, 1988, GENE, V71, P177, DOI 10.1016/0378-1119(88)90089-3; Bremer E, 2000, BACTERIAL STRESS RESPONSES, P79; BROWN AD, 1976, BACTERIOL REV, V40, P803, DOI 10.1128/MMBR.40.4.803-846.1976; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; Caldas T, 1999, MICROBIOL-SGM, V145, P2543, DOI 10.1099/00221287-145-9-2543; Canovas D, 1999, APPL ENVIRON MICROB, V65, P3774; Canovas D, 2001, J BACTERIOL, V183, P3365, DOI 10.1128/JB.183.11.3365-3371.2001; Clarke TE, 2000, NAT STRUCT BIOL, V7, P287; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; CSONKA LN, 1996, ESCHERICHIA COLI SAL, V1, P1210; CULHAM DE, 1993, J MOL BIOL, V229, P268, DOI 10.1006/jmbi.1993.1030; da Costa M. S., 1998, V61, P117; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; DULANEY EUGENE L., 1968, DEVELOP IND MICROBIOL, V9, P260; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FAATZ E, 1988, MOL MICROBIOL, V2, P265, DOI 10.1111/j.1365-2958.1988.tb00028.x; Felder CE, 2002, ACTA CRYSTALLOGR D, V58, P1765, DOI 10.1107/S0907444902011642; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; GALINSKI EA, 1994, FEMS MICROBIOL REV, V15, P95, DOI 10.1111/j.1574-6976.1994.tb00128.x; GOWRISHANKAR J, 1989, J BACTERIOL, V171, P1923, DOI 10.1128/jb.171.4.1923-1931.1989; HAARDT M, 1995, MOL GEN GENET, V246, P783, DOI 10.1007/BF00290728; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1987, J GEN MICROBIOL, V133, P305; Hohmann S, 2002, INT REV CYTOL, V215, P149; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; JEBBAR M, 1992, J BACTERIOL, V174, P5027, DOI 10.1128/JB.174.15.5027-5035.1992; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kempf B, 1998, ARCH MICROBIOL, V170, P319, DOI 10.1007/s002030050649; Kendrick BS, 1997, P NATL ACAD SCI USA, V94, P11917, DOI 10.1073/pnas.94.22.11917; KLEYWEGT GJ, 1994, ESF CCP4 NEWSLETTER, V31, P9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE JC, 1981, J BIOL CHEM, V256, P7193; LEHMANN MS, 1984, BIOCHEMISTRY-US, V23, P1939, DOI 10.1021/bi00304a008; LERUDULIER D, 1984, SCIENCE, V224, P1064, DOI 10.1126/science.224.4653.1064; Li AJ, 1998, PROTEINS, V32, P111, DOI 10.1002/(SICI)1097-0134(19980701)32:1<111::AID-PROT12>3.0.CO;2-H; LIPPERT K, 1992, APPL MICROBIOL BIOT, V37, P61; LUCHT JM, 1994, FEMS MICROBIOL REV, V14, P3, DOI 10.1016/0168-6445(94)90008-6; Magnusson U, 2002, J BIOL CHEM, V277, P14077, DOI 10.1074/jbc.M200514200; MAY G, 1986, MOL GEN GENET, V205, P225, DOI 10.1007/BF00430432; Mecozzi S, 1996, P NATL ACAD SCI USA, V93, P10566, DOI 10.1073/pnas.93.20.10566; Mendum ML, 2002, APPL ENVIRON MICROB, V68, P813, DOI 10.1128/AEM.68.2.813-819.2002; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Minton AP, 2001, J BIOL CHEM, V276, P10577, DOI 10.1074/jbc.R100005200; Momma K, 2002, J MOL BIOL, V316, P1051, DOI 10.1006/jmbi.2001.5393; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NEU HC, 1965, J BIOL CHEM, V240, P3685; PERROUD B, 1985, J BACTERIOL, V161, P393, DOI 10.1128/JB.161.1.393-401.1985; Qu YX, 1998, P NATL ACAD SCI USA, V95, P9268, DOI 10.1073/pnas.95.16.9268; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P143, DOI 10.1016/S0968-0004(98)01196-7; RHODES D, 1993, ANNU REV PLANT PHYS, V44, P357, DOI 10.1146/annurev.pp.44.060193.002041; RICHARME G, 1983, BIOCHIM BIOPHYS ACTA, V742, P16, DOI 10.1016/0167-4838(83)90353-9; RIPOLL DR, 1993, P NATL ACAD SCI USA, V90, P5128, DOI 10.1073/pnas.90.11.5128; Roberts MF, 2000, FRONT BIOSCI-LANDMRK, V5, pD796, DOI 10.2741/roberts; Roderick SL, 2002, NAT STRUCT BIOL, V9, P507, DOI 10.1038/nsb812; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILHAVY TJ, 1984, EXPT GENE FUSIONS, P18; Sleator RD, 2002, FEMS MICROBIOL REV, V26, P49, DOI 10.1111/j.1574-6976.2002.tb00598.x; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; Weiss MS, 1997, J APPL CRYSTALLOGR, V30, P203, DOI 10.1107/S0021889897003907; Welsh DT, 2000, FEMS MICROBIOL REV, V24, P263, DOI 10.1111/j.1574-6976.2000.tb00542.x; Wood JM, 1999, MICROBIOL MOL BIOL R, V63, P230, DOI 10.1128/MMBR.63.1.230-262.1999; Yancey P.H., 1994, CELLULAR MOL PHYSL C, P81; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088	82	103	106	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5588	5596		10.1074/jbc.M309771200	http://dx.doi.org/10.1074/jbc.M309771200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14612446	hybrid, Green Published			2022-12-25	WOS:000188776500068
J	Townsend, PA; Scarabelli, TM; Davidson, SM; Knight, RA; Latchman, DS; Stephanou, A				Townsend, PA; Scarabelli, TM; Davidson, SM; Knight, RA; Latchman, DS; Stephanou, A			STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL ACTIVATION DOMAIN; TRANSCRIPTION FACTOR; IFN-GAMMA; INTERFERON; EXPRESSION; INDUCTION; CELLS; MDM2; ISCHEMIA/REPERFUSION; BINDING	The STAT-1 transcription factor has been implicated as a tumor suppressor by virtue of its ability to inhibit cell growth and promoting apoptosis. However, the mechanisms by which STAT-1 mediates these effects remain unclear. Using human and mouse STAT-1-deficient cells, we show here that STAT-1 is required for optimal DNA damage-induced apoptosis. The basal level of the p53 inhibitor Mdm2 is increased inSTAT-1(-/-) cells, suggesting that STAT-1 is a negative regulator of Mdm2 expression. Correspondingly, both basal p53 levels, and those induced by DNA damage were lower in STAT1(-/-) cells. In agreement with this lower p53 response to DNA damage in cells lacking STAT-1, the induction of p53 responsive genes, such as Bax, Noxa, and Fas, was reduced in STAT-1-deficient cells. Conversely, STAT-1 overexpression enhances transcription of these genes, an effect that is abolished if the p53 response element in their promoters is mutated. Moreover, STAT-1 interacts directly with p53, an association, which is enhanced following DNA damage. Therefore, in addition to negatively regulating Mdm2, STAT-1 also acts as a coactivator for p53. Hence STAT-1 is another member of a growing family of protein partners able to modulate the p53-activated apoptotic pathway.	UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England	University of London; University College London	Stephanou, A (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EH, England.	a.stephanou@ich.ucl.ac.uk	Townsend, Paul/AAF-8234-2020; Davidson, Sean M/F-5275-2010	Davidson, Sean M/0000-0001-5182-4980; Townsend, Paul/0000-0001-8956-9508				Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; Budram-Mahadeo V, 2002, ONCOGENE, V21, P6123, DOI 10.1038/sj.onc.1205842; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; de Rozieres S, 2000, ONCOGENE, V19, P1691, DOI 10.1038/sj.onc.1203468; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; Irminger-Finger I, 2001, MOL CELL, V8, P1255, DOI 10.1016/S1097-2765(01)00406-3; Janjua S, 2002, CELL DEATH DIFFER, V9, P1140, DOI 10.1038/sj.cdd.4401082; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; King P, 1998, J BIOL CHEM, V273, P8699, DOI 10.1074/jbc.273.15.8699; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Lee CK, 2000, J IMMUNOL, V164, P1286, DOI 10.4049/jimmunol.164.3.1286; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LUNA RMD, 1995, NATURE, V378, P203; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Perez-Sanchez C, 2002, NUCLEIC ACIDS RES, V30, P4872, DOI 10.1093/nar/gkf610; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; STANTON GJ, 1987, INVEST RADIOL, V22, P259, DOI 10.1097/00004424-198703000-00017; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stephanou A, 2002, FASEB J, V16, P1841, DOI 10.1096/fj.02-0150fje; Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200; Stephanou A, 2000, J BIOL CHEM, V275, P10002, DOI 10.1074/jbc.275.14.10002; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	38	189	196	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5811	5820		10.1074/jbc.M302637200	http://dx.doi.org/10.1074/jbc.M302637200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14602726	hybrid			2022-12-25	WOS:000188776500095
J	Beavis, AD; Powers, M				Beavis, AD; Powers, M			Temperature dependence of the mitochondrial inner membrane anion channel - The relationship between temperature and inhibition by magnesium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-SCATTERING; PROTONS; MATRIX; CONTRACTION; TRANSPORT; VOLUME	The mitochondrial inner membrane anion channel (IMAC) carries a wide variety of anions and is postulated to be involved in mitochondrial volume homeostasis in conjunction with the K+/H+ antiporter, thus allowing the respiratory chain proton pumps to drive salt efflux. How it is regulated is uncertain; however, it is inhibited by matrix Mg2+ and matrix protons. Previously determined values for the IC50 suggested that the channel would be closed under physiological conditions. In a previous study (Liu, G., Hinch, B., Davatol-Hag, H., Lu, Y., Powers, M., and Beavis, A. D. (1996) J. Biol. Chem. 271, 19717-19723), it was demonstrated that the channel is highly temperature-dependent, and that a large component of this sensitivity resulted from an effect on the pIC(50) for protons. We have now investigated the effect of temperature on the inhibition by Mg2+ and have found that it too is temperature-dependent. When the temperature is raised from 20 degreesC to 45 degreesC, the IC50 increases from 22 to 350 muM at pH 7.4 and from 80 to 1.5 mm at pH 8.4, respectively. The Arrhenius plot for the IC50 is linear with a slope = -80 kJ/mol. The IC50 is also strongly pH-dependent, and at 37 degreesC increases from 90 mum at pH 7.4 to 1230 mum at pH 8.4. In view of the extremely rapid fluxes that IMAC is capable of conducting at 37 degreesC, we conclude that inhibition by matrix Mg2+ and protons is necessary to limit its activity under physiological conditions. We conclude that the primary role of Mg2+ is to ensure IMAC is poised to allow regulation by small changes in pH in the physiological range. This control is mediated by a direct effect of H+ on the activity, in addition to an indirect effect mediated by a change in the Mg2+ IC50. The question that remains is not whether IMAC can be active at physiological concentrations of Mg2+ and H+, but what other factors might increase its sensitivity to changes in mitochondrial volume.	Med Coll Ohio, Dept Pharmacol, Toledo, OH 43614 USA; Univ Toledo, Toledo, OH 43606 USA	University of Toledo	Beavis, AD (corresponding author), Med Coll Ohio, Dept Pharmacol, Toledo, OH 43614 USA.	abeavis@mco.edu						Aon MA, 2003, J BIOL CHEM, V278, P44735, DOI 10.1074/jbc.M302673200; BEAVIS AD, 1987, J BIOL CHEM, V262, P15085; Beavis AD, 1996, J BIOENERG BIOMEMBR, V28, P207, DOI 10.1007/BF02110652; BEAVIS AD, 1989, J BIOL CHEM, V264, P17148; BEAVIS AD, 1990, J BIOL CHEM, V265, P2538; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BEAVIS AD, 1987, J BIOL CHEM, V262, P6165; BEAVIS AD, 1992, J BIOENERG BIOMEMBR, V24, P77, DOI 10.1007/BF00769534; GARLID KD, 1985, J BIOL CHEM, V260, P3434; Jung DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1194, DOI 10.1152/ajpcell.1999.277.6.C1194; Liu GY, 1996, J BIOL CHEM, V271, P19717, DOI 10.1074/jbc.271.33.19717; O'Rourke B, 2000, J PHYSIOL-LONDON, V529, P23, DOI 10.1111/j.1469-7793.2000.00023.x; POWERS MF, 1994, J BIOL CHEM, V269, P10614; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092	14	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4045	4050		10.1074/jbc.M310475200	http://dx.doi.org/10.1074/jbc.M310475200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14615482	hybrid			2022-12-25	WOS:000188554300017
J	Boudreau, NJ; Varner, JA				Boudreau, NJ; Varner, JA			The homeobox transcription factor Hox D3 promotes integrin alpha(5)beta(1) expression and function during angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; IN-VIVO; EXTRACELLULAR-MATRIX; MESODERMAL DEFECTS; CELL-SURVIVAL; ALPHA(V)BETA(3); APOPTOSIS; PROTEIN; CANCER; INHIBITION	Neovascularization promotes wound healing, tumor growth, and arthritis. Endothelial cell migration and survival during neovascularization are regulated by adhesion proteins, including integrin alpha(5)beta(1). Integrin alpha(5)beta(1) is poorly expressed on normal quiescent blood vessels, but its expression is induced on tumor blood vessels and in response to angiogenic factors such as basic fibroblast growth factor, interleukin-8, tumor necrosis factor-a, and the angiomatrix protein Del-1. We show here that alpha(5)beta(1) expression, and hence function, during angiogenesis is regulated by the transcription factor Hox D3, a homeobox gene that also controls the expression of endothelial cell integrin alpha(v)beta(3) and urokinase-type plasminogen activator. Hox D3 expression in endothelial cells enhances integrin alpha(5) protein and message expression, whereas Hox D3 antisense inhibits its expression. Hox D3 promotes alpha(5) expression during angiogenesis in vivo, whereas inhibition of a5 expression by Hox D3 antisense suppresses angiogenesis. Hox D3 binds directly to the promoters of the integrin alpha(5) and beta(3) subunits, inducing subunit expression. As Hox D3, integrin alpha(v)beta(3), and integrin alpha(5)beta(1) are expressed on tumor blood vessels but not on normal quiescent vessels, these studies suggest that Hox D3 coordinately regulates the expression of integrin alpha(5)beta(1) and integrin alpha(v)beta(3) during angiogenesis in vivo. These studies also suggest that Hox D3 inhibition could be a useful approach to inhibit tumor angiogenesis.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Comprehens Canc, La Jolla, CA 92093 USA	University of California System; University of California San Francisco; University of California System; University of California San Diego; University of California System; University of California San Diego	Varner, JA (corresponding author), 9500 Gilman Dr, La Jolla, CA 92093 USA.	jvarner@ucsd.edu		Varner, Judith/0000-0002-9251-0600	NATIONAL CANCER INSTITUTE [R01CA085249, R01CA083133] Funding Source: NIH RePORTER; NCI NIH HHS [CA83133, CA85249] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Aoka Y, 2002, MICROVASC RES, V64, P148, DOI 10.1006/mvre.2002.2414; Boudreau N, 2003, BREAST CANCER RES, V5, P140, DOI 10.1186/bcr589; Boudreau N, 1997, J CELL BIOL, V139, P257, DOI 10.1083/jcb.139.1.257; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cheresh D.A., 1993, ADV MOL CELL BIOL, V6, P225; Cheresh DA, 2002, NAT MED, V8, P193, DOI 10.1038/nm0302-193; Clark RAF, 1996, AM J PATHOL, V148, P1407; CONDIE BG, 1993, DEVELOPMENT, V119, P579; DRAKE CJ, 1995, J CELL SCI, V108, P2655; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fragoso G, 1997, METHODS, V11, P246, DOI 10.1006/meth.1996.0411; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; Goh KL, 1997, DEVELOPMENT, V124, P4309; Hidai C, 1998, GENE DEV, V12, P21, DOI 10.1101/gad.12.1.21; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Kim S, 2002, J CLIN INVEST, V110, P933, DOI 10.1172/JCI200214268; Kloss CUA, 1999, J COMP NEUROL, V411, P162, DOI 10.1002/(SICI)1096-9861(19990816)411:1<162::AID-CNE12>3.0.CO;2-W; Manley NR, 1997, DEV BIOL, V192, P274, DOI 10.1006/dbio.1997.8765; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Myers C, 2000, J CELL BIOL, V148, P343, DOI 10.1083/jcb.148.2.343; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; Penta K, 1999, J BIOL CHEM, V274, P11101, DOI 10.1074/jbc.274.16.11101; Stoeltzing O, 2003, INT J CANCER, V104, P496, DOI 10.1002/ijc.10958; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; TANIGUCHI Y, 1995, BLOOD, V85, P2786, DOI 10.1182/blood.V85.10.2786.bloodjournal85102786; Uyeno LA, 2001, J SURG RES, V100, P46, DOI 10.1006/jsre.2001.6174; Varner J., 1997, REGULATION ANGIOGENE, P361; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; YANG JT, 1993, DEVELOPMENT, V119, P1093; Yoshiji H, 1997, CANCER RES, V57, P3924; Zappavigna V, 1996, EMBO J, V15, P4981, DOI 10.1002/j.1460-2075.1996.tb00878.x; Zhong JP, 2003, J CLIN INVEST, V112, P30, DOI 10.1172/JCI200317034	44	102	106	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4862	4868		10.1074/jbc.M305190200	http://dx.doi.org/10.1074/jbc.M305190200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14610084	hybrid			2022-12-25	WOS:000188554300111
J	Gautier, C; Negrerie, M; Wang, ZQ; Lambry, JC; Stuehr, DJ; Collin, F; Martin, JL; Slama-Schwok, A				Gautier, C; Negrerie, M; Wang, ZQ; Lambry, JC; Stuehr, DJ; Collin, F; Martin, JL; Slama-Schwok, A			Dynamic regulation of the inducible nitric-oxide synthase by NO - Comparison with the endothelial isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAHYDROBIOPTERIN-BINDING-SITE; HEME-DIOXY REDUCTION; OXYGENASE DIMER; COMPLEX; DOMAIN; ROLES	We studied by ultrafast time-resolved absorption spectroscopy the geminate recombination of NO to the oxygenase domain of the inducible NO synthase, iNOSoxy, and to mutated proteins at position Trp-457. This tryptophan interacts with the tetrahydrobiopterin cofactor BH4, and W457A/F mutations largely reduced the catalytic formation of NO. BH4 decreases the rate of NO rebinding to the ferric iNOSoxy compared with that measured in its absence. The pterin has a larger effect on W457A/F than on the WT protein by increasing NO release from the protein. Therefore, BH4 raises the energy barrier for NO recombination to the mutated proteins in contrast with our observations on eNOS (SlamaSchwok, A., Negrerie, M., Berka, V., Lambry, J: C., Tsai, A.-L., Vos, M., and Martin, J.-L. (2002) J. Biol. Chem. 277, 7581-7586). Thus, we show a differential effect of BH4 on NO release from eNOS and iNOS. Compared with the position of this residue in the BH4-repleted enzyme, simulations of the NO dissociation dynamics point out at a swing of Trp-457 toward the missing pterin in the absence of BH4. NO geminate-rebinding data show a more efficient NO release from eNOS than from iNOS once NO is formed. Consistently, NO produced by iNOS is regulated by its ferric nitrosyl complex in contrast with eNOS. We show that the small enhancement of the NO geminate recombination rate in W457A/F compared with that in the WT enzyme cannot explain the decrease of NO yield because of the mutation; the major effect of the mutation thus arises from an uncoupled catalysis (Wang, Z. Q., Wei, C. C., Ghosh, S., Meade, A. L., Hemann, C., Hille, R., and Stuehr, D. J. (2001) Biochemistry 40, 12819-12825).	Ecole Polytech, Lab Opt & Biosci, CNRS, UMR 7645,INSERM,U451, F-91128 Palaiseau, France; Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Polytechnique de Paris; Cleveland Clinic Foundation	Slama-Schwok, A (corresponding author), Ecole Polytech, Lab Opt & Biosci, CNRS, UMR 7645,INSERM,U451, F-91128 Palaiseau, France.	anny.schwok@polytechnique.fr	Slama Schwok, Anny/AAD-8986-2019; Negrerie, Michel/L-2283-2018; Collin, Fabrice/A-7800-2012; Slama-Schwok, Anny/K-6826-2017	Slama Schwok, Anny/0000-0002-2703-9728; Negrerie, Michel/0000-0001-9918-031X; Collin, Fabrice/0000-0003-4310-112X; Lambry, Jean-Christophe/0000-0001-8264-0391				Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P6876, DOI 10.1021/bi010066m; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Aoyagi M, 2001, BIOCHEMISTRY-US, V40, P12826, DOI 10.1021/bi011183k; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Chen PF, 2000, J BIOL CHEM, V275, P13155, DOI 10.1074/jbc.275.17.13155; Crane BR, 2000, BIOCHEMISTRY-US, V39, P4608, DOI 10.1021/bi992409a; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Du M, 2003, J BIOL CHEM, V278, P6002, DOI 10.1074/jbc.M209606200; EBERLEIN G, 1984, J AM CHEM SOC, V106, P7916, DOI 10.1021/ja00337a047; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Ghosh S, 1999, J BIOL CHEM, V274, P24100, DOI 10.1074/jbc.274.34.24100; HURSHMAN AR, 1995, BIOCHEMISTRY-US, V34, P5627, DOI 10.1021/bi00016a038; Kotsonis P, 2001, J BIOL CHEM, V276, P49133, DOI 10.1074/jbc.M011469200; Lambry JC, 1999, J PHYS CHEM A, V103, P10132, DOI 10.1021/jp992587d; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; MARTIN JL, 1992, ANNU REV BIOPH BIOM, V21, P199, DOI 10.1146/annurev.bb.21.060192.001215; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; Negrerie M, 1999, J BIOL CHEM, V274, P24694, DOI 10.1074/jbc.274.35.24694; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; Press W. H., 1988, NUMERICAL RECIPES; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RAMAN CS, 2000, PROPHYRIN HDB, V4; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Rusche KM, 2001, J BIOL CHEM, V276, P421, DOI 10.1074/jbc.M006860200; Santolini J, 2001, J BIOL CHEM, V276, P48887, DOI 10.1074/jbc.M108666200; Schelvis JPM, 2002, BIOCHEMISTRY-US, V41, P5695, DOI 10.1021/bi0118456; Slama-Schwok A, 2002, J BIOL CHEM, V277, P7581, DOI 10.1074/jbc.M108657200; Stuehr D, 2001, J BIOL CHEM, V276, P14533, DOI 10.1074/jbc.R100011200; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Wang ZQ, 2002, J BIOL CHEM, V277, P12830, DOI 10.1074/jbc.M111967200; Wang ZQ, 2001, BIOCHEMISTRY-US, V40, P12819, DOI 10.1021/bi011182s; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200	36	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4358	4365		10.1074/jbc.M305048200	http://dx.doi.org/10.1074/jbc.M305048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14594819	hybrid			2022-12-25	WOS:000188554300054
J	Kagansky, A; Freeman, L; Lukyanov, D; Strunnikov, A				Kagansky, A; Freeman, L; Lukyanov, D; Strunnikov, A			Histone tail-independent chromatin binding activity of recombinant cohesin holocomplex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; CHROMOSOME CONDENSATION; SISTER CHROMATIDS; DNA-REPLICATION; FISSION YEAST; SMC PROTEINS; S-PHASE; COMPLEX; NUCLEOSOME	Cohesin, an SMC (structural maintenance of chromosomes) protein-containing complex, governs several important aspects of chromatin dynamics, including the essential chromosomal process of sister chromatid cohesion. The exact mechanism by which cohesin achieves the bridging of sister chromatids is not known. To elucidate this mechanism, we reconstituted a recombinant cohesin complex and investigated its binding to DNA fragments corresponding to natural chromosomal sites with high and low cohesin occupancy in vivo. Cohesin displayed uniform but nonspecific binding activity with all DNA fragments tested. Interestingly, DNA fragments with high occupancy by cohesin in vivo showed strong nucleosome positioning in vitro. We therefore utilized a defined model chromatin fragment (purified reconstituted dinucleosome) as a substrate to analyze cohesin interaction with chromatin. The four-subunit cohesin holocomplex showed a distinct chromatin binding activity in vitro, whereas the Smc1p-Smc3p dimer was unable to bind chromatin. Histone tails and ATP are dispensable for cohesin binding to chromatin in this reaction. A model for cohesin association with chromatin is proposed.	NICHD, LGRD, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Strunnikov, A (corresponding author), NICHD, LGRD, NIH, 18T Lib Dr,Rm 106, Bethesda, MD 20892 USA.	strunnik@box-s.nih.gov	Kagansky, Alexander/B-3137-2011	Kagansky, Alexander/0000-0002-6219-6892; Strunnikov, Alexander/0000-0002-9058-2256	Intramural NIH HHS [Z01 HD001903-11, Z99 AI999999] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001903] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Akhmedov AT, 1998, J BIOL CHEM, V273, P24088, DOI 10.1074/jbc.273.37.24088; Anderson DE, 2002, J CELL BIOL, V156, P419, DOI 10.1083/jcb.200111002; Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027; Blat Y, 1999, CELL, V98, P249, DOI 10.1016/S0092-8674(00)81019-3; BLOOM KS, 1982, CELL, V29, P305, DOI 10.1016/0092-8674(82)90147-7; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Chandler SP, 1999, BIOCHEMISTRY-US, V38, P7008, DOI 10.1021/bi990224y; Cheng TH, 1998, P NATL ACAD SCI USA, V95, P5521, DOI 10.1073/pnas.95.10.5521; CHIPEV CC, 1992, MOL CELL BIOL, V12, P45, DOI 10.1128/MCB.12.1.45; Ciosk R, 2000, MOL CELL, V5, P243, DOI 10.1016/S1097-2765(00)80420-7; Darwiche N, 1999, GENE, V233, P39, DOI 10.1016/S0378-1119(99)00160-2; Donze D, 1999, GENE DEV, V13, P698, DOI 10.1101/gad.13.6.698; Freeman L, 2000, J CELL BIOL, V149, P811, DOI 10.1083/jcb.149.4.811; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; Ghidelli S, 2001, EMBO J, V20, P4522, DOI 10.1093/emboj/20.16.4522; Goshima G, 2000, CELL, V100, P619, DOI 10.1016/S0092-8674(00)80699-6; Gruber S, 2003, CELL, V112, P765, DOI 10.1016/S0092-8674(03)00162-4; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Guschin D, 1998, BIOCHEMISTRY-US, V37, P8629, DOI 10.1021/bi9805846; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; Hakimi MA, 2002, NATURE, V418, P994, DOI 10.1038/nature01024; He XW, 2000, CELL, V101, P763, DOI 10.1016/S0092-8674(00)80888-0; Hirano T, 2000, ANNU REV BIOCHEM, V69, P115, DOI 10.1146/annurev.biochem.69.1.115; Hirano T, 2002, GENE DEV, V16, P399, DOI 10.1101/gad.955102; Ishii K, 2002, CELL, V109, P551, DOI 10.1016/S0092-8674(02)00756-0; Kim JS, 2002, J BIOL CHEM, V277, P45149, DOI 10.1074/jbc.M209123200; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Laloraya S, 2000, J CELL BIOL, V151, P1047, DOI 10.1083/jcb.151.5.1047; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Losada A, 2001, BIOESSAYS, V23, P924, DOI 10.1002/bies.1133; Losada A, 2001, CURR BIOL, V11, P268, DOI 10.1016/S0960-9822(01)00066-5; Mascarenhas J, 2002, EMBO J, V21, P3108, DOI 10.1093/emboj/cdf314; Megee PC, 1999, MOL CELL, V4, P445, DOI 10.1016/S1097-2765(00)80347-0; Meluh PB, 1997, GENE DEV, V11, P3401, DOI 10.1101/gad.11.24.3401; Meluh PB, 2002, EUR J BIOCHEM, V269, P2300, DOI 10.1046/j.1432-1033.2002.02886.x; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Nemergut ME, 2001, SCIENCE, V292, P1540, DOI 10.1126/science.292.5521.1540; Nonaka N, 2002, NAT CELL BIOL, V4, P89, DOI 10.1038/ncb739; Panizza S, 2000, CURR BIOL, V10, P1557, DOI 10.1016/S0960-9822(00)00854-X; Pasierbek P, 2001, GENE DEV, V15, P1349, DOI 10.1101/gad.192701; SIMON RH, 1978, NUCLEIC ACIDS RES, V5, P4805, DOI 10.1093/nar/5.12.4805; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; Sjogren C, 2001, CURR BIOL, V11, P991, DOI 10.1016/S0960-9822(01)00271-8; Sonoda E, 2001, DEV CELL, V1, P759, DOI 10.1016/S1534-5807(01)00088-0; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; Tanaka TU, 1999, CELL, V98, P847, DOI 10.1016/S0092-8674(00)81518-4; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; Walowsky C, 1999, J BIOL CHEM, V274, P7302, DOI 10.1074/jbc.274.11.7302; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	59	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3382	3388		10.1074/jbc.M306078200	http://dx.doi.org/10.1074/jbc.M306078200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14613943	hybrid, Green Accepted			2022-12-25	WOS:000188379600031
J	Stranzl, GR; Gruber, K; Steinkellner, G; Zangger, K; Schwab, H; Kratky, C				Stranzl, GR; Gruber, K; Steinkellner, G; Zangger, K; Schwab, H; Kratky, C			Observation of a short, strong hydrogen bond in the active site of hydroxynitrile lyase from Hevea brasiliensis explains a large pK(a) shift of the catalytic base induced by the reaction intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POISSON-BOLTZMANN EQUATION; ENZYMATIC CATALYSIS; SERINE PROTEASES; DELTA(5)-3-KETOSTEROID ISOMERASE; (S)-HYDROXYNITRILE LYASE; MANIHOT-ESCULENTA; CRYSTAL-STRUCTURE; NMR EVIDENCE; MECHANISM; CYANOGENESIS	The hydroxynitrile lyase from Hevea brasiliensis (HbHNL) uses a catalytic triad consisting of Ser(80)-His(235)-Asp(207) to enhance the basicity of Ser(80)-Ogamma for abstracting a proton from the OH group of the substrate cyanohydrin. Following the observation of a relatively short distance between a carboxyl oxygen of Asp(207) and the Ndelta(1)(His(235)) in a 1.1 Angstrom crystal structure of HbHNL, we here show by H-1 and N-15-NMR spectroscopy that a short, strong hydrogen bond (SSHB) is formed between the two residues upon binding of the competitive inhibitor thiocyanate to HbHNL: the proton resonance of H-Ndelta1(His(235)) moves from 15.41 ppm in the free enzyme to 19.35 ppm in the complex, the largest downfield shift observed so far upon inhibitor binding. Simultaneously, the D/H fractionation factor decreases from 0.98 to 0.35. In the observable pH range, i.e. between pH 4 and 10, no significant changes in chemical shifts (and therefore hydrogen bond strength) were observed for free HbHNL. For the complex with thiocyanate, the 19.35 ppm signal returned to 15.41 ppm at similar topH 8, which indicates a pK(a) near this value for the H-Nepsilon(2)(His(235)). These NMR results were analyzed on the basis of finite difference Poisson-Boltzmann calculations, which yielded the relative free energies of four protonation states of the His(235)-Asp(207) pair in solution as well as in the protein environment with and without bound inhibitor. The calculations explain all the NMR features, i.e. they suggest why a short, strong hydrogen bond is formed upon inhibitor binding and why this short, strong hydrogen bond reverts back to a normal one at similar topH 8. Importantly, the computations also yield a shift of the free energy of the anionic state relative to the zwitterionic reference state by about 10.6 kcal/mol, equivalent to a shift in the apparent pK(a) of His(235) from 2.5 to 10. This huge inhibitor-induced increase in basicity is a prerequisite for His(235) to act as general base in the HbHNL-catalyzed cyanohydrin reaction.	Karl Franzens Univ Graz, Inst Chem, A-8010 Graz, Austria; Karl Franzens Univ Graz, Inst Phys Chem, A-8010 Graz, Austria; Karl Franzens Univ Graz, Inst Organ & Bioorgan Chem, A-8010 Graz, Austria; Graz Tech Univ, Inst Biotechnol, A-8010 Graz, Austria; Angew Biokatalyse Kompetenzzentrum GmbH, A-8010 Graz, Austria	University of Graz; University of Graz; University of Graz; Graz University of Technology	Kratky, C (corresponding author), Karl Franzens Univ Graz, Inst Chem, Heinrich Str 28, A-8010 Graz, Austria.	Christoph.Kratky@uni-graz.at	Gruber, Karl/GPP-6706-2022	Gruber, Karl/0000-0002-3485-9740; Zangger, Klaus/0000-0003-1682-1594; Schwab, Helmut/0000-0003-2746-0624; Steinkellner, Georg/0000-0001-7565-8868				Ash EL, 1997, SCIENCE, V278, P1128, DOI 10.1126/science.278.5340.1128; Bauer M, 1999, BIOTECHNOL BIOENG, V62, P20, DOI 10.1002/(SICI)1097-0290(19990105)62:1&lt;20::AID-BIT3&gt;3.0.CO;2-I; BLOMBERG F, 1977, J AM CHEM SOC, V99, P1849; Cassidy CS, 1997, BIOCHEMISTRY-US, V36, P4576, DOI 10.1021/bi962013o; CAVANAGH J, 1996, PROTEIN NMR SPECTROS, P478; CHING WM, 1978, J AM CHEM SOC, V100, P6119, DOI 10.1021/ja00487a025; Cleland WW, 2000, ARCH BIOCHEM BIOPHYS, V382, P1, DOI 10.1006/abbi.2000.2011; CLELAND WW, 1992, BIOCHEMISTRY-US, V31, P317, DOI 10.1021/bi00117a001; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; CLELAND WW, 1995, SCIENCE, V269, P102; Conn EE, 1981, BIOCH PLANTS COMPREH, P479; EFFENBERGER F, 1994, ANGEW CHEM INT EDIT, V33, P1555, DOI 10.1002/anie.199415551; Fogolari F, 2002, J MOL RECOGNIT, V15, P377, DOI 10.1002/jmr.577; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; GarciaViloca M, 1997, J PHYS CHEM A, V101, P3880, DOI 10.1021/jp964031l; Gerlt JA, 1997, CHEM BIOL, V4, P259, DOI 10.1016/S1074-5521(97)90069-7; GRIENGL H, 1997, J CHEM SOC CHEM COMM, P1933; Gruber K, 2001, PROTEINS, V44, P26, DOI 10.1002/prot.1068; Gruber K, 1999, BIOL CHEM, V380, P993, DOI 10.1515/BC.1999.123; Ha NC, 2000, J BIOL CHEM, V275, P41100, DOI 10.1074/jbc.M007561200; Hanefeld U, 2001, BBA-PROTEIN STRUCT M, V1544, P133, DOI 10.1016/S0167-4838(00)00212-0; Harris TK, 1997, BIOCHEMISTRY-US, V36, P14661, DOI 10.1021/bi972039v; Harris TK, 2002, IUBMB LIFE, V53, P85, DOI 10.1080/15216540211468; Hasslacher M, 1997, PROTEIN EXPRES PURIF, V11, P61, DOI 10.1006/prep.1997.0765; Hickel A, 1996, PHYSIOL PLANTARUM, V98, P891, DOI 10.1111/j.1399-3054.1996.tb06700.x; Hur O, 1996, BIOCHEMISTRY-US, V35, P7378, DOI 10.1021/bi960240k; Kahyaoglu A, 1997, J BIOL CHEM, V272, P25547, DOI 10.1074/jbc.272.41.25547; KLEMPIER N, 1995, TETRAHEDRON-ASYMMETR, V6, P845, DOI 10.1016/0957-4166(95)00085-4; KLEMPIER N, 1993, TETRAHEDRON LETT, V34, P4769, DOI 10.1016/S0040-4039(00)74084-6; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUSE CG, 1992, CHIRALITY IND, P279; Kuhn P, 1998, BIOCHEMISTRY-US, V37, P13446, DOI 10.1021/bi9813983; Lauble H, 2001, PROTEIN SCI, V10, P1015, DOI 10.1110/ps.01301; Lauble H, 2001, ACTA CRYSTALLOGR D, V57, P194, DOI 10.1107/S0907444900015766; Lin J, 1998, P NATL ACAD SCI USA, V95, P14664, DOI 10.1073/pnas.95.25.14664; Massiah MA, 2001, BIOCHEMISTRY-US, V40, P5682, DOI 10.1021/bi010243j; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mildvan AS, 1999, METHOD ENZYMOL, V308, P219; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Northrop DB, 2001, ACCOUNTS CHEM RES, V34, P790, DOI 10.1021/ar000184m; Perrin CL, 1997, ANNU REV PHYS CHEM, V48, P511, DOI 10.1146/annurev.physchem.48.1.511; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; SCHALL M, 1996, THESIS K FRANZENS U; SCHEINER S, 1995, J AM CHEM SOC, V117, P6970, DOI 10.1021/ja00131a020; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; SEAVEY B R, 1991, Journal of Biomolecular NMR, V1, P217, DOI 10.1007/BF01875516; Shan SO, 1996, SCIENCE, V272, P97, DOI 10.1126/science.272.5258.97; Stratton JR, 2001, BIOCHEMISTRY-US, V40, P10411, DOI 10.1021/bi015542n; STRYER L, 1995, BIOCHEMISTRY-US, P42; TONG HX, 1995, BIOCHEMISTRY-US, V34, P3362, DOI 10.1021/bi00010a027; Viragh C, 2000, BIOCHEMISTRY-US, V39, P16200, DOI 10.1021/bi0022644; Wagner UG, 1996, STRUCTURE, V4, P811, DOI 10.1016/S0969-2126(96)00088-3; Wajant H, 1996, BIOL CHEM, V377, P611; Warshel A, 1996, P NATL ACAD SCI USA, V93, P13665, DOI 10.1073/pnas.93.24.13665; WARSHEL A, 1995, SCIENCE, V269, P102, DOI 10.1126/science.7661987; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P17; Xu XP, 2001, J BIOMOL NMR, V21, P321, DOI 10.1023/A:1013324104681; YANG AS, 1993, PROTEINS, V15, P252, DOI 10.1002/prot.340150304; Zhao QJ, 1997, BIOCHEMISTRY-US, V36, P14616, DOI 10.1021/bi971549m; Zhao QJ, 1996, P NATL ACAD SCI USA, V93, P8220, DOI 10.1073/pnas.93.16.8220; Zuegg J, 1999, PROTEIN SCI, V8, P1990, DOI 10.1110/ps.8.10.1990	61	37	37	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3699	3707		10.1074/jbc.M306814200	http://dx.doi.org/10.1074/jbc.M306814200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14597632	hybrid			2022-12-25	WOS:000188379600070
J	Harrison, JC; Zyla, TR; Bardes, ESG; Lew, DJ				Harrison, JC; Zyla, TR; Bardes, ESG; Lew, DJ			Stress-specific activation mechanisms for the "cell integrity" MAPK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; YEAST SACCHAROMYCES-CEREVISIAE; EXCHANGE FACTOR ROM2; GTP-BINDING PROTEIN; WALL INTEGRITY; SIGNAL-TRANSDUCTION; MORPHOGENESIS CHECKPOINT; FISSION YEAST; BUDDING YEAST; BUD EMERGENCE	Many environmental stresses trigger cellular responses by activating mitogen-activated protein kinase (MAPK) pathways. Once activated, these highly conserved protein kinase cascades can elicit cellular responses such as transcriptional activation of response genes, cytoskeletal rearrangement, and cell cycle arrest. The mechanism of pathway activation by environmental stresses is in most cases unknown. We have analyzed the activation of the budding yeast "cell integrity" MAPK pathway by heat shock, hypoosmotic shock, and actin perturbation, and we report that different stresses regulate this pathway at different steps. In no case can MAPK activation be explained by the prevailing view that stresses simply induce GTP loading of the Rho1p GTPase at the "top" of the pathway. Instead, our findings suggest that the stresses can modulate at least three distinct kinases acting between Rho1p and the MAPK. These findings suggest that stresses provide "lateral" inputs into this regulatory pathway, rather than operating in a linear "top-down" manner.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Lew, DJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	daniel.lew@duke.edu			NIGMS NIH HHS [GM53050] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053050] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrews PD, 2000, J CELL SCI, V113, P2685; [Anonymous], 1991, Methods Enzymol, V194, P1; Bickle M, 1998, EMBO J, V17, P2235, DOI 10.1093/emboj/17.8.2235; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Collister M, 2002, FEBS LETT, V527, P186, DOI 10.1016/S0014-5793(02)03220-9; COSTIGAN C, 1992, MOL CELL BIOL, V12, P1162, DOI 10.1128/MCB.12.3.1162; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; Delley PA, 1999, J CELL BIOL, V147, P163, DOI 10.1083/jcb.147.1.163; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Gray JV, 1997, EMBO J, V16, P4924, DOI 10.1093/emboj/16.16.4924; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hahn JS, 2002, J BIOL CHEM, V277, P21278, DOI 10.1074/jbc.M202557200; Harrison JC, 2001, NAT CELL BIOL, V3, P417, DOI 10.1038/35070104; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; Inagaki M, 1999, MOL CELL BIOL, V19, P8344; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; Krause SA, 2002, CURR BIOL, V12, P588, DOI 10.1016/S0960-9822(02)00760-1; LEE KS, 1992, MOL CELL BIOL, V12, P172, DOI 10.1128/MCB.12.1.172; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; Lorberg A, 2001, MOL GENET GENOMICS, V266, P514; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; Mattison CP, 1999, MOL CELL BIOL, V19, P7651; Moore DD, 1995, GLOB MOB SURV; Moskow JJ, 2000, MOL CELL BIOL, V20, P7559, DOI 10.1128/MCB.20.20.7559-7571.2000; Nguyen AN, 1999, GENE DEV, V13, P1653, DOI 10.1101/gad.13.13.1653; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; Perez P, 2002, J BIOCHEM, V132, P513, DOI 10.1093/oxfordjournals.jbchem.a003250; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; Philip B, 2001, MOL CELL BIOL, V21, P271, DOI 10.1128/MCB.21.1.271-280.2001; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Roumanie O, 2001, FEBS LETT, V506, P149, DOI 10.1016/S0014-5793(01)02906-4; Schmidt A, 2002, MOL MICROBIOL, V45, P1433, DOI 10.1046/j.1365-2958.2002.03110.x; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Shieh JC, 1998, J CELL SCI, V111, P2799; Shiozaki K, 1998, MOL BIOL CELL, V9, P1339, DOI 10.1091/mbc.9.6.1339; Sia RAL, 1996, MOL BIOL CELL, V7, P1657, DOI 10.1091/mbc.7.11.1657; SIKORSKI RS, 1989, GENETICS, V122, P19; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Verna J, 1997, P NATL ACAD SCI USA, V94, P13804, DOI 10.1073/pnas.94.25.13804; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Watanabe D, 2001, YEAST, V18, P943, DOI 10.1002/yea.742; WATANABE M, 1994, J BIOL CHEM, V269, P16829; WATANABE Y, 1995, MOL CELL BIOL, V15, P5740; YAN MH, 1994, J BIOL CHEM, V269, P19067; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	55	69	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2616	2622		10.1074/jbc.M306110200	http://dx.doi.org/10.1074/jbc.M306110200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14610085	hybrid			2022-12-25	WOS:000188211300036
J	West, JM; Tsuruta, H; Kantrowitz, ER				West, JM; Tsuruta, H; Kantrowitz, ER			A fluorescent probe-labeled Escherichia coli aspartate transcarbamoylase that monitors the allosteric conformational state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUATERNARY-STRUCTURE TRANSITION; PYRENE EXCIMER FLUORESCENCE; PHOSPHONACETYL-L-ASPARTATE; RAY SOLUTION SCATTERING; BISUBSTRATE ANALOG; HETEROTROPIC INTERACTIONS; CRYSTAL-STRUCTURES; EFFECTOR BINDING; CARBAMOYLTRANSFERASE; PROTEIN	A new system has been developed capable of monitoring conformational changes of the 240s loop of aspartate transcarbamoylase, which are tightly correlated with the quaternary structural transition, with high sensitivity in solution. Pyrene, a fluorescent probe, was conjugated to residue 241 in the 240s loop of aspartate transcarbamoylase to monitor changes in conformation by fluorescence spectroscopy. Pyrene maleimide was conjugated to a cysteine residue on the 240s loop of a previously constructed double catalytic chain mutant version of the enzyme, C47A/A241C. The pyrene-labeled enzyme undergoes the normal T to R structural transition, as demonstrated by small-angle x-ray scattering. Like the wild-type enzyme, the pyrene-labeled enzyme exhibits cooperativity toward aspartate, and is activated by ATP and inhibited by CTP at subsaturating concentrations of aspartate. The binding of the bisubstrate analogue N-(phosphonoacetyl)-L-aspartate (PALA), or the aspartate analogue succinate, in the presence of saturating carbamoyl phosphate, to the pyrene-labeled enzyme caused a sigmoidal change in the fluorescence emission. Saturation with ATP and CTP ( in the presence of either subsaturating amounts of PALA or succinate and carbamoyl phosphate) caused a hyperbolic increase and decrease, respectively, in the fluorescence emission. The half-saturation values from the fluorescence saturation curves and kinetic saturation curves were, within error, identical. Fluorescence and small-angle x-ray scattering stopped-flow experiments, using aspartate and carbamoyl phosphate, confirm that the change in excimer fluorescence and the quaternary structure change correlate. These results in conjunction with previous studies suggest that the allosteric transition involves both global and local conformational changes and that the heterotropic effect of the nucleotides may be exerted through local conformational changes in the active site by directly influencing the conformation of the 240s loop.	Boston Coll, Merkert Chem Ctr, Dept Chem, Chestnut Hill, MA 02467 USA; Stanford Linear Accelerator Ctr, Stanford Synchrotron Radiat Lab, Menlo Pk, CA 94025 USA	Boston College; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Kantrowitz, ER (corresponding author), Boston Coll, Merkert Chem Ctr, Dept Chem, Chestnut Hill, MA 02467 USA.				NCRR NIH HHS [P41RR01209] Funding Source: Medline; NIGMS NIH HHS [GM26237] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026237] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Birks J., 1970, PHOTOPHYSICS AROMATI, DOI DOI 10.1002/BBPC.19700741223; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANGEUX JP, 1968, BIOCHEMISTRY-US, V7, P531, DOI 10.1021/bi00842a007; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P680; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; Endrizzi JA, 2000, P NATL ACAD SCI USA, V97, P5077, DOI 10.1073/pnas.090087197; FETLER L, 1995, J MOL BIOL, V251, P243, DOI 10.1006/jmbi.1995.0432; FETLER L, 1995, BIOCHEMISTRY-US, V34, P15654, DOI 10.1021/bi00048a008; Fetler L, 2001, BIOCHEMISTRY-US, V40, P8773, DOI 10.1021/bi0029494; GERHART JC, 1968, BIOCHEMISTRY-US, V7, P538, DOI 10.1021/bi00842a600; GERHART JC, 1967, J BIOL CHEM, V242, P2886; GERHART JC, 1965, BIOCHEMISTRY-US, V4, P1054, DOI 10.1021/bi00882a012; GERHART JC, 1962, J BIOL CHEM, V237, P891; GOUAUX JE, 1990, BIOCHEMISTRY-US, V29, P7702, DOI 10.1021/bi00485a020; HERVE G, 1985, J MOL BIOL, V185, P189, DOI 10.1016/0022-2836(85)90190-1; HONZATKO RB, 1982, J MOL BIOL, V160, P219, DOI 10.1016/0022-2836(82)90175-9; HONZATKO RB, 1982, P NATL ACAD SCI-BIOL, V79, P7171, DOI 10.1073/pnas.79.23.7171; HOWLETT GJ, 1977, BIOCHEMISTRY-US, V16, P5091, DOI 10.1021/bi00642a023; HSUANYU Y, 1989, BIOCHIM BIOPHYS ACTA, V995, P54, DOI 10.1016/0167-4838(89)90232-X; Jin L, 1999, PROTEINS, V37, P729, DOI 10.1002/(SICI)1097-0134(19991201)37:4<729::AID-PROT21>3.0.CO;2-F; KANTROWITZ ER, 1988, SCIENCE, V241, P669, DOI 10.1126/science.3041592; KANTROWITZ ER, 1990, TRENDS BIOCHEM SCI, V15, P53, DOI 10.1016/0968-0004(90)90176-C; KE HM, 1988, J MOL BIOL, V204, P725, DOI 10.1016/0022-2836(88)90365-8; KE HM, 1984, P NATL ACAD SCI USA, V81, P4027; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; LADJIMI MM, 1985, J MOL BIOL, V186, P715, DOI 10.1016/0022-2836(85)90391-2; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P276, DOI 10.1021/bi00401a042; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehrer S S, 1995, Subcell Biochem, V24, P115; Lehrer SS, 1997, METHOD ENZYMOL, V278, P286; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MOODY MF, 1979, J MOL BIOL, V133, P517, DOI 10.1016/0022-2836(79)90405-4; NEWTON CJ, 1990, P NATL ACAD SCI USA, V87, P2309, DOI 10.1073/pnas.87.6.2309; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; PASTRALANDIS SC, 1978, J BIOL CHEM, V253, P4624; Sakash JB, 2000, J BIOL CHEM, V275, P752, DOI 10.1074/jbc.275.2.752; SCHACHMAN HK, 1988, J BIOL CHEM, V263, P18583; SILVER RS, 1983, J MOL BIOL, V168, P729, DOI 10.1016/S0022-2836(83)80072-2; STEVENS RC, 1990, BIOCHEMISTRY-US, V29, P7691, DOI 10.1021/bi00485a019; STEVENS RC, 1992, P NATL ACAD SCI USA, V89, P5281, DOI 10.1073/pnas.89.12.5281; Svergun DI, 1997, PROTEINS, V27, P110; TAUC P, 1982, J MOL BIOL, V155, P155, DOI 10.1016/0022-2836(82)90442-9; TSURUTA H, 1990, FEBS LETT, V263, P66, DOI 10.1016/0014-5793(90)80706-O; Tsuruta H, 1998, PROTEINS, V31, P383, DOI 10.1002/(SICI)1097-0134(19980601)31:4<383::AID-PROT5>3.3.CO;2-O; West JM, 2003, J AM CHEM SOC, V125, P9924, DOI 10.1021/ja0360440; West JM, 2002, J BIOL CHEM, V277, P47300, DOI 10.1074/jbc.M209913200; WILD JR, 1989, P NATL ACAD SCI USA, V86, P46, DOI 10.1073/pnas.86.1.46	51	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					945	951		10.1074/jbc.M304018200	http://dx.doi.org/10.1074/jbc.M304018200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14581486	hybrid			2022-12-25	WOS:000187722800017
J	Yamazaki, Y; Takani, K; Atoda, H; Morita, T				Yamazaki, Y; Takani, K; Atoda, H; Morita, T			Snake venom vascular endothelial growth factors (VEGFs) exhibit potent activity through their specific recognition of KDR (VEGF receptor 2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TYROSINE KINASE; PERMEABILITY FACTOR; FLT-1 RECEPTOR; KDR/FLK-1 RECEPTOR; CRYSTAL-STRUCTURE; CELLS SECRETE; TUMOR-CELLS; ORF VIRUS; BINDING	Vascular endothelial growth factor ( VEGF(165)) exhibits multiple effects via the activation of two distinct endothelial receptor tyrosine kinases: Flt-1 (fms-like tyrosine kinase-1) and KDR ( kinase insert domain-containing receptor). KDR shows strong ligand-dependent tyrosine phosphorylation in comparison with Flt-1 and mainly mediates the mitogenic, angiogenic, and permeability-enhancing effects of VEGF(165). Here we show the isolation of two VEGFs from viper venoms and the characterization of their unique biological properties. Snake venom VEGFs strongly stimulated proliferation of vascular endothelial cells in vitro. Interestingly, the maximum activities were almost twice that of VEGF(165). They also induced strong hypotension on rat arterial blood pressure compared with VEGF(165) in vivo. A receptor binding assay revealed that snake venom VEGFs bound to KDR-IgG with high affinity (K-d = similar to 0.1 nM) as well as to VEGF(165) but did not interact with Flt-1, Flt-4, or neuropilin-1 at all. Our data clearly indicate that snake venom VEGFs act through the specific activation of KDR and show potent effects. Snake venom VEGFs are a highly specific ligand to KDR and form a new group of the VEGF family.	Meiji Pharmaceut Univ, Dept Biochem, Tokyo 2048588, Japan	Meiji Pharmaceutical University	Morita, T (corresponding author), Meiji Pharmaceut Univ, Dept Biochem, 2-522-1 Noshio, Tokyo 2048588, Japan.			Yamazaki, Yasuo/0000-0001-5297-9837				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Clauss M, 2000, SEMIN THROMB HEMOST, V26, P561, DOI 10.1055/s-2000-13213; CONN G, 1990, P NATL ACAD SCI USA, V87, P1323, DOI 10.1073/pnas.87.4.1323; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Ferrara N, 2001, ACTA HAEMATOL-BASEL, V106, P148, DOI 10.1159/000046610; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gasmi A, 2002, J BIOL CHEM, V277, P29992, DOI 10.1074/jbc.M202202200; Gelinas DS, 2002, BRIT J PHARMACOL, V137, P1021, DOI 10.1038/sj.bjp.0704956; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054; Joukov V, 1996, EMBO J, V15, P290; Junqueira de Azevedo ILM, 2001, J BIOL CHEM, V276, P39836; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Komori Y, 1999, BIOCHEMISTRY-US, V38, P11796, DOI 10.1021/bi990562z; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Pan B, 2002, J MOL BIOL, V316, P769, DOI 10.1006/jmbi.2001.5370; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; SHIBUYA M, 1990, ONCOGENE, V5, P519; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; Wise LM, 2003, J BIOL CHEM, V278, P38004, DOI 10.1074/jbc.M301194200; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200	39	89	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					51985	51988		10.1074/jbc.C300454200	http://dx.doi.org/10.1074/jbc.C300454200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14600159	hybrid			2022-12-25	WOS:000187480700003
J	Wheatley, SP; Henzing, AJ; Dodson, H; Khaled, W; Earnshaw, WC				Wheatley, SP; Henzing, AJ; Dodson, H; Khaled, W; Earnshaw, WC			Aurora-B phosphorylation in vitro identifies a residue of survivin that is essential for its localization and binding to inner centromere protein (INCENP) in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H3 PHOSPHORYLATION; CHROMOSOME SEGREGATION; KINASE-ACTIVITY; CENTRAL SPINDLE; CYTOKINESIS; MITOSIS; COMPLEX; CONDENSATION; APOPTOSIS; ALIGNMENT	The chromosomal passengers, aurora-B kinase, inner centromere protein (INCENP), and survivin, are essential proteins that have been implicated in the regulation of metaphase chromosome alignment, spindle checkpoint function, and cytokinesis. All three share a common pattern of localization, and it was recently demonstrated that aurora-B, INCENP, and survivin are present in a complex in Xenopus eggs and Saccharomyces cerevisiae. The presence of aurora-B kinase in the complex and its ability to bind the other components directly suggest that INCENP and survivin could potentially be aurora-B substrates. This hypothesis was recently proven for INCENP in vitro. Here we report that human survivin is specifically phosphorylated in vitro by aurora-B kinase at threonine 117 in its carboxyl alpha-helical coil. Mutation of threonine 117 to alanine prevents survivin phosphorylation by aurora-B in vitro but does not alter its localization in HeLa cells. By contrast, a phospho-mimic, in which threonine 117 was mutated to glutamic acid, was unable to localize correctly at any stage in mitosis. Mutation at threonine 117 also prevented immunoprecipitation of INCENP with survivin in vivo. These data suggest that phosphorylation of survivin at threonine 117 by aurora-B may regulate targeting of survivin, and possibly the entire passenger complex, in mammals.	Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Ctr Cell Biol, Chromosome Struct Lab, Edinburgh EH9 3JR, Midlothian, Scotland	University of Edinburgh	Earnshaw, WC (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Ctr Cell Biol, Chromosome Struct Lab, Mayfield Rd, Edinburgh EH9 3JR, Midlothian, Scotland.	bill.earnshaw@ed.ac.uk	Earnshaw, William/AAY-7438-2020; Dodson, Helen/H-4757-2016	Dodson, Helen/0000-0002-8591-1107; Earnshaw, William/0000-0002-7191-0621; Khaled, Walid/0000-0001-9068-5776	Wellcome Trust [073915] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adams RR, 2000, CURR BIOL, V10, P1075, DOI 10.1016/S0960-9822(00)00673-4; Adams RR, 2001, J CELL BIOL, V153, P865, DOI 10.1083/jcb.153.4.865; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bishop JD, 2002, J BIOL CHEM, V277, P27577, DOI 10.1074/jbc.C200307200; Bolton MA, 2002, MOL BIOL CELL, V13, P3064, DOI 10.1091/mbc.E02-02-0092; Buvelot S, 2003, J CELL BIOL, V160, P329, DOI 10.1083/jcb.200209018; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; EARNSHAW WC, 1991, CHROMOSOMA, V100, P139, DOI 10.1007/BF00337241; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Jensen ON, 1998, PROTEINS, P74; Kaitna S, 2000, CURR BIOL, V10, P1172, DOI 10.1016/S0960-9822(00)00721-1; Kang JS, 2001, J CELL BIOL, V155, P763, DOI 10.1083/jcb.200105029; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Leverson JD, 2002, MOL BIOL CELL, V13, P1132, DOI 10.1091/mbc.01-07-0330; Mahotka C, 1999, CANCER RES, V59, P6097; Mollinari C, 2003, DEV CELL, V5, P295, DOI 10.1016/S1534-5807(03)00205-3; Morrison C, 2002, NUCLEIC ACIDS RES, V30, P5318, DOI 10.1093/nar/gkf665; Murata-Hori M, 2002, CURR BIOL, V12, P894, DOI 10.1016/S0960-9822(02)00848-5; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Petersen J, 2003, CURR BIOL, V13, P590, DOI 10.1016/S0960-9822(03)00205-7; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X	28	113	128	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5655	5660		10.1074/jbc.M311299200	http://dx.doi.org/10.1074/jbc.M311299200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14610074	hybrid			2022-12-25	WOS:000188776500076
J	Williams, TL; Baker, TA				Williams, TL; Baker, TA			Reorganization of the Mu transpososome active sites during a cooperative transition between DNA cleavage and joining	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND TRANSFER; PHAGE-MU; BACTERIOPHAGE-MU; B-PROTEIN; SYNAPTIC COMPLEX; TRANSPOSITIONAL RECOMBINATION; MUTATIONAL ANALYSIS; TN5 TRANSPOSITION; TRANSFER STEPS; HOST JUNCTION	Transposition of mobile genetic elements proceeds through a series of DNA phosphoryl transfer reactions, with multiple reaction steps catalyzed by the same set of active site residues. Mu transposase repeatedly utilizes the same active site DDE residues to cleave and join a single DNA strand at each transposon end to a new, distant DNA location (the target DNA). To better understand how DNA is manipulated within the Mu transposase-DNA complex during recombination, the impact of the DNA immediately adjacent to the Mu DNA ends ( the flanking DNA) on the progress of transposition was investigated. We show that, in the absence of the MuB activator, the 3'-flanking strand can slow one or more steps between DNA cleavage and joining. The presence of this flanking DNA strand in just one active site slows the joining step in both active sites. Further evidence suggests that this slow step is not due to a change in the affinity of the transpososome for the target DNA. Finally, we demonstrate that MuB activates transposition by stimulating the reaction step between cleavage and joining that is otherwise slowed by this flanking DNA strand. Based on these results, we propose that the 3'-flanking DNA strand must be removed from, or shifted within, both active sites after the cleavage step; this movement is coupled to a conformational change within the transpososome that properly positions the target DNA simultaneously within both active sites and thereby permits joining.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Baker, TA (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	tabaker@mit.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049224] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM049224, R01 GM049224-11] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aldaz H, 1996, CELL, V85, P257, DOI 10.1016/S0092-8674(00)81102-2; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; Bhasin A, 1999, J BIOL CHEM, V274, P37021, DOI 10.1074/jbc.274.52.37021; Bolland S, 1996, CELL, V84, P223, DOI 10.1016/S0092-8674(00)80977-0; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; Chaconas G, 1996, CURR BIOL, V6, P817, DOI 10.1016/S0960-9822(02)00603-6; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; Davies DR, 2000, SCIENCE, V289, P77, DOI 10.1126/science.289.5476.77; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Kennedy AK, 2000, CELL, V101, P295, DOI 10.1016/S0092-8674(00)80839-9; Kennedy AK, 1998, CELL, V95, P125, DOI 10.1016/S0092-8674(00)81788-2; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; Kleckner N, 1996, CURR TOP MICROBIOL, V204, P49; Krementsova E, 1998, J BIOL CHEM, V273, P31358, DOI 10.1074/jbc.273.47.31358; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; Levchenko I, 1997, GENE DEV, V11, P1561, DOI 10.1101/gad.11.12.1561; Lovell S, 2002, NAT STRUCT BIOL, V9, P278, DOI 10.1038/nsb778; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1995, CELL, V83, P375, DOI 10.1016/0092-8674(95)90115-9; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; Naigamwalla DZ, 1997, EMBO J, V16, P5227, DOI 10.1093/emboj/16.17.5227; Naigamwalla DZ, 1998, J MOL BIOL, V282, P265, DOI 10.1006/jmbi.1998.2011; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; Namgoong SY, 1998, EMBO J, V17, P3775, DOI 10.1093/emboj/17.13.3775; Namgoong SY, 1998, J MOL BIOL, V275, P221, DOI 10.1006/jmbi.1997.1466; Naumann TA, 2000, P NATL ACAD SCI USA, V97, P8944, DOI 10.1073/pnas.160107997; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; Rice PA, 2001, NAT STRUCT BIOL, V8, P302, DOI 10.1038/86166; Sakai J, 1997, CELL, V89, P205, DOI 10.1016/S0092-8674(00)80200-7; Sarnovsky RJ, 1996, EMBO J, V15, P6348, DOI 10.1002/j.1460-2075.1996.tb01024.x; Savilahti H, 1996, CELL, V85, P271, DOI 10.1016/S0092-8674(00)81103-4; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; Stellwagen AE, 1998, TRENDS BIOCHEM SCI, V23, P486, DOI 10.1016/S0968-0004(98)01325-5; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; SURETTE MG, 1991, J BIOL CHEM, V266, P17306; Williams TL, 1999, GENE DEV, V13, P2725, DOI 10.1101/gad.13.20.2725; Wlodawer A, 1999, ADV VIRUS RES, V52, P335, DOI 10.1016/S0065-3527(08)60305-X; WU ZG, 1995, EMBO J, V14, P3835, DOI 10.1002/j.1460-2075.1995.tb00053.x; WU ZG, 1994, J BIOL CHEM, V269, P28829; Yamauchi M, 1998, EMBO J, V17, P5509, DOI 10.1093/emboj/17.18.5509; ZOU A, 1991, J BIOL CHEM, V266, P20476	45	6	6	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5135	5145		10.1074/jbc.M308156200	http://dx.doi.org/10.1074/jbc.M308156200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14585843	hybrid			2022-12-25	WOS:000188776500013
J	Ali, R; Brett, CL; Mukherjee, S; Rao, R				Ali, R; Brett, CL; Mukherjee, S; Rao, R			Inhibition of sodium/proton exchange by a Rab-GTPase-activating protein regulates endosomal traffic in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR PROTON PUMP; TRANS-GOLGI NETWORK; NA+/H+ EXCHANGER; H+-ATPASE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE EXCHANGE; POTASSIUM TRANSPORTER; SALT TOLERANCE; VESICLES; MUTANTS	Endosomal Na+/H+ exchangers are important for salt and osmotolerance, vacuolar pH regulation, and endosomal trafficking. We show that the C terminus of yeast Nhx1 interacts with Gyp6, a GTPase-activating protein for the Ypt/Rab family of GTPases, and that Gyp6 colocalizes with Nhx1 in the endosomal/prevacuolar compartment (PVC). The gyp6 null mutant exhibits novel phenotypes consistent with loss of negative regulation of Nhx1, including increased tolerance to hygromycin, increased vacuolar pH, and decreased plasma membrane potential. In contrast, overexpression of Gyp6 increases sensitivity to hygromycin, decreases vacuolar pH, and results in a slight missorting of vacuolar carboxypeptidase Y to the cell surface. We conclude that Gyp6 is a negative regulator of Nhx1-dependent trafficking out of the PVC. Taken together with its GTPase-activating protein-dependent role as a negative regulator of Ypt6-mediated retrograde traffic to the Golgi, we propose that Gyp6 coordinates upstream and downstream events in the PVC to Golgi pathway. Our findings provide a possible molecular link between intraendosomal pH and regulation of vesicular trafficking.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University	Rao, R (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.	rrao@jhmi.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054214] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54214] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; Bowers K, 2000, MOL BIOL CELL, V11, P4277, DOI 10.1091/mbc.11.12.4277; Brett CL, 2002, AM J PHYSIOL-CELL PH, V282, pC1031, DOI 10.1152/ajpcell.00420.2001; De Antoni A, 2002, J BIOL CHEM, V277, P41023, DOI 10.1074/jbc.M205783200; DEAN N, 1995, P NATL ACAD SCI USA, V92, P1287, DOI 10.1073/pnas.92.5.1287; Du LL, 2001, MOL BIOL CELL, V12, P1215, DOI 10.1091/mbc.12.5.1215; Eitzen G, 2000, EMBO J, V19, P6713, DOI 10.1093/emboj/19.24.6713; Elkind NB, 2000, J CELL BIOL, V149, P95, DOI 10.1083/jcb.149.1.95; Forment J, 2002, BBA-BIOMEMBRANES, V1565, P36, DOI 10.1016/S0005-2736(02)00503-5; Gama L, 1999, BIOTECHNIQUES, V26, P814, DOI 10.2144/99265bm03; Gaskova D, 1999, INT J BIOCHEM CELL B, V31, P575, DOI 10.1016/S1357-2725(99)00002-3; Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480; GONZALEZ A, 1978, BIOCHIM BIOPHYS ACTA, V521, P459, DOI 10.1016/0005-2787(78)90287-3; Goossens A, 2000, MOL CELL BIOL, V20, P7654, DOI 10.1128/MCB.20.20.7654-7661.2000; James P, 1996, GENETICS, V144, P1425; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; Li BJ, 1996, J BIOL CHEM, V271, P16813, DOI 10.1074/jbc.271.28.16813; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Luo ZL, 2003, J BIOL CHEM, V278, P791, DOI 10.1074/jbc.M209120200; Maranda B, 2001, J BIOL CHEM, V276, P18540, DOI 10.1074/jbc.M011577200; Marshansky V, 2002, CURR OPIN NEPHROL HY, V11, P527, DOI 10.1097/00041552-200209000-00009; MELLMAN I, 1992, J EXP BIOL, V172, P39; Mulet JM, 1999, MOL CELL BIOL, V19, P3328; Nass R, 1999, MICROBIOL-SGM, V145, P3221, DOI 10.1099/00221287-145-11-3221; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Nass R, 1998, J BIOL CHEM, V273, P21054, DOI 10.1074/jbc.273.33.21054; Numata M, 2001, J BIOL CHEM, V276, P17387, DOI 10.1074/jbc.M101319200; Ortiz D, 2002, J CELL BIOL, V157, P1005, DOI 10.1083/jcb.200201003; Plant PJ, 1999, J BIOL CHEM, V274, P37270, DOI 10.1074/jbc.274.52.37270; Price A, 2000, J CELL BIOL, V148, P1231, DOI 10.1083/jcb.148.6.1231; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Shin ME, 2001, J BIOL CHEM, V276, P41388, DOI 10.1074/jbc.M105665200; Siniossoglou S, 2000, EMBO J, V19, P4885, DOI 10.1093/emboj/19.18.4885; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; Ungermann C, 2000, P NATL ACAD SCI USA, V97, P8889, DOI 10.1073/pnas.160269997; vanWeert AWM, 1997, EUR J CELL BIOL, V74, P417; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; Wakabayashi S, 1997, BIOCHEMISTRY-US, V36, P12854, DOI 10.1021/bi9715472; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; Wang W, 2002, MOL BIOL CELL, V13, P3336, DOI 10.1091/mbc.01-12-0577; Wells KM, 2001, J BIOL CHEM, V276, P3401, DOI 10.1074/jbc.M001688200; Will E, 2001, J BIOL CHEM, V276, P12135, DOI 10.1074/jbc.M011451200; Yoshida S, 2000, MOL GEN GENET, V263, P877, DOI 10.1007/s004380000255; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; ZEUZEM S, 1992, J MEMBRANE BIOL, V125, P231	48	91	92	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4498	4506		10.1074/jbc.M307446200	http://dx.doi.org/10.1074/jbc.M307446200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14610088	Green Published, hybrid			2022-12-25	WOS:000188554300070
J	Suh, KS; Mutoh, M; Nagashima, K; Fernandez-Salas, E; Edwards, LE; Hayes, DD; Crutchley, JM; Marin, KG; Dumont, RA; Levy, JM; Cheng, C; Garfield, S; Yuspa, SH				Suh, KS; Mutoh, M; Nagashima, K; Fernandez-Salas, E; Edwards, LE; Hayes, DD; Crutchley, JM; Marin, KG; Dumont, RA; Levy, JM; Cheng, C; Garfield, S; Yuspa, SH			The organellular chloride channel protein CLIC4/mtCLIC translocates to the nucleus in response to cellular stress and accelerates apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; INTRACELLULAR PH; CLIC FAMILY; EXPRESSION; P64; ANION; MEMBRANES; BIOLOGY; IMPORT	CLIC4/mtCLIC, a chloride intracellular channel protein, localizes to the mitochondria and cytoplasm of keratinocytes and participates in the apoptotic response to stress. We now show that multiple stress inducers cause the translocation of cytoplasmic CLIC4 to the nucleus. Immunogold electron microscopy and confocal analyses indicate that nuclear CLIC4 is detected prior to the apoptotic phenotype. CLIC4 associates with the Ran, NTF2, and Importin-a nuclear import complexes in immunoprecipitates of lysates from cells treated with apoptotic/stress-inducing agents. Deletion or mutation of the nuclear localization signal in the C terminus of CLIC4 eliminates nuclear translocation, whereas N terminus deletion enhances nuclear localization. Targeting CLIC4 to the nucleus via adenoviral transduction accelerates apoptosis when compared with cytoplasmic CLIC4, and only nuclear-targeted CLIC4 causes apoptosis in Apaf null mouse fibroblasts or in Bcl-2-overexpressing keratinocytes. These results indicate that CLIC4 nuclear translocation is an integral part of the cellular response to stress and may contribute to the initiation of nuclear alterations that are associated with apoptosis.	NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; NCI, Confocal Microscopy Core Facil, Expt Carcinogenesis Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; NCI, Electron Microscope Facil, Image Anal Lab, NIH,Sci Applicat Int Corp Inc, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Yuspa, SH (corresponding author), NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA.	yuspas@dc37a.nci.nih.gov	Mutoh, Michihiro/AAB-1868-2022; Levy, Joshua M/AAM-1583-2020; Walter, Rebecca A Dumont/G-6820-2019	Levy, Joshua M/0000-0001-5907-3421; Walter, Rebecca A Dumont/0000-0002-7416-0483	NATIONAL CANCER INSTITUTE [Z01BC005445, ZIABC005445] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Arnould T, 2003, FASEB J, V17, P2145, DOI 10.1096/fj.03-0075fje; Ashley RH, 2003, MOL MEMBR BIOL, V20, P1, DOI 10.1080/09687680210042746; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Chuang JZ, 1999, J NEUROSCI, V19, P2919; Cromer BA, 2002, EUR BIOPHYS J BIOPHY, V31, P356, DOI 10.1007/s00249-002-0219-1; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Duncan RR, 1997, J BIOL CHEM, V272, P23880, DOI 10.1074/jbc.272.38.23880; EASTMAN A, 1995, METHOD CELL BIOL, V46, P41; Edwards JC, 2000, J BIOL CHEM, V275, P31826, DOI 10.1074/jbc.M005275200; Edwards JC, 1998, J MEMBRANE BIOL, V163, P119; Edwards JC, 1999, AM J PHYSIOL-RENAL, V276, pF398, DOI 10.1152/ajprenal.1999.276.3.F398; Fernandez-Salas E, 2002, MOL CELL BIOL, V22, P3610, DOI 10.1128/MCB.22.11.3610-3620.2002; Fernandez-Salas E, 1999, J BIOL CHEM, V274, P36488, DOI 10.1074/jbc.274.51.36488; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Harrop SJ, 2001, J BIOL CHEM, V276, P44993, DOI 10.1074/jbc.M107804200; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; Hu W, 1999, J BIOL CHEM, V274, P15820, DOI 10.1074/jbc.274.22.15820; Jentsch TJ, 2002, NATURE, V415, P276, DOI 10.1038/415276a; Kitamura A, 2001, BIOCHEM BIOPH RES CO, V287, P435, DOI 10.1006/bbrc.2001.5577; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Miyazaki K, 2001, J BIOCHEM-TOKYO, V129, P963, DOI 10.1093/oxfordjournals.jbchem.a002944; Mizukawa Y, 2002, AM J PHYSIOL-CELL PH, V282, pC786, DOI 10.1152/ajpcell.00239.2001; Pervaiz S, 2002, BIOCHEM BIOPH RES CO, V290, P1145, DOI 10.1006/bbrc.2001.6274; Pfanner N, 2002, CURR OPIN CELL BIOL, V14, P400, DOI 10.1016/S0955-0674(02)00355-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Qian ZJ, 1999, J BIOL CHEM, V274, P1621, DOI 10.1074/jbc.274.3.1621; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Ronnov-Jessen L, 2002, AM J PATHOL, V161, P471, DOI 10.1016/S0002-9440(10)64203-4; Shanks RA, 2002, J BIOL CHEM, V277, P40973, DOI 10.1074/jbc.M112277200; Shorning BY, 2003, DEV GENES EVOL, V213, P514, DOI 10.1007/s00427-003-0356-2; Shrode LD, 1997, J BIOENERG BIOMEMBR, V29, P393, DOI 10.1023/A:1022407116339; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Suginta W, 2001, BIOCHEM J, V359, P55, DOI 10.1042/0264-6021:3590055; Tobin GJ, 1997, VIROLOGY, V236, P307, DOI 10.1006/viro.1997.8745; Tulk BM, 2002, AM J PHYSIOL-CELL PH, V282, pC1103, DOI 10.1152/ajpcell.00402.2001; Wurzer G, 2001, J CELL BIOCHEM, P1	37	111	117	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4632	4641		10.1074/jbc.M311632200	http://dx.doi.org/10.1074/jbc.M311632200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14610078	hybrid			2022-12-25	WOS:000188554300085
J	Berezhnoy, D; Nyfeler, Y; Gonthier, A; Schwob, H; Goeldner, M; Sigel, E				Berezhnoy, D; Nyfeler, Y; Gonthier, A; Schwob, H; Goeldner, M; Sigel, E			On the benzodiazepine binding pocket in GABA(A) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC ACID(A) RECEPTORS; GATED ION CHANNELS; A-RECEPTOR; ALPHA-SUBUNIT; RAT-BRAIN; CHEMICAL SENSORS; CYSTEINE MUTANTS; SITE LIGANDS; BETA-SUBUNIT; STRUCTURAL REQUIREMENTS	Benzodiazepines are used for their sedative/hypnotic, anxiolytic, muscle relaxant, and anticonvulsive effects. They exert their actions through a specific high affinity binding site on the major inhibitory neurotransmitter receptor, the gamma-aminobutyric acid, type A (GABA(A)) receptor channel, where they act as positive allosteric modulators. To start to elucidate the relative positioning of benzodiazepine binding site ligands in their binding pocket, GABA(A) receptor residues thought to reside in the site were individually mutated to cysteine and combined with benzodiazepine analogs carrying substituents reactive to cysteine. Direct apposition of such reactive partners is expected to lead to an irreversible site-directed reaction. We describe here the covalent interaction of alpha(1)H101C with a reactive group attached to the C-7 position of diazepam. This interaction was studied at the level of radioactive ligand binding and at the functional level using electrophysiological methods. Covalent reaction occurs concomitantly with occupancy of the binding pocket. It stabilizes the receptor in its allosterically stimulated conformation. Covalent modification is not observed in wild type receptors or when using mutated alpha(1)H101C-containing receptors in combination with the reactive ligand pre-reacted with a sulfhydryl group, and the modification rate is reduced by the binding site ligand Ro15-1788. We present in addition evidence that gamma(2)Ala-79 is probably located in the access pathway of the ligand to its binding pocket.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland; Univ Strasbourg 1, Chim Bioorgan Lab, CNRS, Unite Mixte Rech 7514, F-67401 Illkirch Graffenstaden, France	University of Bern; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Sigel, E (corresponding author), Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland.	erwin.sigel@pki.unibe.ch	Sigel, Erwin/F-7736-2015					Allman K, 2000, MOL PHARMACOL, V58, P175, DOI 10.1124/mol.58.1.175; AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; Amin J, 1997, MOL PHARMACOL, V51, P833, DOI 10.1124/mol.51.5.833; BACKUS KH, 1993, NEUROREPORT, V5, P285, DOI 10.1097/00001756-199312000-00026; Barnard EA, 1998, PHARMACOL REV, V50, P291; Baumann SW, 2002, J BIOL CHEM, V277, P46020, DOI 10.1074/jbc.M207663200; Baumann SW, 2001, J BIOL CHEM, V276, P36275, DOI 10.1074/jbc.M105240200; BENKE D, 1994, J BIOL CHEM, V269, P27100; BERTOCCI B, 1991, P NATL ACAD SCI USA, V88, P1416, DOI 10.1073/pnas.88.4.1416; Boileau AJ, 1999, J NEUROSCI, V19, P4847; Boileau AJ, 2002, NEUROPHARMACOLOGY, V43, P695, DOI 10.1016/S0028-3908(02)00036-9; Boileau AJ, 2002, J BIOL CHEM, V277, P2931, DOI 10.1074/jbc.M109334200; BOREA PA, 1987, MOL PHARMACOL, V31, P334; BOUCHET MJ, 1992, J NEUROCHEM, V59, P1405, DOI 10.1111/j.1471-4159.1992.tb08454.x; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Buhr A, 1997, MOL PHARMACOL, V52, P676, DOI 10.1124/mol.52.4.676; Buhr A, 1997, P NATL ACAD SCI USA, V94, P8824, DOI 10.1073/pnas.94.16.8824; Buhr A, 1997, J BIOL CHEM, V272, P11799, DOI 10.1074/jbc.272.18.11799; Chang YC, 1996, J NEUROSCI, V16, P5415; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; Davies M, 1998, J NEUROCHEM, V70, P2188; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; Duncalfe LL, 1996, J BIOL CHEM, V271, P9209, DOI 10.1074/jbc.271.16.9209; Dunn SMJ, 1999, MOL PHARMACOL, V56, P768; Ernst M, 2003, NEUROSCIENCE, V119, P933, DOI 10.1016/S0306-4522(03)00288-4; Farrar SJ, 1999, J BIOL CHEM, V274, P10100, DOI 10.1074/jbc.274.15.10100; Foucaud B, 2003, J BIOL CHEM, V278, P24011, DOI 10.1074/jbc.M300219200; Foucaud B, 2001, TRENDS PHARMACOL SCI, V22, P170, DOI 10.1016/S0165-6147(00)01674-6; GALZI JL, 1994, CURR OPIN STRUC BIOL, V4, P554, DOI 10.1016/S0959-440X(94)90218-6; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; HUNKELER W, 1981, NATURE, V290, P514, DOI 10.1038/290514a0; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kreimeyer A, 1999, J MED CHEM, V42, P4394, DOI 10.1021/jm9910730; Kucken AM, 2003, MOL PHARMACOL, V63, P289, DOI 10.1124/mol.63.2.289; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; LOLAIT SJ, 1989, FEBS LETT, V246, P145, DOI 10.1016/0014-5793(89)80271-6; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MALHERBE P, 1990, J NEUROSCI, V10, P2330; MALHERBE P, 1990, MOL BRAIN RES, V8, P199, DOI 10.1016/0169-328X(90)90017-8; Mascia MP, 2000, P NATL ACAD SCI USA, V97, P9305, DOI 10.1073/pnas.160128797; McKernan RM, 1998, MOL PHARMACOL, V54, P33, DOI 10.1124/mol.54.1.33; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; Perret P, 1999, J BIOL CHEM, V274, P25350, DOI 10.1074/jbc.274.36.25350; PRITCHETT DB, 1991, P NATL ACAD SCI USA, V88, P1421, DOI 10.1073/pnas.88.4.1421; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; Sawyer GW, 2002, J BIOL CHEM, V277, P50036, DOI 10.1074/jbc.M209281200; Schaerer MT, 1998, EUR J PHARMACOL, V354, P283, DOI 10.1016/S0014-2999(98)00456-7; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; Schove L T, 1994, Bioorg Med Chem, V2, P1029, DOI 10.1016/S0968-0896(00)82053-2; SIEGHART W, 1995, PHARMACOL REV, V47, P181; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; Sigel E, 1998, MOL PHARMACOL, V54, P1097, DOI 10.1124/mol.54.6.1097; SIGEL E, 1987, J PHYSIOL-LONDON, V386, P73, DOI 10.1113/jphysiol.1987.sp016523; SIGEL E, 1983, J BIOL CHEM, V258, P6965; Sigel E, 2000, J NEUROCHEM, V74, P2590, DOI 10.1046/j.1471-4159.2000.0742590.x; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; SMITH GB, 1994, J BIOL CHEM, V269, P20380; Sullivan DA, 2000, J BIOL CHEM, V275, P12651, DOI 10.1074/jbc.275.17.12651; Tahtaoui C, 2003, J BIOL CHEM, V278, P40010, DOI 10.1074/jbc.M301128200; Teissere JA, 2001, J NEUROSCI, V21, P4977, DOI 10.1523/JNEUROSCI.21-14-04977.2001; Tretter V, 1997, J NEUROSCI, V17, P2728; VILLAR HO, 1989, MOL PHARMACOL, V36, P589; Wagner DA, 2001, J NEUROSCI, V21, P67, DOI 10.1523/JNEUROSCI.21-01-00067.2001; Walters RJ, 2000, NAT NEUROSCI, V3, P1274, DOI 10.1038/81800; WesthHansen SE, 1997, EUR J PHARMACOL, V329, P253, DOI 10.1016/S0014-2999(97)89186-8; Whiting PJ, 1997, J NEUROSCI, V17, P5027; Whiting PJ, 1999, ANN NY ACAD SCI, V868, P645, DOI 10.1111/j.1749-6632.1999.tb11341.x; WIELAND HA, 1994, J MED CHEM, V37, P4576, DOI 10.1021/jm00052a019; WIELAND HA, 1992, J BIOL CHEM, V267, P1426; Wingrove PB, 1997, MOL PHARMACOL, V52, P874, DOI 10.1124/mol.52.5.874; ZHANG W, 1995, DRUG DESIGN DIS, V12, P192	75	62	62	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3160	3168		10.1074/jbc.M311371200	http://dx.doi.org/10.1074/jbc.M311371200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14612433	hybrid			2022-12-25	WOS:000188379600005
J	Verma, UN; Yamamoto, Y; Prajapati, S; Gaynor, RB				Verma, UN; Yamamoto, Y; Prajapati, S; Gaynor, RB			Nuclear role of I kappa B kinase-gamma/NF-kappa B essential modulator (IKK gamma/NEMO) in NF-kappa B-dependent gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; X-LINKED DISORDER; EXPORT SIGNAL; ECTODERMAL DYSPLASIA; REL PROTEINS; ALPHA; ACTIVATION; PHOSPHORYLATION; LOCALIZATION; COMPLEX	The IkappaB kinase (IKK) complex, which is composed of the two kinases IKKalpha and IKKbeta and the regulatory subunit IKKgamma/nuclear factor-kappaB (NF-kappaB) essential modulator (NEMO), is important in the cytokine-induced activation of the NF-kappaB pathway. In addition to modulation of IKK activity, the NF-kappaB pathway is also regulated by other processes, including the nucleocytoplasmic shuttling of various components of this pathway and the post-translational modification of factors bound to NF-kappaB-dependent promoters. In this study, we explored the role of the nucleocytoplasmic shuttling of components of the IKK complex in the regulation of the NF-kappaB pathway. IKKgamma/NEMO was demonstrated to shuttle between the cytoplasm and the nucleus and to interact with the nuclear coactivator cAMP-responsive element-binding protein-binding protein (CBP). Using both in vitro and in vivo analysis, we demonstrated that IKKgamma/NEMO competed with p65 and IKKalpha for binding to the N terminus of CBP, inhibiting CBP-dependent transcriptional activation. These results indicate that, in addition to the key role of IKKgamma/NEMO in regulating cytokine-induced IKK activity, its ability to shuttle between the cytoplasm and the nucleus and to bind to CBP can lead to transcriptional repression of the NF-kappaB pathway.	Univ Texas, SW Med Ctr, Div Hematol Oncol, Dept Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gaynor, RB (corresponding author), Univ Texas, SW Med Ctr, Div Hematol Oncol, Dept Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	gaynor_richard@lilly.com						Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Chiti F, 2003, NATURE, V424, P805, DOI 10.1038/nature01891; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Krappmann D, 2000, J BIOL CHEM, V275, P29779, DOI 10.1074/jbc.M003902200; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Liao GX, 2003, ONCOGENE, V22, P4868, DOI 10.1038/sj.onc.1206761; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rottjakob EM, 1996, J VIROL, V70, P3176, DOI 10.1128/JVI.70.5.3176-3188.1996; Rudolph D, 2000, GENE DEV, V14, P854; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Smahi A, 2000, NATURE, V405, P466; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yamamoto Y, 2001, J BIOL CHEM, V276, P36327, DOI 10.1074/jbc.M104090200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	56	66	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3509	3515		10.1074/jbc.M309300200	http://dx.doi.org/10.1074/jbc.M309300200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14597638	hybrid			2022-12-25	WOS:000188379600047
J	Fairlie, WD; Uboldi, AD; McCoubrie, JE; Wang, CXC; Lee, EF; Yao, SG; De Souza, DP; Mifsud, S; Metcalf, D; Nicola, NA; Norton, RS; Baca, M				Fairlie, WD; Uboldi, AD; McCoubrie, JE; Wang, CXC; Lee, EF; Yao, SG; De Souza, DP; Mifsud, S; Metcalf, D; Nicola, NA; Norton, RS; Baca, M			Affinity maturation of leukemia inhibitory factor and conversion to potent antagonists of signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEUROTROPHIC FACTOR; INTERLEUKIN-6 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN-LIKE DOMAIN; MONOVALENT PHAGE DISPLAY; ONCOSTATIN-M; FACTOR LIF; HEMATOPOIETIC-CELLS; BACKBONE DYNAMICS; ESCHERICHIA-COLI; BINDING PEPTIDES	Leukemia inhibitory factor (LIF)-induced cell signaling occurs following sequential binding to the LIF receptor alpha-chain (LIFR), then to the gp130 co-receptor used by all members of the interleukin-6 family of cytokines. By monovalently displaying human LIF on the surface of M13 phage and randomizing clusters of residues in regions predicted to be important for human LIFR binding, we have identified mutations, which lead to significant increases in affinity for binding to LIFR. Six libraries were constructed in which regions of 4 - 6 amino acids were randomized then panned against LIFR. Mutations identified in three distinct clusters, residues 53 - 57, 102 - 103, and 150 - 155, gave rise to proteins with significantly increased affinity for binding to both human and mouse LIFR. Combining the mutations for each of these regions further increased the affinity, such that the best mutants bound to human LIFR with > 1000-fold higher affinity than wild-type human LIF. NMR analysis indicated that the mutations did not alter the overall structure of the molecule relative to the native protein, although some local changes occurred in the vicinity of the substituted residues. Despite increases in LIFR binding affinity, these mutants did not show any increase in activity as agonists of LIF-induced proliferation of Ba/F3 cells expressing human LIFR and gp130 compared with wild-type LIF. Incorporation of two additional mutations ( Q29A and G124R), which were found to abrogate cell signaling, led to the generation of highly potent antagonists of both human and murine LIF-induced bioactivity.	Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Cooperat Res Ctr Cellular Growth Factors, Parkville, Vic 3050, Australia	Walter & Eliza Hall Institute	Baca, M (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Parkville, Vic 3050, Australia.	baca@wehi.edu.au	Yao, Shenggen/ABH-9989-2020; Lee, Erinna/N-1523-2015; Nicola, Nicos/D-2989-2011; Yao, Shenggen/AAE-1602-2019; De Souza, David P/O-9800-2016; Fairlie, Walter/M-8401-2015	Yao, Shenggen/0000-0002-7137-9615; Lee, Erinna/0000-0003-1255-9808; Nicola, Nicos/0000-0003-1054-7889; De Souza, David P/0000-0002-7225-2632; Fairlie, Walter/0000-0002-2498-1160; Mifsud, Sandra/0000-0002-1010-292X; Norton, Raymond/0000-0001-8893-0584				Ballinger MD, 1998, J BIOL CHEM, V273, P11675, DOI 10.1074/jbc.273.19.11675; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Bitard J, 2003, J BIOL CHEM, V278, P16253, DOI 10.1074/jbc.M207193200; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; Bravo J, 2000, EMBO J, V19, P2399, DOI 10.1093/emboj/19.11.2399; Cai LQ, 2000, CYTOKINE, V12, P1676, DOI 10.1006/cyto.2000.0758; DiMarco A, 1996, P NATL ACAD SCI USA, V93, P9247, DOI 10.1073/pnas.93.17.9247; EHLERS M, 1995, J BIOL CHEM, V270, P8158, DOI 10.1074/jbc.270.14.8158; Fairlie WD, 2002, PROTEIN EXPRES PURIF, V26, P171; Fairlie WD, 2003, BIOCHEMISTRY-US, V42, P13193, DOI 10.1021/bi035303v; Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1989, BIO-TECHNOL, V7, P1157; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; Hinds MG, 1998, J BIOL CHEM, V273, P13738, DOI 10.1074/jbc.273.22.13738; Hinds MG, 1997, J BIOMOL NMR, V9, P113, DOI 10.1023/A:1018636018243; Hudson KR, 1996, J BIOL CHEM, V271, P11971, DOI 10.1074/jbc.271.20.11971; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAYTON MJ, 1992, P NATL ACAD SCI USA, V89, P8616, DOI 10.1073/pnas.89.18.8616; LAYTON MJ, 1994, J BIOL CHEM, V269, P29891; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; METCALF D, 1988, LEUKEMIA, V2, P216; Mitchell MH, 2002, BIOL REPROD, V67, P460, DOI 10.1095/biolreprod67.2.460; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OWCZAREK CM, 1993, EMBO J, V12, P3487, DOI 10.1002/j.1460-2075.1993.tb06023.x; Pearce KH, 1999, BIOCHEMISTRY-US, V38, P81, DOI 10.1021/bi9817008; Plun-Favreau H, 2003, J BIOL CHEM, V278, P27169, DOI 10.1074/jbc.M303168200; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sporeno E, 1996, BLOOD, V87, P4510, DOI 10.1182/blood.V87.11.4510.bloodjournal87114510; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Vernallis AB, 1997, J BIOL CHEM, V272, P26947, DOI 10.1074/jbc.272.43.26947; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Yao SG, 2000, PROTEIN SCI, V9, P671; Yue ZP, 2000, BIOL REPROD, V63, P508, DOI 10.1095/biolreprod63.2.508; Zhang JG, 1997, BIOCHEM J, V325, P693, DOI 10.1042/bj3250693; Zhang Y, 1998, J BIOL CHEM, V273, P34370, DOI 10.1074/jbc.273.51.34370	44	29	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2125	2134		10.1074/jbc.M310103200	http://dx.doi.org/10.1074/jbc.M310103200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14585833	hybrid			2022-12-25	WOS:000188005700069
J	Fournier, M; Dermoun, Z; Durand, MC; Dolla, A				Fournier, M; Dermoun, Z; Durand, MC; Dolla, A			A new function of the Desulfovibrio vulgaris Hildenborough [Fe] hydrogenase in the protection against oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE-REDUCING BACTERIUM; OXYGEN-DEPENDENT GROWTH; ELECTRON-TRANSFER; STRAIN HILDENBOROUGH; CARBON RESERVES; MICROBIAL MAT; PURIFICATION; CYTOCHROMES; MEMBRANE; DELETION	Sulfate-reducing bacteria, like Desulfovibrio vulgaris Hildenborough, have developed a set of reactions allowing them to survive in oxic environments and even to reduce molecular oxygen to water. D. vulgaris contains a cytoplasmic superoxide reductase (SOR) and a periplasmic superoxide dismutase ( SOD) involved in the elimination of superoxide anions. To assign the function of SOD, the periplasmic [ Fe] hydrogenase activity was followed in both wild-type and sod deletant strains. This activity was lower in the strain lacking the SOD than in the wild-type when the cells were exposed to oxygen for a short time. The periplasmic SOD is thus involved in the protection of sensitive iron-sulfur-containing enzyme against superoxide-induced damages. Surprisingly, production of the periplasmic [ Fe] hydrogenase was higher in the cells exposed to oxygen than in those kept in anaerobic conditions. A similar increase in the amount of [ Fe] hydrogenase was observed when an increase in the redox potential was induced by addition of chromate. Viability of the strain lacking the gene encoding [ Fe] hydrogenase after exposure to oxygen for 1 h was lower than that of the wild-type. These data reveal for the first time that production of the periplasmic [ Fe] hydrogenase is up-regulated in response to an oxidative stress. A new function of the periplasmic [ Fe] hydrogenase in the protective mechanisms of D. vulgaris Hildenborough toward an oxidative stress is proposed.	CNRS, Lab Bioenerget & Ingn Prot, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Dolla, A (corresponding author), CNRS, Lab Bioenerget & Ingn Prot, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	dolla@ibsm.cnrs-mrs.fr		Fournier, Marjorie/0000-0002-5202-8262				ABDOLLAHI H, 1990, J GEN MICROBIOL, V136, P1025, DOI 10.1099/00221287-136-6-1025; ADAMS MWW, 1984, J BIOL CHEM, V259, P7045; Aubert C, 2000, BBA-PROTEIN STRUCT M, V1476, P85, DOI 10.1016/S0167-4838(99)00221-6; Baumgarten A, 2001, ARCH MICROBIOL, V176, P306, DOI 10.1007/s002030100329; Bauschlicher CW, 2001, CHEM PHYS, V274, P11, DOI 10.1016/S0301-0104(01)00500-6; CANFIELD DE, 1991, SCIENCE, V251, P1471, DOI 10.1126/science.11538266; Cypionka H, 2000, ANNU REV MICROBIOL, V54, P827, DOI 10.1146/annurev.micro.54.1.827; Dolla A, 2000, ARCH MICROBIOL, V174, P143, DOI 10.1007/s002030000183; Dos Santos WG, 2000, J BACTERIOL, V182, P796, DOI 10.1128/JB.182.3.796-804.2000; ElAntak L, 2003, FEBS LETT, V548, P1, DOI 10.1016/S0014-5793(03)00718-X; Fareleira P, 1997, J BACTERIOL, V179, P3972, DOI 10.1128/jb.179.12.3972-3980.1997; FLINT DH, 1993, J BIOL CHEM, V268, P22369; Fournier M, 2003, J BACTERIOL, V185, P71, DOI 10.1128/JB.185.1.71-79.2003; Freund F, 2001, P NATL ACAD SCI USA, V98, P2142, DOI 10.1073/pnas.061513298; Jenney FE, 1999, SCIENCE, V286, P306, DOI 10.1126/science.286.5438.306; Johnson MS, 1997, J BACTERIOL, V179, P5598, DOI 10.1128/jb.179.17.5598-5601.1997; KITAMURA M, 1995, MICROBIOL IMMUNOL, V39, P75, DOI 10.1111/j.1348-0421.1995.tb02172.x; Kloeke FV, 1995, ANAEROBE, V1, P351, DOI 10.1006/anae.1995.1038; Krekeler D, 1998, FEMS MICROBIOL ECOL, V25, P89, DOI 10.1016/S0168-6496(97)00085-8; Krekeler D, 1997, ARCH MICROBIOL, V167, P369, DOI 10.1007/s002030050457; Lemos RS, 2001, FEBS LETT, V496, P40, DOI 10.1016/S0014-5793(01)02399-7; LISSOLO T, 1986, BIOCHEM BIOPH RES CO, V139, P701, DOI 10.1016/S0006-291X(86)80047-X; Lombard M, 2000, J BIOL CHEM, V275, P115, DOI 10.1074/jbc.275.1.115; Lumppio HL, 1997, J BACTERIOL, V179, P4607, DOI 10.1128/jb.179.14.4607-4615.1997; Lumppio HL, 2001, J BACTERIOL, V183, P101, DOI 10.1128/JB.183.1.101-108.2001; MOURA I, 1990, J BIOL CHEM, V265, P21596; Nicolet Y, 1999, STRUCTURE, V7, P13, DOI 10.1016/S0969-2126(99)80005-7; Odom J.M., 1993, SULFATE REDUCING BAC, P41; Pereira IAC, 1998, J BIOL INORG CHEM, V3, P494, DOI 10.1007/s007750050259; Pohorelic BKJ, 2002, J BACTERIOL, V184, P679, DOI 10.1128/JB.184.3.679-686.2002; Postgate J. R., 1984, SULFATE REDUCING BAC, P12; RISATTI JB, 1994, P NATL ACAD SCI USA, V91, P10173, DOI 10.1073/pnas.91.21.10173; Sansone A, 2002, MICROBIOL-SGM, V148, P719, DOI 10.1099/00221287-148-3-719; SANTOS H, 1993, BIOCHEM BIOPH RES CO, V195, P551, DOI 10.1006/bbrc.1993.2081; SEBBAN C, 1995, FEMS MICROBIOL LETT, V133, P143, DOI 10.1111/j.1574-6968.1995.tb07875.x; Shen YA, 2001, NATURE, V410, P77, DOI 10.1038/35065071; Sigalevich P, 2000, APPL ENVIRON MICROB, V66, P5019, DOI 10.1128/AEM.66.11.5019-5023.2000; Silva G, 2001, J BACTERIOL, V183, P4413, DOI 10.1128/JB.183.4.4413-4420.2001; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Van Ooteghem SA, 2002, APPL BIOCHEM BIOTECH, V98, P177, DOI 10.1385/ABAB:98-100:1-9:177; VANDIJK C, 1983, FEBS LETT, V156, P340, DOI 10.1016/0014-5793(83)80525-0; Voordouw G, 2002, J BACTERIOL, V184, P5903, DOI 10.1128/JB.184.21.5903-5911.2002; Voordouw JK, 1998, APPL ENVIRON MICROB, V64, P2882	44	54	56	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1787	1793		10.1074/jbc.M307965200	http://dx.doi.org/10.1074/jbc.M307965200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14594815	hybrid			2022-12-25	WOS:000188005700028
J	Johansson, E; Garg, P; Burgers, PMJ				Johansson, E; Garg, P; Burgers, PMJ			The pol32 subunit of DNA polymerase delta contains separable domains for processive replication and proliferating cell nuclear antigen (PCNA) binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; CATALYTIC SUBUNIT; 3RD SUBUNIT; IN-VIVO; REPAIR; EPSILON; PROTEIN; CDC27; CHROMATOGRAPHY	We have carried out a domain analysis of POL32, the third subunit of Saccharomyces cerevisiae DNA polymerase delta (Pol delta). Interactions with POL31, the second subunit of Pol delta, are specified by the amino-terminal 92 amino acids, whereas interactions with the replication clamp proliferating cell nuclear antigen (PCNA, POL30) reside at the extreme carboxyl-terminal region. Pol32 binding, in vivo and in vitro, to the large subunit of DNA polymerase alpha, POL1, requires the carboxyl-proximal region of Pol32. The amino-terminal region of Pol32 is essential for damage-induced mutagenesis. However, the presence of its carboxyl-terminal PCNA-binding domain enhances the efficiency of mutagenesis, particularly at high loads of DNA damage. In vitro, in the absence of effector DNA, the PCNA-binding domain of Pol32 is essential for PCNA-Pol delta interactions. However, this domain has minimal importance for processive DNA synthesis by the ternary DNA-PCNA-Pol delta complex. Rather, processivity is determined by PCNA-binding domains located in the Pol3 and/or Pol31 subunits. Using diagnostic PCNA mutants, we show that during DNA synthesis the carboxyl-terminal domain of Pol32 interacts with the carboxyl-terminal region of PCNA, whereas interactions of the other subunit(s) of Pol delta localize largely to a hydrophobic pocket at the interdomain connector loop region of PCNA.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Burgers, PMJ (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.	burgers@biochem.wustl.edu	Burgers, Peter M/AAW-6621-2021	Johansson, Erik/0000-0002-8526-6224	NIGMS NIH HHS [GM 58534, R01 GM032431] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431, R01GM058534] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; Bermudez VP, 2002, J BIOL CHEM, V277, P36853, DOI 10.1074/jbc.M202897200; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; Cliften PF, 2001, GENOME RES, V11, P1175, DOI 10.1101/gr.182901; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; Ducoux M, 2001, J BIOL CHEM, V276, P49258, DOI 10.1074/jbc.M106990200; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; Giot L, 1997, GENETICS, V146, P1239; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; Hindges R, 1997, BIOL CHEM, V378, P345; Huang ME, 1999, MOL GEN GENET, V260, P541, DOI 10.1007/s004380050927; Huang ME, 2000, CURR GENET, V38, P178, DOI 10.1007/s002940000149; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; Johansson E, 2001, J BIOL CHEM, V276, P43824, DOI 10.1074/jbc.M108842200; Karthikeyan R, 2000, J MOL BIOL, V299, P405, DOI 10.1006/jmbi.2000.3744; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Liu L, 2000, J BIOL CHEM, V275, P18739, DOI 10.1074/jbc.M001217200; Lu XQ, 2002, J BIOL CHEM, V277, P24340, DOI 10.1074/jbc.M200065200; MacNeill SA, 1996, EMBO J, V15, P4613, DOI 10.1002/j.1460-2075.1996.tb00839.x; Mo JY, 2000, BIOCHEMISTRY-US, V39, P7245, DOI 10.1021/bi0000871; Ohya T, 2002, J BIOL CHEM, V277, P28099, DOI 10.1074/jbc.M111573200; Pavlov YI, 2002, MOL CELL, V10, P207, DOI 10.1016/S1097-2765(02)00567-1; Podust VN, 2002, J BIOL CHEM, V277, P3894, DOI 10.1074/jbc.M109684200; Reynolds N, 1998, CURR GENET, V34, P250, DOI 10.1007/s002940050394; Reynolds N, 2000, EMBO J, V19, P1108, DOI 10.1093/emboj/19.5.1108; Shcherbakova PV, 1996, GENETICS, V142, P717; Shikata K, 2001, J BIOCHEM-TOKYO, V129, P699, DOI 10.1093/oxfordjournals.jbchem.a002909; TorresRamos CA, 1997, J BIOL CHEM, V272, P25445, DOI 10.1074/jbc.272.41.25445; Tratner I, 1997, BIOCHEM BIOPH RES CO, V231, P321, DOI 10.1006/bbrc.1997.6082; Unk I, 2002, MOL CELL BIOL, V22, P6480, DOI 10.1128/MCB.22.18.6480-6486.2002; Zhang P, 1999, J BIOL CHEM, V274, P26647, DOI 10.1074/jbc.274.38.26647; ZHANG SJ, 1995, J BIOL CHEM, V270, P7988, DOI 10.1074/jbc.270.14.7988; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153; Zuo SJ, 1997, P NATL ACAD SCI USA, V94, P11244, DOI 10.1073/pnas.94.21.11244	40	73	73	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1907	1915		10.1074/jbc.M310362200	http://dx.doi.org/10.1074/jbc.M310362200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14594808	hybrid			2022-12-25	WOS:000188005700044
J	Quinto, I; Puca, A; Greenhouse, J; Silvera, P; Yalley-Ogunro, J; Lewis, MG; Palmieri, C; Trimboli, F; Byrum, R; Adelsberger, J; Venzon, D; Chen, XN; Scala, G				Quinto, I; Puca, A; Greenhouse, J; Silvera, P; Yalley-Ogunro, J; Lewis, MG; Palmieri, C; Trimboli, F; Byrum, R; Adelsberger, J; Venzon, D; Chen, XN; Scala, G			High attenuation and immunogenicity of a simian immunodeficiency virus expressing a proteolysis-resistant inhibitor of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOTOXIC T-LYMPHOCYTES; LONG TERMINAL REPEAT; RHESUS MACAQUES; IN-VITRO; NEF GENE; LIVE; REPLICATION; TAT; PROTECTION; CHALLENGE	NF-kappaB/IkappaB proteins play a major role in the transcriptional regulation of human immunodeficiency virus, type-1 (HIV-1). In the case of simian immunodeficiency virus (SIV) the cellular factors required for the viral transcriptional activation and replication in vivo remain undefined. Here, we demonstrate that the p50/p65 NF-kappaB transcription factors enhanced the Tat-mediated transcriptional activation of SIVmac239. In addition, IkappaB-alphaS32/36A, a proteolysis-resistant inhibitor of NF-kappaB, strongly inhibited the Tat-mediated transactivation of SIVmac239. Based on this evidence, we have generated a self-regulatory virus by endowing the genome of SIVmac239 with IkappaB-alphaS32/36A; the resulting virus, SIVIkappaBalphaS32/36A, was nef-deleted and expressed the NF-kappaB inhibitor. We show that SIVIkappaB-alphaS32/36A was highly and stably attenuated both in cell cultures and in vivo in rhesus macaque as compared with a nef-deleted control virus. Moreover, the high attenuation was associated with a robust immune response as measured by SIV-specific antibody production, tetramer, and intracellular IFN-gamma staining of SIV gag-specific T cells. These results underscore the crucial role of NF-kappaB/IkappaB proteins in the regulation of SIV replication both in cell cultures and in monkeys. Thus, inhibitors of NF-kappaB could efficiently counteract the SIV/HIV replication in vivo and may assist in developing novel approaches for AIDS vaccine and therapy.	Univ Catanzaro, Sch Med, Dept Clin & Expt Med, I-88100 Catanzaro, Italy; Univ Naples Federico II, Sch Med, Dept Biochem & Biomed Technol, I-80131 Naples, Italy; So Res Inst, Frederick, MD 21701 USA; Bioqual, Rockville, MD 20850 USA; NCI, Sci Applicat Int Corp, Frederick Inc, Frederick, MD 21702 USA; NCI, Biostat & Data Management Sect, NIH, Bethesda, MD 20892 USA	Magna Graecia University of Catanzaro; University of Naples Federico II; BIOQUAL Inc.; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Quinto, I (corresponding author), Univ Catanzaro, Sch Med, Dept Clin & Expt Med, I-88100 Catanzaro, Italy.	quinto@dbbm.unina.it	Venzon, David J/B-3078-2008; SCALA, GIUSEPPE/A-3280-2009; Trimboli, Francesca/Y-1143-2019; Palmieri, Camillo/A-3195-2009	Trimboli, Francesca/0000-0002-1766-9179; QUINTO, Ileana/0000-0001-8212-8515; Palmieri, Camillo/0000-0001-6707-4723				ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; ALMOND N, 1995, LANCET, V345, P1342, DOI 10.1016/S0140-6736(95)92540-6; Baba TW, 1999, NAT MED, V5, P194, DOI 10.1038/5557; Beer B, 1997, P NATL ACAD SCI USA, V94, P4062, DOI 10.1073/pnas.94.8.4062; BELLAS RE, 1993, J VIROL, V67, P2908, DOI 10.1128/JVI.67.5.2908-2913.1993; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen XN, 2001, NAT MED, V7, P1225, DOI 10.1038/nm1101-1225; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; Desrosiers RC, 1998, J VIROL, V72, P1431, DOI 10.1128/JVI.72.2.1431-1437.1998; Evans DT, 1997, J IMMUNOL, V159, P1374; Guan YJ, 2001, J VIROL, V75, P2776, DOI 10.1128/JVI.75.6.2776-2785.2001; Guan YJ, 2001, J VIROL, V75, P4056, DOI 10.1128/JVI.75.9.4056-4067.2001; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Ilyinskii PO, 1997, J VIROL, V71, P1880, DOI 10.1128/JVI.71.3.1880-1887.1997; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; Johnson RP, 1999, J VIROL, V73, P4952, DOI 10.1128/JVI.73.6.4952-4961.1999; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Kuiken C, 2000, HIV SEQUENCE COMPEND; Kuroda MJ, 1998, J EXP MED, V187, P1373, DOI 10.1084/jem.187.9.1373; Kwon H, 1998, J BIOL CHEM, V273, P7431, DOI 10.1074/jbc.273.13.7431; LIU JS, 1992, J VIROL, V66, P3883, DOI 10.1128/JVI.66.6.3883-3887.1992; Mallardo M, 1996, J BIOL CHEM, V271, P20820, DOI 10.1074/jbc.271.34.20820; Migueles SA, 2001, IMMUNOL LETT, V79, P141, DOI 10.1016/S0165-2478(01)00276-0; Mori K, 2001, J VIROL, V75, P4023, DOI 10.1128/JVI.75.9.4023-4028.2001; Munch J, 2001, J VIROL, V75, P8137, DOI 10.1128/JVI.75.17.8137-8146.2001; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Nixon DF, 2000, VIROLOGY, V266, P203, DOI 10.1006/viro.1999.0078; Quinto I, 1999, J BIOL CHEM, V274, P17567, DOI 10.1074/jbc.274.25.17567; Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679; Sawai ET, 2000, J VIROL, V74, P2038, DOI 10.1128/JVI.74.4.2038-2045.2000; Shibata R, 1997, J VIROL, V71, P8141, DOI 10.1128/JVI.71.11.8141-8148.1997; von Gegerfelt AS, 1999, J VIROL, V73, P6159, DOI 10.1128/JVI.73.7.6159-6165.1999; WHATMORE AM, 1995, J VIROL, V69, P5117, DOI 10.1128/JVI.69.8.5117-5123.1995; WU BY, 1995, P NATL ACAD SCI USA, V92, P1480, DOI 10.1073/pnas.92.5.1480; Wyand MS, 1999, J VIROL, V73, P8356, DOI 10.1128/JVI.73.10.8356-8363.1999; Yedavalli VSRK, 2003, J BIOL CHEM, V278, P6404, DOI 10.1074/jbc.M209162200	38	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1720	1728		10.1074/jbc.M309375200	http://dx.doi.org/10.1074/jbc.M309375200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14593121	hybrid			2022-12-25	WOS:000188005700021
J	Ehrlich, JR; Pourrier, M; Weerapura, M; Ethier, N; Marmabachi, AM; Hebert, TE; Nattel, S				Ehrlich, JR; Pourrier, M; Weerapura, M; Ethier, N; Marmabachi, AM; Hebert, TE; Nattel, S			KvLQT1 modulates the distribution and biophysical properties of HERG - A novel alpha-subunit interaction between delayed rectifier currents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG QT SYNDROME; CARDIAC POTASSIUM CURRENT; K+-CHANNEL; I-KR; ENDOPLASMIC-RETICULUM; VENTRICULAR MYOCYTES; CANINE ATRIUM; 2 COMPONENTS; HUMAN HEART; GUINEA-PIG	Cardiac repolarization is under joint control of the slow (I-Ks) and rapid (I-Kr) delayed rectifier currents. Experimental and clinical evidence indicates important functional interactions between these components. We hypothesized that there might be more direct interactions between the KvLQT1 and HERG alpha-subunits of I-Ks and I-Kr and tested this notion with a combination of biophysical and biochemical techniques. Co-expression of KvLQT1 with HERG in a mammalian expression system significantly accelerated HERG current deactivation at physiologically relevant potentials by increasing the contribution of the fast component (e.g. upon repolarization from +20 mV to -50 mV: from 20 +/- 3 to 32 +/- 5%, p < 0.05), making HERG current more like native I-Kr. In addition, HERG current density was approximately doubled (e.g. tail current after a step to + 10 mV: 18 +/- 3 versus 39 +/- 7 pA/ picofarad, p < 0.01) by co-expression with KvLQT1. KvLQT1 co-expression also increased the membrane immunolocalization of HERG by similar to2-fold ( p < 0.05). HERG and KvLQT1 co-immunolocalized in canine ventricular myocytes and co-immunoprecipitated in cultured Chinese hamster ovary cells as well as in native cardiac tissue, indicating physical interactions between HERG and KvLQT1 proteins in vitro and in vivo. Protein interaction assays also demonstrated binding of KvLQT1 ( but not another K+ channel alpha-subunit, Kv3.4) to a C-terminal HERG glutathione S-transferase fusion protein. Co-expression with HERG did not affect the membrane localization or ionic current properties of KvLQT1. This study shows that the alpha-subunit of I-Ks can interact with and modify the localization and current-carrying properties of the alpha-subunit of I-Kr, providing potentially novel insights into the molecular function of the delayed rectifier current system.	Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada; Univ Montreal, Dept Med, Montreal, PQ H1T 1C8, Canada; Univ Montreal, Dept Anesthesiol, Montreal, PQ H1T 1C8, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H1T 1C8, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H1T 1C8, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University	Nattel, S (corresponding author), Montreal Heart Inst, Res Ctr, 5000 Belanger St E, Montreal, PQ H1T 1C8, Canada.	nattel@icm.umontreal.ca		Nattel, Stanley/0000-0002-5565-3311				Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Akhavan A, 2003, J BIOL CHEM, V278, P40105, DOI 10.1074/jbc.M307837200; Anantharam A, 2003, J BIOL CHEM, V278, P11739, DOI 10.1074/jbc.M212751200; Aydar E, 2001, J PHYSIOL-LONDON, V534, P1, DOI 10.1111/j.1469-7793.2001.t01-3-00001.x; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Biliczki P, 2002, BRIT J PHARMACOL, V137, P361, DOI 10.1038/sj.bjp.0704881; Cherubini A, 2002, ANN NY ACAD SCI, V973, P559, DOI 10.1111/j.1749-6632.2002.tb04701.x; Clark RB, 2001, J PHYSIOL-LONDON, V537, P979; Cui J, 2001, J BIOL CHEM, V276, P17244, DOI 10.1074/jbc.M010904200; Finley MR, 2002, AM J PHYSIOL-HEART C, V283, pH126, DOI 10.1152/ajpheart.00622.2001; Jenke M, 2003, EMBO J, V22, P395, DOI 10.1093/emboj/cdg035; Kagan A, 2002, EMBO J, V21, P1889, DOI 10.1093/emboj/21.8.1889; Kupershmidt S, 2002, J BIOL CHEM, V277, P27442, DOI 10.1074/jbc.M112375200; Kupershmidt S, 1999, CIRC RES, V84, P146, DOI 10.1161/01.RES.84.2.146; Kupershmidt S, 1998, J BIOL CHEM, V273, P27231, DOI 10.1074/jbc.273.42.27231; LeesMiller JP, 1997, CIRC RES, V81, P719; London B, 1997, CIRC RES, V81, P870; MATSUURA H, 1987, PFLUG ARCH EUR J PHY, V410, P596, DOI 10.1007/BF00581319; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Melnyk P, 2002, AM J PHYSIOL-HEART C, V283, pH1123, DOI 10.1152/ajpheart.00934.2001; Nattel S, 1999, J CARDIOVASC ELECTR, V10, P272, DOI 10.1111/j.1540-8167.1999.tb00673.x; NOBLE D, 1969, J PHYSIOL-LONDON, V200, P205, DOI 10.1113/jphysiol.1969.sp008689; O'Kelly I, 2002, CELL, V111, P577, DOI 10.1016/S0092-8674(02)01040-1; Ohyama H, 2001, PFLUG ARCH EUR J PHY, V442, P329, DOI 10.1007/s004240100547; Pond AL, 2000, J BIOL CHEM, V275, P5997, DOI 10.1074/jbc.275.8.5997; Pourrier M, 2003, CIRC RES, V93, P189, DOI 10.1161/01.RES.0000084851.60947.B5; Robillard L, 2000, CELL SIGNAL, V12, P673, DOI 10.1016/S0898-6568(00)00118-2; Roti ECR, 2002, J BIOL CHEM, V277, P47779, DOI 10.1074/jbc.M206638200; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Varro A, 2000, J PHYSIOL-LONDON, V523, P67, DOI 10.1111/j.1469-7793.2000.00067.x; Weerapura M, 2002, J PHYSIOL-LONDON, V540, P15, DOI 10.1113/jphysiol.2001.013296; YANG T, 1995, CIRC RES, V77, P1246, DOI 10.1161/01.RES.77.6.1246; Yu H, 2001, CIRC RES, V88, pE84, DOI 10.1161/hh1201.093511; Yue LX, 1996, AM J PHYSIOL-HEART C, V270, pH2157, DOI 10.1152/ajpheart.1996.270.6.H2157; Yue LX, 1997, CIRC RES, V81, P512, DOI 10.1161/01.RES.81.4.512; ZENG JL, 1995, CIRC RES, V77, P140, DOI 10.1161/01.RES.77.1.140; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	42	53	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1233	1241		10.1074/jbc.M309087200	http://dx.doi.org/10.1074/jbc.M309087200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14585842	hybrid			2022-12-25	WOS:000187722800049
J	Madani, S; Hichami, A; Charkaoui-Malki, M; Khan, NA				Madani, S; Hichami, A; Charkaoui-Malki, M; Khan, NA			Diacylglycerols containing omega 3 and omega 6 fatty acids bind to RasGRP and modulate MAP kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-RELEASING PROTEIN; AORTIC ENDOTHELIAL-CELLS; HUMAN T-CELLS; PHOSPHOLIPASE-D; EXCHANGE FACTOR; PHORBOL ESTERS; EICOSAPENTAENOIC ACID; ACYL-CHAIN; IDENTIFICATION; GTPASE	We elucidated the effects of different diacylglycerols (DAGs), i.e. 1-stearoyl-2-arachidonoyl-sn-glycerol ( SAG), 1-stearoyl-2-docosahexaenoyl-sn-glycerol (SDG), and 1-stearoyl-2-eicosapentaenoyl-sn-glycerol (SEG), on [H-3] PDBu binding to RasGRP. The competition studies with these DAGs on [H-3] PDBu binding to RasGRP revealed different K-i values for these DAG molecular species. Furthermore, we transfected human Jurkat T cells by a plasmid containing RasGRP and assessed the implication of endogenous DAGs on activation of MAP kinases ERK1/ERK2, induced by phorbol-12-myristate-13-acetate (PMA). In control cells, GF109203X, a protein kinase C inhibitor, inhibited ERK1/ERK2 activation. However, this agent curtailed but failed to completely diminish ERK1/ERK2 phosphorylation in RasGRP-overexpressing cells, though calphostin C, a DAG binding inhibitor, suppressed the phosphorylation of MAP kinases in these cells. In cells incubated with arachidonic acid (AA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA), PMA induced the production of endogenous DAGs containing these fatty acids, respectively: DAG-AA, DAG-DHA, and DAG-EPA. The inhibition of production of DAG-AA and DAG-DHA significantly inhibited MAP kinase activation in RasGRP overexpressing, but not in control, cells. Our study demonstrates that three DAG molecular species bind to RasGRP, but only DAG-AA and DAG-DHA participate in the modulation of RasGRP-mediated activation of MAP kinases in Jurkat T cells.	Univ Bourgogne, Fac Sci, Unite Propre Rech Enseignement Super Lipides & Nu, Equipe Accueil 2422, F-21000 Dijon, France; Univ Bourgogne, Fac Sci, Biol Cellulaire & Mol Lab, Equipe Accueil 2422, F-21000 Dijon, France	Universite de Bourgogne; Universite de Bourgogne	Khan, NA (corresponding author), Univ Bourgogne, Fac Sci, Unite Propre Rech Enseignement Super Lipides & Nu, Equipe Accueil 2422, 6 Blvd Gabriel, F-21000 Dijon, France.	naim.khan@u-bourgogne.fr	Cherkaoui-Malki, Mustapha/B-2412-2012	Cherkaoui-Malki, Mustapha/0000-0001-5010-739X; hichami, aziz/0000-0003-4331-5152				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; AMARAL MC, 1993, IMMUNOLOGY, V79, P24; Bechoua S, 1998, J LIPID RES, V39, P873; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; Bordoni A, 1992, Cardiologia, V37, P631; Bradshaw CD, 1996, IMMUNOL LETT, V53, P69, DOI 10.1016/S0165-2478(96)02614-4; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Denys A, 2001, J LIPID RES, V42, P2015; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ebinu JO, 2000, BLOOD, V95, P3199; FLENGER JH, 1994, J BIOL CHEM, V269, P2550; HA KS, 1993, J BIOL CHEM, V268, P10534; Harbige LS, 1998, P NUTR SOC, V57, P555, DOI 10.1079/PNS19980081; Khan NA, 1999, BIOCHEM J, V344, P199, DOI 10.1042/0264-6021:3440199; KHAN NA, 2002, RT RES DEV LIPIDS, V6, P65; Kuroki T, 1998, BIOCHEM BIOPH RES CO, V247, P473, DOI 10.1006/bbrc.1998.8814; LEACH KL, 1991, J BIOL CHEM, V266, P3215; Lorenzo PS, 2000, MOL PHARMACOL, V57, P840; Lorenzo PS, 2001, CANCER RES, V61, P943; Madani S, 2001, FASEB J, V15, P2595, DOI 10.1096/fj.01-0753int; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Marignani PA, 1996, J NUTR, V126, P2738; Marignani PA, 1996, BIOCHEM BIOPH RES CO, V225, P469, DOI 10.1006/bbrc.1996.1196; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; Pierret P, 2001, NEUROSCIENCE, V108, P381, DOI 10.1016/S0306-4522(01)00429-8; Pierret P, 2000, J NEUROCYTOL, V29, P485, DOI 10.1023/A:1007245728751; PREISS J, 1986, J BIOL CHEM, V261, P8597; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Rebhun JF, 2000, J BIOL CHEM, V275, P13406, DOI 10.1074/jbc.C000085200; Reuther GW, 2002, J BIOL CHEM, V277, P30508, DOI 10.1074/jbc.M111330200; Rong SB, 2002, J MED CHEM, V45, P853, DOI 10.1021/jm010422z; SEBALDT RJ, 1992, BIOCHEM J, V284, P367, DOI 10.1042/bj2840367; SHARKEY NA, 1985, CANCER RES, V45, P19; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; Yang Y, 2002, J BIOL CHEM, V277, P25756, DOI 10.1074/jbc.M202575200	36	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1176	1183		10.1074/jbc.M306252200	http://dx.doi.org/10.1074/jbc.M306252200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14583629	hybrid			2022-12-25	WOS:000187722800042
J	Padmanabhan, B; Adachi, N; Kataoka, K; Horikoshi, M				Padmanabhan, B; Adachi, N; Kataoka, K; Horikoshi, M			Crystal structure of the homolog of the oncoprotein gankyrin, an interactor of Rb and CDK4/6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE CDK6; ANKYRIN-REPEAT; CYCLIN-D; PROTEIN; MOLSCRIPT; DOMAIN	The oncoprotein gankyrin plays a central role in tumorigenesis and cell proliferation. Gankyrin interacts with the retinoblastoma tumor suppressor (Rb) and cyclin-dependent kinase 4/6 (CDK4/6), increases phosphorylation at specific residues of Rb by CDK4/6 in vivo, and promotes tumorigenesis. The phosphorylation of Rb by CDK4/6 leads to the deregulation of the cell cycle during G(1)/S transition. Although how phosphorylation occurs on Rb has been studied extensively, the mechanism of site-specific phosphorylation of Rb remains unclear due to a lack of information on the structural arrangement of Rb and CDK4/6. Here, we have determined and refined to 2.3-Angstrom resolution the crystal structure of a gankyrin homolog, the non-ATPase subunit 6 (Nas6p) of the proteasome from yeast. The crystal structure reveals that Nas6p contains seven ankyrin repeats. The number of the repeats is different from that predicted from the primary structure. Nas6p also possesses an unusual curved structure with two acidic regions at the N- and C-terminal regions separated by one basic region, suggesting that it has at least two functional surfaces. The tertiary structure of Nas6p, together with the previous biochemical studies, indicates that the CDK4/6 and Rb binding surfaces of gankyrin are located at the N- and C-terminal regions, respectively, and face the same side of gankyrin. These observations suggest that gankyrin brings Rb and CDK4/6 together through gankyrin-Rb and gankyrin-CDK4/6 interactions and determines the relative positioning of the substrate ( Rb) and the enzyme (CDK4/6). Our findings provide mechanistic insight into site-specific phosphorylation of Rb caused by CDK4/6.	Japan Sci & Technol Corp, Horikoshi Gene Selector Project, Exploratory Res Adv Technol, Tsukuba, Ibaraki 3002635, Japan; Univ Tokyo, Dev Biol Lab, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	Japan Science & Technology Agency (JST); University of Tokyo	Horikoshi, M (corresponding author), Japan Sci & Technol Corp, Horikoshi Gene Selector Project, Exploratory Res Adv Technol, 5-9-6 Tokodai, Tsukuba, Ibaraki 3002635, Japan.	horikosh@iam.u-tokyo.ac.jp						Adachi N, 2002, ACTA CRYSTALLOGR D, V58, P859, DOI 10.1107/S0907444902004808; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Hori T, 1998, GENE, V216, P113, DOI 10.1016/S0378-1119(98)00309-6; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Michel F, 2001, EMBO J, V20, P6180, DOI 10.1093/emboj/20.22.6180; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; WU EW, 1993, J VIROL, V67, P2402, DOI 10.1128/JVI.67.4.2402-2407.1993	24	21	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1546	1552		10.1074/jbc.M310266200	http://dx.doi.org/10.1074/jbc.M310266200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14583612	hybrid			2022-12-25	WOS:000187722800087
J	Repovic, P; Fears, CY; Gladson, CL; Benveniste, EN				Repovic, P; Fears, CY; Gladson, CL; Benveniste, EN			Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells	ONCOGENE			English	Article						oncostatin-M; VEGF; angiogenesis; astroglioma	HYPOXIA-INDUCIBLE FACTOR-1; NECROSIS-FACTOR-ALPHA; IN-VITRO; GENE-TRANSCRIPTION; SIGNALING PATHWAY; NERVOUS-SYSTEM; FACTOR VEGF; ASTROCYTES; RECEPTOR; INTERLEUKIN-6	Oncostatin-M (OSM), a hematopoietic cytokine, and vascular endothelial growth factor (VEGF), a quintessential angiogenic signal, are coexpressed in development, cancer and inflammation. Here, we report that OSM treatment of human astroglioma cell lines increases VEGF levels by similar tothreefold. Interleukin-1beta (IL-1beta), in combination with OSM, induces up to sevenfold higher VEGF expression, without significantly inducing VEGF on its own. Specifically examining the OSM contribution to VEGF expression, neutralizing antibodies to OSM receptor subunits gp130 and OSMRbeta, but not LIFRbeta, inhibited OSM induction of VEGF, indicating that the OSM-specific receptor OSMRbeta/gp130 transduces the OSM signal for VEGF synthesis. OSM induction of VEGF promoter activity maps to the (-1171, -786) region of the VEGF promoter, which contains a STAT-3-binding site. STAT-3 is indeed essential for this response, since overexpression of a dominant-negative STAT-3 blocks OSM induction of VEGF promoter activity, as well as endogenous VEGF expression. Finally, we demonstrate that OSM is expressed in glioblastoma multiforme tumor biopsies, a particularly malignant form of brain tumor. This novel mechanism of VEGF regulation in astroglioma cells may be active in pathophysiological states where both OSM and IL-1beta are present.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Benveniste, EN (corresponding author), Univ Alabama, Dept Cell Biol, MCLM 395,1918 Univ Blvd, Birmingham, AL 35294 USA.		Repovic, Pavle/AAV-1594-2020		NCI NIH HHS [CA59958, CA97110, CA97247] Funding Source: Medline; NIMH NIH HHS [MH63650] Funding Source: Medline; NINDS NIH HHS [NS39954] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059958, P50CA097247, R01CA097110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Chaudhry IH, 2001, HISTOPATHOLOGY, V39, P409, DOI 10.1046/j.1365-2559.2001.01230.x; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Hao CH, 2002, ACTA NEUROPATHOL, V103, P171; Hecker TP, 2002, CANCER RES, V62, P2699; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kordula T, 1998, J BIOL CHEM, V273, P4112, DOI 10.1074/jbc.273.7.4112; Lilja A, 2001, INT J ONCOL, V19, P495; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; Modur V, 1997, J CLIN INVEST, V100, P158, DOI 10.1172/JCI119508; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; Mukouyama YS, 1998, IMMUNITY, V8, P105, DOI 10.1016/S1074-7613(00)80463-X; Murphy M, 1997, PROG NEUROBIOL, V52, P355, DOI 10.1016/S0301-0082(97)00020-8; Nagashima G, 2002, CLIN NEUROL NEUROSUR, V104, P125, DOI 10.1016/S0303-8467(01)00197-4; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nguyen VT, 2000, J BIOL CHEM, V275, P23674, DOI 10.1074/jbc.M002482200; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Pietsch T, 1997, ACTA NEUROPATHOL, V93, P109, DOI 10.1007/s004010050591; RADKA SF, 1993, J IMMUNOL, V150, P5195; Repovic P, 2003, GLIA, V42, P433, DOI 10.1002/glia.10182; Repovic P, 2002, J NEUROSCI, V22, P5334; Ruprecht K, 2001, J NEUROPATH EXP NEUR, V60, P1087, DOI 10.1093/jnen/60.11.1087; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Schaefer LK, 2000, CYTOKINE, V12, P1647, DOI 10.1006/cyto.2000.0774; Shono T, 2001, CANCER RES, V61, P4375; Skold M, 2000, EUR J NEUROSCI, V12, P3675, DOI 10.1046/j.1460-9568.2000.00263.x; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Taga T, 1997, ANN MED, V29, P63, DOI 10.3109/07853899708998744; Tai YT, 2002, BLOOD, V99, P1419, DOI 10.1182/blood.V99.4.1419; Tanaka T, 2000, J MOL CELL CARDIOL, V32, P1955, DOI 10.1006/jmcc.2000.1228; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Van Wagoner NJ, 2000, J NEUROCHEM, V75, P563, DOI 10.1046/j.1471-4159.2000.0750563.x; Vasse M, 1999, ARTERIOSCL THROM VAS, V19, P1835, DOI 10.1161/01.ATV.19.8.1835; Xu L, 2002, J BIOL CHEM, V277, P11368, DOI 10.1074/jbc.M108347200; Yao Y, 2001, ACTA NEUROCHIR, V143, P159, DOI 10.1007/s007010170122	41	53	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8117	8124		10.1038/sj.onc.1206922	http://dx.doi.org/10.1038/sj.onc.1206922			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603252				2022-12-25	WOS:000186403400006
J	Andreotti, G; Motta, A				Andreotti, G; Motta, A			Modulating calcitonin fibrillogenesis - An antiparallel alpha-helical dimer inhibits fibrillation of salmon calcitonin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ISLET AMYLOID POLYPEPTIDE; STATE C-13 NMR; SECONDARY STRUCTURE; COILED COILS; CONFORMATIONAL TRANSITIONS; IN-VITRO; PROTEINS; SPECTROSCOPY; PREDICTION	We have investigated the prefibrillar state of salmon (s) and human (h) calcitonin (CT). Size exclusion chromatography at pH 3.3 and 7.4 indicates that sCT is present in solution as a dimer, whereas hCT elutes as a monomer at pH 3.3 and as monomer-dimer at pH 7.4. Guanidine hydrochloride unfolding experiments show that dimerization is stabilized by hydrophobic interactions. We investigated the dimeric structure by multidimensional nuclear magnetic resonance spectroscopy and calculations by using an sCT mutant (LAsCT) in which Pro(23) and Arg(24) were substituted for Leu(23) and Ala(24). As indicated by the Leu(9)-Tyr(27) and Leu(12) -Leu(19) contacts, the mutated hormone forms a head-to-tail dimer whose basic unit is an alpha-helix in the region Leu(12)- Tyr(22). The solution behavior of LAsCT is identical to that of sCT, so the dimeric structure can safely be extended to sCT: we believe that such a structure inhibits fibril maturation in sCT. No stable dimer was observed for hCT, which we attributed to the absence of a defined helical structure. However, we suggest that intermolecular collisions of short ordered regions (for example, a sequence of turns) in hCT favors intermolecular contacts, and specific orientation can be obtained through hydrogen bond formation involving Tyr(12), Phe(16), and Phe(19), with the aromatic ring acting as an acceptor. Taken together, our results indicate that hCT fibrillation can be reduced by favoring a helical dimer, obtainable by replacing the three aromatic amino acids with leucines.	CNR, Ist Chim Biomol, I-80078 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR)	Motta, A (corresponding author), CNR, Ist Chim Biomol, Edificio 70,Via Campi Flegrei 34, I-80078 Naples, Italy.	amotta@icmib.na.cnr.it	ANDREOTTI, GIUSEPPINA/AAX-8952-2020	ANDREOTTI, GIUSEPPINA/0000-0002-1594-0156; Motta, Andrea/0000-0002-8643-658X				Amodeo P, 1999, J BIOMOL NMR, V13, P161, DOI 10.1023/A:1008365322148; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; ARVINTE T, 1993, J BIOL CHEM, V268, P6415; ARVINTE T, 1993, J BIOL CHEM, V268, P6408; ARVINTE T, 1996, CIBA F SYMP, V199, P90; Azriel R, 2001, J BIOL CHEM, V276, P34156, DOI 10.1074/jbc.M102883200; BAUER HH, 1995, J STRUCT BIOL, V115, P1, DOI 10.1006/jsbi.1995.1024; BENVENGA S, 1994, J ENDOCRINOL INVEST, V17, P119, DOI 10.1007/BF03347697; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; CUDD A, 1995, J PHARM SCI, V84, P717, DOI 10.1002/jps.2600840610; CUNNINGHAM BC, 1991, SCIENCE, V253, P545, DOI 10.1126/science.1907025; Eilers M, 2002, BIOPHYS J, V82, P2720, DOI 10.1016/S0006-3495(02)75613-0; EPAND RM, 1983, BIOCHEMISTRY-US, V22, P5074, DOI 10.1021/bi00291a005; Gazit E, 2002, FASEB J, V16, P77, DOI 10.1096/fj.01-0442hyp; Gazit E, 2002, CURR MED CHEM, V9, P1725; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; HOFRICHTER J, 1974, P NATL ACAD SCI USA, V71, P4864, DOI 10.1073/pnas.71.12.4864; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kallberg Y, 2001, J BIOL CHEM, V276, P12945, DOI 10.1074/jbc.M010402200; Kamihira M, 2003, J BIOL CHEM, V278, P2859, DOI 10.1074/jbc.M205285200; Kamihira M, 2000, PROTEIN SCI, V9, P867, DOI 10.1110/ps.9.5.867; Kammerer RA, 1998, P NATL ACAD SCI USA, V95, P13419, DOI 10.1073/pnas.95.23.13419; KANAORI K, 1995, BIOCHEMISTRY-US, V34, P12138, DOI 10.1021/bi00038a006; Kayed R, 1999, J MOL BIOL, V287, P781, DOI 10.1006/jmbi.1999.2646; Kazantzis A, 2002, EUR J BIOCHEM, V269, P780, DOI 10.1046/j.0014-2956.2001.02689.x; KONING TMG, 1990, J MAGN RESON, V90, P111, DOI 10.1016/0022-2364(90)90369-K; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Langosch D, 1998, PROTEINS, V31, P150, DOI 10.1002/(SICI)1097-0134(19980501)31:2<150::AID-PROT5>3.0.CO;2-Q; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; LEVY F, 1988, J CLIN ENDOCR METAB, V67, P541, DOI 10.1210/jcem-67-3-541; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MAIER R, 1976, CLIN ENDOCRINOL, V5, pS327, DOI 10.1111/j.1365-2265.1976.tb03841.x; MERELO JJ, 1994, NEUROCOMPUTING, V6, P443, DOI 10.1016/0925-2312(94)90021-3; OTTING G, 1988, EMBO J, V7, P4305, DOI 10.1002/j.1460-2075.1988.tb03329.x; Reches M, 2002, J BIOL CHEM, V277, P35475, DOI 10.1074/jbc.M206039200; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SILIGARDI G, 1994, EUR J BIOCHEM, V221, P1117, DOI 10.1111/j.1432-1033.1994.tb18832.x; Taddei N, 2001, J BIOL CHEM, V276, P37149, DOI 10.1074/jbc.M105720200; Tjernberg L, 2002, J BIOL CHEM, V277, P43243, DOI 10.1074/jbc.M205570200; Tjernberg LO, 1999, J BIOL CHEM, V274, P12619, DOI 10.1074/jbc.274.18.12619; VANGUNSTEREN WF, 1977, MOL PHYS, V34, P1311, DOI 10.1080/00268977700102571; VIETH M, 1994, J MOL BIOL, V237, P361, DOI 10.1006/jmbi.1994.1239; von Bergen M, 2000, P NATL ACAD SCI USA, V97, P5129, DOI 10.1073/pnas.97.10.5129; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P162; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; Zaidi M, 2002, BONE, V30, P655, DOI 10.1016/S8756-3282(02)00688-9	50	20	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6364	6370		10.1074/jbc.M310882200	http://dx.doi.org/10.1074/jbc.M310882200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14594801	hybrid			2022-12-25	WOS:000188969200021
J	Rettinger, J; Schmalzing, G				Rettinger, J; Schmalzing, G			Desensitization masks nanomolar potency of ATP for the P2X(1) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; C-TERMINAL DOMAIN; BINDING CHARACTERISTICS; STRUCTURAL MOTIF; XENOPUS OOCYTES; EXPRESSION; IDENTIFICATION; ECTODOMAIN; ACTIVATION; AFFINITY	ATP-gated P2X(1) receptors feature fast activation and fast desensitization combined with slow recovery from desensitized states. Here, we exploited a non-desensitizing P2X(2)/P2X(1), chimera that includes the entire P2X(1) ectodomain (Werner, P., Seward, E. P., Buell, G. N., and North, M A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 1548515490) to obtain a macroscopic representation of intrinsic receptor kinetics without bias arising from the overlap of channel activation and desensitization. From the stationary currents made amenable to analysis by this chimera, an EC50 for ATP of 3.3 nm was derived, representing a >200- and >7000-fold higher ATP potency than observed for the parental P2X(1) and P2X(2A) receptors, respectively. Also, other agonists activated the P2X(2)/P2X(1), chimera with nanomolar EC50 values ranging from 3.5 to 73 nm in the following rank order: 2-methylthio-ATP, 2',3'-O-(4-benzoylbenzoyl)-ATP, alpha,beta-methylene-ATP, adenosine 5'-0-(3-thiotriphosphate). Upon washout, the P2X(2)/P2X(1) chimera deactivated slowly with a time constant (ranging from 63 to 2.5 s) that is inversely related to the EC50 value for the corresponding agonist. This suggests that deactivation time courses reflect unbinding rates, which by themselves define agonist potencies. The P2X(2)/P2X(1) chimera and the P2X(1) receptor possess virtually identical sensitivity to inhibition by the P2X(1) receptor-selective antagonist NF279, a suramin analog. These results suggest that the P2X(1), ectodomain confers nanomolar ATP sensitivity, which, within the wild-type P2X(1) receptor, is obscured by desensitization such that only a micromolar ATP potency can be deduced from peak current measurements, representing an amalgam of activation and desensitization.	Rhein Westfal TH Aachen, Sch Med, Dept Mol Pharmacol, D-52074 Aachen, Germany; Max Planck Inst Biophys, D-60439 Frankfurt, Germany	RWTH Aachen University; Max Planck Society	Schmalzing, G (corresponding author), Rhein Westfal TH Aachen, Sch Med, Dept Mol Pharmacol, Wendlingweg 2, D-52074 Aachen, Germany.	gschmalzing@ukaachen.de						Boue-Grabot E, 2000, J BIOL CHEM, V275, P10190, DOI 10.1074/jbc.275.14.10190; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Egan TM, 1998, J NEUROSCI, V18, P2350; Eickhorst AN, 2002, J GEN PHYSIOL, V120, P119, DOI 10.1085/jgp.20028535; Ennion S, 2000, J BIOL CHEM, V275, P29361, DOI 10.1074/jbc.M003637200; Ennion SJ, 2001, FEBS LETT, V489, P154, DOI 10.1016/S0014-5793(01)02102-0; Failer BU, 2003, EUR J BIOCHEM, V270, P1802, DOI 10.1046/j.1432-1033.2003.03542.x; Haines WR, 2001, J BIOL CHEM, V276, P32793, DOI 10.1074/jbc.M104216200; He ML, 2003, J BIOL CHEM, V278, P10182, DOI 10.1074/jbc.M209094200; He ML, 2002, MOL PHARMACOL, V62, P1187, DOI 10.1124/mol.62.5.1187; Jiang LH, 2000, J BIOL CHEM, V275, P34190, DOI 10.1074/jbc.M005481200; Kenakin TP., 1993, PHARM ANAL DRUG RECE, V2; Koshimizu T, 1999, J BIOL CHEM, V274, P37651, DOI 10.1074/jbc.274.53.37651; LEFF P, 1986, J THEOR BIOL, V121, P221, DOI 10.1016/S0022-5193(86)80095-9; LESTER RAJ, 1992, J NEUROSCI, V12, P635; Lynch KJ, 1999, MOL PHARMACOL, V56, P1171, DOI 10.1124/mol.56.6.1171; Michel AD, 1996, BRIT J PHARMACOL, V118, P1806, DOI 10.1111/j.1476-5381.1996.tb15607.x; Michel AD, 1996, BRIT J PHARMACOL, V117, P1254, DOI 10.1111/j.1476-5381.1996.tb16723.x; Mike A, 2000, BRAIN RES, V882, P155, DOI 10.1016/S0006-8993(00)02863-8; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; Nicke A, 2003, MOL PHARMACOL, V63, P243, DOI 10.1124/mol.63.1.243; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; Rassendren F, 1997, EMBO J, V16, P3446, DOI 10.1093/emboj/16.12.3446; Rettinger J, 2000, NEUROPHARMACOLOGY, V39, P2044, DOI 10.1016/S0028-3908(00)00022-8; Rettinger J, 2003, J GEN PHYSIOL, V121, P451, DOI 10.1085/jgp.200208730; Rettinger J, 2000, J BIOL CHEM, V275, P33542, DOI 10.1074/jbc.M002918200; SCHMALZING G, 1991, BIOCHEM J, V279, P329, DOI 10.1042/bj2790329; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485; ZIGANSHIN AU, 1995, PFLUG ARCH EUR J PHY, V429, P412, DOI 10.1007/BF00374157	31	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6426	6433		10.1074/jbc.M306987200	http://dx.doi.org/10.1074/jbc.M306987200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14625300	hybrid			2022-12-25	WOS:000188969200028
J	Matsuoka, H; Nada, S; Okada, M				Matsuoka, H; Nada, S; Okada, M			Mechanism of Csk-mediated down-regulation of Src family tyrosine kinases in epidermal growth factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; GREEN FLUORESCENT PROTEIN; T-CELL-ACTIVATION; FACTOR RECEPTOR; C-SRC; LIVING CELLS; LIPID RAFTS; ENRICHED MICRODOMAINS; TRANSMEMBRANE ADAPTER; EGF RECEPTOR	The Src family tyrosine kinases (SFKs) play pivotal roles as molecular switches that link a variety of extracellular cues to intracellular signaling pathway. The function of SFK is regulated by phosphorylation at the C-terminal regulatory site mediated by Csk. Recently a novel SFK target Cbp (or PAG) was identified as a membrane-anchored scaffold protein for Csk. To establish the mechanism of Csk/Cbp-mediated regulation of SFK in vivo, we observed dynamic changes in the interaction of Csk with Cbp by utilizing fusion proteins with modified green fluorescent proteins: cyan fluorescent protein (CFP) or yellow fluorescent protein (YFP). Upon SFK activation induced by epidermal growth factor stimulation, fluorescent resonance energy transfer (FRET) response was detected transiently at membrane ruffles in COS1 cells co-expressing CFP-Csk and Cbp-YFP and in cells expressing a single-molecule FRET indicator consisting of CskSH2 and Cbp. Suppression of SFK by PP2 or use of a mutant Cbp that lacks the Csk binding site abolished the FRET response, although a dominant-negative form of Csk enhanced and sustained the FRET response, demonstrating that the FRET response is dependent upon the SFK activity. These observations show that Csk/Cbp-mediated down-regulation of SFK takes place at membrane ruffles in an early stage of epidermal growth factor signaling and suggest that the Csk/Cbp-based FRET indicators are useful for monitoring the status of SFK in living cells.	Osaka Univ, Dept Oncogene Res, Res Inst Microbial Dis, Osaka 5650871, Japan	Osaka University	Okada, M (corresponding author), Osaka Univ, Dept Oncogene Res, Res Inst Microbial Dis, 3-1 Yamadaoka, Osaka 5650871, Japan.	okadam@biken.osaka-u.ac.jp						Abrahamsen H, 2003, J BIOL CHEM, V278, P17170, DOI 10.1074/jbc.M211426200; Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Cary LA, 2000, NATURE, V404, P945, DOI 10.1038/35010257; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CLOUTIER JF, 1995, MOL CELL BIOL, V15, P5937; Davidson D, 2003, MOL CELL BIOL, V23, P2017, DOI 10.1128/MCB.23.6.2017-2028.2003; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kurokawa K, 2001, J BIOL CHEM, V276, P31305, DOI 10.1074/jbc.M104341200; Lindquist JA, 2003, IMMUNOL REV, V191, P165, DOI 10.1034/j.1600-065X.2003.00007.x; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; Meyer T, 2003, TRENDS CELL BIOL, V13, P101, DOI 10.1016/S0962-8924(02)00040-5; Mitra RD, 1996, GENE, V173, P13, DOI 10.1016/0378-1119(95)00768-7; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Miyawaki A, 2003, DEV CELL, V4, P295, DOI 10.1016/S1534-5807(03)00060-1; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Ohba Y, 2003, EMBO J, V22, P859, DOI 10.1093/emboj/cdg087; RENGIFOCAM W, 2003, IN PRESS ONCOGENE; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Sato M, 2002, NAT BIOTECHNOL, V20, P287, DOI 10.1038/nbt0302-287; Schmid JA, 2003, CURR OPIN ONCOL, V15, P55, DOI 10.1097/00001622-200301000-00008; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Sorkina T, 2002, J BIOL CHEM, V277, P27433, DOI 10.1074/jbc.M201595200; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Takeuchi S, 2000, J BIOL CHEM, V275, P29183, DOI 10.1074/jbc.C000326200; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Torgersen KM, 2001, J BIOL CHEM, V276, P29313, DOI 10.1074/jbc.C100014200; Ware MF, 1997, J BIOL CHEM, V272, P30185, DOI 10.1074/jbc.272.48.30185; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yasuda K, 2002, J IMMUNOL, V169, P2813, DOI 10.4049/jimmunol.169.6.2813; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	43	33	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5975	5983		10.1074/jbc.M311278200	http://dx.doi.org/10.1074/jbc.M311278200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14613929	hybrid			2022-12-25	WOS:000188776500113
J	Han, YP; Zhou, L; Wang, JH; Xiong, SG; Garner, WL; French, SW; Tsukamoto, H				Han, YP; Zhou, L; Wang, JH; Xiong, SG; Garner, WL; French, SW; Tsukamoto, H			Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT-STORING CELLS; TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR-BETA; NORMAL RAT-LIVER; EXTRACELLULAR-MATRIX; FACTOR-ALPHA; IN-VIVO; HEPATOCELLULAR-CARCINOMA; PROTEOLYTIC ACTIVATION; TISSUE INHIBITOR	Located within the perisinusoidal space and surrounded by extracellular matrix, hepatic stellate cells (HSC) undergo phenotypic trans-differentiation called "myofibroblastic activation" in liver fibrogenesis. This study investigated the regulation of interleukin-1 (IL-1alpha) on expression of matrix metalloproteinases (MMPs) by HSC grown in three-dimensional extracellular matrix and the role of MMPs in HSC activation. To recapitulate the in vivo "quiescent" state of HSC, the isolated rat HSC were grown in three-dimensional Matrigel or type I collagen. Stimulation with IL-1alpha caused robust induction of pro-MMP-9 (the precursor of matrix metalloproteinase-9) when HSC were cultured in these matrices. IL-1alpha induced a conversion of the pro-MMP-9 to the active form only when the cells were in type I collagen. In collagen lattices, IL-1alpha provoked activation of HSC with induction of MMP-13, MMP-3, and breakdown of the matrix. The HSC activation was completely prevented by a treatment of the cells with tissue inhibitor of metalloproteinase-1 or deprivation of MMP-9. Once fully activated, HSC failed to express MMP-9 and showed attenuated induction of MMP-13 and MMP-3. Further, we demonstrated colocalization of alpha-smooth muscle actin and MMP-9 in a subpopulation of HSC in human fibrotic liver tissues. Thus, this study provides a novel model to enlighten the role of MMPs, particularly that of MMP-9, in HSC activation regulated by a specific cytokine in liver fibrogenesis.	Univ So Calif, Keck Sch Med, Dept Surg, Div Plast & Reconstruct Surg, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; Harbor UCLA Med Ctr, Dept Pathol, Torrance, CA 90502 USA; Dept Vet Affairs Greater Los Angeles Hlth Syst, Los Angeles, CA 90073 USA	University of Southern California; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Han, YP (corresponding author), Univ So Calif, Keck Sch Med, Dept Surg, Div Plast & Reconstruct Surg, 2011 Zonal Ave,HMR Rm 813, Los Angeles, CA 90033 USA.	yhan@surgery.usc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048522, R01DK069418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA006603] Funding Source: NIH RePORTER; NIAAA NIH HHS [R37AA06603, R24AA122885] Funding Source: Medline; NIDDK NIH HHS [R01 DK069418-01, P30 DK048522, P30DK48522] Funding Source: Medline; NIGMS NIH HHS [R01GM50896] Funding Source: Medline; PHS HHS [P5011999] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARENSON DM, 1988, GASTROENTEROLOGY, V95, P441, DOI 10.1016/0016-5085(88)90502-1; ARTHUR MJP, 1989, J CLIN INVEST, V84, P1076, DOI 10.1172/JCI114270; Arthur MJP, 1999, ALCOHOL CLIN EXP RES, V23, P940, DOI 10.1111/j.1530-0277.1999.tb04208.x; Ashida K, 1996, AM J PATHOL, V149, P1803; BACHEM MG, 1992, J CLIN INVEST, V89, P19, DOI 10.1172/JCI115561; Benyon RC, 2001, SEMIN LIVER DIS, V21, P373, DOI 10.1055/s-2001-17552; DELEEUW AM, 1984, HEPATOLOGY, V4, P392; Eng FJ, 2001, SEMIN LIVER DIS, V21, P385, DOI 10.1055/s-2001-17553; Fan JM, 2001, AM J KIDNEY DIS, V37, P820, DOI 10.1016/S0272-6386(01)80132-3; FRIEDMAN SL, 1992, HEPATOLOGY, V15, P234, DOI 10.1002/hep.1840150211; Friedman SL, 1999, SEMIN LIVER DIS, V19, P129, DOI 10.1055/s-2007-1007105; FRIEDMAN SL, 1989, J CLIN INVEST, V84, P1780, DOI 10.1172/JCI114362; FRIEDMAN SL, 1994, J BIOL CHEM, V269, P10551; FRIEDMAN SL, 1985, P NATL ACAD SCI USA, V82, P8681, DOI 10.1073/pnas.82.24.8681; Furuya Yoshitaka, 2000, Gastric Cancer, V3, P86, DOI 10.1007/PL00011701; Han YP, 2002, J BIOL CHEM, V277, P27319, DOI 10.1074/jbc.M202842200; Han YP, 2001, J BIOL CHEM, V276, P22341, DOI 10.1074/jbc.M010839200; Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514; Hellerbrand C, 1998, AM J PHYSIOL-GASTR L, V275, pG269, DOI 10.1152/ajpgi.1998.275.2.G269; Imai K, 1998, ANAT REC, V250, P430; IREDALE JP, 1995, CLIN SCI, V89, P75, DOI 10.1042/cs0890075; KIMURA A, 1993, AM J HEMATOL, V43, P47, DOI 10.1002/ajh.2830430111; Kossakowska AE, 1998, AM J PATHOL, V153, P1895, DOI 10.1016/S0002-9440(10)65703-3; LIOTTA LA, 1991, CANCER INVEST, V9, P543, DOI 10.3109/07357909109018952; LONNEMAN G, 1995, KIDNEY INT, V47, P837, DOI 10.1038/ki.1995.126; Maatta M, 2000, CLIN CANCER RES, V6, P2726; Maher J J, 1989, Hepatology, V9, P903, DOI 10.1002/hep.1840090621; MAHER JJ, 1988, J CLIN INVEST, V82, P450, DOI 10.1172/JCI113618; MAINARDI CL, 1984, COLLAGEN REL RES, V4, P209; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MATSUOKA M, 1989, LIVER, V9, P71; MATSUOKA M, 1990, HEPATOLOGY, V11, P599, DOI 10.1002/hep.1840110412; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; OGATA Y, 1995, J BIOL CHEM, V270, P18506, DOI 10.1074/jbc.270.31.18506; Parks WC, 1999, WOUND REPAIR REGEN, V7, P423, DOI 10.1046/j.1524-475X.1999.00423.x; PIGUET PF, 1993, CYTOKINE, V5, P57, DOI 10.1016/1043-4666(93)90024-Y; QUINN CO, 1990, J BIOL CHEM, V265, P22342; RAMADORI G, 1987, J HEPATOL, V4, P190, DOI 10.1016/S0168-8278(87)80079-X; Sakamoto Y, 2000, INT J ONCOL, V17, P237; Senoo Haruki, 1994, Acta Anatomica Nipponica, V69, P719; Takahara T, 2003, HEPATOL RES, V26, P318, DOI 10.1016/S1386-6346(03)00169-4; Theret N, 1999, HEPATOLOGY, V30, P462, DOI 10.1002/hep.510300236; Tomimatsu S, 2001, CANCER, V91, P1272, DOI 10.1002/1097-0142(20010401)91:7<1272::AID-CNCR1128>3.0.CO;2-Z; Tsukamoto H, 1999, ALCOHOL CLIN EXP RES, V23, P911, DOI 10.1111/j.1530-0277.1999.tb04202.x; Tsukamoto H, 1996, AM J PHYSIOL-GASTR L, V270, pG581, DOI 10.1152/ajpgi.1996.270.4.G581; VidalVanaclocha F, 1996, JNCI-J NATL CANCER I, V88, P198, DOI 10.1093/jnci/88.3-4.198; Wake K, 1980, Int Rev Cytol, V66, P303; WAKE K, 1987, CELL TISSUE RES, V249, P289; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Werb Z, 1998, ANN NY ACAD SCI, V857, P110, DOI 10.1111/j.1749-6632.1998.tb10111.x; Wielockx B, 2001, NAT MED, V7, P1202, DOI 10.1038/nm1101-1202; WINWOOD PJ, 1995, HEPATOLOGY, V22, P304; WONG L, 1994, J CLIN INVEST, V94, P1563, DOI 10.1172/JCI117497; YOKOI Y, 1984, HEPATOLOGY, V4, P709, DOI 10.1002/hep.1840040425; Yu Q, 2000, GENE DEV, V14, P163; Zeng ZS, 1998, BRIT J CANCER, V78, P349, DOI 10.1038/bjc.1998.497	56	115	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4820	4828		10.1074/jbc.M310999200	http://dx.doi.org/10.1074/jbc.M310999200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14617627	Green Accepted, hybrid			2022-12-25	WOS:000188554300107
J	Kanda, S; Miyata, Y; Kanetake, H				Kanda, S; Miyata, Y; Kanetake, H			Fibroblast growth factor-2-mediated capillary morphogenesis of endothelial cells requires signals via Flt-1/vascular endothelial growth factor receptor-1 - Possible involvement of c-Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; IN-VITRO; VEGF RECEPTORS; ANGIOGENESIS; TRANSDUCTION; ACTIVATION; PHOSPHORYLATION; DIFFERENTIATION; MIGRATION; HEPARIN	Capillary morphogenesis is a crucial angiogenic response of endothelial cells. Although fibroblast growth factor-2 (FGF-2) potently induces capillary morphogenesis, the contribution of vascular endothelial growth factor-A (VEGF-A) in this response has not been clarified well. Here we examined the role of VEGF signaling in FGF-2-induced capillary morphogenesis by murine brain capillary endothelial cells (IBE cells) and human umbilical vein endothelial cells. FGF-2-treated IBE cells rapidly extended on Matrigel in association with actin reorganization. Chimeric protein, of which the extracellular domain of VEGF receptor-1 (VEGFR-1) fused to immunoglobulin Fc, inhibited FGF-2-induced cell extension, resulting in decreased capillary morphogenesis. Blocking antibody against VEGFR-1 inhibited FGF-2-induced capillary formation. Also, anti-VEGF-A antibody inhibited FGF-2-induced capillary morphogenesis, which was restored by the addition of placental growth factor-1. Similar results were obtained by the experiments with human umbilical vein endothelial cells. Expression of kinase-inactive c-Akt in IBE cells showed impaired capillary morphogenesis promoted by FGF-2. Conversely, stable cell lines expressing activated c-Akt demonstrated ligand-independent capillaries, which were resistant to the treatment with anti-VEGFR-1 blocking antibody. Upstream of c-Akt, calmodulin-dependent signals seemed to be involved. Taken together, signals via VEGFR-1 were required for FGF-2-induced capillary morphogenesis by endothelial cells, and c-Akt activity seemed to be involved in this process.	Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Microbiol & Immunol, Div Endothelial Cell Biol, Nagasaki 8528501, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Urol, Nagasaki 8528501, Japan	Nagasaki University; Nagasaki University	Kanda, S (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Microbiol & Immunol, Div Endothelial Cell Biol, 1-7-1 Sakamoto, Nagasaki 8528501, Japan.	shigeruk@net.nagasaki-u.ac.jp						AUERBACH R, 1991, PHARMACOL THERAPEUT, V51, P1, DOI 10.1016/0163-7258(91)90038-N; Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Connolly JO, 2002, MOL BIOL CELL, V13, P2474, DOI 10.1091/mbc.E02-01-0006; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; Ingber DE, 2002, CIRC RES, V91, P877, DOI 10.1161/01.RES.0000039537.73816.E5; Javerzat S, 2002, TRENDS MOL MED, V8, P483, DOI 10.1016/S1471-4914(02)02394-8; Jussila L, 2002, PHYSIOL REV, V82, P673, DOI 10.1152/physrev.00005.2002; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; Kanda S, 2000, J BIOL CHEM, V275, P10105, DOI 10.1074/jbc.275.14.10105; Kanda S, 2003, BIOCHEM BIOPH RES CO, V306, P1056, DOI 10.1016/S0006-291X(03)01106-9; Kanda S, 2003, J BIOL CHEM, V278, P8244, DOI 10.1074/jbc.M210635200; KANDA S, 2000, CURR T BIOCHEM RES, V2, P225; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; KLINT P, 1999, FRONT BIOSCI, V4, P165; Koolwijk Pieter, 2001, Angiogenesis, V4, P53, DOI 10.1023/A:1016637700638; Kubo H, 2002, P NATL ACAD SCI USA, V99, P8868, DOI 10.1073/pnas.062040199; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Mamluk R, 2002, J BIOL CHEM, V277, P24818, DOI 10.1074/jbc.M200730200; MONTESANO R, 1992, EUR J CLIN INVEST, V22, P504, DOI 10.1111/j.1365-2362.1992.tb01498.x; Nakamura T, 2001, BIOCHEM BIOPH RES CO, V289, P801, DOI 10.1006/bbrc.2001.6046; Nakamura T, 2001, ONCOGENE, V20, P7610, DOI 10.1038/sj.onc.1204975; Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257; Ornitz DM, 2001, GENOME BIOL, V2; PAKU S, 1991, LAB INVEST, V65, P334; PEPPER MS, 1994, EXP CELL RES, V210, P298, DOI 10.1006/excr.1994.1042; Pepper MS, 1998, J CELL PHYSIOL, V177, P439, DOI 10.1002/(SICI)1097-4652(199812)177:3<439::AID-JCP7>3.0.CO;2-2; SEETHARAM L, 1995, ONCOGENE, V10, P135; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Shibuya M, 1999, CURR TOP MICROBIOL, V237, P59; Tille JC, 2001, J PHARMACOL EXP THER, V299, P1073; Tsuda S, 2002, BIOCHEM BIOPH RES CO, V290, P1354, DOI 10.1006/bbrc.2002.6345; Vailhe B, 2001, LAB INVEST, V81, P439, DOI 10.1038/labinvest.3780252; Veikkola T, 2000, CANCER RES, V60, P203; Velazquez OC, 2002, FASEB J, V16, P1316, DOI 10.1096/fj.01-1011fje; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; YANAI N, 1991, CELL STRUCT FUNCT, V16, P87, DOI 10.1247/csf.16.87; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yang SY, 2001, ARTERIOSCL THROM VAS, V21, P1934, DOI 10.1161/hq1201.099432; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Ziche M, 1997, LAB INVEST, V76, P517	53	49	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4007	4016		10.1074/jbc.M307569200	http://dx.doi.org/10.1074/jbc.M307569200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14610089	hybrid			2022-12-25	WOS:000188554300013
J	Stroh, A; Anderka, O; Pfeiffer, K; Yagi, T; Finel, M; Ludwig, B; Schagger, H				Stroh, A; Anderka, O; Pfeiffer, K; Yagi, T; Finel, M; Ludwig, B; Schagger, H			Assembly of respiratory complexes I, III, and IV into NADH oxidase supercomplex stabilizes complex I in Paracoccus denitrificans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; UBIQUINONE OXIDOREDUCTASE COMPLEX; BLUE NATIVE ELECTROPHORESIS; BOVINE HEART-MITOCHONDRIA; BC(1) COMPLEX; THERMOACIDOPHILIC ARCHAEON; MUTATIONAL ANALYSIS; ELECTRON-TRANSFER; ESCHERICHIA-COLI; SULFOLOBUS SP	Stable supercomplexes of bacterial respiratory chain complexes III (ubiquinol:cytochrome c oxidoreductase) and IV (cytochrome c oxidase) have been isolated as early as 1985 (Berry, E. A., and Trumpower, B. L. (1985) J. Biol. Chem. 260, 2458-2467). However, these assemblies did not comprise complex I (NADH:ubiquinone oxidoreductase). Using the mild detergent digitonin for solubilization of Paracoccus denitrificans membranes we could isolate NADH oxidase, assembled from complexes I, III, and IV in a 1:4:4 stoichiometry. This is the first chromatographic isolation of a complete "respirasome." Inactivation of the gene for tightly bound cytochrome c(552) did not prevent formation of this supercomplex, indicating that this electron carrier protein is not essential for structurally linking complexes III and IV. Complex I activity was also found in the membranes of mutant strains lacking complexes III or IV. However, no assembled complex I but only dissociated subunits were observed following the same protocols used for electrophoretic separation or chromatographic isolation of the supercomplex from the wild-type strain. This indicates that the P. denitrificans complex I is stabilized by assembly into the NADH oxidase supercomplex. In addition to substrate channeling, structural stabilization of a membrane protein complex thus appears as one of the major functions of respiratory chain supercomplexes.	Univ Frankfurt Klinikum, Zentrum Biol Chem, D-60590 Frankfurt, Germany; Goethe Univ Frankfurt, Inst Biochem, D-60439 Frankfurt, Germany; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA USA; Univ Helsinki, Viikki Drug Discovery Technol Ctr, Dept Pharm, FIN-00014 Helsinki, Finland	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Scripps Research Institute; University of Helsinki	Schagger, H (corresponding author), Univ Frankfurt Klinikum, Zentrum Biol Chem, Theodor Stern Kai 7,Haus 25B, D-60590 Frankfurt, Germany.	schagger@zbc.kgu.de			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033712] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM33712] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker SC, 1998, MICROBIOL MOL BIOL R, V62, P1046, DOI 10.1128/MMBR.62.4.1046-1078.1998; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BERRY EA, 1985, J BIOL CHEM, V260, P2458; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200; DEVRIES GE, 1989, ARCH MICROBIOL, V152, P52, DOI 10.1007/BF00447011; Drose S, 2002, BBA-BIOENERGETICS, V1556, P65, DOI 10.1016/S0005-2728(02)00307-9; Fernandes AS, 2002, J BIOENERG BIOMEMBR, V34, P413, DOI 10.1023/A:1022509907553; Finel M, 1996, FEBS LETT, V393, P81, DOI 10.1016/0014-5793(96)00831-9; GABELLINI N, 1982, EUR J BIOCHEM, V126, P105, DOI 10.1111/j.1432-1033.1982.tb06753.x; Gemperli AC, 2002, J BIOL CHEM, V277, P33811, DOI 10.1074/jbc.M204860200; GENOVA AL, 2003, ITAL J BIOCHEM, V52, P58; HATEFI Y, 1969, J BIOL CHEM, V244, P2350; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HELENIUS A, 1972, J BIOL CHEM, V247, P3656; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; ITZHAKI RF, 1964, ANAL BIOCHEM, V9, P401, DOI 10.1016/0003-2697(64)90200-3; Iwasaki T, 1995, J BIOL CHEM, V270, P30893, DOI 10.1074/jbc.270.52.30893; Iwasaki T, 1995, J BIOL CHEM, V270, P30881, DOI 10.1074/jbc.270.52.30881; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JOHN P, 1975, NATURE, V254, P495, DOI 10.1038/254495a0; KADENBACH B, 1983, ANAL BIOCHEM, V129, P517, DOI 10.1016/0003-2697(83)90586-9; KASHANIPOOR N, 2001, BIOCHIM BIOPHYS ACTA, V1504, P186; Komorowski L, 2002, BIOL CHEM, V383, P1791, DOI 10.1515/BC.2002.200; KORN M, 1994, THESIS JW GOETHE U F; KOZIOL J., 1971, Methods in Enzymology, V18B, P253, DOI 10.1016/S0076-6879(71)18089-5; KUROWSKI B, 1987, J BIOL CHEM, V262, P13805; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; LUDWIG B, 1986, METHOD ENZYMOL, V126, P153; Margulis Lynn, 1970, ORIGIN EUKARYOTE CEL; Niebisch A, 2003, J BIOL CHEM, V278, P4339, DOI 10.1074/jbc.M210499200; Peng GH, 2003, BIOCHEMISTRY-US, V42, P3032, DOI 10.1021/bi026876v; PENNOYER JD, 1998, BIOCHIM BIOPHYS ACTA, V935, P195; RAITIO M, 1994, BBA-BIOENERGETICS, V1186, P100, DOI 10.1016/0005-2728(94)90140-6; RAITIO M, 1987, EMBO J, V6, P2825, DOI 10.1002/j.1460-2075.1987.tb02579.x; Schagger H, 1995, METHOD ENZYMOL, V260, P82, DOI 10.1016/0076-6879(95)60132-5; SCHAGGER H, 1995, ELECTROPHORESIS, V16, P763, DOI 10.1002/elps.11501601125; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Schroter T, 1998, EUR J BIOCHEM, V255, P100, DOI 10.1046/j.1432-1327.1998.2550100.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SONE N, 1987, J BIOL CHEM, V262, P15386; STOUTHAMER AH, 1992, ANTON LEEUW INT J G, V61, P1, DOI 10.1007/BF00572119; TURBA A, 1995, EUR J BIOCHEM, V231, P259, DOI 10.1111/j.1432-1033.1995.0259f.x; TURBA A, 1993, THESIS JW GOETHE U F; VANSPANNING RJM, 1990, J BACTERIOL, V172, P986, DOI 10.1128/jb.172.2.986-996.1990; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; XU XM, 1993, BIOCHEMISTRY-US, V32, P968, DOI 10.1021/bi00054a030; YANG XH, 1986, J BIOL CHEM, V261, P2282; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; Zickermann V, 1998, BIOCHEMISTRY-US, V37, P11792, DOI 10.1021/bi9810555	55	190	199	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					5000	5007		10.1074/jbc.M309505200	http://dx.doi.org/10.1074/jbc.M309505200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14610094	hybrid			2022-12-25	WOS:000188554300126
J	Andreola, F; Hayhurst, GP; Luo, G; Ferguson, SS; Gonzalez, FJ; Goldstein, JA; De Luca, LM				Andreola, F; Hayhurst, GP; Luo, G; Ferguson, SS; Gonzalez, FJ; Goldstein, JA; De Luca, LM			Mouse liver CYP2C39 is a novel retinoic acid 4-hydroxylase - Its down-regulation offers a molecular basis for liver retinoid accumulation and fibrosis in aryl hydrocarbon receptor-null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AH-RECEPTOR; DEFICIENT MICE; CYTOCHROME-P450; METABOLISM; INVOLVEMENT; EXPRESSION; LACKING; CLONING; GROWTH; ALLELE	Livers of aryl hydrocarbon receptor (AHR)-null mice have high levels of retinoic acid (RA), retinol, and retinyl palmitate. Hepatic accumulation of RA in these mice may be responsible in part for the hepatic phenotype characterized by small liver size and fibrosis. The increased levels of hepatic RA may be due to decreased metabolism of RA to 4-hydroxyretinoic acid. To identify the P450 isoform(s) involved in RA metabolism, liver microsomes from AHR-null and wild-type mice were subjected to Western blotting and probed with antibodies to rat P450s that cross-react with murine forms. Signal intensity in Western blots probed with anti-rat CYP2C6 antibodies correlated with levels of RA 4-hydroxylation. Furthermore, this anti-rat CYP2C6 antibody inhibited RA 4-hydroxylase activity of wild-type mouse liver microsomes to the levels of AHR-null mouse liver. When used to screen a mouse liver cDNA expression library, this antibody exclusively recognized the murine P450 CYP2C39. Catalytic assays of five recombinant mouse CYP2Cs expressed in Escherichia coli revealed that only CYP2C39 was competent for RA 4-hydroxylation (K-m=812.3 nM and V-max 47.85 (fmol/min/pmol P450)). Real time reverse transcriptase-PCR used to assess the Cyp2C39 mRNA expression showed decreased levels (30%) of this transcript in AHR-null compared with wild-type liver, consistent with decreased protein levels observed by Western blot analysis using an antibody to a CYP2C39-specific peptide. These data show that CYP2C39 catalyzes RA catabolism and thus possibly controls RA levels in mouse liver. Down-regulation of Cyp2C39 is hypothesized to be responsible for the liver phenotype in the AHR-null mouse.	NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA; NIEHS, Pharmacol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	De Luca, LM (corresponding author), NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bldg 37,Rm 4054C,37 Convent Dr, Bethesda, MD 20892 USA.	luigi_de_luca@nih.gov	Goldstein, Joyce/A-6681-2012; Andreola, Fausto/L-2972-2018	Andreola, Fausto/0000-0003-4926-0121	DIVISION OF BASIC SCIENCES - NCI [Z01BC004798] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [ZIABC005562, Z01BC005562] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES021024, Z01ES021024] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andreola F, 1997, CANCER RES, V57, P2835; DeLuca LM, 1995, SCI AM SCI MED, V2, P28; Elizondo G, 2000, J BIOL CHEM, V275, P39747, DOI 10.1074/jbc.M004987200; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FernandezSalguero PM, 1997, VET PATHOL, V34, P605, DOI 10.1177/030098589703400609; FIORELLA PD, 1995, TOXICOL APPL PHARM, V134, P222, DOI 10.1006/taap.1995.1187; Gonzalez FJ, 1998, DRUG METAB DISPOS, V26, P1194; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; Ibeanu GC, 1998, PHARMACOGENETICS, V8, P129, DOI 10.1097/00008571-199804000-00006; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; Loudig O, 2000, MOL ENDOCRINOL, V14, P1483, DOI 10.1210/me.14.9.1483; Luo G, 1998, ARCH BIOCHEM BIOPHYS, V357, P45, DOI 10.1006/abbi.1998.0806; MacLean G, 2001, MECH DEVELOP, V107, P195, DOI 10.1016/S0925-4773(01)00463-4; McSorley LC, 2000, BIOCHEM PHARMACOL, V60, P517, DOI 10.1016/S0006-2952(00)00356-7; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Ray WJ, 1997, J BIOL CHEM, V272, P18702, DOI 10.1074/jbc.272.30.18702; SAFE SH, 1994, CRIT REV TOXICOL, V24, P87, DOI 10.3109/10408449409049308; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Shimizu Y, 2000, P NATL ACAD SCI USA, V97, P779, DOI 10.1073/pnas.97.2.779; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; Tahayato A, 2003, GENE EXPR PATTERNS, V3, P449, DOI 10.1016/S1567-133X(03)00066-8; Zaher H, 1998, MOL PHARMACOL, V54, P313, DOI 10.1124/mol.54.2.313	23	51	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3434	3438		10.1074/jbc.M305832200	http://dx.doi.org/10.1074/jbc.M305832200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14623888	hybrid			2022-12-25	WOS:000188379600038
J	Lin, CC; Chou, CM; Hsu, YL; Lien, JC; Wang, YM; Chen, ST; Tsai, SC; Hsiao, PW; Huang, CJ				Lin, CC; Chou, CM; Hsu, YL; Lien, JC; Wang, YM; Chen, ST; Tsai, SC; Hsiao, PW; Huang, CJ			Characterization of two mosquito STATs, AaSTAT and CtSTAT - Differential regulation of tyrosine phosphorylation and DNA binding activity by lipopolysaccharide treatment and by Japanese encephalitis virus infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEDES-ALBOPICTUS; DROSOPHILA IMMUNITY; GENOMIC STRUCTURE; PROTEIN; GENE; INNATE; IDENTIFICATION; INTERFERON; EXPRESSION; RECEPTOR	Two mosquito STATs, AaSTAT and CtSTAT, have been cloned from Aedes albopictus and Culex tritaeniorhynchus mosquitoes, respectively. These two STATs are more similar to those of Drosophila, Anopheles, and mammalian STAT5 in the DNA binding and Src homology 2 domains. The mRNA transcripts are expressed at all developmental stages, and the proteins are present predominantly at the pupal and adult stages in both mosquitoes. Stimulation with lipopolysaccharide resulted in an increase of tyrosine phosphorylation and DNA binding activity of AaSTAT and CtSTAT as well as an increase of luciferase activity of a reporter gene containing Drosophila STAT binding motif in mosquito C6/36 cells. After being infected with Japanese encephalitis virus, nuclear extracts of C6/36 cells revealed a decrease of tyrosine phosphorylation and DNA binding activity of AaSTAT which could be restored by sodium orthovanadate treatment. Taking all of the data together, this is the first report to clone and characterize two mosquito STATs with 81% identity and to demonstrate a different response of tyrosine phosphorylation and DNA binding of these two STATs by lipopolysaccharide treatment and by Japanese encephalitis virus infection.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan; Natl Def Med Ctr, Inst Prevent Med, Taipei 114, Taiwan; Acad Sinica, Inst Zool, Taipei 115, Taiwan; Acad Sinica, Inst Bioagr Sci, Taipei 115, Taiwan; Taipei Med Univ, Dept Biochem, Taipei 117, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center; National Defense Medical Center; Academia Sinica - Taiwan; Academia Sinica - Taiwan; Taipei Medical University	Huang, CJ (corresponding author), Acad Sinica, Inst Biol Chem, 128 Sec,2 Acad Rd, Taipei 115, Taiwan.	cjibc@gate.sinica.edu.tw	Hsiao, Pei-Wen/V-5653-2018	Hsiao, Pei-Wen/0000-0002-3589-6754				Ariyoshi K, 2000, J BIOL CHEM, V275, P24407, DOI 10.1074/jbc.M909771199; Baksa K, 2002, DEV BIOL, V243, P166, DOI 10.1006/dbio.2001.0539; Barillas-Mury C, 1999, EMBO J, V18, P959, DOI 10.1093/emboj/18.4.959; Berchtold S, 1997, J BIOL CHEM, V272, P30237, DOI 10.1074/jbc.272.48.30237; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; Borregaard N, 2000, IMMUNOL TODAY, V21, P68, DOI 10.1016/S0167-5699(99)01570-4; Boutros M, 2002, DEV CELL, V3, P711, DOI 10.1016/S1534-5807(02)00325-8; BRES P, 1988, ARBOVIRUSES EPIDEMIO, V1, P1; Brown S, 2001, CURR BIOL, V11, P1700, DOI 10.1016/S0960-9822(01)00524-3; Burke DSMT, 2001, FLAVIVIRUSES FIELDS, V1, P1043; Chang MS, 1996, DNA CELL BIOL, V15, P827, DOI 10.1089/dna.1996.15.827; Chen HW, 2002, GENE DEV, V16, P388, DOI 10.1101/gad.955202; Christophides GK, 2002, SCIENCE, V298, P159, DOI 10.1126/science.1077136; Daniel C, 2000, J BIOL CHEM, V275, P14255, DOI 10.1074/jbc.C000129200; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Diamond MS, 2003, IMMUNOL CELL BIOL, V81, P196, DOI 10.1046/j.1440-1711.2003.01157.x; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Elrod-Erickson M, 2000, CURR BIOL, V10, P781, DOI 10.1016/S0960-9822(00)00569-8; Endy TP, 2002, CURR TOP MICROBIOL, V267, P11; GUBLER DJ, 1976, AM J TROP MED HYG, V25, P146, DOI 10.4269/ajtmh.1976.25.146; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Holick J, 2002, J AM MOSQUITO CONTR, V18, P131; HONG TH, 1989, J IMMUNOL METHODS, V120, P151, DOI 10.1016/0022-1759(89)90236-6; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; HUANG CH, 1982, ADV VIRUS RES, V27, P71, DOI 10.1016/S0065-3527(08)60433-9; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; IGARASHI A, 1978, J GEN VIROL, V40, P531, DOI 10.1099/0022-1317-40-3-531; Imler JL, 2000, J ENDOTOXIN RES, V6, P459, DOI 10.1177/09680519000060060801; Jan LR, 2000, AM J TROP MED HYG, V62, P446, DOI 10.4269/ajtmh.2000.62.446; Khush RS, 2001, TRENDS IMMUNOL, V22, P260, DOI 10.1016/S1471-4906(01)01887-7; Komatsu T, 2000, J VIROL, V74, P2477, DOI 10.1128/JVI.74.5.2477-2480.2000; Konnai S, 2003, VET MICROBIOL, V94, P283, DOI 10.1016/S0378-1135(03)00119-6; Kwon FJ, 2000, J BIOL CHEM, V275, P19824, DOI 10.1074/jbc.M001114200; Lagueux M, 2000, P NATL ACAD SCI USA, V97, P11427, DOI 10.1073/pnas.97.21.11427; LAMOTTE LC, 1960, AM J HYG, V72, P73, DOI 10.1093/oxfordjournals.aje.a120136; Lau JF, 2002, MT SINAI J MED, V69, P156; LEAKE CJ, 1986, T ROY SOC TROP MED H, V80, P831, DOI 10.1016/0035-9203(86)90397-4; LEAKE CJ, 1987, T ROY SOC TROP MED H, V81, P681, DOI 10.1016/0035-9203(87)90454-8; LEDGER TN, 1992, VACCINE, V10, P652, DOI 10.1016/0264-410X(92)90084-W; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Luo H, 2001, BIOESSAYS, V23, P1138, DOI 10.1002/bies.10016; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; RANDOLPH VB, 1988, J GEN VIROL, V69, P2199, DOI 10.1099/0022-1317-69-9-2199; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Shtrichman R, 2001, CURR OPIN MICROBIOL, V4, P251, DOI 10.1016/S1369-5274(00)00199-5; SINGH KRP, 1968, INDIAN J MED RES, V56, P815; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sung SC, 2003, EUR J BIOCHEM, V270, P239, DOI 10.1046/j.1432-1033.2003.03380.x; VYTHILINGAM I, 1995, J AM MOSQUITO CONTR, V11, P94; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Zeidler MP, 2000, ONCOGENE, V19, P2598, DOI 10.1038/sj.onc.1203482; Zhu W, 2002, J BIOL CHEM, V277, P35787, DOI 10.1074/jbc.C200346200	57	67	70	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3308	3317		10.1074/jbc.M309749200	http://dx.doi.org/10.1074/jbc.M309749200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14607839	hybrid			2022-12-25	WOS:000188379600022
J	Oruetxebarria, I; Venturini, F; Kekarainen, T; Houweling, A; Zuijderduijn, LMP; Mohd-Sarip, A; Vries, RGJ; Hoeben, RC; Verrijzer, CP				Oruetxebarria, I; Venturini, F; Kekarainen, T; Houweling, A; Zuijderduijn, LMP; Mohd-Sarip, A; Vries, RGJ; Hoeben, RC; Verrijzer, CP			p16(INK4a) is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; SWI/SNF COMPLEX; CYCLE ARREST; IN-VIVO; GERM-LINE; CANCER; GENE; MUTATIONS; PROTEINS; RB	The hSNF5 chromatin-remodeling factor is a tumor suppressor that is inactivated in malignant rhabdoid tumors (MRTs). A number of studies have shown that hSNF5 re-expression blocks MRT cell proliferation. However, the pathway through which hSNF5 acts remains unknown. To address this question, we generated MRT-derived cell lines in which restoration of hSNF5 expression leads to an accumulation in G(0)/G(1), induces cellular senescence and increased apoptosis. Following hSNF5 expression, we observed transcriptional activation of the tumor suppressor p16(INK4a) but not of p14(ARF), repression of several cyclins and CD44, a cell surface glycoprotein implicated in metastasis. Chromatin immunoprecipitations indicated that hSNF5 activates p16(INK4a) transcription and CD44 down-regulation by mediating recruitment of the SWI/SNF complex. Thus, hSNF5 acts as a dualistic co-regulator that, depending on the promoter context, can either mediate activation or repression. Three lines of evidence established that p16(INK4)a is an essential effector of hSNF5-induced cell cycle arrest. 1) Overexpression of p16(INK4a) mimics the effect of hSNF5 induction and leads to cellular senescence. 2) Expression of a p16(INK4a)-insensitive form of CDK4 obstructs hSNF5-induced cell cycle arrest. 3) Inhibition of p16(INK4a) activation by siRNA blocks hSNF5-mediated cellular senescence. Collectively, these results indicate that in human MRT cells, the p16(INK4a)/pRb, rather than the p14(ARF)/p53 pathway, mediates hSNF5-induced cellular senescence.	Leiden Univ, Med Ctr, Gene Regulat Lab, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Ctr Biomed Genet, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Mol & Cell Biol, Mol Virol Lab, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Verrijzer, CP (corresponding author), Leiden Univ, Med Ctr, Gene Regulat Lab, POB 9503, NL-2300 RA Leiden, Netherlands.	verrijzer@lumc.nl	Kekarainen, Tuija/M-1712-2014; Hoeben, Rob C./A-5771-2008; Kekarainen, Tuija/AAN-6167-2021	Kekarainen, Tuija/0000-0002-0392-4706; Hoeben, Rob C./0000-0001-9443-8377; Kekarainen, Tuija/0000-0002-0392-4706				Ae K, 2002, ONCOGENE, V21, P3112, DOI 10.1038/sj.onc.1205414; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Biegel JA, 1999, CANCER RES, V59, P74; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Cichy J, 2003, J CELL BIOL, V161, P839, DOI 10.1083/jcb.200302098; DE IS, 2001, J BIOL CHEM, V276, P41486; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Drayton S, 2002, CURR OPIN GENET DEV, V12, P98, DOI 10.1016/S0959-437X(01)00271-4; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Geng FQ, 2001, MOL CELL BIOL, V21, P4311, DOI 10.1128/MCB.21.13.4311-4320.2001; Grand F, 1999, CANCER RES, V59, P3870; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Hara E, 1996, MOL CELL BIOL, V16, P859; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Kadam S, 2002, CURR OPIN CELL BIOL, V14, P262, DOI 10.1016/S0955-0674(02)00330-7; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; KnaanShanzer S, 1996, GENE THER, V3, P323; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Mahmoudi T, 2002, EMBO J, V21, P1775, DOI 10.1093/emboj/21.7.1775; Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330; Muller C, 2001, CURR OPIN GENET DEV, V11, P167, DOI 10.1016/S0959-437X(00)00175-1; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Olave IA, 2002, ANNU REV BIOCHEM, V71, P755, DOI 10.1146/annurev.biochem.71.110601.135507; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; Reisman DN, 2003, CANCER RES, V63, P560; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; SumiIchinose C, 1997, MOL CELL BIOL, V17, P5976, DOI 10.1128/MCB.17.10.5976; Taylor MD, 2000, AM J HUM GENET, V66, P1403, DOI 10.1086/302833; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Versteege I, 2002, ONCOGENE, V21, P6403, DOI 10.1038/sj.onc.1205841; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wong AKC, 2000, CANCER RES, V60, P6171; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	59	123	128	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3807	3816		10.1074/jbc.M309333200	http://dx.doi.org/10.1074/jbc.M309333200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14604992	hybrid			2022-12-25	WOS:000188379600083
J	Baek, KH; Kim, MS; Kim, YS; Shin, JM; Choi, HK				Baek, KH; Kim, MS; Kim, YS; Shin, JM; Choi, HK			DUB-1A, a novel deubiquitinating enzyme subfamily member, is polyubiquitinated and cytokine-inducible in B-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEUBIQUITYLATING ENZYME; PROTEIN-DEGRADATION; 26S PROTEASOMES; UBIQUITINATION; GENE; COMPLEX; SYSTEM; FAMILY	Recently, we isolated the Dub-2A gene, which encodes a novel murine deubiquitinating enzyme subfamily member, from a bacterial artificial chromosome library clone by PCR amplification with degenerate PCR primers for the Dub-2 cDNA (Baek, K.- H., Mondoux, M. A., Jaster, R., Fire-Levin E., and D'Andrea, A. D. ( 2001) Blood 98, 636 - 642). In this study, we analyzed two more clones from the library to isolate genes encoding other deubiquitinating enzymes. Dub-1A, which encodes the shortest member of the DUB subfamily of deubiquitinating enzymes so far, has been identified in both clones and characterized. Sequence analysis showed that Dub-1A encodes a 468-amino acid protein that has a molecular mass of similar to 51 kDa and that contains a putative catalytic domain (Cys, His, and Asp) conserved among DUB proteins. The amino acid sequence of DUB-1A is 84.5, 84.7, and 85.3% identical to those of DUB-1, DUB-2, and DUB-2A, respectively. Reverse transcription-PCR revealed that Dub-1A is expressed not only in B-lymphocytes in response to interleukin-3 stimulation, but also in T-lymphocytes, brain, heart, liver, lung, kidney, ovary, and spleen. This suggests that Dub-1A may play essential roles in each of these organs. In vivo and in vitro deubiquitinating enzyme assays showed that DUB-1A has functional deubiquitinating activity and that the 5'-flanking sequence of Dub-1A has a functional enhancer domain as shown in Dub-1 and Dub-2A. Interestingly, immunoblot analysis revealed that DUB-1A is polyubiquitinated, indicating that it is degraded through proteasome-mediated degradation. In the absence of JAK2, Dub-1A was expressed at a lower level. This suggests that DUB-1A functions downstream of JAK2 kinase in the interleukin-3 signaling pathway.	Pochom CHA Univ, CHA Gen Hosp, Cell & Gene Therapy Res Inst, Seoul 135081, South Korea; Pochom CHA Univ, CHA Gen Hosp, Grad Sch Life Sci & Biotechnol, Seoul 135081, South Korea	Pochon Cha University; Pochon Cha University	Baek, KH (corresponding author), Pochom CHA Univ, CHA Gen Hosp, Cell & Gene Therapy Res Inst, 605 Yeoksam 1 Dong, Seoul 135081, South Korea.	baek@cha.ac.kr		Baek, Kwang-Hyun/0000-0001-7662-7190				Baek KH, 2003, EXP MOL MED, V35, P1; Baek KH, 2001, BLOOD, V98, P636, DOI 10.1182/blood.V98.3.636; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; Evans PC, 2003, J BIOL CHEM, V278, P23180, DOI 10.1074/jbc.M301863200; Gewies A, 2003, CANCER RES, V63, P682; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Holzl H, 2000, J CELL BIOL, V150, P119, DOI 10.1083/jcb.150.1.119; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Jaster R, 1997, MOL CELL BIOL, V17, P3364, DOI 10.1128/MCB.17.6.3364; Jaster R, 1999, BBA-GENE STRUCT EXPR, V1446, P308, DOI 10.1016/S0167-4781(99)00095-0; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Layfield R, 2001, NEUROPATH APPL NEURO, V27, P171, DOI 10.1046/j.1365-2990.2001.00335.x; Lee JH, 2001, AM J HEMATOL, V67, P270, DOI 10.1002/ajh.1130; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Migone TS, 2001, BLOOD, V98, P1935, DOI 10.1182/blood.V98.6.1935; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Pantaleon M, 2001, MECH DEVELOP, V109, P151, DOI 10.1016/S0925-4773(01)00551-2; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Park KC, 2002, P NATL ACAD SCI USA, V99, P9733, DOI 10.1073/pnas.152011799; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275; Zhu YA, 1997, J BIOL CHEM, V272, P51	34	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2368	2376		10.1074/jbc.M304774200	http://dx.doi.org/10.1074/jbc.M304774200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14583620	hybrid			2022-12-25	WOS:000188211300007
J	Elias, MD; Nakamura, S; Migita, CT; Miyoshi, H; Toyama, H; Matsushita, K; Adachi, O; Yamada, M				Elias, MD; Nakamura, S; Migita, CT; Miyoshi, H; Toyama, H; Matsushita, K; Adachi, O; Yamada, M			Occurrence of a bound ubiquinone and its function in Escherichia coli membrane-bound quinoprotein glucose dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C OXIDOREDUCTASE; BACTERIAL REACTION CENTERS; PYRROLO-QUINOLINE QUINONE; METHANOL DEHYDROGENASE; METHYLOBACTERIUM-EXTORQUENS; BINDING SITE; ACINETOBACTER-CALCOACETICUS; PSEUDOMONAS-AERUGINOSA; SUBSTRATE-SPECIFICITY; ETHANOL DEHYDROGENASE	The membrane-bound pyrroloquinoline quinone (PQQ)-containing quinoprotein glucose dehydrogenase (mGDH) in Escherichia coli functions by catalyzing glucose oxidation in the periplasm and by transferring electrons directly to ubiquinone (UQ) in the respiratory chain. To clarify the intramolecular electron transfer of mGDH, quantitation and identification of UQ were performed, indicating that purified mGDH contains a tightly bound UQ8 in its molecule. A significant increase in the EPR signal was observed following glucose addition in mGDH reconstituted with PQQ and Mg2+, suggesting that bound UQ8 accepts a single electron from PQQH(2) to generate semiquinone radicals. No such increase in the EPR signal was observed in UQ8-free mGDH under the same conditions. Moreover, a UQ(2) reductase assay with a UQ-related inhibitor (C49) revealed different inhibition kinetics between the wild-type mGDH and UQ8-free mGDH. From these findings, we propose that the native mGDH bears two ubiquinone-binding sites, one (Q(I)) for bound UQ8 in its molecule and the other (Q(II)) for UQ8 in the ubiquinone pool, and that the bound UQ8 in the QI site acts as a single electron mediator in the intramolecular electron transfer in mGDH.	Yamaguchi Univ, Fac Agr, Dept Biol Chem, Yamaguchi 7538515, Japan; Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan	Yamaguchi University; Kyoto University	Yamada, M (corresponding author), Yamaguchi Univ, Fac Agr, Dept Biol Chem, 1677-1 Yoshida, Yamaguchi 7538515, Japan.	m-yamada@yamaguchi-u.ac.jp		Yamada, Mamoru/0000-0003-4354-7324				Adelroth P, 2000, P NATL ACAD SCI USA, V97, P13086, DOI 10.1073/pnas.230439597; AMEYAMA M, 1981, FEBS LETT, V130, P179, DOI 10.1016/0014-5793(81)81114-3; ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; ANTHONY C, 1994, BIOCHEM J, V304, P665, DOI 10.1042/bj3040665; Cecchini G, 2003, FEBS LETT, V545, P31, DOI 10.1016/S0014-5793(03)00390-9; Cozier GE, 1999, BIOCHEM J, V340, P639, DOI 10.1042/0264-6021:3400639; Cozier GE, 1995, BIOCHEM J, V312, P679, DOI 10.1042/bj3120679; COZIER GE, 1995, BIOCHEM J, V308, P375, DOI 10.1042/bj3080375; de Beer R., 1979, Journal of Chemical Physics, V70, P4491, DOI 10.1063/1.437286; DEJONG GAH, 1995, EUR J BIOCHEM, V230, P899; DEVRIES S, 1981, J BIOL CHEM, V256, P1996; DEVRIES S, 1982, BIOCHIM BIOPHYS ACTA, V681, P41, DOI 10.1016/0005-2728(82)90276-6; DUINE JA, 1979, FEBS LETT, V108, P443, DOI 10.1016/0014-5793(79)80584-0; DUINE JA, 1981, EUR J BIOCHEM, V118, P395; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; Elias MD, 2000, J BIOL CHEM, V275, P7321, DOI 10.1074/jbc.275.10.7321; Elias MD, 2001, J BIOL CHEM, V276, P48356, DOI 10.1074/jbc.M107355200; FRANK J, 1989, EUR J BIOCHEM, V184, P187, DOI 10.1111/j.1432-1033.1989.tb15006.x; GHOSH M, 1995, STRUCTURE, V3, P177, DOI 10.1016/S0969-2126(01)00148-4; Gong X, 2003, J BIOL CHEM, V278, P25731, DOI 10.1074/jbc.M302361200; Goodwin PM, 1998, ADV MICROB PHYSIOL, V40, P1, DOI 10.1016/S0065-2911(08)60129-0; Grimaldi S, 2003, BIOCHEMISTRY-US, V42, P5632, DOI 10.1021/bi034010z; HOMMES RWJ, 1984, FEMS MICROBIOL LETT, V24, P329, DOI 10.1016/0378-1097(84)90274-X; Hunte C, 2003, FEBS LETT, V545, P39, DOI 10.1016/S0014-5793(03)00391-0; INGLEDEW WJ, 1995, EUR J BIOCHEM, V227, P903, DOI 10.1111/j.1432-1033.1995.tb20217.x; Keitel T, 2000, J MOL BIOL, V297, P961, DOI 10.1006/jmbi.2000.3603; MATSUSHITA K, 1987, J BACTERIOL, V169, P205, DOI 10.1128/jb.169.1.205-209.1987; Matsushita K, 1997, MICROBIOL-UK, V143, P3149, DOI 10.1099/00221287-143-10-3149; Matsushita K, 1999, BBA-BIOENERGETICS, V1409, P154, DOI 10.1016/S0005-2728(98)00158-3; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Miyoshi H, 1999, BBA-BIOENERGETICS, V1412, P29, DOI 10.1016/S0005-2728(99)00009-2; Okamura MY, 2000, BBA-BIOENERGETICS, V1458, P148, DOI 10.1016/S0005-2728(00)00065-7; OKUDA J, 2000, J BIOCH MOL BIOL BIO, V4, P415; Oubrie A, 1999, EMBO J, V18, P5187, DOI 10.1093/emboj/18.19.5187; Sakamoto K, 1996, EUR J BIOCHEM, V237, P128, DOI 10.1111/j.1432-1033.1996.0128n.x; Sato A, 2001, BIOCHEM J, V357, P893, DOI 10.1042/0264-6021:3570893; SATOWATANABE M, 1994, J BIOL CHEM, V269, P28908; Sode K, 1997, BIOTECHNOL LETT, V19, P1073, DOI 10.1023/A:1018428224215; SUZUKI K, 1994, BIOSCI BIOTECH BIOCH, V58, P1814, DOI 10.1271/bbb.58.1814; VANSCHIE BJ, 1985, J BACTERIOL, V163, P493, DOI 10.1128/JB.163.2.493-499.1985; Veselov AV, 2000, BIOCHEMISTRY-US, V39, P3169, DOI 10.1021/bi9926835; Yamada M, 1999, J BACTERIOL, V181, P1838, DOI 10.1128/JB.181.6.1838-1846.1999; Yamada M, 1998, J BIOL CHEM, V273, P22021, DOI 10.1074/jbc.273.34.22021; YAMADA M, 1993, J BIOL CHEM, V268, P12812; Yamada M, 2003, BBA-PROTEINS PROTEOM, V1647, P185, DOI 10.1016/S1570-9639(03)00100-6; YAMADA M, 1993, J BACTERIOL, V175, P568, DOI 10.1128/JB.175.2.568-571.1993; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; ZHIWEI C, 2002, STRUCTURE, V10, P837	48	25	25	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					3078	3083		10.1074/jbc.M310163200	http://dx.doi.org/10.1074/jbc.M310163200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14612441	hybrid			2022-12-25	WOS:000188211300089
J	Hendriks, G; Koudijs, M; van Balkom, BWM; Oorschot, V; Klumperman, J; Deen, PMT; van der Sluijs, P				Hendriks, G; Koudijs, M; van Balkom, BWM; Oorschot, V; Klumperman, J; Deen, PMT; van der Sluijs, P			Glycosylation is important for cell surface expression of the water channel aquaporin-2 but is not essential for tetramerization in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPHROGENIC DIABETES-INSIPIDUS; WILD-TYPE AQUAPORIN-2; CANINE KIDNEY-CELLS; SECRETORY PATHWAY; MEMBRANE-PROTEINS; BREFELDIN-A; MADIN-DARBY; N-GLYCANS; GOLGI; MUTANT	Aquaporin-2 (AQP2) is a pore-forming protein that is required for regulated reabsorption of water from urine. Mutations in AQP2 lead to nephrogenic diabetes insipidus, a disorder in which functional AQP2 is not expressed on the apical cell surface of kidney collecting duct principal cells. The mechanisms and pathways directing AQP2 from the endoplasmic reticulum to the Golgi complex and beyond have not been defined. We found that similar to25% of newly synthesized AQP2 is glycosylated. Nonglycosylated and complex-glycosylated wildtype AQP2 are stable proteins with a half-life of 6-12 h and are both detectable on the cell surface. We show that AQP2 forms tetramers in the endoplasmic reticulum during or very early after synthesis and reaches the Golgi complex in 1-1.5 h. We also report that glycosylation is neither essential for tetramerization nor for transport from the endoplasmic reticulum to the Golgi complex. Instead, the N-linked glycan is important for exit from the Golgi complex and sorting of AQP2 to the plasma membrane. These results are important for understanding the molecular mechanisms responsible for the intracellular retention of AQP2 in nephrogenic diabetes insipidus.	Univ Med Ctr Utrecht, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Univ Med Ctr, Dept Physiol, NL-6500 HB Nijmegen, Netherlands	Utrecht University; Utrecht University Medical Center; Radboud University Nijmegen	van der Sluijs, P (corresponding author), Univ Med Ctr Utrecht, Dept Cell Biol, AZU Rm G02-525,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	pvander@knoware.nl	Deen, P.M.T./H-8023-2014; Hendriks, Giel/A-9731-2010; Deen, Peter MT/B-9854-2013	Deen, P.M.T./0000-0002-7868-4655; Deen, Peter MT/0000-0002-7868-4655				Baumgarten R, 1998, J AM SOC NEPHROL, V9, P1553; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Deen PMT, 1996, J AM SOC NEPHROL, V7, P836; Deen PMT, 1997, J AM SOC NEPHROL, V8, P1493; DEEN PMT, 1995, J CLIN INVEST, V95, P2291, DOI 10.1172/JCI117920; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; Deneka M, 2003, EMBO J, V22, P2645, DOI 10.1093/emboj/cdg257; Dohke Y, 2002, J BIOL CHEM, V277, P15215, DOI 10.1074/jbc.C100646200; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; Fushimi K, 1997, J BIOL CHEM, V272, P14800, DOI 10.1074/jbc.272.23.14800; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; Goji K, 1998, J CLIN ENDOCR METAB, V83, P3205, DOI 10.1210/jc.83.9.3205; Gouraud S, 2002, J CELL SCI, V115, P3667, DOI 10.1242/jcs.00053; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; Hasler U, 2000, J BIOL CHEM, V275, P29011, DOI 10.1074/jbc.M002867200; HORWITZ MS, 1969, VIROLOGY, V39, P682, DOI 10.1016/0042-6822(69)90006-3; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; Kamsteeg EJ, 1999, EMBO J, V18, P2394, DOI 10.1093/emboj/18.9.2394; Kamsteeg EJ, 2000, J CELL BIOL, V151, P919, DOI 10.1083/jcb.151.4.919; Klussmann E, 2001, J BIOL CHEM, V276, P20451, DOI 10.1074/jbc.M010270200; Kozono D, 2002, J CLIN INVEST, V109, P1395, DOI 10.1172/JCI200215851; Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; Madrid R, 2001, EMBO J, V20, P7008, DOI 10.1093/emboj/20.24.7008; Marr N, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000027355.41663.14; Marr N, 2002, HUM MOL GENET, V11, P779, DOI 10.1093/hmg/11.7.779; MIESENBOCK G, 1995, J CELL BIOL, V129, P309, DOI 10.1083/jcb.129.2.309; Morello JP, 2001, ANNU REV PHYSIOL, V63, P607, DOI 10.1146/annurev.physiol.63.1.607; Mulders SM, 1997, J AM SOC NEPHROL, V8, P242; Mulders SM, 1998, J CLIN INVEST, V102, P57, DOI 10.1172/JCI2605; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; Nilsson I, 2000, J BIOL CHEM, V275, P17338, DOI 10.1074/jbc.M002317200; Nufer O, 2003, J BIOL CHEM, V278, P15886, DOI 10.1074/jbc.M211199200; Reggiori F, 2002, NAT CELL BIOL, V4, P117, DOI 10.1038/ncb743; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SCHLESINGER S, 1976, J VIROL, V17, P239, DOI 10.1128/JVI.17.1.239-246.1976; Schrag JD, 2003, TRENDS BIOCHEM SCI, V28, P49, DOI 10.1016/S0968-0004(02)00004-X; Seemann J, 2000, NATURE, V407, P1022, DOI 10.1038/35039538; SKACH WR, 1994, J CELL BIOL, V125, P803, DOI 10.1083/jcb.125.4.803; SMITH BL, 1994, J CLIN INVEST, V94, P1043, DOI 10.1172/JCI117418; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; Tamarappoo BK, 1999, J BIOL CHEM, V274, P34825, DOI 10.1074/jbc.274.49.34825; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; van Balkom BWM, 2002, J BIOL CHEM, V277, P41473, DOI 10.1074/jbc.M207525200; Yasui M, 1999, NATURE, V402, P184, DOI 10.1038/46045; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoo JS, 2002, J BIOL CHEM, V277, P11401, DOI 10.1074/jbc.M110263200	53	118	121	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2975	2983		10.1074/jbc.M310767200	http://dx.doi.org/10.1074/jbc.M310767200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14593099	Green Published, hybrid			2022-12-25	WOS:000188211300078
J	Nikolay, R; Wiederkehr, T; Rist, W; Kramer, G; Mayer, MP; Bukau, B				Nikolay, R; Wiederkehr, T; Rist, W; Kramer, G; Mayer, MP; Bukau, B			Dimerization of the human E3 ligase CHIP via a coiled-coil domain is essential for its activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; UBIQUITIN LIGASE; IDENTIFICATION; PROTECTION; HSP90; HSC70; DNAJ	The Hsp70-interacting E3-ubiquitin ligase CHIP has been implicated in the decision as to whether a target protein enters the refolding or the degradation pathway. To further characterize the activity of CHIP we purified untagged Homo sapiens and Drosophila melanogaster CHIP (hCHIP, dCHIP). In contrast to other E3-ubiquitin ligases, both hCHIP and dCHIP proteins formed homodimers at physiological concentrations. We identified a predicted coiled-coil region in a mixed charge segment of the hCHIP and dCHIP sequence and found it to be necessary and sufficient for dimer formation. A mutant of hCHIP lacking this segment (hCHIPDelta(128-229)) was incapable of dimer formation, but the segment by itself (hCHIP-(128-229)) readily dimerized. Furthermore, we demonstrated that dimerization is a prerequisite for activity of hCHIP in the reconstituted ubiquitination assay. Control of dimerization may thus provide a mechanism for regulation of CHIP activity.	Heidelberg Univ, Zentrum Mol Biol Heidelberg, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Mayer, MP (corresponding author), Heidelberg Univ, Zentrum Mol Biol Heidelberg, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	m.mayer@zmbh.uni-heidelberg.de; bukau@zmbh.uni-heidelberg.de	Mayer, Matthias P./B-9340-2013	Mayer, Matthias P./0000-0002-7859-3112; Rist, Wolfgang/0000-0002-0626-3544; Nikolay, Rainer/0000-0003-4713-2548; Bukau, Bernd/0000-0003-0521-7199; Kramer, Gunter/0000-0001-7552-8393				Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960-9822(00)00398-5; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; FIEDLER U, 1995, EMBO J, V14, P3696, DOI 10.1002/j.1460-2075.1995.tb00039.x; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Wiederkehr T, 1998, RNA, V4, P1357, DOI 10.1017/S1355838298980955; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Yan JQ, 2003, PLANT PHYSIOL, V132, P861, DOI 10.1104/pp.103.020800	26	87	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2673	2678		10.1074/jbc.M311112200	http://dx.doi.org/10.1074/jbc.M311112200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14610072	hybrid			2022-12-25	WOS:000188211300043
J	Kilav, R; Bell, O; Le, SY; Silver, J; Naveh-Many, T				Kilav, R; Bell, O; Le, SY; Silver, J; Naveh-Many, T			The parathyroid hormone mRNA 3 '-untranslated region AU-rich element is an unstructured functional element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINATION SIGNAL; GENE-EXPRESSION; BINDING; PROTEIN; SEQUENCE; CALCIUM; STABILITY	Parathyroid hormone (PTH) gene expression is regulated post-transcriptionally by hypocalcemia and hypophosphatemia. This regulation is dependent upon binding of protective trans-acting factors to a specific element in the PTH mRNA 3'-untranslated region (UTR). We have previously demonstrated that a 63-nucleotide (nt) AU-rich PTH mRNA element is sufficient to confer regulation of RNA stability by calcium and phosphate in an in vitro degradation assay (IVDA). The 63-nt element consists of a core 26-nt minimal binding sequence and flanking regions. We have now studied the functionality of this element in HEK293 cells using reporter genes and showed that it destabilizes mRNAs for green fluorescent protein (GFP) and growth hormone, similar to its effect in the IVDA. To understand how the cis-element functions as an instability element, we have analyzed its structure by RNase H, primer extension, and computer modeling. The results indicate that the PTH mRNA 3'-UTR and in particular the region of the cis-element are dominated by significant open regions with little folded base pairing. Mutation analysis of the 26-nt core element demonstrated the importance of defined nucleotides for protein-RNA binding. In the GFP reporter system, the same mutations that prevented binding were also ineffective in destabilizing GFP mRNA in HEK293 cells. This is the first study of an AU-rich element that relates function to structure. The PTH mRNA 3'-UTR cis-acting element is an open region that utilizes the distinct sequence pattern to determine mRNA stability by its interaction with trans-acting factors.	Hebrew Univ Jerusalem, Sch Med, Hadassah Hosp, Minerva Ctr Calcium & Bone Metab,Nephrol Serv, IL-91120 Jerusalem, Israel; NCI, Lab Expt & Computat Biol, Frederick Ctr Canc Res, NIH, Frederick, MD 21702 USA	Hebrew University of Jerusalem; Hadassah University Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Naveh-Many, T (corresponding author), Hebrew Univ Jerusalem, Sch Med, Hadassah Hosp, Minerva Ctr Calcium & Bone Metab,Nephrol Serv, POB 12000, IL-91120 Jerusalem, Israel.	tally@huji.ac.il						Argaman L, 2000, J MOL BIOL, V300, P1101, DOI 10.1006/jmbi.2000.3942; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; DONISKELLER H, 1979, NUCLEIC ACIDS RES, V7, P179, DOI 10.1093/nar/7.1.179; He B, 1998, J BIOL CHEM, V273, P18802, DOI 10.1074/jbc.273.30.18802; KILAV R, 1995, J CLIN INVEST, V96, P327, DOI 10.1172/JCI118038; Kilav R, 2001, J BIOL CHEM, V276, P8727, DOI 10.1074/jbc.M005471200; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LE SY, 1989, J THEOR BIOL, V138, P495, DOI 10.1016/S0022-5193(89)80047-5; LE SY, 1988, COMPUT APPL BIOSCI, V4, P153; Le SY, 2003, BIOINFORMATICS, V19, P354, DOI 10.1093/bioinformatics/btf826; LE SY, 1989, NUCLEIC ACIDS RES, V17, P3275, DOI 10.1093/nar/17.8.3275; LE SY, 1990, STRUCTURE METHODS, V6; LE SY, 2002, P INT C METMBS02, P41; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; MACDONALD LE, 1994, J MOL BIOL, V238, P145, DOI 10.1006/jmbi.1994.1277; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; Moallem E, 1998, J BIOL CHEM, V273, P5253, DOI 10.1074/jbc.273.9.5253; NAVEHMANY T, 1995, J CLIN INVEST, V96, P1786, DOI 10.1172/JCI118224; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sela-Brown A, 2000, J BIOL CHEM, V275, P7424, DOI 10.1074/jbc.275.10.7424; SILVER J, 2002, PRINCIPLES BONE BIOL, P407; STOECKLE MY, 1992, NUCLEIC ACIDS RES, V20, P1123, DOI 10.1093/nar/20.5.1123; Theil EC, 2000, J BIOL CHEM, V275, P40659, DOI 10.1074/jbc.R000019200; Toulme JJ, 2001, NAT BIOTECHNOL, V19, P17, DOI 10.1038/83451; Wilson GM, 2001, J BIOL CHEM, V276, P38400, DOI 10.1074/jbc.M106509200; Wilson GM, 2001, J BIOL CHEM, V276, P8695, DOI 10.1074/jbc.M009848200	27	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2109	2116		10.1074/jbc.M305302200	http://dx.doi.org/10.1074/jbc.M305302200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14585848	hybrid			2022-12-25	WOS:000188005700067
J	Nguyen, VT; Arredondo, J; Chernyavsky, AI; Kitajima, Y; Pittelkow, M; Grando, SA				Nguyen, VT; Arredondo, J; Chernyavsky, AI; Kitajima, Y; Pittelkow, M; Grando, SA			Pemphigus vulgaris IgG and methylprednisolone exhibit reciprocal effects on keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CARCINOMA-CELL-LINE; MUSCARINIC ACETYLCHOLINE-RECEPTORS; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE-C; BETA-CATENIN; IN-VIVO; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; INTERMEDIATE-FILAMENTS; EPIDERMAL-CELLS	Pemphigus vulgaris (PV) is a life-threatening autoimmune disease of skin adhesion associated with IgG autoantibodies against keratinocytes (KC). Treatment of PV with systemic corticosteroids is life-saving, but the mechanism of the therapeutic action has not been fully understood. We have developed an animal model that demonstrates that methylprednisolone ( MP) can block PV IgG-induced acantholysis, decreasing the extent of keratinocyte detachment in the epidermis of 3-5-day-old nude mice from 77.5 +/- 0.6 to 24.1 +/- 1.5% ( p < 0.05). We hypothesized that in addition to immunosuppression, MP may exhibit direct anti-acantholytic effects in epidermis, and we compared the effects of PV IgG and MP on KC. The use of DNA microarray showed that PV IgG down-regulated and MP up-regulated expression of the genes encoding keratinocyte adhesion molecules, antigen-processing proteins, regulators of cell cycle and apoptosis, differentiation markers, Na+, K+-ATPase, protein kinases and phosphatases, and serine proteases and their inhibitors. Overall, PV IgG decreased transcription of 198 genes and increased transcription of 31 genes. MP decreased transcription of 14 genes and increased transcription of 818 genes. Specific effects of PV IgG and MP on keratinocyte adhesion molecules were further investigated by Western blot and immunofluorescence assays. By immunoblotting, MP increased the protein levels of E-cadherin and desmogleins 1 and 3 by 300, 180, and 40%, respectively. Specific staining of KC for E-cadherin and desmogleins 1 and 3 increased by 235, 228, and 148%, respectively. In addition, PV IgG increased the level of phosphorylation of E-cadherin by 42%, beta-catenin by 37%, gamma-catenin by 136%, and desmoglein 3 by 300%, whereas pretreatment with 0.25 mM MP abolished phosphorylation of these adhesion molecules. These results suggested that therapeutic effects of MP in PV include both the up-regulated synthesis and posttranslational modification of the keratinocyte adhesion molecules.	Univ Calif Davis, Sch Med, Dept Dermatol, Davis, CA 95616 USA; Gifu Univ, Dept Dermatol, Gifu 5008705, Japan; Mayo Clin, Dept Dermatol, Rochester, MN 55905 USA	University of California System; University of California Davis; Gifu University; Mayo Clinic	Grando, SA (corresponding author), 4860 Y St,Ste 3400, Sacramento, CA 95817 USA.	sagrando@ucdavis.edu		Nguyen, Vu/0000-0002-1142-6352				AHMED AR, 1982, J AM ACAD DERMATOL, V7, P221; AHMED AR, 1980, ANN INTERN MED, V92, P396, DOI 10.7326/0003-4819-92-3-396; Ahmed AR, 2001, J AM ACAD DERMATOL, V45, P679, DOI 10.1067/mjd.2001.116339; Amagai M, 1999, J DERMATOL SCI, V20, P92, DOI 10.1016/S0923-1811(99)00016-X; Amar LS, 1998, CELL ADHES COMMUN, V5, P1, DOI 10.3109/15419069809005594; ANHALT GJ, 1986, J IMMUNOL, V136, P113; ANHALT GJ, 1982, NEW ENGL J MED, V306, P1189, DOI 10.1056/NEJM198205203062001; Aoyama Y, 1999, EUR J IMMUNOL, V29, P2233, DOI 10.1002/(SICI)1521-4141(199907)29:07<2233::AID-IMMU2233>3.0.CO;2-4; Aoyama Y, 1999, J INVEST DERMATOL, V112, P67, DOI 10.1046/j.1523-1747.1999.00463.x; Aronchik I, 2003, J INVEST DERMATOL, V121, P681, DOI 10.1046/j.1523-1747.2003.12472.x; Arredondo J, 2001, LAB INVEST, V81, P1653, DOI 10.1038/labinvest.3780379; BARNETT ML, 1977, J INVEST DERMATOL, V68, P265, DOI 10.1111/1523-1747.ep12494207; Bedane C, 1996, ARCH DERMATOL RES, V288, P343, DOI 10.1007/s004030050061; Behne MJ, 2003, J INVEST DERMATOL, V121, P688, DOI 10.1046/j.1523-1747.2003.12528.x; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BELLONE A G, 1956, G Ital Dermatol, V97, P97; BROWN JH, 1989, MUSCARINIC RECEPTORS, P259; BUTLER WT, 1973, J CLIN INVEST, V52, P2629, DOI 10.1172/JCI107455; Bystryn JC, 2002, J AM ACAD DERMATOL, V47, P358, DOI 10.1067/mjd.2002.122735; Carayol N, 2002, AM J RESP CELL MOL, V26, P341, DOI 10.1165/ajrcmb.26.3.4684; Carson PJ, 1996, J AM ACAD DERMATOL, V34, P645, DOI 10.1016/S0190-9622(96)80066-1; CHRYSSOMALLIS F, 1995, INT J DERMATOL, V34, P438, DOI 10.1111/j.1365-4362.1995.tb04450.x; Cohen Lisa M., 1997, P209; Dajas-Bailador FA, 2002, J NEUROCHEM, V80, P520, DOI 10.1046/j.0022-3042.2001.00725.x; Dumas V, 1999, BRIT J DERMATOL, V140, P1127; ERIKSSON J E, 1992, Current Opinion in Cell Biology, V4, P99, DOI 10.1016/0955-0674(92)90065-K; Falkenstein E, 2000, EUR J CLIN INVEST, V30, P51, DOI 10.1046/j.1365-2362.2000.0300s3051.x; FARB RM, 1978, P NATL ACAD SCI USA, V75, P459, DOI 10.1073/pnas.75.1.459; Feliciani C, 2000, J INVEST DERMATOL, V114, P71, DOI 10.1046/j.1523-1747.2000.00835.x; Fellner MJ, 2001, MT SINAI J MED, V68, P268; Foty RA, 1998, CANCER RES, V58, P3586; Gniadecki R, 1998, ARCH DERMATOL RES, V290, P528, DOI 10.1007/s004030050347; Grando S. A., 1993, J EUR ACAD DERMATOL, V2, P72; GRANDO SA, 1990, INT J ARTIF ORGANS, V13, P181, DOI 10.1177/039139889001300309; Grando SA, 2003, J AM ACAD DERMATOL, V48, P86, DOI 10.1067/mjd.2003.39; GRANDO SA, 1989, IMMUNOL INVEST, V18, P1107, DOI 10.3109/08820138909030611; Grando SA, 2001, J INVEST DERMATOL, V117, P990, DOI 10.1046/j.0022-202x.2001.01489.x; Grando SA, 2000, DERMATOLOGY, V201, P290, DOI 10.1159/000051540; GUSOVSKY F, 1993, J BIOL CHEM, V268, P7768; HASHIMOTO K, 1984, BRIT J DERMATOL, V110, P293, DOI 10.1111/j.1365-2133.1984.tb04634.x; HASHIMOTO K, 1967, J INVEST DERMATOL, V48, P540, DOI 10.1038/jid.1967.86; Hashimoto T, 2003, ARCH DERMATOL RES, V295, pS2, DOI 10.1007/s00403-002-0366-3; Herbst A, 2000, J AM ACAD DERMATOL, V42, P422, DOI 10.1016/S0190-9622(00)90213-5; Holubar K, 1986, PRACTICAL MANAGEMENT, P153; HU CH, 1978, AM J PATHOL, V90, P345; Hu ZL, 2000, NAT GENET, V24, P61, DOI 10.1038/71701; JEFFES EWB, 1984, J CLIN IMMUNOL, V4, P359, DOI 10.1007/BF00917138; JORDON RE, 1979, DERMATOLOGY GENERAL, P310; Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778; Kiela PR, 2000, AM J PHYSIOL-CELL PH, V278, pC629, DOI 10.1152/ajpcell.2000.278.4.C629; Kihara T, 2001, J BIOL CHEM, V276, P13541, DOI 10.1074/jbc.M008035200; Kitajima Y, 1999, J INVEST DERM SYMP P, V4, P137, DOI 10.1038/sj.jidsp.5640197; Kitajima Y, 2003, ARCH DERMATOL RES, V295, pS17, DOI 10.1007/s00403-002-0368-1; Kitajima Y, 2002, CLIN EXP DERMATOL, V27, P684, DOI 10.1046/j.1365-2230.2002.01116.x; KITAJIMA Y, 1986, BRIT J DERMATOL, V114, P171, DOI 10.1111/j.1365-2133.1986.tb02795.x; Kitajima Y, 1995, EPITHELIAL CELL BIOL, V4, P70; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; KRAGBALLE K, 1989, ACTA DERM-VENEREOL, P7; Lecanda F, 2000, J CELL BIOCHEM, V77, P499, DOI 10.1002/(SICI)1097-4644(20000601)77:3<499::AID-JCB14>3.0.CO;2-0; LEE WC, 1992, J CELL BIOCHEM, V49, P378, DOI 10.1002/jcb.240490408; LEVER WF, 1953, MEDICINE, V32, P1; LEVER WF, 1984, ARCH DERMATOL, V120, P44, DOI 10.1001/archderm.120.1.44; LEVER WF, 1977, ARCH DERMATOL, V113, P1236, DOI 10.1001/archderm.113.9.1236; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Luftl M, 2003, BRIT J DERMATOL, V149, P598, DOI 10.1046/j.1365-2133.2003.05513.x; Lukiw WJ, 1999, J BIOL CHEM, V274, P8630, DOI 10.1074/jbc.274.13.8630; Matsuoka Y, 2001, J DERMATOL SCI, V27, P206, DOI 10.1016/S0923-1811(01)00137-2; MCMILLAN R, 1976, J IMMUNOL, V116, P1592; Mignogna MD, 2001, J ORAL PATHOL MED, V30, P268, DOI 10.1034/j.1600-0714.2001.300503.x; Milner Y, 1999, DECADE OF AUTOIMMUNITY, P197, DOI 10.1016/B978-044482824-8/50025-7; MOURELLOU O, 1995, BRIT J DERMATOL, V133, P83; MUELLER H, 1983, J MOL BIOL, V163, P647, DOI 10.1016/0022-2836(83)90116-X; MULLER S, 1990, MANAGEMENT BLISTERIN, P43; MYLES AB, 1974, CORTICOSTEROID ACTH; Nakayama H, 2001, J NEUROCHEM, V79, P489, DOI 10.1046/j.1471-4159.2001.00602.x; Ndoye A, 1998, J INVEST DERMATOL, V111, P410, DOI 10.1046/j.1523-1747.1998.00299.x; Nguyen VT, 2000, J BIOL CHEM, V275, P29466, DOI 10.1074/jbc.M003174200; Nguyen VT, 2000, J CLIN INVEST, V106, P1467, DOI 10.1172/JCI10305; Nguyen VT, 1998, ARCH DERMATOL, V134, P971, DOI 10.1001/archderm.134.8.971; PARRISH EP, 1990, J CELL SCI, V96, P239; PASDAR M, 1995, CELL MOTIL CYTOSKEL, V30, P108, DOI 10.1002/cm.970300203; PIAMPHONGSANT T, 1991, INT J DERMATOL, V30, P139, DOI 10.1111/j.1365-4362.1991.tb04229.x; Puviani M, 2003, J INVEST DERMATOL, V120, P164, DOI 10.1046/j.1523-1747.2003.12014.x; Radoja N, 2000, MOL CELL BIOL, V20, P4328, DOI 10.1128/MCB.20.12.4328-4339.2000; REES DA, 1987, CIBA F SYMP, V125, P1; Roujeau JC, 1996, ARCH DERMATOL, V132, P1499, DOI 10.1001/archderm.132.12.1499; Ruiz-Velasco R, 2002, J BIOL CHEM, V277, P33081, DOI 10.1074/jbc.M202664200; RUOCCO V, 1978, BRIT J DERMATOL, V98, P237, DOI 10.1111/j.1365-2133.1978.tb01630.x; Sadot E, 2002, J CELL SCI, V115, P2771; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; SAXON A, 1978, J CLIN INVEST, V61, P922, DOI 10.1172/JCI109017; SAYAMA K, 1994, J INVEST DERMATOL, V103, P330, DOI 10.1111/1523-1747.ep12394858; SCHILTZ JR, 1979, BRIT J DERMATOL, V101, P279; Schmidt E, 2003, BRIT J DERMATOL, V148, P1222, DOI 10.1046/j.1365-2133.2003.05302.x; SEIDENBAUM M, 1988, INT J DERMATOL, V27, P580, DOI 10.1111/j.1365-4362.1988.tb02409.x; Shasby DM, 2002, AM J PHYSIOL-LUNG C, V282, pL1330, DOI 10.1152/ajplung.00329.2001; Shi LJ, 2001, ARCH BIOCHEM BIOPHYS, V394, P145, DOI 10.1006/abbi.2001.2519; SINGER KH, 1985, ANNU REV IMMUNOL, V3, P87; SINGER KH, 1980, J INVEST DERMATOL, V74, P363, DOI 10.1111/1523-1747.ep12543780; Sondergaard K, 1997, Ther Apher, V1, P155, DOI 10.1111/j.1744-9987.1997.tb00032.x; Stamm C, 1995, EUR J DERMATOL, V5, P664; STAPPENBECK TS, 1994, J BIOL CHEM, V269, P29351; Strassheim D, 2000, J BIOL CHEM, V275, P39767, DOI 10.1074/jbc.M007775200; SWANSON DL, 1983, J INVEST DERMATOL, V81, P258, DOI 10.1111/1523-1747.ep12518278; TAKAHASHI Y, 1985, J INVEST DERMATOL, V84, P41, DOI 10.1111/1523-1747.ep12274679; Toto P, 2000, J IMMUNOL, V164, P522, DOI 10.4049/jimmunol.164.1.522; Vasioukhin V, 2001, CURR OPIN CELL BIOL, V13, P76, DOI 10.1016/S0955-0674(00)00177-0; VIKSTROM KL, 1992, J CELL BIOL, V118, P121, DOI 10.1083/jcb.118.1.121; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; Wakita H, 1997, INT J CANCER, V73, P432, DOI 10.1002/(SICI)1097-0215(19971104)73:3<432::AID-IJC19>3.0.CO;2-E; Werth VP, 1996, ARCH DERMATOL, V132, P1435, DOI 10.1001/archderm.132.12.1435; WILGRAM GF, 1961, J INVEST DERMATOL, V36, P373, DOI 10.1038/jid.1961.58; Woo PL, 1999, J BIOL CHEM, V274, P32818, DOI 10.1074/jbc.274.46.32818; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0; Zia S, 1997, RES COMMUN MOL PATH, V97, P243	115	76	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2135	2146		10.1074/jbc.M309000200	http://dx.doi.org/10.1074/jbc.M309000200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14600150	hybrid			2022-12-25	WOS:000188005700070
J	Strowski, MZ; Cramer, T; Schafer, G; Juttner, S; Walduck, A; Schipani, E; Kemmner, W; Wessler, S; Wunder, C; Weber, M; Meyer, TF; Wiedenmann, B; Jons, T; Naumann, M; Hocker, M				Strowski, MZ; Cramer, T; Schafer, G; Juttner, S; Walduck, A; Schipani, E; Kemmner, W; Wessler, S; Wunder, C; Weber, M; Meyer, TF; Wiedenmann, B; Jons, T; Naumann, M; Hocker, M			Helicobacter pylori stimulates host vascular endothelial growth factor-A (vegf-A) gene expression via MEK/ERK-dependent activation of Sp1 and Sp3	FASEB JOURNAL			English	Article						angiogenesis; Sp1/Sp3 transcription factors; gastric epithelial cells	CAG PATHOGENICITY ISLAND; HISTIDINE-DECARBOXYLASE PROMOTER; GASTRIC-CANCER; TRANSCRIPTIONAL ACTIVATION; OXIDATIVE STRESS; EPITHELIAL-CELLS; PROTEIN-KINASE; FACTOR-ALPHA; ANGIOGENESIS; BINDING	VEGF-A is a key regulator of inflammatory and tumor-associated angiogenesis. H. pylori plays a critical role in the pathogenesis of benign and malignant gastric diseases. It has been suggested that H. pylori infection is associated with activation of host angiogenesis, however, underlying mechanisms as well as angiogenic growth factors activated by the bacterium have not yet been identified. Therefore, we investigated the influence of the bacterium on VEGF-A as a candidate host target gene in vivo and in vitro. We show that H. pylori potently up-regulates production and release of VEGF-A protein as well as vegf-A mRNA levels, and we provide strong evidence that enhanced recruitment of SpI and Sp3 transcription factors to two proximal GC-rich vegf-A promoter elements mediates H. pylori-triggered vegf-A gene expression. In addition, H. pylori infection increased the transactivating capacity of both SpI and Sp3, which suggests additional mechanism(s) of vegf-A gene regulation by the bacterium. Signaling studies identified the MEK>ERK1/-2 kinase cascade as principal host signaling pathway mediating H. pylori-stimulated vegf-A transcription. By identifying H. pylori as potent activator of vegf-A gene expression and characterization of underlying molecular mechanisms, our results provide novel insights into pathways linking the bacterium to host angiogenesis and may help to develop strategies to influence vegf-A gene expression in the setting of H. pylori infection.	Univ Med Berlin, Med Klin Schwerpunkt Hepatol & Gastroenterol, Charite, Sekt Mol Hepatol & Gastroenterol, D-13353 Berlin, Germany; Max Planck Inst Infekt Biol, Berlin, Germany; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Boston, MA USA; Free Univ Berlin, Klinikum Rudolf Virchow, Robert Rossle Klin, D-13122 Berlin, Germany; Max Delbruck Ctr, Berlin, Germany; Otto Von Guericke Univ, Inst Expt Innere Med, Magdeburg, Germany; Univ Med Berlin, Inst Anat, Charite, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society; Harvard University; Harvard Medical School; Massachusetts General Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Otto von Guericke University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hocker, M (corresponding author), Univ Med Berlin, Med Klin Schwerpunkt Hepatol & Gastroenterol, Charite, Sekt Mol Hepatol & Gastroenterol, Campus Virchow Klinikum,Augustenburger Pl 1, D-13353 Berlin, Germany.	hoecker@charite.de	Wunder, Christian/K-8542-2017; Naumann, Michael/B-5285-2011; Meyer, Thomas F. F/J-2485-2013; Wessler, Silja/C-6309-2015; Cramer, Thorsten/S-2479-2016	Wunder, Christian/0000-0001-9091-0080; Naumann, Michael/0000-0002-8060-2313; Meyer, Thomas F. F/0000-0002-6120-8679; Wessler, Silja/0000-0001-7011-6162; Cramer, Thorsten/0000-0002-6462-239X; Wiedenmann, Bertram/0000-0002-7890-2552; Walduck, Anna/0000-0002-9624-4370	Bundesministerium fur Bildung und Forschung (BMBF) [NBLIII-Schnittstellenlabor Tumormetastasierung]; Deutsche Forschungsgemeinschaft (DFG) [HO1288/6-1, Na292/6-2]; DFG-Graduiertenkolleg [GRK276]; Max-Planck-Gesellschaft(Tandemprojekt-Initiative)	Bundesministerium fur Bildung und Forschung (BMBF)(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); DFG-Graduiertenkolleg(German Research Foundation (DFG)); Max-Planck-Gesellschaft(Tandemprojekt-Initiative)	Grant support of M. H. was provided by the Bundesministerium fur Bildung und Forschung (BMBF; Grant NBLIII-Schnittstellenlabor Tumormetastasierung), the Deutsche Forschungsgemeinschaft (DFG; HO1288/6-1), the DFG-Graduiertenkolleg GRK276, and the Max-Planck-Gesellschaft(Tandemprojekt-Initiative). M. N. was supported by the DFG (Na292/6-2). We express our gratitude to M. Cobb, C. Vinson, M. Karin, and G. Suske for providing plasmid DNA.	Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Alroy I, 1999, MOL CELL BIOL, V19, P1961; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CORREA P, 1995, CRIT REV FOOD SCI, V35, P59, DOI 10.1080/10408399509527687; Cox JM, 2001, INFECT IMMUN, V69, P6970, DOI 10.1128/IAI.69.11.6970-6980.2001; CRABTREE JE, 1998, DIG DIS SCI S, V43, P46; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Ernst P, 1999, ALIMENT PHARM THER, V13, P13, DOI 10.1046/j.1365-2036.1999.00003.x; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Glocker E, 1998, INFECT IMMUN, V66, P2346, DOI 10.1128/IAI.66.5.2346-2348.1998; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Houghton J, 2002, J GASTROEN HEPATOL, V17, P495, DOI 10.1046/j.1440-1746.2002.02770.x; Innocenti M, 2002, INFECT IMMUN, V70, P4581, DOI 10.1128/IAI.70.8.4581-4590.2002; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jones MK, 1999, NAT MED, V5, P1418; Jones MK, 2001, GASTROENTEROLOGY, V121, P1040, DOI 10.1053/gast.2001.29308; Kanai T, 1998, INT J CANCER, V77, P933, DOI 10.1002/(SICI)1097-0215(19980911)77:6<933::AID-IJC23>3.0.CO;2-0; Keates S, 1999, J IMMUNOL, V163, P5552; Kempf VAJ, 2001, CELL MICROBIOL, V3, P623, DOI 10.1046/j.1462-5822.2001.00144.x; KOLCH W, 1995, BREAST CANCER RES TR, V36, P139, DOI 10.1007/BF00666036; Lee K, 1996, ENDOCRINOLOGY, V137, P5109, DOI 10.1210/en.137.11.5109; Lucas B, 2001, INFECT IMMUN, V69, P1714, DOI 10.1128/IAI.69.3.1714-1721.2001; Maeda K, 1999, CANCER, V86, P566, DOI 10.1002/(SICI)1097-0142(19990815)86:4<566::AID-CNCR4>3.0.CO;2-1; Maulik N, 2002, FREE RADICAL BIO MED, V33, P1047, DOI 10.1016/S0891-5849(02)01005-5; Megraud F, 2001, DIGEST DIS, V19, P99, DOI 10.1159/000050662; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Naumann M, 2001, INT J MED MICROBIOL, V291, P299, DOI 10.1078/1438-4221-00133; Naumann M, 1999, J BIOL CHEM, V274, P31655, DOI 10.1074/jbc.274.44.31655; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Raychowdhury R, 2002, MOL ENDOCRINOL, V16, P2802, DOI 10.1210/me.2001-0292; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schafer G, 2003, J BIOL CHEM, V278, P8190, DOI 10.1074/jbc.M211999200; Scheiman JM, 1999, AM J MED, V106, P222, DOI 10.1016/S0002-9343(98)00393-3; Shi Q, 2001, CANCER RES, V61, P4143; Shih SC, 2002, AM J PATHOL, V161, P35, DOI 10.1016/S0002-9440(10)64154-5; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Suzuki N, 1998, J PHYSIOL PHARMACOL, V49, P515; Takahashi Y, 1996, CLIN CANCER RES, V2, P1679; Thiel G, 2000, BBA-GENE STRUCT EXPR, V1493, P289, DOI 10.1016/S0167-4781(00)00207-4; van der Flier M, 2000, INFECT IMMUN, V68, P4792, DOI 10.1128/IAI.68.8.4792-4794.2000; Wessler S, 2002, FASEB J, V16, P417, DOI 10.1096/fj.01-0766fje; Wessler S, 2000, J BIOL CHEM, V275, P3629, DOI 10.1074/jbc.275.5.3629; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	47	60	62	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					218	220		10.1096/fj.03-0055fje	http://dx.doi.org/10.1096/fj.03-0055fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597566				2022-12-25	WOS:000188829300078
J	Vlaeminck-Guillem, V; Vanacker, JM; Verger, A; Tomavo, N; Stehelin, D; Laudet, V; Duterque-Coquillaud, M				Vlaeminck-Guillem, V; Vanacker, JM; Verger, A; Tomavo, N; Stehelin, D; Laudet, V; Duterque-Coquillaud, M			Mutual repression of transcriptional activation between the ETS-related factor ERG and estrogen receptor	ONCOGENE			English	Article						nuclear receptors; orphan receptors; ETS proteins; transcription factors; repression	CREB-BINDING-PROTEIN; NUCLEAR RECEPTORS; GLUCOCORTICOID-RECEPTOR; ANDROGEN RECEPTOR; STEROID-HORMONE; GENE-EXPRESSION; DNA-BINDING; FUNCTIONAL INTERFERENCE; FAMILY; DOMAIN	Transcription factors are known to interact with each other to modulate their transcriptional activity. In this study, we found that the transcriptional activity of human Erg (one of the Ets family-transcription factors) was repressed by several nuclear receptors, including human estrogen receptor ERalpha, nonsteroid receptors and orphan receptors. Conversely, Erg inhibited ERalpha-dependent transcription. These reciprocal functional interactions extended to other nuclear receptors such as thyroid hormone and retinoic acid receptors, as well as to Fli1, an ERG-related ETS factor. Although similarly inhibited by overexpression of the orphan nuclear receptors ERR1 and RORalpha, ERG activity was unaffected by either REV-ERBalpha1 or COUP-TFII. The antagonism between ERG and ERalpha did not depend on DNA binding inhibition or direct protein-protein interactions. Repression of ERalpha-dependent transcription required the carboxyterminal and aminoterminal transactivation domains of Erg whereas the carboxyterminal AF-2 domain of ERalpha was necessary for repression of Erg activity. Reciprocal inhibition between Erg and ERalpha was not alleviated by overexpressing CBP, SRC-1 or RIP 140, three nuclear coactivator proteins. A negative cross-talk observed between Erg and ERa expands their potential range of regulation and may be relevant in vivo, particularly in endothelial, urogenital and cartilaginous tissues where both factors are expressed.	Inst Biol Lille, CNRS, UMR 8526, F-59021 Lille, France; Ecole Normale Super Lyon, CNRS, UMR 5665, Lyon, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)	Duterque-Coquillaud, M (corresponding author), Inst Biol Lille, CNRS, UMR 8526, BP 447,1 Rue Calmette, F-59021 Lille, France.			verger, alexis/0000-0002-0299-2344; Duterque-Coquillaud, Martine/0000-0003-3943-5629				Aurrekoetxea-Hernandez K, 2000, J VIROL, V74, P4988, DOI 10.1128/JVI.74.11.4988-4998.2000; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; Chang CY, 1999, MOL CELL BIOL, V19, P8226; COMMITTEE NRN, 1999, CELL, V97, P161; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; Darby TG, 1997, ONCOGENE, V15, P3067, DOI 10.1038/sj.onc.1201503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; Dwivedi PP, 2000, J BIOL CHEM, V275, P47, DOI 10.1074/jbc.275.1.47; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; Glass CK, 2000, GENE DEV, V14, P121; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; INCE BA, 1993, J BIOL CHEM, V268, P14026; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; LIBERMANN TA, 1993, MOL CELL BIOL, V13, P5957, DOI 10.1128/MCB.13.10.5957; Lopez GN, 1999, MOL ENDOCRINOL, V13, P897, DOI 10.1210/me.13.6.897; Luo GY, 2000, MOL ENDOCRINOL, V14, P114, DOI 10.1210/me.14.1.114; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Mullick J, 2001, J BIOL CHEM, V276, P18007, DOI 10.1074/jbc.M100671200; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Potthoff SJ, 1996, MOL ENDOCRINOL, V10, P1095, DOI 10.1210/me.10.9.1095; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; Simpson S, 1997, ONCOGENE, V14, P2149, DOI 10.1038/sj.onc.1201058; Takahashi T, 2000, ONCOGENE, V19, P134, DOI 10.1038/sj.onc.1203228; Tolon RM, 2000, MOL CELL BIOL, V20, P8793, DOI 10.1128/MCB.20.23.8793-8802.2000; Vanacker JM, 1999, MOL ENDOCRINOL, V13, P764, DOI 10.1210/me.13.5.764; Vlaeminck-Guillem V, 2000, MECH DEVELOP, V91, P331, DOI 10.1016/S0925-4773(99)00272-5; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WRENN CK, 1993, J BIOL CHEM, V268, P24089; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	57	7	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8072	8084		10.1038/sj.onc.1207094	http://dx.doi.org/10.1038/sj.onc.1207094			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603248				2022-12-25	WOS:000186403400002
